{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "toc_visible": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "source": [
        "<a href=\"https://colab.research.google.com/github/alisonmitchell/Biomedical-Knowledge-Graph/blob/main/04_Named_Entity_Recognition/KAZU.ipynb\"\n",
        "   target=\"_parent\">\n",
        "   <img src=\"https://colab.research.google.com/assets/colab-badge.svg\"\n",
        "      alt=\"Open in Colab\">\n",
        "</a>\n",
        "\n",
        "# KAZU (Korea AstraZeneca University)"
      ],
      "metadata": {
        "id": "APJltzosz39e"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## 1. Introduction\n",
        "\n",
        "\n",
        "[KAZU](https://github.com/AstraZeneca/KAZU) (Korea AstraZeneca University) is a scalable open source biomedical NLP pipelining framework built by AstraZeneca and Korea University to handle production workloads and support BioNLP for\n",
        "the pharmaceutical sector. KAZU is built around a computationally efficient version of the BERN2 NER model (TinyBERN2), and subsequently wraps several other BioNLP technologies into one coherent system for BioNER and linking to assist the drug discovery/development process in projects such as the [Biological Insights Knowledge Graph](https://www.biorxiv.org/content/10.1101/2021.10.28.466262v1.full) (BIKG).\n",
        "\n",
        "\n",
        "To account for the rapid pace of NLP development, KAZU has been designed in a modular pipeline fashion, wherein new algorithms can be introduced relatively easily, for example a module to perform [NER using an LLM](https://astrazeneca.github.io/KAZU/_autosummary/kazu.steps.ner.llm_ner.html#module-kazu.steps.ner.llm_ner) has been added. In addition to TinyBERN2, it includes distillated PubMedBERT ([Gu et al., 2021](https://dl.acm.org/doi/10.1145/3458754)), components\n",
        "for abbreviation expansion ([Neumann et al., 2019](https://doi.org/10.18653/v1/W19-5034)),\n",
        "entity linking ([Liu et al., 2020](http://arxiv.org/abs/2010.11784)), and additional novel algorithms.\n",
        "\n",
        "As outlined in the research paper ([Yoon, W. et al., 2022](https://aclanthology.org/2022.emnlp-industry.63.pdf)), the KAZU model architecture addresses problems such as nested entities and generalisability. Historically, BioNER models used a single-label classification approach tokenising a string of text and assigning each token a label by calculating the probabilities of whether the token is the\n",
        "beginning, inside or outside (BIO) of named entities. However, this approach cannot properly predict nested entities where the spans of multiple types of entities are overlapped. KAZU mitigates this by applying multi-label label prediction for each token. There is also support for non-contiguous entities, prevalent in biomedical literature.\n",
        "\n",
        "TinyBERN2 addresses generalisability issues, or concerns about the ability to predict unseen entities that are not in the training dataset, by utilising a weakly supervised learning strategy and soft labelling (i.e. training with\n",
        "the confidence values of the supervising model) for entity classes rather than traditional binary or hard labelling (i.e. training with the categorical\n",
        "labels produced by the supervising model) which can hinder weakly labelled training by adding biases."
      ],
      "metadata": {
        "id": "adOSQJgftcEL"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## 2. Install/import libraries"
      ],
      "metadata": {
        "id": "NqZWLC8FvNJ3"
      }
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "A7i5f4whvSFd",
        "collapsed": true
      },
      "outputs": [],
      "source": [
        "!pip install spacy scispacy"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# scispaCy small model\n",
        "!pip install https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/releases/v0.5.4/en_core_sci_sm-0.5.4.tar.gz"
      ],
      "metadata": {
        "id": "MDJ4QT2x-4dI",
        "collapsed": true
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "import matplotlib.pyplot as plt\n",
        "%matplotlib inline\n",
        "import seaborn as sns\n",
        "import pickle\n",
        "import requests\n",
        "import spacy\n",
        "import scispacy\n",
        "import re\n",
        "import warnings\n",
        "warnings.filterwarnings(\"ignore\")\n",
        "\n",
        "from multiprocessing.pool import ThreadPool\n",
        "from time import sleep\n",
        "from collections import Counter\n",
        "from spacy import displacy\n",
        "from spacy.tokens import Doc\n",
        "from spacy import util\n",
        "from spacy.language import Language\n",
        "from scispacy.abbreviation import AbbreviationDetector\n",
        "from scispacy.linking import EntityLinker"
      ],
      "metadata": {
        "id": "lJcDeyDrfwS5"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## 3. KAZU API\n",
        "\n",
        "To install KAZU for use in production systems refer to the [documentation](https://astrazeneca.github.io/KAZU/index.html).\n",
        "\n",
        "Here we will use the [Web API](http://kazu.korea.ac.kr/api/docs#/) designed for light usage. The endpoint for NER and Linking in version 2.0 is http://kazu.korea.ac.kr/api/kazu/ner_and_linking although the earlier version 1.0 was originally used, with endpoint http://kazu.korea.ac.kr/kazu/ner_and_linking.\n",
        "\n",
        "\n",
        "\n",
        "We will define a function to call the API endpoint and perform NER and Linking for some test sentences."
      ],
      "metadata": {
        "id": "ujMySdfSPStE"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def query_kazu(text: str):\n",
        "    \"\"\"Biomedical entity linking API\"\"\"\n",
        "\n",
        "    # KAZU API for cloud service\n",
        "\n",
        "    url=\"http://kazu.korea.ac.kr/api/kazu/ner_and_linking\"\n",
        "\n",
        "    if isinstance(text, str):\n",
        "        response = requests.post(url, json={'text': text}).json()\n",
        "        sleep(1)\n",
        "    else:\n",
        "      raise TypeError(\"Need to supply text\")\n",
        "\n",
        "    return response"
      ],
      "metadata": {
        "id": "4fVPrKpa_Dnx"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def get_entities(text: str):\n",
        "\n",
        "    entity_list = []\n",
        "\n",
        "    for sentence in text:\n",
        "        entity_list.append(query_kazu(sentence))\n",
        "\n",
        "    return entity_list"
      ],
      "metadata": {
        "id": "QxVUMq5gv_RS"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 3.1 NER and Linking\n",
        "\n",
        "We will test using the same two sentences which had nested entities when extracted by BERN2 for comparison."
      ],
      "metadata": {
        "id": "-kEPRelngP-P"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "data = {\n",
        "    'text': [[\"In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.\", \"We used gene expression profiles of SARS-CoV-2 infected samples and a control group from alveolar type II cells and African green monkey kidney cells.\"]]\n",
        "}"
      ],
      "metadata": {
        "id": "eaxeLBNNF_Sj"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "test_df = pd.DataFrame(data, columns=['text'])\n",
        "test_df"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 89
        },
        "id": "7ogkymTOGjGl",
        "outputId": "0eaf40dc-b163-4ee2-c77b-433386a0ffdb"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                                text\n",
              "0  [In the context of the pandemic in that year, ..."
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-0516c4e8-dfb6-40ee-b3c5-b3d3da4c5f64\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>[In the context of the pandemic in that year, ...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-0516c4e8-dfb6-40ee-b3c5-b3d3da4c5f64')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-0516c4e8-dfb6-40ee-b3c5-b3d3da4c5f64 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-0516c4e8-dfb6-40ee-b3c5-b3d3da4c5f64');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "  <div id=\"id_9d841c69-c716-491b-a32a-10925fdf30d7\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('test_df')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_9d841c69-c716-491b-a32a-10925fdf30d7 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('test_df');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "test_df",
              "summary": "{\n  \"name\": \"test_df\",\n  \"rows\": 1,\n  \"fields\": [\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 13
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "%%time\n",
        "\n",
        "with ThreadPool(4) as pool:\n",
        "    entity_list = pool.map(get_entities, test_df.text)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "eHAFBC6eE57R",
        "outputId": "db36a176-7a73-4fd7-f77b-45571e4657a3"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 16.3 ms, sys: 1.12 ms, total: 17.5 ms\n",
            "Wall time: 977 ms\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "entity_list"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "aJm6twgeG5Sr",
        "outputId": "cae1b112-5440-4ed6-c6f9-a0bd0f30a93e"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[[[{'idx': '40155ed2601040e6b7546035c3106a76',\n",
              "    'sections': [{'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "      'name': 'na',\n",
              "      'entities': [{'match': 'COVID-19',\n",
              "        'entity_class': 'disease',\n",
              "        'spans': [{'start': 96, 'end': 104}],\n",
              "        'namespace': 'MemoryEfficientStringMatchingStep',\n",
              "        'start': 96,\n",
              "        'end': 104,\n",
              "        'match_norm': 'COVID-19',\n",
              "        'mention_confidence': 'PROBABLE',\n",
              "        'mappings': [{'default_label': 'COVID-19',\n",
              "          'source': 'MONDO',\n",
              "          'parser_name': 'OPENTARGETS_DISEASE',\n",
              "          'idx': 'MONDO_0100096',\n",
              "          'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "          'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "          'disambiguation_strategy': 'disambiguation_not_required',\n",
              "          'metadata': {'dbXRefs': ['MESH:C000657245',\n",
              "            'SCTID:840539006',\n",
              "            'MESH:D000086382',\n",
              "            'ICD10CM:U07.1',\n",
              "            'DOID:0080600'],\n",
              "           'data_origin': '24.06'}},\n",
              "         {'default_label': 'COVID-19',\n",
              "          'source': 'MONDO',\n",
              "          'parser_name': 'MONDO',\n",
              "          'idx': 'http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "          'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "          'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "          'disambiguation_strategy': 'disambiguation_not_required',\n",
              "          'metadata': {'data_origin': '2024-06-04'}}],\n",
              "        'linking_candidates': [[{'raw_synonyms': ['COVID-19'],\n",
              "           'synonym_norm': 'COVID-19',\n",
              "           'parser_name': 'OPENTARGETS_DISEASE',\n",
              "           'is_symbolic': True,\n",
              "           'associated_id_sets': [{'ids_and_source': [['MONDO_0100096',\n",
              "               'MONDO']]}],\n",
              "           'aggregated_by': 'UNAMBIGUOUS',\n",
              "           'mapping_types': ['name']},\n",
              "          {'exact_match': True}],\n",
              "         [{'raw_synonyms': ['COVID-19'],\n",
              "           'synonym_norm': 'COVID-19',\n",
              "           'parser_name': 'MONDO',\n",
              "           'is_symbolic': True,\n",
              "           'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "               'MONDO']]}],\n",
              "           'aggregated_by': 'UNAMBIGUOUS',\n",
              "           'mapping_types': ['lbl']},\n",
              "          {'exact_match': True}]]},\n",
              "       {'match': 'SARS-CoV-',\n",
              "        'entity_class': 'disease',\n",
              "        'spans': [{'start': 105, 'end': 114}],\n",
              "        'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "        'start': 105,\n",
              "        'end': 114,\n",
              "        'match_norm': 'SARS-COV-'},\n",
              "       {'match': 'COVID-19',\n",
              "        'entity_class': 'disease',\n",
              "        'spans': [{'start': 168, 'end': 176}],\n",
              "        'namespace': 'MemoryEfficientStringMatchingStep',\n",
              "        'start': 168,\n",
              "        'end': 176,\n",
              "        'match_norm': 'COVID-19',\n",
              "        'mention_confidence': 'PROBABLE',\n",
              "        'mappings': [{'default_label': 'COVID-19',\n",
              "          'source': 'MONDO',\n",
              "          'parser_name': 'OPENTARGETS_DISEASE',\n",
              "          'idx': 'MONDO_0100096',\n",
              "          'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "          'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "          'disambiguation_strategy': 'disambiguation_not_required',\n",
              "          'metadata': {'dbXRefs': ['MESH:C000657245',\n",
              "            'SCTID:840539006',\n",
              "            'MESH:D000086382',\n",
              "            'ICD10CM:U07.1',\n",
              "            'DOID:0080600'],\n",
              "           'data_origin': '24.06'}},\n",
              "         {'default_label': 'COVID-19',\n",
              "          'source': 'MONDO',\n",
              "          'parser_name': 'MONDO',\n",
              "          'idx': 'http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "          'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "          'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "          'disambiguation_strategy': 'disambiguation_not_required',\n",
              "          'metadata': {'data_origin': '2024-06-04'}}],\n",
              "        'linking_candidates': [[{'raw_synonyms': ['COVID-19'],\n",
              "           'synonym_norm': 'COVID-19',\n",
              "           'parser_name': 'OPENTARGETS_DISEASE',\n",
              "           'is_symbolic': True,\n",
              "           'associated_id_sets': [{'ids_and_source': [['MONDO_0100096',\n",
              "               'MONDO']]}],\n",
              "           'aggregated_by': 'UNAMBIGUOUS',\n",
              "           'mapping_types': ['name']},\n",
              "          {'exact_match': True}],\n",
              "         [{'raw_synonyms': ['COVID-19'],\n",
              "           'synonym_norm': 'COVID-19',\n",
              "           'parser_name': 'MONDO',\n",
              "           'is_symbolic': True,\n",
              "           'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "               'MONDO']]}],\n",
              "           'aggregated_by': 'UNAMBIGUOUS',\n",
              "           'mapping_types': ['lbl']},\n",
              "          {'exact_match': True}]]},\n",
              "       {'match': 'SARS-CoV-2',\n",
              "        'entity_class': 'species',\n",
              "        'spans': [{'start': 177, 'end': 187}],\n",
              "        'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "        'start': 177,\n",
              "        'end': 187,\n",
              "        'match_norm': 'SARS-COV-2'},\n",
              "       {'match': 'Coronavirus',\n",
              "        'entity_class': 'disease',\n",
              "        'spans': [{'start': 188, 'end': 199}],\n",
              "        'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "        'start': 188,\n",
              "        'end': 199,\n",
              "        'match_norm': 'CORONAVIRU'}]}],\n",
              "    'metadata': {'PROCESSING_EXCEPTION': 'batch failed: affected ids: [\\'40155ed2601040e6b7546035c3106a76\\']\\nTraceback (most recent call last):\\n  File \"/home/kazu/kazu/KAZU/kazu/steps/step.py\", line 140, in step_call\\n    batch_doc_callable(self, docs)\\n  File \"/home/kazu/kazu/KAZU/kazu/steps/linking/dictionary.py\", line 75, in __call__\\n    for candidate, metrics in index.search(\\n  File \"/home/kazu/kazu/KAZU/kazu/utils/link_index.py\", line 96, in search\\n    query_arr = self.vectorizer.transform([match_norm]).todense()\\n  File \"/home/kazu/miniconda3/envs/kazuenv/lib/python3.9/site-packages/sklearn/feature_extraction/text.py\", line 2102, in transform\\n    return self._tfidf.transform(X, copy=False)\\n  File \"/home/kazu/miniconda3/envs/kazuenv/lib/python3.9/site-packages/sklearn/feature_extraction/text.py\", line 1674, in transform\\n    check_is_fitted(self, attributes=[\"idf_\"], msg=\"idf vector is not fitted\")\\n  File \"/home/kazu/miniconda3/envs/kazuenv/lib/python3.9/site-packages/sklearn/utils/validation.py\", line 1209, in check_is_fitted\\n    raise NotFittedError(msg % {\"name\": type(estimator).__name__})\\nsklearn.exceptions.NotFittedError: idf vector is not fitted\\n'}}],\n",
              "  [{'idx': 'e4377e07b2d34c60b99838ecbb7a48bc',\n",
              "    'sections': [{'text': 'We used gene expression profiles of SARS-CoV-2 infected samples and a control group from alveolar type II cells and African green monkey kidney cells.',\n",
              "      'name': 'na',\n",
              "      'entities': [{'match': 'SARS-CoV-2',\n",
              "        'entity_class': 'species',\n",
              "        'spans': [{'start': 36, 'end': 46}],\n",
              "        'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "        'start': 36,\n",
              "        'end': 46,\n",
              "        'match_norm': 'SARS-COV-2'},\n",
              "       {'match': 'alveolar type II cells',\n",
              "        'entity_class': 'cell_type',\n",
              "        'spans': [{'start': 89, 'end': 111}],\n",
              "        'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "        'start': 89,\n",
              "        'end': 111,\n",
              "        'match_norm': 'ALVEOLAR TYPE 2 CELL'},\n",
              "       {'match': 'African green monkey kidney cells',\n",
              "        'entity_class': 'cell_type',\n",
              "        'spans': [{'start': 116, 'end': 149}],\n",
              "        'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "        'start': 116,\n",
              "        'end': 149,\n",
              "        'match_norm': 'AFRICAN GREEN MONKEY KIDNEY CELL'}]}],\n",
              "    'metadata': {'PROCESSING_EXCEPTION': 'batch failed: affected ids: [\\'e4377e07b2d34c60b99838ecbb7a48bc\\']\\nTraceback (most recent call last):\\n  File \"/home/kazu/kazu/KAZU/kazu/steps/step.py\", line 140, in step_call\\n    batch_doc_callable(self, docs)\\n  File \"/home/kazu/kazu/KAZU/kazu/steps/linking/dictionary.py\", line 75, in __call__\\n    for candidate, metrics in index.search(\\n  File \"/home/kazu/kazu/KAZU/kazu/utils/link_index.py\", line 96, in search\\n    query_arr = self.vectorizer.transform([match_norm]).todense()\\n  File \"/home/kazu/miniconda3/envs/kazuenv/lib/python3.9/site-packages/sklearn/feature_extraction/text.py\", line 2102, in transform\\n    return self._tfidf.transform(X, copy=False)\\n  File \"/home/kazu/miniconda3/envs/kazuenv/lib/python3.9/site-packages/sklearn/feature_extraction/text.py\", line 1674, in transform\\n    check_is_fitted(self, attributes=[\"idf_\"], msg=\"idf vector is not fitted\")\\n  File \"/home/kazu/miniconda3/envs/kazuenv/lib/python3.9/site-packages/sklearn/utils/validation.py\", line 1209, in check_is_fitted\\n    raise NotFittedError(msg % {\"name\": type(estimator).__name__})\\nsklearn.exceptions.NotFittedError: idf vector is not fitted\\n'}}]]]"
            ]
          },
          "metadata": {},
          "execution_count": 92
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "The output is in JSON format for each sentence and uses a hashing algorithm to compute the value for the 'idx' key so we do not have to perform this as an extra step as for BERN2.  The output also contains the match, entity class, start and end spans, canonical name and mappings/entity linking information including the ontology mapped to, the parser, CUI, string matching strategy and confidence, disambiguation strategy if this was required, and cross references.\n",
        "\n",
        "The documentation provides more information about the [OntologyParser](https://astrazeneca.github.io/KAZU/ontology_parser.html), and the [challenges of entity linking](https://astrazeneca.github.io/KAZU/introduction.html) such as overlapping ontologies and inconsistencies of knowledge bases and ontologies. Rather than depending on a composite system like UMLS, KAZU links directly to the source ontology URIs.\n",
        "\n",
        "Datasets and models used are listed on the [KAZU repo](https://github.com/AstraZeneca/KAZU?tab=readme-ov-file#dataset-licences) and include popular standard datasets commonly used in drug discovery such as ChEMBL for drug compounds, Mondo for diseases, the Gene Ontology for genes, and others.\n",
        "\n",
        "\n",
        "\n",
        "\n",
        "\n"
      ],
      "metadata": {
        "id": "zB4ThohLXJ16"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 3.2 Visualise NER labels\n",
        "\n",
        "We will use spaCy's displaCy named entity visualiser with custom colours for the entity types to highlight the named entities and their labels."
      ],
      "metadata": {
        "id": "-lol-I04dBqT"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "colors = {'disease': 'linear-gradient(90deg, #66ffcc, #abf763)',\n",
        "          'drug': 'linear-gradient(90deg, #aa9cfc, #fc9ce7)',\n",
        "          \"gene\":'linear-gradient(90deg, #ffff66, #ff6600)',\n",
        "          'species': 'linear-gradient(90deg, #6699ff, #99ccff)',\n",
        "          'cell_line': 'linear-gradient(90deg, #ff99cc, #ffcccc)',\n",
        "          'cell_type': 'linear-gradient(90deg, #99ff99, #66ff66)'}"
      ],
      "metadata": {
        "id": "H7tfgI5cl1cg"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "y1JXQCSV65CM"
      },
      "outputs": [],
      "source": [
        "def get_entities_html(entity_list, title=None, colors=None):\n",
        "    \"\"\"Visualise NER with the help of spaCy\"\"\"\n",
        "    render_data_list = []\n",
        "    options = {\"colors\": colors} if colors else {}\n",
        "\n",
        "    for sublist in entity_list:\n",
        "        for item in sublist:\n",
        "            ents = []\n",
        "            entities = item[0].get('sections', [{}])[0].get('entities', [])  # Accessing the 'entities' list inside 'sections'\n",
        "            for entity in entities:\n",
        "                start = entity['spans'][0]['start'] if 'spans' in entity and entity['spans'] else None\n",
        "                end = entity['spans'][0]['end'] if 'spans' in entity and entity['spans'] else None\n",
        "                label = entity['entity_class'] if 'entity_class' in entity else None\n",
        "                if start is not None and end is not None and label is not None:\n",
        "                    ents.append({\"start\": start, \"end\": end, \"label\": label})\n",
        "\n",
        "            text = item[0].get('sections', [{}])[0].get('text', None)  # Accessing the 'text' value inside 'sections'\n",
        "            render_data = {\"text\": text, \"ents\": ents, \"title\": title}\n",
        "            render_data_list.append(render_data)\n",
        "\n",
        "    displacy.render(render_data_list, style=\"ent\", manual=True, jupyter=True, options=options)"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "test_parsed_entities_html = get_entities_html(entity_list, colors=colors)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 157
        },
        "id": "xHoNuvTcG__E",
        "outputId": "695b24f0-6ca5-48f2-e986-55126cab64ed"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In the context of the pandemic in that year, there was a surge in research on the subject, with \n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #66ffcc, #abf763); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    COVID-19\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">disease</span>\n",
              "</mark>\n",
              "/\n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #66ffcc, #abf763); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    SARS-CoV-\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">disease</span>\n",
              "</mark>\n",
              "2/Coronavirus topping the list of keywords as soon as \n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #66ffcc, #abf763); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    COVID-19\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">disease</span>\n",
              "</mark>\n",
              "/\n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #6699ff, #99ccff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    SARS-CoV-2\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">species</span>\n",
              "</mark>\n",
              "/\n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #66ffcc, #abf763); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Coronavirus\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">disease</span>\n",
              "</mark>\n",
              " appeared that year.</div>\n",
              "\n",
              "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">We used gene expression profiles of \n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #6699ff, #99ccff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    SARS-CoV-2\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">species</span>\n",
              "</mark>\n",
              " infected samples and a control group from \n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #99ff99, #66ff66); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    alveolar type II cells\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">cell_type</span>\n",
              "</mark>\n",
              " and \n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #99ff99, #66ff66); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    African green monkey kidney cells\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">cell_type</span>\n",
              "</mark>\n",
              ".</div></span>"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "This is more accurate than BERN2 insofar as 'African green monkey kidney cells' appears correctly as a merged entity without the nested entities 'African green' and 'African green monkey'.\n",
        "Also, 'SARS-CoV-2' in the second sentence appears correctly without nested entity 'SARS-CoV'.\n",
        "\n",
        "However, if we compare it with the BERN2 output for the same sentences below, the same issue occurs in the first sentence with the first mention of 'SARS-CoV-2' not being fully captured and 'Coronavirus' not identified at all.\n",
        "\n"
      ],
      "metadata": {
        "id": "A-_lWqwUJrOb"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# BERN2 output for same two sentences\n",
        "entities_html = get_entities_html(entity_list)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 227
        },
        "id": "_5LFtpaqebmB",
        "outputId": "e6979b5d-ee6e-413a-e657-052c88907136"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In the context of the pandemic in that year, there was a surge in research on the subject, with \n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #66ffcc, #abf763); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    COVID-19\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">disease</span>\n",
              "</mark>\n",
              "/\n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #6699ff, #99ccff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    SARS\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">species</span>\n",
              "</mark>\n",
              "-CoV-2/Coronavirus topping the list of keywords as soon as \n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #66ffcc, #abf763); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    COVID-19\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">disease</span>\n",
              "</mark>\n",
              "/\n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #66ffcc, #abf763); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    SARS-CoV\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">disease</span>\n",
              "</mark>\n",
              "\n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #6699ff, #99ccff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    SARS-CoV-2\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">species</span>\n",
              "</mark>\n",
              "/\n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #66ffcc, #abf763); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    Coronavirus\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">disease</span>\n",
              "</mark>\n",
              " appeared that year.</div>\n",
              "\n",
              "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">We used \n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #ff6666, #ff9999); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    gene\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DNA</span>\n",
              "</mark>\n",
              " expression profiles of \n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #66ffcc, #abf763); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    SARS-CoV\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">disease</span>\n",
              "</mark>\n",
              "\n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #6699ff, #99ccff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    SARS-CoV-2\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">species</span>\n",
              "</mark>\n",
              " infected samples and a control group from \n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #99ff99, #66ff66); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    alveolar type II cells\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">cell_type</span>\n",
              "</mark>\n",
              " and \n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #ff99cc, #ffcccc); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    African green\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">cell_line</span>\n",
              "</mark>\n",
              "\n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #6699ff, #99ccff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    African green monkey\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">species</span>\n",
              "</mark>\n",
              "\n",
              "<mark class=\"entity\" style=\"background: linear-gradient(90deg, #99ff99, #66ff66); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
              "    African green monkey kidney cells\n",
              "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">cell_type</span>\n",
              "</mark>\n",
              ".</div></span>"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 3.3 NER and Linking for 10 articles\n",
        "\n",
        "We will extract the named entities and labels for coreference resolved text for 10 articles."
      ],
      "metadata": {
        "id": "fukMdbLSXP97"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# load data for 10 articles\n",
        "with open('2024-03-24_pmc_arxiv_full_sent_text_spacy_fastcoref_sent_tok_0_10_df.pickle', 'rb') as f:\n",
        "    coref_sent_tok_0_10_df = pickle.load(f)"
      ],
      "metadata": {
        "id": "lPEoyRrq94NM"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "5217eb45-4477-47d8-eca1-01cbe4b544fd",
        "id": "SJwQiq1wy8Wa"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "RangeIndex: 10 entries, 0 to 9\n",
            "Data columns (total 12 columns):\n",
            " #   Column           Non-Null Count  Dtype \n",
            "---  ------           --------------  ----- \n",
            " 0   article_id       10 non-null     object\n",
            " 1   published        10 non-null     object\n",
            " 2   revised          10 non-null     object\n",
            " 3   title            10 non-null     object\n",
            " 4   journal          10 non-null     object\n",
            " 5   authors          10 non-null     object\n",
            " 6   doi              10 non-null     object\n",
            " 7   pdf_url          10 non-null     object\n",
            " 8   text             10 non-null     object\n",
            " 9   sent_text        10 non-null     object\n",
            " 10  coref_text       10 non-null     object\n",
            " 11  sent_coref_text  10 non-null     object\n",
            "dtypes: object(12)\n",
            "memory usage: 1.1+ KB\n"
          ]
        }
      ],
      "source": [
        "coref_sent_tok_0_10_df.info()"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will call the API endpoint to perform NER and Linking on 10 articles. The function below uses the legacy version 1.0 with endpoint http://kazu.korea.ac.kr/kazu/ner_and_linking."
      ],
      "metadata": {
        "id": "50cihtSNtFze"
      }
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "9X16FbvTHyt7"
      },
      "outputs": [],
      "source": [
        "def query_kazu(text: str):\n",
        "    \"\"\"Biomedical entity linking API\"\"\"\n",
        "\n",
        "    # KAZU API for cloud service\n",
        "\n",
        "    url=\"http://kazu.korea.ac.kr/kazu/ner_and_linking\"\n",
        "\n",
        "    if isinstance(text, str):\n",
        "        response = requests.post(url, json={'text': text}).json()\n",
        "        sleep(1)\n",
        "    else:\n",
        "      raise TypeError(\"Need to supply text\")\n",
        "\n",
        "    return response"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "BR2rBlFUHyt8"
      },
      "outputs": [],
      "source": [
        "def get_entities(text: str):\n",
        "\n",
        "    entity_list = []\n",
        "\n",
        "    for sentence in text:\n",
        "        entity_list.append(query_kazu(sentence))\n",
        "\n",
        "    return entity_list"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "%%time\n",
        "\n",
        "with ThreadPool(4) as pool:\n",
        "     entity_list = pool.map(get_entities, coref_sent_tok_0_10_df.sent_coref_text)\n",
        "with open('2024-03-26_kazu_entity_list_coref_sent_tok_0_10_df.pickle', 'wb') as f:\n",
        "  pickle.dump(entity_list, f)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "d6zgO3iGN6V5",
        "outputId": "4ea125a7-c69f-407a-e54d-4d0c7c5d0595"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 13.8 s, sys: 1.97 s, total: 15.7 s\n",
            "Wall time: 17min 59s\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "h2A8NiBGohGZ",
        "outputId": "80879df2-d693-4429-c978-e072a5e5aae1"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "10"
            ]
          },
          "execution_count": 42,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "len(entity_list)"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# JSON output for first article\n",
        "entity_list[0]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ow9zUKVW2C-D",
        "outputId": "54086e58-039c-425c-9e11-40c507e1c480"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[[{'idx': '9fac46a65c684e9cb308f8056b185981',\n",
              "   'sections': [{'text': 'Sir James Black, a winner of the 1988 Nobel Prize, clearly recognized well before the 21st century that drug repurposing strategies would occupy an important place in the future of new drug discovery.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '52630635919f4fc09eed777af5df84cd',\n",
              "   'sections': [{'text': 'In 2004, Ted T. Ashburn et al. summarized previous research and developed a general approach to drug development using drug repurposing, retrospectively looking for new indications for approved drugs and molecules that are waiting for approval for new pathways of action and targets.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'dac90fc1831b4b84a654152c8bb6b60a',\n",
              "   'sections': [{'text': 'molecules that are waiting for approval for new pathways of action and targets are usually safe in clinical trials but do not show sufficient efficacy for the treatment of the disease originally targeted.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '5414c43c91a64d44845916fad4efc2fc',\n",
              "   'sections': [{'text': 'The definition of the term drug repurposing has been endorsed by scholars and used by scholars.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '27742cffa2c54fc49702f702c306630a',\n",
              "   'sections': [{'text': 'It should be pointed out that the synonyms of drug repurposing often used by academics also include drug repositioning, drug rediscovery, drug redirecting, drug retasking, and therapeutic switching.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'b0b234d52bce4394891db64425ab2962',\n",
              "   'sections': [{'text': 'After the research study by Ted T. Ashburn et al., Allarakhia et al. expanded the starting materials for drug repositioning to include products that were discontinued for commercial reasons, expired patents, and candidates for laboratory testing.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '3e4f17a8d1364111ba4b90ebfb9a8874',\n",
              "   'sections': [{'text': \"In the discovery process of a completely new drug, the difficulty usually lies in a completely new drug's safety and efficacy, which are the main potential causes of failure of most drugs in the approval or clinical development stage.\",\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '78b92f8267274c39ac672dc2bdec780c',\n",
              "   'sections': [{'text': 'Using existing knowledge about a drug or known target, the time, risk, and cost of developing a drug using drug repositioning are reduced, thereby greatly increasing the efficiency and economics of drug development, providing a better risk–reward trade-off, and making it easier to win the favor of venture capital firms.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '22200652f00d4d5fb5875f619734eaed',\n",
              "   'sections': [{'text': 'Since the 1990s, the repositioning of sildenafil for male erectile dysfunction and pulmonary hypertension, the development of a new efficacy of bupropion for smoking cessation, new applications of thalidomide for multiple myeloma, and chronic graft-versus-host disease have generated intense interest from pharmaceutical companies and academics.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'sildenafil',\n",
              "       'entity_class': 'drug',\n",
              "       'spans': [{'start': 38, 'end': 48}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'SILDENAFIL',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'idx': 'CHEMBL192',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Sildenafil',\n",
              "          'mapping_type': 'FDA',\n",
              "          'data_origin': 'chembl_32_sqlite'}},\n",
              "        {'default_label': 'SILDENAFIL',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'idx': 'CHEMBL192',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Aphrodil',\n",
              "          'mapping_type': 'synonyms',\n",
              "          'crossReferences': {'DailyMed': ['sildenafil%20citrate'],\n",
              "           'PubChem': ['26748898', '50085897'],\n",
              "           'drugbank': ['DB00203'],\n",
              "           'chEBI': ['9139']},\n",
              "          'data_origin': 'OPENTARGETS-MOLECULE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['Sildenafil', 'SILDENAFIL'],\n",
              "         'term_norm': 'SILDENAFIL',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL192', 'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['Sildenafil', 'SILDENAFIL'],\n",
              "         'term_norm': 'SILDENAFIL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL192', 'CHEMBL']]}],\n",
              "         'mapping_types': ['ATC',\n",
              "          'FDA',\n",
              "          'INN',\n",
              "          'BNF',\n",
              "          'pref_name',\n",
              "          'BAN',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 38,\n",
              "       'end': 48,\n",
              "       'match_norm': 'SILDENAFIL'},\n",
              "      {'match': 'male erectile dysfunction',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 53, 'end': 78}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'Erectile dysfunction',\n",
              "         'source': 'HP',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/HP_0100639',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Erectile dysfunction',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'erectile dysfunction',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0005362',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'male erectile Disorder',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['SNOMEDCT:397803000',\n",
              "           'MONDO:0005362',\n",
              "           'NCIt:C3133',\n",
              "           'DOID:1875',\n",
              "           'MedDRA:10061461',\n",
              "           'HP:0000802',\n",
              "           'SCTID:397803000',\n",
              "           'MESH:D007172',\n",
              "           'MeSH:D007172',\n",
              "           'NCIT:C34801'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}},\n",
              "        {'default_label': 'erectile dysfunction',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0005362',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'erectile dysfunction',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}}],\n",
              "       'synonym_terms': [{'terms': ['Sleep dysfunction'],\n",
              "         'term_norm': 'SLEEP DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0002360',\n",
              "             'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.92870972861179,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['erectile dysfunction (disease)'],\n",
              "         'term_norm': 'ERECTILE DYSFUNCTION (DISEASE)',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005362',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 75.99933246573848,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['femoral nerve dysfunction'],\n",
              "         'term_norm': 'FEMORAL NERVE DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0006759',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.00307468457486,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['outlet dysfunction constipation'],\n",
              "         'term_norm': 'OUTLET DYSFUNCTION CONSTIPATION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002202',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.128280485219825,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['GI dysfunction'],\n",
              "         'term_norm': 'GI DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0012719', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.26476716017753,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neutrophil actin dysfunction'],\n",
              "         'term_norm': 'NEUTROPHIL ACTIN DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0009755',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 68.44531530113237,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['renal dysfunction'],\n",
              "         'term_norm': 'RENAL DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0001343',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 76.47283568142736,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['hypothalamic dysfunction'],\n",
              "         'term_norm': 'HYPOTHALAMIC DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0043101',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.49487960164283,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Male sexual dysfunction'],\n",
              "         'term_norm': 'MALE SEXUAL DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0040307',\n",
              "             'HP']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.24685214340823,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['cardiac dysfunction'],\n",
              "         'term_norm': 'CARDIAC DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005252',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.31265394016377,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['erectile dysfunction (disease)'],\n",
              "         'term_norm': 'ERECTILE DYSFUNCTION (DISEASE)',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005362',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 76.77015592762609,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Autonomic dysfunction'],\n",
              "         'term_norm': 'AUTONOMIC DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0012332',\n",
              "             'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.78383839289472,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['erectile dysfunction'],\n",
              "         'term_norm': 'ERECTILE DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005362',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 94.23536408568623,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Somatic sensory dysfunction'],\n",
              "         'term_norm': 'SOMATIC SENSORY DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0003474', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.48530528975916,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['male erectile Disorder'],\n",
              "         'term_norm': 'MALE ERECTILE DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005362',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.386878007587974,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bowel dysfunction'],\n",
              "         'term_norm': 'BOWEL DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004880',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 63.95141855391173,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['familial sinus node dysfunction'],\n",
              "         'term_norm': 'FAMILIAL SINUS NODE DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0012061',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.36645744046226,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovarian dysfunction'],\n",
              "         'term_norm': 'OVARIAN DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0001889',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.07359193357527,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['femoral nerve dysfunction'],\n",
              "         'term_norm': 'FEMORAL NERVE DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0006759',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.98524369057213,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovarian dysfunction'],\n",
              "         'term_norm': 'OVARIAN DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0001889',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.71326173984556,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Autonomic dysfunction'],\n",
              "         'term_norm': 'AUTONOMIC DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0012332', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.73033606676155,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Proteostasis dysfunctions', 'Proteostasis dysfunction'],\n",
              "         'term_norm': 'PROTEOSTASIS DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0021179',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.42241358942571,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Vocal cord dysfunction'],\n",
              "         'term_norm': 'VOCAL CORD DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0031801', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.77298241528473,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Mitochondrial dysfunction'],\n",
              "         'term_norm': 'MITOCHONDRIAL DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0003287', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.96476038490431,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Dysfunction, Liver'],\n",
              "         'term_norm': 'DYSFUNCTION LIVER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005154',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 68.00569135728227,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Somatic sensory dysfunction'],\n",
              "         'term_norm': 'SOMATIC SENSORY DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0003474',\n",
              "             'HP']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 63.900836693657695,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['erectile dysfunction', 'Erectile dysfunction'],\n",
              "         'term_norm': 'ERECTILE DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0100639',\n",
              "             'HP'],\n",
              "            ['http://purl.obolibrary.org/obo/MONDO_0005362', 'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 94.56306067241862,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['familial sinus node dysfunction'],\n",
              "         'term_norm': 'FAMILIAL SINUS NODE DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0012061',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.26812862595218,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Interictal vestibular dysfunction'],\n",
              "         'term_norm': 'INTERICTAL VESTIBULAR DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0001751',\n",
              "             'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 63.40918000997291,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['GI dysfunction'],\n",
              "         'term_norm': 'GI DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0012719',\n",
              "             'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 70.66545960684961,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Corticospinal tract dysfunction'],\n",
              "         'term_norm': 'CORTICOSPINAL TRACT DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0002493',\n",
              "             'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 63.14688614810513,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Female sexual dysfunction'],\n",
              "         'term_norm': 'FEMALE SEXUAL DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0030014',\n",
              "             'HP']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.17923576471622,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Proteostasis dysfunctions', 'Proteostasis dysfunction'],\n",
              "         'term_norm': 'PROTEOSTASIS DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0021179',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.28928732585494,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bowel dysfunction'],\n",
              "         'term_norm': 'BOWEL DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004880',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 63.38622491997739,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['immune dysfunction'],\n",
              "         'term_norm': 'IMMUNE DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005046',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.66954245434648,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Liver dysfunction',\n",
              "          'Liver Dysfunctions',\n",
              "          'Liver Dysfunction'],\n",
              "         'term_norm': 'LIVER DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0001410', 'HP'],\n",
              "            ['MONDO_0005154', 'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 71.30472388469096,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Vestibular dysfunction'],\n",
              "         'term_norm': 'VESTIBULAR DYSFUNCTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0001751',\n",
              "             'HP']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.12208582360587,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Fine motor skill dysfunction'],\n",
              "         'term_norm': 'FINE MOTOR SKILL DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0007010', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.51227225963532,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['immune dysfunction'],\n",
              "         'term_norm': 'IMMUNE DYSFUNCTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005046',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 68.4994134755859,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Dysfunctions, Liver'],\n",
              "         'term_norm': 'DYSFUNCTIONS LIVER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005154',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.75563123304778,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 53,\n",
              "       'end': 78,\n",
              "       'match_norm': 'MALE ERECTILE DYSFUNCTION'},\n",
              "      {'match': 'pulmonary hypertension',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 83, 'end': 105}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'pulmonary hypertension',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0005149',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'pulmonary hypertension',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['DOID:6432',\n",
              "           'SCTID:70995007',\n",
              "           'EFO:0001361',\n",
              "           'MedDRA:10037400',\n",
              "           'MESH:D006976'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}},\n",
              "        {'default_label': 'pulmonary arterial hypertension',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0015924',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'PPH1',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['UMLS:CN200519',\n",
              "           'SCTID:11399002',\n",
              "           'Orphanet:182090',\n",
              "           'OMIM:615371',\n",
              "           'NCIt:C3120',\n",
              "           'SNOMEDCT:70995007',\n",
              "           'GARD:0007501',\n",
              "           'DOID:6432',\n",
              "           'UMLS:C2973725',\n",
              "           'MeSH:D006976',\n",
              "           'MONDO:0015924',\n",
              "           'MedDRA:10064911',\n",
              "           'MESH:D000081029'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}},\n",
              "        {'default_label': 'pulmonary hypertension',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0005149',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'pulmonary hypertension',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}}],\n",
              "       'synonym_terms': [{'terms': ['pulmonary hypertension'],\n",
              "         'term_norm': 'PULMONARY HYPERTENSION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005149', 'MONDO'],\n",
              "            ['MONDO_0015924', 'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['pulmonary hypertension'],\n",
              "         'term_norm': 'PULMONARY HYPERTENSION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005149',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 83,\n",
              "       'end': 105,\n",
              "       'match_norm': 'PULMONARY HYPERTENSION'},\n",
              "      {'match': 'bupropion',\n",
              "       'entity_class': 'drug',\n",
              "       'spans': [{'start': 144, 'end': 153}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'BUPROPION',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'idx': 'CHEMBL894',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Amfebutamone',\n",
              "          'mapping_type': 'synonyms',\n",
              "          'crossReferences': {'DailyMed': ['bupropion%20hydrobromide',\n",
              "            'bupropion%20hydrochloride'],\n",
              "           'PubChem': ['174006913', '90340803'],\n",
              "           'Wikipedia': ['Bupropion'],\n",
              "           'drugbank': ['DB01156'],\n",
              "           'chEBI': ['3219']},\n",
              "          'data_origin': 'OPENTARGETS-MOLECULE-23.02'}},\n",
              "        {'default_label': 'BUPROPION',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'idx': 'CHEMBL894',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Bupropion',\n",
              "          'mapping_type': 'FDA',\n",
              "          'data_origin': 'chembl_32_sqlite'}}],\n",
              "       'synonym_terms': [{'terms': ['BUPROPION', 'Bupropion'],\n",
              "         'term_norm': 'BUPROPION',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL894', 'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['BUPROPION', 'Bupropion'],\n",
              "         'term_norm': 'BUPROPION',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL894', 'CHEMBL']]}],\n",
              "         'mapping_types': ['ATC',\n",
              "          'FDA',\n",
              "          'INN',\n",
              "          'pref_name',\n",
              "          'BAN',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 144,\n",
              "       'end': 153,\n",
              "       'match_norm': 'BUPROPION'},\n",
              "      {'match': 'thalidomide',\n",
              "       'entity_class': 'drug',\n",
              "       'spans': [{'start': 197, 'end': 208}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'THALIDOMIDE',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'idx': 'CHEMBL468',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': '.alpha.-phthalimidoglutarimide',\n",
              "          'mapping_type': 'synonyms',\n",
              "          'crossReferences': {'DailyMed': ['thalidomide'],\n",
              "           'PubChem': ['111716',\n",
              "            '11532929',\n",
              "            '124881523',\n",
              "            '144210897',\n",
              "            '170465323',\n",
              "            '174007312',\n",
              "            '26747126',\n",
              "            '26751823',\n",
              "            '50104514',\n",
              "            '90341724'],\n",
              "           'Wikipedia': ['Thalidomide'],\n",
              "           'drugbank': ['DB01041'],\n",
              "           'chEBI': ['74947']},\n",
              "          'data_origin': 'OPENTARGETS-MOLECULE-23.02'}},\n",
              "        {'default_label': 'THALIDOMIDE',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'idx': 'CHEMBL468',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': '.alpha.-phthalimidoglutarimide',\n",
              "          'mapping_type': 'OTHER',\n",
              "          'data_origin': 'chembl_32_sqlite'}}],\n",
              "       'synonym_terms': [{'terms': ['Thalidomide', 'THALIDOMIDE'],\n",
              "         'term_norm': 'THALIDOMIDE',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL468', 'CHEMBL']]}],\n",
              "         'mapping_types': ['ATC',\n",
              "          'JAN',\n",
              "          'USAN',\n",
              "          'FDA',\n",
              "          'INN',\n",
              "          'BNF',\n",
              "          'pref_name',\n",
              "          'BAN',\n",
              "          'USP',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['Thalidomide', 'THALIDOMIDE'],\n",
              "         'term_norm': 'THALIDOMIDE',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL468', 'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 197,\n",
              "       'end': 208,\n",
              "       'match_norm': 'THALIDOMIDE'},\n",
              "      {'match': 'multiple myeloma',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 213, 'end': 229}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'plasma cell myeloma',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0009693',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'plasma cell myeloma',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'multiple myeloma',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0009693',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'myelomatosis',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['DOID:9538',\n",
              "           'EFO:0001378',\n",
              "           'ONCOTREE:PCM',\n",
              "           'MESH:D009101',\n",
              "           'OMIM:254500',\n",
              "           'UMLS:C0026764',\n",
              "           'Orphanet:314701',\n",
              "           'ICD10:C90.0',\n",
              "           'GARD:0007108',\n",
              "           'ICD10CM:C90.0',\n",
              "           'COHD:437233',\n",
              "           'Orphanet:85443',\n",
              "           'MONDO:0009693',\n",
              "           'ICD9:203.0',\n",
              "           'MedDRA:10028228',\n",
              "           'ICDO:9732/3',\n",
              "           'NCIT:C3242',\n",
              "           'ICD10:C90.00',\n",
              "           'Orphanet:29073',\n",
              "           'UMLS:C0268381'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['multiple myeloma'],\n",
              "         'term_norm': 'MULTIPLE MYELOMA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0009693',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['multiple myeloma'],\n",
              "         'term_norm': 'MULTIPLE MYELOMA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0009693',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 213,\n",
              "       'end': 229,\n",
              "       'match_norm': 'MULTIPLE MYELOMA'},\n",
              "      {'match': 'chronic graft-versus-host disease',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 235, 'end': 268}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'chronic graft versus host disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0020547',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'chronic graft versus host disease',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'chronic graft versus host disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0020547',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'GVHD, chronic',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['SCTID:402356004',\n",
              "           'ICD10CM:D89.811',\n",
              "           'NCIT:C4981',\n",
              "           'ICD9:279.52',\n",
              "           'GARD:0010964',\n",
              "           'Orphanet:99921',\n",
              "           'UMLS:C0867389',\n",
              "           'MedDRA:10066261'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['chronic graft versus host disease'],\n",
              "         'term_norm': 'CHRONIC GRAFT VERSUS HOST DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0020547',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['chronic graft versus host disease'],\n",
              "         'term_norm': 'CHRONIC GRAFT VERSUS HOST DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020547',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 235,\n",
              "       'end': 268,\n",
              "       'match_norm': 'CHRONIC GRAFT VERSUS HOST DISEASE'}]}]}],\n",
              " [{'idx': '802703bc6c324adcb350893df3802b71',\n",
              "   'sections': [{'text': 'These classic success stories rely on three traditional approaches 1 molecular biology approaches, 2 in vivo and ex vivo experimental approaches, and 3 expert knowledge-based approaches.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'd2a2c683091e4a61a16ea4c0d8fb29f9',\n",
              "   'sections': [{'text': 'Due to the unknown, complex, and information-fragmented nature of drug candidates and potential new mechanisms of action, drug repositioning is dependent on multiple factors, and success is often fortuitous.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '45575790fc88453a90d6e15b0474e89d',\n",
              "   'sections': [{'text': 'At the beginning of the 21st century, cheminformatics, bioinformatics, systems biology, genomics, polypharmacology, precision medicine, and other disciplines, combined with artificial intelligence, have developed rapidly.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'precision',\n",
              "       'entity_class': 'measurement',\n",
              "       'spans': [{'start': 116, 'end': 125}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'precision',\n",
              "         'source': 'STATO',\n",
              "         'parser_name': 'STATO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'precision',\n",
              "          'mapping_type': 'http://www.w3.org/2000/01/rdf-schema#label',\n",
              "          'data_origin': 'RC1.4'}}],\n",
              "       'synonym_terms': [{'terms': ['precision'],\n",
              "         'term_norm': 'PRECISION',\n",
              "         'parser_name': 'STATO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "             'STATO']]}],\n",
              "         'mapping_types': ['http://www.w3.org/2000/01/rdf-schema#label'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 116,\n",
              "       'end': 125,\n",
              "       'match_norm': 'PRECISION'}]}]}],\n",
              " [{'idx': 'ac22ae2fbeb14ca5baf01f3b0022cd57',\n",
              "   'sections': [{'text': 'cheminformatics, bioinformatics, systems biology, genomics, polypharmacology, precision medicine, and other disciplines have promoted the generation of systematic computer methods to make the drug repositioning process cheaper and shorter.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'precision',\n",
              "       'entity_class': 'measurement',\n",
              "       'spans': [{'start': 78, 'end': 87}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'precision',\n",
              "         'source': 'STATO',\n",
              "         'parser_name': 'STATO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'precision',\n",
              "          'mapping_type': 'http://www.w3.org/2000/01/rdf-schema#label',\n",
              "          'data_origin': 'RC1.4'}}],\n",
              "       'synonym_terms': [{'terms': ['precision'],\n",
              "         'term_norm': 'PRECISION',\n",
              "         'parser_name': 'STATO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "             'STATO']]}],\n",
              "         'mapping_types': ['http://www.w3.org/2000/01/rdf-schema#label'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 78,\n",
              "       'end': 87,\n",
              "       'match_norm': 'PRECISION'}]}]}],\n",
              " [{'idx': '4e035b78610e4801a8b3430d6756c23e',\n",
              "   'sections': [{'text': 'Computational drug repositioning is classified as disease-centric or target/gene-centric or drug-centric depending on the source of discovery.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'ff1c074b8c7a4d15805ef2ab4f043bb1',\n",
              "   'sections': [{'text': 'Computational drug repositioning relies on public biochemical databases such as DrugBank, ChEMBL, Cmap, PDB, OMIM, etc., to provide the appropriate information.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'Cmap',\n",
              "       'entity_class': 'gene',\n",
              "       'spans': [{'start': 98, 'end': 102}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'synonym_terms': [{'terms': ['CMAP'],\n",
              "         'term_norm': 'CMAP',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['ENSG00000077984',\n",
              "             'ENSEMBL']]},\n",
              "          {'ids_and_source': [['ENSG00000136279', 'ENSEMBL']]}],\n",
              "         'mapping_types': ['uniprot', 'NCBI_entrez'],\n",
              "         'aggregated_by': 'CUSTOM',\n",
              "         'exact_match': True}],\n",
              "       'start': 98,\n",
              "       'end': 102,\n",
              "       'match_norm': 'CMAP'}]}]}],\n",
              " [{'idx': '0abe07ed856c403c8b1e397e33be5cdd',\n",
              "   'sections': [{'text': 'In fact, to make the drug repositioning process, including the molecular docking and virtual screening steps, more convenient, database tools specifically developed for drug repurposing, such as EK-DRD, DREIMT, DrugSig, RepoDB, Promiscuous 2.0, etc., have been reported in the last few years.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '877029963d21489ebb5f8796603e8f63',\n",
              "   'sections': [{'text': 'In addition, it has been found in the literature that only 10% of the research results have been carried out in the drug-centric pathway, which holds great prospects for future development.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '8f20fbb5a6614384a0bf2a43778998d7',\n",
              "   'sections': [{'text': 'With the help of database tools, it is now possible to perform computational screening of even a staggering number of hundreds of millions of compounds.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '1f81e232b17c49fb8709470766db5eaa',\n",
              "   'sections': [{'text': 'Computer methods to carry out computational screening of even a staggering number of hundreds of millions of compounds include machine learning, network modeling, text mining, and semantic reasoning, among others.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '4466a9dbd7f4487294800202cb9c7ef0',\n",
              "   'sections': [{'text': 'The ultimate objective of repositioning is to transfer one or two of the most relevant results to clinical applications.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '4d5bf9ebf252429a8c98d737e9f58e70',\n",
              "   'sections': [{'text': 'Therefore, validation is quite important and requires consideration of multiple factors, such as price, toxicity levels, bioavailability, and differences between validated and computational models.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '2f98189ca16e44c0969eb0cf3d2bd075',\n",
              "   'sections': [{'text': 'Current validation methods include experimental validation, electronic health records to aid validation, cross-validation, gold standard dataset evaluation, literature citation validation, and expert consultation.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'ae1f33d77559408bb43f914ac3aa8b88',\n",
              "   'sections': [{'text': 'Today, drug repositioning is increasingly prominent in the development of drugs for a variety of neurological diseases, cancer, rare diseases, and infectious diseases.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'neurological diseases',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 97, 'end': 118}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'nervous system disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0005071',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'neurological disorder',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['SCTID:118940003',\n",
              "           'ICD10CM:G00-G99',\n",
              "           'MONDO:0005071',\n",
              "           'NCIT:C26835',\n",
              "           'DOID:863',\n",
              "           'MedDRA:10029202',\n",
              "           'Wikipedia:Nervous_system_disease',\n",
              "           'ICD9:349.9',\n",
              "           'UMLS:C0027765',\n",
              "           'ICD9:349.89',\n",
              "           'MESH:D009422',\n",
              "           'ICD10:G98'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}},\n",
              "        {'default_label': 'nervous system disorder',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0005071',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'nervous system disorder',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}}],\n",
              "       'synonym_terms': [{'terms': ['diseases, urologic'],\n",
              "         'term_norm': 'DISEASES UROLOGIC',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 72.04186801883571,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurological pain disorder'],\n",
              "         'term_norm': 'NEUROLOGICAL PAIN DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0700057',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 71.16152204100071,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['genetic neurological disorder'],\n",
              "         'term_norm': 'GENETIC NEUROLOGICAL DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0019117',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 72.54912286502817,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['urological diseases'],\n",
              "         'term_norm': 'UROLOGICAL DISEAS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 92.58016995916442,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['rare rheumatological disease'],\n",
              "         'term_norm': 'RARE RHEUMATOLOGICAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0015940',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.35203799758915,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['disease, urological'],\n",
              "         'term_norm': 'DISEASE UROLOGICAL',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 79.574818211301,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurological disorder'],\n",
              "         'term_norm': 'NEUROLOGICAL DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005071',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.31305081406461,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['urological disease'],\n",
              "         'term_norm': 'UROLOGICAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 90.45370804517628,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurologic disorder'],\n",
              "         'term_norm': 'NEUROLOGIC DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005071',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 73.09348025107859,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['urologic disease'],\n",
              "         'term_norm': 'UROLOGIC DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.94167994901062,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neuro-ophthalmological disease'],\n",
              "         'term_norm': 'NEURO OPHTHALMOLOGICAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0015368',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 75.1373104703844,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['hematological disease'],\n",
              "         'term_norm': 'HEMATOLOGICAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005570',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 74.42927774491841,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['urological disease'],\n",
              "         'term_norm': 'UROLOGICAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 90.79999040278757,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['urologic disease'],\n",
              "         'term_norm': 'UROLOGIC DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.08462924398245,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neuro-ophthalmological disease'],\n",
              "         'term_norm': 'NEURO OPHTHALMOLOGICAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0015368',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 74.78240290658995,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['otologic disease'],\n",
              "         'term_norm': 'OTOLOGIC DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002409',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.32193468638897,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['otological disease'],\n",
              "         'term_norm': 'OTOLOGICAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002409',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 78.39350750955929,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['hematological disease'],\n",
              "         'term_norm': 'HEMATOLOGICAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005570',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 74.22599581225239,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurological pain disease'],\n",
              "         'term_norm': 'NEUROLOGICAL PAIN DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0700057',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 85.96320469560168,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['disease, urological'],\n",
              "         'term_norm': 'DISEASE UROLOGICAL',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.16985167438666,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete rare neurologic disease'],\n",
              "         'term_norm': 'OBSOLETE RARE NEUROLOGIC DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020009',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 70.04398033340806,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurologic disease'],\n",
              "         'term_norm': 'NEUROLOGIC DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005071',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 89.76712486724547,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['diseases, urological'],\n",
              "         'term_norm': 'DISEASES UROLOGICAL',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 76.62160080293265,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['urological diseases'],\n",
              "         'term_norm': 'UROLOGICAL DISEAS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 92.87684068269148,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurological pain disorder'],\n",
              "         'term_norm': 'NEUROLOGICAL PAIN DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0700057',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 71.86108264743717,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurologic disorder'],\n",
              "         'term_norm': 'NEUROLOGIC DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005071',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 73.54994025250676,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurologic disease'],\n",
              "         'term_norm': 'NEUROLOGIC DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005071',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 90.19913332182632,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurological Lyme disease'],\n",
              "         'term_norm': 'NEUROLOGICAL LYME DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019632',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 85.16217024834458,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['disease, urologic'],\n",
              "         'term_norm': 'DISEASE UROLOGIC',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 75.33463867316338,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurological disease'],\n",
              "         'term_norm': 'NEUROLOGICAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005071',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 98.02019585874775,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurological Lyme disease'],\n",
              "         'term_norm': 'NEUROLOGICAL LYME DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0019632',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 85.27758869537912,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['disease, urologic'],\n",
              "         'term_norm': 'DISEASE UROLOGIC',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 75.01715711785783,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['urological disorder', 'urological disorders'],\n",
              "         'term_norm': 'UROLOGICAL DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 73.99286455406003,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurological disorder'],\n",
              "         'term_norm': 'NEUROLOGICAL DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005071',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.34333137838692,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['urological disorder', 'urological disorders'],\n",
              "         'term_norm': 'UROLOGICAL DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 72.62605388637148,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurological pain disease'],\n",
              "         'term_norm': 'NEUROLOGICAL PAIN DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0700057',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 85.91226455610823,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurological trauma'],\n",
              "         'term_norm': 'NEUROLOGICAL TRAUMA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0044745',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 71.16757347008048,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neurological disease'],\n",
              "         'term_norm': 'NEUROLOGICAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005071',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 97.97553199254561,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['diseases, urological'],\n",
              "         'term_norm': 'DISEASES UROLOGICAL',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 77.27314700745428,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['diseases, urologic'],\n",
              "         'term_norm': 'DISEASES UROLOGIC',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002118',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 72.41175249943112,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 97,\n",
              "       'end': 118,\n",
              "       'match_norm': 'NEUROLOGICAL DISEAS'},\n",
              "      {'match': 'cancer',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 120, 'end': 126}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'cancer',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'cancer',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'cancer',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0004992',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'organ system cancer',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['SCTID:363346000',\n",
              "           'GARD:0011960',\n",
              "           'DOID:0050687',\n",
              "           'DOID:0050686',\n",
              "           'ICDO:8000/3',\n",
              "           'UMLS:C0006826',\n",
              "           'ICD9:199.1',\n",
              "           'NCIT:C9305',\n",
              "           'ICD9:195.8',\n",
              "           'NIFSTD:birnlex_406',\n",
              "           'ICD9:199',\n",
              "           'ONCOTREE:MT',\n",
              "           'EFO:0000311',\n",
              "           'DOID:162'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['cancer'],\n",
              "         'term_norm': 'CANCER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['cancer'],\n",
              "         'term_norm': 'CANCER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004992',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 120,\n",
              "       'end': 126,\n",
              "       'match_norm': 'CANCER'},\n",
              "      {'match': 'rare diseases',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 128, 'end': 141}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'obsolete rare disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0021200',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'obsolete rare disease',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}}],\n",
              "       'synonym_terms': [{'terms': ['Parasitic Diseases'],\n",
              "         'term_norm': 'PARASITIC DISEAS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005135',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.51497158203401,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['urethral disease'],\n",
              "         'term_norm': 'URETHRAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004184',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.95224673998578,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Parasitic disease', 'parasitic disease'],\n",
              "         'term_norm': 'PARASITIC DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005135',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.71701797652352,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['lane disease'],\n",
              "         'term_norm': 'LANE DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0007570',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 68.95226441352267,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['rare epidermal disease'],\n",
              "         'term_norm': 'RARE EPIDERMAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019268',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.69015814690107,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': [\"Harada's disease\"],\n",
              "         'term_norm': 'HARADAS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018092',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.45698455647859,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['renal disease'],\n",
              "         'term_norm': 'RENAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005240',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.8584859866029,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Disease, Parasitic'],\n",
              "         'term_norm': 'DISEASE PARASITIC',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005135',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 68.37885695512442,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['urethra disease'],\n",
              "         'term_norm': 'URETHRA DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004184',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.19089192271174,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['central core disease'],\n",
              "         'term_norm': 'CENTRAL CORE DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0007294',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 68.7432621469899,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['breast disease or disorder'],\n",
              "         'term_norm': 'BREAST DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002657',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.85050081296741,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['breast disease'],\n",
              "         'term_norm': 'BREAST DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002657',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 70.38631893788049,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['breast diseases'],\n",
              "         'term_norm': 'BREAST DISEAS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002657',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 68.13840066162405,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['heart disease'],\n",
              "         'term_norm': 'HEART DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005267',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.95030685847388,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Parasitic disease, NOS'],\n",
              "         'term_norm': 'PARASITIC DISEASE NOS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005135',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.14666074035294,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['pancreas disease'],\n",
              "         'term_norm': 'PANCREAS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002356',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.67291116019737,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ear disease', 'Ear disease'],\n",
              "         'term_norm': 'EAR DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0021205', 'MONDO'],\n",
              "            ['MONDO_0002409', 'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 75.12360629672393,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['dream disease'],\n",
              "         'term_norm': 'DREAM DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0015263',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.84553480522275,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['oral disease'],\n",
              "         'term_norm': 'ORAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0006858',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 74.1831337422879,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['rare diseases'],\n",
              "         'term_norm': 'RARE DISEAS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0021200',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['Meniere disease'],\n",
              "         'term_norm': 'MENIERE DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0007972',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.98427515631094,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 128,\n",
              "       'end': 141,\n",
              "       'match_norm': 'RARE DISEAS'},\n",
              "      {'match': 'infectious diseases',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 147, 'end': 166}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0005550',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'infectious disease',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0005550',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'disorder due to infection',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['DOID:0050117',\n",
              "           'ICD9:136.8',\n",
              "           'NCIT:C26726',\n",
              "           'ICD10:Z22',\n",
              "           'ICD9:079.0',\n",
              "           'IDO:IDO_0000436',\n",
              "           'MONDO:0005550',\n",
              "           'MESH:D003141',\n",
              "           'ICD10CM:A00-B99',\n",
              "           'SCTID:40733004',\n",
              "           'IDO:0000436',\n",
              "           'ICD9:136.9',\n",
              "           'SNOMEDCT:40733004'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['parasitic infectious disease'],\n",
              "         'term_norm': 'PARASITIC INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005135',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.43634541962096,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['mumps infectious disease'],\n",
              "         'term_norm': 'MUMPS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000989',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.63394267736844,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bacterial infectious disease'],\n",
              "         'term_norm': 'BACTERIAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.83153921618216,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Cestode infectious disease'],\n",
              "         'term_norm': 'CESTODE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0042488',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.42278693462086,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['mumps infectious disease'],\n",
              "         'term_norm': 'MUMPS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000989',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.0057701752537,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Cestode infectious disease'],\n",
              "         'term_norm': 'CESTODE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0042488',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.9740688628782,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious discitis'],\n",
              "         'term_norm': 'INFECTIOUS DISCITI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_8000000',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.92785445314254,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['parasitic infectious disease'],\n",
              "         'term_norm': 'PARASITIC INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005135',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.90038027397682,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ascaridia infectious disease'],\n",
              "         'term_norm': 'ASCARIDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005655',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.76617120233642,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disorder'],\n",
              "         'term_norm': 'INFECTIOUS DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005550',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.06524734672398,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease or post-infectious disorder'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE OR POST INFECTIOUS DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100336',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 88.47689540240974,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['viral infectious disease'],\n",
              "         'term_norm': 'VIRAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005108',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.69773643585833,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious discitis'],\n",
              "         'term_norm': 'INFECTIOUS DISCITI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_8000000',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.75320997203414,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Tinea infectious disease'],\n",
              "         'term_norm': 'TINEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005982',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 90.11809849090459,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['renal infectious disease'],\n",
              "         'term_norm': 'RENAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004369',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 87.98317782414561,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease characteristic'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE CHARACTERISTIC',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0045034',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.53494384176263,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005550',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 97.8980330615247,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Tinea infectious disease'],\n",
              "         'term_norm': 'TINEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005982',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 90.40065650424556,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal diseases'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEAS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.77208644487203,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal disease'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.38314601943658,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease or post-infectious disorder'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE OR POST INFECTIOUS DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0100336',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 88.62412549225198,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005550',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 97.88443442192923,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal diseases'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEAS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.83516114327001,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['anaplasma infectious disease'],\n",
              "         'term_norm': 'ANAPLASMA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0025303',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 79.9013609696188,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Proteus infectious disease'],\n",
              "         'term_norm': 'PROTEUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0006929',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.2160614572425,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['intestinal infectious disease'],\n",
              "         'term_norm': 'INTESTINAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000916',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.03935155200335,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['viral infectious disease'],\n",
              "         'term_norm': 'VIRAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005108',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.61704755443748,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Nocardia infectious disease'],\n",
              "         'term_norm': 'NOCARDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0017776',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.17699173330988,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Bacteria infectious disease'],\n",
              "         'term_norm': 'BACTERIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.27710767478173,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Enoplea infectious disease'],\n",
              "         'term_norm': 'ENOPLEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005745',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 84.45132941319167,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['rare infectious disease'],\n",
              "         'term_norm': 'RARE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0019062',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 89.24213123785673,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Nocardia infectious disease'],\n",
              "         'term_norm': 'NOCARDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017776',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.55031533661773,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['intestinal infectious disease'],\n",
              "         'term_norm': 'INTESTINAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000916',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.5772134339965,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bacterial infectious disease'],\n",
              "         'term_norm': 'BACTERIAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.09674847554227,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Proteus infectious disease'],\n",
              "         'term_norm': 'PROTEUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0006929',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.1660226658925,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal disease'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.31053913349274,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Viruses infectious disease'],\n",
              "         'term_norm': 'VIRUSES INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005108',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.06634051359116,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Enoplea infectious disease'],\n",
              "         'term_norm': 'ENOPLEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005745',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 84.94763161888503,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Bacteria infectious disease'],\n",
              "         'term_norm': 'BACTERIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.96674380661096,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ascaridia infectious disease'],\n",
              "         'term_norm': 'ASCARIDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005655',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.27455442784945,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 147,\n",
              "       'end': 166,\n",
              "       'match_norm': 'INFECTIOUS DISEAS'}]}]}],\n",
              " [{'idx': 'ea7f23e447d3467589624cfd355e7947',\n",
              "   'sections': [{'text': 'An increasing number of pharmaceutical companies are also establishing relevant R&D programs or funding support.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '8bc61508894b408d9b640fae1bc727ba',\n",
              "   'sections': [{'text': 'To translate relevant research results efficiently and smoothly, national departments within the United Kingdom, the United States, and the Netherlands have launched initiatives or programs to build partnerships between pharmaceutical companies and academia and to further explore scientific and commercial opportunities.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'b679f972395d4e458d3d2d9e67c9190e',\n",
              "   'sections': [{'text': 'It is certain that drug repositioning currently presents several dilemmas, such as intellectual property challenges, data platforms, and analytical techniques that need to be improved, that financial support remains important for technology development and clinical trials, and that some scientists deny the practical utility of drug repositioning.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '4f9795a9f25549f081cc4b34c571e921',\n",
              "   'sections': [{'text': 'There have been systematic analyses of terminology in the drug repurposing literature, text mining of drug–disease combinations, and the progression of a particular drug, but no studies have yet provided a broad overview of publications on the topic of drug repurposing research.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '26f9e5c21517416fbb6cfd9a1b52cf77',\n",
              "   'sections': [{'text': 'When independent researchers or collectives including pharmaceutical companies, academia, and government departments seek drug repurposing partnership partners and seek to obtain a concise overview of comprehensive current research hotspots, the lack of relevant intelligence analysis to aid decision-making often makes the process convoluted and time-consuming.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '82ab09f0f9bd4539b612bc196d0aa7b8',\n",
              "   'sections': [{'text': 'The bibliometric approach can solve the aforementioned problems relatively fairly, but at present, scholars have only studied the bibliometrics of aspirin, a drug repurposing there has not been a panoramic study of drug repurposing, and therefore, this study is necessary.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'aspirin',\n",
              "       'entity_class': 'drug',\n",
              "       'spans': [{'start': 147, 'end': 154}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'ASPIRIN',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'idx': 'CHEMBL25',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Acetylsalicylic Acid',\n",
              "          'mapping_type': 'INN',\n",
              "          'data_origin': 'chembl_32_sqlite'}},\n",
              "        {'default_label': 'ASPIRIN',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'idx': 'CHEMBL25',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Acetyl salicylate',\n",
              "          'mapping_type': 'synonyms',\n",
              "          'crossReferences': {'DailyMed': ['aspirin'],\n",
              "           'PubChem': ['144203627',\n",
              "            '144209315',\n",
              "            '144210466',\n",
              "            '170465039',\n",
              "            '17389202',\n",
              "            '17390036',\n",
              "            '174007205',\n",
              "            '26747283',\n",
              "            '26752858',\n",
              "            '47193676',\n",
              "            '50105490',\n",
              "            '85230910',\n",
              "            '87798',\n",
              "            '90340586'],\n",
              "           'TG-GATEs': ['14'],\n",
              "           'Wikipedia': ['Aspirin'],\n",
              "           'drugbank': ['DB00945'],\n",
              "           'chEBI': ['15365']},\n",
              "          'data_origin': 'OPENTARGETS-MOLECULE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['ASPIRIN', 'Aspirin'],\n",
              "         'term_norm': 'ASPIRIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL25', 'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms', 'tradeNames'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['ASPIRIN', 'Aspirin'],\n",
              "         'term_norm': 'ASPIRIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL25', 'CHEMBL']]}],\n",
              "         'mapping_types': ['TRADE_NAME',\n",
              "          'JAN',\n",
              "          'USAN',\n",
              "          'FDA',\n",
              "          'BNF',\n",
              "          'pref_name',\n",
              "          'BAN',\n",
              "          'USP',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 147,\n",
              "       'end': 154,\n",
              "       'match_norm': 'ASPIRIN'}]}]}],\n",
              " [{'idx': '08bcf7a15f6a4fc0a2ef3ba694841f85',\n",
              "   'sections': [{'text': 'Bibliometrics is a useful tool combining multiple parameters for the quantitative analysis of scholarly publications and is currently used to assess research hotspots and trends in a wide range of disciplines and industries, such as management, sociology, economics, medicine, environmental engineering, and agronomy.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'range',\n",
              "       'entity_class': 'measurement',\n",
              "       'spans': [{'start': 188, 'end': 193}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'range',\n",
              "         'source': 'STATO',\n",
              "         'parser_name': 'STATO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/STATO_0000035',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'range',\n",
              "          'mapping_type': 'http://www.w3.org/2000/01/rdf-schema#label',\n",
              "          'data_origin': 'RC1.4'}}],\n",
              "       'synonym_terms': [{'terms': ['range'],\n",
              "         'term_norm': 'RANGE',\n",
              "         'parser_name': 'STATO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/STATO_0000035',\n",
              "             'STATO']]}],\n",
              "         'mapping_types': ['http://www.w3.org/2000/01/rdf-schema#label'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 188,\n",
              "       'end': 193,\n",
              "       'match_norm': 'RANGE'}]}]}],\n",
              " [{'idx': 'b697237f06c04e5293dd359486bcfe63',\n",
              "   'sections': [{'text': 'Therefore, this study uses bibliometric methods to quantitatively assess the following elements of drug repositioning publications 1 major contributors countries, research institutions, and authors 2 modes of collaboration intercountry collaborations 3 the most productive journals 4 the most frequently used disciplinary knowledge and 5 research trends, judged by analyzing author keywords, Essential Science Indicators ESI high citations, and hot research studies.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'efa2ae21ce83437da800d1e85f4c2a68',\n",
              "   'sections': [{'text': 'We use the Web of Science core database, an authoritative academic information data service platform produced by Clarivate version 2021 Clarivate.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '1d5f8d14f50f46c4bb171e76bfcccc37',\n",
              "   'sections': [{'text': \"Due to the Web of Science core database, an authoritative academic information data service platform produced by Clarivate version 2021 Clarivate's rigorous selection of journals, the Web of Science WOS Core Collection Database is now internationally recognized as a database for evaluating the scientific output or disciplinary development of scholars and institutions.\",\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'cc41c30cac3340d4932f882981d0b61f',\n",
              "   'sections': [{'text': 'Among the subdatabases, SCI-E mainly includes global journals in basic science research, covering basic pharmacological and medical research related to the theme of this study, drug repositioning, while SSCI includes social science, covering ethical, nursing, psychological, and other social science research related to this study.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '563a9a61c94c436489e33f128932f7b5',\n",
              "   'sections': [{'text': 'The data were obtained on 25 October 2021 through the WOS Core Collection Database Citation Indexes SCI-E and SSCI, using the formula drug repurposing OR drug repositioning OR drug rediscovery OR therapeutic switching OR drug redirecting OR drug rediscovery OR drug retasking search query, searching in the subject field and defining the document type as Article and Review.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '35c09e22eba045459161eab01d41585e',\n",
              "   'sections': [{'text': 'The publication time parameters were initially limited to publications related to drug repositioning published between 1990 and 2020.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '572dcd96805c4c42b12f5b21dec7c8a4',\n",
              "   'sections': [{'text': 'A total of 3009 documents were obtained, of which these 31 documents were published in two decades from 1990 to 2009.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '03ff92c0c6504e74a126db33c7fe6592',\n",
              "   'sections': [{'text': 'Of these 31 documents, except for one document that is still frequently used by scholars as a retrospective source for drug repurposing definitions in these years, the remaining 30 were cited by other authors during the period of 2010–2020 as shown in.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '8090c72e6eba4367a74580d7dafd0042',\n",
              "   'sections': [{'text': 'The overall level of interest in these studies shows a fluctuating downward trend as opposed to the rising citation fervor for drug repurposing, entering a stage of decline even under the less-demanding evaluation criterion of a 5-year maturation window.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'cac5c80ee5cb44d8bcef7050762ef098',\n",
              "   'sections': [{'text': \"As the literature ages, the literature's content becomes stale and obsolete in the perspective of intelligence sources, and the value of the metrics for judging current research trends is low.\",\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '9a01b9c2c1e84e118a6e9557debc5e68',\n",
              "   'sections': [{'text': 'Therefore, we further narrowed the study to 2978 publications published from 2010 to 2020.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '42f06d045fb44e0280467bbca9237d93',\n",
              "   'sections': [{'text': 'The complete records of all retrieved documents are downloaded and imported for processing into Derwent Data Analyzer DDA version V10, a data cleaning, multiperspective data mining, and visualization software from Clarivate that improves data analysis efficiency and reduces labor costs.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '1adb54ecf14e4e2cb85feb8f094138e5',\n",
              "   'sections': [{'text': 'After importing all records of WOS documents into DDA, all records of WOS documents are classified and measured according to a list of fields such as keyword, country/region, institution, author, research field, journal, etc.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '6c297a555bb74295972c81a3a5ab8ff8',\n",
              "   'sections': [{'text': 'For each item in a list of fields such as keyword, country/region, institution, author, research field, journal, etc, DDA has a built-in data cleaning tool for automatic data deduplication.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'a0d80be5eb5e4936802d074c748e7f8d',\n",
              "   'sections': [{'text': 'After the machine has removed duplicates, the items in a list of fields such as keyword, country/region, institution, author, research field, journal, etc still need to be manually verified for splitting or merging.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'ea5c6411a3994afca39596b814ba5872',\n",
              "   'sections': [{'text': 'It is to be noted that the regions of certain countries are presented separately, while certain countries are usually considered as a single country internationally.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '16fbb2278c7b49a19225d9fdd71c779f',\n",
              "   'sections': [{'text': 'Therefore, we need to perform merging, such as combining Wales, Scotland, England, and Northern Ireland into the United Kingdom column and combining Hong Kong and Macau regions into the China column.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '0a072f55a8be47aa8161ffabb0b1fd3a',\n",
              "   'sections': [{'text': 'To address the possible problem of different authors with the same name, the following two main verification steps were performed 1 returning to the WOS database to search for publications under that author’s name under the original search formula conditions and 2 for authors whose publications provide disputed information this also includes three cases first, two or more authors with the same name but not the same person second, two or more authors with the same abbreviated name, but the full names were found to be different after a search and third, similar signatures being different variants of the same author’s name, in addition to searching the ORCID-related information of the authors concerned for judgment, we checked different institutional websites as well as encyclopedias to look for changes in the study and work history of authors with the same or similar names from 2010 to 2020 to determine whether authors with the same or similar names were the same person.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '9ba76ad552ae4ff6ac886ca4b566da42',\n",
              "   'sections': [{'text': 'Based on the verification, we then split or merged the results.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '6bfaadd0c96f4a21b2feab8ff88fbe42',\n",
              "   'sections': [{'text': 'After data cleaning and matrix analysis by DDA, various types of cluster plots and bubble plots can be obtained to reveal the useful information behind the data.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'ea831efc0db446bf9c371925080cb72d',\n",
              "   'sections': [{'text': 'The bibliometric fields of publication volumes, countries, international collaborations, institutions, research areas, journals, authors, highly cited research studies, and author keywords were analyzed in this study.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '5da55e5a9b1c4c52ab2fa3d3b942fdad',\n",
              "   'sections': [{'text': 'It should be noted that because some studies were published online ahead of time and the study publication date was a year or two behind, for statistical purposes, the year of publication of such research studies was included as the year of online publication.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'date',\n",
              "       'entity_class': 'measurement',\n",
              "       'spans': [{'start': 107, 'end': 111}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'date',\n",
              "         'source': 'STATO',\n",
              "         'parser_name': 'STATO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/STATO_0000093',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'date',\n",
              "          'mapping_type': 'http://www.w3.org/2000/01/rdf-schema#label',\n",
              "          'data_origin': 'RC1.4'}}],\n",
              "       'synonym_terms': [{'terms': ['date'],\n",
              "         'term_norm': 'DATE',\n",
              "         'parser_name': 'STATO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/STATO_0000093',\n",
              "             'STATO']]}],\n",
              "         'mapping_types': ['http://www.w3.org/2000/01/rdf-schema#label'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 107,\n",
              "       'end': 111,\n",
              "       'match_norm': 'DATE'}]}]}],\n",
              " [{'idx': 'd5360608ebc847d0a679ac8fb6340994',\n",
              "   'sections': [{'text': 'e.g., a study shown in the reference as published in 2022 may have been published online in 2020. Of the 2978 papers obtained using the search criteria mentioned previously, the main ones were research studies and reviews.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '61ddbb993f8545c795c06202233b4522',\n",
              "   'sections': [{'text': 'Furthermore, individual publications are not only classified by journals in the single category of research studies or reviews but also belong to other categories.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '7d1da4aa4fa043a586694850506f27ba',\n",
              "   'sections': [{'text': 'individual publications were also related to proceeding studies, early access, book chapters, data studies, and retracted publications.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'cf713ba67d864c8885e60626b8fb5fb7',\n",
              "   'sections': [{'text': 'The vast majority of research studies and reviews were published in English, with the remainder in Japanese, Chinese, Czech, French, German, Hungarian, Korean, and Portuguese.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '418fd8f183814ea2946c0812586a387d',\n",
              "   'sections': [{'text': 'Ninety were from SSCI, and the remaining 2888 were from SCI-E. Further, 1996 were from Open Access.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '07e60fb8f0d34a98a873aaaf3465cd8b',\n",
              "   'sections': [{'text': 'An annual analysis of published research studies is shown in.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '9a89ba32a6d9478f9c743141a7142282',\n",
              "   'sections': [{'text': 'The number of publications for every year expanded from 17 in 2010 to 970 in 2020.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '93283374f9904ec9842d06b3819875c3',\n",
              "   'sections': [{'text': 'Annual publications on the subject have increased by more than 64 times.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '487f27b9fd2446438765e1a7f6a96952',\n",
              "   'sections': [{'text': 'The number of annual publications has been increasing at a relatively high rate since 2015, while in 2020, there was a spike in the number of publications and annual citations, probably due to the COVID-19 pandemic, a global public health emergency that prompted special attention from scientists.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'COVID-19',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 197, 'end': 205}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'COVID-19',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'COVID-19',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'COVID-19',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0100096',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'severe acute respiratory syndrome coronavirus 2 infectious disease',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['MESH:C000657245',\n",
              "           'ICD11:RA01.0',\n",
              "           'ICD11:RA01.2',\n",
              "           'SCTID:840539006',\n",
              "           'MESH:D000086382',\n",
              "           'ICD10CM:U07.1',\n",
              "           'DOID:0080600'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['COVID-19'],\n",
              "         'term_norm': 'COVID-19',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['COVID-19'],\n",
              "         'term_norm': 'COVID-19',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0100096',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 197,\n",
              "       'end': 205,\n",
              "       'match_norm': 'COVID-19'}]}]}],\n",
              " [{'idx': 'aac3d64f772241659634b6842c40a8be',\n",
              "   'sections': [{'text': 'Among the four countries with the highest number of publications the United States, China, the United Kingdom, and India, the United States has maintained a high growth volume since 2010, while China was the fastest in terms of average annual growth rate in the last three years.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '724a068e1009490c98b776b3f62701ba',\n",
              "   'sections': [{'text': 'In 2020, the number of publications in India surged and surpassed the production of the United Kingdom. With respect to the 2978 publications related to drug repositioning research, 89 countries contributed to the field of drug repositioning research.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '2223b0b51f554550b499538b5b9c0dcc',\n",
              "   'sections': [{'text': 'The number of publications and citations from the 20 most productive countries/regions is shown in. There are nine countries/regions in Europe, five in the Americas, five in Asia, and one in Oceania.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'd1df3d3cc8944793ad3053153c455590',\n",
              "   'sections': [{'text': 'the four countries with the highest number of publications the United States, China, the United Kingdom, and India are, in order, the United States, China, the United Kingdom, and India. the United States is the absolute leader in the field of drug repositioning research, with 918 research studies on drug repositioning published since 2010, which is already more than the next highest number of publications in China and the United Kingdom combined.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '13495ccb25294e729329bfa1db04f2f7',\n",
              "   'sections': [{'text': 'This is followed by India, Italy, Germany, South Korea, and Japan.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '09130f2bac2a4748a5e3a4172da572ea',\n",
              "   'sections': [{'text': 'Other productive countries include Brazil, France, Canada, Spain, Australia, the Netherlands, and Switzerland.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'cd2a9c163a8e472eb020143e710f11cd',\n",
              "   'sections': [{'text': 'In terms of publication impact, the United States led the Total citations TC rankings with 27355, twice as many as that of China.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'ccee5b6361224aadab1c21834dcaab1a',\n",
              "   'sections': [{'text': 'We also included the average citations per publication ACPP in the comparison, which is calculated by dividing the TC by the TP total papers value and is a relative number that may better reflect the individual or collective level of attention than the individual TC and TP values.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'ACPP',\n",
              "       'entity_class': 'gene',\n",
              "       'spans': [{'start': 55, 'end': 59}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'ACP3',\n",
              "         'source': 'ENSEMBL',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'idx': 'ENSG00000014257',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Prostatic acid phosphatase',\n",
              "          'mapping_type': 'uniprot',\n",
              "          'approvedName': 'acid phosphatase 3',\n",
              "          'annotation_score': 7,\n",
              "          'data_origin': 'OPENTARGETS-TARGET-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['ACPP'],\n",
              "         'term_norm': 'ACPP',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['ENSG00000014257',\n",
              "             'ENSEMBL']]}],\n",
              "         'mapping_types': ['uniprot', 'NCBI_entrez', 'HGNC'],\n",
              "         'aggregated_by': 'CUSTOM',\n",
              "         'exact_match': True}],\n",
              "       'start': 55,\n",
              "       'end': 59,\n",
              "       'match_norm': 'ACPP'}]}]}],\n",
              " [{'idx': '52dc51b778e545989b3a648661c7cc7c',\n",
              "   'sections': [{'text': 'Canada ranked first in the average citations per publication ACPP at 41.81, closely followed by the United Kingdom and Germany.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'ACPP',\n",
              "       'entity_class': 'gene',\n",
              "       'spans': [{'start': 61, 'end': 65}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'ACP3',\n",
              "         'source': 'ENSEMBL',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'idx': 'ENSG00000014257',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Prostatic acid phosphatase',\n",
              "          'mapping_type': 'uniprot',\n",
              "          'approvedName': 'acid phosphatase 3',\n",
              "          'annotation_score': 7,\n",
              "          'data_origin': 'OPENTARGETS-TARGET-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['ACPP'],\n",
              "         'term_norm': 'ACPP',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['ENSG00000014257',\n",
              "             'ENSEMBL']]}],\n",
              "         'mapping_types': ['uniprot', 'NCBI_entrez', 'HGNC'],\n",
              "         'aggregated_by': 'CUSTOM',\n",
              "         'exact_match': True}],\n",
              "       'start': 61,\n",
              "       'end': 65,\n",
              "       'match_norm': 'ACPP'}]}]}],\n",
              " [{'idx': '8c59cd694c8a4b9b9c444ad3acd7ea05',\n",
              "   'sections': [{'text': 'In addition, the h-index was originally proposed as a simple quantification that a researcher had at least h publications cited h times, reflecting to a certain extent the research results of a researcher.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '5a89f82434b2432dbf518d53c3792905',\n",
              "   'sections': [{'text': 'Later, the word researcher in the definition began to be replaced by collective words such as academic group or institution, journal, and country, becoming an indicator of the level of collective research to some extent.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '49a9a3db99d04b9599acd5507a7471ee',\n",
              "   'sections': [{'text': 'Undoubtedly, the h-index of the United States ranks first in this field with 74 times.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '2ad06030f87748a481a3568e98b54155',\n",
              "   'sections': [{'text': 'Taking all parameters into account, we find that publications in the United Kingdom, the United States, and Canada perform better on average.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '4d67d0ff5ed7410794249cfc37216c4d',\n",
              "   'sections': [{'text': 'While the number of publications in China and India is significant, China and India have received low levels of attention.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'a223c7f971114277ba53d9d2507ea939',\n",
              "   'sections': [{'text': 'It should be noted that DDA analysis software is nationally identified based on the location of each researcher’s institution address provided in the publication.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '2fe4e008b7a840039a2572db9814f3e7',\n",
              "   'sections': [{'text': 'If a publication is coauthored by institutions from more than two countries, a publication is defined as the result of an international collaboration.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '202db12377854cffa954431378a44f04',\n",
              "   'sections': [{'text': 'Whether there is some affiliation between the various institutions of the research group that produces the multicountry collaboration is not taken into account.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '2988023e30e243378e8a7ae761822292',\n",
              "   'sections': [{'text': 'As shown in, among the publications of the top 20 countries and regions, the proportion of international collaborations is quite high in European countries, especially in Sweden and Belgium.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '54dc7442572a41fbbc3b102b8995b24f',\n",
              "   'sections': [{'text': 'Asian and Latin American countries are generally underrepresented.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '6a9f2a20368546f5a5559ff3dd85bc50',\n",
              "   'sections': [{'text': 'In addition, the United Statesstill has over 50% of the studies published overall.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '0858cf6729494ae9b58db51be67caf89',\n",
              "   'sections': [{'text': 'depicts the academic collaboration network for the top 20 countries and regions in terms of productivity.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '0273648e5b424dee86b9e8e7d4934bee',\n",
              "   'sections': [{'text': 'Using DDA software, the academic collaboration network for the top 20 countries and regions was mapped using a co-occurrence matrix.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'b2eab9e22f6144528a67c7befd673f26',\n",
              "   'sections': [{'text': 'The size of the circles is proportional to the extent of each country’s contribution, the lines between the circles represent the collaboration between countries/regions, and the thickness of the connecting lines indicates the frequency of collaboration.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '5b24a428f0a0426a9daa11b046507338',\n",
              "   'sections': [{'text': 'The results show that the United States cooperates most frequently with China and the United Kingdom and has the closest cooperation with China and the United Kingdom.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'e5e793df0e85415cad05811ee4677d58',\n",
              "   'sections': [{'text': 'In addition, Mexico, Belgium, Argentina, Taiwan, Japan, and Korea have slightly sparser cooperation networks among the top 20 countries and regions, while the remaining countries have more extensive cooperation networks among the remaining countries.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'f7ee88aa4861441ebcdf8e0537af7756',\n",
              "   'sections': [{'text': 'A total of 3530 institutes were involved in drug repositioning research.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '540f1937f6904928997430150b10fa02',\n",
              "   'sections': [{'text': 'The top 20 productive institutes are shown in.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'e3e92e421c7f487a8d7972bebdc5ead7',\n",
              "   'sections': [{'text': 'Eight of The top 20 productive institutes are from the United States, again indicating the dominance of the United States in drug repositioning research three are from the United Kingdom two are from China and Brazil, France, Mexico, Canada, the Netherlands, Austria, and Sweden each have one.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'edcf212028884fd98164b2eca6cb7d3d',\n",
              "   'sections': [{'text': 'The Chinese Academy of Science ranked first in terms of the number of research studies, followed by Case Western Reserve University and the NIH.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'cc8c7222ed6d4b6989ab93f1038cdd48',\n",
              "   'sections': [{'text': 'The Icahn School of Medicine at Mt Sinai ranked first in ACPP at 77.32.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'ACPP',\n",
              "       'entity_class': 'gene',\n",
              "       'spans': [{'start': 57, 'end': 61}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'ACP3',\n",
              "         'source': 'ENSEMBL',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'idx': 'ENSG00000014257',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Prostatic acid phosphatase',\n",
              "          'mapping_type': 'uniprot',\n",
              "          'approvedName': 'acid phosphatase 3',\n",
              "          'annotation_score': 7,\n",
              "          'data_origin': 'OPENTARGETS-TARGET-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['ACPP'],\n",
              "         'term_norm': 'ACPP',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['ENSG00000014257',\n",
              "             'ENSEMBL']]}],\n",
              "         'mapping_types': ['uniprot', 'NCBI_entrez', 'HGNC'],\n",
              "         'aggregated_by': 'CUSTOM',\n",
              "         'exact_match': True}],\n",
              "       'start': 57,\n",
              "       'end': 61,\n",
              "       'match_norm': 'ACPP'}]}]}],\n",
              " [{'idx': '9c59f824c1c04e8e8a50aabbe55a7fbf',\n",
              "   'sections': [{'text': 'the NIH had the highest h-index value of 22.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '2ff31d6788c149948f442c70d961a556',\n",
              "   'sections': [{'text': 'The Icahn School of Medicine at Mt Sinai was the best performer in ACPP at 77.32, followed by the University of California, San Francisco and Johns Hopkins University, both of which are US-based research institutions.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'ACPP',\n",
              "       'entity_class': 'gene',\n",
              "       'spans': [{'start': 67, 'end': 71}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'ACP3',\n",
              "         'source': 'ENSEMBL',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'idx': 'ENSG00000014257',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Prostatic acid phosphatase',\n",
              "          'mapping_type': 'uniprot',\n",
              "          'approvedName': 'acid phosphatase 3',\n",
              "          'annotation_score': 7,\n",
              "          'data_origin': 'OPENTARGETS-TARGET-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['ACPP'],\n",
              "         'term_norm': 'ACPP',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['ENSG00000014257',\n",
              "             'ENSEMBL']]}],\n",
              "         'mapping_types': ['uniprot', 'NCBI_entrez', 'HGNC'],\n",
              "         'aggregated_by': 'CUSTOM',\n",
              "         'exact_match': True}],\n",
              "       'start': 67,\n",
              "       'end': 71,\n",
              "       'match_norm': 'ACPP'}]}]}],\n",
              " [{'idx': 'de58f01f99e442d08d6097dc2981c0b0',\n",
              "   'sections': [{'text': \"Compared with US research institutions, Chinese research institutions are at the back of the pack in terms of ACPP, and Chinese research institutions's impact needs to be improved.\",\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'ACPP',\n",
              "       'entity_class': 'gene',\n",
              "       'spans': [{'start': 110, 'end': 114}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'ACP3',\n",
              "         'source': 'ENSEMBL',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'idx': 'ENSG00000014257',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Prostatic acid phosphatase',\n",
              "          'mapping_type': 'uniprot',\n",
              "          'approvedName': 'acid phosphatase 3',\n",
              "          'annotation_score': 7,\n",
              "          'data_origin': 'OPENTARGETS-TARGET-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['ACPP'],\n",
              "         'term_norm': 'ACPP',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['ENSG00000014257',\n",
              "             'ENSEMBL']]}],\n",
              "         'mapping_types': ['uniprot', 'NCBI_entrez', 'HGNC'],\n",
              "         'aggregated_by': 'CUSTOM',\n",
              "         'exact_match': True}],\n",
              "       'start': 110,\n",
              "       'end': 114,\n",
              "       'match_norm': 'ACPP'}]}]}],\n",
              " [{'idx': '1bf04166892a4613b1ee11729fc90921',\n",
              "   'sections': [{'text': 'The collaboration network between the 15 largest institutions in 2010–2020 is shown in.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '1d33eef491df4158b1948a8c97d7243b',\n",
              "   'sections': [{'text': 'The collaboration network between the 15 largest institutions in 2010–2020 provides a more visual view of the collaboration with different institutions and thus helps in the search for more beneficial collaborations.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '6a35ac8f68474d9d8d2dabd00073f32a',\n",
              "   'sections': [{'text': \"Next to the name of each institution is each institution's total number of publications.\",\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '3da0d291b534422194097f7651125adc',\n",
              "   'sections': [{'text': 'At the intersections of the 15 largest institutions in 2010–2020, yellow dots indicate collaborations with the other top 10 research institutions.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'efe68a7e0fec447cb5c27f6b79e64cf1',\n",
              "   'sections': [{'text': 'It should be noted that the number of yellow dots can indicate the output of cooperation and the strength of interagency cooperation.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '201a381914ed406e8ab231689813f096',\n",
              "   'sections': [{'text': \"The nodal data with no crossover points represent the number of publications produced by the institute, either by the institute's independent work or in collaboration with research institutions outside the top 15.\",\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'e6b7749c8f1441b4bec7e05e9dd261dc',\n",
              "   'sections': [{'text': 'From, we see that the University of Cambridge established the largest collaborative network, followed by the large network established by four institutions, the NIH, the Icahn School of Medicine at Mt Sinai, Karolinska Institute, and King’s College London.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'c2762ce83a0c4ec6bbe930dd2b333f70',\n",
              "   'sections': [{'text': 'In terms of the number of copublications with established institutions, the Chinese Academy of Science and Shanghai Jiao Tong University copublished as many as six, followed by the University of Cambridge and King’s College London and the NIH and the Icahn School of Medicine at Mt Sinai.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '3e39e21845c24bf58232dedd3edb0ea2',\n",
              "   'sections': [{'text': 'Analyzing the aforementioned three pairs of institutional combinations, King’s College London has two publications that are the product of collaboration between the three research institutions.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '91be9b7f7fa34a51b49925b1e3e5d946',\n",
              "   'sections': [{'text': 'The University of Sao Paulo and Aix-Marseille University are relatively independent in this research area.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '76f8bf26e958413f952bdaf9aed921ea',\n",
              "   'sections': [{'text': 'Combining the ranking of multiple parameters, we found that the NIH and the Icahn School of Medicine at Mt Sinai in the United States are the most vocal institutions in terms of academic research result perspective on the topic.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'ranking',\n",
              "       'entity_class': 'measurement',\n",
              "       'spans': [{'start': 14, 'end': 21}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'ranking',\n",
              "         'source': 'STATO',\n",
              "         'parser_name': 'STATO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/STATO_0000118',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'ranking',\n",
              "          'mapping_type': 'http://www.w3.org/2000/01/rdf-schema#label',\n",
              "          'data_origin': 'RC1.4'}}],\n",
              "       'synonym_terms': [{'terms': ['ranking'],\n",
              "         'term_norm': 'RANKING',\n",
              "         'parser_name': 'STATO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/STATO_0000118',\n",
              "             'STATO']]}],\n",
              "         'mapping_types': ['http://www.w3.org/2000/01/rdf-schema#label'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 14,\n",
              "       'end': 21,\n",
              "       'match_norm': 'RANKING'}]}]}],\n",
              " [{'idx': '3abc3d256c1f466e9e82b5b0a4e695ba',\n",
              "   'sections': [{'text': 'An analysis of research areas gives a good indication of the scope of application of the topic, with an unrestrained number of 74 areas covered, with the top 20 areas of research in terms of publication volume shown in.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'ed566d04064643d3ac1c5f5f8fa3b2de',\n",
              "   'sections': [{'text': 'Briefly, pharmacology and pharmacy took first place with 962 articles, followed by biochemistry and molecular biology, and for ACPP, the top three were science and technology-other topics, mathematics, and cell biology.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'ACPP',\n",
              "       'entity_class': 'gene',\n",
              "       'spans': [{'start': 127, 'end': 131}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'ACP3',\n",
              "         'source': 'ENSEMBL',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'idx': 'ENSG00000014257',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Prostatic acid phosphatase',\n",
              "          'mapping_type': 'uniprot',\n",
              "          'approvedName': 'acid phosphatase 3',\n",
              "          'annotation_score': 7,\n",
              "          'data_origin': 'OPENTARGETS-TARGET-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['ACPP'],\n",
              "         'term_norm': 'ACPP',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['ENSG00000014257',\n",
              "             'ENSEMBL']]}],\n",
              "         'mapping_types': ['uniprot', 'NCBI_entrez', 'HGNC'],\n",
              "         'aggregated_by': 'CUSTOM',\n",
              "         'exact_match': True}],\n",
              "       'start': 127,\n",
              "       'end': 131,\n",
              "       'match_norm': 'ACPP'}]}]}],\n",
              " [{'idx': '7987734500304795bb8cc342b1a56635',\n",
              "   'sections': [{'text': 'shows a bubble graph of the top 20 drug repositioning research areas.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '6e33ed10c3e2444f880c295b3a4ced76',\n",
              "   'sections': [{'text': 'The bubble plot shows three dimensions of the data, namely, research area, year of publication, and the number of publications.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '3934dc788c304981bf4c19a5ae60d172',\n",
              "   'sections': [{'text': 'The horizontal change in bubble size illustrates the growing trend of research areas over time, the vertical size of the bubble shows the most popular research areas in that year, and the number in the bubble indicates the frequency of the topic in the research area and the number of publications in that year.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '6897b819e0a040ad84eadc88ad8dfab1',\n",
              "   'sections': [{'text': 'The number of research results in each relevant field is increasing year by year.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '0000ecc328734d2b94475b090e4d02d0',\n",
              "   'sections': [{'text': 'Biophysics increased from five in 2019 to 77 in 2020, a more than 15-fold increase, suggesting that drug repositioning may have made a breakthrough or become widely used in Biophysics.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'a938b0ac2e674f41a4a1af8289c5bc10',\n",
              "   'sections': [{'text': 'The field of virology was in a downturn from 2010 to 2014, with only one publication, with a gradual increase in relevant studies after 2015.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '9dc5d0c9d37247b98d3796ac02245e04',\n",
              "   'sections': [{'text': \"For scholars studying drug repositioning-related topics, knowing which journals publish relevant research is important in deciding which journals to read or submit scholars studying drug repositioning-related topics's research studies to.\",\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '25595f58761249fe9708ec0ea28c8066',\n",
              "   'sections': [{'text': 'A total of 2988 publications related to drug repositioning research were published in 845 journals during the period of 2010–2020.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '73a47d94d71f43f59d7a5246acb640c3',\n",
              "   'sections': [{'text': 'The top 25 journals in terms of a total number of studies published are shown in Sci Rep topped the list with 75 studies published, followed by PLoS One, J. Biomol.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'Sci',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 81, 'end': 84}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'severe combined immunodeficiency',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0015974',\n",
              "         'string_match_strategy': 'StrongMatchMappingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'severe combined immunodeficiency (disease)',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['DOID:627',\n",
              "           'MedDRA:10069566',\n",
              "           'UMLS:C0085110',\n",
              "           'MESH:D016511',\n",
              "           'GARD:0007628',\n",
              "           'NCIT:C3472',\n",
              "           'HP:0004430',\n",
              "           'SCTID:31323000',\n",
              "           'Orphanet:183660'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}},\n",
              "        {'default_label': 'severe combined immunodeficiency',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0015974',\n",
              "         'string_match_strategy': 'StrongMatchMappingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'severe combined immunodeficiency',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}}],\n",
              "       'synonym_terms': [{'terms': ['Fascitis'],\n",
              "         'term_norm': 'FASCITI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004830',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.28976526716883,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Sciatica'],\n",
              "         'term_norm': 'SCIATICA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0011868', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.19689295561493,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCT'],\n",
              "         'term_norm': 'SCT',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0010094',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.518071053775124,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['IOSCA'],\n",
              "         'term_norm': 'IOSCA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0010060',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.5754581578188,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCID, Athabascan type'],\n",
              "         'term_norm': 'SCID ATHABASCAN TYPE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0011225',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.61200101727606,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Fasciolosis'],\n",
              "         'term_norm': 'FASCIOLOSIS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004668',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.984506670625805,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['CIN'],\n",
              "         'term_norm': 'CIN',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0042491',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 49.53142186776849,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCh'],\n",
              "         'term_norm': 'SCH',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0016222',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.664821437064745,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCASI'],\n",
              "         'term_norm': 'SCASI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0011811',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.92176267752353,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Discitis', 'discitis'],\n",
              "         'term_norm': 'DISCITI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_8000000',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 71.91138861796856,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCAN'],\n",
              "         'term_norm': 'SCAN',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0020771',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.200166821656104,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCAP'],\n",
              "         'term_norm': 'SCAP',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019392',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 48.818437187118036,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCAN'],\n",
              "         'term_norm': 'SCAN',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020771',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.29018568563972,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Fascioliasis', 'fascioliasis'],\n",
              "         'term_norm': 'FASCIOLIASIS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004668',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 47.70003022672654,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ascites'],\n",
              "         'term_norm': 'ASCITE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0001541',\n",
              "             'HP']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 75.22412789996775,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCID'],\n",
              "         'term_norm': 'SCID',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0015974',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.63179067416206,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ascites'],\n",
              "         'term_norm': 'ASCITE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0001541', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 74.80020197799459,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCID, Athabascan type'],\n",
              "         'term_norm': 'SCID ATHABASCAN TYPE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0011225',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.48041084944658,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCONG'],\n",
              "         'term_norm': 'SCONG',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000839',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 49.31897538741232,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['PASC'],\n",
              "         'term_norm': 'PASC',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100233',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.945772333243006,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ischemic fasciitis'],\n",
              "         'term_norm': 'ISCHEMIC FASCIITI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004834',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.443727748902525,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCID'],\n",
              "         'term_norm': 'SCID',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0015974',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.80447584416409,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['fasciitis', 'Fasciitis'],\n",
              "         'term_norm': 'FASCIITI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004830', 'MONDO'],\n",
              "            ['HP_0100537', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 49.30480997294423,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCh'],\n",
              "         'term_norm': 'SCH',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0016222',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.561894339981556,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['XSCID'],\n",
              "         'term_norm': 'XSCID',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0010315',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 49.334712242173794,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCASI'],\n",
              "         'term_norm': 'SCASI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0011811',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.456607131585855,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCRA'],\n",
              "         'term_norm': 'SCRA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007176',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.264780225534025,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SSc'],\n",
              "         'term_norm': 'SSC',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005100',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.84779170818825,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCT'],\n",
              "         'term_norm': 'SCT',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0010094',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.61257679610394,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCRA'],\n",
              "         'term_norm': 'SCRA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0007176',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.26096813960721,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Scar', 'SCAR'],\n",
              "         'term_norm': 'SCAR',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005594',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.2221059797498,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SSc'],\n",
              "         'term_norm': 'SSC',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005100',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.266126797150996,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['mucinous ascites'],\n",
              "         'term_norm': 'MUCINOUS ASCITE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017048',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.68806043250005,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['sciatica'],\n",
              "         'term_norm': 'SCIATICA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0024333',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.59075618253408,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCAD'],\n",
              "         'term_norm': 'SCAD',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0008722',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.159480942792115,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Fascitis'],\n",
              "         'term_norm': 'FASCITI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004830',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.98403621691563,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCAD'],\n",
              "         'term_norm': 'SCAD',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0008722',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.37025886855131,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['IOSCA'],\n",
              "         'term_norm': 'IOSCA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0010060',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.725137665291754,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Scar', 'SCAR'],\n",
              "         'term_norm': 'SCAR',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005594',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.130556370981836,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Fasciolosis'],\n",
              "         'term_norm': 'FASCIOLOSIS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004668',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.581585180367284,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 81,\n",
              "       'end': 84,\n",
              "       'match_norm': 'SCI'}]}]}],\n",
              " [{'idx': 'f22a89365af54507a357e26a57ab3691',\n",
              "   'sections': [{'text': 'Struct.', 'name': 'na'}]}],\n",
              " [{'idx': '05f21f99a6074400ae908ba9ede5b91a',\n",
              "   'sections': [{'text': 'Dyn, Bioinformatics, and BMC bioinformatics 50 articles 1.78%.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '620d93e5873d444ea47ca81bd6c2b592',\n",
              "   'sections': [{'text': 'The rest of the journals had a share of less than 1.5%.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'c1d9ba22631a470d884ed3a654c7d3fc',\n",
              "   'sections': [{'text': 'In terms of total citations TC, at present, studies in Drug Discov. have been cited a total of 2119 times over the past 10 years, followed in rank by PLoS One and Bioinformatics. For ACPP, Drug Discov. still holds first place with a high frequency of 50.45 times, followed by PLoS Comput 33.14 times.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'ACPP',\n",
              "       'entity_class': 'gene',\n",
              "       'spans': [{'start': 183, 'end': 187}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'ACP3',\n",
              "         'source': 'ENSEMBL',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'idx': 'ENSG00000014257',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Prostatic acid phosphatase',\n",
              "          'mapping_type': 'uniprot',\n",
              "          'approvedName': 'acid phosphatase 3',\n",
              "          'annotation_score': 7,\n",
              "          'data_origin': 'OPENTARGETS-TARGET-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['ACPP'],\n",
              "         'term_norm': 'ACPP',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['ENSG00000014257',\n",
              "             'ENSEMBL']]}],\n",
              "         'mapping_types': ['uniprot', 'NCBI_entrez', 'HGNC'],\n",
              "         'aggregated_by': 'CUSTOM',\n",
              "         'exact_match': True}],\n",
              "       'start': 183,\n",
              "       'end': 187,\n",
              "       'match_norm': 'ACPP'}]}]}],\n",
              " [{'idx': '3d09e6d5ff4f4b24ab149ce60b557b9b',\n",
              "   'sections': [{'text': 'The impact factor IF of a journal is calculated by dividing the total number of citations of all publications in the journal in the previous two years by the number of publications.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '77f443b51ea147feb3974939fda963dd',\n",
              "   'sections': [{'text': 'Thus, shows that the ACPP of drug repurposing publications included in most journals is much higher than that of IF, which roughly verifies that the number of scholars interested in drug repurposing is relatively high.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'ACPP',\n",
              "       'entity_class': 'gene',\n",
              "       'spans': [{'start': 21, 'end': 25}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'ACP3',\n",
              "         'source': 'ENSEMBL',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'idx': 'ENSG00000014257',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Prostatic acid phosphatase',\n",
              "          'mapping_type': 'uniprot',\n",
              "          'approvedName': 'acid phosphatase 3',\n",
              "          'annotation_score': 7,\n",
              "          'data_origin': 'OPENTARGETS-TARGET-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['ACPP'],\n",
              "         'term_norm': 'ACPP',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['ENSG00000014257',\n",
              "             'ENSEMBL']]}],\n",
              "         'mapping_types': ['uniprot', 'NCBI_entrez', 'HGNC'],\n",
              "         'aggregated_by': 'CUSTOM',\n",
              "         'exact_match': True}],\n",
              "       'start': 21,\n",
              "       'end': 25,\n",
              "       'match_norm': 'ACPP'}]}]}],\n",
              " [{'idx': '2f180be6c1cc4dbda75fb3d36fea21c4',\n",
              "   'sections': [{'text': 'In terms of the impact factor IF of specific journals, except for Oncotarget and BMC Syst.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '6f1d6aeb07324791b1981cd08431c03f',\n",
              "   'sections': [{'text': 'Biol., which have not been included in SCI since 2018 and 2020, Brief. Bioinform. has the highest value of 11.622, followed by Drug Discov., Bioinformatics, Cancers, Eur. J. Med.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'SCI',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 39, 'end': 42}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'severe combined immunodeficiency',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0015974',\n",
              "         'string_match_strategy': 'StrongMatchMappingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'severe combined immunodeficiency (disease)',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['DOID:627',\n",
              "           'MedDRA:10069566',\n",
              "           'UMLS:C0085110',\n",
              "           'MESH:D016511',\n",
              "           'GARD:0007628',\n",
              "           'NCIT:C3472',\n",
              "           'HP:0004430',\n",
              "           'SCTID:31323000',\n",
              "           'Orphanet:183660'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}},\n",
              "        {'default_label': 'severe combined immunodeficiency',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0015974',\n",
              "         'string_match_strategy': 'StrongMatchMappingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'severe combined immunodeficiency',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}}],\n",
              "       'synonym_terms': [{'terms': ['Fascitis'],\n",
              "         'term_norm': 'FASCITI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004830',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.28976526716883,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Sciatica'],\n",
              "         'term_norm': 'SCIATICA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0011868', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.19689295561493,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCT'],\n",
              "         'term_norm': 'SCT',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0010094',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.518071053775124,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['IOSCA'],\n",
              "         'term_norm': 'IOSCA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0010060',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.5754581578188,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCID, Athabascan type'],\n",
              "         'term_norm': 'SCID ATHABASCAN TYPE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0011225',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.61200101727606,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Fasciolosis'],\n",
              "         'term_norm': 'FASCIOLOSIS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004668',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.984506670625805,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['CIN'],\n",
              "         'term_norm': 'CIN',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0042491',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 49.53142186776849,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCh'],\n",
              "         'term_norm': 'SCH',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0016222',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.664821437064745,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCASI'],\n",
              "         'term_norm': 'SCASI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0011811',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.92176267752353,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Discitis', 'discitis'],\n",
              "         'term_norm': 'DISCITI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_8000000',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 71.91138861796856,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCAN'],\n",
              "         'term_norm': 'SCAN',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0020771',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.200166821656104,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCAP'],\n",
              "         'term_norm': 'SCAP',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019392',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 48.818437187118036,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCAN'],\n",
              "         'term_norm': 'SCAN',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020771',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.29018568563972,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Fascioliasis', 'fascioliasis'],\n",
              "         'term_norm': 'FASCIOLIASIS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004668',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 47.70003022672654,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ascites'],\n",
              "         'term_norm': 'ASCITE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0001541',\n",
              "             'HP']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 75.22412789996775,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCID'],\n",
              "         'term_norm': 'SCID',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0015974',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.63179067416206,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ascites'],\n",
              "         'term_norm': 'ASCITE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0001541', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 74.80020197799459,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCID, Athabascan type'],\n",
              "         'term_norm': 'SCID ATHABASCAN TYPE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0011225',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.48041084944658,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCONG'],\n",
              "         'term_norm': 'SCONG',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000839',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 49.31897538741232,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['PASC'],\n",
              "         'term_norm': 'PASC',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100233',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.945772333243006,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ischemic fasciitis'],\n",
              "         'term_norm': 'ISCHEMIC FASCIITI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004834',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.443727748902525,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCID'],\n",
              "         'term_norm': 'SCID',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0015974',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.80447584416409,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['fasciitis', 'Fasciitis'],\n",
              "         'term_norm': 'FASCIITI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004830', 'MONDO'],\n",
              "            ['HP_0100537', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 49.30480997294423,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCh'],\n",
              "         'term_norm': 'SCH',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0016222',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.561894339981556,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['XSCID'],\n",
              "         'term_norm': 'XSCID',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0010315',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 49.334712242173794,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCASI'],\n",
              "         'term_norm': 'SCASI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0011811',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.456607131585855,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCRA'],\n",
              "         'term_norm': 'SCRA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007176',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.264780225534025,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SSc'],\n",
              "         'term_norm': 'SSC',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005100',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.84779170818825,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCT'],\n",
              "         'term_norm': 'SCT',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0010094',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.61257679610394,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCRA'],\n",
              "         'term_norm': 'SCRA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0007176',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.26096813960721,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Scar', 'SCAR'],\n",
              "         'term_norm': 'SCAR',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005594',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.2221059797498,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SSc'],\n",
              "         'term_norm': 'SSC',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005100',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.266126797150996,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['mucinous ascites'],\n",
              "         'term_norm': 'MUCINOUS ASCITE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017048',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.68806043250005,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['sciatica'],\n",
              "         'term_norm': 'SCIATICA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0024333',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.59075618253408,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCAD'],\n",
              "         'term_norm': 'SCAD',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0008722',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.159480942792115,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Fascitis'],\n",
              "         'term_norm': 'FASCITI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004830',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.98403621691563,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SCAD'],\n",
              "         'term_norm': 'SCAD',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0008722',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.37025886855131,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['IOSCA'],\n",
              "         'term_norm': 'IOSCA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0010060',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.725137665291754,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Scar', 'SCAR'],\n",
              "         'term_norm': 'SCAR',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005594',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.130556370981836,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Fasciolosis'],\n",
              "         'term_norm': 'FASCIOLOSIS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004668',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.581585180367284,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 39,\n",
              "       'end': 42,\n",
              "       'match_norm': 'SCI'},\n",
              "      {'match': 'Cancers',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 157, 'end': 164}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'cancer',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'cancer',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'cancer',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0004992',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'organ system cancer',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['SCTID:363346000',\n",
              "           'GARD:0011960',\n",
              "           'DOID:0050687',\n",
              "           'DOID:0050686',\n",
              "           'ICDO:8000/3',\n",
              "           'UMLS:C0006826',\n",
              "           'ICD9:199.1',\n",
              "           'NCIT:C9305',\n",
              "           'ICD9:195.8',\n",
              "           'NIFSTD:birnlex_406',\n",
              "           'ICD9:199',\n",
              "           'ONCOTREE:MT',\n",
              "           'EFO:0000311',\n",
              "           'DOID:162'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['cancer'],\n",
              "         'term_norm': 'CANCER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['cancer'],\n",
              "         'term_norm': 'CANCER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004992',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 157,\n",
              "       'end': 164,\n",
              "       'match_norm': 'CANCER'}]}]}],\n",
              " [{'idx': 'df99d8c9e9f748419d296cdbae23e53e',\n",
              "   'sections': [{'text': 'Chem, and Expert.', 'name': 'na'}]}],\n",
              " [{'idx': 'a67be2df47e142deb7c05e53e2417dfa',\n",
              "   'sections': [{'text': 'Opin. Drug Discov.', 'name': 'na'}]}],\n",
              " [{'idx': 'c831371eae554e499bd214fd4c0fecc2',\n",
              "   'sections': [{'text': 'The bubble chart shows that J. Biomol.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'c18ebca7086d4799bf24538b8b86aa0f',\n",
              "   'sections': [{'text': 'Struct.', 'name': 'na'}]}],\n",
              " [{'idx': '3a71dc6a87da4d5bbb1d4f757f3b44a8',\n",
              "   'sections': [{'text': 'Dyn. featured 64 publications in 2020, compared to a combined total of only four publications in the past 10 years the Oncotarget journal inclusion in this category peaked in 2016–2017.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'c73eeab6125d4f42bc7819654d9cc3e7',\n",
              "   'sections': [{'text': 'For scholars interested in the topic of drug repositioning, it is useful to know how other researchers are working on the topic of drug repositioning to facilitate communication and collaboration between scholars.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '3f170cf5d4414082a22fdb09c37c597b',\n",
              "   'sections': [{'text': 'A total of 15620 authors contributed to studies within our measurement consideration, and shows the top 20 prolific authors by a number of publications.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '897b2ed7d75942d9beb1a3348691e0f5',\n",
              "   'sections': [{'text': 'Of the top 20 prolific authors, seven were from the United States, three were from Argentina, and two were from Germany, indicating a relatively high concentration of drug repositioning research in certain countries.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '97f53a7a58984665a52dcb8b9a49c27f',\n",
              "   'sections': [{'text': 'In addition, the NIH the United States, Case Western Reserve University the United States, Tech University Dresden Germany, and the National University of La Plata Argentina each have two of the top 20 prolific authors.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'd3860bbce0da410db1dd4dcf895064dc',\n",
              "   'sections': [{'text': 'Cheng, FX leads the list with 25 research studies, followed by Talevi, A and Mucke, HAM.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '92efd0a6178045c6a0f0cfddbf17095d',\n",
              "   'sections': [{'text': 'For the list of corresponding authors, the top three remain, in order, Mucke, HAM, Cheng, FX, and Talevi, A In terms of ACPP ranking, Butte, AJ was ranked first with 154.33 points, followed by Cheng, FX, Tang, Y, and Dudley, JT.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'ACPP',\n",
              "       'entity_class': 'gene',\n",
              "       'spans': [{'start': 120, 'end': 124}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'ACP3',\n",
              "         'source': 'ENSEMBL',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'idx': 'ENSG00000014257',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Prostatic acid phosphatase',\n",
              "          'mapping_type': 'uniprot',\n",
              "          'approvedName': 'acid phosphatase 3',\n",
              "          'annotation_score': 7,\n",
              "          'data_origin': 'OPENTARGETS-TARGET-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['ACPP'],\n",
              "         'term_norm': 'ACPP',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['ENSG00000014257',\n",
              "             'ENSEMBL']]}],\n",
              "         'mapping_types': ['uniprot', 'NCBI_entrez', 'HGNC'],\n",
              "         'aggregated_by': 'CUSTOM',\n",
              "         'exact_match': True}],\n",
              "       'start': 120,\n",
              "       'end': 124,\n",
              "       'match_norm': 'ACPP'},\n",
              "      {'match': 'ranking',\n",
              "       'entity_class': 'measurement',\n",
              "       'spans': [{'start': 125, 'end': 132}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'ranking',\n",
              "         'source': 'STATO',\n",
              "         'parser_name': 'STATO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/STATO_0000118',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'ranking',\n",
              "          'mapping_type': 'http://www.w3.org/2000/01/rdf-schema#label',\n",
              "          'data_origin': 'RC1.4'}}],\n",
              "       'synonym_terms': [{'terms': ['ranking'],\n",
              "         'term_norm': 'RANKING',\n",
              "         'parser_name': 'STATO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/STATO_0000118',\n",
              "             'STATO']]}],\n",
              "         'mapping_types': ['http://www.w3.org/2000/01/rdf-schema#label'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 125,\n",
              "       'end': 132,\n",
              "       'match_norm': 'RANKING'}]}]}],\n",
              " [{'idx': '2ea0ed61fa59474f8d57cf0bb28317b4',\n",
              "   'sections': [{'text': 'Cheng, FX still has the highest h-index at 21, followed by Zheng, W, Talevi, A, Xu, R, and Schroeder, M. The h-index has two drawbacks when researchers of the same topic are compared with each other.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '652a82b4209b4cffb64436bf0c8a4c59',\n",
              "   'sections': [{'text': \"One is that the scholar’s's h-index does not decrease over time but only grows or stays the same, and it is not possible to obtain information on whether the scholar’s is still in an academic career.\",\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'e8562e7420fb4c54ad35473e8f02c8e9',\n",
              "   'sections': [{'text': 'In this study, we narrow this study to the most recent publications from 2010 to 2020, taking into account the timeliness of the h-index response information.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'f5d4ffb72f504174991eeb33cd20bbfe',\n",
              "   'sections': [{'text': \"Second, older scholars usually enter academia earlier and have an advantage in older scholars's h-indexes in comparison with those of younger scholars.\",\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '86ff74d2d54f46bfac1c9d630094173f',\n",
              "   'sections': [{'text': 'Therefore, this phenomenon must be targeted for analysis or illustration.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'edf581c9b08546a6bceca0f8dfab6bcc',\n",
              "   'sections': [{'text': \"Thus, by combining the authors’ educational experiences and employment relationship changes that were recorded in the WOS database and ORCID business cards, we inferred that more than half of the scholars in the top 20 in terms of the number of publications received more than half of the scholars in the top 20 in terms of the number of publications's Ph.\",\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'dabdfe14b6c84d57b5f6fddb0b8e0b2a',\n",
              "   'sections': [{'text': 'D. before 2008, and two scholars, Mucke, HAM and Zheng, Wei, are older.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '37ac362f94a944b6b47a5dbe98293a3b',\n",
              "   'sections': [{'text': \"In contrast, Cheng, FX, a scholar from Case Western Reserve Univ, completed Cheng, FX, a scholar from Case Western Reserve Univ's Ph.\",\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '453b933add9f46e0866f0ef9bc599501',\n",
              "   'sections': [{'text': \"D. without a gap in 2013 and may have a longer academic career in the future therefore, Cheng, FX, a scholar from Case Western Reserve Univ's h-index in the field of drug repositioning is likely to grow more in the future and Cheng, FX, a scholar from Case Western Reserve Univ is likely to have more academic influence.\",\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '898e406870964b7a961c58624fe6cc7c',\n",
              "   'sections': [{'text': 'To reveal the focus of drug repositioning research and research trends, the author keywords and the highly cited and hot research topics of the ESI for each of the 2978 publications were analyzed, which were also derived from the core database of the WOS database SCI-E/SSCI.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '253388fa2dc84ec1a87f1065e4512a6d',\n",
              "   'sections': [{'text': 'Highly cited studies were defined as studies in the top 1% of the citations for all studies in the same the ESI discipline within the 10-year range of inclusion of the ESI inclusion.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'range',\n",
              "       'entity_class': 'measurement',\n",
              "       'spans': [{'start': 142, 'end': 147}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'range',\n",
              "         'source': 'STATO',\n",
              "         'parser_name': 'STATO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/STATO_0000035',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'range',\n",
              "          'mapping_type': 'http://www.w3.org/2000/01/rdf-schema#label',\n",
              "          'data_origin': 'RC1.4'}}],\n",
              "       'synonym_terms': [{'terms': ['range'],\n",
              "         'term_norm': 'RANGE',\n",
              "         'parser_name': 'STATO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/STATO_0000035',\n",
              "             'STATO']]}],\n",
              "         'mapping_types': ['http://www.w3.org/2000/01/rdf-schema#label'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 142,\n",
              "       'end': 147,\n",
              "       'match_norm': 'RANGE'}]}]}],\n",
              " [{'idx': 'c723b09c74bd4bddb3bfad1f8f254088',\n",
              "   'sections': [{'text': 'A hot research topic of the ESI refers to a study published in two years with a citation frequency within one of the corresponding disciplines in the world in the last two months.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'f697cbf6cae54133a22ee7881d3bc119',\n",
              "   'sections': [{'text': 'Author keywords tend to provide more information and have thus become a widespread focus.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '5af8c8ad1f8b40c086be3cd12f0484bb',\n",
              "   'sections': [{'text': 'The data of 6083 author keywords in the search results were merged to make keywords with the same meaning represented by a single unified word.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '421915cb108149c1904cc951e94bc3eb',\n",
              "   'sections': [{'text': 'In the end, 5616 author keywords were obtained.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '8f2fc4d3ec724d529a1a3a0ffadf7eba',\n",
              "   'sections': [{'text': 'It should be specified that some publications without author keywords were excluded from the statistical analysis.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '67c2327de3004f0b9aff66bba3f562af',\n",
              "   'sections': [{'text': 'Of 5616 author keywords, 4296 were used only once, representing 76.50% of 5616 author keywords.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'defa23343a5c457a9152dd562ecd57c1',\n",
              "   'sections': [{'text': 'A total of 1216 appeared 2–10 times, 79 appeared 10–20 times, 37 appeared 21–50 times, and the remaining eight were used between 51 and 1500 times.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '206954b2ed864006b20508807cf09687',\n",
              "   'sections': [{'text': 'All keywords cumulatively appear a total of 12400 times, while the top 30 most used author keywords appear 2967 times alone, or approximately 23.93%, as shown in.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '1f0efc4db7d845d5a13679a106709ef6',\n",
              "   'sections': [{'text': 'The comparison of keywords in recent years allows for tracking the frontiers of research and predicting hotspots and trends in drug repositioning research.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '21205571dbf64e549b2a091bd78f6269',\n",
              "   'sections': [{'text': 'The bubble plots show the three dimensions of the data, namely, the year of publication, the author’s keywords, and the number of corresponding publications.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'bce315159cf2434c882668a57af31295',\n",
              "   'sections': [{'text': 'The horizontal change in the size of the bubble illustrates the increasing trend of author keywords over time, the vertical size of the bubble shows the most popular keywords in the year of publication, and the numbers in the bubble indicate the frequency of author keywords and the number of publications.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'e8adbb3eb77941f9bd063708854ffb17',\n",
              "   'sections': [{'text': 'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'COVID-19',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 59, 'end': 67}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'COVID-19',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'COVID-19',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'COVID-19',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0100096',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'severe acute respiratory syndrome coronavirus 2 infectious disease',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['MESH:C000657245',\n",
              "           'ICD11:RA01.0',\n",
              "           'ICD11:RA01.2',\n",
              "           'SCTID:840539006',\n",
              "           'MESH:D000086382',\n",
              "           'ICD10CM:U07.1',\n",
              "           'DOID:0080600'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['COVID-19'],\n",
              "         'term_norm': 'COVID-19',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['COVID-19'],\n",
              "         'term_norm': 'COVID-19',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0100096',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 59,\n",
              "       'end': 67,\n",
              "       'match_norm': 'COVID-19'},\n",
              "      {'match': 'SARS',\n",
              "       'entity_class': 'species',\n",
              "       'spans': [{'start': 68, 'end': 72}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'start': 68,\n",
              "       'end': 72,\n",
              "       'match_norm': 'SARS'},\n",
              "      {'match': 'Coronavirus',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 79, 'end': 90}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'synonym_terms': [{'terms': ['disease due to arenavirus'],\n",
              "         'term_norm': 'DISEASE DUE TO ARENAVIRU',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005650',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.21816403679184,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus fever'],\n",
              "         'term_norm': 'HANTAVIRUS FEVER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018081',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.24007749621667,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS-associated coronavirus'],\n",
              "         'term_norm': 'SARS ASSOCIATED CORONAVIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.40073219419624,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus caused disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS CAUSED DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.05404216628945,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Orthocoronavirinae infectious disease'],\n",
              "         'term_norm': 'ORTHOCORONAVIRINAE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020753',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.73008736825084,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete human coronavirus sensitivity'],\n",
              "         'term_norm': 'OBSOLETE HUMAN CORONAVIRUS SENSITIVITY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007386',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.98037005037208,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus infection'],\n",
              "         'term_norm': 'HANTAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.89806976149852,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS ASSOC CORONAVIRUS'],\n",
              "         'term_norm': 'SARS ASSOC CORONAVIRUS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 70.82195539633169,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['acute respiratory coronavirus infection'],\n",
              "         'term_norm': 'ACUTE RESPIRATORY CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.35122632348357,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['hantavirus pulmonary syndrome',\n",
              "          'Hantavirus Pulmonary Syndrome'],\n",
              "         'term_norm': 'HANTAVIRUS PULMONARY SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0017879',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.656633106473485,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.80622088130653,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SAVI'],\n",
              "         'term_norm': 'SAVI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0014405',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.77299471742283,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus infectious disease'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020753',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.32938017054028,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Avulavirus Infections'],\n",
              "         'term_norm': 'AVULAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005660',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.9579067880933,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Alphavirus Infections'],\n",
              "         'term_norm': 'ALPHAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005643',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.877759941927664,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['acute respiratory coronavirus infection'],\n",
              "         'term_norm': 'ACUTE RESPIRATORY CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.40888572843222,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus disease'],\n",
              "         'term_norm': 'CORONAVIRUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005719',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 78.89441059291723,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Henipavirus Infections'],\n",
              "         'term_norm': 'HENIPAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005785',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.64200609630736,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Coronavirus Infections'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005719',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 75.09202138867366,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rubulavirus Infections'],\n",
              "         'term_norm': 'RUBULAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000989',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.19291260849566,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus disease or disorder'],\n",
              "         'term_norm': 'ROTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.064627063389445,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus infectious disease'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0020753', 'MONDO'],\n",
              "            ['MONDO_0005719', 'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 59.740181182141896,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus infectious disease'],\n",
              "         'term_norm': 'SARS CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.54195740206633,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronaviral enteritis of turkeys'],\n",
              "         'term_norm': 'CORONAVIRAL ENTERITIS OF TURKEY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0025404',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.953543592120376,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirosis'],\n",
              "         'term_norm': 'HANTAVIROSIS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018081',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.88965991944546,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus infection', 'Hantavirus Infections'],\n",
              "         'term_norm': 'HANTAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.11863300641681,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus disease or disorder'],\n",
              "         'term_norm': 'ROTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.45941089424701,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['disease due to arenavirus'],\n",
              "         'term_norm': 'DISEASE DUE TO ARENAVIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005650',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.394432281303516,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.98333823779242,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Coronaviridae Infections'],\n",
              "         'term_norm': 'CORONAVIRIDAE INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005718',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.9895515426647,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Polyomavirus nephropathy'],\n",
              "         'term_norm': 'POLYOMAVIRUS NEPHROPATHY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0022529',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.977831929892595,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SAVI'],\n",
              "         'term_norm': 'SAVI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0014405',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.00782837684112,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus infectious disease'],\n",
              "         'term_norm': 'SARS CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.18862243948419,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus disease or disorder'],\n",
              "         'term_norm': 'HANTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.75588308449377,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['rotavirus infection', 'Rotavirus infection'],\n",
              "         'term_norm': 'ROTAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.65598298862336,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus infection'],\n",
              "         'term_norm': 'ROTAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.30599810912499,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['hantavirus pulmonary syndrome'],\n",
              "         'term_norm': 'HANTAVIRUS PULMONARY SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017879',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.540016212736155,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus hemorrhagic fever with renal syndrome, Dobrava-Belgrade virus type'],\n",
              "         'term_norm': 'HANTAVIRUS HEMORRHAGIC FEVER WITH RENAL SYNDROME DOBRAVA BELGRADE VIRUS TYPE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000346',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.44716032814946,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 79,\n",
              "       'end': 90,\n",
              "       'match_norm': 'CORONAVIRU'},\n",
              "      {'match': 'Cancer',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 92, 'end': 98}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'cancer',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'cancer',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'cancer',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0004992',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'organ system cancer',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['SCTID:363346000',\n",
              "           'GARD:0011960',\n",
              "           'DOID:0050687',\n",
              "           'DOID:0050686',\n",
              "           'ICDO:8000/3',\n",
              "           'UMLS:C0006826',\n",
              "           'ICD9:199.1',\n",
              "           'NCIT:C9305',\n",
              "           'ICD9:195.8',\n",
              "           'NIFSTD:birnlex_406',\n",
              "           'ICD9:199',\n",
              "           'ONCOTREE:MT',\n",
              "           'EFO:0000311',\n",
              "           'DOID:162'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['cancer'],\n",
              "         'term_norm': 'CANCER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['cancer'],\n",
              "         'term_norm': 'CANCER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004992',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 92,\n",
              "       'end': 98,\n",
              "       'match_norm': 'CANCER'},\n",
              "      {'match': 'Alzheimer’s disease',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 100, 'end': 119}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'Alzheimer disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0004975',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Alzheimer disease',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'Alzheimer disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0004975',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Alzheimers disease',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['MESH:D000544',\n",
              "           'ICD10CM:G30',\n",
              "           'HP:0002511',\n",
              "           'DOID:10652',\n",
              "           'ICD9:331.0',\n",
              "           'GARD:0000632',\n",
              "           'EFO:0000249',\n",
              "           'ICD9:290.1',\n",
              "           'UMLS:C0002395',\n",
              "           'KEGG:05010',\n",
              "           'SCTID:142811000119104',\n",
              "           'NIFSTD:birnlex_2092',\n",
              "           'Orphanet:238616',\n",
              "           'NCIT:C2866'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['Alzheimers disease',\n",
              "          \"Alzheimer's disease\"],\n",
              "         'term_norm': 'ALZHEIMERS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004975',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['Alzheimers disease', \"Alzheimer's disease\"],\n",
              "         'term_norm': 'ALZHEIMERS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004975',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 100,\n",
              "       'end': 119,\n",
              "       'match_norm': 'ALZHEIMERS DISEASE'},\n",
              "      {'match': 'Breast cancer',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 121, 'end': 134}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'breast cancer',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0007254',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'breast cancer',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'breast cancer',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0007254',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'mammary cancer',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['DOID:1612',\n",
              "           'SCTID:254837009',\n",
              "           'OMIM:605365',\n",
              "           'NCIT:C9335',\n",
              "           'ICD9:174.8',\n",
              "           'ICD10CM:C50',\n",
              "           'OMIM:600048'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['breast cancer'],\n",
              "         'term_norm': 'BREAST CANCER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007254',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['breast cancer'],\n",
              "         'term_norm': 'BREAST CANCER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0007254',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 121,\n",
              "       'end': 134,\n",
              "       'match_norm': 'BREAST CANCER'},\n",
              "      {'match': 'Chagas disease',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 140, 'end': 154}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'Chagas disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0001444',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'infection by trypanosoma cruzi',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['ICD10CM:B57',\n",
              "           'KEGG:05142',\n",
              "           'Orphanet:3386',\n",
              "           'UMLS:C0348782',\n",
              "           'NCIT:C84629',\n",
              "           'DOID:12140',\n",
              "           'MESH:D014355',\n",
              "           'EFO:0008559',\n",
              "           'UMLS:C0153125',\n",
              "           'UMLS:C0348781',\n",
              "           'UMLS:C0041234',\n",
              "           'SCTID:77506005',\n",
              "           'MedDRA:10001935',\n",
              "           'ICD9:086.2'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}},\n",
              "        {'default_label': 'Chagas disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0001444',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Chagas disease',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}}],\n",
              "       'synonym_terms': [{'terms': [\"Chagas' disease\", 'Chagas disease'],\n",
              "         'term_norm': 'CHAGAS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0001444',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': [\"Chagas' disease\", 'Chagas disease'],\n",
              "         'term_norm': 'CHAGAS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0001444',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 140,\n",
              "       'end': 154,\n",
              "       'match_norm': 'CHAGAS DISEASE'}]}]}],\n",
              " [{'idx': '7814d19035cf414fa7a2268c1ed0376d',\n",
              "   'sections': [{'text': 'Drug names appear four times, Antiviral drugs, Metformin, Statins, and Antibiotics, which reveal the diseases and applications to which drugs were often repositioned during recent years.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'Metformin',\n",
              "       'entity_class': 'drug',\n",
              "       'spans': [{'start': 47, 'end': 56}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'METFORMIN',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'idx': 'CHEMBL1431',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'LA-6023',\n",
              "          'mapping_type': 'synonyms',\n",
              "          'crossReferences': {'DailyMed': ['metformin%20hydrochloride'],\n",
              "           'PubChem': ['11112469', '137275802', '144212687', '174006543'],\n",
              "           'TG-GATEs': ['53'],\n",
              "           'Wikipedia': ['Metformin'],\n",
              "           'drugbank': ['DB00331'],\n",
              "           'chEBI': ['6801']},\n",
              "          'data_origin': 'OPENTARGETS-MOLECULE-23.02'}},\n",
              "        {'default_label': 'METFORMIN',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'idx': 'CHEMBL1431',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Metformin',\n",
              "          'mapping_type': 'FDA',\n",
              "          'data_origin': 'chembl_32_sqlite'}}],\n",
              "       'synonym_terms': [{'terms': ['METFORMIN', 'Metformin'],\n",
              "         'term_norm': 'METFORMIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL1431',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['METFORMIN', 'Metformin'],\n",
              "         'term_norm': 'METFORMIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL1431',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['ATC',\n",
              "          'USAN',\n",
              "          'FDA',\n",
              "          'INN',\n",
              "          'pref_name',\n",
              "          'BAN',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 47,\n",
              "       'end': 56,\n",
              "       'match_norm': 'METFORMIN'},\n",
              "      {'match': 'Statins',\n",
              "       'entity_class': 'drug',\n",
              "       'spans': [{'start': 58, 'end': 65}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'synonym_terms': [{'terms': ['ZINOSTATIN', 'Zinostatin'],\n",
              "         'term_norm': 'ZINOSTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL3989835',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['pref_name', 'USAN', 'INN'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 72.93162030663738,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Entinostat', 'ENTINOSTAT'],\n",
              "         'term_norm': 'ENTINOSTAT',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL27759',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['ATC', 'USAN', 'INN', 'pref_name', 'OTHER'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 70.90131689962084,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['BATIMASTAT', 'Batimastat'],\n",
              "         'term_norm': 'BATIMASTAT',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL279786',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.28909028439944,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ULINASTATIN', 'Ulinastatin'],\n",
              "         'term_norm': 'ULINASTATIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL2108163',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 70.49385697998649,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Bestatin'],\n",
              "         'term_norm': 'BESTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL29292',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['OTHER'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 77.70429375985498,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Staticin'],\n",
              "         'term_norm': 'STATICIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL532', 'CHEMBL']]}],\n",
              "         'mapping_types': ['tradeNames'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.0930267289905,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Dopastatin'],\n",
              "         'term_norm': 'DOPASTATIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL4650342',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.90062498278026,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['PHENSTATIN'],\n",
              "         'term_norm': 'PHENSTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL276625',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['pref_name'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.68213904398951,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Entinostat', 'ENTINOSTAT'],\n",
              "         'term_norm': 'ENTINOSTAT',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL27759',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.99330354358408,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Cilastatin', 'CILASTATIN'],\n",
              "         'term_norm': 'CILASTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL766', 'CHEMBL']]}],\n",
              "         'mapping_types': ['FDA',\n",
              "          'INN',\n",
              "          'pref_name',\n",
              "          'BAN',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 68.96647291127702,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['AMASTATIN'],\n",
              "         'term_norm': 'AMASTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL28650',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['pref_name'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 73.7082216555533,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Kitastatin', 'KITASTATIN'],\n",
              "         'term_norm': 'KITASTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL413307',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['pref_name', 'OTHER'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.78149671489572,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Urinastatin'],\n",
              "         'term_norm': 'URINASTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL2108163',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.51865969565675,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Octastatin'],\n",
              "         'term_norm': 'OCTASTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL2218872',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['TRADE_NAME'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 73.68937610450187,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Bestatin'],\n",
              "         'term_norm': 'BESTATIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL29292',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 77.16784413660388,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Somatostatin', 'SOMATOSTATIN'],\n",
              "         'term_norm': 'SOMATOSTATIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL1823872',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 68.15924515883033,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Uristatin'],\n",
              "         'term_norm': 'URISTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL2108163',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['OTHER'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 72.92613094690368,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Tinostamustine', 'TINOSTAMUSTINE'],\n",
              "         'term_norm': 'TINOSTAMUSTINE',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL3989941',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.3732274532756,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Uristatin'],\n",
              "         'term_norm': 'URISTATIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL2108163',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 72.42884559862121,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['CATESTATIN'],\n",
              "         'term_norm': 'CATESTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL2420220',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['pref_name'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 77.46243857129716,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ecostatin'],\n",
              "         'term_norm': 'ECOSTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL1201049',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['TRADE_NAME'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 71.58475350097319,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Itavastatin'],\n",
              "         'term_norm': 'ITAVASTATIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL1201753',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 68.35120725856866,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['FATOSTATIN', 'Fatostatin'],\n",
              "         'term_norm': 'FATOSTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL1621019',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['pref_name', 'OTHER'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 73.86726418008493,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['MARINOSTATIN', 'Marinostatin'],\n",
              "         'term_norm': 'MARINOSTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL409387',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['pref_name', 'OTHER'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.38387709191635,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Capostatin'],\n",
              "         'term_norm': 'CAPOSTATIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL2221250',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.06740356336773,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ritatin'],\n",
              "         'term_norm': 'RITATIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL857', 'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.89913121692909,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ULINASTATIN', 'Ulinastatin'],\n",
              "         'term_norm': 'ULINASTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL2108163',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['ATC', 'JAN', 'INN', 'pref_name', 'OTHER'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.56622693083135,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['NYSTATIN', 'Nystatin'],\n",
              "         'term_norm': 'NYSTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL450895',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['TRADE_NAME',\n",
              "          'ATC',\n",
              "          'JAN',\n",
              "          'FDA',\n",
              "          'INN',\n",
              "          'BNF',\n",
              "          'pref_name',\n",
              "          'BAN',\n",
              "          'USP',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 68.4805843852778,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Domatinostat', 'DOMATINOSTAT'],\n",
              "         'term_norm': 'DOMATINOSTAT',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL4283683',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.83832151763376,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Metastin'],\n",
              "         'term_norm': 'METASTIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL4650403',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.34526481908497,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Urinastatin'],\n",
              "         'term_norm': 'URINASTATIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL2108163',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 70.55341030175408,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Lipstatin'],\n",
              "         'term_norm': 'LIPSTATIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL175247',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.33645890887487,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['NYSTATIN', 'Nystatin'],\n",
              "         'term_norm': 'NYSTATIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL450895',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms', 'tradeNames'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.91929686625977,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ecostatin'],\n",
              "         'term_norm': 'ECOSTATIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL1201049',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['tradeNames'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 71.43564102501968,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Cilastatin', 'CILASTATIN'],\n",
              "         'term_norm': 'CILASTATIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL766', 'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.54224213398602,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Staticin'],\n",
              "         'term_norm': 'STATICIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL532', 'CHEMBL']]}],\n",
              "         'mapping_types': ['TRADE_NAME'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.75083551840436,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Endostatin', 'ENDOSTATIN'],\n",
              "         'term_norm': 'ENDOSTATIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL4297747',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.83962009201039,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Gustastatin', 'GUSTASTATIN'],\n",
              "         'term_norm': 'GUSTASTATIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL481267',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['pref_name', 'OTHER'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 74.79688108509353,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 58,\n",
              "       'end': 65,\n",
              "       'match_norm': 'STATIN'}]}]}],\n",
              " [{'idx': 'edd315d8ae2848c2839e98fd1e71405c',\n",
              "   'sections': [{'text': 'There were four subject categories, Bioinformatics, Polypharmacology, Systems biology, and Precision medicine and eight occurrences of research methods, namely, Virtual screening, Molecular docking, Machine learning 54, eighth, Clinical trials, High-throughput screening, Connectivity map, and Molecular dynamics simulation.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'Precision',\n",
              "       'entity_class': 'measurement',\n",
              "       'spans': [{'start': 91, 'end': 100}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'precision',\n",
              "         'source': 'STATO',\n",
              "         'parser_name': 'STATO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'precision',\n",
              "          'mapping_type': 'http://www.w3.org/2000/01/rdf-schema#label',\n",
              "          'data_origin': 'RC1.4'}}],\n",
              "       'synonym_terms': [{'terms': ['precision'],\n",
              "         'term_norm': 'PRECISION',\n",
              "         'parser_name': 'STATO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "             'STATO']]}],\n",
              "         'mapping_types': ['http://www.w3.org/2000/01/rdf-schema#label'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 91,\n",
              "       'end': 100,\n",
              "       'match_norm': 'PRECISION'}]}]}],\n",
              " [{'idx': '650b870a0f1e4bd089a385567180c322',\n",
              "   'sections': [{'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'COVID-19',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 96, 'end': 104}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'COVID-19',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'COVID-19',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'COVID-19',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0100096',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'severe acute respiratory syndrome coronavirus 2 infectious disease',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['MESH:C000657245',\n",
              "           'ICD11:RA01.0',\n",
              "           'ICD11:RA01.2',\n",
              "           'SCTID:840539006',\n",
              "           'MESH:D000086382',\n",
              "           'ICD10CM:U07.1',\n",
              "           'DOID:0080600'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['COVID-19'],\n",
              "         'term_norm': 'COVID-19',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['COVID-19'],\n",
              "         'term_norm': 'COVID-19',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0100096',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 96,\n",
              "       'end': 104,\n",
              "       'match_norm': 'COVID-19'},\n",
              "      {'match': 'SARS-CoV-',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 105, 'end': 114}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'synonym_terms': [{'terms': ['MSA-c'],\n",
              "         'term_norm': 'MSA-C',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0016418',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 29.571366979639535,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['RARS'],\n",
              "         'term_norm': 'RARS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019157',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 27.661520908970033,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['DORV-TGA'],\n",
              "         'term_norm': 'DORV-TGA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0020387',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 29.680715593239515,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS-CoV infection'],\n",
              "         'term_norm': 'SARS COV INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 30.17941127933846,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ARSA'],\n",
              "         'term_norm': 'ARSA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0016828',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.10303036080892,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS-CoV infection'],\n",
              "         'term_norm': 'SARS COV INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 27.99728617407613,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['MDS-RS'],\n",
              "         'term_norm': 'MDS-RS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0019157',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 33.24314565881858,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HES-R'],\n",
              "         'term_norm': 'HES-R',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017834',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 30.697095280211883,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['MOGS-CDG'],\n",
              "         'term_norm': 'MOGS-CDG',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0011629',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 44.43482671663862,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-Og'],\n",
              "         'term_norm': 'EBS-OG',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0007555',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 26.899970677075096,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-O'],\n",
              "         'term_norm': 'EBS-O',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0007555',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 27.953885944767876,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['MIS-C/A'],\n",
              "         'term_norm': 'MIS-C/A',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0035375',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 36.59727096002584,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HES-L'],\n",
              "         'term_norm': 'HES-L',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017835',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 28.8556199199756,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovary sarcoma'],\n",
              "         'term_norm': 'OVARY SARCOMA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002225',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 29.953110889822714,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ARSA'],\n",
              "         'term_norm': 'ARSA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0016828',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 36.317034617493306,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['CORS'],\n",
              "         'term_norm': 'CORS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0009480',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 30.902446268565313,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bv-FTD'],\n",
              "         'term_norm': 'BV-FTD',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017160',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 33.32131237357089,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HES-N'],\n",
              "         'term_norm': 'HES-N',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017833',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 29.074418133332625,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS'],\n",
              "         'term_norm': 'SARS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 36.317034617493306,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['v-AT'],\n",
              "         'term_norm': 'V-AT',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018266',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 40.024683146269126,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['NS-ARID'],\n",
              "         'term_norm': 'NS-ARID',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019502',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 31.90918394877001,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bv-FTD'],\n",
              "         'term_norm': 'BV-FTD',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0017160',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 27.683285300908228,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS'],\n",
              "         'term_norm': 'SARS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.10303036080892,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['v-AT'],\n",
              "         'term_norm': 'V-AT',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018266',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 46.562625533820444,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['MIS-A'],\n",
              "         'term_norm': 'MIS-A',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100319',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 30.64711878463632,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['MDS-RS'],\n",
              "         'term_norm': 'MDS-RS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019157',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 34.646167422810805,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['CORS'],\n",
              "         'term_norm': 'CORS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0009480',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 29.03080349453918,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['DORV-TGA'],\n",
              "         'term_norm': 'DORV-TGA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020387',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 36.016359439822104,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['NS-ARID'],\n",
              "         'term_norm': 'NS-ARID',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0019502',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 30.436983861599508,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ARSAL'],\n",
              "         'term_norm': 'ARSAL',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0012664',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 34.870244888905304,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-PA'],\n",
              "         'term_norm': 'EBS-PA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0012807',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 28.16671689094983,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['MIS-C'],\n",
              "         'term_norm': 'MIS-C',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100163',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.06023177178497,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ARSAL'],\n",
              "         'term_norm': 'ARSAL',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0012664',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.52545346643931,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['MOGS-CDG'],\n",
              "         'term_norm': 'MOGS-CDG',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0011629',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.39745791871372,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-MP'],\n",
              "         'term_norm': 'EBS-MP',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0007556',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 27.57835157726387,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HES-M'],\n",
              "         'term_norm': 'HES-M',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017833',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 30.04841462650651,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovarian sarcoma'],\n",
              "         'term_norm': 'OVARIAN SARCOMA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002225',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 28.9232768673015,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 105,\n",
              "       'end': 114,\n",
              "       'match_norm': 'SARS-COV-'},\n",
              "      {'match': 'COVID-19',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 168, 'end': 176}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'COVID-19',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'COVID-19',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'COVID-19',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0100096',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'severe acute respiratory syndrome coronavirus 2 infectious disease',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['MESH:C000657245',\n",
              "           'ICD11:RA01.0',\n",
              "           'ICD11:RA01.2',\n",
              "           'SCTID:840539006',\n",
              "           'MESH:D000086382',\n",
              "           'ICD10CM:U07.1',\n",
              "           'DOID:0080600'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['COVID-19'],\n",
              "         'term_norm': 'COVID-19',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['COVID-19'],\n",
              "         'term_norm': 'COVID-19',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0100096',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 168,\n",
              "       'end': 176,\n",
              "       'match_norm': 'COVID-19'},\n",
              "      {'match': 'SARS-CoV-2',\n",
              "       'entity_class': 'species',\n",
              "       'spans': [{'start': 177, 'end': 187}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'start': 177,\n",
              "       'end': 187,\n",
              "       'match_norm': 'SARS-COV-2'},\n",
              "      {'match': 'Coronavirus',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 188, 'end': 199}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'synonym_terms': [{'terms': ['disease due to arenavirus'],\n",
              "         'term_norm': 'DISEASE DUE TO ARENAVIRU',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005650',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.21816403679184,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus fever'],\n",
              "         'term_norm': 'HANTAVIRUS FEVER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018081',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.24007749621667,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS-associated coronavirus'],\n",
              "         'term_norm': 'SARS ASSOCIATED CORONAVIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.40073219419624,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus caused disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS CAUSED DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.05404216628945,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Orthocoronavirinae infectious disease'],\n",
              "         'term_norm': 'ORTHOCORONAVIRINAE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020753',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.73008736825084,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete human coronavirus sensitivity'],\n",
              "         'term_norm': 'OBSOLETE HUMAN CORONAVIRUS SENSITIVITY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007386',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.98037005037208,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus infection'],\n",
              "         'term_norm': 'HANTAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.89806976149852,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS ASSOC CORONAVIRUS'],\n",
              "         'term_norm': 'SARS ASSOC CORONAVIRUS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 70.82195539633169,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['acute respiratory coronavirus infection'],\n",
              "         'term_norm': 'ACUTE RESPIRATORY CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.35122632348357,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['hantavirus pulmonary syndrome',\n",
              "          'Hantavirus Pulmonary Syndrome'],\n",
              "         'term_norm': 'HANTAVIRUS PULMONARY SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0017879',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.656633106473485,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.80622088130653,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SAVI'],\n",
              "         'term_norm': 'SAVI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0014405',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.77299471742283,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus infectious disease'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020753',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.32938017054028,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Avulavirus Infections'],\n",
              "         'term_norm': 'AVULAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005660',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.9579067880933,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Alphavirus Infections'],\n",
              "         'term_norm': 'ALPHAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005643',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.877759941927664,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['acute respiratory coronavirus infection'],\n",
              "         'term_norm': 'ACUTE RESPIRATORY CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.40888572843222,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus disease'],\n",
              "         'term_norm': 'CORONAVIRUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005719',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 78.89441059291723,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Henipavirus Infections'],\n",
              "         'term_norm': 'HENIPAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005785',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.64200609630736,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Coronavirus Infections'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005719',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 75.09202138867366,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rubulavirus Infections'],\n",
              "         'term_norm': 'RUBULAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000989',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.19291260849566,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus disease or disorder'],\n",
              "         'term_norm': 'ROTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.064627063389445,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus infectious disease'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0020753', 'MONDO'],\n",
              "            ['MONDO_0005719', 'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 59.740181182141896,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus infectious disease'],\n",
              "         'term_norm': 'SARS CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.54195740206633,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronaviral enteritis of turkeys'],\n",
              "         'term_norm': 'CORONAVIRAL ENTERITIS OF TURKEY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0025404',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.953543592120376,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirosis'],\n",
              "         'term_norm': 'HANTAVIROSIS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018081',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.88965991944546,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus infection', 'Hantavirus Infections'],\n",
              "         'term_norm': 'HANTAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.11863300641681,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus disease or disorder'],\n",
              "         'term_norm': 'ROTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.45941089424701,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['disease due to arenavirus'],\n",
              "         'term_norm': 'DISEASE DUE TO ARENAVIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005650',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.394432281303516,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.98333823779242,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Coronaviridae Infections'],\n",
              "         'term_norm': 'CORONAVIRIDAE INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005718',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.9895515426647,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Polyomavirus nephropathy'],\n",
              "         'term_norm': 'POLYOMAVIRUS NEPHROPATHY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0022529',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.977831929892595,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SAVI'],\n",
              "         'term_norm': 'SAVI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0014405',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.00782837684112,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus infectious disease'],\n",
              "         'term_norm': 'SARS CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.18862243948419,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus disease or disorder'],\n",
              "         'term_norm': 'HANTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.75588308449377,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['rotavirus infection', 'Rotavirus infection'],\n",
              "         'term_norm': 'ROTAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.65598298862336,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus infection'],\n",
              "         'term_norm': 'ROTAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.30599810912499,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['hantavirus pulmonary syndrome'],\n",
              "         'term_norm': 'HANTAVIRUS PULMONARY SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017879',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.540016212736155,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus hemorrhagic fever with renal syndrome, Dobrava-Belgrade virus type'],\n",
              "         'term_norm': 'HANTAVIRUS HEMORRHAGIC FEVER WITH RENAL SYNDROME DOBRAVA BELGRADE VIRUS TYPE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000346',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.44716032814946,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 188,\n",
              "       'end': 199,\n",
              "       'match_norm': 'CORONAVIRU'}]}]}],\n",
              " [{'idx': '6fa6a8f0cc974115ab132d468b1f6420',\n",
              "   'sections': [{'text': 'Virtual screening is a research method that appeared seven times more frequently in that year than in the previous year.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'b7fac3e613ed469fbce7476202952de0',\n",
              "   'sections': [{'text': 'Since Drug repurposing/repositioning is a subject matter and a strategy for drug discovery/drug development, it would not make much sense to analyze these two keywords.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '0c09a88aad3840288fef26e9cbe164d2',\n",
              "   'sections': [{'text': 'Molecular docking is one of the core steps of virtual screening, and the COVID-19 pandemic generated many opportunities for the practice of drug repositioning.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'COVID-19',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 73, 'end': 81}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'COVID-19',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'COVID-19',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'COVID-19',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0100096',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'severe acute respiratory syndrome coronavirus 2 infectious disease',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['MESH:C000657245',\n",
              "           'ICD11:RA01.0',\n",
              "           'ICD11:RA01.2',\n",
              "           'SCTID:840539006',\n",
              "           'MESH:D000086382',\n",
              "           'ICD10CM:U07.1',\n",
              "           'DOID:0080600'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['COVID-19'],\n",
              "         'term_norm': 'COVID-19',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['COVID-19'],\n",
              "         'term_norm': 'COVID-19',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0100096',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 73,\n",
              "       'end': 81,\n",
              "       'match_norm': 'COVID-19'}]}]}],\n",
              " [{'idx': '94a7fda0918a47c5a1b783a3cfae6ba8',\n",
              "   'sections': [{'text': 'Therefore, high-quality studies of the keywords COVID-19/SARS-CoV-2/Coronavirus, Virtual screening, and Molecular docking were surveyed, as shown in the bubble chart, in the past two years, reflecting the relevant research trend in recent years.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'COVID-19',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 48, 'end': 56}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'COVID-19',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'COVID-19',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'COVID-19',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0100096',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'severe acute respiratory syndrome coronavirus 2 infectious disease',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['MESH:C000657245',\n",
              "           'ICD11:RA01.0',\n",
              "           'ICD11:RA01.2',\n",
              "           'SCTID:840539006',\n",
              "           'MESH:D000086382',\n",
              "           'ICD10CM:U07.1',\n",
              "           'DOID:0080600'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['COVID-19'],\n",
              "         'term_norm': 'COVID-19',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['COVID-19'],\n",
              "         'term_norm': 'COVID-19',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0100096',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 48,\n",
              "       'end': 56,\n",
              "       'match_norm': 'COVID-19'},\n",
              "      {'match': 'SARS-',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 57, 'end': 62}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'synonym_terms': [{'terms': ['RARS'],\n",
              "         'term_norm': 'RARS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019157',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 44.24408762028482,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-loc'],\n",
              "         'term_norm': 'EBS-LOC',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007551',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 44.14756772677498,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-O'],\n",
              "         'term_norm': 'EBS-O',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007555',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 46.35092679623381,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ARSA'],\n",
              "         'term_norm': 'ARSA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0016828',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.54456894093848,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-Og'],\n",
              "         'term_norm': 'EBS-OG',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007555',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 44.576055596242156,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-MD'],\n",
              "         'term_norm': 'EBS-MD',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0009181',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.72692235735377,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-migr'],\n",
              "         'term_norm': 'EBS-MIGR',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0012258',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.466610363522136,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-PA'],\n",
              "         'term_norm': 'EBS-PA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0012807',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 46.629879511996236,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ATS-MR'],\n",
              "         'term_norm': 'ATS-MR',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0010263',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.28453795017436,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['MDS-RS'],\n",
              "         'term_norm': 'MDS-RS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0019157',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.25457362140678,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HES-R'],\n",
              "         'term_norm': 'HES-R',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017834',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.94610715023978,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-Og'],\n",
              "         'term_norm': 'EBS-OG',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0007555',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.02600220487726,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-O'],\n",
              "         'term_norm': 'EBS-O',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0007555',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 44.71172005103641,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HES-L'],\n",
              "         'term_norm': 'HES-L',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017835',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 48.82993360013116,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ARSA'],\n",
              "         'term_norm': 'ARSA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0016828',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.45625683467772,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['RARS'],\n",
              "         'term_norm': 'RARS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0019157',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 44.5589251946197,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['MDS-U'],\n",
              "         'term_norm': 'MDS-U',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018881',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 40.5645974205204,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-loc'],\n",
              "         'term_norm': 'EBS-LOC',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0007551',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 42.5721419972311,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HES-N'],\n",
              "         'term_norm': 'HES-N',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017833',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 49.20018737598766,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS'],\n",
              "         'term_norm': 'SARS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.45625683467772,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['NS-ARID'],\n",
              "         'term_norm': 'NS-ARID',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019502',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.0381455584878,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ers'],\n",
              "         'term_norm': 'ERS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0008771',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.64467568840776,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS'],\n",
              "         'term_norm': 'SARS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.54456894093848,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['MIS-A'],\n",
              "         'term_norm': 'MIS-A',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100319',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.86153613886349,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['MDS-RS'],\n",
              "         'term_norm': 'MDS-RS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019157',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.41589966099141,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['JS-OR'],\n",
              "         'term_norm': 'JS-OR',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0009480',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 40.68463926383707,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['NS-ARID'],\n",
              "         'term_norm': 'NS-ARID',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0019502',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.505942519062145,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-MP'],\n",
              "         'term_norm': 'EBS-MP',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007556',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 46.066614613160965,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ARSAL'],\n",
              "         'term_norm': 'ARSAL',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0012664',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.0079765143718,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-PA'],\n",
              "         'term_norm': 'EBS-PA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0012807',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 45.052139186418394,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['MIS-C'],\n",
              "         'term_norm': 'MIS-C',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100163',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.03481733778901,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ARSAL'],\n",
              "         'term_norm': 'ARSAL',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0012664',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.0212640737939,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-migr'],\n",
              "         'term_norm': 'EBS-MIGR',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0012258',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.66181962713132,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-MP'],\n",
              "         'term_norm': 'EBS-MP',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0007556',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 44.11105982288216,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['EBS-MD'],\n",
              "         'term_norm': 'EBS-MD',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0009181',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.60995873065413,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HES-M'],\n",
              "         'term_norm': 'HES-M',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017833',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.84839955165182,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['JS-O'],\n",
              "         'term_norm': 'JS-O',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0016364',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.15351348549936,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['JS-R'],\n",
              "         'term_norm': 'JS-R',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0012308',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 42.570469053098385,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ATS-MR'],\n",
              "         'term_norm': 'ATS-MR',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0010263',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 42.50479920199137,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 57,\n",
              "       'end': 62,\n",
              "       'match_norm': 'SARS-'},\n",
              "      {'match': 'Coronavirus',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 68, 'end': 79}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'synonym_terms': [{'terms': ['disease due to arenavirus'],\n",
              "         'term_norm': 'DISEASE DUE TO ARENAVIRU',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005650',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.21816403679184,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus fever'],\n",
              "         'term_norm': 'HANTAVIRUS FEVER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018081',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.24007749621667,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS-associated coronavirus'],\n",
              "         'term_norm': 'SARS ASSOCIATED CORONAVIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.40073219419624,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus caused disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS CAUSED DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.05404216628945,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Orthocoronavirinae infectious disease'],\n",
              "         'term_norm': 'ORTHOCORONAVIRINAE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020753',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.73008736825084,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete human coronavirus sensitivity'],\n",
              "         'term_norm': 'OBSOLETE HUMAN CORONAVIRUS SENSITIVITY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007386',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.98037005037208,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus infection'],\n",
              "         'term_norm': 'HANTAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.89806976149852,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS ASSOC CORONAVIRUS'],\n",
              "         'term_norm': 'SARS ASSOC CORONAVIRUS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 70.82195539633169,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['acute respiratory coronavirus infection'],\n",
              "         'term_norm': 'ACUTE RESPIRATORY CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.35122632348357,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['hantavirus pulmonary syndrome',\n",
              "          'Hantavirus Pulmonary Syndrome'],\n",
              "         'term_norm': 'HANTAVIRUS PULMONARY SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0017879',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.656633106473485,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.80622088130653,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SAVI'],\n",
              "         'term_norm': 'SAVI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0014405',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.77299471742283,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus infectious disease'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020753',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.32938017054028,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Avulavirus Infections'],\n",
              "         'term_norm': 'AVULAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005660',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.9579067880933,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Alphavirus Infections'],\n",
              "         'term_norm': 'ALPHAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005643',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.877759941927664,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['acute respiratory coronavirus infection'],\n",
              "         'term_norm': 'ACUTE RESPIRATORY CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.40888572843222,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus disease'],\n",
              "         'term_norm': 'CORONAVIRUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005719',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 78.89441059291723,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Henipavirus Infections'],\n",
              "         'term_norm': 'HENIPAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005785',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.64200609630736,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Coronavirus Infections'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005719',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 75.09202138867366,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rubulavirus Infections'],\n",
              "         'term_norm': 'RUBULAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000989',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.19291260849566,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus disease or disorder'],\n",
              "         'term_norm': 'ROTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.064627063389445,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus infectious disease'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0020753', 'MONDO'],\n",
              "            ['MONDO_0005719', 'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 59.740181182141896,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus infectious disease'],\n",
              "         'term_norm': 'SARS CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.54195740206633,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronaviral enteritis of turkeys'],\n",
              "         'term_norm': 'CORONAVIRAL ENTERITIS OF TURKEY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0025404',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.953543592120376,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirosis'],\n",
              "         'term_norm': 'HANTAVIROSIS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018081',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.88965991944546,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus infection', 'Hantavirus Infections'],\n",
              "         'term_norm': 'HANTAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.11863300641681,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus disease or disorder'],\n",
              "         'term_norm': 'ROTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.45941089424701,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['disease due to arenavirus'],\n",
              "         'term_norm': 'DISEASE DUE TO ARENAVIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005650',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.394432281303516,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.98333823779242,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Coronaviridae Infections'],\n",
              "         'term_norm': 'CORONAVIRIDAE INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005718',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.9895515426647,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Polyomavirus nephropathy'],\n",
              "         'term_norm': 'POLYOMAVIRUS NEPHROPATHY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0022529',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.977831929892595,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SAVI'],\n",
              "         'term_norm': 'SAVI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0014405',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.00782837684112,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus infectious disease'],\n",
              "         'term_norm': 'SARS CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.18862243948419,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus disease or disorder'],\n",
              "         'term_norm': 'HANTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.75588308449377,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['rotavirus infection', 'Rotavirus infection'],\n",
              "         'term_norm': 'ROTAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.65598298862336,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus infection'],\n",
              "         'term_norm': 'ROTAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.30599810912499,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['hantavirus pulmonary syndrome'],\n",
              "         'term_norm': 'HANTAVIRUS PULMONARY SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017879',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.540016212736155,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus hemorrhagic fever with renal syndrome, Dobrava-Belgrade virus type'],\n",
              "         'term_norm': 'HANTAVIRUS HEMORRHAGIC FEVER WITH RENAL SYNDROME DOBRAVA BELGRADE VIRUS TYPE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000346',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.44716032814946,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 68,\n",
              "       'end': 79,\n",
              "       'match_norm': 'CORONAVIRU'}]}]}],\n",
              " [{'idx': '0a9a465d27e544ac997a2d1fdbe39896',\n",
              "   'sections': [{'text': 'Wang, F et al. developed a new free reverse docking server based on a consensus algorithm combining several docking algorithm strategies to address the original shortcomings of computational molecular docking in drug repositioning, such as a low success rate, cumbersome operational steps, and reliance on code writing.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '2a17c5e1b2644478b509a279de6533bd',\n",
              "   'sections': [{'text': 'M Lapillo et al. extensively evaluated the performance assessment of docking-based target fishing methods and developed a consensus docking-based target fishing tactic.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'f17048e74d3e4c09af52d098d5a1b8ac',\n",
              "   'sections': [{'text': 'In a virtual screening process, Gervasoni, S. conducted a literature search for molecular binding sites for SARS-CoV-2-associated protein targets while combining pocket and docking searches to propose a new pocket mapping strategy that identifies binding cavities with significantly better performance than pocket detection alone.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '8c1c71d22b344c2aa70b78a117c89bf2',\n",
              "   'sections': [{'text': 'Xie, L et al. screened antitoxic drugs based on the multitarget structure of the pathway center and stated that this inhibition of multiple targets in one pathway would be more effective than targeting a single protein, and the chance of drug resistance was smaller, which could be applied to other pathways.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'drug resistance',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 238, 'end': 253}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'Refractory drug response',\n",
              "         'source': 'HP',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'HP_0020174',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Drug resistance',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['Drug resistance'],\n",
              "         'term_norm': 'DRUG RESISTANCE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0020174', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 238,\n",
              "       'end': 253,\n",
              "       'match_norm': 'DRUG RESISTANCE'}]}]}],\n",
              " [{'idx': '97feb2dc00064dafbcc4fe3075af22de',\n",
              "   'sections': [{'text': 'Li, Z et al. reported a virtual screening method based on accelerated free energy perturbation absolute binding free energy FEP-ABFE prediction and stated that a virtual screening method based on accelerated free energy perturbation absolute binding free energy FEP-ABFE prediction will play a role in many other drug repositioning studies.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '3ccb2d93d4d44115888b46c5d6d052a5',\n",
              "   'sections': [{'text': 'After a series of drug repurposing computational screens and various validation activities by several scientists, it was agreed that raltegravir, clonidine, chloroquine and hydroxychloroquine have therapeutic effects in the treatment of novel coronavirus.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'raltegravir',\n",
              "       'entity_class': 'drug',\n",
              "       'spans': [{'start': 133, 'end': 144}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'RALTEGRAVIR',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'idx': 'CHEMBL254316',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'MK-0518',\n",
              "          'mapping_type': 'RESEARCH_CODE',\n",
              "          'data_origin': 'chembl_32_sqlite'}},\n",
              "        {'default_label': 'RALTEGRAVIR',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'idx': 'CHEMBL254316',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'MK-0518',\n",
              "          'mapping_type': 'synonyms',\n",
              "          'crossReferences': {'DailyMed': ['raltegravir%20potassium'],\n",
              "           'PubChem': ['124896574', '170466888'],\n",
              "           'Wikipedia': ['Raltegravir'],\n",
              "           'drugbank': ['DB06817']},\n",
              "          'data_origin': 'OPENTARGETS-MOLECULE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['RALTEGRAVIR', 'Raltegravir'],\n",
              "         'term_norm': 'RALTEGRAVIR',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL254316',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['RALTEGRAVIR', 'Raltegravir'],\n",
              "         'term_norm': 'RALTEGRAVIR',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL254316',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['ATC',\n",
              "          'USAN',\n",
              "          'INN',\n",
              "          'BNF',\n",
              "          'pref_name',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 133,\n",
              "       'end': 144,\n",
              "       'match_norm': 'RALTEGRAVIR'},\n",
              "      {'match': 'clonidine',\n",
              "       'entity_class': 'drug',\n",
              "       'spans': [{'start': 146, 'end': 155}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'CLONIDINE',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'idx': 'CHEMBL134',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Catapres',\n",
              "          'mapping_type': 'OTHER',\n",
              "          'data_origin': 'chembl_32_sqlite'}},\n",
              "        {'default_label': 'CLONIDINE',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'idx': 'CHEMBL134',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Catapres',\n",
              "          'mapping_type': 'synonyms',\n",
              "          'crossReferences': {'DailyMed': ['clonidine',\n",
              "            'clonidine%20hydrochloride'],\n",
              "           'PubChem': ['104171138',\n",
              "            '11110984',\n",
              "            '11110985',\n",
              "            '11113648',\n",
              "            '144203669',\n",
              "            '170464900',\n",
              "            '26751841',\n",
              "            '90341662'],\n",
              "           'Wikipedia': ['Clonidine'],\n",
              "           'drugbank': ['DB00575'],\n",
              "           'chEBI': ['3757']},\n",
              "          'data_origin': 'OPENTARGETS-MOLECULE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['Clonidine', 'CLONIDINE'],\n",
              "         'term_norm': 'CLONIDINE',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL134', 'CHEMBL']]}],\n",
              "         'mapping_types': ['TRADE_NAME',\n",
              "          'ATC',\n",
              "          'JAN',\n",
              "          'USAN',\n",
              "          'FDA',\n",
              "          'INN',\n",
              "          'pref_name',\n",
              "          'BAN',\n",
              "          'USP',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['Clonidine', 'CLONIDINE'],\n",
              "         'term_norm': 'CLONIDINE',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL134', 'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms', 'tradeNames'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 146,\n",
              "       'end': 155,\n",
              "       'match_norm': 'CLONIDINE'},\n",
              "      {'match': 'chloroquine',\n",
              "       'entity_class': 'drug',\n",
              "       'spans': [{'start': 157, 'end': 168}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'CHLOROQUINE',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'idx': 'CHEMBL76',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Aralen',\n",
              "          'mapping_type': 'OTHER',\n",
              "          'data_origin': 'chembl_32_sqlite'}},\n",
              "        {'default_label': 'CHLOROQUINE PHOSPHATE',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'idx': 'CHEMBL1326',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Chloroquine',\n",
              "          'mapping_type': 'OTHER',\n",
              "          'data_origin': 'chembl_32_sqlite'}},\n",
              "        {'default_label': 'CHLOROQUINE',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'idx': 'CHEMBL76',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Aralen',\n",
              "          'mapping_type': 'synonyms',\n",
              "          'crossReferences': {'DailyMed': ['chloroquine%20phosphate'],\n",
              "           'PubChem': ['124879700',\n",
              "            '124879705',\n",
              "            '174006958',\n",
              "            '50111008',\n",
              "            '90340711'],\n",
              "           'Wikipedia': ['Chloroquine'],\n",
              "           'drugbank': ['DB00608'],\n",
              "           'chEBI': ['3638']},\n",
              "          'data_origin': 'OPENTARGETS-MOLECULE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['Chloroquine', 'CHLOROQUINE'],\n",
              "         'term_norm': 'CHLOROQUINE',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL76', 'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['Chloroquine', 'CHLOROQUINE'],\n",
              "         'term_norm': 'CHLOROQUINE',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL1326', 'CHEMBL'],\n",
              "            ['CHEMBL76', 'CHEMBL']]}],\n",
              "         'mapping_types': ['ATC',\n",
              "          'USAN',\n",
              "          'FDA',\n",
              "          'INN',\n",
              "          'pref_name',\n",
              "          'BAN',\n",
              "          'USP',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 157,\n",
              "       'end': 168,\n",
              "       'match_norm': 'CHLOROQUINE'},\n",
              "      {'match': 'hydroxychloroquine',\n",
              "       'entity_class': 'drug',\n",
              "       'spans': [{'start': 173, 'end': 191}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'HYDROXYCHLOROQUINE',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'idx': 'CHEMBL1535',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Hydroxychloroquine',\n",
              "          'mapping_type': 'FDA',\n",
              "          'data_origin': 'chembl_32_sqlite'}},\n",
              "        {'default_label': 'HYDROXYCHLOROQUINE',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'idx': 'CHEMBL1535',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Hydroxychloroquine',\n",
              "          'mapping_type': 'synonyms',\n",
              "          'crossReferences': {'DailyMed': ['hydroxychloroquine%20sulfate'],\n",
              "           'PubChem': ['29215442'],\n",
              "           'Wikipedia': ['Hydroxychloroquine'],\n",
              "           'drugbank': ['DB01611'],\n",
              "           'chEBI': ['5801']},\n",
              "          'data_origin': 'OPENTARGETS-MOLECULE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['Hydroxychloroquine',\n",
              "          'HYDROXYCHLOROQUINE'],\n",
              "         'term_norm': 'HYDROXYCHLOROQUINE',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL1535',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['ATC',\n",
              "          'FDA',\n",
              "          'INN',\n",
              "          'pref_name',\n",
              "          'BAN',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['Hydroxychloroquine', 'HYDROXYCHLOROQUINE'],\n",
              "         'term_norm': 'HYDROXYCHLOROQUINE',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL1535',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 173,\n",
              "       'end': 191,\n",
              "       'match_norm': 'HYDROXYCHLOROQUINE'},\n",
              "      {'match': 'coronavirus',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 243, 'end': 254}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'synonym_terms': [{'terms': ['disease due to arenavirus'],\n",
              "         'term_norm': 'DISEASE DUE TO ARENAVIRU',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005650',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.21816403679184,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus fever'],\n",
              "         'term_norm': 'HANTAVIRUS FEVER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018081',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.24007749621667,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS-associated coronavirus'],\n",
              "         'term_norm': 'SARS ASSOCIATED CORONAVIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.40073219419624,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus caused disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS CAUSED DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.05404216628945,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Orthocoronavirinae infectious disease'],\n",
              "         'term_norm': 'ORTHOCORONAVIRINAE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020753',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.73008736825084,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete human coronavirus sensitivity'],\n",
              "         'term_norm': 'OBSOLETE HUMAN CORONAVIRUS SENSITIVITY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007386',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.98037005037208,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus infection'],\n",
              "         'term_norm': 'HANTAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.89806976149852,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS ASSOC CORONAVIRUS'],\n",
              "         'term_norm': 'SARS ASSOC CORONAVIRUS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 70.82195539633169,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['acute respiratory coronavirus infection'],\n",
              "         'term_norm': 'ACUTE RESPIRATORY CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.35122632348357,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['hantavirus pulmonary syndrome',\n",
              "          'Hantavirus Pulmonary Syndrome'],\n",
              "         'term_norm': 'HANTAVIRUS PULMONARY SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0017879',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.656633106473485,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.80622088130653,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SAVI'],\n",
              "         'term_norm': 'SAVI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0014405',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.77299471742283,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus infectious disease'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020753',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.32938017054028,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Avulavirus Infections'],\n",
              "         'term_norm': 'AVULAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005660',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.9579067880933,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Alphavirus Infections'],\n",
              "         'term_norm': 'ALPHAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005643',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.877759941927664,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['acute respiratory coronavirus infection'],\n",
              "         'term_norm': 'ACUTE RESPIRATORY CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.40888572843222,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus disease'],\n",
              "         'term_norm': 'CORONAVIRUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005719',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 78.89441059291723,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Henipavirus Infections'],\n",
              "         'term_norm': 'HENIPAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005785',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.64200609630736,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Coronavirus Infections'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005719',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 75.09202138867366,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rubulavirus Infections'],\n",
              "         'term_norm': 'RUBULAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000989',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.19291260849566,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus disease or disorder'],\n",
              "         'term_norm': 'ROTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.064627063389445,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus infectious disease'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0020753', 'MONDO'],\n",
              "            ['MONDO_0005719', 'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 59.740181182141896,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus infectious disease'],\n",
              "         'term_norm': 'SARS CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.54195740206633,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronaviral enteritis of turkeys'],\n",
              "         'term_norm': 'CORONAVIRAL ENTERITIS OF TURKEY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0025404',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.953543592120376,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirosis'],\n",
              "         'term_norm': 'HANTAVIROSIS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018081',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.88965991944546,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus infection', 'Hantavirus Infections'],\n",
              "         'term_norm': 'HANTAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.11863300641681,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus disease or disorder'],\n",
              "         'term_norm': 'ROTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.45941089424701,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['disease due to arenavirus'],\n",
              "         'term_norm': 'DISEASE DUE TO ARENAVIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005650',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.394432281303516,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.98333823779242,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Coronaviridae Infections'],\n",
              "         'term_norm': 'CORONAVIRIDAE INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005718',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.9895515426647,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Polyomavirus nephropathy'],\n",
              "         'term_norm': 'POLYOMAVIRUS NEPHROPATHY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0022529',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.977831929892595,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SAVI'],\n",
              "         'term_norm': 'SAVI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0014405',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.00782837684112,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus infectious disease'],\n",
              "         'term_norm': 'SARS CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.18862243948419,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus disease or disorder'],\n",
              "         'term_norm': 'HANTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.75588308449377,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['rotavirus infection', 'Rotavirus infection'],\n",
              "         'term_norm': 'ROTAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.65598298862336,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus infection'],\n",
              "         'term_norm': 'ROTAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.30599810912499,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['hantavirus pulmonary syndrome'],\n",
              "         'term_norm': 'HANTAVIRUS PULMONARY SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017879',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.540016212736155,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus hemorrhagic fever with renal syndrome, Dobrava-Belgrade virus type'],\n",
              "         'term_norm': 'HANTAVIRUS HEMORRHAGIC FEVER WITH RENAL SYNDROME DOBRAVA BELGRADE VIRUS TYPE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000346',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.44716032814946,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 243,\n",
              "       'end': 254,\n",
              "       'match_norm': 'CORONAVIRU'}]}]}],\n",
              " [{'idx': 'c8f5a444210f4ef3adfc0bef053b3e39',\n",
              "   'sections': [{'text': 'In addition, from the studies on the keyword Machine learning over the 10-year period shown in the bubble chart, it was found that the classical machine learning algorithms of support vector machines, regularized least squares, logistic regression, and random forests have been widely used in inferring drug–target and drug–disease interactions.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'ee0d9aa3e6c44fe4a0cadad87df2c77c',\n",
              "   'sections': [{'text': 'While the level of influence of a study is reflected by a combination of many aspects, the number of citations remains an important indicator.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'a66befc6658e41b8888844b958ee00a4',\n",
              "   'sections': [{'text': 'Based on the definition of highly cited and hot ESI papers in of this study, a total of 108 highly cited studies were obtained, of which 11 were hot research topics.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '6a47875529604e55b0fb9a13e0ad3d79',\n",
              "   'sections': [{'text': 'Hot research topics are shown in. It should be noted that the first-ranked author is used here as a representative, and the corresponding institution is shown.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '1246e6b2277e412dbdca7ec694b70616',\n",
              "   'sections': [{'text': 'This rule is followed in of this study.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '4fdd1052f46e4bbf9028d14f00806461',\n",
              "   'sections': [{'text': 'All hot research topics were published in 2020, and with the exception of an article describing the damage caused by nonsteroidal anti-inflammatory drugs NSAIDs to multiple organs and new information on drug repurposing, the remaining studies focused on drug repositioning therapeutic target studies in novel coronavirus pneumonia, screening drug studies, reviews of clinical trials, and reports of other coronavirus therapeutic agents and vaccine studies.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'coronavirus pneumonia',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 309, 'end': 330}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'viral pneumonia',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0006012',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Pneumonia, Viral',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['MeSH:D011024',\n",
              "           'UMLS:C0032310',\n",
              "           'MedDRA:10047475',\n",
              "           'DOID:10533',\n",
              "           'MESH:D011024',\n",
              "           'ICD9:480',\n",
              "           'ICD9:480.9',\n",
              "           'MedDRA:10047474',\n",
              "           'ICD9:480.8',\n",
              "           'MONDO:0006012',\n",
              "           'SCTID:75570004'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}},\n",
              "        {'default_label': 'viral pneumonia',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0006012',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'viral pneumonia',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}}],\n",
              "       'synonym_terms': [{'terms': ['Streptococcus pneumoniae pneumonia'],\n",
              "         'term_norm': 'STREPTOCOCCUS PNEUMONIAE PNEUMONIA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005972',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.94967347850613,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Streptococcus pneumoniae caused pneumonia'],\n",
              "         'term_norm': 'STREPTOCOCCUS PNEUMONIAE CAUSED PNEUMONIA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005972',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.644357895352826,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['contagious pleuropneumonia'],\n",
              "         'term_norm': 'CONTAGIOUS PLEUROPNEUMONIA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005716',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.4628686536542,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Streptococcus pneumoniae caused pneumonia'],\n",
              "         'term_norm': 'STREPTOCOCCUS PNEUMONIAE CAUSED PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005972',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.021609452780424,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['noninfectious pneumonia'],\n",
              "         'term_norm': 'NONINFECTIOUS PNEUMONIA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002429',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.071958816877256,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['noninfectious pneumonia'],\n",
              "         'term_norm': 'NONINFECTIOUS PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002429',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.03707023414629,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['viral pneumonia'],\n",
              "         'term_norm': 'VIRAL PNEUMONIA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0006012',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 73.82108041980202,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Pneumocystis pneumonia'],\n",
              "         'term_norm': 'PNEUMOCYSTIS PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0019121',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.14640276845152,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Viruses caused pneumonia'],\n",
              "         'term_norm': 'VIRUSES CAUSED PNEUMONIA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0006012',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 71.65073526589846,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Pneumonia, Viral'],\n",
              "         'term_norm': 'PNEUMONIA VIRAL',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0006012',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.72504264434352,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Mycoplasma pneumoniae pneumonia'],\n",
              "         'term_norm': 'MYCOPLASMA PNEUMONIAE PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005867',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.04655603521596,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['aspiration pneumonia', 'aspiration Pneumonias'],\n",
              "         'term_norm': 'ASPIRATION PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000265',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.924771732409,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['pneumococcal pneumonia'],\n",
              "         'term_norm': 'PNEUMOCOCCAL PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005972',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.09217874454661,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus disease'],\n",
              "         'term_norm': 'CORONAVIRUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005719',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.24331405215351,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Pneumocystis pneumonia'],\n",
              "         'term_norm': 'PNEUMOCYSTIS PNEUMONIA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019121',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.58285183572227,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Coronavirus Infections'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005719',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.97782276149901,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['pneumocystosis pneumonia'],\n",
              "         'term_norm': 'PNEUMOCYSTOSIS PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0019121',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.91867916306484,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Streptococcus pneumoniae pneumonia'],\n",
              "         'term_norm': 'STREPTOCOCCUS PNEUMONIAE PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005972',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.27904245400083,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['pneumocystosis pneumonia', 'Pneumocystosis pneumonia'],\n",
              "         'term_norm': 'PNEUMOCYSTOSIS PNEUMONIA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019121',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.28180897595846,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['viral pneumonia'],\n",
              "         'term_norm': 'VIRAL PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0006012',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 74.69360307521896,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Viruses caused pneumonia'],\n",
              "         'term_norm': 'VIRUSES CAUSED PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0006012',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 72.69029730648899,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Pneumonias, aspiration'],\n",
              "         'term_norm': 'PNEUMONIAS ASPIRATION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000265',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.075923758887065,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['aspiration pneumonitis'],\n",
              "         'term_norm': 'ASPIRATION PNEUMONITI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002572',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.30389382936687,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bronchial pneumonia'],\n",
              "         'term_norm': 'BRONCHIAL PNEUMONIA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005682',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.37126738152287,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['pleuropneumonia'],\n",
              "         'term_norm': 'PLEUROPNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0001940',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.5945869515954,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Pneumonitis', 'pneumonitis'],\n",
              "         'term_norm': 'PNEUMONITI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0043905', 'MONDO'],\n",
              "            ['MONDO_0005249', 'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 59.87095740416234,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['pneumonitis'],\n",
              "         'term_norm': 'PNEUMONITI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0043905',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.633310450113996,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['pneumonia', 'Pneumonia'],\n",
              "         'term_norm': 'PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0002090',\n",
              "             'HP'],\n",
              "            ['http://purl.obolibrary.org/obo/MONDO_0005249', 'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 65.85929529319277,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['cytomegalovirus pneumonia', 'Cytomegalovirus pneumonia'],\n",
              "         'term_norm': 'CYTOMEGALOVIRUS PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0024354',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.92988358954099,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Cytomegalovirus caused pneumonia'],\n",
              "         'term_norm': 'CYTOMEGALOVIRUS CAUSED PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0024354',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.933673872451166,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Pneumonia, Pneumococcal'],\n",
              "         'term_norm': 'PNEUMONIA PNEUMOCOCCAL',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005972',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.187934167984466,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['pneumonia'],\n",
              "         'term_norm': 'PNEUMONIA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005249',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.42855205357493,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['pneumococcal pneumonia'],\n",
              "         'term_norm': 'PNEUMOCOCCAL PNEUMONIA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005972',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.37785094150394,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['contagious pleuropneumonia'],\n",
              "         'term_norm': 'CONTAGIOUS PLEUROPNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005716',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.69555150123808,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Viruses pneumonia'],\n",
              "         'term_norm': 'VIRUSES PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0006012',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.33983303522606,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Mycoplasma pneumoniae pneumonia'],\n",
              "         'term_norm': 'MYCOPLASMA PNEUMONIAE PNEUMONIA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005867',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.961026878600855,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bronchial pneumonia'],\n",
              "         'term_norm': 'BRONCHIAL PNEUMONIA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005682',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.89578720678319,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Pneumonia, Aspiration'],\n",
              "         'term_norm': 'PNEUMONIA ASPIRATION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002572',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.32458819069419,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Viruses pneumonia'],\n",
              "         'term_norm': 'VIRUSES PNEUMONIA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0006012',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.91966499869545,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Pneumonia, Pneumocystis'],\n",
              "         'term_norm': 'PNEUMONIA PNEUMOCYSTI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019121',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.7814291334137,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 309,\n",
              "       'end': 330,\n",
              "       'match_norm': 'CORONAVIRUS PNEUMONIA'}]}]}],\n",
              " [{'idx': 'b263daa731894da0b230792ef1c30329',\n",
              "   'sections': [{'text': 'From the perspective of cooperation, most of the remaining studies were completed by a country’s independent agency.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '1978487b2c8a410dae7b729ef69f9f6a',\n",
              "   'sections': [{'text': 'In terms of the countries and regions studied, four studies involved US scholars, five studies involved Asian scholars, and one contribution was from an African scholar.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '02e40d8c09754950a7f5ccee671d7e73',\n",
              "   'sections': [{'text': 'In addition, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, published in Nature by Gordon, DE with a total of 125 scholars from the United States, the United Kingdom, and France was the most cited publication with 952 citations.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'SARS-CoV-2',\n",
              "       'entity_class': 'species',\n",
              "       'spans': [{'start': 15, 'end': 25}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'start': 15,\n",
              "       'end': 25,\n",
              "       'match_norm': 'SARS-COV-2'}]}]}],\n",
              " [{'idx': '38c648a6becf45d3b0e9bee81c6cf5fb',\n",
              "   'sections': [{'text': 'Eleven hot research topics were removed from 108 highly cited studies, and the top 20 most cited studies were selected from the remaining highly cited studies for analysis.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '115bf8953ac442c6a47d2e2290f8d65e',\n",
              "   'sections': [{'text': 'In terms of year of publication, the study by Dudley, JT et al. published in NUCLEIC ACIDS RESEARCH in February 2011 was the earliest of the top 20 most cited studies.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'bd4786d8bf22446f9e8a4accca76a363',\n",
              "   'sections': [{'text': 'Five highly cited studies were published in 2013, and three studies were published as recently as 2020.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '9ec7c51fd5f94ed59efe9faf1256717d',\n",
              "   'sections': [{'text': 'Two studies were published in Nature, and one each was published in Nat.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'b40fb5d4389f470dad995e1ddd5c9c0a',\n",
              "   'sections': [{'text': 'Rev. Drug Discov. and Nat. Med. subj. of Nature E J. Med.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'aee82e7cd50042c88b34846f88647287',\n",
              "   'sections': [{'text': 'Chem.', 'name': 'na'}]}],\n",
              " [{'idx': '0f46112c6d8845a0aa22a4e919811b3a',\n",
              "   'sections': [{'text': 'L was next with two studies.', 'name': 'na'}]}],\n",
              " [{'idx': 'd88350e4c8454d059c1cc40330f090bd',\n",
              "   'sections': [{'text': 'There were 12 studies with the first author or coauthor from the United States, representing more than half of those in, followed by China, Canada, the United Kingdom, Germany, Japan, and Switzerland in order of contribution of two or more studies.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '27aedc95eb5b4dd1975612ee81c5cae2',\n",
              "   'sections': [{'text': 'Nine studies were based on collaborations between different institutions in multiple countries.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'fef528208ca2483990fc1f0a77194580',\n",
              "   'sections': [{'text': 'One of Nine studies, entitled Alcohol-abuse drug disulfiram targets cancer via p97 segregase adapter NPL4, published in Nature in 2017 by Skrott, Z et al. is a collaboration between scholars from six countries Czech Republic, the United States, Denmark, Sweden, Switzerland, and China.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'Alcohol-abuse',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 30, 'end': 43}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'alcohol abuse',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0002046',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'alcohol abuse',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'alcohol abuse',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0002046',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'alcohol abuse',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['ICD9:305.0',\n",
              "           'SCTID:15167005',\n",
              "           'DOID:1574',\n",
              "           'ICD9:305.00',\n",
              "           'MESH:D000437'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['alcohol abuse'],\n",
              "         'term_norm': 'ALCOHOL ABUSE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002046',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['alcohol abuse'],\n",
              "         'term_norm': 'ALCOHOL ABUSE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002046',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 30,\n",
              "       'end': 43,\n",
              "       'match_norm': 'ALCOHOL ABUSE'},\n",
              "      {'match': 'disulfiram',\n",
              "       'entity_class': 'drug',\n",
              "       'spans': [{'start': 49, 'end': 59}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'DISULFIRAM',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'idx': 'CHEMBL964',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Disulfiram',\n",
              "          'mapping_type': 'USAN',\n",
              "          'data_origin': 'chembl_32_sqlite'}},\n",
              "        {'default_label': 'DISULFIRAM',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'idx': 'CHEMBL964',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Disulfiram',\n",
              "          'mapping_type': 'synonyms',\n",
              "          'crossReferences': {'DailyMed': ['disulfiram'],\n",
              "           'PubChem': ['104171249',\n",
              "            '11111859',\n",
              "            '11111860',\n",
              "            '11533044',\n",
              "            '123060006',\n",
              "            '124881563',\n",
              "            '124881565',\n",
              "            '124881567',\n",
              "            '124881570',\n",
              "            '144203831',\n",
              "            '144210721',\n",
              "            '144214033',\n",
              "            '170464767',\n",
              "            '26747681',\n",
              "            '26747682',\n",
              "            '26753660',\n",
              "            '26753661',\n",
              "            '50107088',\n",
              "            '50107089',\n",
              "            '56422197',\n",
              "            '85231246',\n",
              "            '90340564'],\n",
              "           'TG-GATEs': ['109'],\n",
              "           'Wikipedia': ['Disulfiram'],\n",
              "           'drugbank': ['DB00822'],\n",
              "           'chEBI': ['4659']},\n",
              "          'data_origin': 'OPENTARGETS-MOLECULE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['DISULFIRAM', 'Disulfiram'],\n",
              "         'term_norm': 'DISULFIRAM',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL964', 'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms', 'tradeNames'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['DISULFIRAM', 'Disulfiram'],\n",
              "         'term_norm': 'DISULFIRAM',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL964', 'CHEMBL']]}],\n",
              "         'mapping_types': ['TRADE_NAME',\n",
              "          'ATC',\n",
              "          'JAN',\n",
              "          'USAN',\n",
              "          'FDA',\n",
              "          'INN',\n",
              "          'BNF',\n",
              "          'pref_name',\n",
              "          'BAN',\n",
              "          'USP',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 49,\n",
              "       'end': 59,\n",
              "       'match_norm': 'DISULFIRAM'},\n",
              "      {'match': 'cancer',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 68, 'end': 74}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'cancer',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'cancer',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'cancer',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0004992',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'organ system cancer',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['SCTID:363346000',\n",
              "           'GARD:0011960',\n",
              "           'DOID:0050687',\n",
              "           'DOID:0050686',\n",
              "           'ICDO:8000/3',\n",
              "           'UMLS:C0006826',\n",
              "           'ICD9:199.1',\n",
              "           'NCIT:C9305',\n",
              "           'ICD9:195.8',\n",
              "           'NIFSTD:birnlex_406',\n",
              "           'ICD9:199',\n",
              "           'ONCOTREE:MT',\n",
              "           'EFO:0000311',\n",
              "           'DOID:162'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['cancer'],\n",
              "         'term_norm': 'CANCER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['cancer'],\n",
              "         'term_norm': 'CANCER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004992',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 68,\n",
              "       'end': 74,\n",
              "       'match_norm': 'CANCER'},\n",
              "      {'match': 'p97 segregase',\n",
              "       'entity_class': 'gene',\n",
              "       'spans': [{'start': 79, 'end': 92}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'start': 79,\n",
              "       'end': 92,\n",
              "       'match_norm': 'P 97 SEGREGASE'},\n",
              "      {'match': 'NPL4',\n",
              "       'entity_class': 'gene',\n",
              "       'spans': [{'start': 101, 'end': 105}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'NPLOC4',\n",
              "         'source': 'ENSEMBL',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'idx': 'ENSG00000182446',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Nuclear protein localization protein 4 homolog',\n",
              "          'mapping_type': 'uniprot',\n",
              "          'approvedName': 'NPL4 homolog, ubiquitin recognition factor',\n",
              "          'annotation_score': 6,\n",
              "          'data_origin': 'OPENTARGETS-TARGET-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['NPL4'],\n",
              "         'term_norm': 'NPL 4',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['ENSG00000182446',\n",
              "             'ENSEMBL']]}],\n",
              "         'mapping_types': ['uniprot', 'NCBI_entrez', 'HGNC'],\n",
              "         'aggregated_by': 'CUSTOM',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['OR4'],\n",
              "         'term_norm': 'OR 4',\n",
              "         'parser_name': 'HGNC_GENE_FAMILY',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['151',\n",
              "             'HGNC_GENE_FAMILY']]}],\n",
              "         'mapping_types': ['Common root gene symbol'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 38.01454734466212,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['AP4'],\n",
              "         'term_norm': 'AP 4',\n",
              "         'parser_name': 'HGNC_GENE_FAMILY',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['1674',\n",
              "             'HGNC_GENE_FAMILY']]}],\n",
              "         'mapping_types': ['Common root gene symbol'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 29.682048711562743,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['H4'],\n",
              "         'term_norm': 'H 4',\n",
              "         'parser_name': 'HGNC_GENE_FAMILY',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['1939',\n",
              "             'HGNC_GENE_FAMILY']]}],\n",
              "         'mapping_types': ['Common root gene symbol'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 34.57470048157964,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 101,\n",
              "       'end': 105,\n",
              "       'match_norm': 'NPL 4'}]}]}],\n",
              " [{'idx': '961ec27ee9254a5f867126205a4c4503',\n",
              "   'sections': [{'text': 'In TC, DrugBank 5.0 a major update to the DrugBank database for 2018 by Canadian University of Alberta scientists Wishart, DS et al. ranked first 1820 total citations.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'e209de13a90e44c5990670ec180364ad',\n",
              "   'sections': [{'text': 'The most cited publication on an annual basis was Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, published in 2020, which was authored by Zhou, YD et al. and was the highest annual average cited publication with 609 citations.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'nCoV',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 108, 'end': 112}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'synonym_terms': [{'terms': ['ovarian cancer'],\n",
              "         'term_norm': 'OVARIAN CANCER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0008170',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 46.39686938959544,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovary sarcoma'],\n",
              "         'term_norm': 'OVARY SARCOMA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002225',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.88395524522628,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovarian cancer, somatic'],\n",
              "         'term_norm': 'OVARIAN CANCER SOMATIC',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0008170',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 38.77646739021283,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovary cancer'],\n",
              "         'term_norm': 'OVARY CANCER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0008170',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.76510180593574,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['sarcoma of ovary'],\n",
              "         'term_norm': 'SARCOMA OF OVARY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002225',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 38.67170437323466,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovary NET'],\n",
              "         'term_norm': 'OVARY NET',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002481',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.61596591878684,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovary thecoma'],\n",
              "         'term_norm': 'OVARY THECOMA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0037253',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 46.53192451414228,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['synovium cancer'],\n",
              "         'term_norm': 'SYNOVIUM CANCER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002403',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 40.329822580432115,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Synovialosarcoma'],\n",
              "         'term_norm': 'SYNOVIALOSARCOMA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0010434',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.23579028695034,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['cancer of the ovary'],\n",
              "         'term_norm': 'CANCER OF THE OVARY',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0008170',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.69242526610187,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['thecoma of ovary'],\n",
              "         'term_norm': 'THECOMA OF OVARY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0037253',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 40.497754509503956,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Cancer of Ovary', 'cancer of ovary'],\n",
              "         'term_norm': 'CANCER OF OVARY',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0021068', 'MONDO'],\n",
              "            ['MONDO_0008170', 'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 43.13968943227016,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['synovitis'],\n",
              "         'term_norm': 'SYNOVITI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002400',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 40.34021768765877,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['cancer of ovary'],\n",
              "         'term_norm': 'CANCER OF OVARY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0008170',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.814981806745514,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovarian stromal cancer'],\n",
              "         'term_norm': 'OVARIAN STROMAL CANCER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018364',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.97857024409673,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovary sarcoma'],\n",
              "         'term_norm': 'OVARY SARCOMA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002225',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.38442629646213,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Syncope'],\n",
              "         'term_norm': 'SYNCOPE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0001279',\n",
              "             'HP']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 40.93039283266325,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ENDOVES'],\n",
              "         'term_norm': 'ENDOVES',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0036192',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 42.944709321218674,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovarian sarcoma'],\n",
              "         'term_norm': 'OVARIAN SARCOMA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002225',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 42.30256757188845,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Syncope'],\n",
              "         'term_norm': 'SYNCOPE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0001279', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.160565945564606,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovarian stromal cancer'],\n",
              "         'term_norm': 'OVARIAN STROMAL CANCER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018364',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.01361844295729,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['COVESDEM syndrome'],\n",
              "         'term_norm': 'COVESDEM SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0009999',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.22255316264258,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['pancolitis'],\n",
              "         'term_norm': 'PANCOLITI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005536',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 36.55854608759718,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovarian cancer, somatic'],\n",
              "         'term_norm': 'OVARIAN CANCER SOMATIC',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0008170',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.802019630076494,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ventriculoarterial discordance with atrioventricular concordance'],\n",
              "         'term_norm': 'VENTRICULOARTERIAL DISCORDANCE WITH ATRIOVENTRICULAR CONCORDANCE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019443',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 38.08559779352092,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Anal incontinence'],\n",
              "         'term_norm': 'ANAL INCONTINENCE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0002607',\n",
              "             'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 38.81053558395183,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Increased overbite'],\n",
              "         'term_norm': 'INCREASED OVERBITE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0011094', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.72537082686346,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovarian cancer'],\n",
              "         'term_norm': 'OVARIAN CANCER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005140', 'MONDO'],\n",
              "            ['MONDO_0008170', 'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 45.32249558256727,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['mucoviscidosis'],\n",
              "         'term_norm': 'MUCOVISCIDOSIS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0009061',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 38.02815983099326,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['FANCO'],\n",
              "         'term_norm': 'FANCO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0013248',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 46.444184327194606,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['cancer of the ovary'],\n",
              "         'term_norm': 'CANCER OF THE OVARY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0008170',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 40.436115974908034,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Covering disease'],\n",
              "         'term_norm': 'COVERING DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005734',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.265210591233775,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['sarcoma of ovary'],\n",
              "         'term_norm': 'SARCOMA OF OVARY',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002225',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 38.4238967848632,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['synovial sarcoma'],\n",
              "         'term_norm': 'SYNOVIAL SARCOMA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0010434',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 42.09784332797141,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovarian sarcoma'],\n",
              "         'term_norm': 'OVARIAN SARCOMA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0002225',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.892802991891074,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Synovialosarcoma'],\n",
              "         'term_norm': 'SYNOVIALOSARCOMA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0010434',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.069985249432705,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovary cancer'],\n",
              "         'term_norm': 'OVARY CANCER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0008170',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 49.58541447430087,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['synovitis'],\n",
              "         'term_norm': 'SYNOVITI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002400',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 40.62357446375031,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ovarian thecoma'],\n",
              "         'term_norm': 'OVARIAN THECOMA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0037253',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 44.6590776590689,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['synovial sarcoma'],\n",
              "         'term_norm': 'SYNOVIAL SARCOMA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0010434',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 42.35480797481715,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 108,\n",
              "       'end': 112,\n",
              "       'match_norm': 'NCOV'},\n",
              "      {'match': 'SARS-',\n",
              "       'entity_class': 'species',\n",
              "       'spans': [{'start': 113, 'end': 118}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'start': 113,\n",
              "       'end': 118,\n",
              "       'match_norm': 'SARS-'}]}]}],\n",
              " [{'idx': 'e5d56e4caab54009a4c6f8959f2b922d',\n",
              "   'sections': [{'text': 'The scientists Cheng, FX and Dudley, JT, contributed to two of these 20 publications and are important influencers in the field.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'f3db3b57bba4428aba44326f07663f46',\n",
              "   'sections': [{'text': 'The three studies published in 2020 focus on novel coronavirus-related drug rediscovery activities and the use of deep learning techniques. and Pushpakom, S et al. provided systematic reviews of the methods and challenges of drug repositioning at that time.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '444a207fa65f4549b797b78101f4651f',\n",
              "   'sections': [{'text': 'Initially, Sirota, M et al. explored the role of integrating genome-wide computational approaches for predicting reusable drugs, while from 2013 onward, Peters, JU et al., Medina-Franco et al., JL et al., Reddy, AS et al., and Anighoro, A et al. generally recognized the importance of combining multiple points of pharmacological knowledge for drug repositioning studies.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'eaf4ca3ccfee412496672e85b4e56791',\n",
              "   'sections': [{'text': 'In the face of a worldwide health emergency caused by the Zika virus epidemic, used drug repositioning to identify lead compounds for drug development.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'Zika virus',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 58, 'end': 68}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'Zika virus infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Zika virus infectious disease',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'Zika virus infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0018661',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Zika',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['NCIT:C128423',\n",
              "           'MESH:D000071243',\n",
              "           'GARD:0012894',\n",
              "           'SCTID:3928002',\n",
              "           'DOID:0060478',\n",
              "           'UMLS:CN237724',\n",
              "           'UMLS:C0276289',\n",
              "           'Orphanet:448237',\n",
              "           'ICD10CM:A92.5'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['Zika virus congenital syndrome'],\n",
              "         'term_norm': 'ZIKA VIRUS CONGENITAL SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 77.32866107488648,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete Zika fever'],\n",
              "         'term_norm': 'OBSOLETE ZIKA FEVER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000768',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.99151232354542,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus disease'],\n",
              "         'term_norm': 'ZIKA VIRUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 86.01332425081632,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['antenatal varicella virus infection'],\n",
              "         'term_norm': 'ANTENATAL VARICELLA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017372',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.65407669465763,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rubella virus infectious disease'],\n",
              "         'term_norm': 'RUBELLA VIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004656',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 34.865513892414874,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Lassa virus infection'],\n",
              "         'term_norm': 'LASSA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0044750',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.016008344511896,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus infection'],\n",
              "         'term_norm': 'ZIKA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.13338017680275,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus disease or disorder'],\n",
              "         'term_norm': 'ZIKA VIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 72.30057569892074,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['congenital Zika syndrome'],\n",
              "         'term_norm': 'CONGENITAL ZIKA SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.52949854905874,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['congenital Zika virus infection'],\n",
              "         'term_norm': 'CONGENITAL ZIKA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.10316444332351,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hepatitis D virus'],\n",
              "         'term_norm': 'HEPATITIS D VIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005789',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.31752512214569,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rubella virus disease or disorder'],\n",
              "         'term_norm': 'RUBELLA VIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004656',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 36.04755566526677,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ebola virus disease'],\n",
              "         'term_norm': 'EBOLA VIRUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005737',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.71024603787112,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hardikar syndrome'],\n",
              "         'term_norm': 'HARDIKAR SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0012997',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.380346663575914,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['congenital Zika syndrome'],\n",
              "         'term_norm': 'CONGENITAL ZIKA SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.49717609269621,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika'],\n",
              "         'term_norm': 'ZIKA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 77.22423697624204,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus caused disease or disorder'],\n",
              "         'term_norm': 'ZIKA VIRUS CAUSED DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.02417491177187,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus disease'],\n",
              "         'term_norm': 'ZIKA VIRUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 86.02696838276009,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus caused disease or disorder'],\n",
              "         'term_norm': 'ZIKA VIRUS CAUSED DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.22361885426209,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Kahrizi syndrome'],\n",
              "         'term_norm': 'KAHRIZI SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0012991',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 36.8402642235197,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ebola virus disease'],\n",
              "         'term_norm': 'EBOLA VIRUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005737',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 40.08305927205285,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Kaposi Sarcoma-Associated Herpes Virus'],\n",
              "         'term_norm': 'KAPOSI SARCOMA ASSOCIATED HERPES VIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005187',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.59351417897639,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Karandikar-Maria-Kamble syndrome'],\n",
              "         'term_norm': 'KARANDIKAR MARIA KAMBLE SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0015324',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.69702664133878,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus infection'],\n",
              "         'term_norm': 'ZIKA VIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.88924000862347,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus congenital syndrome'],\n",
              "         'term_norm': 'ZIKA VIRUS CONGENITAL SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 76.53553033455006,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus infectious disease'],\n",
              "         'term_norm': 'ZIKA VIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.93403973803382,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Karandikar-Maria-Kamble syndrome'],\n",
              "         'term_norm': 'KARANDIKAR MARIA KAMBLE SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0015324',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.767332356446715,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Tumor Virus Infections'],\n",
              "         'term_norm': 'TUMOR VIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005111',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 35.41614804954411,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hendra virus infection'],\n",
              "         'term_norm': 'HENDRA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017942',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.3274684977557,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rubella virus disease or disorder'],\n",
              "         'term_norm': 'RUBELLA VIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004656',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 36.17636322856293,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['congenital Zika virus infection'],\n",
              "         'term_norm': 'CONGENITAL ZIKA VIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 68.61507216934324,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika'],\n",
              "         'term_norm': 'ZIKA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 77.40153995014468,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Kaposi Sarcoma Herpes Virus'],\n",
              "         'term_norm': 'KAPOSI SARCOMA HERPES VIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005187',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 47.0203705041426,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus infectious disease'],\n",
              "         'term_norm': 'ZIKA VIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 70.3350594757071,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Kahrizi syndrome'],\n",
              "         'term_norm': 'KAHRIZI SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0012991',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.24057549081976,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['KAND'],\n",
              "         'term_norm': 'KAND',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0700055',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.29361910421804,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['KAND'],\n",
              "         'term_norm': 'KAND',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0700055',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.74148957121119,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hepatitis D virus'],\n",
              "         'term_norm': 'HEPATITIS D VIRU',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005789',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 42.30035910586337,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Lassa virus infection'],\n",
              "         'term_norm': 'LASSA VIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0044750',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 38.486692563808965,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus disease or disorder'],\n",
              "         'term_norm': 'ZIKA VIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 71.88267115048974,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 58,\n",
              "       'end': 68,\n",
              "       'match_norm': 'ZIKA VIRU'}]}]}],\n",
              " [{'idx': 'ad1982807025409ab4867eb17c0949b8',\n",
              "   'sections': [{'text': 'Of course, techniques related to the mining of repositionable drugs through experimental high-throughput screening, a traditional experimental approach, are not without progress for example, explored the challenges of transferring 3D cell culture technology to the use of high-throughput screening HTS.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': '3D cell culture',\n",
              "       'entity_class': 'cell_line',\n",
              "       'spans': [{'start': 231, 'end': 246}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'synonym_terms': [{'terms': ['Relicell hES3'],\n",
              "         'term_norm': 'RELICELL HES 3',\n",
              "         'parser_name': 'CELLOSAURUS',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CVCL_B364',\n",
              "             'CELLOSAURUS']]}],\n",
              "         'mapping_types': ['name'],\n",
              "         'aggregated_by': 'CUSTOM',\n",
              "         'search_score': 41.60617408498058,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 231,\n",
              "       'end': 246,\n",
              "       'match_norm': '3 D CELL CULTURE'}]}]}],\n",
              " [{'idx': '2c15615532b7406aa03b66641ba1ddc4',\n",
              "   'sections': [{'text': 'In 1995, Mchugh et al. investigated the immunomodulatory action mechanism of thalidomide in humans, which was the first relevant publication on drug repositioning.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'thalidomide',\n",
              "       'entity_class': 'drug',\n",
              "       'spans': [{'start': 77, 'end': 88}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'THALIDOMIDE',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'idx': 'CHEMBL468',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': '.alpha.-phthalimidoglutarimide',\n",
              "          'mapping_type': 'synonyms',\n",
              "          'crossReferences': {'DailyMed': ['thalidomide'],\n",
              "           'PubChem': ['111716',\n",
              "            '11532929',\n",
              "            '124881523',\n",
              "            '144210897',\n",
              "            '170465323',\n",
              "            '174007312',\n",
              "            '26747126',\n",
              "            '26751823',\n",
              "            '50104514',\n",
              "            '90341724'],\n",
              "           'Wikipedia': ['Thalidomide'],\n",
              "           'drugbank': ['DB01041'],\n",
              "           'chEBI': ['74947']},\n",
              "          'data_origin': 'OPENTARGETS-MOLECULE-23.02'}},\n",
              "        {'default_label': 'THALIDOMIDE',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'idx': 'CHEMBL468',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': '.alpha.-phthalimidoglutarimide',\n",
              "          'mapping_type': 'OTHER',\n",
              "          'data_origin': 'chembl_32_sqlite'}}],\n",
              "       'synonym_terms': [{'terms': ['Thalidomide', 'THALIDOMIDE'],\n",
              "         'term_norm': 'THALIDOMIDE',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL468', 'CHEMBL']]}],\n",
              "         'mapping_types': ['ATC',\n",
              "          'JAN',\n",
              "          'USAN',\n",
              "          'FDA',\n",
              "          'INN',\n",
              "          'BNF',\n",
              "          'pref_name',\n",
              "          'BAN',\n",
              "          'USP',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['Thalidomide', 'THALIDOMIDE'],\n",
              "         'term_norm': 'THALIDOMIDE',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL468', 'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 77,\n",
              "       'end': 88,\n",
              "       'match_norm': 'THALIDOMIDE'}]}]}],\n",
              " [{'idx': '47f72919d538400996b46ed0df5a4e74',\n",
              "   'sections': [{'text': 'The publication time can be divided into three phases the growth period of 1995–2009, the steady growth period of 2010–2018, and the rapid rise from 2019 and beyond.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'f4d7227544e04082b84c2d2cd9e764bd',\n",
              "   'sections': [{'text': 'The 2978 publications studied between 2010 and 2020 were completed by 15338 authors from 3530 research institutions in 89 countries, and at the time of this study’s completion, the WOS database had surpassed more than 1400 publications in the year under the same search restrictions for the topic, with more than 31000 citations for the year, supporting further evidence that the topic is still gaining momentum worldwide.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '71bc1fcdca024a8d8276cffc51a7db7a',\n",
              "   'sections': [{'text': 'The publication countries/regions are divided into three types first, countries with a traditionally developed medical level, mainly developed countries in Western Europe, North America, and Oceania second, countries with a developed pharmaceutical manufacturing industry, such as India and Japan in Asia and third, developing countries with some research potential, such as China, Brazil, Argentina, and Mexico.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '5efc0e6f2696490b82dc0d7ee219393a',\n",
              "   'sections': [{'text': 'In terms of national cooperation, Western European countries have shown a high degree of cooperation, with the United States, China, and the United Kingdom cooperating more frequently.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '7275ebc08f884c3c9bb8d542b9e4bf6d',\n",
              "   'sections': [{'text': 'This may be because Western European countries have a tradition of cooperation in the field of research, and the United States, China, and the United Kingdom are the most powerful countries in terms of drug repositioning publications and therefore cooperate more with each other.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '08e0bc2dd69a4daaab85a9424521660b',\n",
              "   'sections': [{'text': \"the United States accounts for half of the 20 most productive institutions, which may explain why the United States still publishes more than 50% of the United States's studies independently, despite having the largest international collaborative network base, because the United States already has the most active and high-quality producing institutions within the United States for research institutions seeking collaboration.\",\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'e6fd1eaf44524a639591b74bfe826dca',\n",
              "   'sections': [{'text': 'Furthermore, 19 of the 20 most productive institutions are universities and research institutes, and one is a company, HM Pharma Consultancy, which was established in 2000 to focus on drug repositioning for the development of new drugs.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '0dbd9e6813014b5eac609988f77ddc86',\n",
              "   'sections': [{'text': 'This evidence suggests that the topic of drug repositioning is not only widely studied in academia but also has a place in the industry.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '06c81a21892b4d418c6f87c958064282',\n",
              "   'sections': [{'text': 'The 2978 studies are spread across 74 research areas, but pharmacology and pharmacy and biochemistry and molecular biology account for a larger proportion of the total number of studies.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '7a3b8665d6b54887a9658f32ee9e828e',\n",
              "   'sections': [{'text': 'It is quite notable that the majority of studies reported in biophysics did not rise significantly until 2020.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '8bd030dbc91f468e937d0524b23c3b23',\n",
              "   'sections': [{'text': \"The reasons for this may be the following first, there was a breakthrough in basic research in biophysics in 2020 and second, due to the novel coronavirus, research in this direction has increased research in this direction's application for the prevention and control of the pandemic.\",\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '7c06512daa384e6e855d42668f64cb6f',\n",
              "   'sections': [{'text': 'In terms of journals, Sci Rep ranked first, followed by PLoS One and J. Biomol.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'b15f0ae022f348c8857147ab05b61386',\n",
              "   'sections': [{'text': 'Struct.', 'name': 'na'}]}],\n",
              " [{'idx': 'b1503217036240da91e9606e2f3c42af',\n",
              "   'sections': [{'text': 'Dyn.', 'name': 'na'}]}],\n",
              " [{'idx': 'd5cce64720104088baae55958ff8f53e',\n",
              "   'sections': [{'text': 'In terms of lead authors, three have the most productive and influential positions Cheng, FX is the most prolific author, based on the number of papers and h-index Mucke, HAM is the most frequent corresponding author and Butte, AJ is the top author in terms of ACPP ranking.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'ACPP',\n",
              "       'entity_class': 'gene',\n",
              "       'spans': [{'start': 261, 'end': 265}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'ACP3',\n",
              "         'source': 'ENSEMBL',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'idx': 'ENSG00000014257',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Prostatic acid phosphatase',\n",
              "          'mapping_type': 'uniprot',\n",
              "          'approvedName': 'acid phosphatase 3',\n",
              "          'annotation_score': 7,\n",
              "          'data_origin': 'OPENTARGETS-TARGET-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['ACPP'],\n",
              "         'term_norm': 'ACPP',\n",
              "         'parser_name': 'OPENTARGETS_TARGET',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['ENSG00000014257',\n",
              "             'ENSEMBL']]}],\n",
              "         'mapping_types': ['uniprot', 'NCBI_entrez', 'HGNC'],\n",
              "         'aggregated_by': 'CUSTOM',\n",
              "         'exact_match': True}],\n",
              "       'start': 261,\n",
              "       'end': 265,\n",
              "       'match_norm': 'ACPP'},\n",
              "      {'match': 'ranking',\n",
              "       'entity_class': 'measurement',\n",
              "       'spans': [{'start': 266, 'end': 273}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'ranking',\n",
              "         'source': 'STATO',\n",
              "         'parser_name': 'STATO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/STATO_0000118',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'ranking',\n",
              "          'mapping_type': 'http://www.w3.org/2000/01/rdf-schema#label',\n",
              "          'data_origin': 'RC1.4'}}],\n",
              "       'synonym_terms': [{'terms': ['ranking'],\n",
              "         'term_norm': 'RANKING',\n",
              "         'parser_name': 'STATO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/STATO_0000118',\n",
              "             'STATO']]}],\n",
              "         'mapping_types': ['http://www.w3.org/2000/01/rdf-schema#label'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 266,\n",
              "       'end': 273,\n",
              "       'match_norm': 'RANKING'}]}]}],\n",
              " [{'idx': 'a25f8a2984f945c7befec52a89a06638',\n",
              "   'sections': [{'text': 'Even though Latin American countries do not have an advantage in terms of national cooperation or the total number of institutional funding units, Latin American scholars have overcome many obstacles and are actively at the forefront of scholarship, contributing significantly to the field.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '1c5fece0f80b4c7aa2212bbf70c8c01f',\n",
              "   'sections': [{'text': 'Through the analysis of the authors’ keywords, cancer has been the main disease addressed by this method.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'cancer',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 47, 'end': 53}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'cancer',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'cancer',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'cancer',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0004992',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'organ system cancer',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['SCTID:363346000',\n",
              "           'GARD:0011960',\n",
              "           'DOID:0050687',\n",
              "           'DOID:0050686',\n",
              "           'ICDO:8000/3',\n",
              "           'UMLS:C0006826',\n",
              "           'ICD9:199.1',\n",
              "           'NCIT:C9305',\n",
              "           'ICD9:195.8',\n",
              "           'NIFSTD:birnlex_406',\n",
              "           'ICD9:199',\n",
              "           'ONCOTREE:MT',\n",
              "           'EFO:0000311',\n",
              "           'DOID:162'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['cancer'],\n",
              "         'term_norm': 'CANCER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['cancer'],\n",
              "         'term_norm': 'CANCER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004992',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 47,\n",
              "       'end': 53,\n",
              "       'match_norm': 'CANCER'}]}]}],\n",
              " [{'idx': '7e58d417f4034832823d5b2283c51368',\n",
              "   'sections': [{'text': 'Metformin has been found by many scientists to have a good inhibitory effect on various tumors, mainly in gynecology, and Metformin has become a specific drug that has been most frequently mentioned in drug reuse in recent years.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'Metformin',\n",
              "       'entity_class': 'drug',\n",
              "       'spans': [{'start': 0, 'end': 9}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'METFORMIN',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'idx': 'CHEMBL1431',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'LA-6023',\n",
              "          'mapping_type': 'synonyms',\n",
              "          'crossReferences': {'DailyMed': ['metformin%20hydrochloride'],\n",
              "           'PubChem': ['11112469', '137275802', '144212687', '174006543'],\n",
              "           'TG-GATEs': ['53'],\n",
              "           'Wikipedia': ['Metformin'],\n",
              "           'drugbank': ['DB00331'],\n",
              "           'chEBI': ['6801']},\n",
              "          'data_origin': 'OPENTARGETS-MOLECULE-23.02'}},\n",
              "        {'default_label': 'METFORMIN',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'idx': 'CHEMBL1431',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Metformin',\n",
              "          'mapping_type': 'FDA',\n",
              "          'data_origin': 'chembl_32_sqlite'}}],\n",
              "       'synonym_terms': [{'terms': ['METFORMIN', 'Metformin'],\n",
              "         'term_norm': 'METFORMIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL1431',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['METFORMIN', 'Metformin'],\n",
              "         'term_norm': 'METFORMIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL1431',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['ATC',\n",
              "          'USAN',\n",
              "          'FDA',\n",
              "          'INN',\n",
              "          'pref_name',\n",
              "          'BAN',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 0,\n",
              "       'end': 9,\n",
              "       'match_norm': 'METFORMIN'},\n",
              "      {'match': 'tumors',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 88, 'end': 94}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'neoplasm',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0005070',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'neoplasm',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'Neoplasm',\n",
              "         'source': 'HP',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/HP_0002664',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Neoplasm',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'neoplasm',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0005070',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'neoplasm (disease)',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['DOID:14566',\n",
              "           'NCIT:C3262',\n",
              "           'HP:0002664',\n",
              "           'COHD:438112',\n",
              "           'MESH:D009369',\n",
              "           'ONCOTREE:OTHER',\n",
              "           'MONDO:0005070',\n",
              "           'ICD9:239.9',\n",
              "           'ICD10CM:C7A-C7A',\n",
              "           'UMLS:CN236628',\n",
              "           'ICD10CM:C00-D49',\n",
              "           'ICD9:140-239.99',\n",
              "           'EFO:0000616',\n",
              "           'SCTID:55342001',\n",
              "           'ICD10CM:C7B-C7B',\n",
              "           'ICD10:C00.D48',\n",
              "           'ICD9:239.8'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['Tumor', 'tumor'],\n",
              "         'term_norm': 'TUMOR',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0002664',\n",
              "             'HP'],\n",
              "            ['http://purl.obolibrary.org/obo/MONDO_0005070', 'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['tumor'],\n",
              "         'term_norm': 'TUMOR',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005070',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 88,\n",
              "       'end': 94,\n",
              "       'match_norm': 'TUMOR'},\n",
              "      {'match': 'Metformin',\n",
              "       'entity_class': 'drug',\n",
              "       'spans': [{'start': 122, 'end': 131}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'METFORMIN',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'idx': 'CHEMBL1431',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'LA-6023',\n",
              "          'mapping_type': 'synonyms',\n",
              "          'crossReferences': {'DailyMed': ['metformin%20hydrochloride'],\n",
              "           'PubChem': ['11112469', '137275802', '144212687', '174006543'],\n",
              "           'TG-GATEs': ['53'],\n",
              "           'Wikipedia': ['Metformin'],\n",
              "           'drugbank': ['DB00331'],\n",
              "           'chEBI': ['6801']},\n",
              "          'data_origin': 'OPENTARGETS-MOLECULE-23.02'}},\n",
              "        {'default_label': 'METFORMIN',\n",
              "         'source': 'CHEMBL',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'idx': 'CHEMBL1431',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Metformin',\n",
              "          'mapping_type': 'FDA',\n",
              "          'data_origin': 'chembl_32_sqlite'}}],\n",
              "       'synonym_terms': [{'terms': ['METFORMIN', 'Metformin'],\n",
              "         'term_norm': 'METFORMIN',\n",
              "         'parser_name': 'OPENTARGETS_MOLECULE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL1431',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['synonyms'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['METFORMIN', 'Metformin'],\n",
              "         'term_norm': 'METFORMIN',\n",
              "         'parser_name': 'CHEMBL',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['CHEMBL1431',\n",
              "             'CHEMBL']]}],\n",
              "         'mapping_types': ['ATC',\n",
              "          'USAN',\n",
              "          'FDA',\n",
              "          'INN',\n",
              "          'pref_name',\n",
              "          'BAN',\n",
              "          'OTHER',\n",
              "          'MERCK_INDEX'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 122,\n",
              "       'end': 131,\n",
              "       'match_norm': 'METFORMIN'}]}]}],\n",
              " [{'idx': '2920a306fb83418ea876b251bf4bc1c6',\n",
              "   'sections': [{'text': 'In terms of antiviral drugs, scholars not only use drug repositioning to find antiviral drugs to treat diseases, such as Ebola and HIV, that have plagued humans for a long time but also use drug repositioning to seek treatments for infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'Ebola',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 121, 'end': 126}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'Ebola hemorrhagic fever',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0005737',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Ebola hemorrhagic fever',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'Ebola hemorrhagic fever',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0005737',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Ebolavirus infectious disease',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['MESH:D019142',\n",
              "           'DOID:4325',\n",
              "           'MedDRA:10014071',\n",
              "           'MONDO:0005737',\n",
              "           'UMLS:C0282687',\n",
              "           'MedDRA:10055245',\n",
              "           'MeSH:D019142',\n",
              "           'Orphanet:319218',\n",
              "           'NCIT:C36171',\n",
              "           'SCTID:37109004',\n",
              "           'GARD:0002035'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['Ebola'],\n",
              "         'term_norm': 'EBOLA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005737',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['Ebola'],\n",
              "         'term_norm': 'EBOLA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005737',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 121,\n",
              "       'end': 126,\n",
              "       'match_norm': 'EBOLA'},\n",
              "      {'match': 'HIV',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 131, 'end': 134}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'HIV infection',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0005109',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Human immunodeficiency virus infection',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['SNOMEDCT:86406008',\n",
              "           'NCIt:C3108',\n",
              "           'SNOMEDCT:19030005',\n",
              "           'SCTID:86406008',\n",
              "           'NCIT:C3108',\n",
              "           'ICD9:042',\n",
              "           'SNOMEDCT:72621000119104',\n",
              "           'MONDO:0005109',\n",
              "           'MESH:D015658',\n",
              "           'ICD10:B24',\n",
              "           'UMLS:C0019693',\n",
              "           'MedDRA:10020161',\n",
              "           'DOID:526',\n",
              "           'ICD9:042-042.99',\n",
              "           'MeSH:D015658',\n",
              "           'ICD10CM:B20-B20'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['HIV infectious disease'],\n",
              "         'term_norm': 'H 4 INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005109',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.3387367542887,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HIV'],\n",
              "         'term_norm': 'H 4',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005109',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': ['SMA type 4'],\n",
              "         'term_norm': 'SMA TYPE 4',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0010056',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 42.85085159709796,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HIV-associated nephropathy'],\n",
              "         'term_norm': 'H 4 ASSOCIATED NEPHROPATHY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005798',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.505274480243465,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HIV infection'],\n",
              "         'term_norm': 'H 4 INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005109',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 48.81908452408597,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['MODY type 4'],\n",
              "         'term_norm': 'MODY TYPE 4',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0011667',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 38.46221012391786,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['OI type 4'],\n",
              "         'term_norm': 'OI TYPE 4',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0008148',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 38.422943160281385,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HIV enteropathy'],\n",
              "         'term_norm': 'H 4 ENTEROPATHY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005796',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.22624796096672,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HIV infection, resistance to'],\n",
              "         'term_norm': 'H 4 INFECTION RESISTANCE TO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004951',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.86386029155832,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ALS 4'],\n",
              "         'term_norm': 'ALS 4',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0011223',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 45.60918623165578,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HIV nephropathy'],\n",
              "         'term_norm': 'H 4 NEPHROPATHY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005798',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 47.46936024637601,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HIV-associated cancer'],\n",
              "         'term_norm': 'H 4 ASSOCIATED CANCER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018628',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.28786615095376,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HIV-related cancer'],\n",
              "         'term_norm': 'H 4 RELATED CANCER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018628',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 46.724227151664465,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['grade IV', 'grade 4'],\n",
              "         'term_norm': 'GRADE 4',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0024494',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 44.372311923183716,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Lynch syndrome 4'],\n",
              "         'term_norm': 'LYNCH SYNDROME 4',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0013699',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 49.16756598652333,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['tooth agenesis, selective, 4'],\n",
              "         'term_norm': 'TOOTH AGENESIS SELECTIVE 4',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007881',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 38.93812480882072,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['HIV wasting syndrome'],\n",
              "         'term_norm': 'H 4 WASTING SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005797',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.428767167099394,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['PAH associated with HIV infaction'],\n",
              "         'term_norm': 'PAH ASSOCIATED WITH H 4 INFACTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017153',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 49.08637718545822,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 131,\n",
              "       'end': 134,\n",
              "       'match_norm': 'H 4'},\n",
              "      {'match': 'plagued',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 146, 'end': 153}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'plague',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0019095',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'plague',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'Yersinia pestis infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0019095',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Yersinia pestis infection',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['SCTID:58750007',\n",
              "           'MESH:D015009',\n",
              "           'ICD9:020',\n",
              "           'MESH:D010930',\n",
              "           'MedDRA:10061416',\n",
              "           'ICD9:020.9',\n",
              "           'MONDO:0019095',\n",
              "           'DOID:3482',\n",
              "           'Orphanet:707',\n",
              "           'MedDRA:10035148',\n",
              "           'ICD9:136.8',\n",
              "           'UMLS:C0032064',\n",
              "           'ICD10CM:A20',\n",
              "           'NCIT:C85015'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['plague'],\n",
              "         'term_norm': 'PLAGUE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0019095',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 95.13943034297196,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Fatigue'],\n",
              "         'term_norm': 'FATIGUE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0012378', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.85183898445134,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bluetongue'],\n",
              "         'term_norm': 'BLUETONGUE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0025385',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.921960541344106,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['septicemic plague'],\n",
              "         'term_norm': 'SEPTICEMIC PLAGUE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005956',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.546589504784365,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Posteriorly placed tongue'],\n",
              "         'term_norm': 'POSTERIORLY PLACED TONGUE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0009087', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 48.28105654440052,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['plague'],\n",
              "         'term_norm': 'PLAGUE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0019095',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 94.90219464201763,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['tongue, fissured'],\n",
              "         'term_norm': 'TONGUE FISSURED',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007655',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 47.68486384414351,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['ambulatory plague'],\n",
              "         'term_norm': 'AMBULATORY PLAGUE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000238',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 63.13329124344851,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['pinguecula'],\n",
              "         'term_norm': 'PINGUECULA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0001179',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.99138639898137,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['tongue-tie'],\n",
              "         'term_norm': 'TONGUE TIE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007125',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.47899250224795,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['plicated tongue'],\n",
              "         'term_norm': 'PLICATED TONGUE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007655',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.72792076579472,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['classic dengue'],\n",
              "         'term_norm': 'CLASSIC DENGUE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005502',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 48.16014825183869,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bubonic plague'],\n",
              "         'term_norm': 'BUBONIC PLAGUE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0001112',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 63.29465463809676,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neoplasm of tongue'],\n",
              "         'term_norm': 'NEOPLASM OF TONGUE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0021240',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.27049612265762,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Septicemic plague (disorder)'],\n",
              "         'term_norm': 'SEPTICEMIC PLAGUE (DISORDER)',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005956',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 48.65696489571666,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Neoplasm, Tongue'],\n",
              "         'term_norm': 'NEOPLASM TONGUE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0021240',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.775995084220575,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Neoplasms, Tongue'],\n",
              "         'term_norm': 'NEOPLASMS TONGUE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0021240',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 49.89607540914571,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['esophagus neoplasm'],\n",
              "         'term_norm': 'ESOPHAGUS NEOPLASM',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0021355',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 46.9652124317882,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete plague'],\n",
              "         'term_norm': 'OBSOLETE PLAGUE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0002662',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.6969548096269,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['septicemic plague'],\n",
              "         'term_norm': 'SEPTICEMIC PLAGUE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005956',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.841719516596896,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['fissured tongue'],\n",
              "         'term_norm': 'FISSURED TONGUE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007655',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 48.42486511740815,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hypoplastic tongue'],\n",
              "         'term_norm': 'HYPOPLASTIC TONGUE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0000171', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.14601908610889,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['classic dengue'],\n",
              "         'term_norm': 'CLASSIC DENGUE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005502',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 49.12978096806871,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Dengue'],\n",
              "         'term_norm': 'DENGUE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005502',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.95965060905206,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['tongue neoplasm', 'Tongue Neoplasms'],\n",
              "         'term_norm': 'TONGUE NEOPLASM',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0021240',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.63116420091515,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['pinguecula'],\n",
              "         'term_norm': 'PINGUECULA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0001179',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.83799566062969,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['tongue tumor'],\n",
              "         'term_norm': 'TONGUE TUMOR',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0021240',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 47.00382941938078,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['tongue cancer'],\n",
              "         'term_norm': 'TONGUE CANCER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004631',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 48.45365118403978,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Language delayed'],\n",
              "         'term_norm': 'LANGUAGE DELAYED',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/HP_0000750',\n",
              "             'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 48.39981731043443,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neoplasm of tongue'],\n",
              "         'term_norm': 'NEOPLASM OF TONGUE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0021240',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.201746091077524,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['tongue neoplasm'],\n",
              "         'term_norm': 'TONGUE NEOPLASM',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0021240',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.77624269683261,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['neoplasm of the tongue'],\n",
              "         'term_norm': 'NEOPLASM OF THE TONGUE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0021240',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 47.58630339688036,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['TONGUE NEOPL'],\n",
              "         'term_norm': 'TONGUE NEOPL',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0021240',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.288374853032884,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['pneumonic plague'],\n",
              "         'term_norm': 'PNEUMONIC PLAGUE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0001024',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.23042317002123,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Small tongue'],\n",
              "         'term_norm': 'SMALL TONGUE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0000171', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 48.13690975043588,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['NEOPL TONGUE'],\n",
              "         'term_norm': 'NEOPL TONGUE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0021240',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.03601745220337,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Language delayed'],\n",
              "         'term_norm': 'LANGUAGE DELAYED',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0000750', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 49.04660664748801,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['tongue tumor'],\n",
              "         'term_norm': 'TONGUE TUMOR',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0021240',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 48.2335729433767,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Dengue'],\n",
              "         'term_norm': 'DENGUE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005502',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.063160370901045,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hemorrhagic Dengue'],\n",
              "         'term_norm': 'HEMORRHAGIC DENGUE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005358',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 47.775944858352204,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 146,\n",
              "       'end': 153,\n",
              "       'match_norm': 'PLAGUED'},\n",
              "      {'match': 'infectious diseases',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 232, 'end': 251}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0005550',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'infectious disease',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0005550',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'disorder due to infection',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['DOID:0050117',\n",
              "           'ICD9:136.8',\n",
              "           'NCIT:C26726',\n",
              "           'ICD10:Z22',\n",
              "           'ICD9:079.0',\n",
              "           'IDO:IDO_0000436',\n",
              "           'MONDO:0005550',\n",
              "           'MESH:D003141',\n",
              "           'ICD10CM:A00-B99',\n",
              "           'SCTID:40733004',\n",
              "           'IDO:0000436',\n",
              "           'ICD9:136.9',\n",
              "           'SNOMEDCT:40733004'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['parasitic infectious disease'],\n",
              "         'term_norm': 'PARASITIC INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005135',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.43634541962096,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['mumps infectious disease'],\n",
              "         'term_norm': 'MUMPS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000989',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.63394267736844,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bacterial infectious disease'],\n",
              "         'term_norm': 'BACTERIAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.83153921618216,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Cestode infectious disease'],\n",
              "         'term_norm': 'CESTODE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0042488',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.42278693462086,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['mumps infectious disease'],\n",
              "         'term_norm': 'MUMPS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000989',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.0057701752537,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Cestode infectious disease'],\n",
              "         'term_norm': 'CESTODE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0042488',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.9740688628782,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious discitis'],\n",
              "         'term_norm': 'INFECTIOUS DISCITI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_8000000',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.92785445314254,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['parasitic infectious disease'],\n",
              "         'term_norm': 'PARASITIC INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005135',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.90038027397682,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ascaridia infectious disease'],\n",
              "         'term_norm': 'ASCARIDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005655',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.76617120233642,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disorder'],\n",
              "         'term_norm': 'INFECTIOUS DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005550',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.06524734672398,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease or post-infectious disorder'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE OR POST INFECTIOUS DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100336',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 88.47689540240974,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['viral infectious disease'],\n",
              "         'term_norm': 'VIRAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005108',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.69773643585833,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious discitis'],\n",
              "         'term_norm': 'INFECTIOUS DISCITI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_8000000',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.75320997203414,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Tinea infectious disease'],\n",
              "         'term_norm': 'TINEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005982',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 90.11809849090459,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['renal infectious disease'],\n",
              "         'term_norm': 'RENAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004369',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 87.98317782414561,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease characteristic'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE CHARACTERISTIC',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0045034',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.53494384176263,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005550',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 97.8980330615247,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Tinea infectious disease'],\n",
              "         'term_norm': 'TINEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005982',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 90.40065650424556,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal diseases'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEAS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.77208644487203,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal disease'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.38314601943658,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease or post-infectious disorder'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE OR POST INFECTIOUS DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0100336',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 88.62412549225198,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005550',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 97.88443442192923,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal diseases'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEAS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.83516114327001,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['anaplasma infectious disease'],\n",
              "         'term_norm': 'ANAPLASMA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0025303',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 79.9013609696188,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Proteus infectious disease'],\n",
              "         'term_norm': 'PROTEUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0006929',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.2160614572425,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['intestinal infectious disease'],\n",
              "         'term_norm': 'INTESTINAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000916',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.03935155200335,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['viral infectious disease'],\n",
              "         'term_norm': 'VIRAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005108',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.61704755443748,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Nocardia infectious disease'],\n",
              "         'term_norm': 'NOCARDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0017776',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.17699173330988,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Bacteria infectious disease'],\n",
              "         'term_norm': 'BACTERIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.27710767478173,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Enoplea infectious disease'],\n",
              "         'term_norm': 'ENOPLEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005745',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 84.45132941319167,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['rare infectious disease'],\n",
              "         'term_norm': 'RARE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0019062',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 89.24213123785673,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Nocardia infectious disease'],\n",
              "         'term_norm': 'NOCARDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017776',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.55031533661773,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['intestinal infectious disease'],\n",
              "         'term_norm': 'INTESTINAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000916',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.5772134339965,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bacterial infectious disease'],\n",
              "         'term_norm': 'BACTERIAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.09674847554227,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Proteus infectious disease'],\n",
              "         'term_norm': 'PROTEUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0006929',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.1660226658925,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal disease'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.31053913349274,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Viruses infectious disease'],\n",
              "         'term_norm': 'VIRUSES INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005108',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.06634051359116,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Enoplea infectious disease'],\n",
              "         'term_norm': 'ENOPLEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005745',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 84.94763161888503,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Bacteria infectious disease'],\n",
              "         'term_norm': 'BACTERIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.96674380661096,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ascaridia infectious disease'],\n",
              "         'term_norm': 'ASCARIDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005655',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.27455442784945,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 232,\n",
              "       'end': 251,\n",
              "       'match_norm': 'INFECTIOUS DISEAS'},\n",
              "      {'match': 'Zika virus',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 261, 'end': 271}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'Zika virus infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Zika virus infectious disease',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'Zika virus infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0018661',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Zika',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['NCIT:C128423',\n",
              "           'MESH:D000071243',\n",
              "           'GARD:0012894',\n",
              "           'SCTID:3928002',\n",
              "           'DOID:0060478',\n",
              "           'UMLS:CN237724',\n",
              "           'UMLS:C0276289',\n",
              "           'Orphanet:448237',\n",
              "           'ICD10CM:A92.5'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['Zika virus congenital syndrome'],\n",
              "         'term_norm': 'ZIKA VIRUS CONGENITAL SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 77.32866107488648,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete Zika fever'],\n",
              "         'term_norm': 'OBSOLETE ZIKA FEVER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000768',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.99151232354542,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus disease'],\n",
              "         'term_norm': 'ZIKA VIRUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 86.01332425081632,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['antenatal varicella virus infection'],\n",
              "         'term_norm': 'ANTENATAL VARICELLA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017372',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.65407669465763,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rubella virus infectious disease'],\n",
              "         'term_norm': 'RUBELLA VIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004656',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 34.865513892414874,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Lassa virus infection'],\n",
              "         'term_norm': 'LASSA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0044750',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.016008344511896,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus infection'],\n",
              "         'term_norm': 'ZIKA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.13338017680275,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus disease or disorder'],\n",
              "         'term_norm': 'ZIKA VIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 72.30057569892074,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['congenital Zika syndrome'],\n",
              "         'term_norm': 'CONGENITAL ZIKA SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.52949854905874,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['congenital Zika virus infection'],\n",
              "         'term_norm': 'CONGENITAL ZIKA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.10316444332351,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hepatitis D virus'],\n",
              "         'term_norm': 'HEPATITIS D VIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005789',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.31752512214569,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rubella virus disease or disorder'],\n",
              "         'term_norm': 'RUBELLA VIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004656',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 36.04755566526677,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ebola virus disease'],\n",
              "         'term_norm': 'EBOLA VIRUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005737',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.71024603787112,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hardikar syndrome'],\n",
              "         'term_norm': 'HARDIKAR SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0012997',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.380346663575914,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['congenital Zika syndrome'],\n",
              "         'term_norm': 'CONGENITAL ZIKA SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.49717609269621,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika'],\n",
              "         'term_norm': 'ZIKA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 77.22423697624204,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus caused disease or disorder'],\n",
              "         'term_norm': 'ZIKA VIRUS CAUSED DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.02417491177187,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus disease'],\n",
              "         'term_norm': 'ZIKA VIRUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 86.02696838276009,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus caused disease or disorder'],\n",
              "         'term_norm': 'ZIKA VIRUS CAUSED DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.22361885426209,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Kahrizi syndrome'],\n",
              "         'term_norm': 'KAHRIZI SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0012991',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 36.8402642235197,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ebola virus disease'],\n",
              "         'term_norm': 'EBOLA VIRUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005737',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 40.08305927205285,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Kaposi Sarcoma-Associated Herpes Virus'],\n",
              "         'term_norm': 'KAPOSI SARCOMA ASSOCIATED HERPES VIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005187',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.59351417897639,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Karandikar-Maria-Kamble syndrome'],\n",
              "         'term_norm': 'KARANDIKAR MARIA KAMBLE SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0015324',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.69702664133878,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus infection'],\n",
              "         'term_norm': 'ZIKA VIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.88924000862347,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus congenital syndrome'],\n",
              "         'term_norm': 'ZIKA VIRUS CONGENITAL SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 76.53553033455006,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus infectious disease'],\n",
              "         'term_norm': 'ZIKA VIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.93403973803382,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Karandikar-Maria-Kamble syndrome'],\n",
              "         'term_norm': 'KARANDIKAR MARIA KAMBLE SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0015324',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.767332356446715,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Tumor Virus Infections'],\n",
              "         'term_norm': 'TUMOR VIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005111',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 35.41614804954411,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hendra virus infection'],\n",
              "         'term_norm': 'HENDRA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017942',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.3274684977557,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rubella virus disease or disorder'],\n",
              "         'term_norm': 'RUBELLA VIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004656',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 36.17636322856293,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['congenital Zika virus infection'],\n",
              "         'term_norm': 'CONGENITAL ZIKA VIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 68.61507216934324,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika'],\n",
              "         'term_norm': 'ZIKA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 77.40153995014468,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Kaposi Sarcoma Herpes Virus'],\n",
              "         'term_norm': 'KAPOSI SARCOMA HERPES VIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005187',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 47.0203705041426,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus infectious disease'],\n",
              "         'term_norm': 'ZIKA VIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 70.3350594757071,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Kahrizi syndrome'],\n",
              "         'term_norm': 'KAHRIZI SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0012991',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.24057549081976,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['KAND'],\n",
              "         'term_norm': 'KAND',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0700055',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.29361910421804,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['KAND'],\n",
              "         'term_norm': 'KAND',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0700055',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.74148957121119,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hepatitis D virus'],\n",
              "         'term_norm': 'HEPATITIS D VIRU',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005789',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 42.30035910586337,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Lassa virus infection'],\n",
              "         'term_norm': 'LASSA VIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0044750',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 38.486692563808965,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus disease or disorder'],\n",
              "         'term_norm': 'ZIKA VIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 71.88267115048974,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 261,\n",
              "       'end': 271,\n",
              "       'match_norm': 'ZIKA VIRU'},\n",
              "      {'match': 'coronaviruses',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 282, 'end': 295}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'coronavirus infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0005719',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Coronavinae infectious disease',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['MONDO:0005719',\n",
              "           'MESH:D018352',\n",
              "           'MeSH:D018352',\n",
              "           'DOID:2946'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['Hantavirus fever'],\n",
              "         'term_norm': 'HANTAVIRUS FEVER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018081',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.734239368015366,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS-associated coronavirus'],\n",
              "         'term_norm': 'SARS ASSOCIATED CORONAVIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.77226289874314,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Polyomavirus Infections'],\n",
              "         'term_norm': 'POLYOMAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005927',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.72142160510252,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus caused disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS CAUSED DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.02125384645319,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus hemorrhagic fever with renal syndrome, Seoul virus type'],\n",
              "         'term_norm': 'HANTAVIRUS HEMORRHAGIC FEVER WITH RENAL SYNDROME SEOUL VIRUS TYPE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000283',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.643001955802106,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete human coronavirus sensitivity'],\n",
              "         'term_norm': 'OBSOLETE HUMAN CORONAVIRUS SENSITIVITY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0007386',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 62.59848805133706,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus caused disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS CAUSED DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.96262079152942,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus infection'],\n",
              "         'term_norm': 'HANTAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.12323316532267,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS ASSOC CORONAVIRUS'],\n",
              "         'term_norm': 'SARS ASSOC CORONAVIRUS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 73.69592222831058,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['acute respiratory coronavirus infection'],\n",
              "         'term_norm': 'ACUTE RESPIRATORY CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 65.95627610351315,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['hantavirus pulmonary syndrome',\n",
              "          'Hantavirus Pulmonary Syndrome'],\n",
              "         'term_norm': 'HANTAVIRUS PULMONARY SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0017879',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.51396282633938,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.83269273512554,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus infectious disease'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020753',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.72546441078818,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Avulavirus Infections'],\n",
              "         'term_norm': 'AVULAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005660',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.31510604014771,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Alphavirus Infections'],\n",
              "         'term_norm': 'ALPHAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005643',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.37666513391081,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Avulavirus infectious disease'],\n",
              "         'term_norm': 'AVULAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005660',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.15768941203543,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['acute respiratory coronavirus infection'],\n",
              "         'term_norm': 'ACUTE RESPIRATORY CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 66.81253760822959,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus disease'],\n",
              "         'term_norm': 'CORONAVIRUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005719',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.09595901111174,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Henipavirus Infections'],\n",
              "         'term_norm': 'HENIPAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005785',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.125880056050995,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Coronavirus Infections'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005719',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 77.87960097195331,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rubulavirus Infections'],\n",
              "         'term_norm': 'RUBULAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000989',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.83894716717716,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus disease or disorder'],\n",
              "         'term_norm': 'ROTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.974145761274706,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['coronavirus infectious disease'],\n",
              "         'term_norm': 'CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0020753', 'MONDO'],\n",
              "            ['MONDO_0005719', 'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'MERGED_AS_NON_SYMBOLIC',\n",
              "         'search_score': 66.9184402394135,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus infectious disease'],\n",
              "         'term_norm': 'SARS CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.97545045582232,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirosis'],\n",
              "         'term_norm': 'HANTAVIROSIS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018081',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.82244173457385,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus infection', 'Hantavirus Infections'],\n",
              "         'term_norm': 'HANTAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.76041214967298,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus disease or disorder'],\n",
              "         'term_norm': 'ROTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.985016912614874,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus disease or disorder'],\n",
              "         'term_norm': 'SARS CORONAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.75609766727398,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['arenavirus infectious disease'],\n",
              "         'term_norm': 'ARENAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005650',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.9382983598817,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Coronaviridae Infections'],\n",
              "         'term_norm': 'CORONAVIRIDAE INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005718',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.68909841797605,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Polyomavirus nephropathy'],\n",
              "         'term_norm': 'POLYOMAVIRUS NEPHROPATHY',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0022529',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.971682778080734,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SAVI'],\n",
              "         'term_norm': 'SAVI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0014405',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.074599811651325,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['SARS coronavirus infectious disease'],\n",
              "         'term_norm': 'SARS CORONAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005091',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.93366727512094,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus disease or disorder'],\n",
              "         'term_norm': 'HANTAVIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005780',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.340345540058564,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['rotavirus infection', 'Rotavirus infection'],\n",
              "         'term_norm': 'ROTAVIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.24267691074591,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rotavirus infection'],\n",
              "         'term_norm': 'ROTAVIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005194',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.47265117375495,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['hantavirus pulmonary syndrome'],\n",
              "         'term_norm': 'HANTAVIRUS PULMONARY SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017879',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.085942485899054,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hantavirus hemorrhagic fever with renal syndrome, Dobrava-Belgrade virus type'],\n",
              "         'term_norm': 'HANTAVIRUS HEMORRHAGIC FEVER WITH RENAL SYNDROME DOBRAVA BELGRADE VIRUS TYPE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000346',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.22882903458041,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Avulavirus infectious disease'],\n",
              "         'term_norm': 'AVULAVIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005660',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 57.34656172688884,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 282,\n",
              "       'end': 295,\n",
              "       'match_norm': 'CORONAVIRUS'}]}]}],\n",
              " [{'idx': 'cbaf65f1f4904a53b529e0fd1698ea84',\n",
              "   'sections': [{'text': 'For infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world, emergency research on drug repositioning has played an important role in reducing mortality, calming patient fears, and restoring economic production when no specific drugs or vaccines were initially available during the pandemic.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'infectious diseases',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 4, 'end': 23}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0005550',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'infectious disease',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0005550',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'disorder due to infection',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['DOID:0050117',\n",
              "           'ICD9:136.8',\n",
              "           'NCIT:C26726',\n",
              "           'ICD10:Z22',\n",
              "           'ICD9:079.0',\n",
              "           'IDO:IDO_0000436',\n",
              "           'MONDO:0005550',\n",
              "           'MESH:D003141',\n",
              "           'ICD10CM:A00-B99',\n",
              "           'SCTID:40733004',\n",
              "           'IDO:0000436',\n",
              "           'ICD9:136.9',\n",
              "           'SNOMEDCT:40733004'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['parasitic infectious disease'],\n",
              "         'term_norm': 'PARASITIC INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005135',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.43634541962096,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['mumps infectious disease'],\n",
              "         'term_norm': 'MUMPS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000989',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.63394267736844,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bacterial infectious disease'],\n",
              "         'term_norm': 'BACTERIAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.83153921618216,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Cestode infectious disease'],\n",
              "         'term_norm': 'CESTODE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0042488',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.42278693462086,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['mumps infectious disease'],\n",
              "         'term_norm': 'MUMPS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000989',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.0057701752537,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Cestode infectious disease'],\n",
              "         'term_norm': 'CESTODE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0042488',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.9740688628782,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious discitis'],\n",
              "         'term_norm': 'INFECTIOUS DISCITI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_8000000',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.92785445314254,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['parasitic infectious disease'],\n",
              "         'term_norm': 'PARASITIC INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005135',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.90038027397682,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ascaridia infectious disease'],\n",
              "         'term_norm': 'ASCARIDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005655',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.76617120233642,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disorder'],\n",
              "         'term_norm': 'INFECTIOUS DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005550',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.06524734672398,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease or post-infectious disorder'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE OR POST INFECTIOUS DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100336',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 88.47689540240974,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['viral infectious disease'],\n",
              "         'term_norm': 'VIRAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005108',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.69773643585833,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious discitis'],\n",
              "         'term_norm': 'INFECTIOUS DISCITI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_8000000',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.75320997203414,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Tinea infectious disease'],\n",
              "         'term_norm': 'TINEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005982',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 90.11809849090459,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['renal infectious disease'],\n",
              "         'term_norm': 'RENAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004369',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 87.98317782414561,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease characteristic'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE CHARACTERISTIC',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0045034',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.53494384176263,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005550',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 97.8980330615247,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Tinea infectious disease'],\n",
              "         'term_norm': 'TINEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005982',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 90.40065650424556,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal diseases'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEAS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.77208644487203,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal disease'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.38314601943658,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease or post-infectious disorder'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE OR POST INFECTIOUS DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0100336',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 88.62412549225198,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005550',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 97.88443442192923,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal diseases'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEAS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.83516114327001,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['anaplasma infectious disease'],\n",
              "         'term_norm': 'ANAPLASMA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0025303',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 79.9013609696188,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Proteus infectious disease'],\n",
              "         'term_norm': 'PROTEUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0006929',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.2160614572425,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['intestinal infectious disease'],\n",
              "         'term_norm': 'INTESTINAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000916',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.03935155200335,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['viral infectious disease'],\n",
              "         'term_norm': 'VIRAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005108',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.61704755443748,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Nocardia infectious disease'],\n",
              "         'term_norm': 'NOCARDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0017776',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.17699173330988,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Bacteria infectious disease'],\n",
              "         'term_norm': 'BACTERIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.27710767478173,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Enoplea infectious disease'],\n",
              "         'term_norm': 'ENOPLEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005745',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 84.45132941319167,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['rare infectious disease'],\n",
              "         'term_norm': 'RARE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0019062',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 89.24213123785673,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Nocardia infectious disease'],\n",
              "         'term_norm': 'NOCARDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017776',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.55031533661773,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['intestinal infectious disease'],\n",
              "         'term_norm': 'INTESTINAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000916',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.5772134339965,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bacterial infectious disease'],\n",
              "         'term_norm': 'BACTERIAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.09674847554227,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Proteus infectious disease'],\n",
              "         'term_norm': 'PROTEUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0006929',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.1660226658925,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal disease'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.31053913349274,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Viruses infectious disease'],\n",
              "         'term_norm': 'VIRUSES INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005108',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.06634051359116,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Enoplea infectious disease'],\n",
              "         'term_norm': 'ENOPLEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005745',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 84.94763161888503,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Bacteria infectious disease'],\n",
              "         'term_norm': 'BACTERIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.96674380661096,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ascaridia infectious disease'],\n",
              "         'term_norm': 'ASCARIDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005655',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.27455442784945,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 4,\n",
              "       'end': 23,\n",
              "       'match_norm': 'INFECTIOUS DISEAS'},\n",
              "      {'match': 'Zika virus',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 33, 'end': 43}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'Zika virus infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Zika virus infectious disease',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'Zika virus infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0018661',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Zika',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['NCIT:C128423',\n",
              "           'MESH:D000071243',\n",
              "           'GARD:0012894',\n",
              "           'SCTID:3928002',\n",
              "           'DOID:0060478',\n",
              "           'UMLS:CN237724',\n",
              "           'UMLS:C0276289',\n",
              "           'Orphanet:448237',\n",
              "           'ICD10CM:A92.5'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['Zika virus congenital syndrome'],\n",
              "         'term_norm': 'ZIKA VIRUS CONGENITAL SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 77.32866107488648,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete Zika fever'],\n",
              "         'term_norm': 'OBSOLETE ZIKA FEVER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000768',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.99151232354542,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus disease'],\n",
              "         'term_norm': 'ZIKA VIRUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 86.01332425081632,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['antenatal varicella virus infection'],\n",
              "         'term_norm': 'ANTENATAL VARICELLA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017372',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.65407669465763,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rubella virus infectious disease'],\n",
              "         'term_norm': 'RUBELLA VIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004656',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 34.865513892414874,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Lassa virus infection'],\n",
              "         'term_norm': 'LASSA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0044750',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.016008344511896,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus infection'],\n",
              "         'term_norm': 'ZIKA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.13338017680275,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus disease or disorder'],\n",
              "         'term_norm': 'ZIKA VIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 72.30057569892074,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['congenital Zika syndrome'],\n",
              "         'term_norm': 'CONGENITAL ZIKA SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.52949854905874,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['congenital Zika virus infection'],\n",
              "         'term_norm': 'CONGENITAL ZIKA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.10316444332351,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hepatitis D virus'],\n",
              "         'term_norm': 'HEPATITIS D VIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005789',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.31752512214569,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rubella virus disease or disorder'],\n",
              "         'term_norm': 'RUBELLA VIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0004656',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 36.04755566526677,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ebola virus disease'],\n",
              "         'term_norm': 'EBOLA VIRUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005737',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.71024603787112,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hardikar syndrome'],\n",
              "         'term_norm': 'HARDIKAR SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0012997',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.380346663575914,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['congenital Zika syndrome'],\n",
              "         'term_norm': 'CONGENITAL ZIKA SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.49717609269621,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika'],\n",
              "         'term_norm': 'ZIKA',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 77.22423697624204,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus caused disease or disorder'],\n",
              "         'term_norm': 'ZIKA VIRUS CAUSED DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.02417491177187,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus disease'],\n",
              "         'term_norm': 'ZIKA VIRUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 86.02696838276009,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus caused disease or disorder'],\n",
              "         'term_norm': 'ZIKA VIRUS CAUSED DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 64.22361885426209,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Kahrizi syndrome'],\n",
              "         'term_norm': 'KAHRIZI SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0012991',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 36.8402642235197,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ebola virus disease'],\n",
              "         'term_norm': 'EBOLA VIRUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005737',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 40.08305927205285,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Kaposi Sarcoma-Associated Herpes Virus'],\n",
              "         'term_norm': 'KAPOSI SARCOMA ASSOCIATED HERPES VIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005187',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 41.59351417897639,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Karandikar-Maria-Kamble syndrome'],\n",
              "         'term_norm': 'KARANDIKAR MARIA KAMBLE SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0015324',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.69702664133878,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus infection'],\n",
              "         'term_norm': 'ZIKA VIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.88924000862347,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus congenital syndrome'],\n",
              "         'term_norm': 'ZIKA VIRUS CONGENITAL SYNDROME',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 76.53553033455006,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus infectious disease'],\n",
              "         'term_norm': 'ZIKA VIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 69.93403973803382,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Karandikar-Maria-Kamble syndrome'],\n",
              "         'term_norm': 'KARANDIKAR MARIA KAMBLE SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0015324',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 43.767332356446715,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Tumor Virus Infections'],\n",
              "         'term_norm': 'TUMOR VIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005111',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 35.41614804954411,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hendra virus infection'],\n",
              "         'term_norm': 'HENDRA VIRUS INFECTION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017942',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 39.3274684977557,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Rubella virus disease or disorder'],\n",
              "         'term_norm': 'RUBELLA VIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004656',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 36.17636322856293,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['congenital Zika virus infection'],\n",
              "         'term_norm': 'CONGENITAL ZIKA VIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000890',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 68.61507216934324,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika'],\n",
              "         'term_norm': 'ZIKA',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 77.40153995014468,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Kaposi Sarcoma Herpes Virus'],\n",
              "         'term_norm': 'KAPOSI SARCOMA HERPES VIRU',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005187',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 47.0203705041426,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus infectious disease'],\n",
              "         'term_norm': 'ZIKA VIRUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 70.3350594757071,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Kahrizi syndrome'],\n",
              "         'term_norm': 'KAHRIZI SYNDROME',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0012991',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.24057549081976,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['KAND'],\n",
              "         'term_norm': 'KAND',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0700055',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.29361910421804,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['KAND'],\n",
              "         'term_norm': 'KAND',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': True,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0700055',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 37.74148957121119,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Hepatitis D virus'],\n",
              "         'term_norm': 'HEPATITIS D VIRU',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005789',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 42.30035910586337,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Lassa virus infection'],\n",
              "         'term_norm': 'LASSA VIRUS INFECTION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0044750',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 38.486692563808965,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Zika virus disease or disorder'],\n",
              "         'term_norm': 'ZIKA VIRUS DISEASE OR DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 71.88267115048974,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 33,\n",
              "       'end': 43,\n",
              "       'match_norm': 'ZIKA VIRU'},\n",
              "      {'match': 'mortality',\n",
              "       'entity_class': 'measurement',\n",
              "       'spans': [{'start': 209, 'end': 218}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'mortality',\n",
              "         'source': 'STATO',\n",
              "         'parser_name': 'STATO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/STATO_0000414',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'mortality',\n",
              "          'mapping_type': 'http://www.w3.org/2000/01/rdf-schema#label',\n",
              "          'data_origin': 'RC1.4'}}],\n",
              "       'synonym_terms': [{'terms': ['mortality'],\n",
              "         'term_norm': 'MORTALITY',\n",
              "         'parser_name': 'STATO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/STATO_0000414',\n",
              "             'STATO']]}],\n",
              "         'mapping_types': ['http://www.w3.org/2000/01/rdf-schema#label'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 209,\n",
              "       'end': 218,\n",
              "       'match_norm': 'MORTALITY'}]}]}],\n",
              " [{'idx': '840a6a00009a4778be608892e5e19d71',\n",
              "   'sections': [{'text': 'The combination of precision medicine and drug repositioning studies, often used to seek treatments for rare diseases and, in particular, genetically related diseases, is expected to be fully developed in the future.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'precision',\n",
              "       'entity_class': 'measurement',\n",
              "       'spans': [{'start': 19, 'end': 28}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'precision',\n",
              "         'source': 'STATO',\n",
              "         'parser_name': 'STATO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'precision',\n",
              "          'mapping_type': 'http://www.w3.org/2000/01/rdf-schema#label',\n",
              "          'data_origin': 'RC1.4'}}],\n",
              "       'synonym_terms': [{'terms': ['precision'],\n",
              "         'term_norm': 'PRECISION',\n",
              "         'parser_name': 'STATO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "             'STATO']]}],\n",
              "         'mapping_types': ['http://www.w3.org/2000/01/rdf-schema#label'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 19,\n",
              "       'end': 28,\n",
              "       'match_norm': 'PRECISION'},\n",
              "      {'match': 'rare diseases',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 104, 'end': 117}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'obsolete rare disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0021200',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'obsolete rare disease',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}}],\n",
              "       'synonym_terms': [{'terms': ['rare diseases'],\n",
              "         'term_norm': 'RARE DISEAS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0021200',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 104,\n",
              "       'end': 117,\n",
              "       'match_norm': 'RARE DISEAS'},\n",
              "      {'match': 'genetically related diseases',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 138, 'end': 166}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'synonym_terms': [{'terms': ['genetic renal disease'],\n",
              "         'term_norm': 'GENETIC RENAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100191',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 67.30791117816474,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['AIDS-related disease'],\n",
              "         'term_norm': 'AIDS RELATED DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0024571',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.72427154415017,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['maternal disease-related embryofetopathy'],\n",
              "         'term_norm': 'MATERNAL DISEASE RELATED EMBRYOFETOPATHY',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0016678',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.551317926462204,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['sickle cell disease and related diseases'],\n",
              "         'term_norm': 'SICKLE CELL DISEASE AND RELATED DISEAS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0017146',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 60.31148233167436,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete rare genetic intestinal disease'],\n",
              "         'term_norm': 'OBSOLETE RARE GENETIC INTESTINAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0015616',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.21904686373784,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['disease predisposing to age-related macular degeneration'],\n",
              "         'term_norm': 'DISEASE PREDISPOSING TO AGE RELATED MACULAR DEGENERATION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0020245',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.02026489315909,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['inherited genetic disease'],\n",
              "         'term_norm': 'INHERITED GENETIC DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0003847',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.90871058558254,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete rare genetic renal disease'],\n",
              "         'term_norm': 'OBSOLETE RARE GENETIC RENAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020030',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 59.33466653587926,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['inherited genetic disease'],\n",
              "         'term_norm': 'INHERITED GENETIC DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0003847',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.8691506379175,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['dry age related macular degeneration'],\n",
              "         'term_norm': 'DRY AGE RELATED MACULAR DEGENERATION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0100114',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.5147812722054,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['End Stage Renal Disease', 'End-Stage Renal Disease'],\n",
              "         'term_norm': 'END STAGE RENAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005300',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.189413862391255,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['retinal disease'],\n",
              "         'term_norm': 'RETINAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005283',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.80579509926555,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['genetic vitreoretinal disease'],\n",
              "         'term_norm': 'GENETIC VITREORETINAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020238',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.208055460353734,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['disease predisposing to age-related macular degeneration'],\n",
              "         'term_norm': 'DISEASE PREDISPOSING TO AGE RELATED MACULAR DEGENERATION',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020245',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.5426320938556,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['sickle cell disease and related diseases'],\n",
              "         'term_norm': 'SICKLE CELL DISEASE AND RELATED DISEAS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017146',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.037396444688966,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete rare genetic cardiac disease'],\n",
              "         'term_norm': 'OBSOLETE RARE GENETIC CARDIAC DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020029',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.002958085192084,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Pasteurella caused disease or disorder'],\n",
              "         'term_norm': 'PASTEURELLA CAUSED DISEASE OR DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005901',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 51.3779764460387,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['genetic disease'],\n",
              "         'term_norm': 'GENETIC DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0003847',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 61.24008674118442,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['wet age related macular degeneration'],\n",
              "         'term_norm': 'WET AGE RELATED MACULAR DEGENERATION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005417',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.44237741374297,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['age-related macular degeneration',\n",
              "          'Age-Related Macular Degenerations',\n",
              "          'Age Related Macular Degeneration'],\n",
              "         'term_norm': 'AGE RELATED MACULAR DEGENERATION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005150',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.30744823783835,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['nebulin-related early-onset distal myopathy'],\n",
              "         'term_norm': 'NEBULIN RELATED EARLY ONSET DISTAL MYOPATHY',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0018371',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.857165148348805,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete rare genetic hepatic disease'],\n",
              "         'term_norm': 'OBSOLETE RARE GENETIC HEPATIC DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0015507',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.583812720157695,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete rare genetic urogenital disease'],\n",
              "         'term_norm': 'OBSOLETE RARE GENETIC UROGENITAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0015511',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.799349928500504,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['genetic vitreous-retinal disease'],\n",
              "         'term_norm': 'GENETIC VITREOUS RETINAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0020238',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.11375301047876,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['UMOD-related kidney disease'],\n",
              "         'term_norm': 'UMOD RELATED KIDNEY DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0008073',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.15004706936429,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete rare genetic medullar disease'],\n",
              "         'term_norm': 'OBSOLETE RARE GENETIC MEDULLAR DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0026173',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 58.33973662971338,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete rare genetic disease'],\n",
              "         'term_norm': 'OBSOLETE RARE GENETIC DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0021198',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.03904431276373,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['UMOD-related kidney disease'],\n",
              "         'term_norm': 'UMOD RELATED KIDNEY DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0008073',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.15079830783144,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['genetic vitreoretinal disease'],\n",
              "         'term_norm': 'GENETIC VITREORETINAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0020238',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.13728698622132,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['end stage renal disease'],\n",
              "         'term_norm': 'END STAGE RENAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004375',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 52.98793222827679,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Diabetic renal disease'],\n",
              "         'term_norm': 'DIABETIC RENAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005016',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.91551584543976,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete rare genetic respiratory disease'],\n",
              "         'term_norm': 'OBSOLETE RARE GENETIC RESPIRATORY DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0015510',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 54.430215687619175,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['genetic vitreous-retinal disease'],\n",
              "         'term_norm': 'GENETIC VITREOUS RETINAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0020238',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.061349061949585,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['beta-thalassemia and related diseases'],\n",
              "         'term_norm': 'BETA THALASSEMIA AND RELATED DISEAS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0017145',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.34911882250866,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['genetic intestinal disease'],\n",
              "         'term_norm': 'GENETIC INTESTINAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0015616',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 53.71610895669606,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['late-onset retinal degeneration'],\n",
              "         'term_norm': 'LATE ONSET RETINAL DEGENERATION',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0011579',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 50.08508466070671,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['beta-thalassemia and related diseases'],\n",
              "         'term_norm': 'BETA THALASSEMIA AND RELATED DISEAS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017145',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 56.699683156666424,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['obsolete rare genetic adrenal disease'],\n",
              "         'term_norm': 'OBSOLETE RARE GENETIC ADRENAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0015971',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 55.070833794113504,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 138,\n",
              "       'end': 166,\n",
              "       'match_norm': 'GENETICALLY RELATED DISEAS'}]}]}],\n",
              " [{'idx': '0424f202c36e4b3d85848a32d2f8ff8d',\n",
              "   'sections': [{'text': 'In the past 2 years, Virtual screening, together with Molecular docking and Machine learning, has become the most cutting-edge and important research methods in related technology fields, constantly improving the accuracy of drug reuse and screening.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'accuracy',\n",
              "       'entity_class': 'measurement',\n",
              "       'spans': [{'start': 213, 'end': 221}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'accuracy',\n",
              "         'source': 'STATO',\n",
              "         'parser_name': 'STATO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/STATO_0000415',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'accuracy',\n",
              "          'mapping_type': 'http://www.w3.org/2000/01/rdf-schema#label',\n",
              "          'data_origin': 'RC1.4'}}],\n",
              "       'synonym_terms': [{'terms': ['accuracy'],\n",
              "         'term_norm': 'ACCURACY',\n",
              "         'parser_name': 'STATO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/STATO_0000415',\n",
              "             'STATO']]}],\n",
              "         'mapping_types': ['http://www.w3.org/2000/01/rdf-schema#label'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 213,\n",
              "       'end': 221,\n",
              "       'match_norm': 'ACCURACY'}]}]}],\n",
              " [{'idx': 'ac666521f7e84c40800304836badc30e',\n",
              "   'sections': [{'text': 'Currently, to develop more efficient and accurate research, there are two trends in the use of drug repositioning.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '195f1c61fbdc40a4bbe30ff413420216',\n",
              "   'sections': [{'text': 'One is the combination of various methods, such as the use of text mining and network analysis, and the creation of statistical models for predicting semantic link association to assess the relationship between pharmacological target pairings text analysis combined with machine learning to develop drugs for Parkinson’s disease prediction of new DTIs using data from multiple databases and the obtained relocated anticancer drugs were verified by cross-validation, literature, and experimental verification.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'Parkinson’s disease',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 309, 'end': 328}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'Parkinson disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0005180',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': \"Parkinson's disease\",\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['ICD9:332',\n",
              "           'MESH:D010300',\n",
              "           'DOID:14330',\n",
              "           'NIFSTD:birnlex_2098',\n",
              "           'Orphanet:319705',\n",
              "           'OMIMPS:168600',\n",
              "           'SCTID:49049000',\n",
              "           'UMLS:C0030567',\n",
              "           'KEGG:05012',\n",
              "           'ICD9:332.0',\n",
              "           'NCIT:C26845',\n",
              "           'EFO:0002508'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}},\n",
              "        {'default_label': 'Parkinson disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0005180',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Parkinson disease',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}}],\n",
              "       'synonym_terms': [{'terms': [\"Parkinson's disease\"],\n",
              "         'term_norm': 'PARKINSONS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005180',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True},\n",
              "        {'terms': [\"Parkinson's disease\"],\n",
              "         'term_norm': 'PARKINSONS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005180',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 100.0,\n",
              "         'bool_score': True,\n",
              "         'exact_match': True}],\n",
              "       'start': 309,\n",
              "       'end': 328,\n",
              "       'match_norm': 'PARKINSONS DISEASE'}]}]}],\n",
              " [{'idx': '8233d09f3b5d4e08909aa6b18f75d475',\n",
              "   'sections': [{'text': 'Second, the most advanced algorithms are applied and improved, such as matrix decomposition and matrix completion and deep learning.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'a8ed8bf9b05c44c29c1ee8be0c469f22',\n",
              "   'sections': [{'text': 'In fact, some of the studies in the list of highly cited research topics on novel coronaviruses drug repurposing studies are currently approaching 3000 citations on Google Scholar.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '80e8fc6eb2704cfb876c2d8e0d658f0f',\n",
              "   'sections': [{'text': 'The percentage of highly cited studies and hot research topics related to novel coronaviruses is also a good indication that drug repositioning has made an indelible contribution to the study of novel coronaviruses and similar infectious diseases.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'infectious diseases',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 227, 'end': 246}],\n",
              "       'namespace': 'TransformersModelForTokenClassificationNerStep',\n",
              "       'mention_confidence': 'HIGHLY_LIKELY',\n",
              "       'mappings': [{'default_label': 'infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'MONDO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/MONDO_0005550',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'infectious disease',\n",
              "          'mapping_type': 'lbl',\n",
              "          'data_origin': 'MONDO-v2023-05-01'}},\n",
              "        {'default_label': 'infectious disease',\n",
              "         'source': 'MONDO',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'MONDO_0005550',\n",
              "         'string_match_strategy': 'StrongMatchWithEmbeddingConfirmationStringMatchingStrategy',\n",
              "         'string_match_confidence': 'POSSIBLE',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'disorder due to infection',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'dbXRefs': ['DOID:0050117',\n",
              "           'ICD9:136.8',\n",
              "           'NCIT:C26726',\n",
              "           'ICD10:Z22',\n",
              "           'ICD9:079.0',\n",
              "           'IDO:IDO_0000436',\n",
              "           'MONDO:0005550',\n",
              "           'MESH:D003141',\n",
              "           'ICD10CM:A00-B99',\n",
              "           'SCTID:40733004',\n",
              "           'IDO:0000436',\n",
              "           'ICD9:136.9',\n",
              "           'SNOMEDCT:40733004'],\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['parasitic infectious disease'],\n",
              "         'term_norm': 'PARASITIC INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005135',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.43634541962096,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['mumps infectious disease'],\n",
              "         'term_norm': 'MUMPS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000989',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.63394267736844,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bacterial infectious disease'],\n",
              "         'term_norm': 'BACTERIAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.83153921618216,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Cestode infectious disease'],\n",
              "         'term_norm': 'CESTODE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0042488',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.42278693462086,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['mumps infectious disease'],\n",
              "         'term_norm': 'MUMPS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000989',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.0057701752537,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Cestode infectious disease'],\n",
              "         'term_norm': 'CESTODE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0042488',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.9740688628782,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious discitis'],\n",
              "         'term_norm': 'INFECTIOUS DISCITI',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_8000000',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.92785445314254,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['parasitic infectious disease'],\n",
              "         'term_norm': 'PARASITIC INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005135',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.90038027397682,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ascaridia infectious disease'],\n",
              "         'term_norm': 'ASCARIDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005655',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.76617120233642,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disorder'],\n",
              "         'term_norm': 'INFECTIOUS DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005550',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.06524734672398,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease or post-infectious disorder'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE OR POST INFECTIOUS DISORDER',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0100336',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 88.47689540240974,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['viral infectious disease'],\n",
              "         'term_norm': 'VIRAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005108',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.69773643585833,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious discitis'],\n",
              "         'term_norm': 'INFECTIOUS DISCITI',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_8000000',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.75320997203414,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Tinea infectious disease'],\n",
              "         'term_norm': 'TINEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005982',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 90.11809849090459,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['renal infectious disease'],\n",
              "         'term_norm': 'RENAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0004369',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 87.98317782414561,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease characteristic'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE CHARACTERISTIC',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0045034',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.53494384176263,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005550',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 97.8980330615247,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Tinea infectious disease'],\n",
              "         'term_norm': 'TINEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005982',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 90.40065650424556,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal diseases'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEAS',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.77208644487203,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal disease'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.38314601943658,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease or post-infectious disorder'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE OR POST INFECTIOUS DISORDER',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0100336',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 88.62412549225198,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious disease'],\n",
              "         'term_norm': 'INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005550',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 97.88443442192923,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal diseases'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEAS',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.83516114327001,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['anaplasma infectious disease'],\n",
              "         'term_norm': 'ANAPLASMA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0025303',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 79.9013609696188,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Proteus infectious disease'],\n",
              "         'term_norm': 'PROTEUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0006929',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.2160614572425,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['intestinal infectious disease'],\n",
              "         'term_norm': 'INTESTINAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0000916',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.03935155200335,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['viral infectious disease'],\n",
              "         'term_norm': 'VIRAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005108',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.61704755443748,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Nocardia infectious disease'],\n",
              "         'term_norm': 'NOCARDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0017776',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.17699173330988,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Bacteria infectious disease'],\n",
              "         'term_norm': 'BACTERIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.27710767478173,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Enoplea infectious disease'],\n",
              "         'term_norm': 'ENOPLEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005745',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 84.45132941319167,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['rare infectious disease'],\n",
              "         'term_norm': 'RARE INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0019062',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 89.24213123785673,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Nocardia infectious disease'],\n",
              "         'term_norm': 'NOCARDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0017776',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.55031533661773,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['intestinal infectious disease'],\n",
              "         'term_norm': 'INTESTINAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0000916',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.5772134339965,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['bacterial infectious disease'],\n",
              "         'term_norm': 'BACTERIAL INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym', 'lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.09674847554227,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Proteus infectious disease'],\n",
              "         'term_norm': 'PROTEUS INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0006929',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 83.1660226658925,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['infectious diarrheal disease'],\n",
              "         'term_norm': 'INFECTIOUS DIARRHEAL DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0001517',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 81.31053913349274,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Viruses infectious disease'],\n",
              "         'term_norm': 'VIRUSES INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005108',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.06634051359116,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Enoplea infectious disease'],\n",
              "         'term_norm': 'ENOPLEA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005745',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['lbl'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 84.94763161888503,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Bacteria infectious disease'],\n",
              "         'term_norm': 'BACTERIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['MONDO_0005113',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 80.96674380661096,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False},\n",
              "        {'terms': ['Ascaridia infectious disease'],\n",
              "         'term_norm': 'ASCARIDIA INFECTIOUS DISEASE',\n",
              "         'parser_name': 'MONDO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/MONDO_0005655',\n",
              "             'MONDO']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'search_score': 82.27455442784945,\n",
              "         'bool_score': True,\n",
              "         'exact_match': False}],\n",
              "       'start': 227,\n",
              "       'end': 246,\n",
              "       'match_norm': 'INFECTIOUS DISEAS'}]}]}],\n",
              " [{'idx': '7e57a080e95947ac813fb022a4fcaeee',\n",
              "   'sections': [{'text': 'Auxiliary technology for the experimental screening of traditional drugs is also developing, which also promotes drug repositioning or other drug development processes.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '0599fd2bbc6c427da729f88afbd76f4b',\n",
              "   'sections': [{'text': 'Furthermore, the high-quality results of Elfiky, AA, a scientist from Cairo University, Egypt, suggest that relevant research in some economically underdeveloped countries may reach top levels worldwide due to the return or affiliation of some prominent scientists.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'fd196d6ef559465ea416aebc9828d4ce',\n",
              "   'sections': [{'text': 'For this research, the literature on drug repositioning research published in the SCI-E and SSCI sections of WOS core journals from 2010 to 2020 was analyzed based on bibliometrics and DDA software.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'f1cbd1c2702f4f99bb20e5c6ed839510',\n",
              "   'sections': [{'text': 'This area has been of interest to scientists since the end of the 20th century and entered a period of rapid growth in 2019, with the peak far from being reached.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '7989965080ac4fb689d2ab08af77b7da',\n",
              "   'sections': [{'text': 'Using bibliometrics as a tool, the United States has become a world leader in terms of the number of submissions, number of high-quality studies, funding support, strength of research institutions, and number of top scholars, followed by China and the United Kingdom, where more research is being performed in This area.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '8b787e7bc0ae45ee8325f17a47c25c71',\n",
              "   'sections': [{'text': 'As a method of drug discovery, drug repurposing is closely related to the development of various biomedical disciplines, and computer-related disciplinary methods, such as mathematical computational biology and computer science, have taken an important place in the research of drug repurposing in the last decade.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '42e5eb11a05a4984ad48ead1dbc69a3d',\n",
              "   'sections': [{'text': 'The authors’ keyword analysis suggests that research in the field of the novel coronavirus will remain valuable until the associated pandemic is completely contained.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '28fe425df8774411b0c3fa3d44d21628',\n",
              "   'sections': [{'text': 'Virtual screening, molecular docking, machine learning, and other related technical fields still need long-term development to achieve efficient and accurate repositioning of drugs.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'de70a7f4cfbb4fb48efbf745d7b6beab',\n",
              "   'sections': [{'text': 'Precision medicine, combined with drug repositioning, is the most promising direction for the future.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'Precision',\n",
              "       'entity_class': 'measurement',\n",
              "       'spans': [{'start': 0, 'end': 9}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'precision',\n",
              "         'source': 'STATO',\n",
              "         'parser_name': 'STATO',\n",
              "         'idx': 'http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'precision',\n",
              "          'mapping_type': 'http://www.w3.org/2000/01/rdf-schema#label',\n",
              "          'data_origin': 'RC1.4'}}],\n",
              "       'synonym_terms': [{'terms': ['precision'],\n",
              "         'term_norm': 'PRECISION',\n",
              "         'parser_name': 'STATO',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "             'STATO']]}],\n",
              "         'mapping_types': ['http://www.w3.org/2000/01/rdf-schema#label'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 0,\n",
              "       'end': 9,\n",
              "       'match_norm': 'PRECISION'}]}]}],\n",
              " [{'idx': '0399ec5828814dea8bbfbcb63fb5717e',\n",
              "   'sections': [{'text': 'In conclusion, drug repositioning can help to treat more diseases, such as drug resistance, poor drug selectivity, and limited therapeutic options.',\n",
              "     'name': 'na',\n",
              "     'entities': [{'match': 'drug resistance',\n",
              "       'entity_class': 'disease',\n",
              "       'spans': [{'start': 75, 'end': 90}],\n",
              "       'namespace': 'ExplosionStringMatchingStep',\n",
              "       'mention_confidence': 'PROBABLE',\n",
              "       'mappings': [{'default_label': 'Refractory drug response',\n",
              "         'source': 'HP',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'idx': 'HP_0020174',\n",
              "         'string_match_strategy': 'ExactMatchMappingStrategy',\n",
              "         'string_match_confidence': 'HIGHLY_LIKELY',\n",
              "         'disambiguation_strategy': 'disambiguation_not_required',\n",
              "         'metadata': {'syn': 'Drug resistance',\n",
              "          'mapping_type': 'hasExactSynonym',\n",
              "          'data_origin': 'OPENTARGETS-DISEASE-23.02'}}],\n",
              "       'synonym_terms': [{'terms': ['Drug resistance'],\n",
              "         'term_norm': 'DRUG RESISTANCE',\n",
              "         'parser_name': 'OPENTARGETS_DISEASE',\n",
              "         'is_symbolic': False,\n",
              "         'associated_id_sets': [{'ids_and_source': [['HP_0020174', 'HP']]}],\n",
              "         'mapping_types': ['hasExactSynonym'],\n",
              "         'aggregated_by': 'UNAMBIGUOUS',\n",
              "         'exact_match': True}],\n",
              "       'start': 75,\n",
              "       'end': 90,\n",
              "       'match_norm': 'DRUG RESISTANCE'}]}]}],\n",
              " [{'idx': '79ce14f2e13d44708d596370e34eff8a',\n",
              "   'sections': [{'text': 'This study may help some scholars with an initial interest in drug repositioning-related research to gain a concise and rapid understanding of the current state of global research, as well as offer some relevant information to institutions or groups seeking collaboration.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'ac338f167c404da581b1d6e24a453741',\n",
              "   'sections': [{'text': 'It is worth noting that This study has some biases and limitations.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '93104f0184a747108d6a0d41bcd10bfa',\n",
              "   'sections': [{'text': 'First, there are still some issues with the publications included in This study based on subject terms 1 some relevant publications that do not use the search formula in This study may have been excluded from This study and 2 there may also be a small number of articles whose use of some of the aforementioned search terms deviates significantly from the general understanding yet, such publications are included in This study.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'b1aace7552c348eaa9e07d7d4a118a16',\n",
              "   'sections': [{'text': 'Second, some extraneous factors distort the credibility of the bibliometric statistics.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '35032e77fa57469aa3ec41201598bacf',\n",
              "   'sections': [{'text': '1 When analyzing the keywords of publications, some publications are excluded from the statistical analysis because some publications do not list author keywords e.g. 2 Excessive self-citation by some authors inflates the actual level of interest in the publication.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': 'ac7c2229f75146068ea608b5a395057e',\n",
              "   'sections': [{'text': '3 for a publication, when an author submits more than one institution’s address information, a publication is counted as research results by each institution.',\n",
              "     'name': 'na'}]}],\n",
              " [{'idx': '608be296febf495fade1e5fec390cf97',\n",
              "   'sections': [{'text': 'Finally, in future work, patents from the WOS database associated with the topic of drug repositioning will be analyzed to provide another perspective on the situation of the topic of drug repositioning in terms of applications and technological innovations.',\n",
              "     'name': 'na'}]}]]"
            ]
          },
          "metadata": {},
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 3.4 Parsed entities\n",
        "\n",
        "The following function accesses the 'entities' list inside 'sections', then the 'idx' value, or CUI, from the first element in the 'mappings' list for the entity if available, else it returns the entity mention.  Start and end spans are also accessed from the 'spans' list."
      ],
      "metadata": {
        "id": "2AU7yagYoDlJ"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def get_parsed_entities_kazu(entity_list):\n",
        "    parsed_entities = []\n",
        "    for item in entity_list:\n",
        "        entities = item[0].get('sections', [{}])[0].get('entities', [])  # Accessing the 'entities' list inside 'sections'\n",
        "        for entity in entities:\n",
        "            if 'mappings' in entity:  # Checking if 'mappings' key exists\n",
        "                entity_id = entity['mappings'][0]['idx']  # Accessing the 'idx' value from the first element of 'mappings' list\n",
        "            else:\n",
        "                entity_id = entity.get('match')\n",
        "            spans_list = entity.get('spans', [])  # Accessing the 'spans' list from the entity dictionary\n",
        "            span_start = spans_list[0].get('start')\n",
        "            span_end = spans_list[0].get('end')\n",
        "            parsed_entities.append({\n",
        "                'entity_id': entity_id,\n",
        "                'entity_type': entity.get('entity_class'),\n",
        "                'entity': entity.get('match'),\n",
        "                'span_start': span_start,\n",
        "                'span_end': span_end,\n",
        "                'text': item[0].get('sections', [{}])[0].get('text'),  # Accessing the 'text' value inside 'sections'\n",
        "                'idx': item[0].get('idx')\n",
        "            })\n",
        "    return parsed_entities"
      ],
      "metadata": {
        "id": "D-W9KLJsyKdz"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "parsed_entities = list(map(get_parsed_entities_kazu, entity_list))"
      ],
      "metadata": {
        "id": "upiXQgXJyUI3",
        "collapsed": true
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(parsed_entities)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "iYjb13_lFOfH",
        "outputId": "d2c491ce-7908-47c7-a893-0a2e12c85668"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "10"
            ]
          },
          "metadata": {},
          "execution_count": 12
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-03_kazu_entity_list_entities_only_spans_0_10.pickle', 'wb') as f:\n",
        "  pickle.dump(parsed_entities, f)"
      ],
      "metadata": {
        "id": "DCO7q-wjzHLR"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "parsed_entities[0]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "XpwrJv0BFWQM",
        "outputId": "4729674f-4474-4e16-adb5-0977238cf01e"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'entity_id': 'CHEMBL192',\n",
              "  'entity_type': 'drug',\n",
              "  'entity': 'sildenafil',\n",
              "  'span_start': 38,\n",
              "  'span_end': 48,\n",
              "  'text': 'Since the 1990s, the repositioning of sildenafil for male erectile dysfunction and pulmonary hypertension, the development of a new efficacy of bupropion for smoking cessation, new applications of thalidomide for multiple myeloma, and chronic graft-versus-host disease have generated intense interest from pharmaceutical companies and academics.',\n",
              "  'idx': '22200652f00d4d5fb5875f619734eaed'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/HP_0100639',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'male erectile dysfunction',\n",
              "  'span_start': 53,\n",
              "  'span_end': 78,\n",
              "  'text': 'Since the 1990s, the repositioning of sildenafil for male erectile dysfunction and pulmonary hypertension, the development of a new efficacy of bupropion for smoking cessation, new applications of thalidomide for multiple myeloma, and chronic graft-versus-host disease have generated intense interest from pharmaceutical companies and academics.',\n",
              "  'idx': '22200652f00d4d5fb5875f619734eaed'},\n",
              " {'entity_id': 'MONDO_0005149',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'pulmonary hypertension',\n",
              "  'span_start': 83,\n",
              "  'span_end': 105,\n",
              "  'text': 'Since the 1990s, the repositioning of sildenafil for male erectile dysfunction and pulmonary hypertension, the development of a new efficacy of bupropion for smoking cessation, new applications of thalidomide for multiple myeloma, and chronic graft-versus-host disease have generated intense interest from pharmaceutical companies and academics.',\n",
              "  'idx': '22200652f00d4d5fb5875f619734eaed'},\n",
              " {'entity_id': 'CHEMBL894',\n",
              "  'entity_type': 'drug',\n",
              "  'entity': 'bupropion',\n",
              "  'span_start': 144,\n",
              "  'span_end': 153,\n",
              "  'text': 'Since the 1990s, the repositioning of sildenafil for male erectile dysfunction and pulmonary hypertension, the development of a new efficacy of bupropion for smoking cessation, new applications of thalidomide for multiple myeloma, and chronic graft-versus-host disease have generated intense interest from pharmaceutical companies and academics.',\n",
              "  'idx': '22200652f00d4d5fb5875f619734eaed'},\n",
              " {'entity_id': 'CHEMBL468',\n",
              "  'entity_type': 'drug',\n",
              "  'entity': 'thalidomide',\n",
              "  'span_start': 197,\n",
              "  'span_end': 208,\n",
              "  'text': 'Since the 1990s, the repositioning of sildenafil for male erectile dysfunction and pulmonary hypertension, the development of a new efficacy of bupropion for smoking cessation, new applications of thalidomide for multiple myeloma, and chronic graft-versus-host disease have generated intense interest from pharmaceutical companies and academics.',\n",
              "  'idx': '22200652f00d4d5fb5875f619734eaed'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0009693',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'multiple myeloma',\n",
              "  'span_start': 213,\n",
              "  'span_end': 229,\n",
              "  'text': 'Since the 1990s, the repositioning of sildenafil for male erectile dysfunction and pulmonary hypertension, the development of a new efficacy of bupropion for smoking cessation, new applications of thalidomide for multiple myeloma, and chronic graft-versus-host disease have generated intense interest from pharmaceutical companies and academics.',\n",
              "  'idx': '22200652f00d4d5fb5875f619734eaed'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0020547',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'chronic graft-versus-host disease',\n",
              "  'span_start': 235,\n",
              "  'span_end': 268,\n",
              "  'text': 'Since the 1990s, the repositioning of sildenafil for male erectile dysfunction and pulmonary hypertension, the development of a new efficacy of bupropion for smoking cessation, new applications of thalidomide for multiple myeloma, and chronic graft-versus-host disease have generated intense interest from pharmaceutical companies and academics.',\n",
              "  'idx': '22200652f00d4d5fb5875f619734eaed'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "  'entity_type': 'measurement',\n",
              "  'entity': 'precision',\n",
              "  'span_start': 116,\n",
              "  'span_end': 125,\n",
              "  'text': 'At the beginning of the 21st century, cheminformatics, bioinformatics, systems biology, genomics, polypharmacology, precision medicine, and other disciplines, combined with artificial intelligence, have developed rapidly.',\n",
              "  'idx': '45575790fc88453a90d6e15b0474e89d'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "  'entity_type': 'measurement',\n",
              "  'entity': 'precision',\n",
              "  'span_start': 78,\n",
              "  'span_end': 87,\n",
              "  'text': 'cheminformatics, bioinformatics, systems biology, genomics, polypharmacology, precision medicine, and other disciplines have promoted the generation of systematic computer methods to make the drug repositioning process cheaper and shorter.',\n",
              "  'idx': 'ac22ae2fbeb14ca5baf01f3b0022cd57'},\n",
              " {'entity_id': 'Cmap',\n",
              "  'entity_type': 'gene',\n",
              "  'entity': 'Cmap',\n",
              "  'span_start': 98,\n",
              "  'span_end': 102,\n",
              "  'text': 'Computational drug repositioning relies on public biochemical databases such as DrugBank, ChEMBL, Cmap, PDB, OMIM, etc., to provide the appropriate information.',\n",
              "  'idx': 'ff1c074b8c7a4d15805ef2ab4f043bb1'},\n",
              " {'entity_id': 'MONDO_0005071',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'neurological diseases',\n",
              "  'span_start': 97,\n",
              "  'span_end': 118,\n",
              "  'text': 'Today, drug repositioning is increasingly prominent in the development of drugs for a variety of neurological diseases, cancer, rare diseases, and infectious diseases.',\n",
              "  'idx': 'ae1f33d77559408bb43f914ac3aa8b88'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'cancer',\n",
              "  'span_start': 120,\n",
              "  'span_end': 126,\n",
              "  'text': 'Today, drug repositioning is increasingly prominent in the development of drugs for a variety of neurological diseases, cancer, rare diseases, and infectious diseases.',\n",
              "  'idx': 'ae1f33d77559408bb43f914ac3aa8b88'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0021200',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'rare diseases',\n",
              "  'span_start': 128,\n",
              "  'span_end': 141,\n",
              "  'text': 'Today, drug repositioning is increasingly prominent in the development of drugs for a variety of neurological diseases, cancer, rare diseases, and infectious diseases.',\n",
              "  'idx': 'ae1f33d77559408bb43f914ac3aa8b88'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0005550',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'infectious diseases',\n",
              "  'span_start': 147,\n",
              "  'span_end': 166,\n",
              "  'text': 'Today, drug repositioning is increasingly prominent in the development of drugs for a variety of neurological diseases, cancer, rare diseases, and infectious diseases.',\n",
              "  'idx': 'ae1f33d77559408bb43f914ac3aa8b88'},\n",
              " {'entity_id': 'CHEMBL25',\n",
              "  'entity_type': 'drug',\n",
              "  'entity': 'aspirin',\n",
              "  'span_start': 147,\n",
              "  'span_end': 154,\n",
              "  'text': 'The bibliometric approach can solve the aforementioned problems relatively fairly, but at present, scholars have only studied the bibliometrics of aspirin, a drug repurposing there has not been a panoramic study of drug repurposing, and therefore, this study is necessary.',\n",
              "  'idx': '82ab09f0f9bd4539b612bc196d0aa7b8'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/STATO_0000035',\n",
              "  'entity_type': 'measurement',\n",
              "  'entity': 'range',\n",
              "  'span_start': 188,\n",
              "  'span_end': 193,\n",
              "  'text': 'Bibliometrics is a useful tool combining multiple parameters for the quantitative analysis of scholarly publications and is currently used to assess research hotspots and trends in a wide range of disciplines and industries, such as management, sociology, economics, medicine, environmental engineering, and agronomy.',\n",
              "  'idx': '08bcf7a15f6a4fc0a2ef3ba694841f85'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/STATO_0000093',\n",
              "  'entity_type': 'measurement',\n",
              "  'entity': 'date',\n",
              "  'span_start': 107,\n",
              "  'span_end': 111,\n",
              "  'text': 'It should be noted that because some studies were published online ahead of time and the study publication date was a year or two behind, for statistical purposes, the year of publication of such research studies was included as the year of online publication.',\n",
              "  'idx': '5da55e5a9b1c4c52ab2fa3d3b942fdad'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'COVID-19',\n",
              "  'span_start': 197,\n",
              "  'span_end': 205,\n",
              "  'text': 'The number of annual publications has been increasing at a relatively high rate since 2015, while in 2020, there was a spike in the number of publications and annual citations, probably due to the COVID-19 pandemic, a global public health emergency that prompted special attention from scientists.',\n",
              "  'idx': '487f27b9fd2446438765e1a7f6a96952'},\n",
              " {'entity_id': 'ENSG00000014257',\n",
              "  'entity_type': 'gene',\n",
              "  'entity': 'ACPP',\n",
              "  'span_start': 55,\n",
              "  'span_end': 59,\n",
              "  'text': 'We also included the average citations per publication ACPP in the comparison, which is calculated by dividing the TC by the TP total papers value and is a relative number that may better reflect the individual or collective level of attention than the individual TC and TP values.',\n",
              "  'idx': 'ccee5b6361224aadab1c21834dcaab1a'},\n",
              " {'entity_id': 'ENSG00000014257',\n",
              "  'entity_type': 'gene',\n",
              "  'entity': 'ACPP',\n",
              "  'span_start': 61,\n",
              "  'span_end': 65,\n",
              "  'text': 'Canada ranked first in the average citations per publication ACPP at 41.81, closely followed by the United Kingdom and Germany.',\n",
              "  'idx': '52dc51b778e545989b3a648661c7cc7c'},\n",
              " {'entity_id': 'ENSG00000014257',\n",
              "  'entity_type': 'gene',\n",
              "  'entity': 'ACPP',\n",
              "  'span_start': 57,\n",
              "  'span_end': 61,\n",
              "  'text': 'The Icahn School of Medicine at Mt Sinai ranked first in ACPP at 77.32.',\n",
              "  'idx': 'cc8c7222ed6d4b6989ab93f1038cdd48'},\n",
              " {'entity_id': 'ENSG00000014257',\n",
              "  'entity_type': 'gene',\n",
              "  'entity': 'ACPP',\n",
              "  'span_start': 67,\n",
              "  'span_end': 71,\n",
              "  'text': 'The Icahn School of Medicine at Mt Sinai was the best performer in ACPP at 77.32, followed by the University of California, San Francisco and Johns Hopkins University, both of which are US-based research institutions.',\n",
              "  'idx': '2ff31d6788c149948f442c70d961a556'},\n",
              " {'entity_id': 'ENSG00000014257',\n",
              "  'entity_type': 'gene',\n",
              "  'entity': 'ACPP',\n",
              "  'span_start': 110,\n",
              "  'span_end': 114,\n",
              "  'text': \"Compared with US research institutions, Chinese research institutions are at the back of the pack in terms of ACPP, and Chinese research institutions's impact needs to be improved.\",\n",
              "  'idx': 'de58f01f99e442d08d6097dc2981c0b0'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/STATO_0000118',\n",
              "  'entity_type': 'measurement',\n",
              "  'entity': 'ranking',\n",
              "  'span_start': 14,\n",
              "  'span_end': 21,\n",
              "  'text': 'Combining the ranking of multiple parameters, we found that the NIH and the Icahn School of Medicine at Mt Sinai in the United States are the most vocal institutions in terms of academic research result perspective on the topic.',\n",
              "  'idx': '76f8bf26e958413f952bdaf9aed921ea'},\n",
              " {'entity_id': 'ENSG00000014257',\n",
              "  'entity_type': 'gene',\n",
              "  'entity': 'ACPP',\n",
              "  'span_start': 127,\n",
              "  'span_end': 131,\n",
              "  'text': 'Briefly, pharmacology and pharmacy took first place with 962 articles, followed by biochemistry and molecular biology, and for ACPP, the top three were science and technology-other topics, mathematics, and cell biology.',\n",
              "  'idx': 'ed566d04064643d3ac1c5f5f8fa3b2de'},\n",
              " {'entity_id': 'MONDO_0015974',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Sci',\n",
              "  'span_start': 81,\n",
              "  'span_end': 84,\n",
              "  'text': 'The top 25 journals in terms of a total number of studies published are shown in Sci Rep topped the list with 75 studies published, followed by PLoS One, J. Biomol.',\n",
              "  'idx': '73a47d94d71f43f59d7a5246acb640c3'},\n",
              " {'entity_id': 'ENSG00000014257',\n",
              "  'entity_type': 'gene',\n",
              "  'entity': 'ACPP',\n",
              "  'span_start': 183,\n",
              "  'span_end': 187,\n",
              "  'text': 'In terms of total citations TC, at present, studies in Drug Discov. have been cited a total of 2119 times over the past 10 years, followed in rank by PLoS One and Bioinformatics. For ACPP, Drug Discov. still holds first place with a high frequency of 50.45 times, followed by PLoS Comput 33.14 times.',\n",
              "  'idx': 'c1d9ba22631a470d884ed3a654c7d3fc'},\n",
              " {'entity_id': 'ENSG00000014257',\n",
              "  'entity_type': 'gene',\n",
              "  'entity': 'ACPP',\n",
              "  'span_start': 21,\n",
              "  'span_end': 25,\n",
              "  'text': 'Thus, shows that the ACPP of drug repurposing publications included in most journals is much higher than that of IF, which roughly verifies that the number of scholars interested in drug repurposing is relatively high.',\n",
              "  'idx': '77f443b51ea147feb3974939fda963dd'},\n",
              " {'entity_id': 'MONDO_0015974',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'SCI',\n",
              "  'span_start': 39,\n",
              "  'span_end': 42,\n",
              "  'text': 'Biol., which have not been included in SCI since 2018 and 2020, Brief. Bioinform. has the highest value of 11.622, followed by Drug Discov., Bioinformatics, Cancers, Eur. J. Med.',\n",
              "  'idx': '6f1d6aeb07324791b1981cd08431c03f'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Cancers',\n",
              "  'span_start': 157,\n",
              "  'span_end': 164,\n",
              "  'text': 'Biol., which have not been included in SCI since 2018 and 2020, Brief. Bioinform. has the highest value of 11.622, followed by Drug Discov., Bioinformatics, Cancers, Eur. J. Med.',\n",
              "  'idx': '6f1d6aeb07324791b1981cd08431c03f'},\n",
              " {'entity_id': 'ENSG00000014257',\n",
              "  'entity_type': 'gene',\n",
              "  'entity': 'ACPP',\n",
              "  'span_start': 120,\n",
              "  'span_end': 124,\n",
              "  'text': 'For the list of corresponding authors, the top three remain, in order, Mucke, HAM, Cheng, FX, and Talevi, A In terms of ACPP ranking, Butte, AJ was ranked first with 154.33 points, followed by Cheng, FX, Tang, Y, and Dudley, JT.',\n",
              "  'idx': '92efd0a6178045c6a0f0cfddbf17095d'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/STATO_0000118',\n",
              "  'entity_type': 'measurement',\n",
              "  'entity': 'ranking',\n",
              "  'span_start': 125,\n",
              "  'span_end': 132,\n",
              "  'text': 'For the list of corresponding authors, the top three remain, in order, Mucke, HAM, Cheng, FX, and Talevi, A In terms of ACPP ranking, Butte, AJ was ranked first with 154.33 points, followed by Cheng, FX, Tang, Y, and Dudley, JT.',\n",
              "  'idx': '92efd0a6178045c6a0f0cfddbf17095d'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/STATO_0000035',\n",
              "  'entity_type': 'measurement',\n",
              "  'entity': 'range',\n",
              "  'span_start': 142,\n",
              "  'span_end': 147,\n",
              "  'text': 'Highly cited studies were defined as studies in the top 1% of the citations for all studies in the same the ESI discipline within the 10-year range of inclusion of the ESI inclusion.',\n",
              "  'idx': '253388fa2dc84ec1a87f1065e4512a6d'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'COVID-19',\n",
              "  'span_start': 59,\n",
              "  'span_end': 67,\n",
              "  'text': 'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "  'idx': 'e8adbb3eb77941f9bd063708854ffb17'},\n",
              " {'entity_id': 'SARS',\n",
              "  'entity_type': 'species',\n",
              "  'entity': 'SARS',\n",
              "  'span_start': 68,\n",
              "  'span_end': 72,\n",
              "  'text': 'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "  'idx': 'e8adbb3eb77941f9bd063708854ffb17'},\n",
              " {'entity_id': 'Coronavirus',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Coronavirus',\n",
              "  'span_start': 79,\n",
              "  'span_end': 90,\n",
              "  'text': 'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "  'idx': 'e8adbb3eb77941f9bd063708854ffb17'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Cancer',\n",
              "  'span_start': 92,\n",
              "  'span_end': 98,\n",
              "  'text': 'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "  'idx': 'e8adbb3eb77941f9bd063708854ffb17'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0004975',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Alzheimer’s disease',\n",
              "  'span_start': 100,\n",
              "  'span_end': 119,\n",
              "  'text': 'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "  'idx': 'e8adbb3eb77941f9bd063708854ffb17'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0007254',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Breast cancer',\n",
              "  'span_start': 121,\n",
              "  'span_end': 134,\n",
              "  'text': 'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "  'idx': 'e8adbb3eb77941f9bd063708854ffb17'},\n",
              " {'entity_id': 'MONDO_0001444',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Chagas disease',\n",
              "  'span_start': 140,\n",
              "  'span_end': 154,\n",
              "  'text': 'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "  'idx': 'e8adbb3eb77941f9bd063708854ffb17'},\n",
              " {'entity_id': 'CHEMBL1431',\n",
              "  'entity_type': 'drug',\n",
              "  'entity': 'Metformin',\n",
              "  'span_start': 47,\n",
              "  'span_end': 56,\n",
              "  'text': 'Drug names appear four times, Antiviral drugs, Metformin, Statins, and Antibiotics, which reveal the diseases and applications to which drugs were often repositioned during recent years.',\n",
              "  'idx': '7814d19035cf414fa7a2268c1ed0376d'},\n",
              " {'entity_id': 'Statins',\n",
              "  'entity_type': 'drug',\n",
              "  'entity': 'Statins',\n",
              "  'span_start': 58,\n",
              "  'span_end': 65,\n",
              "  'text': 'Drug names appear four times, Antiviral drugs, Metformin, Statins, and Antibiotics, which reveal the diseases and applications to which drugs were often repositioned during recent years.',\n",
              "  'idx': '7814d19035cf414fa7a2268c1ed0376d'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "  'entity_type': 'measurement',\n",
              "  'entity': 'Precision',\n",
              "  'span_start': 91,\n",
              "  'span_end': 100,\n",
              "  'text': 'There were four subject categories, Bioinformatics, Polypharmacology, Systems biology, and Precision medicine and eight occurrences of research methods, namely, Virtual screening, Molecular docking, Machine learning 54, eighth, Clinical trials, High-throughput screening, Connectivity map, and Molecular dynamics simulation.',\n",
              "  'idx': 'edd315d8ae2848c2839e98fd1e71405c'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'COVID-19',\n",
              "  'span_start': 96,\n",
              "  'span_end': 104,\n",
              "  'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "  'idx': '650b870a0f1e4bd089a385567180c322'},\n",
              " {'entity_id': 'SARS-CoV-',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'SARS-CoV-',\n",
              "  'span_start': 105,\n",
              "  'span_end': 114,\n",
              "  'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "  'idx': '650b870a0f1e4bd089a385567180c322'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'COVID-19',\n",
              "  'span_start': 168,\n",
              "  'span_end': 176,\n",
              "  'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "  'idx': '650b870a0f1e4bd089a385567180c322'},\n",
              " {'entity_id': 'SARS-CoV-2',\n",
              "  'entity_type': 'species',\n",
              "  'entity': 'SARS-CoV-2',\n",
              "  'span_start': 177,\n",
              "  'span_end': 187,\n",
              "  'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "  'idx': '650b870a0f1e4bd089a385567180c322'},\n",
              " {'entity_id': 'Coronavirus',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Coronavirus',\n",
              "  'span_start': 188,\n",
              "  'span_end': 199,\n",
              "  'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "  'idx': '650b870a0f1e4bd089a385567180c322'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'COVID-19',\n",
              "  'span_start': 73,\n",
              "  'span_end': 81,\n",
              "  'text': 'Molecular docking is one of the core steps of virtual screening, and the COVID-19 pandemic generated many opportunities for the practice of drug repositioning.',\n",
              "  'idx': '0c09a88aad3840288fef26e9cbe164d2'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0100096',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'COVID-19',\n",
              "  'span_start': 48,\n",
              "  'span_end': 56,\n",
              "  'text': 'Therefore, high-quality studies of the keywords COVID-19/SARS-CoV-2/Coronavirus, Virtual screening, and Molecular docking were surveyed, as shown in the bubble chart, in the past two years, reflecting the relevant research trend in recent years.',\n",
              "  'idx': '94a7fda0918a47c5a1b783a3cfae6ba8'},\n",
              " {'entity_id': 'SARS-',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'SARS-',\n",
              "  'span_start': 57,\n",
              "  'span_end': 62,\n",
              "  'text': 'Therefore, high-quality studies of the keywords COVID-19/SARS-CoV-2/Coronavirus, Virtual screening, and Molecular docking were surveyed, as shown in the bubble chart, in the past two years, reflecting the relevant research trend in recent years.',\n",
              "  'idx': '94a7fda0918a47c5a1b783a3cfae6ba8'},\n",
              " {'entity_id': 'Coronavirus',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Coronavirus',\n",
              "  'span_start': 68,\n",
              "  'span_end': 79,\n",
              "  'text': 'Therefore, high-quality studies of the keywords COVID-19/SARS-CoV-2/Coronavirus, Virtual screening, and Molecular docking were surveyed, as shown in the bubble chart, in the past two years, reflecting the relevant research trend in recent years.',\n",
              "  'idx': '94a7fda0918a47c5a1b783a3cfae6ba8'},\n",
              " {'entity_id': 'HP_0020174',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'drug resistance',\n",
              "  'span_start': 238,\n",
              "  'span_end': 253,\n",
              "  'text': 'Xie, L et al. screened antitoxic drugs based on the multitarget structure of the pathway center and stated that this inhibition of multiple targets in one pathway would be more effective than targeting a single protein, and the chance of drug resistance was smaller, which could be applied to other pathways.',\n",
              "  'idx': '8c1c71d22b344c2aa70b78a117c89bf2'},\n",
              " {'entity_id': 'CHEMBL254316',\n",
              "  'entity_type': 'drug',\n",
              "  'entity': 'raltegravir',\n",
              "  'span_start': 133,\n",
              "  'span_end': 144,\n",
              "  'text': 'After a series of drug repurposing computational screens and various validation activities by several scientists, it was agreed that raltegravir, clonidine, chloroquine and hydroxychloroquine have therapeutic effects in the treatment of novel coronavirus.',\n",
              "  'idx': '3ccb2d93d4d44115888b46c5d6d052a5'},\n",
              " {'entity_id': 'CHEMBL134',\n",
              "  'entity_type': 'drug',\n",
              "  'entity': 'clonidine',\n",
              "  'span_start': 146,\n",
              "  'span_end': 155,\n",
              "  'text': 'After a series of drug repurposing computational screens and various validation activities by several scientists, it was agreed that raltegravir, clonidine, chloroquine and hydroxychloroquine have therapeutic effects in the treatment of novel coronavirus.',\n",
              "  'idx': '3ccb2d93d4d44115888b46c5d6d052a5'},\n",
              " {'entity_id': 'CHEMBL76',\n",
              "  'entity_type': 'drug',\n",
              "  'entity': 'chloroquine',\n",
              "  'span_start': 157,\n",
              "  'span_end': 168,\n",
              "  'text': 'After a series of drug repurposing computational screens and various validation activities by several scientists, it was agreed that raltegravir, clonidine, chloroquine and hydroxychloroquine have therapeutic effects in the treatment of novel coronavirus.',\n",
              "  'idx': '3ccb2d93d4d44115888b46c5d6d052a5'},\n",
              " {'entity_id': 'CHEMBL1535',\n",
              "  'entity_type': 'drug',\n",
              "  'entity': 'hydroxychloroquine',\n",
              "  'span_start': 173,\n",
              "  'span_end': 191,\n",
              "  'text': 'After a series of drug repurposing computational screens and various validation activities by several scientists, it was agreed that raltegravir, clonidine, chloroquine and hydroxychloroquine have therapeutic effects in the treatment of novel coronavirus.',\n",
              "  'idx': '3ccb2d93d4d44115888b46c5d6d052a5'},\n",
              " {'entity_id': 'coronavirus',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'coronavirus',\n",
              "  'span_start': 243,\n",
              "  'span_end': 254,\n",
              "  'text': 'After a series of drug repurposing computational screens and various validation activities by several scientists, it was agreed that raltegravir, clonidine, chloroquine and hydroxychloroquine have therapeutic effects in the treatment of novel coronavirus.',\n",
              "  'idx': '3ccb2d93d4d44115888b46c5d6d052a5'},\n",
              " {'entity_id': 'MONDO_0006012',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'coronavirus pneumonia',\n",
              "  'span_start': 309,\n",
              "  'span_end': 330,\n",
              "  'text': 'All hot research topics were published in 2020, and with the exception of an article describing the damage caused by nonsteroidal anti-inflammatory drugs NSAIDs to multiple organs and new information on drug repurposing, the remaining studies focused on drug repositioning therapeutic target studies in novel coronavirus pneumonia, screening drug studies, reviews of clinical trials, and reports of other coronavirus therapeutic agents and vaccine studies.',\n",
              "  'idx': '4fdd1052f46e4bbf9028d14f00806461'},\n",
              " {'entity_id': 'SARS-CoV-2',\n",
              "  'entity_type': 'species',\n",
              "  'entity': 'SARS-CoV-2',\n",
              "  'span_start': 15,\n",
              "  'span_end': 25,\n",
              "  'text': 'In addition, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, published in Nature by Gordon, DE with a total of 125 scholars from the United States, the United Kingdom, and France was the most cited publication with 952 citations.',\n",
              "  'idx': '02e40d8c09754950a7f5ccee671d7e73'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0002046',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Alcohol-abuse',\n",
              "  'span_start': 30,\n",
              "  'span_end': 43,\n",
              "  'text': 'One of Nine studies, entitled Alcohol-abuse drug disulfiram targets cancer via p97 segregase adapter NPL4, published in Nature in 2017 by Skrott, Z et al. is a collaboration between scholars from six countries Czech Republic, the United States, Denmark, Sweden, Switzerland, and China.',\n",
              "  'idx': 'fef528208ca2483990fc1f0a77194580'},\n",
              " {'entity_id': 'CHEMBL964',\n",
              "  'entity_type': 'drug',\n",
              "  'entity': 'disulfiram',\n",
              "  'span_start': 49,\n",
              "  'span_end': 59,\n",
              "  'text': 'One of Nine studies, entitled Alcohol-abuse drug disulfiram targets cancer via p97 segregase adapter NPL4, published in Nature in 2017 by Skrott, Z et al. is a collaboration between scholars from six countries Czech Republic, the United States, Denmark, Sweden, Switzerland, and China.',\n",
              "  'idx': 'fef528208ca2483990fc1f0a77194580'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'cancer',\n",
              "  'span_start': 68,\n",
              "  'span_end': 74,\n",
              "  'text': 'One of Nine studies, entitled Alcohol-abuse drug disulfiram targets cancer via p97 segregase adapter NPL4, published in Nature in 2017 by Skrott, Z et al. is a collaboration between scholars from six countries Czech Republic, the United States, Denmark, Sweden, Switzerland, and China.',\n",
              "  'idx': 'fef528208ca2483990fc1f0a77194580'},\n",
              " {'entity_id': 'p97 segregase',\n",
              "  'entity_type': 'gene',\n",
              "  'entity': 'p97 segregase',\n",
              "  'span_start': 79,\n",
              "  'span_end': 92,\n",
              "  'text': 'One of Nine studies, entitled Alcohol-abuse drug disulfiram targets cancer via p97 segregase adapter NPL4, published in Nature in 2017 by Skrott, Z et al. is a collaboration between scholars from six countries Czech Republic, the United States, Denmark, Sweden, Switzerland, and China.',\n",
              "  'idx': 'fef528208ca2483990fc1f0a77194580'},\n",
              " {'entity_id': 'ENSG00000182446',\n",
              "  'entity_type': 'gene',\n",
              "  'entity': 'NPL4',\n",
              "  'span_start': 101,\n",
              "  'span_end': 105,\n",
              "  'text': 'One of Nine studies, entitled Alcohol-abuse drug disulfiram targets cancer via p97 segregase adapter NPL4, published in Nature in 2017 by Skrott, Z et al. is a collaboration between scholars from six countries Czech Republic, the United States, Denmark, Sweden, Switzerland, and China.',\n",
              "  'idx': 'fef528208ca2483990fc1f0a77194580'},\n",
              " {'entity_id': 'nCoV',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'nCoV',\n",
              "  'span_start': 108,\n",
              "  'span_end': 112,\n",
              "  'text': 'The most cited publication on an annual basis was Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, published in 2020, which was authored by Zhou, YD et al. and was the highest annual average cited publication with 609 citations.',\n",
              "  'idx': 'e209de13a90e44c5990670ec180364ad'},\n",
              " {'entity_id': 'SARS-',\n",
              "  'entity_type': 'species',\n",
              "  'entity': 'SARS-',\n",
              "  'span_start': 113,\n",
              "  'span_end': 118,\n",
              "  'text': 'The most cited publication on an annual basis was Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, published in 2020, which was authored by Zhou, YD et al. and was the highest annual average cited publication with 609 citations.',\n",
              "  'idx': 'e209de13a90e44c5990670ec180364ad'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Zika virus',\n",
              "  'span_start': 58,\n",
              "  'span_end': 68,\n",
              "  'text': 'In the face of a worldwide health emergency caused by the Zika virus epidemic, used drug repositioning to identify lead compounds for drug development.',\n",
              "  'idx': 'eaf4ca3ccfee412496672e85b4e56791'},\n",
              " {'entity_id': '3D cell culture',\n",
              "  'entity_type': 'cell_line',\n",
              "  'entity': '3D cell culture',\n",
              "  'span_start': 231,\n",
              "  'span_end': 246,\n",
              "  'text': 'Of course, techniques related to the mining of repositionable drugs through experimental high-throughput screening, a traditional experimental approach, are not without progress for example, explored the challenges of transferring 3D cell culture technology to the use of high-throughput screening HTS.',\n",
              "  'idx': 'ad1982807025409ab4867eb17c0949b8'},\n",
              " {'entity_id': 'CHEMBL468',\n",
              "  'entity_type': 'drug',\n",
              "  'entity': 'thalidomide',\n",
              "  'span_start': 77,\n",
              "  'span_end': 88,\n",
              "  'text': 'In 1995, Mchugh et al. investigated the immunomodulatory action mechanism of thalidomide in humans, which was the first relevant publication on drug repositioning.',\n",
              "  'idx': '2c15615532b7406aa03b66641ba1ddc4'},\n",
              " {'entity_id': 'ENSG00000014257',\n",
              "  'entity_type': 'gene',\n",
              "  'entity': 'ACPP',\n",
              "  'span_start': 261,\n",
              "  'span_end': 265,\n",
              "  'text': 'In terms of lead authors, three have the most productive and influential positions Cheng, FX is the most prolific author, based on the number of papers and h-index Mucke, HAM is the most frequent corresponding author and Butte, AJ is the top author in terms of ACPP ranking.',\n",
              "  'idx': 'd5cce64720104088baae55958ff8f53e'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/STATO_0000118',\n",
              "  'entity_type': 'measurement',\n",
              "  'entity': 'ranking',\n",
              "  'span_start': 266,\n",
              "  'span_end': 273,\n",
              "  'text': 'In terms of lead authors, three have the most productive and influential positions Cheng, FX is the most prolific author, based on the number of papers and h-index Mucke, HAM is the most frequent corresponding author and Butte, AJ is the top author in terms of ACPP ranking.',\n",
              "  'idx': 'd5cce64720104088baae55958ff8f53e'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0004992',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'cancer',\n",
              "  'span_start': 47,\n",
              "  'span_end': 53,\n",
              "  'text': 'Through the analysis of the authors’ keywords, cancer has been the main disease addressed by this method.',\n",
              "  'idx': '1c5fece0f80b4c7aa2212bbf70c8c01f'},\n",
              " {'entity_id': 'CHEMBL1431',\n",
              "  'entity_type': 'drug',\n",
              "  'entity': 'Metformin',\n",
              "  'span_start': 0,\n",
              "  'span_end': 9,\n",
              "  'text': 'Metformin has been found by many scientists to have a good inhibitory effect on various tumors, mainly in gynecology, and Metformin has become a specific drug that has been most frequently mentioned in drug reuse in recent years.',\n",
              "  'idx': '7e58d417f4034832823d5b2283c51368'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0005070',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'tumors',\n",
              "  'span_start': 88,\n",
              "  'span_end': 94,\n",
              "  'text': 'Metformin has been found by many scientists to have a good inhibitory effect on various tumors, mainly in gynecology, and Metformin has become a specific drug that has been most frequently mentioned in drug reuse in recent years.',\n",
              "  'idx': '7e58d417f4034832823d5b2283c51368'},\n",
              " {'entity_id': 'CHEMBL1431',\n",
              "  'entity_type': 'drug',\n",
              "  'entity': 'Metformin',\n",
              "  'span_start': 122,\n",
              "  'span_end': 131,\n",
              "  'text': 'Metformin has been found by many scientists to have a good inhibitory effect on various tumors, mainly in gynecology, and Metformin has become a specific drug that has been most frequently mentioned in drug reuse in recent years.',\n",
              "  'idx': '7e58d417f4034832823d5b2283c51368'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0005737',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Ebola',\n",
              "  'span_start': 121,\n",
              "  'span_end': 126,\n",
              "  'text': 'In terms of antiviral drugs, scholars not only use drug repositioning to find antiviral drugs to treat diseases, such as Ebola and HIV, that have plagued humans for a long time but also use drug repositioning to seek treatments for infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world.',\n",
              "  'idx': '2920a306fb83418ea876b251bf4bc1c6'},\n",
              " {'entity_id': 'MONDO_0005109',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'HIV',\n",
              "  'span_start': 131,\n",
              "  'span_end': 134,\n",
              "  'text': 'In terms of antiviral drugs, scholars not only use drug repositioning to find antiviral drugs to treat diseases, such as Ebola and HIV, that have plagued humans for a long time but also use drug repositioning to seek treatments for infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world.',\n",
              "  'idx': '2920a306fb83418ea876b251bf4bc1c6'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0019095',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'plagued',\n",
              "  'span_start': 146,\n",
              "  'span_end': 153,\n",
              "  'text': 'In terms of antiviral drugs, scholars not only use drug repositioning to find antiviral drugs to treat diseases, such as Ebola and HIV, that have plagued humans for a long time but also use drug repositioning to seek treatments for infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world.',\n",
              "  'idx': '2920a306fb83418ea876b251bf4bc1c6'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0005550',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'infectious diseases',\n",
              "  'span_start': 232,\n",
              "  'span_end': 251,\n",
              "  'text': 'In terms of antiviral drugs, scholars not only use drug repositioning to find antiviral drugs to treat diseases, such as Ebola and HIV, that have plagued humans for a long time but also use drug repositioning to seek treatments for infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world.',\n",
              "  'idx': '2920a306fb83418ea876b251bf4bc1c6'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Zika virus',\n",
              "  'span_start': 261,\n",
              "  'span_end': 271,\n",
              "  'text': 'In terms of antiviral drugs, scholars not only use drug repositioning to find antiviral drugs to treat diseases, such as Ebola and HIV, that have plagued humans for a long time but also use drug repositioning to seek treatments for infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world.',\n",
              "  'idx': '2920a306fb83418ea876b251bf4bc1c6'},\n",
              " {'entity_id': 'MONDO_0005719',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'coronaviruses',\n",
              "  'span_start': 282,\n",
              "  'span_end': 295,\n",
              "  'text': 'In terms of antiviral drugs, scholars not only use drug repositioning to find antiviral drugs to treat diseases, such as Ebola and HIV, that have plagued humans for a long time but also use drug repositioning to seek treatments for infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world.',\n",
              "  'idx': '2920a306fb83418ea876b251bf4bc1c6'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0005550',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'infectious diseases',\n",
              "  'span_start': 4,\n",
              "  'span_end': 23,\n",
              "  'text': 'For infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world, emergency research on drug repositioning has played an important role in reducing mortality, calming patient fears, and restoring economic production when no specific drugs or vaccines were initially available during the pandemic.',\n",
              "  'idx': 'cbaf65f1f4904a53b529e0fd1698ea84'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0018661',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Zika virus',\n",
              "  'span_start': 33,\n",
              "  'span_end': 43,\n",
              "  'text': 'For infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world, emergency research on drug repositioning has played an important role in reducing mortality, calming patient fears, and restoring economic production when no specific drugs or vaccines were initially available during the pandemic.',\n",
              "  'idx': 'cbaf65f1f4904a53b529e0fd1698ea84'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/STATO_0000414',\n",
              "  'entity_type': 'measurement',\n",
              "  'entity': 'mortality',\n",
              "  'span_start': 209,\n",
              "  'span_end': 218,\n",
              "  'text': 'For infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world, emergency research on drug repositioning has played an important role in reducing mortality, calming patient fears, and restoring economic production when no specific drugs or vaccines were initially available during the pandemic.',\n",
              "  'idx': 'cbaf65f1f4904a53b529e0fd1698ea84'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "  'entity_type': 'measurement',\n",
              "  'entity': 'precision',\n",
              "  'span_start': 19,\n",
              "  'span_end': 28,\n",
              "  'text': 'The combination of precision medicine and drug repositioning studies, often used to seek treatments for rare diseases and, in particular, genetically related diseases, is expected to be fully developed in the future.',\n",
              "  'idx': '840a6a00009a4778be608892e5e19d71'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0021200',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'rare diseases',\n",
              "  'span_start': 104,\n",
              "  'span_end': 117,\n",
              "  'text': 'The combination of precision medicine and drug repositioning studies, often used to seek treatments for rare diseases and, in particular, genetically related diseases, is expected to be fully developed in the future.',\n",
              "  'idx': '840a6a00009a4778be608892e5e19d71'},\n",
              " {'entity_id': 'genetically related diseases',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'genetically related diseases',\n",
              "  'span_start': 138,\n",
              "  'span_end': 166,\n",
              "  'text': 'The combination of precision medicine and drug repositioning studies, often used to seek treatments for rare diseases and, in particular, genetically related diseases, is expected to be fully developed in the future.',\n",
              "  'idx': '840a6a00009a4778be608892e5e19d71'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/STATO_0000415',\n",
              "  'entity_type': 'measurement',\n",
              "  'entity': 'accuracy',\n",
              "  'span_start': 213,\n",
              "  'span_end': 221,\n",
              "  'text': 'In the past 2 years, Virtual screening, together with Molecular docking and Machine learning, has become the most cutting-edge and important research methods in related technology fields, constantly improving the accuracy of drug reuse and screening.',\n",
              "  'idx': '0424f202c36e4b3d85848a32d2f8ff8d'},\n",
              " {'entity_id': 'MONDO_0005180',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'Parkinson’s disease',\n",
              "  'span_start': 309,\n",
              "  'span_end': 328,\n",
              "  'text': 'One is the combination of various methods, such as the use of text mining and network analysis, and the creation of statistical models for predicting semantic link association to assess the relationship between pharmacological target pairings text analysis combined with machine learning to develop drugs for Parkinson’s disease prediction of new DTIs using data from multiple databases and the obtained relocated anticancer drugs were verified by cross-validation, literature, and experimental verification.',\n",
              "  'idx': '195f1c61fbdc40a4bbe30ff413420216'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/MONDO_0005550',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'infectious diseases',\n",
              "  'span_start': 227,\n",
              "  'span_end': 246,\n",
              "  'text': 'The percentage of highly cited studies and hot research topics related to novel coronaviruses is also a good indication that drug repositioning has made an indelible contribution to the study of novel coronaviruses and similar infectious diseases.',\n",
              "  'idx': '80e8fc6eb2704cfb876c2d8e0d658f0f'},\n",
              " {'entity_id': 'http://purl.obolibrary.org/obo/STATO_0000416',\n",
              "  'entity_type': 'measurement',\n",
              "  'entity': 'Precision',\n",
              "  'span_start': 0,\n",
              "  'span_end': 9,\n",
              "  'text': 'Precision medicine, combined with drug repositioning, is the most promising direction for the future.',\n",
              "  'idx': 'de70a7f4cfbb4fb48efbf745d7b6beab'},\n",
              " {'entity_id': 'HP_0020174',\n",
              "  'entity_type': 'disease',\n",
              "  'entity': 'drug resistance',\n",
              "  'span_start': 75,\n",
              "  'span_end': 90,\n",
              "  'text': 'In conclusion, drug repositioning can help to treat more diseases, such as drug resistance, poor drug selectivity, and limited therapeutic options.',\n",
              "  'idx': '0399ec5828814dea8bbfbcb63fb5717e'}]"
            ]
          },
          "metadata": {},
          "execution_count": 13
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 3.5 Entities only\n",
        "\n",
        "We will iterate over the list of parsed entities for each article, append the data to a list and convert it to a DataFrame."
      ],
      "metadata": {
        "id": "eRWoJyZSzHLQ"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "entities_only_list = []\n",
        "\n",
        "for article in parsed_entities:\n",
        "    for entity in article:\n",
        "        entities_only_list.append({\n",
        "            'entity_id': entity['entity_id'],\n",
        "            'entity_type': entity['entity_type'],\n",
        "            'entity': entity['entity'],\n",
        "            'span_start': entity['span_start'],\n",
        "            'span_end': entity['span_end'],\n",
        "            'text': entity['text'],\n",
        "            'idx': entity['idx']\n",
        "        })\n",
        "\n",
        "entities_only_df = pd.DataFrame(entities_only_list, columns=['entity_id', 'entity_type', 'entity', 'span_start', 'span_end', 'text', 'idx'])"
      ],
      "metadata": {
        "id": "sjhKIjT4zHLR"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "entities_only_df"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "6e6f8aea-c4f8-49fb-ec27-2272e1c9b7cb",
        "id": "Xk1Y_XJ3zHLR"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                         entity_id entity_type  \\\n",
              "0                                        CHEMBL192        drug   \n",
              "1        http://purl.obolibrary.org/obo/HP_0100639     disease   \n",
              "2                                    MONDO_0005149     disease   \n",
              "3                                        CHEMBL894        drug   \n",
              "4                                        CHEMBL468        drug   \n",
              "...                                            ...         ...   \n",
              "3384                                          CMAP        gene   \n",
              "3385                                    SARS-CoV-2     species   \n",
              "3386     http://purl.obolibrary.org/obo/CL_0002063   cell_type   \n",
              "3387             African green monkey kidney cells   cell_type   \n",
              "3388  http://purl.obolibrary.org/obo/MONDO_0100096     disease   \n",
              "\n",
              "                                 entity  span_start  span_end  \\\n",
              "0                            sildenafil          38        48   \n",
              "1             male erectile dysfunction          53        78   \n",
              "2                pulmonary hypertension          83       105   \n",
              "3                             bupropion         144       153   \n",
              "4                           thalidomide         197       208   \n",
              "...                                 ...         ...       ...   \n",
              "3384                               CMAP         116       120   \n",
              "3385                         SARS-CoV-2          36        46   \n",
              "3386             alveolar type II cells          89       111   \n",
              "3387  African green monkey kidney cells         116       149   \n",
              "3388                           COVID-19          67        75   \n",
              "\n",
              "                                                   text  \\\n",
              "0     Since the 1990s, the repositioning of sildenaf...   \n",
              "1     Since the 1990s, the repositioning of sildenaf...   \n",
              "2     Since the 1990s, the repositioning of sildenaf...   \n",
              "3     Since the 1990s, the repositioning of sildenaf...   \n",
              "4     Since the 1990s, the repositioning of sildenaf...   \n",
              "...                                                 ...   \n",
              "3384  To compare our method with other methods, we u...   \n",
              "3385  We used gene expression profiles of SARS-CoV-2...   \n",
              "3386  We used gene expression profiles of SARS-CoV-2...   \n",
              "3387  We used gene expression profiles of SARS-CoV-2...   \n",
              "3388  We take as ground truth all drugs currently in...   \n",
              "\n",
              "                                   idx  \n",
              "0     22200652f00d4d5fb5875f619734eaed  \n",
              "1     22200652f00d4d5fb5875f619734eaed  \n",
              "2     22200652f00d4d5fb5875f619734eaed  \n",
              "3     22200652f00d4d5fb5875f619734eaed  \n",
              "4     22200652f00d4d5fb5875f619734eaed  \n",
              "...                                ...  \n",
              "3384  1def003b39ea4c6dbe9a5f73b7600a69  \n",
              "3385  a04c0a5ddb544b91a90c308a89e267d9  \n",
              "3386  a04c0a5ddb544b91a90c308a89e267d9  \n",
              "3387  a04c0a5ddb544b91a90c308a89e267d9  \n",
              "3388  af85dcd07def41358eaa7a59139350c1  \n",
              "\n",
              "[3389 rows x 7 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-cb16a92f-face-4f95-b3cf-ef8b57f1fe69\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>entity_id</th>\n",
              "      <th>entity_type</th>\n",
              "      <th>entity</th>\n",
              "      <th>span_start</th>\n",
              "      <th>span_end</th>\n",
              "      <th>text</th>\n",
              "      <th>idx</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>CHEMBL192</td>\n",
              "      <td>drug</td>\n",
              "      <td>sildenafil</td>\n",
              "      <td>38</td>\n",
              "      <td>48</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>http://purl.obolibrary.org/obo/HP_0100639</td>\n",
              "      <td>disease</td>\n",
              "      <td>male erectile dysfunction</td>\n",
              "      <td>53</td>\n",
              "      <td>78</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>MONDO_0005149</td>\n",
              "      <td>disease</td>\n",
              "      <td>pulmonary hypertension</td>\n",
              "      <td>83</td>\n",
              "      <td>105</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>CHEMBL894</td>\n",
              "      <td>drug</td>\n",
              "      <td>bupropion</td>\n",
              "      <td>144</td>\n",
              "      <td>153</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>CHEMBL468</td>\n",
              "      <td>drug</td>\n",
              "      <td>thalidomide</td>\n",
              "      <td>197</td>\n",
              "      <td>208</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3384</th>\n",
              "      <td>CMAP</td>\n",
              "      <td>gene</td>\n",
              "      <td>CMAP</td>\n",
              "      <td>116</td>\n",
              "      <td>120</td>\n",
              "      <td>To compare our method with other methods, we u...</td>\n",
              "      <td>1def003b39ea4c6dbe9a5f73b7600a69</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3385</th>\n",
              "      <td>SARS-CoV-2</td>\n",
              "      <td>species</td>\n",
              "      <td>SARS-CoV-2</td>\n",
              "      <td>36</td>\n",
              "      <td>46</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3386</th>\n",
              "      <td>http://purl.obolibrary.org/obo/CL_0002063</td>\n",
              "      <td>cell_type</td>\n",
              "      <td>alveolar type II cells</td>\n",
              "      <td>89</td>\n",
              "      <td>111</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3387</th>\n",
              "      <td>African green monkey kidney cells</td>\n",
              "      <td>cell_type</td>\n",
              "      <td>African green monkey kidney cells</td>\n",
              "      <td>116</td>\n",
              "      <td>149</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3388</th>\n",
              "      <td>http://purl.obolibrary.org/obo/MONDO_0100096</td>\n",
              "      <td>disease</td>\n",
              "      <td>COVID-19</td>\n",
              "      <td>67</td>\n",
              "      <td>75</td>\n",
              "      <td>We take as ground truth all drugs currently in...</td>\n",
              "      <td>af85dcd07def41358eaa7a59139350c1</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>3389 rows × 7 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-cb16a92f-face-4f95-b3cf-ef8b57f1fe69')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-cb16a92f-face-4f95-b3cf-ef8b57f1fe69 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-cb16a92f-face-4f95-b3cf-ef8b57f1fe69');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-d6260ca5-fe6c-473d-95de-08d11a05e52f\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-d6260ca5-fe6c-473d-95de-08d11a05e52f')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-d6260ca5-fe6c-473d-95de-08d11a05e52f button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "entities_only_df",
              "summary": "{\n  \"name\": \"entities_only_df\",\n  \"rows\": 3389,\n  \"fields\": [\n    {\n      \"column\": \"entity_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 957,\n        \"samples\": [\n          \"CAII\",\n          \"C1\",\n          \"CHEMBL3545185\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity_type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 11,\n        \"samples\": [\n          \"cell_line\",\n          \"drug\",\n          \"go_bp\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1063,\n        \"samples\": [\n          \"SARS-CoV-\",\n          \"Non-structural protein 5 coding\",\n          \"variance\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_start\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 105,\n        \"min\": 0,\n        \"max\": 954,\n        \"num_unique_values\": 445,\n        \"samples\": [\n          302,\n          150,\n          82\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_end\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 105,\n        \"min\": 2,\n        \"max\": 967,\n        \"num_unique_values\": 440,\n        \"samples\": [\n          455,\n          224,\n          190\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1181,\n        \"samples\": [\n          \"Another study used supervised bipartite graph learning approach to predict enzyme interaction and GPCRs interaction network.\",\n          \"the top-scored cavity as shown in C has a higher drug score revealing significant druggability of the active site with a predicted maximum pKd score of 6.99.\",\n          \"For example, approved nucleoside analogues favipiravir and ribavirin and experimental nucleoside analogues remdesivir and galidesivir may have potential against severe acute respiratory syndrome coronavirus 2 SARS-CoV-2.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"idx\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1181,\n        \"samples\": [\n          \"ab747eca8097413ea8fb1d88af107096\",\n          \"f52c38f87b3842ea8f991d2500358bbd\",\n          \"32916c5de598433997410d8631e4a5f5\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 15
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-03_kazu_entity_list_entities_only_spans_df_0_10.pickle', 'wb') as f:\n",
        "  pickle.dump(entities_only_df, f)"
      ],
      "metadata": {
        "id": "U94xsXGX0_xc"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "entities_only_df.to_csv('2024-04-03_kazu_entity_list_entities_only_spans_df_0_10.csv', index=False)"
      ],
      "metadata": {
        "id": "7fHJs747BXnb"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 3.6 CUI-less entities only\n",
        "\n",
        "We will filter for the CUI-less entities where entity_id is the entity name to see how many knowledge base ids are missing.\n",
        "\n",
        "\n"
      ],
      "metadata": {
        "id": "MKXYD_6-5n1y"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "missing_entity_id_df = entities_only_df[entities_only_df['entity_id'] == entities_only_df['entity']]"
      ],
      "metadata": {
        "id": "HyJ-mveo-IYV"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(missing_entity_id_df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "A3SOVFKX-yZv",
        "outputId": "7a0fa12b-dfb7-47a2-938a-f721d499ad3c"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "1113"
            ]
          },
          "metadata": {},
          "execution_count": 83
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-06_missing_entity_id_df.pickle', 'wb') as f:\n",
        "   pickle.dump(missing_entity_id_df, f)"
      ],
      "metadata": {
        "id": "GQxrQ-h7-5xC"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "missing_entity_id_df"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "sJPEvpurB1KD",
        "outputId": "d1ec4299-33a2-472a-c7e0-ad2e8e8670c1"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                              entity_id entity_type  \\\n",
              "9                                  Cmap        gene   \n",
              "34                                 SARS     species   \n",
              "35                          Coronavirus     disease   \n",
              "41                              Statins        drug   \n",
              "44                            SARS-CoV-     disease   \n",
              "...                                 ...         ...   \n",
              "3358                               NCBI        gene   \n",
              "3364                              viral     disease   \n",
              "3384                               CMAP        gene   \n",
              "3385                         SARS-CoV-2     species   \n",
              "3387  African green monkey kidney cells   cell_type   \n",
              "\n",
              "                                 entity  span_start  span_end  \\\n",
              "9                                  Cmap          98       102   \n",
              "34                                 SARS          68        72   \n",
              "35                          Coronavirus          79        90   \n",
              "41                              Statins          58        65   \n",
              "44                            SARS-CoV-         105       114   \n",
              "...                                 ...         ...       ...   \n",
              "3358                               NCBI         117       121   \n",
              "3364                              viral          46        51   \n",
              "3384                               CMAP         116       120   \n",
              "3385                         SARS-CoV-2          36        46   \n",
              "3387  African green monkey kidney cells         116       149   \n",
              "\n",
              "                                                   text  \\\n",
              "9     Computational drug repositioning relies on pub...   \n",
              "34    the top 30 most used author keywords include f...   \n",
              "35    the top 30 most used author keywords include f...   \n",
              "41    Drug names appear four times, Antiviral drugs,...   \n",
              "44    In the context of the pandemic in that year, t...   \n",
              "...                                                 ...   \n",
              "3358  We got differentially expressed genes of all t...   \n",
              "3364  Since drugs can directly or indirectly affect ...   \n",
              "3384  To compare our method with other methods, we u...   \n",
              "3385  We used gene expression profiles of SARS-CoV-2...   \n",
              "3387  We used gene expression profiles of SARS-CoV-2...   \n",
              "\n",
              "                                   idx  \n",
              "9     ff1c074b8c7a4d15805ef2ab4f043bb1  \n",
              "34    e8adbb3eb77941f9bd063708854ffb17  \n",
              "35    e8adbb3eb77941f9bd063708854ffb17  \n",
              "41    7814d19035cf414fa7a2268c1ed0376d  \n",
              "44    650b870a0f1e4bd089a385567180c322  \n",
              "...                                ...  \n",
              "3358  10a9092bf2a6475b89583c244d12e1dc  \n",
              "3364  bc958fd093674d4c899ca04e37df63e0  \n",
              "3384  1def003b39ea4c6dbe9a5f73b7600a69  \n",
              "3385  a04c0a5ddb544b91a90c308a89e267d9  \n",
              "3387  a04c0a5ddb544b91a90c308a89e267d9  \n",
              "\n",
              "[1113 rows x 7 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-e0f6d63e-6d24-4aa5-a0c7-f94124a902c5\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>entity_id</th>\n",
              "      <th>entity_type</th>\n",
              "      <th>entity</th>\n",
              "      <th>span_start</th>\n",
              "      <th>span_end</th>\n",
              "      <th>text</th>\n",
              "      <th>idx</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>Cmap</td>\n",
              "      <td>gene</td>\n",
              "      <td>Cmap</td>\n",
              "      <td>98</td>\n",
              "      <td>102</td>\n",
              "      <td>Computational drug repositioning relies on pub...</td>\n",
              "      <td>ff1c074b8c7a4d15805ef2ab4f043bb1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>34</th>\n",
              "      <td>SARS</td>\n",
              "      <td>species</td>\n",
              "      <td>SARS</td>\n",
              "      <td>68</td>\n",
              "      <td>72</td>\n",
              "      <td>the top 30 most used author keywords include f...</td>\n",
              "      <td>e8adbb3eb77941f9bd063708854ffb17</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>35</th>\n",
              "      <td>Coronavirus</td>\n",
              "      <td>disease</td>\n",
              "      <td>Coronavirus</td>\n",
              "      <td>79</td>\n",
              "      <td>90</td>\n",
              "      <td>the top 30 most used author keywords include f...</td>\n",
              "      <td>e8adbb3eb77941f9bd063708854ffb17</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>41</th>\n",
              "      <td>Statins</td>\n",
              "      <td>drug</td>\n",
              "      <td>Statins</td>\n",
              "      <td>58</td>\n",
              "      <td>65</td>\n",
              "      <td>Drug names appear four times, Antiviral drugs,...</td>\n",
              "      <td>7814d19035cf414fa7a2268c1ed0376d</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>44</th>\n",
              "      <td>SARS-CoV-</td>\n",
              "      <td>disease</td>\n",
              "      <td>SARS-CoV-</td>\n",
              "      <td>105</td>\n",
              "      <td>114</td>\n",
              "      <td>In the context of the pandemic in that year, t...</td>\n",
              "      <td>650b870a0f1e4bd089a385567180c322</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3358</th>\n",
              "      <td>NCBI</td>\n",
              "      <td>gene</td>\n",
              "      <td>NCBI</td>\n",
              "      <td>117</td>\n",
              "      <td>121</td>\n",
              "      <td>We got differentially expressed genes of all t...</td>\n",
              "      <td>10a9092bf2a6475b89583c244d12e1dc</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3364</th>\n",
              "      <td>viral</td>\n",
              "      <td>disease</td>\n",
              "      <td>viral</td>\n",
              "      <td>46</td>\n",
              "      <td>51</td>\n",
              "      <td>Since drugs can directly or indirectly affect ...</td>\n",
              "      <td>bc958fd093674d4c899ca04e37df63e0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3384</th>\n",
              "      <td>CMAP</td>\n",
              "      <td>gene</td>\n",
              "      <td>CMAP</td>\n",
              "      <td>116</td>\n",
              "      <td>120</td>\n",
              "      <td>To compare our method with other methods, we u...</td>\n",
              "      <td>1def003b39ea4c6dbe9a5f73b7600a69</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3385</th>\n",
              "      <td>SARS-CoV-2</td>\n",
              "      <td>species</td>\n",
              "      <td>SARS-CoV-2</td>\n",
              "      <td>36</td>\n",
              "      <td>46</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3387</th>\n",
              "      <td>African green monkey kidney cells</td>\n",
              "      <td>cell_type</td>\n",
              "      <td>African green monkey kidney cells</td>\n",
              "      <td>116</td>\n",
              "      <td>149</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>1113 rows × 7 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-e0f6d63e-6d24-4aa5-a0c7-f94124a902c5')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-e0f6d63e-6d24-4aa5-a0c7-f94124a902c5 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-e0f6d63e-6d24-4aa5-a0c7-f94124a902c5');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-a0067c08-b2af-4adf-bada-339b7decdbfe\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-a0067c08-b2af-4adf-bada-339b7decdbfe')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-a0067c08-b2af-4adf-bada-339b7decdbfe button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "missing_entity_id_df",
              "summary": "{\n  \"name\": \"missing_entity_id_df\",\n  \"rows\": 1113,\n  \"fields\": [\n    {\n      \"column\": \"entity_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 424,\n        \"samples\": [\n          \"Nsp 12 to 16\",\n          \"ginkgolic acid\",\n          \"Asn422\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity_type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"gene\",\n          \"species\",\n          \"cell_type\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 424,\n        \"samples\": [\n          \"Nsp 12 to 16\",\n          \"ginkgolic acid\",\n          \"Asn422\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_start\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 115,\n        \"min\": 0,\n        \"max\": 920,\n        \"num_unique_values\": 334,\n        \"samples\": [\n          109,\n          321,\n          433\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_end\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 115,\n        \"min\": 2,\n        \"max\": 924,\n        \"num_unique_values\": 340,\n        \"samples\": [\n          169,\n          607,\n          177\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 566,\n        \"samples\": [\n          \"We divided these genes into antiviral and proviral genes according to these genes's effect on SARS-CoV-2, SARS-CoV, and MERS-CoV. There are 654 antiviral genes and 756 proviral genes.\",\n          \"Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.\",\n          \"Lopinavir/ritonavir is a drug for the HIV-1 protease, that now evidences potential for the main protease of SARS-CoV-2.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"idx\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 566,\n        \"samples\": [\n          \"d8caf8b204fb4ab0abad9e40218431c3\",\n          \"1108e974f5674c899317ae518c336936\",\n          \"b7a8bd971a614bfeb517eb328b0ad5ef\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 85
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "missing_entity_id_df.to_csv('2024-04-06_missing_entity_id.csv', index=False)"
      ],
      "metadata": {
        "id": "A5QbSyniDV1Q"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# convert missing entity ids to list\n",
        "all_missing_entity_id = missing_entity_id_df.entity.tolist()\n",
        "all_missing_entity_id"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "atViBsFXD4ls",
        "outputId": "1d496181-e3b8-4067-ed32-42651b9b4f19"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['Cmap',\n",
              " 'SARS',\n",
              " 'Coronavirus',\n",
              " 'Statins',\n",
              " 'SARS-CoV-',\n",
              " 'SARS-CoV-2',\n",
              " 'Coronavirus',\n",
              " 'SARS-',\n",
              " 'Coronavirus',\n",
              " 'coronavirus',\n",
              " 'SARS-CoV-2',\n",
              " 'p97 segregase',\n",
              " 'nCoV',\n",
              " 'SARS-',\n",
              " '3D cell culture',\n",
              " 'genetically related diseases',\n",
              " 'COVID‐19',\n",
              " 'Coronaviruses CoVs',\n",
              " 'epidemic diseases',\n",
              " 'CoVs',\n",
              " 'COVID‐19',\n",
              " 'SARS‐CoV',\n",
              " 'respiratory illness',\n",
              " 'SARS‐CoV',\n",
              " 'COVID‐19',\n",
              " 'SARS‐CoV‐2',\n",
              " 'SARS‐CoV‐2',\n",
              " 'phosphoramide',\n",
              " 'phosphate',\n",
              " 'COVID‐19',\n",
              " 'COVID',\n",
              " 'SARS‐CoV',\n",
              " 'SARS',\n",
              " 'CADD',\n",
              " 'SARS',\n",
              " 'COVID',\n",
              " 'SARS',\n",
              " 'paxlovid 3c‐like protease',\n",
              " 'COVID‐19',\n",
              " 'SARS‐CoV',\n",
              " 'COVID‐19',\n",
              " 'COVID',\n",
              " 'SARS',\n",
              " 'COVID‐19',\n",
              " 'COVID‐19',\n",
              " 'COVID‐19',\n",
              " 'SARS',\n",
              " 'SARS',\n",
              " 'pp1ab',\n",
              " 'host cells',\n",
              " '3CLpro',\n",
              " 'papain',\n",
              " 'papain',\n",
              " 'replicase complex',\n",
              " 'papain',\n",
              " 'PLpro',\n",
              " 'papain',\n",
              " 'SARS',\n",
              " 'ZINC',\n",
              " 'SARS‐CoV‐2',\n",
              " 'Mpro',\n",
              " 'SARS',\n",
              " 'SARS',\n",
              " 'SARS‐CoV',\n",
              " 'COVID‐19',\n",
              " 'SARS‐CoV',\n",
              " 'S',\n",
              " 'SARS‐CoV‐2',\n",
              " 'COVID',\n",
              " 'SARS',\n",
              " 'human coronavirus papain‐like proteases',\n",
              " 'SARS‐Coronavirus',\n",
              " 'SARS',\n",
              " 'COVID‐19',\n",
              " 'COVID',\n",
              " 'Mpro',\n",
              " 'SARS‐CoV',\n",
              " 'SARS‐3CL protease',\n",
              " 'dihydropyrimidine',\n",
              " 'SARS',\n",
              " 'COVID‐19',\n",
              " 'COVID‐19',\n",
              " 'COVID‐19',\n",
              " 'host cell',\n",
              " 'SARS‐CoV',\n",
              " 'papain',\n",
              " 'PLpro',\n",
              " 'Mpro',\n",
              " 'RNA‐dependent RNA polymerase RdRp complex',\n",
              " 'spike S receptor binding glycoprotein',\n",
              " 'nonstructural protein NSP',\n",
              " 'small envelope E',\n",
              " 'SARS',\n",
              " 'SARS',\n",
              " 'SARS‐CoV',\n",
              " 'chymotrypsin‐like protease 3CLpro',\n",
              " 'N',\n",
              " 'RdRp',\n",
              " 'RBD',\n",
              " 'S protein',\n",
              " 'nonstructural protein NSP',\n",
              " 'COVID',\n",
              " 'SARS‐CoV',\n",
              " 'SARS‐CoV',\n",
              " \"RBD's receptor\",\n",
              " 'RBD',\n",
              " 'SARS',\n",
              " 'RBD',\n",
              " 'SARS‐CoV',\n",
              " 'RBD',\n",
              " 'SARS',\n",
              " 'COVID',\n",
              " 'SARS‐CoV‐2',\n",
              " 'COVID‐19',\n",
              " 'M.',\n",
              " 'SARS‐CoV‐2',\n",
              " 'COVID‐19',\n",
              " 'SARS‐CoV‐2',\n",
              " 'COVID‐19',\n",
              " 'COVID‐19',\n",
              " 'COVID‐19 Lee',\n",
              " 'COVID',\n",
              " 'COVID‐19',\n",
              " 'COVID‐19',\n",
              " 'COVID‐19',\n",
              " 'COVID',\n",
              " 'DR',\n",
              " 'cutaneous rashes',\n",
              " 'antimalarial',\n",
              " 'cardiovascular problems',\n",
              " 'SARS‐',\n",
              " 'COVID‐19',\n",
              " 'COVID',\n",
              " 'COVID‐19',\n",
              " 'Won',\n",
              " 'COVID‐19',\n",
              " 'COVID‐19',\n",
              " 'SARS',\n",
              " 'SARS',\n",
              " 'His41',\n",
              " 'Ser144',\n",
              " 'His163',\n",
              " 'Gly143',\n",
              " 'Gln166',\n",
              " 'CO‐NH‐C ‐CO‐NH‐C',\n",
              " 'Mpro',\n",
              " 'HCoV',\n",
              " 'SARS',\n",
              " 'SARS‐CoV',\n",
              " 'SARS‐CoV‐2',\n",
              " 'COVID‐19',\n",
              " 'SARS',\n",
              " 'human cells',\n",
              " 'organoid disease',\n",
              " 'SARS',\n",
              " 'SARS',\n",
              " 'SARS‐CoV‐2',\n",
              " 'human lung cell line',\n",
              " 'Calu‐3',\n",
              " 'SARS',\n",
              " 'CVL218',\n",
              " 'poly‐ADP‐ribose polymerase 1 PARP1',\n",
              " 'SARS‐CoV‐2',\n",
              " 'CVL218',\n",
              " 'SARS‐CoV',\n",
              " 'inflammatory diseases of the lung',\n",
              " 'N',\n",
              " 'SARS‐CoV',\n",
              " 'SARS‐CoV‐2',\n",
              " 'SARS‐CoV‐',\n",
              " 'RdRp',\n",
              " 'SARS‐CoV',\n",
              " 'HIV',\n",
              " 'host',\n",
              " 'Mpro',\n",
              " 'COVID‐19',\n",
              " 'COVID‐19',\n",
              " 'COVID‐19',\n",
              " 'COVID‐19',\n",
              " 'SARS‐CoV‐2',\n",
              " 'COVID‐19',\n",
              " 'SARS‐CoV‐2',\n",
              " 'SARS‐CoV‐2',\n",
              " 'COVID‐19',\n",
              " 'Mpro',\n",
              " 'Mpro',\n",
              " 'SARS‐CoV',\n",
              " 'SARS',\n",
              " 'SARS‐CoV',\n",
              " 'SARS',\n",
              " 'mice',\n",
              " 'MERS',\n",
              " 'SARSCoV-2',\n",
              " 'Lagevrio',\n",
              " 'Lagevrio',\n",
              " 'nucleoside',\n",
              " 'SARSCoV-2',\n",
              " 'MERS corona virus',\n",
              " 'Lagevrio',\n",
              " 'SARSCoV-2 virus',\n",
              " 'SARSCoV-2',\n",
              " 'Lagevrio',\n",
              " 'Lagevrio',\n",
              " 'Lagevrio',\n",
              " 'Lagevrio',\n",
              " 'Lagevrio',\n",
              " 'RdRp',\n",
              " 'SARS-CoV-2',\n",
              " 'Lagevrio',\n",
              " 'EIDD-1931',\n",
              " 'EIDD-1931-triphosphate',\n",
              " 'EIDD-1931-triphosphate',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'Lagevrio',\n",
              " 'Lagevrio',\n",
              " 'isopropyl',\n",
              " 'EIDD-1931',\n",
              " 'EIDD-1931',\n",
              " 'EIDD-1931',\n",
              " 'EIDD-1931',\n",
              " 'mice',\n",
              " 'EIDD-1931',\n",
              " 'Lagevrio',\n",
              " 'seasonal flu',\n",
              " 'mice',\n",
              " 'ferrets',\n",
              " 'Lagevrio',\n",
              " 'Lagevrio',\n",
              " 'Lagevrio',\n",
              " 'EIDD-1931',\n",
              " 'EIDD-1931',\n",
              " 'SARS-CoV-2',\n",
              " 'ferrets',\n",
              " 'SARS-CoV-2',\n",
              " 'EIDD-1931',\n",
              " 'SARS-CoV-2 illness',\n",
              " 'MK-4482-006',\n",
              " 'MK-4482-006',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2 illness',\n",
              " 'SARS-CoV-2',\n",
              " 'COVID-',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-',\n",
              " 'SARS-CoV-2',\n",
              " 'HCoV',\n",
              " 'HCoV-OC43 Human Coronavirus',\n",
              " 'hemagglutinin',\n",
              " 'membrane M',\n",
              " 'envelope E',\n",
              " 'M',\n",
              " 'envelope',\n",
              " 'QLA46612',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'immense pain',\n",
              " 'cyclooxygenase',\n",
              " 'Human Immunodeficiency Virus-1 HIV',\n",
              " 'MERS-CoV',\n",
              " 'SARS-CoV-2',\n",
              " 'MERS-CoV',\n",
              " 'SARS-CoV-2',\n",
              " 'extra-cellular vesicles',\n",
              " 'Ralimetiniib mesylate',\n",
              " 'SARS-CoV-2',\n",
              " 'beta-eudesmol',\n",
              " 'SARS-CoV-2',\n",
              " 'ID-184',\n",
              " 'RNRP RNA-dependent RNA polymerase',\n",
              " 'SARS-CoV-',\n",
              " 'SARS-CoV',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'in vitro cell line',\n",
              " 'feline coronavirus',\n",
              " 'SARS-CoV-2',\n",
              " 'RNA-dependent RNA polymerase',\n",
              " 'SARS-CoV-2',\n",
              " '3-chymotrypsin-like',\n",
              " 'SARS',\n",
              " 'platycodin',\n",
              " 'RNA-dependent RNA polymerases RdRp',\n",
              " 'Nsp 12',\n",
              " 'helicase Nsp13',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'helicase Nsp13',\n",
              " 'SARS-CoV-2',\n",
              " 'dinucleoside 123',\n",
              " 'SARS-CoV',\n",
              " 'envelope',\n",
              " 'SARS-CoV-2',\n",
              " 'anyone',\n",
              " 'viral neuraminidases',\n",
              " 'DPP4 cell receptor',\n",
              " 'eridictoyl',\n",
              " 'S protein',\n",
              " 'SARS-CoV-2',\n",
              " 'RdRp',\n",
              " 'SARS-CoV-2',\n",
              " 'Poly ADP-ribose polymerase 1 PARP-1',\n",
              " 'Mefuparib hydrochloride',\n",
              " 'Poly ADP-ribose polymerase 1 PARP-1',\n",
              " 'glycogen synthase kinase 3 GSK-3',\n",
              " 'SARS-CoV-2',\n",
              " '3-chymotrypsin-like',\n",
              " 'SARS',\n",
              " 'Nsps',\n",
              " 'RBD',\n",
              " 'RBD',\n",
              " 'immunoglobulin superfamily IgSF',\n",
              " 'SARS-CoV-2',\n",
              " '3-chymotrypsin-like',\n",
              " 'SARS',\n",
              " 'AZD7442',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV',\n",
              " 'SARS-CoV-',\n",
              " 'coronavirus',\n",
              " 'RNA-dependent RNA polymerase RdRp',\n",
              " 'nsps',\n",
              " 'His272',\n",
              " 'Cys111',\n",
              " 'Asp286',\n",
              " 'ubiquitin-specific proteases USPs',\n",
              " 'ubiquitin',\n",
              " 'Ubl domain',\n",
              " 'N',\n",
              " 'RNA-dependent DNA polymerase',\n",
              " 'RNA-dependent DNA polymerase',\n",
              " 'RNA-dependent DNA polymerase',\n",
              " 'RNA-dependent DNA polymerase',\n",
              " 'RdRp',\n",
              " 'RdRp',\n",
              " 'N',\n",
              " 'beta',\n",
              " 'C',\n",
              " 'RdRp',\n",
              " 'Non-structural protein 5 coding',\n",
              " '3C proteases',\n",
              " '3CLpro',\n",
              " '3CLpro',\n",
              " 'N',\n",
              " 'C',\n",
              " 'SARS CoV-2',\n",
              " 'CoVs',\n",
              " 'N',\n",
              " 'C',\n",
              " 'enveloped',\n",
              " 'N',\n",
              " 'C',\n",
              " 'SARS CoV-2',\n",
              " 'N',\n",
              " 'SARS CoV-2',\n",
              " 'C',\n",
              " 'spike glycoproteins',\n",
              " 'spike glycoprotein',\n",
              " 'spike glycoprotein',\n",
              " 'S1',\n",
              " 'N',\n",
              " 'C',\n",
              " 'spike glycoprotein',\n",
              " 'ab ORF1ab',\n",
              " 'SARS-CoV-2',\n",
              " 'pp1ab',\n",
              " 'Nsp 1 to 11',\n",
              " 'pp1 polyprotein',\n",
              " 'Nsp 12 to 16',\n",
              " 'SARS-CoV-2',\n",
              " 'RBD residues',\n",
              " 'C121',\n",
              " 'E484',\n",
              " 'MAbs REGN10934',\n",
              " 'REGN10989',\n",
              " 'virus',\n",
              " 'n',\n",
              " 'NTD',\n",
              " 'n',\n",
              " 'n',\n",
              " 'spike glycoprotein',\n",
              " 'spike glycoprotein',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'spike glycoproteins',\n",
              " 'eriodictoyl',\n",
              " 'SARS-CoV-2',\n",
              " 'eriodictoyl',\n",
              " 'aclerasteride',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'spike glycoprotein',\n",
              " 'SARS-CoV-2',\n",
              " 'spike glycoprotein',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'Leu6819',\n",
              " 'Met6818',\n",
              " 'Val7021',\n",
              " 'Tyr7020',\n",
              " 'Asp7018',\n",
              " 'Asp6942',\n",
              " 'spike glycoprotein',\n",
              " 'SARS-CoV-2',\n",
              " 'Leu331',\n",
              " 'Tyr333',\n",
              " 'Arg277',\n",
              " 'Phe274',\n",
              " 'Val270',\n",
              " 'Trp301',\n",
              " 'Thr296',\n",
              " 'Ala264',\n",
              " 'Arg262',\n",
              " 'Phe314',\n",
              " 'Gln260',\n",
              " 'Arg259',\n",
              " 'spike glycoprotein',\n",
              " 'Tyr421',\n",
              " 'Asn422',\n",
              " 'Pro491',\n",
              " 'Leu492',\n",
              " 'Gln493',\n",
              " 'Ser494',\n",
              " 'Tyr495',\n",
              " 'Gly496',\n",
              " 'Phe497',\n",
              " 'Gln498',\n",
              " 'Lys444',\n",
              " 'Asp442',\n",
              " 'Tyr351',\n",
              " 'Val350',\n",
              " 'Ser349',\n",
              " 'Ala348',\n",
              " 'Phe347',\n",
              " 'Arg346',\n",
              " 'Arg509',\n",
              " 'Val401',\n",
              " 'favipiravir-nucleocapsid phosphoprotein',\n",
              " 'Lys6822',\n",
              " 'Glu6821',\n",
              " 'Leu6820',\n",
              " 'Val7021',\n",
              " 'Tyr7020',\n",
              " 'Asp6942',\n",
              " 'Asn6941',\n",
              " 'Glu6940',\n",
              " 'Thr6938',\n",
              " 'remdesivir-nucleocapsid phosphoprotein',\n",
              " 'NSP16',\n",
              " 'Arg6817',\n",
              " 'Met6818',\n",
              " 'Leu6819',\n",
              " 'Leu6820',\n",
              " 'Tyr7020',\n",
              " 'Val7021',\n",
              " 'Asp7018',\n",
              " 'Asp6942',\n",
              " 'Phe314',\n",
              " 'Gln260',\n",
              " 'Arg259',\n",
              " 'Arg277',\n",
              " 'Phe274',\n",
              " 'Tyr333',\n",
              " 'Trp330',\n",
              " 'Trp301',\n",
              " 'Thr282',\n",
              " 'Gly284',\n",
              " 'Phe286',\n",
              " 'Leu291',\n",
              " 'Val270',\n",
              " 'SARS viruses',\n",
              " 'MERS-CoV',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'rhesus monkey',\n",
              " 'RdRp',\n",
              " 'NSP12',\n",
              " 'SARS-CoV-2',\n",
              " 'HIV-',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'HIV',\n",
              " 'SARS-CoV-2',\n",
              " 'C1',\n",
              " 'C5a',\n",
              " 'C3a esterases',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'CVL218',\n",
              " 'N',\n",
              " 'SARS-CoV-2',\n",
              " 'lymphoid malignancies',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'spike glycoproteins',\n",
              " 'RDRP',\n",
              " 'enveloped',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS',\n",
              " 'spike S glycoprotein',\n",
              " 'SARS-CoV-2',\n",
              " 'systemic inflammatory response syndrome SIRS',\n",
              " 'COVID-19 infections',\n",
              " 'COVID-19 infections',\n",
              " 'CMap',\n",
              " 'CMap',\n",
              " 'CMap',\n",
              " 'COVID',\n",
              " 'COVID-19 infections',\n",
              " 'immune illnesses',\n",
              " 'critically',\n",
              " 'critically',\n",
              " 'WGCNA',\n",
              " 'magenta',\n",
              " 'M9',\n",
              " 'M18',\n",
              " 'M28',\n",
              " 'M32',\n",
              " 'M36',\n",
              " 'M9',\n",
              " 'immune cells',\n",
              " 'M9',\n",
              " 'M44',\n",
              " 'M46',\n",
              " 'M9',\n",
              " 'peptide antigen',\n",
              " 'M28',\n",
              " 'M32',\n",
              " 'MHC Class II receptor',\n",
              " 'BPs',\n",
              " 'M9',\n",
              " 'M9',\n",
              " 'M16',\n",
              " 'M16',\n",
              " 'NOD-like receptor',\n",
              " 'KEGG',\n",
              " 'M44',\n",
              " 'M332',\n",
              " 'SB-201290',\n",
              " 'CAY-10470',\n",
              " 'mouse',\n",
              " 'yeast',\n",
              " 'COVID-19 infections',\n",
              " 'inflammation',\n",
              " 'septic shock',\n",
              " 'toll-like',\n",
              " 'M1',\n",
              " 'M44',\n",
              " \"M44's\",\n",
              " 'M9',\n",
              " 'T-',\n",
              " 'M9',\n",
              " 'immune cells',\n",
              " 'NOD-like receptor',\n",
              " 'NOD-like receptors NLRs',\n",
              " 'NF-B',\n",
              " 'inflammation',\n",
              " 'mice',\n",
              " 'CMap',\n",
              " 'inflammation',\n",
              " 'COX',\n",
              " 'inflammation',\n",
              " 'histamine',\n",
              " 'TPCA-1',\n",
              " 'porcine',\n",
              " 'NF-B',\n",
              " 'TPCA-1',\n",
              " 'TPCA-1',\n",
              " 'NF-B',\n",
              " 'airway inflammation',\n",
              " 'murine',\n",
              " 'neuroinflammatory symptoms',\n",
              " 'SARS-CoV-2',\n",
              " 'NOD-like receptor',\n",
              " 'convalescent plasma',\n",
              " 'SARS-CoV-2',\n",
              " 'envelope E',\n",
              " 'coronavirus',\n",
              " 'SARS-CoV-2',\n",
              " 'RNA-dependent RNA polymerase',\n",
              " 'S protein',\n",
              " 'host cells',\n",
              " 'S protein',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'Coronavirus',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'spike glycoprotein N 62',\n",
              " 'nonstructural protein N 45',\n",
              " 'papain-like protease N 19',\n",
              " 'spike glycoprotein N 62',\n",
              " 'RNA-dependent RNA polymerase',\n",
              " 'protease N 154',\n",
              " 'eucalyptus',\n",
              " 'Tinospora cordifolia',\n",
              " 'oleanolic acid',\n",
              " 'tinosponone',\n",
              " 'anistone',\n",
              " 'Aloe',\n",
              " 'eucalyptus',\n",
              " 'phenyltriazolinones',\n",
              " 'triazoles',\n",
              " 'benzoylpinostrobin',\n",
              " 'benzylidenechromanones',\n",
              " 'selenium',\n",
              " 'phenyl mercurin',\n",
              " 'SARS-CoV-2',\n",
              " 'RNA-dependent RNA polymerase',\n",
              " 'NSP-14',\n",
              " 'NSP-15',\n",
              " 'infected cell',\n",
              " 'ginkgolic acid',\n",
              " 'bisindolylmaleimide',\n",
              " 'GRL-172',\n",
              " 'lipopeptides',\n",
              " 'Alkenyl sulfonylurea',\n",
              " 'IMU-8381',\n",
              " 'NF- B',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS',\n",
              " 'mouse',\n",
              " 'mouse',\n",
              " 'SARS-CoV',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'COVID-',\n",
              " 'aloe',\n",
              " 'eucalyptus',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'spike glycoprotein',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'acute respiratory syndromes',\n",
              " 'spikes S',\n",
              " 'envelopes E',\n",
              " 'matrixes M',\n",
              " 'nucleocapsids N',\n",
              " '3-C proteases 3CLpro',\n",
              " 'RNA Dependent RNA Polymerases RdRp',\n",
              " 'NSP12',\n",
              " 'RNA-dependent RNA polymerase RdRp',\n",
              " 'various cells',\n",
              " 'RNA-dependent RNA polymerase RdRp',\n",
              " 'human cells',\n",
              " 'RNA-dependent RNA polymerase RdRp',\n",
              " 'nucleotides',\n",
              " 'RNA-dependent RNA polymerase RdRp',\n",
              " 'RNA-dependent RNA polymerase RdRp',\n",
              " 'SARS-CoV-2',\n",
              " 'NAs',\n",
              " '5-triphosphate',\n",
              " 'RdRp substrate',\n",
              " 'nucleotides',\n",
              " 'retinoid',\n",
              " 'SARS-CoV-2 RdRp',\n",
              " 'RdRp',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'RdRp',\n",
              " 'SARS-CoV-2',\n",
              " 'TIP3P',\n",
              " 'Na+',\n",
              " 'RdRp',\n",
              " 'SARS-CoV-2',\n",
              " 'RdRp',\n",
              " 'RdRp',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV',\n",
              " 'SARS-CoV',\n",
              " 'RdRp',\n",
              " 'RdRp',\n",
              " 'SARS-CoV-2 COVID-19',\n",
              " 'SARS-CoV-2',\n",
              " 'quinolone',\n",
              " 'Gastrointestinal complaints',\n",
              " 'SARS-CoV-',\n",
              " 'Androgen',\n",
              " 'AM580',\n",
              " 'MERS-CoV',\n",
              " 'adenoviruses',\n",
              " 'enterovirus A71',\n",
              " 'RdRp',\n",
              " 'SARS-CoV',\n",
              " 'RdRp',\n",
              " 'RdRp',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'RdRp',\n",
              " 'SARS-CoV-2',\n",
              " 'RdRp',\n",
              " 'LEU240',\n",
              " 'TYR129',\n",
              " 'LEU708',\n",
              " 'VAL128',\n",
              " 'ALA125',\n",
              " 'LEU207',\n",
              " 'TYR129',\n",
              " 'HIS133',\n",
              " 'TYR728',\n",
              " 'TYR732 amino acids',\n",
              " 'SARS-CoV-2',\n",
              " 'RdRp',\n",
              " '6NUR',\n",
              " 'RdRp receptor',\n",
              " '6NUR',\n",
              " '6NUR',\n",
              " '6NUR',\n",
              " '6NUR-Bex',\n",
              " '6NUR',\n",
              " '6NUR',\n",
              " '6NUR',\n",
              " 'RdRp',\n",
              " 'SARS-CoV',\n",
              " 'RdRp',\n",
              " 'SARS',\n",
              " 'SARS-',\n",
              " 'SARS-CoV-',\n",
              " '6NUR',\n",
              " '6NUR',\n",
              " 'nucleotide',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'coronavirus',\n",
              " 'distal airway cells',\n",
              " '16 alpha Bromoepiandrosterone',\n",
              " 'RNA-dependent RNA polymerase',\n",
              " 'host cells',\n",
              " 'ZINC',\n",
              " 'Covid-19 main protease',\n",
              " 'ZINC',\n",
              " 'Covid-19 Mpro',\n",
              " 'CMAP',\n",
              " 'living cells',\n",
              " 'PPIN',\n",
              " 'cultured cells',\n",
              " 'Human',\n",
              " 'HCoV',\n",
              " 'SARS-CoV-2',\n",
              " 'coronavirus',\n",
              " 'coronavirus Covid-19',\n",
              " 'HCoV',\n",
              " 'HCoV',\n",
              " 'HCoV',\n",
              " '2019 coronavirus Covid-19',\n",
              " 'SARS-CoV-',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'Phenopedia disease',\n",
              " 'cultured non-human primate cells',\n",
              " 'human-derived cells',\n",
              " 'VeroE6 cells',\n",
              " 'human cells',\n",
              " 'ZINC',\n",
              " 'cMAP',\n",
              " 'poly-ADP-ribose polymerase 1 PARP1',\n",
              " 'CVL218',\n",
              " 'MET',\n",
              " 'capmanitib',\n",
              " 'Artemesian',\n",
              " 'PPINs',\n",
              " 'SARS-CoV-2 virus',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'Betacoronavirus',\n",
              " 'ORF1a',\n",
              " 'ORF1ab polyprotein',\n",
              " 'host cell',\n",
              " 'SARS coronavirus SARS-',\n",
              " 'polymerases',\n",
              " 'polymerases',\n",
              " 'Human Poliovirus PV',\n",
              " 'NS5B',\n",
              " 'N',\n",
              " 'nidovirus',\n",
              " 'C',\n",
              " 'RdRp domain',\n",
              " 'NSP-12',\n",
              " 'NiRAN domain',\n",
              " 'RdRp domain',\n",
              " 'nucleotide triphosphate NTP',\n",
              " 'RdRp domain',\n",
              " 'RdRp domain',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV2',\n",
              " 'NS5B',\n",
              " 'HCV',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV2',\n",
              " 'SARS-CoV-1',\n",
              " 'SARS-CoV-2',\n",
              " 'NS5B',\n",
              " 'HCV',\n",
              " 'PolV',\n",
              " 'Human Coxsackievirus CoxV',\n",
              " 'Human Rhinovirus HRV',\n",
              " 'Human Enterovirus HEV',\n",
              " 'Human Enterovirus 71 HEV71',\n",
              " 'Encephalomyocarditis virus',\n",
              " 'Sapporovirus SapV',\n",
              " 'Rabbit Haemorrhagic Disease Virus RHDV',\n",
              " 'Murine',\n",
              " 'Norwalk Virus NarV',\n",
              " 'Human Norovirus HNV',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'NTP',\n",
              " 'NSP-12',\n",
              " 'Mn2+',\n",
              " 'Mg2+',\n",
              " 'nucleotide',\n",
              " 'nucleotide',\n",
              " 'NTP',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'RdRp domain',\n",
              " 'RdRp domain',\n",
              " 'NSP-12',\n",
              " 'RdRp domain',\n",
              " 'NSP-12',\n",
              " 'RdRp domain',\n",
              " 'GTP',\n",
              " 'UTP',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NS5B',\n",
              " 'HCV',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NS5B',\n",
              " 'HCV',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'GTP',\n",
              " 'UTP',\n",
              " 'NS5B',\n",
              " 'HCV',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NS5B',\n",
              " 'HCV',\n",
              " 'GTP',\n",
              " 'GTP',\n",
              " 'SARS-CoV-2',\n",
              " 'NS5B',\n",
              " 'HCV',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'GTP',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'UTP',\n",
              " 'HCV',\n",
              " '6M71',\n",
              " '6M71',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'Apo NSP-12',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'CAII',\n",
              " 'Apo NSP-12',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'Apo NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NSP-12',\n",
              " 'NSP-12',\n",
              " 'H',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'NSP-12',\n",
              " 'Trp',\n",
              " 'Trp',\n",
              " 'Tyr619',\n",
              " 'Cys622',\n",
              " 'Trp',\n",
              " 'Glu811',\n",
              " 'Ser814',\n",
              " 'Asp761',\n",
              " 'Tyr619',\n",
              " 'Cys622',\n",
              " 'Trp800',\n",
              " 'Glu811',\n",
              " 'Ser814',\n",
              " 'Asp761',\n",
              " 'COVID-19 main protease',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-2',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-',\n",
              " 'NS5B',\n",
              " 'HCV',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NS5',\n",
              " 'NS5B',\n",
              " 'HCV',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'SARS-CoV-1',\n",
              " 'HNV',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'RdRp domain',\n",
              " 'RdRp domain',\n",
              " 'RdRp domain',\n",
              " 'RdRp domain',\n",
              " 'RdRp domain',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV',\n",
              " 'RdRp domain',\n",
              " 'NSP-12',\n",
              " 'nucleoside',\n",
              " 'RdRp domain',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NS5B',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'RdRp domain',\n",
              " 'GTP',\n",
              " 'UTP',\n",
              " 'HCV',\n",
              " 'NS5B',\n",
              " 'HCV',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'RdRp domain',\n",
              " 'NS5B',\n",
              " 'HCV',\n",
              " 'NSP-12',\n",
              " 'SARS-CoV-2',\n",
              " 'NS5B',\n",
              " 'HCV',\n",
              " 'NSP-12',\n",
              " 'TIP3P',\n",
              " ...]"
            ]
          },
          "metadata": {},
          "execution_count": 87
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "A lot of COVID-related entities e.g. COVID, COVID-19, SARS-CoV-2 and variations not being mapped to a kb."
      ],
      "metadata": {
        "id": "D4zCw2j2_1Rh"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-06_missing_entity_id_list_1113.pickle', 'wb') as f:\n",
        "  pickle.dump(all_missing_entity_id, f)"
      ],
      "metadata": {
        "id": "GzIl-xPSEGqk"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# count for each missing entity id\n",
        "counter = Counter(all_missing_entity_id).most_common()"
      ],
      "metadata": {
        "id": "-KmlHXH8GPRd"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "counter"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "iUwqiOBDHAe2",
        "outputId": "1138e6de-e76d-4935-8c2f-d0f00b2947f1"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[('SARS-CoV-2', 174),\n",
              " ('NSP-12', 64),\n",
              " ('SARS', 33),\n",
              " ('COVID‐19', 32),\n",
              " ('RdRp', 23),\n",
              " ('SARS‐CoV', 18),\n",
              " ('RdRp domain', 18),\n",
              " ('Lagevrio', 15),\n",
              " ('NS5B', 15),\n",
              " ('HCV', 15),\n",
              " ('SARS‐CoV‐2', 14),\n",
              " ('COVID', 11),\n",
              " ('N', 11),\n",
              " ('SARS-CoV', 11),\n",
              " ('SARS-CoV-', 10),\n",
              " ('MERS-CoV', 10),\n",
              " ('spike glycoprotein', 10),\n",
              " ('EIDD-1931', 9),\n",
              " ('6NUR', 9),\n",
              " ('M9', 8),\n",
              " ('CoVs', 7),\n",
              " ('Mpro', 7),\n",
              " ('C', 7),\n",
              " ('CMAP', 7),\n",
              " ('RBD', 6),\n",
              " ('S protein', 6),\n",
              " ('HCoV', 6),\n",
              " ('RNA-dependent RNA polymerase RdRp', 6),\n",
              " ('GTP', 6),\n",
              " ('SARS-', 5),\n",
              " ('coronavirus', 5),\n",
              " ('papain', 5),\n",
              " ('RNA-dependent RNA polymerase', 5),\n",
              " ('CoV', 5),\n",
              " ('NSP6 SARS-CoV-2', 5),\n",
              " ('Coronavirus', 4),\n",
              " ('ZINC', 4),\n",
              " ('human cells', 4),\n",
              " ('CVL218', 4),\n",
              " ('mice', 4),\n",
              " ('nucleoside', 4),\n",
              " ('RNA-dependent DNA polymerase', 4),\n",
              " ('COVID-19 infections', 4),\n",
              " ('CMap', 4),\n",
              " ('inflammation', 4),\n",
              " ('UTP', 4),\n",
              " ('host cells', 3),\n",
              " ('3CLpro', 3),\n",
              " ('SARSCoV-2', 3),\n",
              " ('envelope', 3),\n",
              " ('3-chymotrypsin-like', 3),\n",
              " ('SARS CoV-2', 3),\n",
              " ('spike glycoproteins', 3),\n",
              " ('n', 3),\n",
              " ('Val7021', 3),\n",
              " ('Tyr7020', 3),\n",
              " ('Asp6942', 3),\n",
              " ('M44', 3),\n",
              " ('NOD-like receptor', 3),\n",
              " ('mouse', 3),\n",
              " ('NF-B', 3),\n",
              " ('TPCA-1', 3),\n",
              " ('eucalyptus', 3),\n",
              " ('nucleotide', 3),\n",
              " ('Apo NSP-12', 3),\n",
              " ('Trp', 3),\n",
              " ('pp1ab', 2),\n",
              " ('PLpro', 2),\n",
              " ('S', 2),\n",
              " ('host cell', 2),\n",
              " ('nonstructural protein NSP', 2),\n",
              " ('HIV', 2),\n",
              " ('MERS', 2),\n",
              " ('EIDD-1931-triphosphate', 2),\n",
              " ('ferrets', 2),\n",
              " ('SARS-CoV-2 illness', 2),\n",
              " ('MK-4482-006', 2),\n",
              " ('COVID-', 2),\n",
              " ('envelope E', 2),\n",
              " ('M', 2),\n",
              " ('helicase Nsp13', 2),\n",
              " ('Poly ADP-ribose polymerase 1 PARP-1', 2),\n",
              " ('enveloped', 2),\n",
              " ('eriodictoyl', 2),\n",
              " ('Leu6819', 2),\n",
              " ('Met6818', 2),\n",
              " ('Asp7018', 2),\n",
              " ('Tyr333', 2),\n",
              " ('Arg277', 2),\n",
              " ('Phe274', 2),\n",
              " ('Val270', 2),\n",
              " ('Trp301', 2),\n",
              " ('Phe314', 2),\n",
              " ('Gln260', 2),\n",
              " ('Arg259', 2),\n",
              " ('Leu6820', 2),\n",
              " ('NSP12', 2),\n",
              " ('critically', 2),\n",
              " ('M28', 2),\n",
              " ('M32', 2),\n",
              " ('immune cells', 2),\n",
              " ('M16', 2),\n",
              " ('spike glycoprotein N 62', 2),\n",
              " ('nucleotides', 2),\n",
              " ('TIP3P', 2),\n",
              " ('TYR129', 2),\n",
              " ('polymerases', 2),\n",
              " ('SARS-CoV2', 2),\n",
              " ('SARS-CoV-1', 2),\n",
              " ('NTP', 2),\n",
              " ('6M71', 2),\n",
              " ('Tyr619', 2),\n",
              " ('Cys622', 2),\n",
              " ('Glu811', 2),\n",
              " ('Ser814', 2),\n",
              " ('Asp761', 2),\n",
              " ('Paxlovid', 2),\n",
              " ('cannabis', 2),\n",
              " ('EC', 2),\n",
              " ('Cmap', 1),\n",
              " ('Statins', 1),\n",
              " ('p97 segregase', 1),\n",
              " ('nCoV', 1),\n",
              " ('3D cell culture', 1),\n",
              " ('genetically related diseases', 1),\n",
              " ('Coronaviruses CoVs', 1),\n",
              " ('epidemic diseases', 1),\n",
              " ('respiratory illness', 1),\n",
              " ('phosphoramide', 1),\n",
              " ('phosphate', 1),\n",
              " ('CADD', 1),\n",
              " ('paxlovid 3c‐like protease', 1),\n",
              " ('replicase complex', 1),\n",
              " ('human coronavirus papain‐like proteases', 1),\n",
              " ('SARS‐Coronavirus', 1),\n",
              " ('SARS‐3CL protease', 1),\n",
              " ('dihydropyrimidine', 1),\n",
              " ('RNA‐dependent RNA polymerase RdRp complex', 1),\n",
              " ('spike S receptor binding glycoprotein', 1),\n",
              " ('small envelope E', 1),\n",
              " ('chymotrypsin‐like protease 3CLpro', 1),\n",
              " (\"RBD's receptor\", 1),\n",
              " ('M.', 1),\n",
              " ('COVID‐19 Lee', 1),\n",
              " ('DR', 1),\n",
              " ('cutaneous rashes', 1),\n",
              " ('antimalarial', 1),\n",
              " ('cardiovascular problems', 1),\n",
              " ('SARS‐', 1),\n",
              " ('Won', 1),\n",
              " ('His41', 1),\n",
              " ('Ser144', 1),\n",
              " ('His163', 1),\n",
              " ('Gly143', 1),\n",
              " ('Gln166', 1),\n",
              " ('CO‐NH‐C ‐CO‐NH‐C', 1),\n",
              " ('organoid disease', 1),\n",
              " ('human lung cell line', 1),\n",
              " ('Calu‐3', 1),\n",
              " ('poly‐ADP‐ribose polymerase 1 PARP1', 1),\n",
              " ('inflammatory diseases of the lung', 1),\n",
              " ('SARS‐CoV‐', 1),\n",
              " ('host', 1),\n",
              " ('MERS corona virus', 1),\n",
              " ('SARSCoV-2 virus', 1),\n",
              " ('isopropyl', 1),\n",
              " ('seasonal flu', 1),\n",
              " ('HCoV-OC43 Human Coronavirus', 1),\n",
              " ('hemagglutinin', 1),\n",
              " ('membrane M', 1),\n",
              " ('QLA46612', 1),\n",
              " ('immense pain', 1),\n",
              " ('cyclooxygenase', 1),\n",
              " ('Human Immunodeficiency Virus-1 HIV', 1),\n",
              " ('extra-cellular vesicles', 1),\n",
              " ('Ralimetiniib mesylate', 1),\n",
              " ('beta-eudesmol', 1),\n",
              " ('ID-184', 1),\n",
              " ('RNRP RNA-dependent RNA polymerase', 1),\n",
              " ('in vitro cell line', 1),\n",
              " ('feline coronavirus', 1),\n",
              " ('platycodin', 1),\n",
              " ('RNA-dependent RNA polymerases RdRp', 1),\n",
              " ('Nsp 12', 1),\n",
              " ('dinucleoside 123', 1),\n",
              " ('anyone', 1),\n",
              " ('viral neuraminidases', 1),\n",
              " ('DPP4 cell receptor', 1),\n",
              " ('eridictoyl', 1),\n",
              " ('Mefuparib hydrochloride', 1),\n",
              " ('glycogen synthase kinase 3 GSK-3', 1),\n",
              " ('Nsps', 1),\n",
              " ('immunoglobulin superfamily IgSF', 1),\n",
              " ('AZD7442', 1),\n",
              " ('nsps', 1),\n",
              " ('His272', 1),\n",
              " ('Cys111', 1),\n",
              " ('Asp286', 1),\n",
              " ('ubiquitin-specific proteases USPs', 1),\n",
              " ('ubiquitin', 1),\n",
              " ('Ubl domain', 1),\n",
              " ('beta', 1),\n",
              " ('Non-structural protein 5 coding', 1),\n",
              " ('3C proteases', 1),\n",
              " ('S1', 1),\n",
              " ('ab ORF1ab', 1),\n",
              " ('Nsp 1 to 11', 1),\n",
              " ('pp1 polyprotein', 1),\n",
              " ('Nsp 12 to 16', 1),\n",
              " ('RBD residues', 1),\n",
              " ('C121', 1),\n",
              " ('E484', 1),\n",
              " ('MAbs REGN10934', 1),\n",
              " ('REGN10989', 1),\n",
              " ('virus', 1),\n",
              " ('NTD', 1),\n",
              " ('aclerasteride', 1),\n",
              " ('Leu331', 1),\n",
              " ('Thr296', 1),\n",
              " ('Ala264', 1),\n",
              " ('Arg262', 1),\n",
              " ('Tyr421', 1),\n",
              " ('Asn422', 1),\n",
              " ('Pro491', 1),\n",
              " ('Leu492', 1),\n",
              " ('Gln493', 1),\n",
              " ('Ser494', 1),\n",
              " ('Tyr495', 1),\n",
              " ('Gly496', 1),\n",
              " ('Phe497', 1),\n",
              " ('Gln498', 1),\n",
              " ('Lys444', 1),\n",
              " ('Asp442', 1),\n",
              " ('Tyr351', 1),\n",
              " ('Val350', 1),\n",
              " ('Ser349', 1),\n",
              " ('Ala348', 1),\n",
              " ('Phe347', 1),\n",
              " ('Arg346', 1),\n",
              " ('Arg509', 1),\n",
              " ('Val401', 1),\n",
              " ('favipiravir-nucleocapsid phosphoprotein', 1),\n",
              " ('Lys6822', 1),\n",
              " ('Glu6821', 1),\n",
              " ('Asn6941', 1),\n",
              " ('Glu6940', 1),\n",
              " ('Thr6938', 1),\n",
              " ('remdesivir-nucleocapsid phosphoprotein', 1),\n",
              " ('NSP16', 1),\n",
              " ('Arg6817', 1),\n",
              " ('Trp330', 1),\n",
              " ('Thr282', 1),\n",
              " ('Gly284', 1),\n",
              " ('Phe286', 1),\n",
              " ('Leu291', 1),\n",
              " ('SARS viruses', 1),\n",
              " ('rhesus monkey', 1),\n",
              " ('HIV-', 1),\n",
              " ('C1', 1),\n",
              " ('C5a', 1),\n",
              " ('C3a esterases', 1),\n",
              " ('lymphoid malignancies', 1),\n",
              " ('RDRP', 1),\n",
              " ('spike S glycoprotein', 1),\n",
              " ('systemic inflammatory response syndrome SIRS', 1),\n",
              " ('immune illnesses', 1),\n",
              " ('WGCNA', 1),\n",
              " ('magenta', 1),\n",
              " ('M18', 1),\n",
              " ('M36', 1),\n",
              " ('M46', 1),\n",
              " ('peptide antigen', 1),\n",
              " ('MHC Class II receptor', 1),\n",
              " ('BPs', 1),\n",
              " ('KEGG', 1),\n",
              " ('M332', 1),\n",
              " ('SB-201290', 1),\n",
              " ('CAY-10470', 1),\n",
              " ('yeast', 1),\n",
              " ('septic shock', 1),\n",
              " ('toll-like', 1),\n",
              " ('M1', 1),\n",
              " (\"M44's\", 1),\n",
              " ('T-', 1),\n",
              " ('NOD-like receptors NLRs', 1),\n",
              " ('COX', 1),\n",
              " ('histamine', 1),\n",
              " ('porcine', 1),\n",
              " ('airway inflammation', 1),\n",
              " ('murine', 1),\n",
              " ('neuroinflammatory symptoms', 1),\n",
              " ('convalescent plasma', 1),\n",
              " ('nonstructural protein N 45', 1),\n",
              " ('papain-like protease N 19', 1),\n",
              " ('protease N 154', 1),\n",
              " ('Tinospora cordifolia', 1),\n",
              " ('oleanolic acid', 1),\n",
              " ('tinosponone', 1),\n",
              " ('anistone', 1),\n",
              " ('Aloe', 1),\n",
              " ('phenyltriazolinones', 1),\n",
              " ('triazoles', 1),\n",
              " ('benzoylpinostrobin', 1),\n",
              " ('benzylidenechromanones', 1),\n",
              " ('selenium', 1),\n",
              " ('phenyl mercurin', 1),\n",
              " ('NSP-14', 1),\n",
              " ('NSP-15', 1),\n",
              " ('infected cell', 1),\n",
              " ('ginkgolic acid', 1),\n",
              " ('bisindolylmaleimide', 1),\n",
              " ('GRL-172', 1),\n",
              " ('lipopeptides', 1),\n",
              " ('Alkenyl sulfonylurea', 1),\n",
              " ('IMU-8381', 1),\n",
              " ('NF- B', 1),\n",
              " ('aloe', 1),\n",
              " ('acute respiratory syndromes', 1),\n",
              " ('spikes S', 1),\n",
              " ('envelopes E', 1),\n",
              " ('matrixes M', 1),\n",
              " ('nucleocapsids N', 1),\n",
              " ('3-C proteases 3CLpro', 1),\n",
              " ('RNA Dependent RNA Polymerases RdRp', 1),\n",
              " ('various cells', 1),\n",
              " ('NAs', 1),\n",
              " ('5-triphosphate', 1),\n",
              " ('RdRp substrate', 1),\n",
              " ('retinoid', 1),\n",
              " ('SARS-CoV-2 RdRp', 1),\n",
              " ('Na+', 1),\n",
              " ('SARS-CoV-2 COVID-19', 1),\n",
              " ('quinolone', 1),\n",
              " ('Gastrointestinal complaints', 1),\n",
              " ('Androgen', 1),\n",
              " ('AM580', 1),\n",
              " ('adenoviruses', 1),\n",
              " ('enterovirus A71', 1),\n",
              " ('LEU240', 1),\n",
              " ('LEU708', 1),\n",
              " ('VAL128', 1),\n",
              " ('ALA125', 1),\n",
              " ('LEU207', 1),\n",
              " ('HIS133', 1),\n",
              " ('TYR728', 1),\n",
              " ('TYR732 amino acids', 1),\n",
              " ('RdRp receptor', 1),\n",
              " ('6NUR-Bex', 1),\n",
              " ('distal airway cells', 1),\n",
              " ('16 alpha Bromoepiandrosterone', 1),\n",
              " ('Covid-19 main protease', 1),\n",
              " ('Covid-19 Mpro', 1),\n",
              " ('living cells', 1),\n",
              " ('PPIN', 1),\n",
              " ('cultured cells', 1),\n",
              " ('Human', 1),\n",
              " ('coronavirus Covid-19', 1),\n",
              " ('2019 coronavirus Covid-19', 1),\n",
              " ('Phenopedia disease', 1),\n",
              " ('cultured non-human primate cells', 1),\n",
              " ('human-derived cells', 1),\n",
              " ('VeroE6 cells', 1),\n",
              " ('cMAP', 1),\n",
              " ('poly-ADP-ribose polymerase 1 PARP1', 1),\n",
              " ('MET', 1),\n",
              " ('capmanitib', 1),\n",
              " ('Artemesian', 1),\n",
              " ('PPINs', 1),\n",
              " ('SARS-CoV-2 virus', 1),\n",
              " ('Betacoronavirus', 1),\n",
              " ('ORF1a', 1),\n",
              " ('ORF1ab polyprotein', 1),\n",
              " ('SARS coronavirus SARS-', 1),\n",
              " ('Human Poliovirus PV', 1),\n",
              " ('nidovirus', 1),\n",
              " ('NiRAN domain', 1),\n",
              " ('nucleotide triphosphate NTP', 1),\n",
              " ('PolV', 1),\n",
              " ('Human Coxsackievirus CoxV', 1),\n",
              " ('Human Rhinovirus HRV', 1),\n",
              " ('Human Enterovirus HEV', 1),\n",
              " ('Human Enterovirus 71 HEV71', 1),\n",
              " ('Encephalomyocarditis virus', 1),\n",
              " ('Sapporovirus SapV', 1),\n",
              " ('Rabbit Haemorrhagic Disease Virus RHDV', 1),\n",
              " ('Murine', 1),\n",
              " ('Norwalk Virus NarV', 1),\n",
              " ('Human Norovirus HNV', 1),\n",
              " ('Mn2+', 1),\n",
              " ('Mg2+', 1),\n",
              " ('CAII', 1),\n",
              " ('H', 1),\n",
              " ('Trp800', 1),\n",
              " ('COVID-19 main protease', 1),\n",
              " ('NS5', 1),\n",
              " ('HNV', 1),\n",
              " ('MoA', 1),\n",
              " ('congenital disabilities', 1),\n",
              " ('low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3',\n",
              "  1),\n",
              " ('C-type lectin domain family 4', 1),\n",
              " ('phosphatidylinositol 3-kinase PI3K', 1),\n",
              " ('endolysosome', 1),\n",
              " ('chronic underlying diseases', 1),\n",
              " ('s', 1),\n",
              " ('CoV-infected cells', 1),\n",
              " ('complex diseases', 1),\n",
              " ('MERS-', 1),\n",
              " ('oligoadenylate synthase family', 1),\n",
              " ('COVID-19 viral infections', 1),\n",
              " ('iron', 1),\n",
              " ('heme', 1),\n",
              " ('ORF6', 1),\n",
              " ('ORF7a', 1),\n",
              " ('ORF7b', 1),\n",
              " ('viral protein ORF7b', 1),\n",
              " ('infected cells', 1),\n",
              " ('CoV-infected', 1),\n",
              " ('reference-compound-perturbed cells', 1),\n",
              " ('cis', 1),\n",
              " ('HK2', 1),\n",
              " ('CBD', 1),\n",
              " ('NCBI', 1),\n",
              " ('viral', 1),\n",
              " ('African green monkey kidney cells', 1)]"
            ]
          },
          "metadata": {},
          "execution_count": 97
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "It appears as though the same entities are appearing more than once (e.g.SARS-CoV-2) which suggests formatting issues."
      ],
      "metadata": {
        "id": "6mQBKnYFKO0w"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-06_missing_entity_id_unique_424.pickle', 'wb') as f:\n",
        "  pickle.dump(counter, f)"
      ],
      "metadata": {
        "id": "Hf_OfJjpHfj1"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "unique_entities = list(set(all_missing_entity_id))"
      ],
      "metadata": {
        "id": "WMJJYuouHvll"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(unique_entities)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "IHB20iHoIkVP",
        "outputId": "e280ab6c-9675-4997-9507-d007eefe7d9a"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "424"
            ]
          },
          "metadata": {},
          "execution_count": 102
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-06_missing_entity_id_unique_list_424.pickle', 'wb') as f:\n",
        "  pickle.dump(unique_entities, f)"
      ],
      "metadata": {
        "id": "G0F7aApmIngz"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## 4. scispaCy\n",
        "\n",
        "We will build a scispaCy pipeline, add AbbreviationDetector and EntityLinker components, and perform a lookup using the UMLS linker for missing CUIs."
      ],
      "metadata": {
        "id": "g5Zj27W099LV"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 4.1 AbbreviationDetector"
      ],
      "metadata": {
        "id": "TQ0FJjNeLjsz"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Load small English scispaCy model\n",
        "nlp = spacy.load(\"en_core_sci_sm\")"
      ],
      "metadata": {
        "id": "o2Wrh2zg_EjT"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# add abbreviation_detector component\n",
        "nlp.add_pipe(\"abbreviation_detector\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "aeyKrE4f-5OR",
        "outputId": "c0cf1dd4-ae4e-49cc-cff3-997be6afa724"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<scispacy.abbreviation.AbbreviationDetector at 0x7d8b146dbf10>"
            ]
          },
          "metadata": {},
          "execution_count": 35
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "nlp.pipe_names"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "oEFe3cnT6zVK",
        "outputId": "f104d934-ae21-429a-d22b-d6347c9bbda7"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['tok2vec',\n",
              " 'tagger',\n",
              " 'attribute_ruler',\n",
              " 'lemmatizer',\n",
              " 'parser',\n",
              " 'ner',\n",
              " 'abbreviation_detector']"
            ]
          },
          "metadata": {},
          "execution_count": 36
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 4.2 EntityLinker"
      ],
      "metadata": {
        "id": "RfO66JjUBWJW"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "nlp.add_pipe(\"scispacy_linker\", config={\"linker_name\": \"umls\", \"resolve_abbreviations\": True})"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "dyfkpoJ76yFL",
        "outputId": "84ca0142-9b48-4b2a-c52b-6d16a707e00e"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/data/linkers/2023-04-23/umls/tfidf_vectors_sparse.npz not found in cache, downloading to /tmp/tmp9fw7xqe_\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "100%|██████████| 492M/492M [00:13<00:00, 36.9MiB/s]\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Finished download, copying /tmp/tmp9fw7xqe_ to cache at /root/.scispacy/datasets/2b79923846fb52e62d686f2db846392575c8eb5b732d9d26cd3ca9378c622d40.87bd52d0f0ee055c1e455ef54ba45149d188552f07991b765da256a1b512ca0b.tfidf_vectors_sparse.npz\n",
            "https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/data/linkers/2023-04-23/umls/nmslib_index.bin not found in cache, downloading to /tmp/tmpmaf7hycq\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "100%|██████████| 724M/724M [00:21<00:00, 35.2MiB/s]\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Finished download, copying /tmp/tmpmaf7hycq to cache at /root/.scispacy/datasets/7e8e091ec80370b87b1652f461eae9d926e543a403a69c1f0968f71157322c25.6d801a1e14867953e36258b0e19a23723ae84b0abd2a723bdd3574c3e0c873b4.nmslib_index.bin\n",
            "https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/data/linkers/2023-04-23/umls/tfidf_vectorizer.joblib not found in cache, downloading to /tmp/tmpif_fc2sc\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "100%|██████████| 1.32M/1.32M [00:00<00:00, 3.25MiB/s]\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Finished download, copying /tmp/tmpif_fc2sc to cache at /root/.scispacy/datasets/37bc06bb7ce30de7251db5f5cbac788998e33b3984410caed2d0083187e01d38.f0994c1b61cc70d0eb96dea4947dddcb37460fb5ae60975013711228c8fe3fba.tfidf_vectorizer.joblib\n",
            "https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/data/linkers/2023-04-23/umls/concept_aliases.json not found in cache, downloading to /tmp/tmpw8nh2nx9\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "100%|██████████| 264M/264M [00:09<00:00, 30.4MiB/s]\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Finished download, copying /tmp/tmpw8nh2nx9 to cache at /root/.scispacy/datasets/6238f505f56aca33290aab44097f67dd1b88880e3be6d6dcce65e56e9255b7d4.d7f77b1629001b40f1b1bc951f3a890ff2d516fb8fbae3111b236b31b33d6dcf.concept_aliases.json\n",
            "https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/data/kbs/2023-04-23/umls_2022_ab_cat0129.jsonl not found in cache, downloading to /tmp/tmpm7a93sev\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "100%|██████████| 628M/628M [00:17<00:00, 38.1MiB/s]\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Finished download, copying /tmp/tmpm7a93sev to cache at /root/.scispacy/datasets/d5e593bc2d8adeee7754be423cd64f5d331ebf26272074a2575616be55697632.0660f30a60ad00fffd8bbf084a18eb3f462fd192ac5563bf50940fc32a850a3c.umls_2022_ab_cat0129.jsonl\n",
            "https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/data/umls_semantic_type_tree.tsv not found in cache, downloading to /tmp/tmpw3ek_nvk\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "100%|██████████| 4.26k/4.26k [00:00<00:00, 5.71MiB/s]"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Finished download, copying /tmp/tmpw3ek_nvk to cache at /root/.scispacy/datasets/21a1012c532c3a431d60895c509f5b4d45b0f8966c4178b892190a302b21836f.330707f4efe774134872b9f77f0e3208c1d30f50800b3b39a6b8ec21d9adf1b7.umls_semantic_type_tree.tsv\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<scispacy.linking.EntityLinker at 0x785fcb3ed090>"
            ]
          },
          "metadata": {},
          "execution_count": 22
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "nlp.pipe_names"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "8TTrEC2d6f8o",
        "outputId": "92721b6c-397c-4444-c94a-3497d5e60be3"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['tok2vec',\n",
              " 'tagger',\n",
              " 'attribute_ruler',\n",
              " 'lemmatizer',\n",
              " 'parser',\n",
              " 'ner',\n",
              " 'abbreviation_detector',\n",
              " 'scispacy_linker']"
            ]
          },
          "metadata": {},
          "execution_count": 38
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will convert the missing entity ids into spacy Doc objects."
      ],
      "metadata": {
        "id": "8AJZxM2wZ2b2"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def get_missing(docs):\n",
        "    missing_list = []\n",
        "    docs = nlp.pipe(docs)\n",
        "    missing_list.append(list(docs))\n",
        "    return missing_list"
      ],
      "metadata": {
        "id": "TntuP5euZW_1"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "%%time\n",
        "\n",
        "missing_doc_list = get_missing(unique_entities)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ym4ij9PCHIgS",
        "outputId": "46eda00f-a3ba-4d55-c20f-324ca0ae5d8f"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 2.58 s, sys: 84.3 ms, total: 2.66 s\n",
            "Wall time: 2.83 s\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "missing_doc_list"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "vQOkOxqKI5C5",
        "outputId": "f0210e20-78a5-491a-c902-2485af957d9b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[[Tinospora cordifolia,\n",
              "  enterovirus A71,\n",
              "  TPCA-1,\n",
              "  COVID-,\n",
              "  SARS,\n",
              "  eridictoyl,\n",
              "  SARS-CoV-,\n",
              "  human lung cell line,\n",
              "  LEU207,\n",
              "  HCoV,\n",
              "  Mn2+,\n",
              "  CoV-infected,\n",
              "  envelopes E,\n",
              "  papain-like protease N 19,\n",
              "  eucalyptus,\n",
              "  HIV,\n",
              "  aloe,\n",
              "  adenoviruses,\n",
              "  NS5B,\n",
              "  M46,\n",
              "  HCoV-OC43 Human Coronavirus,\n",
              "  anyone,\n",
              "  nidovirus,\n",
              "  RNA Dependent RNA Polymerases RdRp,\n",
              "  RNA-dependent RNA polymerases RdRp,\n",
              "  polymerases,\n",
              "  Phe347,\n",
              "  human-derived cells,\n",
              "  Arg6817,\n",
              "  infected cells,\n",
              "  in vitro cell line,\n",
              "  mice,\n",
              "  MHC Class II receptor,\n",
              "  Arg346,\n",
              "  Lagevrio,\n",
              "  M9,\n",
              "  hemagglutinin,\n",
              "  Asp286,\n",
              "  SARS‐3CL protease,\n",
              "  ORF7a,\n",
              "  Apo NSP-12,\n",
              "  Mg2+,\n",
              "  viral,\n",
              "  REGN10989,\n",
              "  E484,\n",
              "  M44's,\n",
              "  COVID-19 viral infections,\n",
              "  Human,\n",
              "  yeast,\n",
              "  Asn422,\n",
              "  nonstructural protein NSP,\n",
              "  Phe286,\n",
              "  seasonal flu,\n",
              "  systemic inflammatory response syndrome SIRS,\n",
              "  Phe314,\n",
              "  African green monkey kidney cells,\n",
              "  host cells,\n",
              "  RdRp,\n",
              "  MERS corona virus,\n",
              "  Gastrointestinal complaints,\n",
              "  Gln498,\n",
              "  SB-201290,\n",
              "  SARS‐CoV‐2,\n",
              "  Val401,\n",
              "  neuroinflammatory symptoms,\n",
              "  convalescent plasma,\n",
              "  favipiravir-nucleocapsid phosphoprotein,\n",
              "  SARS-CoV2,\n",
              "  coronavirus Covid-19,\n",
              "  M.,\n",
              "  Cys622,\n",
              "  EC,\n",
              "  HIV-,\n",
              "  Coronavirus,\n",
              "  small envelope E,\n",
              "  oligoadenylate synthase family,\n",
              "  inflammation,\n",
              "  CMAP,\n",
              "  Covid-19 main protease,\n",
              "  NOD-like receptor,\n",
              "  3CLpro,\n",
              "  DPP4 cell receptor,\n",
              "  n,\n",
              "  Ralimetiniib mesylate,\n",
              "  genetically related diseases,\n",
              "  Trp330,\n",
              "  WGCNA,\n",
              "  phenyl mercurin,\n",
              "  CMap,\n",
              "  S,\n",
              "  low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3,\n",
              "  SARS‐,\n",
              "  histamine,\n",
              "  H,\n",
              "  RNRP RNA-dependent RNA polymerase,\n",
              "  NSP-15,\n",
              "  3-chymotrypsin-like,\n",
              "  spike S receptor binding glycoprotein,\n",
              "  pp1ab,\n",
              "  MAbs REGN10934,\n",
              "  peptide antigen,\n",
              "  Asn6941,\n",
              "  MERS-CoV,\n",
              "  NSP16,\n",
              "  RdRp substrate,\n",
              "  NSP12,\n",
              "  NF- B,\n",
              "  Gly143,\n",
              "  RdRp domain,\n",
              "  M332,\n",
              "  acute respiratory syndromes,\n",
              "  S1,\n",
              "  Rabbit Haemorrhagic Disease Virus RHDV,\n",
              "  Ala264,\n",
              "  VAL128,\n",
              "  respiratory illness,\n",
              "  2019 coronavirus Covid-19,\n",
              "  VeroE6 cells,\n",
              "  dihydropyrimidine,\n",
              "  RDRP,\n",
              "  NSP6 SARS-CoV-2,\n",
              "  UTP,\n",
              "  NiRAN domain,\n",
              "  Alkenyl sulfonylurea,\n",
              "  Tyr351,\n",
              "  immune cells,\n",
              "  Ser349,\n",
              "  nonstructural protein N 45,\n",
              "  oleanolic acid,\n",
              "  TYR728,\n",
              "  platycodin,\n",
              "  Arg259,\n",
              "  MoA,\n",
              "  matrixes M,\n",
              "  C,\n",
              "  iron,\n",
              "  SARS-CoV-2 RdRp,\n",
              "  KEGG,\n",
              "  epidemic diseases,\n",
              "  Gly284,\n",
              "  6NUR-Bex,\n",
              "  dinucleoside 123,\n",
              "  SARS-,\n",
              "  Arg509,\n",
              "  retinoid,\n",
              "  SARS-CoV-1,\n",
              "  CAII,\n",
              "  HK2,\n",
              "  Gln260,\n",
              "  Mpro,\n",
              "  Encephalomyocarditis virus,\n",
              "  nucleotide triphosphate NTP,\n",
              "  COVID‐19 Lee,\n",
              "  5-triphosphate,\n",
              "  cannabis,\n",
              "  DR,\n",
              "  nucleocapsids N,\n",
              "  MET,\n",
              "  Human Poliovirus PV,\n",
              "  viral protein ORF7b,\n",
              "  M36,\n",
              "  Phe497,\n",
              "  Ser814,\n",
              "  PPINs,\n",
              "  Arg262,\n",
              "  critically,\n",
              "  Na+,\n",
              "  coronavirus,\n",
              "  CoV-infected cells,\n",
              "  T-,\n",
              "  PLpro,\n",
              "  Cys111,\n",
              "  Tyr333,\n",
              "  AM580,\n",
              "  Human Norovirus HNV,\n",
              "  C1,\n",
              "  various cells,\n",
              "  MERS,\n",
              "  EIDD-1931-triphosphate,\n",
              "  nCoV,\n",
              "  NCBI,\n",
              "  NTD,\n",
              "  6M71,\n",
              "  COVID-19 main protease,\n",
              "  LEU240,\n",
              "  Thr6938,\n",
              "  PolV,\n",
              "  poly‐ADP‐ribose polymerase 1 PARP1,\n",
              "  NOD-like receptors NLRs,\n",
              "  ginkgolic acid,\n",
              "  RBD,\n",
              "  SARS‐CoV,\n",
              "  SARS‐CoV‐,\n",
              "  replicase complex,\n",
              "  nucleotide,\n",
              "  poly-ADP-ribose polymerase 1 PARP1,\n",
              "  immune illnesses,\n",
              "  HCV,\n",
              "  heme,\n",
              "  Human Rhinovirus HRV,\n",
              "  cultured non-human primate cells,\n",
              "  Leu331,\n",
              "  CoV,\n",
              "  phenyltriazolinones,\n",
              "  isopropyl,\n",
              "  Phe274,\n",
              "  lymphoid malignancies,\n",
              "  3D cell culture,\n",
              "  Tyr421,\n",
              "  AZD7442,\n",
              "  His163,\n",
              "  s,\n",
              "  spike glycoprotein N 62,\n",
              "  nsps,\n",
              "  benzoylpinostrobin,\n",
              "  SARS-CoV,\n",
              "  Coronaviruses CoVs,\n",
              "  enveloped,\n",
              "  Arg277,\n",
              "  Won,\n",
              "  Norwalk Virus NarV,\n",
              "  Nsp 12,\n",
              "  nucleoside,\n",
              "  Asp7018,\n",
              "  M32,\n",
              "  Ubl domain,\n",
              "  ZINC,\n",
              "  Lys6822,\n",
              "  TYR129,\n",
              "  aclerasteride,\n",
              "  Asp442,\n",
              "  N,\n",
              "  Trp800,\n",
              "  cultured cells,\n",
              "  M28,\n",
              "  virus,\n",
              "  beta-eudesmol,\n",
              "  GRL-172,\n",
              "  SARSCoV-2 virus,\n",
              "  phosphatidylinositol 3-kinase PI3K,\n",
              "  Trp,\n",
              "  viral neuraminidases,\n",
              "  human cells,\n",
              "  helicase Nsp13,\n",
              "  Gln493,\n",
              "  RNA-dependent RNA polymerase RdRp,\n",
              "  EIDD-1931,\n",
              "  SARS coronavirus SARS-,\n",
              "  CoVs,\n",
              "  selenium,\n",
              "  Val350,\n",
              "  C121,\n",
              "  M44,\n",
              "  CVL218,\n",
              "  PPIN,\n",
              "  cyclooxygenase,\n",
              "  spikes S,\n",
              "  M1,\n",
              "  ferrets,\n",
              "  Nsp 1 to 11,\n",
              "  magenta,\n",
              "  protease N 154,\n",
              "  Human Coxsackievirus CoxV,\n",
              "  Leu492,\n",
              "  Nsps,\n",
              "  His272,\n",
              "  antimalarial,\n",
              "  paxlovid 3c‐like protease,\n",
              "  3C proteases,\n",
              "  His41,\n",
              "  quinolone,\n",
              "  M,\n",
              "  Thr296,\n",
              "  Ser494,\n",
              "  Ser144,\n",
              "  QLA46612,\n",
              "  Pro491,\n",
              "  infected cell,\n",
              "  Glu6821,\n",
              "  mouse,\n",
              "  papain,\n",
              "  host cell,\n",
              "  Glu811,\n",
              "  tinosponone,\n",
              "  Paxlovid,\n",
              "  Leu291,\n",
              "  Androgen,\n",
              "  extra-cellular vesicles,\n",
              "  SARS viruses,\n",
              "  cis,\n",
              "  spike S glycoprotein,\n",
              "  distal airway cells,\n",
              "  Sapporovirus SapV,\n",
              "  Non-structural protein 5 coding,\n",
              "  RBD residues,\n",
              "  phosphoramide,\n",
              "  TYR732 amino acids,\n",
              "  SARS‐Coronavirus,\n",
              "  C5a,\n",
              "  capmanitib,\n",
              "  living cells,\n",
              "  NS5,\n",
              "  bisindolylmaleimide,\n",
              "  nucleotides,\n",
              "  feline coronavirus,\n",
              "  congenital disabilities,\n",
              "  Murine,\n",
              "  envelope,\n",
              "  pp1 polyprotein,\n",
              "  Gln166,\n",
              "  Val270,\n",
              "  Leu6820,\n",
              "  M16,\n",
              "  Gly496,\n",
              "  Met6818,\n",
              "  RBD's receptor,\n",
              "  Human Enterovirus HEV,\n",
              "  COX,\n",
              "  Human Immunodeficiency Virus-1 HIV,\n",
              "  anistone,\n",
              "  Val7021,\n",
              "  NSP-12,\n",
              "  SARS-CoV-2 illness,\n",
              "  MERS-,\n",
              "  ORF1a,\n",
              "  Covid-19 Mpro,\n",
              "  porcine,\n",
              "  glycogen synthase kinase 3 GSK-3,\n",
              "  Artemesian,\n",
              "  Human Enterovirus 71 HEV71,\n",
              "  Thr282,\n",
              "  HNV,\n",
              "  host,\n",
              "  reference-compound-perturbed cells,\n",
              "  Nsp 12 to 16,\n",
              "  NTP,\n",
              "  NAs,\n",
              "  cardiovascular problems,\n",
              "  p97 segregase,\n",
              "  Asp761,\n",
              "  Phenopedia disease,\n",
              "  C3a esterases,\n",
              "  ab ORF1ab,\n",
              "  RdRp receptor,\n",
              "  RNA‐dependent RNA polymerase RdRp complex,\n",
              "  airway inflammation,\n",
              "  CAY-10470,\n",
              "  lipopeptides,\n",
              "  Trp301,\n",
              "  remdesivir-nucleocapsid phosphoprotein,\n",
              "  benzylidenechromanones,\n",
              "  Tyr619,\n",
              "  ORF1ab polyprotein,\n",
              "  Lys444,\n",
              "  chymotrypsin‐like protease 3CLpro,\n",
              "  septic shock,\n",
              "  murine,\n",
              "  Cmap,\n",
              "  6NUR,\n",
              "  Mefuparib hydrochloride,\n",
              "  Glu6940,\n",
              "  CO‐NH‐C ‐CO‐NH‐C,\n",
              "  IMU-8381,\n",
              "  CBD,\n",
              "  rhesus monkey,\n",
              "  Tyr7020,\n",
              "  triazoles,\n",
              "  M18,\n",
              "  COVID‐19,\n",
              "  human coronavirus papain‐like proteases,\n",
              "  TIP3P,\n",
              "  immunoglobulin superfamily IgSF,\n",
              "  SARS-CoV-2,\n",
              "  NF-B,\n",
              "  SARS CoV-2,\n",
              "  envelope E,\n",
              "  16 alpha Bromoepiandrosterone,\n",
              "  C-type lectin domain family 4,\n",
              "  3-C proteases 3CLpro,\n",
              "  eriodictoyl,\n",
              "  cMAP,\n",
              "  Asp6942,\n",
              "  ORF6,\n",
              "  SARS-CoV-2 virus,\n",
              "  Betacoronavirus,\n",
              "  GTP,\n",
              "  ubiquitin,\n",
              "  LEU708,\n",
              "  SARSCoV-2,\n",
              "  ubiquitin-specific proteases USPs,\n",
              "  COVID,\n",
              "  chronic underlying diseases,\n",
              "  ALA125,\n",
              "  spike glycoproteins,\n",
              "  toll-like,\n",
              "  NSP-14,\n",
              "  S protein,\n",
              "  complex diseases,\n",
              "  BPs,\n",
              "  RNA-dependent DNA polymerase,\n",
              "  cutaneous rashes,\n",
              "  CADD,\n",
              "  phosphate,\n",
              "  beta,\n",
              "  Statins,\n",
              "  Aloe,\n",
              "  Leu6819,\n",
              "  immense pain,\n",
              "  membrane M,\n",
              "  ID-184,\n",
              "  Ala348,\n",
              "  ORF7b,\n",
              "  endolysosome,\n",
              "  inflammatory diseases of the lung,\n",
              "  Poly ADP-ribose polymerase 1 PARP-1,\n",
              "  Tyr495,\n",
              "  HIS133,\n",
              "  spike glycoprotein,\n",
              "  RNA-dependent RNA polymerase,\n",
              "  Calu‐3,\n",
              "  COVID-19 infections,\n",
              "  SARS-CoV-2 COVID-19,\n",
              "  organoid disease,\n",
              "  MK-4482-006]]"
            ]
          },
          "metadata": {},
          "execution_count": 106
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-06_all_missing_doc_list_424.pickle', 'wb') as f:\n",
        "  pickle.dump(missing_doc_list, f)"
      ],
      "metadata": {
        "id": "VORr9dPraOb7"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#### 4.2.1 Querying knowledge base entries - UMLS\n",
        "\n",
        "We will query the knowledge base for more detail by retrieving the `EntityLinker` component from the pipeline using the `get_pipe()` method. We can then access the entity definition by looking up the CUI in the `linker.kb.cui_to_entity` dictionary using the CUI as the key.  \n",
        "\n",
        "\n"
      ],
      "metadata": {
        "id": "NHO3cF8fKpQD"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "linker = nlp.get_pipe(\"scispacy_linker\")"
      ],
      "metadata": {
        "id": "5tfCkk8wBr10"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def get_detailed_kb_ents(docs):\n",
        "    kb_ent_list = []\n",
        "    for index, doc in enumerate(docs):\n",
        "        entities = doc.ents\n",
        "        for entity in entities:\n",
        "            if entity._.kb_ents:  # Check if kb_ents is not empty\n",
        "                first_cuid = entity._.kb_ents[0][0]\n",
        "                kb_entry = linker.kb.cui_to_entity[first_cuid]\n",
        "                kb_ent_list.append(f\"{entity.text}, {first_cuid}, {kb_entry.canonical_name}, {kb_entry.definition}\")\n",
        "    return kb_ent_list"
      ],
      "metadata": {
        "id": "euyPK5RULiRg"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "%%time\n",
        "\n",
        "detailed_missing_kb_ents = list(map(get_detailed_kb_ents, missing_doc_list))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "nAGHCcKuLiRh",
        "outputId": "c90009cb-d263-4ae2-9945-986a38bb41b2"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 5.22 ms, sys: 1.78 ms, total: 7 ms\n",
            "Wall time: 6.96 ms\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "detailed_missing_kb_ents"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "4zwZkhKILhl_",
        "outputId": "9e42c6df-91d5-4d86-b7b3-e872c84c50ff"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[['Tinospora cordifolia, C1501208, Tinospora cordifolia, None',\n",
              "  'enterovirus, C0014378, Enterovirus Infections, Diseases caused by ENTEROVIRUS.',\n",
              "  'TPCA-1, C1567717, 2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide, None',\n",
              "  'SARS, C1175175, Severe Acute Respiratory Syndrome, A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.',\n",
              "  'SARS-CoV-, C5203676, SARS-CoV-2, A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.',\n",
              "  'human, C0086418, Homo sapiens, Members of the species Homo sapiens.',\n",
              "  'envelopes E, C4528946, Envelopes, Flat paper containers used to protect objects or paperwork during storage or transport. Items are placed inside the envelope, which is then typically sealed shut using adhesive or another mechanism that secures the contents inside. Envelopes may be reusable or disposable.',\n",
              "  'papain-like protease N 19, C0006784, Calpain, Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including NEUROPEPTIDES; CYTOSKELETAL PROTEINS; proteins from SMOOTH MUSCLE; CARDIAC MUSCLE; liver; platelets; and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. This enzyme was formerly listed as EC 3.4.22.4.',\n",
              "  'eucalyptus, C0015148, Eucalyptus, A genus of trees of the Myrtaceae family, native to Australia, that yields gums, oils, and resins which are used as flavoring agents, astringents, and aromatics.',\n",
              "  'HIV, C0019682, HIV, Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.',\n",
              "  'aloe, C0002168, Aloe, A plant genus of the family ASPHODELACEAE which is used medicinally. It contains anthraquinone glycosides such as aloin-emodin or aloe-emodin (EMODIN).',\n",
              "  'M46, C1870739, GHRL protein, human, Appetite-regulating hormone (117 aa, ~13 kDa) is encoded by the human GHRL gene. This protein is involved in satiety, thirst and anxiety and regulating growth hormone release.',\n",
              "  'Human, C0086418, Homo sapiens, Members of the species Homo sapiens.',\n",
              "  'nidovirus, C0949858, Nidovirales, An order comprising three families of eukaryotic viruses possessing linear, nonsegmented, positive sense RNA genomes. The families are Mesoniviridae; CORONAVIRIDAE; ARTERIVIRIDAE; and RONIVIRIDAE.',\n",
              "  'RNA, C0035668, RNA, A polynucleotide consisting essentially of chains with a repeating backbone of phosphate and ribose units to which nitrogenous bases are attached. RNA is unique among biological macromolecules in that it can encode genetic information, serve as an abundant structural component of cells, and also possesses catalytic activity. (Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed)',\n",
              "  \"RdRp, C1152412, RNA-directed RNA polymerase activity, Catalysis of the reaction: nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1); uses an RNA template, i.e. the catalysis of RNA-template-directed extension of the 3'-end of an RNA strand by one nucleotide at a time. [EC:2.7.7.48, GOC:mah, GOC:pf]\",\n",
              "  \"RNA-dependent RNA polymerases, C0035685, RNA-Directed RNA Polymerase, An enzyme that catalyses RNA-template-directed extension of the 3'- end of an RNA strand by one nucleotide at a time, and can initiate a chain de novo. (Enzyme Nomenclature, 1992, p293)\",\n",
              "  \"RdRp, C1152412, RNA-directed RNA polymerase activity, Catalysis of the reaction: nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1); uses an RNA template, i.e. the catalysis of RNA-template-directed extension of the 3'-end of an RNA strand by one nucleotide at a time. [EC:2.7.7.48, GOC:mah, GOC:pf]\",\n",
              "  'polymerases, C1335439, Polymerase, Encoded by Polymerase Genes, Polymerase enzymes catalyze polymerization reactions, especially of nucleotides to polynucleotides. (NCI)',\n",
              "  'infected, C0439663, Infected, None',\n",
              "  'cells, C0007634, Cells, The fundamental, structural, and functional units or subunits of living organisms. They are composed of CYTOPLASM containing various ORGANELLES and a CELL MEMBRANE boundary.',\n",
              "  'in vitro, C0021135, In Vitro [Publication Type], Studies using excised tissues.',\n",
              "  'cell line, C0007600, Cultured Cell Line, Established cell cultures that have the potential to propagate indefinitely.',\n",
              "  'mice, C0025914, House mice, The common mouse species, Mus musculus.',\n",
              "  'MHC, C0024518, Major Histocompatibility Complex, The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement.',\n",
              "  'Class II receptor, C2698968, Canadian Cardiovascular Society Grading Scale Class II, A grading of angina characterized by a slight limitation of ordinary activity. Angina occurs on walking or climbing stairs rapidly, walking uphill, walking or climbing stairs after meals, or in cold, in wind, or under emotional stress, or only during the few hours after awakening. Angina occurs on walking more than 2 blocks on the level and climbing more than 1 flight of ordinary stairs at a normal pace and in normal condition.',\n",
              "  'Lagevrio, C5565851, Lagevrio, None',\n",
              "  'M9, C1539345, EIF3K gene, This gene is involved in translation initiation.',\n",
              "  'hemagglutinin, C0018909, Hemagglutinin, Agents that cause agglutination of red blood cells. They include antibodies, blood group antigens, lectins, autoimmune factors, bacterial, viral, or parasitic blood agglutinins, etc.',\n",
              "  'Mg2, C1417500, MUC7 gene, None',\n",
              "  'viral, C0521026, Viral, None',\n",
              "  'COVID-19, C5203670, COVID19 (disease), A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.',\n",
              "  'viral infections, C0042769, Virus Diseases, A general term for diseases caused by viruses.',\n",
              "  'Human, C0086418, Homo sapiens, Members of the species Homo sapiens.',\n",
              "  'yeast, C0036025, Saccharomyces cerevisiae, A species of the genus SACCHAROMYCES, family Saccharomycetaceae, order Saccharomycetales, known as \"baker\\'s\" or \"brewer\\'s\" yeast. The dried form is used as a dietary supplement.',\n",
              "  'nonstructural protein, C0069065, Viral Nonstructural Proteins, Proteins encoded by a VIRAL GENOME that are not structural components of VIRUS PARTICLES. Some of these proteins may play roles within the infected cell during VIRUS REPLICATION or act in regulation of virus replication or VIRUS ASSEMBLY.',\n",
              "  'systemic, C0205373, Systemic, Affecting an entire system.',\n",
              "  'SIRS, C0242966, Systemic Inflammatory Response Syndrome, A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever >38 degrees C or HYPOTHERMIA <36 degrees C; (2) TACHYCARDIA >90 beat/minute; (3) tachypnea >24 breaths/minute; (4) LEUKOCYTOSIS >12,000 cells/cubic mm or 10% immature forms. While usually related to infection, SIRS can also be associated with noninfectious insults such as TRAUMA; BURNS; or PANCREATITIS. If infection is involved, a patient with SIRS is said to have SEPSIS.',\n",
              "  'African green monkey, C0026438, Cercopithecus aethiops, A medium-sized diurnal primate that is omnivorous, Chlorocebus sabaeus has a life span of 10 years in the wild and 25 years in captivity. The African green monkey has been in use in scientific research since the 1950s and its tissues are used to produce vaccines for polio and smallpox. Additionally Vero cells, an African green monkey kidney epithelial cell line, are widely used in immunology and infectious disease research.',\n",
              "  'kidney cells, C0553257, Epithelial cell of renal tubule, any of the cells comprising the kidney, functioning in filtering the blood.',\n",
              "  'host cells, C0007634, Cells, The fundamental, structural, and functional units or subunits of living organisms. They are composed of CYTOPLASM containing various ORGANELLES and a CELL MEMBRANE boundary.',\n",
              "  \"RdRp, C1152412, RNA-directed RNA polymerase activity, Catalysis of the reaction: nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1); uses an RNA template, i.e. the catalysis of RNA-template-directed extension of the 3'-end of an RNA strand by one nucleotide at a time. [EC:2.7.7.48, GOC:mah, GOC:pf]\",\n",
              "  'MERS, C3694279, Middle East Respiratory Syndrome, A viral disorder characterized by SARS (Severe Acute Respiratory Syndrome)-like symptoms caused by MERS-CoV (MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS).',\n",
              "  'corona virus, C0206750, Coronavirus Infections, Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).',\n",
              "  'Gastrointestinal complaints, C0521362, gastrointestinal, Pertaining to the stomach and intestines.',\n",
              "  'Val401, C4722693, Risperidone Lipid Formulation VAL401, None',\n",
              "  'neuroinflammatory, C5544451, Neuroinflammatory Diseases, Diseases characterized by inflammation of the nervous tissue.',\n",
              "  'convalescent, C0740326, convalescent, None',\n",
              "  'plasma, C0032105, Plasma, The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION.',\n",
              "  'SARS-CoV2, C5203670, COVID19 (disease), A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.',\n",
              "  'coronavirus, C0206419, Genus: Coronavirus, A member of CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of vertebrates.',\n",
              "  'Covid-19, C5203670, COVID19 (disease), A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.',\n",
              "  'M., C0224141, Structure of mentalis muscle, A paired facial muscle that originates from the incisive fossa of the mandible and extends upward to attach to the skin of the lower lip; it functions to elevate and protrude the lower lip and elevate and wrinkle the skin of the chin.',\n",
              "  'EC, C0030016, Oxidoreductase, The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9)',\n",
              "  'HIV-, C0019707, Human immunodeficiency virus 2 (HIV-2), An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian Lentivirus SIMIAN IMMUNODEFICIENCY VIRUS and infects only T4-lymphocytes expressing the CD4 phenotypic marker.',\n",
              "  'Coronavirus, C0206419, Genus: Coronavirus, A member of CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of vertebrates.',\n",
              "  'small envelope E, C1622204, envelope, A multilayered structure surrounding all or part of a cell; encompasses one or more lipid bilayers, and may include a cell wall layer; also includes the space between layers. [GOC:mah, GOC:pz]',\n",
              "  'oligoadenylate, C0133819, oligoadenylate, None',\n",
              "  'synthase family, C0132555, Nitric Oxide Synthase, Expressed in various cell types, Nitric Oxide Synthases (NOS Family) are constitutive or inducible calcium/calmodulin stimulated homodimers stabilized by BH4 that bind FAD and FMN cofactors, generally contain a flavodoxin-like domain, and synthesize reactive free radical nitric oxide messenger from L-arginine. NO can act as a neurotransmitter and has antimicrobial and antitumoral activities in macrophages. IL12 requires NOS to stimulate tyrosine-phosphorylation of STAT4 by TYK2 in NK cytotoxicity. Vascular NO (endothelia) inhibits muscle contraction through a cGMP pathway, inhibits platelet aggregation, and mediates VEGF-induced angiogenesis. Endothelial AKT phosphorylates and enhances NOS activity. Potentially influencing energy balance, NO can trigger cGMP-dependent mitochondrial biogenesis mediated by induction of the master regulator PPARGC1. (NCI)',\n",
              "  'inflammation, C0021368, Inflammation, A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.',\n",
              "  'CMAP, C1413776, CST7 gene, None',\n",
              "  'Covid-19, C5203670, COVID19 (disease), A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.',\n",
              "  'NOD-like receptor, C4277661, NLR Proteins, Intracellular signaling proteins that are defined by the presence of a NUCLEOTIDE-binding region and LEUCINE-rich repeats. Their general structure consists of any of a variety of effector domains at their N-termini such as a caspase recruitment domain (CARD), a central nucleotide-binding domain, and a variable number of C-terminal leucine-rich repeats. They are important for pathogen recognition in the INNATE IMMUNE RESPONSE of animals and plants. Members of the NLR protein family include the NOD SIGNALING ADAPTOR PROTEINS.',\n",
              "  'mesylate, C0025619, Mesylates, Organic salts or esters of methanesulfonic acid.',\n",
              "  'genetically, C1516876, Engineered Gene, A gene that has been artificially altered in sequence or structure.',\n",
              "  'diseases, C0012634, Disease, A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.',\n",
              "  'phenyl mercurin, C0031488, phenylmercuric acetate, A phenyl mercury compound used mainly as a fungicide. Has also been used as a herbicide, slimicide, and bacteriocide.',\n",
              "  'CMap, C1413776, CST7 gene, None',\n",
              "  'S, C0221135, Blood group antigen S, None',\n",
              "  'low-density lipoprotein receptor class A, C3493221, LDLR protein, human, Low-density lipoprotein receptor (860 aa, ~95 kDa) is encoded by the human LDLR gene. This protein is involved in the endocytosis of cholesterol.',\n",
              "  'domain-containing protein, C1869249, PASD1 protein, human, Circadian clock protein PASD1 (773 aa, ~87 kDa) is encoded by the human PASD1 gene. This protein may be involved in the regulation of transcription.',\n",
              "  'LDLRAD3, C1825806, LDLRAD3 gene, None',\n",
              "  'SARS‐, C1175175, Severe Acute Respiratory Syndrome, A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.',\n",
              "  'histamine, C0019588, histamine, An amine derived by enzymatic decarboxylation of HISTIDINE. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter.',\n",
              "  \"RNA-dependent RNA polymerase, C0035685, RNA-Directed RNA Polymerase, An enzyme that catalyses RNA-template-directed extension of the 3'- end of an RNA strand by one nucleotide at a time, and can initiate a chain de novo. (Enzyme Nomenclature, 1992, p293)\",\n",
              "  'MAbs, C1425698, DDX41 gene, This gene may play a role in RNA splicing and tumor suppression.',\n",
              "  'peptide antigen, C1323239, peptide antigen binding, Binding to an antigen peptide. [GOC:add, GOC:jl, GOC:rv]',\n",
              "  'MERS-CoV, C3698360, Middle East Respiratory Syndrome Coronavirus, A coronavirus first reported in the summer of 2012 in a pneumonia patient in SAUDI ARABIA. It is related to SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS. MERS-CoV has an estimated incubation period of 12 days and symptoms include renal failure and severe acute pneumonia with often fatal outcome.',\n",
              "  \"RdRp, C1152412, RNA-directed RNA polymerase activity, Catalysis of the reaction: nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1); uses an RNA template, i.e. the catalysis of RNA-template-directed extension of the 3'-end of an RNA strand by one nucleotide at a time. [EC:2.7.7.48, GOC:mah, GOC:pf]\",\n",
              "  'substrate, C1710236, Substrate Device, None',\n",
              "  \"RdRp, C1152412, RNA-directed RNA polymerase activity, Catalysis of the reaction: nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1); uses an RNA template, i.e. the catalysis of RNA-template-directed extension of the 3'-end of an RNA strand by one nucleotide at a time. [EC:2.7.7.48, GOC:mah, GOC:pf]\",\n",
              "  'acute respiratory syndromes, C0035222, Respiratory Distress Syndrome, Adult, Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.',\n",
              "  'S1, C0879262, S-1 Antimetabolite agent, a kind of cancer treatment drug',\n",
              "  'Rabbit Haemorrhagic Disease Virus RHDV, C0162332, Hemorrhagic Disease Virus, Rabbit, A species in the genus LAGOVIRUS which causes hemorrhagic disease, including hemorrhagic septicemia, in rabbits.',\n",
              "  'respiratory illness, C4528950, Respiratory Hygiene Stations, Stations designed to dispense infection prevention items related to respiratory hygiene/cough etiquette (e.g., masks, tissues, hand sanitizer) in health care. These stations typically consist of a base that may be placed on the floor or a table, a stand, and brackets or slots into which supplies may be placed. Some stations come with instructions or include a sign holder into which instructions may be added. These stations are usually placed in high-traffic areas (e.g., lobbies, elevators and cafeterias) to promote respiratory hygiene.',\n",
              "  'coronavirus, C0206419, Genus: Coronavirus, A member of CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of vertebrates.',\n",
              "  'Covid-19, C5203670, COVID19 (disease), A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.',\n",
              "  'dihydropyrimidine, C0012315, Dihydropyridines, Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.',\n",
              "  \"RDRP, C1152412, RNA-directed RNA polymerase activity, Catalysis of the reaction: nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1); uses an RNA template, i.e. the catalysis of RNA-template-directed extension of the 3'-end of an RNA strand by one nucleotide at a time. [EC:2.7.7.48, GOC:mah, GOC:pf]\",\n",
              "  'SARS-CoV-2, C5203676, SARS-CoV-2, A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.',\n",
              "  \"UTP, C0042010, Uridine Triphosphate, Uridine 5'-(tetrahydrogen triphosphate). A uracil nucleotide containing three phosphate groups esterified to the sugar moiety.\",\n",
              "  'Alkenyl sulfonylurea, C0038766, Sulfonylurea Compounds, A class of compounds in which a sulfone functional group is attached to UREA.',\n",
              "  'immune cells, C4330475, Immune Cell, A cell in the immune system that is involved in host defense. This category may include lymphocytes, monocytes, macrophages, neutrophils, eosinophils, basophils, mast cells, and thrombocytes. Precursor cells in these lineages may also be included.',\n",
              "  'nonstructural protein N 45, C0069065, Viral Nonstructural Proteins, Proteins encoded by a VIRAL GENOME that are not structural components of VIRUS PARTICLES. Some of these proteins may play roles within the infected cell during VIRUS REPLICATION or act in regulation of virus replication or VIRUS ASSEMBLY.',\n",
              "  'oleanolic acid, C0028925, oleanolic acid, A pentacyclic triterpene that occurs widely in many PLANTS as the free acid or the aglycone for many SAPONINS. It is biosynthesized from lupane. It can rearrange to the isomer, ursolic acid, or be oxidized to taraxasterol and amyrin.',\n",
              "  'platycodin, C0071274, platycodin, None',\n",
              "  'MoA, C0547065, Mixed oligoastrocytoma, A type of low-grade glioma with a mixed astrocytoma and oligodendroglioma histology, manifesting with headaches, speech and motor problems, seizures and in some cases subarachnoid hemorrhage.',\n",
              "  'iron, C0302583, iron, A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN.',\n",
              "  'SARS-CoV-2, C5203676, SARS-CoV-2, A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.',\n",
              "  'epidemic diseases, C0277548, Epidemic disease, None',\n",
              "  'dinucleoside, C0028621, Nucleosides, Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed)',\n",
              "  'retinoid, C0035339, Retinoids, A group of tetraterpenes, with four terpene units joined head-to-tail. Biologically active members of this class are used clinically in the treatment of severe cystic ACNE; PSORIASIS; and other disorders of keratinization.',\n",
              "  'SARS-CoV-1, C1175743, Severe acute respiratory syndrome-related coronavirus, A species of CORONAVIRUS causing atypical respiratory disease (SEVERE ACUTE RESPIRATORY SYNDROME) in humans. The organism is believed to have first emerged in Guangdong Province, China, in 2002. The natural host is the Chinese horseshoe bat, RHINOLOPHUS sinicus.',\n",
              "  'CAII, C1413043, CA2 gene, This gene is involved in bone resorption, osteoclast differentiation and fluid transport in the anterior chamber of the eye.',\n",
              "  'HK2, C0618743, Human Glandular Kallikrein 2, Kallikrein-2 (261 aa, ~29 kDa) is encoded by the human KLK2 gene. This protein plays a role in proteolysis and vasodilation.',\n",
              "  'Mpro, C5575367, SARS-CoV-2 3C-Like Proteinase Nsp5, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like proteinase nsp5 (306 aa, ~34 kDa) is encoded by the SARS-CoV-2 rep gene. This protein is involved in viral replication.',\n",
              "  'Encephalomyocarditis virus, C0014080, Encephalomyocarditis virus, The type species of CARDIOVIRUS causing encephalomyelitis and myocarditis in rodents, pigs, and monkeys. Infection in man has been reported with CNS involvement but without myocarditis.',\n",
              "  'nucleotide triphosphate, C0597106, nucleoside triphosphate, glycosamine consisting of a base linked to a deoxyribose or ribose sugar esterified with triphosphate on its glycose moiety.',\n",
              "  'NTP, C3541284, HOXA7 wt Allele, Human HOXA7 wild-type allele is located in the vicinity of 7p15.2 and is approximately 4 kb in length. This allele, which encodes homeobox protein Hox-A7, plays a role in anterior-posterior regulation of gene expression during embryonic development.',\n",
              "  'cannabis, C0024808, Marihuana, Any part of, or extract from, the female hemp plant Cannabis sativa. Marijuana contains cannabinoids, substances with hallucinogenic, psychoactive, and addictive properties. This agent has potential use for treating cancer pain and cachexia. (NCI04)',\n",
              "  'DR, C4761490, Derung Chinese, A Chinese person from the Derung ethnic group.',\n",
              "  'nucleocapsids, C0178774, Nucleocapsid, A protein-nucleic acid complex which forms part or all of a virion. It consists of a CAPSID plus enclosed nucleic acid. Depending on the virus, the nucleocapsid may correspond to a naked core or be surrounded by a membranous envelope.',\n",
              "  'MET, C0025646, methionine, A sulfur-containing essential L-amino acid that is important in many body functions.',\n",
              "  'Human Poliovirus PV, C0206435, poliovirus, A species of ENTEROVIRUS which is the causal agent of POLIOMYELITIS in humans. Three serotypes (strains) exist. Transmission is by the fecal-oral route, pharyngeal secretions, or mechanical vector (flies). Vaccines with both inactivated and live attenuated virus have proven effective in immunizing against the infection.',\n",
              "  'viral protein, C0042736, Viral Proteins, Proteins found in any species of virus.',\n",
              "  'Na+, C0597484, sodium cation, chief cation of the extracellular body fluids.',\n",
              "  'coronavirus, C0206419, Genus: Coronavirus, A member of CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of vertebrates.',\n",
              "  'AM580, C0102885, Am 580, None',\n",
              "  'Human, C0086418, Homo sapiens, Members of the species Homo sapiens.',\n",
              "  'Norovirus, C0949920, Norovirus, A genus of non-enveloped, capsid covered viruses with T=3 icosahedral symmetry, in the family Caliciviridae. The genome is composed of a linear, single-strand of positive sense RNA. Noroviruses are transmitted by the fecal-oral route and cause gastroenteritis in humans.',\n",
              "  'C1, C0456879, TNM certainty factor C1, None',\n",
              "  'cells, C0007634, Cells, The fundamental, structural, and functional units or subunits of living organisms. They are composed of CYTOPLASM containing various ORGANELLES and a CELL MEMBRANE boundary.',\n",
              "  'MERS, C3694279, Middle East Respiratory Syndrome, A viral disorder characterized by SARS (Severe Acute Respiratory Syndrome)-like symptoms caused by MERS-CoV (MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS).',\n",
              "  'nCoV, C5203676, SARS-CoV-2, A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.',\n",
              "  'NCBI, C0995203, NCBI Taxonomy, None',\n",
              "  'NTD, C3891448, NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO, None',\n",
              "  'COVID-19, C5203670, COVID19 (disease), A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.',\n",
              "  'protease, C0030940, Peptide Hydrolases, Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES.',\n",
              "  'PolV, C0265809, Double outlet left ventricle, A congenital defect of heart development characterized by origin of both pulmonary artery and aorta from the morphological left ventricle. [HPO:probinson]',\n",
              "  'poly‐ADP‐ribose polymerase 1, C0032405, Poly(ADP-ribose) Polymerases, Enzymes that catalyze the transfer of multiple ADP-RIBOSE groups from nicotinamide-adenine dinucleotide (NAD) onto protein targets, thus building up a linear or branched homopolymer of repeating ADP-ribose units i.e., POLY ADENOSINE DIPHOSPHATE RIBOSE.',\n",
              "  'PARP1, C1538577, PARP1 gene, This gene is involved in cellular repair and apoptosis.',\n",
              "  'NOD-like receptors, C4277661, NLR Proteins, Intracellular signaling proteins that are defined by the presence of a NUCLEOTIDE-binding region and LEUCINE-rich repeats. Their general structure consists of any of a variety of effector domains at their N-termini such as a caspase recruitment domain (CARD), a central nucleotide-binding domain, and a variable number of C-terminal leucine-rich repeats. They are important for pathogen recognition in the INNATE IMMUNE RESPONSE of animals and plants. Members of the NLR protein family include the NOD SIGNALING ADAPTOR PROTEINS.',\n",
              "  'ginkgolic acid, C0675409, ginkgolic acid, None',\n",
              "  'RBD, C1522002, RNA Recognition Motif, An approximately 80 amino acid RNA binding motif that consists of four anti-parallel surface beta sheets and two alpha helices arranged in a beta-alpha-beta-beta-alpha-beta configuration. One of the surface beta sheets interacts with two or three specific RNA bases. Interactions between additional sequences and the RNA, as well as within the RNA recognition motif increase the affinity and specificity of the protein-RNA interaction.',\n",
              "  'SARS‐CoV, C1175743, Severe acute respiratory syndrome-related coronavirus, A species of CORONAVIRUS causing atypical respiratory disease (SEVERE ACUTE RESPIRATORY SYNDROME) in humans. The organism is believed to have first emerged in Guangdong Province, China, in 2002. The natural host is the Chinese horseshoe bat, RHINOLOPHUS sinicus.',\n",
              "  'nucleotide, C0028630, Nucleotides, The monomeric units from which DNA or RNA polymers are constructed. They consist of a purine or pyrimidine base, a pentose sugar, and a phosphate group. (From King & Stansfield, A Dictionary of Genetics, 4th ed)',\n",
              "  'poly-ADP-ribose polymerase 1, C1567710, PARP1 protein, human, Poly [ADP-ribose] polymerase 1 (1013aa, ~113 kDa) is encoded by the human PARP1 gene. This protein is involved in poly ADP-ribosylation and in the regulation of various cellular processes such as differentiation, proliferation, tumor transformation, and recovery from DNA damage.',\n",
              "  'PARP1, C1538577, PARP1 gene, This gene is involved in cellular repair and apoptosis.',\n",
              "  'immune illnesses, C0221423, Illness (finding), A state of ill health, bodily malfunction, or discomfort.',\n",
              "  'HCV, C0019196, Hepatitis C, INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.',\n",
              "  'heme, C0018966, Heme, The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.',\n",
              "  'Human Rhinovirus, C0318467, Human rhinovirus, None',\n",
              "  'cultured, C0010453, Anthropological Culture, A collective expression for all behavior patterns acquired and socially transmitted through symbols. Culture includes customs, traditions, and language.',\n",
              "  'CoV, C5203676, SARS-CoV-2, A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.',\n",
              "  'isopropyl, C2945717, isopropyl, None',\n",
              "  'lymphoid malignancies, C0006826, Malignant Neoplasms, A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.',\n",
              "  '3D, C1442459, 3 Days, None',\n",
              "  'cell culture, C0007585, Cell Culture Techniques, Any laboratory procedure for growing cells or tissues in vitro.',\n",
              "  'spike glycoprotein, C5391442, spike protein, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (1273 aa, ~141 kDa) is encoded by the SARS-CoV-2 S gene. This protein plays a role in binding to host cell membranes and the initiation of viral infection.',\n",
              "  'nsps, C0085292, Stiff-Person Syndrome, A condition characterized by persistent spasms (SPASM) involving multiple muscles, primarily in the lower limbs and trunk. The illness tends to occur in the fourth to sixth decade of life, presenting with intermittent spasms that become continuous. Minor sensory stimuli, such as noise and light touch, precipitate severe spasms. Spasms do not occur during sleep and only rarely involve cranial muscles. Respiration may become impaired in advanced cases. (Adams et al., Principles of Neurology, 6th ed, p1492; Neurology 1998 Jul;51(1):85-93)',\n",
              "  'SARS-CoV, C1175743, Severe acute respiratory syndrome-related coronavirus, A species of CORONAVIRUS causing atypical respiratory disease (SEVERE ACUTE RESPIRATORY SYNDROME) in humans. The organism is believed to have first emerged in Guangdong Province, China, in 2002. The natural host is the Chinese horseshoe bat, RHINOLOPHUS sinicus.',\n",
              "  'Coronaviruses, C0206419, Genus: Coronavirus, A member of CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of vertebrates.',\n",
              "  'Won, C1879658, Bioconductor caAffy Li Wong Probe Summary Method, Summarizes probe sets using the model described in Li and Wong (2001) to a probe set with I chips and J probes. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html',\n",
              "  'Norwalk Virus, C0028422, Norwalk virus, The type species in the genus NOROVIRUS, first isolated in 1968 from the stools of school children in Norwalk, Ohio, who were suffering from GASTROENTERITIS. The virions are non-enveloped spherical particles containing a single protein. Multiple strains are named after the places where outbreaks have occurred.',\n",
              "  'nucleoside, C0028621, Nucleosides, Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed)',\n",
              "  'domain, C1514562, Protein Domain, Discrete protein structural units that may fold independently of the rest of the protein and have their own functions.',\n",
              "  'ZINC, C0043481, zinc, A metallic element of atomic number 30 and atomic weight 65.38. It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an important role in protein synthesis and in cell division. Zinc deficiency is associated with ANEMIA, short stature, HYPOGONADISM, impaired WOUND HEALING, and geophagia. It is known by the symbol Zn.',\n",
              "  'cultured cells, C0007635, Cultured Cells, Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.',\n",
              "  'beta-eudesmol, C5540459, .beta.-eudesmol, None',\n",
              "  'SARSCoV-2 virus, C5203676, SARS-CoV-2, A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.',\n",
              "  'phosphatidylinositol 3-kinase PI3K, C0044602, 1-Phosphatidylinositol 3-Kinase, A phosphatidylinositol 3-kinase that catalyzes the conversion of 1-phosphatidylinositol into 1-phosphatidylinositol 3-phosphate.',\n",
              "  'Trp, C0041249, tryptophan, An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.',\n",
              "  'viral neuraminidases, C0027803, Neuraminidase, An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992)',\n",
              "  'human cells, C0427861, Human cells, None',\n",
              "  'helicase, C0920283, DNA Helicases, Proteins that catalyze the unwinding of duplex DNA during replication by binding cooperatively to single-stranded regions of DNA or to short regions of duplex DNA that are undergoing transient opening. In addition, DNA helicases are DNA-dependent ATPases that harness the free energy of ATP hydrolysis to translocate DNA strands.',\n",
              "  \"RNA-dependent RNA polymerase RdRp, C0035685, RNA-Directed RNA Polymerase, An enzyme that catalyses RNA-template-directed extension of the 3'- end of an RNA strand by one nucleotide at a time, and can initiate a chain de novo. (Enzyme Nomenclature, 1992, p293)\",\n",
              "  'EIDD-1931, C5545152, EIDD-1931, None',\n",
              "  'SARS coronavirus, C1175743, Severe acute respiratory syndrome-related coronavirus, A species of CORONAVIRUS causing atypical respiratory disease (SEVERE ACUTE RESPIRATORY SYNDROME) in humans. The organism is believed to have first emerged in Guangdong Province, China, in 2002. The natural host is the Chinese horseshoe bat, RHINOLOPHUS sinicus.',\n",
              "  'selenium, C0036581, selenium, An element with the atomic symbol Se, atomic number 34, and atomic weight 78.97. It is an essential micronutrient for mammals and other animals but is toxic in large amounts. Selenium protects intracellular structures against oxidative damage. It is an essential component of GLUTATHIONE PEROXIDASE.',\n",
              "  'PPIN, C1418797, PPID gene, This gene plays a role in the catalysis of protein folding.',\n",
              "  'spikes, C3689447, Cane/Crutch Spikes, Metal spikes applied to the distal end of crutches (i.e., crutch tips) designed to provide skid-resistant traction. Cane/crutch spikes are intended for use outdoors on snow, ice or other slippery or uneven surfaces. These spikes help the crutch user gain traction, ease shock to the shoulder, and help prevent accidental falls. The spikes can easily be retracted or removed for indoor use of canes and crutches.',\n",
              "  'M1, C0441971, Metastasis stage M1, A clinical and/or pathologic distant metastasis TNM finding indicating the spread of cancer to distant anatomic sites.',\n",
              "  'ferrets, C0015859, Ferrets, Semidomesticated variety of European polecat much used for hunting RODENTS and/or RABBITS and as a laboratory animal. It is in the subfamily Mustelinae, family MUSTELIDAE.',\n",
              "  'magenta, C0035856, Rosaniline Dyes, Compounds that contain the triphenylmethane aniline structure found in rosaniline. Many of them have a characteristic magenta color and are used as COLORING AGENTS.',\n",
              "  'Human, C0086418, Homo sapiens, Members of the species Homo sapiens.',\n",
              "  'Coxsackievirus CoxV, C0010247, Coxsackie Viruses, Heterogeneous serotypes of various species in the genus ENTEROVIRUS, found in association with various diseases in man and other animals. The specific coxsackieviruses are distributed among the species HUMAN ENTEROVIRUS A; HUMAN ENTEROVIRUS B; and HUMAN ENTEROVIRUS C. The name is derived from a village in New York State where the virus was first identified.',\n",
              "  'Nsps, C0085292, Stiff-Person Syndrome, A condition characterized by persistent spasms (SPASM) involving multiple muscles, primarily in the lower limbs and trunk. The illness tends to occur in the fourth to sixth decade of life, presenting with intermittent spasms that become continuous. Minor sensory stimuli, such as noise and light touch, precipitate severe spasms. Spasms do not occur during sleep and only rarely involve cranial muscles. Respiration may become impaired in advanced cases. (Adams et al., Principles of Neurology, 6th ed, p1492; Neurology 1998 Jul;51(1):85-93)',\n",
              "  'antimalarial, C0003374, Antimalarials, Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585)',\n",
              "  'protease, C0030940, Peptide Hydrolases, Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES.',\n",
              "  '3C proteases, C2002636, 3C proteases, None',\n",
              "  'quinolone, C0034423, quinoline, None',\n",
              "  'infected, C0439663, Infected, None',\n",
              "  'cell, C0007634, Cells, The fundamental, structural, and functional units or subunits of living organisms. They are composed of CYTOPLASM containing various ORGANELLES and a CELL MEMBRANE boundary.',\n",
              "  'mouse, C0025914, House mice, The common mouse species, Mus musculus.',\n",
              "  'papain, C0030346, papain, A proteolytic enzyme obtained from Carica papaya. It is also the name used for a purified mixture of papain and CHYMOPAPAIN that is used as a topical enzymatic debriding agent. EC 3.4.22.2.',\n",
              "  'host cell, C1819995, Host Cell, A cell within a host organism. Includes the host plasma membrane and any external encapsulating structures such as the host cell wall and cell envelope. [GOC:jl]',\n",
              "  'Paxlovid, C5565871, Paxlovid, None',\n",
              "  'Androgen, C0002844, Androgens, Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.',\n",
              "  'extra-cellular vesicles, C3894683, Extracellular Vesicles, Any vesicle that is part of the extracellular region. [GO_REF:0000064, GOC:pm, GOC:TermGenie, PMID:24769233]',\n",
              "  'SARS viruses, C1175743, Severe acute respiratory syndrome-related coronavirus, A species of CORONAVIRUS causing atypical respiratory disease (SEVERE ACUTE RESPIRATORY SYNDROME) in humans. The organism is believed to have first emerged in Guangdong Province, China, in 2002. The natural host is the Chinese horseshoe bat, RHINOLOPHUS sinicus.',\n",
              "  'spike S glycoprotein, C5391442, spike protein, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (1273 aa, ~141 kDa) is encoded by the SARS-CoV-2 S gene. This protein plays a role in binding to host cell membranes and the initiation of viral infection.',\n",
              "  'distal, C0205108, Distal (qualifier value), Situated farthest from a point of attachment or origin, as of a limb or bone; or directed away from the midline of the body.',\n",
              "  \"airway cells, C0178987, Artificial Airways, Devices designed to permit the passage of gases (e.g., air, oxygen) to the lungs while preventing obstruction of the patient's upper airway. These airways include a variety of devices according to the technique used to facilitate the passage of gases, the intended application, and the expected time of use. In emergency and/or for short-time use, esophageal obturation with one- or two-lumen tubes and oropharyngeal artificial airways are typically used. For a few days of intubation, nasopharyngeal artificial airways are the most commonly used devices, while for longer periods (up to three weeks) endotracheal tubes are the preferred devices. When long-term mechanical ventilation is needed, tracheostomy tubes are used. Artificial airways are available in a variety of configurations from newborn to adult sizes.\",\n",
              "  'Sapporovirus, C0949922, Sapporo virus, A species of non-enveloped viruses in the Caliciviridae family and Sapovirus genus that have characteristic cup-shaped depressions on their spherical capsid surface and a distinctive structure of \"Star-of-David\" configuration. The genome is composed of single-stranded, positive-sense RNA. Sapporo viruses are found in humans and cause gastroenteritis mainly in young children. Sapporo viruses are transmitted via oral ingestion.',\n",
              "  'SapV, C0754188, amprenavir, A synthetic derivative of hydroxyethylamine sulfonamide that selectively binds to and inhibits human immunodeficiency virus (HIV) protease.',\n",
              "  'Non-structural protein 5, C5575367, SARS-CoV-2 3C-Like Proteinase Nsp5, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like proteinase nsp5 (306 aa, ~34 kDa) is encoded by the SARS-CoV-2 rep gene. This protein is involved in viral replication.',\n",
              "  'RBD residues, C1522002, RNA Recognition Motif, An approximately 80 amino acid RNA binding motif that consists of four anti-parallel surface beta sheets and two alpha helices arranged in a beta-alpha-beta-beta-alpha-beta configuration. One of the surface beta sheets interacts with two or three specific RNA bases. Interactions between additional sequences and the RNA, as well as within the RNA recognition motif increase the affinity and specificity of the protein-RNA interaction.',\n",
              "  'phosphoramide, C0070912, phosphoramide, None',\n",
              "  'amino acids, C0002520, Amino Acids, Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins.',\n",
              "  'SARS‐Coronavirus, C1175743, Severe acute respiratory syndrome-related coronavirus, A species of CORONAVIRUS causing atypical respiratory disease (SEVERE ACUTE RESPIRATORY SYNDROME) in humans. The organism is believed to have first emerged in Guangdong Province, China, in 2002. The natural host is the Chinese horseshoe bat, RHINOLOPHUS sinicus.',\n",
              "  'C5a, C1367710, C5 gene, Human C5 wild-type allele is located within 9q33-q34 and is approximately 98 kb in length. This allele, which encodes complement C5 protein, is involved in the complement system, inflammatory responses, and histamine release.',\n",
              "  'capmanitib, C4053698, capmatinib, An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.',\n",
              "  'living cells, C0023914, Living Wills, Written, witnessed declarations in which persons request that if they become disabled beyond reasonable expectation of recovery, they be allowed to die rather than be kept alive by extraordinary means. (Bioethics Thesaurus)',\n",
              "  'NS5, C1706586, RAF1 wt Allele, Human RAF1 wild-type allele is located within 3p25 and is approximately 81 kb in length. This allele, which encodes RAF proto-oncogene serine/threonine-protein kinase protein, plays a role in the transduction of mitogenic signals from the cell membrane to the nucleus. Amplification of the RAF1 gene has been detected in certain cancers such as anaplastic large cell lymphomas, bladder carcinomas, nasopharyngeal carcinomas and hormone-resistant prostate cancer.',\n",
              "  'bisindolylmaleimide, C0256431, bisindolylmaleimide, None',\n",
              "  'nucleotides, C0028630, Nucleotides, The monomeric units from which DNA or RNA polymers are constructed. They consist of a purine or pyrimidine base, a pentose sugar, and a phosphate group. (From King & Stansfield, A Dictionary of Genetics, 4th ed)',\n",
              "  'feline coronavirus, C0936087, Coronavirus, Feline, A species of CORONAVIRUS infecting cats of all ages and commonly found in catteries and zoos. Cats are often found carrying the virus but only a small proportion develop disease. Feline coronavirus and Feline infectious peritonitis virus (FIPV) are virtually the same virus in genetic and antigenetic terms, and are morphologically indistinguishable. Since they only differ in their disease potential (with FIPV causing a more serious illness), they are considered biotypes of each other.',\n",
              "  \"congenital disabilities, C0231170, Disability, Any physical or mental impairment that interferes with an individual's ability to perform desired activities.\",\n",
              "  'Murine, C0026809, Mus, Any of numerous species of small rodents belonging to the genus Mus and various related genera of the family Muridae.',\n",
              "  'pp1 polyprotein, C0032583, Polyproteins, Proteins which are synthesized as a single polymer and then cleaved into several distinct proteins.',\n",
              "  'Human Enterovirus HEV, C0950042, human enterovirus A, A species of ENTEROVIRUS infecting humans and containing 10 serotypes, mostly coxsackieviruses.',\n",
              "  'COX, C0033551, Prostaglandin-Endoperoxide Synthase, An enzyme that converts arachidonic acid into biologically active prostanoids, such as prostaglandins, prostacyclins, and thromboxanes.',\n",
              "  'Human Immunodeficiency Virus-1, C0019682, HIV, Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.',\n",
              "  'HIV, C0019682, HIV, Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.',\n",
              "  'SARS-CoV-2 illness, C5203676, SARS-CoV-2, A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.',\n",
              "  'MERS-, C3698360, Middle East Respiratory Syndrome Coronavirus, A coronavirus first reported in the summer of 2012 in a pneumonia patient in SAUDI ARABIA. It is related to SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS. MERS-CoV has an estimated incubation period of 12 days and symptoms include renal failure and severe acute pneumonia with often fatal outcome.',\n",
              "  'ORF1a, C1419971, SERF1A gene, This gene may play a role in the development of the spine.',\n",
              "  'Covid-19, C5203670, COVID19 (disease), A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.',\n",
              "  'porcine, C0039005, Family suidae, Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).',\n",
              "  'glycogen synthase kinase 3, C0244989, Glycogen Synthase Kinase 3, A family of serine/threonine protein kinases that is involved in intracellular signaling, cellular proliferation, cell migration, inflammation and immune responses, glucose regulation, and apoptosis.',\n",
              "  'GSK-3, C0244989, Glycogen Synthase Kinase 3, A family of serine/threonine protein kinases that is involved in intracellular signaling, cellular proliferation, cell migration, inflammation and immune responses, glucose regulation, and apoptosis.',\n",
              "  'Human Enterovirus 71, C0318431, Enterovirus 71, Human, A type A enterovirus prominently associated with hand, foot, and mouth disease, acute pulmonary edema, and serious neurologic syndromes.',\n",
              "  'host, C1167395, Host (organism), An organism that nourishes and supports another but does not benefit by the association; recipient of transplanted tissue or organ from a donor.',\n",
              "  'NTP, C3541284, HOXA7 wt Allele, Human HOXA7 wild-type allele is located in the vicinity of 7p15.2 and is approximately 4 kb in length. This allele, which encodes homeobox protein Hox-A7, plays a role in anterior-posterior regulation of gene expression during embryonic development.',\n",
              "  'NAs, C0068453, Tobacco containing mixture, None',\n",
              "  'cardiovascular, C0007226, Cardiovascular system, The HEART and the BLOOD VESSELS by which BLOOD is pumped and circulated through the body.',\n",
              "  'p97, C1413354, CFDP1 gene, None',\n",
              "  'segregase, C0080141, Racial Segregation, Barriers based on ethnicity or other group group membership.',\n",
              "  \"RdRp receptor, C1152412, RNA-directed RNA polymerase activity, Catalysis of the reaction: nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1); uses an RNA template, i.e. the catalysis of RNA-template-directed extension of the 3'-end of an RNA strand by one nucleotide at a time. [EC:2.7.7.48, GOC:mah, GOC:pf]\",\n",
              "  \"RNA‐dependent RNA polymerase RdRp complex, C0035685, RNA-Directed RNA Polymerase, An enzyme that catalyses RNA-template-directed extension of the 3'- end of an RNA strand by one nucleotide at a time, and can initiate a chain de novo. (Enzyme Nomenclature, 1992, p293)\",\n",
              "  \"airway, C0178987, Artificial Airways, Devices designed to permit the passage of gases (e.g., air, oxygen) to the lungs while preventing obstruction of the patient's upper airway. These airways include a variety of devices according to the technique used to facilitate the passage of gases, the intended application, and the expected time of use. In emergency and/or for short-time use, esophageal obturation with one- or two-lumen tubes and oropharyngeal artificial airways are typically used. For a few days of intubation, nasopharyngeal artificial airways are the most commonly used devices, while for longer periods (up to three weeks) endotracheal tubes are the preferred devices. When long-term mechanical ventilation is needed, tracheostomy tubes are used. Artificial airways are available in a variety of configurations from newborn to adult sizes.\",\n",
              "  'inflammation, C0021368, Inflammation, A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.',\n",
              "  'lipopeptides, C2266975, Lipopeptides, Compounds consisting of a short peptide chain conjugated with an acyl chain.',\n",
              "  'septic shock, C0036983, Septic Shock, Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.',\n",
              "  'murine, C0026809, Mus, Any of numerous species of small rodents belonging to the genus Mus and various related genera of the family Muridae.',\n",
              "  'Cmap, C1413776, CST7 gene, None',\n",
              "  'CBD, C0006863, cannabidiol, Compound isolated from Cannabis sativa extract.',\n",
              "  'rhesus monkey, C0024400, Macaca mulatta, A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans.',\n",
              "  'triazoles, C0040880, Triazoles, Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.',\n",
              "  'COVID‐19, C5203670, COVID19 (disease), A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.',\n",
              "  'human coronavirus, C0206422, Human coronavirus, None',\n",
              "  'proteases, C0030940, Peptide Hydrolases, Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES.',\n",
              "  'TIP3P, C1416380, IKBKG gene, This gene plays a role in the regulation of signal transduction.',\n",
              "  'immunoglobulin superfamily IgSF, C1309370, CADM1 protein, human, Cell adhesion molecule 1 (442 aa, ~49 kDa) is encoded by the human CADM1 gene. This protein plays a role in calcium-dependent cell-cell adhesion.',\n",
              "  'SARS-CoV-2, C5203676, SARS-CoV-2, A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.',\n",
              "  'NF-B, C3887647, Lymphotoxin-Alpha, human, Lymphotoxin-alpha (205 aa, ~22 kDa) is encoded by the human LTA gene. This protein plays a role in cell-cell signaling and the positive regulation of apoptosis.',\n",
              "  'SARS, C1175175, Severe Acute Respiratory Syndrome, A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.',\n",
              "  'envelope E, C1622204, envelope, A multilayered structure surrounding all or part of a cell; encompasses one or more lipid bilayers, and may include a cell wall layer; also includes the space between layers. [GOC:mah, GOC:pz]',\n",
              "  'Bromoepiandrosterone, C0014483, Epiandrosterone, A dehydroepiandrosterone metabolite and a precursor of testosterone and estradiol with hypolipidemic and anabolic property. Epiandrosterone, a potential neurosteroid, appears to bind to the gamma-aminobutyric acid (GABA)/benzodiazepine-receptor complex (GABA-RC), acting as a negative non-competitive modulator of GABA-RC as well as signal through the N-methyl-D-aspartate receptor. In addition this agent inhibits the pentose phosphate pathway (PPP) thereby dilating blood vessels pre-contracted by partial depolarization. Also, epiandrosterone inhibits the synthesis of thromboxane A2 in activated platelets, reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen, increases serum levels of insulin-like growth factor 1 and increases cyclic guanosine monophosphate and nitric oxide synthesis. These effects may improve circulation in the microvasculature.',\n",
              "  'C-type lectin domain family 4, C1539094, CLEC4C gene, This gene is involved in immune function.',\n",
              "  '3-C proteases, C0030940, Peptide Hydrolases, Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES.',\n",
              "  'cMAP, C1413776, CST7 gene, None',\n",
              "  'ORF6, C1412511, ARF6 gene, This gene plays a role in vesicle trafficking, membrane lipid remodeling and cytoskeleton reorganization.',\n",
              "  'SARS-CoV-2 virus, C5203676, SARS-CoV-2, A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.',\n",
              "  'Betacoronavirus, C2806453, Betacoronavirus, A genus of enveloped and spherical positive sense ssRNA viruses in the subfamily Coronavirinae of the family Coronaviridae with a diameter of about 120 nm. Betacoronaviruses have a nonopartite, linear genome of 27-32 kb. Bats are the most common reservoir for betacoronaviruses.',\n",
              "  \"GTP, C0018353, Guanosine Triphosphate, Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.\",\n",
              "  'ubiquitin, C0041538, Ubiquitin, A highly conserved 76-amino acid peptide universally found in eukaryotic cells that functions as a marker for intracellular PROTEIN TRANSPORT and degradation. Ubiquitin becomes activated through a series of complicated steps and forms an isopeptide bond to lysine residues of specific proteins within the cell. These \"ubiquitinated\" proteins can be recognized and degraded by proteosomes or be transported to specific compartments within the cell.',\n",
              "  'SARSCoV-2, C5203676, SARS-CoV-2, A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.',\n",
              "  'ubiquitin-specific proteases, C0669472, ubiquitin-specific protease, Members of the peptidase C19 family which regulate signal transduction by removing UBIQUITIN from specific protein substrates via a process known as deubiquitination or deubiquitylation.',\n",
              "  'USPs, C0032756, Postal Service, The functions and activities carried out by the U.S. Postal Service, foreign postal services, and private postal services such as Federal Express.',\n",
              "  'COVID, C5203670, COVID19 (disease), A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.',\n",
              "  'chronic, C0205191, chronic, Usually used to describe a condition that is persistent and long standing.',\n",
              "  'diseases, C0012634, Disease, A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.',\n",
              "  'spike glycoproteins, C5391442, spike protein, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (1273 aa, ~141 kDa) is encoded by the SARS-CoV-2 S gene. This protein plays a role in binding to host cell membranes and the initiation of viral infection.',\n",
              "  'NSP-14, C0759905, Caspase 14, A short pro-domain caspase that is almost exclusively expressed in the EPIDERMIS and may play a role in the differentiation of epidermal KERATINOCYTES.',\n",
              "  'S protein, C0072393, protein S, The vitamin K-dependent cofactor of activated PROTEIN C. Together with protein C, it inhibits the action of factors VIIIa and Va. A deficiency in protein S; (PROTEIN S DEFICIENCY); can lead to recurrent venous and arterial thrombosis.',\n",
              "  'complex, C0439855, Complex, Hard, involved or complicated, elaborate, having many parts.',\n",
              "  'BPs, C2740858, BPS, None',\n",
              "  'RNA-dependent DNA polymerase, C0035379, RNA-Directed DNA Polymerase, An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49.',\n",
              "  \"cutaneous rashes, C0015230, Exanthema, Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.\",\n",
              "  'CADD, C0342783, Deficiency of butyryl-CoA dehydrogenase, A genetic disorder characterized by deficiency of the enzyme short-chain acyl-coenzyme A dehydrogenase that metabolizes short-chain fatty acids. Signs and symptoms appear in infancy or childhood and may be triggered during fasting or illness. They include vomiting, hypoglycemia, lethargy, hypotonia and failure to thrive.',\n",
              "  'phosphate, C0031603, Phosphates, Inorganic salts of phosphoric acid.',\n",
              "  'beta, C0330390, Beta plant, None',\n",
              "  'Statins, C0360714, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis.',\n",
              "  'Aloe, C0002168, Aloe, A plant genus of the family ASPHODELACEAE which is used medicinally. It contains anthraquinone glycosides such as aloin-emodin or aloe-emodin (EMODIN).',\n",
              "  'membrane M, C0025255, Tissue membrane, Thin layers of tissue which cover parts of the body, separate adjacent cavities, or connect adjacent structures.',\n",
              "  'endolysosome, C3271504, endolysosome, An transient hybrid organelle formed by fusion of a late endosome with a lysosome, and in which active degradation takes place. [GOC:pde, PMID:21878991]',\n",
              "  'inflammatory diseases, C1290884, Inflammatory disorder, An infectious or non infectious disorder characterized by signs and symptoms derived from focal or extensive tissue infiltration by acute (e.g., polymorphonuclear) or chronic (e.g., lymphocytic-plasmacytic) inflammatory cells. Representative examples of infectious disorders include viral infections, bacterial infections, and parasitic infections. Representative examples of non-infectious inflammatory disorders include inflammatory bowel disease and inflammatory polyps.',\n",
              "  'lung, C0024109, Lung, Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.',\n",
              "  'Poly ADP-ribose polymerase 1, C1567710, PARP1 protein, human, Poly [ADP-ribose] polymerase 1 (1013aa, ~113 kDa) is encoded by the human PARP1 gene. This protein is involved in poly ADP-ribosylation and in the regulation of various cellular processes such as differentiation, proliferation, tumor transformation, and recovery from DNA damage.',\n",
              "  'PARP-1, C1428200, TIPARP gene, This gene is involved in ADP-ribosylation of proteins.',\n",
              "  'spike glycoprotein, C5391442, spike protein, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (1273 aa, ~141 kDa) is encoded by the SARS-CoV-2 S gene. This protein plays a role in binding to host cell membranes and the initiation of viral infection.',\n",
              "  \"RNA-dependent RNA polymerase, C0035685, RNA-Directed RNA Polymerase, An enzyme that catalyses RNA-template-directed extension of the 3'- end of an RNA strand by one nucleotide at a time, and can initiate a chain de novo. (Enzyme Nomenclature, 1992, p293)\",\n",
              "  'COVID-19, C5203670, COVID19 (disease), A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.',\n",
              "  'SARS-CoV-2, C5203676, SARS-CoV-2, A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.',\n",
              "  'COVID-19, C5203670, COVID19 (disease), A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent.',\n",
              "  'MK-4482, C5435401, MK-4482, None']]"
            ]
          },
          "metadata": {},
          "execution_count": 110
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "for i in detailed_missing_kb_ents:\n",
        "    print(len(i))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Mn4Q53W_Kerc",
        "outputId": "79a483dc-b5a8-4ff7-ec05-c73e90c20b49"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "287\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-06_detailed_missing_kb_ents.pickle', 'wb') as f:\n",
        "   pickle.dump(detailed_missing_kb_ents, f)"
      ],
      "metadata": {
        "id": "NQ5CgsajKWVA"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 4.3 scispaCy NER\n",
        "\n",
        "We will create Doc objects from a couple of sentences and extract entities and spans."
      ],
      "metadata": {
        "id": "EO0pZ6jbLnDX"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "text = \"\"\"In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.\n",
        "In addition, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, published in Nature by Gordon, DE with a total of 125 scholars from the United States, the United Kingdom, and France was the most cited publication with 952 citations.\"\"\""
      ],
      "metadata": {
        "id": "x0EFkg01qm4e"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "doc = nlp(text)"
      ],
      "metadata": {
        "id": "k1nWmsjmqzQd"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "list(doc.sents)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "DZYL4sQdrLNb",
        "outputId": "ca323e28-07b0-4782-8d40-d0b5e1666405"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.,\n",
              " In addition, a SARS-CoV-2 protein interaction map reveals targets for drug repurposing, published in Nature by Gordon, DE with a total of 125 scholars from the United States, the United Kingdom, and France was the most cited publication with 952 citations.]"
            ]
          },
          "metadata": {},
          "execution_count": 62
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "for ent in doc.ents:\n",
        "    print(ent.text, ent.start_char, ent.end_char, ent.label_)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "PKfdOD-PLuY5",
        "outputId": "5a781b3f-3af7-4b7e-f5b2-b1b3cb83a4f6"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "pandemic 22 30 ENTITY\n",
            "year 39 43 ENTITY\n",
            "surge 57 62 ENTITY\n",
            "research 66 74 ENTITY\n",
            "subject 82 89 ENTITY\n",
            "COVID-19/SARS-CoV-2/Coronavirus 96 127 ENTITY\n",
            "topping 128 135 ENTITY\n",
            "keywords 148 156 ENTITY\n",
            "COVID-19/SARS-CoV-2/Coronavirus 168 199 ENTITY\n",
            "year 214 218 ENTITY\n",
            "SARS-CoV-2 protein interaction 235 265 ENTITY\n",
            "targets 278 285 ENTITY\n",
            "drug repurposing 290 306 ENTITY\n",
            "published 308 317 ENTITY\n",
            "Nature 321 327 ENTITY\n",
            "Gordon 331 337 ENTITY\n",
            "DE 339 341 ENTITY\n",
            "scholars 362 370 ENTITY\n",
            "United States 380 393 ENTITY\n",
            "United Kingdom 399 413 ENTITY\n",
            "France 419 425 ENTITY\n",
            "publication 445 456 ENTITY\n",
            "citations 466 475 ENTITY\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "'COVID-19/SARS-CoV-2/Coronavirus' is treated as one entity."
      ],
      "metadata": {
        "id": "OgqOypb6NwD2"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## 5. spaCy\n",
        "\n",
        "We will try the same again with spaCy to see if the three are indentified as separate entities."
      ],
      "metadata": {
        "id": "Pl3wlgpEN9i-"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "nlp = spacy.load(\"en_core_web_sm\")"
      ],
      "metadata": {
        "id": "9U1a5um4OEWf"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "doc = nlp(text)"
      ],
      "metadata": {
        "id": "dvn-iskAOJiW"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "list(doc.sents)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "kfu61aPEOLtM",
        "outputId": "3390f83e-cdd0-4fcd-fb3b-9374db6ebe89"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.,\n",
              " In addition, a SARS-CoV-2 protein interaction map reveals targets for drug repurposing, published in Nature by Gordon, DE with a total of 125 scholars from the United States, the United Kingdom, and France was the most cited publication with 952 citations.]"
            ]
          },
          "metadata": {},
          "execution_count": 66
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#### 5.1 spaCy NER"
      ],
      "metadata": {
        "id": "Uja8tIrWP8YF"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "for ent in doc.ents:\n",
        "    print(ent.text, ent.start_char, ent.end_char, ent.label_)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "bARIQ421OQIM",
        "outputId": "2fa9978c-b9b6-46c3-fa0c-33452ed4b0ed"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "that year 34 43 DATE\n",
            "COVID-19 96 104 ORG\n",
            "COVID-19 168 176 ORG\n",
            "that year 209 218 DATE\n",
            "Nature 321 327 WORK_OF_ART\n",
            "Gordon 331 337 PERSON\n",
            "125 358 361 CARDINAL\n",
            "the United States 376 393 GPE\n",
            "the United Kingdom 395 413 GPE\n",
            "France 419 425 GPE\n",
            "952 462 465 CARDINAL\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "spaCy only recognises 'COVID-19' from 'COVID-19/SARS-CoV-2/Coronavirus' from the first sentence, and does not recognise 'SARS-CoV-2' or 'SARS-CoV-2 protein interaction' from the second sentence."
      ],
      "metadata": {
        "id": "kxyhocHeObyf"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 5.2 spaCy custom component\n",
        "\n",
        "We will create a custom pipeline component to implement a rule-based strategy using regex pattern matching for different COVID-related entities."
      ],
      "metadata": {
        "id": "8n_Te_z7E2Fy"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# convert sentence tokenised coref text to list\n",
        "all_article_text = coref_sent_tok_0_10_df.sent_coref_text.tolist()"
      ],
      "metadata": {
        "id": "hrC-O7-RwRRJ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Adapted from https://github.com/librairy/bio-ner/blob/main/bionlp/NER_processing.py\n",
        "\n",
        "@Language.component(\"postprocessing_covid\")\n",
        "def expand_covid_ents(doc):\n",
        "    \"\"\"Post-processing component to expand COVID-related entities in a spaCy document.\n",
        "\n",
        "    :param doc: spacy.Doc, the input spaCy document\n",
        "\n",
        "    :return: The modified spaCy document with expanded COVID-related entities.\n",
        "    \"\"\"\n",
        "    pattern_sars = r\"((sarsr?|mers|severe\\sacute\\srespiratory\\ssyndrome|\\b(?:\\w+?-covs?|n(?:covs?)|2019-ncov|covs?|\\b(?:[A-Za-z]+-)?[Hh]Co[Vv](?:-[A-Za-z]+)?\\b)\\b)(\\s?\\-?\\s?(covs?))?(\\s?\\-?\\s?2)?(\\s?\\binfe.{1,10}?\\b)?)\"\n",
        "    pattern_covid = r\"((covid)(\\s?\\-?\\s?(19))?(\\s?\\binfe.{1,10}?\\b)?)\"\n",
        "    pattern_coronavirus = r\"((coronavir.{0,6}?\\b)(\\s?\\bpneumo.{0,8}?\\b)?(\\s?\\binfe.{1,10}?\\b)?(\\s?\\bdiseas.{1,6}?\\b)?(\\s?\\-?\\s?(20)?(19))?)\"\n",
        "    pattern_variant_lineage = r\"(\\b[A-Z]{1}\\.\\d{1,4}(\\.\\d{1,4}){0,4}\\b)\"\n",
        "\n",
        "    patterns_covid = [{\"label\": \"disease\", \"pattern\": pattern_sars, \"id\": \"covid\"},\n",
        "                      {\"label\": \"disease\", \"pattern\": pattern_covid, \"id\": \"covid\"},\n",
        "                      {\"label\": \"disease\", \"pattern\": pattern_coronavirus, \"id\": \"covid\"},\n",
        "                      {\"label\": \"covid lineage\", \"pattern\": pattern_variant_lineage, \"id\": \"covid\"}]\n",
        "\n",
        "    new_ents = []\n",
        "    doc_ents = list(doc.ents)\n",
        "    for pattern in patterns_covid:\n",
        "        for match in re.finditer(pattern['pattern'], doc.text, re.IGNORECASE):\n",
        "            start, end = match.span()\n",
        "            span = doc.char_span(start, end, label=pattern['label'], kb_id=pattern['id'], alignment_mode='expand')\n",
        "            # This is a Span object or None if match doesn't map to valid token sequence\n",
        "            if span is not None:\n",
        "                new_ents.append(span)\n",
        "    ents = doc_ents + new_ents\n",
        "    filtered_spans = util.filter_spans(ents)\n",
        "    doc.set_ents(filtered_spans)\n",
        "    return doc"
      ],
      "metadata": {
        "id": "i9ElfNnBLlB9"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "nlp = spacy.load(\"en_core_web_sm\", exclude=[\"tok2vec\", \"lemmatizer\"])"
      ],
      "metadata": {
        "id": "iWyadhMAEU16"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# add custom component to pipeline\n",
        "nlp.add_pipe('postprocessing_covid', before='ner')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 173
        },
        "outputId": "de4da024-21d6-43dd-ea85-213eb3d6f198",
        "id": "OUn530gdEU16"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<function __main__.expand_covid_ents(doc)>"
            ],
            "text/html": [
              "<div style=\"max-width:800px; border: 1px solid var(--colab-border-color);\"><style>\n",
              "      pre.function-repr-contents {\n",
              "        overflow-x: auto;\n",
              "        padding: 8px 12px;\n",
              "        max-height: 500px;\n",
              "      }\n",
              "\n",
              "      pre.function-repr-contents.function-repr-contents-collapsed {\n",
              "        cursor: pointer;\n",
              "        max-height: 100px;\n",
              "      }\n",
              "    </style>\n",
              "    <pre style=\"white-space: initial; background:\n",
              "         var(--colab-secondary-surface-color); padding: 8px 12px;\n",
              "         border-bottom: 1px solid var(--colab-border-color);\"><b>expand_covid_ents</b><br/>def expand_covid_ents(doc)</pre><pre class=\"function-repr-contents function-repr-contents-collapsed\" style=\"\"><a class=\"filepath\" style=\"display:none\" href=\"#\">/content/drive/MyDrive/nlp_data/&lt;ipython-input-9-40e460684dc1&gt;</a>Post-processing component to expand COVID-related entities in a spaCy document.\n",
              "\n",
              ":param doc: spacy.Doc, the input spaCy document\n",
              "\n",
              ":return: The modified spaCy document with expanded COVID-related entities.</pre></div>"
            ]
          },
          "metadata": {},
          "execution_count": 11
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "nlp.pipe_names"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "7f6a7469-243c-4396-d7f3-51f393010268",
        "id": "os81F689b97R"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['tagger', 'parser', 'attribute_ruler', 'postprocessing_covid', 'ner']"
            ]
          },
          "metadata": {},
          "execution_count": 12
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def get_docs(docs):\n",
        "    doc_list = []\n",
        "    docs = nlp.pipe(docs)\n",
        "    doc_list.append(list(docs))\n",
        "    return doc_list"
      ],
      "metadata": {
        "id": "DhN7n81PEU17"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "%%time\n",
        "\n",
        "doc_list = list(map(get_docs, all_article_text))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Asq7uoSOoCvY",
        "outputId": "ed4bfabb-9254-4f24-952b-263cfc0c6e07"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 11 s, sys: 547 ms, total: 11.5 s\n",
            "Wall time: 15.1 s\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "len(doc_list)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "rGEb-XhsoUnF",
        "outputId": "f1839379-4e1d-43d7-d641-7cdc37a5d1b8"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "10"
            ]
          },
          "metadata": {},
          "execution_count": 15
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-22_articles_0-10_doclist_web_sm.pickle', 'wb') as f:\n",
        "   pickle.dump(doc_list, f)"
      ],
      "metadata": {
        "id": "TjzN4k-JoSUd"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# flatten the doc list using list comprehension\n",
        "flattened_doc_list = [item for sublist in doc_list for item in sublist]"
      ],
      "metadata": {
        "id": "e7L6dbdCodSN"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-22_articles_0-10_flattened_doclist_web_sm.pickle', 'wb') as f:\n",
        "   pickle.dump(flattened_doc_list, f)"
      ],
      "metadata": {
        "id": "VddGOLYpoi1m"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will define a function to iterate over the Doc objects and append the entity, spans, label (`disease` or `covid lineage`), knowledge base id (set to 'covid' in the `expand_covid_ents` function) and the text where the entity is mentioned."
      ],
      "metadata": {
        "id": "9wTjZ2eeVi8m"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def get_covid_ents(docs):\n",
        "    covid_ent_list = []\n",
        "    for index, doc in enumerate(docs):\n",
        "        for ent in doc.ents:\n",
        "            if ent.label_ in [\"disease\", \"covid lineage\"]:\n",
        "                covid_ent_list.append(f\"{ent.text}, {ent.start_char}, {ent.end_char},  {ent.label_}, {ent.kb_id_}, {doc.text}\")\n",
        "    return covid_ent_list"
      ],
      "metadata": {
        "id": "Wlpdn2VEVi8n"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "covid_ents_only = list(map(get_covid_ents, flattened_doc_list))"
      ],
      "metadata": {
        "id": "a1UKJuy0Vi8o"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(covid_ents_only)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "01lD_KjwWRB0",
        "outputId": "811ab207-948d-4dd6-e151-09d86f8edcc3"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "10"
            ]
          },
          "metadata": {},
          "execution_count": 27
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "covid_ents_only"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "AYZghrQrqqCr",
        "outputId": "e7bd263e-102e-4922-b05b-c17defc0389c"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[['COVID-19, 197, 205,  disease, covid, The number of annual publications has been increasing at a relatively high rate since 2015, while in 2020, there was a spike in the number of publications and annual citations, probably due to the COVID-19 pandemic, a global public health emergency that prompted special attention from scientists.',\n",
              "  'COVID-19, 59, 67,  disease, covid, the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "  'SARS-CoV-2, 68, 78,  disease, covid, the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "  'Coronavirus, 79, 90,  disease, covid, the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "  'COVID-19, 96, 104,  disease, covid, In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "  'SARS-CoV-2, 105, 115,  disease, covid, In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "  'Coronavirus, 116, 127,  disease, covid, In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "  'COVID-19, 168, 176,  disease, covid, In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "  'SARS-CoV-2, 177, 187,  disease, covid, In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "  'Coronavirus, 188, 199,  disease, covid, In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "  'COVID-19, 73, 81,  disease, covid, Molecular docking is one of the core steps of virtual screening, and the COVID-19 pandemic generated many opportunities for the practice of drug repositioning.',\n",
              "  'COVID-19, 48, 56,  disease, covid, Therefore, high-quality studies of the keywords COVID-19/SARS-CoV-2/Coronavirus, Virtual screening, and Molecular docking were surveyed, as shown in the bubble chart, in the past two years, reflecting the relevant research trend in recent years.',\n",
              "  'SARS-CoV-2, 57, 67,  disease, covid, Therefore, high-quality studies of the keywords COVID-19/SARS-CoV-2/Coronavirus, Virtual screening, and Molecular docking were surveyed, as shown in the bubble chart, in the past two years, reflecting the relevant research trend in recent years.',\n",
              "  'Coronavirus, 68, 79,  disease, covid, Therefore, high-quality studies of the keywords COVID-19/SARS-CoV-2/Coronavirus, Virtual screening, and Molecular docking were surveyed, as shown in the bubble chart, in the past two years, reflecting the relevant research trend in recent years.',\n",
              "  'SARS-CoV-2, 108, 118,  disease, covid, In a virtual screening process, Gervasoni, S. conducted a literature search for molecular binding sites for SARS-CoV-2-associated protein targets while combining pocket and docking searches to propose a new pocket mapping strategy that identifies binding cavities with significantly better performance than pocket detection alone.',\n",
              "  'coronavirus, 243, 254,  disease, covid, After a series of drug repurposing computational screens and various validation activities by several scientists, it was agreed that raltegravir, clonidine, chloroquine and hydroxychloroquine have therapeutic effects in the treatment of novel coronavirus.',\n",
              "  'coronavirus pneumonia, 309, 330,  disease, covid, All hot research topics were published in 2020, and with the exception of an article describing the damage caused by nonsteroidal anti-inflammatory drugs NSAIDs to multiple organs and new information on drug repurposing, the remaining studies focused on drug repositioning therapeutic target studies in novel coronavirus pneumonia, screening drug studies, reviews of clinical trials, and reports of other coronavirus therapeutic agents and vaccine studies.',\n",
              "  'coronavirus, 405, 416,  disease, covid, All hot research topics were published in 2020, and with the exception of an article describing the damage caused by nonsteroidal anti-inflammatory drugs NSAIDs to multiple organs and new information on drug repurposing, the remaining studies focused on drug repositioning therapeutic target studies in novel coronavirus pneumonia, screening drug studies, reviews of clinical trials, and reports of other coronavirus therapeutic agents and vaccine studies.',\n",
              "  'SARS-CoV-2, 15, 25,  disease, covid, In addition, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, published in Nature by Gordon, DE with a total of 125 scholars from the United States, the United Kingdom, and France was the most cited publication with 952 citations.',\n",
              "  '2019-nCoV, 103, 112,  disease, covid, The most cited publication on an annual basis was Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, published in 2020, which was authored by Zhou, YD et al. and was the highest annual average cited publication with 609 citations.',\n",
              "  'SARS-CoV-2, 113, 123,  disease, covid, The most cited publication on an annual basis was Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, published in 2020, which was authored by Zhou, YD et al. and was the highest annual average cited publication with 609 citations.',\n",
              "  'coronavirus, 51, 62,  disease, covid, The three studies published in 2020 focus on novel coronavirus-related drug rediscovery activities and the use of deep learning techniques. and Pushpakom, S et al. provided systematic reviews of the methods and challenges of drug repositioning at that time.',\n",
              "  \"coronavirus, 143, 154,  disease, covid, The reasons for this may be the following first, there was a breakthrough in basic research in biophysics in 2020 and second, due to the novel coronavirus, research in this direction has increased research in this direction's application for the prevention and control of the pandemic.\",\n",
              "  'coronaviruses, 282, 295,  disease, covid, In terms of antiviral drugs, scholars not only use drug repositioning to find antiviral drugs to treat diseases, such as Ebola and HIV, that have plagued humans for a long time but also use drug repositioning to seek treatments for infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world.',\n",
              "  'coronaviruses, 54, 67,  disease, covid, For infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world, emergency research on drug repositioning has played an important role in reducing mortality, calming patient fears, and restoring economic production when no specific drugs or vaccines were initially available during the pandemic.',\n",
              "  'coronaviruses, 82, 95,  disease, covid, In fact, some of the studies in the list of highly cited research topics on novel coronaviruses drug repurposing studies are currently approaching 3000 citations on Google Scholar.',\n",
              "  'coronaviruses, 80, 93,  disease, covid, The percentage of highly cited studies and hot research topics related to novel coronaviruses is also a good indication that drug repositioning has made an indelible contribution to the study of novel coronaviruses and similar infectious diseases.',\n",
              "  'coronaviruses, 201, 214,  disease, covid, The percentage of highly cited studies and hot research topics related to novel coronaviruses is also a good indication that drug repositioning has made an indelible contribution to the study of novel coronaviruses and similar infectious diseases.',\n",
              "  'coronavirus, 79, 90,  disease, covid, The authors’ keyword analysis suggests that research in the field of the novel coronavirus will remain valuable until the associated pandemic is completely contained.'],\n",
              " ['COVID‐19, 115, 123,  disease, covid, Most importantly, recent studies have illuminated the potential roles of CADD in designing new drug candidates for COVID‐19 treatment.',\n",
              "  'Coronaviruses, 0, 13,  disease, covid, Coronaviruses CoVs are cross‐species viruses and can spread expeditiously into new host species, which in turn cause epidemic diseases.',\n",
              "  'CoVs, 14, 18,  disease, covid, Coronaviruses CoVs are cross‐species viruses and can spread expeditiously into new host species, which in turn cause epidemic diseases.',\n",
              "  'CoV, 25, 28,  disease, covid, The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.',\n",
              "  'severe acute respiratory syndrome CoV, 76, 113,  disease, covid, The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.',\n",
              "  'SARS‐CoV, 114, 122,  disease, covid, The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.',\n",
              "  'CoV, 160, 163,  disease, covid, The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.',\n",
              "  'MERS‐CoV, 164, 172,  disease, covid, The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.',\n",
              "  'CoVs, 220, 224,  disease, covid, The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.',\n",
              "  'CoV, 8, 11,  disease, covid, The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "  'COVID‐19, 27, 35,  disease, covid, The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "  'SARS‐CoV‐2, 50, 60,  disease, covid, The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "  'severe acute respiratory syndrome CoV, 104, 141,  disease, covid, The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "  'SARS‐CoV, 142, 150,  disease, covid, The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "  'SARS‐CoV‐2, 248, 258,  disease, covid, The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "  'coronavirus, 302, 313,  disease, covid, The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "  'SARS‐CoV‐2, 23, 33,  disease, covid, Since the outgrowth of SARS‐CoV‐2, more than 528 million people have been infected with up to 6.3 million deaths, as reported by the Food and Drug Administration.',\n",
              "  \"COVID‐19, 55, 63,  disease, covid, Although effective vaccines have amazingly reduced the COVID‐19 cases recently, effective vaccines will not change the world right away, and importantly, effective vaccines's permanent efficacy, short‐term and long‐term side effects, and long‐term protection against different variants of SARS‐CoV‐2 are still under debate.\",\n",
              "  \"SARS‐CoV‐2, 289, 299,  disease, covid, Although effective vaccines have amazingly reduced the COVID‐19 cases recently, effective vaccines will not change the world right away, and importantly, effective vaccines's permanent efficacy, short‐term and long‐term side effects, and long‐term protection against different variants of SARS‐CoV‐2 are still under debate.\",\n",
              "  'coronavirus, 168, 179,  disease, covid, These issues are accompanied by mass vaccination campaigns Wen et al. Furthermore, several studies have reported that vaccinated people can also be infected with novel coronavirus variants Largent & Miller.',\n",
              "  'SARS‐CoV‐2, 117, 127,  disease, covid, Therefore, the design and introduction of new drugs, either the current drugs or synthesized agents, for eradicating SARS‐CoV‐2 is of extreme concern.',\n",
              "  \"COVID‐19, 145, 153,  disease, covid, By assessing some antiviral drugs with previously known treatment of hepatitis, HIV, influenza, and Ebola viral diseases's effectiveness against COVID‐19, remdesivir was the one that grabbed much attention and is believed to be the most successful drug for the therapy for combating COVID‐19 Brown et al., Gholivand et al. Further potential macromolecular targets of SARS‐CoV‐2 are depicted in Figure.\",\n",
              "  \"COVID‐19, 283, 291,  disease, covid, By assessing some antiviral drugs with previously known treatment of hepatitis, HIV, influenza, and Ebola viral diseases's effectiveness against COVID‐19, remdesivir was the one that grabbed much attention and is believed to be the most successful drug for the therapy for combating COVID‐19 Brown et al., Gholivand et al. Further potential macromolecular targets of SARS‐CoV‐2 are depicted in Figure.\",\n",
              "  \"SARS‐CoV‐2, 367, 377,  disease, covid, By assessing some antiviral drugs with previously known treatment of hepatitis, HIV, influenza, and Ebola viral diseases's effectiveness against COVID‐19, remdesivir was the one that grabbed much attention and is believed to be the most successful drug for the therapy for combating COVID‐19 Brown et al., Gholivand et al. Further potential macromolecular targets of SARS‐CoV‐2 are depicted in Figure.\",\n",
              "  'SARS‐CoV‐2, 45, 55,  disease, covid, Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.',\n",
              "  'SARS‐CoV‐2, 298, 308,  disease, covid, Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.',\n",
              "  'COVID‐19, 427, 435,  disease, covid, Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.',\n",
              "  'SARS‐CoV‐2, 540, 550,  disease, covid, Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.',\n",
              "  'COVID‐19, 745, 753,  disease, covid, Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.',\n",
              "  'SARS‐CoV‐2, 80, 90,  disease, covid, Vangeel et al. molnupiravir and remdesivir acted on the RdRp enzyme employed by SARS‐CoV‐2 to increase the transcription and replication capability of the viral RNA genome.',\n",
              "  'COVID‐19, 58, 66,  disease, covid, Our focus in this paper is to explore the role of CADD on COVID‐19 most specifically, chemogenomics and DR, with potential examples of COVID‐19 drug discovery. Unfortunately, with boundless energy and time to discover a successful small molecule by utilizing various databases to inhibit the main protease Mpro of SARS‐CoV‐2 via several virtual screening VS approaches, there are no effective drugs that have been approved.',\n",
              "  'COVID‐19, 135, 143,  disease, covid, Our focus in this paper is to explore the role of CADD on COVID‐19 most specifically, chemogenomics and DR, with potential examples of COVID‐19 drug discovery. Unfortunately, with boundless energy and time to discover a successful small molecule by utilizing various databases to inhibit the main protease Mpro of SARS‐CoV‐2 via several virtual screening VS approaches, there are no effective drugs that have been approved.',\n",
              "  'SARS‐CoV‐2, 314, 324,  disease, covid, Our focus in this paper is to explore the role of CADD on COVID‐19 most specifically, chemogenomics and DR, with potential examples of COVID‐19 drug discovery. Unfortunately, with boundless energy and time to discover a successful small molecule by utilizing various databases to inhibit the main protease Mpro of SARS‐CoV‐2 via several virtual screening VS approaches, there are no effective drugs that have been approved.',\n",
              "  \"SARS‐CoV‐2, 148, 158,  disease, covid, Only safety protocols such as wearing face masks, face shields, social distancing, and washing hands frequently are the best approaches to minimize SARS‐CoV‐2's danger and prevent transmission.\",\n",
              "  'COVID‐19, 74, 82,  disease, covid, Basically, the process of bringing an FDA‐approved medicine to market for COVID‐19 drug discovery is extremely challenging, starting from the initial research of scientists for target identification and lead compound generation.',\n",
              "  'COVID‐19, 175, 183,  disease, covid, After lead discovery and development of drug‐like candidates and investigation of in vitro and in vivo results, the process of bringing an FDA‐approved medicine to market for COVID‐19 drug discovery will go into three phases, i.e., preclinical and, if successful, into clinical studies, and ultimately a marketed medicine after FDA approval Schaduangrat et al. It is where CADD is evolved as a valuable and powerful method to aid the challenging tasks of identifying small bioactive molecules and predicting targets.',\n",
              "  'COVID‐19, 21, 29,  disease, covid, In the first days of COVID‐19 outbreak, vHTS was employed and developed efficiently to investigate a group of approved drugs to identify the possible anti‐SARS‐CoV‐2 agents at the National Center for Advancing Translational Sciences NCATS of the National Institutes of Health NIH, embracing a broad spectrum of the SARS‐CoV‐2 life cycle, such as viral entry, viral replication, in vitro infectivity, and live virus infectivity Xu et al. Many possible drug candidates were selected for targeting various stages of the SARS‐CoV‐2 life cycle.',\n",
              "  'anti‐SARS‐CoV‐2, 150, 165,  disease, covid, In the first days of COVID‐19 outbreak, vHTS was employed and developed efficiently to investigate a group of approved drugs to identify the possible anti‐SARS‐CoV‐2 agents at the National Center for Advancing Translational Sciences NCATS of the National Institutes of Health NIH, embracing a broad spectrum of the SARS‐CoV‐2 life cycle, such as viral entry, viral replication, in vitro infectivity, and live virus infectivity Xu et al. Many possible drug candidates were selected for targeting various stages of the SARS‐CoV‐2 life cycle.',\n",
              "  'SARS‐CoV‐2, 315, 325,  disease, covid, In the first days of COVID‐19 outbreak, vHTS was employed and developed efficiently to investigate a group of approved drugs to identify the possible anti‐SARS‐CoV‐2 agents at the National Center for Advancing Translational Sciences NCATS of the National Institutes of Health NIH, embracing a broad spectrum of the SARS‐CoV‐2 life cycle, such as viral entry, viral replication, in vitro infectivity, and live virus infectivity Xu et al. Many possible drug candidates were selected for targeting various stages of the SARS‐CoV‐2 life cycle.',\n",
              "  'SARS‐CoV‐2, 517, 527,  disease, covid, In the first days of COVID‐19 outbreak, vHTS was employed and developed efficiently to investigate a group of approved drugs to identify the possible anti‐SARS‐CoV‐2 agents at the National Center for Advancing Translational Sciences NCATS of the National Institutes of Health NIH, embracing a broad spectrum of the SARS‐CoV‐2 life cycle, such as viral entry, viral replication, in vitro infectivity, and live virus infectivity Xu et al. Many possible drug candidates were selected for targeting various stages of the SARS‐CoV‐2 life cycle.',\n",
              "  'SARS‐CoV‐2, 128, 138,  disease, covid, For instance, cepharanthine, an anti‐inflammatory compound, effectively showed ability to rescue the cytopathic effects CPEs of SARS‐CoV‐2 Rogosnitzky et al., or corilagin, a possible antifibrosis, revealed potential against the angiotensin‐converting enzyme ACE2 receptor‐binding domain RBD Yang et al. Therefore, it is urgent to This strategy a high bio‐safety SARS‐CoV‐2 infection model with a high ability for HTS of drugs against SARS‐CoV‐2.',\n",
              "  'SARS‐CoV‐2, 363, 373,  disease, covid, For instance, cepharanthine, an anti‐inflammatory compound, effectively showed ability to rescue the cytopathic effects CPEs of SARS‐CoV‐2 Rogosnitzky et al., or corilagin, a possible antifibrosis, revealed potential against the angiotensin‐converting enzyme ACE2 receptor‐binding domain RBD Yang et al. Therefore, it is urgent to This strategy a high bio‐safety SARS‐CoV‐2 infection model with a high ability for HTS of drugs against SARS‐CoV‐2.',\n",
              "  'SARS‐CoV‐2, 435, 445,  disease, covid, For instance, cepharanthine, an anti‐inflammatory compound, effectively showed ability to rescue the cytopathic effects CPEs of SARS‐CoV‐2 Rogosnitzky et al., or corilagin, a possible antifibrosis, revealed potential against the angiotensin‐converting enzyme ACE2 receptor‐binding domain RBD Yang et al. Therefore, it is urgent to This strategy a high bio‐safety SARS‐CoV‐2 infection model with a high ability for HTS of drugs against SARS‐CoV‐2.',\n",
              "  \"SARS‐CoV‐2, 313, 323,  disease, covid, After computing molecular descriptors, machine learning techniques play indispensable roles in the quality of QSAR predictions Popelier & Smith, Rad & Maghsoudi, Sliwoski et al. Using machine learning and QSAR, Muratov et al. identified 32 drugs and 32 drugs's 73 selected binary combinations for testing against SARS‐CoV‐2.\",\n",
              "  'SARS‐CoV‐2, 153, 163,  disease, covid, Muratov et al. found that the combinations of four of 32 drugs, including nitazoxanide, remdesivir, amodiaquine, and umifenovir, could synergize against SARS‐CoV‐2.',\n",
              "  'SARS‐CoV‐2, 204, 214,  disease, covid, Interestingly, the combination of nitazoxanide and remdesivir showed a great synergistic interaction, and the combination of remdesivir and hydroxychloroquine exhibited a powerful antagonist role against SARS‐CoV‐2 Bobrowski et al. The two proteins pp1a and pp1ab are quickly translated after entry into the host cells and further separated by two viral proteases, 3 C‐like proteases 3CLpro and papain‐like protease PLpro Amin et al. papain‐like protease PLpro is a critical virus enzyme responsible for producing a functional replicase complex and stimulating viral spread Shin et al. Amin et al used chemical‐informatics approaches to build a Monte Carlo optimization based on a QSAR data of various papain‐like protease PLpro inhibitors, b VS to choose the best in‐house molecules among 67 with the high likelihood of targeting against papain‐like protease PLpro, and c eventually verification of these inhibitors by using receptor–ligand interaction investigation.',\n",
              "  'SARS‐CoV‐2, 83, 93,  disease, covid, Furthermore, molecular docking has proved the potentiality of 13 compounds against SARS‐CoV‐2 PLpro.',\n",
              "  'SARS‐CoV‐2, 484, 494,  disease, covid, The National Center for Advancing Translational Sciences NCATS analyzed 11 of 42 inhibitors which were potential compounds, and three of 11 of total 42 hits which were potential compounds, cenicriviroc AC50 of 8.9 M, proglumetacin tested twice independently, with AC50 of 8.9 M and 12.5 M, and sufugolix AC50 12.6 M. While molecular docking was unsuccessful to accurately distinguish between experimentally active and inactive compounds, QSAR was able to identify three inhibitors of SARS‐CoV‐2 replication through Mpro inhibition.',\n",
              "  'SARS‐CoV‐2, 60, 70,  disease, covid, Overall, these results show that QSAR models proposed using SARS‐CoV‐2 Mpro data can be useful to introduce compounds active against SARS‐CoV‐2 Alves et al. This strategy relies more on target information.',\n",
              "  'SARS‐CoV‐2, 133, 143,  disease, covid, Overall, these results show that QSAR models proposed using SARS‐CoV‐2 Mpro data can be useful to introduce compounds active against SARS‐CoV‐2 Alves et al. This strategy relies more on target information.',\n",
              "  'SARS‐CoV‐2, 403, 413,  disease, covid, In other words, docking enables us to identify novel drug candidates by predicting ligand–target interactions at a molecular level Pinzi & Rastelli, Sargazi et al. There are several references in which the significant role and applications of docking in drug design and development have been discussed De Vivo & Cavalli, Keretsu et al., Kitchen et al., Meng et al. Furthermore, in the current spread of SARS‐CoV‐2, molecular docking is important in screening potential drugs Keretsu et al., Lokhande et al., Marinho et al., Yu et al. The recent work of Khelfaoui et al. could be a good example of using molecular docking combined with MD to find promising candidate drugs against COVID‐19.',\n",
              "  'COVID‐19, 680, 688,  disease, covid, In other words, docking enables us to identify novel drug candidates by predicting ligand–target interactions at a molecular level Pinzi & Rastelli, Sargazi et al. There are several references in which the significant role and applications of docking in drug design and development have been discussed De Vivo & Cavalli, Keretsu et al., Kitchen et al., Meng et al. Furthermore, in the current spread of SARS‐CoV‐2, molecular docking is important in screening potential drugs Keretsu et al., Lokhande et al., Marinho et al., Yu et al. The recent work of Khelfaoui et al. could be a good example of using molecular docking combined with MD to find promising candidate drugs against COVID‐19.',\n",
              "  'SARS‐CoV‐2, 171, 181,  disease, covid, Khelfaoui et al. selected a library of 18 drugs that three of which include ramipril, delapril, and lisinopril, bound to angiotensin‐converting enzyme 2 ACE2 receptor and SARS‐CoV‐2/ACE2 complex well.',\n",
              "  'coronaviruses, 119, 132,  disease, covid, angiotensin‐converting enzyme 2 ACE2 receptor is one of the receptors in the human body with which the S proteins from coronaviruses have a great binding affinity and serve as the entry point into cells for SARS‐CoV‐2.',\n",
              "  'SARS‐CoV‐2, 207, 217,  disease, covid, angiotensin‐converting enzyme 2 ACE2 receptor is one of the receptors in the human body with which the S proteins from coronaviruses have a great binding affinity and serve as the entry point into cells for SARS‐CoV‐2.',\n",
              "  'COVID‐19, 155, 163,  disease, covid, In fact, due to the long time required to discover specific antiviral agents or a vaccine, the best strategy would be to repurpose existing drugs to treat COVID‐19, which will be discussed in the DR section.',\n",
              "  'SARS‐CoV‐main, 152, 165,  disease, covid, In order to identify the most potential drug–target interactions, a molecular operating environment MOE program was carried out against the human ACE2, SARS‐CoV‐main peptidase, serine protease hepsin, human coronavirus papain‐like proteases, and SARS‐Coronavirus NSP12.',\n",
              "  'coronavirus, 207, 218,  disease, covid, In order to identify the most potential drug–target interactions, a molecular operating environment MOE program was carried out against the human ACE2, SARS‐CoV‐main peptidase, serine protease hepsin, human coronavirus papain‐like proteases, and SARS‐Coronavirus NSP12.',\n",
              "  'SARS‐Coronavirus, 246, 262,  disease, covid, In order to identify the most potential drug–target interactions, a molecular operating environment MOE program was carried out against the human ACE2, SARS‐CoV‐main peptidase, serine protease hepsin, human coronavirus papain‐like proteases, and SARS‐Coronavirus NSP12.',\n",
              "  'SARS‐CoV‐2, 117, 127,  disease, covid, Thus, compound d needs to be additionally evaluated in clinical trials as a candidate for potential inhibitor of the SARS‐CoV‐2 Abdellatiif et al. Hosseini et al. evaluated a virtual screening using docking of 1615 FDA‐approved drugs to identify novel potential inhibitors for protease protein of COVID‐19.',\n",
              "  'COVID‐19, 297, 305,  disease, covid, Thus, compound d needs to be additionally evaluated in clinical trials as a candidate for potential inhibitor of the SARS‐CoV‐2 Abdellatiif et al. Hosseini et al. evaluated a virtual screening using docking of 1615 FDA‐approved drugs to identify novel potential inhibitors for protease protein of COVID‐19.',\n",
              "  'COVID‐19, 111, 119,  disease, covid, This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.',\n",
              "  'SARS‐CoV‐2, 235, 245,  disease, covid, This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.',\n",
              "  'SARS‐3CL, 271, 279,  disease, covid, This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.',\n",
              "  'SARS‐Co, 678, 685,  disease, covid, This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.',\n",
              "  'SARS‐CoV‐2, 690, 700,  disease, covid, This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.',\n",
              "  'COVID‐19, 116, 124,  disease, covid, Although many studies are carried out and many drugs are being tested to open a new road for effective treatment of COVID‐19, there are no fully beneficial antiviral drugs against COVID‐19.',\n",
              "  'COVID‐19, 180, 188,  disease, covid, Although many studies are carried out and many drugs are being tested to open a new road for effective treatment of COVID‐19, there are no fully beneficial antiviral drugs against COVID‐19.',\n",
              "  'COVID‐19, 216, 224,  disease, covid, The ultimate goal of chemogenomics is the rapid screening as well as the rational development of target‐specific chemical ligands to decrease the cost and enhance the drug discovery period, especially in the case of COVID‐19 drug investigation Jones & Bunnage.',\n",
              "  \"SARS‐CoV‐2, 325, 335,  disease, covid, Nevertheless, no existing target data thus, by applying the chemogenomics strategy, the hypotheses can be generated of the target by comparing the new biological compounds to the same known target Fourches et al., Weston et al. For example, the target receptors or proteins that are necessary for replication and survival of SARS‐CoV‐2 are viral proteases involving papain‐like protease PLpro, the 3‐chymotrypsin‐like protease 3CLpro, and Mpro, RNA‐dependent RNA polymerase RdRp complex, the spike S receptor binding glycoprotein, the nucleocapsid N protein, nonstructural protein NSP, and the membrane M protein including transmembrane TM as well as small envelope E protein Cavasotto et al. As an example of this part, it can be referred to the work of Mishra and Mishra's coworkers that reported an inclusive computational approach for the identification of drug molecules that are multi‐targeted struggling with the SARS‐CoV‐2 proteins.\",\n",
              "  \"SARS‐CoV‐2, 920, 930,  disease, covid, Nevertheless, no existing target data thus, by applying the chemogenomics strategy, the hypotheses can be generated of the target by comparing the new biological compounds to the same known target Fourches et al., Weston et al. For example, the target receptors or proteins that are necessary for replication and survival of SARS‐CoV‐2 are viral proteases involving papain‐like protease PLpro, the 3‐chymotrypsin‐like protease 3CLpro, and Mpro, RNA‐dependent RNA polymerase RdRp complex, the spike S receptor binding glycoprotein, the nucleocapsid N protein, nonstructural protein NSP, and the membrane M protein including transmembrane TM as well as small envelope E protein Cavasotto et al. As an example of this part, it can be referred to the work of Mishra and Mishra's coworkers that reported an inclusive computational approach for the identification of drug molecules that are multi‐targeted struggling with the SARS‐CoV‐2 proteins.\",\n",
              "  'SARS‐CoV‐2, 59, 69,  disease, covid, drug molecules that are multi‐targeted struggling with the SARS‐CoV‐2 proteins are essentially included in virus replication inside the host body, the viral–host interaction, disease development, and transmission of SARS‐CoV‐2 infection.',\n",
              "  'SARS‐CoV‐2, 216, 226,  disease, covid, drug molecules that are multi‐targeted struggling with the SARS‐CoV‐2 proteins are essentially included in virus replication inside the host body, the viral–host interaction, disease development, and transmission of SARS‐CoV‐2 infection.',\n",
              "  \"SARS‐CoV‐2, 324, 334,  disease, covid, Mishra and his coworkers's finding showed favorable results for seven drugs, among which catechin flavan‐3‐ol can effectively bind to the 3‐chymotrypsin‐like protease 3CLpro, Cathepsin L, RBD of S protein, nonstructural protein NSP, and the nucleocapsid N protein to be used as a potential multi‐targeted agent in combating SARS‐CoV‐2.\",\n",
              "  'SARS‐CoV‐2, 51, 61,  disease, covid, However, due to the limited timeframe of combating SARS‐CoV‐2, it is not realistic to be assured of finding a definitive therapy for combating SARS‐CoV‐2.',\n",
              "  'SARS‐CoV‐2, 143, 153,  disease, covid, However, due to the limited timeframe of combating SARS‐CoV‐2, it is not realistic to be assured of finding a definitive therapy for combating SARS‐CoV‐2.',\n",
              "  \"COVID‐19, 99, 107,  disease, covid, Hence, vigorous attempts are still continuing for the DR as a clinical treatment strategy to fight COVID‐19 Mishra et al. In another research, Omotuyi et al. investigated molecular docking protocols for fast screening of the the FDA database for high‐affinity interaction of the resolved 3D structure of SARS‐CoV‐2 receptor‐binding domain RBD in complex with SARS‐CoV‐2 receptor‐binding domain RBD's receptor hACE‐2 interface.\",\n",
              "  \"SARS‐CoV‐2, 304, 314,  disease, covid, Hence, vigorous attempts are still continuing for the DR as a clinical treatment strategy to fight COVID‐19 Mishra et al. In another research, Omotuyi et al. investigated molecular docking protocols for fast screening of the the FDA database for high‐affinity interaction of the resolved 3D structure of SARS‐CoV‐2 receptor‐binding domain RBD in complex with SARS‐CoV‐2 receptor‐binding domain RBD's receptor hACE‐2 interface.\",\n",
              "  \"SARS‐CoV‐2, 359, 369,  disease, covid, Hence, vigorous attempts are still continuing for the DR as a clinical treatment strategy to fight COVID‐19 Mishra et al. In another research, Omotuyi et al. investigated molecular docking protocols for fast screening of the the FDA database for high‐affinity interaction of the resolved 3D structure of SARS‐CoV‐2 receptor‐binding domain RBD in complex with SARS‐CoV‐2 receptor‐binding domain RBD's receptor hACE‐2 interface.\",\n",
              "  'SARS‐CoV‐2, 95, 105,  disease, covid, Omotuyi et al. reported that UBR breaks the interaction at the RBD/ACE‐2 interface residues of SARS‐CoV‐2 RBD/ACE‐2 complex that might result in protein function losses with direct inference on the oligomerization in RBD and function loss in ACE‐2.',\n",
              "  'SARS‐CoV‐2, 67, 77,  disease, covid, Therefore, UBR exhibits a novel therapeutic candidate in combating SARS‐CoV‐2 since UBR binds to proportionally high affinity with free RBD, ACE‐2 receptor, and SARS‐CoV‐2 RBD/ACE‐2 complex based on only binding affinity calculations Omotuyi et al.. The other studies in this area are demonstrated in Table.',\n",
              "  'SARS‐CoV‐2, 161, 171,  disease, covid, Therefore, UBR exhibits a novel therapeutic candidate in combating SARS‐CoV‐2 since UBR binds to proportionally high affinity with free RBD, ACE‐2 receptor, and SARS‐CoV‐2 RBD/ACE‐2 complex based on only binding affinity calculations Omotuyi et al.. The other studies in this area are demonstrated in Table.',\n",
              "  'COVID, 86, 91,  disease, covid, Therefore, according to the advantages of these proposed drug discovery methods, many COVID research orientations have been focused on DR Galindez et al., R. Liu et al. Computational DR applies available drugs for new or existing diseases that do not have an absolute cure, while available drugs were not originally designed for the novel disease treatment.',\n",
              "  'SARS‐CoV‐2, 296, 306,  disease, covid, Furthermore, utilizing the enormous volumes of available omics information in digital form in conjunction with in silico screening intrigued the researcher to use this appropriate ground to significantly increase the speed of shortlisting promising candidates in reply to spreading diseases like SARS‐CoV‐2.',\n",
              "  'COVID‐19, 82, 90,  disease, covid, Application of a methodology for preclinical computational DR called DrugMerge to COVID‐19 shows that a methodology for preclinical computational DR called DrugMerge can mimic human expert judgment Lucchetta, M. and M. Pellegrini.',\n",
              "  \"SARS‐CoV‐2, 250, 260,  disease, covid, Rima Hajjo and Alexander Tropsha's results approved that Bacillus Calmette–Guérin BCG impacted the generation and maturation of naïve T cells, resulting in increasing long‐lasting trained intrinsic immune replies to combat novel viruses, including SARS‐CoV‐2 in vitro as a protective measurement from the lethal consequences Onozuka et al. Due to the lengthy development cycle of novel drugs, DR turns into an efficient approach to screening drugs of potential therapeutic use for SARS‐CoV‐2.\",\n",
              "  \"SARS‐CoV‐2, 483, 493,  disease, covid, Rima Hajjo and Alexander Tropsha's results approved that Bacillus Calmette–Guérin BCG impacted the generation and maturation of naïve T cells, resulting in increasing long‐lasting trained intrinsic immune replies to combat novel viruses, including SARS‐CoV‐2 in vitro as a protective measurement from the lethal consequences Onozuka et al. Due to the lengthy development cycle of novel drugs, DR turns into an efficient approach to screening drugs of potential therapeutic use for SARS‐CoV‐2.\",\n",
              "  'COVID‐19, 73, 81,  disease, covid, Che et al., in another attempt, screened potential therapeutic drugs for COVID‐19 based on a knowledge‐graph‐based DR method.',\n",
              "  'SARS‐CoV‐2, 120, 130,  disease, covid, The experimental outputs prove that the models can predict drug–disease interaction effectively for normal diseases and SARS‐CoV‐2 Lv et al. Therefore, DR presents a constant source of novel knowledge in virus biology and molecules with previously undefined antiviral properties, which can be applied as molecular tools in unknown molecular mechanisms of virus replication and pathogenesis Mercorelli et al. Further investigation of SARS‐CoV‐2 in related research is summarized in Table.',\n",
              "  'SARS‐CoV‐2, 433, 443,  disease, covid, The experimental outputs prove that the models can predict drug–disease interaction effectively for normal diseases and SARS‐CoV‐2 Lv et al. Therefore, DR presents a constant source of novel knowledge in virus biology and molecules with previously undefined antiviral properties, which can be applied as molecular tools in unknown molecular mechanisms of virus replication and pathogenesis Mercorelli et al. Further investigation of SARS‐CoV‐2 in related research is summarized in Table.',\n",
              "  'COVID‐19, 162, 170,  disease, covid, Thai‐Hoang Pham et al. applied a sound learning framework for a high‐throughput mechanism‐driven neural network‐based method for phenotype compound screening for COVID‐19 DR.',\n",
              "  'COVID‐19, 95, 103,  disease, covid, Furthermore, Thai‐Hoang Pham et al. showed the value of DeepCE by applying DeepCE to the DR of COVID‐19 and produced novel lead compounds that represented clinical evidence.',\n",
              "  \"COVID‐19, 210, 218,  disease, covid, Lee and his coworkers's finding showed that an AI‐DTI, a new method for predicting activation and inhibition of DTIs was a success in discovering about half of the DTIs for drugs that are employed for treating COVID‐19 Lee and his coworkers.\",\n",
              "  'COVID‐19, 341, 349,  disease, covid, A myriad of compounds represent potential drug candidates, but merely a few of potential drug candidates will be formulated, approved, and registered as a drug for individual health issues which investigation for that compound will be a long, intricate, and costly process, while sometimes there is an urgent need for developing a drug like COVID‐19 pandemic Muratov et al. Table demonstrates chemogenomics related to COVID‐19 research.',\n",
              "  'COVID‐19, 418, 426,  disease, covid, A myriad of compounds represent potential drug candidates, but merely a few of potential drug candidates will be formulated, approved, and registered as a drug for individual health issues which investigation for that compound will be a long, intricate, and costly process, while sometimes there is an urgent need for developing a drug like COVID‐19 pandemic Muratov et al. Table demonstrates chemogenomics related to COVID‐19 research.',\n",
              "  'COVID‐19, 59, 67,  disease, covid, Herein, of much current importance is chemogenomics, is in COVID‐19 drug discoveries, which this review paper highlighted specifically.',\n",
              "  'COVID‐19, 468, 476,  disease, covid, The first is that a drug can bind to various targets simultaneously, which is good for searching novel target sites of action for the known biological agents, and the second is that targets related to a disease are often associated with different biological processes of pathogenesis, which is important for choosing of a new indication for the known target Badary, Kamel et al. These are indispensable in proposing new drug candidates for unprecedented diseases like COVID‐19.',\n",
              "  'COVID‐19, 102, 110,  disease, covid, DR has emerged as an alternative way of accelerating the process of developing new treatments against COVID‐19 Yu et al. Based on data brought from PubMed, the number of works of literature on DR has been growing dramatically, and the number of works of literature on DR has increased since the outbreak of SARS‐CoV‐2 Galindez et al. It should be noted that polypharmacolgy and DR are inextricably interrelated with each other Cheng.',\n",
              "  'SARS‐CoV‐2, 307, 317,  disease, covid, DR has emerged as an alternative way of accelerating the process of developing new treatments against COVID‐19 Yu et al. Based on data brought from PubMed, the number of works of literature on DR has been growing dramatically, and the number of works of literature on DR has increased since the outbreak of SARS‐CoV‐2 Galindez et al. It should be noted that polypharmacolgy and DR are inextricably interrelated with each other Cheng.',\n",
              "  'SARS‐CoV‐2, 602, 612,  disease, covid, In contrast to experimental methods, computational drug repositioning methods which are mainly data‐driven utilizes databases and bioinformatics tools to find out interactions between drugs, targets, and diseases Pillaiyar et al. Analyzing a large type of data like chemical structures, gene expression, genotype or proteomic data, and electronic health records EHRs provides the possibility of understanding novel and unexpected functional gene interactions and unclear drug response or mechanisms of disease Pushpakom et al. Since there is no specific and registered therapy to cure the infection of SARS‐CoV‐2, finding effective therapeutics by applying existing drugs is a pressing exigency and established strategy Galindez et al. Concerning the time‐consuming regulatory process of the newly approved drugs, the DR strategy strongly utilizes the identification of new treatment methods by presenting FDA‐approved drugs.',\n",
              "  'COVID‐19, 82, 90,  disease, covid, There are myriad reasons why we need to go through DR for different diseases like COVID‐19 if we intend to accelerate the process of developing a new drug.',\n",
              "  \"COVID‐19, 489, 497,  disease, covid, myriad reasons why we need to go through DR can be i availability of marketed drugs and marketed drugs's excipients and APIs for formulation and distribution, ii the likelihood of taking advantage of a synergistic effect of various drugs with each other, iii cheap and less time‐consuming process for drugs to be marketed and IV emergence of new therapeutic pathways for former drugs and new categories of medicine Chung et al. Therefore, repositioned drugs have very important impacts on COVID‐19 drug discovery.\",\n",
              "  'SARS‐CoV‐2, 105, 115,  disease, covid, Therefore, different categories of drugs are being repositioned in in vivo and in vitro studies to treat SARS‐CoV‐2 Wu et al. different categories of drugs are namely Ebola virus remdesivir, antimalarial chloroquine, anthelmintic and antiprotozoal drugs niclosamide, diarrhea nitazoxanide, antiviral lopinavir and ritonavir, antineoplastic carfilzomib and bortezomib, and antibacterial azithromycin.',\n",
              "  'COVID‐19, 135, 143,  disease, covid, In this regard, the WHO supported repositioning remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine as a potential for COVID‐19, although most might be only supportive symptomatic Won & Lee.',\n",
              "  'COVID‐19, 110, 118,  disease, covid, Nevertheless, remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine will likely be approved for COVID‐19 therapy if remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine pass clinical trials and are published in literature and guidelines from leading health organizations Nain et al. In order to do this, many groups have been attempting enthusiastically to discover the first approved drug for COVID‐19 therapy Erlanson, Low et al., Muratov et al. As a result, we identified several clinical trials, in which 18 studies were at clinical phases 2, 3, or 4.',\n",
              "  'COVID‐19, 423, 431,  disease, covid, Nevertheless, remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine will likely be approved for COVID‐19 therapy if remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine pass clinical trials and are published in literature and guidelines from leading health organizations Nain et al. In order to do this, many groups have been attempting enthusiastically to discover the first approved drug for COVID‐19 therapy Erlanson, Low et al., Muratov et al. As a result, we identified several clinical trials, in which 18 studies were at clinical phases 2, 3, or 4.',\n",
              "  'SARS‐CoV‐2, 179, 189,  disease, covid, Luo et al. investigated the free energy perturbation‐absolute binding free energy FEP‐ABFE method and bioassay validation to reposition 25 potential therapeutic agents to inhibit SARS‐CoV‐2.',\n",
              "  \"SARS‐CoV‐2, 49, 59,  disease, covid, By using the viral proteinase crystal structure, SARS‐CoV‐2 PDB ID 6 LU7, up to 2500 FDA‐approved drugs were first screened via Glide's molecular docking program.\",\n",
              "  \"CoV, 253, 256,  disease, covid, Among 25 possible agents, additionally, dipyridamole passed dipyridamole's first‐round clinical trials with considerable potencies Li, Hu, et al., Li, Li, et al. The network‐based methods have also given satisfying results in investigating the DTIs and CoV–host interactions.\",\n",
              "  'anti‐HCoV, 34, 43,  disease, covid, Zho et al. introduced 16 possible anti‐HCoV drugs such as melatonin, mercaptopurine, toremifene, mesalazine, and sirolimus from more than 2000 FDA‐approved drugs by applying a combination of network‐based approaches and systems pharmacology‐based network medicine platform with the ability to quantify the interactions between the drug targets and virus–host interactome in the human protein–protein interactions network.',\n",
              "  'SARS‐CoV‐2, 119, 129,  disease, covid, Zhou et al. The docking screening method was applied for a set of 2201 approved drugs to find inhibitory activities at SARS‐CoV‐2 main protease, and based on that, carfilzomib, eravacycline, valrubicin, lopinavir, and elbasvir have nominated as an inhibitor for SARS‐CoV‐2 main protease Wang.',\n",
              "  'SARS‐CoV‐2, 262, 272,  disease, covid, Zhou et al. The docking screening method was applied for a set of 2201 approved drugs to find inhibitory activities at SARS‐CoV‐2 main protease, and based on that, carfilzomib, eravacycline, valrubicin, lopinavir, and elbasvir have nominated as an inhibitor for SARS‐CoV‐2 main protease Wang.',\n",
              "  'coronavirus, 63, 74,  disease, covid, Table includes recent studies in terms of computational DR for coronavirus drug discovery and various diseases, respectively.',\n",
              "  'SARS‐CoV‐2, 47, 57,  disease, covid, Various transcriptomic datasets in relation to SARS‐CoV‐2 were reported since the COVID‐19 outbreak.',\n",
              "  'COVID‐19, 82, 90,  disease, covid, Various transcriptomic datasets in relation to SARS‐CoV‐2 were reported since the COVID‐19 outbreak.',\n",
              "  'SARS‐CoV‐2, 501, 511,  disease, covid, Basically, the idea is that for a specific disease signature composing of a class of up and downregulated genes, if there is available drug candidate, where a class of up and downregulated genes are alternatively downregulated and up‐regulated, respectively, this drug might be potential for that disease Hoffmann et al., Le et al. Zho et al. investigated existing computational drug repositioning with remarkably reversed differential gene expression in comparison with manifold input signatures for SARS‐CoV‐2 effects on human cells.',\n",
              "  \"SARS‐CoV‐2, 79, 89,  disease, covid, Zho et al. eventually tested 16 of Zho et al.'s shortlisted candidates in live SARS‐CoV‐2 antiviral assays.\",\n",
              "  'SARS‐CoV‐2, 113, 123,  disease, covid, If a drug could notably FDR < 0.05 reverse the disease signature, then a drug could be a potential inhibitor for SARS‐CoV‐2.',\n",
              "  \"SARS‐CoV‐2, 104, 114,  disease, covid, In the end, Zho et al. found that 16 of Zho et al.'s high predicted hits showed antiviral assay in live SARS‐CoV‐2.\",\n",
              "  'SARS‐CoV‐2, 56, 66,  disease, covid, Four potential inhibitors were tested for inhibition of SARS‐CoV‐2 in a human lung cell line, Calu‐3, infected with SARS‐CoV‐2.',\n",
              "  'SARS‐CoV‐2, 116, 126,  disease, covid, Four potential inhibitors were tested for inhibition of SARS‐CoV‐2 in a human lung cell line, Calu‐3, infected with SARS‐CoV‐2.',\n",
              "  'SARS‐CoV‐2, 351, 361,  disease, covid, Three drugs revealed in vitro antiviral efficacy—bacampicillin, clofazimine, and haloperidol with no toxicity effects Zho et al. Ge et al. used an integrative drug repositioning analysis through machine learning to integrate and mine large‐scale knowledge graph, literature together with transcriptome data to identify the potential compounds against SARS‐CoV‐2.',\n",
              "  \"SARS‐CoV‐2, 72, 82,  disease, covid, Ge et al.'s in vitro data showed an efficient inhibitory effect against SARS‐CoV‐2 replication without a clear cytopathic effect.\",\n",
              "  'SARS‐CoV‐2, 141, 151,  disease, covid, Ge et al. further revealed that CVL218, a poly‐ADP‐ribose polymerase 1 PARP1 inhibitor can effectively bind to the nucleocapsid N protein of SARS‐CoV‐2 and could suppress the LPS‐induced production of many inflammatory cytokine, which are highly related to the prevention of immunopathology induced by SARS‐CoV‐2 infection Zho et al.. Another PARP1 inhibitor, PJ‐34 was previously studied for acute inflammatory including inflammatory diseases of the lung.',\n",
              "  'SARS‐CoV‐2, 302, 312,  disease, covid, Ge et al. further revealed that CVL218, a poly‐ADP‐ribose polymerase 1 PARP1 inhibitor can effectively bind to the nucleocapsid N protein of SARS‐CoV‐2 and could suppress the LPS‐induced production of many inflammatory cytokine, which are highly related to the prevention of immunopathology induced by SARS‐CoV‐2 infection Zho et al.. Another PARP1 inhibitor, PJ‐34 was previously studied for acute inflammatory including inflammatory diseases of the lung.',\n",
              "  'SARS‐CoV‐2, 125, 135,  disease, covid, It was observed that Another PARP1 inhibitor, PJ‐34 can interact with the N‐terminal domain of the nucleocapsid N protein of SARS‐CoV‐2 and decrease the RNA binding ability to inhibit virus replication Zho et al.. Beclabuvir is an antiviral drug for the treatment of hepatitis C virus HCV infection studied for inhibitory activity against SARS‐CoV‐2.',\n",
              "  'SARS‐CoV‐2, 339, 349,  disease, covid, It was observed that Another PARP1 inhibitor, PJ‐34 can interact with the N‐terminal domain of the nucleocapsid N protein of SARS‐CoV‐2 and decrease the RNA binding ability to inhibit virus replication Zho et al.. Beclabuvir is an antiviral drug for the treatment of hepatitis C virus HCV infection studied for inhibitory activity against SARS‐CoV‐2.',\n",
              "  'SARS‐CoV‐2, 83, 93,  disease, covid, It was reported that Beclabuvir could be a potential compound for the treatment of SARS‐CoV‐2 through virtual screening and molecular docking in order to bind to RdRp of the SARS‐CoV‐2 Talluri.',\n",
              "  'SARS‐CoV‐2, 174, 184,  disease, covid, It was reported that Beclabuvir could be a potential compound for the treatment of SARS‐CoV‐2 through virtual screening and molecular docking in order to bind to RdRp of the SARS‐CoV‐2 Talluri.',\n",
              "  'COVID‐19, 120, 128,  disease, covid, Raltegravir was selected as a highly effective drug against Mpro and has been repurposed for the potential treatment of COVID‐19 in many studies Nabi et al. There has been considerable progress in the practical development and the rational application of computational drug discovery, giving rise to a paradigm shift in both industry and academics.',\n",
              "  'COVID‐19, 27, 35,  disease, covid, Over the last 3 years, the COVID‐19 pandemic has killed many people globally since there are no effective drugs against the COVID‐19 pandemic.',\n",
              "  'COVID‐19, 124, 132,  disease, covid, Over the last 3 years, the COVID‐19 pandemic has killed many people globally since there are no effective drugs against the COVID‐19 pandemic.',\n",
              "  'COVID‐19, 119, 127,  disease, covid, In this sense, we need to highlight that DR attempts the search for effective drugs in an urgent situation such as the COVID‐19 pandemic.',\n",
              "  'SARS‐CoV‐2, 28, 38,  disease, covid, In order to use HTS against SARS‐CoV‐2, it is important to take advantage of a similar homology of virus in genomics, specifically, chemogenomics, as a versatile way of drug screening model that provides better bio‐safety.',\n",
              "  'COVID‐19, 59, 67,  disease, covid, Hitherto, CADD is the only way for screening drugs against COVID‐19 and is based on a single viral protein or small‐scale drug screening of formerly FDA antiviral drugs utilizing SARS‐CoV‐2.',\n",
              "  'SARS‐CoV‐2, 179, 189,  disease, covid, Hitherto, CADD is the only way for screening drugs against COVID‐19 and is based on a single viral protein or small‐scale drug screening of formerly FDA antiviral drugs utilizing SARS‐CoV‐2.',\n",
              "  'SARS‐CoV‐2, 121, 131,  disease, covid, Nevertheless, CADD is not well‐suited to high‐throughput screening HTS when focusing on the bio‐security requirements of SARS‐CoV‐2.',\n",
              "  'COVID‐19, 188, 196,  disease, covid, Moreover, developing new drugs takes too much time without having a precise crystal structure of the viral target Liu et al. Thus, the best way to rapidly find a drug for the treatment of COVID‐19 would be the use of CADD methods in order to discover lead compounds for clinical use for instance, we can build a program that takes advantage of structure‐based drug design, HTS, and virtual drug screening to identify new leads targeting the Mpro. More recently, a library of 10000 compounds involving approved drugs, drug candidates in clinical trials, and biologically active compounds to inhibit the Mpro was examined.',\n",
              "  'SARS‐CoV‐2, 191, 201,  disease, covid, Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.',\n",
              "  'CoVs, 316, 320,  disease, covid, Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.',\n",
              "  'MERS‐CoV, 332, 340,  disease, covid, Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.',\n",
              "  'SARS‐CoV‐2, 345, 355,  disease, covid, Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.',\n",
              "  'SARS‐CoV‐2, 438, 448,  disease, covid, Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.',\n",
              "  'anti‐SARS‐CoV‐2, 97, 112,  disease, covid, This effort led to the discovery of nine hits that need further optimization to be identified as anti‐SARS‐CoV‐2 leads.',\n",
              "  \"CoVs, 242, 246,  disease, covid, In addition, an interesting investigation based on an HTS assay employing a compound library of 2000 approved drugs and pharmacologically active compounds has also been carried out to find broad‐spectrum inhibitors against the replication of CoVs Shen et al. From Shen et al's HTS data, 56 hits were screened, and 36 compounds were validated in vitro using genetically engineered human CoV OC43 HCoV‐OC43.\",\n",
              "  \"CoV, 386, 389,  disease, covid, In addition, an interesting investigation based on an HTS assay employing a compound library of 2000 approved drugs and pharmacologically active compounds has also been carried out to find broad‐spectrum inhibitors against the replication of CoVs Shen et al. From Shen et al's HTS data, 56 hits were screened, and 36 compounds were validated in vitro using genetically engineered human CoV OC43 HCoV‐OC43.\",\n",
              "  \"HCoV‐OC43, 395, 404,  disease, covid, In addition, an interesting investigation based on an HTS assay employing a compound library of 2000 approved drugs and pharmacologically active compounds has also been carried out to find broad‐spectrum inhibitors against the replication of CoVs Shen et al. From Shen et al's HTS data, 56 hits were screened, and 36 compounds were validated in vitro using genetically engineered human CoV OC43 HCoV‐OC43.\",\n",
              "  'coronavirus, 144, 155,  disease, covid, Consequently, seven effective compounds were selected as broad‐spectrum inhibitors in which lycorine protected BALB/c mice against lethal human coronavirus OC43 HCoV‐OC43, and emetine blocked MERS‐CoV entry following pseudo‐virus entry assays.',\n",
              "  'HCoV‐OC43, 161, 170,  disease, covid, Consequently, seven effective compounds were selected as broad‐spectrum inhibitors in which lycorine protected BALB/c mice against lethal human coronavirus OC43 HCoV‐OC43, and emetine blocked MERS‐CoV entry following pseudo‐virus entry assays.',\n",
              "  'MERS‐CoV, 192, 200,  disease, covid, Consequently, seven effective compounds were selected as broad‐spectrum inhibitors in which lycorine protected BALB/c mice against lethal human coronavirus OC43 HCoV‐OC43, and emetine blocked MERS‐CoV entry following pseudo‐virus entry assays.'],\n",
              " ['severe acute respiratory syndrome, 4, 37,  disease, covid, The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.',\n",
              "  'coronavirus-2, 38, 51,  disease, covid, The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.',\n",
              "  'SARS-CoV-2, 52, 62,  disease, covid, The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.',\n",
              "  'Coronavirus Disease 2019, 71, 95,  disease, covid, The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.',\n",
              "  'COVID-19, 96, 104,  disease, covid, The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.',\n",
              "  'severe acute respiratory syndrome, 26, 59,  disease, covid, Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.',\n",
              "  'coronavirus-2, 60, 73,  disease, covid, Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.',\n",
              "  'SARS-CoV-2, 74, 84,  disease, covid, Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.',\n",
              "  'Coronavirus Disease 2019, 93, 117,  disease, covid, Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.',\n",
              "  'COVID-19, 118, 126,  disease, covid, Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.',\n",
              "  'severe acute respiratory syndrome, 8, 41,  disease, covid, The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.',\n",
              "  'coronavirus-2, 42, 55,  disease, covid, The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.',\n",
              "  'SARS-CoV-2, 56, 66,  disease, covid, The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.',\n",
              "  'Coronavirus Disease 2019, 75, 99,  disease, covid, The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.',\n",
              "  'COVID-19, 100, 108,  disease, covid, The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.',\n",
              "  'SARSCoV-2 infection, 204, 223,  disease, covid, The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.',\n",
              "  'severe acute respiratory syndrome, 125, 158,  disease, covid, Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.',\n",
              "  'coronavirus-2, 159, 172,  disease, covid, Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.',\n",
              "  'SARS-CoV-2, 173, 183,  disease, covid, Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.',\n",
              "  'Coronavirus Disease 2019, 192, 216,  disease, covid, Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.',\n",
              "  'COVID-19, 217, 225,  disease, covid, Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.',\n",
              "  'severe acute respiratory syndrome, 61, 94,  disease, covid, Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "  'coronavirus-2, 95, 108,  disease, covid, Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "  'SARS-CoV-2, 109, 119,  disease, covid, Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "  'Coronavirus Disease 2019, 128, 152,  disease, covid, Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "  'COVID-19, 153, 161,  disease, covid, Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "  'severe acute respiratory syndrome, 308, 341,  disease, covid, Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "  'coronavirus-2, 342, 355,  disease, covid, Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "  'SARS-CoV-2, 356, 366,  disease, covid, Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "  'Coronavirus Disease 2019, 375, 399,  disease, covid, Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "  'COVID-19, 400, 408,  disease, covid, Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "  'SARSCoV-2, 0, 9,  disease, covid, SARSCoV-2, seasonal or pandemic influenza, and MERS corona virus are all targets of Molnupiravir, commercialized as Lagevrio.',\n",
              "  'MERS, 47, 51,  disease, covid, SARSCoV-2, seasonal or pandemic influenza, and MERS corona virus are all targets of Molnupiravir, commercialized as Lagevrio.',\n",
              "  'COVID-19, 175, 183,  disease, covid, Molnupiravir, commercialized as Lagevrio was reported to be extremely effective in reducing nasopharyngeal infection rate and had a positive safety and tolerability record in COVID-19 patients who received short-course, 5-day treatment.– On 23 December 2021, FDA approved Molnupiravir, commercialized as Lagevrio under an EUA for the treatment of mild-to-moderate COVID-19 in individuals who have a positive consequences of SARSCoV-2 virus test and are at high risk of developing chronic COVID-19.',\n",
              "  'COVID-19, 364, 372,  disease, covid, Molnupiravir, commercialized as Lagevrio was reported to be extremely effective in reducing nasopharyngeal infection rate and had a positive safety and tolerability record in COVID-19 patients who received short-course, 5-day treatment.– On 23 December 2021, FDA approved Molnupiravir, commercialized as Lagevrio under an EUA for the treatment of mild-to-moderate COVID-19 in individuals who have a positive consequences of SARSCoV-2 virus test and are at high risk of developing chronic COVID-19.',\n",
              "  'SARSCoV-2, 424, 433,  disease, covid, Molnupiravir, commercialized as Lagevrio was reported to be extremely effective in reducing nasopharyngeal infection rate and had a positive safety and tolerability record in COVID-19 patients who received short-course, 5-day treatment.– On 23 December 2021, FDA approved Molnupiravir, commercialized as Lagevrio under an EUA for the treatment of mild-to-moderate COVID-19 in individuals who have a positive consequences of SARSCoV-2 virus test and are at high risk of developing chronic COVID-19.',\n",
              "  'COVID-19, 488, 496,  disease, covid, Molnupiravir, commercialized as Lagevrio was reported to be extremely effective in reducing nasopharyngeal infection rate and had a positive safety and tolerability record in COVID-19 patients who received short-course, 5-day treatment.– On 23 December 2021, FDA approved Molnupiravir, commercialized as Lagevrio under an EUA for the treatment of mild-to-moderate COVID-19 in individuals who have a positive consequences of SARSCoV-2 virus test and are at high risk of developing chronic COVID-19.',\n",
              "  'SARSCoV-2, 82, 91,  disease, covid, an EUA is granted for patients who have received a positive test from significant SARSCoV-2 viral testing, or who are at danger of developing severe COVID-19, which could result in hospitalization or death, or for whom other FDA-approved COVID-19 treatment options are not available or efficacious.',\n",
              "  'COVID-19, 149, 157,  disease, covid, an EUA is granted for patients who have received a positive test from significant SARSCoV-2 viral testing, or who are at danger of developing severe COVID-19, which could result in hospitalization or death, or for whom other FDA-approved COVID-19 treatment options are not available or efficacious.',\n",
              "  'COVID-19, 238, 246,  disease, covid, an EUA is granted for patients who have received a positive test from significant SARSCoV-2 viral testing, or who are at danger of developing severe COVID-19, which could result in hospitalization or death, or for whom other FDA-approved COVID-19 treatment options are not available or efficacious.',\n",
              "  'COVID-19, 174, 182,  disease, covid, Molnupiravir, commercialized as Lagevrio is not approved for use in individuals under the age of 18, for the commencement of therapy in patients who require treatment due to COVID-19, for use for more than 5 days, or as a pre-exposure or post-exposure prophylactic for COVID-19 prevention.',\n",
              "  'COVID-19, 269, 277,  disease, covid, Molnupiravir, commercialized as Lagevrio is not approved for use in individuals under the age of 18, for the commencement of therapy in patients who require treatment due to COVID-19, for use for more than 5 days, or as a pre-exposure or post-exposure prophylactic for COVID-19 prevention.',\n",
              "  'SARS-CoV-2, 68, 78,  disease, covid, Molnupiravir, commercialized as Lagevrio acts by inhibiting RdRp of SARS-CoV-2 to induce RNA mutagenesis in two steps.',\n",
              "  'SARS-CoV-2, 93, 103,  disease, covid, the EIDD-1931-triphosphate acts as an alternate/competitive substrate for the RdRp enzyme of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 30, 40,  disease, covid, Therefore, the RdRp enzyme of SARS-CoV-2 This process mutated RNA copies for SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 77, 87,  disease, covid, Therefore, the RdRp enzyme of SARS-CoV-2 This process mutated RNA copies for SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 81, 91,  disease, covid, This process causes the inhibition of the normal functions of the RdRp enzyme of SARS-CoV-2.',\n",
              "  'coronaviruses, 167, 180,  disease, covid, Molnupiravir, commercialized as Lagevrio is an isopropyl prodrug of EIDD-1931, which has been shown to suppress the reproduction of a wide range of viruses, including coronaviruses, with potential safety profiles.',\n",
              "  'COVID-19, 225, 233,  disease, covid, Emory University in Atlanta, Ridgeback Biotherapeutics, Wayne and Wendy Holman, and Merck have also agreed to collaborate on the development of Molnupiravir, commercialized as Lagevrio as an oral therapy for non-hospitalized COVID-19 individuals.',\n",
              "  'COVID-19, 31, 39,  disease, covid, Following the dissemination of COVID-19, the Molnupiravir, commercialized as Lagevrio development effort shifted to COVID-19 therapy.',\n",
              "  'COVID-19, 116, 124,  disease, covid, Following the dissemination of COVID-19, the Molnupiravir, commercialized as Lagevrio development effort shifted to COVID-19 therapy.',\n",
              "  'coronaviruses, 65, 78,  disease, covid, Molnupiravir, commercialized as Lagevrio oral efficiency against coronaviruses was also demonstrated in preclinical research in an animal study.',\n",
              "  'SARS-CoV-2, 0, 10,  disease, covid, SARS-CoV-2 propagation is ineffectively controlled by remdesivir.',\n",
              "  'SARS-CoV-2, 82, 92,  disease, covid, Molnupiravir, on the other hand, was shown to be efficient in ferrets in reducing SARS-CoV-2 virus and halting dissemination.',\n",
              "  'SARS-CoV-2 infection, 78, 98,  disease, covid, As a result, Molnupiravir has been proposed as a protective measure to combat SARS-CoV-2 infection in the community.',\n",
              "  'SARS-CoV-2, 22, 32,  disease, covid, Elderly patients with SARS-CoV-2 illness diagnosed by RT-PCR within 5 days of appearance of symptoms were randomised to standard of care SOC or 300, 600, and 800 mg Molnupiravir orally twice for 5 days by oral route daily.',\n",
              "  'COVID-19, 28, 36,  disease, covid, The safety and tolerance of COVID-19 in patients admitted with minimal to moderate COVID-19 were analyzed in a double-blind, randomized-controlled, multicentric phase 2a MK-4482-006 NCT04405570 study.',\n",
              "  'COVID-19, 83, 91,  disease, covid, The safety and tolerance of COVID-19 in patients admitted with minimal to moderate COVID-19 were analyzed in a double-blind, randomized-controlled, multicentric phase 2a MK-4482-006 NCT04405570 study.',\n",
              "  \"SARS-CoV-2 infection, 120, 140,  disease, covid, Other double-blind phase 2 experiment is now underway to assess the safety of Molnupiravir and Molnupiravir's effect on SARS-CoV-2 infection shedding.\",\n",
              "  'COVID-19, 226, 234,  disease, covid, The independent data safety monitoring board recently halted the phase 3 double-blind, randomised trial MOVe-OUT that was designed to evaluate the efficacy and safety of Molnupiravir in 1850 non-hospitalized participants with COVID-19 NCT04575597, MK-4482-002 due to the increased advantage in the test group compared to Placebo.',\n",
              "  \"SARS-CoV-2, 9, 19,  disease, covid, A proven SARS-CoV-2 illness with samples taken ≤5 days previous to the day of allocation and negative serum testing in light of recent or earlier exposure were among an open label randomised controlled but small phase Ib/IIa study called AGILE NCT04746183's eligibility criteria.\",\n",
              "  'SARS-CoV-2, 17, 27,  disease, covid, Furthermore, the SARS-CoV-2 variant gamma, delta, or mu, the period of onset of manifestations, and the inherent risks had no influence on the effectiveness of Molnupiravir.',\n",
              "  'COVID-19, 177, 185,  disease, covid, A further phase 3 double-blind, randomised research MOVe-IN, NCT04575584 that has been set to investigate the effectiveness and safety of Molnupiravir in 304 hospitalised adult COVID-19 MK-4482-001 subjects was halted after an initial review of the data revealed that a clinical efficacy in hospitalised individuals was improbable.',\n",
              "  'COVID-19, 212, 220,  disease, covid, Nonetheless, a huge n 14 1332 phase 3 multicentric, randomised, double-blind, placebo-controlled investigation NCT04939428 is actively exploring the safety and effectiveness of Molnupiravir for the mitigation of COVID-19 in adults MOVe-AHEAD living with a human who has COVID-19, with the assumption that Molnupiravir would be efficacious in blocking laboratory-confirmed COVID-19 infestation through day 14 especially in comparison to placebo.',\n",
              "  'COVID-19, 270, 278,  disease, covid, Nonetheless, a huge n 14 1332 phase 3 multicentric, randomised, double-blind, placebo-controlled investigation NCT04939428 is actively exploring the safety and effectiveness of Molnupiravir for the mitigation of COVID-19 in adults MOVe-AHEAD living with a human who has COVID-19, with the assumption that Molnupiravir would be efficacious in blocking laboratory-confirmed COVID-19 infestation through day 14 especially in comparison to placebo.',\n",
              "  'COVID-19 infestation, 372, 392,  disease, covid, Nonetheless, a huge n 14 1332 phase 3 multicentric, randomised, double-blind, placebo-controlled investigation NCT04939428 is actively exploring the safety and effectiveness of Molnupiravir for the mitigation of COVID-19 in adults MOVe-AHEAD living with a human who has COVID-19, with the assumption that Molnupiravir would be efficacious in blocking laboratory-confirmed COVID-19 infestation through day 14 especially in comparison to placebo.',\n",
              "  'COVID-19, 130, 138,  disease, covid, Meanwhile, many Indian pharmaceutical firms confirmed preliminary results from phase 3 studies with Molnupiravir in mild/moderate COVID-19 patient populations in India.',\n",
              "  'COVID-19, 100, 108,  disease, covid, The research community has rallied to discover and assess various medicines and vaccinations as the COVID-19 outbreak spreads throughout the world, from academia and government institutions to minor biotechnology startups and major pharmaceutical enterprises.',\n",
              "  'SARS-CoV-2, 90, 100,  disease, covid, Repurposing preexisting medications authorized for other uses as antiviral treatments for SARS-CoV-2 is one feasible method.',\n",
              "  'COVID-19, 123, 131,  disease, covid, Although repurposed medications with acceptable safety records might be beneficial, there are currently no widely marketed COVID-19 preventive or therapy alternatives.'],\n",
              " ['SARS-CoV-2, 23, 33,  disease, covid, The sudden outbreak of SARS-CoV-2 in 2019 took the world by storm and despite there being vaccines, numerous other alternative treatment approaches are also being researched.',\n",
              "  'Coronavirus disease-2019, 0, 24,  disease, covid, Coronavirus disease-2019 COVID-19 is a communicable disease caused by SARS-CoV-2.',\n",
              "  'COVID-19, 25, 33,  disease, covid, Coronavirus disease-2019 COVID-19 is a communicable disease caused by SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 70, 80,  disease, covid, Coronavirus disease-2019 COVID-19 is a communicable disease caused by SARS-CoV-2.',\n",
              "  \"Coronavirus disease-2019, 0, 24,  disease, covid, Coronavirus disease-2019 COVID-19 was first detected in Wuhan, China, and has expanded Coronavirus disease-2019 COVID-19's reach globally, leading to myriad deaths.\",\n",
              "  \"COVID-19, 25, 33,  disease, covid, Coronavirus disease-2019 COVID-19 was first detected in Wuhan, China, and has expanded Coronavirus disease-2019 COVID-19's reach globally, leading to myriad deaths.\",\n",
              "  \"Coronavirus disease-2019, 87, 111,  disease, covid, Coronavirus disease-2019 COVID-19 was first detected in Wuhan, China, and has expanded Coronavirus disease-2019 COVID-19's reach globally, leading to myriad deaths.\",\n",
              "  \"COVID-19, 112, 120,  disease, covid, Coronavirus disease-2019 COVID-19 was first detected in Wuhan, China, and has expanded Coronavirus disease-2019 COVID-19's reach globally, leading to myriad deaths.\",\n",
              "  'Coronavirus disease-2019, 60, 84,  disease, covid, According to World Health Organisation, the total number of Coronavirus disease-2019 COVID-19 confirmed cases worldwide was found to be 532201219 and total number of deaths accounted to 6305358 as of 10th June, 2022.',\n",
              "  'COVID-19, 85, 93,  disease, covid, According to World Health Organisation, the total number of Coronavirus disease-2019 COVID-19 confirmed cases worldwide was found to be 532201219 and total number of deaths accounted to 6305358 as of 10th June, 2022.',\n",
              "  'Coronavirus disease-2019, 81, 105,  disease, covid, Among many regions, Europe holds the top position in highest number of confirmed Coronavirus disease-2019 COVID-19 cases then followed by America, Western Pacific, South-East Asia, Eastern Mediterranean, and Africa respectively.',\n",
              "  'COVID-19, 106, 114,  disease, covid, Among many regions, Europe holds the top position in highest number of confirmed Coronavirus disease-2019 COVID-19 cases then followed by America, Western Pacific, South-East Asia, Eastern Mediterranean, and Africa respectively.',\n",
              "  'Coronavirus disease-2019, 41, 65,  disease, covid, These statistics reveal that even today, Coronavirus disease-2019 COVID-19 is still infecting several people, many of whom die due to complications.',\n",
              "  'COVID-19, 66, 74,  disease, covid, These statistics reveal that even today, Coronavirus disease-2019 COVID-19 is still infecting several people, many of whom die due to complications.',\n",
              "  'Coronavirus disease-2019, 47, 71,  disease, covid, However, the development of specific drugs for Coronavirus disease-2019 COVID-19 takes several years, paving the way for exploring alternative approaches.',\n",
              "  'COVID-19, 72, 80,  disease, covid, However, the development of specific drugs for Coronavirus disease-2019 COVID-19 takes several years, paving the way for exploring alternative approaches.',\n",
              "  'Coronavirus disease-2019, 4, 28,  disease, covid, The Coronavirus disease-2019 COVID-19 pandemic has ensured research to explore various alternatives, drug repurposing being one of various alternatives, as part of the disease management strategy.',\n",
              "  'COVID-19, 29, 37,  disease, covid, The Coronavirus disease-2019 COVID-19 pandemic has ensured research to explore various alternatives, drug repurposing being one of various alternatives, as part of the disease management strategy.',\n",
              "  'Coronavirus disease-2019, 174, 198,  disease, covid, Several drugs such as chloroquine, hydroxychloroquine, remdesivir, tocilizumab, kaletra, and favipiravir are currently being testing in clinal trials for repurposing against Coronavirus disease-2019 COVID-19.',\n",
              "  'COVID-19, 199, 207,  disease, covid, Several drugs such as chloroquine, hydroxychloroquine, remdesivir, tocilizumab, kaletra, and favipiravir are currently being testing in clinal trials for repurposing against Coronavirus disease-2019 COVID-19.',\n",
              "  'SARS-CoV 2, 0, 10,  disease, covid, SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "  'coronaviruses, 61, 74,  disease, covid, SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "  'Coronavirus, 148, 159,  disease, covid, SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "  'MERS-CoV, 160, 168,  disease, covid, SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "  'HCoV, 170, 174,  disease, covid, SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "  'HCoV, 189, 193,  disease, covid, SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "  'Coronavirus, 205, 216,  disease, covid, SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "  'SARS-CoV 2, 19, 29,  disease, covid, The replication of SARS-CoV 2 occurs with the help of mRNAs.',\n",
              "  'SARS-CoV 2, 20, 30,  disease, covid, The nucleocapsid in SARS-CoV 2 protects the viral RNA genomes from external environmental conditions.',\n",
              "  'SARS-CoV 2, 100, 110,  disease, covid, At the relaxed position, The nucleocapsid in the virus appears to be in a helical shape, but within SARS-CoV 2, The nucleocapsid in the virus appears spherical.',\n",
              "  'SARS-CoV 2, 14, 24,  disease, covid, The genome of SARS-CoV 2 codes for four main structural proteins when compared to five in other coronaviruses leaving out the hemagglutinin-esterase HE protein.',\n",
              "  'coronaviruses, 96, 109,  disease, covid, The genome of SARS-CoV 2 codes for four main structural proteins when compared to five in other coronaviruses leaving out the hemagglutinin-esterase HE protein.',\n",
              "  'SARS-CoV 2, 108, 118,  disease, covid, Nucleocapsid N, membrane M, envelope E, and spike S are the four important structural proteins expressed by SARS-CoV 2.',\n",
              "  'SARS-CoV 2, 18, 28,  disease, covid, On the surface of SARS-CoV 2, three structural proteins M, E, and S are present, while the nucleocapsid protein resides in the core region bound to genomic RNA.',\n",
              "  'SARS-CoV 2, 22, 32,  disease, covid, The spike proteins of SARS-CoV 2 help in the attachment, entry, pathogenesis, and tissue tropism, whereas, the infection is carried out by envelope E. Ribonucleoprotein is formed with nucleocapsid protein’s assistance and the membrane proteins aid in the overall viral architecture.',\n",
              "  \"SARS-CoV 2, 0, 10,  disease, covid, SARS-CoV 2 enters with the help of spike proteins by binding to the human angiotensin-converting enzyme 2 hACE2 through the human angiotensin-converting enzyme 2 hACE2's receptor-binding domain RBD and human proteases that make them proteolytically active.\",\n",
              "  'SARS-CoV 2, 71, 81,  disease, covid, Beta, gamma, delta, and omicron are the latest variants of concern for SARS-CoV 2.',\n",
              "  'COVID-19, 53, 61,  disease, covid, South Africa was first to report the beta variant of COVID-19, gamma was noted first in Brazil, delta in India, and omicron in western Europe.',\n",
              "  'COVID-19, 44, 52,  disease, covid, Omicron which is the most recent variant of COVID-19 carried all the mutations that were present in the previous variants along with some new improved functions such as showing partial resistance to the vaccine and enhanced transmissibility compared to others.',\n",
              "  'coronavirus, 10, 21,  disease, covid, The major coronavirus variants can be classified into two previously circulating variants of concern VoC and currently circulating variants of concern.',\n",
              "  'coronavirus, 10, 21,  disease, covid, The major coronavirus variants are the current targets for research to find repurposed drugs for exploring treatment strategies.',\n",
              "  'coronavirus, 65, 76,  disease, covid, In addition to this, certain amino acids are conserved among the coronavirus viruses, while some have a unique mark in the amino acid indicating lineage mutations.',\n",
              "  'coronavirus, 10, 21,  disease, covid, The major coronavirus variants belong to various lineages.',\n",
              "  'B.1.1.7, 0, 7,  covid lineage, covid, B.1.1.7 has the mutations H69-V70del, P618H, and N501Y, all indicating alterations in the amino acids.',\n",
              "  'B.1.351, 8, 15,  covid lineage, covid, Lineage B.1.351 has mutations K417N, N501Y, and E484K.',\n",
              "  'P.1, 48, 51,  covid lineage, covid, Likewise, another variant of concern of lineage P.1 has mutations N501Y, K417T, and E484K.',\n",
              "  'B.1.526, 0, 7,  covid lineage, covid, B.1.526 lineage is mutated at D614G, T95I, D253G, and S477N.',\n",
              "  'B.1.427, 0, 7,  covid lineage, covid, B.1.427 has mutations at L452R and D614G.',\n",
              "  'B.1.429, 0, 7,  covid lineage, covid, B.1.429 is mutated at sites D614G, S13I, W152C, and L452R.',\n",
              "  'B.1.617, 0, 7,  covid lineage, covid, B.1.617 variant has variations P681R, E484Q, and L452R.',\n",
              "  'SARS-CoV 2, 93, 103,  disease, covid, Apart from the variants identified in the most common lineages, there are approximately 1516 SARS-CoV 2 lineages to date.',\n",
              "  'SARS-CoV 2, 108, 118,  disease, covid, To identify the variants in all the existing lineages and those that exist not only in the spike protein of SARS-CoV 2, this study also performed a search in and summarized the different types of variants.',\n",
              "  'SARS-CoV 2, 195, 205,  disease, covid, Synonymous, non-synonymous, deletions, and non-coding variations were identified, and changes in the amino acid positions, and the reference and mutated codon as screened in all 1516 lineages of SARS-CoV 2.',\n",
              "  'SARS-CoV 2, 55, 65,  disease, covid, 131 non-synonymous mutations are in various regions of SARS-CoV 2, including the spike proteins, nucleocapsid proteins, different open reading frames, and membrane and envelope proteins.',\n",
              "  'SARS-CoV 2, 121, 131,  disease, covid, Additionally, some mutations are characteristic of specific regions, while some others are present in all the regions in SARS-CoV 2.',\n",
              "  'SARS-CoV-2, 10, 20,  disease, covid, Thus, the SARS-CoV-2 variants may have different binding sites making the SARS-CoV-2 variants identifying a suitable drug challenging.',\n",
              "  'SARS-CoV-2, 74, 84,  disease, covid, Thus, the SARS-CoV-2 variants may have different binding sites making the SARS-CoV-2 variants identifying a suitable drug challenging.',\n",
              "  'COVID-19, 130, 138,  disease, covid, Currently, there is a huge interest in the repurposing of drugs to speed up the identification of drugs that can prevent or treat COVID-19.',\n",
              "  'COVID-19, 94, 102,  disease, covid, drugs lopinavir and ritonavir were also the first drugs to be repurposed for the treatment of COVID-19.',\n",
              "  'SARS-CoV, 58, 66,  disease, covid, The main reason for this is due to the resemblance of the SARS-CoV and MERS-CoV beta coronavirus genome sequences to SARS-CoV-2.',\n",
              "  'MERS-CoV, 71, 79,  disease, covid, The main reason for this is due to the resemblance of the SARS-CoV and MERS-CoV beta coronavirus genome sequences to SARS-CoV-2.',\n",
              "  'coronavirus, 85, 96,  disease, covid, The main reason for this is due to the resemblance of the SARS-CoV and MERS-CoV beta coronavirus genome sequences to SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 117, 127,  disease, covid, The main reason for this is due to the resemblance of the SARS-CoV and MERS-CoV beta coronavirus genome sequences to SARS-CoV-2.',\n",
              "  \"MERS-CoV, 52, 60,  disease, covid, Thus, the drugs being utilized for the treatment of MERS-CoV and SARS-CoV-2 could be essentially used for COVID-19 treatment, implying that the mechanism of action of repositioned drugs against repositioned drugs's targets should be similar to or resemble repositioned drugs's family target members.\",\n",
              "  \"SARS-CoV-2, 65, 75,  disease, covid, Thus, the drugs being utilized for the treatment of MERS-CoV and SARS-CoV-2 could be essentially used for COVID-19 treatment, implying that the mechanism of action of repositioned drugs against repositioned drugs's targets should be similar to or resemble repositioned drugs's family target members.\",\n",
              "  \"COVID-19, 106, 114,  disease, covid, Thus, the drugs being utilized for the treatment of MERS-CoV and SARS-CoV-2 could be essentially used for COVID-19 treatment, implying that the mechanism of action of repositioned drugs against repositioned drugs's targets should be similar to or resemble repositioned drugs's family target members.\",\n",
              "  'COVID-19, 52, 60,  disease, covid, Successful administration to patients with moderate COVID-19 symptoms has been previously observed, confirming the hypothesis of drug repurposing.',\n",
              "  'COVID-19, 91, 99,  disease, covid, Aside from this, the scope of drug repurposing expands to the following, with instances in COVID-19 research, as discussed in the below sections Precision medicine Precision medicine is an emerging strategy that studies the variability of individual genes, the lifestyle, and the environment for each person to decide upon the correct treatment approach.',\n",
              "  'COVID-19, 174, 182,  disease, covid, Recent studies have implicated the use of computational techniques such as machine learning algorithms as a precision medicine tool for drug repurposing for the treatment of COVID-19.',\n",
              "  'COVID-19, 202, 210,  disease, covid, The decision tree algorithms used in the study identify patients with longer survival rates and better oxygen support when treatment was provided and suggest corticosteroids and remdesivir as effective COVID-19 repurposed drugs.',\n",
              "  'COVID-19, 49, 57,  disease, covid, Rapid therapeutic options With the advent of the COVID-19 pandemic and reduced therapeutic options for COVID-19, repurposing offers rapid therapeutic strategies to combat COVID-19.',\n",
              "  'COVID-19, 103, 111,  disease, covid, Rapid therapeutic options With the advent of the COVID-19 pandemic and reduced therapeutic options for COVID-19, repurposing offers rapid therapeutic strategies to combat COVID-19.',\n",
              "  'COVID-19, 171, 179,  disease, covid, Rapid therapeutic options With the advent of the COVID-19 pandemic and reduced therapeutic options for COVID-19, repurposing offers rapid therapeutic strategies to combat COVID-19.',\n",
              "  'COVID-19, 72, 80,  disease, covid, El Bairi et al. reviewed various anticancer drugs for the management of COVID-19.',\n",
              "  'COVID-19, 374, 382,  disease, covid, Likewise, another study has elucidated and suggested the use of interleukin inhibitors, Janus-kinase pathway inhibitors, interferons, vascular endothelial growth factor VEGF inhibitors, immune check-point inhibitors, Bruton tyrosine kinase inhibitors BTK, and XPO-1 a selective inhibitor of nuclear export as some of the alternative drugs that could be repurposed for rapid COVID-19 treatment.',\n",
              "  'coronaviruses, 135, 148,  disease, covid, Similarly, another study suggested p38 MAPK mitogen-activated protein kinase, as a vital host target for inhibiting the replication of coronaviruses, after studies proved that Ralimetiniib mesylate was found to be active in both Calu-3 and HeLa-ACE2 cells.',\n",
              "  'COVID-19, 29, 37,  disease, covid, Thus, drug repositioning for COVID-19 research has now taken the front seat and has a huge scope for tackling the virus.',\n",
              "  'COVID-19, 56, 64,  disease, covid, With increasing incidences of emerging diseases such as COVID-19, for which immediate treatments were not available, the need for drugs to treat the disease became indispensable.',\n",
              "  'SARS-CoV-2, 104, 114,  disease, covid, Previous studies have most commonly employed molecular docking for virtual screening against targets of SARS-CoV-2, such as the main protease, with possible drugs for repurposing such as digitoxigenin, beta-eudesmol, crocin, rutin, ritonavir, emetine, hesperidin, and indinavir.',\n",
              "  'COVID-19, 65, 73,  disease, covid, Likewise, other virtual screening approaches used previously for COVID-19 drug repurposing include combinations of docking with molecular dynamic MD simulations and calculation of free energy using MM-GBSA studies and two-way docking with in silico ADMET studies.',\n",
              "  'SARS-CoV-2, 85, 95,  disease, covid, The authors’ previous studies have used Molecular docking against various targets of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 143, 153,  disease, covid, Elfiky proved via MD simulations that Setrobuvir, YAK, and ID-184 had the best antiviral activity against RNRP RNA-dependent RNA polymerase of SARS-CoV-2, after screening out 31 compounds that were in clinical trials or had known antiviral activity.',\n",
              "  'SARS-CoV-2, 79, 89,  disease, covid, Similarly, MD simulations identified the stability of lopinavir complexed with SARS-CoV-2 main protease as the most stable in biological conditions, along with other identified antivirals such as carfilzomib, valrubicin, elbasvir, and eravacycline.',\n",
              "  'COVID-19, 15, 23,  disease, covid, With regard to COVID-19, this approach combined with docking and simulations has brought immense benefits to the design and repurposing of drugs for SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 149, 159,  disease, covid, With regard to COVID-19, this approach combined with docking and simulations has brought immense benefits to the design and repurposing of drugs for SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 136, 146,  disease, covid, A study has previously created a QSAR model founded on machine learning strategies utilizing several hundred inhibitor molecules of the SARS-CoV-2 main protease.',\n",
              "  'SARS-CoV-2, 105, 115,  disease, covid, a QSAR model founded on machine learning strategies utilizing several hundred inhibitor molecules of the SARS-CoV-2 main protease was employed for virtual screening and docking, followed by shortlisting of the 20 best candidates for MD simulation validation.',\n",
              "  'SARS-CoV-2, 183, 193,  disease, covid, Similarly, another recent study designed a binary-QSAR model for the virtual screening of several drugs that are FDA-approved and are in clinical studies against the main protease of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 104, 114,  disease, covid, a binary-QSAR model resulted in cefuroxime pivoxetil as a potential drug repositioning molecule against SARS-CoV-2.',\n",
              "  'COVID-19, 120, 128,  disease, covid, Recently, the use of AI technology for drug repositioning has surfaced with several studies focusing on repurposing for COVID-19 research.',\n",
              "  'SARS-CoV-2, 123, 133,  disease, covid, A deep-learning-based approach to screen a huge number of molecules having allocated datasets to seek compounds possessing SARS-CoV-2-inhibiting activities was carried out previously by Ke et al. To validate the designed model and verify the antiviral activity of the compound that the designed model predicted, an in vitro cell line for feline coronavirus replication was also set up in the study.',\n",
              "  'coronavirus, 345, 356,  disease, covid, A deep-learning-based approach to screen a huge number of molecules having allocated datasets to seek compounds possessing SARS-CoV-2-inhibiting activities was carried out previously by Ke et al. To validate the designed model and verify the antiviral activity of the compound that the designed model predicted, an in vitro cell line for feline coronavirus replication was also set up in the study.',\n",
              "  'SARS-CoV-2, 252, 262,  disease, covid, Likewise, Beck et al. utilized an already trained deep-learning prediction model for drug-target interactions known as Molecule Transformer-Drug Target Interaction MT-DTI, to find antiviral drugs that are commercially available and which could perturb SARS-CoV-2 components including RNA-dependent RNA polymerase, proteinase, and helicase.',\n",
              "  'COVID-19, 85, 93,  disease, covid, Thus, AI-based techniques are providing the scientific communities a chance to fight COVID-19 in a much faster way, owing to the accessible web servers, tools, and models that reduce the time required for a drug to come into the market.',\n",
              "  'COVID-19, 71, 79,  disease, covid, The scope and developments of computational medicinal chemistry toward COVID-19 treatment strategies are summarized in Fig. Several computational approaches for repurposing have been used over the years to enhance the efficiency of the predictive outcomes and decrease the drawbacks.',\n",
              "  'COVID-19, 112, 120,  disease, covid, There are several applications of computational biology and chem-bioinformatic approaches for drug discovery in COVID-19 research.',\n",
              "  'COVID-19, 104, 112,  disease, covid, A recent study has developed a multi-model deep learning-based algorithm for drug repurposing to aid in COVID-19 research.',\n",
              "  'COVID-19, 144, 152,  disease, covid, The results from A recent study showed clusters that were employed to identify the drugs that were notably similar to the proposed and existing COVID-19 treatment medication.',\n",
              "  'COVID-19, 170, 178,  disease, covid, Another recent study also proposed a data augmentation approach that extricates only beneficial data from a set of variable datasets, to screen novel drug candidates for COVID-19.',\n",
              "  'COVID-19, 45, 53,  disease, covid, A recent application of signature mapping on COVID-19 research demonstrated the use of Connectivity Map databases for generating drug perturbation profiles.',\n",
              "  'COVID-19, 67, 75,  disease, covid, A modified version of A recent application of signature mapping on COVID-19 research was implemented by Jia et al. where the input used was the expression profile data from healthy and infected individuals to generate a pathway-based drug repurposing framework.',\n",
              "  'SARS-CoV-2, 191, 201,  disease, covid, Another recent study designed and developed Deep Docking, which uses QSAR Quantitative Structure–Activity Relationship models to predict the docking scores of drug candidates that target the SARS-CoV-2 3CL protein.',\n",
              "  'COVID-19, 118, 126,  disease, covid, Deep Docking docked all the compounds and provided a list of potential drug hits, that could be used to repurpose for COVID-19.',\n",
              "  'COVID-19, 100, 108,  disease, covid, Several studies have implemented random-walk algorithms to identify drug repurposing candidates for COVID-19 –. The pathogenic mechanisms instigated by the SARS-CoV-2 3CL protein using the information from all related coronaviruses were also explored and random walk algorithms were implemented on the molecular networks to recognize the most relevant COVID-19 drug targets.',\n",
              "  'SARS-CoV-2, 156, 166,  disease, covid, Several studies have implemented random-walk algorithms to identify drug repurposing candidates for COVID-19 –. The pathogenic mechanisms instigated by the SARS-CoV-2 3CL protein using the information from all related coronaviruses were also explored and random walk algorithms were implemented on the molecular networks to recognize the most relevant COVID-19 drug targets.',\n",
              "  'coronaviruses, 218, 231,  disease, covid, Several studies have implemented random-walk algorithms to identify drug repurposing candidates for COVID-19 –. The pathogenic mechanisms instigated by the SARS-CoV-2 3CL protein using the information from all related coronaviruses were also explored and random walk algorithms were implemented on the molecular networks to recognize the most relevant COVID-19 drug targets.',\n",
              "  'COVID-19, 352, 360,  disease, covid, Several studies have implemented random-walk algorithms to identify drug repurposing candidates for COVID-19 –. The pathogenic mechanisms instigated by the SARS-CoV-2 3CL protein using the information from all related coronaviruses were also explored and random walk algorithms were implemented on the molecular networks to recognize the most relevant COVID-19 drug targets.',\n",
              "  'COVID-19, 137, 145,  disease, covid, Thus, these computational perspectives on drug repurposing provide a unique outlook on the alternative treatment options for the ongoing COVID-19 disease.',\n",
              "  'SARS-CoV-2, 114, 124,  disease, covid, Drugs such as lopinavir, ritonavir, boceprevir, carmofur, and doxycycline act on the 3-chymotrypsin-like proteins/SARS-CoV-2 main protease that play an important role in cleaving and releasing the 16 non-structural proteins.',\n",
              "  'SARS-CoV-2, 26, 36,  disease, covid, For the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of SARS-CoV-2, drugs such as vapreotide, atazanavir, daclatasvir, and bismuth potassium citrate commonly block this function of the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of the virus.',\n",
              "  'SARS-CoV-2, 115, 125,  disease, covid, For the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of SARS-CoV-2, drugs such as vapreotide, atazanavir, daclatasvir, and bismuth potassium citrate commonly block this function of the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of the virus.',\n",
              "  'SARS-CoV-2, 262, 272,  disease, covid, For the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of SARS-CoV-2, drugs such as vapreotide, atazanavir, daclatasvir, and bismuth potassium citrate commonly block this function of the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of the virus.',\n",
              "  'SARS-CoV-2, 181, 191,  disease, covid, Likewise, dinucleoside 123 and raltegravir affect the pathways of methyltransferases guanine-N7-methyltransferase, 2’-O-methyltransferase, while gliclazide and memantine affect the SARS-CoV-2 E protein, which is the envelope protein of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 236, 246,  disease, covid, Likewise, dinucleoside 123 and raltegravir affect the pathways of methyltransferases guanine-N7-methyltransferase, 2’-O-methyltransferase, while gliclazide and memantine affect the SARS-CoV-2 E protein, which is the envelope protein of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 271, 281,  disease, covid, The viral neuraminidases and the DPP4 cell receptor pathways are hindered due to the action of oseltamivir and sitagliptin, while pemirolast, nitrofurantoin, isoniazid pyruvate, eridictoyl, hypericin, cepharanthine, and ergoloid block the human ACE2 and the S protein of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 123, 133,  disease, covid, The most important Janus kinase pathway is hindered by baricitinib, RdRp, helicase, exo-nuclease, and methyltransferase of SARS-CoV-2 by Efavirenz and Poly ADP-ribose polymerase 1 PARP-1 by Mefuparib hydrochloride.',\n",
              "  'SARS-CoV-2, 90, 100,  disease, covid, Other common drugs such as nitazoxanide, ivermectin, and azithromycin tend to symptoms of SARS-CoV-2, and play a role in inhibiting the role of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 144, 154,  disease, covid, Other common drugs such as nitazoxanide, ivermectin, and azithromycin tend to symptoms of SARS-CoV-2, and play a role in inhibiting the role of SARS-CoV-2.',\n",
              "  'COVID-19, 66, 74,  disease, covid, Despite these drugs being implicated as a potential treatment for COVID-19, ethical issues arise regarding the use of these drugs without proper clinical phase trials and FDA Food and Drug Administration approval.',\n",
              "  'COVID-19, 85, 93,  disease, covid, Therefore, a list of the FDA Food and Drug Administration drugs for the treatment of COVID-19 is provided in Table.',\n",
              "  'SARS-CoV-2, 105, 115,  disease, covid, Mahdian et al. and Yuce et al. state that Paritaprevir is important against 3-chymotrypsin-like proteins/SARS-CoV-2 Main protease and plays an important role in cleaving as well as releasing 16 non-structural proteins Nsps.',\n",
              "  'SARS-CoV-2, 35, 45,  disease, covid, Paritaprevir also affects the ACE2-SARS-CoV-2-RBD complex.',\n",
              "  'SARS-CoV-2, 64, 74,  disease, covid, Likewise, ledipasvir, vancomycin, and sirolimus target the ACE2-SARS-CoV-2-RBD complex, a spike protein that helps in the viral entry along with the help of ACE2 protein in the host organism.',\n",
              "  'SARS-CoV-2, 211, 221,  disease, covid, Similarly, FDA-approved irinotecan, abemaciclib, estradiol benzoate, capmatinib, olaparib, lumacaftor, and pazopanib target CD147, a member of the immunoglobulin superfamily IgSF interacts with spike protein of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 230, 240,  disease, covid, Other drugs such as nilotinib, rifabutin, dactinomycin, dihydroergotamine, bromocriptine, entrectinib, selinexor, elbasvir, quinupristin, rifapentine, rutin, digitoxin, diosmin, and antrafenine target 3-chymotrypsin-like proteins/SARS-CoV-2 Main protease that plays an important role in cleaving as well as releasing 16 non-structural proteins Nsps.',\n",
              "  'SARS-CoV-2, 187, 197,  disease, covid, This data is provided in detail in Table and the 2D structures of some of these drugs are shown in Fig. When remdesivir was administered intravenously to the first patient diagnosed with SARS-CoV-2 in the USA, no adverse effects were noted with some clinical benefits in the first patient diagnosed with SARS-CoV-2 in the USA.',\n",
              "  'SARS-CoV-2, 304, 314,  disease, covid, This data is provided in detail in Table and the 2D structures of some of these drugs are shown in Fig. When remdesivir was administered intravenously to the first patient diagnosed with SARS-CoV-2 in the USA, no adverse effects were noted with some clinical benefits in the first patient diagnosed with SARS-CoV-2 in the USA.',\n",
              "  'COVID-19, 203, 211,  disease, covid, Additionally, due to some adverse effects early on, remdesivir was then discontinued, and FDA Food and Drug Administration has now provided a conditional recommendation for the use of remdesivir against COVID-19.',\n",
              "  'COVID-19, 90, 98,  disease, covid, Likewise, real-world usage of lopinavir/ritonavir revealed no beneficial response against COVID-19 hospitalized patients in a randomized, controlled, trial.',\n",
              "  'COVID-19, 141, 149,  disease, covid, Despite there being studies on hydroxychloroquine, an analogue of chloroquine, where improvements have been noted in patients suffering from COVID-19 in a study conducted in Wuhan, there still seems to be very limited data on the reliability of hydroxychloroquine, an analogue of chloroquine.',\n",
              "  'COVID-19, 71, 79,  disease, covid, Interferon-beta-1A has been used in hospitalized patients for treating COVID-19 at Shaid Behesti University of Medical Sciences, in combination with other drugs.',\n",
              "  'SARS-CoV-2, 202, 212,  disease, covid, Therefore, the clinical data presented provide evidence of the efficacy of the use of these drugs,however, more research is indispensable for the proper application and employability of these drugs for SARS-CoV-2 treatment.',\n",
              "  'coronavirus, 25, 36,  disease, covid, According to literature, coronavirus papain-like proteases PLpro, main protease 3CLpro, helicase, and RNA-dependent RNA polymerase RdRp are the considered to be the potential molecular targets and are involved in important functional activities such as protein synthesis, RNA transcription, translation, replication, processing, and infection respectively.',\n",
              "  'coronaviruses, 63, 76,  disease, covid, All these proteins come under non-structural proteins nsps for coronaviruses.',\n",
              "  'SARS CoV-2, 67, 77,  disease, covid, The N-terminal and the C-terminal domain of The nucleoprotein N of SARS CoV-2 share similarities with CoVs N proteins.',\n",
              "  'CoVs, 102, 106,  disease, covid, The N-terminal and the C-terminal domain of The nucleoprotein N of SARS CoV-2 share similarities with CoVs N proteins.',\n",
              "  'protomers, 46, 55,  disease, covid, the C-terminal domain is a homodimer with two protomers resembling a rectangular slab-like structure.',\n",
              "  \"protomers, 45, 54,  disease, covid, The beta hairpin-like structure connects two protomers by inserting The beta hairpin-like structure into two protomers's cavities.\",\n",
              "  \"protomers, 109, 118,  disease, covid, The beta hairpin-like structure connects two protomers by inserting The beta hairpin-like structure into two protomers's cavities.\",\n",
              "  'SARS CoV-2, 43, 53,  disease, covid, The overall size of The nucleoprotein N of SARS CoV-2 is about 8.4–12 kDa and forms the integral membrane protein of the virus comprising 76–109 amino acids.',\n",
              "  'SARS CoV-2, 99, 109,  disease, covid, There are about 7–12 amino acids at The N-terminal which is short and makes The nucleoprotein N of SARS CoV-2 hydrophilic in nature.',\n",
              "  'protomers, 4, 13,  disease, covid, The protomers present in the spike glycoprotein structure contain approximately 1260 amino acids.',\n",
              "  'SARS-CoV-2, 35, 45,  disease, covid, The non-structural proteins of the SARS-CoV-2 are polyproteins pp1a and pp1ab.',\n",
              "  'SARS-CoV-2, 89, 99,  disease, covid, These structural details are of utmost essential when The non-structural proteins of the SARS-CoV-2 interact with the drug candidates, to understand the precise molecular mechanism of action of the small molecule.',\n",
              "  'SARS-CoV-2, 139, 149,  disease, covid, All these studies prove that there is distinct evidence as to the altering of the the virus proteins’ structural antigenicity, causing the SARS-CoV-2 proteins’ to evade the immune system and become more robust.',\n",
              "  'COVID-19, 111, 119,  disease, covid, Currently, as we have seen from various evidences, there are several repurposed drugs reported for use against COVID-19, some already available on the market.',\n",
              "  'SARS-CoV-2, 176, 186,  disease, covid, The potential binding of several FDA-approved drugs has been studied previously however, not much data is revealed on the precise molecular basis of these interactions against SARS-CoV-2 targets.',\n",
              "  'SARS-CoV-2, 94, 104,  disease, covid, In the previous section, evidence of how the variants alter the drug binding efficacy and how SARS-CoV-2 escapes the immune system is provided.',\n",
              "  'SARS-CoV-2, 51, 61,  disease, covid, In our previous study, however, various targets of SARS-CoV-2 were analyzed at the molecular level to comprehend the changes SARS-CoV-2 undergoes during the binding event of some of the important FDA-approved drugs for COVID-19.',\n",
              "  'SARS-CoV-2, 125, 135,  disease, covid, In our previous study, however, various targets of SARS-CoV-2 were analyzed at the molecular level to comprehend the changes SARS-CoV-2 undergoes during the binding event of some of the important FDA-approved drugs for COVID-19.',\n",
              "  'COVID-19, 219, 227,  disease, covid, In our previous study, however, various targets of SARS-CoV-2 were analyzed at the molecular level to comprehend the changes SARS-CoV-2 undergoes during the binding event of some of the important FDA-approved drugs for COVID-19.',\n",
              "  'SARS-CoV-2, 82, 92,  disease, covid, Though there are limited experimental data to highlight the spike glycoprotein of SARS-CoV-2 act as the target for repurposed drugs, however, several computational biology prediction revelated the scope of utilising spike glycoproteins as the putative molecular target for repurposed drugs.',\n",
              "  'SARS-CoV-2, 104, 114,  disease, covid, A recent study stated that drugs ritonavir and eriodictoyl bind to the active sites of spike protein of SARS-CoV-2 with potential binding energy and stability.',\n",
              "  'SARS-CoV-2, 150, 160,  disease, covid, Likewise, another study showed that repurposed drugs such as pralatrexate, carumonam, aclerasteride, and granotapide interacted with spike protein of SARS-CoV-2 and acted as potential binders.',\n",
              "  'SARS-CoV-2, 139, 149,  disease, covid, Additionally, another recent study has reported Remdesivir and ivermectin, potential repurposed drugs interacted with the spike protein of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 86, 96,  disease, covid, another recent study stated that ivermectin bound effectively to the spike protein of SARS-CoV-2, and inhibited the entry of SARS-CoV-2 into the host.',\n",
              "  'SARS-CoV-2, 125, 135,  disease, covid, another recent study stated that ivermectin bound effectively to the spike protein of SARS-CoV-2, and inhibited the entry of SARS-CoV-2 into the host.',\n",
              "  'SARS-CoV-2, 98, 108,  disease, covid, Remdesivir was also suggested to be involved in stable interaction with the spike glycoprotein of SARS-CoV-2, apart from the other targets.',\n",
              "  'SARS-CoV-2, 104, 114,  disease, covid, These studies demonstrate that repurposed drugs were suggested to be targeted the spike glycoprotein of SARS-CoV-2 at various binding pockets and interacted with the spike glycoprotein of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 188, 198,  disease, covid, These studies demonstrate that repurposed drugs were suggested to be targeted the spike glycoprotein of SARS-CoV-2 at various binding pockets and interacted with the spike glycoprotein of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 174, 184,  disease, covid, At a molecular level, Fig. showed that chloroquine interacted with amino acids Leu6820, Leu6819, Met6818, Val7021, Tyr7020, Asp7018, and Asp6942 of the spike glycoprotein of SARS-CoV-2.',\n",
              "  'COVID-19, 125, 133,  disease, covid, The major repurposed drugs displayed in Table dhow that research is ongoing and always improving for tackling the problem of COVID-19.',\n",
              "  'SARS, 77, 81,  disease, covid, Lopinavir/ritonavir was generally used against HIV, remdesivir against major SARS viruses, and favipiravir which was previously used as a general viral pro-drug.',\n",
              "  'COVID-19, 94, 102,  disease, covid, For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.',\n",
              "  'SARS-CoV, 197, 205,  disease, covid, For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.',\n",
              "  'MERS-CoV, 210, 218,  disease, covid, For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.',\n",
              "  'SARS-CoV-2, 319, 329,  disease, covid, For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.',\n",
              "  'COVID-19, 356, 364,  disease, covid, For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.',\n",
              "  'SARS-CoV-2, 88, 98,  disease, covid, Likewise, the in vivo study of remdesivir a broad-spectrum antiviral when infected with SARS-CoV-2, the pathogenic strain of COVID-19 disease infected rhesus monkey demonstrated an improvement in the pulmonary lesions and decreased the viral load after 7 days of treatment with remdesivir a broad-spectrum antiviral.',\n",
              "  'COVID-19, 125, 133,  disease, covid, Likewise, the in vivo study of remdesivir a broad-spectrum antiviral when infected with SARS-CoV-2, the pathogenic strain of COVID-19 disease infected rhesus monkey demonstrated an improvement in the pulmonary lesions and decreased the viral load after 7 days of treatment with remdesivir a broad-spectrum antiviral.',\n",
              "  'coronaviral disease, 3, 22,  disease, covid, No coronaviral disease was observed after the successful use of remdesivir a broad-spectrum antiviral.',\n",
              "  'SARS-CoV-2, 197, 207,  disease, covid, remdesivir a broad-spectrum antiviral was originally meant for treating the Ebola virus against the Ebola RdRp target, and now with potential repurposing capabilities against the RdRp and NSP12 of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 108, 118,  disease, covid, Lopinavir/ritonavir is a drug for the HIV-1 protease, that now evidences potential for the main protease of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 92, 102,  disease, covid, Silmitasertib is also known to inhibit the casein kinase 2 pathway in Sonic hedgehog SHH in SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 117, 127,  disease, covid, Likewise, dipyridamole 100 mg is an inhibitor of phosphodiesterase originally and works against the main protease of SARS-CoV-2 and stops replication.',\n",
              "  'SARS-CoV-2, 124, 134,  disease, covid, Leronlimab 700 mg works against the C–C Chemokine receptor type 5 in HIV and now shows potential against the same target in SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 111, 121,  disease, covid, Ruconest targets the c1 esterase and inhibits angioedema, while Ruconest targets C1, C5a, and C3a esterases in SARS-CoV-2.',\n",
              "  \"SARS-CoV-2, 48, 58,  disease, covid, Infliximab attacks the tumor necrosis factor in SARS-CoV-2 as well as in Infliximab's original target in Rheumatoid arthritis, Crohn’s disease, and ankylosing spondylitis.\",\n",
              "  'SARS-CoV-2, 17, 27,  disease, covid, The emergence of SARS-CoV-2 has illuminated the purpose and benefits of repositioning drugs to provide emergency treatments.',\n",
              "  'COVID-19, 317, 325,  disease, covid, Other advantages of repurposed drugs include Lower cost of productionLesser time for identifying useful, effective, and safe drugs for quick useResearch can be carried out using the existing, easily accessible bioinformatics and chem-informatics data and resources available for specific diseases, as was the case in COVID-19 cases Molecular docking The emergence and prevalence of COVID-19 have paved the way for molecular docking studies.',\n",
              "  'COVID-19, 382, 390,  disease, covid, Other advantages of repurposed drugs include Lower cost of productionLesser time for identifying useful, effective, and safe drugs for quick useResearch can be carried out using the existing, easily accessible bioinformatics and chem-informatics data and resources available for specific diseases, as was the case in COVID-19 cases Molecular docking The emergence and prevalence of COVID-19 have paved the way for molecular docking studies.',\n",
              "  'COVID-19, 109, 117,  disease, covid, Previously, molecular docking has been used to determine the potential anti-virals for curbing the spread of COVID-19.',\n",
              "  'SARS-CoV-2, 117, 127,  disease, covid, Poly-ADP-ribose polymerase-1, CVL218, a potent inhibitor that binds to the N-terminal of the nucleocapsid protein of SARS-CoV-2 was identified.',\n",
              "  'COVID-19, 34, 42,  disease, covid, The use of Signature matching for COVID-19 remains an unexplored avenue.',\n",
              "  'COVID-19, 120, 128,  disease, covid, With so many repurposed drugs in the market today, and several more upcoming owing to the intensity and acceleration of COVID-19 research, there are more advantages than disadvantages to the use of such drugs.',\n",
              "  'COVID-19, 564, 572,  disease, covid, However, some limitations to the drug repositioning, include Weak intellectual property rights protection for repurposed drugs due to reduced rate of returnThe molecular docking technique used for identifying drugs for repurposing cannot be applied to all existing drugs due to the larger computational operationsSome network-based approaches used for drug repurposing do not always yield promising operationsSome network-based approaches used for drug repurposing are data-dependent, due to which the results may be inaccurate due to the lower volume of existing COVID-19 dataLack of strong, solid evidence for the mechanism of action of repurposed drugs on COVID-19 19Experimental evidence is required for validating the predictive outcomesOverall low success rates in new disease settingsExtensive data to be studied before repurposingDosing and safety issues, i.e., approved range of dosage and delivery capabilities are not very strongAccurate, robust toxicological studies of repurposed drugs essential before delivery and testingRare to find unique and novel drug-protein interactions all within the restraints of the approved therapeutic window.',\n",
              "  'COVID-19, 659, 667,  disease, covid, However, some limitations to the drug repositioning, include Weak intellectual property rights protection for repurposed drugs due to reduced rate of returnThe molecular docking technique used for identifying drugs for repurposing cannot be applied to all existing drugs due to the larger computational operationsSome network-based approaches used for drug repurposing do not always yield promising operationsSome network-based approaches used for drug repurposing are data-dependent, due to which the results may be inaccurate due to the lower volume of existing COVID-19 dataLack of strong, solid evidence for the mechanism of action of repurposed drugs on COVID-19 19Experimental evidence is required for validating the predictive outcomesOverall low success rates in new disease settingsExtensive data to be studied before repurposingDosing and safety issues, i.e., approved range of dosage and delivery capabilities are not very strongAccurate, robust toxicological studies of repurposed drugs essential before delivery and testingRare to find unique and novel drug-protein interactions all within the restraints of the approved therapeutic window.',\n",
              "  'SARS-CoV-2, 61, 71,  disease, covid, In the wake of the emergence of highly mutated and resistant SARS-CoV-2 strains, the question of how already repurposed drugs work comes into the picture.',\n",
              "  'COVID-19, 131, 139,  disease, covid, Another perspective is the use of drug repurposing as a therapy for novel diseases for which specific drugs are not yet available, COVID-19 being one such important example.',\n",
              "  'SARS-CoV-2, 91, 101,  disease, covid, Although this review comprehensively lists all the current and latest drugs repurposed for SARS-CoV-2 and the existing computational approaches that in turn improve the process of repurposing, further advancements in the software and techniques such as using ensemble machine learning will improve the process of repurposing.',\n",
              "  'COVID-19, 27, 35,  disease, covid, With high mortality rates, COVID-19 has become one of the most prevailing diseases globally.',\n",
              "  'SARS-CoV-2, 70, 80,  disease, covid, With the CDC and WHO declaring several recent variants of concern for SARS-CoV-2, there is an urgent need to explore alternative options of treatment when there are no specific drugs targeting SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 193, 203,  disease, covid, With the CDC and WHO declaring several recent variants of concern for SARS-CoV-2, there is an urgent need to explore alternative options of treatment when there are no specific drugs targeting SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 96, 106,  disease, covid, this review sheds light on the various existing drugs that have been repurposed for use against SARS-CoV-2 and also illuminates the important drug targets against which the various existing drugs that have been repurposed for use against SARS-CoV-2 are used spike glycoproteins, RDRP, main protease, papain-like protease, nucleoproteins, non-structural proteins, and enveloped proteins of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 238, 248,  disease, covid, this review sheds light on the various existing drugs that have been repurposed for use against SARS-CoV-2 and also illuminates the important drug targets against which the various existing drugs that have been repurposed for use against SARS-CoV-2 are used spike glycoproteins, RDRP, main protease, papain-like protease, nucleoproteins, non-structural proteins, and enveloped proteins of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 389, 399,  disease, covid, this review sheds light on the various existing drugs that have been repurposed for use against SARS-CoV-2 and also illuminates the important drug targets against which the various existing drugs that have been repurposed for use against SARS-CoV-2 are used spike glycoproteins, RDRP, main protease, papain-like protease, nucleoproteins, non-structural proteins, and enveloped proteins of SARS-CoV-2.',\n",
              "  'COVID-19, 60, 68,  disease, covid, The most important advantage of repositioning drugs against COVID-19 is the reduced cost and time of development and the drawback is the absence of safety/toxicity profiles via in vivo trials for COVID-19.',\n",
              "  'COVID-19, 196, 204,  disease, covid, The most important advantage of repositioning drugs against COVID-19 is the reduced cost and time of development and the drawback is the absence of safety/toxicity profiles via in vivo trials for COVID-19.'],\n",
              " ['coronavirus, 15, 26,  disease, covid, The 2019 novel coronavirus, now dubbed SARS-CoV-2, has led to a global pandemic as declared by the World Health Organization WHO on 11 March 2020.',\n",
              "  'SARS-CoV-2, 39, 49,  disease, covid, The 2019 novel coronavirus, now dubbed SARS-CoV-2, has led to a global pandemic as declared by the World Health Organization WHO on 11 March 2020.',\n",
              "  \"coronavirus, 15, 26,  disease, covid, The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\",\n",
              "  \"SARS-CoV-2, 39, 49,  disease, covid, The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\",\n",
              "  \"coronavirus, 72, 83,  disease, covid, The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\",\n",
              "  \"SARS-CoV-2, 96, 106,  disease, covid, The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\",\n",
              "  \"Coronaviridae, 160, 173,  disease, covid, The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\",\n",
              "  \"COVID-19, 579, 587,  disease, covid, The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\",\n",
              "  'coronavirus, 57, 68,  disease, covid, Despite this variance, it is of note that The 2019 novel coronavirus, now dubbed SARS-CoV-2 infections lead to systemic inflammatory response syndrome SIRS and acute respiratory distress syndrome ARDS, two relevant conditions highly correlated with COVID-19 infections.',\n",
              "  'SARS-CoV-2 infections, 81, 102,  disease, covid, Despite this variance, it is of note that The 2019 novel coronavirus, now dubbed SARS-CoV-2 infections lead to systemic inflammatory response syndrome SIRS and acute respiratory distress syndrome ARDS, two relevant conditions highly correlated with COVID-19 infections.',\n",
              "  'COVID-19 infections, 249, 268,  disease, covid, Despite this variance, it is of note that The 2019 novel coronavirus, now dubbed SARS-CoV-2 infections lead to systemic inflammatory response syndrome SIRS and acute respiratory distress syndrome ARDS, two relevant conditions highly correlated with COVID-19 infections.',\n",
              "  'COVID-19 infections, 14, 33,  disease, covid, Specifically, COVID-19 infections are accompanied by an overaggressive inflammatory response corresponding to a significant release of pro-inflammatory cytokines known as a cytokine storm.',\n",
              "  'COVID-19, 47, 55,  disease, covid, Though the biological relevance in relation to COVID-19 of cytokine storms has been questioned, studies have shown significant elevations of pro-inflammatory cytokines in COVID-19 infections as compared to other viral infections, highlighting that virulence may be more immune response-mediated rather than solely due to the viral titer.',\n",
              "  'COVID-19 infections, 171, 190,  disease, covid, Though the biological relevance in relation to COVID-19 of cytokine storms has been questioned, studies have shown significant elevations of pro-inflammatory cytokines in COVID-19 infections as compared to other viral infections, highlighting that virulence may be more immune response-mediated rather than solely due to the viral titer.',\n",
              "  \"COVID-19, 206, 214,  disease, covid, As the mechanisms of the cytokine storm have yet to be fully elucidated, there is a need to understand the cytokine storm's genomic origin by comparing the cytokine storm known conditions that occur during COVID-19, such as SARS and acute respiratory distress syndrome ARDS.\",\n",
              "  \"SARS, 224, 228,  disease, covid, As the mechanisms of the cytokine storm have yet to be fully elucidated, there is a need to understand the cytokine storm's genomic origin by comparing the cytokine storm known conditions that occur during COVID-19, such as SARS and acute respiratory distress syndrome ARDS.\",\n",
              "  'COVID-19, 15, 23,  disease, covid, In the case of COVID-19, studies have most often utilized differential gene analysis and limited research is available on clusters of highly correlated genes.',\n",
              "  \"COVID-19, 15, 23,  disease, covid, In the case of COVID-19, where the variance in symptoms and the unclear mechanisms of the cytokine storm led to challenges in developing therapeutics to treat affected patients, the need arises to solve challenges in developing therapeutics to treat affected patients through relation of the COVID-19 induced cytokine storm to similar ailment SIRS, ARDS, and sepsis, to connect SARS and ARDS's mechanisms and therefore elucidate potential novel drugs.\",\n",
              "  \"COVID-19, 292, 300,  disease, covid, In the case of COVID-19, where the variance in symptoms and the unclear mechanisms of the cytokine storm led to challenges in developing therapeutics to treat affected patients, the need arises to solve challenges in developing therapeutics to treat affected patients through relation of the COVID-19 induced cytokine storm to similar ailment SIRS, ARDS, and sepsis, to connect SARS and ARDS's mechanisms and therefore elucidate potential novel drugs.\",\n",
              "  \"SARS, 378, 382,  disease, covid, In the case of COVID-19, where the variance in symptoms and the unclear mechanisms of the cytokine storm led to challenges in developing therapeutics to treat affected patients, the need arises to solve challenges in developing therapeutics to treat affected patients through relation of the COVID-19 induced cytokine storm to similar ailment SIRS, ARDS, and sepsis, to connect SARS and ARDS's mechanisms and therefore elucidate potential novel drugs.\",\n",
              "  'COVID-19, 140, 148,  disease, covid, The Connectivity Map CMap has allowed for the repurposing of drugs based on gene expression values in neurogenerative diseases, cancer, and COVID-19.',\n",
              "  'COVID-19, 173, 181,  disease, covid, Herein, a bioinformatics and systems biology approach are adopted to study the similarities and differences between the whole blood transcriptome in ARDS, SIRS, sepsis, and COVID-19, to highlight possible reusable i.e., repurposed drugs.',\n",
              "  'COVID-19, 90, 98,  disease, covid, Microarray datasets GSE147902, GSE66890, GSE74224, GSE152641 from ARDS, SIRS, sepsis, and COVID-19 whole blood transcriptomes were taken from the GEO database and analyzed using WGCNA through hierarchal clustering to identify significantly co-expressed modules or clusters of co-expressed genes across the aforementioned conditions.',\n",
              "  'COVID-19 infections, 59, 78,  disease, covid, These ailments have been widely reported to be symptoms of COVID-19 infections, and often occur in conjunction with the so-called cytokine storm.',\n",
              "  'COVID-19, 32, 40,  disease, covid, Although the transcriptomics of COVID-19 have been widely studied, the specific mechanisms of cytokine storms have yet to be fully understood.',\n",
              "  \"COVID-19, 49, 57,  disease, covid, The similarities between ARDS, SIRS, sepsis, and COVID-19 were analyzed at the module level using module preservation analysis and functional and pathway enrichment were used to understand The similarities between ARDS, SIRS, sepsis, and COVID-19's biological significance.\",\n",
              "  \"COVID-19, 238, 246,  disease, covid, The similarities between ARDS, SIRS, sepsis, and COVID-19 were analyzed at the module level using module preservation analysis and functional and pathway enrichment were used to understand The similarities between ARDS, SIRS, sepsis, and COVID-19's biological significance.\",\n",
              "  'COVID-19, 62, 70,  disease, covid, Only the genetic similarities between ARDS, SIRS, sepsis, and COVID-19 were considered in this study, and temporal effects or variations were not accounted for.',\n",
              "  'COVID-19, 220, 228,  disease, covid, It is also important to note that the findings in this study are based on generated gene co-expression and PPI networks built from relating immune illnesses, and hence, offer insights into repurposed drugs to treat post-COVID-19 effects i.e., cytokine storms.',\n",
              "  'COVID-19, 9, 17,  disease, covid, Finally, COVID-19 microarray data was taken from GSE177477 which contains the blood transcriptome of 29 COVID-19 patients and 18 healthy controls.',\n",
              "  'COVID-19, 104, 112,  disease, covid, Finally, COVID-19 microarray data was taken from GSE177477 which contains the blood transcriptome of 29 COVID-19 patients and 18 healthy controls.',\n",
              "  'COVID-19, 139, 147,  disease, covid, After construction of the weighted gene co-expression network of the ARDS dataset whose modules served as reference, the sepsis, SIRS, and COVID-19 datasets were projected onto the ARDS dataset whose modules served as reference to analyze module preservation.',\n",
              "  'COVID-19, 137, 145,  disease, covid, To screen possible repurposed drug candidates that are associated with the identified modules of interest across ARDS, SIRS, sepsis, and COVID-19, connectivity map analysis was performed using the Connectivity Map online webserver.',\n",
              "  'COVID-19, 94, 102,  disease, covid, Specifically, the top three genes were taken from each of the identified modules preserved in COVID-19.',\n",
              "  'COVID-19, 231, 239,  disease, covid, Interestingly, the two largest modules, M44 and M1, were enriched in large-scale macromolecule metabolic processes 2295/5606 and chemical stimulus detection 399/1583 A, cellular processes which have been observed to be affected by COVID-19.',\n",
              "  'COVID-19, 138, 146,  disease, covid, To compare the similarity of gene expression at the module level between the four diseases included in this study ARDS, SIRS, Sepsis, and COVID-19, the network constructed based on the ARDS dataset was used as reference for module preservation analysis where other datasets describing SIRS, Sepsis, and COVID-19 whole blood transcriptome expressions were projected onto the ARDS dataset.',\n",
              "  'COVID-19, 303, 311,  disease, covid, To compare the similarity of gene expression at the module level between the four diseases included in this study ARDS, SIRS, Sepsis, and COVID-19, the network constructed based on the ARDS dataset was used as reference for module preservation analysis where other datasets describing SIRS, Sepsis, and COVID-19 whole blood transcriptome expressions were projected onto the ARDS dataset.',\n",
              "  'COVID-19, 184, 192,  disease, covid, Module preservation analysis revealed that the ARDS modules were most significantly preserved in the sepsis dataset B, while only a few modules were strongly preserved in the SIRS and COVID-19 datasets.',\n",
              "  'COVID-19, 273, 281,  disease, covid, Turquoise M1, sky blue M28, violet M32, and dark orange M45 showed moderate preservation while magenta M9, light cyan M16, light green M18, light yellow M19, orange M25, dark olive green M33, yellow green M36, and floral white M44 showed strong preservation B. Finally, in COVID-19, sky blue M28 showed no preservation, orange M25, dark orange M45, violet M32, and dark olive green M33 showed moderate preservation, and turquoise M1, magenta M9, light cyan M16, light green M18, light yellow M19, yellow green M36, and floral white M44 showed strong preservation C. Collectively, the modules strongly preserved in COVID-19 were also strongly preserved in other modules and were therefore selected for further downstream analysis.',\n",
              "  'COVID-19, 614, 622,  disease, covid, Turquoise M1, sky blue M28, violet M32, and dark orange M45 showed moderate preservation while magenta M9, light cyan M16, light green M18, light yellow M19, orange M25, dark olive green M33, yellow green M36, and floral white M44 showed strong preservation B. Finally, in COVID-19, sky blue M28 showed no preservation, orange M25, dark orange M45, violet M32, and dark olive green M33 showed moderate preservation, and turquoise M1, magenta M9, light cyan M16, light green M18, light yellow M19, yellow green M36, and floral white M44 showed strong preservation C. Collectively, the modules strongly preserved in COVID-19 were also strongly preserved in other modules and were therefore selected for further downstream analysis.',\n",
              "  'COVID-19, 160, 168,  disease, covid, Considering that most drugs have mechanism of actions that target proteins, the hub genes were selected by submitting the genes in each module preserved in the COVID-19 dataset to the STRING database for PPI network construction.',\n",
              "  'COVID-19 infections, 67, 86,  disease, covid, Further, cytokine storms have become recent issue with the rise of COVID-19 infections.',\n",
              "  'COVID-19, 227, 235,  disease, covid, Inherently, with the ARDS and SIRS in this present study, a quantitative network-based approach was employed to statistically determine the co-expressed genes across four related diseases ARDS, SIRS and sepsis, and symptomatic COVID-19, using NCBI GEO datasets to investigate the genetic similarities between four related diseases ARDS, SIRS and sepsis to highlight conserved and divergent pathways in cytokine storms and identify candidate repurposed drugs based on gene co-expression data.',\n",
              "  \"COVID-19, 154, 162,  disease, covid, Considering TREM-1's extensive role in regulating the expression of cytokines and that macrophages have been previously linked to symptoms reminiscent of COVID-19, TREM-1 could be another potential therapeutic target for cytokine storms.\",\n",
              "  'COVID-19, 89, 97,  disease, covid, Interestingly, two of the largest modules M1 and M44 were significantly preserved in the COVID-19 dataset.',\n",
              "  'COVID-19 infections, 113, 132,  disease, covid, M1 genes were found to be significantly enriched in olfactory transduction and may contain genes affected during COVID-19 infections leading to the loss of smell and taste.',\n",
              "  'COVID-19, 73, 81,  disease, covid, Several immune-related pathways were also significantly preserved in the COVID-19 dataset alluding to potential conserved mechanisms across four related diseases ARDS, SIRS and sepsis.',\n",
              "  'COVID-19, 206, 214,  disease, covid, These synergism of IFN- and TNF-, which are macrophage activators and are responsible for cell-mediated immunity has been previously shown to be sufficient in inducing cell and tissue damage reminiscent of COVID-19 symptoms.',\n",
              "  'COVID-19, 56, 64,  disease, covid, Thus, M9 is potentially a significant module related to COVID-19 disease severity brought about by cytokine storms.',\n",
              "  'COVID-19, 90, 98,  disease, covid, Chemokine signaling pathways were also found to be significantly preserved in symptomatic COVID-19.',\n",
              "  \"COVID-19, 358, 366,  disease, covid, Several of the chemokine receptors e.g., CXCR3 and CXCR4 have also been shown to be upregulated during cytokine storm-like symptoms as upon binding of Several of the chemokine receptors e.g., CXCR3 and CXCR4's natural ligands e.g., CXCL12, inflammation is promoted and chemotaxis induces apoptosis potentially leading to significant tissue damage as seen in COVID-19 cases.\",\n",
              "  \"COVID-19, 104, 112,  disease, covid, chemokines's overexpression could be a possible mechanism for observed lung tissue damage i.e., ARDS in COVID-19 cases.\",\n",
              "  'COVID-19, 41, 49,  disease, covid, Another pathway conserved in symptomatic COVID-19 is the NOD-like receptor signaling pathway.',\n",
              "  'COVID-19, 65, 73,  disease, covid, this present study was able to utilize preserved gene modules in COVID-19 to identify such drugs.',\n",
              "  'COVID-19, 86, 94,  disease, covid, The MAPK pathway has been a promising target for novel therapeutic approaches against COVID-19 as the loss of ACE2 activity brought about by viral infection leads to overexpression of p38, which leads to inflammation.',\n",
              "  'COVID-19, 36, 44,  disease, covid, Further, a study that treated 22560 COVID-19 patients with histamine antagonists e.g., loratadine resulted in attenuation of cytokine release leading to moderate to significant relief of COVID-19 symptoms, suggesting the potential of antihistamines in treating COVID-19 and cytokine storms in general.',\n",
              "  'COVID-19, 187, 195,  disease, covid, Further, a study that treated 22560 COVID-19 patients with histamine antagonists e.g., loratadine resulted in attenuation of cytokine release leading to moderate to significant relief of COVID-19 symptoms, suggesting the potential of antihistamines in treating COVID-19 and cytokine storms in general.',\n",
              "  'COVID-19, 261, 269,  disease, covid, Further, a study that treated 22560 COVID-19 patients with histamine antagonists e.g., loratadine resulted in attenuation of cytokine release leading to moderate to significant relief of COVID-19 symptoms, suggesting the potential of antihistamines in treating COVID-19 and cytokine storms in general.',\n",
              "  'COVID-19, 93, 101,  disease, covid, This suggests that TPCA-1 could be a good candidate drug for treatment of cytokine storms in COVID-19.',\n",
              "  \"COVID-19, 37, 45,  disease, covid, Such inflammation is also present in COVID-19 patients and thus points to Mepacrine's potential as a therapeutic.\",\n",
              "  'COVID-19, 94, 102,  disease, covid, Recently, antimalarials have also shown some promising results for being repurposed to tackle COVID-19 cytokine storms and the resulting neuroinflammatory symptoms.',\n",
              "  'SARS-CoV-2, 0, 10,  disease, covid, SARS-CoV-2 with the D614G mutation on the spike protein was the main strain analyzed in this study.',\n",
              "  'COVID-19, 104, 112,  disease, covid, Modules were more strongly preserved in the sepsis dataset, and less strongly preserved in the SIRS and COVID-19 datasets.',\n",
              "  'COVID-19, 102, 110,  disease, covid, Among 13 stable gene co-expression modules, M1, M9, M16, M18, M19, and M44 were strongly preserved in COVID-19 and across ARDS, sepsis, and SIRS.'],\n",
              " ['Coronavirus disease 2019, 0, 24,  disease, covid, Coronavirus disease 2019 COVID-19, which was first identified in December 2019, and shortly after, declared a pandemic by World Health Organization WHO.',\n",
              "  'COVID-19, 25, 33,  disease, covid, Coronavirus disease 2019 COVID-19, which was first identified in December 2019, and shortly after, declared a pandemic by World Health Organization WHO.',\n",
              "  'Coronaviruses, 0, 13,  disease, covid, Coronaviruses belong to the family of Coronaviridae, RNA viruses with crown-like spikes on the surface of the coronavirus particles.',\n",
              "  'Coronaviridae, 38, 51,  disease, covid, Coronaviruses belong to the family of Coronaviridae, RNA viruses with crown-like spikes on the surface of the coronavirus particles.',\n",
              "  'coronavirus, 110, 121,  disease, covid, Coronaviruses belong to the family of Coronaviridae, RNA viruses with crown-like spikes on the surface of the coronavirus particles.',\n",
              "  'COVID-19, 69, 77,  disease, covid, According to a meta-analysis of Macedo et al., the mortality rate of COVID-19 was 17.1% for patients admitted to hospitals, whereas World Health Organization WHO estimated a fatality rate of 6.73%, which was much lower than that calculated from published studies.',\n",
              "  'COVID-19, 28, 36,  disease, covid, Among the critical cases of COVID-19, the mortality rate reaches 40%.',\n",
              "  'COVID-19, 69, 77,  disease, covid, Substantial efforts have been made in the treatment of patients with COVID-19.',\n",
              "  'COVID-19, 70, 78,  disease, covid, The World Health Organization WHO recommendations in the treatment of COVID-19 are as follows molnupiravir conditional, baricitinib strong, ruxolitinib and tofacitinib conditional, sotrovimab conditional, casirivimab and imdevimab conditional, IL-6 receptor blockers tocilizumab and sarilumab strong, remdesivir conditional, and systemic corticosteroids strong.',\n",
              "  'COVID-19, 20, 28,  disease, covid, The pathogenesis of COVID-19 was explained by cytokine storm, reduction in ACE2 expression, and activation of complement pathway-induced microvascular injury and thrombosis.',\n",
              "  'COVID-19, 76, 84,  disease, covid, The mechanisms of the recommended agents are focused on The pathogenesis of COVID-19 to improve the clinical outcome of COVID-19, and antiviral therapies are missing.',\n",
              "  'COVID-19, 120, 128,  disease, covid, The mechanisms of the recommended agents are focused on The pathogenesis of COVID-19 to improve the clinical outcome of COVID-19, and antiviral therapies are missing.',\n",
              "  \"anticoronaviral, 4, 19,  disease, covid, The anticoronaviral strategies include preventing the synthesis of viral RNA, inhibiting virus replication, blocking the virus binding to human cell receptors, or inhibiting the viruses' self-assembly process.\",\n",
              "  'SARS-CoV-2, 4, 14,  disease, covid, The SARS-CoV-2 contains at least four structural proteins spike S protein, envelope E protein, membrane M protein, and nucleocapsid N protein, and 16 nonstructural proteins NSPs.',\n",
              "  'coronavirus, 205, 216,  disease, covid, Among 16 nonstructural proteins NSPs, the main protease, also called chymotrypsin-like protease 3C-like protease, and the papain-like protease are two essential proteases for proteolytic processing of the coronavirus replicase polyprotein, therefore generating functional replication complex of The SARS-CoV-2, whereas RNA-dependent RNA polymerase is the central enzyme for RNA synthesis.',\n",
              "  'SARS-CoV-2, 299, 309,  disease, covid, Among 16 nonstructural proteins NSPs, the main protease, also called chymotrypsin-like protease 3C-like protease, and the papain-like protease are two essential proteases for proteolytic processing of the coronavirus replicase polyprotein, therefore generating functional replication complex of The SARS-CoV-2, whereas RNA-dependent RNA polymerase is the central enzyme for RNA synthesis.',\n",
              "  'coronavirus, 39, 50,  disease, covid, These three NSPs play crucial roles in coronavirus replication, making These three NSPs attractive targets for anticoronaviral drug design.',\n",
              "  'anticoronaviral, 111, 126,  disease, covid, These three NSPs play crucial roles in coronavirus replication, making These three NSPs attractive targets for anticoronaviral drug design.',\n",
              "  'coronaviruses, 58, 71,  disease, covid, The S protein, a surface-located trimeric glycoprotein of coronaviruses, promotes the attachment of viruses to host cells through binding to angiotensin-converting enzyme 2 ACE2 and virus-cell membrane fusion during viral infection.',\n",
              "  'coronaviruses, 64, 77,  disease, covid, Thus, The S protein, a surface-located trimeric glycoprotein of coronaviruses, has been considered as a major target for the development of vaccines and drug.',\n",
              "  'COVID-19, 21, 29,  disease, covid, During the spread of COVID-19 outbreak, great efforts have been made in therapeutic drug discovery against COVID-19.',\n",
              "  'COVID-19, 107, 115,  disease, covid, During the spread of COVID-19 outbreak, great efforts have been made in therapeutic drug discovery against COVID-19.',\n",
              "  'COVID-19, 8, 16,  disease, covid, Because COVID-19 is a new, acute, severe infectious disease, the anti-SARS-CoV-2 drug development strategies are to screen existing drugs to identify potentially effective drugs, to expand indications, and to develop a vaccine.',\n",
              "  'SARS-CoV-2, 70, 80,  disease, covid, Because COVID-19 is a new, acute, severe infectious disease, the anti-SARS-CoV-2 drug development strategies are to screen existing drugs to identify potentially effective drugs, to expand indications, and to develop a vaccine.',\n",
              "  'COVID-19, 72, 80,  disease, covid, Therefore, developing broad-spectrum antiviral drugs not only to combat COVID-19 but also to provide protective arsenals against future viral outbreaks is a requirement.',\n",
              "  'SARS-CoV-2, 25, 35,  disease, covid, Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection based on the strategies from preclinical drug discovery.',\n",
              "  'SARS-CoV-2 infection, 116, 136,  disease, covid, Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection based on the strategies from preclinical drug discovery.',\n",
              "  'Coronavirus, 170, 181,  disease, covid, Studies published in PubMed, Scopus, Web of Science, EMBASE, Google Scholar, and DrugBank were searched from December 2019 to March 2021 using the following search terms Coronavirus, COVID-19, SARS-CoV-2, Drug design, Drug development, In silico, In vitro, and In vivo alone or in combination without language restrictions.',\n",
              "  'COVID-19, 183, 191,  disease, covid, Studies published in PubMed, Scopus, Web of Science, EMBASE, Google Scholar, and DrugBank were searched from December 2019 to March 2021 using the following search terms Coronavirus, COVID-19, SARS-CoV-2, Drug design, Drug development, In silico, In vitro, and In vivo alone or in combination without language restrictions.',\n",
              "  'SARS-CoV-2, 193, 203,  disease, covid, Studies published in PubMed, Scopus, Web of Science, EMBASE, Google Scholar, and DrugBank were searched from December 2019 to March 2021 using the following search terms Coronavirus, COVID-19, SARS-CoV-2, Drug design, Drug development, In silico, In vitro, and In vivo alone or in combination without language restrictions.',\n",
              "  'COVID-19, 107, 115,  disease, covid, Study of drug in cell culture medium effectiveness in these studies means inhibition of the replication of COVID-19 by the compound or drug under study.',\n",
              "  'COVID-19, 134, 142,  disease, covid, In this review, we reported a significant number of articles with in silico, in vitro, and in vivo approaches for drug development of COVID-19.',\n",
              "  'SARS-CoV-2, 157, 167,  disease, covid, The analysis of article contents indicated that 266 studies performed in silico approaches against viral targets 34 studies used in vitro approaches against SARS-CoV-2 and 15 studies used in vivo animal models.',\n",
              "  'COVID-19, 161, 169,  disease, covid, From 266 studies, 98 article studies repurposed approved drugs with a new mechanism of action and 91 studies evaluated natural products e.g., herbal medicine on COVID-19.',\n",
              "  'coronavirus, 56, 67,  disease, covid, In silico studies used the following component of novel coronavirus as targets main protease N 154, spike glycoprotein N 62, nonstructural protein N 45, RNA-dependent RNA polymerase N 21, papain-like protease N 19.',\n",
              "  'COVID-19, 65, 73,  disease, covid, About 260 drugs were repurposed by the computational methods for COVID-19 therapy such as about 120 drugs candidate against main protease N 154, 52 drugs against spike glycoprotein N 62, 14 drugs against RNA-dependent RNA polymerase, and 28 drugs against other nonstructural proteins.',\n",
              "  'COVID-19, 41, 49,  disease, covid, shows target-based synthesis of data for COVID-19 drug repurposing.',\n",
              "  'SARS-CoV-2, 123, 133,  disease, covid, A total of 91 studies used in silico methods to evaluate the effects of natural products including herbal medicine against SARS-CoV-2.',\n",
              "  'COVID-19, 175, 183,  disease, covid, From the plant metabolites, oleanolic acid, hesperidin, epigallocatechin gallate, jensenone, tinosponone, and anistone show promising results in computational methods against COVID-19.',\n",
              "  'COVID-19, 107, 115,  disease, covid, Aloe, green tea, eucalyptus, curcumin, and many Chinese, Indian, and African plants were also effective on COVID-19 in silico.',\n",
              "  'COVID-19, 275, 283,  disease, covid, The derivatives of pyrazoles, oxadiazoles, phenyltriazolinones, triazoles, benzoylpinostrobin, benzoic acid, benzylidenechromanones, coumarin, and selenium show efficacy in computational methods and could be considered as lead molecules for drug design and synthesis against COVID-19.',\n",
              "  'SARS-CoV-2, 82, 92,  disease, covid, Most of 34 studies use the Vero E6 cell line for the assessment of replication of SARS-CoV-2.',\n",
              "  'COVID-19, 236, 244,  disease, covid, Nitric oxide, ginkgolic acid, anacardic acid, troxerutin, bisindolylmaleimide derivatives, small molecules GRL-172, and 5 h, baicalin and baicalein phytochemicals, and bepridil were effective drugs in vitro against the main protease of COVID-19.',\n",
              "  'COVID-19, 72, 80,  disease, covid, The following drugs could inhibit the spike/ACE2-mediated cell entry of COVID-19 in vitro romidepsin, panobinostat, givinostat, sirtinol, saquinavir, lipopeptides, hydroxyzine, azelastine, heparin, and glycyrrhizic acid.',\n",
              "  'SARS-CoV-2, 220, 230,  disease, covid, Alkenyl sulfonylurea derivatives, an IMU-8381 inhibitor of human dihydroorotate dehydrogenase, pyrazole derivatives, and phillyrin, regulated the expression of inflammatory cytokines e.g., IL, TNF-, and NF- B induced by SARS-CoV-2 markedly and could be considered as adjuvant treatment of COVID-19 severe disease.',\n",
              "  'COVID-19, 289, 297,  disease, covid, Alkenyl sulfonylurea derivatives, an IMU-8381 inhibitor of human dihydroorotate dehydrogenase, pyrazole derivatives, and phillyrin, regulated the expression of inflammatory cytokines e.g., IL, TNF-, and NF- B induced by SARS-CoV-2 markedly and could be considered as adjuvant treatment of COVID-19 severe disease.',\n",
              "  'SARS-CoV-2, 183, 193,  disease, covid, Doxycycline, chlorpromazine, azithromycin, heparin, bepridil, tannic acid, and glycyrrhizic acid are well-known drugs that show both in silico and in vitro inhibitory effects against SARS-CoV-2 and should be considered for this purpose.',\n",
              "  'SARS-CoV-2, 116, 126,  disease, covid, Also, in vitro studies show that lopinavir/ritonavir, sofosbuvir, and favipiravir have no antiviral effects against SARS-CoV-2 huge gap between in vitro IC50 and free plasma concentration.',\n",
              "  'SARS-CoV-2, 151, 161,  disease, covid, Human monoclonal antibodies were the most evaluated drugs N 4, promote the reduction in viral load in vitro, and prevent infection in animal models of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 175, 185,  disease, covid, A prodrug of hydroxycytidine molnupiravir improved pulmonary function and reduced viral titer in vivo and was introduced as a potential broad-spectrum antiviral agent against SARS-CoV-2.',\n",
              "  'COVID-19, 88, 96,  disease, covid, Dalbavancin shows significant inhibitory ability in both in vitro and in vivo models of COVID-19.',\n",
              "  \"SARS-CoV-2, 74, 84,  disease, covid, Dalbavancin binds directly to ACE2 and blocks ACE2's interaction with the SARS-CoV-2 spike protein.\",\n",
              "  'coronaviruses, 52, 65,  disease, covid, There are several strategies in antiviral drugs for coronaviruses including empirical testing of known antiviral drugs, large-scale phenotypic screening of compound libraries, and target-based drug discovery.',\n",
              "  'anticoronavirus, 63, 78,  disease, covid, To date, an increasing number of drugs have been shown to have anticoronavirus activities in vitro and in vivo, but only remdesivir and several neutralizing antibodies have been approved by the US FDA for treating COVID-19.',\n",
              "  'COVID-19, 214, 222,  disease, covid, To date, an increasing number of drugs have been shown to have anticoronavirus activities in vitro and in vivo, but only remdesivir and several neutralizing antibodies have been approved by the US FDA for treating COVID-19.',\n",
              "  'SARS-CoV-2, 25, 35,  disease, covid, Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection, which have been conducted in basic research in silico and preclinical study in vitro, in vivo.',\n",
              "  'SARS-CoV-2 infection, 116, 136,  disease, covid, Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection, which have been conducted in basic research in silico and preclinical study in vitro, in vivo.',\n",
              "  'COVID-19, 115, 123,  disease, covid, Our database search identified about 3000 studies, which means a global effort for drug development in the current COVID-19 pandemic.',\n",
              "  'COVID-19, 80, 88,  disease, covid, As summarized in the results, many compounds are in the development process for COVID-19 disease.',\n",
              "  'COVID-19, 115, 123,  disease, covid, Some of many compounds are completely new and could serve as seeds or leads for developing antiviral drugs against COVID-19, but as we need therapeutics as soon as possible, half of the studies focused on drug repurposing repositioning, which is a process of investigation of existing drugs for new therapeutic purposes.',\n",
              "  'COVID-19, 32, 40,  disease, covid, With the emergence of a growing COVID-19 pandemic, the drug repurposing process was being accelerated.',\n",
              "  'COVID-19, 80, 88,  disease, covid, According to our results, 260 drugs repurposed by the computational methods for COVID-19, among them saquinavir, ritonavir, and lopinavir, showed the best efficacy in in silico environment.',\n",
              "  \"COVID-19, 74, 82,  disease, covid, These drugs can be rapidly repurposed for clinic application for treating COVID-19 patients given These drugs's proven safety.\",\n",
              "  'COVID-19, 165, 173,  disease, covid, The results of a systematic review and meta-analysis showed that a combination of ritonavir-lopinavir has no more treatment effects than other therapeutic agents in COVID-19 patients and is currently not used anymore.',\n",
              "  'COVID-19, 123, 131,  disease, covid, We could not find any clinical trial on saquinavir, which is the most studied drug in silico and show high potency against COVID-19.',\n",
              "  'COVID-19, 130, 138,  disease, covid, Our results show that various plants have potential antiviral activities and could use or be a basis for drug development against COVID-19.',\n",
              "  'COVID-19, 86, 94,  disease, covid, A systematic review and meta-analysis of RCTs on herbal medicine in the management of COVID-19 show the significant effects of the combined therapy of herbal medicine in treating COVID-19 without any significant side effects.',\n",
              "  'COVID-19, 179, 187,  disease, covid, A systematic review and meta-analysis of RCTs on herbal medicine in the management of COVID-19 show the significant effects of the combined therapy of herbal medicine in treating COVID-19 without any significant side effects.',\n",
              "  'SARS-CoV-2, 89, 99,  disease, covid, some of these studied active ingredients could possibly have an inhibitory effect on the SARS-CoV-2 and COVID-19.',\n",
              "  'COVID-19, 104, 112,  disease, covid, some of these studied active ingredients could possibly have an inhibitory effect on the SARS-CoV-2 and COVID-19.',\n",
              "  'SARS-CoV-2, 88, 98,  disease, covid, Most evaluated chemical compounds had inhibitory effects against one or two proteins of SARS-CoV-2.',\n",
              "  'COVID-19, 172, 180,  disease, covid, Thus, Most evaluated chemical compounds can be applied as extremely safe therapeutic natural compounds and clinical assessments might have notable outcomes for controlling COVID-19.',\n",
              "  'COVID-19, 101, 109,  disease, covid, In terms of mechanism of action, different targets from the structural and nonstructural proteins of COVID-19 were evaluated.',\n",
              "  'SARS-CoV-2, 65, 75,  disease, covid, Apart from the specific protein that leads to viral replication, SARS-CoV-2 causes a surge of pro-inflammatory cytokines and chemokines, which cause damage to lung tissue and deterioration of lung function.',\n",
              "  'COVID-19, 89, 97,  disease, covid, Therefore, the design of a drug with multitarget of action against different proteins of COVID-19 and also anti-inflammatory potential could be valuable.',\n",
              "  'SARS-CoV-2, 69, 79,  disease, covid, Currently, there is no highly efficacious and specific treatment for SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 21, 31,  disease, covid, Due to the nature of SARS-CoV-2 and the rises of several high transmissible strains, repurposing existing drugs has demonstrated power by bringing several drugs to approval for treating COVID-19 patients, such as remdesivir.',\n",
              "  'COVID-19, 186, 194,  disease, covid, Due to the nature of SARS-CoV-2 and the rises of several high transmissible strains, repurposing existing drugs has demonstrated power by bringing several drugs to approval for treating COVID-19 patients, such as remdesivir.',\n",
              "  'SARS-CoV-2 infection, 105, 125,  disease, covid, Our results confirmed that a large number of repurposed agents are currently being explored for treating SARS-CoV-2 infection.',\n",
              "  'COVID-19, 131, 139,  disease, covid, Our results showed that various natural bioactive compounds are being investigated in the preclinical step of drug development for COVID-19.',\n",
              "  'COVID-19, 133, 141,  disease, covid, Therefore, various natural bioactive compounds can be used as extremely safe therapeutic compounds in drug design studies to control COVID-19.',\n",
              "  'SARS-CoV-2, 286, 296,  disease, covid, However, the pharmacological effects and adverse reactions of some drugs under development are still unclear, and hence, well-designed high-quality studies are needed to further study the effectiveness and safety of some drugs under development to accelerate drug development targeting SARS-CoV-2 and thus promote progress towards ending the pandemic.'],\n",
              " ['COVID-19, 0, 8,  disease, covid, COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.',\n",
              "  'Coronaviruses, 44, 57,  disease, covid, COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.',\n",
              "  'Coronaviridae, 65, 78,  disease, covid, COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.',\n",
              "  'severe acute respiratory syndromes, 129, 163,  disease, covid, COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.',\n",
              "  'SARS Cov-2, 164, 174,  disease, covid, COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.',\n",
              "  \"Coronaviruses, 0, 13,  disease, covid, Coronaviruses are named as such because Coronaviruses's surface is characterized by protrusions resembling crowns.\",\n",
              "  \"Coronaviruses, 40, 53,  disease, covid, Coronaviruses are named as such because Coronaviruses's surface is characterized by protrusions resembling crowns.\",\n",
              "  'COVID-19, 46, 54,  disease, covid, Corona was first reported in China Wuhan, and COVID-19 is unlikely to have been transmitted from animal to human in a seafood market.',\n",
              "  \"COVID-19, 67, 75,  disease, covid, The current vaccines are not providing adequate protection against COVID-19 due to logistical difficulties in The current vaccines's distribution, diminishing immunity, and the possibility of transmission from asymptomatic infected patients.\",\n",
              "  'COVID-19, 145, 153,  disease, covid, Drug repurposing is the most efficient method of rapidly identifying the unique clinical applications of currently licensed medications to treat COVID-19.',\n",
              "  'Coronavirus, 4, 15,  disease, covid, The Coronavirus genome is translated into two classes of proteins within the host cell structural proteins such as spikes S, envelopes E, matrixes M, and nucleocapsids N, and nonstructural proteins such as 3-C proteases 3CLpro, NSP5 and RNA Dependent RNA Polymerases RdRp, NSP12.',\n",
              "  'Coronavirus, 194, 205,  disease, covid, Among these proteins, RNA-dependent RNA polymerase RdRp has been demonstrated to contribute significantly to the replication of the viral genome single-stranded RNA and to the multiplication of Coronavirus in various cells.',\n",
              "  'COVID-19, 249, 257,  disease, covid, It has been established that RNA-dependent RNA polymerase RdRp is an essential enzyme that plays a significant role in the replication and translation of viral genomes this makes RNA-dependent RNA polymerase RdRp an excellent therapeutic target for COVID-19.',\n",
              "  'COVID-19, 41, 49,  disease, covid, Numerous clinical trials have shown that COVID-19 can be effectively treated with antiviral, antimalarial, and anti-HIV drugs.',\n",
              "  'COVID-19, 53, 61,  disease, covid, The FDA has approved Remdesivir Veklury for treating COVID-19 in hospitalized patients aged 12 and older and weighing at least 40 kg.',\n",
              "  'SARS-CoV-2, 36, 46,  disease, covid, Several viral infections, including SARS-CoV-2, have been successfully treated with Remdesivir Veklury.',\n",
              "  'COVID-19 infection, 177, 195,  disease, covid, In a comprehensive two-tier screening approach, Yuan et al. demonstrated that FDA-approved medications cetilistat, abiraterone, diiodohydroxyquinoline, and bexarotene inhibited COVID-19 infection in vitro.',\n",
              "  'SARS-CoV-2, 292, 302,  disease, covid, As part of a comprehensive two-tier screening approach, Yuan et al. this study the interaction between four FDA-approved medications, bexarotene anticancer retinoid, abiraterone synthetic androstenedione steroid, diiodohydroxyquinoline antiparasite, and cetilistat antipancreatic lipase with SARS-CoV-2 RdRp using docking simulation.',\n",
              "  \"COVID-19, 98, 106,  disease, covid, In light of Yuan et al.'s findings, Yuan et al. may be able to develop a new method for combating COVID-19.\",\n",
              "  'SARS-CoV-2, 43, 53,  disease, covid, The screening of the drugs against RdRp of SARS-CoV-2 was performed by AutoDock Vina with MGL tools 1.5.4 which makes more precise docking calculations and runs faster than AutoDock software.',\n",
              "  'SARS-CoV-2, 50, 60,  disease, covid, To perform molecular docking analysis the RdRp of SARS-CoV-2 was converted into PDBQT format.pdbqt.',\n",
              "  'SARS-CoV-2, 107, 117,  disease, covid, Because molecular docking results revealed that bexarotene has the best energy in interaction with RdRp of SARS-CoV-2, Yuan et al. investigated the molecular dynamic simulation of bexarotene with protein.',\n",
              "  'SARS-CoV-2, 142, 152,  disease, covid, We recently reported the in-silico screening of bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir against different SARS-CoV-2 drug targets.',\n",
              "  \"SARS-CoV-2, 242, 252,  disease, covid, The current study used the same strategy to screen the bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir for bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir's potential to inhibit RdRp of SARS-CoV-2, thereby filling the gap.\",\n",
              "  'SARS-CoV-2, 164, 174,  disease, covid, Molecular docking simulation was used to predict the binding of the selected drugs bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir with SARS-CoV-2 RdRp-RNA protein.',\n",
              "  'SARS-CoV-2, 63, 73,  disease, covid, Recently, researchers reported virtual screening inhibitors of SARS-CoV-2 RdRp.',\n",
              "  'SARS-CoV-2, 118, 128,  disease, covid, the FDA-approved RdRp inhibitor drug remdesivir is effective against many RNA viruses, including the newly discovered SARS-CoV-2 COVID-19 and previous coronaviruses.',\n",
              "  'COVID-19, 129, 137,  disease, covid, the FDA-approved RdRp inhibitor drug remdesivir is effective against many RNA viruses, including the newly discovered SARS-CoV-2 COVID-19 and previous coronaviruses.',\n",
              "  'coronaviruses, 151, 164,  disease, covid, the FDA-approved RdRp inhibitor drug remdesivir is effective against many RNA viruses, including the newly discovered SARS-CoV-2 COVID-19 and previous coronaviruses.',\n",
              "  'SARS-CoV-2, 111, 121,  disease, covid, We hypothesized that bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir could disrupt SARS-CoV-2 RdRp.',\n",
              "  'SARS-CoV-2, 81, 91,  disease, covid, Gastrointestinal complaints have been reported in 15–20% of the newly discovered SARS-CoV-2 COVID-19 patients, and some of 15–20% of COVID-19 patients have also shown infectious virus particles and identifiable viral RNA.',\n",
              "  'COVID-19, 92, 100,  disease, covid, Gastrointestinal complaints have been reported in 15–20% of the newly discovered SARS-CoV-2 COVID-19 patients, and some of 15–20% of COVID-19 patients have also shown infectious virus particles and identifiable viral RNA.',\n",
              "  'COVID-19, 133, 141,  disease, covid, Gastrointestinal complaints have been reported in 15–20% of the newly discovered SARS-CoV-2 COVID-19 patients, and some of 15–20% of COVID-19 patients have also shown infectious virus particles and identifiable viral RNA.',\n",
              "  'SARS-CoV-2, 21, 31,  disease, covid, In the intestines of SARS-CoV-2-infected hamsters, high levels of viral nucleocapsid protein, inflammatory processes, and identifiable viral RNA were found.',\n",
              "  'SARS-CoV-2 infection, 232, 252,  disease, covid, Cetilistat, a pancreatic lipase inhibitor and oral diiodohydroxyquinoline may be effective topical luminal antivirals in suppressing viral shedding in the gastrointestinal system in the same way feces may be a significant source of SARS-CoV-2 infection.',\n",
              "  'coronaviruses, 219, 232,  disease, covid, As described by Yuan et al., members of the same medication class as bexarotene, such as tamibarotene and AM580, have demonstrated outstanding antiviral effectiveness against several viruses, including influenza, Zika, coronaviruses SARS-CoV and MERS-CoV, adenoviruses, and enterovirus A71.',\n",
              "  'SARS-CoV, 233, 241,  disease, covid, As described by Yuan et al., members of the same medication class as bexarotene, such as tamibarotene and AM580, have demonstrated outstanding antiviral effectiveness against several viruses, including influenza, Zika, coronaviruses SARS-CoV and MERS-CoV, adenoviruses, and enterovirus A71.',\n",
              "  'MERS-CoV, 246, 254,  disease, covid, As described by Yuan et al., members of the same medication class as bexarotene, such as tamibarotene and AM580, have demonstrated outstanding antiviral effectiveness against several viruses, including influenza, Zika, coronaviruses SARS-CoV and MERS-CoV, adenoviruses, and enterovirus A71.',\n",
              "  'SARS-CoV-2, 67, 77,  disease, covid, The binding energy values of the five compounds mentioned with the SARS-CoV-2 RdRp protein are shown in.',\n",
              "  'SARS-CoV-2, 16, 26,  disease, covid, As evident, The SARS-CoV-2 RdRp protein had hydrophobic interactions with abiraterone and bexarotene.',\n",
              "  'SARS-CoV-2, 90, 100,  disease, covid, Meanwhile, cetilistat, diiodohydroxyquinoline, and remdesivir interacted with the RdRp of SARS-CoV-2 via hydrogen bonds and hydrophobic interactions.',\n",
              "  'SARS-CoV-2, 80, 90,  disease, covid, The chosen drugs interacted with various amino acid residues of the RdRp of the SARS-CoV-2 protein.',\n",
              "  'SARS-CoV-2, 62, 72,  disease, covid, These interactions can disrupt the biological activity of the SARS-CoV-2 protein RdRp, and, consequently, the viral replication process.',\n",
              "  'SARS-CoV-2, 59, 69,  disease, covid, Bexarotene may be a candidate for blocking the RdRp of the SARS-CoV-2 receptor, as shown by the results mentioned above.',\n",
              "  'COVID-19, 218, 226,  disease, covid, Because FDA-approved medications have already been evaluated in terms of toxicity and safety in humans for the treatment of various diseases, repurposing FDA-approved medications will be the best option for developing COVID-19 therapies at this time.',\n",
              "  'SARS-CoV-2, 175, 185,  disease, covid, This research computationally evaluated the inhibitory potential of the FDA-approved drugs bexarotene, diiodohydroxyquinoline, abiraterone, and cetilistat against RdRp of the SARS-CoV-2 receptor.',\n",
              "  'COVID-19, 219, 227,  disease, covid, With further ex vivo and in vivo examinations, our finding suggests that the FDA-approved drugs bexarotene, diiodohydroxyquinoline, abiraterone, and cetilistat could be the potential drug of choice for the treatment of COVID-19.',\n",
              "  'SARS-CoV-2, 106, 116,  disease, covid, Gromacs software was used in This research to simulate the interaction of bexarotene with the RdRp of the SARS-CoV-2 receptor.',\n",
              "  'SARS-CoV-2, 33, 43,  disease, covid, Furthermore, the the RdRp of the SARS-CoV-2 receptor-Bex radius of gyration has values that indicate the systems’ stability.'],\n",
              " ['coronavirus, 8, 19,  disease, covid, A novel coronavirus CoV first appeared by the end of 2019 in Wuhan, China and spread to over 70000 individuals with 1800 death cases within the matter of first 50 days of the disease.',\n",
              "  'CoV, 20, 23,  disease, covid, A novel coronavirus CoV first appeared by the end of 2019 in Wuhan, China and spread to over 70000 individuals with 1800 death cases within the matter of first 50 days of the disease.',\n",
              "  'coronavirus, 99, 110,  disease, covid, The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.',\n",
              "  'CoV, 111, 114,  disease, covid, The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.',\n",
              "  'severe acute respiratory syndrome, 132, 165,  disease, covid, The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.',\n",
              "  'coronavirus-1, 166, 179,  disease, covid, The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.',\n",
              "  'SARS-CoV-1, 180, 190,  disease, covid, The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.',\n",
              "  'coronavirus, 8, 19,  disease, covid, A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "  'CoV, 20, 23,  disease, covid, A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "  'severe acute respiratory syndrome, 37, 70,  disease, covid, A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "  'coronavirus, 71, 82,  disease, covid, A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 85, 95,  disease, covid, A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "  'Covid-19, 194, 202,  disease, covid, A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 203, 213,  disease, covid, A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "  'severe acute respiratory syndrome, 0, 33,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 is a variant of coronavirus with enveloped single-stranded RNA which bears a corona like structure of spikes as shown in a. The main host protein for the attachment of spikes has identified as angiotensin converting enzyme 2 ACE2 receptor.',\n",
              "  'coronavirus, 34, 45,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 is a variant of coronavirus with enveloped single-stranded RNA which bears a corona like structure of spikes as shown in a. The main host protein for the attachment of spikes has identified as angiotensin converting enzyme 2 ACE2 receptor.',\n",
              "  'SARS-CoV-2, 48, 58,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 is a variant of coronavirus with enveloped single-stranded RNA which bears a corona like structure of spikes as shown in a. The main host protein for the attachment of spikes has identified as angiotensin converting enzyme 2 ACE2 receptor.',\n",
              "  'coronavirus, 75, 86,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 is a variant of coronavirus with enveloped single-stranded RNA which bears a corona like structure of spikes as shown in a. The main host protein for the attachment of spikes has identified as angiotensin converting enzyme 2 ACE2 receptor.',\n",
              "  'severe acute respiratory syndrome, 0, 33,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 evolved to become the most contagious and infectious among coronavirus family.',\n",
              "  'coronavirus, 34, 45,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 evolved to become the most contagious and infectious among coronavirus family.',\n",
              "  'SARS-CoV-2, 48, 58,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 evolved to become the most contagious and infectious among coronavirus family.',\n",
              "  'coronavirus, 118, 129,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 evolved to become the most contagious and infectious among coronavirus family.',\n",
              "  'severe acute respiratory syndrome, 0, 33,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 enters the lungs by inhaling the contaminated air with viral bodies and infects distal airway cells leading to further spread towards alveolar epithelial cells and causes the damage starting from infection to severe damage as shown in a. As of May 25, 2021, total number of Covid-19 cases reported have surpassed the 30 million cases globally with 1.6 % in US only.',\n",
              "  'coronavirus, 34, 45,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 enters the lungs by inhaling the contaminated air with viral bodies and infects distal airway cells leading to further spread towards alveolar epithelial cells and causes the damage starting from infection to severe damage as shown in a. As of May 25, 2021, total number of Covid-19 cases reported have surpassed the 30 million cases globally with 1.6 % in US only.',\n",
              "  'SARS-CoV-2, 48, 58,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 enters the lungs by inhaling the contaminated air with viral bodies and infects distal airway cells leading to further spread towards alveolar epithelial cells and causes the damage starting from infection to severe damage as shown in a. As of May 25, 2021, total number of Covid-19 cases reported have surpassed the 30 million cases globally with 1.6 % in US only.',\n",
              "  'Covid-19, 333, 341,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 enters the lungs by inhaling the contaminated air with viral bodies and infects distal airway cells leading to further spread towards alveolar epithelial cells and causes the damage starting from infection to severe damage as shown in a. As of May 25, 2021, total number of Covid-19 cases reported have surpassed the 30 million cases globally with 1.6 % in US only.',\n",
              "  'Covid-19, 49, 57,  disease, covid, Moreover, in the wake of current situation novel Covid-19 severe acute respiratory syndrome coronavirus 2 has infected around 526.7 million people and have caused more than 6 million deaths globally.',\n",
              "  'severe acute respiratory syndrome, 58, 91,  disease, covid, Moreover, in the wake of current situation novel Covid-19 severe acute respiratory syndrome coronavirus 2 has infected around 526.7 million people and have caused more than 6 million deaths globally.',\n",
              "  'coronavirus, 92, 103,  disease, covid, Moreover, in the wake of current situation novel Covid-19 severe acute respiratory syndrome coronavirus 2 has infected around 526.7 million people and have caused more than 6 million deaths globally.',\n",
              "  'Covid-19, 32, 40,  disease, covid, In an emergency situations like Covid-19 de novo drug development is not the feasible option since there is urgent need to find the treatments which can be immediately prescribed to prevent the mortality and morbidity.',\n",
              "  'Covid-19, 107, 115,  disease, covid, So, to face the crisis because of pandemic drug repurposing seems a tangible strategy for fighting against Covid-19 and other such viral diseases.',\n",
              "  'Covid-19, 39, 47,  disease, covid, Additionally, articles summarizing the Covid-19 drug repurposing using machine learning and deep learning, methods are published as well.',\n",
              "  'Covid-19, 139, 147,  disease, covid, To the best of our knowledge, until now there is no review study until now has published which summarizes the drug repurposing studies for Covid-19 with special emphasis on network-based drug repurposing approaches to Covid-19.',\n",
              "  'Covid-19, 218, 226,  disease, covid, To the best of our knowledge, until now there is no review study until now has published which summarizes the drug repurposing studies for Covid-19 with special emphasis on network-based drug repurposing approaches to Covid-19.',\n",
              "  'Covid-19, 251, 259,  disease, covid, Thus, this review is mainly focused to bridge the gap by providing overview of machine learning and deep learning approaches to drug repurposing with focus on recent developments in network-based drug repurposing methods, tools, and databases used in Covid-19 as shown in b. In this connection, first we present an overview to computational drug repurposing studies for Covid-19 along with drug and disease related databases followed by recent machine learning and deep learning-based drug repurposing studies.',\n",
              "  'Covid-19, 370, 378,  disease, covid, Thus, this review is mainly focused to bridge the gap by providing overview of machine learning and deep learning approaches to drug repurposing with focus on recent developments in network-based drug repurposing methods, tools, and databases used in Covid-19 as shown in b. In this connection, first we present an overview to computational drug repurposing studies for Covid-19 along with drug and disease related databases followed by recent machine learning and deep learning-based drug repurposing studies.',\n",
              "  \"Covid-19, 60, 68,  disease, covid, Moreover, recent network-based drug repurposing studies for Covid-19 are discussed and recent network-based drug repurposing studies for Covid-19's limitations, benefits, and tools used are summarized.\",\n",
              "  \"Covid-19, 137, 145,  disease, covid, Moreover, recent network-based drug repurposing studies for Covid-19 are discussed and recent network-based drug repurposing studies for Covid-19's limitations, benefits, and tools used are summarized.\",\n",
              "  'Covid-19, 105, 113,  disease, covid, Finally, limitations and future recommendation for improved outcome of network-based drug repurposing in Covid-19 and in general are discussed followed by conclusion.',\n",
              "  'Covid-19, 66, 74,  disease, covid, Some of the machine learning methods used for drug repurposing in Covid-19 include k-nearest neighbors, random forest, support vector machine, and more.',\n",
              "  'Covid-19, 71, 79,  disease, covid, Various deep learning algorithms utilized in finding treatment against Covid-19 includes artificial neural networks ANN, convolutional neural networks CNN, and long short-term memory LSTM.',\n",
              "  'Covid-19, 67, 75,  disease, covid, Apart from this, to accelerate the process of drug development for Covid-19, machine learning based molecular docking frameworks were utilized on approved as well as new chemical entities.',\n",
              "  'Covid-19, 213, 221,  disease, covid, a feature enriched drug repurposing framework named SperoPredictor which consisted multiple state of art machine learning algorithms as shown in b. was deployed to predict the potential drugs to be repurposed for Covid-19, NASH, and renal fibrosis.',\n",
              "  'Covid-19, 11, 19,  disease, covid, In case of Covid-19, 25 potential candidate drugs were predicted.',\n",
              "  'Covid-19, 112, 120,  disease, covid, Literature survey of peer reviewed journals, databases, and patents suggested 12/25 drugs were already used for Covid-19.',\n",
              "  'Covid-19, 273, 281,  disease, covid, The a feature enriched drug repurposing framework named SperoPredictor which consisted multiple state of art machine learning algorithms as shown in b. results testify the usefulness of having such platforms that can be readily deployed in case of emergent situations like Covid-19.',\n",
              "  'Covid-19, 46, 54,  disease, covid, Another study designed to predict the DTIs in Covid-19 is given in.',\n",
              "  \"Covid-19, 46, 54,  disease, covid, Another study designed to predict the DTIs in Covid-19 avails the proteins and drugs provided in the proteins and drugs's structured format.\",\n",
              "  'Covid-19, 123, 131,  disease, covid, Then the developed model was compared with existing studies using k-fold cross validation b. To deploy the developed model Covid-19 was selected as a case study.',\n",
              "  'Covid-19, 98, 106,  disease, covid, the developed model was deployed as shown in c on the proteins known to have been involved in the Covid-19 to predict the possible interactions or drug-target interactions.',\n",
              "  'Covid-19, 60, 68,  disease, covid, the developed model was further deployed to drugs active in Covid-19 and drugs active in Covid-19 were predicted with 100 % accuracy.',\n",
              "  'Covid-19, 89, 97,  disease, covid, the developed model was further deployed to drugs active in Covid-19 and drugs active in Covid-19 were predicted with 100 % accuracy.',\n",
              "  'Covid-19, 35, 43,  disease, covid, The interaction of drugs active in Covid-19 was shown with ACE2,, self-membrane protein, a key player in Covid-19 enabling disease infection.',\n",
              "  'Covid-19, 105, 113,  disease, covid, The interaction of drugs active in Covid-19 was shown with ACE2,, self-membrane protein, a key player in Covid-19 enabling disease infection.',\n",
              "  'Covid-19, 62, 70,  disease, covid, Machine learning plays a key role in drug repurposing against Covid-19 and pace of research in the field has skyrocketed since the emergence of Covid-19.',\n",
              "  'Covid-19, 144, 152,  disease, covid, Machine learning plays a key role in drug repurposing against Covid-19 and pace of research in the field has skyrocketed since the emergence of Covid-19.',\n",
              "  'Covid-19, 115, 123,  disease, covid, Robust and efficient computational methods making use deep learning are widely required for drug discovery against Covid-19.',\n",
              "  'Covid-19, 143, 151,  disease, covid, Convolutional neural networks and recursive neural networks have been widely used in bioinformatics studies with successful results such as in Covid-19,.',\n",
              "  'Covid-19, 77, 85,  disease, covid, Deep learning methods have also been widely used in drug repurposing against Covid-19.',\n",
              "  'Covid-19, 44, 52,  disease, covid, A recent work involving drug repurposing in Covid-19 using deep learning is given in and are given in.',\n",
              "  'Covid-19, 177, 185,  disease, covid, deep learning model named as Molecule Transformer-Drug Target Interaction MT-DTI predicted several commercially available or in practice anti-viral drugs having potency against Covid-19 protein targets confirmed by the pre-clinical validation assays of Covid-19. deep learning model named as Molecule Transformer-Drug Target Interaction MT-DTI was deployed for the selection of compounds from 1400 FDA approved drugs having the strong affinity against the host cellular targets for viral diseases.',\n",
              "  'Covid-19, 253, 261,  disease, covid, deep learning model named as Molecule Transformer-Drug Target Interaction MT-DTI predicted several commercially available or in practice anti-viral drugs having potency against Covid-19 protein targets confirmed by the pre-clinical validation assays of Covid-19. deep learning model named as Molecule Transformer-Drug Target Interaction MT-DTI was deployed for the selection of compounds from 1400 FDA approved drugs having the strong affinity against the host cellular targets for viral diseases.',\n",
              "  'Covid-19, 145, 153,  disease, covid, Another deep learning-based drug repurposing study done in used deep learning on a massive knowledge graph to identify and select promising anti-Covid-19 drug candidates.',\n",
              "  'Covid-19, 106, 114,  disease, covid, 41 repurposed drug candidates include dexamethasone an anti-inflammatory agent having bioactivity against Covid-19 and Niclosamide validated by proteomics of Covid-19 infected cell and gene expression.',\n",
              "  'Covid-19 infected, 158, 175,  disease, covid, 41 repurposed drug candidates include dexamethasone an anti-inflammatory agent having bioactivity against Covid-19 and Niclosamide validated by proteomics of Covid-19 infected cell and gene expression.',\n",
              "  'Covid-19, 139, 147,  disease, covid, Drug candidate such as pralatrexate and azithromycin predicted from One such study were validated in in-vitro testing and found to inhibit Covid-19.',\n",
              "  'Covid-19, 27, 35,  disease, covid, First drug was active once Covid-19 entered host cells while azithromycin has efficacy in before and after stages.',\n",
              "  'Covid-19, 107, 115,  disease, covid, To demonstrate the drug design features of software tools MolAICal, membrane protein glucagon receptor and Covid-19 main protease were modelled.',\n",
              "  'Covid-19, 134, 142,  disease, covid, Using the proposed method in study led to identification of 1000 top ranked potential drug compound supposed to have efficacy against Covid-19 Mpro.',\n",
              "  'Covid-19, 54, 62,  disease, covid, DL has helped in finding the repurposed drugs against Covid-19 and in other pathogens however certain challenges still exist.',\n",
              "  'coronaviruses, 6, 19,  disease, covid, Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "  'HCoV, 20, 24,  disease, covid, Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "  'severe acute respiratory syndrome, 33, 66,  disease, covid, Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "  'coronavirus, 67, 78,  disease, covid, Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "  'SARS-CoV, 79, 87,  disease, covid, Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "  'coronavirus, 103, 114,  disease, covid, Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "  'Covid-19, 115, 123,  disease, covid, Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 144, 154,  disease, covid, Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "  'severe acute respiratory syndrome, 0, 33,  disease, covid, severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "  'coronavirus, 34, 45,  disease, covid, severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "  'SARS-CoV, 46, 54,  disease, covid, severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "  'coronavirus, 69, 80,  disease, covid, severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "  'severe acute respiratory syndrome, 164, 197,  disease, covid, severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "  'coronavirus, 198, 209,  disease, covid, severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "  'SARS-CoV., 210, 219,  disease, covid, severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "  'coronavirus 2019, 236, 252,  disease, covid, severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "  'nCoV, 253, 257,  disease, covid, severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "  'coronavirus, 139, 150,  disease, covid, Instead of highly accelerated efforts in the field of drug research, until now there is only drug approved for the treatment of novel 2019 coronavirus Covid-19.',\n",
              "  'Covid-19, 151, 159,  disease, covid, Instead of highly accelerated efforts in the field of drug research, until now there is only drug approved for the treatment of novel 2019 coronavirus Covid-19.',\n",
              "  'Covid-19, 176, 184,  disease, covid, Over the period, multiple techniques based on machine learning, deep learning, mining, and network or graph-based approaches have been widely used to repurpose the drugs for a Covid-19.',\n",
              "  'coronavirus, 177, 188,  disease, covid, Herein, we provide the comprehensive review along with benefits, challenges, and future directions of network science-based drug repurposing studies specifically for novel 2019 coronavirus Covid-19.',\n",
              "  'Covid-19, 189, 197,  disease, covid, Herein, we provide the comprehensive review along with benefits, challenges, and future directions of network science-based drug repurposing studies specifically for novel 2019 coronavirus Covid-19.',\n",
              "  'Covid-19, 68, 76,  disease, covid, network science-based drug repurposing studies specifically for the Covid-19 are divided in to three categories based on network proximity, network diffusion, and artificial intelligence.',\n",
              "  \"coronavirus, 457, 468,  disease, covid, Network proximity-based drug repurposing studies use the proximity measures such as network centralities, node degree, and more for identifying and providing the key protein-protein, drug-drug, or drug-target associations to repurpose the drugs a i. One of the recent studies done in presented a powerful network-based drug methodologies for identification of potential repurposable drugs and potential repurposable drugs's combination targeting novel 2019 coronavirus Covid-19.\",\n",
              "  \"Covid-19, 469, 477,  disease, covid, Network proximity-based drug repurposing studies use the proximity measures such as network centralities, node degree, and more for identifying and providing the key protein-protein, drug-drug, or drug-target associations to repurpose the drugs a i. One of the recent studies done in presented a powerful network-based drug methodologies for identification of potential repurposable drugs and potential repurposable drugs's combination targeting novel 2019 coronavirus Covid-19.\",\n",
              "  'HCoV-host, 100, 109,  disease, covid, Presented anti-viral and integrated repurposing methodology mainly quantified the interplay between HCoV-host proteins and drug targets in human protein-protein interactions PPI.',\n",
              "  'HCoV-host, 58, 67,  disease, covid, Use of network proximity analysis as shown in b i between HCoV-host targets and drug targets in human PPI led to prioritization of 16 anti-HCoV drugs potentially repurposable.',\n",
              "  'anti-HCoV, 134, 143,  disease, covid, Use of network proximity analysis as shown in b i between HCoV-host targets and drug targets in human PPI led to prioritization of 16 anti-HCoV drugs potentially repurposable.',\n",
              "  'coronavirus, 139, 150,  disease, covid, Despite successful results, One of the recent studies done in suffered from limitations such as, lack of known host proteins on novel 2019 coronavirus Covid-19, a low binding affinity value of 10 M was used to specify the DTI.',\n",
              "  'Covid-19, 151, 159,  disease, covid, Despite successful results, One of the recent studies done in suffered from limitations such as, lack of known host proteins on novel 2019 coronavirus Covid-19, a low binding affinity value of 10 M was used to specify the DTI.',\n",
              "  'coronavirus, 143, 154,  disease, covid, Another network proximity-based drug repurposing study is given in which used network medicine-based approach to repurpose drugs in novel 2019 coronavirus Covid-19.',\n",
              "  'Covid-19, 155, 163,  disease, covid, Another network proximity-based drug repurposing study is given in which used network medicine-based approach to repurpose drugs in novel 2019 coronavirus Covid-19.',\n",
              "  'coronavirus, 181, 192,  disease, covid, Another network proximity-based drug repurposing study enriched the PPI with transcriptomics and proteomics and then performed network proximity measurement where broach novel 2019 coronavirus Covid-19 associated underlying pathogenesis of disease manifestation was explored.',\n",
              "  'Covid-19, 193, 201,  disease, covid, Another network proximity-based drug repurposing study enriched the PPI with transcriptomics and proteomics and then performed network proximity measurement where broach novel 2019 coronavirus Covid-19 associated underlying pathogenesis of disease manifestation was explored.',\n",
              "  'coronavirus, 163, 174,  disease, covid, Here, the associations between 6 different diseases consisting of autoimmune, malignant, cancer, cardiovascular, metabolic, neurological, pulmonary and novel 2019 coronavirus Covid-19 were created.',\n",
              "  'Covid-19, 175, 183,  disease, covid, Here, the associations between 6 different diseases consisting of autoimmune, malignant, cancer, cardiovascular, metabolic, neurological, pulmonary and novel 2019 coronavirus Covid-19 were created.',\n",
              "  \"coronavirus, 170, 181,  disease, covid, Created network was analyzed followed by the single-cell RNA sequencing to uncover the underlying pathobiological and pathophysiological relationships between novel 2019 coronavirus Covid-19 and novel 2019 coronavirus Covid-19's associated treatments.\",\n",
              "  \"Covid-19, 182, 190,  disease, covid, Created network was analyzed followed by the single-cell RNA sequencing to uncover the underlying pathobiological and pathophysiological relationships between novel 2019 coronavirus Covid-19 and novel 2019 coronavirus Covid-19's associated treatments.\",\n",
              "  \"coronavirus, 206, 217,  disease, covid, Created network was analyzed followed by the single-cell RNA sequencing to uncover the underlying pathobiological and pathophysiological relationships between novel 2019 coronavirus Covid-19 and novel 2019 coronavirus Covid-19's associated treatments.\",\n",
              "  \"Covid-19, 218, 226,  disease, covid, Created network was analyzed followed by the single-cell RNA sequencing to uncover the underlying pathobiological and pathophysiological relationships between novel 2019 coronavirus Covid-19 and novel 2019 coronavirus Covid-19's associated treatments.\",\n",
              "  'SARS-CoV-2, 204, 214,  disease, covid, Although not significant, network proximity results in Another network proximity-based drug repurposing study showed that rheumatoid arthritis has small network proximities negative Z scores across all 5 SARS-CoV-2 datasets.',\n",
              "  'coronavirus, 171, 182,  disease, covid, This type of muti-layered validation of the network predicted drugs find out the key repurposable drugs supposed to have potential to reverse the expression of novel 2019 coronavirus Covid-19 expressed genes.',\n",
              "  'Covid-19, 183, 191,  disease, covid, This type of muti-layered validation of the network predicted drugs find out the key repurposable drugs supposed to have potential to reverse the expression of novel 2019 coronavirus Covid-19 expressed genes.',\n",
              "  'SARS-CoV-2, 101, 111,  disease, covid, In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.',\n",
              "  'SARS2, 121, 126,  disease, covid, In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.',\n",
              "  'SARS2, 132, 137,  disease, covid, In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.',\n",
              "  'HCoV-PPI, 143, 151,  disease, covid, In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.',\n",
              "  'SARS2, 157, 162,  disease, covid, In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.',\n",
              "  'SARS-CoV-2, 53, 63,  disease, covid, These drugs were significantly proximal to 2 or more SARS-CoV-2 host protein sets.',\n",
              "  'SARS-CoV-2, 58, 68,  disease, covid, Additionally, Knowledge of the complex interplays between SARS-CoV-2 targets and human diseases indicate possibilities of drug repurposing, as the drugs that target other diseases could potentially target SARS-CoV-2 through the shared functional PPI networks.',\n",
              "  'SARS-CoV-2, 205, 215,  disease, covid, Additionally, Knowledge of the complex interplays between SARS-CoV-2 targets and human diseases indicate possibilities of drug repurposing, as the drugs that target other diseases could potentially target SARS-CoV-2 through the shared functional PPI networks.',\n",
              "  'coronavirus, 178, 189,  disease, covid, Some studies are combining different network approaches for improved results such as done in which aims to captures the bigger picture of human molecular landscape of novel 2019 coronavirus Covid-19 infection by exploiting the network medicine approach as strategy to repurpose the drugs for novel 2019 coronavirus Covid-19.',\n",
              "  'Covid-19 infection, 190, 208,  disease, covid, Some studies are combining different network approaches for improved results such as done in which aims to captures the bigger picture of human molecular landscape of novel 2019 coronavirus Covid-19 infection by exploiting the network medicine approach as strategy to repurpose the drugs for novel 2019 coronavirus Covid-19.',\n",
              "  'coronavirus, 303, 314,  disease, covid, Some studies are combining different network approaches for improved results such as done in which aims to captures the bigger picture of human molecular landscape of novel 2019 coronavirus Covid-19 infection by exploiting the network medicine approach as strategy to repurpose the drugs for novel 2019 coronavirus Covid-19.',\n",
              "  'Covid-19, 315, 323,  disease, covid, Some studies are combining different network approaches for improved results such as done in which aims to captures the bigger picture of human molecular landscape of novel 2019 coronavirus Covid-19 infection by exploiting the network medicine approach as strategy to repurpose the drugs for novel 2019 coronavirus Covid-19.',\n",
              "  'coronavirus, 74, 85,  disease, covid, As a starting point, experimentally validated host proteins of novel 2019 coronavirus Covid-19 known to have viral interaction, tissue specific gene expression data, were explored by use of techniques such as connectivity significance, network diffusion, and network propagation.',\n",
              "  'Covid-19, 86, 94,  disease, covid, As a starting point, experimentally validated host proteins of novel 2019 coronavirus Covid-19 known to have viral interaction, tissue specific gene expression data, were explored by use of techniques such as connectivity significance, network diffusion, and network propagation.',\n",
              "  'coronavirus, 113, 124,  disease, covid, This process was followed to rank genes followed repurposing drugs targeting genes as a treatment for novel 2019 coronavirus Covid-19.',\n",
              "  'Covid-19, 125, 133,  disease, covid, This process was followed to rank genes followed repurposing drugs targeting genes as a treatment for novel 2019 coronavirus Covid-19.',\n",
              "  'coronavirus, 100, 111,  disease, covid, The prioritized collection of genes which served as key drug targets for repurposed anti-novel 2019 coronavirus Covid-19 drugs responsible for causing pharmacological effect resulted from normalization and aggregation of different scoring methods.',\n",
              "  'Covid-19, 112, 120,  disease, covid, The prioritized collection of genes which served as key drug targets for repurposed anti-novel 2019 coronavirus Covid-19 drugs responsible for causing pharmacological effect resulted from normalization and aggregation of different scoring methods.',\n",
              "  'Covid-19, 61, 69,  disease, covid, Additionally, another network-based repurposing approach for Covid-19 done in was conducted by integrating GWAS and text mining the data.',\n",
              "  'Covid-19, 50, 58,  disease, covid, Here lung-specified gene subnetwork enriched with Covid-19 gene associated data obtained from GWAS was created to screen 220 FDA approved drugs obtained from DrugBank database.',\n",
              "  'Covid-19, 114, 122,  disease, covid, This led to prioritization of 220 FDA approved drugs obtained from DrugBank database as a potential treatment for Covid-19.',\n",
              "  'Covid-19, 160, 168,  disease, covid, Findings provide the timely and valuable insights to repurposed use options of 220 FDA approved drugs obtained from DrugBank database to be further explored in Covid-19.',\n",
              "  \"Covid-19, 135, 143,  disease, covid, Another very distinguished and interesting work in the field of network science and network science's applications to drug repurposing Covid-19 was done in.\",\n",
              "  'Covid-19, 129, 137,  disease, covid, Here in Another very distinguished and interesting work in the field of network science and its applications to drug repurposing Covid-19 multiple layers or approaches normally applied individually on the networks were fused into a single algorithm.',\n",
              "  'Covid-19, 95, 103,  disease, covid, Each of Deployed algorithms was utilized to prioritize the 6340 drugs for expected efficacy in Covid-19.',\n",
              "  'Covid-19, 111, 119,  disease, covid, This led to a successful approach as a network medicine framework for identifying repurposing opportunities in Covid-19.',\n",
              "  'Covid-19, 252, 260,  disease, covid, In practice one cannot find a single algorithm that consistently performs across all the datasets which served as a motivation for Another very distinguished and interesting work in the field of network science and its applications to drug repurposing Covid-19.',\n",
              "  'Covid-19, 149, 157,  disease, covid, 96 % of the drugs tested in Another very distinguished and interesting work in the field of network science and its applications to drug repurposing Covid-19 were FDA approved which is beneficial as 96 % of the drugs tested in the study could be directly moved to clinical trials.',\n",
              "  'Covid-19, 266, 274,  disease, covid, A real predictive power of multimodal approach that combines the predictions from all approaches was demonstrated by the positive outcomes of the second human screen with success rate of 62 % followed by identification of six drugs potentially easily repurposed for Covid-19.',\n",
              "  'Covid-19, 160, 168,  disease, covid, All in all, multimodal approach that combines the predictions from all approaches did not only provided an effective strategy and results in the repurposing of Covid-19 drugs but also provided an algorithmic toolset as well.',\n",
              "  'Covid-19, 44, 52,  disease, covid, Severe and rapidly emerging replications of Covid-19 made the world realize for the combination therapies that were expected to response more effectively.',\n",
              "  'COVID, 112, 117,  disease, covid, To address this gap a study was done in where an integrative network pharmacology inspired web-based tool named COVID-CDR was developed for in-silico repurposing of the drug combinations.',\n",
              "  'COVID, 66, 71,  disease, covid, an integrative network pharmacology inspired web-based tool named COVID-CDR could prioritize Covid-19 repurposable drug combination for synergistic effect.',\n",
              "  'Covid-19, 93, 101,  disease, covid, an integrative network pharmacology inspired web-based tool named COVID-CDR could prioritize Covid-19 repurposable drug combination for synergistic effect.',\n",
              "  'Covid-19, 76, 84,  disease, covid, In this approach, drugs with targets sharing the topological proximity with Covid-19 targets are used to prioritize the drug combinations based on drug-target separation.',\n",
              "  'COVID, 127, 132,  disease, covid, Whereas, successfully evaluated drug combinations because of an integrative network pharmacology inspired web-based tool named COVID-CDR were evaluated using the network computation methods.',\n",
              "  'Covid-19, 121, 129,  disease, covid, One among some of the recent studies, where AI on networks has been applied to repurpose the drugs is done in in which a Covid-19 based knowledge graph was built.',\n",
              "  'Covid-19, 2, 10,  disease, covid, a Covid-19 based knowledge graph consists of virus baits, host genes, pathways, and other information.',\n",
              "  'Covid-19, 129, 137,  disease, covid, Use of deep neural networks and integration of the diverse interactions helped in quick identification of drugs repurposable for Covid-19.',\n",
              "  'Covid-19, 121, 129,  disease, covid, Another very distinguished and interesting work in the field of network science and its applications to drug repurposing Covid-19 suffered from the limitations of missing the effective drugs possibly during the initial drug ranking.',\n",
              "  'Covid-19, 8, 16,  disease, covid, Another Covid-19 based drug repurposing study using the Few-Shot learning is done in.',\n",
              "  'Covid-19, 8, 16,  disease, covid, Another Covid-19 based drug repurposing study using the Few-Shot learning introduces the multi-targeted drug repurposing strategy which is taken as most efficient approach to diseases such as Covid-19.',\n",
              "  'Covid-19, 192, 200,  disease, covid, Another Covid-19 based drug repurposing study using the Few-Shot learning introduces the multi-targeted drug repurposing strategy which is taken as most efficient approach to diseases such as Covid-19.',\n",
              "  'Covid-19, 27, 35,  disease, covid, In connection with Another Covid-19 based drug repurposing study using the Few-Shot learning, molecules are represented as graphs G, nodes are items and bonds between nodes are the edges.',\n",
              "  'Covid-19, 124, 132,  disease, covid, Following this, an input data comprising molecules as graphs in the form of adjacency matrix A, was constructed for Another Covid-19 based drug repurposing study using the Few-Shot learning.',\n",
              "  'Covid-19, 70, 78,  disease, covid, The deployment of the trained models and downstream classification c, Covid-19 related chemical molecules were used.',\n",
              "  'Covid-19, 8, 16,  disease, covid, Another Covid-19 based drug repurposing study using the Few-Shot learning provided a powerful tool for future research in drug repurposing specifically in case of poorly known diseases such as Covid-19.',\n",
              "  'Covid-19, 193, 201,  disease, covid, Another Covid-19 based drug repurposing study using the Few-Shot learning provided a powerful tool for future research in drug repurposing specifically in case of poorly known diseases such as Covid-19.',\n",
              "  'Covid-19, 215, 223,  disease, covid, Instead of these benefits, there are certain limitations such as uncertainties in the datasets used and lack of validation of the predicted drugs in corresponding in-vitro and in-vivo models for efficacy testing in Covid-19.',\n",
              "  'Covid-19, 148, 156,  disease, covid, Moreover, multiple machine learning models are also used disease agnostic fashion for network datasets as done in for repurposing targeted drugs in Covid-19.',\n",
              "  'Covid-19, 39, 47,  disease, covid, Used models are complementary covering Covid-19 and host factors.',\n",
              "  'Covid-19, 140, 148,  disease, covid, Furthermore, results suggest that the drugs ranked using anti-viral of the top predicted broad spectrum were found in clinical practice for Covid-19 and those from graph kernels were found experimentally validated.',\n",
              "  'Covid-19, 16, 24,  disease, covid, Similarly, here Covid-19 drug repurposing explorer abbreviated as CoREx was deployed as an interactive tool.',\n",
              "  'Covid-19, 0, 8,  disease, covid, Covid-19 drug repurposing explorer abbreviated as CoREx can be used to observe and understand the interaction between drugs and host Covid-19 targets in context of biological networks, clinical use of drugs, protein functioning, and cMAP.',\n",
              "  'Covid-19, 133, 141,  disease, covid, Covid-19 drug repurposing explorer abbreviated as CoREx can be used to observe and understand the interaction between drugs and host Covid-19 targets in context of biological networks, clinical use of drugs, protein functioning, and cMAP.',\n",
              "  'Covid-19, 41, 49,  disease, covid, Despite the contribution and benefits of Covid-19 drug repurposing explorer abbreviated as CoREx there some limitations such as the matrix decomposition approach can only be applied to the drugs for which association with viral disease is known.',\n",
              "  'Covid-19, 27, 35,  disease, covid, Main limitation of Another Covid-19 based drug repurposing study using the Few-Shot learning is the annotation of the drug-virus pairs based on the developmental stages and the related data is hard to find.',\n",
              "  'Covid-19, 37, 45,  disease, covid, Similarly, the other part of Another Covid-19 based drug repurposing study using the Few-Shot learning Network medicine has limitation that only those drugs for which targets are known can be used.',\n",
              "  'Covid-19, 11, 19,  disease, covid, Human PPI, Covid-19 specific network, and DTIs were first created like most of the studies and later essential proteins were passed through a set of algorithms Machine learning.',\n",
              "  'Covid-19, 108, 116,  disease, covid, Enrichment analysis was then performed for informative features to validate informative features in case of Covid-19.',\n",
              "  'Covid-19, 64, 72,  disease, covid, One such graph machine learning based drug repurposing study in Covid-19 is presented in which avails the ML and statistical approaches to map and mine the knowledge graph, transcriptomic and literature data on the large scale to uncover the potential drugs for Covid-19.',\n",
              "  'Covid-19, 262, 270,  disease, covid, One such graph machine learning based drug repurposing study in Covid-19 is presented in which avails the ML and statistical approaches to map and mine the knowledge graph, transcriptomic and literature data on the large scale to uncover the potential drugs for Covid-19.',\n",
              "  'Covid-19, 206, 214,  disease, covid, The computational approach in combination with pre-clinical validation indicated that a poly-ADP-ribose polymerase 1 PARP1 inhibitor, CVL218, currently in Phase I clinical trial, may be repurposed to treat Covid-19.',\n",
              "  'Covid-19, 268, 276,  disease, covid, Coupled with cell-based experimental validation One other study that used DrugBank and other databases along with graph convolutional networks GCN came up with several clinically efficient drugs as potential repurposing candidates found as a result GCN application to Covid-19 related data.',\n",
              "  'coronaviruses, 223, 236,  disease, covid, Specifically, as a part of One other study that used DrugBank and other databases along with graph convolutional networks GCN, capmatinib MET inhibitor was found to have potent and wide range antiviral activity in multiple coronaviruses.',\n",
              "  'coronavirus, 160, 171,  disease, covid, The antiviral activity was observed in MET-independent manner and additional roles of capmanitib for host cell proteins promoting the infection caused by human coronavirus thus it can inform further drug discovery studies.',\n",
              "  'Covid-19, 192, 200,  disease, covid, Realizing these problems and tactfully handling these problems can unveil the unfathomable power of the GNN and GCN approaches being applied to network-based approaches to drug repurposing in Covid-19 and in general as well.',\n",
              "  'Covid-19, 89, 97,  disease, covid, There are multiple significant studies utilizing this approach to repurpose the drugs in Covid-19 and other diseases.',\n",
              "  'Covid-19, 12, 20,  disease, covid, Once recent Covid-19 based drug repurposing study is done in where gene co-expression-based network for 1441 genes was constructed and analysis was performed.',\n",
              "  'Covid-19, 110, 118,  disease, covid, Finally, because of proposed network analysis, five drugs were repurposed as candidate repurposable drugs for Covid-19 treatment.',\n",
              "  'Covid-19, 69, 77,  disease, covid, Additionally, around 10 miRNAs were found to be significant to treat Covid-19.',\n",
              "  'Covid-19, 149, 157,  disease, covid, KEGG enrichment, molecular docking, STITCH search tool, and virus-host-drug interactome were used to investigate the interaction network linked with Covid-19 and chloroquine and hydroxychloroquine were utilized as reference drugs to further get into the interaction network linked with Covid-19.',\n",
              "  'Covid-19, 286, 294,  disease, covid, KEGG enrichment, molecular docking, STITCH search tool, and virus-host-drug interactome were used to investigate the interaction network linked with Covid-19 and chloroquine and hydroxychloroquine were utilized as reference drugs to further get into the interaction network linked with Covid-19.',\n",
              "  'Covid-19, 96, 104,  disease, covid, As a result, 47 drug targets were found enriched in TLR pathway and were found overlapping with Covid-19.',\n",
              "  \"Covid-19, 100, 108,  disease, covid, Additional insights from human-drug protein map identified and further confirmed the interaction of Covid-19 with TLR pathway will provide key information for Covid-19 Covid-19 and Covid-19's treatment.\",\n",
              "  \"Covid-19, 159, 167,  disease, covid, Additional insights from human-drug protein map identified and further confirmed the interaction of Covid-19 with TLR pathway will provide key information for Covid-19 Covid-19 and Covid-19's treatment.\",\n",
              "  \"Covid-19, 168, 176,  disease, covid, Additional insights from human-drug protein map identified and further confirmed the interaction of Covid-19 with TLR pathway will provide key information for Covid-19 Covid-19 and Covid-19's treatment.\",\n",
              "  \"Covid-19, 181, 189,  disease, covid, Additional insights from human-drug protein map identified and further confirmed the interaction of Covid-19 with TLR pathway will provide key information for Covid-19 Covid-19 and Covid-19's treatment.\",\n",
              "  'Covid-19, 120, 128,  disease, covid, Furthermore, combination of diffusion and matrix factorization methods is also used to The drug prioritization the Anti-Covid-19 drugs.',\n",
              "  'Covid-19, 161, 169,  disease, covid, Then the gaussian and similarity kernel are diffused and finally the logistic matrix factorization model with kernel diffusion is proposed to identify potential Covid-19 drugs.',\n",
              "  'Covid-19, 30, 38,  disease, covid, Finally, to validate the Anti-Covid-19 drugs molecular docking was performed to find the binding affinity of the drugs potentially repurposable with Covid-19 spike and ACE2 proteins.',\n",
              "  'Covid-19, 149, 157,  disease, covid, Finally, to validate the Anti-Covid-19 drugs molecular docking was performed to find the binding affinity of the drugs potentially repurposable with Covid-19 spike and ACE2 proteins.',\n",
              "  'Covid-19, 208, 216,  disease, covid, Thus, the 5-fold cross-validation leads to conclusion that integration of various biological data features and suitable models, or kernels lead to development of tools that may assist in drug development for Covid-19.',\n",
              "  'Covid-19, 31, 39,  disease, covid, Due to the sudden emergence of Covid-19 pandemic drug repurposing efforts helped greatly to make the treatments available to the patients faster.',\n",
              "  'Covid-19, 96, 104,  disease, covid, These methods have made it possible for the drugs to enter the clinical trials to fight against Covid-19. For example, a network-based drug repurposing study done in predicted the 16 repurposable drugs with anti-viral evidence obtained from the literature and clinical trial data.',\n",
              "  'Covid-19, 132, 140,  disease, covid, Among the 16 repurposable drugs Sirolimus originally approved as an immunosuppressant is registered in phase-II clinical trials for Covid-19.',\n",
              "  'Covid-19, 109, 117,  disease, covid, Another work done in applied machine learning on networks and repurposed 14 potential repurposable drugs for Covid-19, of which Chloroquine is registered in Phase-II & III and Dexamethasone is registered in Phase-IV clinical trials as mentioned in.',\n",
              "  'Covid-19, 145, 153,  disease, covid, Similarly, a machine learning and network medicine drug repurposing work retrieved a list of 23 FDA approved drugs as potential therapeutics for Covid-19.',\n",
              "  'Covid-19, 65, 73,  disease, covid, Many of 23 FDA approved drugs are already in clinical trials for Covid-19.',\n",
              "  'Covid-19, 172, 180,  disease, covid, Additionally, in our recent work of machine learning and molecular docking-based drug repurposing framework, 12 potential drugs were suggested as potential therapeutic for Covid-19.',\n",
              "  'Covid-19, 114, 122,  disease, covid, Similarly, multiple deep learning techniques have also been used to identify the repurposable drug candidates for Covid-19.',\n",
              "  'Covid-19, 243, 251,  disease, covid, One of the deep learning-based studies, is done in where deep learning-based drug screening was performed followed by a study done in where a resource based on deep learning is created to enable the fast repurposing of the drug candidates for Covid-19.',\n",
              "  'Covid-19, 154, 162,  disease, covid, Finally, in the light of the examples tabulated in, it can be concluded that the drug repurposing methods are quite helpful and quick to response in case Covid-19 and related emergent situations.',\n",
              "  'Covid-19, 160, 168,  disease, covid, There is no doubt that network medicine approaches are gaining more attention and have successfully been deployed in several studies to repurpose the drugs for Covid-19. Still there are some limitations which needs to be highlighted along with future recommendations to overcome some limitations for improved results in the future.',\n",
              "  'Coronavirus disease, 4, 23,  disease, covid, The Coronavirus disease Covid-19 is an infectious disease caused by SARS-CoV-2 virus.',\n",
              "  'Covid-19, 24, 32,  disease, covid, The Coronavirus disease Covid-19 is an infectious disease caused by SARS-CoV-2 virus.',\n",
              "  'SARS-CoV-2, 68, 78,  disease, covid, The Coronavirus disease Covid-19 is an infectious disease caused by SARS-CoV-2 virus.',\n",
              "  'Coronavirus disease, 49, 68,  disease, covid, Started in November 2019 in the Wuhan-China, The Coronavirus disease Covid-19 was soon declared as public health emergency of international health concern by the World Health Organization WHO on January 30, and The Coronavirus disease Covid-19 scaled up to pandemic as of March 11, 2020.',\n",
              "  'Covid-19, 69, 77,  disease, covid, Started in November 2019 in the Wuhan-China, The Coronavirus disease Covid-19 was soon declared as public health emergency of international health concern by the World Health Organization WHO on January 30, and The Coronavirus disease Covid-19 scaled up to pandemic as of March 11, 2020.',\n",
              "  'Coronavirus disease, 215, 234,  disease, covid, Started in November 2019 in the Wuhan-China, The Coronavirus disease Covid-19 was soon declared as public health emergency of international health concern by the World Health Organization WHO on January 30, and The Coronavirus disease Covid-19 scaled up to pandemic as of March 11, 2020.',\n",
              "  'Covid-19, 235, 243,  disease, covid, Started in November 2019 in the Wuhan-China, The Coronavirus disease Covid-19 was soon declared as public health emergency of international health concern by the World Health Organization WHO on January 30, and The Coronavirus disease Covid-19 scaled up to pandemic as of March 11, 2020.',\n",
              "  'Coronavirus disease, 99, 118,  disease, covid, Thus, drug repurposing emerged as an efficient and scalable approach to find the treatment for The Coronavirus disease Covid-19.',\n",
              "  'Covid-19, 119, 127,  disease, covid, Thus, drug repurposing emerged as an efficient and scalable approach to find the treatment for The Coronavirus disease Covid-19.',\n",
              "  'Coronavirus disease, 77, 96,  disease, covid, In this review, a comprehensive overview of drug repurposing studies for The Coronavirus disease Covid-19 is provided.',\n",
              "  'Covid-19, 97, 105,  disease, covid, In this review, a comprehensive overview of drug repurposing studies for The Coronavirus disease Covid-19 is provided.',\n",
              "  'Coronavirus disease, 154, 173,  disease, covid, this review spans to machine learning, deep learning, and network-based approaches while specifically network-based approaches to drug repurposing in The Coronavirus disease Covid-19 are focused.',\n",
              "  'Covid-19, 174, 182,  disease, covid, this review spans to machine learning, deep learning, and network-based approaches while specifically network-based approaches to drug repurposing in The Coronavirus disease Covid-19 are focused.',\n",
              "  'Coronavirus disease, 33, 52,  disease, covid, Network based approaches for The Coronavirus disease Covid-19 drug repurposing are further divided in three categories Network diffusion, network proximity, and AI on networks.',\n",
              "  'Covid-19, 53, 61,  disease, covid, Network based approaches for The Coronavirus disease Covid-19 drug repurposing are further divided in three categories Network diffusion, network proximity, and AI on networks.',\n",
              "  'Coronavirus disease, 219, 238,  disease, covid, Moreover, in simplest form machine learning studies take the different type of drug and disease related data, perform feature extraction, create predictive models, and then models are deployed for the prediction in The Coronavirus disease Covid-19 and other diseases.',\n",
              "  'Covid-19, 239, 247,  disease, covid, Moreover, in simplest form machine learning studies take the different type of drug and disease related data, perform feature extraction, create predictive models, and then models are deployed for the prediction in The Coronavirus disease Covid-19 and other diseases.',\n",
              "  'Coronavirus disease, 59, 78,  disease, covid, Despite successful application in drug repurposing for The Coronavirus disease Covid-19, machine learning approaches struggle to handle the diverse and sparse biological data but are easy to interpret which is essential for studies like drug repurposing.',\n",
              "  'Covid-19, 79, 87,  disease, covid, Despite successful application in drug repurposing for The Coronavirus disease Covid-19, machine learning approaches struggle to handle the diverse and sparse biological data but are easy to interpret which is essential for studies like drug repurposing.',\n",
              "  'Coronavirus disease, 160, 179,  disease, covid, Since deep learning models are effective in terms of heterogenous and sparse data handling and have been deployed to predict repurposed candidate drugs for The Coronavirus disease Covid-19.',\n",
              "  'Covid-19, 180, 188,  disease, covid, Since deep learning models are effective in terms of heterogenous and sparse data handling and have been deployed to predict repurposed candidate drugs for The Coronavirus disease Covid-19.',\n",
              "  'Coronavirus disease, 91, 110,  disease, covid, Additionally, network-based methods have also been widely and effectively deployed for The Coronavirus disease Covid-19 repurposing.',\n",
              "  'Covid-19, 111, 119,  disease, covid, Additionally, network-based methods have also been widely and effectively deployed for The Coronavirus disease Covid-19 repurposing.',\n",
              "  'Coronavirus disease, 44, 63,  disease, covid, The biological network-based studies in The Coronavirus disease Covid-19 covered multiple pharmacological aspects such as gene regulations, protein interactions, drug-target or drug-drug interactions, drug-side effect, and metabolic interactions etc.',\n",
              "  'Covid-19, 64, 72,  disease, covid, The biological network-based studies in The Coronavirus disease Covid-19 covered multiple pharmacological aspects such as gene regulations, protein interactions, drug-target or drug-drug interactions, drug-side effect, and metabolic interactions etc.',\n",
              "  'Coronavirus disease, 207, 226,  disease, covid, The integration of such diverse biological entities extracted from many different databases and experiments in network helps to mimic the complex biological systems good for drug repurposing specific in The Coronavirus disease Covid-19 and in general.',\n",
              "  'Covid-19, 227, 235,  disease, covid, The integration of such diverse biological entities extracted from many different databases and experiments in network helps to mimic the complex biological systems good for drug repurposing specific in The Coronavirus disease Covid-19 and in general.'],\n",
              " [\"coronavirus disease 2019, 88, 112,  disease, covid, At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\",\n",
              "  \"COVID-19, 113, 121,  disease, covid, At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\",\n",
              "  \"coronavirus disease 2019, 150, 174,  disease, covid, At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\",\n",
              "  \"COVID-19, 175, 183,  disease, covid, At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\",\n",
              "  \"coronavirus disease 2019, 220, 244,  disease, covid, At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\",\n",
              "  \"COVID-19, 245, 253,  disease, covid, At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\",\n",
              "  'coronavirus disease 2019, 10, 34,  disease, covid, the novel coronavirus disease 2019 COVID-19 first appeared in Wuhan city, China, in late 2019 and is still spreading all over the globe creating a disastrous effect on global health and the economy.',\n",
              "  'COVID-19, 35, 43,  disease, covid, the novel coronavirus disease 2019 COVID-19 first appeared in Wuhan city, China, in late 2019 and is still spreading all over the globe creating a disastrous effect on global health and the economy.',\n",
              "  \"coronavirus disease 2019, 17, 41,  disease, covid, Due to the novel coronavirus disease 2019 COVID-19's highly contagious nature, as of May 2022, the pandemic has spread to more than 200 countries and territories with over 5.5 million confirmed positive cases and mortality of over 350K across the globe.\",\n",
              "  \"COVID-19, 42, 50,  disease, covid, Due to the novel coronavirus disease 2019 COVID-19's highly contagious nature, as of May 2022, the pandemic has spread to more than 200 countries and territories with over 5.5 million confirmed positive cases and mortality of over 350K across the globe.\",\n",
              "  'coronavirus disease 2019, 35, 59,  disease, covid, The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "  'COVID-19, 60, 68,  disease, covid, The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "  'severe acute respiratory syndrome, 72, 105,  disease, covid, The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "  'coronavirus, 106, 117,  disease, covid, The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "  'SARS-CoV-2, 120, 130,  disease, covid, The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "  'severe acute respiratory syndrome, 136, 169,  disease, covid, The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "  'coronavirus, 170, 181,  disease, covid, The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "  'SARS-CoV-2, 184, 194,  disease, covid, The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "  'coronavirus, 242, 253,  disease, covid, The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "  'severe acute respiratory syndrome, 0, 33,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "  'coronavirus, 34, 45,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "  'SARS-CoV-2, 48, 58,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "  'Betacoronavirus, 80, 95,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "  'Coronaviridae, 110, 123,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "  'SARS, 167, 171,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "  'coronavirus, 172, 183,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "  'SARS-CoV-1, 184, 194,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "  'coronavirus, 232, 243,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "  'MERS-CoV, 244, 252,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "  'Coronaviruses, 0, 13,  disease, covid, Coronaviruses are positive-sense single-stranded RNA with a genome size of ~30 kb containing a 5′ cap-structure and 3′-polyadenylated tail.',\n",
              "  \"Coronaviruses, 0, 13,  disease, covid, Coronaviruses's genome encodes for ORF1a and ORF1ab polyprotein which cleaves into multiple subunits and performs a diverse range of functions, i.e., binding and invading the host cell, viral replication, and evading the host immune system.\",\n",
              "  \"coronaviruses, 16, 29,  disease, covid, The proteins of coronaviruses perform The proteins of coronaviruses's function by aggregating multiple subunits into an heteromeric complex, i.e., replication-transcription complex and several other structural proteins that assemble into new virions.\",\n",
              "  \"coronaviruses, 54, 67,  disease, covid, The proteins of coronaviruses perform The proteins of coronaviruses's function by aggregating multiple subunits into an heteromeric complex, i.e., replication-transcription complex and several other structural proteins that assemble into new virions.\",\n",
              "  'SARS, 144, 148,  disease, covid, a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.',\n",
              "  'coronavirus, 149, 160,  disease, covid, a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.',\n",
              "  'SARS-CoV-1, 161, 171,  disease, covid, a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.',\n",
              "  'coronavirus, 218, 229,  disease, covid, a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.',\n",
              "  'MERS-CoV, 230, 238,  disease, covid, a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.',\n",
              "  'SARS-CoV2, 175, 184,  disease, covid, Currently, many studies including single-ligand docking as well as screening of the compounds library have been conducted to search for potential inhibitors against NSP-12 of SARS-CoV2.',\n",
              "  'SARS-CoV2, 98, 107,  disease, covid, The DALI server was employed for the identification of homologous protein structures to NSP-12 of SARS-CoV2 that were already submitted in the PDB repository.',\n",
              "  'Coronaviridae, 86, 99,  disease, covid, 611 structures were involved in the RdRp activity and belonged to four viral families Coronaviridae, Flaviviridae, Picornaviridae, and Caliciviridae and infected a diverse range of hosts.',\n",
              "  'coronaviruses, 151, 164,  disease, covid, the similarity matrix was visualized as a heatmap as shown in A. The heatmap of Z-score-based structural similarity revealed the close relationship of coronaviruses with the members of Flaviviridae as well as Caliciviridae and Picornaviridae.',\n",
              "  'coronaviruses, 247, 260,  disease, covid, Based on structural similarity, the unrooted cladogram of homologous structures to a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity was clustered into four viral families as shown in B. The clade of the coronaviruses, i.e., SARS-CoV-1 and SARS-CoV-2, shares a close relationship with the NS5B of HCV and also with the other representatives of Flaviviridae, i.e., the Zika Virus ZIKV, Dengue Virus DENV, Bovine Viral Diarrhea Virus BVDV, Japanese Encephalitis Virus JEV, and Classical Swine Fever Virus CSFV.',\n",
              "  'SARS-CoV-1, 268, 278,  disease, covid, Based on structural similarity, the unrooted cladogram of homologous structures to a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity was clustered into four viral families as shown in B. The clade of the coronaviruses, i.e., SARS-CoV-1 and SARS-CoV-2, shares a close relationship with the NS5B of HCV and also with the other representatives of Flaviviridae, i.e., the Zika Virus ZIKV, Dengue Virus DENV, Bovine Viral Diarrhea Virus BVDV, Japanese Encephalitis Virus JEV, and Classical Swine Fever Virus CSFV.',\n",
              "  'SARS-CoV-2, 283, 293,  disease, covid, Based on structural similarity, the unrooted cladogram of homologous structures to a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity was clustered into four viral families as shown in B. The clade of the coronaviruses, i.e., SARS-CoV-1 and SARS-CoV-2, shares a close relationship with the NS5B of HCV and also with the other representatives of Flaviviridae, i.e., the Zika Virus ZIKV, Dengue Virus DENV, Bovine Viral Diarrhea Virus BVDV, Japanese Encephalitis Virus JEV, and Classical Swine Fever Virus CSFV.',\n",
              "  'coronaviruses, 30, 43,  disease, covid, The clade of Flaviviridae and coronaviruses shared significant relationships as compared to the members of Caliciviridae and Picornaviridae.',\n",
              "  'Coronaviridae, 213, 226,  disease, covid, To display the conserved orientation of these motifs at the active site of a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity, multiple structures belonging to the family Coronaviridae, Flaviviridae, and Picornaviridae were superposed structurally aligned by using the MatchMaker algorithm implemented in UCSF Chimera.',\n",
              "  'SARS-CoV-2, 140, 150,  disease, covid, The grid box was centered at the active site or druggable cavity and the residues were considered rigid for both receptors, i.e., NSP-12 of SARS-CoV-2 and NS5B of HCV.',\n",
              "  'SARS-CoV-2, 71, 81,  disease, covid, The results score of ligand bindings with the active site of NSP-12 of SARS-CoV-2 and NS5B of HCV has been compared and visualized as a bar chart as shown in B.The docking score of NSP-12 of SARS-CoV-2 with the ligands, i.e., Dasabuvir, Sofosbuvir, Ribavirin, GTP, and UTP was in the range of −6.2 to −8.1 kcal/mol, while for NS5B of HCV, B.The docking score of NSP-12 with the ligands was −6.5 to −9.1 kcal/mol, and both had an average difference of 0.84 kcal/mol.',\n",
              "  'SARS-CoV-2, 191, 201,  disease, covid, The results score of ligand bindings with the active site of NSP-12 of SARS-CoV-2 and NS5B of HCV has been compared and visualized as a bar chart as shown in B.The docking score of NSP-12 of SARS-CoV-2 with the ligands, i.e., Dasabuvir, Sofosbuvir, Ribavirin, GTP, and UTP was in the range of −6.2 to −8.1 kcal/mol, while for NS5B of HCV, B.The docking score of NSP-12 with the ligands was −6.5 to −9.1 kcal/mol, and both had an average difference of 0.84 kcal/mol.',\n",
              "  'SARS-CoV-2, 39, 49,  disease, covid, The average docking score of NSP-12 of SARS-CoV-2 and NS5B of HCV for Sofosbuvir, Dasabuvir, Ribavirin, GTP, and GTP were −8.2, −8.6, −6.35, −8.25, and −7.6 kcal/mol, respectively.',\n",
              "  'SARS-CoV-2, 10, 20,  disease, covid, NSP-12 of SARS-CoV-2 showed the lowest docking score −8.1 kcal/mol with Dasabuvir and higher −6.2 kcal/mol with Ribavirin.',\n",
              "  'SARS-CoV-2, 95, 105,  disease, covid, In general, the ligands showed a higher docking score for NS5B of HCV as compared to NSP-12 of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 110, 120,  disease, covid, To examine the interactions between ligand and the conserved residues present at the active site of NSP-12 of SARS-CoV-2, LigPlot + v2.1, standalone software was used.',\n",
              "  'SARS-CoV-2, 70, 80,  disease, covid, The predicted interactions of Sofosbuvir and Dasabuvir with NSP-12 of SARS-CoV-2 have been shown in A,B, respectively.',\n",
              "  'SARS-CoV-2, 80, 90,  disease, covid, On the other hand, the native competitors such as GTP interacted with NSP-12 of SARS-CoV-2 by forming hydrogen bonds with A554, R555, and T556 of motif-F, Y619, K621, and C622 of motif-A, while UTP interacted with S759, D760, and D761 of motif-C, W800 of motif-D, and G811 and S814 of motif-E In the case of HCV as a receptor, Sofosbuvir binds with motif-B and -C, while Dasabuvir interacted with residues of motif-A, -B, -C, and motif-F, and their receptor–ligand interaction plots have been shown in C,D, respectively.',\n",
              "  'SARS-CoV-2, 61, 71,  disease, covid, However, 6M71/Sofosbuvir has the same evolution to NSP-12 of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 100, 110,  disease, covid, This finding implies that Dasabuvir, Ribavirin, and Sofosbuvir binding helped to maintain NSP-12 of SARS-CoV-2 structurally stable.',\n",
              "  \"SARS-CoV-2, 65, 75,  disease, covid, We examined how binding of different ligands this goal NSP-12 of SARS-CoV-2's overall compactness in the protein's structure.\",\n",
              "  'SARS-CoV-2, 36, 46,  disease, covid, The average Rg values Apo NSP-12 of SARS-CoV-2, NSP-12/Dasabuvir, NSP-12/Ribavirin, and NSP-12/Sofosbuvir complexes were found to be 2.99, 3.00, 2.97, 2.98 nm, respectively, suggesting that the binding of Dasabuvir, Ribavirin, and Sofosbuvir to NSP-12 of SARS-CoV-2 packing did not cause significant change.',\n",
              "  'SARS-CoV-2, 255, 265,  disease, covid, The average Rg values Apo NSP-12 of SARS-CoV-2, NSP-12/Dasabuvir, NSP-12/Ribavirin, and NSP-12/Sofosbuvir complexes were found to be 2.99, 3.00, 2.97, 2.98 nm, respectively, suggesting that the binding of Dasabuvir, Ribavirin, and Sofosbuvir to NSP-12 of SARS-CoV-2 packing did not cause significant change.',\n",
              "  'SARS-CoV-2, 70, 80,  disease, covid, It was noticed that Dasabuvir binds to the active pocket of NSP-12 of SARS-CoV-2 with an average of 3.46 hydrogen bonds and 1.13 pairs within 0.35 nm.',\n",
              "  'SARS-CoV-2, 145, 155,  disease, covid, On the other hand, the H-bonding plot showed that Dasabuvir was able to maintain a more robust interaction with the binding pockets of NSP-12 of SARS-CoV-2 throughout the simulation time than Ribavirin and Sofosbuvir. Before MM/PBSA calculation, each complex between the receptors or inhibitors/ligands should reach the equilibrium state.',\n",
              "  'SARS-CoV-2, 185, 195,  disease, covid, Except for the polar solvation energy, all other forms of energy contributed favorably to the interaction between different molecules Dasabuvir, Ribavirin, and Sofosbuvir and NSP-12 of SARS-CoV-2.',\n",
              "  'COVID-19, 92, 100,  disease, covid, Finally, the Sofosbuvir and Dasabuvir could be established as a repurposed drug against the COVID-19 main protease.',\n",
              "  \"SARS-CoV-2, 74, 84,  disease, covid, Many drugs have been already suggested for the current pandemic caused by SARS-CoV-2, of which the most prominent are FDA-approved Chloroquine and FDA-approved Chloroquine's derivatives—an anti-malarial drug and Remdesivir.\",\n",
              "  'SARS-CoV-2, 55, 65,  disease, covid, Remdesivir, has been shown to significantly reduce the SARS-CoV-2 pathogenicity in in vitro study and is still under investigation.',\n",
              "  \"SARS-CoV-2, 53, 63,  disease, covid, In this study, we searched for homologs of NSP-12 of SARS-CoV-2 and evaluated NSP-12 of SARS-CoV-2's binding affinity with the FDA-approved antivirals, i.e., Sofosbuvir and Dasabuvir, which specifically target the evolutionarily conserved site of NS5B of HCV.\",\n",
              "  \"SARS-CoV-2, 88, 98,  disease, covid, In this study, we searched for homologs of NSP-12 of SARS-CoV-2 and evaluated NSP-12 of SARS-CoV-2's binding affinity with the FDA-approved antivirals, i.e., Sofosbuvir and Dasabuvir, which specifically target the evolutionarily conserved site of NS5B of HCV.\",\n",
              "  'Coronaviridae, 166, 179,  disease, covid, Further screening of 1105 structures based on the quality of structural alignment Z-score ≥ 19 resulted in 611 structures that belonged to four viral families, i.e., Coronaviridae, Flaviviridae, Picornaviridae, and Caliciviridae, responsible for RdRp activity during viral replication.',\n",
              "  'SARS-CoV-2, 14, 24,  disease, covid, The NSP-12 of SARS-CoV-2 displayed significant homology to the NS5 of Flaviviridae or NS5B of HCV as compared to the polymerases of Picornaviridae and Caliciviridae.',\n",
              "  'SARS-CoV-2, 67, 77,  disease, covid, Based on the pairwise alignment of amino acid sequences, NSP-12 of SARS-CoV-2 shares 96% identity with SARS-CoV-1, 11% with HCV and HNV, and 10% with Poli.',\n",
              "  'SARS-CoV-1, 103, 113,  disease, covid, Based on the pairwise alignment of amino acid sequences, NSP-12 of SARS-CoV-2 shares 96% identity with SARS-CoV-1, 11% with HCV and HNV, and 10% with Poli.',\n",
              "  'SARS-CoV-2, 62, 72,  disease, covid, Despite sharing a lower identity based on sequence, NSP-12 of SARS-CoV-2 has seven highly conserved motifs in the RdRp domain that play a key role in viral replication.',\n",
              "  'SARS-CoV-2, 112, 122,  disease, covid, significant overlap included the conserved residues of motifs A, B, C, D, and F of the RdRp domain of NSP-12 of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 48, 58,  disease, covid, The active site of the RdRp domain of NSP-12 of SARS-CoV-2 was further evaluated for binding affinity with FDA-approved antivirals by the molecular docking method.',\n",
              "  'SARS-CoV-2, 111, 121,  disease, covid, Molecular docking was performed using AutoDock Vina which revealed a significant binding affinity of NSP-12 of SARS-CoV-2 with Sofosbuvir and Dasabuvir as compared to Ribavirin.',\n",
              "  'SARS-CoV-2, 96, 106,  disease, covid, Despite that, NS5B showed higher binding affinity lower binding energy as compared to NSP-12 of SARS-CoV-2 however, the differences were still insignificant.',\n",
              "  'SARS-CoV-2, 27, 37,  disease, covid, The profiling of NSP-12 of SARS-CoV-2 and ligand interaction revealed firm binding due to the formation of hydrogen bonds and hydrophobic interactions.',\n",
              "  'SARS-CoV-2, 112, 122,  disease, covid, In general, both Sofosbuvir and Dasabuvir showed higher binding to the active site of NS5B of HCV and NSP-12 of SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 23, 33,  disease, covid, We retrieved NSP-12 of SARS-CoV-2 with PDB ID 6M71 at 2.9 Å resolution from the Protein Data Bank PDB repository that was recently submitted by Gao et al. For the identification of homologous structures in the Protein Data Bank PDB repository, 6M71 chain A was submitted to the DALI server website.fi/dali/ accessed on 16 March 2020.',\n",
              "  'SARS-CoV-2, 72, 82,  disease, covid, To further study the conserved residues at the active site of NSP-12 of SARS-CoV-2, multiple structures were aligned by using the MatchMaker algorithm implemented in the University of California, San Francisco UCSF Chimera v.14 and visualized.',\n",
              "  'v.14, 223, 227,  covid lineage, covid, To further study the conserved residues at the active site of NSP-12 of SARS-CoV-2, multiple structures were aligned by using the MatchMaker algorithm implemented in the University of California, San Francisco UCSF Chimera v.14 and visualized.',\n",
              "  'v.14, 209, 213,  covid lineage, covid, Initially, the Canonical SMILES IDs of the ligand compounds, i.e., Sofosbuvir CID 45375808, Ribavirin CID 37542, and Dasabuvir CID 56640146 were retrieved from the PubChem library and then imported in Chimera v.14 for converting into PDB files.',\n",
              "  'SARS-CoV-2, 54, 64,  disease, covid, The resulting score of molecular docking of NSP-12 of SARS-CoV-2 and NS5B of HCV were compared and plotted using a bar plot.',\n",
              "  'v.2021, 99, 105,  covid lineage, covid, The MD simulation of the apo and ligand-bound complex of NSP-12 protein was done using the GROMACS v.2021 and GROMOS96 54a7 force field.',\n",
              "  \"SARS-CoV-2, 64, 74,  disease, covid, In this study, we searched for structural homologs of NSP-12 of SARS-CoV-2 and identified structural homologs of NSP-12 of SARS-CoV-2's relationship with the members of three viral families, i.e., Flaviviridae, Picornaviridae, and Caliciviridae.\",\n",
              "  \"SARS-CoV-2, 123, 133,  disease, covid, In this study, we searched for structural homologs of NSP-12 of SARS-CoV-2 and identified structural homologs of NSP-12 of SARS-CoV-2's relationship with the members of three viral families, i.e., Flaviviridae, Picornaviridae, and Caliciviridae.\",\n",
              "  'SARS-CoV-2, 29, 39,  disease, covid, The RdRp domain of NSP-12 of SARS-CoV-2 is highly conserved in terms of both sequence and architecture and assessed for binding affinity with FDA-approved antivirals, i.e., Dasabuvir and Sofosbuvir.'],\n",
              " ['Coronavirus disease 2019, 0, 24,  disease, covid, Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.',\n",
              "  'COVID-19, 25, 33,  disease, covid, Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.',\n",
              "  'severe acute respiratory syndrome, 45, 78,  disease, covid, Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.',\n",
              "  'coronavirus, 79, 90,  disease, covid, Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.',\n",
              "  'SARS-CoV-2, 93, 103,  disease, covid, Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.',\n",
              "  'severe acute respiratory syndrome, 0, 33,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has infected more than half a billion people and caused over 5 million deaths, implying a global health threat.',\n",
              "  'coronavirus, 34, 45,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has infected more than half a billion people and caused over 5 million deaths, implying a global health threat.',\n",
              "  'SARS-CoV-2, 48, 58,  disease, covid, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has infected more than half a billion people and caused over 5 million deaths, implying a global health threat.',\n",
              "  'Coronavirus disease 2019, 145, 169,  disease, covid, As the development of a new drug takes years to a decade, drug repositioning can significantly accelerate the development cycle of therapies for Coronavirus disease 2019 COVID-19.',\n",
              "  'COVID-19, 170, 178,  disease, covid, As the development of a new drug takes years to a decade, drug repositioning can significantly accelerate the development cycle of therapies for Coronavirus disease 2019 COVID-19.',\n",
              "  'Coronavirus disease 2019, 33, 57,  disease, covid, The key to drug repositioning of Coronavirus disease 2019 COVID-19 is to identify critical targets for the CoV replication cycle.',\n",
              "  'COVID-19, 58, 66,  disease, covid, The key to drug repositioning of Coronavirus disease 2019 COVID-19 is to identify critical targets for the CoV replication cycle.',\n",
              "  'CoV, 107, 110,  disease, covid, The key to drug repositioning of Coronavirus disease 2019 COVID-19 is to identify critical targets for the CoV replication cycle.',\n",
              "  'CoV, 57, 60,  disease, covid, virus-based targets the virus components involved in the CoV replication cycle.',\n",
              "  'severe acute respiratory syndrome, 161, 194,  disease, covid, For example, approved nucleoside analogues favipiravir and ribavirin and experimental nucleoside analogues remdesivir and galidesivir may have potential against severe acute respiratory syndrome coronavirus 2 SARS-CoV-2.',\n",
              "  'coronavirus, 195, 206,  disease, covid, For example, approved nucleoside analogues favipiravir and ribavirin and experimental nucleoside analogues remdesivir and galidesivir may have potential against severe acute respiratory syndrome coronavirus 2 SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 209, 219,  disease, covid, For example, approved nucleoside analogues favipiravir and ribavirin and experimental nucleoside analogues remdesivir and galidesivir may have potential against severe acute respiratory syndrome coronavirus 2 SARS-CoV-2.',\n",
              "  'CoV, 66, 69,  disease, covid, The host-based approaches target the key host factors utilized by CoV for viral replication or stimulate innate antiviral responses in hosts.',\n",
              "  'severe acute respiratory syndrome, 31, 64,  disease, covid, It was quickly discovered that severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and leverages the serine protease TMPRSS2 for S protein initiation.',\n",
              "  'coronavirus, 65, 76,  disease, covid, It was quickly discovered that severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and leverages the serine protease TMPRSS2 for S protein initiation.',\n",
              "  'SARS-CoV-2, 79, 89,  disease, covid, It was quickly discovered that severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and leverages the serine protease TMPRSS2 for S protein initiation.',\n",
              "  'SARS-CoV, 99, 107,  disease, covid, It was quickly discovered that severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and leverages the serine protease TMPRSS2 for S protein initiation.',\n",
              "  'SARS-CoV, 4, 12,  disease, covid, the SARS-CoV receptor ACE2 regulates the renin-angiotensin system RAS in several diseases and expresses in the lungs and the kidney, small intestine, testis, and heart.',\n",
              "  'SARS-CoV, 19, 27,  disease, covid, In addition to the SARS-CoV receptor ACE2 and the serine protease TMPRSS2, several candidate receptors can aid severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection, such as the cell-surface proteins tyrosine-protein kinase receptor UFO Axl, low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3, and C-type lectin domain family 4 member G CLEC4G.',\n",
              "  'severe acute respiratory syndrome, 111, 144,  disease, covid, In addition to the SARS-CoV receptor ACE2 and the serine protease TMPRSS2, several candidate receptors can aid severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection, such as the cell-surface proteins tyrosine-protein kinase receptor UFO Axl, low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3, and C-type lectin domain family 4 member G CLEC4G.',\n",
              "  'coronavirus, 145, 156,  disease, covid, In addition to the SARS-CoV receptor ACE2 and the serine protease TMPRSS2, several candidate receptors can aid severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection, such as the cell-surface proteins tyrosine-protein kinase receptor UFO Axl, low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3, and C-type lectin domain family 4 member G CLEC4G.',\n",
              "  'SARS-CoV-2 infection, 159, 179,  disease, covid, In addition to the SARS-CoV receptor ACE2 and the serine protease TMPRSS2, several candidate receptors can aid severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection, such as the cell-surface proteins tyrosine-protein kinase receptor UFO Axl, low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3, and C-type lectin domain family 4 member G CLEC4G.',\n",
              "  'severe acute respiratory syndrome, 62, 95,  disease, covid, Several efforts have been made to identify drugs that inhibit severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by targeting host proteins.',\n",
              "  'coronavirus, 96, 107,  disease, covid, Several efforts have been made to identify drugs that inhibit severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by targeting host proteins.',\n",
              "  'SARS-CoV-2, 110, 120,  disease, covid, Several efforts have been made to identify drugs that inhibit severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by targeting host proteins.',\n",
              "  'severe acute respiratory syndrome, 139, 172,  disease, covid, An in vitro study demonstrates that the inhibition of the protease activity of the serine protease TMPRSS2 partially prevents the entry of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 into the lung epithelial cells.',\n",
              "  'coronavirus, 173, 184,  disease, covid, An in vitro study demonstrates that the inhibition of the protease activity of the serine protease TMPRSS2 partially prevents the entry of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 into the lung epithelial cells.',\n",
              "  'SARS-CoV-2, 187, 197,  disease, covid, An in vitro study demonstrates that the inhibition of the protease activity of the serine protease TMPRSS2 partially prevents the entry of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 into the lung epithelial cells.',\n",
              "  'severe acute respiratory syndrome, 99, 132,  disease, covid, In vitro studies suggest that both chloroquine and hydroxychloroquine may prevent the transport of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 from the early endosome to the endolysosome.',\n",
              "  'coronavirus, 133, 144,  disease, covid, In vitro studies suggest that both chloroquine and hydroxychloroquine may prevent the transport of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 from the early endosome to the endolysosome.',\n",
              "  'SARS-CoV-2, 147, 157,  disease, covid, In vitro studies suggest that both chloroquine and hydroxychloroquine may prevent the transport of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 from the early endosome to the endolysosome.',\n",
              "  'severe acute respiratory syndrome, 61, 94,  disease, covid, However, none of these options was confirmed to have an anti-severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 effect, which motivates the discoveries of other uncovered but practical host factors.',\n",
              "  'coronavirus, 95, 106,  disease, covid, However, none of these options was confirmed to have an anti-severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 effect, which motivates the discoveries of other uncovered but practical host factors.',\n",
              "  'SARS-CoV-2, 109, 119,  disease, covid, However, none of these options was confirmed to have an anti-severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 effect, which motivates the discoveries of other uncovered but practical host factors.',\n",
              "  'Coronavirus disease 2019, 252, 276,  disease, covid, The network-based methodology combines the virus-host interactome and drug targets in the human protein-protein interaction PPI network as a systems pharmacology-based network medicine platform, which is vital and widely used in drug repositioning for Coronavirus disease 2019 COVID-19.',\n",
              "  'COVID-19, 277, 285,  disease, covid, The network-based methodology combines the virus-host interactome and drug targets in the human protein-protein interaction PPI network as a systems pharmacology-based network medicine platform, which is vital and widely used in drug repositioning for Coronavirus disease 2019 COVID-19.',\n",
              "  \"Coronavirus disease 2019, 72, 96,  disease, covid, If a drug stimulates some genes and inhibits others, a drug's effect on Coronavirus disease 2019 COVID-19 needs to be reassessed.\",\n",
              "  \"COVID-19, 97, 105,  disease, covid, If a drug stimulates some genes and inhibits others, a drug's effect on Coronavirus disease 2019 COVID-19 needs to be reassessed.\",\n",
              "  'Coronavirus disease 2019, 92, 116,  disease, covid, Importantly, current methods barely avoid the potential side effect of repurposed drugs for Coronavirus disease 2019 COVID-19 patients with chronic underlying diseases, such as diabetes mellitus, cardiovascular disease, chronic pulmonary disease, and cancers.',\n",
              "  'COVID-19, 117, 125,  disease, covid, Importantly, current methods barely avoid the potential side effect of repurposed drugs for Coronavirus disease 2019 COVID-19 patients with chronic underlying diseases, such as diabetes mellitus, cardiovascular disease, chronic pulmonary disease, and cancers.',\n",
              "  '-coronavirus, 127, 139,  disease, covid, In this study, to identify the potential antiviral agents, we applied an end-to-end computational method to search drug-gene s -coronavirus CoV paths in a directional network and inferred the effect of drugs on Coronavirus disease 2019 COVID-19 We constructed a directional network by aggregating three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network.',\n",
              "  'CoV, 140, 143,  disease, covid, In this study, to identify the potential antiviral agents, we applied an end-to-end computational method to search drug-gene s -coronavirus CoV paths in a directional network and inferred the effect of drugs on Coronavirus disease 2019 COVID-19 We constructed a directional network by aggregating three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network.',\n",
              "  'Coronavirus disease 2019, 211, 235,  disease, covid, In this study, to identify the potential antiviral agents, we applied an end-to-end computational method to search drug-gene s -coronavirus CoV paths in a directional network and inferred the effect of drugs on Coronavirus disease 2019 COVID-19 We constructed a directional network by aggregating three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network.',\n",
              "  'COVID-19, 236, 244,  disease, covid, In this study, to identify the potential antiviral agents, we applied an end-to-end computational method to search drug-gene s -coronavirus CoV paths in a directional network and inferred the effect of drugs on Coronavirus disease 2019 COVID-19 We constructed a directional network by aggregating three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network.',\n",
              "  'Coronavirus disease 2019, 211, 235,  disease, covid, By leveraging the edge direction in three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network, we can determine whether a drug is reachable to Coronavirus disease 2019 COVID-19 and the MoA between a drug and the virus protein, i.e., inhibition or stimulation.',\n",
              "  'COVID-19, 236, 244,  disease, covid, By leveraging the edge direction in three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network, we can determine whether a drug is reachable to Coronavirus disease 2019 COVID-19 and the MoA between a drug and the virus protein, i.e., inhibition or stimulation.',\n",
              "  'Coronavirus disease 2019, 78, 102,  disease, covid, Considering that patients with specific comorbidities are more susceptible to Coronavirus disease 2019 COVID-19 infection, we inspected the side effect of the drug candidate on several common comorbidities based on the genetic information of several complex diseases.',\n",
              "  'COVID-19 infection, 103, 121,  disease, covid, Considering that patients with specific comorbidities are more susceptible to Coronavirus disease 2019 COVID-19 infection, we inspected the side effect of the drug candidate on several common comorbidities based on the genetic information of several complex diseases.',\n",
              "  'Coronavirus disease 2019, 68, 92,  disease, covid, We reported 29 FDA-approved drugs 7 currently in clinical trials as Coronavirus disease 2019 COVID-19 treatment by a scoring strategy accounting for the effects of drugs on CoVs and comorbidities and other auxiliary information.',\n",
              "  'COVID-19, 93, 101,  disease, covid, We reported 29 FDA-approved drugs 7 currently in clinical trials as Coronavirus disease 2019 COVID-19 treatment by a scoring strategy accounting for the effects of drugs on CoVs and comorbidities and other auxiliary information.',\n",
              "  'CoVs, 173, 177,  disease, covid, We reported 29 FDA-approved drugs 7 currently in clinical trials as Coronavirus disease 2019 COVID-19 treatment by a scoring strategy accounting for the effects of drugs on CoVs and comorbidities and other auxiliary information.',\n",
              "  'CoV infection, 109, 122,  disease, covid, We first comprehensively collected candidate host genes from three major domains for mechanistic research of CoV infection genetic risk genes, physical interaction genes, and biological regulation genes A. The source of genetic risk genes was mainly collected from the GWASs of Coronavirus disease 2019 COVID-19.',\n",
              "  'Coronavirus disease 2019, 278, 302,  disease, covid, We first comprehensively collected candidate host genes from three major domains for mechanistic research of CoV infection genetic risk genes, physical interaction genes, and biological regulation genes A. The source of genetic risk genes was mainly collected from the GWASs of Coronavirus disease 2019 COVID-19.',\n",
              "  'COVID-19, 303, 311,  disease, covid, We first comprehensively collected candidate host genes from three major domains for mechanistic research of CoV infection genetic risk genes, physical interaction genes, and biological regulation genes A. The source of genetic risk genes was mainly collected from the GWASs of Coronavirus disease 2019 COVID-19.',\n",
              "  'CoV, 88, 91,  disease, covid, The biological regulation genes were collected from the results of the CRISPR screen of CoV-infected cells.',\n",
              "  'CoV, 65, 68,  disease, covid, Thus, we constructed a directed multicomponent network including CoV, host genes, human genes, drug targets, and drugs.',\n",
              "  \"-CoVs, 33, 38,  disease, covid, We then searched for drug-gene s -CoVs paths in a directed multicomponent network including CoV, host genes, human genes, drug targets, and drugs and used the direction information to screen out drugs with suitable MoAs C. To investigate the impact of drug candidates on the underlying disease in patients with COVID-19, we also identified genetic risk genes for common complex diseases and genetic risk genes for common complex diseases's direction to disease from genetic data.\",\n",
              "  \"CoV, 92, 95,  disease, covid, We then searched for drug-gene s -CoVs paths in a directed multicomponent network including CoV, host genes, human genes, drug targets, and drugs and used the direction information to screen out drugs with suitable MoAs C. To investigate the impact of drug candidates on the underlying disease in patients with COVID-19, we also identified genetic risk genes for common complex diseases and genetic risk genes for common complex diseases's direction to disease from genetic data.\",\n",
              "  \"COVID-19, 311, 319,  disease, covid, We then searched for drug-gene s -CoVs paths in a directed multicomponent network including CoV, host genes, human genes, drug targets, and drugs and used the direction information to screen out drugs with suitable MoAs C. To investigate the impact of drug candidates on the underlying disease in patients with COVID-19, we also identified genetic risk genes for common complex diseases and genetic risk genes for common complex diseases's direction to disease from genetic data.\",\n",
              "  'CoVs, 203, 207,  disease, covid, Finally, drugs with a potential inhibitory effect on the disease were prioritized based on a combined score, and conversely, drugs that promote disease were filtered out D.Phylogenetic analysis of human CoVs shows that SARS-CoV-2, SARS-CoV, and MERS-CoV have a high conservative genome.',\n",
              "  'SARS-CoV-2, 219, 229,  disease, covid, Finally, drugs with a potential inhibitory effect on the disease were prioritized based on a combined score, and conversely, drugs that promote disease were filtered out D.Phylogenetic analysis of human CoVs shows that SARS-CoV-2, SARS-CoV, and MERS-CoV have a high conservative genome.',\n",
              "  'SARS-CoV, 231, 239,  disease, covid, Finally, drugs with a potential inhibitory effect on the disease were prioritized based on a combined score, and conversely, drugs that promote disease were filtered out D.Phylogenetic analysis of human CoVs shows that SARS-CoV-2, SARS-CoV, and MERS-CoV have a high conservative genome.',\n",
              "  'MERS-CoV, 245, 253,  disease, covid, Finally, drugs with a potential inhibitory effect on the disease were prioritized based on a combined score, and conversely, drugs that promote disease were filtered out D.Phylogenetic analysis of human CoVs shows that SARS-CoV-2, SARS-CoV, and MERS-CoV have a high conservative genome.',\n",
              "  'SARS-CoV-2, 56, 66,  disease, covid, Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.',\n",
              "  'SARS-CoV, 149, 157,  disease, covid, Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.',\n",
              "  'MERS-CoV, 162, 170,  disease, covid, Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.',\n",
              "  'SARS-CoV-2, 182, 192,  disease, covid, Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.',\n",
              "  'SARS-CoV, 194, 202,  disease, covid, Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.',\n",
              "  'MERS-CoV, 208, 216,  disease, covid, Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.',\n",
              "  'COVID-19, 112, 120,  disease, covid, We systematically integrated candidate host genes from three different angles to identify genetic risk genes of COVID-19, we first got significant risk variants p-value<5 × 10−8 of 517 COVID-19 GWASs from GRASP, yielding 2618 risk variants significantly associated with COVID-19.',\n",
              "  'COVID-19, 185, 193,  disease, covid, We systematically integrated candidate host genes from three different angles to identify genetic risk genes of COVID-19, we first got significant risk variants p-value<5 × 10−8 of 517 COVID-19 GWASs from GRASP, yielding 2618 risk variants significantly associated with COVID-19.',\n",
              "  'COVID-19, 270, 278,  disease, covid, We systematically integrated candidate host genes from three different angles to identify genetic risk genes of COVID-19, we first got significant risk variants p-value<5 × 10−8 of 517 COVID-19 GWASs from GRASP, yielding 2618 risk variants significantly associated with COVID-19.',\n",
              "  'COVID-19, 251, 259,  disease, covid, If the risk variant is an expression quantitative trait locus eQTL of whole blood or lung, we retrieved the eGene of an expression quantitative trait locus eQTL of whole blood or lung as the risk gene and inferred the direction of the risk variant to COVID-19 by matching the effect size of the GWAS and the effect size of an expression quantitative trait locus eQTL of whole blood or lung.',\n",
              "  'COVID-19, 139, 147,  disease, covid, The association on chromosome 19p13.12 colocalizes an eQTL of TYK2, the target of JAK inhibitors, whose high expression is associated with COVID-19.',\n",
              "  'CoVs, 57, 61,  disease, covid, To collect the high confidence proteins interacting with CoVs, we gathered data from PPI databases, public literature, and affinity AP-MS analyses.',\n",
              "  'CoV infection, 47, 60,  disease, covid, We used up- and downregulation of genes in the CoV infection process as gene-to-virus direction.',\n",
              "  'SARS-CoV, 111, 119,  disease, covid, Among 435 genes that interact with viral proteins and their direction of action, 16 genes interacted with both SARS-CoV and SARS-CoV-2 and were significantly differentially expressed in the expression profiles of both SARS-CoV and SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 124, 134,  disease, covid, Among 435 genes that interact with viral proteins and their direction of action, 16 genes interacted with both SARS-CoV and SARS-CoV-2 and were significantly differentially expressed in the expression profiles of both SARS-CoV and SARS-CoV-2.',\n",
              "  'SARS-CoV, 218, 226,  disease, covid, Among 435 genes that interact with viral proteins and their direction of action, 16 genes interacted with both SARS-CoV and SARS-CoV-2 and were significantly differentially expressed in the expression profiles of both SARS-CoV and SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 231, 241,  disease, covid, Among 435 genes that interact with viral proteins and their direction of action, 16 genes interacted with both SARS-CoV and SARS-CoV-2 and were significantly differentially expressed in the expression profiles of both SARS-CoV and SARS-CoV-2.',\n",
              "  'COVID-19, 36, 44,  disease, covid, Aconitase1 ACO1 is overexpressed in COVID-19 and underexpressed in non-COVID-19 viral infections.',\n",
              "  'COVID-19, 71, 79,  disease, covid, Aconitase1 ACO1 is overexpressed in COVID-19 and underexpressed in non-COVID-19 viral infections.',\n",
              "  'COVID-19, 103, 111,  disease, covid, Interestingly, Aconitase1 ACO1 is involved in iron metabolism, and heme appears to be interlinked with COVID-19 pathophysiology.',\n",
              "  'CoVs, 75, 79,  disease, covid, PCDH9, one of the downregulated genes, interacts with multiple proteins of CoVs, including M, NSP6, ORF6, ORF7a, ORF7b, and S proteins.',\n",
              "  'COVID-19 infection, 99, 117,  disease, covid, The disruption of cadherin proteins by viral protein ORF7b could contribute to several symptoms of COVID-19 infection, including multiorgan failure.',\n",
              "  'CoVs, 98, 102,  disease, covid, Genome-wide screens have been widely used to identify host factors for various viruses, including CoVs.',\n",
              "  'SARS-CoV-2, 70, 80,  disease, covid, It is worth noting that seven genes were selected in the screening of SARS-CoV-2, SARS-CoV, and MERS-CoV, including CTSL, which encodes the Cathepsin L protease.',\n",
              "  'SARS-CoV, 82, 90,  disease, covid, It is worth noting that seven genes were selected in the screening of SARS-CoV-2, SARS-CoV, and MERS-CoV, including CTSL, which encodes the Cathepsin L protease.',\n",
              "  'MERS-CoV, 96, 104,  disease, covid, It is worth noting that seven genes were selected in the screening of SARS-CoV-2, SARS-CoV, and MERS-CoV, including CTSL, which encodes the Cathepsin L protease.',\n",
              "  'SARS-CoV-2, 73, 83,  disease, covid, CTSL, which encodes the Cathepsin L protease can functionally cleave the SARS-CoV-2 spike protein and enhance virus entry.',\n",
              "  'SARS-CoV-2, 93, 103,  disease, covid, Studies have shown that inhibitors of the Cathepsin L protease can effectively prevent human SARS-CoV-2, SARS-CoV, and MERS-CoV infection.',\n",
              "  'SARS-CoV, 105, 113,  disease, covid, Studies have shown that inhibitors of the Cathepsin L protease can effectively prevent human SARS-CoV-2, SARS-CoV, and MERS-CoV infection.',\n",
              "  'MERS-CoV infection, 119, 137,  disease, covid, Studies have shown that inhibitors of the Cathepsin L protease can effectively prevent human SARS-CoV-2, SARS-CoV, and MERS-CoV infection.',\n",
              "  'CoV, 237, 240,  disease, covid, Remarkably, no genes were collected from the three sources simultaneously, and the overlap between the three sources is also relatively small, suggesting current biological assays or genetic methods may capture complementary patterns of CoV-host crosstalk.',\n",
              "  'SARS-CoV-2, 133, 143,  disease, covid, For example, only 1 out of the 77 genetic risk genes is derived from the CRISPR screen and physical interaction, respectively A. For SARS-CoV-2, we revealed 882 candidate host genes B. Among 882 candidate host genes B., BMPR2 is not only a genetic risk gene but also interacts with SARS-CoV-2 ORF3 protein.',\n",
              "  'SARS-CoV-2, 282, 292,  disease, covid, For example, only 1 out of the 77 genetic risk genes is derived from the CRISPR screen and physical interaction, respectively A. For SARS-CoV-2, we revealed 882 candidate host genes B. Among 882 candidate host genes B., BMPR2 is not only a genetic risk gene but also interacts with SARS-CoV-2 ORF3 protein.',\n",
              "  'SARS-CoV-2, 0, 10,  disease, covid, SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.',\n",
              "  'SARS-CoV, 15, 23,  disease, covid, SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.',\n",
              "  'SARS-CoV-2, 99, 109,  disease, covid, SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.',\n",
              "  'SARS-CoV-2, 186, 196,  disease, covid, SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.',\n",
              "  'MERS-CoV, 201, 209,  disease, covid, SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.',\n",
              "  \"SARS-CoV-2, 94, 104,  disease, covid, We divided these genes into antiviral and proviral genes according to these genes's effect on SARS-CoV-2, SARS-CoV, and MERS-CoV. There are 654 antiviral genes and 756 proviral genes.\",\n",
              "  \"SARS-CoV, 106, 114,  disease, covid, We divided these genes into antiviral and proviral genes according to these genes's effect on SARS-CoV-2, SARS-CoV, and MERS-CoV. There are 654 antiviral genes and 756 proviral genes.\",\n",
              "  \"MERS-CoV., 120, 129,  disease, covid, We divided these genes into antiviral and proviral genes according to these genes's effect on SARS-CoV-2, SARS-CoV, and MERS-CoV. There are 654 antiviral genes and 756 proviral genes.\",\n",
              "  'CoVs, 42, 46,  disease, covid, The catalog of host genes associated with CoVs and the directional information can provide mechanistic insight for drug target selection.',\n",
              "  'COVID-19, 183, 191,  disease, covid, As the development of a new drug takes a long time and huge cost, we believe our integrated resource could be alternatively suitable for improving drug repositioning opportunities on COVID-19.',\n",
              "  'gene-CoV, 110, 118,  disease, covid, We merged drug-target interactions, human protein interactions, and virus-host interactions into a whole drug-gene-CoV network.',\n",
              "  '-CoVs, 76, 81,  disease, covid, Then we used the random walk with restart RWR algorithm to find drug-gene s -CoVs paths in a whole drug-gene-CoV network and inferred the direction of the drug to the CoVs see.',\n",
              "  'gene-CoV, 104, 112,  disease, covid, Then we used the random walk with restart RWR algorithm to find drug-gene s -CoVs paths in a whole drug-gene-CoV network and inferred the direction of the drug to the CoVs see.',\n",
              "  'CoVs, 167, 171,  disease, covid, Then we used the random walk with restart RWR algorithm to find drug-gene s -CoVs paths in a whole drug-gene-CoV network and inferred the direction of the drug to the CoVs see.',\n",
              "  'CoVs, 47, 51,  disease, covid, Totally, 6234 drugs with inhibitory effects on CoVs were inferred.',\n",
              "  'COVID-19, 80, 88,  disease, covid, Older age and comorbidities play essential roles in influencing the severity of COVID-19.',\n",
              "  '-CoVs, 71, 76,  disease, covid, To select the optimal drugs, we utilized the properties of drug-gene s -CoVs path including drug-target interaction, network mapping, and source of host genes for each drug to derive a combined score and used a combined score to prioritize drug candidates see.',\n",
              "  'COVID-19, 139, 147,  disease, covid, We found that 29 of the top 100 drugs are FDA approved A, and seven of 29 of the top 100 drugs are in clinical trials for the treatment of COVID-19.',\n",
              "  'COVID-19, 46, 54,  disease, covid, We collected 397 drugs in clinical trials for COVID-19 from and overlapped with the top 100 drugs.',\n",
              "  'COVID-19, 93, 101,  disease, covid, None of the drugs in clinical trials prior to phase 3 have been found in clinical trials for COVID-19, and there are nine drugs in phase 3/4 clinical trials for COVID-19 B this may be because most of the COVID-19 clinical trial drugs are in clinical phase 3 or FDA approved.',\n",
              "  'COVID-19, 161, 169,  disease, covid, None of the drugs in clinical trials prior to phase 3 have been found in clinical trials for COVID-19, and there are nine drugs in phase 3/4 clinical trials for COVID-19 B this may be because most of the COVID-19 clinical trial drugs are in clinical phase 3 or FDA approved.',\n",
              "  'COVID-19, 204, 212,  disease, covid, None of the drugs in clinical trials prior to phase 3 have been found in clinical trials for COVID-19, and there are nine drugs in phase 3/4 clinical trials for COVID-19 B this may be because most of the COVID-19 clinical trial drugs are in clinical phase 3 or FDA approved.',\n",
              "  'SARS-CoV-2, 107, 117,  disease, covid, chlorpromazine is an antipsychotic drug that has recently been proposed to have antiviral activity against SARS-CoV-2.',\n",
              "  'SARS-CoV-2, 50, 60,  disease, covid, Recently, bosutinib was found to strongly inhibit SARS-CoV-2 in vitro with low toxicity.',\n",
              "  'COVID-19, 62, 70,  disease, covid, Recently, it was reported that pseudoephedrine can antagonize COVID-19 virus by blocking virus expansion.',\n",
              "  'SARS-CoV2, 59, 68,  disease, covid, Another example is that ponatinib is a potent inhibitor of SARS-CoV2-induced cytokine storm, whereas epinephrine may be considered an intervention to minimize the severity of COVID-19.',\n",
              "  'COVID-19, 175, 183,  disease, covid, Another example is that ponatinib is a potent inhibitor of SARS-CoV2-induced cytokine storm, whereas epinephrine may be considered an intervention to minimize the severity of COVID-19.',\n",
              "  'CoV, 65, 68,  disease, covid, We measured the associations of gene expression patterns between CoV-infected patients and the reference-compound-perturbed cells.',\n",
              "  'COVID-19, 0, 8,  disease, covid, COVID-19 clinical trial drugs are used as ground truth.',\n",
              "  'SARS-CoV-2 infection, 227, 247,  disease, covid, Our method has the highest area under the curve AUC of 0.61 compared with the results calculated by the CMAP method based on similarity analysis of expression profiles, which was frequently used in drug repositioning using two SARS-CoV-2 infection expression profiles C.Network analysis methods such as deep learning, network diffusion, and network proximity can evaluate the accessibility of drugs to SARS-CoV-2 in the background network.',\n",
              "  'SARS-CoV-2, 402, 412,  disease, covid, Our method has the highest area under the curve AUC of 0.61 compared with the results calculated by the CMAP method based on similarity analysis of expression profiles, which was frequently used in drug repositioning using two SARS-CoV-2 infection expression profiles C.Network analysis methods such as deep learning, network diffusion, and network proximity can evaluate the accessibility of drugs to SARS-CoV-2 in the background network.',\n",
              "  'SARS-CoV-2, 45, 55,  disease, covid, For example, SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is identified as a proviral gene in our study.',\n",
              "  'SARS-CoV-2, 96, 106,  disease, covid, Although which class of drugs, i.e., agonists or antagonists of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is responsible for the replication activity of SARS-CoV-2 remains to be verified by more experiments, the latest evidence revealed that knockout or knockdown of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein could cause significant reductions in SARS-CoV-2 replication.',\n",
              "  'SARS-CoV-2, 163, 173,  disease, covid, Although which class of drugs, i.e., agonists or antagonists of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is responsible for the replication activity of SARS-CoV-2 remains to be verified by more experiments, the latest evidence revealed that knockout or knockdown of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein could cause significant reductions in SARS-CoV-2 replication.',\n",
              "  'SARS-CoV-2, 309, 319,  disease, covid, Although which class of drugs, i.e., agonists or antagonists of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is responsible for the replication activity of SARS-CoV-2 remains to be verified by more experiments, the latest evidence revealed that knockout or knockdown of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein could cause significant reductions in SARS-CoV-2 replication.',\n",
              "  'SARS-CoV-2, 366, 376,  disease, covid, Although which class of drugs, i.e., agonists or antagonists of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is responsible for the replication activity of SARS-CoV-2 remains to be verified by more experiments, the latest evidence revealed that knockout or knockdown of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein could cause significant reductions in SARS-CoV-2 replication.',\n",
              "  'SARS-CoV-2, 129, 139,  disease, covid, Furthermore, a clinical trial demonstrated that the antidepressant fluvoxamine, an antagonist of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, could prevent clinical deterioration in adult outpatients infected with SARS-CoV-2 A. However, there are network-based approaches to select SIGMAR1, the target of the NSP6 SARS-CoV-2 protein agonists, such as amitriptyline, as a potential treatment for COVID-19, implying confliction and limitation may largely exist among current methods.',\n",
              "  'SARS-CoV-2, 221, 231,  disease, covid, Furthermore, a clinical trial demonstrated that the antidepressant fluvoxamine, an antagonist of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, could prevent clinical deterioration in adult outpatients infected with SARS-CoV-2 A. However, there are network-based approaches to select SIGMAR1, the target of the NSP6 SARS-CoV-2 protein agonists, such as amitriptyline, as a potential treatment for COVID-19, implying confliction and limitation may largely exist among current methods.',\n",
              "  'SARS-CoV-2, 321, 331,  disease, covid, Furthermore, a clinical trial demonstrated that the antidepressant fluvoxamine, an antagonist of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, could prevent clinical deterioration in adult outpatients infected with SARS-CoV-2 A. However, there are network-based approaches to select SIGMAR1, the target of the NSP6 SARS-CoV-2 protein agonists, such as amitriptyline, as a potential treatment for COVID-19, implying confliction and limitation may largely exist among current methods.',\n",
              "  'COVID-19, 402, 410,  disease, covid, Furthermore, a clinical trial demonstrated that the antidepressant fluvoxamine, an antagonist of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, could prevent clinical deterioration in adult outpatients infected with SARS-CoV-2 A. However, there are network-based approaches to select SIGMAR1, the target of the NSP6 SARS-CoV-2 protein agonists, such as amitriptyline, as a potential treatment for COVID-19, implying confliction and limitation may largely exist among current methods.',\n",
              "  'COVID-19, 126, 134,  disease, covid, There are four clinical trials of cannabidiol CBD, a member of the cannabinoid class of natural products for the treatment of COVID-19.',\n",
              "  'SARS-CoV-2, 141, 151,  disease, covid, Studies have shown that cannabidiol CBD, a member of the cannabinoid class of natural products can inhibit the cell entry and replication of SARS-CoV-2.',\n",
              "  'COVID-19, 267, 275,  disease, covid, The anti-inflammatory and antioxidant effects of cannabidiol CBD, a member of the cannabinoid class of natural products may make cannabidiol CBD, a member of the cannabinoid class of natural products a treatment for coronary heart disease and diabetes, together with COVID-19 B. Estradiol cypionate EC is an estrogen medication used in hormone therapy for menopausal symptoms and low estrogen levels in cis women.',\n",
              "  'COVID-19, 56, 64,  disease, covid, The analysis of electronic health records of over 68000 COVID-19 patients revealed that estrogen therapy is associated with more than 50% reduction in mortality.',\n",
              "  'COVID-19, 43, 51,  disease, covid, Estradiol cypionate EC was repositioned as COVID-19 treatment in other studies and is now in phase 2 clinical trial.',\n",
              "  \"CoVs, 85, 89,  disease, covid, To this end, we comprehensively identified host genes and host genes's directions to CoVs by systematically integrating multi-omics data from mass spectrometry, CRISPR screening, and GWAS.\",\n",
              "  'SARS-CoV-2, 33, 43,  disease, covid, We identified 964 host genes for SARS-CoV-2, 477 host genes for SARS-CoV, 236 host genes for MERS-CoV, and 1410 unique genes.',\n",
              "  'SARS-CoV, 64, 72,  disease, covid, We identified 964 host genes for SARS-CoV-2, 477 host genes for SARS-CoV, 236 host genes for MERS-CoV, and 1410 unique genes.',\n",
              "  'MERS-CoV, 93, 101,  disease, covid, We identified 964 host genes for SARS-CoV-2, 477 host genes for SARS-CoV, 236 host genes for MERS-CoV, and 1410 unique genes.',\n",
              "  \"SARS-CoV-2, 41, 51,  disease, covid, There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\",\n",
              "  \"SARS-CoV, 56, 64,  disease, covid, There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\",\n",
              "  \"SARS-CoV-2, 78, 88,  disease, covid, There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\",\n",
              "  \"MERS-CoV, 93, 101,  disease, covid, There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\",\n",
              "  \"SARS-CoV-2, 150, 160,  disease, covid, There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\",\n",
              "  \"SARS-CoV, 181, 189,  disease, covid, There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\",\n",
              "  'COVID-19, 102, 110,  disease, covid, Twenty-nine of the top 100 prioritized drugs are FDA approved, including seven in clinical trials for COVID-19.',\n",
              "  'SARS-CoV-2, 36, 46,  disease, covid, We found that CBD not only inhibits SARS-CoV-2 but may also act as a therapeutic drug for coronary heart disease and diabetes.',\n",
              "  \"CoVs, 66, 70,  disease, covid, Overall, we first comprehensively characterized the host genes of CoVs and the host genes of CoVs's role in viral infection.\",\n",
              "  \"CoVs, 93, 97,  disease, covid, Overall, we first comprehensively characterized the host genes of CoVs and the host genes of CoVs's role in viral infection.\",\n",
              "  'CoV, 49, 52,  disease, covid, The effects of these host genes we identified on CoV need to be validated in in vivo and in vitro experiments.',\n",
              "  'COVID-19, 14, 22,  disease, covid, Besides, many COVID-19 drug repositioning studies, including our study, have used clinical trial datasets as ground truth for performance evaluation.',\n",
              "  'CoV, 45, 48,  disease, covid, Finally, to infer the direction of a drug to CoV in each drug-gene s -CoVs path, we used a random walk algorithm and then combined multiple drug paths for prioritization.',\n",
              "  '-CoVs, 69, 74,  disease, covid, Finally, to infer the direction of a drug to CoV in each drug-gene s -CoVs path, we used a random walk algorithm and then combined multiple drug paths for prioritization.',\n",
              "  'SARS-CoV-2, 10, 20,  disease, covid, Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "  'SARS-CoV, 60, 68,  disease, covid, Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "  'MERS-CoV, 73, 81,  disease, covid, Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "  'SARS-CoV-2, 87, 97,  disease, covid, Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "  'SARS-CoV, 147, 155,  disease, covid, Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "  'MERS-CoV., 160, 169,  disease, covid, Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "  'CoVs, 266, 270,  disease, covid, Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "  'CoVs, 314, 318,  disease, covid, Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "  'COVID-19, 50, 58,  disease, covid, We first retrieved all risk SNP p-value < 5e-8 in COVID-19 GWAS from GRASP COVID-19 data.',\n",
              "  'COVID-19, 75, 83,  disease, covid, We first retrieved all risk SNP p-value < 5e-8 in COVID-19 GWAS from GRASP COVID-19 data.',\n",
              "  'COVID-19, 37, 45,  disease, covid, Then, all risk SNP p-value < 5e-8 in COVID-19 GWAS were annotated as coding variants and non-coding variants by VEP.',\n",
              "  'COVID-19, 25, 33,  disease, covid, When a variant is both a COVID-19 risk variant and an eQTL, the associated expression gene is identified as the target gene of a variant.',\n",
              "  'CoVs, 41, 45,  disease, covid, We collected host genes interacting with CoVs from four PPI databases, including BioGRID, IntAct, STRING.',\n",
              "  'CoVs, 63, 67,  disease, covid, We also included high-confidence proteins that interacted with CoVs from three AP-MS experiments.',\n",
              "  'CoV, 48, 51,  disease, covid, In addition, we also included the host genes of CoV collected by Zhou, Y. et al. However, there is no information on the direction of host genes to CoV in these datasets.',\n",
              "  'CoV, 148, 151,  disease, covid, In addition, we also included the host genes of CoV collected by Zhou, Y. et al. However, there is no information on the direction of host genes to CoV in these datasets.',\n",
              "  'CoVs, 51, 55,  disease, covid, We got differentially expressed genes of all three CoVs by analyzing corresponding gene expression profiles from the NCBI Gene Expression Omnibus.',\n",
              "  \"CoVs, 92, 96,  disease, covid, We construct a directed virus-host network by combining all gene-virus pairs from all three CoVs and all gene-virus pairs from the three sources's directions.\",\n",
              "  'CoVs, 119, 123,  disease, covid, By integrating the directional networks described above, we can identify the potential repositioning of known drugs on CoVs.',\n",
              "  '-CoVs, 40, 45,  disease, covid, We searched the appropriate drug-gene s -CoVs paths for each compound.',\n",
              "  '-CoVs, 102, 107,  disease, covid, Then, we inspected the accessibility of each drug to host genes and assembled directional drug-gene s -CoVs paths.',\n",
              "  'CoVs, 270, 274,  disease, covid, Since all the interactions in networks were labeled with directions encoded as 1 and -1 for positive effect and negative effect, respectively, we multiply directions encoded as 1 and -1 for positive effect and negative effect, respectively to infer the drug’s effect on CoVs.',\n",
              "  'CoV, 41, 44,  disease, covid, Drugs that have a negative impact on the CoV are considered a potential repositioning, and the proviral drugs were removed.',\n",
              "  \"COVID-19, 136, 144,  disease, covid, Then we predicted disease-associated genes and disease-associated genes's directions of effect on diseases by the same approach linking COVID-19 risk SNPs to genes.\",\n",
              "  '-CoV, 37, 41,  disease, covid, A drug may have multiple drug-gene s -CoV paths.',\n",
              "  '-CoV, 21, 25,  disease, covid, For each Drug-Gene s -CoV path, we assigned a DGV score, which equals the accumulation of drug target score, mapping score, and host gene score.',\n",
              "  'SARS-CoV-2 infected, 36, 55,  disease, covid, We used gene expression profiles of SARS-CoV-2 infected samples and a control group from alveolar type II cells and African green monkey kidney cells.',\n",
              "  'COVID-19, 67, 75,  disease, covid, We take as ground truth all drugs currently in clinical trials for COVID-19.']]"
            ]
          },
          "metadata": {},
          "execution_count": 28
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# print the number of COVID entities matched in each article\n",
        "for i in covid_ents_only:\n",
        "    print(len(i))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "aE-OtUnbrKk_",
        "outputId": "a29ddccc-23cc-40c0-e645-5533e1210811"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "29\n",
            "150\n",
            "70\n",
            "198\n",
            "64\n",
            "82\n",
            "49\n",
            "234\n",
            "89\n",
            "192\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-22_articles_0-10_covid_ents_only_web_sm_1157.pickle', 'wb') as f:\n",
        "   pickle.dump(covid_ents_only, f)"
      ],
      "metadata": {
        "id": "KhdjpGK2rwqJ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will define function to iterate over the COVID entities doc list, extract the entity_id, entity_type, entity, spans and text, and return a list of dictionaries."
      ],
      "metadata": {
        "id": "tZz9Y4BNgC1M"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def get_covid_ents(docs):\n",
        "    covid_ent_list = []\n",
        "    for index, doc in enumerate(docs):\n",
        "        for ent in doc.ents:\n",
        "            if ent.label_ in [\"disease\", \"covid lineage\"]:\n",
        "                entity_dict = {\n",
        "                    \"entity_id\":ent.kb_id_,\n",
        "                    \"entity_type\": ent.label_,\n",
        "                    \"entity\": ent.text,\n",
        "                    \"span_start\": ent.start_char,\n",
        "                    \"span_end\": ent.end_char,\n",
        "                    \"text\": doc.text\n",
        "                }\n",
        "                covid_ent_list.append(entity_dict)\n",
        "    return covid_ent_list"
      ],
      "metadata": {
        "id": "GVwxUANXtA9Y"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "covid_ents_only = list(map(get_covid_ents, flattened_doc_list))"
      ],
      "metadata": {
        "id": "tKAhGtOttA9Z"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(covid_ents_only)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "0912e8cc-cace-495d-b0d8-f35fa4f5b5b7",
        "id": "Hb7hDWbDtA9Z"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "10"
            ]
          },
          "metadata": {},
          "execution_count": 34
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "covid_ents_only"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "a355c398-1e51-4574-f164-26d9cb5a4fdf",
        "id": "9rgaxEUTtA9Z"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[[{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 197,\n",
              "   'span_end': 205,\n",
              "   'text': 'The number of annual publications has been increasing at a relatively high rate since 2015, while in 2020, there was a spike in the number of publications and annual citations, probably due to the COVID-19 pandemic, a global public health emergency that prompted special attention from scientists.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 59,\n",
              "   'span_end': 67,\n",
              "   'text': 'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 68,\n",
              "   'span_end': 78,\n",
              "   'text': 'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 79,\n",
              "   'span_end': 90,\n",
              "   'text': 'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 96,\n",
              "   'span_end': 104,\n",
              "   'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 105,\n",
              "   'span_end': 115,\n",
              "   'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 116,\n",
              "   'span_end': 127,\n",
              "   'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 168,\n",
              "   'span_end': 176,\n",
              "   'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 177,\n",
              "   'span_end': 187,\n",
              "   'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 188,\n",
              "   'span_end': 199,\n",
              "   'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 73,\n",
              "   'span_end': 81,\n",
              "   'text': 'Molecular docking is one of the core steps of virtual screening, and the COVID-19 pandemic generated many opportunities for the practice of drug repositioning.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 48,\n",
              "   'span_end': 56,\n",
              "   'text': 'Therefore, high-quality studies of the keywords COVID-19/SARS-CoV-2/Coronavirus, Virtual screening, and Molecular docking were surveyed, as shown in the bubble chart, in the past two years, reflecting the relevant research trend in recent years.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 57,\n",
              "   'span_end': 67,\n",
              "   'text': 'Therefore, high-quality studies of the keywords COVID-19/SARS-CoV-2/Coronavirus, Virtual screening, and Molecular docking were surveyed, as shown in the bubble chart, in the past two years, reflecting the relevant research trend in recent years.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 68,\n",
              "   'span_end': 79,\n",
              "   'text': 'Therefore, high-quality studies of the keywords COVID-19/SARS-CoV-2/Coronavirus, Virtual screening, and Molecular docking were surveyed, as shown in the bubble chart, in the past two years, reflecting the relevant research trend in recent years.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 108,\n",
              "   'span_end': 118,\n",
              "   'text': 'In a virtual screening process, Gervasoni, S. conducted a literature search for molecular binding sites for SARS-CoV-2-associated protein targets while combining pocket and docking searches to propose a new pocket mapping strategy that identifies binding cavities with significantly better performance than pocket detection alone.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 243,\n",
              "   'span_end': 254,\n",
              "   'text': 'After a series of drug repurposing computational screens and various validation activities by several scientists, it was agreed that raltegravir, clonidine, chloroquine and hydroxychloroquine have therapeutic effects in the treatment of novel coronavirus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus pneumonia',\n",
              "   'span_start': 309,\n",
              "   'span_end': 330,\n",
              "   'text': 'All hot research topics were published in 2020, and with the exception of an article describing the damage caused by nonsteroidal anti-inflammatory drugs NSAIDs to multiple organs and new information on drug repurposing, the remaining studies focused on drug repositioning therapeutic target studies in novel coronavirus pneumonia, screening drug studies, reviews of clinical trials, and reports of other coronavirus therapeutic agents and vaccine studies.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 405,\n",
              "   'span_end': 416,\n",
              "   'text': 'All hot research topics were published in 2020, and with the exception of an article describing the damage caused by nonsteroidal anti-inflammatory drugs NSAIDs to multiple organs and new information on drug repurposing, the remaining studies focused on drug repositioning therapeutic target studies in novel coronavirus pneumonia, screening drug studies, reviews of clinical trials, and reports of other coronavirus therapeutic agents and vaccine studies.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 15,\n",
              "   'span_end': 25,\n",
              "   'text': 'In addition, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, published in Nature by Gordon, DE with a total of 125 scholars from the United States, the United Kingdom, and France was the most cited publication with 952 citations.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '2019-nCoV',\n",
              "   'span_start': 103,\n",
              "   'span_end': 112,\n",
              "   'text': 'The most cited publication on an annual basis was Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, published in 2020, which was authored by Zhou, YD et al. and was the highest annual average cited publication with 609 citations.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 113,\n",
              "   'span_end': 123,\n",
              "   'text': 'The most cited publication on an annual basis was Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, published in 2020, which was authored by Zhou, YD et al. and was the highest annual average cited publication with 609 citations.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 51,\n",
              "   'span_end': 62,\n",
              "   'text': 'The three studies published in 2020 focus on novel coronavirus-related drug rediscovery activities and the use of deep learning techniques. and Pushpakom, S et al. provided systematic reviews of the methods and challenges of drug repositioning at that time.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 143,\n",
              "   'span_end': 154,\n",
              "   'text': \"The reasons for this may be the following first, there was a breakthrough in basic research in biophysics in 2020 and second, due to the novel coronavirus, research in this direction has increased research in this direction's application for the prevention and control of the pandemic.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 282,\n",
              "   'span_end': 295,\n",
              "   'text': 'In terms of antiviral drugs, scholars not only use drug repositioning to find antiviral drugs to treat diseases, such as Ebola and HIV, that have plagued humans for a long time but also use drug repositioning to seek treatments for infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 54,\n",
              "   'span_end': 67,\n",
              "   'text': 'For infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world, emergency research on drug repositioning has played an important role in reducing mortality, calming patient fears, and restoring economic production when no specific drugs or vaccines were initially available during the pandemic.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 82,\n",
              "   'span_end': 95,\n",
              "   'text': 'In fact, some of the studies in the list of highly cited research topics on novel coronaviruses drug repurposing studies are currently approaching 3000 citations on Google Scholar.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 80,\n",
              "   'span_end': 93,\n",
              "   'text': 'The percentage of highly cited studies and hot research topics related to novel coronaviruses is also a good indication that drug repositioning has made an indelible contribution to the study of novel coronaviruses and similar infectious diseases.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 201,\n",
              "   'span_end': 214,\n",
              "   'text': 'The percentage of highly cited studies and hot research topics related to novel coronaviruses is also a good indication that drug repositioning has made an indelible contribution to the study of novel coronaviruses and similar infectious diseases.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 79,\n",
              "   'span_end': 90,\n",
              "   'text': 'The authors’ keyword analysis suggests that research in the field of the novel coronavirus will remain valuable until the associated pandemic is completely contained.'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 115,\n",
              "   'span_end': 123,\n",
              "   'text': 'Most importantly, recent studies have illuminated the potential roles of CADD in designing new drug candidates for COVID‐19 treatment.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviruses',\n",
              "   'span_start': 0,\n",
              "   'span_end': 13,\n",
              "   'text': 'Coronaviruses CoVs are cross‐species viruses and can spread expeditiously into new host species, which in turn cause epidemic diseases.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 14,\n",
              "   'span_end': 18,\n",
              "   'text': 'Coronaviruses CoVs are cross‐species viruses and can spread expeditiously into new host species, which in turn cause epidemic diseases.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 25,\n",
              "   'span_end': 28,\n",
              "   'text': 'The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome CoV',\n",
              "   'span_start': 76,\n",
              "   'span_end': 113,\n",
              "   'text': 'The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV',\n",
              "   'span_start': 114,\n",
              "   'span_end': 122,\n",
              "   'text': 'The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 160,\n",
              "   'span_end': 163,\n",
              "   'text': 'The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS‐CoV',\n",
              "   'span_start': 164,\n",
              "   'span_end': 172,\n",
              "   'text': 'The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 220,\n",
              "   'span_end': 224,\n",
              "   'text': 'The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 8,\n",
              "   'span_end': 11,\n",
              "   'text': 'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 27,\n",
              "   'span_end': 35,\n",
              "   'text': 'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 50,\n",
              "   'span_end': 60,\n",
              "   'text': 'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome CoV',\n",
              "   'span_start': 104,\n",
              "   'span_end': 141,\n",
              "   'text': 'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV',\n",
              "   'span_start': 142,\n",
              "   'span_end': 150,\n",
              "   'text': 'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 248,\n",
              "   'span_end': 258,\n",
              "   'text': 'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 302,\n",
              "   'span_end': 313,\n",
              "   'text': 'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 23,\n",
              "   'span_end': 33,\n",
              "   'text': 'Since the outgrowth of SARS‐CoV‐2, more than 528 million people have been infected with up to 6.3 million deaths, as reported by the Food and Drug Administration.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 55,\n",
              "   'span_end': 63,\n",
              "   'text': \"Although effective vaccines have amazingly reduced the COVID‐19 cases recently, effective vaccines will not change the world right away, and importantly, effective vaccines's permanent efficacy, short‐term and long‐term side effects, and long‐term protection against different variants of SARS‐CoV‐2 are still under debate.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 289,\n",
              "   'span_end': 299,\n",
              "   'text': \"Although effective vaccines have amazingly reduced the COVID‐19 cases recently, effective vaccines will not change the world right away, and importantly, effective vaccines's permanent efficacy, short‐term and long‐term side effects, and long‐term protection against different variants of SARS‐CoV‐2 are still under debate.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 168,\n",
              "   'span_end': 179,\n",
              "   'text': 'These issues are accompanied by mass vaccination campaigns Wen et al. Furthermore, several studies have reported that vaccinated people can also be infected with novel coronavirus variants Largent & Miller.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 117,\n",
              "   'span_end': 127,\n",
              "   'text': 'Therefore, the design and introduction of new drugs, either the current drugs or synthesized agents, for eradicating SARS‐CoV‐2 is of extreme concern.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 145,\n",
              "   'span_end': 153,\n",
              "   'text': \"By assessing some antiviral drugs with previously known treatment of hepatitis, HIV, influenza, and Ebola viral diseases's effectiveness against COVID‐19, remdesivir was the one that grabbed much attention and is believed to be the most successful drug for the therapy for combating COVID‐19 Brown et al., Gholivand et al. Further potential macromolecular targets of SARS‐CoV‐2 are depicted in Figure.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 283,\n",
              "   'span_end': 291,\n",
              "   'text': \"By assessing some antiviral drugs with previously known treatment of hepatitis, HIV, influenza, and Ebola viral diseases's effectiveness against COVID‐19, remdesivir was the one that grabbed much attention and is believed to be the most successful drug for the therapy for combating COVID‐19 Brown et al., Gholivand et al. Further potential macromolecular targets of SARS‐CoV‐2 are depicted in Figure.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 367,\n",
              "   'span_end': 377,\n",
              "   'text': \"By assessing some antiviral drugs with previously known treatment of hepatitis, HIV, influenza, and Ebola viral diseases's effectiveness against COVID‐19, remdesivir was the one that grabbed much attention and is believed to be the most successful drug for the therapy for combating COVID‐19 Brown et al., Gholivand et al. Further potential macromolecular targets of SARS‐CoV‐2 are depicted in Figure.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 45,\n",
              "   'span_end': 55,\n",
              "   'text': 'Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 298,\n",
              "   'span_end': 308,\n",
              "   'text': 'Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 427,\n",
              "   'span_end': 435,\n",
              "   'text': 'Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 540,\n",
              "   'span_end': 550,\n",
              "   'text': 'Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 745,\n",
              "   'span_end': 753,\n",
              "   'text': 'Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 80,\n",
              "   'span_end': 90,\n",
              "   'text': 'Vangeel et al. molnupiravir and remdesivir acted on the RdRp enzyme employed by SARS‐CoV‐2 to increase the transcription and replication capability of the viral RNA genome.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 58,\n",
              "   'span_end': 66,\n",
              "   'text': 'Our focus in this paper is to explore the role of CADD on COVID‐19 most specifically, chemogenomics and DR, with potential examples of COVID‐19 drug discovery. Unfortunately, with boundless energy and time to discover a successful small molecule by utilizing various databases to inhibit the main protease Mpro of SARS‐CoV‐2 via several virtual screening VS approaches, there are no effective drugs that have been approved.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 135,\n",
              "   'span_end': 143,\n",
              "   'text': 'Our focus in this paper is to explore the role of CADD on COVID‐19 most specifically, chemogenomics and DR, with potential examples of COVID‐19 drug discovery. Unfortunately, with boundless energy and time to discover a successful small molecule by utilizing various databases to inhibit the main protease Mpro of SARS‐CoV‐2 via several virtual screening VS approaches, there are no effective drugs that have been approved.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 314,\n",
              "   'span_end': 324,\n",
              "   'text': 'Our focus in this paper is to explore the role of CADD on COVID‐19 most specifically, chemogenomics and DR, with potential examples of COVID‐19 drug discovery. Unfortunately, with boundless energy and time to discover a successful small molecule by utilizing various databases to inhibit the main protease Mpro of SARS‐CoV‐2 via several virtual screening VS approaches, there are no effective drugs that have been approved.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 148,\n",
              "   'span_end': 158,\n",
              "   'text': \"Only safety protocols such as wearing face masks, face shields, social distancing, and washing hands frequently are the best approaches to minimize SARS‐CoV‐2's danger and prevent transmission.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 74,\n",
              "   'span_end': 82,\n",
              "   'text': 'Basically, the process of bringing an FDA‐approved medicine to market for COVID‐19 drug discovery is extremely challenging, starting from the initial research of scientists for target identification and lead compound generation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 175,\n",
              "   'span_end': 183,\n",
              "   'text': 'After lead discovery and development of drug‐like candidates and investigation of in vitro and in vivo results, the process of bringing an FDA‐approved medicine to market for COVID‐19 drug discovery will go into three phases, i.e., preclinical and, if successful, into clinical studies, and ultimately a marketed medicine after FDA approval Schaduangrat et al. It is where CADD is evolved as a valuable and powerful method to aid the challenging tasks of identifying small bioactive molecules and predicting targets.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 21,\n",
              "   'span_end': 29,\n",
              "   'text': 'In the first days of COVID‐19 outbreak, vHTS was employed and developed efficiently to investigate a group of approved drugs to identify the possible anti‐SARS‐CoV‐2 agents at the National Center for Advancing Translational Sciences NCATS of the National Institutes of Health NIH, embracing a broad spectrum of the SARS‐CoV‐2 life cycle, such as viral entry, viral replication, in vitro infectivity, and live virus infectivity Xu et al. Many possible drug candidates were selected for targeting various stages of the SARS‐CoV‐2 life cycle.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'anti‐SARS‐CoV‐2',\n",
              "   'span_start': 150,\n",
              "   'span_end': 165,\n",
              "   'text': 'In the first days of COVID‐19 outbreak, vHTS was employed and developed efficiently to investigate a group of approved drugs to identify the possible anti‐SARS‐CoV‐2 agents at the National Center for Advancing Translational Sciences NCATS of the National Institutes of Health NIH, embracing a broad spectrum of the SARS‐CoV‐2 life cycle, such as viral entry, viral replication, in vitro infectivity, and live virus infectivity Xu et al. Many possible drug candidates were selected for targeting various stages of the SARS‐CoV‐2 life cycle.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 315,\n",
              "   'span_end': 325,\n",
              "   'text': 'In the first days of COVID‐19 outbreak, vHTS was employed and developed efficiently to investigate a group of approved drugs to identify the possible anti‐SARS‐CoV‐2 agents at the National Center for Advancing Translational Sciences NCATS of the National Institutes of Health NIH, embracing a broad spectrum of the SARS‐CoV‐2 life cycle, such as viral entry, viral replication, in vitro infectivity, and live virus infectivity Xu et al. Many possible drug candidates were selected for targeting various stages of the SARS‐CoV‐2 life cycle.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 517,\n",
              "   'span_end': 527,\n",
              "   'text': 'In the first days of COVID‐19 outbreak, vHTS was employed and developed efficiently to investigate a group of approved drugs to identify the possible anti‐SARS‐CoV‐2 agents at the National Center for Advancing Translational Sciences NCATS of the National Institutes of Health NIH, embracing a broad spectrum of the SARS‐CoV‐2 life cycle, such as viral entry, viral replication, in vitro infectivity, and live virus infectivity Xu et al. Many possible drug candidates were selected for targeting various stages of the SARS‐CoV‐2 life cycle.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 128,\n",
              "   'span_end': 138,\n",
              "   'text': 'For instance, cepharanthine, an anti‐inflammatory compound, effectively showed ability to rescue the cytopathic effects CPEs of SARS‐CoV‐2 Rogosnitzky et al., or corilagin, a possible antifibrosis, revealed potential against the angiotensin‐converting enzyme ACE2 receptor‐binding domain RBD Yang et al. Therefore, it is urgent to This strategy a high bio‐safety SARS‐CoV‐2 infection model with a high ability for HTS of drugs against SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 363,\n",
              "   'span_end': 373,\n",
              "   'text': 'For instance, cepharanthine, an anti‐inflammatory compound, effectively showed ability to rescue the cytopathic effects CPEs of SARS‐CoV‐2 Rogosnitzky et al., or corilagin, a possible antifibrosis, revealed potential against the angiotensin‐converting enzyme ACE2 receptor‐binding domain RBD Yang et al. Therefore, it is urgent to This strategy a high bio‐safety SARS‐CoV‐2 infection model with a high ability for HTS of drugs against SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 435,\n",
              "   'span_end': 445,\n",
              "   'text': 'For instance, cepharanthine, an anti‐inflammatory compound, effectively showed ability to rescue the cytopathic effects CPEs of SARS‐CoV‐2 Rogosnitzky et al., or corilagin, a possible antifibrosis, revealed potential against the angiotensin‐converting enzyme ACE2 receptor‐binding domain RBD Yang et al. Therefore, it is urgent to This strategy a high bio‐safety SARS‐CoV‐2 infection model with a high ability for HTS of drugs against SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 313,\n",
              "   'span_end': 323,\n",
              "   'text': \"After computing molecular descriptors, machine learning techniques play indispensable roles in the quality of QSAR predictions Popelier & Smith, Rad & Maghsoudi, Sliwoski et al. Using machine learning and QSAR, Muratov et al. identified 32 drugs and 32 drugs's 73 selected binary combinations for testing against SARS‐CoV‐2.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 153,\n",
              "   'span_end': 163,\n",
              "   'text': 'Muratov et al. found that the combinations of four of 32 drugs, including nitazoxanide, remdesivir, amodiaquine, and umifenovir, could synergize against SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 204,\n",
              "   'span_end': 214,\n",
              "   'text': 'Interestingly, the combination of nitazoxanide and remdesivir showed a great synergistic interaction, and the combination of remdesivir and hydroxychloroquine exhibited a powerful antagonist role against SARS‐CoV‐2 Bobrowski et al. The two proteins pp1a and pp1ab are quickly translated after entry into the host cells and further separated by two viral proteases, 3 C‐like proteases 3CLpro and papain‐like protease PLpro Amin et al. papain‐like protease PLpro is a critical virus enzyme responsible for producing a functional replicase complex and stimulating viral spread Shin et al. Amin et al used chemical‐informatics approaches to build a Monte Carlo optimization based on a QSAR data of various papain‐like protease PLpro inhibitors, b VS to choose the best in‐house molecules among 67 with the high likelihood of targeting against papain‐like protease PLpro, and c eventually verification of these inhibitors by using receptor–ligand interaction investigation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 83,\n",
              "   'span_end': 93,\n",
              "   'text': 'Furthermore, molecular docking has proved the potentiality of 13 compounds against SARS‐CoV‐2 PLpro.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 484,\n",
              "   'span_end': 494,\n",
              "   'text': 'The National Center for Advancing Translational Sciences NCATS analyzed 11 of 42 inhibitors which were potential compounds, and three of 11 of total 42 hits which were potential compounds, cenicriviroc AC50 of 8.9 M, proglumetacin tested twice independently, with AC50 of 8.9 M and 12.5 M, and sufugolix AC50 12.6 M. While molecular docking was unsuccessful to accurately distinguish between experimentally active and inactive compounds, QSAR was able to identify three inhibitors of SARS‐CoV‐2 replication through Mpro inhibition.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 60,\n",
              "   'span_end': 70,\n",
              "   'text': 'Overall, these results show that QSAR models proposed using SARS‐CoV‐2 Mpro data can be useful to introduce compounds active against SARS‐CoV‐2 Alves et al. This strategy relies more on target information.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 133,\n",
              "   'span_end': 143,\n",
              "   'text': 'Overall, these results show that QSAR models proposed using SARS‐CoV‐2 Mpro data can be useful to introduce compounds active against SARS‐CoV‐2 Alves et al. This strategy relies more on target information.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 403,\n",
              "   'span_end': 413,\n",
              "   'text': 'In other words, docking enables us to identify novel drug candidates by predicting ligand–target interactions at a molecular level Pinzi & Rastelli, Sargazi et al. There are several references in which the significant role and applications of docking in drug design and development have been discussed De Vivo & Cavalli, Keretsu et al., Kitchen et al., Meng et al. Furthermore, in the current spread of SARS‐CoV‐2, molecular docking is important in screening potential drugs Keretsu et al., Lokhande et al., Marinho et al., Yu et al. The recent work of Khelfaoui et al. could be a good example of using molecular docking combined with MD to find promising candidate drugs against COVID‐19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 680,\n",
              "   'span_end': 688,\n",
              "   'text': 'In other words, docking enables us to identify novel drug candidates by predicting ligand–target interactions at a molecular level Pinzi & Rastelli, Sargazi et al. There are several references in which the significant role and applications of docking in drug design and development have been discussed De Vivo & Cavalli, Keretsu et al., Kitchen et al., Meng et al. Furthermore, in the current spread of SARS‐CoV‐2, molecular docking is important in screening potential drugs Keretsu et al., Lokhande et al., Marinho et al., Yu et al. The recent work of Khelfaoui et al. could be a good example of using molecular docking combined with MD to find promising candidate drugs against COVID‐19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 171,\n",
              "   'span_end': 181,\n",
              "   'text': 'Khelfaoui et al. selected a library of 18 drugs that three of which include ramipril, delapril, and lisinopril, bound to angiotensin‐converting enzyme 2 ACE2 receptor and SARS‐CoV‐2/ACE2 complex well.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 119,\n",
              "   'span_end': 132,\n",
              "   'text': 'angiotensin‐converting enzyme 2 ACE2 receptor is one of the receptors in the human body with which the S proteins from coronaviruses have a great binding affinity and serve as the entry point into cells for SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 207,\n",
              "   'span_end': 217,\n",
              "   'text': 'angiotensin‐converting enzyme 2 ACE2 receptor is one of the receptors in the human body with which the S proteins from coronaviruses have a great binding affinity and serve as the entry point into cells for SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 155,\n",
              "   'span_end': 163,\n",
              "   'text': 'In fact, due to the long time required to discover specific antiviral agents or a vaccine, the best strategy would be to repurpose existing drugs to treat COVID‐19, which will be discussed in the DR section.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐main',\n",
              "   'span_start': 152,\n",
              "   'span_end': 165,\n",
              "   'text': 'In order to identify the most potential drug–target interactions, a molecular operating environment MOE program was carried out against the human ACE2, SARS‐CoV‐main peptidase, serine protease hepsin, human coronavirus papain‐like proteases, and SARS‐Coronavirus NSP12.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 207,\n",
              "   'span_end': 218,\n",
              "   'text': 'In order to identify the most potential drug–target interactions, a molecular operating environment MOE program was carried out against the human ACE2, SARS‐CoV‐main peptidase, serine protease hepsin, human coronavirus papain‐like proteases, and SARS‐Coronavirus NSP12.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐Coronavirus',\n",
              "   'span_start': 246,\n",
              "   'span_end': 262,\n",
              "   'text': 'In order to identify the most potential drug–target interactions, a molecular operating environment MOE program was carried out against the human ACE2, SARS‐CoV‐main peptidase, serine protease hepsin, human coronavirus papain‐like proteases, and SARS‐Coronavirus NSP12.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 117,\n",
              "   'span_end': 127,\n",
              "   'text': 'Thus, compound d needs to be additionally evaluated in clinical trials as a candidate for potential inhibitor of the SARS‐CoV‐2 Abdellatiif et al. Hosseini et al. evaluated a virtual screening using docking of 1615 FDA‐approved drugs to identify novel potential inhibitors for protease protein of COVID‐19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 297,\n",
              "   'span_end': 305,\n",
              "   'text': 'Thus, compound d needs to be additionally evaluated in clinical trials as a candidate for potential inhibitor of the SARS‐CoV‐2 Abdellatiif et al. Hosseini et al. evaluated a virtual screening using docking of 1615 FDA‐approved drugs to identify novel potential inhibitors for protease protein of COVID‐19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 111,\n",
              "   'span_end': 119,\n",
              "   'text': 'This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 235,\n",
              "   'span_end': 245,\n",
              "   'text': 'This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐3CL',\n",
              "   'span_start': 271,\n",
              "   'span_end': 279,\n",
              "   'text': 'This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐Co',\n",
              "   'span_start': 678,\n",
              "   'span_end': 685,\n",
              "   'text': 'This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 690,\n",
              "   'span_end': 700,\n",
              "   'text': 'This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 116,\n",
              "   'span_end': 124,\n",
              "   'text': 'Although many studies are carried out and many drugs are being tested to open a new road for effective treatment of COVID‐19, there are no fully beneficial antiviral drugs against COVID‐19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 180,\n",
              "   'span_end': 188,\n",
              "   'text': 'Although many studies are carried out and many drugs are being tested to open a new road for effective treatment of COVID‐19, there are no fully beneficial antiviral drugs against COVID‐19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 216,\n",
              "   'span_end': 224,\n",
              "   'text': 'The ultimate goal of chemogenomics is the rapid screening as well as the rational development of target‐specific chemical ligands to decrease the cost and enhance the drug discovery period, especially in the case of COVID‐19 drug investigation Jones & Bunnage.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 325,\n",
              "   'span_end': 335,\n",
              "   'text': \"Nevertheless, no existing target data thus, by applying the chemogenomics strategy, the hypotheses can be generated of the target by comparing the new biological compounds to the same known target Fourches et al., Weston et al. For example, the target receptors or proteins that are necessary for replication and survival of SARS‐CoV‐2 are viral proteases involving papain‐like protease PLpro, the 3‐chymotrypsin‐like protease 3CLpro, and Mpro, RNA‐dependent RNA polymerase RdRp complex, the spike S receptor binding glycoprotein, the nucleocapsid N protein, nonstructural protein NSP, and the membrane M protein including transmembrane TM as well as small envelope E protein Cavasotto et al. As an example of this part, it can be referred to the work of Mishra and Mishra's coworkers that reported an inclusive computational approach for the identification of drug molecules that are multi‐targeted struggling with the SARS‐CoV‐2 proteins.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 920,\n",
              "   'span_end': 930,\n",
              "   'text': \"Nevertheless, no existing target data thus, by applying the chemogenomics strategy, the hypotheses can be generated of the target by comparing the new biological compounds to the same known target Fourches et al., Weston et al. For example, the target receptors or proteins that are necessary for replication and survival of SARS‐CoV‐2 are viral proteases involving papain‐like protease PLpro, the 3‐chymotrypsin‐like protease 3CLpro, and Mpro, RNA‐dependent RNA polymerase RdRp complex, the spike S receptor binding glycoprotein, the nucleocapsid N protein, nonstructural protein NSP, and the membrane M protein including transmembrane TM as well as small envelope E protein Cavasotto et al. As an example of this part, it can be referred to the work of Mishra and Mishra's coworkers that reported an inclusive computational approach for the identification of drug molecules that are multi‐targeted struggling with the SARS‐CoV‐2 proteins.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 59,\n",
              "   'span_end': 69,\n",
              "   'text': 'drug molecules that are multi‐targeted struggling with the SARS‐CoV‐2 proteins are essentially included in virus replication inside the host body, the viral–host interaction, disease development, and transmission of SARS‐CoV‐2 infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 216,\n",
              "   'span_end': 226,\n",
              "   'text': 'drug molecules that are multi‐targeted struggling with the SARS‐CoV‐2 proteins are essentially included in virus replication inside the host body, the viral–host interaction, disease development, and transmission of SARS‐CoV‐2 infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 324,\n",
              "   'span_end': 334,\n",
              "   'text': \"Mishra and his coworkers's finding showed favorable results for seven drugs, among which catechin flavan‐3‐ol can effectively bind to the 3‐chymotrypsin‐like protease 3CLpro, Cathepsin L, RBD of S protein, nonstructural protein NSP, and the nucleocapsid N protein to be used as a potential multi‐targeted agent in combating SARS‐CoV‐2.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 51,\n",
              "   'span_end': 61,\n",
              "   'text': 'However, due to the limited timeframe of combating SARS‐CoV‐2, it is not realistic to be assured of finding a definitive therapy for combating SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 143,\n",
              "   'span_end': 153,\n",
              "   'text': 'However, due to the limited timeframe of combating SARS‐CoV‐2, it is not realistic to be assured of finding a definitive therapy for combating SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 99,\n",
              "   'span_end': 107,\n",
              "   'text': \"Hence, vigorous attempts are still continuing for the DR as a clinical treatment strategy to fight COVID‐19 Mishra et al. In another research, Omotuyi et al. investigated molecular docking protocols for fast screening of the the FDA database for high‐affinity interaction of the resolved 3D structure of SARS‐CoV‐2 receptor‐binding domain RBD in complex with SARS‐CoV‐2 receptor‐binding domain RBD's receptor hACE‐2 interface.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 304,\n",
              "   'span_end': 314,\n",
              "   'text': \"Hence, vigorous attempts are still continuing for the DR as a clinical treatment strategy to fight COVID‐19 Mishra et al. In another research, Omotuyi et al. investigated molecular docking protocols for fast screening of the the FDA database for high‐affinity interaction of the resolved 3D structure of SARS‐CoV‐2 receptor‐binding domain RBD in complex with SARS‐CoV‐2 receptor‐binding domain RBD's receptor hACE‐2 interface.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 359,\n",
              "   'span_end': 369,\n",
              "   'text': \"Hence, vigorous attempts are still continuing for the DR as a clinical treatment strategy to fight COVID‐19 Mishra et al. In another research, Omotuyi et al. investigated molecular docking protocols for fast screening of the the FDA database for high‐affinity interaction of the resolved 3D structure of SARS‐CoV‐2 receptor‐binding domain RBD in complex with SARS‐CoV‐2 receptor‐binding domain RBD's receptor hACE‐2 interface.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 95,\n",
              "   'span_end': 105,\n",
              "   'text': 'Omotuyi et al. reported that UBR breaks the interaction at the RBD/ACE‐2 interface residues of SARS‐CoV‐2 RBD/ACE‐2 complex that might result in protein function losses with direct inference on the oligomerization in RBD and function loss in ACE‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 67,\n",
              "   'span_end': 77,\n",
              "   'text': 'Therefore, UBR exhibits a novel therapeutic candidate in combating SARS‐CoV‐2 since UBR binds to proportionally high affinity with free RBD, ACE‐2 receptor, and SARS‐CoV‐2 RBD/ACE‐2 complex based on only binding affinity calculations Omotuyi et al.. The other studies in this area are demonstrated in Table.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 161,\n",
              "   'span_end': 171,\n",
              "   'text': 'Therefore, UBR exhibits a novel therapeutic candidate in combating SARS‐CoV‐2 since UBR binds to proportionally high affinity with free RBD, ACE‐2 receptor, and SARS‐CoV‐2 RBD/ACE‐2 complex based on only binding affinity calculations Omotuyi et al.. The other studies in this area are demonstrated in Table.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID',\n",
              "   'span_start': 86,\n",
              "   'span_end': 91,\n",
              "   'text': 'Therefore, according to the advantages of these proposed drug discovery methods, many COVID research orientations have been focused on DR Galindez et al., R. Liu et al. Computational DR applies available drugs for new or existing diseases that do not have an absolute cure, while available drugs were not originally designed for the novel disease treatment.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 296,\n",
              "   'span_end': 306,\n",
              "   'text': 'Furthermore, utilizing the enormous volumes of available omics information in digital form in conjunction with in silico screening intrigued the researcher to use this appropriate ground to significantly increase the speed of shortlisting promising candidates in reply to spreading diseases like SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 82,\n",
              "   'span_end': 90,\n",
              "   'text': 'Application of a methodology for preclinical computational DR called DrugMerge to COVID‐19 shows that a methodology for preclinical computational DR called DrugMerge can mimic human expert judgment Lucchetta, M. and M. Pellegrini.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 250,\n",
              "   'span_end': 260,\n",
              "   'text': \"Rima Hajjo and Alexander Tropsha's results approved that Bacillus Calmette–Guérin BCG impacted the generation and maturation of naïve T cells, resulting in increasing long‐lasting trained intrinsic immune replies to combat novel viruses, including SARS‐CoV‐2 in vitro as a protective measurement from the lethal consequences Onozuka et al. Due to the lengthy development cycle of novel drugs, DR turns into an efficient approach to screening drugs of potential therapeutic use for SARS‐CoV‐2.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 483,\n",
              "   'span_end': 493,\n",
              "   'text': \"Rima Hajjo and Alexander Tropsha's results approved that Bacillus Calmette–Guérin BCG impacted the generation and maturation of naïve T cells, resulting in increasing long‐lasting trained intrinsic immune replies to combat novel viruses, including SARS‐CoV‐2 in vitro as a protective measurement from the lethal consequences Onozuka et al. Due to the lengthy development cycle of novel drugs, DR turns into an efficient approach to screening drugs of potential therapeutic use for SARS‐CoV‐2.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 73,\n",
              "   'span_end': 81,\n",
              "   'text': 'Che et al., in another attempt, screened potential therapeutic drugs for COVID‐19 based on a knowledge‐graph‐based DR method.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 120,\n",
              "   'span_end': 130,\n",
              "   'text': 'The experimental outputs prove that the models can predict drug–disease interaction effectively for normal diseases and SARS‐CoV‐2 Lv et al. Therefore, DR presents a constant source of novel knowledge in virus biology and molecules with previously undefined antiviral properties, which can be applied as molecular tools in unknown molecular mechanisms of virus replication and pathogenesis Mercorelli et al. Further investigation of SARS‐CoV‐2 in related research is summarized in Table.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 433,\n",
              "   'span_end': 443,\n",
              "   'text': 'The experimental outputs prove that the models can predict drug–disease interaction effectively for normal diseases and SARS‐CoV‐2 Lv et al. Therefore, DR presents a constant source of novel knowledge in virus biology and molecules with previously undefined antiviral properties, which can be applied as molecular tools in unknown molecular mechanisms of virus replication and pathogenesis Mercorelli et al. Further investigation of SARS‐CoV‐2 in related research is summarized in Table.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 162,\n",
              "   'span_end': 170,\n",
              "   'text': 'Thai‐Hoang Pham et al. applied a sound learning framework for a high‐throughput mechanism‐driven neural network‐based method for phenotype compound screening for COVID‐19 DR.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 95,\n",
              "   'span_end': 103,\n",
              "   'text': 'Furthermore, Thai‐Hoang Pham et al. showed the value of DeepCE by applying DeepCE to the DR of COVID‐19 and produced novel lead compounds that represented clinical evidence.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 210,\n",
              "   'span_end': 218,\n",
              "   'text': \"Lee and his coworkers's finding showed that an AI‐DTI, a new method for predicting activation and inhibition of DTIs was a success in discovering about half of the DTIs for drugs that are employed for treating COVID‐19 Lee and his coworkers.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 341,\n",
              "   'span_end': 349,\n",
              "   'text': 'A myriad of compounds represent potential drug candidates, but merely a few of potential drug candidates will be formulated, approved, and registered as a drug for individual health issues which investigation for that compound will be a long, intricate, and costly process, while sometimes there is an urgent need for developing a drug like COVID‐19 pandemic Muratov et al. Table demonstrates chemogenomics related to COVID‐19 research.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 418,\n",
              "   'span_end': 426,\n",
              "   'text': 'A myriad of compounds represent potential drug candidates, but merely a few of potential drug candidates will be formulated, approved, and registered as a drug for individual health issues which investigation for that compound will be a long, intricate, and costly process, while sometimes there is an urgent need for developing a drug like COVID‐19 pandemic Muratov et al. Table demonstrates chemogenomics related to COVID‐19 research.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 59,\n",
              "   'span_end': 67,\n",
              "   'text': 'Herein, of much current importance is chemogenomics, is in COVID‐19 drug discoveries, which this review paper highlighted specifically.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 468,\n",
              "   'span_end': 476,\n",
              "   'text': 'The first is that a drug can bind to various targets simultaneously, which is good for searching novel target sites of action for the known biological agents, and the second is that targets related to a disease are often associated with different biological processes of pathogenesis, which is important for choosing of a new indication for the known target Badary, Kamel et al. These are indispensable in proposing new drug candidates for unprecedented diseases like COVID‐19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 102,\n",
              "   'span_end': 110,\n",
              "   'text': 'DR has emerged as an alternative way of accelerating the process of developing new treatments against COVID‐19 Yu et al. Based on data brought from PubMed, the number of works of literature on DR has been growing dramatically, and the number of works of literature on DR has increased since the outbreak of SARS‐CoV‐2 Galindez et al. It should be noted that polypharmacolgy and DR are inextricably interrelated with each other Cheng.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 307,\n",
              "   'span_end': 317,\n",
              "   'text': 'DR has emerged as an alternative way of accelerating the process of developing new treatments against COVID‐19 Yu et al. Based on data brought from PubMed, the number of works of literature on DR has been growing dramatically, and the number of works of literature on DR has increased since the outbreak of SARS‐CoV‐2 Galindez et al. It should be noted that polypharmacolgy and DR are inextricably interrelated with each other Cheng.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 602,\n",
              "   'span_end': 612,\n",
              "   'text': 'In contrast to experimental methods, computational drug repositioning methods which are mainly data‐driven utilizes databases and bioinformatics tools to find out interactions between drugs, targets, and diseases Pillaiyar et al. Analyzing a large type of data like chemical structures, gene expression, genotype or proteomic data, and electronic health records EHRs provides the possibility of understanding novel and unexpected functional gene interactions and unclear drug response or mechanisms of disease Pushpakom et al. Since there is no specific and registered therapy to cure the infection of SARS‐CoV‐2, finding effective therapeutics by applying existing drugs is a pressing exigency and established strategy Galindez et al. Concerning the time‐consuming regulatory process of the newly approved drugs, the DR strategy strongly utilizes the identification of new treatment methods by presenting FDA‐approved drugs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 82,\n",
              "   'span_end': 90,\n",
              "   'text': 'There are myriad reasons why we need to go through DR for different diseases like COVID‐19 if we intend to accelerate the process of developing a new drug.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 489,\n",
              "   'span_end': 497,\n",
              "   'text': \"myriad reasons why we need to go through DR can be i availability of marketed drugs and marketed drugs's excipients and APIs for formulation and distribution, ii the likelihood of taking advantage of a synergistic effect of various drugs with each other, iii cheap and less time‐consuming process for drugs to be marketed and IV emergence of new therapeutic pathways for former drugs and new categories of medicine Chung et al. Therefore, repositioned drugs have very important impacts on COVID‐19 drug discovery.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 105,\n",
              "   'span_end': 115,\n",
              "   'text': 'Therefore, different categories of drugs are being repositioned in in vivo and in vitro studies to treat SARS‐CoV‐2 Wu et al. different categories of drugs are namely Ebola virus remdesivir, antimalarial chloroquine, anthelmintic and antiprotozoal drugs niclosamide, diarrhea nitazoxanide, antiviral lopinavir and ritonavir, antineoplastic carfilzomib and bortezomib, and antibacterial azithromycin.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 135,\n",
              "   'span_end': 143,\n",
              "   'text': 'In this regard, the WHO supported repositioning remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine as a potential for COVID‐19, although most might be only supportive symptomatic Won & Lee.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 110,\n",
              "   'span_end': 118,\n",
              "   'text': 'Nevertheless, remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine will likely be approved for COVID‐19 therapy if remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine pass clinical trials and are published in literature and guidelines from leading health organizations Nain et al. In order to do this, many groups have been attempting enthusiastically to discover the first approved drug for COVID‐19 therapy Erlanson, Low et al., Muratov et al. As a result, we identified several clinical trials, in which 18 studies were at clinical phases 2, 3, or 4.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 423,\n",
              "   'span_end': 431,\n",
              "   'text': 'Nevertheless, remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine will likely be approved for COVID‐19 therapy if remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine pass clinical trials and are published in literature and guidelines from leading health organizations Nain et al. In order to do this, many groups have been attempting enthusiastically to discover the first approved drug for COVID‐19 therapy Erlanson, Low et al., Muratov et al. As a result, we identified several clinical trials, in which 18 studies were at clinical phases 2, 3, or 4.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 179,\n",
              "   'span_end': 189,\n",
              "   'text': 'Luo et al. investigated the free energy perturbation‐absolute binding free energy FEP‐ABFE method and bioassay validation to reposition 25 potential therapeutic agents to inhibit SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 49,\n",
              "   'span_end': 59,\n",
              "   'text': \"By using the viral proteinase crystal structure, SARS‐CoV‐2 PDB ID 6 LU7, up to 2500 FDA‐approved drugs were first screened via Glide's molecular docking program.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 253,\n",
              "   'span_end': 256,\n",
              "   'text': \"Among 25 possible agents, additionally, dipyridamole passed dipyridamole's first‐round clinical trials with considerable potencies Li, Hu, et al., Li, Li, et al. The network‐based methods have also given satisfying results in investigating the DTIs and CoV–host interactions.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'anti‐HCoV',\n",
              "   'span_start': 34,\n",
              "   'span_end': 43,\n",
              "   'text': 'Zho et al. introduced 16 possible anti‐HCoV drugs such as melatonin, mercaptopurine, toremifene, mesalazine, and sirolimus from more than 2000 FDA‐approved drugs by applying a combination of network‐based approaches and systems pharmacology‐based network medicine platform with the ability to quantify the interactions between the drug targets and virus–host interactome in the human protein–protein interactions network.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 119,\n",
              "   'span_end': 129,\n",
              "   'text': 'Zhou et al. The docking screening method was applied for a set of 2201 approved drugs to find inhibitory activities at SARS‐CoV‐2 main protease, and based on that, carfilzomib, eravacycline, valrubicin, lopinavir, and elbasvir have nominated as an inhibitor for SARS‐CoV‐2 main protease Wang.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 262,\n",
              "   'span_end': 272,\n",
              "   'text': 'Zhou et al. The docking screening method was applied for a set of 2201 approved drugs to find inhibitory activities at SARS‐CoV‐2 main protease, and based on that, carfilzomib, eravacycline, valrubicin, lopinavir, and elbasvir have nominated as an inhibitor for SARS‐CoV‐2 main protease Wang.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 63,\n",
              "   'span_end': 74,\n",
              "   'text': 'Table includes recent studies in terms of computational DR for coronavirus drug discovery and various diseases, respectively.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 47,\n",
              "   'span_end': 57,\n",
              "   'text': 'Various transcriptomic datasets in relation to SARS‐CoV‐2 were reported since the COVID‐19 outbreak.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 82,\n",
              "   'span_end': 90,\n",
              "   'text': 'Various transcriptomic datasets in relation to SARS‐CoV‐2 were reported since the COVID‐19 outbreak.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 501,\n",
              "   'span_end': 511,\n",
              "   'text': 'Basically, the idea is that for a specific disease signature composing of a class of up and downregulated genes, if there is available drug candidate, where a class of up and downregulated genes are alternatively downregulated and up‐regulated, respectively, this drug might be potential for that disease Hoffmann et al., Le et al. Zho et al. investigated existing computational drug repositioning with remarkably reversed differential gene expression in comparison with manifold input signatures for SARS‐CoV‐2 effects on human cells.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 79,\n",
              "   'span_end': 89,\n",
              "   'text': \"Zho et al. eventually tested 16 of Zho et al.'s shortlisted candidates in live SARS‐CoV‐2 antiviral assays.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 113,\n",
              "   'span_end': 123,\n",
              "   'text': 'If a drug could notably FDR < 0.05 reverse the disease signature, then a drug could be a potential inhibitor for SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 104,\n",
              "   'span_end': 114,\n",
              "   'text': \"In the end, Zho et al. found that 16 of Zho et al.'s high predicted hits showed antiviral assay in live SARS‐CoV‐2.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 56,\n",
              "   'span_end': 66,\n",
              "   'text': 'Four potential inhibitors were tested for inhibition of SARS‐CoV‐2 in a human lung cell line, Calu‐3, infected with SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 116,\n",
              "   'span_end': 126,\n",
              "   'text': 'Four potential inhibitors were tested for inhibition of SARS‐CoV‐2 in a human lung cell line, Calu‐3, infected with SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 351,\n",
              "   'span_end': 361,\n",
              "   'text': 'Three drugs revealed in vitro antiviral efficacy—bacampicillin, clofazimine, and haloperidol with no toxicity effects Zho et al. Ge et al. used an integrative drug repositioning analysis through machine learning to integrate and mine large‐scale knowledge graph, literature together with transcriptome data to identify the potential compounds against SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 72,\n",
              "   'span_end': 82,\n",
              "   'text': \"Ge et al.'s in vitro data showed an efficient inhibitory effect against SARS‐CoV‐2 replication without a clear cytopathic effect.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 141,\n",
              "   'span_end': 151,\n",
              "   'text': 'Ge et al. further revealed that CVL218, a poly‐ADP‐ribose polymerase 1 PARP1 inhibitor can effectively bind to the nucleocapsid N protein of SARS‐CoV‐2 and could suppress the LPS‐induced production of many inflammatory cytokine, which are highly related to the prevention of immunopathology induced by SARS‐CoV‐2 infection Zho et al.. Another PARP1 inhibitor, PJ‐34 was previously studied for acute inflammatory including inflammatory diseases of the lung.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 302,\n",
              "   'span_end': 312,\n",
              "   'text': 'Ge et al. further revealed that CVL218, a poly‐ADP‐ribose polymerase 1 PARP1 inhibitor can effectively bind to the nucleocapsid N protein of SARS‐CoV‐2 and could suppress the LPS‐induced production of many inflammatory cytokine, which are highly related to the prevention of immunopathology induced by SARS‐CoV‐2 infection Zho et al.. Another PARP1 inhibitor, PJ‐34 was previously studied for acute inflammatory including inflammatory diseases of the lung.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 125,\n",
              "   'span_end': 135,\n",
              "   'text': 'It was observed that Another PARP1 inhibitor, PJ‐34 can interact with the N‐terminal domain of the nucleocapsid N protein of SARS‐CoV‐2 and decrease the RNA binding ability to inhibit virus replication Zho et al.. Beclabuvir is an antiviral drug for the treatment of hepatitis C virus HCV infection studied for inhibitory activity against SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 339,\n",
              "   'span_end': 349,\n",
              "   'text': 'It was observed that Another PARP1 inhibitor, PJ‐34 can interact with the N‐terminal domain of the nucleocapsid N protein of SARS‐CoV‐2 and decrease the RNA binding ability to inhibit virus replication Zho et al.. Beclabuvir is an antiviral drug for the treatment of hepatitis C virus HCV infection studied for inhibitory activity against SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 83,\n",
              "   'span_end': 93,\n",
              "   'text': 'It was reported that Beclabuvir could be a potential compound for the treatment of SARS‐CoV‐2 through virtual screening and molecular docking in order to bind to RdRp of the SARS‐CoV‐2 Talluri.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 174,\n",
              "   'span_end': 184,\n",
              "   'text': 'It was reported that Beclabuvir could be a potential compound for the treatment of SARS‐CoV‐2 through virtual screening and molecular docking in order to bind to RdRp of the SARS‐CoV‐2 Talluri.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 120,\n",
              "   'span_end': 128,\n",
              "   'text': 'Raltegravir was selected as a highly effective drug against Mpro and has been repurposed for the potential treatment of COVID‐19 in many studies Nabi et al. There has been considerable progress in the practical development and the rational application of computational drug discovery, giving rise to a paradigm shift in both industry and academics.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 27,\n",
              "   'span_end': 35,\n",
              "   'text': 'Over the last 3 years, the COVID‐19 pandemic has killed many people globally since there are no effective drugs against the COVID‐19 pandemic.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 124,\n",
              "   'span_end': 132,\n",
              "   'text': 'Over the last 3 years, the COVID‐19 pandemic has killed many people globally since there are no effective drugs against the COVID‐19 pandemic.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 119,\n",
              "   'span_end': 127,\n",
              "   'text': 'In this sense, we need to highlight that DR attempts the search for effective drugs in an urgent situation such as the COVID‐19 pandemic.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 28,\n",
              "   'span_end': 38,\n",
              "   'text': 'In order to use HTS against SARS‐CoV‐2, it is important to take advantage of a similar homology of virus in genomics, specifically, chemogenomics, as a versatile way of drug screening model that provides better bio‐safety.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 59,\n",
              "   'span_end': 67,\n",
              "   'text': 'Hitherto, CADD is the only way for screening drugs against COVID‐19 and is based on a single viral protein or small‐scale drug screening of formerly FDA antiviral drugs utilizing SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 179,\n",
              "   'span_end': 189,\n",
              "   'text': 'Hitherto, CADD is the only way for screening drugs against COVID‐19 and is based on a single viral protein or small‐scale drug screening of formerly FDA antiviral drugs utilizing SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 121,\n",
              "   'span_end': 131,\n",
              "   'text': 'Nevertheless, CADD is not well‐suited to high‐throughput screening HTS when focusing on the bio‐security requirements of SARS‐CoV‐2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 188,\n",
              "   'span_end': 196,\n",
              "   'text': 'Moreover, developing new drugs takes too much time without having a precise crystal structure of the viral target Liu et al. Thus, the best way to rapidly find a drug for the treatment of COVID‐19 would be the use of CADD methods in order to discover lead compounds for clinical use for instance, we can build a program that takes advantage of structure‐based drug design, HTS, and virtual drug screening to identify new leads targeting the Mpro. More recently, a library of 10000 compounds involving approved drugs, drug candidates in clinical trials, and biologically active compounds to inhibit the Mpro was examined.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 191,\n",
              "   'span_end': 201,\n",
              "   'text': 'Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 316,\n",
              "   'span_end': 320,\n",
              "   'text': 'Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS‐CoV',\n",
              "   'span_start': 332,\n",
              "   'span_end': 340,\n",
              "   'text': 'Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 345,\n",
              "   'span_end': 355,\n",
              "   'text': 'Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 438,\n",
              "   'span_end': 448,\n",
              "   'text': 'Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'anti‐SARS‐CoV‐2',\n",
              "   'span_start': 97,\n",
              "   'span_end': 112,\n",
              "   'text': 'This effort led to the discovery of nine hits that need further optimization to be identified as anti‐SARS‐CoV‐2 leads.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 242,\n",
              "   'span_end': 246,\n",
              "   'text': \"In addition, an interesting investigation based on an HTS assay employing a compound library of 2000 approved drugs and pharmacologically active compounds has also been carried out to find broad‐spectrum inhibitors against the replication of CoVs Shen et al. From Shen et al's HTS data, 56 hits were screened, and 36 compounds were validated in vitro using genetically engineered human CoV OC43 HCoV‐OC43.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 386,\n",
              "   'span_end': 389,\n",
              "   'text': \"In addition, an interesting investigation based on an HTS assay employing a compound library of 2000 approved drugs and pharmacologically active compounds has also been carried out to find broad‐spectrum inhibitors against the replication of CoVs Shen et al. From Shen et al's HTS data, 56 hits were screened, and 36 compounds were validated in vitro using genetically engineered human CoV OC43 HCoV‐OC43.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV‐OC43',\n",
              "   'span_start': 395,\n",
              "   'span_end': 404,\n",
              "   'text': \"In addition, an interesting investigation based on an HTS assay employing a compound library of 2000 approved drugs and pharmacologically active compounds has also been carried out to find broad‐spectrum inhibitors against the replication of CoVs Shen et al. From Shen et al's HTS data, 56 hits were screened, and 36 compounds were validated in vitro using genetically engineered human CoV OC43 HCoV‐OC43.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 144,\n",
              "   'span_end': 155,\n",
              "   'text': 'Consequently, seven effective compounds were selected as broad‐spectrum inhibitors in which lycorine protected BALB/c mice against lethal human coronavirus OC43 HCoV‐OC43, and emetine blocked MERS‐CoV entry following pseudo‐virus entry assays.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV‐OC43',\n",
              "   'span_start': 161,\n",
              "   'span_end': 170,\n",
              "   'text': 'Consequently, seven effective compounds were selected as broad‐spectrum inhibitors in which lycorine protected BALB/c mice against lethal human coronavirus OC43 HCoV‐OC43, and emetine blocked MERS‐CoV entry following pseudo‐virus entry assays.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS‐CoV',\n",
              "   'span_start': 192,\n",
              "   'span_end': 200,\n",
              "   'text': 'Consequently, seven effective compounds were selected as broad‐spectrum inhibitors in which lycorine protected BALB/c mice against lethal human coronavirus OC43 HCoV‐OC43, and emetine blocked MERS‐CoV entry following pseudo‐virus entry assays.'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 4,\n",
              "   'span_end': 37,\n",
              "   'text': 'The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus-2',\n",
              "   'span_start': 38,\n",
              "   'span_end': 51,\n",
              "   'text': 'The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 52,\n",
              "   'span_end': 62,\n",
              "   'text': 'The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus Disease 2019',\n",
              "   'span_start': 71,\n",
              "   'span_end': 95,\n",
              "   'text': 'The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 96,\n",
              "   'span_end': 104,\n",
              "   'text': 'The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 26,\n",
              "   'span_end': 59,\n",
              "   'text': 'Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus-2',\n",
              "   'span_start': 60,\n",
              "   'span_end': 73,\n",
              "   'text': 'Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 74,\n",
              "   'span_end': 84,\n",
              "   'text': 'Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus Disease 2019',\n",
              "   'span_start': 93,\n",
              "   'span_end': 117,\n",
              "   'text': 'Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 118,\n",
              "   'span_end': 126,\n",
              "   'text': 'Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 8,\n",
              "   'span_end': 41,\n",
              "   'text': 'The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus-2',\n",
              "   'span_start': 42,\n",
              "   'span_end': 55,\n",
              "   'text': 'The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 56,\n",
              "   'span_end': 66,\n",
              "   'text': 'The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus Disease 2019',\n",
              "   'span_start': 75,\n",
              "   'span_end': 99,\n",
              "   'text': 'The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 100,\n",
              "   'span_end': 108,\n",
              "   'text': 'The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARSCoV-2 infection',\n",
              "   'span_start': 204,\n",
              "   'span_end': 223,\n",
              "   'text': 'The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 125,\n",
              "   'span_end': 158,\n",
              "   'text': 'Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus-2',\n",
              "   'span_start': 159,\n",
              "   'span_end': 172,\n",
              "   'text': 'Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 173,\n",
              "   'span_end': 183,\n",
              "   'text': 'Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus Disease 2019',\n",
              "   'span_start': 192,\n",
              "   'span_end': 216,\n",
              "   'text': 'Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 217,\n",
              "   'span_end': 225,\n",
              "   'text': 'Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 61,\n",
              "   'span_end': 94,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus-2',\n",
              "   'span_start': 95,\n",
              "   'span_end': 108,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 109,\n",
              "   'span_end': 119,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus Disease 2019',\n",
              "   'span_start': 128,\n",
              "   'span_end': 152,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 153,\n",
              "   'span_end': 161,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 308,\n",
              "   'span_end': 341,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus-2',\n",
              "   'span_start': 342,\n",
              "   'span_end': 355,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 356,\n",
              "   'span_end': 366,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus Disease 2019',\n",
              "   'span_start': 375,\n",
              "   'span_end': 399,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 400,\n",
              "   'span_end': 408,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARSCoV-2',\n",
              "   'span_start': 0,\n",
              "   'span_end': 9,\n",
              "   'text': 'SARSCoV-2, seasonal or pandemic influenza, and MERS corona virus are all targets of Molnupiravir, commercialized as Lagevrio.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS',\n",
              "   'span_start': 47,\n",
              "   'span_end': 51,\n",
              "   'text': 'SARSCoV-2, seasonal or pandemic influenza, and MERS corona virus are all targets of Molnupiravir, commercialized as Lagevrio.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 175,\n",
              "   'span_end': 183,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio was reported to be extremely effective in reducing nasopharyngeal infection rate and had a positive safety and tolerability record in COVID-19 patients who received short-course, 5-day treatment.– On 23 December 2021, FDA approved Molnupiravir, commercialized as Lagevrio under an EUA for the treatment of mild-to-moderate COVID-19 in individuals who have a positive consequences of SARSCoV-2 virus test and are at high risk of developing chronic COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 364,\n",
              "   'span_end': 372,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio was reported to be extremely effective in reducing nasopharyngeal infection rate and had a positive safety and tolerability record in COVID-19 patients who received short-course, 5-day treatment.– On 23 December 2021, FDA approved Molnupiravir, commercialized as Lagevrio under an EUA for the treatment of mild-to-moderate COVID-19 in individuals who have a positive consequences of SARSCoV-2 virus test and are at high risk of developing chronic COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARSCoV-2',\n",
              "   'span_start': 424,\n",
              "   'span_end': 433,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio was reported to be extremely effective in reducing nasopharyngeal infection rate and had a positive safety and tolerability record in COVID-19 patients who received short-course, 5-day treatment.– On 23 December 2021, FDA approved Molnupiravir, commercialized as Lagevrio under an EUA for the treatment of mild-to-moderate COVID-19 in individuals who have a positive consequences of SARSCoV-2 virus test and are at high risk of developing chronic COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 488,\n",
              "   'span_end': 496,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio was reported to be extremely effective in reducing nasopharyngeal infection rate and had a positive safety and tolerability record in COVID-19 patients who received short-course, 5-day treatment.– On 23 December 2021, FDA approved Molnupiravir, commercialized as Lagevrio under an EUA for the treatment of mild-to-moderate COVID-19 in individuals who have a positive consequences of SARSCoV-2 virus test and are at high risk of developing chronic COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARSCoV-2',\n",
              "   'span_start': 82,\n",
              "   'span_end': 91,\n",
              "   'text': 'an EUA is granted for patients who have received a positive test from significant SARSCoV-2 viral testing, or who are at danger of developing severe COVID-19, which could result in hospitalization or death, or for whom other FDA-approved COVID-19 treatment options are not available or efficacious.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 149,\n",
              "   'span_end': 157,\n",
              "   'text': 'an EUA is granted for patients who have received a positive test from significant SARSCoV-2 viral testing, or who are at danger of developing severe COVID-19, which could result in hospitalization or death, or for whom other FDA-approved COVID-19 treatment options are not available or efficacious.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 238,\n",
              "   'span_end': 246,\n",
              "   'text': 'an EUA is granted for patients who have received a positive test from significant SARSCoV-2 viral testing, or who are at danger of developing severe COVID-19, which could result in hospitalization or death, or for whom other FDA-approved COVID-19 treatment options are not available or efficacious.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 174,\n",
              "   'span_end': 182,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio is not approved for use in individuals under the age of 18, for the commencement of therapy in patients who require treatment due to COVID-19, for use for more than 5 days, or as a pre-exposure or post-exposure prophylactic for COVID-19 prevention.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 269,\n",
              "   'span_end': 277,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio is not approved for use in individuals under the age of 18, for the commencement of therapy in patients who require treatment due to COVID-19, for use for more than 5 days, or as a pre-exposure or post-exposure prophylactic for COVID-19 prevention.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 68,\n",
              "   'span_end': 78,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio acts by inhibiting RdRp of SARS-CoV-2 to induce RNA mutagenesis in two steps.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 93,\n",
              "   'span_end': 103,\n",
              "   'text': 'the EIDD-1931-triphosphate acts as an alternate/competitive substrate for the RdRp enzyme of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 30,\n",
              "   'span_end': 40,\n",
              "   'text': 'Therefore, the RdRp enzyme of SARS-CoV-2 This process mutated RNA copies for SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 77,\n",
              "   'span_end': 87,\n",
              "   'text': 'Therefore, the RdRp enzyme of SARS-CoV-2 This process mutated RNA copies for SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 81,\n",
              "   'span_end': 91,\n",
              "   'text': 'This process causes the inhibition of the normal functions of the RdRp enzyme of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 167,\n",
              "   'span_end': 180,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio is an isopropyl prodrug of EIDD-1931, which has been shown to suppress the reproduction of a wide range of viruses, including coronaviruses, with potential safety profiles.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 225,\n",
              "   'span_end': 233,\n",
              "   'text': 'Emory University in Atlanta, Ridgeback Biotherapeutics, Wayne and Wendy Holman, and Merck have also agreed to collaborate on the development of Molnupiravir, commercialized as Lagevrio as an oral therapy for non-hospitalized COVID-19 individuals.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 31,\n",
              "   'span_end': 39,\n",
              "   'text': 'Following the dissemination of COVID-19, the Molnupiravir, commercialized as Lagevrio development effort shifted to COVID-19 therapy.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 116,\n",
              "   'span_end': 124,\n",
              "   'text': 'Following the dissemination of COVID-19, the Molnupiravir, commercialized as Lagevrio development effort shifted to COVID-19 therapy.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 65,\n",
              "   'span_end': 78,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio oral efficiency against coronaviruses was also demonstrated in preclinical research in an animal study.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 0,\n",
              "   'span_end': 10,\n",
              "   'text': 'SARS-CoV-2 propagation is ineffectively controlled by remdesivir.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 82,\n",
              "   'span_end': 92,\n",
              "   'text': 'Molnupiravir, on the other hand, was shown to be efficient in ferrets in reducing SARS-CoV-2 virus and halting dissemination.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 78,\n",
              "   'span_end': 98,\n",
              "   'text': 'As a result, Molnupiravir has been proposed as a protective measure to combat SARS-CoV-2 infection in the community.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 22,\n",
              "   'span_end': 32,\n",
              "   'text': 'Elderly patients with SARS-CoV-2 illness diagnosed by RT-PCR within 5 days of appearance of symptoms were randomised to standard of care SOC or 300, 600, and 800 mg Molnupiravir orally twice for 5 days by oral route daily.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 28,\n",
              "   'span_end': 36,\n",
              "   'text': 'The safety and tolerance of COVID-19 in patients admitted with minimal to moderate COVID-19 were analyzed in a double-blind, randomized-controlled, multicentric phase 2a MK-4482-006 NCT04405570 study.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 83,\n",
              "   'span_end': 91,\n",
              "   'text': 'The safety and tolerance of COVID-19 in patients admitted with minimal to moderate COVID-19 were analyzed in a double-blind, randomized-controlled, multicentric phase 2a MK-4482-006 NCT04405570 study.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 120,\n",
              "   'span_end': 140,\n",
              "   'text': \"Other double-blind phase 2 experiment is now underway to assess the safety of Molnupiravir and Molnupiravir's effect on SARS-CoV-2 infection shedding.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 226,\n",
              "   'span_end': 234,\n",
              "   'text': 'The independent data safety monitoring board recently halted the phase 3 double-blind, randomised trial MOVe-OUT that was designed to evaluate the efficacy and safety of Molnupiravir in 1850 non-hospitalized participants with COVID-19 NCT04575597, MK-4482-002 due to the increased advantage in the test group compared to Placebo.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 9,\n",
              "   'span_end': 19,\n",
              "   'text': \"A proven SARS-CoV-2 illness with samples taken ≤5 days previous to the day of allocation and negative serum testing in light of recent or earlier exposure were among an open label randomised controlled but small phase Ib/IIa study called AGILE NCT04746183's eligibility criteria.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 17,\n",
              "   'span_end': 27,\n",
              "   'text': 'Furthermore, the SARS-CoV-2 variant gamma, delta, or mu, the period of onset of manifestations, and the inherent risks had no influence on the effectiveness of Molnupiravir.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 177,\n",
              "   'span_end': 185,\n",
              "   'text': 'A further phase 3 double-blind, randomised research MOVe-IN, NCT04575584 that has been set to investigate the effectiveness and safety of Molnupiravir in 304 hospitalised adult COVID-19 MK-4482-001 subjects was halted after an initial review of the data revealed that a clinical efficacy in hospitalised individuals was improbable.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 212,\n",
              "   'span_end': 220,\n",
              "   'text': 'Nonetheless, a huge n 14 1332 phase 3 multicentric, randomised, double-blind, placebo-controlled investigation NCT04939428 is actively exploring the safety and effectiveness of Molnupiravir for the mitigation of COVID-19 in adults MOVe-AHEAD living with a human who has COVID-19, with the assumption that Molnupiravir would be efficacious in blocking laboratory-confirmed COVID-19 infestation through day 14 especially in comparison to placebo.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 270,\n",
              "   'span_end': 278,\n",
              "   'text': 'Nonetheless, a huge n 14 1332 phase 3 multicentric, randomised, double-blind, placebo-controlled investigation NCT04939428 is actively exploring the safety and effectiveness of Molnupiravir for the mitigation of COVID-19 in adults MOVe-AHEAD living with a human who has COVID-19, with the assumption that Molnupiravir would be efficacious in blocking laboratory-confirmed COVID-19 infestation through day 14 especially in comparison to placebo.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infestation',\n",
              "   'span_start': 372,\n",
              "   'span_end': 392,\n",
              "   'text': 'Nonetheless, a huge n 14 1332 phase 3 multicentric, randomised, double-blind, placebo-controlled investigation NCT04939428 is actively exploring the safety and effectiveness of Molnupiravir for the mitigation of COVID-19 in adults MOVe-AHEAD living with a human who has COVID-19, with the assumption that Molnupiravir would be efficacious in blocking laboratory-confirmed COVID-19 infestation through day 14 especially in comparison to placebo.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 130,\n",
              "   'span_end': 138,\n",
              "   'text': 'Meanwhile, many Indian pharmaceutical firms confirmed preliminary results from phase 3 studies with Molnupiravir in mild/moderate COVID-19 patient populations in India.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 100,\n",
              "   'span_end': 108,\n",
              "   'text': 'The research community has rallied to discover and assess various medicines and vaccinations as the COVID-19 outbreak spreads throughout the world, from academia and government institutions to minor biotechnology startups and major pharmaceutical enterprises.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 90,\n",
              "   'span_end': 100,\n",
              "   'text': 'Repurposing preexisting medications authorized for other uses as antiviral treatments for SARS-CoV-2 is one feasible method.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 123,\n",
              "   'span_end': 131,\n",
              "   'text': 'Although repurposed medications with acceptable safety records might be beneficial, there are currently no widely marketed COVID-19 preventive or therapy alternatives.'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 23,\n",
              "   'span_end': 33,\n",
              "   'text': 'The sudden outbreak of SARS-CoV-2 in 2019 took the world by storm and despite there being vaccines, numerous other alternative treatment approaches are also being researched.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 0,\n",
              "   'span_end': 24,\n",
              "   'text': 'Coronavirus disease-2019 COVID-19 is a communicable disease caused by SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 25,\n",
              "   'span_end': 33,\n",
              "   'text': 'Coronavirus disease-2019 COVID-19 is a communicable disease caused by SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 70,\n",
              "   'span_end': 80,\n",
              "   'text': 'Coronavirus disease-2019 COVID-19 is a communicable disease caused by SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 0,\n",
              "   'span_end': 24,\n",
              "   'text': \"Coronavirus disease-2019 COVID-19 was first detected in Wuhan, China, and has expanded Coronavirus disease-2019 COVID-19's reach globally, leading to myriad deaths.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 25,\n",
              "   'span_end': 33,\n",
              "   'text': \"Coronavirus disease-2019 COVID-19 was first detected in Wuhan, China, and has expanded Coronavirus disease-2019 COVID-19's reach globally, leading to myriad deaths.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 87,\n",
              "   'span_end': 111,\n",
              "   'text': \"Coronavirus disease-2019 COVID-19 was first detected in Wuhan, China, and has expanded Coronavirus disease-2019 COVID-19's reach globally, leading to myriad deaths.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 112,\n",
              "   'span_end': 120,\n",
              "   'text': \"Coronavirus disease-2019 COVID-19 was first detected in Wuhan, China, and has expanded Coronavirus disease-2019 COVID-19's reach globally, leading to myriad deaths.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 60,\n",
              "   'span_end': 84,\n",
              "   'text': 'According to World Health Organisation, the total number of Coronavirus disease-2019 COVID-19 confirmed cases worldwide was found to be 532201219 and total number of deaths accounted to 6305358 as of 10th June, 2022.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 85,\n",
              "   'span_end': 93,\n",
              "   'text': 'According to World Health Organisation, the total number of Coronavirus disease-2019 COVID-19 confirmed cases worldwide was found to be 532201219 and total number of deaths accounted to 6305358 as of 10th June, 2022.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 81,\n",
              "   'span_end': 105,\n",
              "   'text': 'Among many regions, Europe holds the top position in highest number of confirmed Coronavirus disease-2019 COVID-19 cases then followed by America, Western Pacific, South-East Asia, Eastern Mediterranean, and Africa respectively.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 106,\n",
              "   'span_end': 114,\n",
              "   'text': 'Among many regions, Europe holds the top position in highest number of confirmed Coronavirus disease-2019 COVID-19 cases then followed by America, Western Pacific, South-East Asia, Eastern Mediterranean, and Africa respectively.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 41,\n",
              "   'span_end': 65,\n",
              "   'text': 'These statistics reveal that even today, Coronavirus disease-2019 COVID-19 is still infecting several people, many of whom die due to complications.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 66,\n",
              "   'span_end': 74,\n",
              "   'text': 'These statistics reveal that even today, Coronavirus disease-2019 COVID-19 is still infecting several people, many of whom die due to complications.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 47,\n",
              "   'span_end': 71,\n",
              "   'text': 'However, the development of specific drugs for Coronavirus disease-2019 COVID-19 takes several years, paving the way for exploring alternative approaches.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 72,\n",
              "   'span_end': 80,\n",
              "   'text': 'However, the development of specific drugs for Coronavirus disease-2019 COVID-19 takes several years, paving the way for exploring alternative approaches.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 4,\n",
              "   'span_end': 28,\n",
              "   'text': 'The Coronavirus disease-2019 COVID-19 pandemic has ensured research to explore various alternatives, drug repurposing being one of various alternatives, as part of the disease management strategy.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 29,\n",
              "   'span_end': 37,\n",
              "   'text': 'The Coronavirus disease-2019 COVID-19 pandemic has ensured research to explore various alternatives, drug repurposing being one of various alternatives, as part of the disease management strategy.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 174,\n",
              "   'span_end': 198,\n",
              "   'text': 'Several drugs such as chloroquine, hydroxychloroquine, remdesivir, tocilizumab, kaletra, and favipiravir are currently being testing in clinal trials for repurposing against Coronavirus disease-2019 COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 199,\n",
              "   'span_end': 207,\n",
              "   'text': 'Several drugs such as chloroquine, hydroxychloroquine, remdesivir, tocilizumab, kaletra, and favipiravir are currently being testing in clinal trials for repurposing against Coronavirus disease-2019 COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 0,\n",
              "   'span_end': 10,\n",
              "   'text': 'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 61,\n",
              "   'span_end': 74,\n",
              "   'text': 'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 148,\n",
              "   'span_end': 159,\n",
              "   'text': 'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 160,\n",
              "   'span_end': 168,\n",
              "   'text': 'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV',\n",
              "   'span_start': 170,\n",
              "   'span_end': 174,\n",
              "   'text': 'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV',\n",
              "   'span_start': 189,\n",
              "   'span_end': 193,\n",
              "   'text': 'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 205,\n",
              "   'span_end': 216,\n",
              "   'text': 'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 19,\n",
              "   'span_end': 29,\n",
              "   'text': 'The replication of SARS-CoV 2 occurs with the help of mRNAs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 20,\n",
              "   'span_end': 30,\n",
              "   'text': 'The nucleocapsid in SARS-CoV 2 protects the viral RNA genomes from external environmental conditions.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 100,\n",
              "   'span_end': 110,\n",
              "   'text': 'At the relaxed position, The nucleocapsid in the virus appears to be in a helical shape, but within SARS-CoV 2, The nucleocapsid in the virus appears spherical.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 14,\n",
              "   'span_end': 24,\n",
              "   'text': 'The genome of SARS-CoV 2 codes for four main structural proteins when compared to five in other coronaviruses leaving out the hemagglutinin-esterase HE protein.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 96,\n",
              "   'span_end': 109,\n",
              "   'text': 'The genome of SARS-CoV 2 codes for four main structural proteins when compared to five in other coronaviruses leaving out the hemagglutinin-esterase HE protein.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 108,\n",
              "   'span_end': 118,\n",
              "   'text': 'Nucleocapsid N, membrane M, envelope E, and spike S are the four important structural proteins expressed by SARS-CoV 2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 18,\n",
              "   'span_end': 28,\n",
              "   'text': 'On the surface of SARS-CoV 2, three structural proteins M, E, and S are present, while the nucleocapsid protein resides in the core region bound to genomic RNA.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 22,\n",
              "   'span_end': 32,\n",
              "   'text': 'The spike proteins of SARS-CoV 2 help in the attachment, entry, pathogenesis, and tissue tropism, whereas, the infection is carried out by envelope E. Ribonucleoprotein is formed with nucleocapsid protein’s assistance and the membrane proteins aid in the overall viral architecture.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 0,\n",
              "   'span_end': 10,\n",
              "   'text': \"SARS-CoV 2 enters with the help of spike proteins by binding to the human angiotensin-converting enzyme 2 hACE2 through the human angiotensin-converting enzyme 2 hACE2's receptor-binding domain RBD and human proteases that make them proteolytically active.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 71,\n",
              "   'span_end': 81,\n",
              "   'text': 'Beta, gamma, delta, and omicron are the latest variants of concern for SARS-CoV 2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 53,\n",
              "   'span_end': 61,\n",
              "   'text': 'South Africa was first to report the beta variant of COVID-19, gamma was noted first in Brazil, delta in India, and omicron in western Europe.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 44,\n",
              "   'span_end': 52,\n",
              "   'text': 'Omicron which is the most recent variant of COVID-19 carried all the mutations that were present in the previous variants along with some new improved functions such as showing partial resistance to the vaccine and enhanced transmissibility compared to others.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 10,\n",
              "   'span_end': 21,\n",
              "   'text': 'The major coronavirus variants can be classified into two previously circulating variants of concern VoC and currently circulating variants of concern.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 10,\n",
              "   'span_end': 21,\n",
              "   'text': 'The major coronavirus variants are the current targets for research to find repurposed drugs for exploring treatment strategies.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 65,\n",
              "   'span_end': 76,\n",
              "   'text': 'In addition to this, certain amino acids are conserved among the coronavirus viruses, while some have a unique mark in the amino acid indicating lineage mutations.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 10,\n",
              "   'span_end': 21,\n",
              "   'text': 'The major coronavirus variants belong to various lineages.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'B.1.1.7',\n",
              "   'span_start': 0,\n",
              "   'span_end': 7,\n",
              "   'text': 'B.1.1.7 has the mutations H69-V70del, P618H, and N501Y, all indicating alterations in the amino acids.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'B.1.351',\n",
              "   'span_start': 8,\n",
              "   'span_end': 15,\n",
              "   'text': 'Lineage B.1.351 has mutations K417N, N501Y, and E484K.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'P.1',\n",
              "   'span_start': 48,\n",
              "   'span_end': 51,\n",
              "   'text': 'Likewise, another variant of concern of lineage P.1 has mutations N501Y, K417T, and E484K.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'B.1.526',\n",
              "   'span_start': 0,\n",
              "   'span_end': 7,\n",
              "   'text': 'B.1.526 lineage is mutated at D614G, T95I, D253G, and S477N.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'B.1.427',\n",
              "   'span_start': 0,\n",
              "   'span_end': 7,\n",
              "   'text': 'B.1.427 has mutations at L452R and D614G.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'B.1.429',\n",
              "   'span_start': 0,\n",
              "   'span_end': 7,\n",
              "   'text': 'B.1.429 is mutated at sites D614G, S13I, W152C, and L452R.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'B.1.617',\n",
              "   'span_start': 0,\n",
              "   'span_end': 7,\n",
              "   'text': 'B.1.617 variant has variations P681R, E484Q, and L452R.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 93,\n",
              "   'span_end': 103,\n",
              "   'text': 'Apart from the variants identified in the most common lineages, there are approximately 1516 SARS-CoV 2 lineages to date.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 108,\n",
              "   'span_end': 118,\n",
              "   'text': 'To identify the variants in all the existing lineages and those that exist not only in the spike protein of SARS-CoV 2, this study also performed a search in and summarized the different types of variants.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 195,\n",
              "   'span_end': 205,\n",
              "   'text': 'Synonymous, non-synonymous, deletions, and non-coding variations were identified, and changes in the amino acid positions, and the reference and mutated codon as screened in all 1516 lineages of SARS-CoV 2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 55,\n",
              "   'span_end': 65,\n",
              "   'text': '131 non-synonymous mutations are in various regions of SARS-CoV 2, including the spike proteins, nucleocapsid proteins, different open reading frames, and membrane and envelope proteins.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 121,\n",
              "   'span_end': 131,\n",
              "   'text': 'Additionally, some mutations are characteristic of specific regions, while some others are present in all the regions in SARS-CoV 2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 10,\n",
              "   'span_end': 20,\n",
              "   'text': 'Thus, the SARS-CoV-2 variants may have different binding sites making the SARS-CoV-2 variants identifying a suitable drug challenging.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 74,\n",
              "   'span_end': 84,\n",
              "   'text': 'Thus, the SARS-CoV-2 variants may have different binding sites making the SARS-CoV-2 variants identifying a suitable drug challenging.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 130,\n",
              "   'span_end': 138,\n",
              "   'text': 'Currently, there is a huge interest in the repurposing of drugs to speed up the identification of drugs that can prevent or treat COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 94,\n",
              "   'span_end': 102,\n",
              "   'text': 'drugs lopinavir and ritonavir were also the first drugs to be repurposed for the treatment of COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 58,\n",
              "   'span_end': 66,\n",
              "   'text': 'The main reason for this is due to the resemblance of the SARS-CoV and MERS-CoV beta coronavirus genome sequences to SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 71,\n",
              "   'span_end': 79,\n",
              "   'text': 'The main reason for this is due to the resemblance of the SARS-CoV and MERS-CoV beta coronavirus genome sequences to SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 85,\n",
              "   'span_end': 96,\n",
              "   'text': 'The main reason for this is due to the resemblance of the SARS-CoV and MERS-CoV beta coronavirus genome sequences to SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 117,\n",
              "   'span_end': 127,\n",
              "   'text': 'The main reason for this is due to the resemblance of the SARS-CoV and MERS-CoV beta coronavirus genome sequences to SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 52,\n",
              "   'span_end': 60,\n",
              "   'text': \"Thus, the drugs being utilized for the treatment of MERS-CoV and SARS-CoV-2 could be essentially used for COVID-19 treatment, implying that the mechanism of action of repositioned drugs against repositioned drugs's targets should be similar to or resemble repositioned drugs's family target members.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 65,\n",
              "   'span_end': 75,\n",
              "   'text': \"Thus, the drugs being utilized for the treatment of MERS-CoV and SARS-CoV-2 could be essentially used for COVID-19 treatment, implying that the mechanism of action of repositioned drugs against repositioned drugs's targets should be similar to or resemble repositioned drugs's family target members.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 106,\n",
              "   'span_end': 114,\n",
              "   'text': \"Thus, the drugs being utilized for the treatment of MERS-CoV and SARS-CoV-2 could be essentially used for COVID-19 treatment, implying that the mechanism of action of repositioned drugs against repositioned drugs's targets should be similar to or resemble repositioned drugs's family target members.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 52,\n",
              "   'span_end': 60,\n",
              "   'text': 'Successful administration to patients with moderate COVID-19 symptoms has been previously observed, confirming the hypothesis of drug repurposing.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 91,\n",
              "   'span_end': 99,\n",
              "   'text': 'Aside from this, the scope of drug repurposing expands to the following, with instances in COVID-19 research, as discussed in the below sections Precision medicine Precision medicine is an emerging strategy that studies the variability of individual genes, the lifestyle, and the environment for each person to decide upon the correct treatment approach.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 174,\n",
              "   'span_end': 182,\n",
              "   'text': 'Recent studies have implicated the use of computational techniques such as machine learning algorithms as a precision medicine tool for drug repurposing for the treatment of COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 202,\n",
              "   'span_end': 210,\n",
              "   'text': 'The decision tree algorithms used in the study identify patients with longer survival rates and better oxygen support when treatment was provided and suggest corticosteroids and remdesivir as effective COVID-19 repurposed drugs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 49,\n",
              "   'span_end': 57,\n",
              "   'text': 'Rapid therapeutic options With the advent of the COVID-19 pandemic and reduced therapeutic options for COVID-19, repurposing offers rapid therapeutic strategies to combat COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 103,\n",
              "   'span_end': 111,\n",
              "   'text': 'Rapid therapeutic options With the advent of the COVID-19 pandemic and reduced therapeutic options for COVID-19, repurposing offers rapid therapeutic strategies to combat COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 171,\n",
              "   'span_end': 179,\n",
              "   'text': 'Rapid therapeutic options With the advent of the COVID-19 pandemic and reduced therapeutic options for COVID-19, repurposing offers rapid therapeutic strategies to combat COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 72,\n",
              "   'span_end': 80,\n",
              "   'text': 'El Bairi et al. reviewed various anticancer drugs for the management of COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 374,\n",
              "   'span_end': 382,\n",
              "   'text': 'Likewise, another study has elucidated and suggested the use of interleukin inhibitors, Janus-kinase pathway inhibitors, interferons, vascular endothelial growth factor VEGF inhibitors, immune check-point inhibitors, Bruton tyrosine kinase inhibitors BTK, and XPO-1 a selective inhibitor of nuclear export as some of the alternative drugs that could be repurposed for rapid COVID-19 treatment.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 135,\n",
              "   'span_end': 148,\n",
              "   'text': 'Similarly, another study suggested p38 MAPK mitogen-activated protein kinase, as a vital host target for inhibiting the replication of coronaviruses, after studies proved that Ralimetiniib mesylate was found to be active in both Calu-3 and HeLa-ACE2 cells.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 29,\n",
              "   'span_end': 37,\n",
              "   'text': 'Thus, drug repositioning for COVID-19 research has now taken the front seat and has a huge scope for tackling the virus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 56,\n",
              "   'span_end': 64,\n",
              "   'text': 'With increasing incidences of emerging diseases such as COVID-19, for which immediate treatments were not available, the need for drugs to treat the disease became indispensable.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 104,\n",
              "   'span_end': 114,\n",
              "   'text': 'Previous studies have most commonly employed molecular docking for virtual screening against targets of SARS-CoV-2, such as the main protease, with possible drugs for repurposing such as digitoxigenin, beta-eudesmol, crocin, rutin, ritonavir, emetine, hesperidin, and indinavir.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 65,\n",
              "   'span_end': 73,\n",
              "   'text': 'Likewise, other virtual screening approaches used previously for COVID-19 drug repurposing include combinations of docking with molecular dynamic MD simulations and calculation of free energy using MM-GBSA studies and two-way docking with in silico ADMET studies.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 85,\n",
              "   'span_end': 95,\n",
              "   'text': 'The authors’ previous studies have used Molecular docking against various targets of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 143,\n",
              "   'span_end': 153,\n",
              "   'text': 'Elfiky proved via MD simulations that Setrobuvir, YAK, and ID-184 had the best antiviral activity against RNRP RNA-dependent RNA polymerase of SARS-CoV-2, after screening out 31 compounds that were in clinical trials or had known antiviral activity.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 79,\n",
              "   'span_end': 89,\n",
              "   'text': 'Similarly, MD simulations identified the stability of lopinavir complexed with SARS-CoV-2 main protease as the most stable in biological conditions, along with other identified antivirals such as carfilzomib, valrubicin, elbasvir, and eravacycline.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 15,\n",
              "   'span_end': 23,\n",
              "   'text': 'With regard to COVID-19, this approach combined with docking and simulations has brought immense benefits to the design and repurposing of drugs for SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 149,\n",
              "   'span_end': 159,\n",
              "   'text': 'With regard to COVID-19, this approach combined with docking and simulations has brought immense benefits to the design and repurposing of drugs for SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 136,\n",
              "   'span_end': 146,\n",
              "   'text': 'A study has previously created a QSAR model founded on machine learning strategies utilizing several hundred inhibitor molecules of the SARS-CoV-2 main protease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 105,\n",
              "   'span_end': 115,\n",
              "   'text': 'a QSAR model founded on machine learning strategies utilizing several hundred inhibitor molecules of the SARS-CoV-2 main protease was employed for virtual screening and docking, followed by shortlisting of the 20 best candidates for MD simulation validation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 183,\n",
              "   'span_end': 193,\n",
              "   'text': 'Similarly, another recent study designed a binary-QSAR model for the virtual screening of several drugs that are FDA-approved and are in clinical studies against the main protease of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 104,\n",
              "   'span_end': 114,\n",
              "   'text': 'a binary-QSAR model resulted in cefuroxime pivoxetil as a potential drug repositioning molecule against SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 120,\n",
              "   'span_end': 128,\n",
              "   'text': 'Recently, the use of AI technology for drug repositioning has surfaced with several studies focusing on repurposing for COVID-19 research.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 123,\n",
              "   'span_end': 133,\n",
              "   'text': 'A deep-learning-based approach to screen a huge number of molecules having allocated datasets to seek compounds possessing SARS-CoV-2-inhibiting activities was carried out previously by Ke et al. To validate the designed model and verify the antiviral activity of the compound that the designed model predicted, an in vitro cell line for feline coronavirus replication was also set up in the study.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 345,\n",
              "   'span_end': 356,\n",
              "   'text': 'A deep-learning-based approach to screen a huge number of molecules having allocated datasets to seek compounds possessing SARS-CoV-2-inhibiting activities was carried out previously by Ke et al. To validate the designed model and verify the antiviral activity of the compound that the designed model predicted, an in vitro cell line for feline coronavirus replication was also set up in the study.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 252,\n",
              "   'span_end': 262,\n",
              "   'text': 'Likewise, Beck et al. utilized an already trained deep-learning prediction model for drug-target interactions known as Molecule Transformer-Drug Target Interaction MT-DTI, to find antiviral drugs that are commercially available and which could perturb SARS-CoV-2 components including RNA-dependent RNA polymerase, proteinase, and helicase.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 85,\n",
              "   'span_end': 93,\n",
              "   'text': 'Thus, AI-based techniques are providing the scientific communities a chance to fight COVID-19 in a much faster way, owing to the accessible web servers, tools, and models that reduce the time required for a drug to come into the market.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 71,\n",
              "   'span_end': 79,\n",
              "   'text': 'The scope and developments of computational medicinal chemistry toward COVID-19 treatment strategies are summarized in Fig. Several computational approaches for repurposing have been used over the years to enhance the efficiency of the predictive outcomes and decrease the drawbacks.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 112,\n",
              "   'span_end': 120,\n",
              "   'text': 'There are several applications of computational biology and chem-bioinformatic approaches for drug discovery in COVID-19 research.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 104,\n",
              "   'span_end': 112,\n",
              "   'text': 'A recent study has developed a multi-model deep learning-based algorithm for drug repurposing to aid in COVID-19 research.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 144,\n",
              "   'span_end': 152,\n",
              "   'text': 'The results from A recent study showed clusters that were employed to identify the drugs that were notably similar to the proposed and existing COVID-19 treatment medication.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 170,\n",
              "   'span_end': 178,\n",
              "   'text': 'Another recent study also proposed a data augmentation approach that extricates only beneficial data from a set of variable datasets, to screen novel drug candidates for COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 45,\n",
              "   'span_end': 53,\n",
              "   'text': 'A recent application of signature mapping on COVID-19 research demonstrated the use of Connectivity Map databases for generating drug perturbation profiles.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 67,\n",
              "   'span_end': 75,\n",
              "   'text': 'A modified version of A recent application of signature mapping on COVID-19 research was implemented by Jia et al. where the input used was the expression profile data from healthy and infected individuals to generate a pathway-based drug repurposing framework.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 191,\n",
              "   'span_end': 201,\n",
              "   'text': 'Another recent study designed and developed Deep Docking, which uses QSAR Quantitative Structure–Activity Relationship models to predict the docking scores of drug candidates that target the SARS-CoV-2 3CL protein.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 118,\n",
              "   'span_end': 126,\n",
              "   'text': 'Deep Docking docked all the compounds and provided a list of potential drug hits, that could be used to repurpose for COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 100,\n",
              "   'span_end': 108,\n",
              "   'text': 'Several studies have implemented random-walk algorithms to identify drug repurposing candidates for COVID-19 –. The pathogenic mechanisms instigated by the SARS-CoV-2 3CL protein using the information from all related coronaviruses were also explored and random walk algorithms were implemented on the molecular networks to recognize the most relevant COVID-19 drug targets.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 156,\n",
              "   'span_end': 166,\n",
              "   'text': 'Several studies have implemented random-walk algorithms to identify drug repurposing candidates for COVID-19 –. The pathogenic mechanisms instigated by the SARS-CoV-2 3CL protein using the information from all related coronaviruses were also explored and random walk algorithms were implemented on the molecular networks to recognize the most relevant COVID-19 drug targets.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 218,\n",
              "   'span_end': 231,\n",
              "   'text': 'Several studies have implemented random-walk algorithms to identify drug repurposing candidates for COVID-19 –. The pathogenic mechanisms instigated by the SARS-CoV-2 3CL protein using the information from all related coronaviruses were also explored and random walk algorithms were implemented on the molecular networks to recognize the most relevant COVID-19 drug targets.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 352,\n",
              "   'span_end': 360,\n",
              "   'text': 'Several studies have implemented random-walk algorithms to identify drug repurposing candidates for COVID-19 –. The pathogenic mechanisms instigated by the SARS-CoV-2 3CL protein using the information from all related coronaviruses were also explored and random walk algorithms were implemented on the molecular networks to recognize the most relevant COVID-19 drug targets.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 137,\n",
              "   'span_end': 145,\n",
              "   'text': 'Thus, these computational perspectives on drug repurposing provide a unique outlook on the alternative treatment options for the ongoing COVID-19 disease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 114,\n",
              "   'span_end': 124,\n",
              "   'text': 'Drugs such as lopinavir, ritonavir, boceprevir, carmofur, and doxycycline act on the 3-chymotrypsin-like proteins/SARS-CoV-2 main protease that play an important role in cleaving and releasing the 16 non-structural proteins.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 26,\n",
              "   'span_end': 36,\n",
              "   'text': 'For the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of SARS-CoV-2, drugs such as vapreotide, atazanavir, daclatasvir, and bismuth potassium citrate commonly block this function of the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of the virus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 115,\n",
              "   'span_end': 125,\n",
              "   'text': 'For the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of SARS-CoV-2, drugs such as vapreotide, atazanavir, daclatasvir, and bismuth potassium citrate commonly block this function of the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of the virus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 262,\n",
              "   'span_end': 272,\n",
              "   'text': 'For the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of SARS-CoV-2, drugs such as vapreotide, atazanavir, daclatasvir, and bismuth potassium citrate commonly block this function of the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of the virus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 181,\n",
              "   'span_end': 191,\n",
              "   'text': 'Likewise, dinucleoside 123 and raltegravir affect the pathways of methyltransferases guanine-N7-methyltransferase, 2’-O-methyltransferase, while gliclazide and memantine affect the SARS-CoV-2 E protein, which is the envelope protein of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 236,\n",
              "   'span_end': 246,\n",
              "   'text': 'Likewise, dinucleoside 123 and raltegravir affect the pathways of methyltransferases guanine-N7-methyltransferase, 2’-O-methyltransferase, while gliclazide and memantine affect the SARS-CoV-2 E protein, which is the envelope protein of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 271,\n",
              "   'span_end': 281,\n",
              "   'text': 'The viral neuraminidases and the DPP4 cell receptor pathways are hindered due to the action of oseltamivir and sitagliptin, while pemirolast, nitrofurantoin, isoniazid pyruvate, eridictoyl, hypericin, cepharanthine, and ergoloid block the human ACE2 and the S protein of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 123,\n",
              "   'span_end': 133,\n",
              "   'text': 'The most important Janus kinase pathway is hindered by baricitinib, RdRp, helicase, exo-nuclease, and methyltransferase of SARS-CoV-2 by Efavirenz and Poly ADP-ribose polymerase 1 PARP-1 by Mefuparib hydrochloride.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 90,\n",
              "   'span_end': 100,\n",
              "   'text': 'Other common drugs such as nitazoxanide, ivermectin, and azithromycin tend to symptoms of SARS-CoV-2, and play a role in inhibiting the role of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 144,\n",
              "   'span_end': 154,\n",
              "   'text': 'Other common drugs such as nitazoxanide, ivermectin, and azithromycin tend to symptoms of SARS-CoV-2, and play a role in inhibiting the role of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 66,\n",
              "   'span_end': 74,\n",
              "   'text': 'Despite these drugs being implicated as a potential treatment for COVID-19, ethical issues arise regarding the use of these drugs without proper clinical phase trials and FDA Food and Drug Administration approval.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 85,\n",
              "   'span_end': 93,\n",
              "   'text': 'Therefore, a list of the FDA Food and Drug Administration drugs for the treatment of COVID-19 is provided in Table.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 105,\n",
              "   'span_end': 115,\n",
              "   'text': 'Mahdian et al. and Yuce et al. state that Paritaprevir is important against 3-chymotrypsin-like proteins/SARS-CoV-2 Main protease and plays an important role in cleaving as well as releasing 16 non-structural proteins Nsps.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 35,\n",
              "   'span_end': 45,\n",
              "   'text': 'Paritaprevir also affects the ACE2-SARS-CoV-2-RBD complex.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 64,\n",
              "   'span_end': 74,\n",
              "   'text': 'Likewise, ledipasvir, vancomycin, and sirolimus target the ACE2-SARS-CoV-2-RBD complex, a spike protein that helps in the viral entry along with the help of ACE2 protein in the host organism.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 211,\n",
              "   'span_end': 221,\n",
              "   'text': 'Similarly, FDA-approved irinotecan, abemaciclib, estradiol benzoate, capmatinib, olaparib, lumacaftor, and pazopanib target CD147, a member of the immunoglobulin superfamily IgSF interacts with spike protein of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 230,\n",
              "   'span_end': 240,\n",
              "   'text': 'Other drugs such as nilotinib, rifabutin, dactinomycin, dihydroergotamine, bromocriptine, entrectinib, selinexor, elbasvir, quinupristin, rifapentine, rutin, digitoxin, diosmin, and antrafenine target 3-chymotrypsin-like proteins/SARS-CoV-2 Main protease that plays an important role in cleaving as well as releasing 16 non-structural proteins Nsps.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 187,\n",
              "   'span_end': 197,\n",
              "   'text': 'This data is provided in detail in Table and the 2D structures of some of these drugs are shown in Fig. When remdesivir was administered intravenously to the first patient diagnosed with SARS-CoV-2 in the USA, no adverse effects were noted with some clinical benefits in the first patient diagnosed with SARS-CoV-2 in the USA.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 304,\n",
              "   'span_end': 314,\n",
              "   'text': 'This data is provided in detail in Table and the 2D structures of some of these drugs are shown in Fig. When remdesivir was administered intravenously to the first patient diagnosed with SARS-CoV-2 in the USA, no adverse effects were noted with some clinical benefits in the first patient diagnosed with SARS-CoV-2 in the USA.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 203,\n",
              "   'span_end': 211,\n",
              "   'text': 'Additionally, due to some adverse effects early on, remdesivir was then discontinued, and FDA Food and Drug Administration has now provided a conditional recommendation for the use of remdesivir against COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 90,\n",
              "   'span_end': 98,\n",
              "   'text': 'Likewise, real-world usage of lopinavir/ritonavir revealed no beneficial response against COVID-19 hospitalized patients in a randomized, controlled, trial.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 141,\n",
              "   'span_end': 149,\n",
              "   'text': 'Despite there being studies on hydroxychloroquine, an analogue of chloroquine, where improvements have been noted in patients suffering from COVID-19 in a study conducted in Wuhan, there still seems to be very limited data on the reliability of hydroxychloroquine, an analogue of chloroquine.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 71,\n",
              "   'span_end': 79,\n",
              "   'text': 'Interferon-beta-1A has been used in hospitalized patients for treating COVID-19 at Shaid Behesti University of Medical Sciences, in combination with other drugs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 202,\n",
              "   'span_end': 212,\n",
              "   'text': 'Therefore, the clinical data presented provide evidence of the efficacy of the use of these drugs,however, more research is indispensable for the proper application and employability of these drugs for SARS-CoV-2 treatment.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 25,\n",
              "   'span_end': 36,\n",
              "   'text': 'According to literature, coronavirus papain-like proteases PLpro, main protease 3CLpro, helicase, and RNA-dependent RNA polymerase RdRp are the considered to be the potential molecular targets and are involved in important functional activities such as protein synthesis, RNA transcription, translation, replication, processing, and infection respectively.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 63,\n",
              "   'span_end': 76,\n",
              "   'text': 'All these proteins come under non-structural proteins nsps for coronaviruses.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS CoV-2',\n",
              "   'span_start': 67,\n",
              "   'span_end': 77,\n",
              "   'text': 'The N-terminal and the C-terminal domain of The nucleoprotein N of SARS CoV-2 share similarities with CoVs N proteins.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 102,\n",
              "   'span_end': 106,\n",
              "   'text': 'The N-terminal and the C-terminal domain of The nucleoprotein N of SARS CoV-2 share similarities with CoVs N proteins.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'protomers',\n",
              "   'span_start': 46,\n",
              "   'span_end': 55,\n",
              "   'text': 'the C-terminal domain is a homodimer with two protomers resembling a rectangular slab-like structure.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'protomers',\n",
              "   'span_start': 45,\n",
              "   'span_end': 54,\n",
              "   'text': \"The beta hairpin-like structure connects two protomers by inserting The beta hairpin-like structure into two protomers's cavities.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'protomers',\n",
              "   'span_start': 109,\n",
              "   'span_end': 118,\n",
              "   'text': \"The beta hairpin-like structure connects two protomers by inserting The beta hairpin-like structure into two protomers's cavities.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS CoV-2',\n",
              "   'span_start': 43,\n",
              "   'span_end': 53,\n",
              "   'text': 'The overall size of The nucleoprotein N of SARS CoV-2 is about 8.4–12 kDa and forms the integral membrane protein of the virus comprising 76–109 amino acids.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS CoV-2',\n",
              "   'span_start': 99,\n",
              "   'span_end': 109,\n",
              "   'text': 'There are about 7–12 amino acids at The N-terminal which is short and makes The nucleoprotein N of SARS CoV-2 hydrophilic in nature.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'protomers',\n",
              "   'span_start': 4,\n",
              "   'span_end': 13,\n",
              "   'text': 'The protomers present in the spike glycoprotein structure contain approximately 1260 amino acids.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 35,\n",
              "   'span_end': 45,\n",
              "   'text': 'The non-structural proteins of the SARS-CoV-2 are polyproteins pp1a and pp1ab.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 89,\n",
              "   'span_end': 99,\n",
              "   'text': 'These structural details are of utmost essential when The non-structural proteins of the SARS-CoV-2 interact with the drug candidates, to understand the precise molecular mechanism of action of the small molecule.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 139,\n",
              "   'span_end': 149,\n",
              "   'text': 'All these studies prove that there is distinct evidence as to the altering of the the virus proteins’ structural antigenicity, causing the SARS-CoV-2 proteins’ to evade the immune system and become more robust.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 111,\n",
              "   'span_end': 119,\n",
              "   'text': 'Currently, as we have seen from various evidences, there are several repurposed drugs reported for use against COVID-19, some already available on the market.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 176,\n",
              "   'span_end': 186,\n",
              "   'text': 'The potential binding of several FDA-approved drugs has been studied previously however, not much data is revealed on the precise molecular basis of these interactions against SARS-CoV-2 targets.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 94,\n",
              "   'span_end': 104,\n",
              "   'text': 'In the previous section, evidence of how the variants alter the drug binding efficacy and how SARS-CoV-2 escapes the immune system is provided.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 51,\n",
              "   'span_end': 61,\n",
              "   'text': 'In our previous study, however, various targets of SARS-CoV-2 were analyzed at the molecular level to comprehend the changes SARS-CoV-2 undergoes during the binding event of some of the important FDA-approved drugs for COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 125,\n",
              "   'span_end': 135,\n",
              "   'text': 'In our previous study, however, various targets of SARS-CoV-2 were analyzed at the molecular level to comprehend the changes SARS-CoV-2 undergoes during the binding event of some of the important FDA-approved drugs for COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 219,\n",
              "   'span_end': 227,\n",
              "   'text': 'In our previous study, however, various targets of SARS-CoV-2 were analyzed at the molecular level to comprehend the changes SARS-CoV-2 undergoes during the binding event of some of the important FDA-approved drugs for COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 82,\n",
              "   'span_end': 92,\n",
              "   'text': 'Though there are limited experimental data to highlight the spike glycoprotein of SARS-CoV-2 act as the target for repurposed drugs, however, several computational biology prediction revelated the scope of utilising spike glycoproteins as the putative molecular target for repurposed drugs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 104,\n",
              "   'span_end': 114,\n",
              "   'text': 'A recent study stated that drugs ritonavir and eriodictoyl bind to the active sites of spike protein of SARS-CoV-2 with potential binding energy and stability.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 150,\n",
              "   'span_end': 160,\n",
              "   'text': 'Likewise, another study showed that repurposed drugs such as pralatrexate, carumonam, aclerasteride, and granotapide interacted with spike protein of SARS-CoV-2 and acted as potential binders.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 139,\n",
              "   'span_end': 149,\n",
              "   'text': 'Additionally, another recent study has reported Remdesivir and ivermectin, potential repurposed drugs interacted with the spike protein of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 86,\n",
              "   'span_end': 96,\n",
              "   'text': 'another recent study stated that ivermectin bound effectively to the spike protein of SARS-CoV-2, and inhibited the entry of SARS-CoV-2 into the host.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 125,\n",
              "   'span_end': 135,\n",
              "   'text': 'another recent study stated that ivermectin bound effectively to the spike protein of SARS-CoV-2, and inhibited the entry of SARS-CoV-2 into the host.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 98,\n",
              "   'span_end': 108,\n",
              "   'text': 'Remdesivir was also suggested to be involved in stable interaction with the spike glycoprotein of SARS-CoV-2, apart from the other targets.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 104,\n",
              "   'span_end': 114,\n",
              "   'text': 'These studies demonstrate that repurposed drugs were suggested to be targeted the spike glycoprotein of SARS-CoV-2 at various binding pockets and interacted with the spike glycoprotein of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 188,\n",
              "   'span_end': 198,\n",
              "   'text': 'These studies demonstrate that repurposed drugs were suggested to be targeted the spike glycoprotein of SARS-CoV-2 at various binding pockets and interacted with the spike glycoprotein of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 174,\n",
              "   'span_end': 184,\n",
              "   'text': 'At a molecular level, Fig. showed that chloroquine interacted with amino acids Leu6820, Leu6819, Met6818, Val7021, Tyr7020, Asp7018, and Asp6942 of the spike glycoprotein of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 125,\n",
              "   'span_end': 133,\n",
              "   'text': 'The major repurposed drugs displayed in Table dhow that research is ongoing and always improving for tackling the problem of COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS',\n",
              "   'span_start': 77,\n",
              "   'span_end': 81,\n",
              "   'text': 'Lopinavir/ritonavir was generally used against HIV, remdesivir against major SARS viruses, and favipiravir which was previously used as a general viral pro-drug.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 94,\n",
              "   'span_end': 102,\n",
              "   'text': 'For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 197,\n",
              "   'span_end': 205,\n",
              "   'text': 'For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 210,\n",
              "   'span_end': 218,\n",
              "   'text': 'For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 319,\n",
              "   'span_end': 329,\n",
              "   'text': 'For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 356,\n",
              "   'span_end': 364,\n",
              "   'text': 'For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 88,\n",
              "   'span_end': 98,\n",
              "   'text': 'Likewise, the in vivo study of remdesivir a broad-spectrum antiviral when infected with SARS-CoV-2, the pathogenic strain of COVID-19 disease infected rhesus monkey demonstrated an improvement in the pulmonary lesions and decreased the viral load after 7 days of treatment with remdesivir a broad-spectrum antiviral.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 125,\n",
              "   'span_end': 133,\n",
              "   'text': 'Likewise, the in vivo study of remdesivir a broad-spectrum antiviral when infected with SARS-CoV-2, the pathogenic strain of COVID-19 disease infected rhesus monkey demonstrated an improvement in the pulmonary lesions and decreased the viral load after 7 days of treatment with remdesivir a broad-spectrum antiviral.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviral disease',\n",
              "   'span_start': 3,\n",
              "   'span_end': 22,\n",
              "   'text': 'No coronaviral disease was observed after the successful use of remdesivir a broad-spectrum antiviral.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 197,\n",
              "   'span_end': 207,\n",
              "   'text': 'remdesivir a broad-spectrum antiviral was originally meant for treating the Ebola virus against the Ebola RdRp target, and now with potential repurposing capabilities against the RdRp and NSP12 of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 108,\n",
              "   'span_end': 118,\n",
              "   'text': 'Lopinavir/ritonavir is a drug for the HIV-1 protease, that now evidences potential for the main protease of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 92,\n",
              "   'span_end': 102,\n",
              "   'text': 'Silmitasertib is also known to inhibit the casein kinase 2 pathway in Sonic hedgehog SHH in SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 117,\n",
              "   'span_end': 127,\n",
              "   'text': 'Likewise, dipyridamole 100 mg is an inhibitor of phosphodiesterase originally and works against the main protease of SARS-CoV-2 and stops replication.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 124,\n",
              "   'span_end': 134,\n",
              "   'text': 'Leronlimab 700 mg works against the C–C Chemokine receptor type 5 in HIV and now shows potential against the same target in SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 111,\n",
              "   'span_end': 121,\n",
              "   'text': 'Ruconest targets the c1 esterase and inhibits angioedema, while Ruconest targets C1, C5a, and C3a esterases in SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 48,\n",
              "   'span_end': 58,\n",
              "   'text': \"Infliximab attacks the tumor necrosis factor in SARS-CoV-2 as well as in Infliximab's original target in Rheumatoid arthritis, Crohn’s disease, and ankylosing spondylitis.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 17,\n",
              "   'span_end': 27,\n",
              "   'text': 'The emergence of SARS-CoV-2 has illuminated the purpose and benefits of repositioning drugs to provide emergency treatments.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 317,\n",
              "   'span_end': 325,\n",
              "   'text': 'Other advantages of repurposed drugs include Lower cost of productionLesser time for identifying useful, effective, and safe drugs for quick useResearch can be carried out using the existing, easily accessible bioinformatics and chem-informatics data and resources available for specific diseases, as was the case in COVID-19 cases Molecular docking The emergence and prevalence of COVID-19 have paved the way for molecular docking studies.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 382,\n",
              "   'span_end': 390,\n",
              "   'text': 'Other advantages of repurposed drugs include Lower cost of productionLesser time for identifying useful, effective, and safe drugs for quick useResearch can be carried out using the existing, easily accessible bioinformatics and chem-informatics data and resources available for specific diseases, as was the case in COVID-19 cases Molecular docking The emergence and prevalence of COVID-19 have paved the way for molecular docking studies.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 109,\n",
              "   'span_end': 117,\n",
              "   'text': 'Previously, molecular docking has been used to determine the potential anti-virals for curbing the spread of COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 117,\n",
              "   'span_end': 127,\n",
              "   'text': 'Poly-ADP-ribose polymerase-1, CVL218, a potent inhibitor that binds to the N-terminal of the nucleocapsid protein of SARS-CoV-2 was identified.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 34,\n",
              "   'span_end': 42,\n",
              "   'text': 'The use of Signature matching for COVID-19 remains an unexplored avenue.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 120,\n",
              "   'span_end': 128,\n",
              "   'text': 'With so many repurposed drugs in the market today, and several more upcoming owing to the intensity and acceleration of COVID-19 research, there are more advantages than disadvantages to the use of such drugs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 564,\n",
              "   'span_end': 572,\n",
              "   'text': 'However, some limitations to the drug repositioning, include Weak intellectual property rights protection for repurposed drugs due to reduced rate of returnThe molecular docking technique used for identifying drugs for repurposing cannot be applied to all existing drugs due to the larger computational operationsSome network-based approaches used for drug repurposing do not always yield promising operationsSome network-based approaches used for drug repurposing are data-dependent, due to which the results may be inaccurate due to the lower volume of existing COVID-19 dataLack of strong, solid evidence for the mechanism of action of repurposed drugs on COVID-19 19Experimental evidence is required for validating the predictive outcomesOverall low success rates in new disease settingsExtensive data to be studied before repurposingDosing and safety issues, i.e., approved range of dosage and delivery capabilities are not very strongAccurate, robust toxicological studies of repurposed drugs essential before delivery and testingRare to find unique and novel drug-protein interactions all within the restraints of the approved therapeutic window.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 659,\n",
              "   'span_end': 667,\n",
              "   'text': 'However, some limitations to the drug repositioning, include Weak intellectual property rights protection for repurposed drugs due to reduced rate of returnThe molecular docking technique used for identifying drugs for repurposing cannot be applied to all existing drugs due to the larger computational operationsSome network-based approaches used for drug repurposing do not always yield promising operationsSome network-based approaches used for drug repurposing are data-dependent, due to which the results may be inaccurate due to the lower volume of existing COVID-19 dataLack of strong, solid evidence for the mechanism of action of repurposed drugs on COVID-19 19Experimental evidence is required for validating the predictive outcomesOverall low success rates in new disease settingsExtensive data to be studied before repurposingDosing and safety issues, i.e., approved range of dosage and delivery capabilities are not very strongAccurate, robust toxicological studies of repurposed drugs essential before delivery and testingRare to find unique and novel drug-protein interactions all within the restraints of the approved therapeutic window.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 61,\n",
              "   'span_end': 71,\n",
              "   'text': 'In the wake of the emergence of highly mutated and resistant SARS-CoV-2 strains, the question of how already repurposed drugs work comes into the picture.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 131,\n",
              "   'span_end': 139,\n",
              "   'text': 'Another perspective is the use of drug repurposing as a therapy for novel diseases for which specific drugs are not yet available, COVID-19 being one such important example.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 91,\n",
              "   'span_end': 101,\n",
              "   'text': 'Although this review comprehensively lists all the current and latest drugs repurposed for SARS-CoV-2 and the existing computational approaches that in turn improve the process of repurposing, further advancements in the software and techniques such as using ensemble machine learning will improve the process of repurposing.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 27,\n",
              "   'span_end': 35,\n",
              "   'text': 'With high mortality rates, COVID-19 has become one of the most prevailing diseases globally.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 70,\n",
              "   'span_end': 80,\n",
              "   'text': 'With the CDC and WHO declaring several recent variants of concern for SARS-CoV-2, there is an urgent need to explore alternative options of treatment when there are no specific drugs targeting SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 193,\n",
              "   'span_end': 203,\n",
              "   'text': 'With the CDC and WHO declaring several recent variants of concern for SARS-CoV-2, there is an urgent need to explore alternative options of treatment when there are no specific drugs targeting SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 96,\n",
              "   'span_end': 106,\n",
              "   'text': 'this review sheds light on the various existing drugs that have been repurposed for use against SARS-CoV-2 and also illuminates the important drug targets against which the various existing drugs that have been repurposed for use against SARS-CoV-2 are used spike glycoproteins, RDRP, main protease, papain-like protease, nucleoproteins, non-structural proteins, and enveloped proteins of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 238,\n",
              "   'span_end': 248,\n",
              "   'text': 'this review sheds light on the various existing drugs that have been repurposed for use against SARS-CoV-2 and also illuminates the important drug targets against which the various existing drugs that have been repurposed for use against SARS-CoV-2 are used spike glycoproteins, RDRP, main protease, papain-like protease, nucleoproteins, non-structural proteins, and enveloped proteins of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 389,\n",
              "   'span_end': 399,\n",
              "   'text': 'this review sheds light on the various existing drugs that have been repurposed for use against SARS-CoV-2 and also illuminates the important drug targets against which the various existing drugs that have been repurposed for use against SARS-CoV-2 are used spike glycoproteins, RDRP, main protease, papain-like protease, nucleoproteins, non-structural proteins, and enveloped proteins of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 60,\n",
              "   'span_end': 68,\n",
              "   'text': 'The most important advantage of repositioning drugs against COVID-19 is the reduced cost and time of development and the drawback is the absence of safety/toxicity profiles via in vivo trials for COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 196,\n",
              "   'span_end': 204,\n",
              "   'text': 'The most important advantage of repositioning drugs against COVID-19 is the reduced cost and time of development and the drawback is the absence of safety/toxicity profiles via in vivo trials for COVID-19.'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 15,\n",
              "   'span_end': 26,\n",
              "   'text': 'The 2019 novel coronavirus, now dubbed SARS-CoV-2, has led to a global pandemic as declared by the World Health Organization WHO on 11 March 2020.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 39,\n",
              "   'span_end': 49,\n",
              "   'text': 'The 2019 novel coronavirus, now dubbed SARS-CoV-2, has led to a global pandemic as declared by the World Health Organization WHO on 11 March 2020.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 15,\n",
              "   'span_end': 26,\n",
              "   'text': \"The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 39,\n",
              "   'span_end': 49,\n",
              "   'text': \"The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 72,\n",
              "   'span_end': 83,\n",
              "   'text': \"The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 96,\n",
              "   'span_end': 106,\n",
              "   'text': \"The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviridae',\n",
              "   'span_start': 160,\n",
              "   'span_end': 173,\n",
              "   'text': \"The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 579,\n",
              "   'span_end': 587,\n",
              "   'text': \"The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 57,\n",
              "   'span_end': 68,\n",
              "   'text': 'Despite this variance, it is of note that The 2019 novel coronavirus, now dubbed SARS-CoV-2 infections lead to systemic inflammatory response syndrome SIRS and acute respiratory distress syndrome ARDS, two relevant conditions highly correlated with COVID-19 infections.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infections',\n",
              "   'span_start': 81,\n",
              "   'span_end': 102,\n",
              "   'text': 'Despite this variance, it is of note that The 2019 novel coronavirus, now dubbed SARS-CoV-2 infections lead to systemic inflammatory response syndrome SIRS and acute respiratory distress syndrome ARDS, two relevant conditions highly correlated with COVID-19 infections.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infections',\n",
              "   'span_start': 249,\n",
              "   'span_end': 268,\n",
              "   'text': 'Despite this variance, it is of note that The 2019 novel coronavirus, now dubbed SARS-CoV-2 infections lead to systemic inflammatory response syndrome SIRS and acute respiratory distress syndrome ARDS, two relevant conditions highly correlated with COVID-19 infections.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infections',\n",
              "   'span_start': 14,\n",
              "   'span_end': 33,\n",
              "   'text': 'Specifically, COVID-19 infections are accompanied by an overaggressive inflammatory response corresponding to a significant release of pro-inflammatory cytokines known as a cytokine storm.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 47,\n",
              "   'span_end': 55,\n",
              "   'text': 'Though the biological relevance in relation to COVID-19 of cytokine storms has been questioned, studies have shown significant elevations of pro-inflammatory cytokines in COVID-19 infections as compared to other viral infections, highlighting that virulence may be more immune response-mediated rather than solely due to the viral titer.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infections',\n",
              "   'span_start': 171,\n",
              "   'span_end': 190,\n",
              "   'text': 'Though the biological relevance in relation to COVID-19 of cytokine storms has been questioned, studies have shown significant elevations of pro-inflammatory cytokines in COVID-19 infections as compared to other viral infections, highlighting that virulence may be more immune response-mediated rather than solely due to the viral titer.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 206,\n",
              "   'span_end': 214,\n",
              "   'text': \"As the mechanisms of the cytokine storm have yet to be fully elucidated, there is a need to understand the cytokine storm's genomic origin by comparing the cytokine storm known conditions that occur during COVID-19, such as SARS and acute respiratory distress syndrome ARDS.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS',\n",
              "   'span_start': 224,\n",
              "   'span_end': 228,\n",
              "   'text': \"As the mechanisms of the cytokine storm have yet to be fully elucidated, there is a need to understand the cytokine storm's genomic origin by comparing the cytokine storm known conditions that occur during COVID-19, such as SARS and acute respiratory distress syndrome ARDS.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 15,\n",
              "   'span_end': 23,\n",
              "   'text': 'In the case of COVID-19, studies have most often utilized differential gene analysis and limited research is available on clusters of highly correlated genes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 15,\n",
              "   'span_end': 23,\n",
              "   'text': \"In the case of COVID-19, where the variance in symptoms and the unclear mechanisms of the cytokine storm led to challenges in developing therapeutics to treat affected patients, the need arises to solve challenges in developing therapeutics to treat affected patients through relation of the COVID-19 induced cytokine storm to similar ailment SIRS, ARDS, and sepsis, to connect SARS and ARDS's mechanisms and therefore elucidate potential novel drugs.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 292,\n",
              "   'span_end': 300,\n",
              "   'text': \"In the case of COVID-19, where the variance in symptoms and the unclear mechanisms of the cytokine storm led to challenges in developing therapeutics to treat affected patients, the need arises to solve challenges in developing therapeutics to treat affected patients through relation of the COVID-19 induced cytokine storm to similar ailment SIRS, ARDS, and sepsis, to connect SARS and ARDS's mechanisms and therefore elucidate potential novel drugs.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS',\n",
              "   'span_start': 378,\n",
              "   'span_end': 382,\n",
              "   'text': \"In the case of COVID-19, where the variance in symptoms and the unclear mechanisms of the cytokine storm led to challenges in developing therapeutics to treat affected patients, the need arises to solve challenges in developing therapeutics to treat affected patients through relation of the COVID-19 induced cytokine storm to similar ailment SIRS, ARDS, and sepsis, to connect SARS and ARDS's mechanisms and therefore elucidate potential novel drugs.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 140,\n",
              "   'span_end': 148,\n",
              "   'text': 'The Connectivity Map CMap has allowed for the repurposing of drugs based on gene expression values in neurogenerative diseases, cancer, and COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 173,\n",
              "   'span_end': 181,\n",
              "   'text': 'Herein, a bioinformatics and systems biology approach are adopted to study the similarities and differences between the whole blood transcriptome in ARDS, SIRS, sepsis, and COVID-19, to highlight possible reusable i.e., repurposed drugs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 90,\n",
              "   'span_end': 98,\n",
              "   'text': 'Microarray datasets GSE147902, GSE66890, GSE74224, GSE152641 from ARDS, SIRS, sepsis, and COVID-19 whole blood transcriptomes were taken from the GEO database and analyzed using WGCNA through hierarchal clustering to identify significantly co-expressed modules or clusters of co-expressed genes across the aforementioned conditions.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infections',\n",
              "   'span_start': 59,\n",
              "   'span_end': 78,\n",
              "   'text': 'These ailments have been widely reported to be symptoms of COVID-19 infections, and often occur in conjunction with the so-called cytokine storm.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 32,\n",
              "   'span_end': 40,\n",
              "   'text': 'Although the transcriptomics of COVID-19 have been widely studied, the specific mechanisms of cytokine storms have yet to be fully understood.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 49,\n",
              "   'span_end': 57,\n",
              "   'text': \"The similarities between ARDS, SIRS, sepsis, and COVID-19 were analyzed at the module level using module preservation analysis and functional and pathway enrichment were used to understand The similarities between ARDS, SIRS, sepsis, and COVID-19's biological significance.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 238,\n",
              "   'span_end': 246,\n",
              "   'text': \"The similarities between ARDS, SIRS, sepsis, and COVID-19 were analyzed at the module level using module preservation analysis and functional and pathway enrichment were used to understand The similarities between ARDS, SIRS, sepsis, and COVID-19's biological significance.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 62,\n",
              "   'span_end': 70,\n",
              "   'text': 'Only the genetic similarities between ARDS, SIRS, sepsis, and COVID-19 were considered in this study, and temporal effects or variations were not accounted for.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 220,\n",
              "   'span_end': 228,\n",
              "   'text': 'It is also important to note that the findings in this study are based on generated gene co-expression and PPI networks built from relating immune illnesses, and hence, offer insights into repurposed drugs to treat post-COVID-19 effects i.e., cytokine storms.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 9,\n",
              "   'span_end': 17,\n",
              "   'text': 'Finally, COVID-19 microarray data was taken from GSE177477 which contains the blood transcriptome of 29 COVID-19 patients and 18 healthy controls.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 104,\n",
              "   'span_end': 112,\n",
              "   'text': 'Finally, COVID-19 microarray data was taken from GSE177477 which contains the blood transcriptome of 29 COVID-19 patients and 18 healthy controls.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 139,\n",
              "   'span_end': 147,\n",
              "   'text': 'After construction of the weighted gene co-expression network of the ARDS dataset whose modules served as reference, the sepsis, SIRS, and COVID-19 datasets were projected onto the ARDS dataset whose modules served as reference to analyze module preservation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 137,\n",
              "   'span_end': 145,\n",
              "   'text': 'To screen possible repurposed drug candidates that are associated with the identified modules of interest across ARDS, SIRS, sepsis, and COVID-19, connectivity map analysis was performed using the Connectivity Map online webserver.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 94,\n",
              "   'span_end': 102,\n",
              "   'text': 'Specifically, the top three genes were taken from each of the identified modules preserved in COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 231,\n",
              "   'span_end': 239,\n",
              "   'text': 'Interestingly, the two largest modules, M44 and M1, were enriched in large-scale macromolecule metabolic processes 2295/5606 and chemical stimulus detection 399/1583 A, cellular processes which have been observed to be affected by COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 138,\n",
              "   'span_end': 146,\n",
              "   'text': 'To compare the similarity of gene expression at the module level between the four diseases included in this study ARDS, SIRS, Sepsis, and COVID-19, the network constructed based on the ARDS dataset was used as reference for module preservation analysis where other datasets describing SIRS, Sepsis, and COVID-19 whole blood transcriptome expressions were projected onto the ARDS dataset.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 303,\n",
              "   'span_end': 311,\n",
              "   'text': 'To compare the similarity of gene expression at the module level between the four diseases included in this study ARDS, SIRS, Sepsis, and COVID-19, the network constructed based on the ARDS dataset was used as reference for module preservation analysis where other datasets describing SIRS, Sepsis, and COVID-19 whole blood transcriptome expressions were projected onto the ARDS dataset.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 184,\n",
              "   'span_end': 192,\n",
              "   'text': 'Module preservation analysis revealed that the ARDS modules were most significantly preserved in the sepsis dataset B, while only a few modules were strongly preserved in the SIRS and COVID-19 datasets.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 273,\n",
              "   'span_end': 281,\n",
              "   'text': 'Turquoise M1, sky blue M28, violet M32, and dark orange M45 showed moderate preservation while magenta M9, light cyan M16, light green M18, light yellow M19, orange M25, dark olive green M33, yellow green M36, and floral white M44 showed strong preservation B. Finally, in COVID-19, sky blue M28 showed no preservation, orange M25, dark orange M45, violet M32, and dark olive green M33 showed moderate preservation, and turquoise M1, magenta M9, light cyan M16, light green M18, light yellow M19, yellow green M36, and floral white M44 showed strong preservation C. Collectively, the modules strongly preserved in COVID-19 were also strongly preserved in other modules and were therefore selected for further downstream analysis.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 614,\n",
              "   'span_end': 622,\n",
              "   'text': 'Turquoise M1, sky blue M28, violet M32, and dark orange M45 showed moderate preservation while magenta M9, light cyan M16, light green M18, light yellow M19, orange M25, dark olive green M33, yellow green M36, and floral white M44 showed strong preservation B. Finally, in COVID-19, sky blue M28 showed no preservation, orange M25, dark orange M45, violet M32, and dark olive green M33 showed moderate preservation, and turquoise M1, magenta M9, light cyan M16, light green M18, light yellow M19, yellow green M36, and floral white M44 showed strong preservation C. Collectively, the modules strongly preserved in COVID-19 were also strongly preserved in other modules and were therefore selected for further downstream analysis.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 160,\n",
              "   'span_end': 168,\n",
              "   'text': 'Considering that most drugs have mechanism of actions that target proteins, the hub genes were selected by submitting the genes in each module preserved in the COVID-19 dataset to the STRING database for PPI network construction.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infections',\n",
              "   'span_start': 67,\n",
              "   'span_end': 86,\n",
              "   'text': 'Further, cytokine storms have become recent issue with the rise of COVID-19 infections.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 227,\n",
              "   'span_end': 235,\n",
              "   'text': 'Inherently, with the ARDS and SIRS in this present study, a quantitative network-based approach was employed to statistically determine the co-expressed genes across four related diseases ARDS, SIRS and sepsis, and symptomatic COVID-19, using NCBI GEO datasets to investigate the genetic similarities between four related diseases ARDS, SIRS and sepsis to highlight conserved and divergent pathways in cytokine storms and identify candidate repurposed drugs based on gene co-expression data.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 154,\n",
              "   'span_end': 162,\n",
              "   'text': \"Considering TREM-1's extensive role in regulating the expression of cytokines and that macrophages have been previously linked to symptoms reminiscent of COVID-19, TREM-1 could be another potential therapeutic target for cytokine storms.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 89,\n",
              "   'span_end': 97,\n",
              "   'text': 'Interestingly, two of the largest modules M1 and M44 were significantly preserved in the COVID-19 dataset.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infections',\n",
              "   'span_start': 113,\n",
              "   'span_end': 132,\n",
              "   'text': 'M1 genes were found to be significantly enriched in olfactory transduction and may contain genes affected during COVID-19 infections leading to the loss of smell and taste.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 73,\n",
              "   'span_end': 81,\n",
              "   'text': 'Several immune-related pathways were also significantly preserved in the COVID-19 dataset alluding to potential conserved mechanisms across four related diseases ARDS, SIRS and sepsis.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 206,\n",
              "   'span_end': 214,\n",
              "   'text': 'These synergism of IFN- and TNF-, which are macrophage activators and are responsible for cell-mediated immunity has been previously shown to be sufficient in inducing cell and tissue damage reminiscent of COVID-19 symptoms.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 56,\n",
              "   'span_end': 64,\n",
              "   'text': 'Thus, M9 is potentially a significant module related to COVID-19 disease severity brought about by cytokine storms.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 90,\n",
              "   'span_end': 98,\n",
              "   'text': 'Chemokine signaling pathways were also found to be significantly preserved in symptomatic COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 358,\n",
              "   'span_end': 366,\n",
              "   'text': \"Several of the chemokine receptors e.g., CXCR3 and CXCR4 have also been shown to be upregulated during cytokine storm-like symptoms as upon binding of Several of the chemokine receptors e.g., CXCR3 and CXCR4's natural ligands e.g., CXCL12, inflammation is promoted and chemotaxis induces apoptosis potentially leading to significant tissue damage as seen in COVID-19 cases.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 104,\n",
              "   'span_end': 112,\n",
              "   'text': \"chemokines's overexpression could be a possible mechanism for observed lung tissue damage i.e., ARDS in COVID-19 cases.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 41,\n",
              "   'span_end': 49,\n",
              "   'text': 'Another pathway conserved in symptomatic COVID-19 is the NOD-like receptor signaling pathway.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 65,\n",
              "   'span_end': 73,\n",
              "   'text': 'this present study was able to utilize preserved gene modules in COVID-19 to identify such drugs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 86,\n",
              "   'span_end': 94,\n",
              "   'text': 'The MAPK pathway has been a promising target for novel therapeutic approaches against COVID-19 as the loss of ACE2 activity brought about by viral infection leads to overexpression of p38, which leads to inflammation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 36,\n",
              "   'span_end': 44,\n",
              "   'text': 'Further, a study that treated 22560 COVID-19 patients with histamine antagonists e.g., loratadine resulted in attenuation of cytokine release leading to moderate to significant relief of COVID-19 symptoms, suggesting the potential of antihistamines in treating COVID-19 and cytokine storms in general.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 187,\n",
              "   'span_end': 195,\n",
              "   'text': 'Further, a study that treated 22560 COVID-19 patients with histamine antagonists e.g., loratadine resulted in attenuation of cytokine release leading to moderate to significant relief of COVID-19 symptoms, suggesting the potential of antihistamines in treating COVID-19 and cytokine storms in general.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 261,\n",
              "   'span_end': 269,\n",
              "   'text': 'Further, a study that treated 22560 COVID-19 patients with histamine antagonists e.g., loratadine resulted in attenuation of cytokine release leading to moderate to significant relief of COVID-19 symptoms, suggesting the potential of antihistamines in treating COVID-19 and cytokine storms in general.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 93,\n",
              "   'span_end': 101,\n",
              "   'text': 'This suggests that TPCA-1 could be a good candidate drug for treatment of cytokine storms in COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 37,\n",
              "   'span_end': 45,\n",
              "   'text': \"Such inflammation is also present in COVID-19 patients and thus points to Mepacrine's potential as a therapeutic.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 94,\n",
              "   'span_end': 102,\n",
              "   'text': 'Recently, antimalarials have also shown some promising results for being repurposed to tackle COVID-19 cytokine storms and the resulting neuroinflammatory symptoms.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 0,\n",
              "   'span_end': 10,\n",
              "   'text': 'SARS-CoV-2 with the D614G mutation on the spike protein was the main strain analyzed in this study.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 104,\n",
              "   'span_end': 112,\n",
              "   'text': 'Modules were more strongly preserved in the sepsis dataset, and less strongly preserved in the SIRS and COVID-19 datasets.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 102,\n",
              "   'span_end': 110,\n",
              "   'text': 'Among 13 stable gene co-expression modules, M1, M9, M16, M18, M19, and M44 were strongly preserved in COVID-19 and across ARDS, sepsis, and SIRS.'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 0,\n",
              "   'span_end': 24,\n",
              "   'text': 'Coronavirus disease 2019 COVID-19, which was first identified in December 2019, and shortly after, declared a pandemic by World Health Organization WHO.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 25,\n",
              "   'span_end': 33,\n",
              "   'text': 'Coronavirus disease 2019 COVID-19, which was first identified in December 2019, and shortly after, declared a pandemic by World Health Organization WHO.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviruses',\n",
              "   'span_start': 0,\n",
              "   'span_end': 13,\n",
              "   'text': 'Coronaviruses belong to the family of Coronaviridae, RNA viruses with crown-like spikes on the surface of the coronavirus particles.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviridae',\n",
              "   'span_start': 38,\n",
              "   'span_end': 51,\n",
              "   'text': 'Coronaviruses belong to the family of Coronaviridae, RNA viruses with crown-like spikes on the surface of the coronavirus particles.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 110,\n",
              "   'span_end': 121,\n",
              "   'text': 'Coronaviruses belong to the family of Coronaviridae, RNA viruses with crown-like spikes on the surface of the coronavirus particles.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 69,\n",
              "   'span_end': 77,\n",
              "   'text': 'According to a meta-analysis of Macedo et al., the mortality rate of COVID-19 was 17.1% for patients admitted to hospitals, whereas World Health Organization WHO estimated a fatality rate of 6.73%, which was much lower than that calculated from published studies.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 28,\n",
              "   'span_end': 36,\n",
              "   'text': 'Among the critical cases of COVID-19, the mortality rate reaches 40%.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 69,\n",
              "   'span_end': 77,\n",
              "   'text': 'Substantial efforts have been made in the treatment of patients with COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 70,\n",
              "   'span_end': 78,\n",
              "   'text': 'The World Health Organization WHO recommendations in the treatment of COVID-19 are as follows molnupiravir conditional, baricitinib strong, ruxolitinib and tofacitinib conditional, sotrovimab conditional, casirivimab and imdevimab conditional, IL-6 receptor blockers tocilizumab and sarilumab strong, remdesivir conditional, and systemic corticosteroids strong.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 20,\n",
              "   'span_end': 28,\n",
              "   'text': 'The pathogenesis of COVID-19 was explained by cytokine storm, reduction in ACE2 expression, and activation of complement pathway-induced microvascular injury and thrombosis.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 76,\n",
              "   'span_end': 84,\n",
              "   'text': 'The mechanisms of the recommended agents are focused on The pathogenesis of COVID-19 to improve the clinical outcome of COVID-19, and antiviral therapies are missing.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 120,\n",
              "   'span_end': 128,\n",
              "   'text': 'The mechanisms of the recommended agents are focused on The pathogenesis of COVID-19 to improve the clinical outcome of COVID-19, and antiviral therapies are missing.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'anticoronaviral',\n",
              "   'span_start': 4,\n",
              "   'span_end': 19,\n",
              "   'text': \"The anticoronaviral strategies include preventing the synthesis of viral RNA, inhibiting virus replication, blocking the virus binding to human cell receptors, or inhibiting the viruses' self-assembly process.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 4,\n",
              "   'span_end': 14,\n",
              "   'text': 'The SARS-CoV-2 contains at least four structural proteins spike S protein, envelope E protein, membrane M protein, and nucleocapsid N protein, and 16 nonstructural proteins NSPs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 205,\n",
              "   'span_end': 216,\n",
              "   'text': 'Among 16 nonstructural proteins NSPs, the main protease, also called chymotrypsin-like protease 3C-like protease, and the papain-like protease are two essential proteases for proteolytic processing of the coronavirus replicase polyprotein, therefore generating functional replication complex of The SARS-CoV-2, whereas RNA-dependent RNA polymerase is the central enzyme for RNA synthesis.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 299,\n",
              "   'span_end': 309,\n",
              "   'text': 'Among 16 nonstructural proteins NSPs, the main protease, also called chymotrypsin-like protease 3C-like protease, and the papain-like protease are two essential proteases for proteolytic processing of the coronavirus replicase polyprotein, therefore generating functional replication complex of The SARS-CoV-2, whereas RNA-dependent RNA polymerase is the central enzyme for RNA synthesis.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 39,\n",
              "   'span_end': 50,\n",
              "   'text': 'These three NSPs play crucial roles in coronavirus replication, making These three NSPs attractive targets for anticoronaviral drug design.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'anticoronaviral',\n",
              "   'span_start': 111,\n",
              "   'span_end': 126,\n",
              "   'text': 'These three NSPs play crucial roles in coronavirus replication, making These three NSPs attractive targets for anticoronaviral drug design.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 58,\n",
              "   'span_end': 71,\n",
              "   'text': 'The S protein, a surface-located trimeric glycoprotein of coronaviruses, promotes the attachment of viruses to host cells through binding to angiotensin-converting enzyme 2 ACE2 and virus-cell membrane fusion during viral infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 64,\n",
              "   'span_end': 77,\n",
              "   'text': 'Thus, The S protein, a surface-located trimeric glycoprotein of coronaviruses, has been considered as a major target for the development of vaccines and drug.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 21,\n",
              "   'span_end': 29,\n",
              "   'text': 'During the spread of COVID-19 outbreak, great efforts have been made in therapeutic drug discovery against COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 107,\n",
              "   'span_end': 115,\n",
              "   'text': 'During the spread of COVID-19 outbreak, great efforts have been made in therapeutic drug discovery against COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 8,\n",
              "   'span_end': 16,\n",
              "   'text': 'Because COVID-19 is a new, acute, severe infectious disease, the anti-SARS-CoV-2 drug development strategies are to screen existing drugs to identify potentially effective drugs, to expand indications, and to develop a vaccine.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 70,\n",
              "   'span_end': 80,\n",
              "   'text': 'Because COVID-19 is a new, acute, severe infectious disease, the anti-SARS-CoV-2 drug development strategies are to screen existing drugs to identify potentially effective drugs, to expand indications, and to develop a vaccine.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 72,\n",
              "   'span_end': 80,\n",
              "   'text': 'Therefore, developing broad-spectrum antiviral drugs not only to combat COVID-19 but also to provide protective arsenals against future viral outbreaks is a requirement.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 25,\n",
              "   'span_end': 35,\n",
              "   'text': 'Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection based on the strategies from preclinical drug discovery.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 116,\n",
              "   'span_end': 136,\n",
              "   'text': 'Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection based on the strategies from preclinical drug discovery.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 170,\n",
              "   'span_end': 181,\n",
              "   'text': 'Studies published in PubMed, Scopus, Web of Science, EMBASE, Google Scholar, and DrugBank were searched from December 2019 to March 2021 using the following search terms Coronavirus, COVID-19, SARS-CoV-2, Drug design, Drug development, In silico, In vitro, and In vivo alone or in combination without language restrictions.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 183,\n",
              "   'span_end': 191,\n",
              "   'text': 'Studies published in PubMed, Scopus, Web of Science, EMBASE, Google Scholar, and DrugBank were searched from December 2019 to March 2021 using the following search terms Coronavirus, COVID-19, SARS-CoV-2, Drug design, Drug development, In silico, In vitro, and In vivo alone or in combination without language restrictions.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 193,\n",
              "   'span_end': 203,\n",
              "   'text': 'Studies published in PubMed, Scopus, Web of Science, EMBASE, Google Scholar, and DrugBank were searched from December 2019 to March 2021 using the following search terms Coronavirus, COVID-19, SARS-CoV-2, Drug design, Drug development, In silico, In vitro, and In vivo alone or in combination without language restrictions.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 107,\n",
              "   'span_end': 115,\n",
              "   'text': 'Study of drug in cell culture medium effectiveness in these studies means inhibition of the replication of COVID-19 by the compound or drug under study.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 134,\n",
              "   'span_end': 142,\n",
              "   'text': 'In this review, we reported a significant number of articles with in silico, in vitro, and in vivo approaches for drug development of COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 157,\n",
              "   'span_end': 167,\n",
              "   'text': 'The analysis of article contents indicated that 266 studies performed in silico approaches against viral targets 34 studies used in vitro approaches against SARS-CoV-2 and 15 studies used in vivo animal models.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 161,\n",
              "   'span_end': 169,\n",
              "   'text': 'From 266 studies, 98 article studies repurposed approved drugs with a new mechanism of action and 91 studies evaluated natural products e.g., herbal medicine on COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 56,\n",
              "   'span_end': 67,\n",
              "   'text': 'In silico studies used the following component of novel coronavirus as targets main protease N 154, spike glycoprotein N 62, nonstructural protein N 45, RNA-dependent RNA polymerase N 21, papain-like protease N 19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 65,\n",
              "   'span_end': 73,\n",
              "   'text': 'About 260 drugs were repurposed by the computational methods for COVID-19 therapy such as about 120 drugs candidate against main protease N 154, 52 drugs against spike glycoprotein N 62, 14 drugs against RNA-dependent RNA polymerase, and 28 drugs against other nonstructural proteins.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 41,\n",
              "   'span_end': 49,\n",
              "   'text': 'shows target-based synthesis of data for COVID-19 drug repurposing.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 123,\n",
              "   'span_end': 133,\n",
              "   'text': 'A total of 91 studies used in silico methods to evaluate the effects of natural products including herbal medicine against SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 175,\n",
              "   'span_end': 183,\n",
              "   'text': 'From the plant metabolites, oleanolic acid, hesperidin, epigallocatechin gallate, jensenone, tinosponone, and anistone show promising results in computational methods against COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 107,\n",
              "   'span_end': 115,\n",
              "   'text': 'Aloe, green tea, eucalyptus, curcumin, and many Chinese, Indian, and African plants were also effective on COVID-19 in silico.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 275,\n",
              "   'span_end': 283,\n",
              "   'text': 'The derivatives of pyrazoles, oxadiazoles, phenyltriazolinones, triazoles, benzoylpinostrobin, benzoic acid, benzylidenechromanones, coumarin, and selenium show efficacy in computational methods and could be considered as lead molecules for drug design and synthesis against COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 82,\n",
              "   'span_end': 92,\n",
              "   'text': 'Most of 34 studies use the Vero E6 cell line for the assessment of replication of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 236,\n",
              "   'span_end': 244,\n",
              "   'text': 'Nitric oxide, ginkgolic acid, anacardic acid, troxerutin, bisindolylmaleimide derivatives, small molecules GRL-172, and 5 h, baicalin and baicalein phytochemicals, and bepridil were effective drugs in vitro against the main protease of COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 72,\n",
              "   'span_end': 80,\n",
              "   'text': 'The following drugs could inhibit the spike/ACE2-mediated cell entry of COVID-19 in vitro romidepsin, panobinostat, givinostat, sirtinol, saquinavir, lipopeptides, hydroxyzine, azelastine, heparin, and glycyrrhizic acid.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 220,\n",
              "   'span_end': 230,\n",
              "   'text': 'Alkenyl sulfonylurea derivatives, an IMU-8381 inhibitor of human dihydroorotate dehydrogenase, pyrazole derivatives, and phillyrin, regulated the expression of inflammatory cytokines e.g., IL, TNF-, and NF- B induced by SARS-CoV-2 markedly and could be considered as adjuvant treatment of COVID-19 severe disease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 289,\n",
              "   'span_end': 297,\n",
              "   'text': 'Alkenyl sulfonylurea derivatives, an IMU-8381 inhibitor of human dihydroorotate dehydrogenase, pyrazole derivatives, and phillyrin, regulated the expression of inflammatory cytokines e.g., IL, TNF-, and NF- B induced by SARS-CoV-2 markedly and could be considered as adjuvant treatment of COVID-19 severe disease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 183,\n",
              "   'span_end': 193,\n",
              "   'text': 'Doxycycline, chlorpromazine, azithromycin, heparin, bepridil, tannic acid, and glycyrrhizic acid are well-known drugs that show both in silico and in vitro inhibitory effects against SARS-CoV-2 and should be considered for this purpose.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 116,\n",
              "   'span_end': 126,\n",
              "   'text': 'Also, in vitro studies show that lopinavir/ritonavir, sofosbuvir, and favipiravir have no antiviral effects against SARS-CoV-2 huge gap between in vitro IC50 and free plasma concentration.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 151,\n",
              "   'span_end': 161,\n",
              "   'text': 'Human monoclonal antibodies were the most evaluated drugs N 4, promote the reduction in viral load in vitro, and prevent infection in animal models of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 175,\n",
              "   'span_end': 185,\n",
              "   'text': 'A prodrug of hydroxycytidine molnupiravir improved pulmonary function and reduced viral titer in vivo and was introduced as a potential broad-spectrum antiviral agent against SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 88,\n",
              "   'span_end': 96,\n",
              "   'text': 'Dalbavancin shows significant inhibitory ability in both in vitro and in vivo models of COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 74,\n",
              "   'span_end': 84,\n",
              "   'text': \"Dalbavancin binds directly to ACE2 and blocks ACE2's interaction with the SARS-CoV-2 spike protein.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 52,\n",
              "   'span_end': 65,\n",
              "   'text': 'There are several strategies in antiviral drugs for coronaviruses including empirical testing of known antiviral drugs, large-scale phenotypic screening of compound libraries, and target-based drug discovery.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'anticoronavirus',\n",
              "   'span_start': 63,\n",
              "   'span_end': 78,\n",
              "   'text': 'To date, an increasing number of drugs have been shown to have anticoronavirus activities in vitro and in vivo, but only remdesivir and several neutralizing antibodies have been approved by the US FDA for treating COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 214,\n",
              "   'span_end': 222,\n",
              "   'text': 'To date, an increasing number of drugs have been shown to have anticoronavirus activities in vitro and in vivo, but only remdesivir and several neutralizing antibodies have been approved by the US FDA for treating COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 25,\n",
              "   'span_end': 35,\n",
              "   'text': 'Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection, which have been conducted in basic research in silico and preclinical study in vitro, in vivo.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 116,\n",
              "   'span_end': 136,\n",
              "   'text': 'Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection, which have been conducted in basic research in silico and preclinical study in vitro, in vivo.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 115,\n",
              "   'span_end': 123,\n",
              "   'text': 'Our database search identified about 3000 studies, which means a global effort for drug development in the current COVID-19 pandemic.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 80,\n",
              "   'span_end': 88,\n",
              "   'text': 'As summarized in the results, many compounds are in the development process for COVID-19 disease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 115,\n",
              "   'span_end': 123,\n",
              "   'text': 'Some of many compounds are completely new and could serve as seeds or leads for developing antiviral drugs against COVID-19, but as we need therapeutics as soon as possible, half of the studies focused on drug repurposing repositioning, which is a process of investigation of existing drugs for new therapeutic purposes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 32,\n",
              "   'span_end': 40,\n",
              "   'text': 'With the emergence of a growing COVID-19 pandemic, the drug repurposing process was being accelerated.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 80,\n",
              "   'span_end': 88,\n",
              "   'text': 'According to our results, 260 drugs repurposed by the computational methods for COVID-19, among them saquinavir, ritonavir, and lopinavir, showed the best efficacy in in silico environment.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 74,\n",
              "   'span_end': 82,\n",
              "   'text': \"These drugs can be rapidly repurposed for clinic application for treating COVID-19 patients given These drugs's proven safety.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 165,\n",
              "   'span_end': 173,\n",
              "   'text': 'The results of a systematic review and meta-analysis showed that a combination of ritonavir-lopinavir has no more treatment effects than other therapeutic agents in COVID-19 patients and is currently not used anymore.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 123,\n",
              "   'span_end': 131,\n",
              "   'text': 'We could not find any clinical trial on saquinavir, which is the most studied drug in silico and show high potency against COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 130,\n",
              "   'span_end': 138,\n",
              "   'text': 'Our results show that various plants have potential antiviral activities and could use or be a basis for drug development against COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 86,\n",
              "   'span_end': 94,\n",
              "   'text': 'A systematic review and meta-analysis of RCTs on herbal medicine in the management of COVID-19 show the significant effects of the combined therapy of herbal medicine in treating COVID-19 without any significant side effects.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 179,\n",
              "   'span_end': 187,\n",
              "   'text': 'A systematic review and meta-analysis of RCTs on herbal medicine in the management of COVID-19 show the significant effects of the combined therapy of herbal medicine in treating COVID-19 without any significant side effects.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 89,\n",
              "   'span_end': 99,\n",
              "   'text': 'some of these studied active ingredients could possibly have an inhibitory effect on the SARS-CoV-2 and COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 104,\n",
              "   'span_end': 112,\n",
              "   'text': 'some of these studied active ingredients could possibly have an inhibitory effect on the SARS-CoV-2 and COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 88,\n",
              "   'span_end': 98,\n",
              "   'text': 'Most evaluated chemical compounds had inhibitory effects against one or two proteins of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 172,\n",
              "   'span_end': 180,\n",
              "   'text': 'Thus, Most evaluated chemical compounds can be applied as extremely safe therapeutic natural compounds and clinical assessments might have notable outcomes for controlling COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 101,\n",
              "   'span_end': 109,\n",
              "   'text': 'In terms of mechanism of action, different targets from the structural and nonstructural proteins of COVID-19 were evaluated.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 65,\n",
              "   'span_end': 75,\n",
              "   'text': 'Apart from the specific protein that leads to viral replication, SARS-CoV-2 causes a surge of pro-inflammatory cytokines and chemokines, which cause damage to lung tissue and deterioration of lung function.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 89,\n",
              "   'span_end': 97,\n",
              "   'text': 'Therefore, the design of a drug with multitarget of action against different proteins of COVID-19 and also anti-inflammatory potential could be valuable.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 69,\n",
              "   'span_end': 79,\n",
              "   'text': 'Currently, there is no highly efficacious and specific treatment for SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 21,\n",
              "   'span_end': 31,\n",
              "   'text': 'Due to the nature of SARS-CoV-2 and the rises of several high transmissible strains, repurposing existing drugs has demonstrated power by bringing several drugs to approval for treating COVID-19 patients, such as remdesivir.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 186,\n",
              "   'span_end': 194,\n",
              "   'text': 'Due to the nature of SARS-CoV-2 and the rises of several high transmissible strains, repurposing existing drugs has demonstrated power by bringing several drugs to approval for treating COVID-19 patients, such as remdesivir.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 105,\n",
              "   'span_end': 125,\n",
              "   'text': 'Our results confirmed that a large number of repurposed agents are currently being explored for treating SARS-CoV-2 infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 131,\n",
              "   'span_end': 139,\n",
              "   'text': 'Our results showed that various natural bioactive compounds are being investigated in the preclinical step of drug development for COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 133,\n",
              "   'span_end': 141,\n",
              "   'text': 'Therefore, various natural bioactive compounds can be used as extremely safe therapeutic compounds in drug design studies to control COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 286,\n",
              "   'span_end': 296,\n",
              "   'text': 'However, the pharmacological effects and adverse reactions of some drugs under development are still unclear, and hence, well-designed high-quality studies are needed to further study the effectiveness and safety of some drugs under development to accelerate drug development targeting SARS-CoV-2 and thus promote progress towards ending the pandemic.'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 0,\n",
              "   'span_end': 8,\n",
              "   'text': 'COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviruses',\n",
              "   'span_start': 44,\n",
              "   'span_end': 57,\n",
              "   'text': 'COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviridae',\n",
              "   'span_start': 65,\n",
              "   'span_end': 78,\n",
              "   'text': 'COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndromes',\n",
              "   'span_start': 129,\n",
              "   'span_end': 163,\n",
              "   'text': 'COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS Cov-2',\n",
              "   'span_start': 164,\n",
              "   'span_end': 174,\n",
              "   'text': 'COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviruses',\n",
              "   'span_start': 0,\n",
              "   'span_end': 13,\n",
              "   'text': \"Coronaviruses are named as such because Coronaviruses's surface is characterized by protrusions resembling crowns.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviruses',\n",
              "   'span_start': 40,\n",
              "   'span_end': 53,\n",
              "   'text': \"Coronaviruses are named as such because Coronaviruses's surface is characterized by protrusions resembling crowns.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 46,\n",
              "   'span_end': 54,\n",
              "   'text': 'Corona was first reported in China Wuhan, and COVID-19 is unlikely to have been transmitted from animal to human in a seafood market.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 67,\n",
              "   'span_end': 75,\n",
              "   'text': \"The current vaccines are not providing adequate protection against COVID-19 due to logistical difficulties in The current vaccines's distribution, diminishing immunity, and the possibility of transmission from asymptomatic infected patients.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 145,\n",
              "   'span_end': 153,\n",
              "   'text': 'Drug repurposing is the most efficient method of rapidly identifying the unique clinical applications of currently licensed medications to treat COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 4,\n",
              "   'span_end': 15,\n",
              "   'text': 'The Coronavirus genome is translated into two classes of proteins within the host cell structural proteins such as spikes S, envelopes E, matrixes M, and nucleocapsids N, and nonstructural proteins such as 3-C proteases 3CLpro, NSP5 and RNA Dependent RNA Polymerases RdRp, NSP12.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 194,\n",
              "   'span_end': 205,\n",
              "   'text': 'Among these proteins, RNA-dependent RNA polymerase RdRp has been demonstrated to contribute significantly to the replication of the viral genome single-stranded RNA and to the multiplication of Coronavirus in various cells.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 249,\n",
              "   'span_end': 257,\n",
              "   'text': 'It has been established that RNA-dependent RNA polymerase RdRp is an essential enzyme that plays a significant role in the replication and translation of viral genomes this makes RNA-dependent RNA polymerase RdRp an excellent therapeutic target for COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 41,\n",
              "   'span_end': 49,\n",
              "   'text': 'Numerous clinical trials have shown that COVID-19 can be effectively treated with antiviral, antimalarial, and anti-HIV drugs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 53,\n",
              "   'span_end': 61,\n",
              "   'text': 'The FDA has approved Remdesivir Veklury for treating COVID-19 in hospitalized patients aged 12 and older and weighing at least 40 kg.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 36,\n",
              "   'span_end': 46,\n",
              "   'text': 'Several viral infections, including SARS-CoV-2, have been successfully treated with Remdesivir Veklury.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infection',\n",
              "   'span_start': 177,\n",
              "   'span_end': 195,\n",
              "   'text': 'In a comprehensive two-tier screening approach, Yuan et al. demonstrated that FDA-approved medications cetilistat, abiraterone, diiodohydroxyquinoline, and bexarotene inhibited COVID-19 infection in vitro.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 292,\n",
              "   'span_end': 302,\n",
              "   'text': 'As part of a comprehensive two-tier screening approach, Yuan et al. this study the interaction between four FDA-approved medications, bexarotene anticancer retinoid, abiraterone synthetic androstenedione steroid, diiodohydroxyquinoline antiparasite, and cetilistat antipancreatic lipase with SARS-CoV-2 RdRp using docking simulation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 98,\n",
              "   'span_end': 106,\n",
              "   'text': \"In light of Yuan et al.'s findings, Yuan et al. may be able to develop a new method for combating COVID-19.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 43,\n",
              "   'span_end': 53,\n",
              "   'text': 'The screening of the drugs against RdRp of SARS-CoV-2 was performed by AutoDock Vina with MGL tools 1.5.4 which makes more precise docking calculations and runs faster than AutoDock software.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 50,\n",
              "   'span_end': 60,\n",
              "   'text': 'To perform molecular docking analysis the RdRp of SARS-CoV-2 was converted into PDBQT format.pdbqt.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 107,\n",
              "   'span_end': 117,\n",
              "   'text': 'Because molecular docking results revealed that bexarotene has the best energy in interaction with RdRp of SARS-CoV-2, Yuan et al. investigated the molecular dynamic simulation of bexarotene with protein.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 142,\n",
              "   'span_end': 152,\n",
              "   'text': 'We recently reported the in-silico screening of bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir against different SARS-CoV-2 drug targets.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 242,\n",
              "   'span_end': 252,\n",
              "   'text': \"The current study used the same strategy to screen the bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir for bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir's potential to inhibit RdRp of SARS-CoV-2, thereby filling the gap.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 164,\n",
              "   'span_end': 174,\n",
              "   'text': 'Molecular docking simulation was used to predict the binding of the selected drugs bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir with SARS-CoV-2 RdRp-RNA protein.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 63,\n",
              "   'span_end': 73,\n",
              "   'text': 'Recently, researchers reported virtual screening inhibitors of SARS-CoV-2 RdRp.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 118,\n",
              "   'span_end': 128,\n",
              "   'text': 'the FDA-approved RdRp inhibitor drug remdesivir is effective against many RNA viruses, including the newly discovered SARS-CoV-2 COVID-19 and previous coronaviruses.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 129,\n",
              "   'span_end': 137,\n",
              "   'text': 'the FDA-approved RdRp inhibitor drug remdesivir is effective against many RNA viruses, including the newly discovered SARS-CoV-2 COVID-19 and previous coronaviruses.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 151,\n",
              "   'span_end': 164,\n",
              "   'text': 'the FDA-approved RdRp inhibitor drug remdesivir is effective against many RNA viruses, including the newly discovered SARS-CoV-2 COVID-19 and previous coronaviruses.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 111,\n",
              "   'span_end': 121,\n",
              "   'text': 'We hypothesized that bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir could disrupt SARS-CoV-2 RdRp.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 81,\n",
              "   'span_end': 91,\n",
              "   'text': 'Gastrointestinal complaints have been reported in 15–20% of the newly discovered SARS-CoV-2 COVID-19 patients, and some of 15–20% of COVID-19 patients have also shown infectious virus particles and identifiable viral RNA.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 92,\n",
              "   'span_end': 100,\n",
              "   'text': 'Gastrointestinal complaints have been reported in 15–20% of the newly discovered SARS-CoV-2 COVID-19 patients, and some of 15–20% of COVID-19 patients have also shown infectious virus particles and identifiable viral RNA.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 133,\n",
              "   'span_end': 141,\n",
              "   'text': 'Gastrointestinal complaints have been reported in 15–20% of the newly discovered SARS-CoV-2 COVID-19 patients, and some of 15–20% of COVID-19 patients have also shown infectious virus particles and identifiable viral RNA.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 21,\n",
              "   'span_end': 31,\n",
              "   'text': 'In the intestines of SARS-CoV-2-infected hamsters, high levels of viral nucleocapsid protein, inflammatory processes, and identifiable viral RNA were found.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 232,\n",
              "   'span_end': 252,\n",
              "   'text': 'Cetilistat, a pancreatic lipase inhibitor and oral diiodohydroxyquinoline may be effective topical luminal antivirals in suppressing viral shedding in the gastrointestinal system in the same way feces may be a significant source of SARS-CoV-2 infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 219,\n",
              "   'span_end': 232,\n",
              "   'text': 'As described by Yuan et al., members of the same medication class as bexarotene, such as tamibarotene and AM580, have demonstrated outstanding antiviral effectiveness against several viruses, including influenza, Zika, coronaviruses SARS-CoV and MERS-CoV, adenoviruses, and enterovirus A71.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 233,\n",
              "   'span_end': 241,\n",
              "   'text': 'As described by Yuan et al., members of the same medication class as bexarotene, such as tamibarotene and AM580, have demonstrated outstanding antiviral effectiveness against several viruses, including influenza, Zika, coronaviruses SARS-CoV and MERS-CoV, adenoviruses, and enterovirus A71.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 246,\n",
              "   'span_end': 254,\n",
              "   'text': 'As described by Yuan et al., members of the same medication class as bexarotene, such as tamibarotene and AM580, have demonstrated outstanding antiviral effectiveness against several viruses, including influenza, Zika, coronaviruses SARS-CoV and MERS-CoV, adenoviruses, and enterovirus A71.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 67,\n",
              "   'span_end': 77,\n",
              "   'text': 'The binding energy values of the five compounds mentioned with the SARS-CoV-2 RdRp protein are shown in.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 16,\n",
              "   'span_end': 26,\n",
              "   'text': 'As evident, The SARS-CoV-2 RdRp protein had hydrophobic interactions with abiraterone and bexarotene.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 90,\n",
              "   'span_end': 100,\n",
              "   'text': 'Meanwhile, cetilistat, diiodohydroxyquinoline, and remdesivir interacted with the RdRp of SARS-CoV-2 via hydrogen bonds and hydrophobic interactions.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 80,\n",
              "   'span_end': 90,\n",
              "   'text': 'The chosen drugs interacted with various amino acid residues of the RdRp of the SARS-CoV-2 protein.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 62,\n",
              "   'span_end': 72,\n",
              "   'text': 'These interactions can disrupt the biological activity of the SARS-CoV-2 protein RdRp, and, consequently, the viral replication process.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 59,\n",
              "   'span_end': 69,\n",
              "   'text': 'Bexarotene may be a candidate for blocking the RdRp of the SARS-CoV-2 receptor, as shown by the results mentioned above.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 218,\n",
              "   'span_end': 226,\n",
              "   'text': 'Because FDA-approved medications have already been evaluated in terms of toxicity and safety in humans for the treatment of various diseases, repurposing FDA-approved medications will be the best option for developing COVID-19 therapies at this time.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 175,\n",
              "   'span_end': 185,\n",
              "   'text': 'This research computationally evaluated the inhibitory potential of the FDA-approved drugs bexarotene, diiodohydroxyquinoline, abiraterone, and cetilistat against RdRp of the SARS-CoV-2 receptor.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 219,\n",
              "   'span_end': 227,\n",
              "   'text': 'With further ex vivo and in vivo examinations, our finding suggests that the FDA-approved drugs bexarotene, diiodohydroxyquinoline, abiraterone, and cetilistat could be the potential drug of choice for the treatment of COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 106,\n",
              "   'span_end': 116,\n",
              "   'text': 'Gromacs software was used in This research to simulate the interaction of bexarotene with the RdRp of the SARS-CoV-2 receptor.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 33,\n",
              "   'span_end': 43,\n",
              "   'text': 'Furthermore, the the RdRp of the SARS-CoV-2 receptor-Bex radius of gyration has values that indicate the systems’ stability.'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 8,\n",
              "   'span_end': 19,\n",
              "   'text': 'A novel coronavirus CoV first appeared by the end of 2019 in Wuhan, China and spread to over 70000 individuals with 1800 death cases within the matter of first 50 days of the disease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 20,\n",
              "   'span_end': 23,\n",
              "   'text': 'A novel coronavirus CoV first appeared by the end of 2019 in Wuhan, China and spread to over 70000 individuals with 1800 death cases within the matter of first 50 days of the disease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 99,\n",
              "   'span_end': 110,\n",
              "   'text': 'The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 111,\n",
              "   'span_end': 114,\n",
              "   'text': 'The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 132,\n",
              "   'span_end': 165,\n",
              "   'text': 'The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus-1',\n",
              "   'span_start': 166,\n",
              "   'span_end': 179,\n",
              "   'text': 'The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-1',\n",
              "   'span_start': 180,\n",
              "   'span_end': 190,\n",
              "   'text': 'The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 8,\n",
              "   'span_end': 19,\n",
              "   'text': 'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 20,\n",
              "   'span_end': 23,\n",
              "   'text': 'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 37,\n",
              "   'span_end': 70,\n",
              "   'text': 'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 71,\n",
              "   'span_end': 82,\n",
              "   'text': 'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 85,\n",
              "   'span_end': 95,\n",
              "   'text': 'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 194,\n",
              "   'span_end': 202,\n",
              "   'text': 'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 203,\n",
              "   'span_end': 213,\n",
              "   'text': 'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 0,\n",
              "   'span_end': 33,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 is a variant of coronavirus with enveloped single-stranded RNA which bears a corona like structure of spikes as shown in a. The main host protein for the attachment of spikes has identified as angiotensin converting enzyme 2 ACE2 receptor.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 34,\n",
              "   'span_end': 45,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 is a variant of coronavirus with enveloped single-stranded RNA which bears a corona like structure of spikes as shown in a. The main host protein for the attachment of spikes has identified as angiotensin converting enzyme 2 ACE2 receptor.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 48,\n",
              "   'span_end': 58,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 is a variant of coronavirus with enveloped single-stranded RNA which bears a corona like structure of spikes as shown in a. The main host protein for the attachment of spikes has identified as angiotensin converting enzyme 2 ACE2 receptor.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 75,\n",
              "   'span_end': 86,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 is a variant of coronavirus with enveloped single-stranded RNA which bears a corona like structure of spikes as shown in a. The main host protein for the attachment of spikes has identified as angiotensin converting enzyme 2 ACE2 receptor.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 0,\n",
              "   'span_end': 33,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 evolved to become the most contagious and infectious among coronavirus family.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 34,\n",
              "   'span_end': 45,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 evolved to become the most contagious and infectious among coronavirus family.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 48,\n",
              "   'span_end': 58,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 evolved to become the most contagious and infectious among coronavirus family.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 118,\n",
              "   'span_end': 129,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 evolved to become the most contagious and infectious among coronavirus family.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 0,\n",
              "   'span_end': 33,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 enters the lungs by inhaling the contaminated air with viral bodies and infects distal airway cells leading to further spread towards alveolar epithelial cells and causes the damage starting from infection to severe damage as shown in a. As of May 25, 2021, total number of Covid-19 cases reported have surpassed the 30 million cases globally with 1.6 % in US only.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 34,\n",
              "   'span_end': 45,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 enters the lungs by inhaling the contaminated air with viral bodies and infects distal airway cells leading to further spread towards alveolar epithelial cells and causes the damage starting from infection to severe damage as shown in a. As of May 25, 2021, total number of Covid-19 cases reported have surpassed the 30 million cases globally with 1.6 % in US only.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 48,\n",
              "   'span_end': 58,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 enters the lungs by inhaling the contaminated air with viral bodies and infects distal airway cells leading to further spread towards alveolar epithelial cells and causes the damage starting from infection to severe damage as shown in a. As of May 25, 2021, total number of Covid-19 cases reported have surpassed the 30 million cases globally with 1.6 % in US only.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 333,\n",
              "   'span_end': 341,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 enters the lungs by inhaling the contaminated air with viral bodies and infects distal airway cells leading to further spread towards alveolar epithelial cells and causes the damage starting from infection to severe damage as shown in a. As of May 25, 2021, total number of Covid-19 cases reported have surpassed the 30 million cases globally with 1.6 % in US only.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 49,\n",
              "   'span_end': 57,\n",
              "   'text': 'Moreover, in the wake of current situation novel Covid-19 severe acute respiratory syndrome coronavirus 2 has infected around 526.7 million people and have caused more than 6 million deaths globally.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 58,\n",
              "   'span_end': 91,\n",
              "   'text': 'Moreover, in the wake of current situation novel Covid-19 severe acute respiratory syndrome coronavirus 2 has infected around 526.7 million people and have caused more than 6 million deaths globally.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 92,\n",
              "   'span_end': 103,\n",
              "   'text': 'Moreover, in the wake of current situation novel Covid-19 severe acute respiratory syndrome coronavirus 2 has infected around 526.7 million people and have caused more than 6 million deaths globally.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 32,\n",
              "   'span_end': 40,\n",
              "   'text': 'In an emergency situations like Covid-19 de novo drug development is not the feasible option since there is urgent need to find the treatments which can be immediately prescribed to prevent the mortality and morbidity.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 107,\n",
              "   'span_end': 115,\n",
              "   'text': 'So, to face the crisis because of pandemic drug repurposing seems a tangible strategy for fighting against Covid-19 and other such viral diseases.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 39,\n",
              "   'span_end': 47,\n",
              "   'text': 'Additionally, articles summarizing the Covid-19 drug repurposing using machine learning and deep learning, methods are published as well.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 139,\n",
              "   'span_end': 147,\n",
              "   'text': 'To the best of our knowledge, until now there is no review study until now has published which summarizes the drug repurposing studies for Covid-19 with special emphasis on network-based drug repurposing approaches to Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 218,\n",
              "   'span_end': 226,\n",
              "   'text': 'To the best of our knowledge, until now there is no review study until now has published which summarizes the drug repurposing studies for Covid-19 with special emphasis on network-based drug repurposing approaches to Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 251,\n",
              "   'span_end': 259,\n",
              "   'text': 'Thus, this review is mainly focused to bridge the gap by providing overview of machine learning and deep learning approaches to drug repurposing with focus on recent developments in network-based drug repurposing methods, tools, and databases used in Covid-19 as shown in b. In this connection, first we present an overview to computational drug repurposing studies for Covid-19 along with drug and disease related databases followed by recent machine learning and deep learning-based drug repurposing studies.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 370,\n",
              "   'span_end': 378,\n",
              "   'text': 'Thus, this review is mainly focused to bridge the gap by providing overview of machine learning and deep learning approaches to drug repurposing with focus on recent developments in network-based drug repurposing methods, tools, and databases used in Covid-19 as shown in b. In this connection, first we present an overview to computational drug repurposing studies for Covid-19 along with drug and disease related databases followed by recent machine learning and deep learning-based drug repurposing studies.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 60,\n",
              "   'span_end': 68,\n",
              "   'text': \"Moreover, recent network-based drug repurposing studies for Covid-19 are discussed and recent network-based drug repurposing studies for Covid-19's limitations, benefits, and tools used are summarized.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 137,\n",
              "   'span_end': 145,\n",
              "   'text': \"Moreover, recent network-based drug repurposing studies for Covid-19 are discussed and recent network-based drug repurposing studies for Covid-19's limitations, benefits, and tools used are summarized.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 105,\n",
              "   'span_end': 113,\n",
              "   'text': 'Finally, limitations and future recommendation for improved outcome of network-based drug repurposing in Covid-19 and in general are discussed followed by conclusion.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 66,\n",
              "   'span_end': 74,\n",
              "   'text': 'Some of the machine learning methods used for drug repurposing in Covid-19 include k-nearest neighbors, random forest, support vector machine, and more.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 71,\n",
              "   'span_end': 79,\n",
              "   'text': 'Various deep learning algorithms utilized in finding treatment against Covid-19 includes artificial neural networks ANN, convolutional neural networks CNN, and long short-term memory LSTM.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 67,\n",
              "   'span_end': 75,\n",
              "   'text': 'Apart from this, to accelerate the process of drug development for Covid-19, machine learning based molecular docking frameworks were utilized on approved as well as new chemical entities.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 213,\n",
              "   'span_end': 221,\n",
              "   'text': 'a feature enriched drug repurposing framework named SperoPredictor which consisted multiple state of art machine learning algorithms as shown in b. was deployed to predict the potential drugs to be repurposed for Covid-19, NASH, and renal fibrosis.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 11,\n",
              "   'span_end': 19,\n",
              "   'text': 'In case of Covid-19, 25 potential candidate drugs were predicted.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 112,\n",
              "   'span_end': 120,\n",
              "   'text': 'Literature survey of peer reviewed journals, databases, and patents suggested 12/25 drugs were already used for Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 273,\n",
              "   'span_end': 281,\n",
              "   'text': 'The a feature enriched drug repurposing framework named SperoPredictor which consisted multiple state of art machine learning algorithms as shown in b. results testify the usefulness of having such platforms that can be readily deployed in case of emergent situations like Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 46,\n",
              "   'span_end': 54,\n",
              "   'text': 'Another study designed to predict the DTIs in Covid-19 is given in.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 46,\n",
              "   'span_end': 54,\n",
              "   'text': \"Another study designed to predict the DTIs in Covid-19 avails the proteins and drugs provided in the proteins and drugs's structured format.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 123,\n",
              "   'span_end': 131,\n",
              "   'text': 'Then the developed model was compared with existing studies using k-fold cross validation b. To deploy the developed model Covid-19 was selected as a case study.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 98,\n",
              "   'span_end': 106,\n",
              "   'text': 'the developed model was deployed as shown in c on the proteins known to have been involved in the Covid-19 to predict the possible interactions or drug-target interactions.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 60,\n",
              "   'span_end': 68,\n",
              "   'text': 'the developed model was further deployed to drugs active in Covid-19 and drugs active in Covid-19 were predicted with 100 % accuracy.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 89,\n",
              "   'span_end': 97,\n",
              "   'text': 'the developed model was further deployed to drugs active in Covid-19 and drugs active in Covid-19 were predicted with 100 % accuracy.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 35,\n",
              "   'span_end': 43,\n",
              "   'text': 'The interaction of drugs active in Covid-19 was shown with ACE2,, self-membrane protein, a key player in Covid-19 enabling disease infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 105,\n",
              "   'span_end': 113,\n",
              "   'text': 'The interaction of drugs active in Covid-19 was shown with ACE2,, self-membrane protein, a key player in Covid-19 enabling disease infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 62,\n",
              "   'span_end': 70,\n",
              "   'text': 'Machine learning plays a key role in drug repurposing against Covid-19 and pace of research in the field has skyrocketed since the emergence of Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 144,\n",
              "   'span_end': 152,\n",
              "   'text': 'Machine learning plays a key role in drug repurposing against Covid-19 and pace of research in the field has skyrocketed since the emergence of Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 115,\n",
              "   'span_end': 123,\n",
              "   'text': 'Robust and efficient computational methods making use deep learning are widely required for drug discovery against Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 143,\n",
              "   'span_end': 151,\n",
              "   'text': 'Convolutional neural networks and recursive neural networks have been widely used in bioinformatics studies with successful results such as in Covid-19,.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 77,\n",
              "   'span_end': 85,\n",
              "   'text': 'Deep learning methods have also been widely used in drug repurposing against Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 44,\n",
              "   'span_end': 52,\n",
              "   'text': 'A recent work involving drug repurposing in Covid-19 using deep learning is given in and are given in.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 177,\n",
              "   'span_end': 185,\n",
              "   'text': 'deep learning model named as Molecule Transformer-Drug Target Interaction MT-DTI predicted several commercially available or in practice anti-viral drugs having potency against Covid-19 protein targets confirmed by the pre-clinical validation assays of Covid-19. deep learning model named as Molecule Transformer-Drug Target Interaction MT-DTI was deployed for the selection of compounds from 1400 FDA approved drugs having the strong affinity against the host cellular targets for viral diseases.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 253,\n",
              "   'span_end': 261,\n",
              "   'text': 'deep learning model named as Molecule Transformer-Drug Target Interaction MT-DTI predicted several commercially available or in practice anti-viral drugs having potency against Covid-19 protein targets confirmed by the pre-clinical validation assays of Covid-19. deep learning model named as Molecule Transformer-Drug Target Interaction MT-DTI was deployed for the selection of compounds from 1400 FDA approved drugs having the strong affinity against the host cellular targets for viral diseases.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 145,\n",
              "   'span_end': 153,\n",
              "   'text': 'Another deep learning-based drug repurposing study done in used deep learning on a massive knowledge graph to identify and select promising anti-Covid-19 drug candidates.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 106,\n",
              "   'span_end': 114,\n",
              "   'text': '41 repurposed drug candidates include dexamethasone an anti-inflammatory agent having bioactivity against Covid-19 and Niclosamide validated by proteomics of Covid-19 infected cell and gene expression.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19 infected',\n",
              "   'span_start': 158,\n",
              "   'span_end': 175,\n",
              "   'text': '41 repurposed drug candidates include dexamethasone an anti-inflammatory agent having bioactivity against Covid-19 and Niclosamide validated by proteomics of Covid-19 infected cell and gene expression.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 139,\n",
              "   'span_end': 147,\n",
              "   'text': 'Drug candidate such as pralatrexate and azithromycin predicted from One such study were validated in in-vitro testing and found to inhibit Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 27,\n",
              "   'span_end': 35,\n",
              "   'text': 'First drug was active once Covid-19 entered host cells while azithromycin has efficacy in before and after stages.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 107,\n",
              "   'span_end': 115,\n",
              "   'text': 'To demonstrate the drug design features of software tools MolAICal, membrane protein glucagon receptor and Covid-19 main protease were modelled.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 134,\n",
              "   'span_end': 142,\n",
              "   'text': 'Using the proposed method in study led to identification of 1000 top ranked potential drug compound supposed to have efficacy against Covid-19 Mpro.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 54,\n",
              "   'span_end': 62,\n",
              "   'text': 'DL has helped in finding the repurposed drugs against Covid-19 and in other pathogens however certain challenges still exist.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 6,\n",
              "   'span_end': 19,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV',\n",
              "   'span_start': 20,\n",
              "   'span_end': 24,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 33,\n",
              "   'span_end': 66,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 67,\n",
              "   'span_end': 78,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 79,\n",
              "   'span_end': 87,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 103,\n",
              "   'span_end': 114,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 115,\n",
              "   'span_end': 123,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 144,\n",
              "   'span_end': 154,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 0,\n",
              "   'span_end': 33,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 34,\n",
              "   'span_end': 45,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 46,\n",
              "   'span_end': 54,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 69,\n",
              "   'span_end': 80,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 164,\n",
              "   'span_end': 197,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 198,\n",
              "   'span_end': 209,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV.',\n",
              "   'span_start': 210,\n",
              "   'span_end': 219,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus 2019',\n",
              "   'span_start': 236,\n",
              "   'span_end': 252,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'nCoV',\n",
              "   'span_start': 253,\n",
              "   'span_end': 257,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 139,\n",
              "   'span_end': 150,\n",
              "   'text': 'Instead of highly accelerated efforts in the field of drug research, until now there is only drug approved for the treatment of novel 2019 coronavirus Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 151,\n",
              "   'span_end': 159,\n",
              "   'text': 'Instead of highly accelerated efforts in the field of drug research, until now there is only drug approved for the treatment of novel 2019 coronavirus Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 176,\n",
              "   'span_end': 184,\n",
              "   'text': 'Over the period, multiple techniques based on machine learning, deep learning, mining, and network or graph-based approaches have been widely used to repurpose the drugs for a Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 177,\n",
              "   'span_end': 188,\n",
              "   'text': 'Herein, we provide the comprehensive review along with benefits, challenges, and future directions of network science-based drug repurposing studies specifically for novel 2019 coronavirus Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 189,\n",
              "   'span_end': 197,\n",
              "   'text': 'Herein, we provide the comprehensive review along with benefits, challenges, and future directions of network science-based drug repurposing studies specifically for novel 2019 coronavirus Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 68,\n",
              "   'span_end': 76,\n",
              "   'text': 'network science-based drug repurposing studies specifically for the Covid-19 are divided in to three categories based on network proximity, network diffusion, and artificial intelligence.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 457,\n",
              "   'span_end': 468,\n",
              "   'text': \"Network proximity-based drug repurposing studies use the proximity measures such as network centralities, node degree, and more for identifying and providing the key protein-protein, drug-drug, or drug-target associations to repurpose the drugs a i. One of the recent studies done in presented a powerful network-based drug methodologies for identification of potential repurposable drugs and potential repurposable drugs's combination targeting novel 2019 coronavirus Covid-19.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 469,\n",
              "   'span_end': 477,\n",
              "   'text': \"Network proximity-based drug repurposing studies use the proximity measures such as network centralities, node degree, and more for identifying and providing the key protein-protein, drug-drug, or drug-target associations to repurpose the drugs a i. One of the recent studies done in presented a powerful network-based drug methodologies for identification of potential repurposable drugs and potential repurposable drugs's combination targeting novel 2019 coronavirus Covid-19.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV-host',\n",
              "   'span_start': 100,\n",
              "   'span_end': 109,\n",
              "   'text': 'Presented anti-viral and integrated repurposing methodology mainly quantified the interplay between HCoV-host proteins and drug targets in human protein-protein interactions PPI.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV-host',\n",
              "   'span_start': 58,\n",
              "   'span_end': 67,\n",
              "   'text': 'Use of network proximity analysis as shown in b i between HCoV-host targets and drug targets in human PPI led to prioritization of 16 anti-HCoV drugs potentially repurposable.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'anti-HCoV',\n",
              "   'span_start': 134,\n",
              "   'span_end': 143,\n",
              "   'text': 'Use of network proximity analysis as shown in b i between HCoV-host targets and drug targets in human PPI led to prioritization of 16 anti-HCoV drugs potentially repurposable.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 139,\n",
              "   'span_end': 150,\n",
              "   'text': 'Despite successful results, One of the recent studies done in suffered from limitations such as, lack of known host proteins on novel 2019 coronavirus Covid-19, a low binding affinity value of 10 M was used to specify the DTI.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 151,\n",
              "   'span_end': 159,\n",
              "   'text': 'Despite successful results, One of the recent studies done in suffered from limitations such as, lack of known host proteins on novel 2019 coronavirus Covid-19, a low binding affinity value of 10 M was used to specify the DTI.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 143,\n",
              "   'span_end': 154,\n",
              "   'text': 'Another network proximity-based drug repurposing study is given in which used network medicine-based approach to repurpose drugs in novel 2019 coronavirus Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 155,\n",
              "   'span_end': 163,\n",
              "   'text': 'Another network proximity-based drug repurposing study is given in which used network medicine-based approach to repurpose drugs in novel 2019 coronavirus Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 181,\n",
              "   'span_end': 192,\n",
              "   'text': 'Another network proximity-based drug repurposing study enriched the PPI with transcriptomics and proteomics and then performed network proximity measurement where broach novel 2019 coronavirus Covid-19 associated underlying pathogenesis of disease manifestation was explored.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 193,\n",
              "   'span_end': 201,\n",
              "   'text': 'Another network proximity-based drug repurposing study enriched the PPI with transcriptomics and proteomics and then performed network proximity measurement where broach novel 2019 coronavirus Covid-19 associated underlying pathogenesis of disease manifestation was explored.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 163,\n",
              "   'span_end': 174,\n",
              "   'text': 'Here, the associations between 6 different diseases consisting of autoimmune, malignant, cancer, cardiovascular, metabolic, neurological, pulmonary and novel 2019 coronavirus Covid-19 were created.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 175,\n",
              "   'span_end': 183,\n",
              "   'text': 'Here, the associations between 6 different diseases consisting of autoimmune, malignant, cancer, cardiovascular, metabolic, neurological, pulmonary and novel 2019 coronavirus Covid-19 were created.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 170,\n",
              "   'span_end': 181,\n",
              "   'text': \"Created network was analyzed followed by the single-cell RNA sequencing to uncover the underlying pathobiological and pathophysiological relationships between novel 2019 coronavirus Covid-19 and novel 2019 coronavirus Covid-19's associated treatments.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 182,\n",
              "   'span_end': 190,\n",
              "   'text': \"Created network was analyzed followed by the single-cell RNA sequencing to uncover the underlying pathobiological and pathophysiological relationships between novel 2019 coronavirus Covid-19 and novel 2019 coronavirus Covid-19's associated treatments.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 206,\n",
              "   'span_end': 217,\n",
              "   'text': \"Created network was analyzed followed by the single-cell RNA sequencing to uncover the underlying pathobiological and pathophysiological relationships between novel 2019 coronavirus Covid-19 and novel 2019 coronavirus Covid-19's associated treatments.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 218,\n",
              "   'span_end': 226,\n",
              "   'text': \"Created network was analyzed followed by the single-cell RNA sequencing to uncover the underlying pathobiological and pathophysiological relationships between novel 2019 coronavirus Covid-19 and novel 2019 coronavirus Covid-19's associated treatments.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 204,\n",
              "   'span_end': 214,\n",
              "   'text': 'Although not significant, network proximity results in Another network proximity-based drug repurposing study showed that rheumatoid arthritis has small network proximities negative Z scores across all 5 SARS-CoV-2 datasets.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 171,\n",
              "   'span_end': 182,\n",
              "   'text': 'This type of muti-layered validation of the network predicted drugs find out the key repurposable drugs supposed to have potential to reverse the expression of novel 2019 coronavirus Covid-19 expressed genes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 183,\n",
              "   'span_end': 191,\n",
              "   'text': 'This type of muti-layered validation of the network predicted drugs find out the key repurposable drugs supposed to have potential to reverse the expression of novel 2019 coronavirus Covid-19 expressed genes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 101,\n",
              "   'span_end': 111,\n",
              "   'text': 'In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS2',\n",
              "   'span_start': 121,\n",
              "   'span_end': 126,\n",
              "   'text': 'In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS2',\n",
              "   'span_start': 132,\n",
              "   'span_end': 137,\n",
              "   'text': 'In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV-PPI',\n",
              "   'span_start': 143,\n",
              "   'span_end': 151,\n",
              "   'text': 'In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS2',\n",
              "   'span_start': 157,\n",
              "   'span_end': 162,\n",
              "   'text': 'In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 53,\n",
              "   'span_end': 63,\n",
              "   'text': 'These drugs were significantly proximal to 2 or more SARS-CoV-2 host protein sets.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 58,\n",
              "   'span_end': 68,\n",
              "   'text': 'Additionally, Knowledge of the complex interplays between SARS-CoV-2 targets and human diseases indicate possibilities of drug repurposing, as the drugs that target other diseases could potentially target SARS-CoV-2 through the shared functional PPI networks.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 205,\n",
              "   'span_end': 215,\n",
              "   'text': 'Additionally, Knowledge of the complex interplays between SARS-CoV-2 targets and human diseases indicate possibilities of drug repurposing, as the drugs that target other diseases could potentially target SARS-CoV-2 through the shared functional PPI networks.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 178,\n",
              "   'span_end': 189,\n",
              "   'text': 'Some studies are combining different network approaches for improved results such as done in which aims to captures the bigger picture of human molecular landscape of novel 2019 coronavirus Covid-19 infection by exploiting the network medicine approach as strategy to repurpose the drugs for novel 2019 coronavirus Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19 infection',\n",
              "   'span_start': 190,\n",
              "   'span_end': 208,\n",
              "   'text': 'Some studies are combining different network approaches for improved results such as done in which aims to captures the bigger picture of human molecular landscape of novel 2019 coronavirus Covid-19 infection by exploiting the network medicine approach as strategy to repurpose the drugs for novel 2019 coronavirus Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 303,\n",
              "   'span_end': 314,\n",
              "   'text': 'Some studies are combining different network approaches for improved results such as done in which aims to captures the bigger picture of human molecular landscape of novel 2019 coronavirus Covid-19 infection by exploiting the network medicine approach as strategy to repurpose the drugs for novel 2019 coronavirus Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 315,\n",
              "   'span_end': 323,\n",
              "   'text': 'Some studies are combining different network approaches for improved results such as done in which aims to captures the bigger picture of human molecular landscape of novel 2019 coronavirus Covid-19 infection by exploiting the network medicine approach as strategy to repurpose the drugs for novel 2019 coronavirus Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 74,\n",
              "   'span_end': 85,\n",
              "   'text': 'As a starting point, experimentally validated host proteins of novel 2019 coronavirus Covid-19 known to have viral interaction, tissue specific gene expression data, were explored by use of techniques such as connectivity significance, network diffusion, and network propagation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 86,\n",
              "   'span_end': 94,\n",
              "   'text': 'As a starting point, experimentally validated host proteins of novel 2019 coronavirus Covid-19 known to have viral interaction, tissue specific gene expression data, were explored by use of techniques such as connectivity significance, network diffusion, and network propagation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 113,\n",
              "   'span_end': 124,\n",
              "   'text': 'This process was followed to rank genes followed repurposing drugs targeting genes as a treatment for novel 2019 coronavirus Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 125,\n",
              "   'span_end': 133,\n",
              "   'text': 'This process was followed to rank genes followed repurposing drugs targeting genes as a treatment for novel 2019 coronavirus Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 100,\n",
              "   'span_end': 111,\n",
              "   'text': 'The prioritized collection of genes which served as key drug targets for repurposed anti-novel 2019 coronavirus Covid-19 drugs responsible for causing pharmacological effect resulted from normalization and aggregation of different scoring methods.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 112,\n",
              "   'span_end': 120,\n",
              "   'text': 'The prioritized collection of genes which served as key drug targets for repurposed anti-novel 2019 coronavirus Covid-19 drugs responsible for causing pharmacological effect resulted from normalization and aggregation of different scoring methods.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 61,\n",
              "   'span_end': 69,\n",
              "   'text': 'Additionally, another network-based repurposing approach for Covid-19 done in was conducted by integrating GWAS and text mining the data.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 50,\n",
              "   'span_end': 58,\n",
              "   'text': 'Here lung-specified gene subnetwork enriched with Covid-19 gene associated data obtained from GWAS was created to screen 220 FDA approved drugs obtained from DrugBank database.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 114,\n",
              "   'span_end': 122,\n",
              "   'text': 'This led to prioritization of 220 FDA approved drugs obtained from DrugBank database as a potential treatment for Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 160,\n",
              "   'span_end': 168,\n",
              "   'text': 'Findings provide the timely and valuable insights to repurposed use options of 220 FDA approved drugs obtained from DrugBank database to be further explored in Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 135,\n",
              "   'span_end': 143,\n",
              "   'text': \"Another very distinguished and interesting work in the field of network science and network science's applications to drug repurposing Covid-19 was done in.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 129,\n",
              "   'span_end': 137,\n",
              "   'text': 'Here in Another very distinguished and interesting work in the field of network science and its applications to drug repurposing Covid-19 multiple layers or approaches normally applied individually on the networks were fused into a single algorithm.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 95,\n",
              "   'span_end': 103,\n",
              "   'text': 'Each of Deployed algorithms was utilized to prioritize the 6340 drugs for expected efficacy in Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 111,\n",
              "   'span_end': 119,\n",
              "   'text': 'This led to a successful approach as a network medicine framework for identifying repurposing opportunities in Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 252,\n",
              "   'span_end': 260,\n",
              "   'text': 'In practice one cannot find a single algorithm that consistently performs across all the datasets which served as a motivation for Another very distinguished and interesting work in the field of network science and its applications to drug repurposing Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 149,\n",
              "   'span_end': 157,\n",
              "   'text': '96 % of the drugs tested in Another very distinguished and interesting work in the field of network science and its applications to drug repurposing Covid-19 were FDA approved which is beneficial as 96 % of the drugs tested in the study could be directly moved to clinical trials.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 266,\n",
              "   'span_end': 274,\n",
              "   'text': 'A real predictive power of multimodal approach that combines the predictions from all approaches was demonstrated by the positive outcomes of the second human screen with success rate of 62 % followed by identification of six drugs potentially easily repurposed for Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 160,\n",
              "   'span_end': 168,\n",
              "   'text': 'All in all, multimodal approach that combines the predictions from all approaches did not only provided an effective strategy and results in the repurposing of Covid-19 drugs but also provided an algorithmic toolset as well.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 44,\n",
              "   'span_end': 52,\n",
              "   'text': 'Severe and rapidly emerging replications of Covid-19 made the world realize for the combination therapies that were expected to response more effectively.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID',\n",
              "   'span_start': 112,\n",
              "   'span_end': 117,\n",
              "   'text': 'To address this gap a study was done in where an integrative network pharmacology inspired web-based tool named COVID-CDR was developed for in-silico repurposing of the drug combinations.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID',\n",
              "   'span_start': 66,\n",
              "   'span_end': 71,\n",
              "   'text': 'an integrative network pharmacology inspired web-based tool named COVID-CDR could prioritize Covid-19 repurposable drug combination for synergistic effect.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 93,\n",
              "   'span_end': 101,\n",
              "   'text': 'an integrative network pharmacology inspired web-based tool named COVID-CDR could prioritize Covid-19 repurposable drug combination for synergistic effect.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 76,\n",
              "   'span_end': 84,\n",
              "   'text': 'In this approach, drugs with targets sharing the topological proximity with Covid-19 targets are used to prioritize the drug combinations based on drug-target separation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID',\n",
              "   'span_start': 127,\n",
              "   'span_end': 132,\n",
              "   'text': 'Whereas, successfully evaluated drug combinations because of an integrative network pharmacology inspired web-based tool named COVID-CDR were evaluated using the network computation methods.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 121,\n",
              "   'span_end': 129,\n",
              "   'text': 'One among some of the recent studies, where AI on networks has been applied to repurpose the drugs is done in in which a Covid-19 based knowledge graph was built.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 2,\n",
              "   'span_end': 10,\n",
              "   'text': 'a Covid-19 based knowledge graph consists of virus baits, host genes, pathways, and other information.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 129,\n",
              "   'span_end': 137,\n",
              "   'text': 'Use of deep neural networks and integration of the diverse interactions helped in quick identification of drugs repurposable for Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 121,\n",
              "   'span_end': 129,\n",
              "   'text': 'Another very distinguished and interesting work in the field of network science and its applications to drug repurposing Covid-19 suffered from the limitations of missing the effective drugs possibly during the initial drug ranking.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 8,\n",
              "   'span_end': 16,\n",
              "   'text': 'Another Covid-19 based drug repurposing study using the Few-Shot learning is done in.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 8,\n",
              "   'span_end': 16,\n",
              "   'text': 'Another Covid-19 based drug repurposing study using the Few-Shot learning introduces the multi-targeted drug repurposing strategy which is taken as most efficient approach to diseases such as Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 192,\n",
              "   'span_end': 200,\n",
              "   'text': 'Another Covid-19 based drug repurposing study using the Few-Shot learning introduces the multi-targeted drug repurposing strategy which is taken as most efficient approach to diseases such as Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 27,\n",
              "   'span_end': 35,\n",
              "   'text': 'In connection with Another Covid-19 based drug repurposing study using the Few-Shot learning, molecules are represented as graphs G, nodes are items and bonds between nodes are the edges.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 124,\n",
              "   'span_end': 132,\n",
              "   'text': 'Following this, an input data comprising molecules as graphs in the form of adjacency matrix A, was constructed for Another Covid-19 based drug repurposing study using the Few-Shot learning.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 70,\n",
              "   'span_end': 78,\n",
              "   'text': 'The deployment of the trained models and downstream classification c, Covid-19 related chemical molecules were used.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 8,\n",
              "   'span_end': 16,\n",
              "   'text': 'Another Covid-19 based drug repurposing study using the Few-Shot learning provided a powerful tool for future research in drug repurposing specifically in case of poorly known diseases such as Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 193,\n",
              "   'span_end': 201,\n",
              "   'text': 'Another Covid-19 based drug repurposing study using the Few-Shot learning provided a powerful tool for future research in drug repurposing specifically in case of poorly known diseases such as Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 215,\n",
              "   'span_end': 223,\n",
              "   'text': 'Instead of these benefits, there are certain limitations such as uncertainties in the datasets used and lack of validation of the predicted drugs in corresponding in-vitro and in-vivo models for efficacy testing in Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 148,\n",
              "   'span_end': 156,\n",
              "   'text': 'Moreover, multiple machine learning models are also used disease agnostic fashion for network datasets as done in for repurposing targeted drugs in Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 39,\n",
              "   'span_end': 47,\n",
              "   'text': 'Used models are complementary covering Covid-19 and host factors.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 140,\n",
              "   'span_end': 148,\n",
              "   'text': 'Furthermore, results suggest that the drugs ranked using anti-viral of the top predicted broad spectrum were found in clinical practice for Covid-19 and those from graph kernels were found experimentally validated.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 16,\n",
              "   'span_end': 24,\n",
              "   'text': 'Similarly, here Covid-19 drug repurposing explorer abbreviated as CoREx was deployed as an interactive tool.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 0,\n",
              "   'span_end': 8,\n",
              "   'text': 'Covid-19 drug repurposing explorer abbreviated as CoREx can be used to observe and understand the interaction between drugs and host Covid-19 targets in context of biological networks, clinical use of drugs, protein functioning, and cMAP.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 133,\n",
              "   'span_end': 141,\n",
              "   'text': 'Covid-19 drug repurposing explorer abbreviated as CoREx can be used to observe and understand the interaction between drugs and host Covid-19 targets in context of biological networks, clinical use of drugs, protein functioning, and cMAP.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 41,\n",
              "   'span_end': 49,\n",
              "   'text': 'Despite the contribution and benefits of Covid-19 drug repurposing explorer abbreviated as CoREx there some limitations such as the matrix decomposition approach can only be applied to the drugs for which association with viral disease is known.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 27,\n",
              "   'span_end': 35,\n",
              "   'text': 'Main limitation of Another Covid-19 based drug repurposing study using the Few-Shot learning is the annotation of the drug-virus pairs based on the developmental stages and the related data is hard to find.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 37,\n",
              "   'span_end': 45,\n",
              "   'text': 'Similarly, the other part of Another Covid-19 based drug repurposing study using the Few-Shot learning Network medicine has limitation that only those drugs for which targets are known can be used.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 11,\n",
              "   'span_end': 19,\n",
              "   'text': 'Human PPI, Covid-19 specific network, and DTIs were first created like most of the studies and later essential proteins were passed through a set of algorithms Machine learning.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 108,\n",
              "   'span_end': 116,\n",
              "   'text': 'Enrichment analysis was then performed for informative features to validate informative features in case of Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 64,\n",
              "   'span_end': 72,\n",
              "   'text': 'One such graph machine learning based drug repurposing study in Covid-19 is presented in which avails the ML and statistical approaches to map and mine the knowledge graph, transcriptomic and literature data on the large scale to uncover the potential drugs for Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 262,\n",
              "   'span_end': 270,\n",
              "   'text': 'One such graph machine learning based drug repurposing study in Covid-19 is presented in which avails the ML and statistical approaches to map and mine the knowledge graph, transcriptomic and literature data on the large scale to uncover the potential drugs for Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 206,\n",
              "   'span_end': 214,\n",
              "   'text': 'The computational approach in combination with pre-clinical validation indicated that a poly-ADP-ribose polymerase 1 PARP1 inhibitor, CVL218, currently in Phase I clinical trial, may be repurposed to treat Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 268,\n",
              "   'span_end': 276,\n",
              "   'text': 'Coupled with cell-based experimental validation One other study that used DrugBank and other databases along with graph convolutional networks GCN came up with several clinically efficient drugs as potential repurposing candidates found as a result GCN application to Covid-19 related data.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 223,\n",
              "   'span_end': 236,\n",
              "   'text': 'Specifically, as a part of One other study that used DrugBank and other databases along with graph convolutional networks GCN, capmatinib MET inhibitor was found to have potent and wide range antiviral activity in multiple coronaviruses.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 160,\n",
              "   'span_end': 171,\n",
              "   'text': 'The antiviral activity was observed in MET-independent manner and additional roles of capmanitib for host cell proteins promoting the infection caused by human coronavirus thus it can inform further drug discovery studies.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 192,\n",
              "   'span_end': 200,\n",
              "   'text': 'Realizing these problems and tactfully handling these problems can unveil the unfathomable power of the GNN and GCN approaches being applied to network-based approaches to drug repurposing in Covid-19 and in general as well.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 89,\n",
              "   'span_end': 97,\n",
              "   'text': 'There are multiple significant studies utilizing this approach to repurpose the drugs in Covid-19 and other diseases.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 12,\n",
              "   'span_end': 20,\n",
              "   'text': 'Once recent Covid-19 based drug repurposing study is done in where gene co-expression-based network for 1441 genes was constructed and analysis was performed.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 110,\n",
              "   'span_end': 118,\n",
              "   'text': 'Finally, because of proposed network analysis, five drugs were repurposed as candidate repurposable drugs for Covid-19 treatment.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 69,\n",
              "   'span_end': 77,\n",
              "   'text': 'Additionally, around 10 miRNAs were found to be significant to treat Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 149,\n",
              "   'span_end': 157,\n",
              "   'text': 'KEGG enrichment, molecular docking, STITCH search tool, and virus-host-drug interactome were used to investigate the interaction network linked with Covid-19 and chloroquine and hydroxychloroquine were utilized as reference drugs to further get into the interaction network linked with Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 286,\n",
              "   'span_end': 294,\n",
              "   'text': 'KEGG enrichment, molecular docking, STITCH search tool, and virus-host-drug interactome were used to investigate the interaction network linked with Covid-19 and chloroquine and hydroxychloroquine were utilized as reference drugs to further get into the interaction network linked with Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 96,\n",
              "   'span_end': 104,\n",
              "   'text': 'As a result, 47 drug targets were found enriched in TLR pathway and were found overlapping with Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 100,\n",
              "   'span_end': 108,\n",
              "   'text': \"Additional insights from human-drug protein map identified and further confirmed the interaction of Covid-19 with TLR pathway will provide key information for Covid-19 Covid-19 and Covid-19's treatment.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 159,\n",
              "   'span_end': 167,\n",
              "   'text': \"Additional insights from human-drug protein map identified and further confirmed the interaction of Covid-19 with TLR pathway will provide key information for Covid-19 Covid-19 and Covid-19's treatment.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 168,\n",
              "   'span_end': 176,\n",
              "   'text': \"Additional insights from human-drug protein map identified and further confirmed the interaction of Covid-19 with TLR pathway will provide key information for Covid-19 Covid-19 and Covid-19's treatment.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 181,\n",
              "   'span_end': 189,\n",
              "   'text': \"Additional insights from human-drug protein map identified and further confirmed the interaction of Covid-19 with TLR pathway will provide key information for Covid-19 Covid-19 and Covid-19's treatment.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 120,\n",
              "   'span_end': 128,\n",
              "   'text': 'Furthermore, combination of diffusion and matrix factorization methods is also used to The drug prioritization the Anti-Covid-19 drugs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 161,\n",
              "   'span_end': 169,\n",
              "   'text': 'Then the gaussian and similarity kernel are diffused and finally the logistic matrix factorization model with kernel diffusion is proposed to identify potential Covid-19 drugs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 30,\n",
              "   'span_end': 38,\n",
              "   'text': 'Finally, to validate the Anti-Covid-19 drugs molecular docking was performed to find the binding affinity of the drugs potentially repurposable with Covid-19 spike and ACE2 proteins.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 149,\n",
              "   'span_end': 157,\n",
              "   'text': 'Finally, to validate the Anti-Covid-19 drugs molecular docking was performed to find the binding affinity of the drugs potentially repurposable with Covid-19 spike and ACE2 proteins.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 208,\n",
              "   'span_end': 216,\n",
              "   'text': 'Thus, the 5-fold cross-validation leads to conclusion that integration of various biological data features and suitable models, or kernels lead to development of tools that may assist in drug development for Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 31,\n",
              "   'span_end': 39,\n",
              "   'text': 'Due to the sudden emergence of Covid-19 pandemic drug repurposing efforts helped greatly to make the treatments available to the patients faster.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 96,\n",
              "   'span_end': 104,\n",
              "   'text': 'These methods have made it possible for the drugs to enter the clinical trials to fight against Covid-19. For example, a network-based drug repurposing study done in predicted the 16 repurposable drugs with anti-viral evidence obtained from the literature and clinical trial data.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 132,\n",
              "   'span_end': 140,\n",
              "   'text': 'Among the 16 repurposable drugs Sirolimus originally approved as an immunosuppressant is registered in phase-II clinical trials for Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 109,\n",
              "   'span_end': 117,\n",
              "   'text': 'Another work done in applied machine learning on networks and repurposed 14 potential repurposable drugs for Covid-19, of which Chloroquine is registered in Phase-II & III and Dexamethasone is registered in Phase-IV clinical trials as mentioned in.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 145,\n",
              "   'span_end': 153,\n",
              "   'text': 'Similarly, a machine learning and network medicine drug repurposing work retrieved a list of 23 FDA approved drugs as potential therapeutics for Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 65,\n",
              "   'span_end': 73,\n",
              "   'text': 'Many of 23 FDA approved drugs are already in clinical trials for Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 172,\n",
              "   'span_end': 180,\n",
              "   'text': 'Additionally, in our recent work of machine learning and molecular docking-based drug repurposing framework, 12 potential drugs were suggested as potential therapeutic for Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 114,\n",
              "   'span_end': 122,\n",
              "   'text': 'Similarly, multiple deep learning techniques have also been used to identify the repurposable drug candidates for Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 243,\n",
              "   'span_end': 251,\n",
              "   'text': 'One of the deep learning-based studies, is done in where deep learning-based drug screening was performed followed by a study done in where a resource based on deep learning is created to enable the fast repurposing of the drug candidates for Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 154,\n",
              "   'span_end': 162,\n",
              "   'text': 'Finally, in the light of the examples tabulated in, it can be concluded that the drug repurposing methods are quite helpful and quick to response in case Covid-19 and related emergent situations.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 160,\n",
              "   'span_end': 168,\n",
              "   'text': 'There is no doubt that network medicine approaches are gaining more attention and have successfully been deployed in several studies to repurpose the drugs for Covid-19. Still there are some limitations which needs to be highlighted along with future recommendations to overcome some limitations for improved results in the future.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 4,\n",
              "   'span_end': 23,\n",
              "   'text': 'The Coronavirus disease Covid-19 is an infectious disease caused by SARS-CoV-2 virus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 24,\n",
              "   'span_end': 32,\n",
              "   'text': 'The Coronavirus disease Covid-19 is an infectious disease caused by SARS-CoV-2 virus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 68,\n",
              "   'span_end': 78,\n",
              "   'text': 'The Coronavirus disease Covid-19 is an infectious disease caused by SARS-CoV-2 virus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 49,\n",
              "   'span_end': 68,\n",
              "   'text': 'Started in November 2019 in the Wuhan-China, The Coronavirus disease Covid-19 was soon declared as public health emergency of international health concern by the World Health Organization WHO on January 30, and The Coronavirus disease Covid-19 scaled up to pandemic as of March 11, 2020.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 69,\n",
              "   'span_end': 77,\n",
              "   'text': 'Started in November 2019 in the Wuhan-China, The Coronavirus disease Covid-19 was soon declared as public health emergency of international health concern by the World Health Organization WHO on January 30, and The Coronavirus disease Covid-19 scaled up to pandemic as of March 11, 2020.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 215,\n",
              "   'span_end': 234,\n",
              "   'text': 'Started in November 2019 in the Wuhan-China, The Coronavirus disease Covid-19 was soon declared as public health emergency of international health concern by the World Health Organization WHO on January 30, and The Coronavirus disease Covid-19 scaled up to pandemic as of March 11, 2020.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 235,\n",
              "   'span_end': 243,\n",
              "   'text': 'Started in November 2019 in the Wuhan-China, The Coronavirus disease Covid-19 was soon declared as public health emergency of international health concern by the World Health Organization WHO on January 30, and The Coronavirus disease Covid-19 scaled up to pandemic as of March 11, 2020.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 99,\n",
              "   'span_end': 118,\n",
              "   'text': 'Thus, drug repurposing emerged as an efficient and scalable approach to find the treatment for The Coronavirus disease Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 119,\n",
              "   'span_end': 127,\n",
              "   'text': 'Thus, drug repurposing emerged as an efficient and scalable approach to find the treatment for The Coronavirus disease Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 77,\n",
              "   'span_end': 96,\n",
              "   'text': 'In this review, a comprehensive overview of drug repurposing studies for The Coronavirus disease Covid-19 is provided.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 97,\n",
              "   'span_end': 105,\n",
              "   'text': 'In this review, a comprehensive overview of drug repurposing studies for The Coronavirus disease Covid-19 is provided.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 154,\n",
              "   'span_end': 173,\n",
              "   'text': 'this review spans to machine learning, deep learning, and network-based approaches while specifically network-based approaches to drug repurposing in The Coronavirus disease Covid-19 are focused.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 174,\n",
              "   'span_end': 182,\n",
              "   'text': 'this review spans to machine learning, deep learning, and network-based approaches while specifically network-based approaches to drug repurposing in The Coronavirus disease Covid-19 are focused.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 33,\n",
              "   'span_end': 52,\n",
              "   'text': 'Network based approaches for The Coronavirus disease Covid-19 drug repurposing are further divided in three categories Network diffusion, network proximity, and AI on networks.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 53,\n",
              "   'span_end': 61,\n",
              "   'text': 'Network based approaches for The Coronavirus disease Covid-19 drug repurposing are further divided in three categories Network diffusion, network proximity, and AI on networks.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 219,\n",
              "   'span_end': 238,\n",
              "   'text': 'Moreover, in simplest form machine learning studies take the different type of drug and disease related data, perform feature extraction, create predictive models, and then models are deployed for the prediction in The Coronavirus disease Covid-19 and other diseases.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 239,\n",
              "   'span_end': 247,\n",
              "   'text': 'Moreover, in simplest form machine learning studies take the different type of drug and disease related data, perform feature extraction, create predictive models, and then models are deployed for the prediction in The Coronavirus disease Covid-19 and other diseases.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 59,\n",
              "   'span_end': 78,\n",
              "   'text': 'Despite successful application in drug repurposing for The Coronavirus disease Covid-19, machine learning approaches struggle to handle the diverse and sparse biological data but are easy to interpret which is essential for studies like drug repurposing.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 79,\n",
              "   'span_end': 87,\n",
              "   'text': 'Despite successful application in drug repurposing for The Coronavirus disease Covid-19, machine learning approaches struggle to handle the diverse and sparse biological data but are easy to interpret which is essential for studies like drug repurposing.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 160,\n",
              "   'span_end': 179,\n",
              "   'text': 'Since deep learning models are effective in terms of heterogenous and sparse data handling and have been deployed to predict repurposed candidate drugs for The Coronavirus disease Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 180,\n",
              "   'span_end': 188,\n",
              "   'text': 'Since deep learning models are effective in terms of heterogenous and sparse data handling and have been deployed to predict repurposed candidate drugs for The Coronavirus disease Covid-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 91,\n",
              "   'span_end': 110,\n",
              "   'text': 'Additionally, network-based methods have also been widely and effectively deployed for The Coronavirus disease Covid-19 repurposing.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 111,\n",
              "   'span_end': 119,\n",
              "   'text': 'Additionally, network-based methods have also been widely and effectively deployed for The Coronavirus disease Covid-19 repurposing.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 44,\n",
              "   'span_end': 63,\n",
              "   'text': 'The biological network-based studies in The Coronavirus disease Covid-19 covered multiple pharmacological aspects such as gene regulations, protein interactions, drug-target or drug-drug interactions, drug-side effect, and metabolic interactions etc.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 64,\n",
              "   'span_end': 72,\n",
              "   'text': 'The biological network-based studies in The Coronavirus disease Covid-19 covered multiple pharmacological aspects such as gene regulations, protein interactions, drug-target or drug-drug interactions, drug-side effect, and metabolic interactions etc.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 207,\n",
              "   'span_end': 226,\n",
              "   'text': 'The integration of such diverse biological entities extracted from many different databases and experiments in network helps to mimic the complex biological systems good for drug repurposing specific in The Coronavirus disease Covid-19 and in general.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 227,\n",
              "   'span_end': 235,\n",
              "   'text': 'The integration of such diverse biological entities extracted from many different databases and experiments in network helps to mimic the complex biological systems good for drug repurposing specific in The Coronavirus disease Covid-19 and in general.'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus disease 2019',\n",
              "   'span_start': 88,\n",
              "   'span_end': 112,\n",
              "   'text': \"At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 113,\n",
              "   'span_end': 121,\n",
              "   'text': \"At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus disease 2019',\n",
              "   'span_start': 150,\n",
              "   'span_end': 174,\n",
              "   'text': \"At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 175,\n",
              "   'span_end': 183,\n",
              "   'text': \"At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus disease 2019',\n",
              "   'span_start': 220,\n",
              "   'span_end': 244,\n",
              "   'text': \"At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 245,\n",
              "   'span_end': 253,\n",
              "   'text': \"At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus disease 2019',\n",
              "   'span_start': 10,\n",
              "   'span_end': 34,\n",
              "   'text': 'the novel coronavirus disease 2019 COVID-19 first appeared in Wuhan city, China, in late 2019 and is still spreading all over the globe creating a disastrous effect on global health and the economy.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 35,\n",
              "   'span_end': 43,\n",
              "   'text': 'the novel coronavirus disease 2019 COVID-19 first appeared in Wuhan city, China, in late 2019 and is still spreading all over the globe creating a disastrous effect on global health and the economy.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus disease 2019',\n",
              "   'span_start': 17,\n",
              "   'span_end': 41,\n",
              "   'text': \"Due to the novel coronavirus disease 2019 COVID-19's highly contagious nature, as of May 2022, the pandemic has spread to more than 200 countries and territories with over 5.5 million confirmed positive cases and mortality of over 350K across the globe.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 42,\n",
              "   'span_end': 50,\n",
              "   'text': \"Due to the novel coronavirus disease 2019 COVID-19's highly contagious nature, as of May 2022, the pandemic has spread to more than 200 countries and territories with over 5.5 million confirmed positive cases and mortality of over 350K across the globe.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus disease 2019',\n",
              "   'span_start': 35,\n",
              "   'span_end': 59,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 60,\n",
              "   'span_end': 68,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 72,\n",
              "   'span_end': 105,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 106,\n",
              "   'span_end': 117,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 120,\n",
              "   'span_end': 130,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 136,\n",
              "   'span_end': 169,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 170,\n",
              "   'span_end': 181,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 184,\n",
              "   'span_end': 194,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 242,\n",
              "   'span_end': 253,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 0,\n",
              "   'span_end': 33,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 34,\n",
              "   'span_end': 45,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 48,\n",
              "   'span_end': 58,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Betacoronavirus',\n",
              "   'span_start': 80,\n",
              "   'span_end': 95,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviridae',\n",
              "   'span_start': 110,\n",
              "   'span_end': 123,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS',\n",
              "   'span_start': 167,\n",
              "   'span_end': 171,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 172,\n",
              "   'span_end': 183,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-1',\n",
              "   'span_start': 184,\n",
              "   'span_end': 194,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 232,\n",
              "   'span_end': 243,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 244,\n",
              "   'span_end': 252,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviruses',\n",
              "   'span_start': 0,\n",
              "   'span_end': 13,\n",
              "   'text': 'Coronaviruses are positive-sense single-stranded RNA with a genome size of ~30 kb containing a 5′ cap-structure and 3′-polyadenylated tail.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviruses',\n",
              "   'span_start': 0,\n",
              "   'span_end': 13,\n",
              "   'text': \"Coronaviruses's genome encodes for ORF1a and ORF1ab polyprotein which cleaves into multiple subunits and performs a diverse range of functions, i.e., binding and invading the host cell, viral replication, and evading the host immune system.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 16,\n",
              "   'span_end': 29,\n",
              "   'text': \"The proteins of coronaviruses perform The proteins of coronaviruses's function by aggregating multiple subunits into an heteromeric complex, i.e., replication-transcription complex and several other structural proteins that assemble into new virions.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 54,\n",
              "   'span_end': 67,\n",
              "   'text': \"The proteins of coronaviruses perform The proteins of coronaviruses's function by aggregating multiple subunits into an heteromeric complex, i.e., replication-transcription complex and several other structural proteins that assemble into new virions.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS',\n",
              "   'span_start': 144,\n",
              "   'span_end': 148,\n",
              "   'text': 'a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 149,\n",
              "   'span_end': 160,\n",
              "   'text': 'a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-1',\n",
              "   'span_start': 161,\n",
              "   'span_end': 171,\n",
              "   'text': 'a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 218,\n",
              "   'span_end': 229,\n",
              "   'text': 'a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 230,\n",
              "   'span_end': 238,\n",
              "   'text': 'a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV2',\n",
              "   'span_start': 175,\n",
              "   'span_end': 184,\n",
              "   'text': 'Currently, many studies including single-ligand docking as well as screening of the compounds library have been conducted to search for potential inhibitors against NSP-12 of SARS-CoV2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV2',\n",
              "   'span_start': 98,\n",
              "   'span_end': 107,\n",
              "   'text': 'The DALI server was employed for the identification of homologous protein structures to NSP-12 of SARS-CoV2 that were already submitted in the PDB repository.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviridae',\n",
              "   'span_start': 86,\n",
              "   'span_end': 99,\n",
              "   'text': '611 structures were involved in the RdRp activity and belonged to four viral families Coronaviridae, Flaviviridae, Picornaviridae, and Caliciviridae and infected a diverse range of hosts.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 151,\n",
              "   'span_end': 164,\n",
              "   'text': 'the similarity matrix was visualized as a heatmap as shown in A. The heatmap of Z-score-based structural similarity revealed the close relationship of coronaviruses with the members of Flaviviridae as well as Caliciviridae and Picornaviridae.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 247,\n",
              "   'span_end': 260,\n",
              "   'text': 'Based on structural similarity, the unrooted cladogram of homologous structures to a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity was clustered into four viral families as shown in B. The clade of the coronaviruses, i.e., SARS-CoV-1 and SARS-CoV-2, shares a close relationship with the NS5B of HCV and also with the other representatives of Flaviviridae, i.e., the Zika Virus ZIKV, Dengue Virus DENV, Bovine Viral Diarrhea Virus BVDV, Japanese Encephalitis Virus JEV, and Classical Swine Fever Virus CSFV.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-1',\n",
              "   'span_start': 268,\n",
              "   'span_end': 278,\n",
              "   'text': 'Based on structural similarity, the unrooted cladogram of homologous structures to a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity was clustered into four viral families as shown in B. The clade of the coronaviruses, i.e., SARS-CoV-1 and SARS-CoV-2, shares a close relationship with the NS5B of HCV and also with the other representatives of Flaviviridae, i.e., the Zika Virus ZIKV, Dengue Virus DENV, Bovine Viral Diarrhea Virus BVDV, Japanese Encephalitis Virus JEV, and Classical Swine Fever Virus CSFV.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 283,\n",
              "   'span_end': 293,\n",
              "   'text': 'Based on structural similarity, the unrooted cladogram of homologous structures to a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity was clustered into four viral families as shown in B. The clade of the coronaviruses, i.e., SARS-CoV-1 and SARS-CoV-2, shares a close relationship with the NS5B of HCV and also with the other representatives of Flaviviridae, i.e., the Zika Virus ZIKV, Dengue Virus DENV, Bovine Viral Diarrhea Virus BVDV, Japanese Encephalitis Virus JEV, and Classical Swine Fever Virus CSFV.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 30,\n",
              "   'span_end': 43,\n",
              "   'text': 'The clade of Flaviviridae and coronaviruses shared significant relationships as compared to the members of Caliciviridae and Picornaviridae.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviridae',\n",
              "   'span_start': 213,\n",
              "   'span_end': 226,\n",
              "   'text': 'To display the conserved orientation of these motifs at the active site of a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity, multiple structures belonging to the family Coronaviridae, Flaviviridae, and Picornaviridae were superposed structurally aligned by using the MatchMaker algorithm implemented in UCSF Chimera.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 140,\n",
              "   'span_end': 150,\n",
              "   'text': 'The grid box was centered at the active site or druggable cavity and the residues were considered rigid for both receptors, i.e., NSP-12 of SARS-CoV-2 and NS5B of HCV.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 71,\n",
              "   'span_end': 81,\n",
              "   'text': 'The results score of ligand bindings with the active site of NSP-12 of SARS-CoV-2 and NS5B of HCV has been compared and visualized as a bar chart as shown in B.The docking score of NSP-12 of SARS-CoV-2 with the ligands, i.e., Dasabuvir, Sofosbuvir, Ribavirin, GTP, and UTP was in the range of −6.2 to −8.1 kcal/mol, while for NS5B of HCV, B.The docking score of NSP-12 with the ligands was −6.5 to −9.1 kcal/mol, and both had an average difference of 0.84 kcal/mol.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 191,\n",
              "   'span_end': 201,\n",
              "   'text': 'The results score of ligand bindings with the active site of NSP-12 of SARS-CoV-2 and NS5B of HCV has been compared and visualized as a bar chart as shown in B.The docking score of NSP-12 of SARS-CoV-2 with the ligands, i.e., Dasabuvir, Sofosbuvir, Ribavirin, GTP, and UTP was in the range of −6.2 to −8.1 kcal/mol, while for NS5B of HCV, B.The docking score of NSP-12 with the ligands was −6.5 to −9.1 kcal/mol, and both had an average difference of 0.84 kcal/mol.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 39,\n",
              "   'span_end': 49,\n",
              "   'text': 'The average docking score of NSP-12 of SARS-CoV-2 and NS5B of HCV for Sofosbuvir, Dasabuvir, Ribavirin, GTP, and GTP were −8.2, −8.6, −6.35, −8.25, and −7.6 kcal/mol, respectively.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 10,\n",
              "   'span_end': 20,\n",
              "   'text': 'NSP-12 of SARS-CoV-2 showed the lowest docking score −8.1 kcal/mol with Dasabuvir and higher −6.2 kcal/mol with Ribavirin.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 95,\n",
              "   'span_end': 105,\n",
              "   'text': 'In general, the ligands showed a higher docking score for NS5B of HCV as compared to NSP-12 of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 110,\n",
              "   'span_end': 120,\n",
              "   'text': 'To examine the interactions between ligand and the conserved residues present at the active site of NSP-12 of SARS-CoV-2, LigPlot + v2.1, standalone software was used.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 70,\n",
              "   'span_end': 80,\n",
              "   'text': 'The predicted interactions of Sofosbuvir and Dasabuvir with NSP-12 of SARS-CoV-2 have been shown in A,B, respectively.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 80,\n",
              "   'span_end': 90,\n",
              "   'text': 'On the other hand, the native competitors such as GTP interacted with NSP-12 of SARS-CoV-2 by forming hydrogen bonds with A554, R555, and T556 of motif-F, Y619, K621, and C622 of motif-A, while UTP interacted with S759, D760, and D761 of motif-C, W800 of motif-D, and G811 and S814 of motif-E In the case of HCV as a receptor, Sofosbuvir binds with motif-B and -C, while Dasabuvir interacted with residues of motif-A, -B, -C, and motif-F, and their receptor–ligand interaction plots have been shown in C,D, respectively.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 61,\n",
              "   'span_end': 71,\n",
              "   'text': 'However, 6M71/Sofosbuvir has the same evolution to NSP-12 of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 100,\n",
              "   'span_end': 110,\n",
              "   'text': 'This finding implies that Dasabuvir, Ribavirin, and Sofosbuvir binding helped to maintain NSP-12 of SARS-CoV-2 structurally stable.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 65,\n",
              "   'span_end': 75,\n",
              "   'text': \"We examined how binding of different ligands this goal NSP-12 of SARS-CoV-2's overall compactness in the protein's structure.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 36,\n",
              "   'span_end': 46,\n",
              "   'text': 'The average Rg values Apo NSP-12 of SARS-CoV-2, NSP-12/Dasabuvir, NSP-12/Ribavirin, and NSP-12/Sofosbuvir complexes were found to be 2.99, 3.00, 2.97, 2.98 nm, respectively, suggesting that the binding of Dasabuvir, Ribavirin, and Sofosbuvir to NSP-12 of SARS-CoV-2 packing did not cause significant change.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 255,\n",
              "   'span_end': 265,\n",
              "   'text': 'The average Rg values Apo NSP-12 of SARS-CoV-2, NSP-12/Dasabuvir, NSP-12/Ribavirin, and NSP-12/Sofosbuvir complexes were found to be 2.99, 3.00, 2.97, 2.98 nm, respectively, suggesting that the binding of Dasabuvir, Ribavirin, and Sofosbuvir to NSP-12 of SARS-CoV-2 packing did not cause significant change.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 70,\n",
              "   'span_end': 80,\n",
              "   'text': 'It was noticed that Dasabuvir binds to the active pocket of NSP-12 of SARS-CoV-2 with an average of 3.46 hydrogen bonds and 1.13 pairs within 0.35 nm.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 145,\n",
              "   'span_end': 155,\n",
              "   'text': 'On the other hand, the H-bonding plot showed that Dasabuvir was able to maintain a more robust interaction with the binding pockets of NSP-12 of SARS-CoV-2 throughout the simulation time than Ribavirin and Sofosbuvir. Before MM/PBSA calculation, each complex between the receptors or inhibitors/ligands should reach the equilibrium state.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 185,\n",
              "   'span_end': 195,\n",
              "   'text': 'Except for the polar solvation energy, all other forms of energy contributed favorably to the interaction between different molecules Dasabuvir, Ribavirin, and Sofosbuvir and NSP-12 of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 92,\n",
              "   'span_end': 100,\n",
              "   'text': 'Finally, the Sofosbuvir and Dasabuvir could be established as a repurposed drug against the COVID-19 main protease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 74,\n",
              "   'span_end': 84,\n",
              "   'text': \"Many drugs have been already suggested for the current pandemic caused by SARS-CoV-2, of which the most prominent are FDA-approved Chloroquine and FDA-approved Chloroquine's derivatives—an anti-malarial drug and Remdesivir.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 55,\n",
              "   'span_end': 65,\n",
              "   'text': 'Remdesivir, has been shown to significantly reduce the SARS-CoV-2 pathogenicity in in vitro study and is still under investigation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 53,\n",
              "   'span_end': 63,\n",
              "   'text': \"In this study, we searched for homologs of NSP-12 of SARS-CoV-2 and evaluated NSP-12 of SARS-CoV-2's binding affinity with the FDA-approved antivirals, i.e., Sofosbuvir and Dasabuvir, which specifically target the evolutionarily conserved site of NS5B of HCV.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 88,\n",
              "   'span_end': 98,\n",
              "   'text': \"In this study, we searched for homologs of NSP-12 of SARS-CoV-2 and evaluated NSP-12 of SARS-CoV-2's binding affinity with the FDA-approved antivirals, i.e., Sofosbuvir and Dasabuvir, which specifically target the evolutionarily conserved site of NS5B of HCV.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviridae',\n",
              "   'span_start': 166,\n",
              "   'span_end': 179,\n",
              "   'text': 'Further screening of 1105 structures based on the quality of structural alignment Z-score ≥ 19 resulted in 611 structures that belonged to four viral families, i.e., Coronaviridae, Flaviviridae, Picornaviridae, and Caliciviridae, responsible for RdRp activity during viral replication.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 14,\n",
              "   'span_end': 24,\n",
              "   'text': 'The NSP-12 of SARS-CoV-2 displayed significant homology to the NS5 of Flaviviridae or NS5B of HCV as compared to the polymerases of Picornaviridae and Caliciviridae.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 67,\n",
              "   'span_end': 77,\n",
              "   'text': 'Based on the pairwise alignment of amino acid sequences, NSP-12 of SARS-CoV-2 shares 96% identity with SARS-CoV-1, 11% with HCV and HNV, and 10% with Poli.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-1',\n",
              "   'span_start': 103,\n",
              "   'span_end': 113,\n",
              "   'text': 'Based on the pairwise alignment of amino acid sequences, NSP-12 of SARS-CoV-2 shares 96% identity with SARS-CoV-1, 11% with HCV and HNV, and 10% with Poli.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 62,\n",
              "   'span_end': 72,\n",
              "   'text': 'Despite sharing a lower identity based on sequence, NSP-12 of SARS-CoV-2 has seven highly conserved motifs in the RdRp domain that play a key role in viral replication.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 112,\n",
              "   'span_end': 122,\n",
              "   'text': 'significant overlap included the conserved residues of motifs A, B, C, D, and F of the RdRp domain of NSP-12 of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 48,\n",
              "   'span_end': 58,\n",
              "   'text': 'The active site of the RdRp domain of NSP-12 of SARS-CoV-2 was further evaluated for binding affinity with FDA-approved antivirals by the molecular docking method.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 111,\n",
              "   'span_end': 121,\n",
              "   'text': 'Molecular docking was performed using AutoDock Vina which revealed a significant binding affinity of NSP-12 of SARS-CoV-2 with Sofosbuvir and Dasabuvir as compared to Ribavirin.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 96,\n",
              "   'span_end': 106,\n",
              "   'text': 'Despite that, NS5B showed higher binding affinity lower binding energy as compared to NSP-12 of SARS-CoV-2 however, the differences were still insignificant.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 27,\n",
              "   'span_end': 37,\n",
              "   'text': 'The profiling of NSP-12 of SARS-CoV-2 and ligand interaction revealed firm binding due to the formation of hydrogen bonds and hydrophobic interactions.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 112,\n",
              "   'span_end': 122,\n",
              "   'text': 'In general, both Sofosbuvir and Dasabuvir showed higher binding to the active site of NS5B of HCV and NSP-12 of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 23,\n",
              "   'span_end': 33,\n",
              "   'text': 'We retrieved NSP-12 of SARS-CoV-2 with PDB ID 6M71 at 2.9 Å resolution from the Protein Data Bank PDB repository that was recently submitted by Gao et al. For the identification of homologous structures in the Protein Data Bank PDB repository, 6M71 chain A was submitted to the DALI server website.fi/dali/ accessed on 16 March 2020.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 72,\n",
              "   'span_end': 82,\n",
              "   'text': 'To further study the conserved residues at the active site of NSP-12 of SARS-CoV-2, multiple structures were aligned by using the MatchMaker algorithm implemented in the University of California, San Francisco UCSF Chimera v.14 and visualized.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'v.14',\n",
              "   'span_start': 223,\n",
              "   'span_end': 227,\n",
              "   'text': 'To further study the conserved residues at the active site of NSP-12 of SARS-CoV-2, multiple structures were aligned by using the MatchMaker algorithm implemented in the University of California, San Francisco UCSF Chimera v.14 and visualized.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'v.14',\n",
              "   'span_start': 209,\n",
              "   'span_end': 213,\n",
              "   'text': 'Initially, the Canonical SMILES IDs of the ligand compounds, i.e., Sofosbuvir CID 45375808, Ribavirin CID 37542, and Dasabuvir CID 56640146 were retrieved from the PubChem library and then imported in Chimera v.14 for converting into PDB files.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 54,\n",
              "   'span_end': 64,\n",
              "   'text': 'The resulting score of molecular docking of NSP-12 of SARS-CoV-2 and NS5B of HCV were compared and plotted using a bar plot.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'v.2021',\n",
              "   'span_start': 99,\n",
              "   'span_end': 105,\n",
              "   'text': 'The MD simulation of the apo and ligand-bound complex of NSP-12 protein was done using the GROMACS v.2021 and GROMOS96 54a7 force field.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 64,\n",
              "   'span_end': 74,\n",
              "   'text': \"In this study, we searched for structural homologs of NSP-12 of SARS-CoV-2 and identified structural homologs of NSP-12 of SARS-CoV-2's relationship with the members of three viral families, i.e., Flaviviridae, Picornaviridae, and Caliciviridae.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 123,\n",
              "   'span_end': 133,\n",
              "   'text': \"In this study, we searched for structural homologs of NSP-12 of SARS-CoV-2 and identified structural homologs of NSP-12 of SARS-CoV-2's relationship with the members of three viral families, i.e., Flaviviridae, Picornaviridae, and Caliciviridae.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 29,\n",
              "   'span_end': 39,\n",
              "   'text': 'The RdRp domain of NSP-12 of SARS-CoV-2 is highly conserved in terms of both sequence and architecture and assessed for binding affinity with FDA-approved antivirals, i.e., Dasabuvir and Sofosbuvir.'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 0,\n",
              "   'span_end': 24,\n",
              "   'text': 'Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 25,\n",
              "   'span_end': 33,\n",
              "   'text': 'Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 45,\n",
              "   'span_end': 78,\n",
              "   'text': 'Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 79,\n",
              "   'span_end': 90,\n",
              "   'text': 'Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 93,\n",
              "   'span_end': 103,\n",
              "   'text': 'Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 0,\n",
              "   'span_end': 33,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has infected more than half a billion people and caused over 5 million deaths, implying a global health threat.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 34,\n",
              "   'span_end': 45,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has infected more than half a billion people and caused over 5 million deaths, implying a global health threat.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 48,\n",
              "   'span_end': 58,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has infected more than half a billion people and caused over 5 million deaths, implying a global health threat.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 145,\n",
              "   'span_end': 169,\n",
              "   'text': 'As the development of a new drug takes years to a decade, drug repositioning can significantly accelerate the development cycle of therapies for Coronavirus disease 2019 COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 170,\n",
              "   'span_end': 178,\n",
              "   'text': 'As the development of a new drug takes years to a decade, drug repositioning can significantly accelerate the development cycle of therapies for Coronavirus disease 2019 COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 33,\n",
              "   'span_end': 57,\n",
              "   'text': 'The key to drug repositioning of Coronavirus disease 2019 COVID-19 is to identify critical targets for the CoV replication cycle.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 58,\n",
              "   'span_end': 66,\n",
              "   'text': 'The key to drug repositioning of Coronavirus disease 2019 COVID-19 is to identify critical targets for the CoV replication cycle.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 107,\n",
              "   'span_end': 110,\n",
              "   'text': 'The key to drug repositioning of Coronavirus disease 2019 COVID-19 is to identify critical targets for the CoV replication cycle.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 57,\n",
              "   'span_end': 60,\n",
              "   'text': 'virus-based targets the virus components involved in the CoV replication cycle.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 161,\n",
              "   'span_end': 194,\n",
              "   'text': 'For example, approved nucleoside analogues favipiravir and ribavirin and experimental nucleoside analogues remdesivir and galidesivir may have potential against severe acute respiratory syndrome coronavirus 2 SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 195,\n",
              "   'span_end': 206,\n",
              "   'text': 'For example, approved nucleoside analogues favipiravir and ribavirin and experimental nucleoside analogues remdesivir and galidesivir may have potential against severe acute respiratory syndrome coronavirus 2 SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 209,\n",
              "   'span_end': 219,\n",
              "   'text': 'For example, approved nucleoside analogues favipiravir and ribavirin and experimental nucleoside analogues remdesivir and galidesivir may have potential against severe acute respiratory syndrome coronavirus 2 SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 66,\n",
              "   'span_end': 69,\n",
              "   'text': 'The host-based approaches target the key host factors utilized by CoV for viral replication or stimulate innate antiviral responses in hosts.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 31,\n",
              "   'span_end': 64,\n",
              "   'text': 'It was quickly discovered that severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and leverages the serine protease TMPRSS2 for S protein initiation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 65,\n",
              "   'span_end': 76,\n",
              "   'text': 'It was quickly discovered that severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and leverages the serine protease TMPRSS2 for S protein initiation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 79,\n",
              "   'span_end': 89,\n",
              "   'text': 'It was quickly discovered that severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and leverages the serine protease TMPRSS2 for S protein initiation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 99,\n",
              "   'span_end': 107,\n",
              "   'text': 'It was quickly discovered that severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and leverages the serine protease TMPRSS2 for S protein initiation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 4,\n",
              "   'span_end': 12,\n",
              "   'text': 'the SARS-CoV receptor ACE2 regulates the renin-angiotensin system RAS in several diseases and expresses in the lungs and the kidney, small intestine, testis, and heart.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 19,\n",
              "   'span_end': 27,\n",
              "   'text': 'In addition to the SARS-CoV receptor ACE2 and the serine protease TMPRSS2, several candidate receptors can aid severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection, such as the cell-surface proteins tyrosine-protein kinase receptor UFO Axl, low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3, and C-type lectin domain family 4 member G CLEC4G.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 111,\n",
              "   'span_end': 144,\n",
              "   'text': 'In addition to the SARS-CoV receptor ACE2 and the serine protease TMPRSS2, several candidate receptors can aid severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection, such as the cell-surface proteins tyrosine-protein kinase receptor UFO Axl, low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3, and C-type lectin domain family 4 member G CLEC4G.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 145,\n",
              "   'span_end': 156,\n",
              "   'text': 'In addition to the SARS-CoV receptor ACE2 and the serine protease TMPRSS2, several candidate receptors can aid severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection, such as the cell-surface proteins tyrosine-protein kinase receptor UFO Axl, low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3, and C-type lectin domain family 4 member G CLEC4G.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 159,\n",
              "   'span_end': 179,\n",
              "   'text': 'In addition to the SARS-CoV receptor ACE2 and the serine protease TMPRSS2, several candidate receptors can aid severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection, such as the cell-surface proteins tyrosine-protein kinase receptor UFO Axl, low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3, and C-type lectin domain family 4 member G CLEC4G.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 62,\n",
              "   'span_end': 95,\n",
              "   'text': 'Several efforts have been made to identify drugs that inhibit severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by targeting host proteins.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 96,\n",
              "   'span_end': 107,\n",
              "   'text': 'Several efforts have been made to identify drugs that inhibit severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by targeting host proteins.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 110,\n",
              "   'span_end': 120,\n",
              "   'text': 'Several efforts have been made to identify drugs that inhibit severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by targeting host proteins.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 139,\n",
              "   'span_end': 172,\n",
              "   'text': 'An in vitro study demonstrates that the inhibition of the protease activity of the serine protease TMPRSS2 partially prevents the entry of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 into the lung epithelial cells.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 173,\n",
              "   'span_end': 184,\n",
              "   'text': 'An in vitro study demonstrates that the inhibition of the protease activity of the serine protease TMPRSS2 partially prevents the entry of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 into the lung epithelial cells.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 187,\n",
              "   'span_end': 197,\n",
              "   'text': 'An in vitro study demonstrates that the inhibition of the protease activity of the serine protease TMPRSS2 partially prevents the entry of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 into the lung epithelial cells.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 99,\n",
              "   'span_end': 132,\n",
              "   'text': 'In vitro studies suggest that both chloroquine and hydroxychloroquine may prevent the transport of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 from the early endosome to the endolysosome.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 133,\n",
              "   'span_end': 144,\n",
              "   'text': 'In vitro studies suggest that both chloroquine and hydroxychloroquine may prevent the transport of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 from the early endosome to the endolysosome.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 147,\n",
              "   'span_end': 157,\n",
              "   'text': 'In vitro studies suggest that both chloroquine and hydroxychloroquine may prevent the transport of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 from the early endosome to the endolysosome.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 61,\n",
              "   'span_end': 94,\n",
              "   'text': 'However, none of these options was confirmed to have an anti-severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 effect, which motivates the discoveries of other uncovered but practical host factors.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 95,\n",
              "   'span_end': 106,\n",
              "   'text': 'However, none of these options was confirmed to have an anti-severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 effect, which motivates the discoveries of other uncovered but practical host factors.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 109,\n",
              "   'span_end': 119,\n",
              "   'text': 'However, none of these options was confirmed to have an anti-severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 effect, which motivates the discoveries of other uncovered but practical host factors.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 252,\n",
              "   'span_end': 276,\n",
              "   'text': 'The network-based methodology combines the virus-host interactome and drug targets in the human protein-protein interaction PPI network as a systems pharmacology-based network medicine platform, which is vital and widely used in drug repositioning for Coronavirus disease 2019 COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 277,\n",
              "   'span_end': 285,\n",
              "   'text': 'The network-based methodology combines the virus-host interactome and drug targets in the human protein-protein interaction PPI network as a systems pharmacology-based network medicine platform, which is vital and widely used in drug repositioning for Coronavirus disease 2019 COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 72,\n",
              "   'span_end': 96,\n",
              "   'text': \"If a drug stimulates some genes and inhibits others, a drug's effect on Coronavirus disease 2019 COVID-19 needs to be reassessed.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 97,\n",
              "   'span_end': 105,\n",
              "   'text': \"If a drug stimulates some genes and inhibits others, a drug's effect on Coronavirus disease 2019 COVID-19 needs to be reassessed.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 92,\n",
              "   'span_end': 116,\n",
              "   'text': 'Importantly, current methods barely avoid the potential side effect of repurposed drugs for Coronavirus disease 2019 COVID-19 patients with chronic underlying diseases, such as diabetes mellitus, cardiovascular disease, chronic pulmonary disease, and cancers.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 117,\n",
              "   'span_end': 125,\n",
              "   'text': 'Importantly, current methods barely avoid the potential side effect of repurposed drugs for Coronavirus disease 2019 COVID-19 patients with chronic underlying diseases, such as diabetes mellitus, cardiovascular disease, chronic pulmonary disease, and cancers.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-coronavirus',\n",
              "   'span_start': 127,\n",
              "   'span_end': 139,\n",
              "   'text': 'In this study, to identify the potential antiviral agents, we applied an end-to-end computational method to search drug-gene s -coronavirus CoV paths in a directional network and inferred the effect of drugs on Coronavirus disease 2019 COVID-19 We constructed a directional network by aggregating three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 140,\n",
              "   'span_end': 143,\n",
              "   'text': 'In this study, to identify the potential antiviral agents, we applied an end-to-end computational method to search drug-gene s -coronavirus CoV paths in a directional network and inferred the effect of drugs on Coronavirus disease 2019 COVID-19 We constructed a directional network by aggregating three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 211,\n",
              "   'span_end': 235,\n",
              "   'text': 'In this study, to identify the potential antiviral agents, we applied an end-to-end computational method to search drug-gene s -coronavirus CoV paths in a directional network and inferred the effect of drugs on Coronavirus disease 2019 COVID-19 We constructed a directional network by aggregating three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 236,\n",
              "   'span_end': 244,\n",
              "   'text': 'In this study, to identify the potential antiviral agents, we applied an end-to-end computational method to search drug-gene s -coronavirus CoV paths in a directional network and inferred the effect of drugs on Coronavirus disease 2019 COVID-19 We constructed a directional network by aggregating three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 211,\n",
              "   'span_end': 235,\n",
              "   'text': 'By leveraging the edge direction in three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network, we can determine whether a drug is reachable to Coronavirus disease 2019 COVID-19 and the MoA between a drug and the virus protein, i.e., inhibition or stimulation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 236,\n",
              "   'span_end': 244,\n",
              "   'text': 'By leveraging the edge direction in three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network, we can determine whether a drug is reachable to Coronavirus disease 2019 COVID-19 and the MoA between a drug and the virus protein, i.e., inhibition or stimulation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 78,\n",
              "   'span_end': 102,\n",
              "   'text': 'Considering that patients with specific comorbidities are more susceptible to Coronavirus disease 2019 COVID-19 infection, we inspected the side effect of the drug candidate on several common comorbidities based on the genetic information of several complex diseases.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infection',\n",
              "   'span_start': 103,\n",
              "   'span_end': 121,\n",
              "   'text': 'Considering that patients with specific comorbidities are more susceptible to Coronavirus disease 2019 COVID-19 infection, we inspected the side effect of the drug candidate on several common comorbidities based on the genetic information of several complex diseases.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 68,\n",
              "   'span_end': 92,\n",
              "   'text': 'We reported 29 FDA-approved drugs 7 currently in clinical trials as Coronavirus disease 2019 COVID-19 treatment by a scoring strategy accounting for the effects of drugs on CoVs and comorbidities and other auxiliary information.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 93,\n",
              "   'span_end': 101,\n",
              "   'text': 'We reported 29 FDA-approved drugs 7 currently in clinical trials as Coronavirus disease 2019 COVID-19 treatment by a scoring strategy accounting for the effects of drugs on CoVs and comorbidities and other auxiliary information.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 173,\n",
              "   'span_end': 177,\n",
              "   'text': 'We reported 29 FDA-approved drugs 7 currently in clinical trials as Coronavirus disease 2019 COVID-19 treatment by a scoring strategy accounting for the effects of drugs on CoVs and comorbidities and other auxiliary information.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV infection',\n",
              "   'span_start': 109,\n",
              "   'span_end': 122,\n",
              "   'text': 'We first comprehensively collected candidate host genes from three major domains for mechanistic research of CoV infection genetic risk genes, physical interaction genes, and biological regulation genes A. The source of genetic risk genes was mainly collected from the GWASs of Coronavirus disease 2019 COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 278,\n",
              "   'span_end': 302,\n",
              "   'text': 'We first comprehensively collected candidate host genes from three major domains for mechanistic research of CoV infection genetic risk genes, physical interaction genes, and biological regulation genes A. The source of genetic risk genes was mainly collected from the GWASs of Coronavirus disease 2019 COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 303,\n",
              "   'span_end': 311,\n",
              "   'text': 'We first comprehensively collected candidate host genes from three major domains for mechanistic research of CoV infection genetic risk genes, physical interaction genes, and biological regulation genes A. The source of genetic risk genes was mainly collected from the GWASs of Coronavirus disease 2019 COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 88,\n",
              "   'span_end': 91,\n",
              "   'text': 'The biological regulation genes were collected from the results of the CRISPR screen of CoV-infected cells.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 65,\n",
              "   'span_end': 68,\n",
              "   'text': 'Thus, we constructed a directed multicomponent network including CoV, host genes, human genes, drug targets, and drugs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoVs',\n",
              "   'span_start': 33,\n",
              "   'span_end': 38,\n",
              "   'text': \"We then searched for drug-gene s -CoVs paths in a directed multicomponent network including CoV, host genes, human genes, drug targets, and drugs and used the direction information to screen out drugs with suitable MoAs C. To investigate the impact of drug candidates on the underlying disease in patients with COVID-19, we also identified genetic risk genes for common complex diseases and genetic risk genes for common complex diseases's direction to disease from genetic data.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 92,\n",
              "   'span_end': 95,\n",
              "   'text': \"We then searched for drug-gene s -CoVs paths in a directed multicomponent network including CoV, host genes, human genes, drug targets, and drugs and used the direction information to screen out drugs with suitable MoAs C. To investigate the impact of drug candidates on the underlying disease in patients with COVID-19, we also identified genetic risk genes for common complex diseases and genetic risk genes for common complex diseases's direction to disease from genetic data.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 311,\n",
              "   'span_end': 319,\n",
              "   'text': \"We then searched for drug-gene s -CoVs paths in a directed multicomponent network including CoV, host genes, human genes, drug targets, and drugs and used the direction information to screen out drugs with suitable MoAs C. To investigate the impact of drug candidates on the underlying disease in patients with COVID-19, we also identified genetic risk genes for common complex diseases and genetic risk genes for common complex diseases's direction to disease from genetic data.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 203,\n",
              "   'span_end': 207,\n",
              "   'text': 'Finally, drugs with a potential inhibitory effect on the disease were prioritized based on a combined score, and conversely, drugs that promote disease were filtered out D.Phylogenetic analysis of human CoVs shows that SARS-CoV-2, SARS-CoV, and MERS-CoV have a high conservative genome.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 219,\n",
              "   'span_end': 229,\n",
              "   'text': 'Finally, drugs with a potential inhibitory effect on the disease were prioritized based on a combined score, and conversely, drugs that promote disease were filtered out D.Phylogenetic analysis of human CoVs shows that SARS-CoV-2, SARS-CoV, and MERS-CoV have a high conservative genome.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 231,\n",
              "   'span_end': 239,\n",
              "   'text': 'Finally, drugs with a potential inhibitory effect on the disease were prioritized based on a combined score, and conversely, drugs that promote disease were filtered out D.Phylogenetic analysis of human CoVs shows that SARS-CoV-2, SARS-CoV, and MERS-CoV have a high conservative genome.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 245,\n",
              "   'span_end': 253,\n",
              "   'text': 'Finally, drugs with a potential inhibitory effect on the disease were prioritized based on a combined score, and conversely, drugs that promote disease were filtered out D.Phylogenetic analysis of human CoVs shows that SARS-CoV-2, SARS-CoV, and MERS-CoV have a high conservative genome.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 56,\n",
              "   'span_end': 66,\n",
              "   'text': 'Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 149,\n",
              "   'span_end': 157,\n",
              "   'text': 'Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 162,\n",
              "   'span_end': 170,\n",
              "   'text': 'Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 182,\n",
              "   'span_end': 192,\n",
              "   'text': 'Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 194,\n",
              "   'span_end': 202,\n",
              "   'text': 'Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 208,\n",
              "   'span_end': 216,\n",
              "   'text': 'Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 112,\n",
              "   'span_end': 120,\n",
              "   'text': 'We systematically integrated candidate host genes from three different angles to identify genetic risk genes of COVID-19, we first got significant risk variants p-value<5 × 10−8 of 517 COVID-19 GWASs from GRASP, yielding 2618 risk variants significantly associated with COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 185,\n",
              "   'span_end': 193,\n",
              "   'text': 'We systematically integrated candidate host genes from three different angles to identify genetic risk genes of COVID-19, we first got significant risk variants p-value<5 × 10−8 of 517 COVID-19 GWASs from GRASP, yielding 2618 risk variants significantly associated with COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 270,\n",
              "   'span_end': 278,\n",
              "   'text': 'We systematically integrated candidate host genes from three different angles to identify genetic risk genes of COVID-19, we first got significant risk variants p-value<5 × 10−8 of 517 COVID-19 GWASs from GRASP, yielding 2618 risk variants significantly associated with COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 251,\n",
              "   'span_end': 259,\n",
              "   'text': 'If the risk variant is an expression quantitative trait locus eQTL of whole blood or lung, we retrieved the eGene of an expression quantitative trait locus eQTL of whole blood or lung as the risk gene and inferred the direction of the risk variant to COVID-19 by matching the effect size of the GWAS and the effect size of an expression quantitative trait locus eQTL of whole blood or lung.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 139,\n",
              "   'span_end': 147,\n",
              "   'text': 'The association on chromosome 19p13.12 colocalizes an eQTL of TYK2, the target of JAK inhibitors, whose high expression is associated with COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 57,\n",
              "   'span_end': 61,\n",
              "   'text': 'To collect the high confidence proteins interacting with CoVs, we gathered data from PPI databases, public literature, and affinity AP-MS analyses.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV infection',\n",
              "   'span_start': 47,\n",
              "   'span_end': 60,\n",
              "   'text': 'We used up- and downregulation of genes in the CoV infection process as gene-to-virus direction.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 111,\n",
              "   'span_end': 119,\n",
              "   'text': 'Among 435 genes that interact with viral proteins and their direction of action, 16 genes interacted with both SARS-CoV and SARS-CoV-2 and were significantly differentially expressed in the expression profiles of both SARS-CoV and SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 124,\n",
              "   'span_end': 134,\n",
              "   'text': 'Among 435 genes that interact with viral proteins and their direction of action, 16 genes interacted with both SARS-CoV and SARS-CoV-2 and were significantly differentially expressed in the expression profiles of both SARS-CoV and SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 218,\n",
              "   'span_end': 226,\n",
              "   'text': 'Among 435 genes that interact with viral proteins and their direction of action, 16 genes interacted with both SARS-CoV and SARS-CoV-2 and were significantly differentially expressed in the expression profiles of both SARS-CoV and SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 231,\n",
              "   'span_end': 241,\n",
              "   'text': 'Among 435 genes that interact with viral proteins and their direction of action, 16 genes interacted with both SARS-CoV and SARS-CoV-2 and were significantly differentially expressed in the expression profiles of both SARS-CoV and SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 36,\n",
              "   'span_end': 44,\n",
              "   'text': 'Aconitase1 ACO1 is overexpressed in COVID-19 and underexpressed in non-COVID-19 viral infections.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 71,\n",
              "   'span_end': 79,\n",
              "   'text': 'Aconitase1 ACO1 is overexpressed in COVID-19 and underexpressed in non-COVID-19 viral infections.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 103,\n",
              "   'span_end': 111,\n",
              "   'text': 'Interestingly, Aconitase1 ACO1 is involved in iron metabolism, and heme appears to be interlinked with COVID-19 pathophysiology.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 75,\n",
              "   'span_end': 79,\n",
              "   'text': 'PCDH9, one of the downregulated genes, interacts with multiple proteins of CoVs, including M, NSP6, ORF6, ORF7a, ORF7b, and S proteins.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infection',\n",
              "   'span_start': 99,\n",
              "   'span_end': 117,\n",
              "   'text': 'The disruption of cadherin proteins by viral protein ORF7b could contribute to several symptoms of COVID-19 infection, including multiorgan failure.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 98,\n",
              "   'span_end': 102,\n",
              "   'text': 'Genome-wide screens have been widely used to identify host factors for various viruses, including CoVs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 70,\n",
              "   'span_end': 80,\n",
              "   'text': 'It is worth noting that seven genes were selected in the screening of SARS-CoV-2, SARS-CoV, and MERS-CoV, including CTSL, which encodes the Cathepsin L protease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 82,\n",
              "   'span_end': 90,\n",
              "   'text': 'It is worth noting that seven genes were selected in the screening of SARS-CoV-2, SARS-CoV, and MERS-CoV, including CTSL, which encodes the Cathepsin L protease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 96,\n",
              "   'span_end': 104,\n",
              "   'text': 'It is worth noting that seven genes were selected in the screening of SARS-CoV-2, SARS-CoV, and MERS-CoV, including CTSL, which encodes the Cathepsin L protease.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 73,\n",
              "   'span_end': 83,\n",
              "   'text': 'CTSL, which encodes the Cathepsin L protease can functionally cleave the SARS-CoV-2 spike protein and enhance virus entry.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 93,\n",
              "   'span_end': 103,\n",
              "   'text': 'Studies have shown that inhibitors of the Cathepsin L protease can effectively prevent human SARS-CoV-2, SARS-CoV, and MERS-CoV infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 105,\n",
              "   'span_end': 113,\n",
              "   'text': 'Studies have shown that inhibitors of the Cathepsin L protease can effectively prevent human SARS-CoV-2, SARS-CoV, and MERS-CoV infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV infection',\n",
              "   'span_start': 119,\n",
              "   'span_end': 137,\n",
              "   'text': 'Studies have shown that inhibitors of the Cathepsin L protease can effectively prevent human SARS-CoV-2, SARS-CoV, and MERS-CoV infection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 237,\n",
              "   'span_end': 240,\n",
              "   'text': 'Remarkably, no genes were collected from the three sources simultaneously, and the overlap between the three sources is also relatively small, suggesting current biological assays or genetic methods may capture complementary patterns of CoV-host crosstalk.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 133,\n",
              "   'span_end': 143,\n",
              "   'text': 'For example, only 1 out of the 77 genetic risk genes is derived from the CRISPR screen and physical interaction, respectively A. For SARS-CoV-2, we revealed 882 candidate host genes B. Among 882 candidate host genes B., BMPR2 is not only a genetic risk gene but also interacts with SARS-CoV-2 ORF3 protein.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 282,\n",
              "   'span_end': 292,\n",
              "   'text': 'For example, only 1 out of the 77 genetic risk genes is derived from the CRISPR screen and physical interaction, respectively A. For SARS-CoV-2, we revealed 882 candidate host genes B. Among 882 candidate host genes B., BMPR2 is not only a genetic risk gene but also interacts with SARS-CoV-2 ORF3 protein.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 0,\n",
              "   'span_end': 10,\n",
              "   'text': 'SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 15,\n",
              "   'span_end': 23,\n",
              "   'text': 'SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 99,\n",
              "   'span_end': 109,\n",
              "   'text': 'SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 186,\n",
              "   'span_end': 196,\n",
              "   'text': 'SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 201,\n",
              "   'span_end': 209,\n",
              "   'text': 'SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 94,\n",
              "   'span_end': 104,\n",
              "   'text': \"We divided these genes into antiviral and proviral genes according to these genes's effect on SARS-CoV-2, SARS-CoV, and MERS-CoV. There are 654 antiviral genes and 756 proviral genes.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 106,\n",
              "   'span_end': 114,\n",
              "   'text': \"We divided these genes into antiviral and proviral genes according to these genes's effect on SARS-CoV-2, SARS-CoV, and MERS-CoV. There are 654 antiviral genes and 756 proviral genes.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV.',\n",
              "   'span_start': 120,\n",
              "   'span_end': 129,\n",
              "   'text': \"We divided these genes into antiviral and proviral genes according to these genes's effect on SARS-CoV-2, SARS-CoV, and MERS-CoV. There are 654 antiviral genes and 756 proviral genes.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 42,\n",
              "   'span_end': 46,\n",
              "   'text': 'The catalog of host genes associated with CoVs and the directional information can provide mechanistic insight for drug target selection.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 183,\n",
              "   'span_end': 191,\n",
              "   'text': 'As the development of a new drug takes a long time and huge cost, we believe our integrated resource could be alternatively suitable for improving drug repositioning opportunities on COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'gene-CoV',\n",
              "   'span_start': 110,\n",
              "   'span_end': 118,\n",
              "   'text': 'We merged drug-target interactions, human protein interactions, and virus-host interactions into a whole drug-gene-CoV network.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoVs',\n",
              "   'span_start': 76,\n",
              "   'span_end': 81,\n",
              "   'text': 'Then we used the random walk with restart RWR algorithm to find drug-gene s -CoVs paths in a whole drug-gene-CoV network and inferred the direction of the drug to the CoVs see.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'gene-CoV',\n",
              "   'span_start': 104,\n",
              "   'span_end': 112,\n",
              "   'text': 'Then we used the random walk with restart RWR algorithm to find drug-gene s -CoVs paths in a whole drug-gene-CoV network and inferred the direction of the drug to the CoVs see.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 167,\n",
              "   'span_end': 171,\n",
              "   'text': 'Then we used the random walk with restart RWR algorithm to find drug-gene s -CoVs paths in a whole drug-gene-CoV network and inferred the direction of the drug to the CoVs see.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 47,\n",
              "   'span_end': 51,\n",
              "   'text': 'Totally, 6234 drugs with inhibitory effects on CoVs were inferred.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 80,\n",
              "   'span_end': 88,\n",
              "   'text': 'Older age and comorbidities play essential roles in influencing the severity of COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoVs',\n",
              "   'span_start': 71,\n",
              "   'span_end': 76,\n",
              "   'text': 'To select the optimal drugs, we utilized the properties of drug-gene s -CoVs path including drug-target interaction, network mapping, and source of host genes for each drug to derive a combined score and used a combined score to prioritize drug candidates see.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 139,\n",
              "   'span_end': 147,\n",
              "   'text': 'We found that 29 of the top 100 drugs are FDA approved A, and seven of 29 of the top 100 drugs are in clinical trials for the treatment of COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 46,\n",
              "   'span_end': 54,\n",
              "   'text': 'We collected 397 drugs in clinical trials for COVID-19 from and overlapped with the top 100 drugs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 93,\n",
              "   'span_end': 101,\n",
              "   'text': 'None of the drugs in clinical trials prior to phase 3 have been found in clinical trials for COVID-19, and there are nine drugs in phase 3/4 clinical trials for COVID-19 B this may be because most of the COVID-19 clinical trial drugs are in clinical phase 3 or FDA approved.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 161,\n",
              "   'span_end': 169,\n",
              "   'text': 'None of the drugs in clinical trials prior to phase 3 have been found in clinical trials for COVID-19, and there are nine drugs in phase 3/4 clinical trials for COVID-19 B this may be because most of the COVID-19 clinical trial drugs are in clinical phase 3 or FDA approved.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 204,\n",
              "   'span_end': 212,\n",
              "   'text': 'None of the drugs in clinical trials prior to phase 3 have been found in clinical trials for COVID-19, and there are nine drugs in phase 3/4 clinical trials for COVID-19 B this may be because most of the COVID-19 clinical trial drugs are in clinical phase 3 or FDA approved.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 107,\n",
              "   'span_end': 117,\n",
              "   'text': 'chlorpromazine is an antipsychotic drug that has recently been proposed to have antiviral activity against SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 50,\n",
              "   'span_end': 60,\n",
              "   'text': 'Recently, bosutinib was found to strongly inhibit SARS-CoV-2 in vitro with low toxicity.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 62,\n",
              "   'span_end': 70,\n",
              "   'text': 'Recently, it was reported that pseudoephedrine can antagonize COVID-19 virus by blocking virus expansion.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV2',\n",
              "   'span_start': 59,\n",
              "   'span_end': 68,\n",
              "   'text': 'Another example is that ponatinib is a potent inhibitor of SARS-CoV2-induced cytokine storm, whereas epinephrine may be considered an intervention to minimize the severity of COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 175,\n",
              "   'span_end': 183,\n",
              "   'text': 'Another example is that ponatinib is a potent inhibitor of SARS-CoV2-induced cytokine storm, whereas epinephrine may be considered an intervention to minimize the severity of COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 65,\n",
              "   'span_end': 68,\n",
              "   'text': 'We measured the associations of gene expression patterns between CoV-infected patients and the reference-compound-perturbed cells.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 0,\n",
              "   'span_end': 8,\n",
              "   'text': 'COVID-19 clinical trial drugs are used as ground truth.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 227,\n",
              "   'span_end': 247,\n",
              "   'text': 'Our method has the highest area under the curve AUC of 0.61 compared with the results calculated by the CMAP method based on similarity analysis of expression profiles, which was frequently used in drug repositioning using two SARS-CoV-2 infection expression profiles C.Network analysis methods such as deep learning, network diffusion, and network proximity can evaluate the accessibility of drugs to SARS-CoV-2 in the background network.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 402,\n",
              "   'span_end': 412,\n",
              "   'text': 'Our method has the highest area under the curve AUC of 0.61 compared with the results calculated by the CMAP method based on similarity analysis of expression profiles, which was frequently used in drug repositioning using two SARS-CoV-2 infection expression profiles C.Network analysis methods such as deep learning, network diffusion, and network proximity can evaluate the accessibility of drugs to SARS-CoV-2 in the background network.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 45,\n",
              "   'span_end': 55,\n",
              "   'text': 'For example, SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is identified as a proviral gene in our study.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 96,\n",
              "   'span_end': 106,\n",
              "   'text': 'Although which class of drugs, i.e., agonists or antagonists of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is responsible for the replication activity of SARS-CoV-2 remains to be verified by more experiments, the latest evidence revealed that knockout or knockdown of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein could cause significant reductions in SARS-CoV-2 replication.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 163,\n",
              "   'span_end': 173,\n",
              "   'text': 'Although which class of drugs, i.e., agonists or antagonists of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is responsible for the replication activity of SARS-CoV-2 remains to be verified by more experiments, the latest evidence revealed that knockout or knockdown of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein could cause significant reductions in SARS-CoV-2 replication.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 309,\n",
              "   'span_end': 319,\n",
              "   'text': 'Although which class of drugs, i.e., agonists or antagonists of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is responsible for the replication activity of SARS-CoV-2 remains to be verified by more experiments, the latest evidence revealed that knockout or knockdown of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein could cause significant reductions in SARS-CoV-2 replication.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 366,\n",
              "   'span_end': 376,\n",
              "   'text': 'Although which class of drugs, i.e., agonists or antagonists of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is responsible for the replication activity of SARS-CoV-2 remains to be verified by more experiments, the latest evidence revealed that knockout or knockdown of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein could cause significant reductions in SARS-CoV-2 replication.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 129,\n",
              "   'span_end': 139,\n",
              "   'text': 'Furthermore, a clinical trial demonstrated that the antidepressant fluvoxamine, an antagonist of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, could prevent clinical deterioration in adult outpatients infected with SARS-CoV-2 A. However, there are network-based approaches to select SIGMAR1, the target of the NSP6 SARS-CoV-2 protein agonists, such as amitriptyline, as a potential treatment for COVID-19, implying confliction and limitation may largely exist among current methods.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 221,\n",
              "   'span_end': 231,\n",
              "   'text': 'Furthermore, a clinical trial demonstrated that the antidepressant fluvoxamine, an antagonist of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, could prevent clinical deterioration in adult outpatients infected with SARS-CoV-2 A. However, there are network-based approaches to select SIGMAR1, the target of the NSP6 SARS-CoV-2 protein agonists, such as amitriptyline, as a potential treatment for COVID-19, implying confliction and limitation may largely exist among current methods.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 321,\n",
              "   'span_end': 331,\n",
              "   'text': 'Furthermore, a clinical trial demonstrated that the antidepressant fluvoxamine, an antagonist of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, could prevent clinical deterioration in adult outpatients infected with SARS-CoV-2 A. However, there are network-based approaches to select SIGMAR1, the target of the NSP6 SARS-CoV-2 protein agonists, such as amitriptyline, as a potential treatment for COVID-19, implying confliction and limitation may largely exist among current methods.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 402,\n",
              "   'span_end': 410,\n",
              "   'text': 'Furthermore, a clinical trial demonstrated that the antidepressant fluvoxamine, an antagonist of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, could prevent clinical deterioration in adult outpatients infected with SARS-CoV-2 A. However, there are network-based approaches to select SIGMAR1, the target of the NSP6 SARS-CoV-2 protein agonists, such as amitriptyline, as a potential treatment for COVID-19, implying confliction and limitation may largely exist among current methods.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 126,\n",
              "   'span_end': 134,\n",
              "   'text': 'There are four clinical trials of cannabidiol CBD, a member of the cannabinoid class of natural products for the treatment of COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 141,\n",
              "   'span_end': 151,\n",
              "   'text': 'Studies have shown that cannabidiol CBD, a member of the cannabinoid class of natural products can inhibit the cell entry and replication of SARS-CoV-2.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 267,\n",
              "   'span_end': 275,\n",
              "   'text': 'The anti-inflammatory and antioxidant effects of cannabidiol CBD, a member of the cannabinoid class of natural products may make cannabidiol CBD, a member of the cannabinoid class of natural products a treatment for coronary heart disease and diabetes, together with COVID-19 B. Estradiol cypionate EC is an estrogen medication used in hormone therapy for menopausal symptoms and low estrogen levels in cis women.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 56,\n",
              "   'span_end': 64,\n",
              "   'text': 'The analysis of electronic health records of over 68000 COVID-19 patients revealed that estrogen therapy is associated with more than 50% reduction in mortality.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 43,\n",
              "   'span_end': 51,\n",
              "   'text': 'Estradiol cypionate EC was repositioned as COVID-19 treatment in other studies and is now in phase 2 clinical trial.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 85,\n",
              "   'span_end': 89,\n",
              "   'text': \"To this end, we comprehensively identified host genes and host genes's directions to CoVs by systematically integrating multi-omics data from mass spectrometry, CRISPR screening, and GWAS.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 33,\n",
              "   'span_end': 43,\n",
              "   'text': 'We identified 964 host genes for SARS-CoV-2, 477 host genes for SARS-CoV, 236 host genes for MERS-CoV, and 1410 unique genes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 64,\n",
              "   'span_end': 72,\n",
              "   'text': 'We identified 964 host genes for SARS-CoV-2, 477 host genes for SARS-CoV, 236 host genes for MERS-CoV, and 1410 unique genes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 93,\n",
              "   'span_end': 101,\n",
              "   'text': 'We identified 964 host genes for SARS-CoV-2, 477 host genes for SARS-CoV, 236 host genes for MERS-CoV, and 1410 unique genes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 41,\n",
              "   'span_end': 51,\n",
              "   'text': \"There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 56,\n",
              "   'span_end': 64,\n",
              "   'text': \"There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 78,\n",
              "   'span_end': 88,\n",
              "   'text': \"There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 93,\n",
              "   'span_end': 101,\n",
              "   'text': \"There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 150,\n",
              "   'span_end': 160,\n",
              "   'text': \"There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 181,\n",
              "   'span_end': 189,\n",
              "   'text': \"There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 102,\n",
              "   'span_end': 110,\n",
              "   'text': 'Twenty-nine of the top 100 prioritized drugs are FDA approved, including seven in clinical trials for COVID-19.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 36,\n",
              "   'span_end': 46,\n",
              "   'text': 'We found that CBD not only inhibits SARS-CoV-2 but may also act as a therapeutic drug for coronary heart disease and diabetes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 66,\n",
              "   'span_end': 70,\n",
              "   'text': \"Overall, we first comprehensively characterized the host genes of CoVs and the host genes of CoVs's role in viral infection.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 93,\n",
              "   'span_end': 97,\n",
              "   'text': \"Overall, we first comprehensively characterized the host genes of CoVs and the host genes of CoVs's role in viral infection.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 49,\n",
              "   'span_end': 52,\n",
              "   'text': 'The effects of these host genes we identified on CoV need to be validated in in vivo and in vitro experiments.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 14,\n",
              "   'span_end': 22,\n",
              "   'text': 'Besides, many COVID-19 drug repositioning studies, including our study, have used clinical trial datasets as ground truth for performance evaluation.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 45,\n",
              "   'span_end': 48,\n",
              "   'text': 'Finally, to infer the direction of a drug to CoV in each drug-gene s -CoVs path, we used a random walk algorithm and then combined multiple drug paths for prioritization.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoVs',\n",
              "   'span_start': 69,\n",
              "   'span_end': 74,\n",
              "   'text': 'Finally, to infer the direction of a drug to CoV in each drug-gene s -CoVs path, we used a random walk algorithm and then combined multiple drug paths for prioritization.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 10,\n",
              "   'span_end': 20,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 60,\n",
              "   'span_end': 68,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 73,\n",
              "   'span_end': 81,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 87,\n",
              "   'span_end': 97,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 147,\n",
              "   'span_end': 155,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV.',\n",
              "   'span_start': 160,\n",
              "   'span_end': 169,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 266,\n",
              "   'span_end': 270,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 314,\n",
              "   'span_end': 318,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 50,\n",
              "   'span_end': 58,\n",
              "   'text': 'We first retrieved all risk SNP p-value < 5e-8 in COVID-19 GWAS from GRASP COVID-19 data.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 75,\n",
              "   'span_end': 83,\n",
              "   'text': 'We first retrieved all risk SNP p-value < 5e-8 in COVID-19 GWAS from GRASP COVID-19 data.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 37,\n",
              "   'span_end': 45,\n",
              "   'text': 'Then, all risk SNP p-value < 5e-8 in COVID-19 GWAS were annotated as coding variants and non-coding variants by VEP.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 25,\n",
              "   'span_end': 33,\n",
              "   'text': 'When a variant is both a COVID-19 risk variant and an eQTL, the associated expression gene is identified as the target gene of a variant.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 41,\n",
              "   'span_end': 45,\n",
              "   'text': 'We collected host genes interacting with CoVs from four PPI databases, including BioGRID, IntAct, STRING.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 63,\n",
              "   'span_end': 67,\n",
              "   'text': 'We also included high-confidence proteins that interacted with CoVs from three AP-MS experiments.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 48,\n",
              "   'span_end': 51,\n",
              "   'text': 'In addition, we also included the host genes of CoV collected by Zhou, Y. et al. However, there is no information on the direction of host genes to CoV in these datasets.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 148,\n",
              "   'span_end': 151,\n",
              "   'text': 'In addition, we also included the host genes of CoV collected by Zhou, Y. et al. However, there is no information on the direction of host genes to CoV in these datasets.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 51,\n",
              "   'span_end': 55,\n",
              "   'text': 'We got differentially expressed genes of all three CoVs by analyzing corresponding gene expression profiles from the NCBI Gene Expression Omnibus.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 92,\n",
              "   'span_end': 96,\n",
              "   'text': \"We construct a directed virus-host network by combining all gene-virus pairs from all three CoVs and all gene-virus pairs from the three sources's directions.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 119,\n",
              "   'span_end': 123,\n",
              "   'text': 'By integrating the directional networks described above, we can identify the potential repositioning of known drugs on CoVs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoVs',\n",
              "   'span_start': 40,\n",
              "   'span_end': 45,\n",
              "   'text': 'We searched the appropriate drug-gene s -CoVs paths for each compound.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoVs',\n",
              "   'span_start': 102,\n",
              "   'span_end': 107,\n",
              "   'text': 'Then, we inspected the accessibility of each drug to host genes and assembled directional drug-gene s -CoVs paths.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 270,\n",
              "   'span_end': 274,\n",
              "   'text': 'Since all the interactions in networks were labeled with directions encoded as 1 and -1 for positive effect and negative effect, respectively, we multiply directions encoded as 1 and -1 for positive effect and negative effect, respectively to infer the drug’s effect on CoVs.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 41,\n",
              "   'span_end': 44,\n",
              "   'text': 'Drugs that have a negative impact on the CoV are considered a potential repositioning, and the proviral drugs were removed.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 136,\n",
              "   'span_end': 144,\n",
              "   'text': \"Then we predicted disease-associated genes and disease-associated genes's directions of effect on diseases by the same approach linking COVID-19 risk SNPs to genes.\"},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoV',\n",
              "   'span_start': 37,\n",
              "   'span_end': 41,\n",
              "   'text': 'A drug may have multiple drug-gene s -CoV paths.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoV',\n",
              "   'span_start': 21,\n",
              "   'span_end': 25,\n",
              "   'text': 'For each Drug-Gene s -CoV path, we assigned a DGV score, which equals the accumulation of drug target score, mapping score, and host gene score.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infected',\n",
              "   'span_start': 36,\n",
              "   'span_end': 55,\n",
              "   'text': 'We used gene expression profiles of SARS-CoV-2 infected samples and a control group from alveolar type II cells and African green monkey kidney cells.'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 67,\n",
              "   'span_end': 75,\n",
              "   'text': 'We take as ground truth all drugs currently in clinical trials for COVID-19.'}]]"
            ]
          },
          "metadata": {},
          "execution_count": 35
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-22_articles_0-10_covid_ents_only_plus_text_web_sm_dict_1157.pickle', 'wb') as f:\n",
        "   pickle.dump(covid_ents_only, f)"
      ],
      "metadata": {
        "id": "wj7xMWrwtA9Z"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## 6. Postprocessing\n",
        "\n",
        "We will add article_id as a key to the entity_list originally extracted by the API for all 10 articles."
      ],
      "metadata": {
        "id": "_u8HC_zx9wvK"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# load dataset with article_id column\n",
        "with open('2024-03-24_pmc_arxiv_full_sent_text_spacy_fastcoref_sent_tok_0_10_df.pickle', 'rb') as f:\n",
        "    coref_sent_tok_0_10_df = pickle.load(f)"
      ],
      "metadata": {
        "id": "A3acfjui-PCL"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "coref_sent_tok_0_10_df.article_id.head(10)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "O-lD7obp-0yK",
        "outputId": "9aed1eba-2967-46c5-b18f-d8b6c039dd6e"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "0    PMC9549161\n",
              "1    PMC9539342\n",
              "2    PMC9357751\n",
              "3    PMC9346052\n",
              "4    PMC9775208\n",
              "5    PMC9527439\n",
              "6    PMC9729590\n",
              "7    PMC9236981\n",
              "8    PMC9694939\n",
              "9    PMC9556799\n",
              "Name: article_id, dtype: object"
            ]
          },
          "metadata": {},
          "execution_count": 10
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# load entity_list extracted by the API for 10 articles\n",
        "with open('2024-03-26_kazu_entity_list_coref_sent_tok_0_10_df.pickle', 'rb') as f:\n",
        "    entity_list = pickle.load(f)"
      ],
      "metadata": {
        "id": "WcVTHDQilTJ4"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(entity_list)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "lUqiSxBSpOPC",
        "outputId": "6dc0ba45-7724-4789-a67e-b6bc8a8e5a89"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "10"
            ]
          },
          "metadata": {},
          "execution_count": 11
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Define function to add article_id to entity_list for all sentences."
      ],
      "metadata": {
        "id": "kcbSQHb2C4sC"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def add_article_id_all(entity_list, df):\n",
        "    modified_sents_list = []\n",
        "    for i, article_data in enumerate(entity_list):\n",
        "        article_id = df.iloc[i]['article_id']\n",
        "        modified_article_data = []  # Initialise modified data for the current article\n",
        "        for sentence in article_data:\n",
        "            sentence[0]['article_id'] = article_id\n",
        "            modified_article_data.append(sentence[0])\n",
        "        modified_sents_list.append(modified_article_data)\n",
        "    return modified_sents_list"
      ],
      "metadata": {
        "id": "474pE3z7Qn_v"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "all_sents_article_id = add_article_id_all(entity_list, coref_sent_tok_0_10_df)"
      ],
      "metadata": {
        "id": "vN4wK990V26l"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(all_sents_article_id)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ek8zUiLTV5ku",
        "outputId": "570d1b21-5c46-439a-9002-debd4e2ce97a"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "10"
            ]
          },
          "metadata": {},
          "execution_count": 44
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-19_articles_0-10_all_kazu_sents_article_id.pickle', 'wb') as f:\n",
        "   pickle.dump(all_sents_article_id, f)"
      ],
      "metadata": {
        "id": "esMIjjYeYaLs"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will define a function to return a list of dictionaries with text, idx and article_id for all sentences, and entity_id, entity_type, entity, and spans where available."
      ],
      "metadata": {
        "id": "6K12H5pQlDUs"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def get_parsed_sents_kazu(entity_list):\n",
        "    parsed_sents_nested = []  # Initialise an empty list to store nested lists of sentences for each article\n",
        "    for article in entity_list:\n",
        "        article_id = article[0].get('article_id')  # Get the article_id\n",
        "        parsed_sents = []  # Initialise an empty list to store sentences for the current article\n",
        "        for item in article:\n",
        "            section = item.get('sections', [{}])[0]  # Accessing the first section, or an empty dictionary if no sections exist\n",
        "            entities = section.get('entities', [])  # Accessing the 'entities' list inside 'sections'\n",
        "            if not entities:  # If no entities found in the section, append the sentence without entity details\n",
        "                parsed_sents.append({\n",
        "                    'entity_id': None,\n",
        "                    'entity_type': None,\n",
        "                    'entity': None,\n",
        "                    'span_start': None,\n",
        "                    'span_end': None,\n",
        "                    'text': section.get('text'),\n",
        "                    'idx': item.get('idx'),\n",
        "                    'article_id': article_id\n",
        "                })\n",
        "            else:\n",
        "                for entity in entities:\n",
        "                    if 'mappings' in entity:  # Checking if 'mappings' key exists\n",
        "                        entity_id = entity['mappings'][0]['idx']  # Accessing the 'idx' value from the first element of 'mappings' list\n",
        "                    else:\n",
        "                        entity_id = entity.get('match')\n",
        "                    spans_list = entity.get('spans', [])  # Accessing the 'spans' list from the entity dictionary\n",
        "                    span_start = spans_list[0].get('start') if spans_list else None\n",
        "                    span_end = spans_list[0].get('end') if spans_list else None\n",
        "                    parsed_sents.append({\n",
        "                        'entity_id': entity_id,\n",
        "                        'entity_type': entity.get('entity_class'),\n",
        "                        'entity': entity.get('match'),\n",
        "                        'span_start': span_start,\n",
        "                        'span_end': span_end,\n",
        "                        'text': section.get('text'),  # Accessing the 'text' value inside 'sections'\n",
        "                        'idx': item.get('idx'),\n",
        "                        'article_id': article_id\n",
        "                    })\n",
        "        parsed_sents_nested.append(parsed_sents)  # Append the list of sentences for the current article to the nested list\n",
        "    return parsed_sents_nested"
      ],
      "metadata": {
        "id": "NPDVDZ_9lLMZ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "parsed_sents_nested = get_parsed_sents_kazu(all_sents_article_id)"
      ],
      "metadata": {
        "id": "2Vrv0JV7lblY"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(parsed_sents_nested)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "qiyDp8nQlhXc",
        "outputId": "75620c91-25cf-4ac5-ffff-6b3a1de55b19"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "10"
            ]
          },
          "metadata": {},
          "execution_count": 62
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-19_articles_0-10_kazu_all_parsed_sents_nested.pickle', 'wb') as f:\n",
        "   pickle.dump(parsed_sents_nested, f)"
      ],
      "metadata": {
        "id": "oFnRYEjAl_Jy"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will flatten the nested list of dictionaries and create a DataFrame for all sentences in the dataset."
      ],
      "metadata": {
        "id": "cOOZ8dHiy3-B"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Flatten the nested list of dictionaries\n",
        "flattened_list = [item for sublist in parsed_sents_nested for item in sublist]"
      ],
      "metadata": {
        "id": "j5OfpcOmyB_Y"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Create a DataFrame from the flattened list\n",
        "kazu_all_sents_df = pd.DataFrame(flattened_list)"
      ],
      "metadata": {
        "id": "7fGDFDwcyFWO"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_all_sents_df"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "WANZavdNyYKF",
        "outputId": "310fd94c-ca0e-4dcc-f2d2-51a40abe952d"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                         entity_id entity_type  \\\n",
              "0                                             None        None   \n",
              "1                                             None        None   \n",
              "2                                             None        None   \n",
              "3                                             None        None   \n",
              "4                                             None        None   \n",
              "...                                            ...         ...   \n",
              "4553             African green monkey kidney cells   cell_type   \n",
              "4554                                          None        None   \n",
              "4555  http://purl.obolibrary.org/obo/MONDO_0100096     disease   \n",
              "4556                                          None        None   \n",
              "4557                                          None        None   \n",
              "\n",
              "                                 entity  span_start  span_end  \\\n",
              "0                                  None         NaN       NaN   \n",
              "1                                  None         NaN       NaN   \n",
              "2                                  None         NaN       NaN   \n",
              "3                                  None         NaN       NaN   \n",
              "4                                  None         NaN       NaN   \n",
              "...                                 ...         ...       ...   \n",
              "4553  African green monkey kidney cells       116.0     149.0   \n",
              "4554                               None         NaN       NaN   \n",
              "4555                           COVID-19        67.0      75.0   \n",
              "4556                               None         NaN       NaN   \n",
              "4557                               None         NaN       NaN   \n",
              "\n",
              "                                                   text  \\\n",
              "0     Sir James Black, a winner of the 1988 Nobel Pr...   \n",
              "1     In 2004, Ted T. Ashburn et al. summarized prev...   \n",
              "2     molecules that are waiting for approval for ne...   \n",
              "3     The definition of the term drug repurposing ha...   \n",
              "4     It should be pointed out that the synonyms of ...   \n",
              "...                                                 ...   \n",
              "4553  We used gene expression profiles of SARS-CoV-2...   \n",
              "4554  We input the top-50 up- and downregulated gene...   \n",
              "4555  We take as ground truth all drugs currently in...   \n",
              "4556  Then we computed the receiver operating charac...   \n",
              "4557  Functional enrichment analysis was conducted u...   \n",
              "\n",
              "                                   idx  article_id  \n",
              "0     9fac46a65c684e9cb308f8056b185981  PMC9549161  \n",
              "1     52630635919f4fc09eed777af5df84cd  PMC9549161  \n",
              "2     dac90fc1831b4b84a654152c8bb6b60a  PMC9549161  \n",
              "3     5414c43c91a64d44845916fad4efc2fc  PMC9549161  \n",
              "4     27742cffa2c54fc49702f702c306630a  PMC9549161  \n",
              "...                                ...         ...  \n",
              "4553  a04c0a5ddb544b91a90c308a89e267d9  PMC9556799  \n",
              "4554  6fe83ef06b55422a8319ee57eb628c91  PMC9556799  \n",
              "4555  af85dcd07def41358eaa7a59139350c1  PMC9556799  \n",
              "4556  6b6a938cf2af46149b1a6583b47e58bb  PMC9556799  \n",
              "4557  a93658c2517e4614a39f2e87ac805ab2  PMC9556799  \n",
              "\n",
              "[4558 rows x 8 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-38a9cf09-0b75-44ba-a364-cc794f913d8b\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>entity_id</th>\n",
              "      <th>entity_type</th>\n",
              "      <th>entity</th>\n",
              "      <th>span_start</th>\n",
              "      <th>span_end</th>\n",
              "      <th>text</th>\n",
              "      <th>idx</th>\n",
              "      <th>article_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Sir James Black, a winner of the 1988 Nobel Pr...</td>\n",
              "      <td>9fac46a65c684e9cb308f8056b185981</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>In 2004, Ted T. Ashburn et al. summarized prev...</td>\n",
              "      <td>52630635919f4fc09eed777af5df84cd</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>molecules that are waiting for approval for ne...</td>\n",
              "      <td>dac90fc1831b4b84a654152c8bb6b60a</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>The definition of the term drug repurposing ha...</td>\n",
              "      <td>5414c43c91a64d44845916fad4efc2fc</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>It should be pointed out that the synonyms of ...</td>\n",
              "      <td>27742cffa2c54fc49702f702c306630a</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4553</th>\n",
              "      <td>African green monkey kidney cells</td>\n",
              "      <td>cell_type</td>\n",
              "      <td>African green monkey kidney cells</td>\n",
              "      <td>116.0</td>\n",
              "      <td>149.0</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4554</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>We input the top-50 up- and downregulated gene...</td>\n",
              "      <td>6fe83ef06b55422a8319ee57eb628c91</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4555</th>\n",
              "      <td>http://purl.obolibrary.org/obo/MONDO_0100096</td>\n",
              "      <td>disease</td>\n",
              "      <td>COVID-19</td>\n",
              "      <td>67.0</td>\n",
              "      <td>75.0</td>\n",
              "      <td>We take as ground truth all drugs currently in...</td>\n",
              "      <td>af85dcd07def41358eaa7a59139350c1</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4556</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Then we computed the receiver operating charac...</td>\n",
              "      <td>6b6a938cf2af46149b1a6583b47e58bb</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4557</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Functional enrichment analysis was conducted u...</td>\n",
              "      <td>a93658c2517e4614a39f2e87ac805ab2</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>4558 rows × 8 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-38a9cf09-0b75-44ba-a364-cc794f913d8b')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-38a9cf09-0b75-44ba-a364-cc794f913d8b button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-38a9cf09-0b75-44ba-a364-cc794f913d8b');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-682adbcb-d97b-45b8-9092-b7e2750b2c28\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-682adbcb-d97b-45b8-9092-b7e2750b2c28')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-682adbcb-d97b-45b8-9092-b7e2750b2c28 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "kazu_all_sents_df",
              "summary": "{\n  \"name\": \"kazu_all_sents_df\",\n  \"rows\": 4558,\n  \"fields\": [\n    {\n      \"column\": \"entity_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 957,\n        \"samples\": [\n          \"CAII\",\n          \"C1\",\n          \"CHEMBL3545185\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity_type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 11,\n        \"samples\": [\n          \"cell_line\",\n          \"drug\",\n          \"go_bp\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1063,\n        \"samples\": [\n          \"SARS-CoV-\",\n          \"Non-structural protein 5 coding\",\n          \"variance\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_start\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 105.48817510194746,\n        \"min\": 0.0,\n        \"max\": 954.0,\n        \"num_unique_values\": 445,\n        \"samples\": [\n          302.0,\n          150.0,\n          82.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_end\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 105.64685799581633,\n        \"min\": 2.0,\n        \"max\": 967.0,\n        \"num_unique_values\": 440,\n        \"samples\": [\n          455.0,\n          224.0,\n          190.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 2344,\n        \"samples\": [\n          \"GNNs were used to model the ability of the drugs to target proteins and proteins's interaction.\",\n          \"Identification of direct-acting and host-targeting antivirals Drug repurposing also has applications in the identification of existing antivirals that are either direct-acting or host-targeting.\",\n          \"However, 6M71/Sofosbuvir has the same evolution to NSP-12 of SARS-CoV-2.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"idx\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 2350,\n        \"samples\": [\n          \"e14817e50d8d4c5da985f0f66e388dc2\",\n          \"aaa8e99f359847adaca3c17f6e09d9f1\",\n          \"20a86461e6474b06a6730206e3c9bd48\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"article_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 10,\n        \"samples\": [\n          \"PMC9694939\",\n          \"PMC9539342\",\n          \"PMC9527439\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 82
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_all_sents_df.info()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "1dS2D40S3msV",
        "outputId": "9afc569d-6363-4919-c4e1-ebf2a97308e5"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "RangeIndex: 4558 entries, 0 to 4557\n",
            "Data columns (total 8 columns):\n",
            " #   Column       Non-Null Count  Dtype  \n",
            "---  ------       --------------  -----  \n",
            " 0   entity_id    3389 non-null   object \n",
            " 1   entity_type  3389 non-null   object \n",
            " 2   entity       3389 non-null   object \n",
            " 3   span_start   3389 non-null   float64\n",
            " 4   span_end     3389 non-null   float64\n",
            " 5   text         4558 non-null   object \n",
            " 6   idx          4558 non-null   object \n",
            " 7   article_id   4558 non-null   object \n",
            "dtypes: float64(2), object(6)\n",
            "memory usage: 285.0+ KB\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Spans have been converted to floats instead of integers due to the fact that `NaN` values are floats and you cannot have these in an `int` column. We will convert the span_start and span_end columns into [nullable integer data types](https://pandas.pydata.org/pandas-docs/stable/user_guide/integer_na.html)."
      ],
      "metadata": {
        "id": "_D3gw9piGYnc"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Convert 'span_start' and 'span_end' columns to nullable integer type\n",
        "kazu_all_sents_df['span_start'] = kazu_all_sents_df['span_start'].astype('Int64')\n",
        "kazu_all_sents_df['span_end'] = kazu_all_sents_df['span_end'].astype('Int64')"
      ],
      "metadata": {
        "id": "mmg66yuB2OoC"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_all_sents_df.info()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "fde5da7a-d44a-43d3-a23a-39e6be8299fa",
        "id": "WRzJ2jv0K4n2"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "RangeIndex: 4558 entries, 0 to 4557\n",
            "Data columns (total 8 columns):\n",
            " #   Column       Non-Null Count  Dtype \n",
            "---  ------       --------------  ----- \n",
            " 0   entity_id    3389 non-null   object\n",
            " 1   entity_type  3389 non-null   object\n",
            " 2   entity       3389 non-null   object\n",
            " 3   span_start   3389 non-null   Int64 \n",
            " 4   span_end     3389 non-null   Int64 \n",
            " 5   text         4558 non-null   object\n",
            " 6   idx          4558 non-null   object\n",
            " 7   article_id   4558 non-null   object\n",
            "dtypes: Int64(2), object(6)\n",
            "memory usage: 293.9+ KB\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_all_sents_df"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "xz8AFq2Y6aWx",
        "outputId": "e42f4950-082d-4e90-d8fd-b3ca4e83a653"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                         entity_id entity_type  \\\n",
              "0                                             None        None   \n",
              "1                                             None        None   \n",
              "2                                             None        None   \n",
              "3                                             None        None   \n",
              "4                                             None        None   \n",
              "...                                            ...         ...   \n",
              "4553             African green monkey kidney cells   cell_type   \n",
              "4554                                          None        None   \n",
              "4555  http://purl.obolibrary.org/obo/MONDO_0100096     disease   \n",
              "4556                                          None        None   \n",
              "4557                                          None        None   \n",
              "\n",
              "                                 entity  span_start  span_end  \\\n",
              "0                                  None        <NA>      <NA>   \n",
              "1                                  None        <NA>      <NA>   \n",
              "2                                  None        <NA>      <NA>   \n",
              "3                                  None        <NA>      <NA>   \n",
              "4                                  None        <NA>      <NA>   \n",
              "...                                 ...         ...       ...   \n",
              "4553  African green monkey kidney cells         116       149   \n",
              "4554                               None        <NA>      <NA>   \n",
              "4555                           COVID-19          67        75   \n",
              "4556                               None        <NA>      <NA>   \n",
              "4557                               None        <NA>      <NA>   \n",
              "\n",
              "                                                   text  \\\n",
              "0     Sir James Black, a winner of the 1988 Nobel Pr...   \n",
              "1     In 2004, Ted T. Ashburn et al. summarized prev...   \n",
              "2     molecules that are waiting for approval for ne...   \n",
              "3     The definition of the term drug repurposing ha...   \n",
              "4     It should be pointed out that the synonyms of ...   \n",
              "...                                                 ...   \n",
              "4553  We used gene expression profiles of SARS-CoV-2...   \n",
              "4554  We input the top-50 up- and downregulated gene...   \n",
              "4555  We take as ground truth all drugs currently in...   \n",
              "4556  Then we computed the receiver operating charac...   \n",
              "4557  Functional enrichment analysis was conducted u...   \n",
              "\n",
              "                                   idx  article_id  \n",
              "0     9fac46a65c684e9cb308f8056b185981  PMC9549161  \n",
              "1     52630635919f4fc09eed777af5df84cd  PMC9549161  \n",
              "2     dac90fc1831b4b84a654152c8bb6b60a  PMC9549161  \n",
              "3     5414c43c91a64d44845916fad4efc2fc  PMC9549161  \n",
              "4     27742cffa2c54fc49702f702c306630a  PMC9549161  \n",
              "...                                ...         ...  \n",
              "4553  a04c0a5ddb544b91a90c308a89e267d9  PMC9556799  \n",
              "4554  6fe83ef06b55422a8319ee57eb628c91  PMC9556799  \n",
              "4555  af85dcd07def41358eaa7a59139350c1  PMC9556799  \n",
              "4556  6b6a938cf2af46149b1a6583b47e58bb  PMC9556799  \n",
              "4557  a93658c2517e4614a39f2e87ac805ab2  PMC9556799  \n",
              "\n",
              "[4558 rows x 8 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-94035e27-4a2a-42df-89f2-d63cc74ee5f8\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>entity_id</th>\n",
              "      <th>entity_type</th>\n",
              "      <th>entity</th>\n",
              "      <th>span_start</th>\n",
              "      <th>span_end</th>\n",
              "      <th>text</th>\n",
              "      <th>idx</th>\n",
              "      <th>article_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>Sir James Black, a winner of the 1988 Nobel Pr...</td>\n",
              "      <td>9fac46a65c684e9cb308f8056b185981</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>In 2004, Ted T. Ashburn et al. summarized prev...</td>\n",
              "      <td>52630635919f4fc09eed777af5df84cd</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>molecules that are waiting for approval for ne...</td>\n",
              "      <td>dac90fc1831b4b84a654152c8bb6b60a</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>The definition of the term drug repurposing ha...</td>\n",
              "      <td>5414c43c91a64d44845916fad4efc2fc</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>It should be pointed out that the synonyms of ...</td>\n",
              "      <td>27742cffa2c54fc49702f702c306630a</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4553</th>\n",
              "      <td>African green monkey kidney cells</td>\n",
              "      <td>cell_type</td>\n",
              "      <td>African green monkey kidney cells</td>\n",
              "      <td>116</td>\n",
              "      <td>149</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4554</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>We input the top-50 up- and downregulated gene...</td>\n",
              "      <td>6fe83ef06b55422a8319ee57eb628c91</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4555</th>\n",
              "      <td>http://purl.obolibrary.org/obo/MONDO_0100096</td>\n",
              "      <td>disease</td>\n",
              "      <td>COVID-19</td>\n",
              "      <td>67</td>\n",
              "      <td>75</td>\n",
              "      <td>We take as ground truth all drugs currently in...</td>\n",
              "      <td>af85dcd07def41358eaa7a59139350c1</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4556</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>Then we computed the receiver operating charac...</td>\n",
              "      <td>6b6a938cf2af46149b1a6583b47e58bb</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4557</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>Functional enrichment analysis was conducted u...</td>\n",
              "      <td>a93658c2517e4614a39f2e87ac805ab2</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>4558 rows × 8 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-94035e27-4a2a-42df-89f2-d63cc74ee5f8')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-94035e27-4a2a-42df-89f2-d63cc74ee5f8 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-94035e27-4a2a-42df-89f2-d63cc74ee5f8');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-02ede664-3df7-4d74-9e8f-86427f9e9472\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-02ede664-3df7-4d74-9e8f-86427f9e9472')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-02ede664-3df7-4d74-9e8f-86427f9e9472 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "kazu_all_sents_df",
              "summary": "{\n  \"name\": \"kazu_all_sents_df\",\n  \"rows\": 4558,\n  \"fields\": [\n    {\n      \"column\": \"entity_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 957,\n        \"samples\": [\n          \"CAII\",\n          \"C1\",\n          \"CHEMBL3545185\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity_type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 11,\n        \"samples\": [\n          \"cell_line\",\n          \"drug\",\n          \"go_bp\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1063,\n        \"samples\": [\n          \"SARS-CoV-\",\n          \"Non-structural protein 5 coding\",\n          \"variance\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_start\",\n      \"properties\": {\n        \"dtype\": \"Int64\",\n        \"num_unique_values\": 445,\n        \"samples\": [\n          302,\n          150,\n          82\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_end\",\n      \"properties\": {\n        \"dtype\": \"Int64\",\n        \"num_unique_values\": 440,\n        \"samples\": [\n          455,\n          224,\n          190\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 2344,\n        \"samples\": [\n          \"GNNs were used to model the ability of the drugs to target proteins and proteins's interaction.\",\n          \"Identification of direct-acting and host-targeting antivirals Drug repurposing also has applications in the identification of existing antivirals that are either direct-acting or host-targeting.\",\n          \"However, 6M71/Sofosbuvir has the same evolution to NSP-12 of SARS-CoV-2.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"idx\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 2350,\n        \"samples\": [\n          \"e14817e50d8d4c5da985f0f66e388dc2\",\n          \"aaa8e99f359847adaca3c17f6e09d9f1\",\n          \"20a86461e6474b06a6730206e3c9bd48\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"article_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 10,\n        \"samples\": [\n          \"PMC9694939\",\n          \"PMC9539342\",\n          \"PMC9527439\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 90
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-19_articles_0-10_kazu_all_sents_4558_df.pickle', 'wb') as f:\n",
        "   pickle.dump(kazu_all_sents_df, f)"
      ],
      "metadata": {
        "id": "tmkFXxoT6nYY"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will define a function to update the list of dictionaries of COVID entities by adding 'article_id' and 'idx' keys."
      ],
      "metadata": {
        "id": "ZhVfBCS2JDbz"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# load COVID entities only dataset\n",
        "with open('2024-04-22_articles_0-10_covid_ents_only_plus_text_web_sm_dict_1157.pickle', 'rb') as f:\n",
        "   covid_ents_only = pickle.load(f)"
      ],
      "metadata": {
        "id": "4bJrKSH9uZw0"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# load parsed sentences dataset for all 10 articles\n",
        "with open('2024-04-19_articles_0-10_kazu_all_parsed_sents_nested.pickle', 'rb') as f:\n",
        "   parsed_sents_nested = pickle.load(f)"
      ],
      "metadata": {
        "id": "V3sJifXcuZw0"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def match_and_append_idx(first_data, second_data):\n",
        "    # Initialise a dictionary to store text and idx mappings from the second dataset\n",
        "    text_idx_map = {item['text']: {'idx': item['idx'], 'article_id': item['article_id']} for sublist in second_data for item in sublist}\n",
        "\n",
        "    # Iterate through the first dataset and match text with idx from the second dataset\n",
        "    for sublist in first_data:\n",
        "        for item in sublist:\n",
        "            text = item['text']\n",
        "            if text in text_idx_map:\n",
        "                matched_item = text_idx_map[text]\n",
        "                item['idx'] = matched_item['idx']\n",
        "                item['article_id'] = matched_item['article_id']\n",
        "\n",
        "    return first_data"
      ],
      "metadata": {
        "id": "Jy3l9L8iuZw1"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "updated_spacy_data =  match_and_append_idx(covid_ents_only, parsed_sents_nested)"
      ],
      "metadata": {
        "id": "t0j5RtGsuZw1"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(updated_spacy_data)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "4a6c86b1-ebce-46ad-bd35-dfc7b3e62904",
        "id": "labb5b0KuZw2"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "10"
            ]
          },
          "metadata": {},
          "execution_count": 41
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# COVID entities dictionaries updated with idx and article_id\n",
        "updated_spacy_data"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "e5828a00-50ca-437a-99f8-fad6d8e19159",
        "id": "TyAdkfBcuZw3"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[[{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 197,\n",
              "   'span_end': 205,\n",
              "   'text': 'The number of annual publications has been increasing at a relatively high rate since 2015, while in 2020, there was a spike in the number of publications and annual citations, probably due to the COVID-19 pandemic, a global public health emergency that prompted special attention from scientists.',\n",
              "   'idx': '487f27b9fd2446438765e1a7f6a96952',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 59,\n",
              "   'span_end': 67,\n",
              "   'text': 'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "   'idx': 'e8adbb3eb77941f9bd063708854ffb17',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 68,\n",
              "   'span_end': 78,\n",
              "   'text': 'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "   'idx': 'e8adbb3eb77941f9bd063708854ffb17',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 79,\n",
              "   'span_end': 90,\n",
              "   'text': 'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "   'idx': 'e8adbb3eb77941f9bd063708854ffb17',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 96,\n",
              "   'span_end': 104,\n",
              "   'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "   'idx': '650b870a0f1e4bd089a385567180c322',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 105,\n",
              "   'span_end': 115,\n",
              "   'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "   'idx': '650b870a0f1e4bd089a385567180c322',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 116,\n",
              "   'span_end': 127,\n",
              "   'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "   'idx': '650b870a0f1e4bd089a385567180c322',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 168,\n",
              "   'span_end': 176,\n",
              "   'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "   'idx': '650b870a0f1e4bd089a385567180c322',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 177,\n",
              "   'span_end': 187,\n",
              "   'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "   'idx': '650b870a0f1e4bd089a385567180c322',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 188,\n",
              "   'span_end': 199,\n",
              "   'text': 'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "   'idx': '650b870a0f1e4bd089a385567180c322',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 73,\n",
              "   'span_end': 81,\n",
              "   'text': 'Molecular docking is one of the core steps of virtual screening, and the COVID-19 pandemic generated many opportunities for the practice of drug repositioning.',\n",
              "   'idx': '0c09a88aad3840288fef26e9cbe164d2',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 48,\n",
              "   'span_end': 56,\n",
              "   'text': 'Therefore, high-quality studies of the keywords COVID-19/SARS-CoV-2/Coronavirus, Virtual screening, and Molecular docking were surveyed, as shown in the bubble chart, in the past two years, reflecting the relevant research trend in recent years.',\n",
              "   'idx': '94a7fda0918a47c5a1b783a3cfae6ba8',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 57,\n",
              "   'span_end': 67,\n",
              "   'text': 'Therefore, high-quality studies of the keywords COVID-19/SARS-CoV-2/Coronavirus, Virtual screening, and Molecular docking were surveyed, as shown in the bubble chart, in the past two years, reflecting the relevant research trend in recent years.',\n",
              "   'idx': '94a7fda0918a47c5a1b783a3cfae6ba8',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 68,\n",
              "   'span_end': 79,\n",
              "   'text': 'Therefore, high-quality studies of the keywords COVID-19/SARS-CoV-2/Coronavirus, Virtual screening, and Molecular docking were surveyed, as shown in the bubble chart, in the past two years, reflecting the relevant research trend in recent years.',\n",
              "   'idx': '94a7fda0918a47c5a1b783a3cfae6ba8',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 108,\n",
              "   'span_end': 118,\n",
              "   'text': 'In a virtual screening process, Gervasoni, S. conducted a literature search for molecular binding sites for SARS-CoV-2-associated protein targets while combining pocket and docking searches to propose a new pocket mapping strategy that identifies binding cavities with significantly better performance than pocket detection alone.',\n",
              "   'idx': 'f17048e74d3e4c09af52d098d5a1b8ac',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 243,\n",
              "   'span_end': 254,\n",
              "   'text': 'After a series of drug repurposing computational screens and various validation activities by several scientists, it was agreed that raltegravir, clonidine, chloroquine and hydroxychloroquine have therapeutic effects in the treatment of novel coronavirus.',\n",
              "   'idx': '3ccb2d93d4d44115888b46c5d6d052a5',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus pneumonia',\n",
              "   'span_start': 309,\n",
              "   'span_end': 330,\n",
              "   'text': 'All hot research topics were published in 2020, and with the exception of an article describing the damage caused by nonsteroidal anti-inflammatory drugs NSAIDs to multiple organs and new information on drug repurposing, the remaining studies focused on drug repositioning therapeutic target studies in novel coronavirus pneumonia, screening drug studies, reviews of clinical trials, and reports of other coronavirus therapeutic agents and vaccine studies.',\n",
              "   'idx': '4fdd1052f46e4bbf9028d14f00806461',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 405,\n",
              "   'span_end': 416,\n",
              "   'text': 'All hot research topics were published in 2020, and with the exception of an article describing the damage caused by nonsteroidal anti-inflammatory drugs NSAIDs to multiple organs and new information on drug repurposing, the remaining studies focused on drug repositioning therapeutic target studies in novel coronavirus pneumonia, screening drug studies, reviews of clinical trials, and reports of other coronavirus therapeutic agents and vaccine studies.',\n",
              "   'idx': '4fdd1052f46e4bbf9028d14f00806461',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 15,\n",
              "   'span_end': 25,\n",
              "   'text': 'In addition, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, published in Nature by Gordon, DE with a total of 125 scholars from the United States, the United Kingdom, and France was the most cited publication with 952 citations.',\n",
              "   'idx': '02e40d8c09754950a7f5ccee671d7e73',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '2019-nCoV',\n",
              "   'span_start': 103,\n",
              "   'span_end': 112,\n",
              "   'text': 'The most cited publication on an annual basis was Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, published in 2020, which was authored by Zhou, YD et al. and was the highest annual average cited publication with 609 citations.',\n",
              "   'idx': 'e209de13a90e44c5990670ec180364ad',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 113,\n",
              "   'span_end': 123,\n",
              "   'text': 'The most cited publication on an annual basis was Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, published in 2020, which was authored by Zhou, YD et al. and was the highest annual average cited publication with 609 citations.',\n",
              "   'idx': 'e209de13a90e44c5990670ec180364ad',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 51,\n",
              "   'span_end': 62,\n",
              "   'text': 'The three studies published in 2020 focus on novel coronavirus-related drug rediscovery activities and the use of deep learning techniques. and Pushpakom, S et al. provided systematic reviews of the methods and challenges of drug repositioning at that time.',\n",
              "   'idx': 'f3db3b57bba4428aba44326f07663f46',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 143,\n",
              "   'span_end': 154,\n",
              "   'text': \"The reasons for this may be the following first, there was a breakthrough in basic research in biophysics in 2020 and second, due to the novel coronavirus, research in this direction has increased research in this direction's application for the prevention and control of the pandemic.\",\n",
              "   'idx': '8bd030dbc91f468e937d0524b23c3b23',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 282,\n",
              "   'span_end': 295,\n",
              "   'text': 'In terms of antiviral drugs, scholars not only use drug repositioning to find antiviral drugs to treat diseases, such as Ebola and HIV, that have plagued humans for a long time but also use drug repositioning to seek treatments for infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world.',\n",
              "   'idx': '2920a306fb83418ea876b251bf4bc1c6',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 54,\n",
              "   'span_end': 67,\n",
              "   'text': 'For infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world, emergency research on drug repositioning has played an important role in reducing mortality, calming patient fears, and restoring economic production when no specific drugs or vaccines were initially available during the pandemic.',\n",
              "   'idx': 'cbaf65f1f4904a53b529e0fd1698ea84',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 82,\n",
              "   'span_end': 95,\n",
              "   'text': 'In fact, some of the studies in the list of highly cited research topics on novel coronaviruses drug repurposing studies are currently approaching 3000 citations on Google Scholar.',\n",
              "   'idx': 'a8ed8bf9b05c44c29c1ee8be0c469f22',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 80,\n",
              "   'span_end': 93,\n",
              "   'text': 'The percentage of highly cited studies and hot research topics related to novel coronaviruses is also a good indication that drug repositioning has made an indelible contribution to the study of novel coronaviruses and similar infectious diseases.',\n",
              "   'idx': '80e8fc6eb2704cfb876c2d8e0d658f0f',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 201,\n",
              "   'span_end': 214,\n",
              "   'text': 'The percentage of highly cited studies and hot research topics related to novel coronaviruses is also a good indication that drug repositioning has made an indelible contribution to the study of novel coronaviruses and similar infectious diseases.',\n",
              "   'idx': '80e8fc6eb2704cfb876c2d8e0d658f0f',\n",
              "   'article_id': 'PMC9549161'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 79,\n",
              "   'span_end': 90,\n",
              "   'text': 'The authors’ keyword analysis suggests that research in the field of the novel coronavirus will remain valuable until the associated pandemic is completely contained.',\n",
              "   'idx': '42e5eb11a05a4984ad48ead1dbc69a3d',\n",
              "   'article_id': 'PMC9549161'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 115,\n",
              "   'span_end': 123,\n",
              "   'text': 'Most importantly, recent studies have illuminated the potential roles of CADD in designing new drug candidates for COVID‐19 treatment.',\n",
              "   'idx': '793e96203b02441d9db7570ef5cfa4c0',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviruses',\n",
              "   'span_start': 0,\n",
              "   'span_end': 13,\n",
              "   'text': 'Coronaviruses CoVs are cross‐species viruses and can spread expeditiously into new host species, which in turn cause epidemic diseases.',\n",
              "   'idx': 'a2b0d114820a43f1b8fa8b59ec292c27',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 14,\n",
              "   'span_end': 18,\n",
              "   'text': 'Coronaviruses CoVs are cross‐species viruses and can spread expeditiously into new host species, which in turn cause epidemic diseases.',\n",
              "   'idx': 'a2b0d114820a43f1b8fa8b59ec292c27',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 25,\n",
              "   'span_end': 28,\n",
              "   'text': 'The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.',\n",
              "   'idx': 'bd9245f5ba33424dbb63df6d033cdd05',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome CoV',\n",
              "   'span_start': 76,\n",
              "   'span_end': 113,\n",
              "   'text': 'The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.',\n",
              "   'idx': 'bd9245f5ba33424dbb63df6d033cdd05',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV',\n",
              "   'span_start': 114,\n",
              "   'span_end': 122,\n",
              "   'text': 'The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.',\n",
              "   'idx': 'bd9245f5ba33424dbb63df6d033cdd05',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 160,\n",
              "   'span_end': 163,\n",
              "   'text': 'The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.',\n",
              "   'idx': 'bd9245f5ba33424dbb63df6d033cdd05',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS‐CoV',\n",
              "   'span_start': 164,\n",
              "   'span_end': 172,\n",
              "   'text': 'The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.',\n",
              "   'idx': 'bd9245f5ba33424dbb63df6d033cdd05',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 220,\n",
              "   'span_end': 224,\n",
              "   'text': 'The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.',\n",
              "   'idx': 'bd9245f5ba33424dbb63df6d033cdd05',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 8,\n",
              "   'span_end': 11,\n",
              "   'text': 'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "   'idx': 'c454a81ded04447ebde54c179558ba86',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 27,\n",
              "   'span_end': 35,\n",
              "   'text': 'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "   'idx': 'c454a81ded04447ebde54c179558ba86',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 50,\n",
              "   'span_end': 60,\n",
              "   'text': 'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "   'idx': 'c454a81ded04447ebde54c179558ba86',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome CoV',\n",
              "   'span_start': 104,\n",
              "   'span_end': 141,\n",
              "   'text': 'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "   'idx': 'c454a81ded04447ebde54c179558ba86',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV',\n",
              "   'span_start': 142,\n",
              "   'span_end': 150,\n",
              "   'text': 'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "   'idx': 'c454a81ded04447ebde54c179558ba86',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 248,\n",
              "   'span_end': 258,\n",
              "   'text': 'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "   'idx': 'c454a81ded04447ebde54c179558ba86',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 302,\n",
              "   'span_end': 313,\n",
              "   'text': 'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "   'idx': 'c454a81ded04447ebde54c179558ba86',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 23,\n",
              "   'span_end': 33,\n",
              "   'text': 'Since the outgrowth of SARS‐CoV‐2, more than 528 million people have been infected with up to 6.3 million deaths, as reported by the Food and Drug Administration.',\n",
              "   'idx': '4ffe52752edf4b03bec03a4ffe6cf3b2',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 55,\n",
              "   'span_end': 63,\n",
              "   'text': \"Although effective vaccines have amazingly reduced the COVID‐19 cases recently, effective vaccines will not change the world right away, and importantly, effective vaccines's permanent efficacy, short‐term and long‐term side effects, and long‐term protection against different variants of SARS‐CoV‐2 are still under debate.\",\n",
              "   'idx': '706accd9816a45ba88fcb8993a41e0de',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 289,\n",
              "   'span_end': 299,\n",
              "   'text': \"Although effective vaccines have amazingly reduced the COVID‐19 cases recently, effective vaccines will not change the world right away, and importantly, effective vaccines's permanent efficacy, short‐term and long‐term side effects, and long‐term protection against different variants of SARS‐CoV‐2 are still under debate.\",\n",
              "   'idx': '706accd9816a45ba88fcb8993a41e0de',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 168,\n",
              "   'span_end': 179,\n",
              "   'text': 'These issues are accompanied by mass vaccination campaigns Wen et al. Furthermore, several studies have reported that vaccinated people can also be infected with novel coronavirus variants Largent & Miller.',\n",
              "   'idx': 'f7b4f38f2a2248868800e219608b82c6',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 117,\n",
              "   'span_end': 127,\n",
              "   'text': 'Therefore, the design and introduction of new drugs, either the current drugs or synthesized agents, for eradicating SARS‐CoV‐2 is of extreme concern.',\n",
              "   'idx': '82bd7af63cbe4dd0bc5b94593ddd179c',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 145,\n",
              "   'span_end': 153,\n",
              "   'text': \"By assessing some antiviral drugs with previously known treatment of hepatitis, HIV, influenza, and Ebola viral diseases's effectiveness against COVID‐19, remdesivir was the one that grabbed much attention and is believed to be the most successful drug for the therapy for combating COVID‐19 Brown et al., Gholivand et al. Further potential macromolecular targets of SARS‐CoV‐2 are depicted in Figure.\",\n",
              "   'idx': 'b07dba5cf115429695875e89412b70b2',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 283,\n",
              "   'span_end': 291,\n",
              "   'text': \"By assessing some antiviral drugs with previously known treatment of hepatitis, HIV, influenza, and Ebola viral diseases's effectiveness against COVID‐19, remdesivir was the one that grabbed much attention and is believed to be the most successful drug for the therapy for combating COVID‐19 Brown et al., Gholivand et al. Further potential macromolecular targets of SARS‐CoV‐2 are depicted in Figure.\",\n",
              "   'idx': 'b07dba5cf115429695875e89412b70b2',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 367,\n",
              "   'span_end': 377,\n",
              "   'text': \"By assessing some antiviral drugs with previously known treatment of hepatitis, HIV, influenza, and Ebola viral diseases's effectiveness against COVID‐19, remdesivir was the one that grabbed much attention and is believed to be the most successful drug for the therapy for combating COVID‐19 Brown et al., Gholivand et al. Further potential macromolecular targets of SARS‐CoV‐2 are depicted in Figure.\",\n",
              "   'idx': 'b07dba5cf115429695875e89412b70b2',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 45,\n",
              "   'span_end': 55,\n",
              "   'text': 'Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.',\n",
              "   'idx': '59462b7cce1a4957a3383873b16ad88e',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 298,\n",
              "   'span_end': 308,\n",
              "   'text': 'Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.',\n",
              "   'idx': '59462b7cce1a4957a3383873b16ad88e',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 427,\n",
              "   'span_end': 435,\n",
              "   'text': 'Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.',\n",
              "   'idx': '59462b7cce1a4957a3383873b16ad88e',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 540,\n",
              "   'span_end': 550,\n",
              "   'text': 'Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.',\n",
              "   'idx': '59462b7cce1a4957a3383873b16ad88e',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 745,\n",
              "   'span_end': 753,\n",
              "   'text': 'Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.',\n",
              "   'idx': '59462b7cce1a4957a3383873b16ad88e',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 80,\n",
              "   'span_end': 90,\n",
              "   'text': 'Vangeel et al. molnupiravir and remdesivir acted on the RdRp enzyme employed by SARS‐CoV‐2 to increase the transcription and replication capability of the viral RNA genome.',\n",
              "   'idx': '59583e32c32c4e70972b7d0677e4f1b2',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 58,\n",
              "   'span_end': 66,\n",
              "   'text': 'Our focus in this paper is to explore the role of CADD on COVID‐19 most specifically, chemogenomics and DR, with potential examples of COVID‐19 drug discovery. Unfortunately, with boundless energy and time to discover a successful small molecule by utilizing various databases to inhibit the main protease Mpro of SARS‐CoV‐2 via several virtual screening VS approaches, there are no effective drugs that have been approved.',\n",
              "   'idx': 'c867186bd57246a7882da50214221a9a',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 135,\n",
              "   'span_end': 143,\n",
              "   'text': 'Our focus in this paper is to explore the role of CADD on COVID‐19 most specifically, chemogenomics and DR, with potential examples of COVID‐19 drug discovery. Unfortunately, with boundless energy and time to discover a successful small molecule by utilizing various databases to inhibit the main protease Mpro of SARS‐CoV‐2 via several virtual screening VS approaches, there are no effective drugs that have been approved.',\n",
              "   'idx': 'c867186bd57246a7882da50214221a9a',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 314,\n",
              "   'span_end': 324,\n",
              "   'text': 'Our focus in this paper is to explore the role of CADD on COVID‐19 most specifically, chemogenomics and DR, with potential examples of COVID‐19 drug discovery. Unfortunately, with boundless energy and time to discover a successful small molecule by utilizing various databases to inhibit the main protease Mpro of SARS‐CoV‐2 via several virtual screening VS approaches, there are no effective drugs that have been approved.',\n",
              "   'idx': 'c867186bd57246a7882da50214221a9a',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 148,\n",
              "   'span_end': 158,\n",
              "   'text': \"Only safety protocols such as wearing face masks, face shields, social distancing, and washing hands frequently are the best approaches to minimize SARS‐CoV‐2's danger and prevent transmission.\",\n",
              "   'idx': '609533bbdcc848638f7c9aa0460255a0',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 74,\n",
              "   'span_end': 82,\n",
              "   'text': 'Basically, the process of bringing an FDA‐approved medicine to market for COVID‐19 drug discovery is extremely challenging, starting from the initial research of scientists for target identification and lead compound generation.',\n",
              "   'idx': '75c006f8f2764f3c9b78936345335bc4',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 175,\n",
              "   'span_end': 183,\n",
              "   'text': 'After lead discovery and development of drug‐like candidates and investigation of in vitro and in vivo results, the process of bringing an FDA‐approved medicine to market for COVID‐19 drug discovery will go into three phases, i.e., preclinical and, if successful, into clinical studies, and ultimately a marketed medicine after FDA approval Schaduangrat et al. It is where CADD is evolved as a valuable and powerful method to aid the challenging tasks of identifying small bioactive molecules and predicting targets.',\n",
              "   'idx': '0cabee7cec6e42539e48e4d00708f229',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 21,\n",
              "   'span_end': 29,\n",
              "   'text': 'In the first days of COVID‐19 outbreak, vHTS was employed and developed efficiently to investigate a group of approved drugs to identify the possible anti‐SARS‐CoV‐2 agents at the National Center for Advancing Translational Sciences NCATS of the National Institutes of Health NIH, embracing a broad spectrum of the SARS‐CoV‐2 life cycle, such as viral entry, viral replication, in vitro infectivity, and live virus infectivity Xu et al. Many possible drug candidates were selected for targeting various stages of the SARS‐CoV‐2 life cycle.',\n",
              "   'idx': '617ac057bfc44ee5929905f9dd59b0dd',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'anti‐SARS‐CoV‐2',\n",
              "   'span_start': 150,\n",
              "   'span_end': 165,\n",
              "   'text': 'In the first days of COVID‐19 outbreak, vHTS was employed and developed efficiently to investigate a group of approved drugs to identify the possible anti‐SARS‐CoV‐2 agents at the National Center for Advancing Translational Sciences NCATS of the National Institutes of Health NIH, embracing a broad spectrum of the SARS‐CoV‐2 life cycle, such as viral entry, viral replication, in vitro infectivity, and live virus infectivity Xu et al. Many possible drug candidates were selected for targeting various stages of the SARS‐CoV‐2 life cycle.',\n",
              "   'idx': '617ac057bfc44ee5929905f9dd59b0dd',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 315,\n",
              "   'span_end': 325,\n",
              "   'text': 'In the first days of COVID‐19 outbreak, vHTS was employed and developed efficiently to investigate a group of approved drugs to identify the possible anti‐SARS‐CoV‐2 agents at the National Center for Advancing Translational Sciences NCATS of the National Institutes of Health NIH, embracing a broad spectrum of the SARS‐CoV‐2 life cycle, such as viral entry, viral replication, in vitro infectivity, and live virus infectivity Xu et al. Many possible drug candidates were selected for targeting various stages of the SARS‐CoV‐2 life cycle.',\n",
              "   'idx': '617ac057bfc44ee5929905f9dd59b0dd',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 517,\n",
              "   'span_end': 527,\n",
              "   'text': 'In the first days of COVID‐19 outbreak, vHTS was employed and developed efficiently to investigate a group of approved drugs to identify the possible anti‐SARS‐CoV‐2 agents at the National Center for Advancing Translational Sciences NCATS of the National Institutes of Health NIH, embracing a broad spectrum of the SARS‐CoV‐2 life cycle, such as viral entry, viral replication, in vitro infectivity, and live virus infectivity Xu et al. Many possible drug candidates were selected for targeting various stages of the SARS‐CoV‐2 life cycle.',\n",
              "   'idx': '617ac057bfc44ee5929905f9dd59b0dd',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 128,\n",
              "   'span_end': 138,\n",
              "   'text': 'For instance, cepharanthine, an anti‐inflammatory compound, effectively showed ability to rescue the cytopathic effects CPEs of SARS‐CoV‐2 Rogosnitzky et al., or corilagin, a possible antifibrosis, revealed potential against the angiotensin‐converting enzyme ACE2 receptor‐binding domain RBD Yang et al. Therefore, it is urgent to This strategy a high bio‐safety SARS‐CoV‐2 infection model with a high ability for HTS of drugs against SARS‐CoV‐2.',\n",
              "   'idx': 'd5f5ba0ccdde4e998308072bccd19147',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 363,\n",
              "   'span_end': 373,\n",
              "   'text': 'For instance, cepharanthine, an anti‐inflammatory compound, effectively showed ability to rescue the cytopathic effects CPEs of SARS‐CoV‐2 Rogosnitzky et al., or corilagin, a possible antifibrosis, revealed potential against the angiotensin‐converting enzyme ACE2 receptor‐binding domain RBD Yang et al. Therefore, it is urgent to This strategy a high bio‐safety SARS‐CoV‐2 infection model with a high ability for HTS of drugs against SARS‐CoV‐2.',\n",
              "   'idx': 'd5f5ba0ccdde4e998308072bccd19147',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 435,\n",
              "   'span_end': 445,\n",
              "   'text': 'For instance, cepharanthine, an anti‐inflammatory compound, effectively showed ability to rescue the cytopathic effects CPEs of SARS‐CoV‐2 Rogosnitzky et al., or corilagin, a possible antifibrosis, revealed potential against the angiotensin‐converting enzyme ACE2 receptor‐binding domain RBD Yang et al. Therefore, it is urgent to This strategy a high bio‐safety SARS‐CoV‐2 infection model with a high ability for HTS of drugs against SARS‐CoV‐2.',\n",
              "   'idx': 'd5f5ba0ccdde4e998308072bccd19147',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 313,\n",
              "   'span_end': 323,\n",
              "   'text': \"After computing molecular descriptors, machine learning techniques play indispensable roles in the quality of QSAR predictions Popelier & Smith, Rad & Maghsoudi, Sliwoski et al. Using machine learning and QSAR, Muratov et al. identified 32 drugs and 32 drugs's 73 selected binary combinations for testing against SARS‐CoV‐2.\",\n",
              "   'idx': 'e70dcb51b0664a85bf17e79cadebde1a',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 153,\n",
              "   'span_end': 163,\n",
              "   'text': 'Muratov et al. found that the combinations of four of 32 drugs, including nitazoxanide, remdesivir, amodiaquine, and umifenovir, could synergize against SARS‐CoV‐2.',\n",
              "   'idx': '20f96f51b42843c49cc24cd38a8fff9d',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 204,\n",
              "   'span_end': 214,\n",
              "   'text': 'Interestingly, the combination of nitazoxanide and remdesivir showed a great synergistic interaction, and the combination of remdesivir and hydroxychloroquine exhibited a powerful antagonist role against SARS‐CoV‐2 Bobrowski et al. The two proteins pp1a and pp1ab are quickly translated after entry into the host cells and further separated by two viral proteases, 3 C‐like proteases 3CLpro and papain‐like protease PLpro Amin et al. papain‐like protease PLpro is a critical virus enzyme responsible for producing a functional replicase complex and stimulating viral spread Shin et al. Amin et al used chemical‐informatics approaches to build a Monte Carlo optimization based on a QSAR data of various papain‐like protease PLpro inhibitors, b VS to choose the best in‐house molecules among 67 with the high likelihood of targeting against papain‐like protease PLpro, and c eventually verification of these inhibitors by using receptor–ligand interaction investigation.',\n",
              "   'idx': 'd4d822414e24466fa30d224412c1eddc',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 83,\n",
              "   'span_end': 93,\n",
              "   'text': 'Furthermore, molecular docking has proved the potentiality of 13 compounds against SARS‐CoV‐2 PLpro.',\n",
              "   'idx': '00b171b214dc46a2bf9b143b2ea6aa4d',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 484,\n",
              "   'span_end': 494,\n",
              "   'text': 'The National Center for Advancing Translational Sciences NCATS analyzed 11 of 42 inhibitors which were potential compounds, and three of 11 of total 42 hits which were potential compounds, cenicriviroc AC50 of 8.9 M, proglumetacin tested twice independently, with AC50 of 8.9 M and 12.5 M, and sufugolix AC50 12.6 M. While molecular docking was unsuccessful to accurately distinguish between experimentally active and inactive compounds, QSAR was able to identify three inhibitors of SARS‐CoV‐2 replication through Mpro inhibition.',\n",
              "   'idx': 'a079810a06ac4ec299cd0263e11799a1',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 60,\n",
              "   'span_end': 70,\n",
              "   'text': 'Overall, these results show that QSAR models proposed using SARS‐CoV‐2 Mpro data can be useful to introduce compounds active against SARS‐CoV‐2 Alves et al. This strategy relies more on target information.',\n",
              "   'idx': '818e0411377f4748aafe81556c32e6b0',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 133,\n",
              "   'span_end': 143,\n",
              "   'text': 'Overall, these results show that QSAR models proposed using SARS‐CoV‐2 Mpro data can be useful to introduce compounds active against SARS‐CoV‐2 Alves et al. This strategy relies more on target information.',\n",
              "   'idx': '818e0411377f4748aafe81556c32e6b0',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 403,\n",
              "   'span_end': 413,\n",
              "   'text': 'In other words, docking enables us to identify novel drug candidates by predicting ligand–target interactions at a molecular level Pinzi & Rastelli, Sargazi et al. There are several references in which the significant role and applications of docking in drug design and development have been discussed De Vivo & Cavalli, Keretsu et al., Kitchen et al., Meng et al. Furthermore, in the current spread of SARS‐CoV‐2, molecular docking is important in screening potential drugs Keretsu et al., Lokhande et al., Marinho et al., Yu et al. The recent work of Khelfaoui et al. could be a good example of using molecular docking combined with MD to find promising candidate drugs against COVID‐19.',\n",
              "   'idx': 'a660801db86a4393b2bd4a1b7e6c6d1e',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 680,\n",
              "   'span_end': 688,\n",
              "   'text': 'In other words, docking enables us to identify novel drug candidates by predicting ligand–target interactions at a molecular level Pinzi & Rastelli, Sargazi et al. There are several references in which the significant role and applications of docking in drug design and development have been discussed De Vivo & Cavalli, Keretsu et al., Kitchen et al., Meng et al. Furthermore, in the current spread of SARS‐CoV‐2, molecular docking is important in screening potential drugs Keretsu et al., Lokhande et al., Marinho et al., Yu et al. The recent work of Khelfaoui et al. could be a good example of using molecular docking combined with MD to find promising candidate drugs against COVID‐19.',\n",
              "   'idx': 'a660801db86a4393b2bd4a1b7e6c6d1e',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 171,\n",
              "   'span_end': 181,\n",
              "   'text': 'Khelfaoui et al. selected a library of 18 drugs that three of which include ramipril, delapril, and lisinopril, bound to angiotensin‐converting enzyme 2 ACE2 receptor and SARS‐CoV‐2/ACE2 complex well.',\n",
              "   'idx': '61ab092db64c4297a9a853bef4d87f47',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 119,\n",
              "   'span_end': 132,\n",
              "   'text': 'angiotensin‐converting enzyme 2 ACE2 receptor is one of the receptors in the human body with which the S proteins from coronaviruses have a great binding affinity and serve as the entry point into cells for SARS‐CoV‐2.',\n",
              "   'idx': '3e06be9d7bc443969a9a5c7d8930147e',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 207,\n",
              "   'span_end': 217,\n",
              "   'text': 'angiotensin‐converting enzyme 2 ACE2 receptor is one of the receptors in the human body with which the S proteins from coronaviruses have a great binding affinity and serve as the entry point into cells for SARS‐CoV‐2.',\n",
              "   'idx': '3e06be9d7bc443969a9a5c7d8930147e',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 155,\n",
              "   'span_end': 163,\n",
              "   'text': 'In fact, due to the long time required to discover specific antiviral agents or a vaccine, the best strategy would be to repurpose existing drugs to treat COVID‐19, which will be discussed in the DR section.',\n",
              "   'idx': '23dd49ed11a94a70b8ce62856f732716',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐main',\n",
              "   'span_start': 152,\n",
              "   'span_end': 165,\n",
              "   'text': 'In order to identify the most potential drug–target interactions, a molecular operating environment MOE program was carried out against the human ACE2, SARS‐CoV‐main peptidase, serine protease hepsin, human coronavirus papain‐like proteases, and SARS‐Coronavirus NSP12.',\n",
              "   'idx': '93cc950e234a4fe286eb5a7c2f7ea558',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 207,\n",
              "   'span_end': 218,\n",
              "   'text': 'In order to identify the most potential drug–target interactions, a molecular operating environment MOE program was carried out against the human ACE2, SARS‐CoV‐main peptidase, serine protease hepsin, human coronavirus papain‐like proteases, and SARS‐Coronavirus NSP12.',\n",
              "   'idx': '93cc950e234a4fe286eb5a7c2f7ea558',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐Coronavirus',\n",
              "   'span_start': 246,\n",
              "   'span_end': 262,\n",
              "   'text': 'In order to identify the most potential drug–target interactions, a molecular operating environment MOE program was carried out against the human ACE2, SARS‐CoV‐main peptidase, serine protease hepsin, human coronavirus papain‐like proteases, and SARS‐Coronavirus NSP12.',\n",
              "   'idx': '93cc950e234a4fe286eb5a7c2f7ea558',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 117,\n",
              "   'span_end': 127,\n",
              "   'text': 'Thus, compound d needs to be additionally evaluated in clinical trials as a candidate for potential inhibitor of the SARS‐CoV‐2 Abdellatiif et al. Hosseini et al. evaluated a virtual screening using docking of 1615 FDA‐approved drugs to identify novel potential inhibitors for protease protein of COVID‐19.',\n",
              "   'idx': 'ea0b807c2495430581ba691471fe9f86',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 297,\n",
              "   'span_end': 305,\n",
              "   'text': 'Thus, compound d needs to be additionally evaluated in clinical trials as a candidate for potential inhibitor of the SARS‐CoV‐2 Abdellatiif et al. Hosseini et al. evaluated a virtual screening using docking of 1615 FDA‐approved drugs to identify novel potential inhibitors for protease protein of COVID‐19.',\n",
              "   'idx': 'ea0b807c2495430581ba691471fe9f86',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 111,\n",
              "   'span_end': 119,\n",
              "   'text': 'This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.',\n",
              "   'idx': 'd4a4e37935804d2f9b336fea1f44f445',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 235,\n",
              "   'span_end': 245,\n",
              "   'text': 'This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.',\n",
              "   'idx': 'd4a4e37935804d2f9b336fea1f44f445',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐3CL',\n",
              "   'span_start': 271,\n",
              "   'span_end': 279,\n",
              "   'text': 'This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.',\n",
              "   'idx': 'd4a4e37935804d2f9b336fea1f44f445',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐Co',\n",
              "   'span_start': 678,\n",
              "   'span_end': 685,\n",
              "   'text': 'This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.',\n",
              "   'idx': 'd4a4e37935804d2f9b336fea1f44f445',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 690,\n",
              "   'span_end': 700,\n",
              "   'text': 'This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.',\n",
              "   'idx': 'd4a4e37935804d2f9b336fea1f44f445',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 116,\n",
              "   'span_end': 124,\n",
              "   'text': 'Although many studies are carried out and many drugs are being tested to open a new road for effective treatment of COVID‐19, there are no fully beneficial antiviral drugs against COVID‐19.',\n",
              "   'idx': 'aae4557a93c643a696be33755ffa71d1',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 180,\n",
              "   'span_end': 188,\n",
              "   'text': 'Although many studies are carried out and many drugs are being tested to open a new road for effective treatment of COVID‐19, there are no fully beneficial antiviral drugs against COVID‐19.',\n",
              "   'idx': 'aae4557a93c643a696be33755ffa71d1',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 216,\n",
              "   'span_end': 224,\n",
              "   'text': 'The ultimate goal of chemogenomics is the rapid screening as well as the rational development of target‐specific chemical ligands to decrease the cost and enhance the drug discovery period, especially in the case of COVID‐19 drug investigation Jones & Bunnage.',\n",
              "   'idx': 'd86c14b963cd496a9e9a914438fdeb18',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 325,\n",
              "   'span_end': 335,\n",
              "   'text': \"Nevertheless, no existing target data thus, by applying the chemogenomics strategy, the hypotheses can be generated of the target by comparing the new biological compounds to the same known target Fourches et al., Weston et al. For example, the target receptors or proteins that are necessary for replication and survival of SARS‐CoV‐2 are viral proteases involving papain‐like protease PLpro, the 3‐chymotrypsin‐like protease 3CLpro, and Mpro, RNA‐dependent RNA polymerase RdRp complex, the spike S receptor binding glycoprotein, the nucleocapsid N protein, nonstructural protein NSP, and the membrane M protein including transmembrane TM as well as small envelope E protein Cavasotto et al. As an example of this part, it can be referred to the work of Mishra and Mishra's coworkers that reported an inclusive computational approach for the identification of drug molecules that are multi‐targeted struggling with the SARS‐CoV‐2 proteins.\",\n",
              "   'idx': 'ec81828a85b1403d9e47cabd4af24a5e',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 920,\n",
              "   'span_end': 930,\n",
              "   'text': \"Nevertheless, no existing target data thus, by applying the chemogenomics strategy, the hypotheses can be generated of the target by comparing the new biological compounds to the same known target Fourches et al., Weston et al. For example, the target receptors or proteins that are necessary for replication and survival of SARS‐CoV‐2 are viral proteases involving papain‐like protease PLpro, the 3‐chymotrypsin‐like protease 3CLpro, and Mpro, RNA‐dependent RNA polymerase RdRp complex, the spike S receptor binding glycoprotein, the nucleocapsid N protein, nonstructural protein NSP, and the membrane M protein including transmembrane TM as well as small envelope E protein Cavasotto et al. As an example of this part, it can be referred to the work of Mishra and Mishra's coworkers that reported an inclusive computational approach for the identification of drug molecules that are multi‐targeted struggling with the SARS‐CoV‐2 proteins.\",\n",
              "   'idx': 'ec81828a85b1403d9e47cabd4af24a5e',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 59,\n",
              "   'span_end': 69,\n",
              "   'text': 'drug molecules that are multi‐targeted struggling with the SARS‐CoV‐2 proteins are essentially included in virus replication inside the host body, the viral–host interaction, disease development, and transmission of SARS‐CoV‐2 infection.',\n",
              "   'idx': '211964ffac114e85908de18821360b51',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 216,\n",
              "   'span_end': 226,\n",
              "   'text': 'drug molecules that are multi‐targeted struggling with the SARS‐CoV‐2 proteins are essentially included in virus replication inside the host body, the viral–host interaction, disease development, and transmission of SARS‐CoV‐2 infection.',\n",
              "   'idx': '211964ffac114e85908de18821360b51',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 324,\n",
              "   'span_end': 334,\n",
              "   'text': \"Mishra and his coworkers's finding showed favorable results for seven drugs, among which catechin flavan‐3‐ol can effectively bind to the 3‐chymotrypsin‐like protease 3CLpro, Cathepsin L, RBD of S protein, nonstructural protein NSP, and the nucleocapsid N protein to be used as a potential multi‐targeted agent in combating SARS‐CoV‐2.\",\n",
              "   'idx': '4cfea5d000674582b7770902c5bd9df2',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 51,\n",
              "   'span_end': 61,\n",
              "   'text': 'However, due to the limited timeframe of combating SARS‐CoV‐2, it is not realistic to be assured of finding a definitive therapy for combating SARS‐CoV‐2.',\n",
              "   'idx': '0ac6142dcf9e49d89943f1e69965fb25',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 143,\n",
              "   'span_end': 153,\n",
              "   'text': 'However, due to the limited timeframe of combating SARS‐CoV‐2, it is not realistic to be assured of finding a definitive therapy for combating SARS‐CoV‐2.',\n",
              "   'idx': '0ac6142dcf9e49d89943f1e69965fb25',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 99,\n",
              "   'span_end': 107,\n",
              "   'text': \"Hence, vigorous attempts are still continuing for the DR as a clinical treatment strategy to fight COVID‐19 Mishra et al. In another research, Omotuyi et al. investigated molecular docking protocols for fast screening of the the FDA database for high‐affinity interaction of the resolved 3D structure of SARS‐CoV‐2 receptor‐binding domain RBD in complex with SARS‐CoV‐2 receptor‐binding domain RBD's receptor hACE‐2 interface.\",\n",
              "   'idx': 'e14435678b8047779eb8abc0fe665467',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 304,\n",
              "   'span_end': 314,\n",
              "   'text': \"Hence, vigorous attempts are still continuing for the DR as a clinical treatment strategy to fight COVID‐19 Mishra et al. In another research, Omotuyi et al. investigated molecular docking protocols for fast screening of the the FDA database for high‐affinity interaction of the resolved 3D structure of SARS‐CoV‐2 receptor‐binding domain RBD in complex with SARS‐CoV‐2 receptor‐binding domain RBD's receptor hACE‐2 interface.\",\n",
              "   'idx': 'e14435678b8047779eb8abc0fe665467',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 359,\n",
              "   'span_end': 369,\n",
              "   'text': \"Hence, vigorous attempts are still continuing for the DR as a clinical treatment strategy to fight COVID‐19 Mishra et al. In another research, Omotuyi et al. investigated molecular docking protocols for fast screening of the the FDA database for high‐affinity interaction of the resolved 3D structure of SARS‐CoV‐2 receptor‐binding domain RBD in complex with SARS‐CoV‐2 receptor‐binding domain RBD's receptor hACE‐2 interface.\",\n",
              "   'idx': 'e14435678b8047779eb8abc0fe665467',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 95,\n",
              "   'span_end': 105,\n",
              "   'text': 'Omotuyi et al. reported that UBR breaks the interaction at the RBD/ACE‐2 interface residues of SARS‐CoV‐2 RBD/ACE‐2 complex that might result in protein function losses with direct inference on the oligomerization in RBD and function loss in ACE‐2.',\n",
              "   'idx': 'e878820cfe0e48faa6bee7d162355eee',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 67,\n",
              "   'span_end': 77,\n",
              "   'text': 'Therefore, UBR exhibits a novel therapeutic candidate in combating SARS‐CoV‐2 since UBR binds to proportionally high affinity with free RBD, ACE‐2 receptor, and SARS‐CoV‐2 RBD/ACE‐2 complex based on only binding affinity calculations Omotuyi et al.. The other studies in this area are demonstrated in Table.',\n",
              "   'idx': 'edb7efe352a74537be85460e1f21058d',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 161,\n",
              "   'span_end': 171,\n",
              "   'text': 'Therefore, UBR exhibits a novel therapeutic candidate in combating SARS‐CoV‐2 since UBR binds to proportionally high affinity with free RBD, ACE‐2 receptor, and SARS‐CoV‐2 RBD/ACE‐2 complex based on only binding affinity calculations Omotuyi et al.. The other studies in this area are demonstrated in Table.',\n",
              "   'idx': 'edb7efe352a74537be85460e1f21058d',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID',\n",
              "   'span_start': 86,\n",
              "   'span_end': 91,\n",
              "   'text': 'Therefore, according to the advantages of these proposed drug discovery methods, many COVID research orientations have been focused on DR Galindez et al., R. Liu et al. Computational DR applies available drugs for new or existing diseases that do not have an absolute cure, while available drugs were not originally designed for the novel disease treatment.',\n",
              "   'idx': 'f88a4f39b06948e6841e316af404a713',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 296,\n",
              "   'span_end': 306,\n",
              "   'text': 'Furthermore, utilizing the enormous volumes of available omics information in digital form in conjunction with in silico screening intrigued the researcher to use this appropriate ground to significantly increase the speed of shortlisting promising candidates in reply to spreading diseases like SARS‐CoV‐2.',\n",
              "   'idx': 'dd62e58bca144da8af997db3cc0fe69a',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 82,\n",
              "   'span_end': 90,\n",
              "   'text': 'Application of a methodology for preclinical computational DR called DrugMerge to COVID‐19 shows that a methodology for preclinical computational DR called DrugMerge can mimic human expert judgment Lucchetta, M. and M. Pellegrini.',\n",
              "   'idx': '9430d1bde7594b579e0d5b1f5a4e6c5b',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 250,\n",
              "   'span_end': 260,\n",
              "   'text': \"Rima Hajjo and Alexander Tropsha's results approved that Bacillus Calmette–Guérin BCG impacted the generation and maturation of naïve T cells, resulting in increasing long‐lasting trained intrinsic immune replies to combat novel viruses, including SARS‐CoV‐2 in vitro as a protective measurement from the lethal consequences Onozuka et al. Due to the lengthy development cycle of novel drugs, DR turns into an efficient approach to screening drugs of potential therapeutic use for SARS‐CoV‐2.\",\n",
              "   'idx': 'f6bb4ae0ad90455b8e063ddc4ee0e5e7',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 483,\n",
              "   'span_end': 493,\n",
              "   'text': \"Rima Hajjo and Alexander Tropsha's results approved that Bacillus Calmette–Guérin BCG impacted the generation and maturation of naïve T cells, resulting in increasing long‐lasting trained intrinsic immune replies to combat novel viruses, including SARS‐CoV‐2 in vitro as a protective measurement from the lethal consequences Onozuka et al. Due to the lengthy development cycle of novel drugs, DR turns into an efficient approach to screening drugs of potential therapeutic use for SARS‐CoV‐2.\",\n",
              "   'idx': 'f6bb4ae0ad90455b8e063ddc4ee0e5e7',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 73,\n",
              "   'span_end': 81,\n",
              "   'text': 'Che et al., in another attempt, screened potential therapeutic drugs for COVID‐19 based on a knowledge‐graph‐based DR method.',\n",
              "   'idx': '91a495ded3304445b144229afc01ab7b',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 120,\n",
              "   'span_end': 130,\n",
              "   'text': 'The experimental outputs prove that the models can predict drug–disease interaction effectively for normal diseases and SARS‐CoV‐2 Lv et al. Therefore, DR presents a constant source of novel knowledge in virus biology and molecules with previously undefined antiviral properties, which can be applied as molecular tools in unknown molecular mechanisms of virus replication and pathogenesis Mercorelli et al. Further investigation of SARS‐CoV‐2 in related research is summarized in Table.',\n",
              "   'idx': 'a0b2fc597ecb47fdb8d3bdb1e9c73801',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 433,\n",
              "   'span_end': 443,\n",
              "   'text': 'The experimental outputs prove that the models can predict drug–disease interaction effectively for normal diseases and SARS‐CoV‐2 Lv et al. Therefore, DR presents a constant source of novel knowledge in virus biology and molecules with previously undefined antiviral properties, which can be applied as molecular tools in unknown molecular mechanisms of virus replication and pathogenesis Mercorelli et al. Further investigation of SARS‐CoV‐2 in related research is summarized in Table.',\n",
              "   'idx': 'a0b2fc597ecb47fdb8d3bdb1e9c73801',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 162,\n",
              "   'span_end': 170,\n",
              "   'text': 'Thai‐Hoang Pham et al. applied a sound learning framework for a high‐throughput mechanism‐driven neural network‐based method for phenotype compound screening for COVID‐19 DR.',\n",
              "   'idx': '4b9bc4c7f1cc4ca88ed78b20df894b76',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 95,\n",
              "   'span_end': 103,\n",
              "   'text': 'Furthermore, Thai‐Hoang Pham et al. showed the value of DeepCE by applying DeepCE to the DR of COVID‐19 and produced novel lead compounds that represented clinical evidence.',\n",
              "   'idx': '4c68e668265741f8a9d44eb4af141a77',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 210,\n",
              "   'span_end': 218,\n",
              "   'text': \"Lee and his coworkers's finding showed that an AI‐DTI, a new method for predicting activation and inhibition of DTIs was a success in discovering about half of the DTIs for drugs that are employed for treating COVID‐19 Lee and his coworkers.\",\n",
              "   'idx': '8e10c7b5b5634b0e926938bc9dd1359a',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 341,\n",
              "   'span_end': 349,\n",
              "   'text': 'A myriad of compounds represent potential drug candidates, but merely a few of potential drug candidates will be formulated, approved, and registered as a drug for individual health issues which investigation for that compound will be a long, intricate, and costly process, while sometimes there is an urgent need for developing a drug like COVID‐19 pandemic Muratov et al. Table demonstrates chemogenomics related to COVID‐19 research.',\n",
              "   'idx': 'cc2e5bfff4984b92962fa659f7b034e4',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 418,\n",
              "   'span_end': 426,\n",
              "   'text': 'A myriad of compounds represent potential drug candidates, but merely a few of potential drug candidates will be formulated, approved, and registered as a drug for individual health issues which investigation for that compound will be a long, intricate, and costly process, while sometimes there is an urgent need for developing a drug like COVID‐19 pandemic Muratov et al. Table demonstrates chemogenomics related to COVID‐19 research.',\n",
              "   'idx': 'cc2e5bfff4984b92962fa659f7b034e4',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 59,\n",
              "   'span_end': 67,\n",
              "   'text': 'Herein, of much current importance is chemogenomics, is in COVID‐19 drug discoveries, which this review paper highlighted specifically.',\n",
              "   'idx': '008b9be8eb6b429180f74d0546813412',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 468,\n",
              "   'span_end': 476,\n",
              "   'text': 'The first is that a drug can bind to various targets simultaneously, which is good for searching novel target sites of action for the known biological agents, and the second is that targets related to a disease are often associated with different biological processes of pathogenesis, which is important for choosing of a new indication for the known target Badary, Kamel et al. These are indispensable in proposing new drug candidates for unprecedented diseases like COVID‐19.',\n",
              "   'idx': 'd1a39f9818fb4e4ea607f1abc58c0be8',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 102,\n",
              "   'span_end': 110,\n",
              "   'text': 'DR has emerged as an alternative way of accelerating the process of developing new treatments against COVID‐19 Yu et al. Based on data brought from PubMed, the number of works of literature on DR has been growing dramatically, and the number of works of literature on DR has increased since the outbreak of SARS‐CoV‐2 Galindez et al. It should be noted that polypharmacolgy and DR are inextricably interrelated with each other Cheng.',\n",
              "   'idx': '36a0bc0e45064e81ab95195bb551cf90',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 307,\n",
              "   'span_end': 317,\n",
              "   'text': 'DR has emerged as an alternative way of accelerating the process of developing new treatments against COVID‐19 Yu et al. Based on data brought from PubMed, the number of works of literature on DR has been growing dramatically, and the number of works of literature on DR has increased since the outbreak of SARS‐CoV‐2 Galindez et al. It should be noted that polypharmacolgy and DR are inextricably interrelated with each other Cheng.',\n",
              "   'idx': '36a0bc0e45064e81ab95195bb551cf90',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 602,\n",
              "   'span_end': 612,\n",
              "   'text': 'In contrast to experimental methods, computational drug repositioning methods which are mainly data‐driven utilizes databases and bioinformatics tools to find out interactions between drugs, targets, and diseases Pillaiyar et al. Analyzing a large type of data like chemical structures, gene expression, genotype or proteomic data, and electronic health records EHRs provides the possibility of understanding novel and unexpected functional gene interactions and unclear drug response or mechanisms of disease Pushpakom et al. Since there is no specific and registered therapy to cure the infection of SARS‐CoV‐2, finding effective therapeutics by applying existing drugs is a pressing exigency and established strategy Galindez et al. Concerning the time‐consuming regulatory process of the newly approved drugs, the DR strategy strongly utilizes the identification of new treatment methods by presenting FDA‐approved drugs.',\n",
              "   'idx': '2576ea8045be4f4fac91fd71cca931ba',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 82,\n",
              "   'span_end': 90,\n",
              "   'text': 'There are myriad reasons why we need to go through DR for different diseases like COVID‐19 if we intend to accelerate the process of developing a new drug.',\n",
              "   'idx': '0ee0e495e3424f42b51f8e4edf8db790',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 489,\n",
              "   'span_end': 497,\n",
              "   'text': \"myriad reasons why we need to go through DR can be i availability of marketed drugs and marketed drugs's excipients and APIs for formulation and distribution, ii the likelihood of taking advantage of a synergistic effect of various drugs with each other, iii cheap and less time‐consuming process for drugs to be marketed and IV emergence of new therapeutic pathways for former drugs and new categories of medicine Chung et al. Therefore, repositioned drugs have very important impacts on COVID‐19 drug discovery.\",\n",
              "   'idx': '034856eb84944c5d8397c00e769f0c13',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 105,\n",
              "   'span_end': 115,\n",
              "   'text': 'Therefore, different categories of drugs are being repositioned in in vivo and in vitro studies to treat SARS‐CoV‐2 Wu et al. different categories of drugs are namely Ebola virus remdesivir, antimalarial chloroquine, anthelmintic and antiprotozoal drugs niclosamide, diarrhea nitazoxanide, antiviral lopinavir and ritonavir, antineoplastic carfilzomib and bortezomib, and antibacterial azithromycin.',\n",
              "   'idx': '64b2e24121df4e59a1e5e3b4d240ea3e',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 135,\n",
              "   'span_end': 143,\n",
              "   'text': 'In this regard, the WHO supported repositioning remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine as a potential for COVID‐19, although most might be only supportive symptomatic Won & Lee.',\n",
              "   'idx': 'c677710b8fea4f7eac1f60ac86d4a5a2',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 110,\n",
              "   'span_end': 118,\n",
              "   'text': 'Nevertheless, remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine will likely be approved for COVID‐19 therapy if remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine pass clinical trials and are published in literature and guidelines from leading health organizations Nain et al. In order to do this, many groups have been attempting enthusiastically to discover the first approved drug for COVID‐19 therapy Erlanson, Low et al., Muratov et al. As a result, we identified several clinical trials, in which 18 studies were at clinical phases 2, 3, or 4.',\n",
              "   'idx': '6b8cc17a673b4b1da8a17ba0dc4df2ca',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 423,\n",
              "   'span_end': 431,\n",
              "   'text': 'Nevertheless, remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine will likely be approved for COVID‐19 therapy if remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine pass clinical trials and are published in literature and guidelines from leading health organizations Nain et al. In order to do this, many groups have been attempting enthusiastically to discover the first approved drug for COVID‐19 therapy Erlanson, Low et al., Muratov et al. As a result, we identified several clinical trials, in which 18 studies were at clinical phases 2, 3, or 4.',\n",
              "   'idx': '6b8cc17a673b4b1da8a17ba0dc4df2ca',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 179,\n",
              "   'span_end': 189,\n",
              "   'text': 'Luo et al. investigated the free energy perturbation‐absolute binding free energy FEP‐ABFE method and bioassay validation to reposition 25 potential therapeutic agents to inhibit SARS‐CoV‐2.',\n",
              "   'idx': 'a5b9bf354bac46dc9b5ae8ded0b3faf4',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 49,\n",
              "   'span_end': 59,\n",
              "   'text': \"By using the viral proteinase crystal structure, SARS‐CoV‐2 PDB ID 6 LU7, up to 2500 FDA‐approved drugs were first screened via Glide's molecular docking program.\",\n",
              "   'idx': '56f396b676ae4c91aaf019efdc08755c',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 253,\n",
              "   'span_end': 256,\n",
              "   'text': \"Among 25 possible agents, additionally, dipyridamole passed dipyridamole's first‐round clinical trials with considerable potencies Li, Hu, et al., Li, Li, et al. The network‐based methods have also given satisfying results in investigating the DTIs and CoV–host interactions.\",\n",
              "   'idx': 'fe03e21b556f4d739f1a602821e2a78f',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'anti‐HCoV',\n",
              "   'span_start': 34,\n",
              "   'span_end': 43,\n",
              "   'text': 'Zho et al. introduced 16 possible anti‐HCoV drugs such as melatonin, mercaptopurine, toremifene, mesalazine, and sirolimus from more than 2000 FDA‐approved drugs by applying a combination of network‐based approaches and systems pharmacology‐based network medicine platform with the ability to quantify the interactions between the drug targets and virus–host interactome in the human protein–protein interactions network.',\n",
              "   'idx': '2436b3dca5a045368220cc626968f0f2',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 119,\n",
              "   'span_end': 129,\n",
              "   'text': 'Zhou et al. The docking screening method was applied for a set of 2201 approved drugs to find inhibitory activities at SARS‐CoV‐2 main protease, and based on that, carfilzomib, eravacycline, valrubicin, lopinavir, and elbasvir have nominated as an inhibitor for SARS‐CoV‐2 main protease Wang.',\n",
              "   'idx': '1270e964624842a18dc2f6155787417f',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 262,\n",
              "   'span_end': 272,\n",
              "   'text': 'Zhou et al. The docking screening method was applied for a set of 2201 approved drugs to find inhibitory activities at SARS‐CoV‐2 main protease, and based on that, carfilzomib, eravacycline, valrubicin, lopinavir, and elbasvir have nominated as an inhibitor for SARS‐CoV‐2 main protease Wang.',\n",
              "   'idx': '1270e964624842a18dc2f6155787417f',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 63,\n",
              "   'span_end': 74,\n",
              "   'text': 'Table includes recent studies in terms of computational DR for coronavirus drug discovery and various diseases, respectively.',\n",
              "   'idx': '75384881ea524ddda6dde4c43193e5d7',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 47,\n",
              "   'span_end': 57,\n",
              "   'text': 'Various transcriptomic datasets in relation to SARS‐CoV‐2 were reported since the COVID‐19 outbreak.',\n",
              "   'idx': 'd702030e27e84c949718fc2acb4365fc',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 82,\n",
              "   'span_end': 90,\n",
              "   'text': 'Various transcriptomic datasets in relation to SARS‐CoV‐2 were reported since the COVID‐19 outbreak.',\n",
              "   'idx': 'd702030e27e84c949718fc2acb4365fc',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 501,\n",
              "   'span_end': 511,\n",
              "   'text': 'Basically, the idea is that for a specific disease signature composing of a class of up and downregulated genes, if there is available drug candidate, where a class of up and downregulated genes are alternatively downregulated and up‐regulated, respectively, this drug might be potential for that disease Hoffmann et al., Le et al. Zho et al. investigated existing computational drug repositioning with remarkably reversed differential gene expression in comparison with manifold input signatures for SARS‐CoV‐2 effects on human cells.',\n",
              "   'idx': 'ada0b2254ad14dd0adeac0df82d9d0bb',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 79,\n",
              "   'span_end': 89,\n",
              "   'text': \"Zho et al. eventually tested 16 of Zho et al.'s shortlisted candidates in live SARS‐CoV‐2 antiviral assays.\",\n",
              "   'idx': 'd6f92314380445cb9cf87d026cfd72bf',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 113,\n",
              "   'span_end': 123,\n",
              "   'text': 'If a drug could notably FDR < 0.05 reverse the disease signature, then a drug could be a potential inhibitor for SARS‐CoV‐2.',\n",
              "   'idx': 'dac9764996224ba6ae7bf94e5dfeed6a',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 104,\n",
              "   'span_end': 114,\n",
              "   'text': \"In the end, Zho et al. found that 16 of Zho et al.'s high predicted hits showed antiviral assay in live SARS‐CoV‐2.\",\n",
              "   'idx': '80538bf42bb2416a9d7c277342404407',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 56,\n",
              "   'span_end': 66,\n",
              "   'text': 'Four potential inhibitors were tested for inhibition of SARS‐CoV‐2 in a human lung cell line, Calu‐3, infected with SARS‐CoV‐2.',\n",
              "   'idx': 'aff872208b3d4bd3a043d9e41c0f4be8',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 116,\n",
              "   'span_end': 126,\n",
              "   'text': 'Four potential inhibitors were tested for inhibition of SARS‐CoV‐2 in a human lung cell line, Calu‐3, infected with SARS‐CoV‐2.',\n",
              "   'idx': 'aff872208b3d4bd3a043d9e41c0f4be8',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 351,\n",
              "   'span_end': 361,\n",
              "   'text': 'Three drugs revealed in vitro antiviral efficacy—bacampicillin, clofazimine, and haloperidol with no toxicity effects Zho et al. Ge et al. used an integrative drug repositioning analysis through machine learning to integrate and mine large‐scale knowledge graph, literature together with transcriptome data to identify the potential compounds against SARS‐CoV‐2.',\n",
              "   'idx': 'a5821a977323473bb5a9afde3b2bb1e8',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 72,\n",
              "   'span_end': 82,\n",
              "   'text': \"Ge et al.'s in vitro data showed an efficient inhibitory effect against SARS‐CoV‐2 replication without a clear cytopathic effect.\",\n",
              "   'idx': '4cb99d8616a84828bb18950b19560002',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 141,\n",
              "   'span_end': 151,\n",
              "   'text': 'Ge et al. further revealed that CVL218, a poly‐ADP‐ribose polymerase 1 PARP1 inhibitor can effectively bind to the nucleocapsid N protein of SARS‐CoV‐2 and could suppress the LPS‐induced production of many inflammatory cytokine, which are highly related to the prevention of immunopathology induced by SARS‐CoV‐2 infection Zho et al.. Another PARP1 inhibitor, PJ‐34 was previously studied for acute inflammatory including inflammatory diseases of the lung.',\n",
              "   'idx': '6cb62560b7664810bf02aa899fe8f46b',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 302,\n",
              "   'span_end': 312,\n",
              "   'text': 'Ge et al. further revealed that CVL218, a poly‐ADP‐ribose polymerase 1 PARP1 inhibitor can effectively bind to the nucleocapsid N protein of SARS‐CoV‐2 and could suppress the LPS‐induced production of many inflammatory cytokine, which are highly related to the prevention of immunopathology induced by SARS‐CoV‐2 infection Zho et al.. Another PARP1 inhibitor, PJ‐34 was previously studied for acute inflammatory including inflammatory diseases of the lung.',\n",
              "   'idx': '6cb62560b7664810bf02aa899fe8f46b',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 125,\n",
              "   'span_end': 135,\n",
              "   'text': 'It was observed that Another PARP1 inhibitor, PJ‐34 can interact with the N‐terminal domain of the nucleocapsid N protein of SARS‐CoV‐2 and decrease the RNA binding ability to inhibit virus replication Zho et al.. Beclabuvir is an antiviral drug for the treatment of hepatitis C virus HCV infection studied for inhibitory activity against SARS‐CoV‐2.',\n",
              "   'idx': '3b2a977eae22463f95d0cc9f7b5856e2',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 339,\n",
              "   'span_end': 349,\n",
              "   'text': 'It was observed that Another PARP1 inhibitor, PJ‐34 can interact with the N‐terminal domain of the nucleocapsid N protein of SARS‐CoV‐2 and decrease the RNA binding ability to inhibit virus replication Zho et al.. Beclabuvir is an antiviral drug for the treatment of hepatitis C virus HCV infection studied for inhibitory activity against SARS‐CoV‐2.',\n",
              "   'idx': '3b2a977eae22463f95d0cc9f7b5856e2',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 83,\n",
              "   'span_end': 93,\n",
              "   'text': 'It was reported that Beclabuvir could be a potential compound for the treatment of SARS‐CoV‐2 through virtual screening and molecular docking in order to bind to RdRp of the SARS‐CoV‐2 Talluri.',\n",
              "   'idx': '61ce8bd7dd73453d93b20b8b8713eadb',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 174,\n",
              "   'span_end': 184,\n",
              "   'text': 'It was reported that Beclabuvir could be a potential compound for the treatment of SARS‐CoV‐2 through virtual screening and molecular docking in order to bind to RdRp of the SARS‐CoV‐2 Talluri.',\n",
              "   'idx': '61ce8bd7dd73453d93b20b8b8713eadb',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 120,\n",
              "   'span_end': 128,\n",
              "   'text': 'Raltegravir was selected as a highly effective drug against Mpro and has been repurposed for the potential treatment of COVID‐19 in many studies Nabi et al. There has been considerable progress in the practical development and the rational application of computational drug discovery, giving rise to a paradigm shift in both industry and academics.',\n",
              "   'idx': '26cf781f636e4a08b2733f38805cce74',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 27,\n",
              "   'span_end': 35,\n",
              "   'text': 'Over the last 3 years, the COVID‐19 pandemic has killed many people globally since there are no effective drugs against the COVID‐19 pandemic.',\n",
              "   'idx': 'd30d27c3f7904da1b0f0fd0283166ac7',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 124,\n",
              "   'span_end': 132,\n",
              "   'text': 'Over the last 3 years, the COVID‐19 pandemic has killed many people globally since there are no effective drugs against the COVID‐19 pandemic.',\n",
              "   'idx': 'd30d27c3f7904da1b0f0fd0283166ac7',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 119,\n",
              "   'span_end': 127,\n",
              "   'text': 'In this sense, we need to highlight that DR attempts the search for effective drugs in an urgent situation such as the COVID‐19 pandemic.',\n",
              "   'idx': '8f01c241452a49389409f33701a7b49a',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 28,\n",
              "   'span_end': 38,\n",
              "   'text': 'In order to use HTS against SARS‐CoV‐2, it is important to take advantage of a similar homology of virus in genomics, specifically, chemogenomics, as a versatile way of drug screening model that provides better bio‐safety.',\n",
              "   'idx': 'ac1463daa20549af81e7deb281f89709',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 59,\n",
              "   'span_end': 67,\n",
              "   'text': 'Hitherto, CADD is the only way for screening drugs against COVID‐19 and is based on a single viral protein or small‐scale drug screening of formerly FDA antiviral drugs utilizing SARS‐CoV‐2.',\n",
              "   'idx': '823ff1f206464647a184ea0f6dacf06a',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 179,\n",
              "   'span_end': 189,\n",
              "   'text': 'Hitherto, CADD is the only way for screening drugs against COVID‐19 and is based on a single viral protein or small‐scale drug screening of formerly FDA antiviral drugs utilizing SARS‐CoV‐2.',\n",
              "   'idx': '823ff1f206464647a184ea0f6dacf06a',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 121,\n",
              "   'span_end': 131,\n",
              "   'text': 'Nevertheless, CADD is not well‐suited to high‐throughput screening HTS when focusing on the bio‐security requirements of SARS‐CoV‐2.',\n",
              "   'idx': 'f366cc7ae5e94b799b2c5273de47b081',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID‐19',\n",
              "   'span_start': 188,\n",
              "   'span_end': 196,\n",
              "   'text': 'Moreover, developing new drugs takes too much time without having a precise crystal structure of the viral target Liu et al. Thus, the best way to rapidly find a drug for the treatment of COVID‐19 would be the use of CADD methods in order to discover lead compounds for clinical use for instance, we can build a program that takes advantage of structure‐based drug design, HTS, and virtual drug screening to identify new leads targeting the Mpro. More recently, a library of 10000 compounds involving approved drugs, drug candidates in clinical trials, and biologically active compounds to inhibit the Mpro was examined.',\n",
              "   'idx': 'dc8e0c2bccea46529f6dff464c891edf',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 191,\n",
              "   'span_end': 201,\n",
              "   'text': 'Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.',\n",
              "   'idx': '098e63d61c20486093b2e89927ed2701',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 316,\n",
              "   'span_end': 320,\n",
              "   'text': 'Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.',\n",
              "   'idx': '098e63d61c20486093b2e89927ed2701',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS‐CoV',\n",
              "   'span_start': 332,\n",
              "   'span_end': 340,\n",
              "   'text': 'Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.',\n",
              "   'idx': '098e63d61c20486093b2e89927ed2701',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 345,\n",
              "   'span_end': 355,\n",
              "   'text': 'Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.',\n",
              "   'idx': '098e63d61c20486093b2e89927ed2701',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS‐CoV‐2',\n",
              "   'span_start': 438,\n",
              "   'span_end': 448,\n",
              "   'text': 'Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.',\n",
              "   'idx': '098e63d61c20486093b2e89927ed2701',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'anti‐SARS‐CoV‐2',\n",
              "   'span_start': 97,\n",
              "   'span_end': 112,\n",
              "   'text': 'This effort led to the discovery of nine hits that need further optimization to be identified as anti‐SARS‐CoV‐2 leads.',\n",
              "   'idx': 'a1b0adebc7d1407b9d85dc73efc7552f',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 242,\n",
              "   'span_end': 246,\n",
              "   'text': \"In addition, an interesting investigation based on an HTS assay employing a compound library of 2000 approved drugs and pharmacologically active compounds has also been carried out to find broad‐spectrum inhibitors against the replication of CoVs Shen et al. From Shen et al's HTS data, 56 hits were screened, and 36 compounds were validated in vitro using genetically engineered human CoV OC43 HCoV‐OC43.\",\n",
              "   'idx': 'c04f032707a64c88a962debebb1c8410',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 386,\n",
              "   'span_end': 389,\n",
              "   'text': \"In addition, an interesting investigation based on an HTS assay employing a compound library of 2000 approved drugs and pharmacologically active compounds has also been carried out to find broad‐spectrum inhibitors against the replication of CoVs Shen et al. From Shen et al's HTS data, 56 hits were screened, and 36 compounds were validated in vitro using genetically engineered human CoV OC43 HCoV‐OC43.\",\n",
              "   'idx': 'c04f032707a64c88a962debebb1c8410',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV‐OC43',\n",
              "   'span_start': 395,\n",
              "   'span_end': 404,\n",
              "   'text': \"In addition, an interesting investigation based on an HTS assay employing a compound library of 2000 approved drugs and pharmacologically active compounds has also been carried out to find broad‐spectrum inhibitors against the replication of CoVs Shen et al. From Shen et al's HTS data, 56 hits were screened, and 36 compounds were validated in vitro using genetically engineered human CoV OC43 HCoV‐OC43.\",\n",
              "   'idx': 'c04f032707a64c88a962debebb1c8410',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 144,\n",
              "   'span_end': 155,\n",
              "   'text': 'Consequently, seven effective compounds were selected as broad‐spectrum inhibitors in which lycorine protected BALB/c mice against lethal human coronavirus OC43 HCoV‐OC43, and emetine blocked MERS‐CoV entry following pseudo‐virus entry assays.',\n",
              "   'idx': 'd69c4607b37a484ca8ff44a11b6db352',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV‐OC43',\n",
              "   'span_start': 161,\n",
              "   'span_end': 170,\n",
              "   'text': 'Consequently, seven effective compounds were selected as broad‐spectrum inhibitors in which lycorine protected BALB/c mice against lethal human coronavirus OC43 HCoV‐OC43, and emetine blocked MERS‐CoV entry following pseudo‐virus entry assays.',\n",
              "   'idx': 'd69c4607b37a484ca8ff44a11b6db352',\n",
              "   'article_id': 'PMC9539342'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS‐CoV',\n",
              "   'span_start': 192,\n",
              "   'span_end': 200,\n",
              "   'text': 'Consequently, seven effective compounds were selected as broad‐spectrum inhibitors in which lycorine protected BALB/c mice against lethal human coronavirus OC43 HCoV‐OC43, and emetine blocked MERS‐CoV entry following pseudo‐virus entry assays.',\n",
              "   'idx': 'd69c4607b37a484ca8ff44a11b6db352',\n",
              "   'article_id': 'PMC9539342'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 4,\n",
              "   'span_end': 37,\n",
              "   'text': 'The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.',\n",
              "   'idx': 'a742d241e0084e8ba52f0177e747a0ed',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus-2',\n",
              "   'span_start': 38,\n",
              "   'span_end': 51,\n",
              "   'text': 'The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.',\n",
              "   'idx': 'a742d241e0084e8ba52f0177e747a0ed',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 52,\n",
              "   'span_end': 62,\n",
              "   'text': 'The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.',\n",
              "   'idx': 'a742d241e0084e8ba52f0177e747a0ed',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus Disease 2019',\n",
              "   'span_start': 71,\n",
              "   'span_end': 95,\n",
              "   'text': 'The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.',\n",
              "   'idx': 'a742d241e0084e8ba52f0177e747a0ed',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 96,\n",
              "   'span_end': 104,\n",
              "   'text': 'The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.',\n",
              "   'idx': 'a742d241e0084e8ba52f0177e747a0ed',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 26,\n",
              "   'span_end': 59,\n",
              "   'text': 'Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.',\n",
              "   'idx': 'de3a95ab590f472f86ee9eb485fd1971',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus-2',\n",
              "   'span_start': 60,\n",
              "   'span_end': 73,\n",
              "   'text': 'Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.',\n",
              "   'idx': 'de3a95ab590f472f86ee9eb485fd1971',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 74,\n",
              "   'span_end': 84,\n",
              "   'text': 'Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.',\n",
              "   'idx': 'de3a95ab590f472f86ee9eb485fd1971',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus Disease 2019',\n",
              "   'span_start': 93,\n",
              "   'span_end': 117,\n",
              "   'text': 'Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.',\n",
              "   'idx': 'de3a95ab590f472f86ee9eb485fd1971',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 118,\n",
              "   'span_end': 126,\n",
              "   'text': 'Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.',\n",
              "   'idx': 'de3a95ab590f472f86ee9eb485fd1971',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 8,\n",
              "   'span_end': 41,\n",
              "   'text': 'The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.',\n",
              "   'idx': 'a45c44dbbdd54637a7d4c44bcaebe6af',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus-2',\n",
              "   'span_start': 42,\n",
              "   'span_end': 55,\n",
              "   'text': 'The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.',\n",
              "   'idx': 'a45c44dbbdd54637a7d4c44bcaebe6af',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 56,\n",
              "   'span_end': 66,\n",
              "   'text': 'The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.',\n",
              "   'idx': 'a45c44dbbdd54637a7d4c44bcaebe6af',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus Disease 2019',\n",
              "   'span_start': 75,\n",
              "   'span_end': 99,\n",
              "   'text': 'The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.',\n",
              "   'idx': 'a45c44dbbdd54637a7d4c44bcaebe6af',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 100,\n",
              "   'span_end': 108,\n",
              "   'text': 'The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.',\n",
              "   'idx': 'a45c44dbbdd54637a7d4c44bcaebe6af',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARSCoV-2 infection',\n",
              "   'span_start': 204,\n",
              "   'span_end': 223,\n",
              "   'text': 'The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.',\n",
              "   'idx': 'a45c44dbbdd54637a7d4c44bcaebe6af',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 125,\n",
              "   'span_end': 158,\n",
              "   'text': 'Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.',\n",
              "   'idx': 'ba9cc63886394fdc9ea03cb0f8393ddb',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus-2',\n",
              "   'span_start': 159,\n",
              "   'span_end': 172,\n",
              "   'text': 'Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.',\n",
              "   'idx': 'ba9cc63886394fdc9ea03cb0f8393ddb',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 173,\n",
              "   'span_end': 183,\n",
              "   'text': 'Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.',\n",
              "   'idx': 'ba9cc63886394fdc9ea03cb0f8393ddb',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus Disease 2019',\n",
              "   'span_start': 192,\n",
              "   'span_end': 216,\n",
              "   'text': 'Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.',\n",
              "   'idx': 'ba9cc63886394fdc9ea03cb0f8393ddb',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 217,\n",
              "   'span_end': 225,\n",
              "   'text': 'Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.',\n",
              "   'idx': 'ba9cc63886394fdc9ea03cb0f8393ddb',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 61,\n",
              "   'span_end': 94,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "   'idx': 'c8775cda0e0241fca65f98fd47735af6',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus-2',\n",
              "   'span_start': 95,\n",
              "   'span_end': 108,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "   'idx': 'c8775cda0e0241fca65f98fd47735af6',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 109,\n",
              "   'span_end': 119,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "   'idx': 'c8775cda0e0241fca65f98fd47735af6',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus Disease 2019',\n",
              "   'span_start': 128,\n",
              "   'span_end': 152,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "   'idx': 'c8775cda0e0241fca65f98fd47735af6',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 153,\n",
              "   'span_end': 161,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "   'idx': 'c8775cda0e0241fca65f98fd47735af6',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 308,\n",
              "   'span_end': 341,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "   'idx': 'c8775cda0e0241fca65f98fd47735af6',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus-2',\n",
              "   'span_start': 342,\n",
              "   'span_end': 355,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "   'idx': 'c8775cda0e0241fca65f98fd47735af6',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 356,\n",
              "   'span_end': 366,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "   'idx': 'c8775cda0e0241fca65f98fd47735af6',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus Disease 2019',\n",
              "   'span_start': 375,\n",
              "   'span_end': 399,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "   'idx': 'c8775cda0e0241fca65f98fd47735af6',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 400,\n",
              "   'span_end': 408,\n",
              "   'text': 'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "   'idx': 'c8775cda0e0241fca65f98fd47735af6',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARSCoV-2',\n",
              "   'span_start': 0,\n",
              "   'span_end': 9,\n",
              "   'text': 'SARSCoV-2, seasonal or pandemic influenza, and MERS corona virus are all targets of Molnupiravir, commercialized as Lagevrio.',\n",
              "   'idx': '444240c7f9524d82a2a6c62800251f09',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS',\n",
              "   'span_start': 47,\n",
              "   'span_end': 51,\n",
              "   'text': 'SARSCoV-2, seasonal or pandemic influenza, and MERS corona virus are all targets of Molnupiravir, commercialized as Lagevrio.',\n",
              "   'idx': '444240c7f9524d82a2a6c62800251f09',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 175,\n",
              "   'span_end': 183,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio was reported to be extremely effective in reducing nasopharyngeal infection rate and had a positive safety and tolerability record in COVID-19 patients who received short-course, 5-day treatment.– On 23 December 2021, FDA approved Molnupiravir, commercialized as Lagevrio under an EUA for the treatment of mild-to-moderate COVID-19 in individuals who have a positive consequences of SARSCoV-2 virus test and are at high risk of developing chronic COVID-19.',\n",
              "   'idx': '1b576667408242dd9f86803e84269ebc',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 364,\n",
              "   'span_end': 372,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio was reported to be extremely effective in reducing nasopharyngeal infection rate and had a positive safety and tolerability record in COVID-19 patients who received short-course, 5-day treatment.– On 23 December 2021, FDA approved Molnupiravir, commercialized as Lagevrio under an EUA for the treatment of mild-to-moderate COVID-19 in individuals who have a positive consequences of SARSCoV-2 virus test and are at high risk of developing chronic COVID-19.',\n",
              "   'idx': '1b576667408242dd9f86803e84269ebc',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARSCoV-2',\n",
              "   'span_start': 424,\n",
              "   'span_end': 433,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio was reported to be extremely effective in reducing nasopharyngeal infection rate and had a positive safety and tolerability record in COVID-19 patients who received short-course, 5-day treatment.– On 23 December 2021, FDA approved Molnupiravir, commercialized as Lagevrio under an EUA for the treatment of mild-to-moderate COVID-19 in individuals who have a positive consequences of SARSCoV-2 virus test and are at high risk of developing chronic COVID-19.',\n",
              "   'idx': '1b576667408242dd9f86803e84269ebc',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 488,\n",
              "   'span_end': 496,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio was reported to be extremely effective in reducing nasopharyngeal infection rate and had a positive safety and tolerability record in COVID-19 patients who received short-course, 5-day treatment.– On 23 December 2021, FDA approved Molnupiravir, commercialized as Lagevrio under an EUA for the treatment of mild-to-moderate COVID-19 in individuals who have a positive consequences of SARSCoV-2 virus test and are at high risk of developing chronic COVID-19.',\n",
              "   'idx': '1b576667408242dd9f86803e84269ebc',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARSCoV-2',\n",
              "   'span_start': 82,\n",
              "   'span_end': 91,\n",
              "   'text': 'an EUA is granted for patients who have received a positive test from significant SARSCoV-2 viral testing, or who are at danger of developing severe COVID-19, which could result in hospitalization or death, or for whom other FDA-approved COVID-19 treatment options are not available or efficacious.',\n",
              "   'idx': '3d41bdbcaa53403ab13342c1c6dfc616',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 149,\n",
              "   'span_end': 157,\n",
              "   'text': 'an EUA is granted for patients who have received a positive test from significant SARSCoV-2 viral testing, or who are at danger of developing severe COVID-19, which could result in hospitalization or death, or for whom other FDA-approved COVID-19 treatment options are not available or efficacious.',\n",
              "   'idx': '3d41bdbcaa53403ab13342c1c6dfc616',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 238,\n",
              "   'span_end': 246,\n",
              "   'text': 'an EUA is granted for patients who have received a positive test from significant SARSCoV-2 viral testing, or who are at danger of developing severe COVID-19, which could result in hospitalization or death, or for whom other FDA-approved COVID-19 treatment options are not available or efficacious.',\n",
              "   'idx': '3d41bdbcaa53403ab13342c1c6dfc616',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 174,\n",
              "   'span_end': 182,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio is not approved for use in individuals under the age of 18, for the commencement of therapy in patients who require treatment due to COVID-19, for use for more than 5 days, or as a pre-exposure or post-exposure prophylactic for COVID-19 prevention.',\n",
              "   'idx': 'cb6a73f6f1714e43a4cac59413b609a1',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 269,\n",
              "   'span_end': 277,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio is not approved for use in individuals under the age of 18, for the commencement of therapy in patients who require treatment due to COVID-19, for use for more than 5 days, or as a pre-exposure or post-exposure prophylactic for COVID-19 prevention.',\n",
              "   'idx': 'cb6a73f6f1714e43a4cac59413b609a1',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 68,\n",
              "   'span_end': 78,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio acts by inhibiting RdRp of SARS-CoV-2 to induce RNA mutagenesis in two steps.',\n",
              "   'idx': '6b97231815ad4afd9c190cb124731ceb',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 93,\n",
              "   'span_end': 103,\n",
              "   'text': 'the EIDD-1931-triphosphate acts as an alternate/competitive substrate for the RdRp enzyme of SARS-CoV-2.',\n",
              "   'idx': '995bcc87397e4aa7a7162cb1e8d5c2a9',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 30,\n",
              "   'span_end': 40,\n",
              "   'text': 'Therefore, the RdRp enzyme of SARS-CoV-2 This process mutated RNA copies for SARS-CoV-2.',\n",
              "   'idx': 'c14bfe94fd7647968cd96ea37ad4c4d9',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 77,\n",
              "   'span_end': 87,\n",
              "   'text': 'Therefore, the RdRp enzyme of SARS-CoV-2 This process mutated RNA copies for SARS-CoV-2.',\n",
              "   'idx': 'c14bfe94fd7647968cd96ea37ad4c4d9',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 81,\n",
              "   'span_end': 91,\n",
              "   'text': 'This process causes the inhibition of the normal functions of the RdRp enzyme of SARS-CoV-2.',\n",
              "   'idx': '32d7030e29584b2e9ec34280e34b78b3',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 167,\n",
              "   'span_end': 180,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio is an isopropyl prodrug of EIDD-1931, which has been shown to suppress the reproduction of a wide range of viruses, including coronaviruses, with potential safety profiles.',\n",
              "   'idx': '74727b96782645aeb5c348dd29b7f297',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 225,\n",
              "   'span_end': 233,\n",
              "   'text': 'Emory University in Atlanta, Ridgeback Biotherapeutics, Wayne and Wendy Holman, and Merck have also agreed to collaborate on the development of Molnupiravir, commercialized as Lagevrio as an oral therapy for non-hospitalized COVID-19 individuals.',\n",
              "   'idx': 'a788bff7219d4bd4b6a00895aae064d4',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 31,\n",
              "   'span_end': 39,\n",
              "   'text': 'Following the dissemination of COVID-19, the Molnupiravir, commercialized as Lagevrio development effort shifted to COVID-19 therapy.',\n",
              "   'idx': '1b34a67a4e264d03887b8bbdff08ce02',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 116,\n",
              "   'span_end': 124,\n",
              "   'text': 'Following the dissemination of COVID-19, the Molnupiravir, commercialized as Lagevrio development effort shifted to COVID-19 therapy.',\n",
              "   'idx': '1b34a67a4e264d03887b8bbdff08ce02',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 65,\n",
              "   'span_end': 78,\n",
              "   'text': 'Molnupiravir, commercialized as Lagevrio oral efficiency against coronaviruses was also demonstrated in preclinical research in an animal study.',\n",
              "   'idx': '9d7b0b6854a34ac6ae7af13174e6fb9c',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 0,\n",
              "   'span_end': 10,\n",
              "   'text': 'SARS-CoV-2 propagation is ineffectively controlled by remdesivir.',\n",
              "   'idx': 'a06db65e390d4420a8690a867675f464',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 82,\n",
              "   'span_end': 92,\n",
              "   'text': 'Molnupiravir, on the other hand, was shown to be efficient in ferrets in reducing SARS-CoV-2 virus and halting dissemination.',\n",
              "   'idx': '6c6202d69f8c45348c581ea4f6490e43',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 78,\n",
              "   'span_end': 98,\n",
              "   'text': 'As a result, Molnupiravir has been proposed as a protective measure to combat SARS-CoV-2 infection in the community.',\n",
              "   'idx': '20618fbce8ea4e98b7bf8245d515ad53',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 22,\n",
              "   'span_end': 32,\n",
              "   'text': 'Elderly patients with SARS-CoV-2 illness diagnosed by RT-PCR within 5 days of appearance of symptoms were randomised to standard of care SOC or 300, 600, and 800 mg Molnupiravir orally twice for 5 days by oral route daily.',\n",
              "   'idx': 'd9676b807949470e99f3f6140c2c3d04',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 28,\n",
              "   'span_end': 36,\n",
              "   'text': 'The safety and tolerance of COVID-19 in patients admitted with minimal to moderate COVID-19 were analyzed in a double-blind, randomized-controlled, multicentric phase 2a MK-4482-006 NCT04405570 study.',\n",
              "   'idx': '8b6b43ed8dfb434e978470bd032ea889',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 83,\n",
              "   'span_end': 91,\n",
              "   'text': 'The safety and tolerance of COVID-19 in patients admitted with minimal to moderate COVID-19 were analyzed in a double-blind, randomized-controlled, multicentric phase 2a MK-4482-006 NCT04405570 study.',\n",
              "   'idx': '8b6b43ed8dfb434e978470bd032ea889',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 120,\n",
              "   'span_end': 140,\n",
              "   'text': \"Other double-blind phase 2 experiment is now underway to assess the safety of Molnupiravir and Molnupiravir's effect on SARS-CoV-2 infection shedding.\",\n",
              "   'idx': '29f3d1ef08f74836b4e8d9c820107b9d',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 226,\n",
              "   'span_end': 234,\n",
              "   'text': 'The independent data safety monitoring board recently halted the phase 3 double-blind, randomised trial MOVe-OUT that was designed to evaluate the efficacy and safety of Molnupiravir in 1850 non-hospitalized participants with COVID-19 NCT04575597, MK-4482-002 due to the increased advantage in the test group compared to Placebo.',\n",
              "   'idx': 'aba423674a12448b97a5fcb69f9f8249',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 9,\n",
              "   'span_end': 19,\n",
              "   'text': \"A proven SARS-CoV-2 illness with samples taken ≤5 days previous to the day of allocation and negative serum testing in light of recent or earlier exposure were among an open label randomised controlled but small phase Ib/IIa study called AGILE NCT04746183's eligibility criteria.\",\n",
              "   'idx': '24324ec9a324478a8a23893a8c6756cb',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 17,\n",
              "   'span_end': 27,\n",
              "   'text': 'Furthermore, the SARS-CoV-2 variant gamma, delta, or mu, the period of onset of manifestations, and the inherent risks had no influence on the effectiveness of Molnupiravir.',\n",
              "   'idx': 'e71ec347371a49ab96c75c896841c690',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 177,\n",
              "   'span_end': 185,\n",
              "   'text': 'A further phase 3 double-blind, randomised research MOVe-IN, NCT04575584 that has been set to investigate the effectiveness and safety of Molnupiravir in 304 hospitalised adult COVID-19 MK-4482-001 subjects was halted after an initial review of the data revealed that a clinical efficacy in hospitalised individuals was improbable.',\n",
              "   'idx': '9b3ec8156827490d8717be7c93264729',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 212,\n",
              "   'span_end': 220,\n",
              "   'text': 'Nonetheless, a huge n 14 1332 phase 3 multicentric, randomised, double-blind, placebo-controlled investigation NCT04939428 is actively exploring the safety and effectiveness of Molnupiravir for the mitigation of COVID-19 in adults MOVe-AHEAD living with a human who has COVID-19, with the assumption that Molnupiravir would be efficacious in blocking laboratory-confirmed COVID-19 infestation through day 14 especially in comparison to placebo.',\n",
              "   'idx': '23760fc5559f417eaa90f64fd72ed6e6',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 270,\n",
              "   'span_end': 278,\n",
              "   'text': 'Nonetheless, a huge n 14 1332 phase 3 multicentric, randomised, double-blind, placebo-controlled investigation NCT04939428 is actively exploring the safety and effectiveness of Molnupiravir for the mitigation of COVID-19 in adults MOVe-AHEAD living with a human who has COVID-19, with the assumption that Molnupiravir would be efficacious in blocking laboratory-confirmed COVID-19 infestation through day 14 especially in comparison to placebo.',\n",
              "   'idx': '23760fc5559f417eaa90f64fd72ed6e6',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infestation',\n",
              "   'span_start': 372,\n",
              "   'span_end': 392,\n",
              "   'text': 'Nonetheless, a huge n 14 1332 phase 3 multicentric, randomised, double-blind, placebo-controlled investigation NCT04939428 is actively exploring the safety and effectiveness of Molnupiravir for the mitigation of COVID-19 in adults MOVe-AHEAD living with a human who has COVID-19, with the assumption that Molnupiravir would be efficacious in blocking laboratory-confirmed COVID-19 infestation through day 14 especially in comparison to placebo.',\n",
              "   'idx': '23760fc5559f417eaa90f64fd72ed6e6',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 130,\n",
              "   'span_end': 138,\n",
              "   'text': 'Meanwhile, many Indian pharmaceutical firms confirmed preliminary results from phase 3 studies with Molnupiravir in mild/moderate COVID-19 patient populations in India.',\n",
              "   'idx': '488c9cfee5e64d6e8bbe98e0ffdf0aff',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 100,\n",
              "   'span_end': 108,\n",
              "   'text': 'The research community has rallied to discover and assess various medicines and vaccinations as the COVID-19 outbreak spreads throughout the world, from academia and government institutions to minor biotechnology startups and major pharmaceutical enterprises.',\n",
              "   'idx': 'e518020f205245c6a967db6be0d9e73c',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 90,\n",
              "   'span_end': 100,\n",
              "   'text': 'Repurposing preexisting medications authorized for other uses as antiviral treatments for SARS-CoV-2 is one feasible method.',\n",
              "   'idx': '0b9d94337fb34f50b76dba31131c8463',\n",
              "   'article_id': 'PMC9357751'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 123,\n",
              "   'span_end': 131,\n",
              "   'text': 'Although repurposed medications with acceptable safety records might be beneficial, there are currently no widely marketed COVID-19 preventive or therapy alternatives.',\n",
              "   'idx': '70531ae8cf5144da9f3c44de8579acb4',\n",
              "   'article_id': 'PMC9357751'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 23,\n",
              "   'span_end': 33,\n",
              "   'text': 'The sudden outbreak of SARS-CoV-2 in 2019 took the world by storm and despite there being vaccines, numerous other alternative treatment approaches are also being researched.',\n",
              "   'idx': '016c76585ff24d2a90262672e1c0f60e',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 0,\n",
              "   'span_end': 24,\n",
              "   'text': 'Coronavirus disease-2019 COVID-19 is a communicable disease caused by SARS-CoV-2.',\n",
              "   'idx': '1028c6b87b5945d7aea40b4154b52201',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 25,\n",
              "   'span_end': 33,\n",
              "   'text': 'Coronavirus disease-2019 COVID-19 is a communicable disease caused by SARS-CoV-2.',\n",
              "   'idx': '1028c6b87b5945d7aea40b4154b52201',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 70,\n",
              "   'span_end': 80,\n",
              "   'text': 'Coronavirus disease-2019 COVID-19 is a communicable disease caused by SARS-CoV-2.',\n",
              "   'idx': '1028c6b87b5945d7aea40b4154b52201',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 0,\n",
              "   'span_end': 24,\n",
              "   'text': \"Coronavirus disease-2019 COVID-19 was first detected in Wuhan, China, and has expanded Coronavirus disease-2019 COVID-19's reach globally, leading to myriad deaths.\",\n",
              "   'idx': 'e6beba15edb347fcb78face5be998e97',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 25,\n",
              "   'span_end': 33,\n",
              "   'text': \"Coronavirus disease-2019 COVID-19 was first detected in Wuhan, China, and has expanded Coronavirus disease-2019 COVID-19's reach globally, leading to myriad deaths.\",\n",
              "   'idx': 'e6beba15edb347fcb78face5be998e97',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 87,\n",
              "   'span_end': 111,\n",
              "   'text': \"Coronavirus disease-2019 COVID-19 was first detected in Wuhan, China, and has expanded Coronavirus disease-2019 COVID-19's reach globally, leading to myriad deaths.\",\n",
              "   'idx': 'e6beba15edb347fcb78face5be998e97',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 112,\n",
              "   'span_end': 120,\n",
              "   'text': \"Coronavirus disease-2019 COVID-19 was first detected in Wuhan, China, and has expanded Coronavirus disease-2019 COVID-19's reach globally, leading to myriad deaths.\",\n",
              "   'idx': 'e6beba15edb347fcb78face5be998e97',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 60,\n",
              "   'span_end': 84,\n",
              "   'text': 'According to World Health Organisation, the total number of Coronavirus disease-2019 COVID-19 confirmed cases worldwide was found to be 532201219 and total number of deaths accounted to 6305358 as of 10th June, 2022.',\n",
              "   'idx': '015458c1bf2b4de682105b3218f95b65',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 85,\n",
              "   'span_end': 93,\n",
              "   'text': 'According to World Health Organisation, the total number of Coronavirus disease-2019 COVID-19 confirmed cases worldwide was found to be 532201219 and total number of deaths accounted to 6305358 as of 10th June, 2022.',\n",
              "   'idx': '015458c1bf2b4de682105b3218f95b65',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 81,\n",
              "   'span_end': 105,\n",
              "   'text': 'Among many regions, Europe holds the top position in highest number of confirmed Coronavirus disease-2019 COVID-19 cases then followed by America, Western Pacific, South-East Asia, Eastern Mediterranean, and Africa respectively.',\n",
              "   'idx': '93d38a17599a40438e23b8777aaaa86c',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 106,\n",
              "   'span_end': 114,\n",
              "   'text': 'Among many regions, Europe holds the top position in highest number of confirmed Coronavirus disease-2019 COVID-19 cases then followed by America, Western Pacific, South-East Asia, Eastern Mediterranean, and Africa respectively.',\n",
              "   'idx': '93d38a17599a40438e23b8777aaaa86c',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 41,\n",
              "   'span_end': 65,\n",
              "   'text': 'These statistics reveal that even today, Coronavirus disease-2019 COVID-19 is still infecting several people, many of whom die due to complications.',\n",
              "   'idx': 'ed2a7c3774244468b878b67c41103028',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 66,\n",
              "   'span_end': 74,\n",
              "   'text': 'These statistics reveal that even today, Coronavirus disease-2019 COVID-19 is still infecting several people, many of whom die due to complications.',\n",
              "   'idx': 'ed2a7c3774244468b878b67c41103028',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 47,\n",
              "   'span_end': 71,\n",
              "   'text': 'However, the development of specific drugs for Coronavirus disease-2019 COVID-19 takes several years, paving the way for exploring alternative approaches.',\n",
              "   'idx': '8f9d74ebe4c34dcebad333e1dd395aa4',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 72,\n",
              "   'span_end': 80,\n",
              "   'text': 'However, the development of specific drugs for Coronavirus disease-2019 COVID-19 takes several years, paving the way for exploring alternative approaches.',\n",
              "   'idx': '8f9d74ebe4c34dcebad333e1dd395aa4',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 4,\n",
              "   'span_end': 28,\n",
              "   'text': 'The Coronavirus disease-2019 COVID-19 pandemic has ensured research to explore various alternatives, drug repurposing being one of various alternatives, as part of the disease management strategy.',\n",
              "   'idx': 'ed0a48816bab42a984a12ef60f06bcf6',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 29,\n",
              "   'span_end': 37,\n",
              "   'text': 'The Coronavirus disease-2019 COVID-19 pandemic has ensured research to explore various alternatives, drug repurposing being one of various alternatives, as part of the disease management strategy.',\n",
              "   'idx': 'ed0a48816bab42a984a12ef60f06bcf6',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease-2019',\n",
              "   'span_start': 174,\n",
              "   'span_end': 198,\n",
              "   'text': 'Several drugs such as chloroquine, hydroxychloroquine, remdesivir, tocilizumab, kaletra, and favipiravir are currently being testing in clinal trials for repurposing against Coronavirus disease-2019 COVID-19.',\n",
              "   'idx': '7362f6dcec4b4b55a3a2e69600384b5b',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 199,\n",
              "   'span_end': 207,\n",
              "   'text': 'Several drugs such as chloroquine, hydroxychloroquine, remdesivir, tocilizumab, kaletra, and favipiravir are currently being testing in clinal trials for repurposing against Coronavirus disease-2019 COVID-19.',\n",
              "   'idx': '7362f6dcec4b4b55a3a2e69600384b5b',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 0,\n",
              "   'span_end': 10,\n",
              "   'text': 'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "   'idx': '0594adb9b50c4ac2a870f1804693ca61',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 61,\n",
              "   'span_end': 74,\n",
              "   'text': 'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "   'idx': '0594adb9b50c4ac2a870f1804693ca61',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 148,\n",
              "   'span_end': 159,\n",
              "   'text': 'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "   'idx': '0594adb9b50c4ac2a870f1804693ca61',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 160,\n",
              "   'span_end': 168,\n",
              "   'text': 'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "   'idx': '0594adb9b50c4ac2a870f1804693ca61',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV',\n",
              "   'span_start': 170,\n",
              "   'span_end': 174,\n",
              "   'text': 'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "   'idx': '0594adb9b50c4ac2a870f1804693ca61',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV',\n",
              "   'span_start': 189,\n",
              "   'span_end': 193,\n",
              "   'text': 'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "   'idx': '0594adb9b50c4ac2a870f1804693ca61',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 205,\n",
              "   'span_end': 216,\n",
              "   'text': 'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "   'idx': '0594adb9b50c4ac2a870f1804693ca61',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 19,\n",
              "   'span_end': 29,\n",
              "   'text': 'The replication of SARS-CoV 2 occurs with the help of mRNAs.',\n",
              "   'idx': '7f4c638b03ce42c893b23abf5c8a40f9',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 20,\n",
              "   'span_end': 30,\n",
              "   'text': 'The nucleocapsid in SARS-CoV 2 protects the viral RNA genomes from external environmental conditions.',\n",
              "   'idx': '270d777c944f4bbea5cb737c40c37190',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 100,\n",
              "   'span_end': 110,\n",
              "   'text': 'At the relaxed position, The nucleocapsid in the virus appears to be in a helical shape, but within SARS-CoV 2, The nucleocapsid in the virus appears spherical.',\n",
              "   'idx': '0353066e48e443b0853c155f1f8e5921',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 14,\n",
              "   'span_end': 24,\n",
              "   'text': 'The genome of SARS-CoV 2 codes for four main structural proteins when compared to five in other coronaviruses leaving out the hemagglutinin-esterase HE protein.',\n",
              "   'idx': '4be01e276d0f4b09999c5d39ad1205c3',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 96,\n",
              "   'span_end': 109,\n",
              "   'text': 'The genome of SARS-CoV 2 codes for four main structural proteins when compared to five in other coronaviruses leaving out the hemagglutinin-esterase HE protein.',\n",
              "   'idx': '4be01e276d0f4b09999c5d39ad1205c3',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 108,\n",
              "   'span_end': 118,\n",
              "   'text': 'Nucleocapsid N, membrane M, envelope E, and spike S are the four important structural proteins expressed by SARS-CoV 2.',\n",
              "   'idx': '6a41874a43df42a68a5ef6ae2db954c6',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 18,\n",
              "   'span_end': 28,\n",
              "   'text': 'On the surface of SARS-CoV 2, three structural proteins M, E, and S are present, while the nucleocapsid protein resides in the core region bound to genomic RNA.',\n",
              "   'idx': '150fa21eab0047b0ae808ef5dbda29cd',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 22,\n",
              "   'span_end': 32,\n",
              "   'text': 'The spike proteins of SARS-CoV 2 help in the attachment, entry, pathogenesis, and tissue tropism, whereas, the infection is carried out by envelope E. Ribonucleoprotein is formed with nucleocapsid protein’s assistance and the membrane proteins aid in the overall viral architecture.',\n",
              "   'idx': '53a936e1b3b54478bcf0f6cb9d7b35c4',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 0,\n",
              "   'span_end': 10,\n",
              "   'text': \"SARS-CoV 2 enters with the help of spike proteins by binding to the human angiotensin-converting enzyme 2 hACE2 through the human angiotensin-converting enzyme 2 hACE2's receptor-binding domain RBD and human proteases that make them proteolytically active.\",\n",
              "   'idx': 'df50639d3a514a5ba3fc2f6bd2d4335a',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 71,\n",
              "   'span_end': 81,\n",
              "   'text': 'Beta, gamma, delta, and omicron are the latest variants of concern for SARS-CoV 2.',\n",
              "   'idx': 'e4582c8866b942e2ab22539ed9b62d8d',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 53,\n",
              "   'span_end': 61,\n",
              "   'text': 'South Africa was first to report the beta variant of COVID-19, gamma was noted first in Brazil, delta in India, and omicron in western Europe.',\n",
              "   'idx': 'c3f516fbf1a44198a639fef9c70ab7f7',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 44,\n",
              "   'span_end': 52,\n",
              "   'text': 'Omicron which is the most recent variant of COVID-19 carried all the mutations that were present in the previous variants along with some new improved functions such as showing partial resistance to the vaccine and enhanced transmissibility compared to others.',\n",
              "   'idx': 'c0913acbafff43c6b9f2be72fa3b7673',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 10,\n",
              "   'span_end': 21,\n",
              "   'text': 'The major coronavirus variants can be classified into two previously circulating variants of concern VoC and currently circulating variants of concern.',\n",
              "   'idx': 'aa00f6f2363c4de78aec303dea7c4425',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 10,\n",
              "   'span_end': 21,\n",
              "   'text': 'The major coronavirus variants are the current targets for research to find repurposed drugs for exploring treatment strategies.',\n",
              "   'idx': '56c95993e1394c7bb629230e2d3a5525',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 65,\n",
              "   'span_end': 76,\n",
              "   'text': 'In addition to this, certain amino acids are conserved among the coronavirus viruses, while some have a unique mark in the amino acid indicating lineage mutations.',\n",
              "   'idx': '77ce90d540144acb8309bb418373de80',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 10,\n",
              "   'span_end': 21,\n",
              "   'text': 'The major coronavirus variants belong to various lineages.',\n",
              "   'idx': '18d277555387467186c8bb4bc9ac58c4',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'B.1.1.7',\n",
              "   'span_start': 0,\n",
              "   'span_end': 7,\n",
              "   'text': 'B.1.1.7 has the mutations H69-V70del, P618H, and N501Y, all indicating alterations in the amino acids.',\n",
              "   'idx': 'e4085cfb653343e8a17e6bbfbf89cfeb',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'B.1.351',\n",
              "   'span_start': 8,\n",
              "   'span_end': 15,\n",
              "   'text': 'Lineage B.1.351 has mutations K417N, N501Y, and E484K.',\n",
              "   'idx': '96bb156b11994d20bd1f4a49cf2bfd51',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'P.1',\n",
              "   'span_start': 48,\n",
              "   'span_end': 51,\n",
              "   'text': 'Likewise, another variant of concern of lineage P.1 has mutations N501Y, K417T, and E484K.',\n",
              "   'idx': 'd53fa374854a42f0a8bb91de8a38c7b0',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'B.1.526',\n",
              "   'span_start': 0,\n",
              "   'span_end': 7,\n",
              "   'text': 'B.1.526 lineage is mutated at D614G, T95I, D253G, and S477N.',\n",
              "   'idx': '5023cf4a6c944a3489c3a20b034eeeea',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'B.1.427',\n",
              "   'span_start': 0,\n",
              "   'span_end': 7,\n",
              "   'text': 'B.1.427 has mutations at L452R and D614G.',\n",
              "   'idx': 'dcc5e5c0dd9b46e285a0b4ce921b1c23',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'B.1.429',\n",
              "   'span_start': 0,\n",
              "   'span_end': 7,\n",
              "   'text': 'B.1.429 is mutated at sites D614G, S13I, W152C, and L452R.',\n",
              "   'idx': '1a585116fc6e48e293eab5880f9b156c',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'B.1.617',\n",
              "   'span_start': 0,\n",
              "   'span_end': 7,\n",
              "   'text': 'B.1.617 variant has variations P681R, E484Q, and L452R.',\n",
              "   'idx': '2c7b72d4b97b4fa7846457547acb37da',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 93,\n",
              "   'span_end': 103,\n",
              "   'text': 'Apart from the variants identified in the most common lineages, there are approximately 1516 SARS-CoV 2 lineages to date.',\n",
              "   'idx': 'fbcab2c0c61442caa185c072f05f3b1a',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 108,\n",
              "   'span_end': 118,\n",
              "   'text': 'To identify the variants in all the existing lineages and those that exist not only in the spike protein of SARS-CoV 2, this study also performed a search in and summarized the different types of variants.',\n",
              "   'idx': '2fc89616dade4f33a4eb882589ca81f5',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 195,\n",
              "   'span_end': 205,\n",
              "   'text': 'Synonymous, non-synonymous, deletions, and non-coding variations were identified, and changes in the amino acid positions, and the reference and mutated codon as screened in all 1516 lineages of SARS-CoV 2.',\n",
              "   'idx': '06ac9c53804543f7a9620a0afba1f9d2',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 55,\n",
              "   'span_end': 65,\n",
              "   'text': '131 non-synonymous mutations are in various regions of SARS-CoV 2, including the spike proteins, nucleocapsid proteins, different open reading frames, and membrane and envelope proteins.',\n",
              "   'idx': '0f83f96857334666a7a833f5ff1519f4',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV 2',\n",
              "   'span_start': 121,\n",
              "   'span_end': 131,\n",
              "   'text': 'Additionally, some mutations are characteristic of specific regions, while some others are present in all the regions in SARS-CoV 2.',\n",
              "   'idx': '0db0d49d5bf543fd98b8337a49f8f03c',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 10,\n",
              "   'span_end': 20,\n",
              "   'text': 'Thus, the SARS-CoV-2 variants may have different binding sites making the SARS-CoV-2 variants identifying a suitable drug challenging.',\n",
              "   'idx': '7a1a4ecaf92645ceb9152e1328aa1365',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 74,\n",
              "   'span_end': 84,\n",
              "   'text': 'Thus, the SARS-CoV-2 variants may have different binding sites making the SARS-CoV-2 variants identifying a suitable drug challenging.',\n",
              "   'idx': '7a1a4ecaf92645ceb9152e1328aa1365',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 130,\n",
              "   'span_end': 138,\n",
              "   'text': 'Currently, there is a huge interest in the repurposing of drugs to speed up the identification of drugs that can prevent or treat COVID-19.',\n",
              "   'idx': '7e2d6302573849edb12751a08f250908',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 94,\n",
              "   'span_end': 102,\n",
              "   'text': 'drugs lopinavir and ritonavir were also the first drugs to be repurposed for the treatment of COVID-19.',\n",
              "   'idx': '0384cf8298874571a3e48c85d2a096fd',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 58,\n",
              "   'span_end': 66,\n",
              "   'text': 'The main reason for this is due to the resemblance of the SARS-CoV and MERS-CoV beta coronavirus genome sequences to SARS-CoV-2.',\n",
              "   'idx': 'd278dc972e03465ebf54eef035a15200',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 71,\n",
              "   'span_end': 79,\n",
              "   'text': 'The main reason for this is due to the resemblance of the SARS-CoV and MERS-CoV beta coronavirus genome sequences to SARS-CoV-2.',\n",
              "   'idx': 'd278dc972e03465ebf54eef035a15200',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 85,\n",
              "   'span_end': 96,\n",
              "   'text': 'The main reason for this is due to the resemblance of the SARS-CoV and MERS-CoV beta coronavirus genome sequences to SARS-CoV-2.',\n",
              "   'idx': 'd278dc972e03465ebf54eef035a15200',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 117,\n",
              "   'span_end': 127,\n",
              "   'text': 'The main reason for this is due to the resemblance of the SARS-CoV and MERS-CoV beta coronavirus genome sequences to SARS-CoV-2.',\n",
              "   'idx': 'd278dc972e03465ebf54eef035a15200',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 52,\n",
              "   'span_end': 60,\n",
              "   'text': \"Thus, the drugs being utilized for the treatment of MERS-CoV and SARS-CoV-2 could be essentially used for COVID-19 treatment, implying that the mechanism of action of repositioned drugs against repositioned drugs's targets should be similar to or resemble repositioned drugs's family target members.\",\n",
              "   'idx': 'f711e9bee0af466f8fc58e2b3f8e127b',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 65,\n",
              "   'span_end': 75,\n",
              "   'text': \"Thus, the drugs being utilized for the treatment of MERS-CoV and SARS-CoV-2 could be essentially used for COVID-19 treatment, implying that the mechanism of action of repositioned drugs against repositioned drugs's targets should be similar to or resemble repositioned drugs's family target members.\",\n",
              "   'idx': 'f711e9bee0af466f8fc58e2b3f8e127b',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 106,\n",
              "   'span_end': 114,\n",
              "   'text': \"Thus, the drugs being utilized for the treatment of MERS-CoV and SARS-CoV-2 could be essentially used for COVID-19 treatment, implying that the mechanism of action of repositioned drugs against repositioned drugs's targets should be similar to or resemble repositioned drugs's family target members.\",\n",
              "   'idx': 'f711e9bee0af466f8fc58e2b3f8e127b',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 52,\n",
              "   'span_end': 60,\n",
              "   'text': 'Successful administration to patients with moderate COVID-19 symptoms has been previously observed, confirming the hypothesis of drug repurposing.',\n",
              "   'idx': '97620928e69a48909caa7a1b9851cbcd',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 91,\n",
              "   'span_end': 99,\n",
              "   'text': 'Aside from this, the scope of drug repurposing expands to the following, with instances in COVID-19 research, as discussed in the below sections Precision medicine Precision medicine is an emerging strategy that studies the variability of individual genes, the lifestyle, and the environment for each person to decide upon the correct treatment approach.',\n",
              "   'idx': '26325260106b4b018bd525f11bae3a98',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 174,\n",
              "   'span_end': 182,\n",
              "   'text': 'Recent studies have implicated the use of computational techniques such as machine learning algorithms as a precision medicine tool for drug repurposing for the treatment of COVID-19.',\n",
              "   'idx': '0593312fb66945ab93332572f4cbc3a9',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 202,\n",
              "   'span_end': 210,\n",
              "   'text': 'The decision tree algorithms used in the study identify patients with longer survival rates and better oxygen support when treatment was provided and suggest corticosteroids and remdesivir as effective COVID-19 repurposed drugs.',\n",
              "   'idx': 'a69e99633de0403495f0baaff435d76a',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 49,\n",
              "   'span_end': 57,\n",
              "   'text': 'Rapid therapeutic options With the advent of the COVID-19 pandemic and reduced therapeutic options for COVID-19, repurposing offers rapid therapeutic strategies to combat COVID-19.',\n",
              "   'idx': '0214318379fb4259a2835acfae827556',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 103,\n",
              "   'span_end': 111,\n",
              "   'text': 'Rapid therapeutic options With the advent of the COVID-19 pandemic and reduced therapeutic options for COVID-19, repurposing offers rapid therapeutic strategies to combat COVID-19.',\n",
              "   'idx': '0214318379fb4259a2835acfae827556',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 171,\n",
              "   'span_end': 179,\n",
              "   'text': 'Rapid therapeutic options With the advent of the COVID-19 pandemic and reduced therapeutic options for COVID-19, repurposing offers rapid therapeutic strategies to combat COVID-19.',\n",
              "   'idx': '0214318379fb4259a2835acfae827556',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 72,\n",
              "   'span_end': 80,\n",
              "   'text': 'El Bairi et al. reviewed various anticancer drugs for the management of COVID-19.',\n",
              "   'idx': 'dfb9761c02d2440694d9cb9744494772',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 374,\n",
              "   'span_end': 382,\n",
              "   'text': 'Likewise, another study has elucidated and suggested the use of interleukin inhibitors, Janus-kinase pathway inhibitors, interferons, vascular endothelial growth factor VEGF inhibitors, immune check-point inhibitors, Bruton tyrosine kinase inhibitors BTK, and XPO-1 a selective inhibitor of nuclear export as some of the alternative drugs that could be repurposed for rapid COVID-19 treatment.',\n",
              "   'idx': '5c0d3cd2c27c44d2a6db8637e86b09ca',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 135,\n",
              "   'span_end': 148,\n",
              "   'text': 'Similarly, another study suggested p38 MAPK mitogen-activated protein kinase, as a vital host target for inhibiting the replication of coronaviruses, after studies proved that Ralimetiniib mesylate was found to be active in both Calu-3 and HeLa-ACE2 cells.',\n",
              "   'idx': 'c8315bd0e46447d89502eeb6db0bb88a',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 29,\n",
              "   'span_end': 37,\n",
              "   'text': 'Thus, drug repositioning for COVID-19 research has now taken the front seat and has a huge scope for tackling the virus.',\n",
              "   'idx': 'e3011fb70d7b44ff92e45d854d51af63',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 56,\n",
              "   'span_end': 64,\n",
              "   'text': 'With increasing incidences of emerging diseases such as COVID-19, for which immediate treatments were not available, the need for drugs to treat the disease became indispensable.',\n",
              "   'idx': 'a8c11b6c696e4f34864a4e88eef2952b',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 104,\n",
              "   'span_end': 114,\n",
              "   'text': 'Previous studies have most commonly employed molecular docking for virtual screening against targets of SARS-CoV-2, such as the main protease, with possible drugs for repurposing such as digitoxigenin, beta-eudesmol, crocin, rutin, ritonavir, emetine, hesperidin, and indinavir.',\n",
              "   'idx': 'bd00e68d54f5462f823012d9c27f18c8',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 65,\n",
              "   'span_end': 73,\n",
              "   'text': 'Likewise, other virtual screening approaches used previously for COVID-19 drug repurposing include combinations of docking with molecular dynamic MD simulations and calculation of free energy using MM-GBSA studies and two-way docking with in silico ADMET studies.',\n",
              "   'idx': '1df86404f76b41eba27ce62b59caf5ce',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 85,\n",
              "   'span_end': 95,\n",
              "   'text': 'The authors’ previous studies have used Molecular docking against various targets of SARS-CoV-2.',\n",
              "   'idx': '7ea48c72751e4a5e9b2bba9f9d74e36d',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 143,\n",
              "   'span_end': 153,\n",
              "   'text': 'Elfiky proved via MD simulations that Setrobuvir, YAK, and ID-184 had the best antiviral activity against RNRP RNA-dependent RNA polymerase of SARS-CoV-2, after screening out 31 compounds that were in clinical trials or had known antiviral activity.',\n",
              "   'idx': '6246f31dbe7449f9873fc6d8ea3f5736',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 79,\n",
              "   'span_end': 89,\n",
              "   'text': 'Similarly, MD simulations identified the stability of lopinavir complexed with SARS-CoV-2 main protease as the most stable in biological conditions, along with other identified antivirals such as carfilzomib, valrubicin, elbasvir, and eravacycline.',\n",
              "   'idx': '4fa06fb2037a4031b5d729db784fb381',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 15,\n",
              "   'span_end': 23,\n",
              "   'text': 'With regard to COVID-19, this approach combined with docking and simulations has brought immense benefits to the design and repurposing of drugs for SARS-CoV-2.',\n",
              "   'idx': '5e9738f92a0441a0b1a2b56749652abf',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 149,\n",
              "   'span_end': 159,\n",
              "   'text': 'With regard to COVID-19, this approach combined with docking and simulations has brought immense benefits to the design and repurposing of drugs for SARS-CoV-2.',\n",
              "   'idx': '5e9738f92a0441a0b1a2b56749652abf',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 136,\n",
              "   'span_end': 146,\n",
              "   'text': 'A study has previously created a QSAR model founded on machine learning strategies utilizing several hundred inhibitor molecules of the SARS-CoV-2 main protease.',\n",
              "   'idx': '0ffb8ec044fe4140b760c3a82a721541',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 105,\n",
              "   'span_end': 115,\n",
              "   'text': 'a QSAR model founded on machine learning strategies utilizing several hundred inhibitor molecules of the SARS-CoV-2 main protease was employed for virtual screening and docking, followed by shortlisting of the 20 best candidates for MD simulation validation.',\n",
              "   'idx': '17a57b35326e4f88875a88f0650aed6d',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 183,\n",
              "   'span_end': 193,\n",
              "   'text': 'Similarly, another recent study designed a binary-QSAR model for the virtual screening of several drugs that are FDA-approved and are in clinical studies against the main protease of SARS-CoV-2.',\n",
              "   'idx': 'ee9eb2892db24941b344bdf09ef97b10',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 104,\n",
              "   'span_end': 114,\n",
              "   'text': 'a binary-QSAR model resulted in cefuroxime pivoxetil as a potential drug repositioning molecule against SARS-CoV-2.',\n",
              "   'idx': 'c4b939f2970c4548bf94f6b00fae2687',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 120,\n",
              "   'span_end': 128,\n",
              "   'text': 'Recently, the use of AI technology for drug repositioning has surfaced with several studies focusing on repurposing for COVID-19 research.',\n",
              "   'idx': '257107d51e9a49b380cf9dfbdebcf010',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 123,\n",
              "   'span_end': 133,\n",
              "   'text': 'A deep-learning-based approach to screen a huge number of molecules having allocated datasets to seek compounds possessing SARS-CoV-2-inhibiting activities was carried out previously by Ke et al. To validate the designed model and verify the antiviral activity of the compound that the designed model predicted, an in vitro cell line for feline coronavirus replication was also set up in the study.',\n",
              "   'idx': '21b67bd2c7e74ecb89652b17da7b1282',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 345,\n",
              "   'span_end': 356,\n",
              "   'text': 'A deep-learning-based approach to screen a huge number of molecules having allocated datasets to seek compounds possessing SARS-CoV-2-inhibiting activities was carried out previously by Ke et al. To validate the designed model and verify the antiviral activity of the compound that the designed model predicted, an in vitro cell line for feline coronavirus replication was also set up in the study.',\n",
              "   'idx': '21b67bd2c7e74ecb89652b17da7b1282',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 252,\n",
              "   'span_end': 262,\n",
              "   'text': 'Likewise, Beck et al. utilized an already trained deep-learning prediction model for drug-target interactions known as Molecule Transformer-Drug Target Interaction MT-DTI, to find antiviral drugs that are commercially available and which could perturb SARS-CoV-2 components including RNA-dependent RNA polymerase, proteinase, and helicase.',\n",
              "   'idx': '0e886ea9056a42b5958ef12eecdd7a94',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 85,\n",
              "   'span_end': 93,\n",
              "   'text': 'Thus, AI-based techniques are providing the scientific communities a chance to fight COVID-19 in a much faster way, owing to the accessible web servers, tools, and models that reduce the time required for a drug to come into the market.',\n",
              "   'idx': '66d8373730604a78a2cde983a4a0df17',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 71,\n",
              "   'span_end': 79,\n",
              "   'text': 'The scope and developments of computational medicinal chemistry toward COVID-19 treatment strategies are summarized in Fig. Several computational approaches for repurposing have been used over the years to enhance the efficiency of the predictive outcomes and decrease the drawbacks.',\n",
              "   'idx': 'eb963488d2a947b3a3c51fac23f63fa5',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 112,\n",
              "   'span_end': 120,\n",
              "   'text': 'There are several applications of computational biology and chem-bioinformatic approaches for drug discovery in COVID-19 research.',\n",
              "   'idx': 'e840c84d674844ad95a7aedfcd97acc5',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 104,\n",
              "   'span_end': 112,\n",
              "   'text': 'A recent study has developed a multi-model deep learning-based algorithm for drug repurposing to aid in COVID-19 research.',\n",
              "   'idx': 'e359c048722743f5b272c6a9dfe20232',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 144,\n",
              "   'span_end': 152,\n",
              "   'text': 'The results from A recent study showed clusters that were employed to identify the drugs that were notably similar to the proposed and existing COVID-19 treatment medication.',\n",
              "   'idx': '2d64dde029184337b5454a99cf27a119',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 170,\n",
              "   'span_end': 178,\n",
              "   'text': 'Another recent study also proposed a data augmentation approach that extricates only beneficial data from a set of variable datasets, to screen novel drug candidates for COVID-19.',\n",
              "   'idx': '41679a5d32f94f78a6453b75c47d43a6',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 45,\n",
              "   'span_end': 53,\n",
              "   'text': 'A recent application of signature mapping on COVID-19 research demonstrated the use of Connectivity Map databases for generating drug perturbation profiles.',\n",
              "   'idx': '811da5fc3e6d4ddab5f5a2dc3f056642',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 67,\n",
              "   'span_end': 75,\n",
              "   'text': 'A modified version of A recent application of signature mapping on COVID-19 research was implemented by Jia et al. where the input used was the expression profile data from healthy and infected individuals to generate a pathway-based drug repurposing framework.',\n",
              "   'idx': 'f9280dd1ea37452cb8f5ee4e8ba1acfd',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 191,\n",
              "   'span_end': 201,\n",
              "   'text': 'Another recent study designed and developed Deep Docking, which uses QSAR Quantitative Structure–Activity Relationship models to predict the docking scores of drug candidates that target the SARS-CoV-2 3CL protein.',\n",
              "   'idx': 'b1b12af0d09647939d1f94940069c1c5',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 118,\n",
              "   'span_end': 126,\n",
              "   'text': 'Deep Docking docked all the compounds and provided a list of potential drug hits, that could be used to repurpose for COVID-19.',\n",
              "   'idx': '88ea4524307546be892eb6b3eda89ad2',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 100,\n",
              "   'span_end': 108,\n",
              "   'text': 'Several studies have implemented random-walk algorithms to identify drug repurposing candidates for COVID-19 –. The pathogenic mechanisms instigated by the SARS-CoV-2 3CL protein using the information from all related coronaviruses were also explored and random walk algorithms were implemented on the molecular networks to recognize the most relevant COVID-19 drug targets.',\n",
              "   'idx': '773625e2a7d740af98a4147dad1e1de6',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 156,\n",
              "   'span_end': 166,\n",
              "   'text': 'Several studies have implemented random-walk algorithms to identify drug repurposing candidates for COVID-19 –. The pathogenic mechanisms instigated by the SARS-CoV-2 3CL protein using the information from all related coronaviruses were also explored and random walk algorithms were implemented on the molecular networks to recognize the most relevant COVID-19 drug targets.',\n",
              "   'idx': '773625e2a7d740af98a4147dad1e1de6',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 218,\n",
              "   'span_end': 231,\n",
              "   'text': 'Several studies have implemented random-walk algorithms to identify drug repurposing candidates for COVID-19 –. The pathogenic mechanisms instigated by the SARS-CoV-2 3CL protein using the information from all related coronaviruses were also explored and random walk algorithms were implemented on the molecular networks to recognize the most relevant COVID-19 drug targets.',\n",
              "   'idx': '773625e2a7d740af98a4147dad1e1de6',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 352,\n",
              "   'span_end': 360,\n",
              "   'text': 'Several studies have implemented random-walk algorithms to identify drug repurposing candidates for COVID-19 –. The pathogenic mechanisms instigated by the SARS-CoV-2 3CL protein using the information from all related coronaviruses were also explored and random walk algorithms were implemented on the molecular networks to recognize the most relevant COVID-19 drug targets.',\n",
              "   'idx': '773625e2a7d740af98a4147dad1e1de6',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 137,\n",
              "   'span_end': 145,\n",
              "   'text': 'Thus, these computational perspectives on drug repurposing provide a unique outlook on the alternative treatment options for the ongoing COVID-19 disease.',\n",
              "   'idx': '2c4805ff3f9943a4983b63b7f1adc872',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 114,\n",
              "   'span_end': 124,\n",
              "   'text': 'Drugs such as lopinavir, ritonavir, boceprevir, carmofur, and doxycycline act on the 3-chymotrypsin-like proteins/SARS-CoV-2 main protease that play an important role in cleaving and releasing the 16 non-structural proteins.',\n",
              "   'idx': 'f09aa4b3dfb64aaf8f820d14598e06b7',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 26,\n",
              "   'span_end': 36,\n",
              "   'text': 'For the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of SARS-CoV-2, drugs such as vapreotide, atazanavir, daclatasvir, and bismuth potassium citrate commonly block this function of the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of the virus.',\n",
              "   'idx': 'bfef62c067a54034bf94fe26119e9220',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 115,\n",
              "   'span_end': 125,\n",
              "   'text': 'For the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of SARS-CoV-2, drugs such as vapreotide, atazanavir, daclatasvir, and bismuth potassium citrate commonly block this function of the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of the virus.',\n",
              "   'idx': 'bfef62c067a54034bf94fe26119e9220',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 262,\n",
              "   'span_end': 272,\n",
              "   'text': 'For the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of SARS-CoV-2, drugs such as vapreotide, atazanavir, daclatasvir, and bismuth potassium citrate commonly block this function of the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of the virus.',\n",
              "   'idx': 'bfef62c067a54034bf94fe26119e9220',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 181,\n",
              "   'span_end': 191,\n",
              "   'text': 'Likewise, dinucleoside 123 and raltegravir affect the pathways of methyltransferases guanine-N7-methyltransferase, 2’-O-methyltransferase, while gliclazide and memantine affect the SARS-CoV-2 E protein, which is the envelope protein of SARS-CoV-2.',\n",
              "   'idx': 'd81d6527e7804df5b98eb18ed7862fa8',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 236,\n",
              "   'span_end': 246,\n",
              "   'text': 'Likewise, dinucleoside 123 and raltegravir affect the pathways of methyltransferases guanine-N7-methyltransferase, 2’-O-methyltransferase, while gliclazide and memantine affect the SARS-CoV-2 E protein, which is the envelope protein of SARS-CoV-2.',\n",
              "   'idx': 'd81d6527e7804df5b98eb18ed7862fa8',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 271,\n",
              "   'span_end': 281,\n",
              "   'text': 'The viral neuraminidases and the DPP4 cell receptor pathways are hindered due to the action of oseltamivir and sitagliptin, while pemirolast, nitrofurantoin, isoniazid pyruvate, eridictoyl, hypericin, cepharanthine, and ergoloid block the human ACE2 and the S protein of SARS-CoV-2.',\n",
              "   'idx': '1dd07fcd31d047dc9a8bc232b463b77d',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 123,\n",
              "   'span_end': 133,\n",
              "   'text': 'The most important Janus kinase pathway is hindered by baricitinib, RdRp, helicase, exo-nuclease, and methyltransferase of SARS-CoV-2 by Efavirenz and Poly ADP-ribose polymerase 1 PARP-1 by Mefuparib hydrochloride.',\n",
              "   'idx': '946e5de9488243ba93f84b17ebe5a8f0',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 90,\n",
              "   'span_end': 100,\n",
              "   'text': 'Other common drugs such as nitazoxanide, ivermectin, and azithromycin tend to symptoms of SARS-CoV-2, and play a role in inhibiting the role of SARS-CoV-2.',\n",
              "   'idx': '08d1f6e8fb1a4a509879a612a7ea9e86',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 144,\n",
              "   'span_end': 154,\n",
              "   'text': 'Other common drugs such as nitazoxanide, ivermectin, and azithromycin tend to symptoms of SARS-CoV-2, and play a role in inhibiting the role of SARS-CoV-2.',\n",
              "   'idx': '08d1f6e8fb1a4a509879a612a7ea9e86',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 66,\n",
              "   'span_end': 74,\n",
              "   'text': 'Despite these drugs being implicated as a potential treatment for COVID-19, ethical issues arise regarding the use of these drugs without proper clinical phase trials and FDA Food and Drug Administration approval.',\n",
              "   'idx': '08018b04273e4924a71238a0cb73c3ce',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 85,\n",
              "   'span_end': 93,\n",
              "   'text': 'Therefore, a list of the FDA Food and Drug Administration drugs for the treatment of COVID-19 is provided in Table.',\n",
              "   'idx': '39180a9113054f7887cd6a7d1d3f66a8',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 105,\n",
              "   'span_end': 115,\n",
              "   'text': 'Mahdian et al. and Yuce et al. state that Paritaprevir is important against 3-chymotrypsin-like proteins/SARS-CoV-2 Main protease and plays an important role in cleaving as well as releasing 16 non-structural proteins Nsps.',\n",
              "   'idx': '606cabdab91b49c39f649f016e3900b9',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 35,\n",
              "   'span_end': 45,\n",
              "   'text': 'Paritaprevir also affects the ACE2-SARS-CoV-2-RBD complex.',\n",
              "   'idx': 'df1d2a6179754110a6ec1fec85882462',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 64,\n",
              "   'span_end': 74,\n",
              "   'text': 'Likewise, ledipasvir, vancomycin, and sirolimus target the ACE2-SARS-CoV-2-RBD complex, a spike protein that helps in the viral entry along with the help of ACE2 protein in the host organism.',\n",
              "   'idx': '4b9c84d5e52f410e98f1f108fe9239d6',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 211,\n",
              "   'span_end': 221,\n",
              "   'text': 'Similarly, FDA-approved irinotecan, abemaciclib, estradiol benzoate, capmatinib, olaparib, lumacaftor, and pazopanib target CD147, a member of the immunoglobulin superfamily IgSF interacts with spike protein of SARS-CoV-2.',\n",
              "   'idx': '42c7cf479ec24b3fa6199b937018ee47',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 230,\n",
              "   'span_end': 240,\n",
              "   'text': 'Other drugs such as nilotinib, rifabutin, dactinomycin, dihydroergotamine, bromocriptine, entrectinib, selinexor, elbasvir, quinupristin, rifapentine, rutin, digitoxin, diosmin, and antrafenine target 3-chymotrypsin-like proteins/SARS-CoV-2 Main protease that plays an important role in cleaving as well as releasing 16 non-structural proteins Nsps.',\n",
              "   'idx': 'c24eedbf736640d4bd8f6e705e0438db',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 187,\n",
              "   'span_end': 197,\n",
              "   'text': 'This data is provided in detail in Table and the 2D structures of some of these drugs are shown in Fig. When remdesivir was administered intravenously to the first patient diagnosed with SARS-CoV-2 in the USA, no adverse effects were noted with some clinical benefits in the first patient diagnosed with SARS-CoV-2 in the USA.',\n",
              "   'idx': '7a3144765dec4024a71321a3ce8456f9',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 304,\n",
              "   'span_end': 314,\n",
              "   'text': 'This data is provided in detail in Table and the 2D structures of some of these drugs are shown in Fig. When remdesivir was administered intravenously to the first patient diagnosed with SARS-CoV-2 in the USA, no adverse effects were noted with some clinical benefits in the first patient diagnosed with SARS-CoV-2 in the USA.',\n",
              "   'idx': '7a3144765dec4024a71321a3ce8456f9',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 203,\n",
              "   'span_end': 211,\n",
              "   'text': 'Additionally, due to some adverse effects early on, remdesivir was then discontinued, and FDA Food and Drug Administration has now provided a conditional recommendation for the use of remdesivir against COVID-19.',\n",
              "   'idx': '1737d5f7ad8b4404b2b2cd388a02c929',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 90,\n",
              "   'span_end': 98,\n",
              "   'text': 'Likewise, real-world usage of lopinavir/ritonavir revealed no beneficial response against COVID-19 hospitalized patients in a randomized, controlled, trial.',\n",
              "   'idx': 'f5e0ec3115494dc7a7950cdb64f2d691',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 141,\n",
              "   'span_end': 149,\n",
              "   'text': 'Despite there being studies on hydroxychloroquine, an analogue of chloroquine, where improvements have been noted in patients suffering from COVID-19 in a study conducted in Wuhan, there still seems to be very limited data on the reliability of hydroxychloroquine, an analogue of chloroquine.',\n",
              "   'idx': '774fea97bbc9495fac647772b80e4d86',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 71,\n",
              "   'span_end': 79,\n",
              "   'text': 'Interferon-beta-1A has been used in hospitalized patients for treating COVID-19 at Shaid Behesti University of Medical Sciences, in combination with other drugs.',\n",
              "   'idx': '63bc8b289e6b4a13a2286c76bd5fcdf2',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 202,\n",
              "   'span_end': 212,\n",
              "   'text': 'Therefore, the clinical data presented provide evidence of the efficacy of the use of these drugs,however, more research is indispensable for the proper application and employability of these drugs for SARS-CoV-2 treatment.',\n",
              "   'idx': 'e677bae390cd4c8c9c6602d362f4e544',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 25,\n",
              "   'span_end': 36,\n",
              "   'text': 'According to literature, coronavirus papain-like proteases PLpro, main protease 3CLpro, helicase, and RNA-dependent RNA polymerase RdRp are the considered to be the potential molecular targets and are involved in important functional activities such as protein synthesis, RNA transcription, translation, replication, processing, and infection respectively.',\n",
              "   'idx': 'ad6d6e85d1454126af20ccdd28b28e30',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 63,\n",
              "   'span_end': 76,\n",
              "   'text': 'All these proteins come under non-structural proteins nsps for coronaviruses.',\n",
              "   'idx': '995714d83a2d426f8dbe21b5613af847',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS CoV-2',\n",
              "   'span_start': 67,\n",
              "   'span_end': 77,\n",
              "   'text': 'The N-terminal and the C-terminal domain of The nucleoprotein N of SARS CoV-2 share similarities with CoVs N proteins.',\n",
              "   'idx': '0542c18fbc624df0965765d6aca020b7',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 102,\n",
              "   'span_end': 106,\n",
              "   'text': 'The N-terminal and the C-terminal domain of The nucleoprotein N of SARS CoV-2 share similarities with CoVs N proteins.',\n",
              "   'idx': '0542c18fbc624df0965765d6aca020b7',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'protomers',\n",
              "   'span_start': 46,\n",
              "   'span_end': 55,\n",
              "   'text': 'the C-terminal domain is a homodimer with two protomers resembling a rectangular slab-like structure.',\n",
              "   'idx': '34ba52b0b9984ebdb63174ce359ba5be',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'protomers',\n",
              "   'span_start': 45,\n",
              "   'span_end': 54,\n",
              "   'text': \"The beta hairpin-like structure connects two protomers by inserting The beta hairpin-like structure into two protomers's cavities.\",\n",
              "   'idx': '616094361a7b4e1c911af884ccda8e6b',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'protomers',\n",
              "   'span_start': 109,\n",
              "   'span_end': 118,\n",
              "   'text': \"The beta hairpin-like structure connects two protomers by inserting The beta hairpin-like structure into two protomers's cavities.\",\n",
              "   'idx': '616094361a7b4e1c911af884ccda8e6b',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS CoV-2',\n",
              "   'span_start': 43,\n",
              "   'span_end': 53,\n",
              "   'text': 'The overall size of The nucleoprotein N of SARS CoV-2 is about 8.4–12 kDa and forms the integral membrane protein of the virus comprising 76–109 amino acids.',\n",
              "   'idx': '1be1bf180b3b4ee1b0ec8d543d3ba322',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS CoV-2',\n",
              "   'span_start': 99,\n",
              "   'span_end': 109,\n",
              "   'text': 'There are about 7–12 amino acids at The N-terminal which is short and makes The nucleoprotein N of SARS CoV-2 hydrophilic in nature.',\n",
              "   'idx': 'e14270f2f3cc48c38e6baf45b4a7c058',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'protomers',\n",
              "   'span_start': 4,\n",
              "   'span_end': 13,\n",
              "   'text': 'The protomers present in the spike glycoprotein structure contain approximately 1260 amino acids.',\n",
              "   'idx': '4cebd76ca51d42b49b29c78f22947665',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 35,\n",
              "   'span_end': 45,\n",
              "   'text': 'The non-structural proteins of the SARS-CoV-2 are polyproteins pp1a and pp1ab.',\n",
              "   'idx': '47746f9939bd4e3d831e8aa615dad257',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 89,\n",
              "   'span_end': 99,\n",
              "   'text': 'These structural details are of utmost essential when The non-structural proteins of the SARS-CoV-2 interact with the drug candidates, to understand the precise molecular mechanism of action of the small molecule.',\n",
              "   'idx': '157038460ec946d2919b983afb70f03e',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 139,\n",
              "   'span_end': 149,\n",
              "   'text': 'All these studies prove that there is distinct evidence as to the altering of the the virus proteins’ structural antigenicity, causing the SARS-CoV-2 proteins’ to evade the immune system and become more robust.',\n",
              "   'idx': '33d8cfee53d14d2e8dbb7dc773c54742',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 111,\n",
              "   'span_end': 119,\n",
              "   'text': 'Currently, as we have seen from various evidences, there are several repurposed drugs reported for use against COVID-19, some already available on the market.',\n",
              "   'idx': 'b53f35657b9e4c079144ff0898ba4f50',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 176,\n",
              "   'span_end': 186,\n",
              "   'text': 'The potential binding of several FDA-approved drugs has been studied previously however, not much data is revealed on the precise molecular basis of these interactions against SARS-CoV-2 targets.',\n",
              "   'idx': 'fc7e4cfbbaf044199f4881c10699271d',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 94,\n",
              "   'span_end': 104,\n",
              "   'text': 'In the previous section, evidence of how the variants alter the drug binding efficacy and how SARS-CoV-2 escapes the immune system is provided.',\n",
              "   'idx': '3c36e7af4a9f412392c46f6f9e9272c2',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 51,\n",
              "   'span_end': 61,\n",
              "   'text': 'In our previous study, however, various targets of SARS-CoV-2 were analyzed at the molecular level to comprehend the changes SARS-CoV-2 undergoes during the binding event of some of the important FDA-approved drugs for COVID-19.',\n",
              "   'idx': 'd0017d5042db461a87471472013f6cf9',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 125,\n",
              "   'span_end': 135,\n",
              "   'text': 'In our previous study, however, various targets of SARS-CoV-2 were analyzed at the molecular level to comprehend the changes SARS-CoV-2 undergoes during the binding event of some of the important FDA-approved drugs for COVID-19.',\n",
              "   'idx': 'd0017d5042db461a87471472013f6cf9',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 219,\n",
              "   'span_end': 227,\n",
              "   'text': 'In our previous study, however, various targets of SARS-CoV-2 were analyzed at the molecular level to comprehend the changes SARS-CoV-2 undergoes during the binding event of some of the important FDA-approved drugs for COVID-19.',\n",
              "   'idx': 'd0017d5042db461a87471472013f6cf9',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 82,\n",
              "   'span_end': 92,\n",
              "   'text': 'Though there are limited experimental data to highlight the spike glycoprotein of SARS-CoV-2 act as the target for repurposed drugs, however, several computational biology prediction revelated the scope of utilising spike glycoproteins as the putative molecular target for repurposed drugs.',\n",
              "   'idx': '1ce2cf2fb0bf476d92641782b084b361',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 104,\n",
              "   'span_end': 114,\n",
              "   'text': 'A recent study stated that drugs ritonavir and eriodictoyl bind to the active sites of spike protein of SARS-CoV-2 with potential binding energy and stability.',\n",
              "   'idx': '0b90024b3d5d4230873d40ab2e17fec5',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 150,\n",
              "   'span_end': 160,\n",
              "   'text': 'Likewise, another study showed that repurposed drugs such as pralatrexate, carumonam, aclerasteride, and granotapide interacted with spike protein of SARS-CoV-2 and acted as potential binders.',\n",
              "   'idx': '948ed6379fce4437b64547ca7a755736',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 139,\n",
              "   'span_end': 149,\n",
              "   'text': 'Additionally, another recent study has reported Remdesivir and ivermectin, potential repurposed drugs interacted with the spike protein of SARS-CoV-2.',\n",
              "   'idx': 'cdd4c4508fbe40bf94a23f2da74eb1cd',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 86,\n",
              "   'span_end': 96,\n",
              "   'text': 'another recent study stated that ivermectin bound effectively to the spike protein of SARS-CoV-2, and inhibited the entry of SARS-CoV-2 into the host.',\n",
              "   'idx': 'd12d0d71bda84611a334e47c24a92bc3',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 125,\n",
              "   'span_end': 135,\n",
              "   'text': 'another recent study stated that ivermectin bound effectively to the spike protein of SARS-CoV-2, and inhibited the entry of SARS-CoV-2 into the host.',\n",
              "   'idx': 'd12d0d71bda84611a334e47c24a92bc3',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 98,\n",
              "   'span_end': 108,\n",
              "   'text': 'Remdesivir was also suggested to be involved in stable interaction with the spike glycoprotein of SARS-CoV-2, apart from the other targets.',\n",
              "   'idx': 'ccf36b83cf324ca582a97baa8d490956',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 104,\n",
              "   'span_end': 114,\n",
              "   'text': 'These studies demonstrate that repurposed drugs were suggested to be targeted the spike glycoprotein of SARS-CoV-2 at various binding pockets and interacted with the spike glycoprotein of SARS-CoV-2.',\n",
              "   'idx': 'b82484a4455e4427905fc5bd8c2df039',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 188,\n",
              "   'span_end': 198,\n",
              "   'text': 'These studies demonstrate that repurposed drugs were suggested to be targeted the spike glycoprotein of SARS-CoV-2 at various binding pockets and interacted with the spike glycoprotein of SARS-CoV-2.',\n",
              "   'idx': 'b82484a4455e4427905fc5bd8c2df039',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 174,\n",
              "   'span_end': 184,\n",
              "   'text': 'At a molecular level, Fig. showed that chloroquine interacted with amino acids Leu6820, Leu6819, Met6818, Val7021, Tyr7020, Asp7018, and Asp6942 of the spike glycoprotein of SARS-CoV-2.',\n",
              "   'idx': 'bdfe0919de7542609e21d9c16cea9c6d',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 125,\n",
              "   'span_end': 133,\n",
              "   'text': 'The major repurposed drugs displayed in Table dhow that research is ongoing and always improving for tackling the problem of COVID-19.',\n",
              "   'idx': '8e5321a5e3d445e78fa9966abcc2bcb7',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS',\n",
              "   'span_start': 77,\n",
              "   'span_end': 81,\n",
              "   'text': 'Lopinavir/ritonavir was generally used against HIV, remdesivir against major SARS viruses, and favipiravir which was previously used as a general viral pro-drug.',\n",
              "   'idx': '364d4a57d46446a688b58c652aed3947',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 94,\n",
              "   'span_end': 102,\n",
              "   'text': 'For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.',\n",
              "   'idx': '9a07e67470504645a68ad406c3f46137',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 197,\n",
              "   'span_end': 205,\n",
              "   'text': 'For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.',\n",
              "   'idx': '9a07e67470504645a68ad406c3f46137',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 210,\n",
              "   'span_end': 218,\n",
              "   'text': 'For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.',\n",
              "   'idx': '9a07e67470504645a68ad406c3f46137',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 319,\n",
              "   'span_end': 329,\n",
              "   'text': 'For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.',\n",
              "   'idx': '9a07e67470504645a68ad406c3f46137',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 356,\n",
              "   'span_end': 364,\n",
              "   'text': 'For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.',\n",
              "   'idx': '9a07e67470504645a68ad406c3f46137',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 88,\n",
              "   'span_end': 98,\n",
              "   'text': 'Likewise, the in vivo study of remdesivir a broad-spectrum antiviral when infected with SARS-CoV-2, the pathogenic strain of COVID-19 disease infected rhesus monkey demonstrated an improvement in the pulmonary lesions and decreased the viral load after 7 days of treatment with remdesivir a broad-spectrum antiviral.',\n",
              "   'idx': '95f285fcae8c43bf8df7cbf725e668af',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 125,\n",
              "   'span_end': 133,\n",
              "   'text': 'Likewise, the in vivo study of remdesivir a broad-spectrum antiviral when infected with SARS-CoV-2, the pathogenic strain of COVID-19 disease infected rhesus monkey demonstrated an improvement in the pulmonary lesions and decreased the viral load after 7 days of treatment with remdesivir a broad-spectrum antiviral.',\n",
              "   'idx': '95f285fcae8c43bf8df7cbf725e668af',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviral disease',\n",
              "   'span_start': 3,\n",
              "   'span_end': 22,\n",
              "   'text': 'No coronaviral disease was observed after the successful use of remdesivir a broad-spectrum antiviral.',\n",
              "   'idx': '13d40e0652e847cfad26556c94cb29f6',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 197,\n",
              "   'span_end': 207,\n",
              "   'text': 'remdesivir a broad-spectrum antiviral was originally meant for treating the Ebola virus against the Ebola RdRp target, and now with potential repurposing capabilities against the RdRp and NSP12 of SARS-CoV-2.',\n",
              "   'idx': '6d1cab4d15904f9ab762b2e4f5a2e2e8',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 108,\n",
              "   'span_end': 118,\n",
              "   'text': 'Lopinavir/ritonavir is a drug for the HIV-1 protease, that now evidences potential for the main protease of SARS-CoV-2.',\n",
              "   'idx': 'b7a8bd971a614bfeb517eb328b0ad5ef',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 92,\n",
              "   'span_end': 102,\n",
              "   'text': 'Silmitasertib is also known to inhibit the casein kinase 2 pathway in Sonic hedgehog SHH in SARS-CoV-2.',\n",
              "   'idx': '6c1e88ad19ec41c9b43f6a997f56b359',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 117,\n",
              "   'span_end': 127,\n",
              "   'text': 'Likewise, dipyridamole 100 mg is an inhibitor of phosphodiesterase originally and works against the main protease of SARS-CoV-2 and stops replication.',\n",
              "   'idx': 'ec1c082824394b5e9c512b0b244f3aec',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 124,\n",
              "   'span_end': 134,\n",
              "   'text': 'Leronlimab 700 mg works against the C–C Chemokine receptor type 5 in HIV and now shows potential against the same target in SARS-CoV-2.',\n",
              "   'idx': 'faa160c700d3403ea22bfac6fb629f88',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 111,\n",
              "   'span_end': 121,\n",
              "   'text': 'Ruconest targets the c1 esterase and inhibits angioedema, while Ruconest targets C1, C5a, and C3a esterases in SARS-CoV-2.',\n",
              "   'idx': 'e59d9b7f367044d9abdbb41f29b258c3',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 48,\n",
              "   'span_end': 58,\n",
              "   'text': \"Infliximab attacks the tumor necrosis factor in SARS-CoV-2 as well as in Infliximab's original target in Rheumatoid arthritis, Crohn’s disease, and ankylosing spondylitis.\",\n",
              "   'idx': '260c1b231d0b4bea8d863d5967be4ad2',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 17,\n",
              "   'span_end': 27,\n",
              "   'text': 'The emergence of SARS-CoV-2 has illuminated the purpose and benefits of repositioning drugs to provide emergency treatments.',\n",
              "   'idx': '324b92f3df254d8b8f75cd093e4c0946',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 317,\n",
              "   'span_end': 325,\n",
              "   'text': 'Other advantages of repurposed drugs include Lower cost of productionLesser time for identifying useful, effective, and safe drugs for quick useResearch can be carried out using the existing, easily accessible bioinformatics and chem-informatics data and resources available for specific diseases, as was the case in COVID-19 cases Molecular docking The emergence and prevalence of COVID-19 have paved the way for molecular docking studies.',\n",
              "   'idx': '2198e1214ef743bebb21a32e601101ce',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 382,\n",
              "   'span_end': 390,\n",
              "   'text': 'Other advantages of repurposed drugs include Lower cost of productionLesser time for identifying useful, effective, and safe drugs for quick useResearch can be carried out using the existing, easily accessible bioinformatics and chem-informatics data and resources available for specific diseases, as was the case in COVID-19 cases Molecular docking The emergence and prevalence of COVID-19 have paved the way for molecular docking studies.',\n",
              "   'idx': '2198e1214ef743bebb21a32e601101ce',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 109,\n",
              "   'span_end': 117,\n",
              "   'text': 'Previously, molecular docking has been used to determine the potential anti-virals for curbing the spread of COVID-19.',\n",
              "   'idx': '88bb80524d104173a97d278cfc91db58',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 117,\n",
              "   'span_end': 127,\n",
              "   'text': 'Poly-ADP-ribose polymerase-1, CVL218, a potent inhibitor that binds to the N-terminal of the nucleocapsid protein of SARS-CoV-2 was identified.',\n",
              "   'idx': '312bcdb53aa148c385ec3fbdf4f01f23',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 34,\n",
              "   'span_end': 42,\n",
              "   'text': 'The use of Signature matching for COVID-19 remains an unexplored avenue.',\n",
              "   'idx': 'e7fd8a43dda546a9a4347433043997f3',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 120,\n",
              "   'span_end': 128,\n",
              "   'text': 'With so many repurposed drugs in the market today, and several more upcoming owing to the intensity and acceleration of COVID-19 research, there are more advantages than disadvantages to the use of such drugs.',\n",
              "   'idx': '329a9f34062f441dafb4486b8d8e602a',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 564,\n",
              "   'span_end': 572,\n",
              "   'text': 'However, some limitations to the drug repositioning, include Weak intellectual property rights protection for repurposed drugs due to reduced rate of returnThe molecular docking technique used for identifying drugs for repurposing cannot be applied to all existing drugs due to the larger computational operationsSome network-based approaches used for drug repurposing do not always yield promising operationsSome network-based approaches used for drug repurposing are data-dependent, due to which the results may be inaccurate due to the lower volume of existing COVID-19 dataLack of strong, solid evidence for the mechanism of action of repurposed drugs on COVID-19 19Experimental evidence is required for validating the predictive outcomesOverall low success rates in new disease settingsExtensive data to be studied before repurposingDosing and safety issues, i.e., approved range of dosage and delivery capabilities are not very strongAccurate, robust toxicological studies of repurposed drugs essential before delivery and testingRare to find unique and novel drug-protein interactions all within the restraints of the approved therapeutic window.',\n",
              "   'idx': 'e7a6fa6b0f2a45869e9c842ee0a89d87',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 659,\n",
              "   'span_end': 667,\n",
              "   'text': 'However, some limitations to the drug repositioning, include Weak intellectual property rights protection for repurposed drugs due to reduced rate of returnThe molecular docking technique used for identifying drugs for repurposing cannot be applied to all existing drugs due to the larger computational operationsSome network-based approaches used for drug repurposing do not always yield promising operationsSome network-based approaches used for drug repurposing are data-dependent, due to which the results may be inaccurate due to the lower volume of existing COVID-19 dataLack of strong, solid evidence for the mechanism of action of repurposed drugs on COVID-19 19Experimental evidence is required for validating the predictive outcomesOverall low success rates in new disease settingsExtensive data to be studied before repurposingDosing and safety issues, i.e., approved range of dosage and delivery capabilities are not very strongAccurate, robust toxicological studies of repurposed drugs essential before delivery and testingRare to find unique and novel drug-protein interactions all within the restraints of the approved therapeutic window.',\n",
              "   'idx': 'e7a6fa6b0f2a45869e9c842ee0a89d87',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 61,\n",
              "   'span_end': 71,\n",
              "   'text': 'In the wake of the emergence of highly mutated and resistant SARS-CoV-2 strains, the question of how already repurposed drugs work comes into the picture.',\n",
              "   'idx': '88bd779ae22e4637b9edd15a30be433b',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 131,\n",
              "   'span_end': 139,\n",
              "   'text': 'Another perspective is the use of drug repurposing as a therapy for novel diseases for which specific drugs are not yet available, COVID-19 being one such important example.',\n",
              "   'idx': '3986601c2bce4ad79f4163ce0a053faf',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 91,\n",
              "   'span_end': 101,\n",
              "   'text': 'Although this review comprehensively lists all the current and latest drugs repurposed for SARS-CoV-2 and the existing computational approaches that in turn improve the process of repurposing, further advancements in the software and techniques such as using ensemble machine learning will improve the process of repurposing.',\n",
              "   'idx': '099901bbb2fb41d1bd6415c130fca698',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 27,\n",
              "   'span_end': 35,\n",
              "   'text': 'With high mortality rates, COVID-19 has become one of the most prevailing diseases globally.',\n",
              "   'idx': '9444c484099a4bd0a56909a76c1a0767',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 70,\n",
              "   'span_end': 80,\n",
              "   'text': 'With the CDC and WHO declaring several recent variants of concern for SARS-CoV-2, there is an urgent need to explore alternative options of treatment when there are no specific drugs targeting SARS-CoV-2.',\n",
              "   'idx': '07739bf5e5944b599dc70dd12aa9de6e',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 193,\n",
              "   'span_end': 203,\n",
              "   'text': 'With the CDC and WHO declaring several recent variants of concern for SARS-CoV-2, there is an urgent need to explore alternative options of treatment when there are no specific drugs targeting SARS-CoV-2.',\n",
              "   'idx': '07739bf5e5944b599dc70dd12aa9de6e',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 96,\n",
              "   'span_end': 106,\n",
              "   'text': 'this review sheds light on the various existing drugs that have been repurposed for use against SARS-CoV-2 and also illuminates the important drug targets against which the various existing drugs that have been repurposed for use against SARS-CoV-2 are used spike glycoproteins, RDRP, main protease, papain-like protease, nucleoproteins, non-structural proteins, and enveloped proteins of SARS-CoV-2.',\n",
              "   'idx': 'ad3e6c813bea40d691644db6050112f7',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 238,\n",
              "   'span_end': 248,\n",
              "   'text': 'this review sheds light on the various existing drugs that have been repurposed for use against SARS-CoV-2 and also illuminates the important drug targets against which the various existing drugs that have been repurposed for use against SARS-CoV-2 are used spike glycoproteins, RDRP, main protease, papain-like protease, nucleoproteins, non-structural proteins, and enveloped proteins of SARS-CoV-2.',\n",
              "   'idx': 'ad3e6c813bea40d691644db6050112f7',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 389,\n",
              "   'span_end': 399,\n",
              "   'text': 'this review sheds light on the various existing drugs that have been repurposed for use against SARS-CoV-2 and also illuminates the important drug targets against which the various existing drugs that have been repurposed for use against SARS-CoV-2 are used spike glycoproteins, RDRP, main protease, papain-like protease, nucleoproteins, non-structural proteins, and enveloped proteins of SARS-CoV-2.',\n",
              "   'idx': 'ad3e6c813bea40d691644db6050112f7',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 60,\n",
              "   'span_end': 68,\n",
              "   'text': 'The most important advantage of repositioning drugs against COVID-19 is the reduced cost and time of development and the drawback is the absence of safety/toxicity profiles via in vivo trials for COVID-19.',\n",
              "   'idx': '86bfb1069f9d47c3800712067c5531c3',\n",
              "   'article_id': 'PMC9346052'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 196,\n",
              "   'span_end': 204,\n",
              "   'text': 'The most important advantage of repositioning drugs against COVID-19 is the reduced cost and time of development and the drawback is the absence of safety/toxicity profiles via in vivo trials for COVID-19.',\n",
              "   'idx': '86bfb1069f9d47c3800712067c5531c3',\n",
              "   'article_id': 'PMC9346052'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 15,\n",
              "   'span_end': 26,\n",
              "   'text': 'The 2019 novel coronavirus, now dubbed SARS-CoV-2, has led to a global pandemic as declared by the World Health Organization WHO on 11 March 2020.',\n",
              "   'idx': 'd89028074a0d44388b8a6b58e51639cd',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 39,\n",
              "   'span_end': 49,\n",
              "   'text': 'The 2019 novel coronavirus, now dubbed SARS-CoV-2, has led to a global pandemic as declared by the World Health Organization WHO on 11 March 2020.',\n",
              "   'idx': 'd89028074a0d44388b8a6b58e51639cd',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 15,\n",
              "   'span_end': 26,\n",
              "   'text': \"The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\",\n",
              "   'idx': '827f90315a9343fdaa3fc2fdc76c61dd',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 39,\n",
              "   'span_end': 49,\n",
              "   'text': \"The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\",\n",
              "   'idx': '827f90315a9343fdaa3fc2fdc76c61dd',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 72,\n",
              "   'span_end': 83,\n",
              "   'text': \"The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\",\n",
              "   'idx': '827f90315a9343fdaa3fc2fdc76c61dd',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 96,\n",
              "   'span_end': 106,\n",
              "   'text': \"The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\",\n",
              "   'idx': '827f90315a9343fdaa3fc2fdc76c61dd',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviridae',\n",
              "   'span_start': 160,\n",
              "   'span_end': 173,\n",
              "   'text': \"The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\",\n",
              "   'idx': '827f90315a9343fdaa3fc2fdc76c61dd',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 579,\n",
              "   'span_end': 587,\n",
              "   'text': \"The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\",\n",
              "   'idx': '827f90315a9343fdaa3fc2fdc76c61dd',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 57,\n",
              "   'span_end': 68,\n",
              "   'text': 'Despite this variance, it is of note that The 2019 novel coronavirus, now dubbed SARS-CoV-2 infections lead to systemic inflammatory response syndrome SIRS and acute respiratory distress syndrome ARDS, two relevant conditions highly correlated with COVID-19 infections.',\n",
              "   'idx': 'd886ef84fca74948a70bf1812d7d5a36',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infections',\n",
              "   'span_start': 81,\n",
              "   'span_end': 102,\n",
              "   'text': 'Despite this variance, it is of note that The 2019 novel coronavirus, now dubbed SARS-CoV-2 infections lead to systemic inflammatory response syndrome SIRS and acute respiratory distress syndrome ARDS, two relevant conditions highly correlated with COVID-19 infections.',\n",
              "   'idx': 'd886ef84fca74948a70bf1812d7d5a36',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infections',\n",
              "   'span_start': 249,\n",
              "   'span_end': 268,\n",
              "   'text': 'Despite this variance, it is of note that The 2019 novel coronavirus, now dubbed SARS-CoV-2 infections lead to systemic inflammatory response syndrome SIRS and acute respiratory distress syndrome ARDS, two relevant conditions highly correlated with COVID-19 infections.',\n",
              "   'idx': 'd886ef84fca74948a70bf1812d7d5a36',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infections',\n",
              "   'span_start': 14,\n",
              "   'span_end': 33,\n",
              "   'text': 'Specifically, COVID-19 infections are accompanied by an overaggressive inflammatory response corresponding to a significant release of pro-inflammatory cytokines known as a cytokine storm.',\n",
              "   'idx': 'ff7cb5c01e9c431ba5ed092e7eed7930',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 47,\n",
              "   'span_end': 55,\n",
              "   'text': 'Though the biological relevance in relation to COVID-19 of cytokine storms has been questioned, studies have shown significant elevations of pro-inflammatory cytokines in COVID-19 infections as compared to other viral infections, highlighting that virulence may be more immune response-mediated rather than solely due to the viral titer.',\n",
              "   'idx': '103d7a6d6b064dc7b3ccb67d11b8bf9f',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infections',\n",
              "   'span_start': 171,\n",
              "   'span_end': 190,\n",
              "   'text': 'Though the biological relevance in relation to COVID-19 of cytokine storms has been questioned, studies have shown significant elevations of pro-inflammatory cytokines in COVID-19 infections as compared to other viral infections, highlighting that virulence may be more immune response-mediated rather than solely due to the viral titer.',\n",
              "   'idx': '103d7a6d6b064dc7b3ccb67d11b8bf9f',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 206,\n",
              "   'span_end': 214,\n",
              "   'text': \"As the mechanisms of the cytokine storm have yet to be fully elucidated, there is a need to understand the cytokine storm's genomic origin by comparing the cytokine storm known conditions that occur during COVID-19, such as SARS and acute respiratory distress syndrome ARDS.\",\n",
              "   'idx': 'afa58dad3e5742d693af202682ba3ea2',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS',\n",
              "   'span_start': 224,\n",
              "   'span_end': 228,\n",
              "   'text': \"As the mechanisms of the cytokine storm have yet to be fully elucidated, there is a need to understand the cytokine storm's genomic origin by comparing the cytokine storm known conditions that occur during COVID-19, such as SARS and acute respiratory distress syndrome ARDS.\",\n",
              "   'idx': 'afa58dad3e5742d693af202682ba3ea2',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 15,\n",
              "   'span_end': 23,\n",
              "   'text': 'In the case of COVID-19, studies have most often utilized differential gene analysis and limited research is available on clusters of highly correlated genes.',\n",
              "   'idx': '7045eb72b25f4984b3380f1aa61b171b',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 15,\n",
              "   'span_end': 23,\n",
              "   'text': \"In the case of COVID-19, where the variance in symptoms and the unclear mechanisms of the cytokine storm led to challenges in developing therapeutics to treat affected patients, the need arises to solve challenges in developing therapeutics to treat affected patients through relation of the COVID-19 induced cytokine storm to similar ailment SIRS, ARDS, and sepsis, to connect SARS and ARDS's mechanisms and therefore elucidate potential novel drugs.\",\n",
              "   'idx': 'dd3f3b14ae954e8cbd2aaff82bb37d14',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 292,\n",
              "   'span_end': 300,\n",
              "   'text': \"In the case of COVID-19, where the variance in symptoms and the unclear mechanisms of the cytokine storm led to challenges in developing therapeutics to treat affected patients, the need arises to solve challenges in developing therapeutics to treat affected patients through relation of the COVID-19 induced cytokine storm to similar ailment SIRS, ARDS, and sepsis, to connect SARS and ARDS's mechanisms and therefore elucidate potential novel drugs.\",\n",
              "   'idx': 'dd3f3b14ae954e8cbd2aaff82bb37d14',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS',\n",
              "   'span_start': 378,\n",
              "   'span_end': 382,\n",
              "   'text': \"In the case of COVID-19, where the variance in symptoms and the unclear mechanisms of the cytokine storm led to challenges in developing therapeutics to treat affected patients, the need arises to solve challenges in developing therapeutics to treat affected patients through relation of the COVID-19 induced cytokine storm to similar ailment SIRS, ARDS, and sepsis, to connect SARS and ARDS's mechanisms and therefore elucidate potential novel drugs.\",\n",
              "   'idx': 'dd3f3b14ae954e8cbd2aaff82bb37d14',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 140,\n",
              "   'span_end': 148,\n",
              "   'text': 'The Connectivity Map CMap has allowed for the repurposing of drugs based on gene expression values in neurogenerative diseases, cancer, and COVID-19.',\n",
              "   'idx': '5b8dff92325d4b9fa1b98e6b9dc3b9e9',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 173,\n",
              "   'span_end': 181,\n",
              "   'text': 'Herein, a bioinformatics and systems biology approach are adopted to study the similarities and differences between the whole blood transcriptome in ARDS, SIRS, sepsis, and COVID-19, to highlight possible reusable i.e., repurposed drugs.',\n",
              "   'idx': '33693784a8c14a509eebc677ac7133af',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 90,\n",
              "   'span_end': 98,\n",
              "   'text': 'Microarray datasets GSE147902, GSE66890, GSE74224, GSE152641 from ARDS, SIRS, sepsis, and COVID-19 whole blood transcriptomes were taken from the GEO database and analyzed using WGCNA through hierarchal clustering to identify significantly co-expressed modules or clusters of co-expressed genes across the aforementioned conditions.',\n",
              "   'idx': '8cfe9e21c2314a0da1afd986394075bc',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infections',\n",
              "   'span_start': 59,\n",
              "   'span_end': 78,\n",
              "   'text': 'These ailments have been widely reported to be symptoms of COVID-19 infections, and often occur in conjunction with the so-called cytokine storm.',\n",
              "   'idx': 'e192dcd3dd084f0a99ab978316d3be61',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 32,\n",
              "   'span_end': 40,\n",
              "   'text': 'Although the transcriptomics of COVID-19 have been widely studied, the specific mechanisms of cytokine storms have yet to be fully understood.',\n",
              "   'idx': '9266bde772c34b0eb37edbe26679a7a9',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 49,\n",
              "   'span_end': 57,\n",
              "   'text': \"The similarities between ARDS, SIRS, sepsis, and COVID-19 were analyzed at the module level using module preservation analysis and functional and pathway enrichment were used to understand The similarities between ARDS, SIRS, sepsis, and COVID-19's biological significance.\",\n",
              "   'idx': 'edbbab23588949feaf11aa24e43e09c5',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 238,\n",
              "   'span_end': 246,\n",
              "   'text': \"The similarities between ARDS, SIRS, sepsis, and COVID-19 were analyzed at the module level using module preservation analysis and functional and pathway enrichment were used to understand The similarities between ARDS, SIRS, sepsis, and COVID-19's biological significance.\",\n",
              "   'idx': 'edbbab23588949feaf11aa24e43e09c5',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 62,\n",
              "   'span_end': 70,\n",
              "   'text': 'Only the genetic similarities between ARDS, SIRS, sepsis, and COVID-19 were considered in this study, and temporal effects or variations were not accounted for.',\n",
              "   'idx': 'fc6b15904d784a8993166373a6ed4914',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 220,\n",
              "   'span_end': 228,\n",
              "   'text': 'It is also important to note that the findings in this study are based on generated gene co-expression and PPI networks built from relating immune illnesses, and hence, offer insights into repurposed drugs to treat post-COVID-19 effects i.e., cytokine storms.',\n",
              "   'idx': '44caa35cb2c043beaa33764045303e40',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 9,\n",
              "   'span_end': 17,\n",
              "   'text': 'Finally, COVID-19 microarray data was taken from GSE177477 which contains the blood transcriptome of 29 COVID-19 patients and 18 healthy controls.',\n",
              "   'idx': 'f8af29c18b3c42bc860480564e58e770',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 104,\n",
              "   'span_end': 112,\n",
              "   'text': 'Finally, COVID-19 microarray data was taken from GSE177477 which contains the blood transcriptome of 29 COVID-19 patients and 18 healthy controls.',\n",
              "   'idx': 'f8af29c18b3c42bc860480564e58e770',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 139,\n",
              "   'span_end': 147,\n",
              "   'text': 'After construction of the weighted gene co-expression network of the ARDS dataset whose modules served as reference, the sepsis, SIRS, and COVID-19 datasets were projected onto the ARDS dataset whose modules served as reference to analyze module preservation.',\n",
              "   'idx': 'f9fa80c68e5644b88bcd1195badcee63',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 137,\n",
              "   'span_end': 145,\n",
              "   'text': 'To screen possible repurposed drug candidates that are associated with the identified modules of interest across ARDS, SIRS, sepsis, and COVID-19, connectivity map analysis was performed using the Connectivity Map online webserver.',\n",
              "   'idx': 'b0a5f7f0478247a98c3405035422ddd4',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 94,\n",
              "   'span_end': 102,\n",
              "   'text': 'Specifically, the top three genes were taken from each of the identified modules preserved in COVID-19.',\n",
              "   'idx': 'c01673924907498aa7de6f19322ab2e3',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 231,\n",
              "   'span_end': 239,\n",
              "   'text': 'Interestingly, the two largest modules, M44 and M1, were enriched in large-scale macromolecule metabolic processes 2295/5606 and chemical stimulus detection 399/1583 A, cellular processes which have been observed to be affected by COVID-19.',\n",
              "   'idx': '049823cfa0b44cd287e298021ff14bb7',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 138,\n",
              "   'span_end': 146,\n",
              "   'text': 'To compare the similarity of gene expression at the module level between the four diseases included in this study ARDS, SIRS, Sepsis, and COVID-19, the network constructed based on the ARDS dataset was used as reference for module preservation analysis where other datasets describing SIRS, Sepsis, and COVID-19 whole blood transcriptome expressions were projected onto the ARDS dataset.',\n",
              "   'idx': 'aa6461a981cf43a0ad3554b342b402b3',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 303,\n",
              "   'span_end': 311,\n",
              "   'text': 'To compare the similarity of gene expression at the module level between the four diseases included in this study ARDS, SIRS, Sepsis, and COVID-19, the network constructed based on the ARDS dataset was used as reference for module preservation analysis where other datasets describing SIRS, Sepsis, and COVID-19 whole blood transcriptome expressions were projected onto the ARDS dataset.',\n",
              "   'idx': 'aa6461a981cf43a0ad3554b342b402b3',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 184,\n",
              "   'span_end': 192,\n",
              "   'text': 'Module preservation analysis revealed that the ARDS modules were most significantly preserved in the sepsis dataset B, while only a few modules were strongly preserved in the SIRS and COVID-19 datasets.',\n",
              "   'idx': '47c290c64ab849b68f0a6ed2dbfd278d',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 273,\n",
              "   'span_end': 281,\n",
              "   'text': 'Turquoise M1, sky blue M28, violet M32, and dark orange M45 showed moderate preservation while magenta M9, light cyan M16, light green M18, light yellow M19, orange M25, dark olive green M33, yellow green M36, and floral white M44 showed strong preservation B. Finally, in COVID-19, sky blue M28 showed no preservation, orange M25, dark orange M45, violet M32, and dark olive green M33 showed moderate preservation, and turquoise M1, magenta M9, light cyan M16, light green M18, light yellow M19, yellow green M36, and floral white M44 showed strong preservation C. Collectively, the modules strongly preserved in COVID-19 were also strongly preserved in other modules and were therefore selected for further downstream analysis.',\n",
              "   'idx': 'a5a2175f58ac45b9b2b96a88917a8bff',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 614,\n",
              "   'span_end': 622,\n",
              "   'text': 'Turquoise M1, sky blue M28, violet M32, and dark orange M45 showed moderate preservation while magenta M9, light cyan M16, light green M18, light yellow M19, orange M25, dark olive green M33, yellow green M36, and floral white M44 showed strong preservation B. Finally, in COVID-19, sky blue M28 showed no preservation, orange M25, dark orange M45, violet M32, and dark olive green M33 showed moderate preservation, and turquoise M1, magenta M9, light cyan M16, light green M18, light yellow M19, yellow green M36, and floral white M44 showed strong preservation C. Collectively, the modules strongly preserved in COVID-19 were also strongly preserved in other modules and were therefore selected for further downstream analysis.',\n",
              "   'idx': 'a5a2175f58ac45b9b2b96a88917a8bff',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 160,\n",
              "   'span_end': 168,\n",
              "   'text': 'Considering that most drugs have mechanism of actions that target proteins, the hub genes were selected by submitting the genes in each module preserved in the COVID-19 dataset to the STRING database for PPI network construction.',\n",
              "   'idx': 'f7fcd48db6b64e15bdea79da98e1ad4d',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infections',\n",
              "   'span_start': 67,\n",
              "   'span_end': 86,\n",
              "   'text': 'Further, cytokine storms have become recent issue with the rise of COVID-19 infections.',\n",
              "   'idx': '77e5be47a42049e2a70aac23eebc38fd',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 227,\n",
              "   'span_end': 235,\n",
              "   'text': 'Inherently, with the ARDS and SIRS in this present study, a quantitative network-based approach was employed to statistically determine the co-expressed genes across four related diseases ARDS, SIRS and sepsis, and symptomatic COVID-19, using NCBI GEO datasets to investigate the genetic similarities between four related diseases ARDS, SIRS and sepsis to highlight conserved and divergent pathways in cytokine storms and identify candidate repurposed drugs based on gene co-expression data.',\n",
              "   'idx': 'a310f2a5d0944368a5372e3b24ce1e08',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 154,\n",
              "   'span_end': 162,\n",
              "   'text': \"Considering TREM-1's extensive role in regulating the expression of cytokines and that macrophages have been previously linked to symptoms reminiscent of COVID-19, TREM-1 could be another potential therapeutic target for cytokine storms.\",\n",
              "   'idx': '15c53708fc80438bb98a5a1e85332932',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 89,\n",
              "   'span_end': 97,\n",
              "   'text': 'Interestingly, two of the largest modules M1 and M44 were significantly preserved in the COVID-19 dataset.',\n",
              "   'idx': '32408bcd02624fc9851d3301eff37713',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infections',\n",
              "   'span_start': 113,\n",
              "   'span_end': 132,\n",
              "   'text': 'M1 genes were found to be significantly enriched in olfactory transduction and may contain genes affected during COVID-19 infections leading to the loss of smell and taste.',\n",
              "   'idx': '9bc3d89c72fc4d5fbc0ff19b725da489',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 73,\n",
              "   'span_end': 81,\n",
              "   'text': 'Several immune-related pathways were also significantly preserved in the COVID-19 dataset alluding to potential conserved mechanisms across four related diseases ARDS, SIRS and sepsis.',\n",
              "   'idx': '67e1c2a2868548ff8068bcc9b2a13ed2',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 206,\n",
              "   'span_end': 214,\n",
              "   'text': 'These synergism of IFN- and TNF-, which are macrophage activators and are responsible for cell-mediated immunity has been previously shown to be sufficient in inducing cell and tissue damage reminiscent of COVID-19 symptoms.',\n",
              "   'idx': '5cf029e9b00f4f9aaecbb3069c4a813a',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 56,\n",
              "   'span_end': 64,\n",
              "   'text': 'Thus, M9 is potentially a significant module related to COVID-19 disease severity brought about by cytokine storms.',\n",
              "   'idx': '8efba652be3c470a84f2f42069932b4a',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 90,\n",
              "   'span_end': 98,\n",
              "   'text': 'Chemokine signaling pathways were also found to be significantly preserved in symptomatic COVID-19.',\n",
              "   'idx': '6e73e06f677f4b83a4a40a1ab2d02637',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 358,\n",
              "   'span_end': 366,\n",
              "   'text': \"Several of the chemokine receptors e.g., CXCR3 and CXCR4 have also been shown to be upregulated during cytokine storm-like symptoms as upon binding of Several of the chemokine receptors e.g., CXCR3 and CXCR4's natural ligands e.g., CXCL12, inflammation is promoted and chemotaxis induces apoptosis potentially leading to significant tissue damage as seen in COVID-19 cases.\",\n",
              "   'idx': '9d02a97486c946329297203c13d1615c',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 104,\n",
              "   'span_end': 112,\n",
              "   'text': \"chemokines's overexpression could be a possible mechanism for observed lung tissue damage i.e., ARDS in COVID-19 cases.\",\n",
              "   'idx': 'c17c80a0c01a47bc97d5b15f035cad8d',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 41,\n",
              "   'span_end': 49,\n",
              "   'text': 'Another pathway conserved in symptomatic COVID-19 is the NOD-like receptor signaling pathway.',\n",
              "   'idx': 'ecb937adda314513997638c4bdf3f2d1',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 65,\n",
              "   'span_end': 73,\n",
              "   'text': 'this present study was able to utilize preserved gene modules in COVID-19 to identify such drugs.',\n",
              "   'idx': 'f48bf6f88f284fd19834ee3d610c76b8',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 86,\n",
              "   'span_end': 94,\n",
              "   'text': 'The MAPK pathway has been a promising target for novel therapeutic approaches against COVID-19 as the loss of ACE2 activity brought about by viral infection leads to overexpression of p38, which leads to inflammation.',\n",
              "   'idx': 'd7982e1df0474d43b1e68e092660cb81',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 36,\n",
              "   'span_end': 44,\n",
              "   'text': 'Further, a study that treated 22560 COVID-19 patients with histamine antagonists e.g., loratadine resulted in attenuation of cytokine release leading to moderate to significant relief of COVID-19 symptoms, suggesting the potential of antihistamines in treating COVID-19 and cytokine storms in general.',\n",
              "   'idx': 'efe142e9bc764d31904f87d37b89fe02',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 187,\n",
              "   'span_end': 195,\n",
              "   'text': 'Further, a study that treated 22560 COVID-19 patients with histamine antagonists e.g., loratadine resulted in attenuation of cytokine release leading to moderate to significant relief of COVID-19 symptoms, suggesting the potential of antihistamines in treating COVID-19 and cytokine storms in general.',\n",
              "   'idx': 'efe142e9bc764d31904f87d37b89fe02',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 261,\n",
              "   'span_end': 269,\n",
              "   'text': 'Further, a study that treated 22560 COVID-19 patients with histamine antagonists e.g., loratadine resulted in attenuation of cytokine release leading to moderate to significant relief of COVID-19 symptoms, suggesting the potential of antihistamines in treating COVID-19 and cytokine storms in general.',\n",
              "   'idx': 'efe142e9bc764d31904f87d37b89fe02',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 93,\n",
              "   'span_end': 101,\n",
              "   'text': 'This suggests that TPCA-1 could be a good candidate drug for treatment of cytokine storms in COVID-19.',\n",
              "   'idx': '95522adae56f467b88049150a5134385',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 37,\n",
              "   'span_end': 45,\n",
              "   'text': \"Such inflammation is also present in COVID-19 patients and thus points to Mepacrine's potential as a therapeutic.\",\n",
              "   'idx': '50224432702a4dca8b3f26d032bdaafb',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 94,\n",
              "   'span_end': 102,\n",
              "   'text': 'Recently, antimalarials have also shown some promising results for being repurposed to tackle COVID-19 cytokine storms and the resulting neuroinflammatory symptoms.',\n",
              "   'idx': '16bbd7145fa340cbb4adcd32fbea0f84',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 0,\n",
              "   'span_end': 10,\n",
              "   'text': 'SARS-CoV-2 with the D614G mutation on the spike protein was the main strain analyzed in this study.',\n",
              "   'idx': 'a2d0d608b6db4ad7b075873912dc62fd',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 104,\n",
              "   'span_end': 112,\n",
              "   'text': 'Modules were more strongly preserved in the sepsis dataset, and less strongly preserved in the SIRS and COVID-19 datasets.',\n",
              "   'idx': 'c4f44176cd1946b69364b8e237443584',\n",
              "   'article_id': 'PMC9775208'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 102,\n",
              "   'span_end': 110,\n",
              "   'text': 'Among 13 stable gene co-expression modules, M1, M9, M16, M18, M19, and M44 were strongly preserved in COVID-19 and across ARDS, sepsis, and SIRS.',\n",
              "   'idx': 'f7e37ec5e76e491c9eef6fe378dfc267',\n",
              "   'article_id': 'PMC9775208'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 0,\n",
              "   'span_end': 24,\n",
              "   'text': 'Coronavirus disease 2019 COVID-19, which was first identified in December 2019, and shortly after, declared a pandemic by World Health Organization WHO.',\n",
              "   'idx': '5335d14b2a7d45f7a08da5b7e674ac32',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 25,\n",
              "   'span_end': 33,\n",
              "   'text': 'Coronavirus disease 2019 COVID-19, which was first identified in December 2019, and shortly after, declared a pandemic by World Health Organization WHO.',\n",
              "   'idx': '5335d14b2a7d45f7a08da5b7e674ac32',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviruses',\n",
              "   'span_start': 0,\n",
              "   'span_end': 13,\n",
              "   'text': 'Coronaviruses belong to the family of Coronaviridae, RNA viruses with crown-like spikes on the surface of the coronavirus particles.',\n",
              "   'idx': '5fa420f093394891aaa310f99544e593',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviridae',\n",
              "   'span_start': 38,\n",
              "   'span_end': 51,\n",
              "   'text': 'Coronaviruses belong to the family of Coronaviridae, RNA viruses with crown-like spikes on the surface of the coronavirus particles.',\n",
              "   'idx': '5fa420f093394891aaa310f99544e593',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 110,\n",
              "   'span_end': 121,\n",
              "   'text': 'Coronaviruses belong to the family of Coronaviridae, RNA viruses with crown-like spikes on the surface of the coronavirus particles.',\n",
              "   'idx': '5fa420f093394891aaa310f99544e593',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 69,\n",
              "   'span_end': 77,\n",
              "   'text': 'According to a meta-analysis of Macedo et al., the mortality rate of COVID-19 was 17.1% for patients admitted to hospitals, whereas World Health Organization WHO estimated a fatality rate of 6.73%, which was much lower than that calculated from published studies.',\n",
              "   'idx': '5af2259cca5e40d3bd4dc44d368d4c46',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 28,\n",
              "   'span_end': 36,\n",
              "   'text': 'Among the critical cases of COVID-19, the mortality rate reaches 40%.',\n",
              "   'idx': '70b4f71e539d4a0db2ef0dfe55fa2b91',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 69,\n",
              "   'span_end': 77,\n",
              "   'text': 'Substantial efforts have been made in the treatment of patients with COVID-19.',\n",
              "   'idx': '0d577cd6dff64abbaaaa54652bfbc302',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 70,\n",
              "   'span_end': 78,\n",
              "   'text': 'The World Health Organization WHO recommendations in the treatment of COVID-19 are as follows molnupiravir conditional, baricitinib strong, ruxolitinib and tofacitinib conditional, sotrovimab conditional, casirivimab and imdevimab conditional, IL-6 receptor blockers tocilizumab and sarilumab strong, remdesivir conditional, and systemic corticosteroids strong.',\n",
              "   'idx': 'cf5874e8e60b440da22a340af1ed71eb',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 20,\n",
              "   'span_end': 28,\n",
              "   'text': 'The pathogenesis of COVID-19 was explained by cytokine storm, reduction in ACE2 expression, and activation of complement pathway-induced microvascular injury and thrombosis.',\n",
              "   'idx': '22c2865d8c6845c2a684ab9f9b96d993',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 76,\n",
              "   'span_end': 84,\n",
              "   'text': 'The mechanisms of the recommended agents are focused on The pathogenesis of COVID-19 to improve the clinical outcome of COVID-19, and antiviral therapies are missing.',\n",
              "   'idx': '0961ba5e0f284a9b81ceea2e04f509f9',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 120,\n",
              "   'span_end': 128,\n",
              "   'text': 'The mechanisms of the recommended agents are focused on The pathogenesis of COVID-19 to improve the clinical outcome of COVID-19, and antiviral therapies are missing.',\n",
              "   'idx': '0961ba5e0f284a9b81ceea2e04f509f9',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'anticoronaviral',\n",
              "   'span_start': 4,\n",
              "   'span_end': 19,\n",
              "   'text': \"The anticoronaviral strategies include preventing the synthesis of viral RNA, inhibiting virus replication, blocking the virus binding to human cell receptors, or inhibiting the viruses' self-assembly process.\",\n",
              "   'idx': '4293c6e6fecc44eabe7f28420c6ca986',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 4,\n",
              "   'span_end': 14,\n",
              "   'text': 'The SARS-CoV-2 contains at least four structural proteins spike S protein, envelope E protein, membrane M protein, and nucleocapsid N protein, and 16 nonstructural proteins NSPs.',\n",
              "   'idx': 'f2ed24bac1904da2aad9f85db33f4c44',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 205,\n",
              "   'span_end': 216,\n",
              "   'text': 'Among 16 nonstructural proteins NSPs, the main protease, also called chymotrypsin-like protease 3C-like protease, and the papain-like protease are two essential proteases for proteolytic processing of the coronavirus replicase polyprotein, therefore generating functional replication complex of The SARS-CoV-2, whereas RNA-dependent RNA polymerase is the central enzyme for RNA synthesis.',\n",
              "   'idx': '92ea1bd3bffc44438c82cba9bcf1810e',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 299,\n",
              "   'span_end': 309,\n",
              "   'text': 'Among 16 nonstructural proteins NSPs, the main protease, also called chymotrypsin-like protease 3C-like protease, and the papain-like protease are two essential proteases for proteolytic processing of the coronavirus replicase polyprotein, therefore generating functional replication complex of The SARS-CoV-2, whereas RNA-dependent RNA polymerase is the central enzyme for RNA synthesis.',\n",
              "   'idx': '92ea1bd3bffc44438c82cba9bcf1810e',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 39,\n",
              "   'span_end': 50,\n",
              "   'text': 'These three NSPs play crucial roles in coronavirus replication, making These three NSPs attractive targets for anticoronaviral drug design.',\n",
              "   'idx': '168979c59ab84d2697be3d86b61df3d2',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'anticoronaviral',\n",
              "   'span_start': 111,\n",
              "   'span_end': 126,\n",
              "   'text': 'These three NSPs play crucial roles in coronavirus replication, making These three NSPs attractive targets for anticoronaviral drug design.',\n",
              "   'idx': '168979c59ab84d2697be3d86b61df3d2',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 58,\n",
              "   'span_end': 71,\n",
              "   'text': 'The S protein, a surface-located trimeric glycoprotein of coronaviruses, promotes the attachment of viruses to host cells through binding to angiotensin-converting enzyme 2 ACE2 and virus-cell membrane fusion during viral infection.',\n",
              "   'idx': 'f17549ebf9a14d3186fb67a439ed2ee5',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 64,\n",
              "   'span_end': 77,\n",
              "   'text': 'Thus, The S protein, a surface-located trimeric glycoprotein of coronaviruses, has been considered as a major target for the development of vaccines and drug.',\n",
              "   'idx': '4416f80582c546d5acedacd75d771197',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 21,\n",
              "   'span_end': 29,\n",
              "   'text': 'During the spread of COVID-19 outbreak, great efforts have been made in therapeutic drug discovery against COVID-19.',\n",
              "   'idx': '17923053290b430abcddf74193c186e7',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 107,\n",
              "   'span_end': 115,\n",
              "   'text': 'During the spread of COVID-19 outbreak, great efforts have been made in therapeutic drug discovery against COVID-19.',\n",
              "   'idx': '17923053290b430abcddf74193c186e7',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 8,\n",
              "   'span_end': 16,\n",
              "   'text': 'Because COVID-19 is a new, acute, severe infectious disease, the anti-SARS-CoV-2 drug development strategies are to screen existing drugs to identify potentially effective drugs, to expand indications, and to develop a vaccine.',\n",
              "   'idx': 'b203e9d4ef5048d5bc5228165c247300',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 70,\n",
              "   'span_end': 80,\n",
              "   'text': 'Because COVID-19 is a new, acute, severe infectious disease, the anti-SARS-CoV-2 drug development strategies are to screen existing drugs to identify potentially effective drugs, to expand indications, and to develop a vaccine.',\n",
              "   'idx': 'b203e9d4ef5048d5bc5228165c247300',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 72,\n",
              "   'span_end': 80,\n",
              "   'text': 'Therefore, developing broad-spectrum antiviral drugs not only to combat COVID-19 but also to provide protective arsenals against future viral outbreaks is a requirement.',\n",
              "   'idx': 'fa956538d84f439297c0483d2f4a0200',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 25,\n",
              "   'span_end': 35,\n",
              "   'text': 'Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection based on the strategies from preclinical drug discovery.',\n",
              "   'idx': '1337a3766f8d421db61d8f97c8b44a05',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 116,\n",
              "   'span_end': 136,\n",
              "   'text': 'Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection based on the strategies from preclinical drug discovery.',\n",
              "   'idx': '1337a3766f8d421db61d8f97c8b44a05',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 170,\n",
              "   'span_end': 181,\n",
              "   'text': 'Studies published in PubMed, Scopus, Web of Science, EMBASE, Google Scholar, and DrugBank were searched from December 2019 to March 2021 using the following search terms Coronavirus, COVID-19, SARS-CoV-2, Drug design, Drug development, In silico, In vitro, and In vivo alone or in combination without language restrictions.',\n",
              "   'idx': '367dfe8a42f74de789839402385589d9',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 183,\n",
              "   'span_end': 191,\n",
              "   'text': 'Studies published in PubMed, Scopus, Web of Science, EMBASE, Google Scholar, and DrugBank were searched from December 2019 to March 2021 using the following search terms Coronavirus, COVID-19, SARS-CoV-2, Drug design, Drug development, In silico, In vitro, and In vivo alone or in combination without language restrictions.',\n",
              "   'idx': '367dfe8a42f74de789839402385589d9',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 193,\n",
              "   'span_end': 203,\n",
              "   'text': 'Studies published in PubMed, Scopus, Web of Science, EMBASE, Google Scholar, and DrugBank were searched from December 2019 to March 2021 using the following search terms Coronavirus, COVID-19, SARS-CoV-2, Drug design, Drug development, In silico, In vitro, and In vivo alone or in combination without language restrictions.',\n",
              "   'idx': '367dfe8a42f74de789839402385589d9',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 107,\n",
              "   'span_end': 115,\n",
              "   'text': 'Study of drug in cell culture medium effectiveness in these studies means inhibition of the replication of COVID-19 by the compound or drug under study.',\n",
              "   'idx': '40a912eaea064e6fa081ae67c6c6c75c',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 134,\n",
              "   'span_end': 142,\n",
              "   'text': 'In this review, we reported a significant number of articles with in silico, in vitro, and in vivo approaches for drug development of COVID-19.',\n",
              "   'idx': 'bb658bc556f84048b937bcba331d5cf4',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 157,\n",
              "   'span_end': 167,\n",
              "   'text': 'The analysis of article contents indicated that 266 studies performed in silico approaches against viral targets 34 studies used in vitro approaches against SARS-CoV-2 and 15 studies used in vivo animal models.',\n",
              "   'idx': '2b3e11bdacf3427789b646ce5b8a49b0',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 161,\n",
              "   'span_end': 169,\n",
              "   'text': 'From 266 studies, 98 article studies repurposed approved drugs with a new mechanism of action and 91 studies evaluated natural products e.g., herbal medicine on COVID-19.',\n",
              "   'idx': '236d02300537462ca88f121b6617e914',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 56,\n",
              "   'span_end': 67,\n",
              "   'text': 'In silico studies used the following component of novel coronavirus as targets main protease N 154, spike glycoprotein N 62, nonstructural protein N 45, RNA-dependent RNA polymerase N 21, papain-like protease N 19.',\n",
              "   'idx': 'ed61535684264e0395db8150f7b647b3',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 65,\n",
              "   'span_end': 73,\n",
              "   'text': 'About 260 drugs were repurposed by the computational methods for COVID-19 therapy such as about 120 drugs candidate against main protease N 154, 52 drugs against spike glycoprotein N 62, 14 drugs against RNA-dependent RNA polymerase, and 28 drugs against other nonstructural proteins.',\n",
              "   'idx': 'b576753409b9443e8ca6e6e7fdafdf70',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 41,\n",
              "   'span_end': 49,\n",
              "   'text': 'shows target-based synthesis of data for COVID-19 drug repurposing.',\n",
              "   'idx': 'adef3d6fc24c4ebb987cbfbb89488b10',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 123,\n",
              "   'span_end': 133,\n",
              "   'text': 'A total of 91 studies used in silico methods to evaluate the effects of natural products including herbal medicine against SARS-CoV-2.',\n",
              "   'idx': '79f0724eaf2a4b5980b6405acc5a45d7',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 175,\n",
              "   'span_end': 183,\n",
              "   'text': 'From the plant metabolites, oleanolic acid, hesperidin, epigallocatechin gallate, jensenone, tinosponone, and anistone show promising results in computational methods against COVID-19.',\n",
              "   'idx': '5578f7813f4e484f92200d2c4e8d161e',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 107,\n",
              "   'span_end': 115,\n",
              "   'text': 'Aloe, green tea, eucalyptus, curcumin, and many Chinese, Indian, and African plants were also effective on COVID-19 in silico.',\n",
              "   'idx': '00f28a5d6bb349f4b657dd3d692d47d8',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 275,\n",
              "   'span_end': 283,\n",
              "   'text': 'The derivatives of pyrazoles, oxadiazoles, phenyltriazolinones, triazoles, benzoylpinostrobin, benzoic acid, benzylidenechromanones, coumarin, and selenium show efficacy in computational methods and could be considered as lead molecules for drug design and synthesis against COVID-19.',\n",
              "   'idx': 'b7509e69a7994e65a55bc1d6f0a818d9',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 82,\n",
              "   'span_end': 92,\n",
              "   'text': 'Most of 34 studies use the Vero E6 cell line for the assessment of replication of SARS-CoV-2.',\n",
              "   'idx': '89524f775f4c4810bb3c2bbea711937b',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 236,\n",
              "   'span_end': 244,\n",
              "   'text': 'Nitric oxide, ginkgolic acid, anacardic acid, troxerutin, bisindolylmaleimide derivatives, small molecules GRL-172, and 5 h, baicalin and baicalein phytochemicals, and bepridil were effective drugs in vitro against the main protease of COVID-19.',\n",
              "   'idx': '462e5e99809e4ba79fb323a1f49d84af',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 72,\n",
              "   'span_end': 80,\n",
              "   'text': 'The following drugs could inhibit the spike/ACE2-mediated cell entry of COVID-19 in vitro romidepsin, panobinostat, givinostat, sirtinol, saquinavir, lipopeptides, hydroxyzine, azelastine, heparin, and glycyrrhizic acid.',\n",
              "   'idx': 'df038129790d4f7abe429e8fed9eed0b',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 220,\n",
              "   'span_end': 230,\n",
              "   'text': 'Alkenyl sulfonylurea derivatives, an IMU-8381 inhibitor of human dihydroorotate dehydrogenase, pyrazole derivatives, and phillyrin, regulated the expression of inflammatory cytokines e.g., IL, TNF-, and NF- B induced by SARS-CoV-2 markedly and could be considered as adjuvant treatment of COVID-19 severe disease.',\n",
              "   'idx': 'd8438a8b3721426b9a978c5aa0fed7b3',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 289,\n",
              "   'span_end': 297,\n",
              "   'text': 'Alkenyl sulfonylurea derivatives, an IMU-8381 inhibitor of human dihydroorotate dehydrogenase, pyrazole derivatives, and phillyrin, regulated the expression of inflammatory cytokines e.g., IL, TNF-, and NF- B induced by SARS-CoV-2 markedly and could be considered as adjuvant treatment of COVID-19 severe disease.',\n",
              "   'idx': 'd8438a8b3721426b9a978c5aa0fed7b3',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 183,\n",
              "   'span_end': 193,\n",
              "   'text': 'Doxycycline, chlorpromazine, azithromycin, heparin, bepridil, tannic acid, and glycyrrhizic acid are well-known drugs that show both in silico and in vitro inhibitory effects against SARS-CoV-2 and should be considered for this purpose.',\n",
              "   'idx': '5c586dffc29f44c9839b4c89acc15669',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 116,\n",
              "   'span_end': 126,\n",
              "   'text': 'Also, in vitro studies show that lopinavir/ritonavir, sofosbuvir, and favipiravir have no antiviral effects against SARS-CoV-2 huge gap between in vitro IC50 and free plasma concentration.',\n",
              "   'idx': '41106e76fdcb465c9b091f7fd89a0757',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 151,\n",
              "   'span_end': 161,\n",
              "   'text': 'Human monoclonal antibodies were the most evaluated drugs N 4, promote the reduction in viral load in vitro, and prevent infection in animal models of SARS-CoV-2.',\n",
              "   'idx': '404738cccf21479daedef3b6471348f0',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 175,\n",
              "   'span_end': 185,\n",
              "   'text': 'A prodrug of hydroxycytidine molnupiravir improved pulmonary function and reduced viral titer in vivo and was introduced as a potential broad-spectrum antiviral agent against SARS-CoV-2.',\n",
              "   'idx': 'c3293cdc8f67454dae363758da204598',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 88,\n",
              "   'span_end': 96,\n",
              "   'text': 'Dalbavancin shows significant inhibitory ability in both in vitro and in vivo models of COVID-19.',\n",
              "   'idx': 'e1a7db2636e346f7821d7a2e136ac466',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 74,\n",
              "   'span_end': 84,\n",
              "   'text': \"Dalbavancin binds directly to ACE2 and blocks ACE2's interaction with the SARS-CoV-2 spike protein.\",\n",
              "   'idx': 'aa27e80eed5e4a26a85e3633c9b22227',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 52,\n",
              "   'span_end': 65,\n",
              "   'text': 'There are several strategies in antiviral drugs for coronaviruses including empirical testing of known antiviral drugs, large-scale phenotypic screening of compound libraries, and target-based drug discovery.',\n",
              "   'idx': '5f29564678b747e78ec23d3fadb53b7d',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'anticoronavirus',\n",
              "   'span_start': 63,\n",
              "   'span_end': 78,\n",
              "   'text': 'To date, an increasing number of drugs have been shown to have anticoronavirus activities in vitro and in vivo, but only remdesivir and several neutralizing antibodies have been approved by the US FDA for treating COVID-19.',\n",
              "   'idx': '9c0d28af90b34d6dba8915a7177ac1cd',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 214,\n",
              "   'span_end': 222,\n",
              "   'text': 'To date, an increasing number of drugs have been shown to have anticoronavirus activities in vitro and in vivo, but only remdesivir and several neutralizing antibodies have been approved by the US FDA for treating COVID-19.',\n",
              "   'idx': '9c0d28af90b34d6dba8915a7177ac1cd',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 25,\n",
              "   'span_end': 35,\n",
              "   'text': 'Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection, which have been conducted in basic research in silico and preclinical study in vitro, in vivo.',\n",
              "   'idx': '8b8a582c9fbd46998b0cd3e7a0e7d65f',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 116,\n",
              "   'span_end': 136,\n",
              "   'text': 'Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection, which have been conducted in basic research in silico and preclinical study in vitro, in vivo.',\n",
              "   'idx': '8b8a582c9fbd46998b0cd3e7a0e7d65f',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 115,\n",
              "   'span_end': 123,\n",
              "   'text': 'Our database search identified about 3000 studies, which means a global effort for drug development in the current COVID-19 pandemic.',\n",
              "   'idx': '113d974056614f808aa9f5d452aa9c6a',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 80,\n",
              "   'span_end': 88,\n",
              "   'text': 'As summarized in the results, many compounds are in the development process for COVID-19 disease.',\n",
              "   'idx': '85573cfeb81b416d948dffdb69827dfa',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 115,\n",
              "   'span_end': 123,\n",
              "   'text': 'Some of many compounds are completely new and could serve as seeds or leads for developing antiviral drugs against COVID-19, but as we need therapeutics as soon as possible, half of the studies focused on drug repurposing repositioning, which is a process of investigation of existing drugs for new therapeutic purposes.',\n",
              "   'idx': 'b346d6a59ebf4eada1db0526487d5917',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 32,\n",
              "   'span_end': 40,\n",
              "   'text': 'With the emergence of a growing COVID-19 pandemic, the drug repurposing process was being accelerated.',\n",
              "   'idx': 'fcb10c6adc024d5697dfc2490dc30778',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 80,\n",
              "   'span_end': 88,\n",
              "   'text': 'According to our results, 260 drugs repurposed by the computational methods for COVID-19, among them saquinavir, ritonavir, and lopinavir, showed the best efficacy in in silico environment.',\n",
              "   'idx': '569c3b734a19430f81a27432f75f9c7c',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 74,\n",
              "   'span_end': 82,\n",
              "   'text': \"These drugs can be rapidly repurposed for clinic application for treating COVID-19 patients given These drugs's proven safety.\",\n",
              "   'idx': '3eb9d90914bd4036bf99178f30360fd1',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 165,\n",
              "   'span_end': 173,\n",
              "   'text': 'The results of a systematic review and meta-analysis showed that a combination of ritonavir-lopinavir has no more treatment effects than other therapeutic agents in COVID-19 patients and is currently not used anymore.',\n",
              "   'idx': '364f22654b8047eca321d8bfd213f0eb',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 123,\n",
              "   'span_end': 131,\n",
              "   'text': 'We could not find any clinical trial on saquinavir, which is the most studied drug in silico and show high potency against COVID-19.',\n",
              "   'idx': '0e0b0c9c23034133a7270b63b943c0c6',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 130,\n",
              "   'span_end': 138,\n",
              "   'text': 'Our results show that various plants have potential antiviral activities and could use or be a basis for drug development against COVID-19.',\n",
              "   'idx': 'e45c589520dc4e7ca85a50b2dd571c7a',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 86,\n",
              "   'span_end': 94,\n",
              "   'text': 'A systematic review and meta-analysis of RCTs on herbal medicine in the management of COVID-19 show the significant effects of the combined therapy of herbal medicine in treating COVID-19 without any significant side effects.',\n",
              "   'idx': '38679e7d6133470085d09bcb5ad7e593',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 179,\n",
              "   'span_end': 187,\n",
              "   'text': 'A systematic review and meta-analysis of RCTs on herbal medicine in the management of COVID-19 show the significant effects of the combined therapy of herbal medicine in treating COVID-19 without any significant side effects.',\n",
              "   'idx': '38679e7d6133470085d09bcb5ad7e593',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 89,\n",
              "   'span_end': 99,\n",
              "   'text': 'some of these studied active ingredients could possibly have an inhibitory effect on the SARS-CoV-2 and COVID-19.',\n",
              "   'idx': '264949cfd2784003aa6c1447c58e5ab4',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 104,\n",
              "   'span_end': 112,\n",
              "   'text': 'some of these studied active ingredients could possibly have an inhibitory effect on the SARS-CoV-2 and COVID-19.',\n",
              "   'idx': '264949cfd2784003aa6c1447c58e5ab4',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 88,\n",
              "   'span_end': 98,\n",
              "   'text': 'Most evaluated chemical compounds had inhibitory effects against one or two proteins of SARS-CoV-2.',\n",
              "   'idx': '9a17a1f35f954a5384219a9cdc118092',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 172,\n",
              "   'span_end': 180,\n",
              "   'text': 'Thus, Most evaluated chemical compounds can be applied as extremely safe therapeutic natural compounds and clinical assessments might have notable outcomes for controlling COVID-19.',\n",
              "   'idx': '1475707c58254ba2b84f908487fc9868',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 101,\n",
              "   'span_end': 109,\n",
              "   'text': 'In terms of mechanism of action, different targets from the structural and nonstructural proteins of COVID-19 were evaluated.',\n",
              "   'idx': '2378de6c05984462b8f911f164f2d1f2',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 65,\n",
              "   'span_end': 75,\n",
              "   'text': 'Apart from the specific protein that leads to viral replication, SARS-CoV-2 causes a surge of pro-inflammatory cytokines and chemokines, which cause damage to lung tissue and deterioration of lung function.',\n",
              "   'idx': 'bf63f4e761b449ea9b01d7478df25fd4',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 89,\n",
              "   'span_end': 97,\n",
              "   'text': 'Therefore, the design of a drug with multitarget of action against different proteins of COVID-19 and also anti-inflammatory potential could be valuable.',\n",
              "   'idx': '60d7974a9f5549568dd93834646f28ec',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 69,\n",
              "   'span_end': 79,\n",
              "   'text': 'Currently, there is no highly efficacious and specific treatment for SARS-CoV-2.',\n",
              "   'idx': '0b2252351fe549d88ba9ae9994a25f6d',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 21,\n",
              "   'span_end': 31,\n",
              "   'text': 'Due to the nature of SARS-CoV-2 and the rises of several high transmissible strains, repurposing existing drugs has demonstrated power by bringing several drugs to approval for treating COVID-19 patients, such as remdesivir.',\n",
              "   'idx': 'aee11106530f47e5af92af38a30f35b8',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 186,\n",
              "   'span_end': 194,\n",
              "   'text': 'Due to the nature of SARS-CoV-2 and the rises of several high transmissible strains, repurposing existing drugs has demonstrated power by bringing several drugs to approval for treating COVID-19 patients, such as remdesivir.',\n",
              "   'idx': 'aee11106530f47e5af92af38a30f35b8',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 105,\n",
              "   'span_end': 125,\n",
              "   'text': 'Our results confirmed that a large number of repurposed agents are currently being explored for treating SARS-CoV-2 infection.',\n",
              "   'idx': '3ae49f031de24ea2af266e50b0a058b8',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 131,\n",
              "   'span_end': 139,\n",
              "   'text': 'Our results showed that various natural bioactive compounds are being investigated in the preclinical step of drug development for COVID-19.',\n",
              "   'idx': 'f1f94d10e380479397a17a4a0428b7e1',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 133,\n",
              "   'span_end': 141,\n",
              "   'text': 'Therefore, various natural bioactive compounds can be used as extremely safe therapeutic compounds in drug design studies to control COVID-19.',\n",
              "   'idx': '6ea7fb22b575409e9e2d15c51c7b39bd',\n",
              "   'article_id': 'PMC9527439'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 286,\n",
              "   'span_end': 296,\n",
              "   'text': 'However, the pharmacological effects and adverse reactions of some drugs under development are still unclear, and hence, well-designed high-quality studies are needed to further study the effectiveness and safety of some drugs under development to accelerate drug development targeting SARS-CoV-2 and thus promote progress towards ending the pandemic.',\n",
              "   'idx': 'b3ac3ac08e1044a6bac7bcf9f31d485b',\n",
              "   'article_id': 'PMC9527439'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 0,\n",
              "   'span_end': 8,\n",
              "   'text': 'COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.',\n",
              "   'idx': '61ed3a0232b84f2fb1798597668e7b32',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviruses',\n",
              "   'span_start': 44,\n",
              "   'span_end': 57,\n",
              "   'text': 'COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.',\n",
              "   'idx': '61ed3a0232b84f2fb1798597668e7b32',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviridae',\n",
              "   'span_start': 65,\n",
              "   'span_end': 78,\n",
              "   'text': 'COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.',\n",
              "   'idx': '61ed3a0232b84f2fb1798597668e7b32',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndromes',\n",
              "   'span_start': 129,\n",
              "   'span_end': 163,\n",
              "   'text': 'COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.',\n",
              "   'idx': '61ed3a0232b84f2fb1798597668e7b32',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS Cov-2',\n",
              "   'span_start': 164,\n",
              "   'span_end': 174,\n",
              "   'text': 'COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.',\n",
              "   'idx': '61ed3a0232b84f2fb1798597668e7b32',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviruses',\n",
              "   'span_start': 0,\n",
              "   'span_end': 13,\n",
              "   'text': \"Coronaviruses are named as such because Coronaviruses's surface is characterized by protrusions resembling crowns.\",\n",
              "   'idx': '647580f250bf453494be8a0b67a52921',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviruses',\n",
              "   'span_start': 40,\n",
              "   'span_end': 53,\n",
              "   'text': \"Coronaviruses are named as such because Coronaviruses's surface is characterized by protrusions resembling crowns.\",\n",
              "   'idx': '647580f250bf453494be8a0b67a52921',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 46,\n",
              "   'span_end': 54,\n",
              "   'text': 'Corona was first reported in China Wuhan, and COVID-19 is unlikely to have been transmitted from animal to human in a seafood market.',\n",
              "   'idx': '2fd3583873bb49c495634bff17ce7d66',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 67,\n",
              "   'span_end': 75,\n",
              "   'text': \"The current vaccines are not providing adequate protection against COVID-19 due to logistical difficulties in The current vaccines's distribution, diminishing immunity, and the possibility of transmission from asymptomatic infected patients.\",\n",
              "   'idx': 'a3c3a12d159a490a978583aed3b333fb',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 145,\n",
              "   'span_end': 153,\n",
              "   'text': 'Drug repurposing is the most efficient method of rapidly identifying the unique clinical applications of currently licensed medications to treat COVID-19.',\n",
              "   'idx': 'edd5f549777346a38e42f0fd41977ed1',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 4,\n",
              "   'span_end': 15,\n",
              "   'text': 'The Coronavirus genome is translated into two classes of proteins within the host cell structural proteins such as spikes S, envelopes E, matrixes M, and nucleocapsids N, and nonstructural proteins such as 3-C proteases 3CLpro, NSP5 and RNA Dependent RNA Polymerases RdRp, NSP12.',\n",
              "   'idx': '8bedc6b6aba14ed7a6ebbcbdd7508a19',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus',\n",
              "   'span_start': 194,\n",
              "   'span_end': 205,\n",
              "   'text': 'Among these proteins, RNA-dependent RNA polymerase RdRp has been demonstrated to contribute significantly to the replication of the viral genome single-stranded RNA and to the multiplication of Coronavirus in various cells.',\n",
              "   'idx': '27f89c5f174d44ddbff542710982215c',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 249,\n",
              "   'span_end': 257,\n",
              "   'text': 'It has been established that RNA-dependent RNA polymerase RdRp is an essential enzyme that plays a significant role in the replication and translation of viral genomes this makes RNA-dependent RNA polymerase RdRp an excellent therapeutic target for COVID-19.',\n",
              "   'idx': '992e2f4ba9a04a75ba4852f94fe19efc',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 41,\n",
              "   'span_end': 49,\n",
              "   'text': 'Numerous clinical trials have shown that COVID-19 can be effectively treated with antiviral, antimalarial, and anti-HIV drugs.',\n",
              "   'idx': '091a058f062c4068ab98b8c07311d6a6',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 53,\n",
              "   'span_end': 61,\n",
              "   'text': 'The FDA has approved Remdesivir Veklury for treating COVID-19 in hospitalized patients aged 12 and older and weighing at least 40 kg.',\n",
              "   'idx': '74f0eb210d1c4bf2997b3d48880c9d59',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 36,\n",
              "   'span_end': 46,\n",
              "   'text': 'Several viral infections, including SARS-CoV-2, have been successfully treated with Remdesivir Veklury.',\n",
              "   'idx': 'f245435b5900466ea2d54ee008aa6576',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infection',\n",
              "   'span_start': 177,\n",
              "   'span_end': 195,\n",
              "   'text': 'In a comprehensive two-tier screening approach, Yuan et al. demonstrated that FDA-approved medications cetilistat, abiraterone, diiodohydroxyquinoline, and bexarotene inhibited COVID-19 infection in vitro.',\n",
              "   'idx': '52a506db7b734725a0052b75dbbfc3c2',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 292,\n",
              "   'span_end': 302,\n",
              "   'text': 'As part of a comprehensive two-tier screening approach, Yuan et al. this study the interaction between four FDA-approved medications, bexarotene anticancer retinoid, abiraterone synthetic androstenedione steroid, diiodohydroxyquinoline antiparasite, and cetilistat antipancreatic lipase with SARS-CoV-2 RdRp using docking simulation.',\n",
              "   'idx': 'c0b21522fffc46dea6c31b392d779064',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 98,\n",
              "   'span_end': 106,\n",
              "   'text': \"In light of Yuan et al.'s findings, Yuan et al. may be able to develop a new method for combating COVID-19.\",\n",
              "   'idx': '7237f1a282bc4e5bb3083255653a83da',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 43,\n",
              "   'span_end': 53,\n",
              "   'text': 'The screening of the drugs against RdRp of SARS-CoV-2 was performed by AutoDock Vina with MGL tools 1.5.4 which makes more precise docking calculations and runs faster than AutoDock software.',\n",
              "   'idx': '9c34fefd6a204fe4b4cc4ed621bfa9d3',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 50,\n",
              "   'span_end': 60,\n",
              "   'text': 'To perform molecular docking analysis the RdRp of SARS-CoV-2 was converted into PDBQT format.pdbqt.',\n",
              "   'idx': '757ccb4a18a6408988537b9dcf5301d8',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 107,\n",
              "   'span_end': 117,\n",
              "   'text': 'Because molecular docking results revealed that bexarotene has the best energy in interaction with RdRp of SARS-CoV-2, Yuan et al. investigated the molecular dynamic simulation of bexarotene with protein.',\n",
              "   'idx': '4c37129ea3bf4eeab0867f2d73d722fc',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 142,\n",
              "   'span_end': 152,\n",
              "   'text': 'We recently reported the in-silico screening of bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir against different SARS-CoV-2 drug targets.',\n",
              "   'idx': '8e72596b2f7d4dc898732398d2135547',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 242,\n",
              "   'span_end': 252,\n",
              "   'text': \"The current study used the same strategy to screen the bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir for bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir's potential to inhibit RdRp of SARS-CoV-2, thereby filling the gap.\",\n",
              "   'idx': '6a7baffd39474ce0a146d2bbb7677029',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 164,\n",
              "   'span_end': 174,\n",
              "   'text': 'Molecular docking simulation was used to predict the binding of the selected drugs bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir with SARS-CoV-2 RdRp-RNA protein.',\n",
              "   'idx': '8652426b719847ddb8bf6c48d43d7a1a',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 63,\n",
              "   'span_end': 73,\n",
              "   'text': 'Recently, researchers reported virtual screening inhibitors of SARS-CoV-2 RdRp.',\n",
              "   'idx': 'c6cb7a0ef4dc43f994d5a4c98029d36d',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 118,\n",
              "   'span_end': 128,\n",
              "   'text': 'the FDA-approved RdRp inhibitor drug remdesivir is effective against many RNA viruses, including the newly discovered SARS-CoV-2 COVID-19 and previous coronaviruses.',\n",
              "   'idx': '337d3e21a277480599c81fdfc272b3dc',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 129,\n",
              "   'span_end': 137,\n",
              "   'text': 'the FDA-approved RdRp inhibitor drug remdesivir is effective against many RNA viruses, including the newly discovered SARS-CoV-2 COVID-19 and previous coronaviruses.',\n",
              "   'idx': '337d3e21a277480599c81fdfc272b3dc',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 151,\n",
              "   'span_end': 164,\n",
              "   'text': 'the FDA-approved RdRp inhibitor drug remdesivir is effective against many RNA viruses, including the newly discovered SARS-CoV-2 COVID-19 and previous coronaviruses.',\n",
              "   'idx': '337d3e21a277480599c81fdfc272b3dc',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 111,\n",
              "   'span_end': 121,\n",
              "   'text': 'We hypothesized that bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir could disrupt SARS-CoV-2 RdRp.',\n",
              "   'idx': '1284cd6b8b7d411da9be62c78dc5e460',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 81,\n",
              "   'span_end': 91,\n",
              "   'text': 'Gastrointestinal complaints have been reported in 15–20% of the newly discovered SARS-CoV-2 COVID-19 patients, and some of 15–20% of COVID-19 patients have also shown infectious virus particles and identifiable viral RNA.',\n",
              "   'idx': '97cfce8004a94c1d8d2538d2726e07aa',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 92,\n",
              "   'span_end': 100,\n",
              "   'text': 'Gastrointestinal complaints have been reported in 15–20% of the newly discovered SARS-CoV-2 COVID-19 patients, and some of 15–20% of COVID-19 patients have also shown infectious virus particles and identifiable viral RNA.',\n",
              "   'idx': '97cfce8004a94c1d8d2538d2726e07aa',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 133,\n",
              "   'span_end': 141,\n",
              "   'text': 'Gastrointestinal complaints have been reported in 15–20% of the newly discovered SARS-CoV-2 COVID-19 patients, and some of 15–20% of COVID-19 patients have also shown infectious virus particles and identifiable viral RNA.',\n",
              "   'idx': '97cfce8004a94c1d8d2538d2726e07aa',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 21,\n",
              "   'span_end': 31,\n",
              "   'text': 'In the intestines of SARS-CoV-2-infected hamsters, high levels of viral nucleocapsid protein, inflammatory processes, and identifiable viral RNA were found.',\n",
              "   'idx': '568c246925244d42a39a8ac295633782',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 232,\n",
              "   'span_end': 252,\n",
              "   'text': 'Cetilistat, a pancreatic lipase inhibitor and oral diiodohydroxyquinoline may be effective topical luminal antivirals in suppressing viral shedding in the gastrointestinal system in the same way feces may be a significant source of SARS-CoV-2 infection.',\n",
              "   'idx': 'ef9934bd81304193ab6a95f9685890a8',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 219,\n",
              "   'span_end': 232,\n",
              "   'text': 'As described by Yuan et al., members of the same medication class as bexarotene, such as tamibarotene and AM580, have demonstrated outstanding antiviral effectiveness against several viruses, including influenza, Zika, coronaviruses SARS-CoV and MERS-CoV, adenoviruses, and enterovirus A71.',\n",
              "   'idx': '2055d6aef54f4b1fae4e47f0966653ae',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 233,\n",
              "   'span_end': 241,\n",
              "   'text': 'As described by Yuan et al., members of the same medication class as bexarotene, such as tamibarotene and AM580, have demonstrated outstanding antiviral effectiveness against several viruses, including influenza, Zika, coronaviruses SARS-CoV and MERS-CoV, adenoviruses, and enterovirus A71.',\n",
              "   'idx': '2055d6aef54f4b1fae4e47f0966653ae',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 246,\n",
              "   'span_end': 254,\n",
              "   'text': 'As described by Yuan et al., members of the same medication class as bexarotene, such as tamibarotene and AM580, have demonstrated outstanding antiviral effectiveness against several viruses, including influenza, Zika, coronaviruses SARS-CoV and MERS-CoV, adenoviruses, and enterovirus A71.',\n",
              "   'idx': '2055d6aef54f4b1fae4e47f0966653ae',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 67,\n",
              "   'span_end': 77,\n",
              "   'text': 'The binding energy values of the five compounds mentioned with the SARS-CoV-2 RdRp protein are shown in.',\n",
              "   'idx': 'ebd774e6d43c40ce84cf73d98856dc58',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 16,\n",
              "   'span_end': 26,\n",
              "   'text': 'As evident, The SARS-CoV-2 RdRp protein had hydrophobic interactions with abiraterone and bexarotene.',\n",
              "   'idx': '14e06eb64df04f0996e4cb3dd37f56fe',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 90,\n",
              "   'span_end': 100,\n",
              "   'text': 'Meanwhile, cetilistat, diiodohydroxyquinoline, and remdesivir interacted with the RdRp of SARS-CoV-2 via hydrogen bonds and hydrophobic interactions.',\n",
              "   'idx': '26c2041a6e9744acb99c8c2fba3b94a0',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 80,\n",
              "   'span_end': 90,\n",
              "   'text': 'The chosen drugs interacted with various amino acid residues of the RdRp of the SARS-CoV-2 protein.',\n",
              "   'idx': '95bf6ddaadcb46f59c32e39885e90ddb',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 62,\n",
              "   'span_end': 72,\n",
              "   'text': 'These interactions can disrupt the biological activity of the SARS-CoV-2 protein RdRp, and, consequently, the viral replication process.',\n",
              "   'idx': '66a3f1aeeaa9464ab97d2e5627b97740',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 59,\n",
              "   'span_end': 69,\n",
              "   'text': 'Bexarotene may be a candidate for blocking the RdRp of the SARS-CoV-2 receptor, as shown by the results mentioned above.',\n",
              "   'idx': '6f0eb84e90e4433bb8c90afc55ad08f1',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 218,\n",
              "   'span_end': 226,\n",
              "   'text': 'Because FDA-approved medications have already been evaluated in terms of toxicity and safety in humans for the treatment of various diseases, repurposing FDA-approved medications will be the best option for developing COVID-19 therapies at this time.',\n",
              "   'idx': 'ceb0ad092c90496cb52d80091d0c0555',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 175,\n",
              "   'span_end': 185,\n",
              "   'text': 'This research computationally evaluated the inhibitory potential of the FDA-approved drugs bexarotene, diiodohydroxyquinoline, abiraterone, and cetilistat against RdRp of the SARS-CoV-2 receptor.',\n",
              "   'idx': '99ed9e390e8f487cb0de8fd0f6cdbf5e',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 219,\n",
              "   'span_end': 227,\n",
              "   'text': 'With further ex vivo and in vivo examinations, our finding suggests that the FDA-approved drugs bexarotene, diiodohydroxyquinoline, abiraterone, and cetilistat could be the potential drug of choice for the treatment of COVID-19.',\n",
              "   'idx': '476ec34447f24388b1b1d7118adbc5b1',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 106,\n",
              "   'span_end': 116,\n",
              "   'text': 'Gromacs software was used in This research to simulate the interaction of bexarotene with the RdRp of the SARS-CoV-2 receptor.',\n",
              "   'idx': 'e02f74f08fc2449ba10f2bce21685ea8',\n",
              "   'article_id': 'PMC9729590'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 33,\n",
              "   'span_end': 43,\n",
              "   'text': 'Furthermore, the the RdRp of the SARS-CoV-2 receptor-Bex radius of gyration has values that indicate the systems’ stability.',\n",
              "   'idx': 'b1b4ea702bfd4f4fafebd4b5044b6320',\n",
              "   'article_id': 'PMC9729590'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 8,\n",
              "   'span_end': 19,\n",
              "   'text': 'A novel coronavirus CoV first appeared by the end of 2019 in Wuhan, China and spread to over 70000 individuals with 1800 death cases within the matter of first 50 days of the disease.',\n",
              "   'idx': '1ac3295bdb16493dbc18bc83a80950f2',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 20,\n",
              "   'span_end': 23,\n",
              "   'text': 'A novel coronavirus CoV first appeared by the end of 2019 in Wuhan, China and spread to over 70000 individuals with 1800 death cases within the matter of first 50 days of the disease.',\n",
              "   'idx': '1ac3295bdb16493dbc18bc83a80950f2',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 99,\n",
              "   'span_end': 110,\n",
              "   'text': 'The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.',\n",
              "   'idx': 'f9622a25314d444a9fbf16981602c330',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 111,\n",
              "   'span_end': 114,\n",
              "   'text': 'The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.',\n",
              "   'idx': 'f9622a25314d444a9fbf16981602c330',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 132,\n",
              "   'span_end': 165,\n",
              "   'text': 'The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.',\n",
              "   'idx': 'f9622a25314d444a9fbf16981602c330',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus-1',\n",
              "   'span_start': 166,\n",
              "   'span_end': 179,\n",
              "   'text': 'The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.',\n",
              "   'idx': 'f9622a25314d444a9fbf16981602c330',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-1',\n",
              "   'span_start': 180,\n",
              "   'span_end': 190,\n",
              "   'text': 'The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.',\n",
              "   'idx': 'f9622a25314d444a9fbf16981602c330',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 8,\n",
              "   'span_end': 19,\n",
              "   'text': 'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "   'idx': '0a6c415f0b70453fbd8b62edf98a822e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 20,\n",
              "   'span_end': 23,\n",
              "   'text': 'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "   'idx': '0a6c415f0b70453fbd8b62edf98a822e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 37,\n",
              "   'span_end': 70,\n",
              "   'text': 'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "   'idx': '0a6c415f0b70453fbd8b62edf98a822e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 71,\n",
              "   'span_end': 82,\n",
              "   'text': 'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "   'idx': '0a6c415f0b70453fbd8b62edf98a822e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 85,\n",
              "   'span_end': 95,\n",
              "   'text': 'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "   'idx': '0a6c415f0b70453fbd8b62edf98a822e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 194,\n",
              "   'span_end': 202,\n",
              "   'text': 'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "   'idx': '0a6c415f0b70453fbd8b62edf98a822e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 203,\n",
              "   'span_end': 213,\n",
              "   'text': 'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "   'idx': '0a6c415f0b70453fbd8b62edf98a822e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 0,\n",
              "   'span_end': 33,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 is a variant of coronavirus with enveloped single-stranded RNA which bears a corona like structure of spikes as shown in a. The main host protein for the attachment of spikes has identified as angiotensin converting enzyme 2 ACE2 receptor.',\n",
              "   'idx': '4f87790e96894622899b35b9fbde0e4f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 34,\n",
              "   'span_end': 45,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 is a variant of coronavirus with enveloped single-stranded RNA which bears a corona like structure of spikes as shown in a. The main host protein for the attachment of spikes has identified as angiotensin converting enzyme 2 ACE2 receptor.',\n",
              "   'idx': '4f87790e96894622899b35b9fbde0e4f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 48,\n",
              "   'span_end': 58,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 is a variant of coronavirus with enveloped single-stranded RNA which bears a corona like structure of spikes as shown in a. The main host protein for the attachment of spikes has identified as angiotensin converting enzyme 2 ACE2 receptor.',\n",
              "   'idx': '4f87790e96894622899b35b9fbde0e4f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 75,\n",
              "   'span_end': 86,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 is a variant of coronavirus with enveloped single-stranded RNA which bears a corona like structure of spikes as shown in a. The main host protein for the attachment of spikes has identified as angiotensin converting enzyme 2 ACE2 receptor.',\n",
              "   'idx': '4f87790e96894622899b35b9fbde0e4f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 0,\n",
              "   'span_end': 33,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 evolved to become the most contagious and infectious among coronavirus family.',\n",
              "   'idx': 'f55ee4c274324773889ad89b147e4bad',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 34,\n",
              "   'span_end': 45,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 evolved to become the most contagious and infectious among coronavirus family.',\n",
              "   'idx': 'f55ee4c274324773889ad89b147e4bad',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 48,\n",
              "   'span_end': 58,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 evolved to become the most contagious and infectious among coronavirus family.',\n",
              "   'idx': 'f55ee4c274324773889ad89b147e4bad',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 118,\n",
              "   'span_end': 129,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 evolved to become the most contagious and infectious among coronavirus family.',\n",
              "   'idx': 'f55ee4c274324773889ad89b147e4bad',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 0,\n",
              "   'span_end': 33,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 enters the lungs by inhaling the contaminated air with viral bodies and infects distal airway cells leading to further spread towards alveolar epithelial cells and causes the damage starting from infection to severe damage as shown in a. As of May 25, 2021, total number of Covid-19 cases reported have surpassed the 30 million cases globally with 1.6 % in US only.',\n",
              "   'idx': 'c7fbd8f2cde84b809b9894c09948789b',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 34,\n",
              "   'span_end': 45,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 enters the lungs by inhaling the contaminated air with viral bodies and infects distal airway cells leading to further spread towards alveolar epithelial cells and causes the damage starting from infection to severe damage as shown in a. As of May 25, 2021, total number of Covid-19 cases reported have surpassed the 30 million cases globally with 1.6 % in US only.',\n",
              "   'idx': 'c7fbd8f2cde84b809b9894c09948789b',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 48,\n",
              "   'span_end': 58,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 enters the lungs by inhaling the contaminated air with viral bodies and infects distal airway cells leading to further spread towards alveolar epithelial cells and causes the damage starting from infection to severe damage as shown in a. As of May 25, 2021, total number of Covid-19 cases reported have surpassed the 30 million cases globally with 1.6 % in US only.',\n",
              "   'idx': 'c7fbd8f2cde84b809b9894c09948789b',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 333,\n",
              "   'span_end': 341,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 enters the lungs by inhaling the contaminated air with viral bodies and infects distal airway cells leading to further spread towards alveolar epithelial cells and causes the damage starting from infection to severe damage as shown in a. As of May 25, 2021, total number of Covid-19 cases reported have surpassed the 30 million cases globally with 1.6 % in US only.',\n",
              "   'idx': 'c7fbd8f2cde84b809b9894c09948789b',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 49,\n",
              "   'span_end': 57,\n",
              "   'text': 'Moreover, in the wake of current situation novel Covid-19 severe acute respiratory syndrome coronavirus 2 has infected around 526.7 million people and have caused more than 6 million deaths globally.',\n",
              "   'idx': '371e4a610e5d4072bcad71a83f205bf3',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 58,\n",
              "   'span_end': 91,\n",
              "   'text': 'Moreover, in the wake of current situation novel Covid-19 severe acute respiratory syndrome coronavirus 2 has infected around 526.7 million people and have caused more than 6 million deaths globally.',\n",
              "   'idx': '371e4a610e5d4072bcad71a83f205bf3',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 92,\n",
              "   'span_end': 103,\n",
              "   'text': 'Moreover, in the wake of current situation novel Covid-19 severe acute respiratory syndrome coronavirus 2 has infected around 526.7 million people and have caused more than 6 million deaths globally.',\n",
              "   'idx': '371e4a610e5d4072bcad71a83f205bf3',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 32,\n",
              "   'span_end': 40,\n",
              "   'text': 'In an emergency situations like Covid-19 de novo drug development is not the feasible option since there is urgent need to find the treatments which can be immediately prescribed to prevent the mortality and morbidity.',\n",
              "   'idx': '6a87f95ab4af4089a560e591f4962481',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 107,\n",
              "   'span_end': 115,\n",
              "   'text': 'So, to face the crisis because of pandemic drug repurposing seems a tangible strategy for fighting against Covid-19 and other such viral diseases.',\n",
              "   'idx': 'c573254750444e48b2c80422c54ffcc8',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 39,\n",
              "   'span_end': 47,\n",
              "   'text': 'Additionally, articles summarizing the Covid-19 drug repurposing using machine learning and deep learning, methods are published as well.',\n",
              "   'idx': 'c6081cf9204943459e2f46cab9c071be',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 139,\n",
              "   'span_end': 147,\n",
              "   'text': 'To the best of our knowledge, until now there is no review study until now has published which summarizes the drug repurposing studies for Covid-19 with special emphasis on network-based drug repurposing approaches to Covid-19.',\n",
              "   'idx': '0dc22dfadf3e42bdb1fc5575b23eea1a',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 218,\n",
              "   'span_end': 226,\n",
              "   'text': 'To the best of our knowledge, until now there is no review study until now has published which summarizes the drug repurposing studies for Covid-19 with special emphasis on network-based drug repurposing approaches to Covid-19.',\n",
              "   'idx': '0dc22dfadf3e42bdb1fc5575b23eea1a',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 251,\n",
              "   'span_end': 259,\n",
              "   'text': 'Thus, this review is mainly focused to bridge the gap by providing overview of machine learning and deep learning approaches to drug repurposing with focus on recent developments in network-based drug repurposing methods, tools, and databases used in Covid-19 as shown in b. In this connection, first we present an overview to computational drug repurposing studies for Covid-19 along with drug and disease related databases followed by recent machine learning and deep learning-based drug repurposing studies.',\n",
              "   'idx': '01fb106467444a92b555b5e233526852',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 370,\n",
              "   'span_end': 378,\n",
              "   'text': 'Thus, this review is mainly focused to bridge the gap by providing overview of machine learning and deep learning approaches to drug repurposing with focus on recent developments in network-based drug repurposing methods, tools, and databases used in Covid-19 as shown in b. In this connection, first we present an overview to computational drug repurposing studies for Covid-19 along with drug and disease related databases followed by recent machine learning and deep learning-based drug repurposing studies.',\n",
              "   'idx': '01fb106467444a92b555b5e233526852',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 60,\n",
              "   'span_end': 68,\n",
              "   'text': \"Moreover, recent network-based drug repurposing studies for Covid-19 are discussed and recent network-based drug repurposing studies for Covid-19's limitations, benefits, and tools used are summarized.\",\n",
              "   'idx': '86eaccb410db4c7bb063681d2a2fb338',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 137,\n",
              "   'span_end': 145,\n",
              "   'text': \"Moreover, recent network-based drug repurposing studies for Covid-19 are discussed and recent network-based drug repurposing studies for Covid-19's limitations, benefits, and tools used are summarized.\",\n",
              "   'idx': '86eaccb410db4c7bb063681d2a2fb338',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 105,\n",
              "   'span_end': 113,\n",
              "   'text': 'Finally, limitations and future recommendation for improved outcome of network-based drug repurposing in Covid-19 and in general are discussed followed by conclusion.',\n",
              "   'idx': '37df00cc0659436f95b464ea055a9ce7',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 66,\n",
              "   'span_end': 74,\n",
              "   'text': 'Some of the machine learning methods used for drug repurposing in Covid-19 include k-nearest neighbors, random forest, support vector machine, and more.',\n",
              "   'idx': '3bb7abcd52744f2baa6f4f6c45b414d1',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 71,\n",
              "   'span_end': 79,\n",
              "   'text': 'Various deep learning algorithms utilized in finding treatment against Covid-19 includes artificial neural networks ANN, convolutional neural networks CNN, and long short-term memory LSTM.',\n",
              "   'idx': 'da5f8946edc24bdb8f641c5a71b810c3',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 67,\n",
              "   'span_end': 75,\n",
              "   'text': 'Apart from this, to accelerate the process of drug development for Covid-19, machine learning based molecular docking frameworks were utilized on approved as well as new chemical entities.',\n",
              "   'idx': '4850daf9157d449c9ece0af3d12148af',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 213,\n",
              "   'span_end': 221,\n",
              "   'text': 'a feature enriched drug repurposing framework named SperoPredictor which consisted multiple state of art machine learning algorithms as shown in b. was deployed to predict the potential drugs to be repurposed for Covid-19, NASH, and renal fibrosis.',\n",
              "   'idx': '65128ab4c5904cb08a7581e82d366766',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 11,\n",
              "   'span_end': 19,\n",
              "   'text': 'In case of Covid-19, 25 potential candidate drugs were predicted.',\n",
              "   'idx': 'f8cfa3d5dd1e46419e55a90e68900142',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 112,\n",
              "   'span_end': 120,\n",
              "   'text': 'Literature survey of peer reviewed journals, databases, and patents suggested 12/25 drugs were already used for Covid-19.',\n",
              "   'idx': '1962e6367cb3435c8240e4954ef04f03',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 273,\n",
              "   'span_end': 281,\n",
              "   'text': 'The a feature enriched drug repurposing framework named SperoPredictor which consisted multiple state of art machine learning algorithms as shown in b. results testify the usefulness of having such platforms that can be readily deployed in case of emergent situations like Covid-19.',\n",
              "   'idx': '002779f028604015b039b0c2b1a75e46',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 46,\n",
              "   'span_end': 54,\n",
              "   'text': 'Another study designed to predict the DTIs in Covid-19 is given in.',\n",
              "   'idx': 'f98eb5d9b73c4bd58c963837190e0d43',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 46,\n",
              "   'span_end': 54,\n",
              "   'text': \"Another study designed to predict the DTIs in Covid-19 avails the proteins and drugs provided in the proteins and drugs's structured format.\",\n",
              "   'idx': '891f7f47588347dc8c2290d45d503699',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 123,\n",
              "   'span_end': 131,\n",
              "   'text': 'Then the developed model was compared with existing studies using k-fold cross validation b. To deploy the developed model Covid-19 was selected as a case study.',\n",
              "   'idx': '7a2629d0ed9f4a3b9709bcd5b5e3e452',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 98,\n",
              "   'span_end': 106,\n",
              "   'text': 'the developed model was deployed as shown in c on the proteins known to have been involved in the Covid-19 to predict the possible interactions or drug-target interactions.',\n",
              "   'idx': '97ac6b57805844da8989b356af818601',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 60,\n",
              "   'span_end': 68,\n",
              "   'text': 'the developed model was further deployed to drugs active in Covid-19 and drugs active in Covid-19 were predicted with 100 % accuracy.',\n",
              "   'idx': '6fc5edf469c24ee8877fea17912a2be4',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 89,\n",
              "   'span_end': 97,\n",
              "   'text': 'the developed model was further deployed to drugs active in Covid-19 and drugs active in Covid-19 were predicted with 100 % accuracy.',\n",
              "   'idx': '6fc5edf469c24ee8877fea17912a2be4',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 35,\n",
              "   'span_end': 43,\n",
              "   'text': 'The interaction of drugs active in Covid-19 was shown with ACE2,, self-membrane protein, a key player in Covid-19 enabling disease infection.',\n",
              "   'idx': '3d196cc189eb4f5abe24e58758c6168a',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 105,\n",
              "   'span_end': 113,\n",
              "   'text': 'The interaction of drugs active in Covid-19 was shown with ACE2,, self-membrane protein, a key player in Covid-19 enabling disease infection.',\n",
              "   'idx': '3d196cc189eb4f5abe24e58758c6168a',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 62,\n",
              "   'span_end': 70,\n",
              "   'text': 'Machine learning plays a key role in drug repurposing against Covid-19 and pace of research in the field has skyrocketed since the emergence of Covid-19.',\n",
              "   'idx': '957a3b035d2940b3afd3e2bbc9e7b2b8',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 144,\n",
              "   'span_end': 152,\n",
              "   'text': 'Machine learning plays a key role in drug repurposing against Covid-19 and pace of research in the field has skyrocketed since the emergence of Covid-19.',\n",
              "   'idx': '957a3b035d2940b3afd3e2bbc9e7b2b8',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 115,\n",
              "   'span_end': 123,\n",
              "   'text': 'Robust and efficient computational methods making use deep learning are widely required for drug discovery against Covid-19.',\n",
              "   'idx': '07be9e55b93c466c80774e12505f252d',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 143,\n",
              "   'span_end': 151,\n",
              "   'text': 'Convolutional neural networks and recursive neural networks have been widely used in bioinformatics studies with successful results such as in Covid-19,.',\n",
              "   'idx': '6bfb8b216029466a9e8733da8797e379',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 77,\n",
              "   'span_end': 85,\n",
              "   'text': 'Deep learning methods have also been widely used in drug repurposing against Covid-19.',\n",
              "   'idx': 'c580058e80184643b417a406a6648273',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 44,\n",
              "   'span_end': 52,\n",
              "   'text': 'A recent work involving drug repurposing in Covid-19 using deep learning is given in and are given in.',\n",
              "   'idx': '3be805484e3e43619a04bc262bc53a96',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 177,\n",
              "   'span_end': 185,\n",
              "   'text': 'deep learning model named as Molecule Transformer-Drug Target Interaction MT-DTI predicted several commercially available or in practice anti-viral drugs having potency against Covid-19 protein targets confirmed by the pre-clinical validation assays of Covid-19. deep learning model named as Molecule Transformer-Drug Target Interaction MT-DTI was deployed for the selection of compounds from 1400 FDA approved drugs having the strong affinity against the host cellular targets for viral diseases.',\n",
              "   'idx': '24628de9a11f4b8198514b01b871912f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 253,\n",
              "   'span_end': 261,\n",
              "   'text': 'deep learning model named as Molecule Transformer-Drug Target Interaction MT-DTI predicted several commercially available or in practice anti-viral drugs having potency against Covid-19 protein targets confirmed by the pre-clinical validation assays of Covid-19. deep learning model named as Molecule Transformer-Drug Target Interaction MT-DTI was deployed for the selection of compounds from 1400 FDA approved drugs having the strong affinity against the host cellular targets for viral diseases.',\n",
              "   'idx': '24628de9a11f4b8198514b01b871912f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 145,\n",
              "   'span_end': 153,\n",
              "   'text': 'Another deep learning-based drug repurposing study done in used deep learning on a massive knowledge graph to identify and select promising anti-Covid-19 drug candidates.',\n",
              "   'idx': '1f3c33eb268d4f2690bb9536a5d84579',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 106,\n",
              "   'span_end': 114,\n",
              "   'text': '41 repurposed drug candidates include dexamethasone an anti-inflammatory agent having bioactivity against Covid-19 and Niclosamide validated by proteomics of Covid-19 infected cell and gene expression.',\n",
              "   'idx': '969d1ea3a11e43fdbf4e29daf65738d5',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19 infected',\n",
              "   'span_start': 158,\n",
              "   'span_end': 175,\n",
              "   'text': '41 repurposed drug candidates include dexamethasone an anti-inflammatory agent having bioactivity against Covid-19 and Niclosamide validated by proteomics of Covid-19 infected cell and gene expression.',\n",
              "   'idx': '969d1ea3a11e43fdbf4e29daf65738d5',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 139,\n",
              "   'span_end': 147,\n",
              "   'text': 'Drug candidate such as pralatrexate and azithromycin predicted from One such study were validated in in-vitro testing and found to inhibit Covid-19.',\n",
              "   'idx': '54d9069315ff4349b4f6e414ae2aa70b',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 27,\n",
              "   'span_end': 35,\n",
              "   'text': 'First drug was active once Covid-19 entered host cells while azithromycin has efficacy in before and after stages.',\n",
              "   'idx': '83de5e7edba34a45b3edca63934ee0df',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 107,\n",
              "   'span_end': 115,\n",
              "   'text': 'To demonstrate the drug design features of software tools MolAICal, membrane protein glucagon receptor and Covid-19 main protease were modelled.',\n",
              "   'idx': '09b40f9e2fb7403296a613d2e56eb7f8',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 134,\n",
              "   'span_end': 142,\n",
              "   'text': 'Using the proposed method in study led to identification of 1000 top ranked potential drug compound supposed to have efficacy against Covid-19 Mpro.',\n",
              "   'idx': 'cd232385f78940cca424afcaff2b6c04',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 54,\n",
              "   'span_end': 62,\n",
              "   'text': 'DL has helped in finding the repurposed drugs against Covid-19 and in other pathogens however certain challenges still exist.',\n",
              "   'idx': '65fb30e50b8b43f28f602fb47d067943',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 6,\n",
              "   'span_end': 19,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "   'idx': '85aa68ed035f4c3981a7740e31691c63',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV',\n",
              "   'span_start': 20,\n",
              "   'span_end': 24,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "   'idx': '85aa68ed035f4c3981a7740e31691c63',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 33,\n",
              "   'span_end': 66,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "   'idx': '85aa68ed035f4c3981a7740e31691c63',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 67,\n",
              "   'span_end': 78,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "   'idx': '85aa68ed035f4c3981a7740e31691c63',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 79,\n",
              "   'span_end': 87,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "   'idx': '85aa68ed035f4c3981a7740e31691c63',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 103,\n",
              "   'span_end': 114,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "   'idx': '85aa68ed035f4c3981a7740e31691c63',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 115,\n",
              "   'span_end': 123,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "   'idx': '85aa68ed035f4c3981a7740e31691c63',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 144,\n",
              "   'span_end': 154,\n",
              "   'text': 'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "   'idx': '85aa68ed035f4c3981a7740e31691c63',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 0,\n",
              "   'span_end': 33,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "   'idx': '4598fd9e86fd415597bb9209f1747cb6',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 34,\n",
              "   'span_end': 45,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "   'idx': '4598fd9e86fd415597bb9209f1747cb6',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 46,\n",
              "   'span_end': 54,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "   'idx': '4598fd9e86fd415597bb9209f1747cb6',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 69,\n",
              "   'span_end': 80,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "   'idx': '4598fd9e86fd415597bb9209f1747cb6',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 164,\n",
              "   'span_end': 197,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "   'idx': '4598fd9e86fd415597bb9209f1747cb6',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 198,\n",
              "   'span_end': 209,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "   'idx': '4598fd9e86fd415597bb9209f1747cb6',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV.',\n",
              "   'span_start': 210,\n",
              "   'span_end': 219,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "   'idx': '4598fd9e86fd415597bb9209f1747cb6',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus 2019',\n",
              "   'span_start': 236,\n",
              "   'span_end': 252,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "   'idx': '4598fd9e86fd415597bb9209f1747cb6',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'nCoV',\n",
              "   'span_start': 253,\n",
              "   'span_end': 257,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "   'idx': '4598fd9e86fd415597bb9209f1747cb6',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 139,\n",
              "   'span_end': 150,\n",
              "   'text': 'Instead of highly accelerated efforts in the field of drug research, until now there is only drug approved for the treatment of novel 2019 coronavirus Covid-19.',\n",
              "   'idx': 'c1055bf866e340faaa27e1180afd30f9',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 151,\n",
              "   'span_end': 159,\n",
              "   'text': 'Instead of highly accelerated efforts in the field of drug research, until now there is only drug approved for the treatment of novel 2019 coronavirus Covid-19.',\n",
              "   'idx': 'c1055bf866e340faaa27e1180afd30f9',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 176,\n",
              "   'span_end': 184,\n",
              "   'text': 'Over the period, multiple techniques based on machine learning, deep learning, mining, and network or graph-based approaches have been widely used to repurpose the drugs for a Covid-19.',\n",
              "   'idx': '02923c9fc1434dfda55357736a480342',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 177,\n",
              "   'span_end': 188,\n",
              "   'text': 'Herein, we provide the comprehensive review along with benefits, challenges, and future directions of network science-based drug repurposing studies specifically for novel 2019 coronavirus Covid-19.',\n",
              "   'idx': 'faee1ea7e71a4cd49a35cdf7c58c0d9e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 189,\n",
              "   'span_end': 197,\n",
              "   'text': 'Herein, we provide the comprehensive review along with benefits, challenges, and future directions of network science-based drug repurposing studies specifically for novel 2019 coronavirus Covid-19.',\n",
              "   'idx': 'faee1ea7e71a4cd49a35cdf7c58c0d9e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 68,\n",
              "   'span_end': 76,\n",
              "   'text': 'network science-based drug repurposing studies specifically for the Covid-19 are divided in to three categories based on network proximity, network diffusion, and artificial intelligence.',\n",
              "   'idx': 'ecc9e5d14a324fa79b2c686502193310',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 457,\n",
              "   'span_end': 468,\n",
              "   'text': \"Network proximity-based drug repurposing studies use the proximity measures such as network centralities, node degree, and more for identifying and providing the key protein-protein, drug-drug, or drug-target associations to repurpose the drugs a i. One of the recent studies done in presented a powerful network-based drug methodologies for identification of potential repurposable drugs and potential repurposable drugs's combination targeting novel 2019 coronavirus Covid-19.\",\n",
              "   'idx': '05dc0a4025ac412e9179d279fc13bbd0',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 469,\n",
              "   'span_end': 477,\n",
              "   'text': \"Network proximity-based drug repurposing studies use the proximity measures such as network centralities, node degree, and more for identifying and providing the key protein-protein, drug-drug, or drug-target associations to repurpose the drugs a i. One of the recent studies done in presented a powerful network-based drug methodologies for identification of potential repurposable drugs and potential repurposable drugs's combination targeting novel 2019 coronavirus Covid-19.\",\n",
              "   'idx': '05dc0a4025ac412e9179d279fc13bbd0',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV-host',\n",
              "   'span_start': 100,\n",
              "   'span_end': 109,\n",
              "   'text': 'Presented anti-viral and integrated repurposing methodology mainly quantified the interplay between HCoV-host proteins and drug targets in human protein-protein interactions PPI.',\n",
              "   'idx': 'eebe748e7bff429395bd158f4342e8d1',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV-host',\n",
              "   'span_start': 58,\n",
              "   'span_end': 67,\n",
              "   'text': 'Use of network proximity analysis as shown in b i between HCoV-host targets and drug targets in human PPI led to prioritization of 16 anti-HCoV drugs potentially repurposable.',\n",
              "   'idx': 'fd281da5a2c243959ab0b052f04d5fe8',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'anti-HCoV',\n",
              "   'span_start': 134,\n",
              "   'span_end': 143,\n",
              "   'text': 'Use of network proximity analysis as shown in b i between HCoV-host targets and drug targets in human PPI led to prioritization of 16 anti-HCoV drugs potentially repurposable.',\n",
              "   'idx': 'fd281da5a2c243959ab0b052f04d5fe8',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 139,\n",
              "   'span_end': 150,\n",
              "   'text': 'Despite successful results, One of the recent studies done in suffered from limitations such as, lack of known host proteins on novel 2019 coronavirus Covid-19, a low binding affinity value of 10 M was used to specify the DTI.',\n",
              "   'idx': 'bc0f5d03930d45b197f7d47ededaeeb3',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 151,\n",
              "   'span_end': 159,\n",
              "   'text': 'Despite successful results, One of the recent studies done in suffered from limitations such as, lack of known host proteins on novel 2019 coronavirus Covid-19, a low binding affinity value of 10 M was used to specify the DTI.',\n",
              "   'idx': 'bc0f5d03930d45b197f7d47ededaeeb3',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 143,\n",
              "   'span_end': 154,\n",
              "   'text': 'Another network proximity-based drug repurposing study is given in which used network medicine-based approach to repurpose drugs in novel 2019 coronavirus Covid-19.',\n",
              "   'idx': '1ab647476fd245fa83a1b17cf7e21b78',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 155,\n",
              "   'span_end': 163,\n",
              "   'text': 'Another network proximity-based drug repurposing study is given in which used network medicine-based approach to repurpose drugs in novel 2019 coronavirus Covid-19.',\n",
              "   'idx': '1ab647476fd245fa83a1b17cf7e21b78',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 181,\n",
              "   'span_end': 192,\n",
              "   'text': 'Another network proximity-based drug repurposing study enriched the PPI with transcriptomics and proteomics and then performed network proximity measurement where broach novel 2019 coronavirus Covid-19 associated underlying pathogenesis of disease manifestation was explored.',\n",
              "   'idx': 'c9bd33ff65ab4c25b13513ead6d8b78f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 193,\n",
              "   'span_end': 201,\n",
              "   'text': 'Another network proximity-based drug repurposing study enriched the PPI with transcriptomics and proteomics and then performed network proximity measurement where broach novel 2019 coronavirus Covid-19 associated underlying pathogenesis of disease manifestation was explored.',\n",
              "   'idx': 'c9bd33ff65ab4c25b13513ead6d8b78f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 163,\n",
              "   'span_end': 174,\n",
              "   'text': 'Here, the associations between 6 different diseases consisting of autoimmune, malignant, cancer, cardiovascular, metabolic, neurological, pulmonary and novel 2019 coronavirus Covid-19 were created.',\n",
              "   'idx': 'e3a736cb581e4b98bdf9415ac05b039a',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 175,\n",
              "   'span_end': 183,\n",
              "   'text': 'Here, the associations between 6 different diseases consisting of autoimmune, malignant, cancer, cardiovascular, metabolic, neurological, pulmonary and novel 2019 coronavirus Covid-19 were created.',\n",
              "   'idx': 'e3a736cb581e4b98bdf9415ac05b039a',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 170,\n",
              "   'span_end': 181,\n",
              "   'text': \"Created network was analyzed followed by the single-cell RNA sequencing to uncover the underlying pathobiological and pathophysiological relationships between novel 2019 coronavirus Covid-19 and novel 2019 coronavirus Covid-19's associated treatments.\",\n",
              "   'idx': '1b055873a0044114a4b07b4b29031e2a',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 182,\n",
              "   'span_end': 190,\n",
              "   'text': \"Created network was analyzed followed by the single-cell RNA sequencing to uncover the underlying pathobiological and pathophysiological relationships between novel 2019 coronavirus Covid-19 and novel 2019 coronavirus Covid-19's associated treatments.\",\n",
              "   'idx': '1b055873a0044114a4b07b4b29031e2a',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 206,\n",
              "   'span_end': 217,\n",
              "   'text': \"Created network was analyzed followed by the single-cell RNA sequencing to uncover the underlying pathobiological and pathophysiological relationships between novel 2019 coronavirus Covid-19 and novel 2019 coronavirus Covid-19's associated treatments.\",\n",
              "   'idx': '1b055873a0044114a4b07b4b29031e2a',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 218,\n",
              "   'span_end': 226,\n",
              "   'text': \"Created network was analyzed followed by the single-cell RNA sequencing to uncover the underlying pathobiological and pathophysiological relationships between novel 2019 coronavirus Covid-19 and novel 2019 coronavirus Covid-19's associated treatments.\",\n",
              "   'idx': '1b055873a0044114a4b07b4b29031e2a',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 204,\n",
              "   'span_end': 214,\n",
              "   'text': 'Although not significant, network proximity results in Another network proximity-based drug repurposing study showed that rheumatoid arthritis has small network proximities negative Z scores across all 5 SARS-CoV-2 datasets.',\n",
              "   'idx': 'c7d8ae15b9d147e2acac41abd35cc3c8',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 171,\n",
              "   'span_end': 182,\n",
              "   'text': 'This type of muti-layered validation of the network predicted drugs find out the key repurposable drugs supposed to have potential to reverse the expression of novel 2019 coronavirus Covid-19 expressed genes.',\n",
              "   'idx': 'adb9f502bfd742da8c56de3c31b3f87f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 183,\n",
              "   'span_end': 191,\n",
              "   'text': 'This type of muti-layered validation of the network predicted drugs find out the key repurposable drugs supposed to have potential to reverse the expression of novel 2019 coronavirus Covid-19 expressed genes.',\n",
              "   'idx': 'adb9f502bfd742da8c56de3c31b3f87f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 101,\n",
              "   'span_end': 111,\n",
              "   'text': 'In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.',\n",
              "   'idx': 'df795ac36f324589a318c63677b8f105',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS2',\n",
              "   'span_start': 121,\n",
              "   'span_end': 126,\n",
              "   'text': 'In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.',\n",
              "   'idx': 'df795ac36f324589a318c63677b8f105',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS2',\n",
              "   'span_start': 132,\n",
              "   'span_end': 137,\n",
              "   'text': 'In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.',\n",
              "   'idx': 'df795ac36f324589a318c63677b8f105',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'HCoV-PPI',\n",
              "   'span_start': 143,\n",
              "   'span_end': 151,\n",
              "   'text': 'In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.',\n",
              "   'idx': 'df795ac36f324589a318c63677b8f105',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS2',\n",
              "   'span_start': 157,\n",
              "   'span_end': 162,\n",
              "   'text': 'In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.',\n",
              "   'idx': 'df795ac36f324589a318c63677b8f105',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 53,\n",
              "   'span_end': 63,\n",
              "   'text': 'These drugs were significantly proximal to 2 or more SARS-CoV-2 host protein sets.',\n",
              "   'idx': 'd9b9081c3d2949e6a3425e7c0001f3ee',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 58,\n",
              "   'span_end': 68,\n",
              "   'text': 'Additionally, Knowledge of the complex interplays between SARS-CoV-2 targets and human diseases indicate possibilities of drug repurposing, as the drugs that target other diseases could potentially target SARS-CoV-2 through the shared functional PPI networks.',\n",
              "   'idx': 'cd66008589da44bbb90f652b2d204b6b',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 205,\n",
              "   'span_end': 215,\n",
              "   'text': 'Additionally, Knowledge of the complex interplays between SARS-CoV-2 targets and human diseases indicate possibilities of drug repurposing, as the drugs that target other diseases could potentially target SARS-CoV-2 through the shared functional PPI networks.',\n",
              "   'idx': 'cd66008589da44bbb90f652b2d204b6b',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 178,\n",
              "   'span_end': 189,\n",
              "   'text': 'Some studies are combining different network approaches for improved results such as done in which aims to captures the bigger picture of human molecular landscape of novel 2019 coronavirus Covid-19 infection by exploiting the network medicine approach as strategy to repurpose the drugs for novel 2019 coronavirus Covid-19.',\n",
              "   'idx': '0c90be6d39d24ba489d099394452011e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19 infection',\n",
              "   'span_start': 190,\n",
              "   'span_end': 208,\n",
              "   'text': 'Some studies are combining different network approaches for improved results such as done in which aims to captures the bigger picture of human molecular landscape of novel 2019 coronavirus Covid-19 infection by exploiting the network medicine approach as strategy to repurpose the drugs for novel 2019 coronavirus Covid-19.',\n",
              "   'idx': '0c90be6d39d24ba489d099394452011e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 303,\n",
              "   'span_end': 314,\n",
              "   'text': 'Some studies are combining different network approaches for improved results such as done in which aims to captures the bigger picture of human molecular landscape of novel 2019 coronavirus Covid-19 infection by exploiting the network medicine approach as strategy to repurpose the drugs for novel 2019 coronavirus Covid-19.',\n",
              "   'idx': '0c90be6d39d24ba489d099394452011e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 315,\n",
              "   'span_end': 323,\n",
              "   'text': 'Some studies are combining different network approaches for improved results such as done in which aims to captures the bigger picture of human molecular landscape of novel 2019 coronavirus Covid-19 infection by exploiting the network medicine approach as strategy to repurpose the drugs for novel 2019 coronavirus Covid-19.',\n",
              "   'idx': '0c90be6d39d24ba489d099394452011e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 74,\n",
              "   'span_end': 85,\n",
              "   'text': 'As a starting point, experimentally validated host proteins of novel 2019 coronavirus Covid-19 known to have viral interaction, tissue specific gene expression data, were explored by use of techniques such as connectivity significance, network diffusion, and network propagation.',\n",
              "   'idx': '61b972c48b3e4422979eeb5b45a81917',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 86,\n",
              "   'span_end': 94,\n",
              "   'text': 'As a starting point, experimentally validated host proteins of novel 2019 coronavirus Covid-19 known to have viral interaction, tissue specific gene expression data, were explored by use of techniques such as connectivity significance, network diffusion, and network propagation.',\n",
              "   'idx': '61b972c48b3e4422979eeb5b45a81917',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 113,\n",
              "   'span_end': 124,\n",
              "   'text': 'This process was followed to rank genes followed repurposing drugs targeting genes as a treatment for novel 2019 coronavirus Covid-19.',\n",
              "   'idx': '49e9dbb5809f4f4b9c735361ab3a16c2',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 125,\n",
              "   'span_end': 133,\n",
              "   'text': 'This process was followed to rank genes followed repurposing drugs targeting genes as a treatment for novel 2019 coronavirus Covid-19.',\n",
              "   'idx': '49e9dbb5809f4f4b9c735361ab3a16c2',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 100,\n",
              "   'span_end': 111,\n",
              "   'text': 'The prioritized collection of genes which served as key drug targets for repurposed anti-novel 2019 coronavirus Covid-19 drugs responsible for causing pharmacological effect resulted from normalization and aggregation of different scoring methods.',\n",
              "   'idx': '72774c4ef77f45fea95a3ecab5de3a24',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 112,\n",
              "   'span_end': 120,\n",
              "   'text': 'The prioritized collection of genes which served as key drug targets for repurposed anti-novel 2019 coronavirus Covid-19 drugs responsible for causing pharmacological effect resulted from normalization and aggregation of different scoring methods.',\n",
              "   'idx': '72774c4ef77f45fea95a3ecab5de3a24',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 61,\n",
              "   'span_end': 69,\n",
              "   'text': 'Additionally, another network-based repurposing approach for Covid-19 done in was conducted by integrating GWAS and text mining the data.',\n",
              "   'idx': '412fae520b74445b8266309acf25d2fe',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 50,\n",
              "   'span_end': 58,\n",
              "   'text': 'Here lung-specified gene subnetwork enriched with Covid-19 gene associated data obtained from GWAS was created to screen 220 FDA approved drugs obtained from DrugBank database.',\n",
              "   'idx': 'a728d247d93e4fc4b876c9febd9d6974',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 114,\n",
              "   'span_end': 122,\n",
              "   'text': 'This led to prioritization of 220 FDA approved drugs obtained from DrugBank database as a potential treatment for Covid-19.',\n",
              "   'idx': '4058fd0e67e0454aa6c73345cea8d52f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 160,\n",
              "   'span_end': 168,\n",
              "   'text': 'Findings provide the timely and valuable insights to repurposed use options of 220 FDA approved drugs obtained from DrugBank database to be further explored in Covid-19.',\n",
              "   'idx': 'b8c0369b22ec46bca5b303e7d96c72bb',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 135,\n",
              "   'span_end': 143,\n",
              "   'text': \"Another very distinguished and interesting work in the field of network science and network science's applications to drug repurposing Covid-19 was done in.\",\n",
              "   'idx': 'a704937f0e564aa692a2dc1332c0c798',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 129,\n",
              "   'span_end': 137,\n",
              "   'text': 'Here in Another very distinguished and interesting work in the field of network science and its applications to drug repurposing Covid-19 multiple layers or approaches normally applied individually on the networks were fused into a single algorithm.',\n",
              "   'idx': '9c6535ce2b5f4b2d86dd5cf396f4aa0e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 95,\n",
              "   'span_end': 103,\n",
              "   'text': 'Each of Deployed algorithms was utilized to prioritize the 6340 drugs for expected efficacy in Covid-19.',\n",
              "   'idx': '170373e5dd7e421b9fe880021aa707a6',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 111,\n",
              "   'span_end': 119,\n",
              "   'text': 'This led to a successful approach as a network medicine framework for identifying repurposing opportunities in Covid-19.',\n",
              "   'idx': '68da3ea3a64048cd96bb2b0cfda7fa32',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 252,\n",
              "   'span_end': 260,\n",
              "   'text': 'In practice one cannot find a single algorithm that consistently performs across all the datasets which served as a motivation for Another very distinguished and interesting work in the field of network science and its applications to drug repurposing Covid-19.',\n",
              "   'idx': 'd6d52a3070c147df844fa9f1609228d2',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 149,\n",
              "   'span_end': 157,\n",
              "   'text': '96 % of the drugs tested in Another very distinguished and interesting work in the field of network science and its applications to drug repurposing Covid-19 were FDA approved which is beneficial as 96 % of the drugs tested in the study could be directly moved to clinical trials.',\n",
              "   'idx': '30d024751346416188cf07ffd0f658c1',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 266,\n",
              "   'span_end': 274,\n",
              "   'text': 'A real predictive power of multimodal approach that combines the predictions from all approaches was demonstrated by the positive outcomes of the second human screen with success rate of 62 % followed by identification of six drugs potentially easily repurposed for Covid-19.',\n",
              "   'idx': '860193f0dfb945588ea5afcdc865fa2f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 160,\n",
              "   'span_end': 168,\n",
              "   'text': 'All in all, multimodal approach that combines the predictions from all approaches did not only provided an effective strategy and results in the repurposing of Covid-19 drugs but also provided an algorithmic toolset as well.',\n",
              "   'idx': '433f973ee1254c50a9d5c54cc1ddd5ca',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 44,\n",
              "   'span_end': 52,\n",
              "   'text': 'Severe and rapidly emerging replications of Covid-19 made the world realize for the combination therapies that were expected to response more effectively.',\n",
              "   'idx': '1de0153f2e6c47bd9d43c75984602ad8',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID',\n",
              "   'span_start': 112,\n",
              "   'span_end': 117,\n",
              "   'text': 'To address this gap a study was done in where an integrative network pharmacology inspired web-based tool named COVID-CDR was developed for in-silico repurposing of the drug combinations.',\n",
              "   'idx': 'd4a943db9e47413d88eb2ee96c2d1bc0',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID',\n",
              "   'span_start': 66,\n",
              "   'span_end': 71,\n",
              "   'text': 'an integrative network pharmacology inspired web-based tool named COVID-CDR could prioritize Covid-19 repurposable drug combination for synergistic effect.',\n",
              "   'idx': 'cfbe22eb42d84617a1751d0b25903f15',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 93,\n",
              "   'span_end': 101,\n",
              "   'text': 'an integrative network pharmacology inspired web-based tool named COVID-CDR could prioritize Covid-19 repurposable drug combination for synergistic effect.',\n",
              "   'idx': 'cfbe22eb42d84617a1751d0b25903f15',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 76,\n",
              "   'span_end': 84,\n",
              "   'text': 'In this approach, drugs with targets sharing the topological proximity with Covid-19 targets are used to prioritize the drug combinations based on drug-target separation.',\n",
              "   'idx': 'c65ad8ed7cb4424090ec7556a746a0f3',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID',\n",
              "   'span_start': 127,\n",
              "   'span_end': 132,\n",
              "   'text': 'Whereas, successfully evaluated drug combinations because of an integrative network pharmacology inspired web-based tool named COVID-CDR were evaluated using the network computation methods.',\n",
              "   'idx': '40b7cb765fd041df9eecf7ac81e83546',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 121,\n",
              "   'span_end': 129,\n",
              "   'text': 'One among some of the recent studies, where AI on networks has been applied to repurpose the drugs is done in in which a Covid-19 based knowledge graph was built.',\n",
              "   'idx': '4214d06cb1af48e896ba0c39523190f3',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 2,\n",
              "   'span_end': 10,\n",
              "   'text': 'a Covid-19 based knowledge graph consists of virus baits, host genes, pathways, and other information.',\n",
              "   'idx': '1067aba3abe6459caa24172137760e50',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 129,\n",
              "   'span_end': 137,\n",
              "   'text': 'Use of deep neural networks and integration of the diverse interactions helped in quick identification of drugs repurposable for Covid-19.',\n",
              "   'idx': '1a2d50d1c1c74f2da795084454fc6da1',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 121,\n",
              "   'span_end': 129,\n",
              "   'text': 'Another very distinguished and interesting work in the field of network science and its applications to drug repurposing Covid-19 suffered from the limitations of missing the effective drugs possibly during the initial drug ranking.',\n",
              "   'idx': 'dd255b8c7ac74bc897fd2376102ffd4f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 8,\n",
              "   'span_end': 16,\n",
              "   'text': 'Another Covid-19 based drug repurposing study using the Few-Shot learning is done in.',\n",
              "   'idx': '4d4b98f105d9483da5ecb9ad19644919',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 8,\n",
              "   'span_end': 16,\n",
              "   'text': 'Another Covid-19 based drug repurposing study using the Few-Shot learning introduces the multi-targeted drug repurposing strategy which is taken as most efficient approach to diseases such as Covid-19.',\n",
              "   'idx': '382aa7a0dbc044129d378d7101131b1f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 192,\n",
              "   'span_end': 200,\n",
              "   'text': 'Another Covid-19 based drug repurposing study using the Few-Shot learning introduces the multi-targeted drug repurposing strategy which is taken as most efficient approach to diseases such as Covid-19.',\n",
              "   'idx': '382aa7a0dbc044129d378d7101131b1f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 27,\n",
              "   'span_end': 35,\n",
              "   'text': 'In connection with Another Covid-19 based drug repurposing study using the Few-Shot learning, molecules are represented as graphs G, nodes are items and bonds between nodes are the edges.',\n",
              "   'idx': '512221dbc04249c895e8036b2f9c76d3',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 124,\n",
              "   'span_end': 132,\n",
              "   'text': 'Following this, an input data comprising molecules as graphs in the form of adjacency matrix A, was constructed for Another Covid-19 based drug repurposing study using the Few-Shot learning.',\n",
              "   'idx': 'b3caf7f73821478ba178dcbd39f308bd',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 70,\n",
              "   'span_end': 78,\n",
              "   'text': 'The deployment of the trained models and downstream classification c, Covid-19 related chemical molecules were used.',\n",
              "   'idx': '291667eb888c404c928feba6d475de44',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 8,\n",
              "   'span_end': 16,\n",
              "   'text': 'Another Covid-19 based drug repurposing study using the Few-Shot learning provided a powerful tool for future research in drug repurposing specifically in case of poorly known diseases such as Covid-19.',\n",
              "   'idx': '74e3a4da835145acb2f453133e5bce2d',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 193,\n",
              "   'span_end': 201,\n",
              "   'text': 'Another Covid-19 based drug repurposing study using the Few-Shot learning provided a powerful tool for future research in drug repurposing specifically in case of poorly known diseases such as Covid-19.',\n",
              "   'idx': '74e3a4da835145acb2f453133e5bce2d',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 215,\n",
              "   'span_end': 223,\n",
              "   'text': 'Instead of these benefits, there are certain limitations such as uncertainties in the datasets used and lack of validation of the predicted drugs in corresponding in-vitro and in-vivo models for efficacy testing in Covid-19.',\n",
              "   'idx': '117817035b1742fc9332babd79ee35e9',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 148,\n",
              "   'span_end': 156,\n",
              "   'text': 'Moreover, multiple machine learning models are also used disease agnostic fashion for network datasets as done in for repurposing targeted drugs in Covid-19.',\n",
              "   'idx': '0dc8526946a7407ca77f7d032265f156',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 39,\n",
              "   'span_end': 47,\n",
              "   'text': 'Used models are complementary covering Covid-19 and host factors.',\n",
              "   'idx': '8878ec91630f44b597cdaa0bd71f417d',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 140,\n",
              "   'span_end': 148,\n",
              "   'text': 'Furthermore, results suggest that the drugs ranked using anti-viral of the top predicted broad spectrum were found in clinical practice for Covid-19 and those from graph kernels were found experimentally validated.',\n",
              "   'idx': '1fd34a04f5554f24b34e6ce39f51a321',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 16,\n",
              "   'span_end': 24,\n",
              "   'text': 'Similarly, here Covid-19 drug repurposing explorer abbreviated as CoREx was deployed as an interactive tool.',\n",
              "   'idx': '1615f1d9976246c599a8b43dd735f980',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 0,\n",
              "   'span_end': 8,\n",
              "   'text': 'Covid-19 drug repurposing explorer abbreviated as CoREx can be used to observe and understand the interaction between drugs and host Covid-19 targets in context of biological networks, clinical use of drugs, protein functioning, and cMAP.',\n",
              "   'idx': '5b8eac89c11846a0ae333e4aa58112db',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 133,\n",
              "   'span_end': 141,\n",
              "   'text': 'Covid-19 drug repurposing explorer abbreviated as CoREx can be used to observe and understand the interaction between drugs and host Covid-19 targets in context of biological networks, clinical use of drugs, protein functioning, and cMAP.',\n",
              "   'idx': '5b8eac89c11846a0ae333e4aa58112db',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 41,\n",
              "   'span_end': 49,\n",
              "   'text': 'Despite the contribution and benefits of Covid-19 drug repurposing explorer abbreviated as CoREx there some limitations such as the matrix decomposition approach can only be applied to the drugs for which association with viral disease is known.',\n",
              "   'idx': 'c8dd8b4c1a8b4cb68eb507aeeb8c1e2e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 27,\n",
              "   'span_end': 35,\n",
              "   'text': 'Main limitation of Another Covid-19 based drug repurposing study using the Few-Shot learning is the annotation of the drug-virus pairs based on the developmental stages and the related data is hard to find.',\n",
              "   'idx': '9ad8e0d49a4f44a5a0dedd6674bcc40d',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 37,\n",
              "   'span_end': 45,\n",
              "   'text': 'Similarly, the other part of Another Covid-19 based drug repurposing study using the Few-Shot learning Network medicine has limitation that only those drugs for which targets are known can be used.',\n",
              "   'idx': 'ddb940517e8a433694e0624903ff7c71',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 11,\n",
              "   'span_end': 19,\n",
              "   'text': 'Human PPI, Covid-19 specific network, and DTIs were first created like most of the studies and later essential proteins were passed through a set of algorithms Machine learning.',\n",
              "   'idx': '963fc1d5eb774ab791f94cbd790d3748',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 108,\n",
              "   'span_end': 116,\n",
              "   'text': 'Enrichment analysis was then performed for informative features to validate informative features in case of Covid-19.',\n",
              "   'idx': '63cb67956bad467f9572d8575680c0d4',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 64,\n",
              "   'span_end': 72,\n",
              "   'text': 'One such graph machine learning based drug repurposing study in Covid-19 is presented in which avails the ML and statistical approaches to map and mine the knowledge graph, transcriptomic and literature data on the large scale to uncover the potential drugs for Covid-19.',\n",
              "   'idx': '576d757cb166459da410868335d23b33',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 262,\n",
              "   'span_end': 270,\n",
              "   'text': 'One such graph machine learning based drug repurposing study in Covid-19 is presented in which avails the ML and statistical approaches to map and mine the knowledge graph, transcriptomic and literature data on the large scale to uncover the potential drugs for Covid-19.',\n",
              "   'idx': '576d757cb166459da410868335d23b33',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 206,\n",
              "   'span_end': 214,\n",
              "   'text': 'The computational approach in combination with pre-clinical validation indicated that a poly-ADP-ribose polymerase 1 PARP1 inhibitor, CVL218, currently in Phase I clinical trial, may be repurposed to treat Covid-19.',\n",
              "   'idx': '36740db981f746b284e61cb8e13fa53c',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 268,\n",
              "   'span_end': 276,\n",
              "   'text': 'Coupled with cell-based experimental validation One other study that used DrugBank and other databases along with graph convolutional networks GCN came up with several clinically efficient drugs as potential repurposing candidates found as a result GCN application to Covid-19 related data.',\n",
              "   'idx': 'bf3f0cd1cd8a483ebecb0b68cb73b294',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 223,\n",
              "   'span_end': 236,\n",
              "   'text': 'Specifically, as a part of One other study that used DrugBank and other databases along with graph convolutional networks GCN, capmatinib MET inhibitor was found to have potent and wide range antiviral activity in multiple coronaviruses.',\n",
              "   'idx': 'c528013384454243b68e17a49b4f4f0a',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 160,\n",
              "   'span_end': 171,\n",
              "   'text': 'The antiviral activity was observed in MET-independent manner and additional roles of capmanitib for host cell proteins promoting the infection caused by human coronavirus thus it can inform further drug discovery studies.',\n",
              "   'idx': '35c351d0951a460cbfae2e1b7c04e18f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 192,\n",
              "   'span_end': 200,\n",
              "   'text': 'Realizing these problems and tactfully handling these problems can unveil the unfathomable power of the GNN and GCN approaches being applied to network-based approaches to drug repurposing in Covid-19 and in general as well.',\n",
              "   'idx': 'c2c50983fbfc4cef8a5b65ee1d450c43',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 89,\n",
              "   'span_end': 97,\n",
              "   'text': 'There are multiple significant studies utilizing this approach to repurpose the drugs in Covid-19 and other diseases.',\n",
              "   'idx': '33fd7b9eb0b14cd6b14a5588e277acf5',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 12,\n",
              "   'span_end': 20,\n",
              "   'text': 'Once recent Covid-19 based drug repurposing study is done in where gene co-expression-based network for 1441 genes was constructed and analysis was performed.',\n",
              "   'idx': '827863e495634723919a2d414af6cee2',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 110,\n",
              "   'span_end': 118,\n",
              "   'text': 'Finally, because of proposed network analysis, five drugs were repurposed as candidate repurposable drugs for Covid-19 treatment.',\n",
              "   'idx': 'f97b260e3baf4557a07409a53dcafa5e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 69,\n",
              "   'span_end': 77,\n",
              "   'text': 'Additionally, around 10 miRNAs were found to be significant to treat Covid-19.',\n",
              "   'idx': '05947a2192274976906a748ce4c58213',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 149,\n",
              "   'span_end': 157,\n",
              "   'text': 'KEGG enrichment, molecular docking, STITCH search tool, and virus-host-drug interactome were used to investigate the interaction network linked with Covid-19 and chloroquine and hydroxychloroquine were utilized as reference drugs to further get into the interaction network linked with Covid-19.',\n",
              "   'idx': '97559f901d254bf2a792d75f8f0524bf',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 286,\n",
              "   'span_end': 294,\n",
              "   'text': 'KEGG enrichment, molecular docking, STITCH search tool, and virus-host-drug interactome were used to investigate the interaction network linked with Covid-19 and chloroquine and hydroxychloroquine were utilized as reference drugs to further get into the interaction network linked with Covid-19.',\n",
              "   'idx': '97559f901d254bf2a792d75f8f0524bf',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 96,\n",
              "   'span_end': 104,\n",
              "   'text': 'As a result, 47 drug targets were found enriched in TLR pathway and were found overlapping with Covid-19.',\n",
              "   'idx': 'cad32dab54ab4bb484ab460c18fab1c7',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 100,\n",
              "   'span_end': 108,\n",
              "   'text': \"Additional insights from human-drug protein map identified and further confirmed the interaction of Covid-19 with TLR pathway will provide key information for Covid-19 Covid-19 and Covid-19's treatment.\",\n",
              "   'idx': 'b843220acef745628827b58baac3c0db',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 159,\n",
              "   'span_end': 167,\n",
              "   'text': \"Additional insights from human-drug protein map identified and further confirmed the interaction of Covid-19 with TLR pathway will provide key information for Covid-19 Covid-19 and Covid-19's treatment.\",\n",
              "   'idx': 'b843220acef745628827b58baac3c0db',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 168,\n",
              "   'span_end': 176,\n",
              "   'text': \"Additional insights from human-drug protein map identified and further confirmed the interaction of Covid-19 with TLR pathway will provide key information for Covid-19 Covid-19 and Covid-19's treatment.\",\n",
              "   'idx': 'b843220acef745628827b58baac3c0db',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 181,\n",
              "   'span_end': 189,\n",
              "   'text': \"Additional insights from human-drug protein map identified and further confirmed the interaction of Covid-19 with TLR pathway will provide key information for Covid-19 Covid-19 and Covid-19's treatment.\",\n",
              "   'idx': 'b843220acef745628827b58baac3c0db',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 120,\n",
              "   'span_end': 128,\n",
              "   'text': 'Furthermore, combination of diffusion and matrix factorization methods is also used to The drug prioritization the Anti-Covid-19 drugs.',\n",
              "   'idx': '8ab5db993ba74ff39a65d754dbe9ac9e',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 161,\n",
              "   'span_end': 169,\n",
              "   'text': 'Then the gaussian and similarity kernel are diffused and finally the logistic matrix factorization model with kernel diffusion is proposed to identify potential Covid-19 drugs.',\n",
              "   'idx': 'ab1cefef93a044419a8e9c12070ed1b4',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 30,\n",
              "   'span_end': 38,\n",
              "   'text': 'Finally, to validate the Anti-Covid-19 drugs molecular docking was performed to find the binding affinity of the drugs potentially repurposable with Covid-19 spike and ACE2 proteins.',\n",
              "   'idx': '31ef06f2ed70407790d2931f22b1abd2',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 149,\n",
              "   'span_end': 157,\n",
              "   'text': 'Finally, to validate the Anti-Covid-19 drugs molecular docking was performed to find the binding affinity of the drugs potentially repurposable with Covid-19 spike and ACE2 proteins.',\n",
              "   'idx': '31ef06f2ed70407790d2931f22b1abd2',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 208,\n",
              "   'span_end': 216,\n",
              "   'text': 'Thus, the 5-fold cross-validation leads to conclusion that integration of various biological data features and suitable models, or kernels lead to development of tools that may assist in drug development for Covid-19.',\n",
              "   'idx': 'cc3b3fe61d164a618dd9a73016ee0ad1',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 31,\n",
              "   'span_end': 39,\n",
              "   'text': 'Due to the sudden emergence of Covid-19 pandemic drug repurposing efforts helped greatly to make the treatments available to the patients faster.',\n",
              "   'idx': 'a73ba97724274db09fe98a6d051a7d6d',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 96,\n",
              "   'span_end': 104,\n",
              "   'text': 'These methods have made it possible for the drugs to enter the clinical trials to fight against Covid-19. For example, a network-based drug repurposing study done in predicted the 16 repurposable drugs with anti-viral evidence obtained from the literature and clinical trial data.',\n",
              "   'idx': 'f10ada30febb457897ce809aced7d959',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 132,\n",
              "   'span_end': 140,\n",
              "   'text': 'Among the 16 repurposable drugs Sirolimus originally approved as an immunosuppressant is registered in phase-II clinical trials for Covid-19.',\n",
              "   'idx': 'a541797f4b894fe4903d63059feafd34',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 109,\n",
              "   'span_end': 117,\n",
              "   'text': 'Another work done in applied machine learning on networks and repurposed 14 potential repurposable drugs for Covid-19, of which Chloroquine is registered in Phase-II & III and Dexamethasone is registered in Phase-IV clinical trials as mentioned in.',\n",
              "   'idx': '78c465a901a14b179b482f31fe617a1f',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 145,\n",
              "   'span_end': 153,\n",
              "   'text': 'Similarly, a machine learning and network medicine drug repurposing work retrieved a list of 23 FDA approved drugs as potential therapeutics for Covid-19.',\n",
              "   'idx': '09669e6e59304c4fb67b52254d4a52f9',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 65,\n",
              "   'span_end': 73,\n",
              "   'text': 'Many of 23 FDA approved drugs are already in clinical trials for Covid-19.',\n",
              "   'idx': 'b18c412562304d0e9e3ac012e7e97828',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 172,\n",
              "   'span_end': 180,\n",
              "   'text': 'Additionally, in our recent work of machine learning and molecular docking-based drug repurposing framework, 12 potential drugs were suggested as potential therapeutic for Covid-19.',\n",
              "   'idx': '0f1cfa46a5384a1987c206b597c6feff',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 114,\n",
              "   'span_end': 122,\n",
              "   'text': 'Similarly, multiple deep learning techniques have also been used to identify the repurposable drug candidates for Covid-19.',\n",
              "   'idx': 'cae4ef44ac5644ce8a438b6c8e6db865',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 243,\n",
              "   'span_end': 251,\n",
              "   'text': 'One of the deep learning-based studies, is done in where deep learning-based drug screening was performed followed by a study done in where a resource based on deep learning is created to enable the fast repurposing of the drug candidates for Covid-19.',\n",
              "   'idx': '7f75591d53124287a93e51c511cc9988',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 154,\n",
              "   'span_end': 162,\n",
              "   'text': 'Finally, in the light of the examples tabulated in, it can be concluded that the drug repurposing methods are quite helpful and quick to response in case Covid-19 and related emergent situations.',\n",
              "   'idx': '5cc3e374ae2d46eda29bd9f1ced2d08d',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 160,\n",
              "   'span_end': 168,\n",
              "   'text': 'There is no doubt that network medicine approaches are gaining more attention and have successfully been deployed in several studies to repurpose the drugs for Covid-19. Still there are some limitations which needs to be highlighted along with future recommendations to overcome some limitations for improved results in the future.',\n",
              "   'idx': 'b1e84e673c3748e181ed0772a741634c',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 4,\n",
              "   'span_end': 23,\n",
              "   'text': 'The Coronavirus disease Covid-19 is an infectious disease caused by SARS-CoV-2 virus.',\n",
              "   'idx': '6e2781d06e1a4020a7c25892f55c0b7d',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 24,\n",
              "   'span_end': 32,\n",
              "   'text': 'The Coronavirus disease Covid-19 is an infectious disease caused by SARS-CoV-2 virus.',\n",
              "   'idx': '6e2781d06e1a4020a7c25892f55c0b7d',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 68,\n",
              "   'span_end': 78,\n",
              "   'text': 'The Coronavirus disease Covid-19 is an infectious disease caused by SARS-CoV-2 virus.',\n",
              "   'idx': '6e2781d06e1a4020a7c25892f55c0b7d',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 49,\n",
              "   'span_end': 68,\n",
              "   'text': 'Started in November 2019 in the Wuhan-China, The Coronavirus disease Covid-19 was soon declared as public health emergency of international health concern by the World Health Organization WHO on January 30, and The Coronavirus disease Covid-19 scaled up to pandemic as of March 11, 2020.',\n",
              "   'idx': 'c16f13bfb4ae4e8aa58b66a57d74bdd1',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 69,\n",
              "   'span_end': 77,\n",
              "   'text': 'Started in November 2019 in the Wuhan-China, The Coronavirus disease Covid-19 was soon declared as public health emergency of international health concern by the World Health Organization WHO on January 30, and The Coronavirus disease Covid-19 scaled up to pandemic as of March 11, 2020.',\n",
              "   'idx': 'c16f13bfb4ae4e8aa58b66a57d74bdd1',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 215,\n",
              "   'span_end': 234,\n",
              "   'text': 'Started in November 2019 in the Wuhan-China, The Coronavirus disease Covid-19 was soon declared as public health emergency of international health concern by the World Health Organization WHO on January 30, and The Coronavirus disease Covid-19 scaled up to pandemic as of March 11, 2020.',\n",
              "   'idx': 'c16f13bfb4ae4e8aa58b66a57d74bdd1',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 235,\n",
              "   'span_end': 243,\n",
              "   'text': 'Started in November 2019 in the Wuhan-China, The Coronavirus disease Covid-19 was soon declared as public health emergency of international health concern by the World Health Organization WHO on January 30, and The Coronavirus disease Covid-19 scaled up to pandemic as of March 11, 2020.',\n",
              "   'idx': 'c16f13bfb4ae4e8aa58b66a57d74bdd1',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 99,\n",
              "   'span_end': 118,\n",
              "   'text': 'Thus, drug repurposing emerged as an efficient and scalable approach to find the treatment for The Coronavirus disease Covid-19.',\n",
              "   'idx': 'ebcb5de498b447ba91581a5010c29db8',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 119,\n",
              "   'span_end': 127,\n",
              "   'text': 'Thus, drug repurposing emerged as an efficient and scalable approach to find the treatment for The Coronavirus disease Covid-19.',\n",
              "   'idx': 'ebcb5de498b447ba91581a5010c29db8',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 77,\n",
              "   'span_end': 96,\n",
              "   'text': 'In this review, a comprehensive overview of drug repurposing studies for The Coronavirus disease Covid-19 is provided.',\n",
              "   'idx': '5e70fc621ccc4adf9ed9c1bbc43550f5',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 97,\n",
              "   'span_end': 105,\n",
              "   'text': 'In this review, a comprehensive overview of drug repurposing studies for The Coronavirus disease Covid-19 is provided.',\n",
              "   'idx': '5e70fc621ccc4adf9ed9c1bbc43550f5',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 154,\n",
              "   'span_end': 173,\n",
              "   'text': 'this review spans to machine learning, deep learning, and network-based approaches while specifically network-based approaches to drug repurposing in The Coronavirus disease Covid-19 are focused.',\n",
              "   'idx': '20ba898a5b6444718cbe0bf3ca773cda',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 174,\n",
              "   'span_end': 182,\n",
              "   'text': 'this review spans to machine learning, deep learning, and network-based approaches while specifically network-based approaches to drug repurposing in The Coronavirus disease Covid-19 are focused.',\n",
              "   'idx': '20ba898a5b6444718cbe0bf3ca773cda',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 33,\n",
              "   'span_end': 52,\n",
              "   'text': 'Network based approaches for The Coronavirus disease Covid-19 drug repurposing are further divided in three categories Network diffusion, network proximity, and AI on networks.',\n",
              "   'idx': '93f48ad723ed41f19826baf41c0644c7',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 53,\n",
              "   'span_end': 61,\n",
              "   'text': 'Network based approaches for The Coronavirus disease Covid-19 drug repurposing are further divided in three categories Network diffusion, network proximity, and AI on networks.',\n",
              "   'idx': '93f48ad723ed41f19826baf41c0644c7',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 219,\n",
              "   'span_end': 238,\n",
              "   'text': 'Moreover, in simplest form machine learning studies take the different type of drug and disease related data, perform feature extraction, create predictive models, and then models are deployed for the prediction in The Coronavirus disease Covid-19 and other diseases.',\n",
              "   'idx': 'd5c785df55974ad68f6d413b05ecc710',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 239,\n",
              "   'span_end': 247,\n",
              "   'text': 'Moreover, in simplest form machine learning studies take the different type of drug and disease related data, perform feature extraction, create predictive models, and then models are deployed for the prediction in The Coronavirus disease Covid-19 and other diseases.',\n",
              "   'idx': 'd5c785df55974ad68f6d413b05ecc710',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 59,\n",
              "   'span_end': 78,\n",
              "   'text': 'Despite successful application in drug repurposing for The Coronavirus disease Covid-19, machine learning approaches struggle to handle the diverse and sparse biological data but are easy to interpret which is essential for studies like drug repurposing.',\n",
              "   'idx': 'b24f89946e514acbb11c12ecec5887f0',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 79,\n",
              "   'span_end': 87,\n",
              "   'text': 'Despite successful application in drug repurposing for The Coronavirus disease Covid-19, machine learning approaches struggle to handle the diverse and sparse biological data but are easy to interpret which is essential for studies like drug repurposing.',\n",
              "   'idx': 'b24f89946e514acbb11c12ecec5887f0',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 160,\n",
              "   'span_end': 179,\n",
              "   'text': 'Since deep learning models are effective in terms of heterogenous and sparse data handling and have been deployed to predict repurposed candidate drugs for The Coronavirus disease Covid-19.',\n",
              "   'idx': '495ca02fde90437fb3087b1ee6892af8',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 180,\n",
              "   'span_end': 188,\n",
              "   'text': 'Since deep learning models are effective in terms of heterogenous and sparse data handling and have been deployed to predict repurposed candidate drugs for The Coronavirus disease Covid-19.',\n",
              "   'idx': '495ca02fde90437fb3087b1ee6892af8',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 91,\n",
              "   'span_end': 110,\n",
              "   'text': 'Additionally, network-based methods have also been widely and effectively deployed for The Coronavirus disease Covid-19 repurposing.',\n",
              "   'idx': '53410c98d7024c0697a676ef4e42d500',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 111,\n",
              "   'span_end': 119,\n",
              "   'text': 'Additionally, network-based methods have also been widely and effectively deployed for The Coronavirus disease Covid-19 repurposing.',\n",
              "   'idx': '53410c98d7024c0697a676ef4e42d500',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 44,\n",
              "   'span_end': 63,\n",
              "   'text': 'The biological network-based studies in The Coronavirus disease Covid-19 covered multiple pharmacological aspects such as gene regulations, protein interactions, drug-target or drug-drug interactions, drug-side effect, and metabolic interactions etc.',\n",
              "   'idx': '26690c57519d4b2eb48c0a95da7dde68',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 64,\n",
              "   'span_end': 72,\n",
              "   'text': 'The biological network-based studies in The Coronavirus disease Covid-19 covered multiple pharmacological aspects such as gene regulations, protein interactions, drug-target or drug-drug interactions, drug-side effect, and metabolic interactions etc.',\n",
              "   'idx': '26690c57519d4b2eb48c0a95da7dde68',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease',\n",
              "   'span_start': 207,\n",
              "   'span_end': 226,\n",
              "   'text': 'The integration of such diverse biological entities extracted from many different databases and experiments in network helps to mimic the complex biological systems good for drug repurposing specific in The Coronavirus disease Covid-19 and in general.',\n",
              "   'idx': 'c225ed9099714f43bd3a96fd98467ec0',\n",
              "   'article_id': 'PMC9236981'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Covid-19',\n",
              "   'span_start': 227,\n",
              "   'span_end': 235,\n",
              "   'text': 'The integration of such diverse biological entities extracted from many different databases and experiments in network helps to mimic the complex biological systems good for drug repurposing specific in The Coronavirus disease Covid-19 and in general.',\n",
              "   'idx': 'c225ed9099714f43bd3a96fd98467ec0',\n",
              "   'article_id': 'PMC9236981'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus disease 2019',\n",
              "   'span_start': 88,\n",
              "   'span_end': 112,\n",
              "   'text': \"At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\",\n",
              "   'idx': '3e974310deb94d5ea94bf191c2797b58',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 113,\n",
              "   'span_end': 121,\n",
              "   'text': \"At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\",\n",
              "   'idx': '3e974310deb94d5ea94bf191c2797b58',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus disease 2019',\n",
              "   'span_start': 150,\n",
              "   'span_end': 174,\n",
              "   'text': \"At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\",\n",
              "   'idx': '3e974310deb94d5ea94bf191c2797b58',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 175,\n",
              "   'span_end': 183,\n",
              "   'text': \"At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\",\n",
              "   'idx': '3e974310deb94d5ea94bf191c2797b58',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus disease 2019',\n",
              "   'span_start': 220,\n",
              "   'span_end': 244,\n",
              "   'text': \"At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\",\n",
              "   'idx': '3e974310deb94d5ea94bf191c2797b58',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 245,\n",
              "   'span_end': 253,\n",
              "   'text': \"At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\",\n",
              "   'idx': '3e974310deb94d5ea94bf191c2797b58',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus disease 2019',\n",
              "   'span_start': 10,\n",
              "   'span_end': 34,\n",
              "   'text': 'the novel coronavirus disease 2019 COVID-19 first appeared in Wuhan city, China, in late 2019 and is still spreading all over the globe creating a disastrous effect on global health and the economy.',\n",
              "   'idx': '3f4f6b3a53fc473e9dd9b46e6bd40c64',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 35,\n",
              "   'span_end': 43,\n",
              "   'text': 'the novel coronavirus disease 2019 COVID-19 first appeared in Wuhan city, China, in late 2019 and is still spreading all over the globe creating a disastrous effect on global health and the economy.',\n",
              "   'idx': '3f4f6b3a53fc473e9dd9b46e6bd40c64',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus disease 2019',\n",
              "   'span_start': 17,\n",
              "   'span_end': 41,\n",
              "   'text': \"Due to the novel coronavirus disease 2019 COVID-19's highly contagious nature, as of May 2022, the pandemic has spread to more than 200 countries and territories with over 5.5 million confirmed positive cases and mortality of over 350K across the globe.\",\n",
              "   'idx': '23a6a78ef46b479985cd3a364ae16caa',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 42,\n",
              "   'span_end': 50,\n",
              "   'text': \"Due to the novel coronavirus disease 2019 COVID-19's highly contagious nature, as of May 2022, the pandemic has spread to more than 200 countries and territories with over 5.5 million confirmed positive cases and mortality of over 350K across the globe.\",\n",
              "   'idx': '23a6a78ef46b479985cd3a364ae16caa',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus disease 2019',\n",
              "   'span_start': 35,\n",
              "   'span_end': 59,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "   'idx': '528b8b1edd014df4bacb79c43f8bfba0',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 60,\n",
              "   'span_end': 68,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "   'idx': '528b8b1edd014df4bacb79c43f8bfba0',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 72,\n",
              "   'span_end': 105,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "   'idx': '528b8b1edd014df4bacb79c43f8bfba0',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 106,\n",
              "   'span_end': 117,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "   'idx': '528b8b1edd014df4bacb79c43f8bfba0',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 120,\n",
              "   'span_end': 130,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "   'idx': '528b8b1edd014df4bacb79c43f8bfba0',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 136,\n",
              "   'span_end': 169,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "   'idx': '528b8b1edd014df4bacb79c43f8bfba0',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 170,\n",
              "   'span_end': 181,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "   'idx': '528b8b1edd014df4bacb79c43f8bfba0',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 184,\n",
              "   'span_end': 194,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "   'idx': '528b8b1edd014df4bacb79c43f8bfba0',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 242,\n",
              "   'span_end': 253,\n",
              "   'text': 'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "   'idx': '528b8b1edd014df4bacb79c43f8bfba0',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 0,\n",
              "   'span_end': 33,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "   'idx': '984bdc6e2b8e477c9c55770ee06255a3',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 34,\n",
              "   'span_end': 45,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "   'idx': '984bdc6e2b8e477c9c55770ee06255a3',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 48,\n",
              "   'span_end': 58,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "   'idx': '984bdc6e2b8e477c9c55770ee06255a3',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Betacoronavirus',\n",
              "   'span_start': 80,\n",
              "   'span_end': 95,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "   'idx': '984bdc6e2b8e477c9c55770ee06255a3',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviridae',\n",
              "   'span_start': 110,\n",
              "   'span_end': 123,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "   'idx': '984bdc6e2b8e477c9c55770ee06255a3',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS',\n",
              "   'span_start': 167,\n",
              "   'span_end': 171,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "   'idx': '984bdc6e2b8e477c9c55770ee06255a3',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 172,\n",
              "   'span_end': 183,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "   'idx': '984bdc6e2b8e477c9c55770ee06255a3',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-1',\n",
              "   'span_start': 184,\n",
              "   'span_end': 194,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "   'idx': '984bdc6e2b8e477c9c55770ee06255a3',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 232,\n",
              "   'span_end': 243,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "   'idx': '984bdc6e2b8e477c9c55770ee06255a3',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 244,\n",
              "   'span_end': 252,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "   'idx': '984bdc6e2b8e477c9c55770ee06255a3',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviruses',\n",
              "   'span_start': 0,\n",
              "   'span_end': 13,\n",
              "   'text': 'Coronaviruses are positive-sense single-stranded RNA with a genome size of ~30 kb containing a 5′ cap-structure and 3′-polyadenylated tail.',\n",
              "   'idx': '59c9ccb42d134737b44428670dd082c2',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviruses',\n",
              "   'span_start': 0,\n",
              "   'span_end': 13,\n",
              "   'text': \"Coronaviruses's genome encodes for ORF1a and ORF1ab polyprotein which cleaves into multiple subunits and performs a diverse range of functions, i.e., binding and invading the host cell, viral replication, and evading the host immune system.\",\n",
              "   'idx': 'ba43c42ccacd450fb59c5eabea17a94c',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 16,\n",
              "   'span_end': 29,\n",
              "   'text': \"The proteins of coronaviruses perform The proteins of coronaviruses's function by aggregating multiple subunits into an heteromeric complex, i.e., replication-transcription complex and several other structural proteins that assemble into new virions.\",\n",
              "   'idx': 'c968523b1afa4e07b54034a542862aca',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 54,\n",
              "   'span_end': 67,\n",
              "   'text': \"The proteins of coronaviruses perform The proteins of coronaviruses's function by aggregating multiple subunits into an heteromeric complex, i.e., replication-transcription complex and several other structural proteins that assemble into new virions.\",\n",
              "   'idx': 'c968523b1afa4e07b54034a542862aca',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS',\n",
              "   'span_start': 144,\n",
              "   'span_end': 148,\n",
              "   'text': 'a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.',\n",
              "   'idx': 'efc1aa2e8299430cbe502f04098c8a53',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 149,\n",
              "   'span_end': 160,\n",
              "   'text': 'a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.',\n",
              "   'idx': 'efc1aa2e8299430cbe502f04098c8a53',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-1',\n",
              "   'span_start': 161,\n",
              "   'span_end': 171,\n",
              "   'text': 'a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.',\n",
              "   'idx': 'efc1aa2e8299430cbe502f04098c8a53',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 218,\n",
              "   'span_end': 229,\n",
              "   'text': 'a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.',\n",
              "   'idx': 'efc1aa2e8299430cbe502f04098c8a53',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 230,\n",
              "   'span_end': 238,\n",
              "   'text': 'a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.',\n",
              "   'idx': 'efc1aa2e8299430cbe502f04098c8a53',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV2',\n",
              "   'span_start': 175,\n",
              "   'span_end': 184,\n",
              "   'text': 'Currently, many studies including single-ligand docking as well as screening of the compounds library have been conducted to search for potential inhibitors against NSP-12 of SARS-CoV2.',\n",
              "   'idx': 'e017d960c5fd41f6a53fcc0961d50b32',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV2',\n",
              "   'span_start': 98,\n",
              "   'span_end': 107,\n",
              "   'text': 'The DALI server was employed for the identification of homologous protein structures to NSP-12 of SARS-CoV2 that were already submitted in the PDB repository.',\n",
              "   'idx': '803a2a0c196d4c4c8b68d54f05daf5b8',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviridae',\n",
              "   'span_start': 86,\n",
              "   'span_end': 99,\n",
              "   'text': '611 structures were involved in the RdRp activity and belonged to four viral families Coronaviridae, Flaviviridae, Picornaviridae, and Caliciviridae and infected a diverse range of hosts.',\n",
              "   'idx': '539df892d3cd448b8488b54eeee2c413',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 151,\n",
              "   'span_end': 164,\n",
              "   'text': 'the similarity matrix was visualized as a heatmap as shown in A. The heatmap of Z-score-based structural similarity revealed the close relationship of coronaviruses with the members of Flaviviridae as well as Caliciviridae and Picornaviridae.',\n",
              "   'idx': '889fc8a0b0a640389978dd2eb9319b27',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 247,\n",
              "   'span_end': 260,\n",
              "   'text': 'Based on structural similarity, the unrooted cladogram of homologous structures to a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity was clustered into four viral families as shown in B. The clade of the coronaviruses, i.e., SARS-CoV-1 and SARS-CoV-2, shares a close relationship with the NS5B of HCV and also with the other representatives of Flaviviridae, i.e., the Zika Virus ZIKV, Dengue Virus DENV, Bovine Viral Diarrhea Virus BVDV, Japanese Encephalitis Virus JEV, and Classical Swine Fever Virus CSFV.',\n",
              "   'idx': 'cc561b2cf8f047c8820fb776565abaf6',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-1',\n",
              "   'span_start': 268,\n",
              "   'span_end': 278,\n",
              "   'text': 'Based on structural similarity, the unrooted cladogram of homologous structures to a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity was clustered into four viral families as shown in B. The clade of the coronaviruses, i.e., SARS-CoV-1 and SARS-CoV-2, shares a close relationship with the NS5B of HCV and also with the other representatives of Flaviviridae, i.e., the Zika Virus ZIKV, Dengue Virus DENV, Bovine Viral Diarrhea Virus BVDV, Japanese Encephalitis Virus JEV, and Classical Swine Fever Virus CSFV.',\n",
              "   'idx': 'cc561b2cf8f047c8820fb776565abaf6',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 283,\n",
              "   'span_end': 293,\n",
              "   'text': 'Based on structural similarity, the unrooted cladogram of homologous structures to a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity was clustered into four viral families as shown in B. The clade of the coronaviruses, i.e., SARS-CoV-1 and SARS-CoV-2, shares a close relationship with the NS5B of HCV and also with the other representatives of Flaviviridae, i.e., the Zika Virus ZIKV, Dengue Virus DENV, Bovine Viral Diarrhea Virus BVDV, Japanese Encephalitis Virus JEV, and Classical Swine Fever Virus CSFV.',\n",
              "   'idx': 'cc561b2cf8f047c8820fb776565abaf6',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronaviruses',\n",
              "   'span_start': 30,\n",
              "   'span_end': 43,\n",
              "   'text': 'The clade of Flaviviridae and coronaviruses shared significant relationships as compared to the members of Caliciviridae and Picornaviridae.',\n",
              "   'idx': '2424f205b5ca4eecaf410ab6ecb9251c',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviridae',\n",
              "   'span_start': 213,\n",
              "   'span_end': 226,\n",
              "   'text': 'To display the conserved orientation of these motifs at the active site of a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity, multiple structures belonging to the family Coronaviridae, Flaviviridae, and Picornaviridae were superposed structurally aligned by using the MatchMaker algorithm implemented in UCSF Chimera.',\n",
              "   'idx': 'be18a9c939974b95803263396863bc01',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 140,\n",
              "   'span_end': 150,\n",
              "   'text': 'The grid box was centered at the active site or druggable cavity and the residues were considered rigid for both receptors, i.e., NSP-12 of SARS-CoV-2 and NS5B of HCV.',\n",
              "   'idx': 'dbf125c196534d7f9c834326ef4f00ad',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 71,\n",
              "   'span_end': 81,\n",
              "   'text': 'The results score of ligand bindings with the active site of NSP-12 of SARS-CoV-2 and NS5B of HCV has been compared and visualized as a bar chart as shown in B.The docking score of NSP-12 of SARS-CoV-2 with the ligands, i.e., Dasabuvir, Sofosbuvir, Ribavirin, GTP, and UTP was in the range of −6.2 to −8.1 kcal/mol, while for NS5B of HCV, B.The docking score of NSP-12 with the ligands was −6.5 to −9.1 kcal/mol, and both had an average difference of 0.84 kcal/mol.',\n",
              "   'idx': 'bdead57aaac743c5994883c75bc14689',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 191,\n",
              "   'span_end': 201,\n",
              "   'text': 'The results score of ligand bindings with the active site of NSP-12 of SARS-CoV-2 and NS5B of HCV has been compared and visualized as a bar chart as shown in B.The docking score of NSP-12 of SARS-CoV-2 with the ligands, i.e., Dasabuvir, Sofosbuvir, Ribavirin, GTP, and UTP was in the range of −6.2 to −8.1 kcal/mol, while for NS5B of HCV, B.The docking score of NSP-12 with the ligands was −6.5 to −9.1 kcal/mol, and both had an average difference of 0.84 kcal/mol.',\n",
              "   'idx': 'bdead57aaac743c5994883c75bc14689',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 39,\n",
              "   'span_end': 49,\n",
              "   'text': 'The average docking score of NSP-12 of SARS-CoV-2 and NS5B of HCV for Sofosbuvir, Dasabuvir, Ribavirin, GTP, and GTP were −8.2, −8.6, −6.35, −8.25, and −7.6 kcal/mol, respectively.',\n",
              "   'idx': '29d93a89912e4f0d82dcfb1f0396e069',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 10,\n",
              "   'span_end': 20,\n",
              "   'text': 'NSP-12 of SARS-CoV-2 showed the lowest docking score −8.1 kcal/mol with Dasabuvir and higher −6.2 kcal/mol with Ribavirin.',\n",
              "   'idx': '87b3a3487faf482a9b4c6035f8890d40',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 95,\n",
              "   'span_end': 105,\n",
              "   'text': 'In general, the ligands showed a higher docking score for NS5B of HCV as compared to NSP-12 of SARS-CoV-2.',\n",
              "   'idx': 'fd0ef6550e6e4fd7ab2ce510b3782d15',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 110,\n",
              "   'span_end': 120,\n",
              "   'text': 'To examine the interactions between ligand and the conserved residues present at the active site of NSP-12 of SARS-CoV-2, LigPlot + v2.1, standalone software was used.',\n",
              "   'idx': 'e52a1b73ae0843ab86fe12e7d39f59c5',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 70,\n",
              "   'span_end': 80,\n",
              "   'text': 'The predicted interactions of Sofosbuvir and Dasabuvir with NSP-12 of SARS-CoV-2 have been shown in A,B, respectively.',\n",
              "   'idx': '0e4179065c1941b3a673adc16ffe01c0',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 80,\n",
              "   'span_end': 90,\n",
              "   'text': 'On the other hand, the native competitors such as GTP interacted with NSP-12 of SARS-CoV-2 by forming hydrogen bonds with A554, R555, and T556 of motif-F, Y619, K621, and C622 of motif-A, while UTP interacted with S759, D760, and D761 of motif-C, W800 of motif-D, and G811 and S814 of motif-E In the case of HCV as a receptor, Sofosbuvir binds with motif-B and -C, while Dasabuvir interacted with residues of motif-A, -B, -C, and motif-F, and their receptor–ligand interaction plots have been shown in C,D, respectively.',\n",
              "   'idx': 'a40a2fd0804c4a089d152e1f0747215e',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 61,\n",
              "   'span_end': 71,\n",
              "   'text': 'However, 6M71/Sofosbuvir has the same evolution to NSP-12 of SARS-CoV-2.',\n",
              "   'idx': '081ed7a9c7b4499789704cb7a1139561',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 100,\n",
              "   'span_end': 110,\n",
              "   'text': 'This finding implies that Dasabuvir, Ribavirin, and Sofosbuvir binding helped to maintain NSP-12 of SARS-CoV-2 structurally stable.',\n",
              "   'idx': '9029902141e544e29387eeb4780a482a',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 65,\n",
              "   'span_end': 75,\n",
              "   'text': \"We examined how binding of different ligands this goal NSP-12 of SARS-CoV-2's overall compactness in the protein's structure.\",\n",
              "   'idx': '48698cd0d7bd4bcdac03c9191030a1a9',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 36,\n",
              "   'span_end': 46,\n",
              "   'text': 'The average Rg values Apo NSP-12 of SARS-CoV-2, NSP-12/Dasabuvir, NSP-12/Ribavirin, and NSP-12/Sofosbuvir complexes were found to be 2.99, 3.00, 2.97, 2.98 nm, respectively, suggesting that the binding of Dasabuvir, Ribavirin, and Sofosbuvir to NSP-12 of SARS-CoV-2 packing did not cause significant change.',\n",
              "   'idx': '456a4863d4184127abdda318acb9f391',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 255,\n",
              "   'span_end': 265,\n",
              "   'text': 'The average Rg values Apo NSP-12 of SARS-CoV-2, NSP-12/Dasabuvir, NSP-12/Ribavirin, and NSP-12/Sofosbuvir complexes were found to be 2.99, 3.00, 2.97, 2.98 nm, respectively, suggesting that the binding of Dasabuvir, Ribavirin, and Sofosbuvir to NSP-12 of SARS-CoV-2 packing did not cause significant change.',\n",
              "   'idx': '456a4863d4184127abdda318acb9f391',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 70,\n",
              "   'span_end': 80,\n",
              "   'text': 'It was noticed that Dasabuvir binds to the active pocket of NSP-12 of SARS-CoV-2 with an average of 3.46 hydrogen bonds and 1.13 pairs within 0.35 nm.',\n",
              "   'idx': '7075d545a13b4a5e9f316fd9eb6721e6',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 145,\n",
              "   'span_end': 155,\n",
              "   'text': 'On the other hand, the H-bonding plot showed that Dasabuvir was able to maintain a more robust interaction with the binding pockets of NSP-12 of SARS-CoV-2 throughout the simulation time than Ribavirin and Sofosbuvir. Before MM/PBSA calculation, each complex between the receptors or inhibitors/ligands should reach the equilibrium state.',\n",
              "   'idx': '933339c08db64ce7820dcdb262fe8f7b',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 185,\n",
              "   'span_end': 195,\n",
              "   'text': 'Except for the polar solvation energy, all other forms of energy contributed favorably to the interaction between different molecules Dasabuvir, Ribavirin, and Sofosbuvir and NSP-12 of SARS-CoV-2.',\n",
              "   'idx': 'c0ddd686a3d546f38e5c46537d6ccdc0',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 92,\n",
              "   'span_end': 100,\n",
              "   'text': 'Finally, the Sofosbuvir and Dasabuvir could be established as a repurposed drug against the COVID-19 main protease.',\n",
              "   'idx': 'c52c47fd092b4656a11885c6951a3f3b',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 74,\n",
              "   'span_end': 84,\n",
              "   'text': \"Many drugs have been already suggested for the current pandemic caused by SARS-CoV-2, of which the most prominent are FDA-approved Chloroquine and FDA-approved Chloroquine's derivatives—an anti-malarial drug and Remdesivir.\",\n",
              "   'idx': '57fd202bff5c4df1b084886cc60f5cfc',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 55,\n",
              "   'span_end': 65,\n",
              "   'text': 'Remdesivir, has been shown to significantly reduce the SARS-CoV-2 pathogenicity in in vitro study and is still under investigation.',\n",
              "   'idx': 'cab0a848b5ff4167a2c3c168fbe57e54',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 53,\n",
              "   'span_end': 63,\n",
              "   'text': \"In this study, we searched for homologs of NSP-12 of SARS-CoV-2 and evaluated NSP-12 of SARS-CoV-2's binding affinity with the FDA-approved antivirals, i.e., Sofosbuvir and Dasabuvir, which specifically target the evolutionarily conserved site of NS5B of HCV.\",\n",
              "   'idx': 'c5b9712032c4455296f0fba42eb0d516',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 88,\n",
              "   'span_end': 98,\n",
              "   'text': \"In this study, we searched for homologs of NSP-12 of SARS-CoV-2 and evaluated NSP-12 of SARS-CoV-2's binding affinity with the FDA-approved antivirals, i.e., Sofosbuvir and Dasabuvir, which specifically target the evolutionarily conserved site of NS5B of HCV.\",\n",
              "   'idx': 'c5b9712032c4455296f0fba42eb0d516',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronaviridae',\n",
              "   'span_start': 166,\n",
              "   'span_end': 179,\n",
              "   'text': 'Further screening of 1105 structures based on the quality of structural alignment Z-score ≥ 19 resulted in 611 structures that belonged to four viral families, i.e., Coronaviridae, Flaviviridae, Picornaviridae, and Caliciviridae, responsible for RdRp activity during viral replication.',\n",
              "   'idx': '6baa1c4a1e2d4644b61a40421038f570',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 14,\n",
              "   'span_end': 24,\n",
              "   'text': 'The NSP-12 of SARS-CoV-2 displayed significant homology to the NS5 of Flaviviridae or NS5B of HCV as compared to the polymerases of Picornaviridae and Caliciviridae.',\n",
              "   'idx': '2fa03e3a2ef54cdb980b9b7453cc0e3e',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 67,\n",
              "   'span_end': 77,\n",
              "   'text': 'Based on the pairwise alignment of amino acid sequences, NSP-12 of SARS-CoV-2 shares 96% identity with SARS-CoV-1, 11% with HCV and HNV, and 10% with Poli.',\n",
              "   'idx': '1d717eb9986243b5a30d1c9f203a5f5e',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-1',\n",
              "   'span_start': 103,\n",
              "   'span_end': 113,\n",
              "   'text': 'Based on the pairwise alignment of amino acid sequences, NSP-12 of SARS-CoV-2 shares 96% identity with SARS-CoV-1, 11% with HCV and HNV, and 10% with Poli.',\n",
              "   'idx': '1d717eb9986243b5a30d1c9f203a5f5e',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 62,\n",
              "   'span_end': 72,\n",
              "   'text': 'Despite sharing a lower identity based on sequence, NSP-12 of SARS-CoV-2 has seven highly conserved motifs in the RdRp domain that play a key role in viral replication.',\n",
              "   'idx': '9433b453cd024679a4113938bd2b3367',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 112,\n",
              "   'span_end': 122,\n",
              "   'text': 'significant overlap included the conserved residues of motifs A, B, C, D, and F of the RdRp domain of NSP-12 of SARS-CoV-2.',\n",
              "   'idx': '2e776162ad9d42d5b369df84d21348be',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 48,\n",
              "   'span_end': 58,\n",
              "   'text': 'The active site of the RdRp domain of NSP-12 of SARS-CoV-2 was further evaluated for binding affinity with FDA-approved antivirals by the molecular docking method.',\n",
              "   'idx': '65ed4ac271044630a4db2324b464b53b',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 111,\n",
              "   'span_end': 121,\n",
              "   'text': 'Molecular docking was performed using AutoDock Vina which revealed a significant binding affinity of NSP-12 of SARS-CoV-2 with Sofosbuvir and Dasabuvir as compared to Ribavirin.',\n",
              "   'idx': 'c69ee5830e9843e4b6abab0bce9e61c3',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 96,\n",
              "   'span_end': 106,\n",
              "   'text': 'Despite that, NS5B showed higher binding affinity lower binding energy as compared to NSP-12 of SARS-CoV-2 however, the differences were still insignificant.',\n",
              "   'idx': 'a31e6c48bfa34313a6194461a8829015',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 27,\n",
              "   'span_end': 37,\n",
              "   'text': 'The profiling of NSP-12 of SARS-CoV-2 and ligand interaction revealed firm binding due to the formation of hydrogen bonds and hydrophobic interactions.',\n",
              "   'idx': 'd3004a62d446442985de6ae7be78c748',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 112,\n",
              "   'span_end': 122,\n",
              "   'text': 'In general, both Sofosbuvir and Dasabuvir showed higher binding to the active site of NS5B of HCV and NSP-12 of SARS-CoV-2.',\n",
              "   'idx': 'd7f24f7263394892bbe5a9a02fd3d99a',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 23,\n",
              "   'span_end': 33,\n",
              "   'text': 'We retrieved NSP-12 of SARS-CoV-2 with PDB ID 6M71 at 2.9 Å resolution from the Protein Data Bank PDB repository that was recently submitted by Gao et al. For the identification of homologous structures in the Protein Data Bank PDB repository, 6M71 chain A was submitted to the DALI server website.fi/dali/ accessed on 16 March 2020.',\n",
              "   'idx': '16b295c5423644c58d8c75bf58baae09',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 72,\n",
              "   'span_end': 82,\n",
              "   'text': 'To further study the conserved residues at the active site of NSP-12 of SARS-CoV-2, multiple structures were aligned by using the MatchMaker algorithm implemented in the University of California, San Francisco UCSF Chimera v.14 and visualized.',\n",
              "   'idx': '858800f1b1b1471a9b13863eb2acd594',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'v.14',\n",
              "   'span_start': 223,\n",
              "   'span_end': 227,\n",
              "   'text': 'To further study the conserved residues at the active site of NSP-12 of SARS-CoV-2, multiple structures were aligned by using the MatchMaker algorithm implemented in the University of California, San Francisco UCSF Chimera v.14 and visualized.',\n",
              "   'idx': '858800f1b1b1471a9b13863eb2acd594',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'v.14',\n",
              "   'span_start': 209,\n",
              "   'span_end': 213,\n",
              "   'text': 'Initially, the Canonical SMILES IDs of the ligand compounds, i.e., Sofosbuvir CID 45375808, Ribavirin CID 37542, and Dasabuvir CID 56640146 were retrieved from the PubChem library and then imported in Chimera v.14 for converting into PDB files.',\n",
              "   'idx': '2baf47069d7d4fe0bf60944f7ebfaa75',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 54,\n",
              "   'span_end': 64,\n",
              "   'text': 'The resulting score of molecular docking of NSP-12 of SARS-CoV-2 and NS5B of HCV were compared and plotted using a bar plot.',\n",
              "   'idx': '23ab0c8ce0aa41e3a3b5278355b917a1',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'covid lineage',\n",
              "   'entity': 'v.2021',\n",
              "   'span_start': 99,\n",
              "   'span_end': 105,\n",
              "   'text': 'The MD simulation of the apo and ligand-bound complex of NSP-12 protein was done using the GROMACS v.2021 and GROMOS96 54a7 force field.',\n",
              "   'idx': '696c98ecd1c748c8b065dbfc276ab4a1',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 64,\n",
              "   'span_end': 74,\n",
              "   'text': \"In this study, we searched for structural homologs of NSP-12 of SARS-CoV-2 and identified structural homologs of NSP-12 of SARS-CoV-2's relationship with the members of three viral families, i.e., Flaviviridae, Picornaviridae, and Caliciviridae.\",\n",
              "   'idx': '0dd652ff248b4203a404ab66dab2a1df',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 123,\n",
              "   'span_end': 133,\n",
              "   'text': \"In this study, we searched for structural homologs of NSP-12 of SARS-CoV-2 and identified structural homologs of NSP-12 of SARS-CoV-2's relationship with the members of three viral families, i.e., Flaviviridae, Picornaviridae, and Caliciviridae.\",\n",
              "   'idx': '0dd652ff248b4203a404ab66dab2a1df',\n",
              "   'article_id': 'PMC9694939'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 29,\n",
              "   'span_end': 39,\n",
              "   'text': 'The RdRp domain of NSP-12 of SARS-CoV-2 is highly conserved in terms of both sequence and architecture and assessed for binding affinity with FDA-approved antivirals, i.e., Dasabuvir and Sofosbuvir.',\n",
              "   'idx': '4e42c23509b74ad0919cb9c8ab9e39cd',\n",
              "   'article_id': 'PMC9694939'}],\n",
              " [{'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 0,\n",
              "   'span_end': 24,\n",
              "   'text': 'Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.',\n",
              "   'idx': 'c81ad9661b8948a5b2ae4b57fd83dffa',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 25,\n",
              "   'span_end': 33,\n",
              "   'text': 'Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.',\n",
              "   'idx': 'c81ad9661b8948a5b2ae4b57fd83dffa',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 45,\n",
              "   'span_end': 78,\n",
              "   'text': 'Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.',\n",
              "   'idx': 'c81ad9661b8948a5b2ae4b57fd83dffa',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 79,\n",
              "   'span_end': 90,\n",
              "   'text': 'Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.',\n",
              "   'idx': 'c81ad9661b8948a5b2ae4b57fd83dffa',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 93,\n",
              "   'span_end': 103,\n",
              "   'text': 'Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.',\n",
              "   'idx': 'c81ad9661b8948a5b2ae4b57fd83dffa',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 0,\n",
              "   'span_end': 33,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has infected more than half a billion people and caused over 5 million deaths, implying a global health threat.',\n",
              "   'idx': '79bbb350f7e84dc6aa6cfef69230a2af',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 34,\n",
              "   'span_end': 45,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has infected more than half a billion people and caused over 5 million deaths, implying a global health threat.',\n",
              "   'idx': '79bbb350f7e84dc6aa6cfef69230a2af',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 48,\n",
              "   'span_end': 58,\n",
              "   'text': 'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has infected more than half a billion people and caused over 5 million deaths, implying a global health threat.',\n",
              "   'idx': '79bbb350f7e84dc6aa6cfef69230a2af',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 145,\n",
              "   'span_end': 169,\n",
              "   'text': 'As the development of a new drug takes years to a decade, drug repositioning can significantly accelerate the development cycle of therapies for Coronavirus disease 2019 COVID-19.',\n",
              "   'idx': '6902fc36c9624eb7b7e825e500d6583b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 170,\n",
              "   'span_end': 178,\n",
              "   'text': 'As the development of a new drug takes years to a decade, drug repositioning can significantly accelerate the development cycle of therapies for Coronavirus disease 2019 COVID-19.',\n",
              "   'idx': '6902fc36c9624eb7b7e825e500d6583b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 33,\n",
              "   'span_end': 57,\n",
              "   'text': 'The key to drug repositioning of Coronavirus disease 2019 COVID-19 is to identify critical targets for the CoV replication cycle.',\n",
              "   'idx': 'f46542ff79704c4d8d8f98bd18010056',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 58,\n",
              "   'span_end': 66,\n",
              "   'text': 'The key to drug repositioning of Coronavirus disease 2019 COVID-19 is to identify critical targets for the CoV replication cycle.',\n",
              "   'idx': 'f46542ff79704c4d8d8f98bd18010056',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 107,\n",
              "   'span_end': 110,\n",
              "   'text': 'The key to drug repositioning of Coronavirus disease 2019 COVID-19 is to identify critical targets for the CoV replication cycle.',\n",
              "   'idx': 'f46542ff79704c4d8d8f98bd18010056',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 57,\n",
              "   'span_end': 60,\n",
              "   'text': 'virus-based targets the virus components involved in the CoV replication cycle.',\n",
              "   'idx': 'be1dd655b92140ac90a8a02ef2a2575b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 161,\n",
              "   'span_end': 194,\n",
              "   'text': 'For example, approved nucleoside analogues favipiravir and ribavirin and experimental nucleoside analogues remdesivir and galidesivir may have potential against severe acute respiratory syndrome coronavirus 2 SARS-CoV-2.',\n",
              "   'idx': '32916c5de598433997410d8631e4a5f5',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 195,\n",
              "   'span_end': 206,\n",
              "   'text': 'For example, approved nucleoside analogues favipiravir and ribavirin and experimental nucleoside analogues remdesivir and galidesivir may have potential against severe acute respiratory syndrome coronavirus 2 SARS-CoV-2.',\n",
              "   'idx': '32916c5de598433997410d8631e4a5f5',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 209,\n",
              "   'span_end': 219,\n",
              "   'text': 'For example, approved nucleoside analogues favipiravir and ribavirin and experimental nucleoside analogues remdesivir and galidesivir may have potential against severe acute respiratory syndrome coronavirus 2 SARS-CoV-2.',\n",
              "   'idx': '32916c5de598433997410d8631e4a5f5',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 66,\n",
              "   'span_end': 69,\n",
              "   'text': 'The host-based approaches target the key host factors utilized by CoV for viral replication or stimulate innate antiviral responses in hosts.',\n",
              "   'idx': '9bea4e7b223a43548f6f574f06612597',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 31,\n",
              "   'span_end': 64,\n",
              "   'text': 'It was quickly discovered that severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and leverages the serine protease TMPRSS2 for S protein initiation.',\n",
              "   'idx': '14d858f65e344b66b794bb7591bfca19',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 65,\n",
              "   'span_end': 76,\n",
              "   'text': 'It was quickly discovered that severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and leverages the serine protease TMPRSS2 for S protein initiation.',\n",
              "   'idx': '14d858f65e344b66b794bb7591bfca19',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 79,\n",
              "   'span_end': 89,\n",
              "   'text': 'It was quickly discovered that severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and leverages the serine protease TMPRSS2 for S protein initiation.',\n",
              "   'idx': '14d858f65e344b66b794bb7591bfca19',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 99,\n",
              "   'span_end': 107,\n",
              "   'text': 'It was quickly discovered that severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and leverages the serine protease TMPRSS2 for S protein initiation.',\n",
              "   'idx': '14d858f65e344b66b794bb7591bfca19',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 4,\n",
              "   'span_end': 12,\n",
              "   'text': 'the SARS-CoV receptor ACE2 regulates the renin-angiotensin system RAS in several diseases and expresses in the lungs and the kidney, small intestine, testis, and heart.',\n",
              "   'idx': '30c54529097a41c797f2c067e4988f5a',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 19,\n",
              "   'span_end': 27,\n",
              "   'text': 'In addition to the SARS-CoV receptor ACE2 and the serine protease TMPRSS2, several candidate receptors can aid severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection, such as the cell-surface proteins tyrosine-protein kinase receptor UFO Axl, low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3, and C-type lectin domain family 4 member G CLEC4G.',\n",
              "   'idx': 'f9286c2702a14eafa04a2cde880b23ef',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 111,\n",
              "   'span_end': 144,\n",
              "   'text': 'In addition to the SARS-CoV receptor ACE2 and the serine protease TMPRSS2, several candidate receptors can aid severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection, such as the cell-surface proteins tyrosine-protein kinase receptor UFO Axl, low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3, and C-type lectin domain family 4 member G CLEC4G.',\n",
              "   'idx': 'f9286c2702a14eafa04a2cde880b23ef',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 145,\n",
              "   'span_end': 156,\n",
              "   'text': 'In addition to the SARS-CoV receptor ACE2 and the serine protease TMPRSS2, several candidate receptors can aid severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection, such as the cell-surface proteins tyrosine-protein kinase receptor UFO Axl, low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3, and C-type lectin domain family 4 member G CLEC4G.',\n",
              "   'idx': 'f9286c2702a14eafa04a2cde880b23ef',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 159,\n",
              "   'span_end': 179,\n",
              "   'text': 'In addition to the SARS-CoV receptor ACE2 and the serine protease TMPRSS2, several candidate receptors can aid severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection, such as the cell-surface proteins tyrosine-protein kinase receptor UFO Axl, low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3, and C-type lectin domain family 4 member G CLEC4G.',\n",
              "   'idx': 'f9286c2702a14eafa04a2cde880b23ef',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 62,\n",
              "   'span_end': 95,\n",
              "   'text': 'Several efforts have been made to identify drugs that inhibit severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by targeting host proteins.',\n",
              "   'idx': '5101efe370b34262b70ea35d212a4696',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 96,\n",
              "   'span_end': 107,\n",
              "   'text': 'Several efforts have been made to identify drugs that inhibit severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by targeting host proteins.',\n",
              "   'idx': '5101efe370b34262b70ea35d212a4696',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 110,\n",
              "   'span_end': 120,\n",
              "   'text': 'Several efforts have been made to identify drugs that inhibit severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by targeting host proteins.',\n",
              "   'idx': '5101efe370b34262b70ea35d212a4696',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 139,\n",
              "   'span_end': 172,\n",
              "   'text': 'An in vitro study demonstrates that the inhibition of the protease activity of the serine protease TMPRSS2 partially prevents the entry of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 into the lung epithelial cells.',\n",
              "   'idx': 'ca27b2892a60470da4bc691d1bc617ee',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 173,\n",
              "   'span_end': 184,\n",
              "   'text': 'An in vitro study demonstrates that the inhibition of the protease activity of the serine protease TMPRSS2 partially prevents the entry of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 into the lung epithelial cells.',\n",
              "   'idx': 'ca27b2892a60470da4bc691d1bc617ee',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 187,\n",
              "   'span_end': 197,\n",
              "   'text': 'An in vitro study demonstrates that the inhibition of the protease activity of the serine protease TMPRSS2 partially prevents the entry of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 into the lung epithelial cells.',\n",
              "   'idx': 'ca27b2892a60470da4bc691d1bc617ee',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 99,\n",
              "   'span_end': 132,\n",
              "   'text': 'In vitro studies suggest that both chloroquine and hydroxychloroquine may prevent the transport of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 from the early endosome to the endolysosome.',\n",
              "   'idx': '21603279e65a4ff98d25268d983b6b53',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 133,\n",
              "   'span_end': 144,\n",
              "   'text': 'In vitro studies suggest that both chloroquine and hydroxychloroquine may prevent the transport of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 from the early endosome to the endolysosome.',\n",
              "   'idx': '21603279e65a4ff98d25268d983b6b53',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 147,\n",
              "   'span_end': 157,\n",
              "   'text': 'In vitro studies suggest that both chloroquine and hydroxychloroquine may prevent the transport of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 from the early endosome to the endolysosome.',\n",
              "   'idx': '21603279e65a4ff98d25268d983b6b53',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'severe acute respiratory syndrome',\n",
              "   'span_start': 61,\n",
              "   'span_end': 94,\n",
              "   'text': 'However, none of these options was confirmed to have an anti-severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 effect, which motivates the discoveries of other uncovered but practical host factors.',\n",
              "   'idx': '7bd4b09e7fc84907a2bead5d68cdb458',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'coronavirus',\n",
              "   'span_start': 95,\n",
              "   'span_end': 106,\n",
              "   'text': 'However, none of these options was confirmed to have an anti-severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 effect, which motivates the discoveries of other uncovered but practical host factors.',\n",
              "   'idx': '7bd4b09e7fc84907a2bead5d68cdb458',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 109,\n",
              "   'span_end': 119,\n",
              "   'text': 'However, none of these options was confirmed to have an anti-severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 effect, which motivates the discoveries of other uncovered but practical host factors.',\n",
              "   'idx': '7bd4b09e7fc84907a2bead5d68cdb458',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 252,\n",
              "   'span_end': 276,\n",
              "   'text': 'The network-based methodology combines the virus-host interactome and drug targets in the human protein-protein interaction PPI network as a systems pharmacology-based network medicine platform, which is vital and widely used in drug repositioning for Coronavirus disease 2019 COVID-19.',\n",
              "   'idx': 'daa30ca1042a445eaa54e1f33fc02fbe',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 277,\n",
              "   'span_end': 285,\n",
              "   'text': 'The network-based methodology combines the virus-host interactome and drug targets in the human protein-protein interaction PPI network as a systems pharmacology-based network medicine platform, which is vital and widely used in drug repositioning for Coronavirus disease 2019 COVID-19.',\n",
              "   'idx': 'daa30ca1042a445eaa54e1f33fc02fbe',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 72,\n",
              "   'span_end': 96,\n",
              "   'text': \"If a drug stimulates some genes and inhibits others, a drug's effect on Coronavirus disease 2019 COVID-19 needs to be reassessed.\",\n",
              "   'idx': 'c66c910df1e74edb8d07867e230d42d9',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 97,\n",
              "   'span_end': 105,\n",
              "   'text': \"If a drug stimulates some genes and inhibits others, a drug's effect on Coronavirus disease 2019 COVID-19 needs to be reassessed.\",\n",
              "   'idx': 'c66c910df1e74edb8d07867e230d42d9',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 92,\n",
              "   'span_end': 116,\n",
              "   'text': 'Importantly, current methods barely avoid the potential side effect of repurposed drugs for Coronavirus disease 2019 COVID-19 patients with chronic underlying diseases, such as diabetes mellitus, cardiovascular disease, chronic pulmonary disease, and cancers.',\n",
              "   'idx': '7ff3fb8af6d442c69bc5daa4c6dbd2da',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 117,\n",
              "   'span_end': 125,\n",
              "   'text': 'Importantly, current methods barely avoid the potential side effect of repurposed drugs for Coronavirus disease 2019 COVID-19 patients with chronic underlying diseases, such as diabetes mellitus, cardiovascular disease, chronic pulmonary disease, and cancers.',\n",
              "   'idx': '7ff3fb8af6d442c69bc5daa4c6dbd2da',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-coronavirus',\n",
              "   'span_start': 127,\n",
              "   'span_end': 139,\n",
              "   'text': 'In this study, to identify the potential antiviral agents, we applied an end-to-end computational method to search drug-gene s -coronavirus CoV paths in a directional network and inferred the effect of drugs on Coronavirus disease 2019 COVID-19 We constructed a directional network by aggregating three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network.',\n",
              "   'idx': 'a76502f07f6b4e5589ceb659bde922d2',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 140,\n",
              "   'span_end': 143,\n",
              "   'text': 'In this study, to identify the potential antiviral agents, we applied an end-to-end computational method to search drug-gene s -coronavirus CoV paths in a directional network and inferred the effect of drugs on Coronavirus disease 2019 COVID-19 We constructed a directional network by aggregating three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network.',\n",
              "   'idx': 'a76502f07f6b4e5589ceb659bde922d2',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 211,\n",
              "   'span_end': 235,\n",
              "   'text': 'In this study, to identify the potential antiviral agents, we applied an end-to-end computational method to search drug-gene s -coronavirus CoV paths in a directional network and inferred the effect of drugs on Coronavirus disease 2019 COVID-19 We constructed a directional network by aggregating three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network.',\n",
              "   'idx': 'a76502f07f6b4e5589ceb659bde922d2',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 236,\n",
              "   'span_end': 244,\n",
              "   'text': 'In this study, to identify the potential antiviral agents, we applied an end-to-end computational method to search drug-gene s -coronavirus CoV paths in a directional network and inferred the effect of drugs on Coronavirus disease 2019 COVID-19 We constructed a directional network by aggregating three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network.',\n",
              "   'idx': 'a76502f07f6b4e5589ceb659bde922d2',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 211,\n",
              "   'span_end': 235,\n",
              "   'text': 'By leveraging the edge direction in three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network, we can determine whether a drug is reachable to Coronavirus disease 2019 COVID-19 and the MoA between a drug and the virus protein, i.e., inhibition or stimulation.',\n",
              "   'idx': 'ba4e823f379d488a8dd82d819b08177b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 236,\n",
              "   'span_end': 244,\n",
              "   'text': 'By leveraging the edge direction in three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network, we can determine whether a drug is reachable to Coronavirus disease 2019 COVID-19 and the MoA between a drug and the virus protein, i.e., inhibition or stimulation.',\n",
              "   'idx': 'ba4e823f379d488a8dd82d819b08177b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 78,\n",
              "   'span_end': 102,\n",
              "   'text': 'Considering that patients with specific comorbidities are more susceptible to Coronavirus disease 2019 COVID-19 infection, we inspected the side effect of the drug candidate on several common comorbidities based on the genetic information of several complex diseases.',\n",
              "   'idx': '76f003fad66b4e1d982858199a1e255b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infection',\n",
              "   'span_start': 103,\n",
              "   'span_end': 121,\n",
              "   'text': 'Considering that patients with specific comorbidities are more susceptible to Coronavirus disease 2019 COVID-19 infection, we inspected the side effect of the drug candidate on several common comorbidities based on the genetic information of several complex diseases.',\n",
              "   'idx': '76f003fad66b4e1d982858199a1e255b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 68,\n",
              "   'span_end': 92,\n",
              "   'text': 'We reported 29 FDA-approved drugs 7 currently in clinical trials as Coronavirus disease 2019 COVID-19 treatment by a scoring strategy accounting for the effects of drugs on CoVs and comorbidities and other auxiliary information.',\n",
              "   'idx': 'd6892bf1546143209df9cb19177a2912',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 93,\n",
              "   'span_end': 101,\n",
              "   'text': 'We reported 29 FDA-approved drugs 7 currently in clinical trials as Coronavirus disease 2019 COVID-19 treatment by a scoring strategy accounting for the effects of drugs on CoVs and comorbidities and other auxiliary information.',\n",
              "   'idx': 'd6892bf1546143209df9cb19177a2912',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 173,\n",
              "   'span_end': 177,\n",
              "   'text': 'We reported 29 FDA-approved drugs 7 currently in clinical trials as Coronavirus disease 2019 COVID-19 treatment by a scoring strategy accounting for the effects of drugs on CoVs and comorbidities and other auxiliary information.',\n",
              "   'idx': 'd6892bf1546143209df9cb19177a2912',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV infection',\n",
              "   'span_start': 109,\n",
              "   'span_end': 122,\n",
              "   'text': 'We first comprehensively collected candidate host genes from three major domains for mechanistic research of CoV infection genetic risk genes, physical interaction genes, and biological regulation genes A. The source of genetic risk genes was mainly collected from the GWASs of Coronavirus disease 2019 COVID-19.',\n",
              "   'idx': 'e1c30026e61047ba884fff01765e8b96',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'Coronavirus disease 2019',\n",
              "   'span_start': 278,\n",
              "   'span_end': 302,\n",
              "   'text': 'We first comprehensively collected candidate host genes from three major domains for mechanistic research of CoV infection genetic risk genes, physical interaction genes, and biological regulation genes A. The source of genetic risk genes was mainly collected from the GWASs of Coronavirus disease 2019 COVID-19.',\n",
              "   'idx': 'e1c30026e61047ba884fff01765e8b96',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 303,\n",
              "   'span_end': 311,\n",
              "   'text': 'We first comprehensively collected candidate host genes from three major domains for mechanistic research of CoV infection genetic risk genes, physical interaction genes, and biological regulation genes A. The source of genetic risk genes was mainly collected from the GWASs of Coronavirus disease 2019 COVID-19.',\n",
              "   'idx': 'e1c30026e61047ba884fff01765e8b96',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 88,\n",
              "   'span_end': 91,\n",
              "   'text': 'The biological regulation genes were collected from the results of the CRISPR screen of CoV-infected cells.',\n",
              "   'idx': 'c38058264d0a41529a3de6f1197eeb6f',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 65,\n",
              "   'span_end': 68,\n",
              "   'text': 'Thus, we constructed a directed multicomponent network including CoV, host genes, human genes, drug targets, and drugs.',\n",
              "   'idx': 'bd6abf2c33ca425dad3566339c26a194',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoVs',\n",
              "   'span_start': 33,\n",
              "   'span_end': 38,\n",
              "   'text': \"We then searched for drug-gene s -CoVs paths in a directed multicomponent network including CoV, host genes, human genes, drug targets, and drugs and used the direction information to screen out drugs with suitable MoAs C. To investigate the impact of drug candidates on the underlying disease in patients with COVID-19, we also identified genetic risk genes for common complex diseases and genetic risk genes for common complex diseases's direction to disease from genetic data.\",\n",
              "   'idx': '6912f51641c04ef0a8ef6b13e8a4084f',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 92,\n",
              "   'span_end': 95,\n",
              "   'text': \"We then searched for drug-gene s -CoVs paths in a directed multicomponent network including CoV, host genes, human genes, drug targets, and drugs and used the direction information to screen out drugs with suitable MoAs C. To investigate the impact of drug candidates on the underlying disease in patients with COVID-19, we also identified genetic risk genes for common complex diseases and genetic risk genes for common complex diseases's direction to disease from genetic data.\",\n",
              "   'idx': '6912f51641c04ef0a8ef6b13e8a4084f',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 311,\n",
              "   'span_end': 319,\n",
              "   'text': \"We then searched for drug-gene s -CoVs paths in a directed multicomponent network including CoV, host genes, human genes, drug targets, and drugs and used the direction information to screen out drugs with suitable MoAs C. To investigate the impact of drug candidates on the underlying disease in patients with COVID-19, we also identified genetic risk genes for common complex diseases and genetic risk genes for common complex diseases's direction to disease from genetic data.\",\n",
              "   'idx': '6912f51641c04ef0a8ef6b13e8a4084f',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 203,\n",
              "   'span_end': 207,\n",
              "   'text': 'Finally, drugs with a potential inhibitory effect on the disease were prioritized based on a combined score, and conversely, drugs that promote disease were filtered out D.Phylogenetic analysis of human CoVs shows that SARS-CoV-2, SARS-CoV, and MERS-CoV have a high conservative genome.',\n",
              "   'idx': 'd8679380212946558466453545fba0bd',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 219,\n",
              "   'span_end': 229,\n",
              "   'text': 'Finally, drugs with a potential inhibitory effect on the disease were prioritized based on a combined score, and conversely, drugs that promote disease were filtered out D.Phylogenetic analysis of human CoVs shows that SARS-CoV-2, SARS-CoV, and MERS-CoV have a high conservative genome.',\n",
              "   'idx': 'd8679380212946558466453545fba0bd',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 231,\n",
              "   'span_end': 239,\n",
              "   'text': 'Finally, drugs with a potential inhibitory effect on the disease were prioritized based on a combined score, and conversely, drugs that promote disease were filtered out D.Phylogenetic analysis of human CoVs shows that SARS-CoV-2, SARS-CoV, and MERS-CoV have a high conservative genome.',\n",
              "   'idx': 'd8679380212946558466453545fba0bd',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 245,\n",
              "   'span_end': 253,\n",
              "   'text': 'Finally, drugs with a potential inhibitory effect on the disease were prioritized based on a combined score, and conversely, drugs that promote disease were filtered out D.Phylogenetic analysis of human CoVs shows that SARS-CoV-2, SARS-CoV, and MERS-CoV have a high conservative genome.',\n",
              "   'idx': 'd8679380212946558466453545fba0bd',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 56,\n",
              "   'span_end': 66,\n",
              "   'text': 'Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.',\n",
              "   'idx': '1108e974f5674c899317ae518c336936',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 149,\n",
              "   'span_end': 157,\n",
              "   'text': 'Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.',\n",
              "   'idx': '1108e974f5674c899317ae518c336936',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 162,\n",
              "   'span_end': 170,\n",
              "   'text': 'Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.',\n",
              "   'idx': '1108e974f5674c899317ae518c336936',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 182,\n",
              "   'span_end': 192,\n",
              "   'text': 'Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.',\n",
              "   'idx': '1108e974f5674c899317ae518c336936',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 194,\n",
              "   'span_end': 202,\n",
              "   'text': 'Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.',\n",
              "   'idx': '1108e974f5674c899317ae518c336936',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 208,\n",
              "   'span_end': 216,\n",
              "   'text': 'Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.',\n",
              "   'idx': '1108e974f5674c899317ae518c336936',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 112,\n",
              "   'span_end': 120,\n",
              "   'text': 'We systematically integrated candidate host genes from three different angles to identify genetic risk genes of COVID-19, we first got significant risk variants p-value<5 × 10−8 of 517 COVID-19 GWASs from GRASP, yielding 2618 risk variants significantly associated with COVID-19.',\n",
              "   'idx': '56a7586ff4c847a9addfb716b2efb38a',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 185,\n",
              "   'span_end': 193,\n",
              "   'text': 'We systematically integrated candidate host genes from three different angles to identify genetic risk genes of COVID-19, we first got significant risk variants p-value<5 × 10−8 of 517 COVID-19 GWASs from GRASP, yielding 2618 risk variants significantly associated with COVID-19.',\n",
              "   'idx': '56a7586ff4c847a9addfb716b2efb38a',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 270,\n",
              "   'span_end': 278,\n",
              "   'text': 'We systematically integrated candidate host genes from three different angles to identify genetic risk genes of COVID-19, we first got significant risk variants p-value<5 × 10−8 of 517 COVID-19 GWASs from GRASP, yielding 2618 risk variants significantly associated with COVID-19.',\n",
              "   'idx': '56a7586ff4c847a9addfb716b2efb38a',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 251,\n",
              "   'span_end': 259,\n",
              "   'text': 'If the risk variant is an expression quantitative trait locus eQTL of whole blood or lung, we retrieved the eGene of an expression quantitative trait locus eQTL of whole blood or lung as the risk gene and inferred the direction of the risk variant to COVID-19 by matching the effect size of the GWAS and the effect size of an expression quantitative trait locus eQTL of whole blood or lung.',\n",
              "   'idx': 'd2598f4dbdf24a08837e1bb4da62de17',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 139,\n",
              "   'span_end': 147,\n",
              "   'text': 'The association on chromosome 19p13.12 colocalizes an eQTL of TYK2, the target of JAK inhibitors, whose high expression is associated with COVID-19.',\n",
              "   'idx': '976f651e845d4d44bbff0a08db780330',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 57,\n",
              "   'span_end': 61,\n",
              "   'text': 'To collect the high confidence proteins interacting with CoVs, we gathered data from PPI databases, public literature, and affinity AP-MS analyses.',\n",
              "   'idx': '2a1771acb3954f05a4375376a6293311',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV infection',\n",
              "   'span_start': 47,\n",
              "   'span_end': 60,\n",
              "   'text': 'We used up- and downregulation of genes in the CoV infection process as gene-to-virus direction.',\n",
              "   'idx': '58d959291dd747809cd13288aa93ce1f',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 111,\n",
              "   'span_end': 119,\n",
              "   'text': 'Among 435 genes that interact with viral proteins and their direction of action, 16 genes interacted with both SARS-CoV and SARS-CoV-2 and were significantly differentially expressed in the expression profiles of both SARS-CoV and SARS-CoV-2.',\n",
              "   'idx': '0ca7e64552a24cdfaddd96abb2594bcd',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 124,\n",
              "   'span_end': 134,\n",
              "   'text': 'Among 435 genes that interact with viral proteins and their direction of action, 16 genes interacted with both SARS-CoV and SARS-CoV-2 and were significantly differentially expressed in the expression profiles of both SARS-CoV and SARS-CoV-2.',\n",
              "   'idx': '0ca7e64552a24cdfaddd96abb2594bcd',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 218,\n",
              "   'span_end': 226,\n",
              "   'text': 'Among 435 genes that interact with viral proteins and their direction of action, 16 genes interacted with both SARS-CoV and SARS-CoV-2 and were significantly differentially expressed in the expression profiles of both SARS-CoV and SARS-CoV-2.',\n",
              "   'idx': '0ca7e64552a24cdfaddd96abb2594bcd',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 231,\n",
              "   'span_end': 241,\n",
              "   'text': 'Among 435 genes that interact with viral proteins and their direction of action, 16 genes interacted with both SARS-CoV and SARS-CoV-2 and were significantly differentially expressed in the expression profiles of both SARS-CoV and SARS-CoV-2.',\n",
              "   'idx': '0ca7e64552a24cdfaddd96abb2594bcd',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 36,\n",
              "   'span_end': 44,\n",
              "   'text': 'Aconitase1 ACO1 is overexpressed in COVID-19 and underexpressed in non-COVID-19 viral infections.',\n",
              "   'idx': 'c0a3bcdbe1224412a56df52116493737',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 71,\n",
              "   'span_end': 79,\n",
              "   'text': 'Aconitase1 ACO1 is overexpressed in COVID-19 and underexpressed in non-COVID-19 viral infections.',\n",
              "   'idx': 'c0a3bcdbe1224412a56df52116493737',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 103,\n",
              "   'span_end': 111,\n",
              "   'text': 'Interestingly, Aconitase1 ACO1 is involved in iron metabolism, and heme appears to be interlinked with COVID-19 pathophysiology.',\n",
              "   'idx': '7a26070238d6443490703b524ba4525e',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 75,\n",
              "   'span_end': 79,\n",
              "   'text': 'PCDH9, one of the downregulated genes, interacts with multiple proteins of CoVs, including M, NSP6, ORF6, ORF7a, ORF7b, and S proteins.',\n",
              "   'idx': 'ca2e00b3b75149de8852f6528feb4333',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19 infection',\n",
              "   'span_start': 99,\n",
              "   'span_end': 117,\n",
              "   'text': 'The disruption of cadherin proteins by viral protein ORF7b could contribute to several symptoms of COVID-19 infection, including multiorgan failure.',\n",
              "   'idx': 'f1975ef1cd374a5086480229efe9aadf',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 98,\n",
              "   'span_end': 102,\n",
              "   'text': 'Genome-wide screens have been widely used to identify host factors for various viruses, including CoVs.',\n",
              "   'idx': 'c90f0a0d3a1d49a2a848eecefd4ec1e2',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 70,\n",
              "   'span_end': 80,\n",
              "   'text': 'It is worth noting that seven genes were selected in the screening of SARS-CoV-2, SARS-CoV, and MERS-CoV, including CTSL, which encodes the Cathepsin L protease.',\n",
              "   'idx': 'a6cf6f47bf51410184b2fabca1cde1df',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 82,\n",
              "   'span_end': 90,\n",
              "   'text': 'It is worth noting that seven genes were selected in the screening of SARS-CoV-2, SARS-CoV, and MERS-CoV, including CTSL, which encodes the Cathepsin L protease.',\n",
              "   'idx': 'a6cf6f47bf51410184b2fabca1cde1df',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 96,\n",
              "   'span_end': 104,\n",
              "   'text': 'It is worth noting that seven genes were selected in the screening of SARS-CoV-2, SARS-CoV, and MERS-CoV, including CTSL, which encodes the Cathepsin L protease.',\n",
              "   'idx': 'a6cf6f47bf51410184b2fabca1cde1df',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 73,\n",
              "   'span_end': 83,\n",
              "   'text': 'CTSL, which encodes the Cathepsin L protease can functionally cleave the SARS-CoV-2 spike protein and enhance virus entry.',\n",
              "   'idx': '3102d43668d644b695dfea3c6f38cc86',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 93,\n",
              "   'span_end': 103,\n",
              "   'text': 'Studies have shown that inhibitors of the Cathepsin L protease can effectively prevent human SARS-CoV-2, SARS-CoV, and MERS-CoV infection.',\n",
              "   'idx': '7027f9ca02634a65a952477588fda0e9',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 105,\n",
              "   'span_end': 113,\n",
              "   'text': 'Studies have shown that inhibitors of the Cathepsin L protease can effectively prevent human SARS-CoV-2, SARS-CoV, and MERS-CoV infection.',\n",
              "   'idx': '7027f9ca02634a65a952477588fda0e9',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV infection',\n",
              "   'span_start': 119,\n",
              "   'span_end': 137,\n",
              "   'text': 'Studies have shown that inhibitors of the Cathepsin L protease can effectively prevent human SARS-CoV-2, SARS-CoV, and MERS-CoV infection.',\n",
              "   'idx': '7027f9ca02634a65a952477588fda0e9',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 237,\n",
              "   'span_end': 240,\n",
              "   'text': 'Remarkably, no genes were collected from the three sources simultaneously, and the overlap between the three sources is also relatively small, suggesting current biological assays or genetic methods may capture complementary patterns of CoV-host crosstalk.',\n",
              "   'idx': '3aa0955cb1e44fbaab26e28518dede1c',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 133,\n",
              "   'span_end': 143,\n",
              "   'text': 'For example, only 1 out of the 77 genetic risk genes is derived from the CRISPR screen and physical interaction, respectively A. For SARS-CoV-2, we revealed 882 candidate host genes B. Among 882 candidate host genes B., BMPR2 is not only a genetic risk gene but also interacts with SARS-CoV-2 ORF3 protein.',\n",
              "   'idx': '4008657275dc42a49b90990baea64197',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 282,\n",
              "   'span_end': 292,\n",
              "   'text': 'For example, only 1 out of the 77 genetic risk genes is derived from the CRISPR screen and physical interaction, respectively A. For SARS-CoV-2, we revealed 882 candidate host genes B. Among 882 candidate host genes B., BMPR2 is not only a genetic risk gene but also interacts with SARS-CoV-2 ORF3 protein.',\n",
              "   'idx': '4008657275dc42a49b90990baea64197',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 0,\n",
              "   'span_end': 10,\n",
              "   'text': 'SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.',\n",
              "   'idx': 'a43835975c29486da2b6fa11366bb063',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 15,\n",
              "   'span_end': 23,\n",
              "   'text': 'SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.',\n",
              "   'idx': 'a43835975c29486da2b6fa11366bb063',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 99,\n",
              "   'span_end': 109,\n",
              "   'text': 'SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.',\n",
              "   'idx': 'a43835975c29486da2b6fa11366bb063',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 186,\n",
              "   'span_end': 196,\n",
              "   'text': 'SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.',\n",
              "   'idx': 'a43835975c29486da2b6fa11366bb063',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 201,\n",
              "   'span_end': 209,\n",
              "   'text': 'SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.',\n",
              "   'idx': 'a43835975c29486da2b6fa11366bb063',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 94,\n",
              "   'span_end': 104,\n",
              "   'text': \"We divided these genes into antiviral and proviral genes according to these genes's effect on SARS-CoV-2, SARS-CoV, and MERS-CoV. There are 654 antiviral genes and 756 proviral genes.\",\n",
              "   'idx': 'd8caf8b204fb4ab0abad9e40218431c3',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 106,\n",
              "   'span_end': 114,\n",
              "   'text': \"We divided these genes into antiviral and proviral genes according to these genes's effect on SARS-CoV-2, SARS-CoV, and MERS-CoV. There are 654 antiviral genes and 756 proviral genes.\",\n",
              "   'idx': 'd8caf8b204fb4ab0abad9e40218431c3',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV.',\n",
              "   'span_start': 120,\n",
              "   'span_end': 129,\n",
              "   'text': \"We divided these genes into antiviral and proviral genes according to these genes's effect on SARS-CoV-2, SARS-CoV, and MERS-CoV. There are 654 antiviral genes and 756 proviral genes.\",\n",
              "   'idx': 'd8caf8b204fb4ab0abad9e40218431c3',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 42,\n",
              "   'span_end': 46,\n",
              "   'text': 'The catalog of host genes associated with CoVs and the directional information can provide mechanistic insight for drug target selection.',\n",
              "   'idx': '1d44090f601c400a82cb9d468fa92c3a',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 183,\n",
              "   'span_end': 191,\n",
              "   'text': 'As the development of a new drug takes a long time and huge cost, we believe our integrated resource could be alternatively suitable for improving drug repositioning opportunities on COVID-19.',\n",
              "   'idx': '803fabcf94d44010be0bc1c83051df27',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'gene-CoV',\n",
              "   'span_start': 110,\n",
              "   'span_end': 118,\n",
              "   'text': 'We merged drug-target interactions, human protein interactions, and virus-host interactions into a whole drug-gene-CoV network.',\n",
              "   'idx': '7b1d5864791247dc8fe8364badfca5db',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoVs',\n",
              "   'span_start': 76,\n",
              "   'span_end': 81,\n",
              "   'text': 'Then we used the random walk with restart RWR algorithm to find drug-gene s -CoVs paths in a whole drug-gene-CoV network and inferred the direction of the drug to the CoVs see.',\n",
              "   'idx': '00033b20f680410cabc297dd2321bd55',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'gene-CoV',\n",
              "   'span_start': 104,\n",
              "   'span_end': 112,\n",
              "   'text': 'Then we used the random walk with restart RWR algorithm to find drug-gene s -CoVs paths in a whole drug-gene-CoV network and inferred the direction of the drug to the CoVs see.',\n",
              "   'idx': '00033b20f680410cabc297dd2321bd55',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 167,\n",
              "   'span_end': 171,\n",
              "   'text': 'Then we used the random walk with restart RWR algorithm to find drug-gene s -CoVs paths in a whole drug-gene-CoV network and inferred the direction of the drug to the CoVs see.',\n",
              "   'idx': '00033b20f680410cabc297dd2321bd55',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 47,\n",
              "   'span_end': 51,\n",
              "   'text': 'Totally, 6234 drugs with inhibitory effects on CoVs were inferred.',\n",
              "   'idx': 'b198ca31f00e4641b70341cef05f6364',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 80,\n",
              "   'span_end': 88,\n",
              "   'text': 'Older age and comorbidities play essential roles in influencing the severity of COVID-19.',\n",
              "   'idx': 'b1c13169c7df4a849bd3868976a08917',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoVs',\n",
              "   'span_start': 71,\n",
              "   'span_end': 76,\n",
              "   'text': 'To select the optimal drugs, we utilized the properties of drug-gene s -CoVs path including drug-target interaction, network mapping, and source of host genes for each drug to derive a combined score and used a combined score to prioritize drug candidates see.',\n",
              "   'idx': '0af4e0b1dc534ddb8e7a70bac48eb265',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 139,\n",
              "   'span_end': 147,\n",
              "   'text': 'We found that 29 of the top 100 drugs are FDA approved A, and seven of 29 of the top 100 drugs are in clinical trials for the treatment of COVID-19.',\n",
              "   'idx': '75e55c81ad58463bb9511e05cc1d2492',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 46,\n",
              "   'span_end': 54,\n",
              "   'text': 'We collected 397 drugs in clinical trials for COVID-19 from and overlapped with the top 100 drugs.',\n",
              "   'idx': '7ef5d73c94624ffca6c983efdf0777f4',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 93,\n",
              "   'span_end': 101,\n",
              "   'text': 'None of the drugs in clinical trials prior to phase 3 have been found in clinical trials for COVID-19, and there are nine drugs in phase 3/4 clinical trials for COVID-19 B this may be because most of the COVID-19 clinical trial drugs are in clinical phase 3 or FDA approved.',\n",
              "   'idx': '0510e4339af9427ea7ee9ab0ca47e67e',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 161,\n",
              "   'span_end': 169,\n",
              "   'text': 'None of the drugs in clinical trials prior to phase 3 have been found in clinical trials for COVID-19, and there are nine drugs in phase 3/4 clinical trials for COVID-19 B this may be because most of the COVID-19 clinical trial drugs are in clinical phase 3 or FDA approved.',\n",
              "   'idx': '0510e4339af9427ea7ee9ab0ca47e67e',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 204,\n",
              "   'span_end': 212,\n",
              "   'text': 'None of the drugs in clinical trials prior to phase 3 have been found in clinical trials for COVID-19, and there are nine drugs in phase 3/4 clinical trials for COVID-19 B this may be because most of the COVID-19 clinical trial drugs are in clinical phase 3 or FDA approved.',\n",
              "   'idx': '0510e4339af9427ea7ee9ab0ca47e67e',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 107,\n",
              "   'span_end': 117,\n",
              "   'text': 'chlorpromazine is an antipsychotic drug that has recently been proposed to have antiviral activity against SARS-CoV-2.',\n",
              "   'idx': '74f0686c468c4f5bb9bc1af2a4aa45e7',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 50,\n",
              "   'span_end': 60,\n",
              "   'text': 'Recently, bosutinib was found to strongly inhibit SARS-CoV-2 in vitro with low toxicity.',\n",
              "   'idx': 'b8e2ea66e53f4b0e89e886e0f4a50cbf',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 62,\n",
              "   'span_end': 70,\n",
              "   'text': 'Recently, it was reported that pseudoephedrine can antagonize COVID-19 virus by blocking virus expansion.',\n",
              "   'idx': '93f6727668b349cd8f6e25694cdb7531',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV2',\n",
              "   'span_start': 59,\n",
              "   'span_end': 68,\n",
              "   'text': 'Another example is that ponatinib is a potent inhibitor of SARS-CoV2-induced cytokine storm, whereas epinephrine may be considered an intervention to minimize the severity of COVID-19.',\n",
              "   'idx': '4f5ea7cb0d68449ca8bb3348c07f3a79',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 175,\n",
              "   'span_end': 183,\n",
              "   'text': 'Another example is that ponatinib is a potent inhibitor of SARS-CoV2-induced cytokine storm, whereas epinephrine may be considered an intervention to minimize the severity of COVID-19.',\n",
              "   'idx': '4f5ea7cb0d68449ca8bb3348c07f3a79',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 65,\n",
              "   'span_end': 68,\n",
              "   'text': 'We measured the associations of gene expression patterns between CoV-infected patients and the reference-compound-perturbed cells.',\n",
              "   'idx': '60378c19f0f74093888f7ed786ec68f5',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 0,\n",
              "   'span_end': 8,\n",
              "   'text': 'COVID-19 clinical trial drugs are used as ground truth.',\n",
              "   'idx': '5d4389e6722144f49dfcab06fd1f540d',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infection',\n",
              "   'span_start': 227,\n",
              "   'span_end': 247,\n",
              "   'text': 'Our method has the highest area under the curve AUC of 0.61 compared with the results calculated by the CMAP method based on similarity analysis of expression profiles, which was frequently used in drug repositioning using two SARS-CoV-2 infection expression profiles C.Network analysis methods such as deep learning, network diffusion, and network proximity can evaluate the accessibility of drugs to SARS-CoV-2 in the background network.',\n",
              "   'idx': '77edf322f4294443aee11f89f07e864e',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 402,\n",
              "   'span_end': 412,\n",
              "   'text': 'Our method has the highest area under the curve AUC of 0.61 compared with the results calculated by the CMAP method based on similarity analysis of expression profiles, which was frequently used in drug repositioning using two SARS-CoV-2 infection expression profiles C.Network analysis methods such as deep learning, network diffusion, and network proximity can evaluate the accessibility of drugs to SARS-CoV-2 in the background network.',\n",
              "   'idx': '77edf322f4294443aee11f89f07e864e',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 45,\n",
              "   'span_end': 55,\n",
              "   'text': 'For example, SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is identified as a proviral gene in our study.',\n",
              "   'idx': '91734dee057a464b9cdce2a2efd4d27b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 96,\n",
              "   'span_end': 106,\n",
              "   'text': 'Although which class of drugs, i.e., agonists or antagonists of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is responsible for the replication activity of SARS-CoV-2 remains to be verified by more experiments, the latest evidence revealed that knockout or knockdown of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein could cause significant reductions in SARS-CoV-2 replication.',\n",
              "   'idx': 'f05c38ee3d604790a47ba596b25f3df3',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 163,\n",
              "   'span_end': 173,\n",
              "   'text': 'Although which class of drugs, i.e., agonists or antagonists of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is responsible for the replication activity of SARS-CoV-2 remains to be verified by more experiments, the latest evidence revealed that knockout or knockdown of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein could cause significant reductions in SARS-CoV-2 replication.',\n",
              "   'idx': 'f05c38ee3d604790a47ba596b25f3df3',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 309,\n",
              "   'span_end': 319,\n",
              "   'text': 'Although which class of drugs, i.e., agonists or antagonists of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is responsible for the replication activity of SARS-CoV-2 remains to be verified by more experiments, the latest evidence revealed that knockout or knockdown of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein could cause significant reductions in SARS-CoV-2 replication.',\n",
              "   'idx': 'f05c38ee3d604790a47ba596b25f3df3',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 366,\n",
              "   'span_end': 376,\n",
              "   'text': 'Although which class of drugs, i.e., agonists or antagonists of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is responsible for the replication activity of SARS-CoV-2 remains to be verified by more experiments, the latest evidence revealed that knockout or knockdown of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein could cause significant reductions in SARS-CoV-2 replication.',\n",
              "   'idx': 'f05c38ee3d604790a47ba596b25f3df3',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 129,\n",
              "   'span_end': 139,\n",
              "   'text': 'Furthermore, a clinical trial demonstrated that the antidepressant fluvoxamine, an antagonist of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, could prevent clinical deterioration in adult outpatients infected with SARS-CoV-2 A. However, there are network-based approaches to select SIGMAR1, the target of the NSP6 SARS-CoV-2 protein agonists, such as amitriptyline, as a potential treatment for COVID-19, implying confliction and limitation may largely exist among current methods.',\n",
              "   'idx': '044be9d2418146688181cc6f83a6872f',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 221,\n",
              "   'span_end': 231,\n",
              "   'text': 'Furthermore, a clinical trial demonstrated that the antidepressant fluvoxamine, an antagonist of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, could prevent clinical deterioration in adult outpatients infected with SARS-CoV-2 A. However, there are network-based approaches to select SIGMAR1, the target of the NSP6 SARS-CoV-2 protein agonists, such as amitriptyline, as a potential treatment for COVID-19, implying confliction and limitation may largely exist among current methods.',\n",
              "   'idx': '044be9d2418146688181cc6f83a6872f',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 321,\n",
              "   'span_end': 331,\n",
              "   'text': 'Furthermore, a clinical trial demonstrated that the antidepressant fluvoxamine, an antagonist of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, could prevent clinical deterioration in adult outpatients infected with SARS-CoV-2 A. However, there are network-based approaches to select SIGMAR1, the target of the NSP6 SARS-CoV-2 protein agonists, such as amitriptyline, as a potential treatment for COVID-19, implying confliction and limitation may largely exist among current methods.',\n",
              "   'idx': '044be9d2418146688181cc6f83a6872f',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 402,\n",
              "   'span_end': 410,\n",
              "   'text': 'Furthermore, a clinical trial demonstrated that the antidepressant fluvoxamine, an antagonist of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, could prevent clinical deterioration in adult outpatients infected with SARS-CoV-2 A. However, there are network-based approaches to select SIGMAR1, the target of the NSP6 SARS-CoV-2 protein agonists, such as amitriptyline, as a potential treatment for COVID-19, implying confliction and limitation may largely exist among current methods.',\n",
              "   'idx': '044be9d2418146688181cc6f83a6872f',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 126,\n",
              "   'span_end': 134,\n",
              "   'text': 'There are four clinical trials of cannabidiol CBD, a member of the cannabinoid class of natural products for the treatment of COVID-19.',\n",
              "   'idx': '79fe30234b36484090c2ff7d811babf0',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 141,\n",
              "   'span_end': 151,\n",
              "   'text': 'Studies have shown that cannabidiol CBD, a member of the cannabinoid class of natural products can inhibit the cell entry and replication of SARS-CoV-2.',\n",
              "   'idx': '0a81088b31a847c89660691ce0dfb364',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 267,\n",
              "   'span_end': 275,\n",
              "   'text': 'The anti-inflammatory and antioxidant effects of cannabidiol CBD, a member of the cannabinoid class of natural products may make cannabidiol CBD, a member of the cannabinoid class of natural products a treatment for coronary heart disease and diabetes, together with COVID-19 B. Estradiol cypionate EC is an estrogen medication used in hormone therapy for menopausal symptoms and low estrogen levels in cis women.',\n",
              "   'idx': 'ad4d9d1cc1a548a99a1de936d16df6b1',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 56,\n",
              "   'span_end': 64,\n",
              "   'text': 'The analysis of electronic health records of over 68000 COVID-19 patients revealed that estrogen therapy is associated with more than 50% reduction in mortality.',\n",
              "   'idx': '91465071947c40a1b6f9ec708fe2648f',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 43,\n",
              "   'span_end': 51,\n",
              "   'text': 'Estradiol cypionate EC was repositioned as COVID-19 treatment in other studies and is now in phase 2 clinical trial.',\n",
              "   'idx': 'c34b6640f1364dd8882228c25df5d063',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 85,\n",
              "   'span_end': 89,\n",
              "   'text': \"To this end, we comprehensively identified host genes and host genes's directions to CoVs by systematically integrating multi-omics data from mass spectrometry, CRISPR screening, and GWAS.\",\n",
              "   'idx': 'a39c963e4f6247cebb0aab75de2e1b3a',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 33,\n",
              "   'span_end': 43,\n",
              "   'text': 'We identified 964 host genes for SARS-CoV-2, 477 host genes for SARS-CoV, 236 host genes for MERS-CoV, and 1410 unique genes.',\n",
              "   'idx': '74b5bf53914042d8a4a50f3d71df498f',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 64,\n",
              "   'span_end': 72,\n",
              "   'text': 'We identified 964 host genes for SARS-CoV-2, 477 host genes for SARS-CoV, 236 host genes for MERS-CoV, and 1410 unique genes.',\n",
              "   'idx': '74b5bf53914042d8a4a50f3d71df498f',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 93,\n",
              "   'span_end': 101,\n",
              "   'text': 'We identified 964 host genes for SARS-CoV-2, 477 host genes for SARS-CoV, 236 host genes for MERS-CoV, and 1410 unique genes.',\n",
              "   'idx': '74b5bf53914042d8a4a50f3d71df498f',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 41,\n",
              "   'span_end': 51,\n",
              "   'text': \"There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\",\n",
              "   'idx': '2a410129c90344429f68f56fff9de17b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 56,\n",
              "   'span_end': 64,\n",
              "   'text': \"There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\",\n",
              "   'idx': '2a410129c90344429f68f56fff9de17b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 78,\n",
              "   'span_end': 88,\n",
              "   'text': \"There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\",\n",
              "   'idx': '2a410129c90344429f68f56fff9de17b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 93,\n",
              "   'span_end': 101,\n",
              "   'text': \"There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\",\n",
              "   'idx': '2a410129c90344429f68f56fff9de17b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 150,\n",
              "   'span_end': 160,\n",
              "   'text': \"There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\",\n",
              "   'idx': '2a410129c90344429f68f56fff9de17b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 181,\n",
              "   'span_end': 189,\n",
              "   'text': \"There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\",\n",
              "   'idx': '2a410129c90344429f68f56fff9de17b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 102,\n",
              "   'span_end': 110,\n",
              "   'text': 'Twenty-nine of the top 100 prioritized drugs are FDA approved, including seven in clinical trials for COVID-19.',\n",
              "   'idx': '97a5cf2bea8846759ce8b52d7b136df1',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 36,\n",
              "   'span_end': 46,\n",
              "   'text': 'We found that CBD not only inhibits SARS-CoV-2 but may also act as a therapeutic drug for coronary heart disease and diabetes.',\n",
              "   'idx': 'e04ca73bdcd54e3a8d198f4fcbe63ee1',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 66,\n",
              "   'span_end': 70,\n",
              "   'text': \"Overall, we first comprehensively characterized the host genes of CoVs and the host genes of CoVs's role in viral infection.\",\n",
              "   'idx': '6b9bb623e9194769a5328af1ebd1845c',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 93,\n",
              "   'span_end': 97,\n",
              "   'text': \"Overall, we first comprehensively characterized the host genes of CoVs and the host genes of CoVs's role in viral infection.\",\n",
              "   'idx': '6b9bb623e9194769a5328af1ebd1845c',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 49,\n",
              "   'span_end': 52,\n",
              "   'text': 'The effects of these host genes we identified on CoV need to be validated in in vivo and in vitro experiments.',\n",
              "   'idx': '0593dea743f44786a8045d5c1d51ff7d',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 14,\n",
              "   'span_end': 22,\n",
              "   'text': 'Besides, many COVID-19 drug repositioning studies, including our study, have used clinical trial datasets as ground truth for performance evaluation.',\n",
              "   'idx': '2da7fbc333b243588d00b768f6243ffb',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 45,\n",
              "   'span_end': 48,\n",
              "   'text': 'Finally, to infer the direction of a drug to CoV in each drug-gene s -CoVs path, we used a random walk algorithm and then combined multiple drug paths for prioritization.',\n",
              "   'idx': 'e46ca7bf5d6b4bbbb4e49b7ff936c4a0',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoVs',\n",
              "   'span_start': 69,\n",
              "   'span_end': 74,\n",
              "   'text': 'Finally, to infer the direction of a drug to CoV in each drug-gene s -CoVs path, we used a random walk algorithm and then combined multiple drug paths for prioritization.',\n",
              "   'idx': 'e46ca7bf5d6b4bbbb4e49b7ff936c4a0',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 10,\n",
              "   'span_end': 20,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "   'idx': '5b98c27664bb4973a8a3a794513bcbb5',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 60,\n",
              "   'span_end': 68,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "   'idx': '5b98c27664bb4973a8a3a794513bcbb5',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV',\n",
              "   'span_start': 73,\n",
              "   'span_end': 81,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "   'idx': '5b98c27664bb4973a8a3a794513bcbb5',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2',\n",
              "   'span_start': 87,\n",
              "   'span_end': 97,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "   'idx': '5b98c27664bb4973a8a3a794513bcbb5',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV',\n",
              "   'span_start': 147,\n",
              "   'span_end': 155,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "   'idx': '5b98c27664bb4973a8a3a794513bcbb5',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'MERS-CoV.',\n",
              "   'span_start': 160,\n",
              "   'span_end': 169,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "   'idx': '5b98c27664bb4973a8a3a794513bcbb5',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 266,\n",
              "   'span_end': 270,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "   'idx': '5b98c27664bb4973a8a3a794513bcbb5',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 314,\n",
              "   'span_end': 318,\n",
              "   'text': 'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "   'idx': '5b98c27664bb4973a8a3a794513bcbb5',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 50,\n",
              "   'span_end': 58,\n",
              "   'text': 'We first retrieved all risk SNP p-value < 5e-8 in COVID-19 GWAS from GRASP COVID-19 data.',\n",
              "   'idx': 'dafc4edfb4f041a4873d34103ac8cd9b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 75,\n",
              "   'span_end': 83,\n",
              "   'text': 'We first retrieved all risk SNP p-value < 5e-8 in COVID-19 GWAS from GRASP COVID-19 data.',\n",
              "   'idx': 'dafc4edfb4f041a4873d34103ac8cd9b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 37,\n",
              "   'span_end': 45,\n",
              "   'text': 'Then, all risk SNP p-value < 5e-8 in COVID-19 GWAS were annotated as coding variants and non-coding variants by VEP.',\n",
              "   'idx': '08c7c8abcb2a48ef9b2d6b806c696305',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 25,\n",
              "   'span_end': 33,\n",
              "   'text': 'When a variant is both a COVID-19 risk variant and an eQTL, the associated expression gene is identified as the target gene of a variant.',\n",
              "   'idx': '2e423bc5d9b6479f98bcb5e602c7b10d',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 41,\n",
              "   'span_end': 45,\n",
              "   'text': 'We collected host genes interacting with CoVs from four PPI databases, including BioGRID, IntAct, STRING.',\n",
              "   'idx': '5dc797832c93466793f961350748b2e0',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 63,\n",
              "   'span_end': 67,\n",
              "   'text': 'We also included high-confidence proteins that interacted with CoVs from three AP-MS experiments.',\n",
              "   'idx': '1dd745598a754269b634be786723fd64',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 48,\n",
              "   'span_end': 51,\n",
              "   'text': 'In addition, we also included the host genes of CoV collected by Zhou, Y. et al. However, there is no information on the direction of host genes to CoV in these datasets.',\n",
              "   'idx': 'd0047603e90f4b188dccb79668b7063d',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 148,\n",
              "   'span_end': 151,\n",
              "   'text': 'In addition, we also included the host genes of CoV collected by Zhou, Y. et al. However, there is no information on the direction of host genes to CoV in these datasets.',\n",
              "   'idx': 'd0047603e90f4b188dccb79668b7063d',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 51,\n",
              "   'span_end': 55,\n",
              "   'text': 'We got differentially expressed genes of all three CoVs by analyzing corresponding gene expression profiles from the NCBI Gene Expression Omnibus.',\n",
              "   'idx': '10a9092bf2a6475b89583c244d12e1dc',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 92,\n",
              "   'span_end': 96,\n",
              "   'text': \"We construct a directed virus-host network by combining all gene-virus pairs from all three CoVs and all gene-virus pairs from the three sources's directions.\",\n",
              "   'idx': '1eaa72b9df8f4148b7122772e6b103bd',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 119,\n",
              "   'span_end': 123,\n",
              "   'text': 'By integrating the directional networks described above, we can identify the potential repositioning of known drugs on CoVs.',\n",
              "   'idx': 'be47c0e63809444abbe8bc69cf65342a',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoVs',\n",
              "   'span_start': 40,\n",
              "   'span_end': 45,\n",
              "   'text': 'We searched the appropriate drug-gene s -CoVs paths for each compound.',\n",
              "   'idx': 'b86c69f0300d46e9b23074bce186d439',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoVs',\n",
              "   'span_start': 102,\n",
              "   'span_end': 107,\n",
              "   'text': 'Then, we inspected the accessibility of each drug to host genes and assembled directional drug-gene s -CoVs paths.',\n",
              "   'idx': '7a0ee77ac17b42ce87e3d3b10e593bdc',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoVs',\n",
              "   'span_start': 270,\n",
              "   'span_end': 274,\n",
              "   'text': 'Since all the interactions in networks were labeled with directions encoded as 1 and -1 for positive effect and negative effect, respectively, we multiply directions encoded as 1 and -1 for positive effect and negative effect, respectively to infer the drug’s effect on CoVs.',\n",
              "   'idx': 'a21c6878e3484f39af5ecb32aa6a0b5b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'CoV',\n",
              "   'span_start': 41,\n",
              "   'span_end': 44,\n",
              "   'text': 'Drugs that have a negative impact on the CoV are considered a potential repositioning, and the proviral drugs were removed.',\n",
              "   'idx': '6569e16086ab4383b6dbf59ee987f340',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 136,\n",
              "   'span_end': 144,\n",
              "   'text': \"Then we predicted disease-associated genes and disease-associated genes's directions of effect on diseases by the same approach linking COVID-19 risk SNPs to genes.\",\n",
              "   'idx': '863b9483717440afb5407e17b31c9b8b',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoV',\n",
              "   'span_start': 37,\n",
              "   'span_end': 41,\n",
              "   'text': 'A drug may have multiple drug-gene s -CoV paths.',\n",
              "   'idx': '6da7a1a5972b48169fbef04b9b587f73',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': '-CoV',\n",
              "   'span_start': 21,\n",
              "   'span_end': 25,\n",
              "   'text': 'For each Drug-Gene s -CoV path, we assigned a DGV score, which equals the accumulation of drug target score, mapping score, and host gene score.',\n",
              "   'idx': '9c5ec989d27846e3813a4264ac89358d',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'SARS-CoV-2 infected',\n",
              "   'span_start': 36,\n",
              "   'span_end': 55,\n",
              "   'text': 'We used gene expression profiles of SARS-CoV-2 infected samples and a control group from alveolar type II cells and African green monkey kidney cells.',\n",
              "   'idx': 'a04c0a5ddb544b91a90c308a89e267d9',\n",
              "   'article_id': 'PMC9556799'},\n",
              "  {'entity_id': 'covid',\n",
              "   'entity_type': 'disease',\n",
              "   'entity': 'COVID-19',\n",
              "   'span_start': 67,\n",
              "   'span_end': 75,\n",
              "   'text': 'We take as ground truth all drugs currently in clinical trials for COVID-19.',\n",
              "   'idx': 'af85dcd07def41358eaa7a59139350c1',\n",
              "   'article_id': 'PMC9556799'}]]"
            ]
          },
          "metadata": {},
          "execution_count": 42
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-22_articles_0-10_covid_ents_only_plus_text_idx_article_id_1157', 'wb') as f:\n",
        "   pickle.dump(updated_spacy_data, f)"
      ],
      "metadata": {
        "id": "8xfidPtvuZw3"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will flatten the nested list of dictionaries and create a DataFrame for all sentences in the COVID entities dataset."
      ],
      "metadata": {
        "id": "Im0ZtEPOKVeu"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Flatten the nested list of dictionaries\n",
        "flattened_list = [item for sublist in updated_spacy_data for item in sublist]"
      ],
      "metadata": {
        "id": "hR6hL46bwCiF"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Create a DataFrame from the flattened list\n",
        "covid_ents_only_df = pd.DataFrame(flattened_list)"
      ],
      "metadata": {
        "id": "Y_Gk0saSwCiG"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "covid_ents_only_df"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "fd2437d3-20c1-4f4f-fab1-66c717d61f16",
        "id": "4sly8nGwwCiG"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "     entity_id entity_type               entity  span_start  span_end  \\\n",
              "0        covid     disease             COVID-19         197       205   \n",
              "1        covid     disease             COVID-19          59        67   \n",
              "2        covid     disease           SARS-CoV-2          68        78   \n",
              "3        covid     disease          Coronavirus          79        90   \n",
              "4        covid     disease             COVID-19          96       104   \n",
              "...        ...         ...                  ...         ...       ...   \n",
              "1152     covid     disease             COVID-19         136       144   \n",
              "1153     covid     disease                 -CoV          37        41   \n",
              "1154     covid     disease                 -CoV          21        25   \n",
              "1155     covid     disease  SARS-CoV-2 infected          36        55   \n",
              "1156     covid     disease             COVID-19          67        75   \n",
              "\n",
              "                                                   text  \\\n",
              "0     The number of annual publications has been inc...   \n",
              "1     the top 30 most used author keywords include f...   \n",
              "2     the top 30 most used author keywords include f...   \n",
              "3     the top 30 most used author keywords include f...   \n",
              "4     In the context of the pandemic in that year, t...   \n",
              "...                                                 ...   \n",
              "1152  Then we predicted disease-associated genes and...   \n",
              "1153   A drug may have multiple drug-gene s -CoV paths.   \n",
              "1154  For each Drug-Gene s -CoV path, we assigned a ...   \n",
              "1155  We used gene expression profiles of SARS-CoV-2...   \n",
              "1156  We take as ground truth all drugs currently in...   \n",
              "\n",
              "                                   idx  article_id  \n",
              "0     487f27b9fd2446438765e1a7f6a96952  PMC9549161  \n",
              "1     e8adbb3eb77941f9bd063708854ffb17  PMC9549161  \n",
              "2     e8adbb3eb77941f9bd063708854ffb17  PMC9549161  \n",
              "3     e8adbb3eb77941f9bd063708854ffb17  PMC9549161  \n",
              "4     650b870a0f1e4bd089a385567180c322  PMC9549161  \n",
              "...                                ...         ...  \n",
              "1152  863b9483717440afb5407e17b31c9b8b  PMC9556799  \n",
              "1153  6da7a1a5972b48169fbef04b9b587f73  PMC9556799  \n",
              "1154  9c5ec989d27846e3813a4264ac89358d  PMC9556799  \n",
              "1155  a04c0a5ddb544b91a90c308a89e267d9  PMC9556799  \n",
              "1156  af85dcd07def41358eaa7a59139350c1  PMC9556799  \n",
              "\n",
              "[1157 rows x 8 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-d426efed-09e5-4721-8b44-b9ba9b49ae06\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>entity_id</th>\n",
              "      <th>entity_type</th>\n",
              "      <th>entity</th>\n",
              "      <th>span_start</th>\n",
              "      <th>span_end</th>\n",
              "      <th>text</th>\n",
              "      <th>idx</th>\n",
              "      <th>article_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>covid</td>\n",
              "      <td>disease</td>\n",
              "      <td>COVID-19</td>\n",
              "      <td>197</td>\n",
              "      <td>205</td>\n",
              "      <td>The number of annual publications has been inc...</td>\n",
              "      <td>487f27b9fd2446438765e1a7f6a96952</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>covid</td>\n",
              "      <td>disease</td>\n",
              "      <td>COVID-19</td>\n",
              "      <td>59</td>\n",
              "      <td>67</td>\n",
              "      <td>the top 30 most used author keywords include f...</td>\n",
              "      <td>e8adbb3eb77941f9bd063708854ffb17</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>covid</td>\n",
              "      <td>disease</td>\n",
              "      <td>SARS-CoV-2</td>\n",
              "      <td>68</td>\n",
              "      <td>78</td>\n",
              "      <td>the top 30 most used author keywords include f...</td>\n",
              "      <td>e8adbb3eb77941f9bd063708854ffb17</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>covid</td>\n",
              "      <td>disease</td>\n",
              "      <td>Coronavirus</td>\n",
              "      <td>79</td>\n",
              "      <td>90</td>\n",
              "      <td>the top 30 most used author keywords include f...</td>\n",
              "      <td>e8adbb3eb77941f9bd063708854ffb17</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>covid</td>\n",
              "      <td>disease</td>\n",
              "      <td>COVID-19</td>\n",
              "      <td>96</td>\n",
              "      <td>104</td>\n",
              "      <td>In the context of the pandemic in that year, t...</td>\n",
              "      <td>650b870a0f1e4bd089a385567180c322</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1152</th>\n",
              "      <td>covid</td>\n",
              "      <td>disease</td>\n",
              "      <td>COVID-19</td>\n",
              "      <td>136</td>\n",
              "      <td>144</td>\n",
              "      <td>Then we predicted disease-associated genes and...</td>\n",
              "      <td>863b9483717440afb5407e17b31c9b8b</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1153</th>\n",
              "      <td>covid</td>\n",
              "      <td>disease</td>\n",
              "      <td>-CoV</td>\n",
              "      <td>37</td>\n",
              "      <td>41</td>\n",
              "      <td>A drug may have multiple drug-gene s -CoV paths.</td>\n",
              "      <td>6da7a1a5972b48169fbef04b9b587f73</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1154</th>\n",
              "      <td>covid</td>\n",
              "      <td>disease</td>\n",
              "      <td>-CoV</td>\n",
              "      <td>21</td>\n",
              "      <td>25</td>\n",
              "      <td>For each Drug-Gene s -CoV path, we assigned a ...</td>\n",
              "      <td>9c5ec989d27846e3813a4264ac89358d</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1155</th>\n",
              "      <td>covid</td>\n",
              "      <td>disease</td>\n",
              "      <td>SARS-CoV-2 infected</td>\n",
              "      <td>36</td>\n",
              "      <td>55</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1156</th>\n",
              "      <td>covid</td>\n",
              "      <td>disease</td>\n",
              "      <td>COVID-19</td>\n",
              "      <td>67</td>\n",
              "      <td>75</td>\n",
              "      <td>We take as ground truth all drugs currently in...</td>\n",
              "      <td>af85dcd07def41358eaa7a59139350c1</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>1157 rows × 8 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-d426efed-09e5-4721-8b44-b9ba9b49ae06')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-d426efed-09e5-4721-8b44-b9ba9b49ae06 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-d426efed-09e5-4721-8b44-b9ba9b49ae06');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-37ac3f80-4d8d-444d-89b0-1e9a7984e048\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-37ac3f80-4d8d-444d-89b0-1e9a7984e048')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-37ac3f80-4d8d-444d-89b0-1e9a7984e048 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "covid_ents_only_df",
              "summary": "{\n  \"name\": \"covid_ents_only_df\",\n  \"rows\": 1157,\n  \"fields\": [\n    {\n      \"column\": \"entity_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"covid\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity_type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"covid lineage\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 82,\n        \"samples\": [\n          \"COVID-19 infestation\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_start\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 106,\n        \"min\": 0,\n        \"max\": 920,\n        \"num_unique_values\": 332,\n        \"samples\": [\n          80\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_end\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 106,\n        \"min\": 7,\n        \"max\": 930,\n        \"num_unique_values\": 348,\n        \"samples\": [\n          26\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 720,\n        \"samples\": [\n          \"During the spread of COVID-19 outbreak, great efforts have been made in therapeutic drug discovery against COVID-19.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"idx\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 720,\n        \"samples\": [\n          \"17923053290b430abcddf74193c186e7\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"article_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 10,\n        \"samples\": [\n          \"PMC9694939\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 46
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-22_articles_0-10_covid_ents_only_1157_df.pickle', 'wb') as f:\n",
        "   pickle.dump(covid_ents_only_df, f)"
      ],
      "metadata": {
        "id": "539c9MemwCiM"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will use the COVID entities only subset of 1157 rows to update the DataFrame of 10 articles and 4558 rows."
      ],
      "metadata": {
        "id": "dNpbNrWQLsdq"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "covid_ents_only_df.info()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "70261537-1622-45b2-d756-91c8568868e1",
        "id": "U-8230nLwCiN"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "RangeIndex: 1157 entries, 0 to 1156\n",
            "Data columns (total 8 columns):\n",
            " #   Column       Non-Null Count  Dtype \n",
            "---  ------       --------------  ----- \n",
            " 0   entity_id    1157 non-null   object\n",
            " 1   entity_type  1157 non-null   object\n",
            " 2   entity       1157 non-null   object\n",
            " 3   span_start   1157 non-null   int64 \n",
            " 4   span_end     1157 non-null   int64 \n",
            " 5   text         1157 non-null   object\n",
            " 6   idx          1157 non-null   object\n",
            " 7   article_id   1157 non-null   object\n",
            "dtypes: int64(2), object(6)\n",
            "memory usage: 72.4+ KB\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_all_sents_df.info()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "fde5da7a-d44a-43d3-a23a-39e6be8299fa",
        "id": "aNU0XUwlwCiV"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "RangeIndex: 4558 entries, 0 to 4557\n",
            "Data columns (total 8 columns):\n",
            " #   Column       Non-Null Count  Dtype \n",
            "---  ------       --------------  ----- \n",
            " 0   entity_id    3389 non-null   object\n",
            " 1   entity_type  3389 non-null   object\n",
            " 2   entity       3389 non-null   object\n",
            " 3   span_start   3389 non-null   Int64 \n",
            " 4   span_end     3389 non-null   Int64 \n",
            " 5   text         4558 non-null   object\n",
            " 6   idx          4558 non-null   object\n",
            " 7   article_id   4558 non-null   object\n",
            "dtypes: Int64(2), object(6)\n",
            "memory usage: 293.9+ KB\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# copy larger DataFrame before updating\n",
        "kazu_all_sents_df_updated = kazu_all_sents_df.copy()"
      ],
      "metadata": {
        "id": "x9ClW7CqwCiV"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 6.1 Overlapping spans\n",
        "\n",
        "\n",
        "Before updating the larger dataset we will resolve two issues which create discrepancies - nested or partial entities and missing entities.\n",
        "\n",
        "The spaCy custom Language component matched entities that were not fully identified by KAZU resulting in discrepant start and end spans e.g. where KAZU identified 'SARS-CoV-' instead of 'SARS-CoV-2'.\n",
        "\n",
        "It also identified entities which were missed by KAZU.\n",
        "\n",
        "We will define a function to calculate the percentage overlap of spans in the two DataFrames for the same idx keys."
      ],
      "metadata": {
        "id": "wpUkGvW6NX3K"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def calculate_overlap_percentage(df1, df2):\n",
        "    overlap_percentages = []\n",
        "\n",
        "    for idx in df1['idx'].unique():\n",
        "        # Get all rows with the same idx from both dataframes\n",
        "        df1_subset = df1[df1['idx'] == idx]\n",
        "        df2_subset = df2[df2['idx'] == idx]\n",
        "\n",
        "        # Check if there are rows with the same idx in both dataframes\n",
        "        if not df1_subset.empty and not df2_subset.empty:\n",
        "            for _, row1 in df1_subset.iterrows():\n",
        "                max_overlap_percentage = 0.0\n",
        "                for _, row2 in df2_subset.iterrows():\n",
        "                    if not pd.isnull(row1['span_start']) and not pd.isnull(row1['span_end']) and not pd.isnull(row2['span_start']) and not pd.isnull(row2['span_end']):\n",
        "                        start1, end1 = row1['span_start'], row1['span_end']\n",
        "                        start2, end2 = row2['span_start'], row2['span_end']\n",
        "\n",
        "                        overlap = max(0, min(end1, end2) - max(start1, start2))\n",
        "                        span1 = end1 - start1\n",
        "                        overlap_percentage = (overlap / span1) * 100\n",
        "\n",
        "                        max_overlap_percentage = max(max_overlap_percentage, overlap_percentage)\n",
        "\n",
        "                overlap_percentages.append({'idx': idx, 'overlap': round(max_overlap_percentage, 2)})\n",
        "        else:\n",
        "            # If there are no rows with the same idx in df2, add the overlap percentage as 0\n",
        "            overlap_percentages.append({'idx': idx, 'overlap': 0.0})\n",
        "\n",
        "    overlap_df = pd.DataFrame(overlap_percentages)\n",
        "    return overlap_df"
      ],
      "metadata": {
        "id": "kEzRkqnS3DU-"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "%%time\n",
        "overlap_percentage_df = calculate_overlap_percentage(covid_ents_only_df, kazu_all_sents_df_updated)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "066433da-b035-44f0-d209-828a780d1bc8",
        "id": "gUkjHluz3DU-"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 2.9 s, sys: 17.8 ms, total: 2.92 s\n",
            "Wall time: 3.02 s\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "len(overlap_percentage_df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "d2266f93-0ef5-45e4-da32-85619562c6b4",
        "id": "fz1qQtjZ3DU-"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "1157"
            ]
          },
          "metadata": {},
          "execution_count": 55
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# check first 20 rows to see if the calculation has worked\n",
        "overlap_percentage_df.head(20)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 676
        },
        "outputId": "7bb83072-636f-4854-fd02-aa208fb08ded",
        "id": "h3moMVR33DU_"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                 idx  overlap\n",
              "0   487f27b9fd2446438765e1a7f6a96952   100.00\n",
              "1   e8adbb3eb77941f9bd063708854ffb17   100.00\n",
              "2   e8adbb3eb77941f9bd063708854ffb17    40.00\n",
              "3   e8adbb3eb77941f9bd063708854ffb17   100.00\n",
              "4   650b870a0f1e4bd089a385567180c322   100.00\n",
              "5   650b870a0f1e4bd089a385567180c322    90.00\n",
              "6   650b870a0f1e4bd089a385567180c322     0.00\n",
              "7   650b870a0f1e4bd089a385567180c322   100.00\n",
              "8   650b870a0f1e4bd089a385567180c322   100.00\n",
              "9   650b870a0f1e4bd089a385567180c322   100.00\n",
              "10  0c09a88aad3840288fef26e9cbe164d2   100.00\n",
              "11  94a7fda0918a47c5a1b783a3cfae6ba8   100.00\n",
              "12  94a7fda0918a47c5a1b783a3cfae6ba8    50.00\n",
              "13  94a7fda0918a47c5a1b783a3cfae6ba8   100.00\n",
              "14  f17048e74d3e4c09af52d098d5a1b8ac   100.00\n",
              "15  3ccb2d93d4d44115888b46c5d6d052a5   100.00\n",
              "16  4fdd1052f46e4bbf9028d14f00806461   100.00\n",
              "17  4fdd1052f46e4bbf9028d14f00806461     0.00\n",
              "18  02e40d8c09754950a7f5ccee671d7e73   100.00\n",
              "19  e209de13a90e44c5990670ec180364ad    44.44"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-ea2b3cdb-6d4f-427d-b3c3-d03efef57654\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>idx</th>\n",
              "      <th>overlap</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>487f27b9fd2446438765e1a7f6a96952</td>\n",
              "      <td>100.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>e8adbb3eb77941f9bd063708854ffb17</td>\n",
              "      <td>100.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>e8adbb3eb77941f9bd063708854ffb17</td>\n",
              "      <td>40.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>e8adbb3eb77941f9bd063708854ffb17</td>\n",
              "      <td>100.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>650b870a0f1e4bd089a385567180c322</td>\n",
              "      <td>100.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>650b870a0f1e4bd089a385567180c322</td>\n",
              "      <td>90.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>650b870a0f1e4bd089a385567180c322</td>\n",
              "      <td>0.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>650b870a0f1e4bd089a385567180c322</td>\n",
              "      <td>100.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>650b870a0f1e4bd089a385567180c322</td>\n",
              "      <td>100.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>650b870a0f1e4bd089a385567180c322</td>\n",
              "      <td>100.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>0c09a88aad3840288fef26e9cbe164d2</td>\n",
              "      <td>100.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>94a7fda0918a47c5a1b783a3cfae6ba8</td>\n",
              "      <td>100.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>94a7fda0918a47c5a1b783a3cfae6ba8</td>\n",
              "      <td>50.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>94a7fda0918a47c5a1b783a3cfae6ba8</td>\n",
              "      <td>100.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>f17048e74d3e4c09af52d098d5a1b8ac</td>\n",
              "      <td>100.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>3ccb2d93d4d44115888b46c5d6d052a5</td>\n",
              "      <td>100.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>4fdd1052f46e4bbf9028d14f00806461</td>\n",
              "      <td>100.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>4fdd1052f46e4bbf9028d14f00806461</td>\n",
              "      <td>0.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>02e40d8c09754950a7f5ccee671d7e73</td>\n",
              "      <td>100.00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>e209de13a90e44c5990670ec180364ad</td>\n",
              "      <td>44.44</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-ea2b3cdb-6d4f-427d-b3c3-d03efef57654')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-ea2b3cdb-6d4f-427d-b3c3-d03efef57654 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-ea2b3cdb-6d4f-427d-b3c3-d03efef57654');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-d9c61507-c839-44a1-a3ac-151f682b42f4\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-d9c61507-c839-44a1-a3ac-151f682b42f4')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-d9c61507-c839-44a1-a3ac-151f682b42f4 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "overlap_percentage_df",
              "summary": "{\n  \"name\": \"overlap_percentage_df\",\n  \"rows\": 1157,\n  \"fields\": [\n    {\n      \"column\": \"idx\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 720,\n        \"samples\": [\n          \"17923053290b430abcddf74193c186e7\",\n          \"8cfe9e21c2314a0da1afd986394075bc\",\n          \"e878820cfe0e48faa6bee7d162355eee\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"overlap\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 38.21520118897362,\n        \"min\": 0.0,\n        \"max\": 100.0,\n        \"num_unique_values\": 25,\n        \"samples\": [\n          62.5,\n          42.11,\n          100.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 57
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-22_overlap_percentage_df_1157.pickle', 'wb') as f:\n",
        "  pickle.dump(overlap_percentage_df, f)"
      ],
      "metadata": {
        "id": "48b0grU93DU_"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will define a function to replace the rows in the full DataFrame with the rows from the COVID entities DataFrame where there are overlapping spans."
      ],
      "metadata": {
        "id": "PNl-FXI5RP7d"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def replace_overlapping_spans(df1, df2):\n",
        "\n",
        "    for idx in df1['idx'].unique():\n",
        "        # Get all rows with the same idx from both dataframes\n",
        "        df1_subset = df1[df1['idx'] == idx]\n",
        "        df2_subset = df2[df2['idx'] == idx]\n",
        "\n",
        "        # Check if there are rows with the same idx in both dataframes\n",
        "        if not df1_subset.empty and not df2_subset.empty:\n",
        "            for index, row1 in df1_subset.iterrows():\n",
        "                overlapping_rows = []\n",
        "                for index, row2 in df2_subset.iterrows():\n",
        "                    if not pd.isnull(row1['span_start']) and not pd.isnull(row1['span_end']) and not pd.isnull(row2['span_start']) and not pd.isnull(row2['span_end']):\n",
        "                        start1, end1 = row1['span_start'], row1['span_end']\n",
        "                        start2, end2 = row2['span_start'], row2['span_end']\n",
        "\n",
        "                        overlap = max(0, min(end1, end2) - max(start1, start2))\n",
        "                        span1 = end1 - start1\n",
        "                        overlap_percentage = (overlap / span1) * 100\n",
        "\n",
        "                        if overlap_percentage > 0:\n",
        "                            # Replace the row in df2 with the row from df1\n",
        "                            df2.loc[row2.name] = row1\n",
        "\n",
        "    return df2"
      ],
      "metadata": {
        "id": "zRxUoRv03DVA"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "%%time\n",
        "replaced_spans_df = replace_overlapping_spans(covid_ents_only_df, kazu_all_sents_df_updated)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "f8a0a8ff-68d3-493c-ea2b-225faab3994c",
        "id": "Zvg8I0GX3DVA"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 3.85 s, sys: 33.6 ms, total: 3.89 s\n",
            "Wall time: 4.05 s\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "len(replaced_spans_df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "15720850-d894-4cfd-bf63-ce7fbbcc2823",
        "id": "kK2i2xrP3DVB"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "4558"
            ]
          },
          "metadata": {},
          "execution_count": 77
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-22_replaced_spans_df_4558.pickle', 'wb') as f:\n",
        "  pickle.dump(replaced_spans_df, f)"
      ],
      "metadata": {
        "id": "mhayFKej3DVB"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "replaced_spans_df.to_csv('2024-04-22_replaced_spans_df_4558.csv', index=False)"
      ],
      "metadata": {
        "id": "YQtpmRj73DVB"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "replaced_spans_df.info()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "_mAKCpDYWMWh",
        "outputId": "b949e354-2ad9-4421-ffaa-9ac8ec9849e5"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "RangeIndex: 4558 entries, 0 to 4557\n",
            "Data columns (total 8 columns):\n",
            " #   Column       Non-Null Count  Dtype \n",
            "---  ------       --------------  ----- \n",
            " 0   entity_id    3389 non-null   object\n",
            " 1   entity_type  3389 non-null   object\n",
            " 2   entity       3389 non-null   object\n",
            " 3   span_start   3389 non-null   Int64 \n",
            " 4   span_end     3389 non-null   Int64 \n",
            " 5   text         4558 non-null   object\n",
            " 6   idx          4558 non-null   object\n",
            " 7   article_id   4558 non-null   object\n",
            "dtypes: Int64(2), object(6)\n",
            "memory usage: 293.9+ KB\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "replaced_spans_df.tail()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 521
        },
        "id": "0zgJ-HhCWQIu",
        "outputId": "b3b61dfa-d1c7-42d2-c7af-0e8d7e1daf93"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                              entity_id entity_type  \\\n",
              "4553  African green monkey kidney cells   cell_type   \n",
              "4554                               None        None   \n",
              "4555                              covid     disease   \n",
              "4556                               None        None   \n",
              "4557                               None        None   \n",
              "\n",
              "                                 entity  span_start  span_end  \\\n",
              "4553  African green monkey kidney cells         116       149   \n",
              "4554                               None        <NA>      <NA>   \n",
              "4555                           COVID-19          67        75   \n",
              "4556                               None        <NA>      <NA>   \n",
              "4557                               None        <NA>      <NA>   \n",
              "\n",
              "                                                   text  \\\n",
              "4553  We used gene expression profiles of SARS-CoV-2...   \n",
              "4554  We input the top-50 up- and downregulated gene...   \n",
              "4555  We take as ground truth all drugs currently in...   \n",
              "4556  Then we computed the receiver operating charac...   \n",
              "4557  Functional enrichment analysis was conducted u...   \n",
              "\n",
              "                                   idx  article_id  \n",
              "4553  a04c0a5ddb544b91a90c308a89e267d9  PMC9556799  \n",
              "4554  6fe83ef06b55422a8319ee57eb628c91  PMC9556799  \n",
              "4555  af85dcd07def41358eaa7a59139350c1  PMC9556799  \n",
              "4556  6b6a938cf2af46149b1a6583b47e58bb  PMC9556799  \n",
              "4557  a93658c2517e4614a39f2e87ac805ab2  PMC9556799  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-da9a5333-3437-418f-9d44-c7878c2f6d76\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>entity_id</th>\n",
              "      <th>entity_type</th>\n",
              "      <th>entity</th>\n",
              "      <th>span_start</th>\n",
              "      <th>span_end</th>\n",
              "      <th>text</th>\n",
              "      <th>idx</th>\n",
              "      <th>article_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>4553</th>\n",
              "      <td>African green monkey kidney cells</td>\n",
              "      <td>cell_type</td>\n",
              "      <td>African green monkey kidney cells</td>\n",
              "      <td>116</td>\n",
              "      <td>149</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4554</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>We input the top-50 up- and downregulated gene...</td>\n",
              "      <td>6fe83ef06b55422a8319ee57eb628c91</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4555</th>\n",
              "      <td>covid</td>\n",
              "      <td>disease</td>\n",
              "      <td>COVID-19</td>\n",
              "      <td>67</td>\n",
              "      <td>75</td>\n",
              "      <td>We take as ground truth all drugs currently in...</td>\n",
              "      <td>af85dcd07def41358eaa7a59139350c1</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4556</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>Then we computed the receiver operating charac...</td>\n",
              "      <td>6b6a938cf2af46149b1a6583b47e58bb</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4557</th>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>None</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>&lt;NA&gt;</td>\n",
              "      <td>Functional enrichment analysis was conducted u...</td>\n",
              "      <td>a93658c2517e4614a39f2e87ac805ab2</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-da9a5333-3437-418f-9d44-c7878c2f6d76')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-da9a5333-3437-418f-9d44-c7878c2f6d76 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-da9a5333-3437-418f-9d44-c7878c2f6d76');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-60111f6c-9797-44e0-871a-352105492bcb\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-60111f6c-9797-44e0-871a-352105492bcb')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-60111f6c-9797-44e0-871a-352105492bcb button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"replaced_spans_df\",\n  \"rows\": 5,\n  \"fields\": [\n    {\n      \"column\": \"entity_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"covid\",\n          \"African green monkey kidney cells\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity_type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"disease\",\n          \"cell_type\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"COVID-19\",\n          \"African green monkey kidney cells\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_start\",\n      \"properties\": {\n        \"dtype\": \"Int64\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          67,\n          116\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_end\",\n      \"properties\": {\n        \"dtype\": \"Int64\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          75,\n          149\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"We input the top-50 up- and downregulated genes into the web tool and got the drug candidates ranked by connectivity map scores.\",\n          \"Functional enrichment analysis was conducted using clusterProfiler with significance threshold set at FDR<0.05.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"idx\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"6fe83ef06b55422a8319ee57eb628c91\",\n          \"a93658c2517e4614a39f2e87ac805ab2\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"article_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"PMC9556799\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 8
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "We can see that the rows with overlapping spans have been replaced as there is an example of a  COVID entity, 'COVID-19', which now has 'covid' as the entity_id so that COVID entities can easily be identified."
      ],
      "metadata": {
        "id": "cSqEwQHnWwKw"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 6.2 Missing spans\n",
        "\n",
        "We will define a function to check if spans in the larger dataset are null for the same idx in the COVID dataset, drop these rows from the larger dataset and insert the corresponding rows from the COVID dataset."
      ],
      "metadata": {
        "id": "CFyvNN6TTtYc"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def replace_missing_spans(df1, df2):\n",
        "\n",
        "    # Iterate over each idx in df2\n",
        "    for idx in df2['idx'].unique():\n",
        "        # Check if idx is present in df1 and spans are null in df2\n",
        "        if idx in df1['idx'].values and (df2.loc[df2['idx'] == idx, ['span_start', 'span_end']].isnull().any(axis=1).all()):\n",
        "            # Get the index of the row in df2 with missing spans\n",
        "            replace_index = df2[(df2['idx'] == idx) & (df2['span_start'].isnull() | df2['span_end'].isnull())].index[0]\n",
        "            # Remove the row from df2\n",
        "            df2.drop(replace_index, inplace=True)\n",
        "            # Get rows from df1 with the same idx\n",
        "            rows_to_insert = df1[df1['idx'] == idx].copy()\n",
        "            # Insert rows from df1 into df2 at the same position\n",
        "            df2 = pd.concat([df2.iloc[:replace_index], rows_to_insert, df2.iloc[replace_index:]], ignore_index=True)\n",
        "\n",
        "    return df2"
      ],
      "metadata": {
        "id": "rraJ8ulV3DVC"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "%%time\n",
        "replaced_missing_spans_df = replace_missing_spans(covid_ents_only_df, replaced_spans_df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "3ebef33a-582c-4a3e-fedc-db9df3b00a5e",
        "id": "qjTZiB3y3DVC"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 2.06 s, sys: 67.5 ms, total: 2.12 s\n",
            "Wall time: 2.08 s\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "len(replaced_missing_spans_df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "21bd9553-b262-42c3-aaeb-a151fc04579c",
        "id": "xor9AH5y3DVD"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "4583"
            ]
          },
          "metadata": {},
          "execution_count": 84
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "An extra 25 previously missing COVID entities have now been added."
      ],
      "metadata": {
        "id": "41PNMt1Zyiio"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-04-22_replaced_missing_spans_df_4583.pickle', 'wb') as f:\n",
        "  pickle.dump(replaced_missing_spans_df, f)"
      ],
      "metadata": {
        "id": "jcJsusnt3DVD"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "replaced_missing_spans_df.to_csv('2024-04-22_replaced_missing_spans_df_4583.csv', index=False)"
      ],
      "metadata": {
        "id": "t2btMSop3DVD"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "Looking at the csv output there are some entities that have been incorrectly labelled."
      ],
      "metadata": {
        "id": "S5s9szz43DVD"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 6.3 Normalise entity IDs\n",
        "\n",
        "Some of the values in the entity_id column which map to onotologies are in URL format e.g. http://purl.obolibrary.org/obo/ and others have the URI.\n",
        "\n",
        "We will normalise these and replace them with the format `prefix:identifier` so that they can be appended to the [Bioregistry](https://bioregistry.io/) URL used to standardise prefixes for normalised entity identifiers.\n",
        "\n",
        "\n",
        "\n"
      ],
      "metadata": {
        "id": "4bRgn8eczc9x"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def remove_purls(data):\n",
        "    return data.replace('http://purl.obolibrary.org/obo/', '')\n",
        "\n",
        "def add_chembl(data):\n",
        "    return data.replace('CHEMBL', 'chembl:CHEMBL')\n",
        "\n",
        "def add_ensembl(data):\n",
        "    return data.replace('ENSG', 'ensembl:ENSG')\n",
        "\n",
        "def add_cellosaurus(data):\n",
        "    return data.replace('CVCL_', 'cellosaurus:')\n",
        "\n",
        "def add_colon(data):\n",
        "    return data.replace('_', ':')\n",
        "\n"
      ],
      "metadata": {
        "id": "LoUoWKmy9F7O"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def normalise_data(data):\n",
        "\n",
        "    if data is None:\n",
        "      return data\n",
        "\n",
        "    data = remove_purls(data)\n",
        "    data = add_chembl(data)\n",
        "    data = add_ensembl(data)\n",
        "    data = add_cellosaurus(data)\n",
        "    data = add_colon(data)\n",
        "\n",
        "    return data\n",
        "\n"
      ],
      "metadata": {
        "id": "jPvkYlaH9F7P"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "replaced_missing_spans_df['entity_id'] = replaced_missing_spans_df['entity_id'].map(normalise_data)"
      ],
      "metadata": {
        "id": "l3JkhHUa9F7P"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(replaced_missing_spans_df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "sSD3rb44-TVF",
        "outputId": "d4d4d68f-e5a9-426d-a4f5-2e55dfffef95"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "4583"
            ]
          },
          "metadata": {},
          "execution_count": 9
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-05-10_normalised_kazu_entity_ids_df_4583.pickle', 'wb') as f:\n",
        "  pickle.dump(replaced_missing_spans_df, f)"
      ],
      "metadata": {
        "id": "3vQO-mbi9F7Q"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "replaced_missing_spans_df.to_csv('2024-05-10_normalised_kazu_entity_ids_4583.csv', index=False)"
      ],
      "metadata": {
        "id": "CZLtoXGs9F7Q"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 6.4 Replace incorrect abbreviations\n",
        "\n",
        "Some entities were incorrectly mapped as biomedical entities. We will define a function to identify and replace values in the appropriate rows with pd.NA to provide a \"missing\" indicator that can be used consistently across data types."
      ],
      "metadata": {
        "id": "xfgBm-TQ_G2l"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "replaced_abbrevs_df = replaced_missing_spans_df.copy()"
      ],
      "metadata": {
        "id": "DQUtj4hh_G2m"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def replace_abbrevs(df):\n",
        "    # Define the entities to match (case-insensitive)\n",
        "    entities_to_replace = ['ACPP', 'Cmap', 'Sci', 'CADD']\n",
        "\n",
        "    # Convert entities to lowercase for case-insensitive matching\n",
        "    entities_to_replace = [entity.lower() for entity in entities_to_replace]\n",
        "\n",
        "    # Filter rows where entity matches one of the specified entities (case-insensitive)\n",
        "    mask = df['entity'].str.lower().isin(entities_to_replace)\n",
        "\n",
        "    # Replace values in specified columns with pd.NA where mask is True\n",
        "    columns_to_replace = ['entity_id', 'entity_type', 'entity', 'span_start', 'span_end']\n",
        "    df.loc[mask, columns_to_replace] = pd.NA\n",
        "\n",
        "    return df"
      ],
      "metadata": {
        "id": "JuyHpQvn_G2n"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "replaced_abbrevs_df = replace_abbrevs(replaced_abbrevs_df)"
      ],
      "metadata": {
        "id": "CZsb8aFu_G2o"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(replaced_abbrevs_df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "gOo9txV3_QTO",
        "outputId": "cee88a24-c217-473f-e2cc-18e2806c094d"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "4583"
            ]
          },
          "metadata": {},
          "execution_count": 15
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-05-10_replaced_abbrevs_df_4583.pickle', 'wb') as f:\n",
        "  pickle.dump(replaced_abbrevs_df, f)"
      ],
      "metadata": {
        "id": "XVFi9m5Z_G2q"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "replaced_abbrevs_df.to_csv('2024-05-10_replaced_abbrevs_df_4583.csv', index=False)"
      ],
      "metadata": {
        "id": "sUpvoHuQ_G2r"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 6.5 Replace incorrect entity types\n",
        "\n",
        "The entity 'enzyme' has been labelled 'measurement' so we will replace this with 'gene'."
      ],
      "metadata": {
        "id": "bQSjAJxYAiNu"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def replace_enzyme(df):\n",
        "    # Create a mask for rows where 'entity' column value is 'enzyme'\n",
        "    entity_mask = df['entity'] == 'enzyme'\n",
        "\n",
        "    # Create a mask for rows where 'entity_type' column value is 'measurement'\n",
        "    entity_type_mask = df['entity_type'] == 'measurement'\n",
        "\n",
        "    # Combine the masks to select rows where both conditions are met\n",
        "    combined_mask = entity_mask & entity_type_mask\n",
        "\n",
        "    # Replace 'measurement' with 'gene' in the 'entity_type' column for the selected rows\n",
        "    df.loc[combined_mask, 'entity_type'] = 'gene'\n",
        "\n",
        "    return df"
      ],
      "metadata": {
        "id": "CQ0BPVDZAiNv"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "replace_enzyme_df = replace_enzyme(replaced_abbrevs_df)"
      ],
      "metadata": {
        "id": "kMxjIJDdAiNv"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(replace_enzyme_df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "e4d931ba-271e-4764-f034-49b318217e83",
        "id": "1AcVRm2SAiNw"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "4583"
            ]
          },
          "metadata": {},
          "execution_count": 21
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-05-10_replaced_enzyme_df_4583.pickle', 'wb') as f:\n",
        "  pickle.dump(replace_enzyme_df, f)"
      ],
      "metadata": {
        "id": "oCo3HNopAiNw"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "replace_enzyme_df.to_csv('2024-05-10_replaced_enzyme_df_4583.csv', index=False)"
      ],
      "metadata": {
        "id": "ncCSYsunAiNx"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will also replace values in the entity_id column for 'HCoV' (Human Coronavirus) with 'covid' since this is a COVID entity that was not matched by the regex in the custom Language component."
      ],
      "metadata": {
        "id": "ZSVe2piqA45i"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def replace_hcov(df):\n",
        "    # Create a mask for rows where 'entity' column value is 'HCoV'\n",
        "    entity_mask = df['entity'] == 'HCoV'\n",
        "\n",
        "    # Use the mask to select rows where 'entity' column value is 'HCoV'\n",
        "    # and replace the value in the 'entity_id' column with 'covid'\n",
        "    df.loc[entity_mask, 'entity_id'] = 'covid'\n",
        "\n",
        "    # Similarly, replace the value in the 'entity_type' column with 'disease'\n",
        "    df.loc[entity_mask, 'entity_type'] = 'disease'\n",
        "\n",
        "    return df"
      ],
      "metadata": {
        "id": "2Kr4nA_lA45j"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "replace_hcov_df = replace_hcov(replace_enzyme_df)"
      ],
      "metadata": {
        "id": "vyrZ9XwHA45j"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(replace_hcov_df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "3c4500e5-066c-4928-ee47-3bc48dea8804",
        "id": "izGQQ_TXA45k"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "4583"
            ]
          },
          "metadata": {},
          "execution_count": 26
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-05-10_replaced_hcov_df_4583.pickle', 'wb') as f:\n",
        "  pickle.dump(replace_hcov_df, f)"
      ],
      "metadata": {
        "id": "n6phBC2dA45l"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "replace_hcov_df.to_csv('2024-05-10_replaced_hcov_df_4583.csv', index=False)"
      ],
      "metadata": {
        "id": "ZQBE63MKA45l"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## 7. Visualise dataset\n",
        "\n",
        "We will plot the distribution of entities and entity types in the data."
      ],
      "metadata": {
        "id": "HDPFICWF6GPh"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 7.1 Plot entity types"
      ],
      "metadata": {
        "id": "ubGv8VGV7jCa"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "counts = replace_hcov_df['entity_type'].value_counts()\n",
        "counts"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 492
        },
        "id": "HsRCSDFq6mE1",
        "outputId": "9c383f4d-bac9-42cb-a27a-b5446302eaf0"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "entity_type\n",
              "disease          1387\n",
              "drug             1044\n",
              "gene              594\n",
              "measurement       208\n",
              "cell_type          48\n",
              "species            47\n",
              "anatomy            30\n",
              "go_cc              25\n",
              "go_mf              21\n",
              "go_bp              20\n",
              "cell_line          17\n",
              "covid lineage       6\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>entity_type</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>disease</th>\n",
              "      <td>1387</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>drug</th>\n",
              "      <td>1044</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>gene</th>\n",
              "      <td>594</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>measurement</th>\n",
              "      <td>208</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>cell_type</th>\n",
              "      <td>48</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>species</th>\n",
              "      <td>47</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>anatomy</th>\n",
              "      <td>30</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>go_cc</th>\n",
              "      <td>25</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>go_mf</th>\n",
              "      <td>21</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>go_bp</th>\n",
              "      <td>20</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>cell_line</th>\n",
              "      <td>17</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>covid lineage</th>\n",
              "      <td>6</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 15
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def plot_entity_type(title_txt, data):\n",
        "    # Calculate the value counts of 'entity_type' and get the index for ordering\n",
        "    order = data['entity_type'].value_counts().index\n",
        "\n",
        "    # Create a count plot for the 'entity_type' column, ordered by count from highest to lowest\n",
        "    ax = sns.countplot(y='entity_type', hue='entity_type', data=data, order=order, palette='viridis', legend=False)\n",
        "\n",
        "    # Set the title of the plot\n",
        "    ax.set_title(title_txt, size=12)\n",
        "\n",
        "    # Show the plot\n",
        "    plt.show()"
      ],
      "metadata": {
        "id": "BRrVUr9ABjwq"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "title_txt = 'Count of entity types'\n",
        "plot_entity_type(title_txt, replace_hcov_df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 472
        },
        "outputId": "e6626d5e-fbd1-4dd0-86f4-d77381e06973",
        "id": "bwgZ54hyBjwr"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 640x480 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "The most frequently occurring concepts are 'disease', 'drug' and 'gene'. For BERN2 the order was 'drug', 'disease', and 'gene'.\n",
        "\n",
        "KAZU also splits the gene ontology entity types into `go_bp`, `go_cc` and `go_mf` representing the Biological Process, Cellular Component and Molecular Function groups of GO."
      ],
      "metadata": {
        "id": "_PC3FLXR73_u"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 7.1 Plot entities"
      ],
      "metadata": {
        "id": "xYVGx0yCCKqd"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def plot_sentence_entity_counts(df):\n",
        "    # Get the count of entities per 'idx'\n",
        "    entity_counts = df.groupby('idx')['entity'].count()\n",
        "\n",
        "    # Create a range of consecutive numbers from min to max of entity counts\n",
        "    full_range = pd.Series(range(entity_counts.min(), entity_counts.max() + 1))\n",
        "\n",
        "    # Compute the distribution of entity counts and reindex with the full range\n",
        "    entity_count_distribution = entity_counts.value_counts().sort_index()\n",
        "\n",
        "    # Reindex the distribution to include missing counts and fill missing values with 0\n",
        "    entity_count_distribution = entity_count_distribution.reindex(full_range, fill_value=0)\n",
        "\n",
        "    # Plot the distribution\n",
        "    plt.figure(figsize=(10, 6))\n",
        "    sns.barplot(x=entity_count_distribution.index, hue=entity_count_distribution.index, y=entity_count_distribution.values, palette='viridis', legend=False)\n",
        "    plt.title('Number of Entities in Sentences', size=12)\n",
        "    plt.xlabel('Number of Entities', size=10)\n",
        "    plt.ylabel('Number of Sentences', size=10)\n",
        "    plt.show()"
      ],
      "metadata": {
        "id": "bbxAgQu64iJo"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "plot_sentence_entity_counts(replace_hcov_df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 584
        },
        "id": "Jx6OqzCY4riX",
        "outputId": "95ffec3e-1ab9-4f35-a4c6-625437f815e2"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x600 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "This dataset includes the sentences without labelled entities and it appears that most sentences do not actually contain a labelled entity.\n",
        "\n",
        "We will identify the sentence with 24 entities which was also visualised when analysing the BERN2 data."
      ],
      "metadata": {
        "id": "GSxZrg8F_l3V"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Filter the DataFrame to get rows from the sentence with 24 entities\n",
        "sentence_with_24_entities = replace_hcov_df.groupby('idx').filter(lambda x: len(x) == 24)\n",
        "sentence_with_24_entities"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "405e559b-e348-47b3-8b0e-558ea7101ee1",
        "id": "FxLa8_rdCpxf"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "              entity_id entity_type              entity  span_start  span_end  \\\n",
              "1673              NSP16        gene               NSP16           0         5   \n",
              "1674  chembl:CHEMBL1535        drug  hydroxychloroquine          22        40   \n",
              "1675            Arg6817        drug             Arg6817          53        60   \n",
              "1676            Met6818        drug             Met6818          62        69   \n",
              "1677            Leu6819        drug             Leu6819          71        78   \n",
              "1678            Leu6820        drug             Leu6820          80        87   \n",
              "1679            Tyr7020        drug             Tyr7020          89        96   \n",
              "1680            Val7021        drug             Val7021          98       105   \n",
              "1681            Asp7018        drug             Asp7018         107       114   \n",
              "1682            Asp6942        drug             Asp6942         120       127   \n",
              "1683   chembl:CHEMBL163        drug           ritonavir         137       146   \n",
              "1684             Phe314        drug              Phe314         159       165   \n",
              "1685             Gln260        drug              Gln260         167       173   \n",
              "1686             Arg259        drug              Arg259         175       181   \n",
              "1687             Arg277        drug              Arg277         183       189   \n",
              "1688             Phe274        drug              Phe274         191       197   \n",
              "1689             Tyr333        drug              Tyr333         199       205   \n",
              "1690             Trp330        drug              Trp330         207       213   \n",
              "1691             Trp301        drug              Trp301         215       221   \n",
              "1692             Thr282        drug              Thr282         223       229   \n",
              "1693             Gly284        drug              Gly284         231       237   \n",
              "1694             Phe286        drug              Phe286         239       245   \n",
              "1695             Leu291        drug              Leu291         247       253   \n",
              "1696             Val270        drug              Val270         259       265   \n",
              "\n",
              "                                                   text  \\\n",
              "1673  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1674  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1675  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1676  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1677  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1678  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1679  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1680  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1681  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1682  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1683  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1684  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1685  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1686  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1687  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1688  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1689  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1690  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1691  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1692  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1693  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1694  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1695  NSP16 interacted with hydroxychloroquine at re...   \n",
              "1696  NSP16 interacted with hydroxychloroquine at re...   \n",
              "\n",
              "                                   idx  article_id  \n",
              "1673  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1674  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1675  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1676  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1677  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1678  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1679  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1680  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1681  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1682  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1683  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1684  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1685  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1686  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1687  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1688  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1689  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1690  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1691  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1692  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1693  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1694  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1695  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  \n",
              "1696  eca551a43a334a3a822c05cc5ef66c71  PMC9346052  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-edd273db-7427-4c95-a6b7-0735ddf2398e\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>entity_id</th>\n",
              "      <th>entity_type</th>\n",
              "      <th>entity</th>\n",
              "      <th>span_start</th>\n",
              "      <th>span_end</th>\n",
              "      <th>text</th>\n",
              "      <th>idx</th>\n",
              "      <th>article_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>1673</th>\n",
              "      <td>NSP16</td>\n",
              "      <td>gene</td>\n",
              "      <td>NSP16</td>\n",
              "      <td>0</td>\n",
              "      <td>5</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1674</th>\n",
              "      <td>chembl:CHEMBL1535</td>\n",
              "      <td>drug</td>\n",
              "      <td>hydroxychloroquine</td>\n",
              "      <td>22</td>\n",
              "      <td>40</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1675</th>\n",
              "      <td>Arg6817</td>\n",
              "      <td>drug</td>\n",
              "      <td>Arg6817</td>\n",
              "      <td>53</td>\n",
              "      <td>60</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1676</th>\n",
              "      <td>Met6818</td>\n",
              "      <td>drug</td>\n",
              "      <td>Met6818</td>\n",
              "      <td>62</td>\n",
              "      <td>69</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1677</th>\n",
              "      <td>Leu6819</td>\n",
              "      <td>drug</td>\n",
              "      <td>Leu6819</td>\n",
              "      <td>71</td>\n",
              "      <td>78</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1678</th>\n",
              "      <td>Leu6820</td>\n",
              "      <td>drug</td>\n",
              "      <td>Leu6820</td>\n",
              "      <td>80</td>\n",
              "      <td>87</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1679</th>\n",
              "      <td>Tyr7020</td>\n",
              "      <td>drug</td>\n",
              "      <td>Tyr7020</td>\n",
              "      <td>89</td>\n",
              "      <td>96</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1680</th>\n",
              "      <td>Val7021</td>\n",
              "      <td>drug</td>\n",
              "      <td>Val7021</td>\n",
              "      <td>98</td>\n",
              "      <td>105</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1681</th>\n",
              "      <td>Asp7018</td>\n",
              "      <td>drug</td>\n",
              "      <td>Asp7018</td>\n",
              "      <td>107</td>\n",
              "      <td>114</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1682</th>\n",
              "      <td>Asp6942</td>\n",
              "      <td>drug</td>\n",
              "      <td>Asp6942</td>\n",
              "      <td>120</td>\n",
              "      <td>127</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1683</th>\n",
              "      <td>chembl:CHEMBL163</td>\n",
              "      <td>drug</td>\n",
              "      <td>ritonavir</td>\n",
              "      <td>137</td>\n",
              "      <td>146</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1684</th>\n",
              "      <td>Phe314</td>\n",
              "      <td>drug</td>\n",
              "      <td>Phe314</td>\n",
              "      <td>159</td>\n",
              "      <td>165</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1685</th>\n",
              "      <td>Gln260</td>\n",
              "      <td>drug</td>\n",
              "      <td>Gln260</td>\n",
              "      <td>167</td>\n",
              "      <td>173</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1686</th>\n",
              "      <td>Arg259</td>\n",
              "      <td>drug</td>\n",
              "      <td>Arg259</td>\n",
              "      <td>175</td>\n",
              "      <td>181</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1687</th>\n",
              "      <td>Arg277</td>\n",
              "      <td>drug</td>\n",
              "      <td>Arg277</td>\n",
              "      <td>183</td>\n",
              "      <td>189</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1688</th>\n",
              "      <td>Phe274</td>\n",
              "      <td>drug</td>\n",
              "      <td>Phe274</td>\n",
              "      <td>191</td>\n",
              "      <td>197</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1689</th>\n",
              "      <td>Tyr333</td>\n",
              "      <td>drug</td>\n",
              "      <td>Tyr333</td>\n",
              "      <td>199</td>\n",
              "      <td>205</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1690</th>\n",
              "      <td>Trp330</td>\n",
              "      <td>drug</td>\n",
              "      <td>Trp330</td>\n",
              "      <td>207</td>\n",
              "      <td>213</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1691</th>\n",
              "      <td>Trp301</td>\n",
              "      <td>drug</td>\n",
              "      <td>Trp301</td>\n",
              "      <td>215</td>\n",
              "      <td>221</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1692</th>\n",
              "      <td>Thr282</td>\n",
              "      <td>drug</td>\n",
              "      <td>Thr282</td>\n",
              "      <td>223</td>\n",
              "      <td>229</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1693</th>\n",
              "      <td>Gly284</td>\n",
              "      <td>drug</td>\n",
              "      <td>Gly284</td>\n",
              "      <td>231</td>\n",
              "      <td>237</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1694</th>\n",
              "      <td>Phe286</td>\n",
              "      <td>drug</td>\n",
              "      <td>Phe286</td>\n",
              "      <td>239</td>\n",
              "      <td>245</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1695</th>\n",
              "      <td>Leu291</td>\n",
              "      <td>drug</td>\n",
              "      <td>Leu291</td>\n",
              "      <td>247</td>\n",
              "      <td>253</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1696</th>\n",
              "      <td>Val270</td>\n",
              "      <td>drug</td>\n",
              "      <td>Val270</td>\n",
              "      <td>259</td>\n",
              "      <td>265</td>\n",
              "      <td>NSP16 interacted with hydroxychloroquine at re...</td>\n",
              "      <td>eca551a43a334a3a822c05cc5ef66c71</td>\n",
              "      <td>PMC9346052</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-edd273db-7427-4c95-a6b7-0735ddf2398e')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-edd273db-7427-4c95-a6b7-0735ddf2398e button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-edd273db-7427-4c95-a6b7-0735ddf2398e');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-7a737989-c9ae-4ba1-bf8d-50497ef61f02\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-7a737989-c9ae-4ba1-bf8d-50497ef61f02')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-7a737989-c9ae-4ba1-bf8d-50497ef61f02 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "sentence_with_24_entities",
              "summary": "{\n  \"name\": \"sentence_with_24_entities\",\n  \"rows\": 24,\n  \"fields\": [\n    {\n      \"column\": \"entity_id\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 24,\n        \"samples\": [\n          \"Asp7018\",\n          \"Tyr333\",\n          \"NSP16\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity_type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"drug\",\n          \"gene\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 24,\n        \"samples\": [\n          \"Asp7018\",\n          \"Tyr333\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_start\",\n      \"properties\": {\n        \"dtype\": \"Int64\",\n        \"num_unique_values\": 24,\n        \"samples\": [\n          107,\n          199\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_end\",\n      \"properties\": {\n        \"dtype\": \"Int64\",\n        \"num_unique_values\": 24,\n        \"samples\": [\n          114,\n          205\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"NSP16 interacted with hydroxychloroquine at residues Arg6817, Met6818, Leu6819, Leu6820, Tyr7020, Val7021, Asp7018, and Asp6942 and with ritonavir at residues Phe314, Gln260, Arg259, Arg277, Phe274, Tyr333, Trp330, Trp301, Thr282, Gly284, Phe286, Leu291, and Val270.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"idx\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"eca551a43a334a3a822c05cc5ef66c71\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"article_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"PMC9346052\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 36
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "len(sentence_with_24_entities)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "GOKbud7tCg2l",
        "outputId": "337fa0ab-2412-44f2-a253-5f48118dbf08"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "24"
            ]
          },
          "metadata": {},
          "execution_count": 20
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Print the full text of the sentence with 24 entities\n",
        "sentence_with_24_entities.iloc[0]['text']"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 90
        },
        "outputId": "d7b3deb1-a496-4e0e-f3a8-7238d4d707ed",
        "id": "HLNWStTECpxf"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'NSP16 interacted with hydroxychloroquine at residues Arg6817, Met6818, Leu6819, Leu6820, Tyr7020, Val7021, Asp7018, and Asp6942 and with ritonavir at residues Phe314, Gln260, Arg259, Arg277, Phe274, Tyr333, Trp330, Trp301, Thr282, Gly284, Phe286, Leu291, and Val270.'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 38
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Not surprisingly, it is a long list of entities.\n",
        "\n"
      ],
      "metadata": {
        "id": "KhDJpXFBDN-m"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## 8. Create entities only datasets\n",
        "\n",
        "We will create a subset of data which contains only sentences with one or more labelled entity."
      ],
      "metadata": {
        "id": "GCkl8PpYCyke"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Sum of missing values to calculate rows without entities\n",
        "replace_hcov_df.entity.isnull().sum()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "8a412212-be85-49c6-9b23-82feffb07f12",
        "id": "QmfthqhCDPqO"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "1136"
            ]
          },
          "metadata": {},
          "execution_count": 42
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "replace_hcov_df.info()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "89f87e0f-7986-4de9-b641-a7fb73c48464",
        "id": "AHQG69IcDPqO"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "RangeIndex: 4583 entries, 0 to 4582\n",
            "Data columns (total 8 columns):\n",
            " #   Column       Non-Null Count  Dtype \n",
            "---  ------       --------------  ----- \n",
            " 0   entity_id    3447 non-null   object\n",
            " 1   entity_type  3447 non-null   object\n",
            " 2   entity       3447 non-null   object\n",
            " 3   span_start   3447 non-null   Int64 \n",
            " 4   span_end     3447 non-null   Int64 \n",
            " 5   text         4583 non-null   object\n",
            " 6   idx          4583 non-null   object\n",
            " 7   article_id   4583 non-null   object\n",
            "dtypes: Int64(2), object(6)\n",
            "memory usage: 295.5+ KB\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Drop rows with null values\n",
        "kazu_entities_only = replace_hcov_df.dropna()"
      ],
      "metadata": {
        "id": "etARnHGPDPqP"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Reset index\n",
        "kazu_entities_only = kazu_entities_only.reset_index(drop=True)"
      ],
      "metadata": {
        "id": "qoPbK771DPqP"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_entities_only.info()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "fefbed2d-0a34-4f6e-9281-58f7612cc7c8",
        "id": "2TcfKr3SDPqP"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "RangeIndex: 3447 entries, 0 to 3446\n",
            "Data columns (total 8 columns):\n",
            " #   Column       Non-Null Count  Dtype \n",
            "---  ------       --------------  ----- \n",
            " 0   entity_id    3447 non-null   object\n",
            " 1   entity_type  3447 non-null   object\n",
            " 2   entity       3447 non-null   object\n",
            " 3   span_start   3447 non-null   Int64 \n",
            " 4   span_end     3447 non-null   Int64 \n",
            " 5   text         3447 non-null   object\n",
            " 6   idx          3447 non-null   object\n",
            " 7   article_id   3447 non-null   object\n",
            "dtypes: Int64(2), object(6)\n",
            "memory usage: 222.3+ KB\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-05-10_kazu_entities_only_3447.pickle', 'wb') as f:\n",
        "  pickle.dump(kazu_entities_only, f)"
      ],
      "metadata": {
        "id": "umCrV6-ODPqP"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 8.1 Single-entity sentence counts"
      ],
      "metadata": {
        "id": "CIydOCo4uU3A"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will get a count of unique sentences with at least one entity."
      ],
      "metadata": {
        "id": "VRyvbyRY-gu3"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Count unique sentences\n",
        "kazu_entities_only['idx'].nunique()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "A6meJF8W9X68",
        "outputId": "ca1fddc9-45b0-4c6c-cce8-17e1af808654"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "1224"
            ]
          },
          "metadata": {},
          "execution_count": 6
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_entities_only_unique_sents = kazu_entities_only['text'].unique()"
      ],
      "metadata": {
        "id": "_el6H53H9wZM"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_entities_only_unique_sents"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "cb9cf11b-fc2b-4b7c-f023-e63d8f8e0f85",
        "id": "CuWaJy5X9wZM"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "array(['Since the 1990s, the repositioning of sildenafil for male erectile dysfunction and pulmonary hypertension, the development of a new efficacy of bupropion for smoking cessation, new applications of thalidomide for multiple myeloma, and chronic graft-versus-host disease have generated intense interest from pharmaceutical companies and academics.',\n",
              "       'At the beginning of the 21st century, cheminformatics, bioinformatics, systems biology, genomics, polypharmacology, precision medicine, and other disciplines, combined with artificial intelligence, have developed rapidly.',\n",
              "       'cheminformatics, bioinformatics, systems biology, genomics, polypharmacology, precision medicine, and other disciplines have promoted the generation of systematic computer methods to make the drug repositioning process cheaper and shorter.',\n",
              "       ...,\n",
              "       \"The score for each drug is equal to the sum of all each drug's DGV scores.\",\n",
              "       'We used gene expression profiles of SARS-CoV-2 infected samples and a control group from alveolar type II cells and African green monkey kidney cells.',\n",
              "       'We take as ground truth all drugs currently in clinical trials for COVID-19.'],\n",
              "      dtype=object)"
            ]
          },
          "metadata": {},
          "execution_count": 8
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-10-29_kazu_entities_only_unique_sents_1224.pickle', 'wb') as f:\n",
        "  pickle.dump(kazu_entities_only_unique_sents, f)"
      ],
      "metadata": {
        "id": "OoVydLLq_MPR"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will get a count of the number of unique entities in the sentences with at least one entity."
      ],
      "metadata": {
        "id": "CNSD2NZl_wXd"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Count unique entities\n",
        "kazu_entities_only['entity'].nunique()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "6259b483-442e-4098-bb8c-57bab1f9698f",
        "id": "TODu3ZXT_wXd"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "1053"
            ]
          },
          "metadata": {},
          "execution_count": 11
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_entities_only_unique = kazu_entities_only['entity'].unique()"
      ],
      "metadata": {
        "id": "psRul1KN_wXe"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_entities_only_unique"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "6a758b1c-0c39-4c90-9e05-88e13db9f340",
        "id": "-pWcVrgV_wXe"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "array(['sildenafil', 'male erectile dysfunction',\n",
              "       'pulmonary hypertension', ..., 'SARS-CoV-2 infected',\n",
              "       'alveolar type II cells', 'African green monkey kidney cells'],\n",
              "      dtype=object)"
            ]
          },
          "metadata": {},
          "execution_count": 13
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-10-29_kazu_entities_only_unique_1053.pickle', 'wb') as f:\n",
        "  pickle.dump(kazu_entities_only_unique, f)"
      ],
      "metadata": {
        "id": "4mOpkOlw_wXf"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will get a count of the unique entity types."
      ],
      "metadata": {
        "id": "socqp-O2_wXf"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Count unique entity types\n",
        "kazu_entities_only['entity_type'].nunique()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "e652ca83-95aa-47d7-c705-73ce8c65af67",
        "id": "DQhxFoFw_wXf"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "12"
            ]
          },
          "metadata": {},
          "execution_count": 16
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Array of unique entity types\n",
        "kazu_entities_only['entity_type'].unique()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "22a92cc9-42ef-40db-a25e-2a211bed86b8",
        "id": "ypHJFhr2_wXf"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "array(['drug', 'disease', 'measurement', 'gene', 'cell_line', 'anatomy',\n",
              "       'cell_type', 'go_cc', 'species', 'covid lineage', 'go_bp', 'go_mf'],\n",
              "      dtype=object)"
            ]
          },
          "metadata": {},
          "execution_count": 17
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 8.2 Embed labels in single-entity sentences\n",
        "\n",
        "We will create a dataset of unique sentences containing at least one entity and embed the `entity_type` labels in each sentence using parentheses as delimiters in the format `(entity_type: entity)`, for example `(drug: Baricitinib) was selected as a potential repurposed drug against (disease: SARS-CoV-2) through an artificial intelligence algorithm.`"
      ],
      "metadata": {
        "id": "AOyzWLWYteBC"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# load entities only dataset\n",
        "with open('2024-05-10_kazu_entities_only_3447.pickle', 'rb') as f:\n",
        "  kazu_entities_only = pickle.load(f)"
      ],
      "metadata": {
        "id": "wzW-sF4VhZps"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# create copy of DataFrame\n",
        "kazu_entities_only_delimiters = kazu_entities_only.copy()"
      ],
      "metadata": {
        "id": "J_xsBPKGvYvO"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will define a function to add parenthesis delimiters around entities and then add a `text_ner` column to the DataFrame."
      ],
      "metadata": {
        "id": "iVLRRuniw_Eg"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Create a dictionary to hold sentences and their corresponding entities with spans\n",
        "sentences_entities = {}\n",
        "\n",
        "for _, row in kazu_entities_only_delimiters.iterrows():\n",
        "    text = row['text']\n",
        "    entity = row['entity']\n",
        "    span_start = row['span_start']\n",
        "    span_end = row['span_end']\n",
        "    if text not in sentences_entities:\n",
        "        sentences_entities[text] = []\n",
        "    sentences_entities[text].append((entity, span_start, span_end))\n",
        "\n",
        "# Function to add delimiters around entities in a sentence using their spans\n",
        "def add_delimiters(sentence, entities_with_spans):\n",
        "    # Sort entities by span_start in descending order\n",
        "    entities_with_spans = sorted(entities_with_spans, key=lambda x: x[1], reverse=True)\n",
        "    for entity, span_start, span_end in entities_with_spans:\n",
        "        sentence = sentence[:span_start] + f'({entity})' + sentence[span_end:]\n",
        "    return sentence\n",
        "\n",
        "# Create a new column with sentences having delimiters around entities\n",
        "kazu_entities_only_delimiters['text_ner'] = kazu_entities_only_delimiters['text'].apply(\n",
        "    lambda x: add_delimiters(x, sentences_entities[x])\n",
        ")"
      ],
      "metadata": {
        "id": "I4JA9UJ0iZQs"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-06-10_kazu_entities_only_delimiters_v2.pickle', 'wb') as f:\n",
        "  pickle.dump(kazu_entities_only_delimiters, f)"
      ],
      "metadata": {
        "id": "o8Lf2zkJjizt"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_entities_only_delimiters.to_csv('2024-06-10_kazu_entities_only_delimiters_v2.csv', index=False)"
      ],
      "metadata": {
        "id": "X6mx_59qjizu"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_entities_only_delimiters.info()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "t_QfhUSuv6me",
        "outputId": "30bc3b5c-a26c-43b7-db30-00a3fe38ba69"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "RangeIndex: 3447 entries, 0 to 3446\n",
            "Data columns (total 9 columns):\n",
            " #   Column       Non-Null Count  Dtype \n",
            "---  ------       --------------  ----- \n",
            " 0   entity_id    3447 non-null   object\n",
            " 1   entity_type  3447 non-null   object\n",
            " 2   entity       3447 non-null   object\n",
            " 3   span_start   3447 non-null   Int64 \n",
            " 4   span_end     3447 non-null   Int64 \n",
            " 5   text         3447 non-null   object\n",
            " 6   idx          3447 non-null   object\n",
            " 7   article_id   3447 non-null   object\n",
            " 8   text_ner     3447 non-null   object\n",
            "dtypes: Int64(2), object(7)\n",
            "memory usage: 249.2+ KB\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_entities_only_delimiters"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "oENz6JfVinEE",
        "outputId": "3065670c-0e08-4fe9-92ab-d0abf2389e53"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                              entity_id  entity_type  \\\n",
              "0                      chembl:CHEMBL192         drug   \n",
              "1                            HP:0100639      disease   \n",
              "2                         MONDO:0005149      disease   \n",
              "3                      chembl:CHEMBL894         drug   \n",
              "4                      chembl:CHEMBL468         drug   \n",
              "...                                 ...          ...   \n",
              "3442                      STATO:0000569  measurement   \n",
              "3443                              covid      disease   \n",
              "3444                         CL:0002063    cell_type   \n",
              "3445  African green monkey kidney cells    cell_type   \n",
              "3446                              covid      disease   \n",
              "\n",
              "                                 entity  span_start  span_end  \\\n",
              "0                            sildenafil          38        48   \n",
              "1             male erectile dysfunction          53        78   \n",
              "2                pulmonary hypertension          83       105   \n",
              "3                             bupropion         144       153   \n",
              "4                           thalidomide         197       208   \n",
              "...                                 ...         ...       ...   \n",
              "3442                              score           4         9   \n",
              "3443                SARS-CoV-2 infected          36        55   \n",
              "3444             alveolar type II cells          89       111   \n",
              "3445  African green monkey kidney cells         116       149   \n",
              "3446                           COVID-19          67        75   \n",
              "\n",
              "                                                   text  \\\n",
              "0     Since the 1990s, the repositioning of sildenaf...   \n",
              "1     Since the 1990s, the repositioning of sildenaf...   \n",
              "2     Since the 1990s, the repositioning of sildenaf...   \n",
              "3     Since the 1990s, the repositioning of sildenaf...   \n",
              "4     Since the 1990s, the repositioning of sildenaf...   \n",
              "...                                                 ...   \n",
              "3442  The score for each drug is equal to the sum of...   \n",
              "3443  We used gene expression profiles of SARS-CoV-2...   \n",
              "3444  We used gene expression profiles of SARS-CoV-2...   \n",
              "3445  We used gene expression profiles of SARS-CoV-2...   \n",
              "3446  We take as ground truth all drugs currently in...   \n",
              "\n",
              "                                   idx  article_id  \\\n",
              "0     22200652f00d4d5fb5875f619734eaed  PMC9549161   \n",
              "1     22200652f00d4d5fb5875f619734eaed  PMC9549161   \n",
              "2     22200652f00d4d5fb5875f619734eaed  PMC9549161   \n",
              "3     22200652f00d4d5fb5875f619734eaed  PMC9549161   \n",
              "4     22200652f00d4d5fb5875f619734eaed  PMC9549161   \n",
              "...                                ...         ...   \n",
              "3442  f06e07ee624e49de824cb35e524cef19  PMC9556799   \n",
              "3443  a04c0a5ddb544b91a90c308a89e267d9  PMC9556799   \n",
              "3444  a04c0a5ddb544b91a90c308a89e267d9  PMC9556799   \n",
              "3445  a04c0a5ddb544b91a90c308a89e267d9  PMC9556799   \n",
              "3446  af85dcd07def41358eaa7a59139350c1  PMC9556799   \n",
              "\n",
              "                                               text_ner  \n",
              "0     Since the 1990s, the repositioning of (sildena...  \n",
              "1     Since the 1990s, the repositioning of (sildena...  \n",
              "2     Since the 1990s, the repositioning of (sildena...  \n",
              "3     Since the 1990s, the repositioning of (sildena...  \n",
              "4     Since the 1990s, the repositioning of (sildena...  \n",
              "...                                                 ...  \n",
              "3442  The (score) for each drug is equal to the sum ...  \n",
              "3443  We used gene expression profiles of (SARS-CoV-...  \n",
              "3444  We used gene expression profiles of (SARS-CoV-...  \n",
              "3445  We used gene expression profiles of (SARS-CoV-...  \n",
              "3446  We take as ground truth all drugs currently in...  \n",
              "\n",
              "[3447 rows x 9 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-08a7faf5-a30c-41cb-a698-0747d772a5c5\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>entity_id</th>\n",
              "      <th>entity_type</th>\n",
              "      <th>entity</th>\n",
              "      <th>span_start</th>\n",
              "      <th>span_end</th>\n",
              "      <th>text</th>\n",
              "      <th>idx</th>\n",
              "      <th>article_id</th>\n",
              "      <th>text_ner</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>chembl:CHEMBL192</td>\n",
              "      <td>drug</td>\n",
              "      <td>sildenafil</td>\n",
              "      <td>38</td>\n",
              "      <td>48</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "      <td>PMC9549161</td>\n",
              "      <td>Since the 1990s, the repositioning of (sildena...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>HP:0100639</td>\n",
              "      <td>disease</td>\n",
              "      <td>male erectile dysfunction</td>\n",
              "      <td>53</td>\n",
              "      <td>78</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "      <td>PMC9549161</td>\n",
              "      <td>Since the 1990s, the repositioning of (sildena...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>MONDO:0005149</td>\n",
              "      <td>disease</td>\n",
              "      <td>pulmonary hypertension</td>\n",
              "      <td>83</td>\n",
              "      <td>105</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "      <td>PMC9549161</td>\n",
              "      <td>Since the 1990s, the repositioning of (sildena...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>chembl:CHEMBL894</td>\n",
              "      <td>drug</td>\n",
              "      <td>bupropion</td>\n",
              "      <td>144</td>\n",
              "      <td>153</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "      <td>PMC9549161</td>\n",
              "      <td>Since the 1990s, the repositioning of (sildena...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>chembl:CHEMBL468</td>\n",
              "      <td>drug</td>\n",
              "      <td>thalidomide</td>\n",
              "      <td>197</td>\n",
              "      <td>208</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "      <td>PMC9549161</td>\n",
              "      <td>Since the 1990s, the repositioning of (sildena...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3442</th>\n",
              "      <td>STATO:0000569</td>\n",
              "      <td>measurement</td>\n",
              "      <td>score</td>\n",
              "      <td>4</td>\n",
              "      <td>9</td>\n",
              "      <td>The score for each drug is equal to the sum of...</td>\n",
              "      <td>f06e07ee624e49de824cb35e524cef19</td>\n",
              "      <td>PMC9556799</td>\n",
              "      <td>The (score) for each drug is equal to the sum ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3443</th>\n",
              "      <td>covid</td>\n",
              "      <td>disease</td>\n",
              "      <td>SARS-CoV-2 infected</td>\n",
              "      <td>36</td>\n",
              "      <td>55</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "      <td>PMC9556799</td>\n",
              "      <td>We used gene expression profiles of (SARS-CoV-...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3444</th>\n",
              "      <td>CL:0002063</td>\n",
              "      <td>cell_type</td>\n",
              "      <td>alveolar type II cells</td>\n",
              "      <td>89</td>\n",
              "      <td>111</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "      <td>PMC9556799</td>\n",
              "      <td>We used gene expression profiles of (SARS-CoV-...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3445</th>\n",
              "      <td>African green monkey kidney cells</td>\n",
              "      <td>cell_type</td>\n",
              "      <td>African green monkey kidney cells</td>\n",
              "      <td>116</td>\n",
              "      <td>149</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "      <td>PMC9556799</td>\n",
              "      <td>We used gene expression profiles of (SARS-CoV-...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3446</th>\n",
              "      <td>covid</td>\n",
              "      <td>disease</td>\n",
              "      <td>COVID-19</td>\n",
              "      <td>67</td>\n",
              "      <td>75</td>\n",
              "      <td>We take as ground truth all drugs currently in...</td>\n",
              "      <td>af85dcd07def41358eaa7a59139350c1</td>\n",
              "      <td>PMC9556799</td>\n",
              "      <td>We take as ground truth all drugs currently in...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>3447 rows × 9 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-08a7faf5-a30c-41cb-a698-0747d772a5c5')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-08a7faf5-a30c-41cb-a698-0747d772a5c5 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-08a7faf5-a30c-41cb-a698-0747d772a5c5');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-21797bf0-8e8b-43a2-82fd-27eb5fa280f9\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-21797bf0-8e8b-43a2-82fd-27eb5fa280f9')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-21797bf0-8e8b-43a2-82fd-27eb5fa280f9 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "kazu_entities_only_delimiters",
              "summary": "{\n  \"name\": \"kazu_entities_only_delimiters\",\n  \"rows\": 3447,\n  \"fields\": [\n    {\n      \"column\": \"entity_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 885,\n        \"samples\": [\n          \"MONDO:0005812\",\n          \"Pro491\",\n          \"ensembl:ENSG00000196712\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity_type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 12,\n        \"samples\": [\n          \"go_bp\",\n          \"covid lineage\",\n          \"drug\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1053,\n        \"samples\": [\n          \"His272\",\n          \"Mpro\",\n          \"OAS3\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_start\",\n      \"properties\": {\n        \"dtype\": \"Int64\",\n        \"num_unique_values\": 443,\n        \"samples\": [\n          18,\n          384,\n          76\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_end\",\n      \"properties\": {\n        \"dtype\": \"Int64\",\n        \"num_unique_values\": 448,\n        \"samples\": [\n          340,\n          269,\n          183\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1224,\n        \"samples\": [\n          \"COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.\",\n          \"Meanwhile, many Indian pharmaceutical firms confirmed preliminary results from phase 3 studies with Molnupiravir in mild/moderate COVID-19 patient populations in India.\",\n          \"Nevertheless, CADD is not well\\u2010suited to high\\u2010throughput screening HTS when focusing on the bio\\u2010security requirements of SARS\\u2010CoV\\u20102.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"idx\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1224,\n        \"samples\": [\n          \"61ed3a0232b84f2fb1798597668e7b32\",\n          \"488c9cfee5e64d6e8bbe98e0ffdf0aff\",\n          \"f366cc7ae5e94b799b2c5273de47b081\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"article_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 10,\n        \"samples\": [\n          \"PMC9694939\",\n          \"PMC9539342\",\n          \"PMC9527439\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text_ner\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1224,\n        \"samples\": [\n          \"(COVID-19) is an (infectious disease) caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of (severe acute respiratory syndromes) (SARS Cov-2).\",\n          \"Meanwhile, many Indian pharmaceutical firms confirmed preliminary results from phase 3 studies with (Molnupiravir) in mild/moderate (COVID-19) patient populations in India.\",\n          \"Nevertheless, CADD is not well\\u2010suited to high\\u2010throughput screening HTS when focusing on the bio\\u2010security requirements of (SARS\\u2010CoV\\u20102).\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 15
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_entities_only_delimiters.info()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "30bc3b5c-a26c-43b7-db30-00a3fe38ba69",
        "id": "TgiC2ocizAm8"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "RangeIndex: 3447 entries, 0 to 3446\n",
            "Data columns (total 9 columns):\n",
            " #   Column       Non-Null Count  Dtype \n",
            "---  ------       --------------  ----- \n",
            " 0   entity_id    3447 non-null   object\n",
            " 1   entity_type  3447 non-null   object\n",
            " 2   entity       3447 non-null   object\n",
            " 3   span_start   3447 non-null   Int64 \n",
            " 4   span_end     3447 non-null   Int64 \n",
            " 5   text         3447 non-null   object\n",
            " 6   idx          3447 non-null   object\n",
            " 7   article_id   3447 non-null   object\n",
            " 8   text_ner     3447 non-null   object\n",
            "dtypes: Int64(2), object(7)\n",
            "memory usage: 249.2+ KB\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will define a function to add parenthesis delimiters and entity type labels around entities and then add a `text_ner_labels` column to the DataFrame."
      ],
      "metadata": {
        "id": "_plo6q3RzLko"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Create a dictionary to hold sentences and their corresponding entities with spans and types\n",
        "sentences_entities = {}\n",
        "\n",
        "for _, row in kazu_entities_only_delimiters.iterrows():\n",
        "    text = row['text']\n",
        "    entity = row['entity']\n",
        "    entity_type = row['entity_type']\n",
        "    span_start = row['span_start']\n",
        "    span_end = row['span_end']\n",
        "    if text not in sentences_entities:\n",
        "        sentences_entities[text] = []\n",
        "    sentences_entities[text].append((entity, entity_type, span_start, span_end))\n",
        "\n",
        "# Function to add delimiters and labels around entities in a sentence using their spans\n",
        "def add_delimiters_with_labels(sentence, entities_with_spans_types):\n",
        "    # Sort entities by span_start in descending order\n",
        "    entities_with_spans_types = sorted(entities_with_spans_types, key=lambda x: x[2], reverse=True)\n",
        "    for entity, entity_type, span_start, span_end in entities_with_spans_types:\n",
        "        sentence = sentence[:span_start] + f'({entity_type}: {entity})' + sentence[span_end:]\n",
        "    return sentence\n",
        "\n",
        "kazu_entities_only_delimiters['text_ner_label'] = kazu_entities_only_delimiters['text'].apply(\n",
        "    lambda x: add_delimiters_with_labels(x, sentences_entities[x])\n",
        ")"
      ],
      "metadata": {
        "id": "baHnyHo-zYIo"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_entities_only_delimiters.info()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "kPNCCI_FrEwt",
        "outputId": "c948c676-44c7-42ff-8407-58ce0300050b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "RangeIndex: 3447 entries, 0 to 3446\n",
            "Data columns (total 10 columns):\n",
            " #   Column          Non-Null Count  Dtype \n",
            "---  ------          --------------  ----- \n",
            " 0   entity_id       3447 non-null   object\n",
            " 1   entity_type     3447 non-null   object\n",
            " 2   entity          3447 non-null   object\n",
            " 3   span_start      3447 non-null   Int64 \n",
            " 4   span_end        3447 non-null   Int64 \n",
            " 5   text            3447 non-null   object\n",
            " 6   idx             3447 non-null   object\n",
            " 7   article_id      3447 non-null   object\n",
            " 8   text_ner        3447 non-null   object\n",
            " 9   text_ner_label  3447 non-null   object\n",
            "dtypes: Int64(2), object(8)\n",
            "memory usage: 276.2+ KB\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-06-10_kazu_entities_only_text_ner_labels.pickle', 'wb') as f:\n",
        "  pickle.dump(kazu_entities_only_delimiters, f)"
      ],
      "metadata": {
        "id": "oOC4jTU6rFAM"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_entities_only_delimiters.to_csv('2024-06-10_kazu_entities_only_text_ner_labels.csv', index=False)"
      ],
      "metadata": {
        "id": "WA2aZcQprFAN"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will drop duplicate rows and keep the unique sentences with delimiters."
      ],
      "metadata": {
        "id": "3vNszpLB0nSu"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "unique_rows_ner = kazu_entities_only_delimiters.drop_duplicates(subset=['text', 'text_ner', 'text_ner_label', 'idx', 'article_id']).reset_index(drop=True)\n",
        "\n",
        "unique_rows_ner_df = unique_rows_ner[['text', 'text_ner', 'text_ner_label', 'idx', 'article_id']]"
      ],
      "metadata": {
        "id": "Shod0ZSusZzT"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(unique_rows_ner_df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "a86aedf0-30b0-44f5-ea5a-ed796e2a95be",
        "id": "X3Hv7SFTsZzU"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "1224"
            ]
          },
          "metadata": {},
          "execution_count": 36
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-06-10_text_ner_labels_1224.pickle', \"wb\") as f:\n",
        "    pickle.dump(unique_rows_ner_df, f)"
      ],
      "metadata": {
        "id": "DBnA9QUIsZzU"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "unique_rows_ner_df.to_csv('2024-06-10_text_ner_labels_1224.csv', index=False)"
      ],
      "metadata": {
        "id": "z9wZ7B47sZzV"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "Some manual postprocessing to the csv was required."
      ],
      "metadata": {
        "id": "iaxYevlf1Loo"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "text_ner_labels_data =  pd.read_csv('2024-06-10_text_ner_labels_1224_edited.csv')\n",
        "text_ner_labels_data"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 929
        },
        "outputId": "287ff41d-ee97-4299-c238-da4d1952ea08",
        "id": "fsPXV2Fo26Gq"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                                   text  \\\n",
              "0     Since the 1990s, the repositioning of sildenaf...   \n",
              "1     At the beginning of the 21st century, cheminfo...   \n",
              "2     cheminformatics, bioinformatics, systems biolo...   \n",
              "3     Today, drug repositioning is increasingly prom...   \n",
              "4     The bibliometric approach can solve the aforem...   \n",
              "...                                                 ...   \n",
              "1219  For mapping score, the score is set as the inv...   \n",
              "1220  For host gene score, host gene score got 1 poi...   \n",
              "1221  The score for each drug is equal to the sum of...   \n",
              "1222  We used gene expression profiles of SARS-CoV-2...   \n",
              "1223  We take as ground truth all drugs currently in...   \n",
              "\n",
              "                                               text_ner  \\\n",
              "0     Since the 1990s, the repositioning of (sildena...   \n",
              "1     At the beginning of the 21st century, cheminfo...   \n",
              "2     cheminformatics, bioinformatics, systems biolo...   \n",
              "3     Today, drug repositioning is increasingly prom...   \n",
              "4     The bibliometric approach can solve the aforem...   \n",
              "...                                                 ...   \n",
              "1219  For mapping (score), the (score) is set as the...   \n",
              "1220  For host gene (score), host gene (score) got 1...   \n",
              "1221  The (score) for each drug is equal to the sum ...   \n",
              "1222  We used gene expression profiles of (SARS-CoV-...   \n",
              "1223  We take as ground truth all drugs currently in...   \n",
              "\n",
              "                                         text_ner_label  \\\n",
              "0     Since the 1990s, the repositioning of (drug: s...   \n",
              "1     At the beginning of the 21st century, cheminfo...   \n",
              "2     cheminformatics, bioinformatics, systems biolo...   \n",
              "3     Today, drug repositioning is increasingly prom...   \n",
              "4     The bibliometric approach can solve the aforem...   \n",
              "...                                                 ...   \n",
              "1219  For mapping (measurement: score), the (measure...   \n",
              "1220  For host gene (measurement: score), host gene ...   \n",
              "1221  The (measurement: score) for each drug is equa...   \n",
              "1222  We used gene expression profiles of (disease: ...   \n",
              "1223  We take as ground truth all drugs currently in...   \n",
              "\n",
              "                                   idx  article_id  \n",
              "0     22200652f00d4d5fb5875f619734eaed  PMC9549161  \n",
              "1     45575790fc88453a90d6e15b0474e89d  PMC9549161  \n",
              "2     ac22ae2fbeb14ca5baf01f3b0022cd57  PMC9549161  \n",
              "3     ae1f33d77559408bb43f914ac3aa8b88  PMC9549161  \n",
              "4     82ab09f0f9bd4539b612bc196d0aa7b8  PMC9549161  \n",
              "...                                ...         ...  \n",
              "1219  1fc0f648521b4af882a2f95db57e947b  PMC9556799  \n",
              "1220  400fdc45284e4336a9d4d2ed0a88e928  PMC9556799  \n",
              "1221  f06e07ee624e49de824cb35e524cef19  PMC9556799  \n",
              "1222  a04c0a5ddb544b91a90c308a89e267d9  PMC9556799  \n",
              "1223  af85dcd07def41358eaa7a59139350c1  PMC9556799  \n",
              "\n",
              "[1224 rows x 5 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-ae31aae0-560b-49ad-94b5-c77d5e05bd2e\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>text</th>\n",
              "      <th>text_ner</th>\n",
              "      <th>text_ner_label</th>\n",
              "      <th>idx</th>\n",
              "      <th>article_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>Since the 1990s, the repositioning of (sildena...</td>\n",
              "      <td>Since the 1990s, the repositioning of (drug: s...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>At the beginning of the 21st century, cheminfo...</td>\n",
              "      <td>At the beginning of the 21st century, cheminfo...</td>\n",
              "      <td>At the beginning of the 21st century, cheminfo...</td>\n",
              "      <td>45575790fc88453a90d6e15b0474e89d</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>cheminformatics, bioinformatics, systems biolo...</td>\n",
              "      <td>cheminformatics, bioinformatics, systems biolo...</td>\n",
              "      <td>cheminformatics, bioinformatics, systems biolo...</td>\n",
              "      <td>ac22ae2fbeb14ca5baf01f3b0022cd57</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Today, drug repositioning is increasingly prom...</td>\n",
              "      <td>Today, drug repositioning is increasingly prom...</td>\n",
              "      <td>Today, drug repositioning is increasingly prom...</td>\n",
              "      <td>ae1f33d77559408bb43f914ac3aa8b88</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>The bibliometric approach can solve the aforem...</td>\n",
              "      <td>The bibliometric approach can solve the aforem...</td>\n",
              "      <td>The bibliometric approach can solve the aforem...</td>\n",
              "      <td>82ab09f0f9bd4539b612bc196d0aa7b8</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1219</th>\n",
              "      <td>For mapping score, the score is set as the inv...</td>\n",
              "      <td>For mapping (score), the (score) is set as the...</td>\n",
              "      <td>For mapping (measurement: score), the (measure...</td>\n",
              "      <td>1fc0f648521b4af882a2f95db57e947b</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1220</th>\n",
              "      <td>For host gene score, host gene score got 1 poi...</td>\n",
              "      <td>For host gene (score), host gene (score) got 1...</td>\n",
              "      <td>For host gene (measurement: score), host gene ...</td>\n",
              "      <td>400fdc45284e4336a9d4d2ed0a88e928</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1221</th>\n",
              "      <td>The score for each drug is equal to the sum of...</td>\n",
              "      <td>The (score) for each drug is equal to the sum ...</td>\n",
              "      <td>The (measurement: score) for each drug is equa...</td>\n",
              "      <td>f06e07ee624e49de824cb35e524cef19</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1222</th>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>We used gene expression profiles of (SARS-CoV-...</td>\n",
              "      <td>We used gene expression profiles of (disease: ...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1223</th>\n",
              "      <td>We take as ground truth all drugs currently in...</td>\n",
              "      <td>We take as ground truth all drugs currently in...</td>\n",
              "      <td>We take as ground truth all drugs currently in...</td>\n",
              "      <td>af85dcd07def41358eaa7a59139350c1</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>1224 rows × 5 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-ae31aae0-560b-49ad-94b5-c77d5e05bd2e')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-ae31aae0-560b-49ad-94b5-c77d5e05bd2e button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-ae31aae0-560b-49ad-94b5-c77d5e05bd2e');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-c77ce6a7-c39f-437a-9f32-fbe682566f21\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-c77ce6a7-c39f-437a-9f32-fbe682566f21')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-c77ce6a7-c39f-437a-9f32-fbe682566f21 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "full_data",
              "summary": "{\n  \"name\": \"full_data\",\n  \"rows\": 1224,\n  \"fields\": [\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1224,\n        \"samples\": [\n          \"COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.\",\n          \"Meanwhile, many Indian pharmaceutical firms confirmed preliminary results from phase 3 studies with Molnupiravir in mild/moderate COVID-19 patient populations in India.\",\n          \"Nevertheless, CADD is not well\\u2010suited to high\\u2010throughput screening HTS when focusing on the bio\\u2010security requirements of SARS\\u2010CoV\\u20102.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text_ner\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1224,\n        \"samples\": [\n          \"(COVID-19) is an (infectious disease) caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of (severe acute respiratory syndromes) (SARS Cov-2).\",\n          \"Meanwhile, many Indian pharmaceutical firms confirmed preliminary results from phase 3 studies with (Molnupiravir) in mild/moderate (COVID-19) patient populations in India.\",\n          \"Nevertheless, CADD is not well\\u2010suited to high\\u2010throughput screening HTS when focusing on the bio\\u2010security requirements of (SARS\\u2010CoV\\u20102).\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text_ner_label\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1224,\n        \"samples\": [\n          \"(disease: COVID-19) is an (disease: infectious disease) caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of (disease: severe acute respiratory syndromes) (disease: SARS Cov-2).\",\n          \"Meanwhile, many Indian pharmaceutical firms confirmed preliminary results from phase 3 studies with (drug: Molnupiravir) in mild/moderate (disease: COVID-19) patient populations in India.\",\n          \"Nevertheless, CADD is not well\\u2010suited to high\\u2010throughput screening HTS when focusing on the bio\\u2010security requirements of (disease: SARS\\u2010CoV\\u20102).\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"idx\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1224,\n        \"samples\": [\n          \"61ed3a0232b84f2fb1798597668e7b32\",\n          \"488c9cfee5e64d6e8bbe98e0ffdf0aff\",\n          \"f366cc7ae5e94b799b2c5273de47b081\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"article_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 10,\n        \"samples\": [\n          \"PMC9694939\",\n          \"PMC9539342\",\n          \"PMC9527439\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "text_ner_labels_data.to_json('2024-06-10_text_ner_labels_1224_edited.json', orient='records')"
      ],
      "metadata": {
        "id": "Pb_2eoHFJZR5"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Load JSON file\n",
        "with open('2024-06-10_text_ner_labels_1224_edited.json', 'r') as f:\n",
        "    text_ner_labels_data = json.load(f)"
      ],
      "metadata": {
        "id": "-ZGl6t-gJZSE"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# display sample sentence\n",
        "text_ner_labels_data[1219]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "57ce91ad-232d-4de6-88a6-97788201da0e",
        "id": "t8-hasAQJZSF"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'text': 'For mapping score, the score is set as the inverse of the number of genes.',\n",
              " 'text_ner': 'For mapping (score), the (score) is set as the inverse of the number of genes.',\n",
              " 'text_ner_label': 'For mapping (measurement: score), the (measurement: score) is set as the inverse of the number of genes.',\n",
              " 'idx': '1fc0f648521b4af882a2f95db57e947b',\n",
              " 'article_id': 'PMC9556799'}"
            ]
          },
          "metadata": {},
          "execution_count": 10
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### 8.3 Multiple-entity sentences\n",
        "\n",
        "\n",
        "We will also keep a subset of sentences with two or more entities which could be used for sentence-level relation extraction, as there would need to be a minimum of two entities in a sentence for there to be a relation between them.\n",
        "\n"
      ],
      "metadata": {
        "id": "QGAau4d5RSfT"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_multiple_entities = kazu_entities_only[kazu_entities_only.duplicated('idx', keep=False)]"
      ],
      "metadata": {
        "id": "RG-tnlnNO5fN"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(kazu_multiple_entities)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "fntm4qyePA3e",
        "outputId": "93664228-0546-4df9-8f13-61200f4dc1e2"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "2946"
            ]
          },
          "metadata": {},
          "execution_count": 27
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_multiple_entities = kazu_multiple_entities.reset_index(drop=True)"
      ],
      "metadata": {
        "id": "JJjxcoYDPJ6W"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_multiple_entities.info()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "N4dcfgscP2ZR",
        "outputId": "a1dcb299-52ad-4725-85fe-dc741c360622"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "RangeIndex: 2946 entries, 0 to 2945\n",
            "Data columns (total 8 columns):\n",
            " #   Column       Non-Null Count  Dtype \n",
            "---  ------       --------------  ----- \n",
            " 0   entity_id    2946 non-null   object\n",
            " 1   entity_type  2946 non-null   object\n",
            " 2   entity       2946 non-null   object\n",
            " 3   span_start   2946 non-null   Int64 \n",
            " 4   span_end     2946 non-null   Int64 \n",
            " 5   text         2946 non-null   object\n",
            " 6   idx          2946 non-null   object\n",
            " 7   article_id   2946 non-null   object\n",
            "dtypes: Int64(2), object(6)\n",
            "memory usage: 190.0+ KB\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_multiple_entities"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "L8of7eJ9PZtR",
        "outputId": "3ad52bd2-8783-4994-8339-9415f81c9ecc"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                              entity_id  entity_type  \\\n",
              "0                      chembl:CHEMBL192         drug   \n",
              "1                            HP:0100639      disease   \n",
              "2                         MONDO:0005149      disease   \n",
              "3                      chembl:CHEMBL894         drug   \n",
              "4                      chembl:CHEMBL468         drug   \n",
              "...                                 ...          ...   \n",
              "2941                      STATO:0000569  measurement   \n",
              "2942                      STATO:0000569  measurement   \n",
              "2943                              covid      disease   \n",
              "2944                         CL:0002063    cell_type   \n",
              "2945  African green monkey kidney cells    cell_type   \n",
              "\n",
              "                                 entity  span_start  span_end  \\\n",
              "0                            sildenafil          38        48   \n",
              "1             male erectile dysfunction          53        78   \n",
              "2                pulmonary hypertension          83       105   \n",
              "3                             bupropion         144       153   \n",
              "4                           thalidomide         197       208   \n",
              "...                                 ...         ...       ...   \n",
              "2941                              score          14        19   \n",
              "2942                              score          31        36   \n",
              "2943                SARS-CoV-2 infected          36        55   \n",
              "2944             alveolar type II cells          89       111   \n",
              "2945  African green monkey kidney cells         116       149   \n",
              "\n",
              "                                                   text  \\\n",
              "0     Since the 1990s, the repositioning of sildenaf...   \n",
              "1     Since the 1990s, the repositioning of sildenaf...   \n",
              "2     Since the 1990s, the repositioning of sildenaf...   \n",
              "3     Since the 1990s, the repositioning of sildenaf...   \n",
              "4     Since the 1990s, the repositioning of sildenaf...   \n",
              "...                                                 ...   \n",
              "2941  For host gene score, host gene score got 1 poi...   \n",
              "2942  For host gene score, host gene score got 1 poi...   \n",
              "2943  We used gene expression profiles of SARS-CoV-2...   \n",
              "2944  We used gene expression profiles of SARS-CoV-2...   \n",
              "2945  We used gene expression profiles of SARS-CoV-2...   \n",
              "\n",
              "                                   idx  article_id  \n",
              "0     22200652f00d4d5fb5875f619734eaed  PMC9549161  \n",
              "1     22200652f00d4d5fb5875f619734eaed  PMC9549161  \n",
              "2     22200652f00d4d5fb5875f619734eaed  PMC9549161  \n",
              "3     22200652f00d4d5fb5875f619734eaed  PMC9549161  \n",
              "4     22200652f00d4d5fb5875f619734eaed  PMC9549161  \n",
              "...                                ...         ...  \n",
              "2941  400fdc45284e4336a9d4d2ed0a88e928  PMC9556799  \n",
              "2942  400fdc45284e4336a9d4d2ed0a88e928  PMC9556799  \n",
              "2943  a04c0a5ddb544b91a90c308a89e267d9  PMC9556799  \n",
              "2944  a04c0a5ddb544b91a90c308a89e267d9  PMC9556799  \n",
              "2945  a04c0a5ddb544b91a90c308a89e267d9  PMC9556799  \n",
              "\n",
              "[2946 rows x 8 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-f6b6350f-b826-4eca-9eb0-88f01e714e5d\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>entity_id</th>\n",
              "      <th>entity_type</th>\n",
              "      <th>entity</th>\n",
              "      <th>span_start</th>\n",
              "      <th>span_end</th>\n",
              "      <th>text</th>\n",
              "      <th>idx</th>\n",
              "      <th>article_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>chembl:CHEMBL192</td>\n",
              "      <td>drug</td>\n",
              "      <td>sildenafil</td>\n",
              "      <td>38</td>\n",
              "      <td>48</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>HP:0100639</td>\n",
              "      <td>disease</td>\n",
              "      <td>male erectile dysfunction</td>\n",
              "      <td>53</td>\n",
              "      <td>78</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>MONDO:0005149</td>\n",
              "      <td>disease</td>\n",
              "      <td>pulmonary hypertension</td>\n",
              "      <td>83</td>\n",
              "      <td>105</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>chembl:CHEMBL894</td>\n",
              "      <td>drug</td>\n",
              "      <td>bupropion</td>\n",
              "      <td>144</td>\n",
              "      <td>153</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>chembl:CHEMBL468</td>\n",
              "      <td>drug</td>\n",
              "      <td>thalidomide</td>\n",
              "      <td>197</td>\n",
              "      <td>208</td>\n",
              "      <td>Since the 1990s, the repositioning of sildenaf...</td>\n",
              "      <td>22200652f00d4d5fb5875f619734eaed</td>\n",
              "      <td>PMC9549161</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2941</th>\n",
              "      <td>STATO:0000569</td>\n",
              "      <td>measurement</td>\n",
              "      <td>score</td>\n",
              "      <td>14</td>\n",
              "      <td>19</td>\n",
              "      <td>For host gene score, host gene score got 1 poi...</td>\n",
              "      <td>400fdc45284e4336a9d4d2ed0a88e928</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2942</th>\n",
              "      <td>STATO:0000569</td>\n",
              "      <td>measurement</td>\n",
              "      <td>score</td>\n",
              "      <td>31</td>\n",
              "      <td>36</td>\n",
              "      <td>For host gene score, host gene score got 1 poi...</td>\n",
              "      <td>400fdc45284e4336a9d4d2ed0a88e928</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2943</th>\n",
              "      <td>covid</td>\n",
              "      <td>disease</td>\n",
              "      <td>SARS-CoV-2 infected</td>\n",
              "      <td>36</td>\n",
              "      <td>55</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2944</th>\n",
              "      <td>CL:0002063</td>\n",
              "      <td>cell_type</td>\n",
              "      <td>alveolar type II cells</td>\n",
              "      <td>89</td>\n",
              "      <td>111</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2945</th>\n",
              "      <td>African green monkey kidney cells</td>\n",
              "      <td>cell_type</td>\n",
              "      <td>African green monkey kidney cells</td>\n",
              "      <td>116</td>\n",
              "      <td>149</td>\n",
              "      <td>We used gene expression profiles of SARS-CoV-2...</td>\n",
              "      <td>a04c0a5ddb544b91a90c308a89e267d9</td>\n",
              "      <td>PMC9556799</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>2946 rows × 8 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-f6b6350f-b826-4eca-9eb0-88f01e714e5d')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-f6b6350f-b826-4eca-9eb0-88f01e714e5d button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-f6b6350f-b826-4eca-9eb0-88f01e714e5d');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-aeae0f07-69ea-4305-84d2-e21c3e11fb80\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-aeae0f07-69ea-4305-84d2-e21c3e11fb80')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-aeae0f07-69ea-4305-84d2-e21c3e11fb80 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "  <div id=\"id_21767d62-6a00-4e34-be91-30fcfbdfe008\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('kazu_multiple_entities')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_21767d62-6a00-4e34-be91-30fcfbdfe008 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('kazu_multiple_entities');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "kazu_multiple_entities",
              "summary": "{\n  \"name\": \"kazu_multiple_entities\",\n  \"rows\": 2946,\n  \"fields\": [\n    {\n      \"column\": \"entity_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 838,\n        \"samples\": [\n          \"cellosaurus:0609\",\n          \"UBERON:0004535\",\n          \"chembl:CHEMBL266158\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity_type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 11,\n        \"samples\": [\n          \"cell_type\",\n          \"drug\",\n          \"go_bp\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"entity\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 986,\n        \"samples\": [\n          \"NSPs\",\n          \"Lys6822\",\n          \"amoebiasis\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_start\",\n      \"properties\": {\n        \"dtype\": \"Int64\",\n        \"num_unique_values\": 438,\n        \"samples\": [\n          127,\n          80,\n          272\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"span_end\",\n      \"properties\": {\n        \"dtype\": \"Int64\",\n        \"num_unique_values\": 442,\n        \"samples\": [\n          182,\n          404,\n          377\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 723,\n        \"samples\": [\n          \"Several of the chemokine receptors e.g., CXCR3 and CXCR4 have also been shown to be upregulated during cytokine storm-like symptoms as upon binding of Several of the chemokine receptors e.g., CXCR3 and CXCR4's natural ligands e.g., CXCL12, inflammation is promoted and chemotaxis induces apoptosis potentially leading to significant tissue damage as seen in COVID-19 cases.\",\n          \"Clustering was performed on the drugs and quality score was computed to adjust the network similarity and finally normalization of similarity score was carried out using sigmoid function.\",\n          \"Dasabuvir showed the least binding free energy \\u221242.151 KJ/mol among 6M71, 6M71-Dasabuvir, Ribavirin, and Sofosbuvir complexes.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"idx\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 723,\n        \"samples\": [\n          \"9d02a97486c946329297203c13d1615c\",\n          \"82bc185d2ecf44ef840d9c9965a1d34f\",\n          \"568e23dea5764ea088f5371d20e2d853\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"article_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 10,\n        \"samples\": [\n          \"PMC9694939\",\n          \"PMC9539342\",\n          \"PMC9527439\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 29
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-05-10_kazu_multiple_entities_2946.pickle', 'wb') as f:\n",
        "  pickle.dump(kazu_multiple_entities, f)"
      ],
      "metadata": {
        "id": "g89p0oQ5PuEZ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will get a count of unique sentences with more than one entity."
      ],
      "metadata": {
        "id": "8h7qKmwovTox"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Count unique sentences with > 1 entity\n",
        "kazu_multiple_entities['idx'].nunique()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "594a6821-bc01-4f9f-df30-c657efdbee1c",
        "id": "sCICTDS-EqPU"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "723"
            ]
          },
          "metadata": {},
          "execution_count": 53
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_multi_ents_unique_sents = kazu_multiple_entities['text'].unique()"
      ],
      "metadata": {
        "id": "AF2OBeXYEqPc"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_multi_ents_unique_sents"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "w2KqL6X_R4KB",
        "outputId": "3773c7cd-5302-49ff-e859-eb67deec9d7e"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "array(['Since the 1990s, the repositioning of sildenafil for male erectile dysfunction and pulmonary hypertension, the development of a new efficacy of bupropion for smoking cessation, new applications of thalidomide for multiple myeloma, and chronic graft-versus-host disease have generated intense interest from pharmaceutical companies and academics.',\n",
              "       'Today, drug repositioning is increasingly prominent in the development of drugs for a variety of neurological diseases, cancer, rare diseases, and infectious diseases.',\n",
              "       'the top 30 most used author keywords include five diseases COVID-19/SARS-CoV-2/Coronavirus, Cancer, Alzheimer’s disease, Breast cancer, and Chagas disease.',\n",
              "       'Drug names appear four times, Antiviral drugs, Metformin, Statins, and Antibiotics, which reveal the diseases and applications to which drugs were often repositioned during recent years.',\n",
              "       'In the context of the pandemic in that year, there was a surge in research on the subject, with COVID-19/SARS-CoV-2/Coronavirus topping the list of keywords as soon as COVID-19/SARS-CoV-2/Coronavirus appeared that year.',\n",
              "       'Therefore, high-quality studies of the keywords COVID-19/SARS-CoV-2/Coronavirus, Virtual screening, and Molecular docking were surveyed, as shown in the bubble chart, in the past two years, reflecting the relevant research trend in recent years.',\n",
              "       'After a series of drug repurposing computational screens and various validation activities by several scientists, it was agreed that raltegravir, clonidine, chloroquine and hydroxychloroquine have therapeutic effects in the treatment of novel coronavirus.',\n",
              "       'One of Nine studies, entitled Alcohol-abuse drug disulfiram targets cancer via p97 segregase adapter NPL4, published in Nature in 2017 by Skrott, Z et al. is a collaboration between scholars from six countries Czech Republic, the United States, Denmark, Sweden, Switzerland, and China.',\n",
              "       'The most cited publication on an annual basis was Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, published in 2020, which was authored by Zhou, YD et al. and was the highest annual average cited publication with 609 citations.',\n",
              "       'Metformin has been found by many scientists to have a good inhibitory effect on various tumors, mainly in gynecology, and Metformin has become a specific drug that has been most frequently mentioned in drug reuse in recent years.',\n",
              "       'In terms of antiviral drugs, scholars not only use drug repositioning to find antiviral drugs to treat diseases, such as Ebola and HIV, that have plagued humans for a long time but also use drug repositioning to seek treatments for infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world.',\n",
              "       'For infectious diseases, such as Zika virus and novel coronaviruses that have threatened several countries and even the world, emergency research on drug repositioning has played an important role in reducing mortality, calming patient fears, and restoring economic production when no specific drugs or vaccines were initially available during the pandemic.',\n",
              "       'The combination of precision medicine and drug repositioning studies, often used to seek treatments for rare diseases and, in particular, genetically related diseases, is expected to be fully developed in the future.',\n",
              "       'Coronaviruses CoVs are cross‐species viruses and can spread expeditiously into new host species, which in turn cause epidemic diseases.',\n",
              "       'The whole members of the CoV family have a similar genome sequence, and the severe acute respiratory syndrome CoV SARS‐CoV and Middle East respiratory syndrome CoV MERS‐CoV are considered the two prototypical well‐known CoVs Aghamirza Moghim Aliabadi et al., Seidi et al., Yin & Wunderink.',\n",
              "       'The new CoV, identified as COVID‐19 and caused by SARS‐CoV‐2, has a very similar genome sequence to the severe acute respiratory syndrome CoV SARS‐CoV C. Wang et al. The lack of effective drugs led to considerable unwholesomeness and death rate of SARS‐CoV‐2, especially in 2020 and 2021, when a novel coronavirus strain brought about a fatal respiratory illness.',\n",
              "       \"Although effective vaccines have amazingly reduced the COVID‐19 cases recently, effective vaccines will not change the world right away, and importantly, effective vaccines's permanent efficacy, short‐term and long‐term side effects, and long‐term protection against different variants of SARS‐CoV‐2 are still under debate.\",\n",
              "       'To accelerate this process, repositioning broad‐spectrum antiviral drugs can be a potential strategy concerning the presence of the pharmacokinetic, pharmacodynamic, and toxicity data of broad‐spectrum antiviral drugs Serafin et al. For instance, the efficacy of some antiviral drugs with previously known treatment of hepatitis, HIV, influenza, and Ebola viral diseases has been investigated.',\n",
              "       \"These agents, including adefovir, foscarnet, tenofovir, sofosbuvir, and uprifosbuvir, have phosphoramide and phosphate with various azole rings in some antiviral drugs with previously known treatment of hepatitis, HIV, influenza, and Ebola viral diseases's structures.\",\n",
              "       \"By assessing some antiviral drugs with previously known treatment of hepatitis, HIV, influenza, and Ebola viral diseases's effectiveness against COVID‐19, remdesivir was the one that grabbed much attention and is believed to be the most successful drug for the therapy for combating COVID‐19 Brown et al., Gholivand et al. Further potential macromolecular targets of SARS‐CoV‐2 are depicted in Figure.\",\n",
              "       'Therefore, finding the drugs that can target SARS‐CoV‐2 may decrease the possibility of mutation‐mediated drug resistance and show significant antiviral activity Pachetti et al. Thus, it is likely that CADD might be able to provide us with effective small molecules targeting the main receptors of SARS‐CoV‐2 with fully therapeutical and preventional‐oriented outlooks Muratov et al. The more recent update of FDA approval for COVID‐19 drug discovery shows that authorization of remdesivir inhibits the RNA‐dependent RNA polymerase RdRp of SARS‐CoV‐2, molnupiravir inhibition of viral reproduction through enhancing the vast mutations in the replication of viral RNA and paxlovid 3c‐like protease inhibitor for the treatment of mild‐to‐moderate COVID‐19.',\n",
              "       'These drugs are used for various viral diseases such as hepatitis C, Ebola virus, influenza, etc.',\n",
              "       'Vangeel et al. molnupiravir and remdesivir acted on the RdRp enzyme employed by SARS‐CoV‐2 to increase the transcription and replication capability of the viral RNA genome.',\n",
              "       'While some groups reported the promising results of remdesivir, others showed a lack of efficacy, and therefore, the Food and Drug Administration did not suggest using remdesivir Mahase.',\n",
              "       'Our focus in this paper is to explore the role of CADD on COVID‐19 most specifically, chemogenomics and DR, with potential examples of COVID‐19 drug discovery. Unfortunately, with boundless energy and time to discover a successful small molecule by utilizing various databases to inhibit the main protease Mpro of SARS‐CoV‐2 via several virtual screening VS approaches, there are no effective drugs that have been approved.',\n",
              "       'After lead discovery and development of drug‐like candidates and investigation of in vitro and in vivo results, the process of bringing an FDA‐approved medicine to market for COVID‐19 drug discovery will go into three phases, i.e., preclinical and, if successful, into clinical studies, and ultimately a marketed medicine after FDA approval Schaduangrat et al. It is where CADD is evolved as a valuable and powerful method to aid the challenging tasks of identifying small bioactive molecules and predicting targets.',\n",
              "       'high‐throughput screening HTS enables us to screen the entire compound library of either number of chemicals or biological compounds in a target‐based assay or even a cell‐based assay to obtain the desired biological response Bittker & Ross, Maghsoudi et al. It can spring to the mind that the stringent requirement of large resources of targets and ligands in HTS makes HTS expensive and time‐consuming, and we should overlook the use of the useless ligands having no probability of showing success. But, the CADD technologies are very powerful and able to address this issue easily by employing virtual high‐throughput screening vHTS that uses virtual compound libraries and allows experimentalists to focus on ligands which are more likely to have any activity of interest Leelananda & Lindert.',\n",
              "       'In the first days of COVID‐19 outbreak, vHTS was employed and developed efficiently to investigate a group of approved drugs to identify the possible anti‐SARS‐CoV‐2 agents at the National Center for Advancing Translational Sciences NCATS of the National Institutes of Health NIH, embracing a broad spectrum of the SARS‐CoV‐2 life cycle, such as viral entry, viral replication, in vitro infectivity, and live virus infectivity Xu et al. Many possible drug candidates were selected for targeting various stages of the SARS‐CoV‐2 life cycle.',\n",
              "       'For instance, cepharanthine, an anti‐inflammatory compound, effectively showed ability to rescue the cytopathic effects CPEs of SARS‐CoV‐2 Rogosnitzky et al., or corilagin, a possible antifibrosis, revealed potential against the angiotensin‐converting enzyme ACE2 receptor‐binding domain RBD Yang et al. Therefore, it is urgent to This strategy a high bio‐safety SARS‐CoV‐2 infection model with a high ability for HTS of drugs against SARS‐CoV‐2.',\n",
              "       'Muratov et al. found that the combinations of four of 32 drugs, including nitazoxanide, remdesivir, amodiaquine, and umifenovir, could synergize against SARS‐CoV‐2.',\n",
              "       'Interestingly, the combination of nitazoxanide and remdesivir showed a great synergistic interaction, and the combination of remdesivir and hydroxychloroquine exhibited a powerful antagonist role against SARS‐CoV‐2 Bobrowski et al. The two proteins pp1a and pp1ab are quickly translated after entry into the host cells and further separated by two viral proteases, 3 C‐like proteases 3CLpro and papain‐like protease PLpro Amin et al. papain‐like protease PLpro is a critical virus enzyme responsible for producing a functional replicase complex and stimulating viral spread Shin et al. Amin et al used chemical‐informatics approaches to build a Monte Carlo optimization based on a QSAR data of various papain‐like protease PLpro inhibitors, b VS to choose the best in‐house molecules among 67 with the high likelihood of targeting against papain‐like protease PLpro, and c eventually verification of these inhibitors by using receptor–ligand interaction investigation.',\n",
              "       'The National Center for Advancing Translational Sciences NCATS analyzed 11 of 42 inhibitors which were potential compounds, and three of 11 of total 42 hits which were potential compounds, cenicriviroc AC50 of 8.9 M, proglumetacin tested twice independently, with AC50 of 8.9 M and 12.5 M, and sufugolix AC50 12.6 M. While molecular docking was unsuccessful to accurately distinguish between experimentally active and inactive compounds, QSAR was able to identify three inhibitors of SARS‐CoV‐2 replication through Mpro inhibition.',\n",
              "       'Overall, these results show that QSAR models proposed using SARS‐CoV‐2 Mpro data can be useful to introduce compounds active against SARS‐CoV‐2 Alves et al. This strategy relies more on target information.',\n",
              "       'In other words, docking enables us to identify novel drug candidates by predicting ligand–target interactions at a molecular level Pinzi & Rastelli, Sargazi et al. There are several references in which the significant role and applications of docking in drug design and development have been discussed De Vivo & Cavalli, Keretsu et al., Kitchen et al., Meng et al. Furthermore, in the current spread of SARS‐CoV‐2, molecular docking is important in screening potential drugs Keretsu et al., Lokhande et al., Marinho et al., Yu et al. The recent work of Khelfaoui et al. could be a good example of using molecular docking combined with MD to find promising candidate drugs against COVID‐19.',\n",
              "       'Khelfaoui et al. selected a library of 18 drugs that three of which include ramipril, delapril, and lisinopril, bound to angiotensin‐converting enzyme 2 ACE2 receptor and SARS‐CoV‐2/ACE2 complex well.',\n",
              "       'angiotensin‐converting enzyme 2 ACE2 receptor is one of the receptors in the human body with which the S proteins from coronaviruses have a great binding affinity and serve as the entry point into cells for SARS‐CoV‐2.',\n",
              "       \"Using VS and molecular docking, Muratov et al. identified some promising antimicrobial and chemotherapeutic agents having coumarin and pyridine derivatives in some promising antimicrobial and chemotherapeutic agents having coumarin and pyridine derivatives in their structures's structures.\",\n",
              "       'In order to identify the most potential drug–target interactions, a molecular operating environment MOE program was carried out against the human ACE2, SARS‐CoV‐main peptidase, serine protease hepsin, human coronavirus papain‐like proteases, and SARS‐Coronavirus NSP12.',\n",
              "       'As shown in Figure, among compounds a, b, c, d, and e with binding score energy values of −6.08, −6.48, −6.78, −7.08, and −6.63, respectively, compound d had the binding score energy against the aforementioned targets.',\n",
              "       'Thus, compound d needs to be additionally evaluated in clinical trials as a candidate for potential inhibitor of the SARS‐CoV‐2 Abdellatiif et al. Hosseini et al. evaluated a virtual screening using docking of 1615 FDA‐approved drugs to identify novel potential inhibitors for protease protein of COVID‐19.',\n",
              "       'Hosseini et al. showed that among all investigated FDA‐approved drugs, simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor, manifested high affinity to protease binding pocket and placed effectively into protease binding pocket more beneficially than the lopinavir‐ritonavir.',\n",
              "       'This study suggested simeprevir, a Hepatitis C virus HCV NS3/4A protease inhibitor as a potential inhibitor of COVID‐19 Hosseini et al.. In another docking study, Motiwale et al. worked to identify potential inhibitors against Mpro of SARS‐CoV‐2 from previously reported SARS‐3CL protease inhibitors where among 61 previously reported potential inhibitors, 4‐benzoic acid and 4‐ 4‐methoxyphenyl ‐6‐oxo‐2‐ 2‐phenylethyl sulfanyl ‐1,6‐dihydropyrimidine‐5‐carbonitrile revealed a minimum and maximum binding energy, respectively Motiwale et al. Table presents a selection of recent studies that researched the docking strategy of different pharmacological classes as treatments of SARS‐Co and SARS‐CoV‐2.',\n",
              "       'Although many studies are carried out and many drugs are being tested to open a new road for effective treatment of COVID‐19, there are no fully beneficial antiviral drugs against COVID‐19.',\n",
              "       'The ultimate goal of chemogenomics is the rapid screening as well as the rational development of target‐specific chemical ligands to decrease the cost and enhance the drug discovery period, especially in the case of COVID‐19 drug investigation Jones & Bunnage.',\n",
              "       \"Nevertheless, no existing target data thus, by applying the chemogenomics strategy, the hypotheses can be generated of the target by comparing the new biological compounds to the same known target Fourches et al., Weston et al. For example, the target receptors or proteins that are necessary for replication and survival of SARS‐CoV‐2 are viral proteases involving papain‐like protease PLpro, the 3‐chymotrypsin‐like protease 3CLpro, and Mpro, RNA‐dependent RNA polymerase RdRp complex, the spike S receptor binding glycoprotein, the nucleocapsid N protein, nonstructural protein NSP, and the membrane M protein including transmembrane TM as well as small envelope E protein Cavasotto et al. As an example of this part, it can be referred to the work of Mishra and Mishra's coworkers that reported an inclusive computational approach for the identification of drug molecules that are multi‐targeted struggling with the SARS‐CoV‐2 proteins.\",\n",
              "       'drug molecules that are multi‐targeted struggling with the SARS‐CoV‐2 proteins are essentially included in virus replication inside the host body, the viral–host interaction, disease development, and transmission of SARS‐CoV‐2 infection.',\n",
              "       'Mishra and his coworkers screened 72 potential antiviral drugs approved by the FDA against the S glycoprotein, hACE2, the 3‐chymotrypsin‐like protease 3CLpro, Cathepsin L, N protein, RdRp, and NSP6 proteins.',\n",
              "       \"Mishra and his coworkers's finding showed favorable results for seven drugs, among which catechin flavan‐3‐ol can effectively bind to the 3‐chymotrypsin‐like protease 3CLpro, Cathepsin L, RBD of S protein, nonstructural protein NSP, and the nucleocapsid N protein to be used as a potential multi‐targeted agent in combating SARS‐CoV‐2.\",\n",
              "       'However, due to the limited timeframe of combating SARS‐CoV‐2, it is not realistic to be assured of finding a definitive therapy for combating SARS‐CoV‐2.',\n",
              "       \"Hence, vigorous attempts are still continuing for the DR as a clinical treatment strategy to fight COVID‐19 Mishra et al. In another research, Omotuyi et al. investigated molecular docking protocols for fast screening of the the FDA database for high‐affinity interaction of the resolved 3D structure of SARS‐CoV‐2 receptor‐binding domain RBD in complex with SARS‐CoV‐2 receptor‐binding domain RBD's receptor hACE‐2 interface.\",\n",
              "       'Omotuyi et al. reported that UBR breaks the interaction at the RBD/ACE‐2 interface residues of SARS‐CoV‐2 RBD/ACE‐2 complex that might result in protein function losses with direct inference on the oligomerization in RBD and function loss in ACE‐2.',\n",
              "       'Therefore, UBR exhibits a novel therapeutic candidate in combating SARS‐CoV‐2 since UBR binds to proportionally high affinity with free RBD, ACE‐2 receptor, and SARS‐CoV‐2 RBD/ACE‐2 complex based on only binding affinity calculations Omotuyi et al.. The other studies in this area are demonstrated in Table.',\n",
              "       'Application of a methodology for preclinical computational DR called DrugMerge to COVID‐19 shows that a methodology for preclinical computational DR called DrugMerge can mimic human expert judgment Lucchetta, M. and M. Pellegrini.',\n",
              "       'Rima Hajjo and Alexander Tropsha reported that the identification of Bacillus Calmette–Guérin BCG and small molecules of Bacillus Calmette–Guérin BCG mimics involving antiviral drugs raltegravir, emetine, and lopinavir as high confidence hits are capable of boosting immunity and preventing emerging new viruses.',\n",
              "       \"Rima Hajjo and Alexander Tropsha's results approved that Bacillus Calmette–Guérin BCG impacted the generation and maturation of naïve T cells, resulting in increasing long‐lasting trained intrinsic immune replies to combat novel viruses, including SARS‐CoV‐2 in vitro as a protective measurement from the lethal consequences Onozuka et al. Due to the lengthy development cycle of novel drugs, DR turns into an efficient approach to screening drugs of potential therapeutic use for SARS‐CoV‐2.\",\n",
              "       'The experimental outputs prove that the models can predict drug–disease interaction effectively for normal diseases and SARS‐CoV‐2 Lv et al. Therefore, DR presents a constant source of novel knowledge in virus biology and molecules with previously undefined antiviral properties, which can be applied as molecular tools in unknown molecular mechanisms of virus replication and pathogenesis Mercorelli et al. Further investigation of SARS‐CoV‐2 in related research is summarized in Table.',\n",
              "       'A myriad of compounds represent potential drug candidates, but merely a few of potential drug candidates will be formulated, approved, and registered as a drug for individual health issues which investigation for that compound will be a long, intricate, and costly process, while sometimes there is an urgent need for developing a drug like COVID‐19 pandemic Muratov et al. Table demonstrates chemogenomics related to COVID‐19 research.',\n",
              "       'DR has emerged as an alternative way of accelerating the process of developing new treatments against COVID‐19 Yu et al. Based on data brought from PubMed, the number of works of literature on DR has been growing dramatically, and the number of works of literature on DR has increased since the outbreak of SARS‐CoV‐2 Galindez et al. It should be noted that polypharmacolgy and DR are inextricably interrelated with each other Cheng.',\n",
              "       'Sildenafil is considered the most prominent one, beginning with cardiovascular treatment followed by accidentally treating erectile dysfunction clinical trial and later in low dosages, treating pulmonary hypertension Ghofrani et al., Prasad et al. Furthermore, as repurposed drugs pass the preliminary clinical trials phase I or safety level, the time needed for drugs to reach the market can be reduced significantly.',\n",
              "       'The history of discovering the effect of an established drug on new indications dates back to World War II, since considerable improvement had been observed for cutaneous rashes and arthritis in soldiers who were under treatment with an antimalarial medicine, Chloroquine Schlitzer.',\n",
              "       'an antimalarial medicine, Chloroquine Schlitzer is a well‐known antimalarial drug that was synthesized in 1934 and later on demonstrated successful various therapeutic effects, including anti‐inflammatory/immunomodulating, anti‐infective, antithrombotic, and metabolic.',\n",
              "       'Furthermore, antitumoral properties make an antimalarial medicine, Chloroquine Schlitzer available for the treatment of a number of cancers Plantone & Koudriavtseva.',\n",
              "       'In 1942, Marcel Jonbon used sulfonamide antibiotics for typhoid treatment, but Marcel Jonbon faced hypoglycemia as an unexpected side effect in some patients therefore, sulfonamides presented the role of an anti‐diabetic drug Quianzon & Cheikh.',\n",
              "       'Aspirin is one of the most famous DR examples with an original indication as an analgesic drug that for the first time repositioned as an antiplatelet aggregation drug in 1980 and a second indication still is commonly used for cardiovascular problems Jourdan et al. Furthermore, several types of research have been conducted on the anticancer effect of aspirin such as colorectal cancer Drew et al., lung, and breast cancer Li, Hu, et al. The notable potential and extensive applications of DR in novel therapies are entirely apparent and accordingly, the number of acceptable research studies which have been done or are under processing are growing every day.',\n",
              "       'In contrast to experimental methods, computational drug repositioning methods which are mainly data‐driven utilizes databases and bioinformatics tools to find out interactions between drugs, targets, and diseases Pillaiyar et al. Analyzing a large type of data like chemical structures, gene expression, genotype or proteomic data, and electronic health records EHRs provides the possibility of understanding novel and unexpected functional gene interactions and unclear drug response or mechanisms of disease Pushpakom et al. Since there is no specific and registered therapy to cure the infection of SARS‐CoV‐2, finding effective therapeutics by applying existing drugs is a pressing exigency and established strategy Galindez et al. Concerning the time‐consuming regulatory process of the newly approved drugs, the DR strategy strongly utilizes the identification of new treatment methods by presenting FDA‐approved drugs.',\n",
              "       'Therefore, different categories of drugs are being repositioned in in vivo and in vitro studies to treat SARS‐CoV‐2 Wu et al. different categories of drugs are namely Ebola virus remdesivir, antimalarial chloroquine, anthelmintic and antiprotozoal drugs niclosamide, diarrhea nitazoxanide, antiviral lopinavir and ritonavir, antineoplastic carfilzomib and bortezomib, and antibacterial azithromycin.',\n",
              "       'In this regard, the WHO supported repositioning remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine as a potential for COVID‐19, although most might be only supportive symptomatic Won & Lee.',\n",
              "       'Nevertheless, remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine will likely be approved for COVID‐19 therapy if remdesivir, lopinavir/ritonavir, and chloroquine/hydroxychloroquine pass clinical trials and are published in literature and guidelines from leading health organizations Nain et al. In order to do this, many groups have been attempting enthusiastically to discover the first approved drug for COVID‐19 therapy Erlanson, Low et al., Muratov et al. As a result, we identified several clinical trials, in which 18 studies were at clinical phases 2, 3, or 4.',\n",
              "       'They found that Cys145‐His41/Ser144‐His163 could be the nucleophilic agent and acid responsible for hydrolysis of the substrate proteins, and Gly143 and Gln166 can form a hydrogen bond with the CO‐NH‐C ‐CO‐NH‐C structure of the backbone of the substrate protein.',\n",
              "       \"Among 25 possible agents, additionally, dipyridamole passed dipyridamole's first‐round clinical trials with considerable potencies Li, Hu, et al., Li, Li, et al. The network‐based methods have also given satisfying results in investigating the DTIs and CoV–host interactions.\",\n",
              "       'Zho et al. introduced 16 possible anti‐HCoV drugs such as melatonin, mercaptopurine, toremifene, mesalazine, and sirolimus from more than 2000 FDA‐approved drugs by applying a combination of network‐based approaches and systems pharmacology‐based network medicine platform with the ability to quantify the interactions between the drug targets and virus–host interactome in the human protein–protein interactions network.',\n",
              "       'Zhou et al. The docking screening method was applied for a set of 2201 approved drugs to find inhibitory activities at SARS‐CoV‐2 main protease, and based on that, carfilzomib, eravacycline, valrubicin, lopinavir, and elbasvir have nominated as an inhibitor for SARS‐CoV‐2 main protease Wang.',\n",
              "       'Various transcriptomic datasets in relation to SARS‐CoV‐2 were reported since the COVID‐19 outbreak.',\n",
              "       'Basically, the idea is that for a specific disease signature composing of a class of up and downregulated genes, if there is available drug candidate, where a class of up and downregulated genes are alternatively downregulated and up‐regulated, respectively, this drug might be potential for that disease Hoffmann et al., Le et al. Zho et al. investigated existing computational drug repositioning with remarkably reversed differential gene expression in comparison with manifold input signatures for SARS‐CoV‐2 effects on human cells.',\n",
              "       'Zho et al. tried to predict the potential drugs toward differentially expressed gene sets from both cell line and organoid disease models and human samples.',\n",
              "       \"In the end, Zho et al. found that 16 of Zho et al.'s high predicted hits showed antiviral assay in live SARS‐CoV‐2.\",\n",
              "       'Four potential inhibitors were tested for inhibition of SARS‐CoV‐2 in a human lung cell line, Calu‐3, infected with SARS‐CoV‐2.',\n",
              "       'Three drugs revealed in vitro antiviral efficacy—bacampicillin, clofazimine, and haloperidol with no toxicity effects Zho et al. Ge et al. used an integrative drug repositioning analysis through machine learning to integrate and mine large‐scale knowledge graph, literature together with transcriptome data to identify the potential compounds against SARS‐CoV‐2.',\n",
              "       'Ge et al. chose to work on CVL218, a poly‐ADP‐ribose polymerase 1 PARP1 inhibitor.',\n",
              "       'Ge et al. further revealed that CVL218, a poly‐ADP‐ribose polymerase 1 PARP1 inhibitor can effectively bind to the nucleocapsid N protein of SARS‐CoV‐2 and could suppress the LPS‐induced production of many inflammatory cytokine, which are highly related to the prevention of immunopathology induced by SARS‐CoV‐2 infection Zho et al.. Another PARP1 inhibitor, PJ‐34 was previously studied for acute inflammatory including inflammatory diseases of the lung.',\n",
              "       'It was observed that Another PARP1 inhibitor, PJ‐34 can interact with the N‐terminal domain of the nucleocapsid N protein of SARS‐CoV‐2 and decrease the RNA binding ability to inhibit virus replication Zho et al.. Beclabuvir is an antiviral drug for the treatment of hepatitis C virus HCV infection studied for inhibitory activity against SARS‐CoV‐2.',\n",
              "       'It was reported that Beclabuvir could be a potential compound for the treatment of SARS‐CoV‐2 through virtual screening and molecular docking in order to bind to RdRp of the SARS‐CoV‐2 Talluri.',\n",
              "       'Raltegravir belongs to a class of HIV integrase inhibitors used in the treatment of HIV‐1 infection.',\n",
              "       'Raltegravir obstructs the insertion of HIV‐1 DNA into the host cell genome.',\n",
              "       'Raltegravir was selected as a highly effective drug against Mpro and has been repurposed for the potential treatment of COVID‐19 in many studies Nabi et al. There has been considerable progress in the practical development and the rational application of computational drug discovery, giving rise to a paradigm shift in both industry and academics.',\n",
              "       'Over the last 3 years, the COVID‐19 pandemic has killed many people globally since there are no effective drugs against the COVID‐19 pandemic.',\n",
              "       'high‐throughput screening HTS lets us screen the entire compound library of the number of chemicals or biological compounds in a target‐based assay or even a cell‐based assay to obtain the desired biological response.',\n",
              "       'Hitherto, CADD is the only way for screening drugs against COVID‐19 and is based on a single viral protein or small‐scale drug screening of formerly FDA antiviral drugs utilizing SARS‐CoV‐2.',\n",
              "       'Moreover, using CADD, the crystal structure of the Mpro in complex with Michael acceptor inhibitor known as N3 can be determined Jin et al. It is also possible to identify drug leads against SARS‐CoV‐2 by targeting the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme performing a vital role in the life cycle of CoVs, including MERS‐CoV and SARS‐CoV‐2 Ul Qamar et al. Scientists employed vHTS tools to predict the 3D structure of the SARS‐CoV‐2 3CLpro enzyme by constructing a 3D homology model and screening the 3‐chymotrypsin‐like cysteine protease 3CLpro enzyme against 32297 potential antiviral phytochemicals/traditional Chinese medicinal compounds of a medicinal plant library.',\n",
              "       \"In addition, an interesting investigation based on an HTS assay employing a compound library of 2000 approved drugs and pharmacologically active compounds has also been carried out to find broad‐spectrum inhibitors against the replication of CoVs Shen et al. From Shen et al's HTS data, 56 hits were screened, and 36 compounds were validated in vitro using genetically engineered human CoV OC43 HCoV‐OC43.\",\n",
              "       'Consequently, seven effective compounds were selected as broad‐spectrum inhibitors in which lycorine protected BALB/c mice against lethal human coronavirus OC43 HCoV‐OC43, and emetine blocked MERS‐CoV entry following pseudo‐virus entry assays.',\n",
              "       'The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has resulted in a significant increase in morbidity and mortality around the world.',\n",
              "       'Finding therapies for The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 has taken a significant amount of time and effort.',\n",
              "       'The The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 pandemic has prompted the researchers and doctors to repurpose antiviral medications to combat SARSCoV-2 infection.',\n",
              "       'Regulatory authorities throughout the world have established fast-track methods to speed up the research and approval of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 therapeutics.',\n",
              "       'Many medicines have demonstrated potent activity against The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in animal/preclinical investigations and have progressed to human clinical trials, among which Molnupiravir being authorized for treatment of The severe acute respiratory syndrome coronavirus-2 SARS-CoV-2 -caused Coronavirus Disease 2019 COVID-19 in the United States, India, the United Kingdom, and other countries.',\n",
              "       'Because of the specific characteristics of the medicine for a mechanism, De novo identification and development of new molecular entities NME is arduous, time-consuming, and costly, and De novo identification and development of new molecular entities NME comes with a significant risk of failure.',\n",
              "       'Molnupiravir, commercialized as Lagevrio, is an orally bioavailable, directly acting antiviral therapeutic medicine that was initially approved to treat influenza.',\n",
              "       'Molnupiravir, commercialized as Lagevrio’s a precursor of -d-N4-hydroxycytidine, a new antiviral nucleoside analogue.',\n",
              "       'SARSCoV-2, seasonal or pandemic influenza, and MERS corona virus are all targets of Molnupiravir, commercialized as Lagevrio.',\n",
              "       'Molnupiravir, commercialized as Lagevrio was reported to be extremely effective in reducing nasopharyngeal infection rate and had a positive safety and tolerability record in COVID-19 patients who received short-course, 5-day treatment.– On 23 December 2021, FDA approved Molnupiravir, commercialized as Lagevrio under an EUA for the treatment of mild-to-moderate COVID-19 in individuals who have a positive consequences of SARSCoV-2 virus test and are at high risk of developing chronic COVID-19.',\n",
              "       'an EUA is granted for patients who have received a positive test from significant SARSCoV-2 viral testing, or who are at danger of developing severe COVID-19, which could result in hospitalization or death, or for whom other FDA-approved COVID-19 treatment options are not available or efficacious.',\n",
              "       'Molnupiravir, commercialized as Lagevrio is not approved for use in individuals under the age of 18, for the commencement of therapy in patients who require treatment due to COVID-19, for use for more than 5 days, or as a pre-exposure or post-exposure prophylactic for COVID-19 prevention.',\n",
              "       'Molnupiravir, commercialized as Lagevrio is not indicated for usage during pregnancy.',\n",
              "       'For 5 days, four capsules of Molnupiravir, commercialized as Lagevrio must be consumed per 12 h. Even if the patient feels well, it is critical to finish the entire 5-days course of therapy with Molnupiravir, commercialized as Lagevrio.',\n",
              "       'Molnupiravir, commercialized as Lagevrio acts by inhibiting RdRp of SARS-CoV-2 to induce RNA mutagenesis in two steps.',\n",
              "       'Molnupiravir, commercialized as Lagevrio is converted to EIDD-1931 in the body, which on phosphorylation by host kinases provides the EIDD-1931-triphosphate.',\n",
              "       'the EIDD-1931-triphosphate acts as an alternate/competitive substrate for the RdRp enzyme of SARS-CoV-2.',\n",
              "       'Therefore, the RdRp enzyme of SARS-CoV-2 This process mutated RNA copies for SARS-CoV-2.',\n",
              "       'This process causes the inhibition of the normal functions of the RdRp enzyme of SARS-CoV-2.',\n",
              "       'Molnupiravir, commercialized as Lagevrio is a better electron donor than electron acceptor, and hence this reducing property can contribute to the antiviral activity as this reducing property affects the conditions required for viral infection.',\n",
              "       'Molnupiravir, commercialized as Lagevrio is an isopropyl prodrug of EIDD-1931, which has been shown to suppress the reproduction of a wide range of viruses, including coronaviruses, with potential safety profiles.',\n",
              "       'EIDD-1931 was quickly metabolised in nonhuman monkeys’ enterocytes after oral administration.',\n",
              "       'In the papers, there is information on EIDD-1931 uptake and distribution in mice.',\n",
              "       \"EIDD-1931's low bioavailability was addressed with the development of Molnupiravir, commercialized as Lagevrio.\",\n",
              "       'Emory University in Atlanta, Ridgeback Biotherapeutics, Wayne and Wendy Holman, and Merck have also agreed to collaborate on the development of Molnupiravir, commercialized as Lagevrio as an oral therapy for non-hospitalized COVID-19 individuals.',\n",
              "       'Molnupiravir, commercialized as Lagevrio was under pre-clinical development for seasonal flu at the period of the pandemic’s outbreak.',\n",
              "       'Following the dissemination of COVID-19, the Molnupiravir, commercialized as Lagevrio development effort shifted to COVID-19 therapy.',\n",
              "       'In mice, ferrets, and nonhuman primates, Molnupiravir, commercialized as Lagevrio showed significant anti-influenza efficacy and high oral absorption.',\n",
              "       'Molnupiravir, commercialized as Lagevrio found a therapeutic window of >1713 antiviral effectiveness vs. cytotoxic effects and proposed that Molnupiravir, commercialized as Lagevrio be tested further in clinical trials for influenza therapy.',\n",
              "       'Molnupiravir, commercialized as Lagevrio oral efficiency against coronaviruses was also demonstrated in preclinical research in an animal study.',\n",
              "       'EIDD-1931 was also shown to be effective against a remdesivir-resistant infection, suggesting that EIDD-1931 may be potent against a larger variety of viruses than remdesivir.',\n",
              "       'SARS-CoV-2 propagation is ineffectively controlled by remdesivir.',\n",
              "       'Molnupiravir, on the other hand, was shown to be efficient in ferrets in reducing SARS-CoV-2 virus and halting dissemination.',\n",
              "       'As a result, Molnupiravir has been proposed as a protective measure to combat SARS-CoV-2 infection in the community.',\n",
              "       \"Molnupiravir is quickly degraded to Molnupiravir's active component EIDD-1931 after oral ingestion, with an average time of maximum detected concentration of 1–1.75 h. During the absorptive state, there was no decline in absorption, but there was a drop in the absorption rate.\",\n",
              "       'A single oral dose of up to 1600 mg and a range of 50–800 mg twice day for 5.5 days were shown to be harmless.',\n",
              "       'Elderly patients with SARS-CoV-2 illness diagnosed by RT-PCR within 5 days of appearance of symptoms were randomised to standard of care SOC or 300, 600, and 800 mg Molnupiravir orally twice for 5 days by oral route daily.',\n",
              "       'The safety and tolerance of COVID-19 in patients admitted with minimal to moderate COVID-19 were analyzed in a double-blind, randomized-controlled, multicentric phase 2a MK-4482-006 NCT04405570 study.',\n",
              "       \"Placebo. a double-blind, randomized-controlled, multicentric phase 2a MK-4482-006 NCT04405570 study's performance, wellbeing, and tolerance were evaluated for 4 weeks after a double-blind, randomized-controlled, multicentric phase 2a MK-4482-006 NCT04405570 study commenced.\",\n",
              "       \"Other double-blind phase 2 experiment is now underway to assess the safety of Molnupiravir and Molnupiravir's effect on SARS-CoV-2 infection shedding.\",\n",
              "       'The independent data safety monitoring board recently halted the phase 3 double-blind, randomised trial MOVe-OUT that was designed to evaluate the efficacy and safety of Molnupiravir in 1850 non-hospitalized participants with COVID-19 NCT04575597, MK-4482-002 due to the increased advantage in the test group compared to Placebo.',\n",
              "       \"A proven SARS-CoV-2 illness with samples taken ≤5 days previous to the day of allocation and negative serum testing in light of recent or earlier exposure were among an open label randomised controlled but small phase Ib/IIa study called AGILE NCT04746183's eligibility criteria.\",\n",
              "       'On day 29, no deaths were recorded in the Molnupiravir population, compared to eight casualties in the placebo arm.',\n",
              "       'Furthermore, the SARS-CoV-2 variant gamma, delta, or mu, the period of onset of manifestations, and the inherent risks had no influence on the effectiveness of Molnupiravir.',\n",
              "       'In both the Molnupiravir and control arms, the prevalence of all side-effects and drug-related side effects was revealed to be similar.',\n",
              "       'A further phase 3 double-blind, randomised research MOVe-IN, NCT04575584 that has been set to investigate the effectiveness and safety of Molnupiravir in 304 hospitalised adult COVID-19 MK-4482-001 subjects was halted after an initial review of the data revealed that a clinical efficacy in hospitalised individuals was improbable.',\n",
              "       'Nonetheless, a huge n 14 1332 phase 3 multicentric, randomised, double-blind, placebo-controlled investigation NCT04939428 is actively exploring the safety and effectiveness of Molnupiravir for the mitigation of COVID-19 in adults MOVe-AHEAD living with a human who has COVID-19, with the assumption that Molnupiravir would be efficacious in blocking laboratory-confirmed COVID-19 infestation through day 14 especially in comparison to placebo.',\n",
              "       'Meanwhile, many Indian pharmaceutical firms confirmed preliminary results from phase 3 studies with Molnupiravir in mild/moderate COVID-19 patient populations in India.',\n",
              "       'Coronavirus disease-2019 COVID-19 is a communicable disease caused by SARS-CoV-2.',\n",
              "       \"Coronavirus disease-2019 COVID-19 was first detected in Wuhan, China, and has expanded Coronavirus disease-2019 COVID-19's reach globally, leading to myriad deaths.\",\n",
              "       'According to World Health Organisation, the total number of Coronavirus disease-2019 COVID-19 confirmed cases worldwide was found to be 532201219 and total number of deaths accounted to 6305358 as of 10th June, 2022.',\n",
              "       'Among many regions, Europe holds the top position in highest number of confirmed Coronavirus disease-2019 COVID-19 cases then followed by America, Western Pacific, South-East Asia, Eastern Mediterranean, and Africa respectively.',\n",
              "       'These statistics reveal that even today, Coronavirus disease-2019 COVID-19 is still infecting several people, many of whom die due to complications.',\n",
              "       'However, the development of specific drugs for Coronavirus disease-2019 COVID-19 takes several years, paving the way for exploring alternative approaches.',\n",
              "       'The Coronavirus disease-2019 COVID-19 pandemic has ensured research to explore various alternatives, drug repurposing being one of various alternatives, as part of the disease management strategy.',\n",
              "       'Several drugs such as chloroquine, hydroxychloroquine, remdesivir, tocilizumab, kaletra, and favipiravir are currently being testing in clinal trials for repurposing against Coronavirus disease-2019 COVID-19.',\n",
              "       'SARS-CoV 2 belongs to the Nidovirales family, under the beta coronaviruses genera along with other viruses such as Middle East Respiratory Syndrome Coronavirus MERS-CoV, HCoV-HKU1, and the HCoV-OC43 Human Coronavirus variants.',\n",
              "       'The nucleocapsid in SARS-CoV 2 protects the viral RNA genomes from external environmental conditions.',\n",
              "       'At the relaxed position, The nucleocapsid in the virus appears to be in a helical shape, but within SARS-CoV 2, The nucleocapsid in the virus appears spherical.',\n",
              "       'The genome of SARS-CoV 2 codes for four main structural proteins when compared to five in other coronaviruses leaving out the hemagglutinin-esterase HE protein.',\n",
              "       'Nucleocapsid N, membrane M, envelope E, and spike S are the four important structural proteins expressed by SARS-CoV 2.',\n",
              "       'On the surface of SARS-CoV 2, three structural proteins M, E, and S are present, while the nucleocapsid protein resides in the core region bound to genomic RNA.',\n",
              "       'The spike proteins of SARS-CoV 2 help in the attachment, entry, pathogenesis, and tissue tropism, whereas, the infection is carried out by envelope E. Ribonucleoprotein is formed with nucleocapsid protein’s assistance and the membrane proteins aid in the overall viral architecture.',\n",
              "       \"SARS-CoV 2 enters with the help of spike proteins by binding to the human angiotensin-converting enzyme 2 hACE2 through the human angiotensin-converting enzyme 2 hACE2's receptor-binding domain RBD and human proteases that make them proteolytically active.\",\n",
              "       'In addition to this, certain amino acids are conserved among the coronavirus viruses, while some have a unique mark in the amino acid indicating lineage mutations.',\n",
              "       'Apart from the variants identified in the most common lineages, there are approximately 1516 SARS-CoV 2 lineages to date.',\n",
              "       'To identify the variants in all the existing lineages and those that exist not only in the spike protein of SARS-CoV 2, this study also performed a search in and summarized the different types of variants.',\n",
              "       'Synonymous, non-synonymous, deletions, and non-coding variations were identified, and changes in the amino acid positions, and the reference and mutated codon as screened in all 1516 lineages of SARS-CoV 2.',\n",
              "       '131 non-synonymous mutations are in various regions of SARS-CoV 2, including the spike proteins, nucleocapsid proteins, different open reading frames, and membrane and envelope proteins.',\n",
              "       'Thus, the SARS-CoV-2 variants may have different binding sites making the SARS-CoV-2 variants identifying a suitable drug challenging.',\n",
              "       'Recently, an mRNA-based vaccine BNT162b2 was reported to have adverse side effects such as fatigue, headaches, and immense pain at the site of injection.',\n",
              "       \"Variants are concerns among the present therapies due to severe mutations that occur in the spike protein as well as the increased transmission rate when compared to the spike protein's predecessor.\",\n",
              "       'Some examples of approved repositioned drugs include aspirin, the cyclooxygenase inhibitor for coronary heart disease, antibiotic erythromycin for gastric motility, and sildenafil, a phosphodiesterase inhibitor for erectile dysfunction.',\n",
              "       'Other drugs that have disconcerting side effects also merit repurposing as corroborated by the successful implementation of thalidomide, an antiemetic against multiple myeloma.',\n",
              "       'For instance, drugs lopinavir and ritonavir have been used for the treatment of Human Immunodeficiency Virus-1 and 2 HIV.',\n",
              "       'drugs lopinavir and ritonavir were also the first drugs to be repurposed for the treatment of COVID-19.',\n",
              "       'The main reason for this is due to the resemblance of the SARS-CoV and MERS-CoV beta coronavirus genome sequences to SARS-CoV-2.',\n",
              "       \"Thus, the drugs being utilized for the treatment of MERS-CoV and SARS-CoV-2 could be essentially used for COVID-19 treatment, implying that the mechanism of action of repositioned drugs against repositioned drugs's targets should be similar to or resemble repositioned drugs's family target members.\",\n",
              "       'Successful administration to patients with moderate COVID-19 symptoms has been previously observed, confirming the hypothesis of drug repurposing.',\n",
              "       'Aside from this, the scope of drug repurposing expands to the following, with instances in COVID-19 research, as discussed in the below sections Precision medicine Precision medicine is an emerging strategy that studies the variability of individual genes, the lifestyle, and the environment for each person to decide upon the correct treatment approach.',\n",
              "       'Recent studies have implicated the use of computational techniques such as machine learning algorithms as a precision medicine tool for drug repurposing for the treatment of COVID-19.',\n",
              "       'The decision tree algorithms used in the study identify patients with longer survival rates and better oxygen support when treatment was provided and suggest corticosteroids and remdesivir as effective COVID-19 repurposed drugs.',\n",
              "       'Rapid therapeutic options With the advent of the COVID-19 pandemic and reduced therapeutic options for COVID-19, repurposing offers rapid therapeutic strategies to combat COVID-19.',\n",
              "       'Likewise, another study has elucidated and suggested the use of interleukin inhibitors, Janus-kinase pathway inhibitors, interferons, vascular endothelial growth factor VEGF inhibitors, immune check-point inhibitors, Bruton tyrosine kinase inhibitors BTK, and XPO-1 a selective inhibitor of nuclear export as some of the alternative drugs that could be repurposed for rapid COVID-19 treatment.',\n",
              "       'For instance, a recent study has repurposed antiviral protease inhibitors such as chloroquine, remdesivir, and lopinavir, which have already shown efficient inhibition of the virus in in vitro studies, using the extra-cellular vesicles, to make antiviral protease inhibitors such as chloroquine, remdesivir, and lopinavir more robust against the virus.',\n",
              "       'Similarly, another study suggested p38 MAPK mitogen-activated protein kinase, as a vital host target for inhibiting the replication of coronaviruses, after studies proved that Ralimetiniib mesylate was found to be active in both Calu-3 and HeLa-ACE2 cells.',\n",
              "       'Previous studies have most commonly employed molecular docking for virtual screening against targets of SARS-CoV-2, such as the main protease, with possible drugs for repurposing such as digitoxigenin, beta-eudesmol, crocin, rutin, ritonavir, emetine, hesperidin, and indinavir.',\n",
              "       'Elfiky proved via MD simulations that Setrobuvir, YAK, and ID-184 had the best antiviral activity against RNRP RNA-dependent RNA polymerase of SARS-CoV-2, after screening out 31 compounds that were in clinical trials or had known antiviral activity.',\n",
              "       'Similarly, MD simulations identified the stability of lopinavir complexed with SARS-CoV-2 main protease as the most stable in biological conditions, along with other identified antivirals such as carfilzomib, valrubicin, elbasvir, and eravacycline.',\n",
              "       'With regard to COVID-19, this approach combined with docking and simulations has brought immense benefits to the design and repurposing of drugs for SARS-CoV-2.',\n",
              "       'a binary-QSAR model resulted in cefuroxime pivoxetil as a potential drug repositioning molecule against SARS-CoV-2.',\n",
              "       'A deep-learning-based approach to screen a huge number of molecules having allocated datasets to seek compounds possessing SARS-CoV-2-inhibiting activities was carried out previously by Ke et al. To validate the designed model and verify the antiviral activity of the compound that the designed model predicted, an in vitro cell line for feline coronavirus replication was also set up in the study.',\n",
              "       'Likewise, Beck et al. utilized an already trained deep-learning prediction model for drug-target interactions known as Molecule Transformer-Drug Target Interaction MT-DTI, to find antiviral drugs that are commercially available and which could perturb SARS-CoV-2 components including RNA-dependent RNA polymerase, proteinase, and helicase.',\n",
              "       'Another recent study also proposed a data augmentation approach that extricates only beneficial data from a set of variable datasets, to screen novel drug candidates for COVID-19.',\n",
              "       'Several studies have implemented random-walk algorithms to identify drug repurposing candidates for COVID-19 –. The pathogenic mechanisms instigated by the SARS-CoV-2 3CL protein using the information from all related coronaviruses were also explored and random walk algorithms were implemented on the molecular networks to recognize the most relevant COVID-19 drug targets.',\n",
              "       'Drugs such as lopinavir, ritonavir, boceprevir, carmofur, and doxycycline act on the 3-chymotrypsin-like proteins/SARS-CoV-2 main protease that play an important role in cleaving and releasing the 16 non-structural proteins.',\n",
              "       'Fostamatinib disodium and platycodin target the Nsp3 proteins which play a major role in the infection and pathogenesis.',\n",
              "       'The RNA-dependent RNA polymerases RdRp, Nsp 12 that are primarily involved in important activities such as transcription and replication of the viral RNA genome are targeted by drugs such as remdesivir, favipiravir, and ribavirin.',\n",
              "       'For the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of SARS-CoV-2, drugs such as vapreotide, atazanavir, daclatasvir, and bismuth potassium citrate commonly block this function of the helicase Nsp13 of SARS-CoV-2, a multifunctional protein that helps in the proliferation and replication of the virus.',\n",
              "       'Likewise, dinucleoside 123 and raltegravir affect the pathways of methyltransferases guanine-N7-methyltransferase, 2’-O-methyltransferase, while gliclazide and memantine affect the SARS-CoV-2 E protein, which is the envelope protein of SARS-CoV-2.',\n",
              "       'Arbidol and chloroquine target the spike protein that helps in the viral entry, along with ACE2 protein in the host, thereby affecting the spike protein pathway.',\n",
              "       'The ACE receptors are blocked via losartan and captopril, transmembrane protease serine 2 TMPRSS2 is blocked by camostat mesylate and with anyone, and cathepsin L is inhibited by hydroxychloroquine, which and teicoplanin.',\n",
              "       'The viral neuraminidases and the DPP4 cell receptor pathways are hindered due to the action of oseltamivir and sitagliptin, while pemirolast, nitrofurantoin, isoniazid pyruvate, eridictoyl, hypericin, cepharanthine, and ergoloid block the human ACE2 and the S protein of SARS-CoV-2.',\n",
              "       'The most important Janus kinase pathway is hindered by baricitinib, RdRp, helicase, exo-nuclease, and methyltransferase of SARS-CoV-2 by Efavirenz and Poly ADP-ribose polymerase 1 PARP-1 by Mefuparib hydrochloride.',\n",
              "       'Poly ADP-ribose polymerase 1 PARP-1, glycogen synthase kinase 3 GSK-3, and also biological pathways such as NF-kappa B signaling are all affected by the use of repurposed drugs toremifene, sirolimus, mercaptopurine, irbesartan, emodin, dactinomycin, and melatonin.',\n",
              "       'Other common drugs such as nitazoxanide, ivermectin, and azithromycin tend to symptoms of SARS-CoV-2, and play a role in inhibiting the role of SARS-CoV-2.',\n",
              "       'Mahdian et al. and Yuce et al. state that Paritaprevir is important against 3-chymotrypsin-like proteins/SARS-CoV-2 Main protease and plays an important role in cleaving as well as releasing 16 non-structural proteins Nsps.',\n",
              "       'Paritaprevir also affects the ACE2-SARS-CoV-2-RBD complex.',\n",
              "       'Likewise, ledipasvir, vancomycin, and sirolimus target the ACE2-SARS-CoV-2-RBD complex, a spike protein that helps in the viral entry along with the help of ACE2 protein in the host organism.',\n",
              "       'Similarly, FDA-approved irinotecan, abemaciclib, estradiol benzoate, capmatinib, olaparib, lumacaftor, and pazopanib target CD147, a member of the immunoglobulin superfamily IgSF interacts with spike protein of SARS-CoV-2.',\n",
              "       'Other drugs such as nilotinib, rifabutin, dactinomycin, dihydroergotamine, bromocriptine, entrectinib, selinexor, elbasvir, quinupristin, rifapentine, rutin, digitoxin, diosmin, and antrafenine target 3-chymotrypsin-like proteins/SARS-CoV-2 Main protease that plays an important role in cleaving as well as releasing 16 non-structural proteins Nsps.',\n",
              "       'According to the latest updates from, phase 3 trials are completed for Paritaprevir, lopinavir/ritonavir, interferon beta-1A, hydroxychloroquine, and AZD7442 registration number NCT04315948.',\n",
              "       'Trials for Silmitasertib are active and in phase 2, while for Pioglitazone, phase 4 trials are completed registration number NCT04473274.',\n",
              "       'Phase 2 clinical trials are completed for dipyridamole 100 mg NCT04391179, and phase 2 is completed for Leronlimab 700 mg NCT04678830.',\n",
              "       'L-ascorbic acid has phases 1 and 2 completed NCT04357782, and phase 1 for aerolized hydroxychloroquine sulfate completed NCT04461353.',\n",
              "       'Similarly, drugs duvelisib NCT04487886, ruconest NCT04530136, and infliximab NCT04425538 have phase 2 clinical trials completed.',\n",
              "       'This data is provided in detail in Table and the 2D structures of some of these drugs are shown in Fig. When remdesivir was administered intravenously to the first patient diagnosed with SARS-CoV-2 in the USA, no adverse effects were noted with some clinical benefits in the first patient diagnosed with SARS-CoV-2 in the USA.',\n",
              "       'Additionally, due to some adverse effects early on, remdesivir was then discontinued, and FDA Food and Drug Administration has now provided a conditional recommendation for the use of remdesivir against COVID-19.',\n",
              "       'Likewise, real-world usage of lopinavir/ritonavir revealed no beneficial response against COVID-19 hospitalized patients in a randomized, controlled, trial.',\n",
              "       'Overall, the available data show an unfavourable response of patients to lopinavir/ritonavir, and hence the use of lopinavir/ritonavir has to be monitored and controlled vigilantly.',\n",
              "       'Despite there being studies on hydroxychloroquine, an analogue of chloroquine, where improvements have been noted in patients suffering from COVID-19 in a study conducted in Wuhan, there still seems to be very limited data on the reliability of hydroxychloroquine, an analogue of chloroquine.',\n",
              "       'Interferon-beta-1A has been used in hospitalized patients for treating COVID-19 at Shaid Behesti University of Medical Sciences, in combination with other drugs.',\n",
              "       'However, despite Interferon-beta-1A showing promising outcomes, more clinical data is required to corroborate the reliability of Interferon-beta-1A.',\n",
              "       'According to literature, coronavirus papain-like proteases PLpro, main protease 3CLpro, helicase, and RNA-dependent RNA polymerase RdRp are the considered to be the potential molecular targets and are involved in important functional activities such as protein synthesis, RNA transcription, translation, replication, processing, and infection respectively.',\n",
              "       'The active site residues/binding pockets present in domains and subdomains are His272, Cys111, and Asp286 which form the catalytic triad of the same protease/protein.',\n",
              "       \"The papain-like proteases share The papain-like proteases's structure with the ubiquitin-specific proteases USPs which have two main domains, ubiquitin-like Ubl domain, an N-terminal domain along with the catalytic triad which forms thumb-palm-fingers architecture.\",\n",
              "       'Since RNA-dependent DNA polymerase plays an important role in viral infection and hence RNA-dependent DNA polymerase is considered a potential molecular target of the virus, human telomerase reverse transcriptase hTERT was first thought to be RNA-dependent DNA polymerase but human telomerase reverse transcriptase hTERT is DNA polymerase that shares structural similarities with RdRp.',\n",
              "       'At N-terminal, there is the presence of beta-hairpin nidovirus RdRp-associated nucleotidyltransferase NiRAN domain residues ranging from D60 to R249 and C-terminal/polymerase domain residues ranging from S367 to F920 which houses thumb-fingers-palm subdomains.',\n",
              "       'There are seven motifs present in the RdRp protein of the virus ranging from A to G, where five are said to be present in the most conserved domain, i.e., the thumb domain –. Non-structural protein 5 coding gene encodes the main protease 3CLpro which is mainly involved in the proteolytic activity of viral polyproteins and replicates.',\n",
              "       'The size of the main protease 3CLpro which is mainly involved in the proteolytic activity of viral polyproteins and replicates is approximately 30 kDa which has three domains rich in cysteine amino acids.',\n",
              "       'the main protease 3CLpro which is mainly involved in the proteolytic activity of viral polyproteins and replicates comprises chymotrypsin-like folds along with a catalytic triad and a domain that is inundated with cysteine.',\n",
              "       'The N-terminal and the C-terminal domain of The nucleoprotein N of SARS CoV-2 share similarities with CoVs N proteins.',\n",
              "       \"The beta hairpin-like structure connects two protomers by inserting The beta hairpin-like structure into two protomers's cavities.\",\n",
              "       'There are three domains in the enveloped protein of the virus which comprise of The N-terminal domain, C-terminal domain, and transmembrane domain.',\n",
              "       'The overall size of The nucleoprotein N of SARS CoV-2 is about 8.4–12 kDa and forms the integral membrane protein of the virus comprising 76–109 amino acids.',\n",
              "       'There are about 7–12 amino acids at The N-terminal which is short and makes The nucleoprotein N of SARS CoV-2 hydrophilic in nature.',\n",
              "       'The protomers present in the spike glycoprotein structure contain approximately 1260 amino acids.',\n",
              "       'The first and foremost part of the spike glycoprotein is the surface subunit S1 which comprises four domains two SD1, SD2 subdomains, N-terminal domain, and C-terminal domain which is also the receptor-binding domain of the spike glycoprotein with 672 amino acids in length.',\n",
              "       'The non-structural proteins of the SARS-CoV-2 are polyproteins pp1a and pp1ab.',\n",
              "       'Nsp 1 to 11 is categorized under pp1 polyprotein, while Nsp 12 to 16 is classified under polyprotein pp1ab.',\n",
              "       'Studies have shown that among all the receptor-binding domains RBD residues for which mutations in the form of substitutions affected the recognition by certain convalescent serums, E484 was identified by deep mutation scanning as having importance, with changes to amino acids K, P, or Q. Moreover, E484 is recognized as an escape mutation, that occurs when exposure to monoclonal antibodies C144 and C121 occurs.',\n",
              "       'Moreover, E484 was the only variable that was found to reduce the neutralization capacity of MAbs REGN10934 and REGN10989.',\n",
              "       'Similarly, the substitution N439K enhances the the virus ACE2 receptor affinity.',\n",
              "       'This discrepancy could be because immune escape caused by the substitution N439K is via ACE2 affinity than by direct antibody epitope identification, making the substitution N439K a variant that should compel more studies.',\n",
              "       'Studies have also identified that the n-terminal domain NTD mutations in spike also cause immune escape.',\n",
              "       'Moreover, deletions in n-terminal domain NTD have been noted to be the cause of the virus evolution repeatedly, by altering the antigenicity of n-terminal domain NTD.',\n",
              "       'Our previous studies show that mutations in the spike glycoprotein demonstrated enhanced stability in spike, and the residues that were undergoing mutations were also part of the hydroxychloroquine drug-binding active pockets.',\n",
              "       'The mutations that occurred in other prioritized proteins of interest were also part of the drug-binding active sites of remdesivir, favipiravir, and dexamethasone.',\n",
              "       'The study also concluded that the presence of mutations in various regions reduced the effect of remdesivir on the targets, thereby allowing remdesivir, favipiravir, and dexamethasone to not work on the targets.',\n",
              "       'This shows the presence and effect the variants have on the drug-binding active sites of remdesivir, favipiravir, and dexamethasone.',\n",
              "       'All these studies prove that there is distinct evidence as to the altering of the the virus proteins’ structural antigenicity, causing the SARS-CoV-2 proteins’ to evade the immune system and become more robust.',\n",
              "       'In the previous section, evidence of how the variants alter the drug binding efficacy and how SARS-CoV-2 escapes the immune system is provided.',\n",
              "       'In our previous study, however, various targets of SARS-CoV-2 were analyzed at the molecular level to comprehend the changes SARS-CoV-2 undergoes during the binding event of some of the important FDA-approved drugs for COVID-19.',\n",
              "       'Favipiravir, lopinavir, chloroquine, hydroxychloroquine, lopinavir, ritonavir, and remdesivir were studied.',\n",
              "       'Though there are limited experimental data to highlight the spike glycoprotein of SARS-CoV-2 act as the target for repurposed drugs, however, several computational biology prediction revelated the scope of utilising spike glycoproteins as the putative molecular target for repurposed drugs.',\n",
              "       'A recent study stated that drugs ritonavir and eriodictoyl bind to the active sites of spike protein of SARS-CoV-2 with potential binding energy and stability.',\n",
              "       'drugs ritonavir and eriodictoyl interacted with the binding energy of −7.6 kcal/mol, indicating stable binding.',\n",
              "       'Likewise, another study showed that repurposed drugs such as pralatrexate, carumonam, aclerasteride, and granotapide interacted with spike protein of SARS-CoV-2 and acted as potential binders.',\n",
              "       'Additionally, another recent study has reported Remdesivir and ivermectin, potential repurposed drugs interacted with the spike protein of SARS-CoV-2.',\n",
              "       'another recent study stated that ivermectin bound effectively to the spike protein of SARS-CoV-2, and inhibited the entry of SARS-CoV-2 into the host.',\n",
              "       'Remdesivir was also suggested to be involved in stable interaction with the spike glycoprotein of SARS-CoV-2, apart from the other targets.',\n",
              "       'These studies demonstrate that repurposed drugs were suggested to be targeted the spike glycoprotein of SARS-CoV-2 at various binding pockets and interacted with the spike glycoprotein of SARS-CoV-2.',\n",
              "       'To understand further on the interaction modelling of some important repurposed drugs, molecular docking and molecular dynamic studies were performed in our previous study and the results showed ritonavir and Lopinavir with better binding energy, followed by Remdesivir against the prioritized targets.',\n",
              "       'At a molecular level, Fig. showed that chloroquine interacted with amino acids Leu6820, Leu6819, Met6818, Val7021, Tyr7020, Asp7018, and Asp6942 of the spike glycoprotein of SARS-CoV-2.',\n",
              "       'Leu331, Tyr333, Arg277, Phe274, Val270, Trp301, Thr296, Ala264, Arg262, Phe314, Gln260, and Arg259 were the major amino acids involved when spike glycoprotein interacted with Lopinavir.',\n",
              "       'Likewise, Tyr421, Asn422, Pro491, Leu492, Gln493, Ser494, Tyr495, Gly496, Phe497, Gln498, Lys444, Asp442, Tyr351, Val350, Ser349, Ala348, Phe347, Arg346, Arg509, and Val401 were involved in complex favipiravir-nucleocapsid phosphoprotein.',\n",
              "       'Lys6822, Glu6821, Leu6820, Val7021, Tyr7020, Asp6942, Asn6941, Glu6940, and Thr6938 were observed for complex remdesivir-nucleocapsid phosphoprotein.',\n",
              "       'NSP16 interacted with hydroxychloroquine at residues Arg6817, Met6818, Leu6819, Leu6820, Tyr7020, Val7021, Asp7018, and Asp6942 and with ritonavir at residues Phe314, Gln260, Arg259, Arg277, Phe274, Tyr333, Trp330, Trp301, Thr282, Gly284, Phe286, Leu291, and Val270.',\n",
              "       'Drugs such as lopinavir, ritonavir, remdesivir, ribavirin, and favipiravir are some repurposed drugs.',\n",
              "       'Lopinavir/ritonavir was generally used against HIV, remdesivir against major SARS viruses, and favipiravir which was previously used as a general viral pro-drug.',\n",
              "       'For example, remdesivir a broad-spectrum antiviral came into the market to be repurposed as a COVID-19 drug after in vitro studies revealed that remdesivir a broad-spectrum antiviral inhibited the SARS-CoV and MERS-CoV in the human respiratory epithelial cells initially, followed by inhibiting the epithelial cells in SARS-CoV-2, the pathogenic strain of COVID-19 disease.',\n",
              "       'Likewise, the in vivo study of remdesivir a broad-spectrum antiviral when infected with SARS-CoV-2, the pathogenic strain of COVID-19 disease infected rhesus monkey demonstrated an improvement in the pulmonary lesions and decreased the viral load after 7 days of treatment with remdesivir a broad-spectrum antiviral.',\n",
              "       'No coronaviral disease was observed after the successful use of remdesivir a broad-spectrum antiviral.',\n",
              "       'remdesivir a broad-spectrum antiviral was originally meant for treating the Ebola virus against the Ebola RdRp target, and now with potential repurposing capabilities against the RdRp and NSP12 of SARS-CoV-2.',\n",
              "       'Lopinavir/ritonavir is a drug for the HIV-1 protease, that now evidences potential for the main protease of SARS-CoV-2.',\n",
              "       \"Silmitasertib has Silmitasertib's original target as casein kinase 2, which inhibits the casein kinase 2 pathway in Sonic hedgehog SHH.\",\n",
              "       'Silmitasertib is also known to inhibit the casein kinase 2 pathway in Sonic hedgehog SHH in SARS-CoV-2.',\n",
              "       'Likewise, dipyridamole 100 mg is an inhibitor of phosphodiesterase originally and works against the main protease of SARS-CoV-2 and stops replication.',\n",
              "       'Leronlimab 700 mg works against the C–C Chemokine receptor type 5 in HIV and now shows potential against the same target in SARS-CoV-2.',\n",
              "       'Ruconest targets the c1 esterase and inhibits angioedema, while Ruconest targets C1, C5a, and C3a esterases in SARS-CoV-2.',\n",
              "       \"Infliximab attacks the tumor necrosis factor in SARS-CoV-2 as well as in Infliximab's original target in Rheumatoid arthritis, Crohn’s disease, and ankylosing spondylitis.\",\n",
              "       'Other advantages of repurposed drugs include Lower cost of productionLesser time for identifying useful, effective, and safe drugs for quick useResearch can be carried out using the existing, easily accessible bioinformatics and chem-informatics data and resources available for specific diseases, as was the case in COVID-19 cases Molecular docking The emergence and prevalence of COVID-19 have paved the way for molecular docking studies.',\n",
              "       'Poly-ADP-ribose polymerase-1, CVL218, a potent inhibitor that binds to the N-terminal of the nucleocapsid protein of SARS-CoV-2 was identified.',\n",
              "       'However, some limitations to the drug repositioning, include Weak intellectual property rights protection for repurposed drugs due to reduced rate of returnThe molecular docking technique used for identifying drugs for repurposing cannot be applied to all existing drugs due to the larger computational operationsSome network-based approaches used for drug repurposing do not always yield promising operationsSome network-based approaches used for drug repurposing are data-dependent, due to which the results may be inaccurate due to the lower volume of existing COVID-19 dataLack of strong, solid evidence for the mechanism of action of repurposed drugs on COVID-19 19Experimental evidence is required for validating the predictive outcomesOverall low success rates in new disease settingsExtensive data to be studied before repurposingDosing and safety issues, i.e., approved range of dosage and delivery capabilities are not very strongAccurate, robust toxicological studies of repurposed drugs essential before delivery and testingRare to find unique and novel drug-protein interactions all within the restraints of the approved therapeutic window.',\n",
              "       'With high mortality rates, COVID-19 has become one of the most prevailing diseases globally.',\n",
              "       'With the CDC and WHO declaring several recent variants of concern for SARS-CoV-2, there is an urgent need to explore alternative options of treatment when there are no specific drugs targeting SARS-CoV-2.',\n",
              "       'this review sheds light on the various existing drugs that have been repurposed for use against SARS-CoV-2 and also illuminates the important drug targets against which the various existing drugs that have been repurposed for use against SARS-CoV-2 are used spike glycoproteins, RDRP, main protease, papain-like protease, nucleoproteins, non-structural proteins, and enveloped proteins of SARS-CoV-2.',\n",
              "       'The most important advantage of repositioning drugs against COVID-19 is the reduced cost and time of development and the drawback is the absence of safety/toxicity profiles via in vivo trials for COVID-19.',\n",
              "       'The 2019 novel coronavirus, now dubbed SARS-CoV-2, has led to a global pandemic as declared by the World Health Organization WHO on 11 March 2020.',\n",
              "       \"The 2019 novel coronavirus, now dubbed SARS-CoV-2 shares The 2019 novel coronavirus, now dubbed SARS-CoV-2's mechanism of viral entry with other viruses of the Coronaviridae family as its mechanism of viral entry is mediated by the spike S glycoprotein which binds to angiotensin converting enzyme 2 ACE2 receptors that are localized in a variety of cell types, such as in the heart, liver, kidney, but most abundantly in the lungs and respiratory system i.e., alveolar epithelial cells and capillary endothelial cells, leading to a wide range of various symptoms experienced by COVID-19 patients.\",\n",
              "       'Despite this variance, it is of note that The 2019 novel coronavirus, now dubbed SARS-CoV-2 infections lead to systemic inflammatory response syndrome SIRS and acute respiratory distress syndrome ARDS, two relevant conditions highly correlated with COVID-19 infections.',\n",
              "       'Specifically, COVID-19 infections are accompanied by an overaggressive inflammatory response corresponding to a significant release of pro-inflammatory cytokines known as a cytokine storm.',\n",
              "       'Though the biological relevance in relation to COVID-19 of cytokine storms has been questioned, studies have shown significant elevations of pro-inflammatory cytokines in COVID-19 infections as compared to other viral infections, highlighting that virulence may be more immune response-mediated rather than solely due to the viral titer.',\n",
              "       \"As the mechanisms of the cytokine storm have yet to be fully elucidated, there is a need to understand the cytokine storm's genomic origin by comparing the cytokine storm known conditions that occur during COVID-19, such as SARS and acute respiratory distress syndrome ARDS.\",\n",
              "       \"In the case of COVID-19, where the variance in symptoms and the unclear mechanisms of the cytokine storm led to challenges in developing therapeutics to treat affected patients, the need arises to solve challenges in developing therapeutics to treat affected patients through relation of the COVID-19 induced cytokine storm to similar ailment SIRS, ARDS, and sepsis, to connect SARS and ARDS's mechanisms and therefore elucidate potential novel drugs.\",\n",
              "       'The Connectivity Map CMap has allowed for the repurposing of drugs based on gene expression values in neurogenerative diseases, cancer, and COVID-19.',\n",
              "       'An integration of drug repurposing with systems biology is through module preservation analysis to identify module hub genes preserved across different diseases such as SIRS, sepsis, burns, and severe trauma.',\n",
              "       'module hub genes preserved across different diseases such as SIRS, sepsis, burns, and severe trauma serve as inputs into The Connectivity Map CMap analysis to identify repurposed drugs.',\n",
              "       'Herein, a bioinformatics and systems biology approach are adopted to study the similarities and differences between the whole blood transcriptome in ARDS, SIRS, sepsis, and COVID-19, to highlight possible reusable i.e., repurposed drugs.',\n",
              "       'Microarray datasets GSE147902, GSE66890, GSE74224, GSE152641 from ARDS, SIRS, sepsis, and COVID-19 whole blood transcriptomes were taken from the GEO database and analyzed using WGCNA through hierarchal clustering to identify significantly co-expressed modules or clusters of co-expressed genes across the aforementioned conditions.',\n",
              "       'These ailments have been widely reported to be symptoms of COVID-19 infections, and often occur in conjunction with the so-called cytokine storm.',\n",
              "       \"The similarities between ARDS, SIRS, sepsis, and COVID-19 were analyzed at the module level using module preservation analysis and functional and pathway enrichment were used to understand The similarities between ARDS, SIRS, sepsis, and COVID-19's biological significance.\",\n",
              "       'Only the genetic similarities between ARDS, SIRS, sepsis, and COVID-19 were considered in this study, and temporal effects or variations were not accounted for.',\n",
              "       'It is also important to note that the findings in this study are based on generated gene co-expression and PPI networks built from relating immune illnesses, and hence, offer insights into repurposed drugs to treat post-COVID-19 effects i.e., cytokine storms.',\n",
              "       'Microarray data was sourced from the the World Health Organization WHO GEO website.gov/geo accessed on 24 January 2022 database, a public repository of high throughput genomics data.',\n",
              "       'ARDS microarray data was taken from GSE147902 which contains the blood transcriptome of 96 patients within 24 h of ARDS onset, and from GSE66890, which contains the blood transcriptome of critically-ill patients with sepsis and sepsis-related ARDS.',\n",
              "       'SIRS and Sepsis microarray data were taken from GSE74224 which contains the blood transcriptome of 74 sepsis and 31 SIRS patients.',\n",
              "       'Finally, COVID-19 microarray data was taken from GSE177477 which contains the blood transcriptome of 29 COVID-19 patients and 18 healthy controls.',\n",
              "       'For GSE66890, which contains the blood transcriptome of critically-ill patients with sepsis and sepsis-related ARDS, five of the datasets marked as excluded were removed from the analysis as per the source study.',\n",
              "       'To minimize memory requirements, probe set level expression values were filtered using the coefficient of variation CV wherein only the highest the coefficient of variation CV probe for genes with multiple probes was retained.',\n",
              "       'Additional filtering was done by only considering genes with average expression intensities of greater than 100 by removing data with lowest 20% percentile mean expression value shared by all samples and by removing data with lowest 20% percentile variance across samples.',\n",
              "       'After construction of the weighted gene co-expression network of the ARDS dataset whose modules served as reference, the sepsis, SIRS, and COVID-19 datasets were projected onto the ARDS dataset whose modules served as reference to analyze module preservation.',\n",
              "       'To screen possible repurposed drug candidates that are associated with the identified modules of interest across ARDS, SIRS, sepsis, and COVID-19, connectivity map analysis was performed using the Connectivity Map online webserver.',\n",
              "       'All datasets were gene expression profiles obtained from the whole blood samples of individuals within 24 h of ARDS onset.',\n",
              "       'The turquoise module had a total of 2803 genes the magenta module had 410 genes the light cyan module had 915 genes the light green module has 265 genes the light yellow module has 455 genes the orange module has 123 genes the sky blue module had 100 genes the violet module had 94 genes the dark olive green module had 91 genes the yellow green module had 87 genes the floral white module, which was the largest, had 6699 genes the dark orange module had 120 genes and finally, the brown module had 39 genes.',\n",
              "       'Of relevance to the topic of this paper are the upregulated M9, M18, M28, M32, and M36, all of which were observed to be enriched in biological processes directly linked to the immune response A–C. the upregulated M9, M18, M28, M32, and M36 were also observed to be enriched in cellular components related to immune cells, such as M9 being enriched in the T-cell receptor complex.',\n",
              "       'Interestingly, the two largest modules, M44 and M1, were enriched in large-scale macromolecule metabolic processes 2295/5606 and chemical stimulus detection 399/1583 A, cellular processes which have been observed to be affected by COVID-19.',\n",
              "       'However, only a small percentage of the genes in the M46 were found to be involved in spermatogenesis.',\n",
              "       'M9 genes were observed to be enriched in peptide antigen binding M28 genes were enriched in antigen binding and M32 genes were involved in MHC Class II receptor activity.',\n",
              "       \"For example, M1 was enriched in olfactory transduction, similar to M1's observed enriched GO term M9 genes played a role in Th1 and Th2 cell differentiation which is linked to M9 genes's role in the adaptive immune response and the T-cell receptor complex and M16 genes were involved in the chemokine signaling pathway pathways linked to immune processes which suggest M16 genes's involvement in ARDS, an inflammatory complication.\",\n",
              "       'For example, M18, M33, and M36 were enriched in the NOD-like receptor signaling pathway KEGG 04621, B-cell receptor signaling pathway KEGG hsa04662, and platelet activation KEGG 04611, respectively.',\n",
              "       'Further, some modules were involved in cell transport and differentiation, such as M44 and M332, which were involved in nucleocytoplasmic transport KEGG 03013 and hematopoietic cell lineage KEGG 04640, respectively.',\n",
              "       'To compare the similarity of gene expression at the module level between the four diseases included in this study ARDS, SIRS, Sepsis, and COVID-19, the network constructed based on the ARDS dataset was used as reference for module preservation analysis where other datasets describing SIRS, Sepsis, and COVID-19 whole blood transcriptome expressions were projected onto the ARDS dataset.',\n",
              "       'Module preservation analysis revealed that the ARDS modules were most significantly preserved in the sepsis dataset B, while only a few modules were strongly preserved in the SIRS and COVID-19 datasets.',\n",
              "       'Turquoise M1, sky blue M28, violet M32, and dark orange M45 showed moderate preservation while magenta M9, light cyan M16, light green M18, light yellow M19, orange M25, dark olive green M33, yellow green M36, and floral white M44 showed strong preservation B. Finally, in COVID-19, sky blue M28 showed no preservation, orange M25, dark orange M45, violet M32, and dark olive green M33 showed moderate preservation, and turquoise M1, magenta M9, light cyan M16, light green M18, light yellow M19, yellow green M36, and floral white M44 showed strong preservation C. Collectively, the modules strongly preserved in COVID-19 were also strongly preserved in other modules and were therefore selected for further downstream analysis.',\n",
              "       'Results showed that SB-201290 was the drug with the lowest connectivity score, while CAY-10470 had the highest score.',\n",
              "       'Such an approach has been used to identify candidate biomarkers and therapeutic targets in cancer, mouse and yeast genetics, and the analysis of brain imaging data.',\n",
              "       'Despite the knowledge that cytokine storms are often accompanied by ARDS, SIRS, and sepsis, the relationship between ARDS, SIRS, and sepsis has yet to be elucidated.',\n",
              "       'Inherently, with the ARDS and SIRS in this present study, a quantitative network-based approach was employed to statistically determine the co-expressed genes across four related diseases ARDS, SIRS and sepsis, and symptomatic COVID-19, using NCBI GEO datasets to investigate the genetic similarities between four related diseases ARDS, SIRS and sepsis to highlight conserved and divergent pathways in cytokine storms and identify candidate repurposed drugs based on gene co-expression data.',\n",
              "       'Though this present study does not consider the temporal nature of NCBI GEO datasets, this module-based analysis is thought to give more consistent results despite the time-series nature of sepsis microarray samples as the function of module is more stable than that of a single gene.',\n",
              "       'Several of the hub genes screened via intramodular connectivity have been linked to ARDS and inflammation and consequently, cytokine storms, as highlighted in the table.',\n",
              "       'Of particular interest is TREM-1, which has been previously reported to accentuate lung injury during ARDS and has shown promise as an inflammatory biomarker and as therapeutic target for sepsis and septic shock.',\n",
              "       'TREM-1 has been reported to function in regulating T-cell proliferation and activation of antigen presenting cells during the antiviral immune response by amplifying toll-like receptor TLR -initiated responses against microbial challenges.',\n",
              "       \"Recently, the extracellular cold-inducible RNA-binding protein eCIRP, which is the endogenous ligand of TREM-1, was found to induce acute lung injury during sepsis and has been shown to induce inflammation in alveolar cells through induction of TREM-1 and activation of cytokine production in macrophages, further highlighting TREM-1's role in stimulating the immune response.\",\n",
              "       \"Considering TREM-1's extensive role in regulating the expression of cytokines and that macrophages have been previously linked to symptoms reminiscent of COVID-19, TREM-1 could be another potential therapeutic target for cytokine storms.\",\n",
              "       'the hub genes screened via intramodular connectivity could be interesting biomarker and therapeutic target candidates for four related diseases ARDS, SIRS and sepsis and warrant further study.',\n",
              "       'M1 genes were found to be significantly enriched in olfactory transduction and may contain genes affected during COVID-19 infections leading to the loss of smell and taste.',\n",
              "       \"M44, on the other hand, was enriched in nucleocytoplasmic transport and M44's hub gene has been implicated in modulating cytokine production during sepsis.\",\n",
              "       'Several immune-related pathways were also significantly preserved in the COVID-19 dataset alluding to potential conserved mechanisms across four related diseases ARDS, SIRS and sepsis.',\n",
              "       'M9 was enriched in Th1 and Th2 cell differentiation.',\n",
              "       'T-helper Th cells regulate and produce IFN- and TNF-, which are macrophage activators and are responsible for cell-mediated immunity.',\n",
              "       'These synergism of IFN- and TNF-, which are macrophage activators and are responsible for cell-mediated immunity has been previously shown to be sufficient in inducing cell and tissue damage reminiscent of COVID-19 symptoms.',\n",
              "       'Under normal conditions Th1 cells can control the infection sufficiently and has even been linked with a favorable outcome.',\n",
              "       'Thus, M9 is potentially a significant module related to COVID-19 disease severity brought about by cytokine storms.',\n",
              "       'This pathway is initiated by ligand-receptor binding in several chemokine receptors and is responsible for activation of several downstream signaling events such as the MAPK pathway, which has been implicated in cytokine storms.',\n",
              "       \"Several of the chemokine receptors e.g., CXCR3 and CXCR4 have also been shown to be upregulated during cytokine storm-like symptoms as upon binding of Several of the chemokine receptors e.g., CXCR3 and CXCR4's natural ligands e.g., CXCL12, inflammation is promoted and chemotaxis induces apoptosis potentially leading to significant tissue damage as seen in COVID-19 cases.\",\n",
              "       'Considering also that cytokine storms begin with the accumulation of pro-inflammatory cells in sites of severe infection, chemokines are an important driver for inflammation as chemokines serve as chemoattractants.',\n",
              "       \"chemokines's overexpression could be a possible mechanism for observed lung tissue damage i.e., ARDS in COVID-19 cases.\",\n",
              "       'This further emphasizes the importance of chemokine signaling in the movement of immune cells during a cytokine storm and serves as additional support for chemokine receptors to be potential druggable targets.',\n",
              "       'Another pathway conserved in symptomatic COVID-19 is the NOD-like receptor signaling pathway.',\n",
              "       'NOD-like receptors NLRs are essential for detecting pathogen-specific molecules and upon sensing infections, activates signaling pathways that drive NF-B-dependent expression of pro-inflammatory cytokines.',\n",
              "       'Some hub genes e.g., STAT1, STAT3 were present in both methods of selection, suggesting at least partial similarity between methods.',\n",
              "       'These genes, similar to the hubs identified by screening intramodular connectivity, have been closely linked with inflammation and potentially, cytokine storms.',\n",
              "       \"Interestingly, STRINGdb was able to identify several biologically relevant proteins such as TLR4 and IRF1 which have both been linked to cytokine storms with TLR4 being responsible for induction of cytokine production and IRF1 having been shown to alleviate cytokine storm-like symptoms upon IRF1's downregulation in mice models.\",\n",
              "       'The MAPK pathway has been a promising target for novel therapeutic approaches against COVID-19 as the loss of ACE2 activity brought about by viral infection leads to overexpression of p38, which leads to inflammation.',\n",
              "       'COX-inhibitors are common in treating inflammation and has been used for treating ARDS.',\n",
              "       'Antihistamines alleviate symptoms of allergies through inhibition of histamine receptors which have been theorized to induce TNF--stimulated accumulation of pro-inflammatory cytokines.',\n",
              "       'Further, a study that treated 22560 COVID-19 patients with histamine antagonists e.g., loratadine resulted in attenuation of cytokine release leading to moderate to significant relief of COVID-19 symptoms, suggesting the potential of antihistamines in treating COVID-19 and cytokine storms in general.',\n",
              "       \"Additionally, IKK is a protein responsible for transducing pro-inflammatory signals leading to IKK's anti-inflammatory properties.\",\n",
              "       'Recently, a study has shown that nanosomal delivery of TPCA-1 to porcine chondrocytes can prevent TNF- stimulation thereby lowering inflammation.',\n",
              "       'Another paper has also shown that targeted delivery of TPCA-1 using platelet-derived extracellular vesicles is able to calm the cytokine storm in pneumonia mice models through inhibition of pro-inflammatory factors.',\n",
              "       'This suggests that TPCA-1 could be a good candidate drug for treatment of cytokine storms in COVID-19.',\n",
              "       'Mepacrine is a known anti-malarial drug that has since been discovered to have inhibitory activity against NF-B and is now used as an NSAID to inhibit cytokine production.',\n",
              "       'Previous studies have shown that Mepacrine is effective in alleviating airway inflammation in murine models of asthma.',\n",
              "       \"Such inflammation is also present in COVID-19 patients and thus points to Mepacrine's potential as a therapeutic.\",\n",
              "       'Recently, antimalarials have also shown some promising results for being repurposed to tackle COVID-19 cytokine storms and the resulting neuroinflammatory symptoms.',\n",
              "       'Cytokine storms have been observed to lead to ARDS, sepsis, and SIRS, which may indicate specific shared genetic mechanisms.',\n",
              "       'Herein, a network-based approach was applied to correlate the gene expression patterns between ARDS, sepsis, and SIRS by using WGCNA and module preservation analysis to identify co-expressed genes preserved across ARDS, sepsis, and SIRS.',\n",
              "       'SARS-CoV-2 with the D614G mutation on the spike protein was the main strain analyzed in this study.',\n",
              "       'A total of 13 stable gene co-expression modules were identified from the whole blood transcriptome of ARDS patients.',\n",
              "       'Modules were more strongly preserved in the sepsis dataset, and less strongly preserved in the SIRS and COVID-19 datasets.',\n",
              "       'Among 13 stable gene co-expression modules, M1, M9, M16, M18, M19, and M44 were strongly preserved in COVID-19 and across ARDS, sepsis, and SIRS.',\n",
              "       '13 stable gene co-expression modules were enriched in olfactory transduction, Th1 and Th2 cell differentiation, chemokine signaling, NOD-like receptor signaling, mitophagy-animal, and nucleocytoplasmic transport KEGG pathways.',\n",
              "       'The seven identified candidate drugs also warrant further investigation as potential therapeutics against cytokine storms.',\n",
              "       'Coronavirus disease 2019 COVID-19, which was first identified in December 2019, and shortly after, declared a pandemic by World Health Organization WHO.',\n",
              "       'Coronaviruses belong to the family of Coronaviridae, RNA viruses with crown-like spikes on the surface of the coronavirus particles.',\n",
              "       'According to a meta-analysis of Macedo et al., the mortality rate of COVID-19 was 17.1% for patients admitted to hospitals, whereas World Health Organization WHO estimated a fatality rate of 6.73%, which was much lower than that calculated from published studies.',\n",
              "       'Among the critical cases of COVID-19, the mortality rate reaches 40%.',\n",
              "       'The World Health Organization WHO recommendations in the treatment of COVID-19 are as follows molnupiravir conditional, baricitinib strong, ruxolitinib and tofacitinib conditional, sotrovimab conditional, casirivimab and imdevimab conditional, IL-6 receptor blockers tocilizumab and sarilumab strong, remdesivir conditional, and systemic corticosteroids strong.',\n",
              "       'World Health Organization WHO recommends not to use ivermectin, lopinavir/ritonavir, hydroxychloroquine, and convalescent plasma.',\n",
              "       'The pathogenesis of COVID-19 was explained by cytokine storm, reduction in ACE2 expression, and activation of complement pathway-induced microvascular injury and thrombosis.',\n",
              "       'The mechanisms of the recommended agents are focused on The pathogenesis of COVID-19 to improve the clinical outcome of COVID-19, and antiviral therapies are missing.',\n",
              "       'The SARS-CoV-2 contains at least four structural proteins spike S protein, envelope E protein, membrane M protein, and nucleocapsid N protein, and 16 nonstructural proteins NSPs.',\n",
              "       'Among 16 nonstructural proteins NSPs, the main protease, also called chymotrypsin-like protease 3C-like protease, and the papain-like protease are two essential proteases for proteolytic processing of the coronavirus replicase polyprotein, therefore generating functional replication complex of The SARS-CoV-2, whereas RNA-dependent RNA polymerase is the central enzyme for RNA synthesis.',\n",
              "       'These three NSPs play crucial roles in coronavirus replication, making These three NSPs attractive targets for anticoronaviral drug design.',\n",
              "       'The S protein, a surface-located trimeric glycoprotein of coronaviruses, promotes the attachment of viruses to host cells through binding to angiotensin-converting enzyme 2 ACE2 and virus-cell membrane fusion during viral infection.',\n",
              "       'During the spread of COVID-19 outbreak, great efforts have been made in therapeutic drug discovery against COVID-19.',\n",
              "       'Because COVID-19 is a new, acute, severe infectious disease, the anti-SARS-CoV-2 drug development strategies are to screen existing drugs to identify potentially effective drugs, to expand indications, and to develop a vaccine.',\n",
              "       'Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection based on the strategies from preclinical drug discovery.',\n",
              "       'Studies published in PubMed, Scopus, Web of Science, EMBASE, Google Scholar, and DrugBank were searched from December 2019 to March 2021 using the following search terms Coronavirus, COVID-19, SARS-CoV-2, Drug design, Drug development, In silico, In vitro, and In vivo alone or in combination without language restrictions.',\n",
              "       'Study of drug in cell culture medium effectiveness in these studies means inhibition of the replication of COVID-19 by the compound or drug under study.',\n",
              "       'In vivo studies are those in which the effects of drugs are tested on whole living organisms or cells usually animals as opposed to a tissue organism or dead organism.',\n",
              "       'In silico studies used the following component of novel coronavirus as targets main protease N 154, spike glycoprotein N 62, nonstructural protein N 45, RNA-dependent RNA polymerase N 21, papain-like protease N 19.',\n",
              "       'About 260 drugs were repurposed by the computational methods for COVID-19 therapy such as about 120 drugs candidate against main protease N 154, 52 drugs against spike glycoprotein N 62, 14 drugs against RNA-dependent RNA polymerase, and 28 drugs against other nonstructural proteins.',\n",
              "       'Among About 260 drugs, the best results regarding efficacy were observed with saquinavir N 9 study, ritonavir N 8 study, lopinavir N 6 study, remdesivir N 3 study, and amikacin, danoprevir, favipiravir, and telaprevir.',\n",
              "       'As presented, at least two studies show the efficacy of aprepitant, cobicistat, dipyridamole, and dihydroergotamine against main protease N 154 and tegobuvir N 2 against spike protein.',\n",
              "       'The following list of drugs had multitarget action avapritinib, famotidine, bictegravir, ziprasidone, capmatinib, pexidartinib, amprenavir, zafirlukast, cilostazol, paromomycin, lopinavir, and remdesivir.',\n",
              "       'Among them, 54 studies used the main protease as main target, in which eucalyptus N 3, Tinospora cordifolia N 3, and flavonoids e.g., hesperidin, rutin, and herbacetin were the most studied and effective.',\n",
              "       'From the plant metabolites, oleanolic acid, hesperidin, epigallocatechin gallate, jensenone, tinosponone, and anistone show promising results in computational methods against COVID-19.',\n",
              "       'Aloe, green tea, eucalyptus, curcumin, and many Chinese, Indian, and African plants were also effective on COVID-19 in silico.',\n",
              "       'The derivatives of pyrazoles, oxadiazoles, phenyltriazolinones, triazoles, benzoylpinostrobin, benzoic acid, benzylidenechromanones, coumarin, and selenium show efficacy in computational methods and could be considered as lead molecules for drug design and synthesis against COVID-19.',\n",
              "       'Melatonin, ebselen, phenyl furoxan, thimerosal, isatin, romidepsin, phenyl mercurin, pleconaril, and tyrosine kinase inhibitors such as nilotinib and imatinib are examples of other drugs that are effective in in silico methods.',\n",
              "       'Most of 34 studies use the Vero E6 cell line for the assessment of replication of SARS-CoV-2.',\n",
              "       'In particular, main protease, papain-like protease, RNA-dependent RNA polymerase, NSP-14, NSP-15, spike protein, and TMPRSS2 were evaluated in vitro as targets.',\n",
              "       'Also, three studies focused on in vitro inhibition of inflammatory markers such as interleukins and the effects of the cytopathic effect on infected cell.',\n",
              "       'Nitric oxide, ginkgolic acid, anacardic acid, troxerutin, bisindolylmaleimide derivatives, small molecules GRL-172, and 5 h, baicalin and baicalein phytochemicals, and bepridil were effective drugs in vitro against the main protease of COVID-19.',\n",
              "       'The following drugs could inhibit the spike/ACE2-mediated cell entry of COVID-19 in vitro romidepsin, panobinostat, givinostat, sirtinol, saquinavir, lipopeptides, hydroxyzine, azelastine, heparin, and glycyrrhizic acid.',\n",
              "       'Alkenyl sulfonylurea derivatives, an IMU-8381 inhibitor of human dihydroorotate dehydrogenase, pyrazole derivatives, and phillyrin, regulated the expression of inflammatory cytokines e.g., IL, TNF-, and NF- B induced by SARS-CoV-2 markedly and could be considered as adjuvant treatment of COVID-19 severe disease.',\n",
              "       'Doxycycline, chlorpromazine, azithromycin, heparin, bepridil, tannic acid, and glycyrrhizic acid are well-known drugs that show both in silico and in vitro inhibitory effects against SARS-CoV-2 and should be considered for this purpose.',\n",
              "       'Also, in vitro studies show that lopinavir/ritonavir, sofosbuvir, and favipiravir have no antiviral effects against SARS-CoV-2 huge gap between in vitro IC50 and free plasma concentration.',\n",
              "       'Human monoclonal antibodies were the most evaluated drugs N 4, promote the reduction in viral load in vitro, and prevent infection in animal models of SARS-CoV-2.',\n",
              "       'A prodrug of hydroxycytidine molnupiravir improved pulmonary function and reduced viral titer in vivo and was introduced as a potential broad-spectrum antiviral agent against SARS-CoV-2.',\n",
              "       'Chloroquine and chlorpromazine did not inhibit viral replication in mouse lungs, but protected mouse lungs against clinical disease.',\n",
              "       'Dalbavancin shows significant inhibitory ability in both in vitro and in vivo models of COVID-19.',\n",
              "       \"Dalbavancin binds directly to ACE2 and blocks ACE2's interaction with the SARS-CoV-2 spike protein.\",\n",
              "       'To date, an increasing number of drugs have been shown to have anticoronavirus activities in vitro and in vivo, but only remdesivir and several neutralizing antibodies have been approved by the US FDA for treating COVID-19.',\n",
              "       'Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection, which have been conducted in basic research in silico and preclinical study in vitro, in vivo.',\n",
              "       'Some of many compounds are completely new and could serve as seeds or leads for developing antiviral drugs against COVID-19, but as we need therapeutics as soon as possible, half of the studies focused on drug repurposing repositioning, which is a process of investigation of existing drugs for new therapeutic purposes.',\n",
              "       'According to our results, 260 drugs repurposed by the computational methods for COVID-19, among them saquinavir, ritonavir, and lopinavir, showed the best efficacy in in silico environment.',\n",
              "       'Many trials are performed using a combination of ritonavir-lopinavir.',\n",
              "       'The results of a systematic review and meta-analysis showed that a combination of ritonavir-lopinavir has no more treatment effects than other therapeutic agents in COVID-19 patients and is currently not used anymore.',\n",
              "       'We could not find any clinical trial on saquinavir, which is the most studied drug in silico and show high potency against COVID-19.',\n",
              "       \"Natural products and Natural products's structural analogs have historically made a major contribution to pharmacotherapy, especially for cancer and infectious diseases.\",\n",
              "       'Some of the studied plants are among what used by people on a daily basis, such as green tea, aloe, curcumin, and eucalyptus.',\n",
              "       'A systematic review and meta-analysis of RCTs on herbal medicine in the management of COVID-19 show the significant effects of the combined therapy of herbal medicine in treating COVID-19 without any significant side effects.',\n",
              "       'some of these studied active ingredients could possibly have an inhibitory effect on the SARS-CoV-2 and COVID-19.',\n",
              "       'Some of repurposed drugs such as saquinavir, heparin, glycyrrhizic acid, and chlorpromazine show efficacy in both in vitro and in silico environments.',\n",
              "       'Most of the studies focused on the main protease, papain-like protease, and spike glycoprotein.',\n",
              "       'Due to the nature of SARS-CoV-2 and the rises of several high transmissible strains, repurposing existing drugs has demonstrated power by bringing several drugs to approval for treating COVID-19 patients, such as remdesivir.',\n",
              "       'COVID-19 is an infectious disease caused by Coronaviruses family Coronaviridae, which has recently been identified as a cause of severe acute respiratory syndromes SARS Cov-2.',\n",
              "       \"Coronaviruses are named as such because Coronaviruses's surface is characterized by protrusions resembling crowns.\",\n",
              "       \"In terms of mathematics, molecular computation has several forms, some of which can be used in biology and protein research because of some of which can be used in biology and protein research because of their ability to handle a wide range of particle systems's ability to handle a wide range of particle systems.\",\n",
              "       'The Coronavirus genome is translated into two classes of proteins within the host cell structural proteins such as spikes S, envelopes E, matrixes M, and nucleocapsids N, and nonstructural proteins such as 3-C proteases 3CLpro, NSP5 and RNA Dependent RNA Polymerases RdRp, NSP12.',\n",
              "       'Among these proteins, RNA-dependent RNA polymerase RdRp has been demonstrated to contribute significantly to the replication of the viral genome single-stranded RNA and to the multiplication of Coronavirus in various cells.',\n",
              "       'It is essential to inhibit RNA-dependent RNA polymerase RdRp in order to control the progression of infection in human cells and, as a consequence, the viral load in patients, as RNA-dependent RNA polymerase RdRp replicates viral genomes by synthesizing new RNA nucleotides.',\n",
              "       'It has been established that RNA-dependent RNA polymerase RdRp is an essential enzyme that plays a significant role in the replication and translation of viral genomes this makes RNA-dependent RNA polymerase RdRp an excellent therapeutic target for COVID-19.',\n",
              "       'Numerous clinical trials have shown that COVID-19 can be effectively treated with antiviral, antimalarial, and anti-HIV drugs.',\n",
              "       'The FDA has approved Remdesivir Veklury for treating COVID-19 in hospitalized patients aged 12 and older and weighing at least 40 kg.',\n",
              "       'Several viral infections, including SARS-CoV-2, have been successfully treated with Remdesivir Veklury.',\n",
              "       'In the presence of NAs, a 5-triphosphate is formed in the cell, which replaces the RdRp substrate and competes with the endogenous nucleotides for incorporation into viral RNA.',\n",
              "       'In a comprehensive two-tier screening approach, Yuan et al. demonstrated that FDA-approved medications cetilistat, abiraterone, diiodohydroxyquinoline, and bexarotene inhibited COVID-19 infection in vitro.',\n",
              "       'As part of a comprehensive two-tier screening approach, Yuan et al. this study the interaction between four FDA-approved medications, bexarotene anticancer retinoid, abiraterone synthetic androstenedione steroid, diiodohydroxyquinoline antiparasite, and cetilistat antipancreatic lipase with SARS-CoV-2 RdRp using docking simulation.',\n",
              "       'In this study, Remdesivir Veklury was compared to the outcomes obtained with Remdesivir Veklury.',\n",
              "       'The screening of the drugs against RdRp of SARS-CoV-2 was performed by AutoDock Vina with MGL tools 1.5.4 which makes more precise docking calculations and runs faster than AutoDock software.',\n",
              "       'The 3D structure of bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir were received from PubChem as SDF files.sdf and converted to PDB format.pdb before perform docking utilizing MGL tools 1.5.4 which makes more precise docking calculations and runs faster than AutoDock software.',\n",
              "       'Because molecular docking results revealed that bexarotene has the best energy in interaction with RdRp of SARS-CoV-2, Yuan et al. investigated the molecular dynamic simulation of bexarotene with protein.',\n",
              "       'The free protein and protein-drug complex were solved using TIP3P water in the cubic box with periodic boundary situations in three directions.',\n",
              "       'We recently reported the in-silico screening of bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir against different SARS-CoV-2 drug targets.',\n",
              "       \"The current study used the same strategy to screen the bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir for bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir's potential to inhibit RdRp of SARS-CoV-2, thereby filling the gap.\",\n",
              "       'Molecular docking simulation was used to predict the binding of the selected drugs bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir with SARS-CoV-2 RdRp-RNA protein.',\n",
              "       'In our study, the FDA-approved RdRp inhibitor drug remdesivir was used as a comparator drug.',\n",
              "       'the FDA-approved RdRp inhibitor drug remdesivir is effective against many RNA viruses, including the newly discovered SARS-CoV-2 COVID-19 and previous coronaviruses.',\n",
              "       'We hypothesized that bexarotene, diiodohydroxyquinoline, abiraterone, cetilistat, and remdesivir could disrupt SARS-CoV-2 RdRp.',\n",
              "       'Cetilistat, a pancreatic lipase inhibitor, can be prescribed for obesity treatment.',\n",
              "       'Cetilistat, a pancreatic lipase inhibitor inhibits fat digestion and absorption.',\n",
              "       'Diiodohydroxyquinoline is a quinolone derivative used to treat amoebiasis as a luminal amebicide.',\n",
              "       \"When bile is available, diiodohydroxyquinoline is unlikely to be absorbed into the circulation, whereas Cetilistat, a pancreatic lipase inhibitor is rapidly hydrolyzed into Cetilistat, a pancreatic lipase inhibitor's metabolites.\",\n",
              "       'Gastrointestinal complaints have been reported in 15–20% of the newly discovered SARS-CoV-2 COVID-19 patients, and some of 15–20% of COVID-19 patients have also shown infectious virus particles and identifiable viral RNA.',\n",
              "       'Cetilistat, a pancreatic lipase inhibitor and oral diiodohydroxyquinoline may be effective topical luminal antivirals in suppressing viral shedding in the gastrointestinal system in the same way feces may be a significant source of SARS-CoV-2 infection.',\n",
              "       'Nonchemotherapeutic antineoplastic medicines, including bexarotene and abiraterone acetate, have been shown to have minimal immunosuppressive properties.',\n",
              "       'Breast cancer, non-small cell lung cancer NSCLC, and cutaneous T-cell lymphoma are effectively treated with bexarotene.',\n",
              "       'abiraterone acetate suppressed the activity of the enzyme CYP17A1, which is responsible for androgen synthesis when coupled with a corticosteroid.',\n",
              "       'Androgen deprivation is the mechanism employed in this therapy to treat resistant prostate cancer.',\n",
              "       'As described by Yuan et al., members of the same medication class as bexarotene, such as tamibarotene and AM580, have demonstrated outstanding antiviral effectiveness against several viruses, including influenza, Zika, coronaviruses SARS-CoV and MERS-CoV, adenoviruses, and enterovirus A71.',\n",
              "       'According to molecular docking studies, the binding energies of bexarotene, abiraterone, cetilistat, remdesivir, and diiodohydroxyquinoline to the RdRp were - 8.4, - 7.9, −7.6, −7.6 and - 5.5 kcal/mol, respectively, which demonstrate good binding potential towards the RdRp.',\n",
              "       'According to our findings, bexarotene was the most effective compound against RdRp, with the lowest binding energy.',\n",
              "       'Also, bexarotene and abiraterone were discovered to have the lowest binding energies than remdesivir.',\n",
              "       'In the meantime, the binding energies of cetilistat are equal to those of remdesivir.',\n",
              "       'Moreover, the binding energy value for diiodohydroxyquinoline −5.5 kcal/mol suggests that the ligand-protein complex is stable.,, represent the amino acid residues involved, bond lengths, and the type of interactions.,, depict the the RdRp amino acid residues that interacted with drugs.',\n",
              "       'As evident, The SARS-CoV-2 RdRp protein had hydrophobic interactions with abiraterone and bexarotene.',\n",
              "       'Meanwhile, cetilistat, diiodohydroxyquinoline, and remdesivir interacted with the RdRp of SARS-CoV-2 via hydrogen bonds and hydrophobic interactions.',\n",
              "       'The chosen drugs interacted with various amino acid residues of the RdRp of the SARS-CoV-2 protein.',\n",
              "       'It is evident from that bexarotene interacted with RdRp with LEU240, TYR129, LEU708, VAL128, ALA125, LEU207, TYR129, HIS133, TYR728, and TYR732 amino acids.',\n",
              "       'For further investigation, bexarotene was chosen as the compound with the highest interaction energy.',\n",
              "       \"The findings from the MD simulations provide unequivocal proof that bexarotene may construct a stable complex with 6NUR, which is an indication of bexarotene's inhibitory effects on the RdRp receptor.\",\n",
              "       'illustrates the RMSD graph of the backbone atoms in the 6NUR complex containing bexarotene and 6NUR.',\n",
              "       \"The RMSF values for 6NUR-Bex were exceptionally minimal Average RMSF 0.28 A0 thus, the 6NUR complex with bexarotene and 6NUR displayed negligible movement, which demonstrates the 6NUR complex with bexarotene and 6NUR's stability.\",\n",
              "       'the 6NUR complex with bexarotene and 6NUR appeared stable overall based on the protein RMSF values.',\n",
              "       'The bexarotene linked exclusively with the 6NUR protein, as shown by the binding free energies of 6NUR-Bex, which were found to be −89.635 ± 0.295 kJ/mol.',\n",
              "       'Bexarotene may be a candidate for blocking the RdRp of the SARS-CoV-2 receptor, as shown by the results mentioned above.',\n",
              "       'This research computationally evaluated the inhibitory potential of the FDA-approved drugs bexarotene, diiodohydroxyquinoline, abiraterone, and cetilistat against RdRp of the SARS-CoV-2 receptor.',\n",
              "       'With further ex vivo and in vivo examinations, our finding suggests that the FDA-approved drugs bexarotene, diiodohydroxyquinoline, abiraterone, and cetilistat could be the potential drug of choice for the treatment of COVID-19.',\n",
              "       'Gromacs software was used in This research to simulate the interaction of bexarotene with the RdRp of the SARS-CoV-2 receptor.',\n",
              "       'The binding free energy of 6NUR-Bex was determined to be −89.635 ± 0.295 kJ/mol, indicating that bexarotene interacted with 6NUR-Bex uniquely.',\n",
              "       'A novel coronavirus CoV first appeared by the end of 2019 in Wuhan, China and spread to over 70000 individuals with 1800 death cases within the matter of first 50 days of the disease.',\n",
              "       'The analytical methods like amino acid and nucleotide sequencing confirmed the relation of A novel coronavirus CoV to same class as severe acute respiratory syndrome coronavirus-1 SARS-CoV-1.',\n",
              "       'A novel coronavirus CoV was named as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the international committee on the taxonomy of viruses and similarly, the disease was named as Covid-19/SARS-CoV-2.',\n",
              "       'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 is a variant of coronavirus with enveloped single-stranded RNA which bears a corona like structure of spikes as shown in a. The main host protein for the attachment of spikes has identified as angiotensin converting enzyme 2 ACE2 receptor.',\n",
              "       'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 evolved to become the most contagious and infectious among coronavirus family.',\n",
              "       'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 enters the lungs by inhaling the contaminated air with viral bodies and infects distal airway cells leading to further spread towards alveolar epithelial cells and causes the damage starting from infection to severe damage as shown in a. As of May 25, 2021, total number of Covid-19 cases reported have surpassed the 30 million cases globally with 1.6 % in US only.',\n",
              "       'In an emergency situations like Covid-19 de novo drug development is not the feasible option since there is urgent need to find the treatments which can be immediately prescribed to prevent the mortality and morbidity.',\n",
              "       'So, to face the crisis because of pandemic drug repurposing seems a tangible strategy for fighting against Covid-19 and other such viral diseases.',\n",
              "       'To the best of our knowledge, until now there is no review study until now has published which summarizes the drug repurposing studies for Covid-19 with special emphasis on network-based drug repurposing approaches to Covid-19.',\n",
              "       'Thus, this review is mainly focused to bridge the gap by providing overview of machine learning and deep learning approaches to drug repurposing with focus on recent developments in network-based drug repurposing methods, tools, and databases used in Covid-19 as shown in b. In this connection, first we present an overview to computational drug repurposing studies for Covid-19 along with drug and disease related databases followed by recent machine learning and deep learning-based drug repurposing studies.',\n",
              "       \"Moreover, recent network-based drug repurposing studies for Covid-19 are discussed and recent network-based drug repurposing studies for Covid-19's limitations, benefits, and tools used are summarized.\",\n",
              "       'Some of the machine learning methods used for drug repurposing in Covid-19 include k-nearest neighbors, random forest, support vector machine, and more.',\n",
              "       'multiple state of art machine learning algorithms were tested on the performance parameters such as accuracy, precision, f1 score, Mathew’s correlation coefficient MCC, sensitivity, and specificity.',\n",
              "       'a feature enriched drug repurposing framework named SperoPredictor which consisted multiple state of art machine learning algorithms as shown in b. was deployed to predict the potential drugs to be repurposed for Covid-19, NASH, and renal fibrosis.',\n",
              "       'Additionally, molecular docking validation results suggested that four drugs Balaglitazone, Cortivazol, Velusetrag, and 16 alpha Bromoepiandrosterone can be used for preclinical validation and clinical trials prior to use in patients.',\n",
              "       'the developed model was further deployed to drugs active in Covid-19 and drugs active in Covid-19 were predicted with 100 % accuracy.',\n",
              "       'The interaction of drugs active in Covid-19 was shown with ACE2,, self-membrane protein, a key player in Covid-19 enabling disease infection.',\n",
              "       'Machine learning plays a key role in drug repurposing against Covid-19 and pace of research in the field has skyrocketed since the emergence of Covid-19.',\n",
              "       '41 repurposed drug candidates include dexamethasone an anti-inflammatory agent having bioactivity against Covid-19 and Niclosamide validated by proteomics of Covid-19 infected cell and gene expression.',\n",
              "       'Drug candidate such as pralatrexate and azithromycin predicted from One such study were validated in in-vitro testing and found to inhibit Covid-19.',\n",
              "       'First drug was active once Covid-19 entered host cells while azithromycin has efficacy in before and after stages.',\n",
              "       'To demonstrate the drug design features of software tools MolAICal, membrane protein glucagon receptor and Covid-19 main protease were modelled.',\n",
              "       'one such study which used neighborhood scoring, interconnectivity, and propagation random walks methods was confined to case studies such as scleroderma, different types of cancer and type 1 diabetes with results evaluated using area under the curve AUC.',\n",
              "       'Z-score and standard deviation are used as an evaluation criterion to judge the performance of developed models.',\n",
              "       'Another study used supervised bipartite graph learning approach to predict enzyme interaction and GPCRs interaction network.',\n",
              "       'Human coronaviruses HCoV include severe acute respiratory syndrome coronavirus SARS-CoV and novel 2019 coronavirus Covid-19 also referred to as SARS-CoV-2.',\n",
              "       'severe acute respiratory syndrome coronavirus SARS-CoV is pathogenic coronavirus that is known to emerge from zoonotic reservoir leading to global dissemination of severe acute respiratory syndrome coronavirus SARS-CoV. Recently, novel coronavirus 2019 nCoV has caused global pandemic with high morbidity and mortality rate.',\n",
              "       'Instead of highly accelerated efforts in the field of drug research, until now there is only drug approved for the treatment of novel 2019 coronavirus Covid-19.',\n",
              "       'Herein, we provide the comprehensive review along with benefits, challenges, and future directions of network science-based drug repurposing studies specifically for novel 2019 coronavirus Covid-19.',\n",
              "       'Use of network proximity analysis as shown in b i between HCoV-host targets and drug targets in human PPI led to prioritization of 16 anti-HCoV drugs potentially repurposable.',\n",
              "       'Hypothesis of One of the recent studies done in was that, for successful replication of viruses and infection host cellular factors are required, thus systematic study of human PPI a ii and virus hosts can present an effective method toward understanding the viral mechanism.',\n",
              "       'Despite successful results, One of the recent studies done in suffered from limitations such as, lack of known host proteins on novel 2019 coronavirus Covid-19, a low binding affinity value of 10 M was used to specify the DTI.',\n",
              "       'Another network proximity-based drug repurposing study enriched the PPI with transcriptomics and proteomics and then performed network proximity measurement where broach novel 2019 coronavirus Covid-19 associated underlying pathogenesis of disease manifestation was explored.',\n",
              "       \"Created network was analyzed followed by the single-cell RNA sequencing to uncover the underlying pathobiological and pathophysiological relationships between novel 2019 coronavirus Covid-19 and novel 2019 coronavirus Covid-19's associated treatments.\",\n",
              "       'Although not significant, network proximity results in Another network proximity-based drug repurposing study showed that rheumatoid arthritis has small network proximities negative Z scores across all 5 SARS-CoV-2 datasets.',\n",
              "       'This type of muti-layered validation of the network predicted drugs find out the key repurposable drugs supposed to have potential to reverse the expression of novel 2019 coronavirus Covid-19 expressed genes.',\n",
              "       'In total 34 drugs Z< −1.5 and P< 0.05, permutation test b i were computationally repurposed with the SARS-CoV-2 datasets SARS2-DEG, SARS2-DEP, HCoV-PPI, and SARS2-PPI using the above-mentioned criteria.',\n",
              "       'Additionally, Knowledge of the complex interplays between SARS-CoV-2 targets and human diseases indicate possibilities of drug repurposing, as the drugs that target other diseases could potentially target SARS-CoV-2 through the shared functional PPI networks.',\n",
              "       'As a starting point, experimentally validated host proteins of novel 2019 coronavirus Covid-19 known to have viral interaction, tissue specific gene expression data, were explored by use of techniques such as connectivity significance, network diffusion, and network propagation.',\n",
              "       'This process was followed to rank genes followed repurposing drugs targeting genes as a treatment for novel 2019 coronavirus Covid-19.',\n",
              "       'The prioritized collection of genes which served as key drug targets for repurposed anti-novel 2019 coronavirus Covid-19 drugs responsible for causing pharmacological effect resulted from normalization and aggregation of different scoring methods.',\n",
              "       'Ranking of genes focused on the contrasting the different phases of the virus infection and viral replication of the cycle.',\n",
              "       'Clustering was performed on the drugs and quality score was computed to adjust the network similarity and finally normalization of similarity score was carried out using sigmoid function.',\n",
              "       'As a step further 77/918 were tested in human-derived cells and 76/77 drugs showed the efficacy against viral disease.',\n",
              "       'Finally, it is also possible that some drugs that lacked activity in VeroE6 cells may nevertheless show efficacy in human cells, like loratadine.',\n",
              "       'Another very distinguished and interesting work in the field of network science and its applications to drug repurposing Covid-19 suffered from the limitations of missing the effective drugs possibly during the initial drug ranking.',\n",
              "       'The validation of the initial group of 3635 drugs was carried out using the population based retrospective EHRs analysis and EHRs are incomplete and prone to errors in comparison to randomized experimental data.',\n",
              "       'Another Covid-19 based drug repurposing study using the Few-Shot learning introduces the multi-targeted drug repurposing strategy which is taken as most efficient approach to diseases such as Covid-19.',\n",
              "       'Another Covid-19 based drug repurposing study using the Few-Shot learning provided a powerful tool for future research in drug repurposing specifically in case of poorly known diseases such as Covid-19.',\n",
              "       'Covid-19 drug repurposing explorer abbreviated as CoREx can be used to observe and understand the interaction between drugs and host Covid-19 targets in context of biological networks, clinical use of drugs, protein functioning, and cMAP.',\n",
              "       'Despite the contribution and benefits of Covid-19 drug repurposing explorer abbreviated as CoREx there some limitations such as the matrix decomposition approach can only be applied to the drugs for which association with viral disease is known.',\n",
              "       'One such graph machine learning based drug repurposing study in Covid-19 is presented in which avails the ML and statistical approaches to map and mine the knowledge graph, transcriptomic and literature data on the large scale to uncover the potential drugs for Covid-19.',\n",
              "       'The computational approach in combination with pre-clinical validation indicated that a poly-ADP-ribose polymerase 1 PARP1 inhibitor, CVL218, currently in Phase I clinical trial, may be repurposed to treat Covid-19.',\n",
              "       'Specifically, as a part of One other study that used DrugBank and other databases along with graph convolutional networks GCN, capmatinib MET inhibitor was found to have potent and wide range antiviral activity in multiple coronaviruses.',\n",
              "       'The antiviral activity was observed in MET-independent manner and additional roles of capmanitib for host cell proteins promoting the infection caused by human coronavirus thus it can inform further drug discovery studies.',\n",
              "       'KEGG enrichment, molecular docking, STITCH search tool, and virus-host-drug interactome were used to investigate the interaction network linked with Covid-19 and chloroquine and hydroxychloroquine were utilized as reference drugs to further get into the interaction network linked with Covid-19.',\n",
              "       'As a result, 47 drug targets were found enriched in TLR pathway and were found overlapping with Covid-19.',\n",
              "       'Another step of molecular docking and dynamics in investigation led to confirmation of binding affinity of TLR9 to five drugs.',\n",
              "       \"Additional insights from human-drug protein map identified and further confirmed the interaction of Covid-19 with TLR pathway will provide key information for Covid-19 Covid-19 and Covid-19's treatment.\",\n",
              "       'Finally, to validate the Anti-Covid-19 drugs molecular docking was performed to find the binding affinity of the drugs potentially repurposable with Covid-19 spike and ACE2 proteins.',\n",
              "       'Among the 16 repurposable drugs Sirolimus originally approved as an immunosuppressant is registered in phase-II clinical trials for Covid-19.',\n",
              "       'Another work done in applied machine learning on networks and repurposed 14 potential repurposable drugs for Covid-19, of which Chloroquine is registered in Phase-II & III and Dexamethasone is registered in Phase-IV clinical trials as mentioned in.',\n",
              "       'Out of 12 potential drugs, Ebselen was found under trial in Phase-II whereas Artemesian and Nitrendipine are in Phase-IV clinical trials as shown in.',\n",
              "       'The Coronavirus disease Covid-19 is an infectious disease caused by SARS-CoV-2 virus.',\n",
              "       'Started in November 2019 in the Wuhan-China, The Coronavirus disease Covid-19 was soon declared as public health emergency of international health concern by the World Health Organization WHO on January 30, and The Coronavirus disease Covid-19 scaled up to pandemic as of March 11, 2020.',\n",
              "       \"At the beginning of February 2020, the World Health Organization WHO declared the novel coronavirus disease 2019 COVID-19 a pandemic due to the novel coronavirus disease 2019 COVID-19's rapid spread as well as the novel coronavirus disease 2019 COVID-19's high mortality and morbidity rates.\",\n",
              "       \"Due to the novel coronavirus disease 2019 COVID-19's highly contagious nature, as of May 2022, the pandemic has spread to more than 200 countries and territories with over 5.5 million confirmed positive cases and mortality of over 350K across the globe.\",\n",
              "       'The etiological agent of the novel coronavirus disease 2019 COVID-19 is severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, and severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has been reported to originate from the animal coronavirus.',\n",
              "       'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae which already has two other members, i.e., SARS coronavirus SARS-CoV-1 and Middle East respiratory syndrome coronavirus MERS-CoV which caused pandemic onslaughts in 2002 and 2012, respectively, resulting in severe human losses both in terms of morbidity and mortality.',\n",
              "       \"Coronaviruses's genome encodes for ORF1a and ORF1ab polyprotein which cleaves into multiple subunits and performs a diverse range of functions, i.e., binding and invading the host cell, viral replication, and evading the host immune system.\",\n",
              "       \"The proteins of coronaviruses perform The proteins of coronaviruses's function by aggregating multiple subunits into an heteromeric complex, i.e., replication-transcription complex and several other structural proteins that assemble into new virions.\",\n",
              "       'a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved by sharing 96% similarity with SARS coronavirus SARS-CoV-1 and 70% with Middle East respiratory syndrome coronavirus MERS-CoV The recently resolved structure has also revealed conserved structural architecture by comparison with non-structural protein 5 NS5 of flaviviruses and polymerases of picornaviruses.',\n",
              "       'However, a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity has a length of ~930 amino acids in contrast to the polymerases of Human Poliovirus PV and NS5B of Hepatitis C Virus HCV which usually comprises ~500 amino acids.',\n",
              "       'a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is responsible for viral replication and transcription once the virus invades into the host cellular environment by aggregating with cofactors such as NSP-7 and NSP-8 along with some additional subunits to initiate viral replication.',\n",
              "       \"a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity's tertiary structure comprises three highly conserved domains N-terminal nucleotidyltransferase also known as nidovirus RdRp-associated nucleotidyltransferase NiRAN, interface, and C-terminal RdRp domain.\",\n",
              "       'The RdRp domain of a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity is highly conserved and responsible for viral replication and has been reported in several families of RNA genome viruses, while the NiRAN domain is only conserved among the members of nidoviruses by possessing kinase-like fold and involves in attachment with NSP-7 and NSP-8.',\n",
              "       'RdRp domain contains seven conserved motifs motif A-G that involve attachment with nucleotide triphosphate NTP and RNA primer during the viral replication.',\n",
              "       'Due to these conserved evolutionary features of RdRp domain, RdRp domain has been suggested to be an important therapeutic target.',\n",
              "       'Currently, many studies including single-ligand docking as well as screening of the compounds library have been conducted to search for potential inhibitors against NSP-12 of SARS-CoV2.',\n",
              "       'The selected FDA-approved inhibitors were Dasabuvir Sodium Dasabuvir and Sofosbuvir which were previously authorized for inhibiting the NS5B of HCV.',\n",
              "       'Furthermore, the conserved active site of a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity was characterized and the affinity of The selected FDA-approved inhibitors were evaluated using in silico assessments, i.e., molecular docking and simulations.',\n",
              "       'The DALI server was employed for the identification of homologous protein structures to NSP-12 of SARS-CoV2 that were already submitted in the PDB repository.',\n",
              "       '611 structures were involved in the RdRp activity and belonged to four viral families Coronaviridae, Flaviviridae, Picornaviridae, and Caliciviridae and infected a diverse range of hosts.',\n",
              "       'Based on structural similarity, the unrooted cladogram of homologous structures to a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity was clustered into four viral families as shown in B. The clade of the coronaviruses, i.e., SARS-CoV-1 and SARS-CoV-2, shares a close relationship with the NS5B of HCV and also with the other representatives of Flaviviridae, i.e., the Zika Virus ZIKV, Dengue Virus DENV, Bovine Viral Diarrhea Virus BVDV, Japanese Encephalitis Virus JEV, and Classical Swine Fever Virus CSFV.',\n",
              "       'The members of Picornaviridae included PolV, Human Coxsackievirus CoxV, Human Rhinovirus HRV, Human Enterovirus HEV, Human Enterovirus 71 HEV71, Foot and Mouth Disease Virus FMDV, and Encephalomyocarditis virus.',\n",
              "       'The representatives of Caliciviridae were the Sapporovirus SapV, Rabbit Haemorrhagic Disease Virus RHDV, Murine Norovirus MNV, Norwalk Virus NarV, and Human Norovirus HNV.',\n",
              "       'The conserved motifs in a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity were analyzed by multiple structures and sequence alignments implemented at the PROMALS3D server.',\n",
              "       'The identified conserved motifs in a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity have been displayed in A. a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity has seven highly conserved motifs motif A-G which are responsible for NTP catalysis, binding to the 3′ of RNA template, and viral replication by agglomerating with NSP7 and NSP8.',\n",
              "       'To display the conserved orientation of these motifs at the active site of a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity, multiple structures belonging to the family Coronaviridae, Flaviviridae, and Picornaviridae were superposed structurally aligned by using the MatchMaker algorithm implemented in UCSF Chimera.',\n",
              "       'Motifs A and C have highly conserved aspartic acid residues which bind to the divalent ions Mn2+ or Mg2+ and are responsible for executing the catalysis of nucleotide-binding.',\n",
              "       'Motif F is enriched with positively charged basic residues which interact with the triphosphate moieties of the NTP.',\n",
              "       \"The analysis resulted in the prediction of a total of 27 cavities in a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity and a total of 27 cavities in NSP-12's information has been shown in.\",\n",
              "       'the top-scored cavity as shown in C has a higher drug score revealing significant druggability of the active site with a predicted maximum pKd score of 6.99.',\n",
              "       'There was a total of 154 amino acid residues constituting the predicted cavity and a total of 154 amino acid residues constituting the predicted cavity were The comparison with the evolutionarily conserved residues of the RdRp domain of a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity from multiple sequence alignments.',\n",
              "       'The comparison has been plotted as a Venn diagram as shown in A. the evolutionarily conserved residues of the RdRp domain of NSP-12 were K545 and R555 of motif F, D618, and D623 of motif A, S682, G683, T687, and N691 of motif B, D760, and D761 of motif C and W800 of motif D. the evolutionarily conserved residues of the RdRp domain of NSP-12 were further represented as a target in the RdRp domain of a non-structural protein 12 NSP-12 which involves RNA-dependent RNA polymerase RdRp activity for molecular docking with the FDA-approved antivirals.',\n",
              "       'Before molecular docking, the ligands, i.e., Dasabuvir, Sofosbuvir, Ribavirin, GTP, and UTP, were prepared using AutoDock Tools.',\n",
              "       'The grid box was centered at the active site or druggable cavity and the residues were considered rigid for both receptors, i.e., NSP-12 of SARS-CoV-2 and NS5B of HCV.',\n",
              "       'The results score of ligand bindings with the active site of NSP-12 of SARS-CoV-2 and NS5B of HCV has been compared and visualized as a bar chart as shown in B.The docking score of NSP-12 of SARS-CoV-2 with the ligands, i.e., Dasabuvir, Sofosbuvir, Ribavirin, GTP, and UTP was in the range of −6.2 to −8.1 kcal/mol, while for NS5B of HCV, B.The docking score of NSP-12 with the ligands was −6.5 to −9.1 kcal/mol, and both had an average difference of 0.84 kcal/mol.',\n",
              "       'The average docking score of NSP-12 of SARS-CoV-2 and NS5B of HCV for Sofosbuvir, Dasabuvir, Ribavirin, GTP, and GTP were −8.2, −8.6, −6.35, −8.25, and −7.6 kcal/mol, respectively.',\n",
              "       'NSP-12 of SARS-CoV-2 showed the lowest docking score −8.1 kcal/mol with Dasabuvir and higher −6.2 kcal/mol with Ribavirin.',\n",
              "       'In general, the ligands showed a higher docking score for NS5B of HCV as compared to NSP-12 of SARS-CoV-2.',\n",
              "       'To examine the interactions between ligand and the conserved residues present at the active site of NSP-12 of SARS-CoV-2, LigPlot + v2.1, standalone software was used.',\n",
              "       'The predicted interactions of Sofosbuvir and Dasabuvir with NSP-12 of SARS-CoV-2 have been shown in A,B, respectively.',\n",
              "       'The conserved residues involved in forming hydrogen bonds with Sofosbuvir were C622 of motif-A, W800 of motif-D, G811, and S814 of motif-E, while Dasabuvir interacted by the formation of hydrogen bonds with D761 of motif-C and W800 of motif-D. In addition, several conserved residues of motif-A, -C, and -E were also involved in hydrophobic interactions with Sofosbuvir and the residues of motif-A, -B, -C, -E, and -F with Dasabuvir.',\n",
              "       'On the other hand, the native competitors such as GTP interacted with NSP-12 of SARS-CoV-2 by forming hydrogen bonds with A554, R555, and T556 of motif-F, Y619, K621, and C622 of motif-A, while UTP interacted with S759, D760, and D761 of motif-C, W800 of motif-D, and G811 and S814 of motif-E In the case of HCV as a receptor, Sofosbuvir binds with motif-B and -C, while Dasabuvir interacted with residues of motif-A, -B, -C, and motif-F, and their receptor–ligand interaction plots have been shown in C,D, respectively.',\n",
              "       'The average RMSD for the protein, the protein-Dasabuvir, Ribavirin, and Sofosbuvir complexes was calculated as 0.23, 0.23, 0.27, and 0.27 nm, respectively.',\n",
              "       'displays the RMSD plots of 6M71, 6M71-Dasabuvir, Ribavirin, and Sofosbuvir complexes vs. simulated time.',\n",
              "       'The resulting RMSD graph showed increasing trends with increasing RMSD values ranging from 0.10 to 0.33 nm between 0 and 60 ns in the case of 6M71/Ribavirin and 6M71/Sofosbuvir, suggesting Sofosbuvir and Dasabuvir were becoming accustomed to a new conformation inside the binding pocket after that, the plateau continued and finally, settled at 0.29 nm, which does not exceed the 0.3 nm threshold.',\n",
              "       'However, 6M71/Sofosbuvir has the same evolution to NSP-12 of SARS-CoV-2.',\n",
              "       'Lower RMSD values for 6M71, 6M71-Dasabuvir, Ribavirin, and Sofosbuvir complexes shows that Dasabuvir is stable inside the protein and gives a strong foundation for our research.',\n",
              "       'In, RMSFs of the Apo NSP-12, NSP-12/Dasabuvir, NSP-12/Ribavirin, and NSP-12/Sofosbuvir complexes are displayed.',\n",
              "       'Furthermore, the average RMSF values of Apo NSP-12, NSP-12/Dasabuvir, NSP-12/Ribavirin, and NSP-12/Sofosbuvir complexes were 0.10, 0.10, 0.11 and 0.11 nm, respectively.',\n",
              "       'This finding implies that Dasabuvir, Ribavirin, and Sofosbuvir binding helped to maintain NSP-12 of SARS-CoV-2 structurally stable.',\n",
              "       \"We examined how binding of different ligands this goal NSP-12 of SARS-CoV-2's overall compactness in the protein's structure.\",\n",
              "       'The average Rg values Apo NSP-12 of SARS-CoV-2, NSP-12/Dasabuvir, NSP-12/Ribavirin, and NSP-12/Sofosbuvir complexes were found to be 2.99, 3.00, 2.97, 2.98 nm, respectively, suggesting that the binding of Dasabuvir, Ribavirin, and Sofosbuvir to NSP-12 of SARS-CoV-2 packing did not cause significant change.',\n",
              "       'Moreover, based on the graph, it appears that the Rg of NSP-12/Dasabuvir reached a stable equilibrium during the 100 ns simulation than NSP-12/Ribavirin and NSP-12/Sofosbuvir complexes.',\n",
              "       'displays the number of hydrogen bonds and pairs within 0.35 nm generated between NSP-12/Dasabuvir, NSP-12/Ribavirin, and NSP-12/Sofosbuvir complexes during the MD simulation.',\n",
              "       'It was noticed that Dasabuvir binds to the active pocket of NSP-12 of SARS-CoV-2 with an average of 3.46 hydrogen bonds and 1.13 pairs within 0.35 nm.',\n",
              "       'Similarly, Ribavirin acting as a ligand interacted with NSP-12 as a target within the binding site with an average of 3.97 hydrogen bonds, although the average of pairs within 0.35 nm is 1.66.',\n",
              "       'However, the average of both hydrogen bonds and pairs within 0.35 nm for the NSP-12/Sofosbuvir complex was 1.',\n",
              "       'On the other hand, the H-bonding plot showed that Dasabuvir was able to maintain a more robust interaction with the binding pockets of NSP-12 of SARS-CoV-2 throughout the simulation time than Ribavirin and Sofosbuvir. Before MM/PBSA calculation, each complex between the receptors or inhibitors/ligands should reach the equilibrium state.',\n",
              "       'After that, we utilized a python script MmPbSaStat.py to calculate average free binding energy of 6M71, 6M71-Dasabuvir, Ribavirin, and Sofosbuvir complexes, as provided in the g mmpbsa package.',\n",
              "       'Except for the polar solvation energy, all other forms of energy contributed favorably to the interaction between different molecules Dasabuvir, Ribavirin, and Sofosbuvir and NSP-12 of SARS-CoV-2.',\n",
              "       'Dasabuvir showed the least binding free energy −42.151 KJ/mol among 6M71, 6M71-Dasabuvir, Ribavirin, and Sofosbuvir complexes.',\n",
              "       'A comparison of the binding free energies of 6M71, 6M71-Dasabuvir, Ribavirin, and Sofosbuvir complexes was made by plotting the binding energy versus time graphs.',\n",
              "       \"From the overall results, it was observed that the amino acid residue Trp 800 showed the lowest contribution binding energy for all the tree complexes, suggesting the amino acid residue Trp 800's significant role in binding indeed, contribution energy analysis of amino acid residues Tyr619, Cys622, the amino acid residue Trp 800, Glu811, Ser814, and Asp761 revealed that amino acid residues Tyr619, Cys622, Trp800, Glu811, Ser814, and Asp761 played an important role during interaction, which confirms the docking result.\",\n",
              "       'Finally, the Sofosbuvir and Dasabuvir could be established as a repurposed drug against the COVID-19 main protease.',\n",
              "       \"Many drugs have been already suggested for the current pandemic caused by SARS-CoV-2, of which the most prominent are FDA-approved Chloroquine and FDA-approved Chloroquine's derivatives—an anti-malarial drug and Remdesivir.\",\n",
              "       'Remdesivir, has been shown to significantly reduce the SARS-CoV-2 pathogenicity in in vitro study and is still under investigation.',\n",
              "       \"In this study, we searched for homologs of NSP-12 of SARS-CoV-2 and evaluated NSP-12 of SARS-CoV-2's binding affinity with the FDA-approved antivirals, i.e., Sofosbuvir and Dasabuvir, which specifically target the evolutionarily conserved site of NS5B of HCV.\",\n",
              "       'Further screening of 1105 structures based on the quality of structural alignment Z-score ≥ 19 resulted in 611 structures that belonged to four viral families, i.e., Coronaviridae, Flaviviridae, Picornaviridae, and Caliciviridae, responsible for RdRp activity during viral replication.',\n",
              "       'The NSP-12 of SARS-CoV-2 displayed significant homology to the NS5 of Flaviviridae or NS5B of HCV as compared to the polymerases of Picornaviridae and Caliciviridae.',\n",
              "       'Based on the pairwise alignment of amino acid sequences, NSP-12 of SARS-CoV-2 shares 96% identity with SARS-CoV-1, 11% with HCV and HNV, and 10% with Poli.',\n",
              "       'Despite sharing a lower identity based on sequence, NSP-12 of SARS-CoV-2 has seven highly conserved motifs in the RdRp domain that play a key role in viral replication.',\n",
              "       'the active site of the RdRp domain was also identified as a suitable site for drug targeting based on the highest druggability score evaluated by using the CavityPlus webserver.',\n",
              "       'significant overlap included the conserved residues of motifs A, B, C, D, and F of the RdRp domain of NSP-12 of SARS-CoV-2.',\n",
              "       'the conserved residues of motifs A, B, C, D, and F of the RdRp domain of NSP-12 have been also described previously to involve interactions with nucleoside, RNA primer attachment, and the RdRp activity.',\n",
              "       'The active site of the RdRp domain of NSP-12 of SARS-CoV-2 was further evaluated for binding affinity with FDA-approved antivirals by the molecular docking method.',\n",
              "       'Molecular docking was performed using AutoDock Vina which revealed a significant binding affinity of NSP-12 of SARS-CoV-2 with Sofosbuvir and Dasabuvir as compared to Ribavirin.',\n",
              "       'Despite that, NS5B showed higher binding affinity lower binding energy as compared to NSP-12 of SARS-CoV-2 however, the differences were still insignificant.',\n",
              "       'The profiling of NSP-12 of SARS-CoV-2 and ligand interaction revealed firm binding due to the formation of hydrogen bonds and hydrophobic interactions.',\n",
              "       \"The participating conserved residues of motif-A, -B, -C, -D, -E, and -F of the RdRp domain were involved in these interactions with the ligands, i.e., Dasabuvir, Sofosbuvir, as well as with Sofosbuvir and Dasabuvir's native competitors, i.e., GTP and UTP.\",\n",
              "       'Similarly, in the case of HCV as a receptor, the residues of motif-A, -B, -C, and -F were involved in interactions with Sofosbuvir and Dasabuvir.',\n",
              "       'In general, both Sofosbuvir and Dasabuvir showed higher binding to the active site of NS5B of HCV and NSP-12 of SARS-CoV-2.',\n",
              "       'We retrieved NSP-12 of SARS-CoV-2 with PDB ID 6M71 at 2.9 Å resolution from the Protein Data Bank PDB repository that was recently submitted by Gao et al. For the identification of homologous structures in the Protein Data Bank PDB repository, 6M71 chain A was submitted to the DALI server website.fi/dali/ accessed on 16 March 2020.',\n",
              "       \"a Z-score is a quantitative expression for comparing the intramolecular similarity between two homologous protein structures and a Z-score's value ≥2 is suggested to be significant.\",\n",
              "       'To further study the conserved residues at the active site of NSP-12 of SARS-CoV-2, multiple structures were aligned by using the MatchMaker algorithm implemented in the University of California, San Francisco UCSF Chimera v.14 and visualized.',\n",
              "       'Initially, the Canonical SMILES IDs of the ligand compounds, i.e., Sofosbuvir CID 45375808, Ribavirin CID 37542, and Dasabuvir CID 56640146 were retrieved from the PubChem library and then imported in Chimera v.14 for converting into PDB files.',\n",
              "       'On the other hand, the receptor structures were acquired from PDB and then processed in AutoDock Tools by removing water molecules, isolation of a single chain, addition of charges, merging non-polar hydrogens, and assigning appropriate atom types.',\n",
              "       'A grid box of size 48 × 44 × 54 Å was selected and centered at the druggable cavity of 6M71-A oriented at 117.4, 115.3, 129.5 Å, while the NS5B of HCV PDB ID 1YUY-A was considered as a control with the same size of A grid box of size 48 × 44 × 54 Å used at the origin of 0.6, 80.0, and 64.2 Å. The parameters for molecular docking were used as described for running the single-docking experiment.',\n",
              "       'The resulting score of molecular docking of NSP-12 of SARS-CoV-2 and NS5B of HCV were compared and plotted using a bar plot.',\n",
              "       'The systems were solvated in a cubic box of TIP3P water model and neutralized with the addition of counter ions.',\n",
              "       'The molecular mechanic/Poisson–Boltzmann surface area MM-PBSA methods were used to This calculation of binding free energy NSP-12/Dasabuvir, NSP-12/Ribavirin, and NSP-12/Sofosbuvir complexes.',\n",
              "       \"In this study, we searched for structural homologs of NSP-12 of SARS-CoV-2 and identified structural homologs of NSP-12 of SARS-CoV-2's relationship with the members of three viral families, i.e., Flaviviridae, Picornaviridae, and Caliciviridae.\",\n",
              "       'The RdRp domain of NSP-12 of SARS-CoV-2 is highly conserved in terms of both sequence and architecture and assessed for binding affinity with FDA-approved antivirals, i.e., Dasabuvir and Sofosbuvir.',\n",
              "       'FDA-approved antivirals, i.e., Dasabuvir and Sofosbuvir were initially approved for targeting the NS5B of HCV and serve as competitive inhibitors for binding to the active site that results in reducing viral pathogenesis.',\n",
              "       'The results of this study revealed that the six conserved motifs motif A-F were involved in the formation of hydrogen bonds and hydrophobic interactions with FDA-approved antivirals, i.e., Dasabuvir and Sofosbuvir.',\n",
              "       \"However, there is still a further need for in vitro analysis of FDA-approved antivirals, i.e., Dasabuvir and Sofosbuvir to assess FDA-approved antivirals, i.e., Dasabuvir and Sofosbuvir's efficiency before entering into clinical trials.\",\n",
              "       'Coronavirus disease 2019 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, is currently spreading around the world rapidly.',\n",
              "       'severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has infected more than half a billion people and caused over 5 million deaths, implying a global health threat.',\n",
              "       'For example, approved nucleoside analogues favipiravir and ribavirin and experimental nucleoside analogues remdesivir and galidesivir may have potential against severe acute respiratory syndrome coronavirus 2 SARS-CoV-2.',\n",
              "       'Two oral antiviral treatments, Molnupiravir and Paxlovid, were recently authorized by the Food and Drug Adminstration FDA.',\n",
              "       'Molnupiravir has relatively low efficacy and may have potentially serious adverse effects, such as mutagenicity and congenital disabilities.',\n",
              "       'It was quickly discovered that severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and leverages the serine protease TMPRSS2 for S protein initiation.',\n",
              "       'the SARS-CoV receptor ACE2 regulates the renin-angiotensin system RAS in several diseases and expresses in the lungs and the kidney, small intestine, testis, and heart.',\n",
              "       'the serine protease TMPRSS2 activates the virus-membrane fusion on the cell surface by cleaving the S protein.',\n",
              "       'In addition to the SARS-CoV receptor ACE2 and the serine protease TMPRSS2, several candidate receptors can aid severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection, such as the cell-surface proteins tyrosine-protein kinase receptor UFO Axl, low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3, and C-type lectin domain family 4 member G CLEC4G.',\n",
              "       'Moreover, members of pathways that mediate membrane fusion and lipid metabolism, such as PI3K type 3 PIK3C3 and PI3K regulatory subunit 4 PIK3R4 from phosphatidylinositol 3-kinase PI3K pathway and sterol regulatory element-binding protein 1 and 2 SREBF1 and SREBF2, are also crucial for infection.',\n",
              "       'Several efforts have been made to identify drugs that inhibit severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by targeting host proteins.',\n",
              "       'An in vitro study demonstrates that the inhibition of the protease activity of the serine protease TMPRSS2 partially prevents the entry of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 into the lung epithelial cells.',\n",
              "       'In vitro studies suggest that both chloroquine and hydroxychloroquine may prevent the transport of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 from the early endosome to the endolysosome.',\n",
              "       'In addition to treating malaria, chloroquine and hydroxychloroquine also have immunomodulatory effects.',\n",
              "       'Importantly, current methods barely avoid the potential side effect of repurposed drugs for Coronavirus disease 2019 COVID-19 patients with chronic underlying diseases, such as diabetes mellitus, cardiovascular disease, chronic pulmonary disease, and cancers.',\n",
              "       'In this study, to identify the potential antiviral agents, we applied an end-to-end computational method to search drug-gene s -coronavirus CoV paths in a directional network and inferred the effect of drugs on Coronavirus disease 2019 COVID-19 We constructed a directional network by aggregating three networks with direction information, including a virus-host interactome, a human PPI network, and a drug-target network.',\n",
              "       'We reported 29 FDA-approved drugs 7 currently in clinical trials as Coronavirus disease 2019 COVID-19 treatment by a scoring strategy accounting for the effects of drugs on CoVs and comorbidities and other auxiliary information.',\n",
              "       'We first comprehensively collected candidate host genes from three major domains for mechanistic research of CoV infection genetic risk genes, physical interaction genes, and biological regulation genes A. The source of genetic risk genes was mainly collected from the GWASs of Coronavirus disease 2019 COVID-19.',\n",
              "       \"We then searched for drug-gene s -CoVs paths in a directed multicomponent network including CoV, host genes, human genes, drug targets, and drugs and used the direction information to screen out drugs with suitable MoAs C. To investigate the impact of drug candidates on the underlying disease in patients with COVID-19, we also identified genetic risk genes for common complex diseases and genetic risk genes for common complex diseases's direction to disease from genetic data.\",\n",
              "       'Finally, drugs with a potential inhibitory effect on the disease were prioritized based on a combined score, and conversely, drugs that promote disease were filtered out D.Phylogenetic analysis of human CoVs shows that SARS-CoV-2, SARS-CoV, and MERS-CoV have a high conservative genome.',\n",
              "       'Specifically, the envelope and nucleocapsid proteins of SARS-CoV-2 are two evolutionarily conserved regions, having high sequence identities between SARS-CoV and MERS-CoV Therefore, SARS-CoV-2, SARS-CoV, and MERS-CoV may share infectious mechanisms through common host genes, and the therapeutic drugs could be overlapped.',\n",
              "       'We systematically integrated candidate host genes from three different angles to identify genetic risk genes of COVID-19, we first got significant risk variants p-value<5 × 10−8 of 517 COVID-19 GWASs from GRASP, yielding 2618 risk variants significantly associated with COVID-19.',\n",
              "       'If the risk variant is an expression quantitative trait locus eQTL of whole blood or lung, we retrieved the eGene of an expression quantitative trait locus eQTL of whole blood or lung as the risk gene and inferred the direction of the risk variant to COVID-19 by matching the effect size of the GWAS and the effect size of an expression quantitative trait locus eQTL of whole blood or lung.',\n",
              "       'We identified 77 genetic risk genes, including innate antiviral defenses, which are critical early in infection IFNAR2, OAS1, and OAS3.',\n",
              "       \"OAS3 encodes for the oligoadenylate synthase family of proteins that degrades viral RNA and activates antiviral responses, and OAS3's expression was predicted to be significantly associated with the disease.\",\n",
              "       'The association on chromosome 19p13.12 colocalizes an eQTL of TYK2, the target of JAK inhibitors, whose high expression is associated with COVID-19.',\n",
              "       'Among 435 genes that interact with viral proteins and their direction of action, 16 genes interacted with both SARS-CoV and SARS-CoV-2 and were significantly differentially expressed in the expression profiles of both SARS-CoV and SARS-CoV-2.',\n",
              "       'Aconitase1 ACO1 is overexpressed in COVID-19 and underexpressed in non-COVID-19 viral infections.',\n",
              "       'Interestingly, Aconitase1 ACO1 is involved in iron metabolism, and heme appears to be interlinked with COVID-19 pathophysiology.',\n",
              "       'PCDH9, one of the downregulated genes, interacts with multiple proteins of CoVs, including M, NSP6, ORF6, ORF7a, ORF7b, and S proteins.',\n",
              "       'PCDH9, one of the downregulated genes protocadherin is essential in epithelial cell-cell adhesion and the integrity of endothelial barrier function.',\n",
              "       'The disruption of cadherin proteins by viral protein ORF7b could contribute to several symptoms of COVID-19 infection, including multiorgan failure.',\n",
              "       'Genome-wide perturbations can identify genes in human cells that play a key role in viral infection and the body’s response.',\n",
              "       'It is worth noting that seven genes were selected in the screening of SARS-CoV-2, SARS-CoV, and MERS-CoV, including CTSL, which encodes the Cathepsin L protease.',\n",
              "       'CTSL, which encodes the Cathepsin L protease can functionally cleave the SARS-CoV-2 spike protein and enhance virus entry.',\n",
              "       'Studies have shown that inhibitors of the Cathepsin L protease can effectively prevent human SARS-CoV-2, SARS-CoV, and MERS-CoV infection.',\n",
              "       'For example, only 1 out of the 77 genetic risk genes is derived from the CRISPR screen and physical interaction, respectively A. For SARS-CoV-2, we revealed 882 candidate host genes B. Among 882 candidate host genes B., BMPR2 is not only a genetic risk gene but also interacts with SARS-CoV-2 ORF3 protein.',\n",
              "       'Heterozygous mutations in BMPR2 can cause hereditary pulmonary hypertension.',\n",
              "       'Drugs targeting BMPR2 may affect the prognosis of patients with pulmonary hypertension based on genetic evidence.',\n",
              "       'SARS-CoV-2 and SARS-CoV share 67 host genes C, including ACE2, the primary cell entry receptor for SARS-CoV-2, whereas 35 genes, including TMEM41B, were identified as host genes of both SARS-CoV-2 and MERS-CoV TMEM41B can promote lipid localization in infected cells.',\n",
              "       \"We divided these genes into antiviral and proviral genes according to these genes's effect on SARS-CoV-2, SARS-CoV, and MERS-CoV. There are 654 antiviral genes and 756 proviral genes.\",\n",
              "       'Antiviral genes were enriched in viral-infection-related pathways such as influenza A and hepatitis C and inflammation-related pathways such as cytokine-cytokine receptor interaction and Th17 cell differentiation D. Proviral genes were also enriched in some infection-related pathways, such as human papillomavirus infection, Salmonella infection, and Vibrio cholerae infection E. Both proviral and antiviral genes were also enriched in autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease.',\n",
              "       'Then we used the random walk with restart RWR algorithm to find drug-gene s -CoVs paths in a whole drug-gene-CoV network and inferred the direction of the drug to the CoVs see.',\n",
              "       'We applied a genetics-based method to predict the impact of repurposed drugs on comorbidities, including diabetes mellitus, cardiovascular disease, cerebrovascular disease, chronic liver disease, chronic kidney injury, autoimmune disease, and cancers.',\n",
              "       \"According to our previous strategy, we filtered and prioritized potential drugs by inspecting potential drugs's impact on diabetes mellitus, cardiovascular disease, cerebrovascular disease, chronic liver disease, chronic kidney injury, autoimmune disease, and cancers.\",\n",
              "       'To select the optimal drugs, we utilized the properties of drug-gene s -CoVs path including drug-target interaction, network mapping, and source of host genes for each drug to derive a combined score and used a combined score to prioritize drug candidates see.',\n",
              "       'None of the drugs in clinical trials prior to phase 3 have been found in clinical trials for COVID-19, and there are nine drugs in phase 3/4 clinical trials for COVID-19 B this may be because most of the COVID-19 clinical trial drugs are in clinical phase 3 or FDA approved.',\n",
              "       'We identified well-studied drugs with clinical trials, such as aspirin and chlorpromazine.',\n",
              "       'chlorpromazine is an antipsychotic drug that has recently been proposed to have antiviral activity against SARS-CoV-2.',\n",
              "       'The MoA of chlorpromazine is either via inhibition of clathrin-mediated endocytosis and/or at later stages of virus assembly and egress.',\n",
              "       'bosutinib is a treatment for chronic myeloid leukemia by inhibiting the Abelson kinase signaling pathway.',\n",
              "       'Recently, bosutinib was found to strongly inhibit SARS-CoV-2 in vitro with low toxicity.',\n",
              "       'Recently, it was reported that pseudoephedrine can antagonize COVID-19 virus by blocking virus expansion.',\n",
              "       'Another example is that ponatinib is a potent inhibitor of SARS-CoV2-induced cytokine storm, whereas epinephrine may be considered an intervention to minimize the severity of COVID-19.',\n",
              "       'We measured the associations of gene expression patterns between CoV-infected patients and the reference-compound-perturbed cells.',\n",
              "       'Our method has the highest area under the curve AUC of 0.61 compared with the results calculated by the CMAP method based on similarity analysis of expression profiles, which was frequently used in drug repositioning using two SARS-CoV-2 infection expression profiles C.Network analysis methods such as deep learning, network diffusion, and network proximity can evaluate the accessibility of drugs to SARS-CoV-2 in the background network.',\n",
              "       'For example, SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is identified as a proviral gene in our study.',\n",
              "       'Although which class of drugs, i.e., agonists or antagonists of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, is responsible for the replication activity of SARS-CoV-2 remains to be verified by more experiments, the latest evidence revealed that knockout or knockdown of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein could cause significant reductions in SARS-CoV-2 replication.',\n",
              "       'Furthermore, a clinical trial demonstrated that the antidepressant fluvoxamine, an antagonist of SIGMAR1, the target of the NSP6 SARS-CoV-2 protein, could prevent clinical deterioration in adult outpatients infected with SARS-CoV-2 A. However, there are network-based approaches to select SIGMAR1, the target of the NSP6 SARS-CoV-2 protein agonists, such as amitriptyline, as a potential treatment for COVID-19, implying confliction and limitation may largely exist among current methods.',\n",
              "       'For instance, cannabidiol CBD, a member of the cannabinoid class of natural products, is an FDA-approved drug for epilepsy treatment.',\n",
              "       'There are four clinical trials of cannabidiol CBD, a member of the cannabinoid class of natural products for the treatment of COVID-19.',\n",
              "       'Studies have shown that cannabidiol CBD, a member of the cannabinoid class of natural products can inhibit the cell entry and replication of SARS-CoV-2.',\n",
              "       'Our comorbidity treatment analysis found that cannabidiol CBD, a member of the cannabinoid class of natural products is also an agonist of PPARG and GPX1.',\n",
              "       'Since 1997, a group of PPARG agonists, thiazolidinediones, has been used to treat type 2 diabetes by alleviating insulin resistance.',\n",
              "       \"In theory, cannabis has desirable effects on hyperglycemia through cannabis's anti-inflammatory and antioxidant properties.\",\n",
              "       'GPX1 has been shown to exert a protective effect against the presence of coronary artery disease CAD.',\n",
              "       \"GPX1's activity was a useful marker for monitoring cardiovascular disease.\",\n",
              "       'There is now a growing body of evidence that cannabidiol CBD, a member of the cannabinoid class of natural products is also beneficial for the cardiovascular system.',\n",
              "       'The anti-inflammatory and antioxidant effects of cannabidiol CBD, a member of the cannabinoid class of natural products may make cannabidiol CBD, a member of the cannabinoid class of natural products a treatment for coronary heart disease and diabetes, together with COVID-19 B. Estradiol cypionate EC is an estrogen medication used in hormone therapy for menopausal symptoms and low estrogen levels in cis women.',\n",
              "       'The analysis of electronic health records of over 68000 COVID-19 patients revealed that estrogen therapy is associated with more than 50% reduction in mortality.',\n",
              "       'Estradiol cypionate EC was repositioned as COVID-19 treatment in other studies and is now in phase 2 clinical trial.',\n",
              "       'In our analysis, Estradiol cypionate EC can indirectly target HK2 and PLCB4 through ESR2, identified as a risk factor for atrial fibrillation.',\n",
              "       'Furthermore, estrogen may increase the risk of myocardial infarction in transgender women by promoting thrombosis.',\n",
              "       \"Therefore, Estradiol cypionate EC, despite Estradiol cypionate EC's potential antiviral effect, could be excluded due to Estradiol cypionate EC's possible cardiovascular side effects C. Together, our new drug repositioning strategy utilizes the direction information in the network to screen the MoA of the candidate drugs and, from a genetic perspective, considers the potential unwanted side effects of many complex diseases.\",\n",
              "       'We identified 964 host genes for SARS-CoV-2, 477 host genes for SARS-CoV, 236 host genes for MERS-CoV, and 1410 unique genes.',\n",
              "       '1410 unique genes include genetic risk genes such as TYK2, physical interaction genes such as ACO1, and biological regulation genes such as CTSL.',\n",
              "       \"There are more overlapping genes between SARS-CoV-2 and SARS-CoV than between SARS-CoV-2 and MERS-CoV this may be because the genome and structure of SARS-CoV-2 are more similar to SARS-CoV We also used multi-omics data to determine the direction of host genes to viruses, that is, host genes's effects on viral infection.\",\n",
              "       'We found that CBD not only inhibits SARS-CoV-2 but may also act as a therapeutic drug for coronary heart disease and diabetes.',\n",
              "       'EC also has antiviral potential, but we found that EC may increase the risk of cardiovascular disease.',\n",
              "       \"Overall, we first comprehensively characterized the host genes of CoVs and the host genes of CoVs's role in viral infection.\",\n",
              "       'Finally, to infer the direction of a drug to CoV in each drug-gene s -CoVs path, we used a random walk algorithm and then combined multiple drug paths for prioritization.',\n",
              "       'Since the SARS-CoV-2 was most evolutionarily conserved with SARS-CoV and MERS-CoV, the SARS-CoV-2 may share host genes or therapeutic targets with SARS-CoV and MERS-CoV. Thus, by fully utilizing the relevant information and shared mechanism of infection among these CoVs, we curated as many as host genes of these CoVs from three categories genetic risk genes, physical interaction genes, and biological regulatory genes.',\n",
              "       'We first retrieved all risk SNP p-value < 5e-8 in COVID-19 GWAS from GRASP COVID-19 data.',\n",
              "       'Then, all risk SNP p-value < 5e-8 in COVID-19 GWAS were annotated as coding variants and non-coding variants by VEP.',\n",
              "       'We assigned the direction of effect as 1 for a B-SIFT score higher than 0.5 and −1 for a B-SIFT score lower than −0.95.',\n",
              "       'To predict the impact of repurposed drugs on comorbidities, we first selected the largest GWAS for 17 complex diseases including diabetes mellitus, cardiovascular disease, cerebrovascular disease, chronic liver disease, chronic kidney injury, autoimmune disease, and many cancers from CAUSALdb.',\n",
              "       'For each Drug-Gene s -CoV path, we assigned a DGV score, which equals the accumulation of drug target score, mapping score, and host gene score.',\n",
              "       'For mapping score, the score is set as the inverse of the number of genes.',\n",
              "       'For host gene score, host gene score got 1 point if the direction of the interaction was identified by eQTLs and CRISPR screen or half a point if the direction of the interaction was identified by gene expression profile.',\n",
              "       'We used gene expression profiles of SARS-CoV-2 infected samples and a control group from alveolar type II cells and African green monkey kidney cells.'],\n",
              "      dtype=object)"
            ]
          },
          "metadata": {},
          "execution_count": 36
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-05-10_kazu_multi_ents_unique_sents_723.pickle', 'wb') as f:\n",
        "  pickle.dump(kazu_multi_ents_unique_sents, f)"
      ],
      "metadata": {
        "id": "PZxb2k_jEqPc"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will get a count of the number of unique entities in the sentences with more than one entity."
      ],
      "metadata": {
        "id": "Ri7FWvwgz8qJ"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Count unique entities\n",
        "kazu_multiple_entities['entity'].nunique()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "695994c2-a224-4805-eea9-18b4d0d19b70",
        "id": "PujXQiv4EqPf"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "855"
            ]
          },
          "metadata": {},
          "execution_count": 56
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_multi_ents_unique = kazu_multiple_entities['entity'].unique()"
      ],
      "metadata": {
        "id": "_nhNV7ttEqPl"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "kazu_multi_ents_unique"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "fM_k18mDTzfd",
        "outputId": "bda577df-9701-47e6-cd1f-8001292f7bb0"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "array(['male erectile dysfunction', 'pulmonary hypertension', 'bupropion',\n",
              "       'thalidomide', 'multiple myeloma',\n",
              "       'chronic graft-versus-host disease', 'cancer', 'rare diseases',\n",
              "       'infectious diseases', 'SARS-CoV-2', 'Coronavirus', 'Cancer',\n",
              "       'Alzheimer’s disease', 'Breast cancer', 'Chagas disease',\n",
              "       'Statins', 'COVID-19', 'clonidine', 'chloroquine',\n",
              "       'hydroxychloroquine', 'coronavirus', 'disulfiram', 'p97 segregase',\n",
              "       'NPL4', 'tumors', 'Metformin', 'HIV', 'plagued', 'Zika virus',\n",
              "       'coronaviruses', 'mortality', 'genetically related diseases',\n",
              "       'epidemic diseases', 'MERS‐CoV', 'CoVs', 'SARS‐CoV‐2',\n",
              "       'severe acute respiratory syndrome CoV', 'respiratory illness',\n",
              "       'influenza', 'Ebola viral diseases', 'foscarnet', 'tenofovir',\n",
              "       'sofosbuvir', 'uprifosbuvir', 'phosphoramide', 'phosphate',\n",
              "       'azole', 'hepatitis', 'COVID‐19', 'remdesivir', 'drug resistance',\n",
              "       'molnupiravir', 'paxlovid 3c‐like protease', 'hepatitis C',\n",
              "       'Ebola virus', 'enzyme', 'assay', 'life cycle', 'corilagin',\n",
              "       'infection', 'amodiaquine', 'umifenovir', 'pp1a', 'pp1ab',\n",
              "       'host cells', '3CLpro', 'papain', 'replicase complex', 'Shi',\n",
              "       'PLpro', 'investigation', 'proglumetacin', 'sufugolix', 'Mpro',\n",
              "       'delapril', 'lisinopril', 'ACE2', 'S', 'pyridine', 'coumarin',\n",
              "       'SARS‐CoV‐main', 'serine protease hepsin', 'SARS‐Coronavirus',\n",
              "       'score', 'Hepatitis C', 'lopinavir', 'ritonavir', 'SARS‐3CL',\n",
              "       'benzoic acid', 'dihydropyrimidine', 'SARS‐Co', 'chymotrypsin',\n",
              "       'RNA‐dependent RNA polymerase RdRp complex',\n",
              "       'spike S receptor binding glycoprotein', 'nucleocapsid',\n",
              "       'nonstructural protein NSP', 'M protein', 'small envelope E',\n",
              "       'hACE2', 'chymotrypsin‐like protease 3CLpro', 'Cathepsin L', 'N',\n",
              "       'RdRp', 'NSP6', 'RBD', 'S protein', \"RBD's receptor\", 'ACE‐2',\n",
              "       'UBR', 'ACE‐2 receptor', 'M.', 'emetine', 'DR',\n",
              "       'erectile dysfunction', 'arthritis', 'Chloroquine', 'antimalarial',\n",
              "       'cancers', 'typhoid', 'hypoglycemia', 'sulfonamides', 'diabetic',\n",
              "       'cardiovascular problems', 'aspirin', 'colorectal cancer',\n",
              "       'breast cancer', 'lung cancer', 'niclosamide', 'diarrhea',\n",
              "       'nitazoxanide', 'carfilzomib', 'bortezomib', 'azithromycin', 'Won',\n",
              "       'Ser144', 'His163', 'Gly143', 'Gln166', 'hydrogen',\n",
              "       'CO‐NH‐C ‐CO‐NH‐C', 'dipyridamole', 'melatonin', 'mercaptopurine',\n",
              "       'toremifene', 'mesalazine', 'sirolimus', 'eravacycline',\n",
              "       'valrubicin', 'elbasvir', 'human cells', 'organoid disease',\n",
              "       'human lung cell line', 'Calu‐3', 'clofazimine', 'haloperidol',\n",
              "       'poly‐ADP‐ribose polymerase 1 PARP1', 'PARP1',\n",
              "       'inflammatory diseases of the lung', 'Beclabuvir', 'HCV infection',\n",
              "       'HIV‐1 infection', 'host', 'cysteine protease', 'mice',\n",
              "       'Coronavirus Disease 2019', 'SARSCoV-2 infection', 'Molnupiravir',\n",
              "       'severe acute respiratory syndrome', 'NME', 'Lagevrio',\n",
              "       'nucleoside', 'MERS', 'SARSCoV-2', 'EIDD-1931',\n",
              "       'EIDD-1931-triphosphate', 'viral infection', 'isopropyl', 'range',\n",
              "       'enterocytes', 'seasonal flu', 'ferrets', 'SARS-CoV-2 infection',\n",
              "       'MK-4482', 'MK-4482-006', 'serum', 'population', 'prevalence',\n",
              "       'COVID-19 infestation', 'communicable disease',\n",
              "       'Coronavirus disease-2019', 'tocilizumab', 'kaletra',\n",
              "       'favipiravir', 'Middle East Respiratory Syndrome', 'HCoV',\n",
              "       'SARS-CoV 2', 'hemagglutinin', 'esterase HE', 'membrane M',\n",
              "       'envelope E', 'spike S', 'M', 'angiotensin-converting enzyme',\n",
              "       'human angiotensin-converting enzyme 2', 'amino acid', 'date',\n",
              "       'spike', 'envelope', 'headaches', 'immense pain', 'cyclooxygenase',\n",
              "       'coronary heart disease', 'erythromycin', 'sildenafil',\n",
              "       'Immunodeficiency', 'Human Immunodeficiency Virus-1 HIV',\n",
              "       'MERS-CoV', 'hypothesis', 'Precision', 'Janus-kinase',\n",
              "       'interferons', 'vascular endothelial growth factor VEGF',\n",
              "       'Bruton tyrosine kinase', 'BTK', 'XPO-1', 'nuclear export',\n",
              "       'extra-cellular vesicles', 'Ralimetiniib mesylate', 'Calu-3',\n",
              "       'HeLa-ACE2', 'digitoxigenin', 'beta-eudesmol', 'crocin', 'rutin',\n",
              "       'hesperidin', 'indinavir', 'ID-184',\n",
              "       'RNRP RNA-dependent RNA polymerase',\n",
              "       'RNA-dependent RNA polymerase', 'proteinase', 'helicase',\n",
              "       'boceprevir', 'carmofur', 'doxycycline', '3-chymotrypsin-like',\n",
              "       'platycodin', 'Nsp3', 'Nsp 12', 'ribavirin', 'vapreotide',\n",
              "       'atazanavir', 'daclatasvir', 'potassium citrate', 'helicase Nsp13',\n",
              "       'raltegravir', 'methyltransferases guanine-N7-methyltransferase',\n",
              "       '2’-O-methyltransferase', 'gliclazide', 'memantine', 'losartan',\n",
              "       'captopril', 'TMPRSS2', 'camostat mesylate', 'anyone',\n",
              "       'cathepsin L', 'teicoplanin', 'DPP4 cell receptor', 'oseltamivir',\n",
              "       'sitagliptin', 'pemirolast', 'nitrofurantoin', 'isoniazid',\n",
              "       'eridictoyl', 'hypericin', 'cepharanthine', 'ergoloid',\n",
              "       'baricitinib', 'exo-nuclease', 'methyltransferase', 'Efavirenz',\n",
              "       'Poly ADP-ribose polymerase 1 PARP-1', 'Mefuparib hydrochloride',\n",
              "       'glycogen synthase kinase 3 GSK-3', 'NF-kappa B', 'irbesartan',\n",
              "       'emodin', 'dactinomycin', 'ivermectin', 'Nsps', 'vancomycin',\n",
              "       'host organism', 'abemaciclib', 'estradiol benzoate', 'capmatinib',\n",
              "       'olaparib', 'lumacaftor', 'pazopanib', 'CD147',\n",
              "       'immunoglobulin superfamily IgSF', 'rifabutin',\n",
              "       'dihydroergotamine', 'bromocriptine', 'entrectinib', 'selinexor',\n",
              "       'quinupristin', 'rifapentine', 'digitoxin', 'diosmin',\n",
              "       'antrafenine', 'interferon beta-1A', 'AZD7442', 'Pioglitazone',\n",
              "       'Leronlimab', 'hydroxychloroquine sulfate', 'ruconest',\n",
              "       'infliximab', 'Interferon-beta-1A',\n",
              "       'RNA-dependent RNA polymerase RdRp', 'protein synthesis', 'Cys111',\n",
              "       'Asp286', 'papain-like proteases',\n",
              "       'ubiquitin-specific proteases USPs', 'ubiquitin', 'Ubl domain',\n",
              "       'RNA-dependent DNA polymerase',\n",
              "       'human telomerase reverse transcriptase hTERT', 'DNA polymerase',\n",
              "       'beta', 'C', 'Non-structural protein 5 coding', 'cysteine',\n",
              "       'chymotrypsin-like', 'SARS CoV-2', 'protomers', 'amino acids',\n",
              "       'S1', 'spike glycoprotein', 'pp1 polyprotein', 'Nsp 12 to 16',\n",
              "       'C121', 'variable', 'MAbs REGN10934', 'REGN10989', 'antibody',\n",
              "       'NTD', 'n', 'dexamethasone', 'immune system',\n",
              "       'spike glycoproteins', 'eriodictoyl', 'carumonam', 'aclerasteride',\n",
              "       'granotapide', 'Lopinavir', 'Remdesivir', 'Leu6819', 'Met6818',\n",
              "       'Val7021', 'Tyr7020', 'Asp7018', 'Asp6942', 'Tyr333', 'Arg277',\n",
              "       'Phe274', 'Val270', 'Trp301', 'Thr296', 'Ala264', 'Arg262',\n",
              "       'Phe314', 'Gln260', 'Arg259', 'Asn422', 'Pro491', 'Leu492',\n",
              "       'Gln493', 'Ser494', 'Tyr495', 'Gly496', 'Phe497', 'Gln498',\n",
              "       'Lys444', 'Asp442', 'Tyr351', 'Val350', 'Ser349', 'Ala348',\n",
              "       'Phe347', 'Arg346', 'Arg509', 'Val401',\n",
              "       'favipiravir-nucleocapsid phosphoprotein', 'Glu6821', 'Leu6820',\n",
              "       'Asn6941', 'Glu6940', 'Thr6938',\n",
              "       'remdesivir-nucleocapsid phosphoprotein', 'Arg6817', 'Trp330',\n",
              "       'Thr282', 'Gly284', 'Phe286', 'Leu291', 'SARS', 'SARS-CoV',\n",
              "       'human respiratory epithelial cells', 'epithelial cells',\n",
              "       'rhesus monkey', 'pulmonary lesions', 'Ebola', 'NSP12', 'HIV-',\n",
              "       'Silmitasertib', 'casein kinase 2', 'Sonic hedgehog SHH',\n",
              "       'C–C Chemokine receptor type 5', 'c1 esterase', 'angioedema',\n",
              "       'Ruconest', 'C1', 'C5a', 'C3a esterases', 'tumor necrosis factor',\n",
              "       'Infliximab', 'Rheumatoid arthritis', 'Crohn’s disease',\n",
              "       'ankylosing spondylitis', 'CVL218', 'RDRP', 'papain-like protease',\n",
              "       'enveloped', 'Organization', 'spike S glycoprotein',\n",
              "       'angiotensin converting enzyme', 'heart', 'respiratory system',\n",
              "       'alveolar epithelial cells', 'capillary endothelial cells',\n",
              "       'SARS-CoV-2 infections',\n",
              "       'systemic inflammatory response syndrome SIRS',\n",
              "       'acute respiratory distress syndrome ARDS', 'COVID-19 infections',\n",
              "       'cytokine storm', 'viral infections', 'variance', 'SIRS', 'ARDS',\n",
              "       'sepsis', 'burns', 'trauma', 'blood', 'microarray', 'critically',\n",
              "       'coefficient of variation', 'percentile', 'sky', 'M18', 'M28',\n",
              "       'M32', 'M36', 'M9', 'immune cells', 'T-cell receptor complex',\n",
              "       'spermatogenesis', 'peptide antigen', 'MHC Class II receptor',\n",
              "       'Th1', 'Th2 cell', 'adaptive immune response', 'M16', 'KEGG',\n",
              "       'B-cell receptor signaling pathway', 'platelet activation', 'M332',\n",
              "       'hematopoietic cell', 'Sepsis', 'CAY-10470', 'mouse', 'yeast',\n",
              "       'inflammation', 'cytokine', 'lung injury', 'septic shock',\n",
              "       'T-cell proliferation', 'antigen presenting cells', 'toll-like',\n",
              "       'TREM-1', 'acute lung injury', 'alveolar cells', 'macrophages',\n",
              "       'loss of smell', \"M44's\", 'IFN-', 'TNF-', 'macrophage', 'MAPK',\n",
              "       'CXCR3', 'CXCR4', 'chemokine receptors', 'CXCL12', 'chemotaxis',\n",
              "       'severe infection', 'NOD-like receptor', 'NF-B', 'STAT3', 'IRF1',\n",
              "       'TLR4', 'p38', 'histamine receptors', 'TNF', 'histamine',\n",
              "       'loratadine', 'cytokine storms', 'IKK', 'porcine', 'extracellular',\n",
              "       'pneumonia', 'malarial', 'airway inflammation', 'murine', 'asthma',\n",
              "       'Mepacrine', 'neuroinflammatory symptoms', 'Coronaviridae',\n",
              "       'ruxolitinib', 'tofacitinib', 'sotrovimab', 'casirivimab',\n",
              "       'imdevimab', 'IL-6', 'sarilumab', 'convalescent plasma', 'injury',\n",
              "       'thrombosis', 'NSPs', 'RNA synthesis', 'anticoronaviral',\n",
              "       'membrane fusion', 'infectious disease', 'organism',\n",
              "       'nonstructural protein N 45', 'papain-like protease N 19',\n",
              "       'spike glycoprotein N 62', 'amikacin', 'danoprevir', 'telaprevir',\n",
              "       'cobicistat', 'protease N 154', 'tegobuvir', 'famotidine',\n",
              "       'bictegravir', 'ziprasidone', 'pexidartinib', 'amprenavir',\n",
              "       'zafirlukast', 'cilostazol', 'paromomycin', 'Tinospora cordifolia',\n",
              "       'flavonoids', 'herbacetin', 'epigallocatechin', 'jensenone',\n",
              "       'tinosponone', 'anistone', 'eucalyptus', 'curcumin', 'oxadiazoles',\n",
              "       'phenyltriazolinones', 'triazoles', 'benzoylpinostrobin',\n",
              "       'benzylidenechromanones', 'selenium', 'ebselen', 'furoxan',\n",
              "       'thimerosal', 'isatin', 'romidepsin', 'phenyl mercurin',\n",
              "       'pleconaril', 'tyrosine kinase', 'nilotinib', 'imatinib', 'NSP-14',\n",
              "       'NSP-15', 'infected cell', 'ginkgolic acid', 'anacardic acid',\n",
              "       'troxerutin', 'bisindolylmaleimide', 'GRL-172', 'baicalin',\n",
              "       'baicalein', 'bepridil', 'panobinostat', 'givinostat', 'sirtinol',\n",
              "       'saquinavir', 'lipopeptides', 'hydroxyzine', 'azelastine',\n",
              "       'heparin', 'glycyrrhizic acid', 'IMU-8381',\n",
              "       'human dihydroorotate dehydrogenase', 'pyrazole', 'phillyrin',\n",
              "       'IL', 'NF- B', 'chlorpromazine', 'tannic acid',\n",
              "       'severe acute respiratory syndromes', 'SARS Cov-2',\n",
              "       'Coronaviruses', 'envelopes E', 'matrixes M', 'nucleocapsids N',\n",
              "       '3-C proteases 3CLpro', 'NSP5',\n",
              "       'RNA Dependent RNA Polymerases RdRp', 'various cells',\n",
              "       'nucleotides', '5-triphosphate', 'RdRp substrate', 'abiraterone',\n",
              "       'diiodohydroxyquinoline', 'bexarotene', 'COVID-19 infection',\n",
              "       'retinoid', 'androstenedione', 'cetilistat', 'Veklury', 'water',\n",
              "       'pancreatic lipase', 'obesity', 'quinolone', 'amoebiasis',\n",
              "       'luminal', 'Cetilistat', 'viral shedding', 'feces',\n",
              "       'abiraterone acetate', 'non-small cell lung cancer NSCLC',\n",
              "       'cutaneous T-cell lymphoma', 'CYP17A1', 'androgen synthesis',\n",
              "       'resistant prostate cancer', 'tamibarotene', 'AM580', 'Zika',\n",
              "       'adenoviruses', 'enterovirus A71', 'LEU240', 'TYR129', 'LEU708',\n",
              "       'VAL128', 'ALA125', 'LEU207', 'HIS133', 'TYR728',\n",
              "       'TYR732 amino acids', '6NUR', 'RdRp receptor', 'CoV', 'nucleotide',\n",
              "       'coronavirus-1', 'Covid-19', 'distal airway cells',\n",
              "       'viral diseases', 'k-nearest neighbors', 'precision',\n",
              "       'correlation coefficient', 'NASH', 'renal fibrosis', 'Cortivazol',\n",
              "       'Velusetrag', '16 alpha Bromoepiandrosterone', 'accuracy', 'self',\n",
              "       'Niclosamide', 'Covid-19 infected', 'type 1 diabetes',\n",
              "       'standard deviation', 'GPCRs', 'coronavirus 2019', 'anti-HCoV',\n",
              "       'PPI a ii', 'SARS2', 'HCoV-PPI', 'virus infection',\n",
              "       'viral disease', 'ranking', 'capmanitib', 'TLR9', 'TLR',\n",
              "       'Dexamethasone', 'Artemesian', 'Nitrendipine',\n",
              "       'Coronavirus disease', 'coronavirus disease 2019',\n",
              "       'Betacoronavirus', 'Middle East respiratory syndrome',\n",
              "       'ORF1ab polyprotein', 'host cell', 'SARS-CoV-1', 'polymerases',\n",
              "       'Human Poliovirus PV', 'NS5B', 'NSP-7', 'NSP-8', 'nidovirus',\n",
              "       'NSP-12', 'RdRp activity', 'NiRAN domain',\n",
              "       'nucleotide triphosphate NTP', 'RdRp domain', 'SARS-CoV2',\n",
              "       'Sofosbuvir', 'HCV', 'Zika Virus', 'Dengue', 'Diarrhea',\n",
              "       'Japanese Encephalitis', 'Classical Swine Fever',\n",
              "       'Human Coxsackievirus CoxV', 'Human Rhinovirus HRV',\n",
              "       'Human Enterovirus HEV', 'Human Enterovirus 71 HEV71',\n",
              "       'Foot and Mouth Disease', 'Encephalomyocarditis virus',\n",
              "       'Rabbit Haemorrhagic Disease Virus RHDV', 'Murine',\n",
              "       'Norwalk Virus NarV', 'Human Norovirus HNV', 'NTP', 'NSP7', 'NSP8',\n",
              "       'Mn2+', 'Mg2+', 'Ribavirin', 'GTP', 'UTP', 'bar chart',\n",
              "       'Dasabuvir', '6M71', 'Trp', 'Tyr619', 'Cys622', 'Glu811', 'Ser814',\n",
              "       'Asp761', 'Trp800', 'NS5', 'HNV', 'Poli', 'Z-score', 'hydrogens',\n",
              "       'galidesivir', 'Paxlovid', 'congenital disabilities',\n",
              "       'serine protease', 'renin-angiotensin system', 'RAS',\n",
              "       'small intestine', 'testis', 'cell surface', 'cell-surface',\n",
              "       'low-density lipoprotein receptor class A domain-containing protein 3 LDLRAD3',\n",
              "       'C-type lectin domain family 4', 'lipid metabolism', 'PIK3C3',\n",
              "       'PIK3R4', 'phosphatidylinositol 3-kinase PI3K',\n",
              "       'sterol regulatory element-binding protein 1', 'SREBF1', 'SREBF2',\n",
              "       'lung epithelial cells', 'endolysosome',\n",
              "       'chronic underlying diseases', 'diabetes mellitus',\n",
              "       'cardiovascular disease', 'chronic pulmonary disease',\n",
              "       'Coronavirus disease 2019', 'CoV infection', 'complex diseases',\n",
              "       'GRASP', 'IFNAR2', 'OAS1', 'OAS3',\n",
              "       'oligoadenylate synthase family', 'JAK', 'iron', 'heme', 'ORF6',\n",
              "       'ORF7a', 'ORF7b', 'protocadherin', 'epithelial cell',\n",
              "       'viral protein ORF7b', 'multiorgan failure', 'CTSL',\n",
              "       'MERS-CoV infection', 'BMPR2', 'ORF3',\n",
              "       'hereditary pulmonary hypertension', 'TMEM41B',\n",
              "       'lipid localization', 'infected cells', 'MERS-CoV.', 'Th17 cell',\n",
              "       'human papillomavirus infection', 'Salmonella infection',\n",
              "       'Vibrio cholerae', 'autoimmune diseases', 'rheumatoid arthritis',\n",
              "       'inflammatory bowel disease', 'gene-CoV',\n",
              "       'cerebrovascular disease', 'liver disease',\n",
              "       'chronic kidney injury', 'autoimmune disease',\n",
              "       'clathrin-mediated endocytosis', 'virus assembly',\n",
              "       'chronic myeloid leukemia', 'Abelson kinase', 'epinephrine',\n",
              "       'reference-compound-perturbed cells', 'SIGMAR1', 'amitriptyline',\n",
              "       'epilepsy', 'PPARG', 'GPX1', 'thiazolidinediones',\n",
              "       'type 2 diabetes', 'insulin resistance', 'hyperglycemia',\n",
              "       'cannabis', 'coronary artery disease CAD', 'cardiovascular system',\n",
              "       'cannabidiol', 'diabetes', 'Estradiol cypionate', 'estrogen',\n",
              "       'cis', 'HK2', 'PLCB4', 'ESR2', 'atrial fibrillation',\n",
              "       'myocardial infarction', 'ACO1', 'EC', '-CoVs',\n",
              "       'alveolar type II cells', 'African green monkey kidney cells'],\n",
              "      dtype=object)"
            ]
          },
          "metadata": {},
          "execution_count": 41
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open('2024-05-10_kazu_multi_ents_unique_855.pickle', 'wb') as f:\n",
        "  pickle.dump(kazu_multi_ents_unique, f)"
      ],
      "metadata": {
        "id": "Ib2ELzvVEqPm"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "We will get a count of the unique entity types."
      ],
      "metadata": {
        "id": "4y8fMF78UtFJ"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Count unique entity types\n",
        "kazu_multiple_entities['entity_type'].nunique()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "f51cfe07-132e-49ba-f5cc-58d24d5b2af3",
        "id": "kv9TOO4TEqPt"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "11"
            ]
          },
          "metadata": {},
          "execution_count": 60
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Array of unique entity types\n",
        "kazu_multiple_entities['entity_type'].unique()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "d08e89d7-f7e4-4717-af24-3c118b448384",
        "id": "NQc5MaNPEqPt"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "array(['disease', 'drug', 'gene', 'measurement', 'anatomy', 'cell_type',\n",
              "       'go_cc', 'species', 'cell_line', 'go_bp', 'go_mf'], dtype=object)"
            ]
          },
          "metadata": {},
          "execution_count": 61
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "We can see that the entity type 'covid lineage' is missing. There were very few of these and none in sentences with more than one entity."
      ],
      "metadata": {
        "id": "wxtqQ6uSU6gu"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "### References\n",
        "\n",
        "* Yoon, W. et al. (2022). Biomedical NER for the Enterprise with Distillated BERN2 and the Kazu Framework. In *Proceedings of the 2022 Conference on Empirical Methods in Natural Language Processing: Industry Track*, pages 619-626, Abu Dhabi, UAE. Association for Computational Linguistics. [doi:10.18653/v1/2022.emnlp-industry.63](https://doi.org/10.18653/v1/2022.emnlp-industry.63)\n",
        "\n",
        "\n",
        "* https://github.com/AstraZeneca/KAZU\n",
        "\n",
        "* KAZU documentation: https://astrazeneca.github.io/KAZU/\n",
        "\n",
        "* KAZU web API demo: http://kazu.korea.ac.kr/api/docs#/\n",
        "\n",
        "* BioNER spaCy Language component: https://github.com/librairy/bio-ner/blob/main/bionlp/NER_processing.py\n",
        "\n",
        "\n",
        "\n"
      ],
      "metadata": {
        "id": "2PnFT8QXVfDl"
      }
    }
  ]
}